0001493152-24-04589210-Q GT Biopharma, Inc. 20241114202411141615391615391615 39 0 0001493152-24-045892 10-Q 64 20240930 20241114 20241114 GT Biopharma, Inc. 0000109657 2834 941620407 DE 1231 10-Q 34 001-40023 241462531 315 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94104 (800) 304-9888 315 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94104 OXIS INTERNATIONAL INC 19940916 DDI PHARMACEUTICALS INC 19920703 DIAGNOSTIC DATA INC /DE/ 19850312 10-Q 1 form10-q.htm false --12-31 Q3 0000109657 0000109657 2024-01-01 2024-09-30 0000109657 2024-11-10 0000109657 2024-09-30 0000109657 2023-12-31 0000109657 us-gaap:SeriesCPreferredStockMember 2024-09-30 0000109657 us-gaap:SeriesCPreferredStockMember 2023-12-31 0000109657 2024-07-01 2024-09-30 0000109657 2023-07-01 2023-09-30 0000109657 2023-01-01 2023-09-30 0000109657 us-gaap:SellingGeneralAndAdministrativeExpensesMember GTBP:OfficersEmployeesAndDirectorsMember 2024-07-01 2024-09-30 0000109657 us-gaap:SellingGeneralAndAdministrativeExpensesMember GTBP:OfficersEmployeesAndDirectorsMember 2023-07-01 2023-09-30 0000109657 us-gaap:SellingGeneralAndAdministrativeExpensesMember GTBP:OfficersEmployeesAndDirectorsMember 2024-01-01 2024-09-30 0000109657 us-gaap:SellingGeneralAndAdministrativeExpensesMember GTBP:OfficersEmployeesAndDirectorsMember 2023-01-01 2023-09-30 0000109657 us-gaap:PreferredStockMember 2024-06-30 0000109657 us-gaap:CommonStockMember 2024-06-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000109657 us-gaap:RetainedEarningsMember 2024-06-30 0000109657 2024-06-30 0000109657 us-gaap:PreferredStockMember 2023-12-31 0000109657 us-gaap:CommonStockMember 2023-12-31 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000109657 us-gaap:RetainedEarningsMember 2023-12-31 0000109657 us-gaap:PreferredStockMember 2023-06-30 0000109657 us-gaap:CommonStockMember 2023-06-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000109657 us-gaap:RetainedEarningsMember 2023-06-30 0000109657 2023-06-30 0000109657 us-gaap:PreferredStockMember 2022-12-31 0000109657 us-gaap:CommonStockMember 2022-12-31 0000109657 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000109657 us-gaap:RetainedEarningsMember 2022-12-31 0000109657 2022-12-31 0000109657 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000109657 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000109657 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000109657 us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0000109657 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0000109657 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0000109657 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0000109657 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000109657 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000109657 us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0000109657 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0000109657 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0000109657 us-gaap:PreferredStockMember 2024-09-30 0000109657 us-gaap:CommonStockMember 2024-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000109657 us-gaap:RetainedEarningsMember 2024-09-30 0000109657 us-gaap:PreferredStockMember 2023-09-30 0000109657 us-gaap:CommonStockMember 2023-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000109657 us-gaap:RetainedEarningsMember 2023-09-30 0000109657 2023-09-30 0000109657 us-gaap:CommonStockMember 2024-02-02 0000109657 us-gaap:CommonStockMember 2024-02-05 0000109657 srt:MaximumMember 2024-09-30 0000109657 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000109657 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000109657 us-gaap:WarrantMember 2024-01-01 2024-09-30 0000109657 us-gaap:WarrantMember 2023-01-01 2023-09-30 0000109657 us-gaap:ShortTermInvestmentsMember 2024-09-30 0000109657 us-gaap:ShortTermInvestmentsMember 2024-01-01 2024-09-30 0000109657 us-gaap:ShortTermInvestmentsMember 2023-12-31 0000109657 us-gaap:ShortTermInvestmentsMember 2023-01-01 2023-12-31 0000109657 2023-01-01 2023-12-31 0000109657 us-gaap:MoneyMarketFundsMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2024-09-30 0000109657 us-gaap:USTreasurySecuritiesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2024-09-30 0000109657 GTBP:USTreasuriesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel1Member GTBP:USTreasuriesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel2Member GTBP:USTreasuriesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel3Member GTBP:USTreasuriesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel1Member 2024-09-30 0000109657 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000109657 us-gaap:FairValueInputsLevel3Member 2024-09-30 0000109657 us-gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000109657 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000109657 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000109657 GTBP:CytovanceBiologicsIncMember 2024-09-30 0000109657 GTBP:CytovanceBiologicsIncMember 2023-12-31 0000109657 GTBP:UniversityOfMinnesotaMember 2024-09-30 0000109657 GTBP:UniversityOfMinnesotaMember 2023-12-31 0000109657 GTBP:CytovanceBiologicsIncMember 2022-12-31 0000109657 GTBP:CytovanceBiologicsIncMember 2024-01-01 2024-09-30 0000109657 GTBP:CytovanceBiologicsIncMember 2023-01-01 2023-09-30 0000109657 GTBP:CytovanceBiologicsIncMember 2023-09-30 0000109657 GTBP:TwoThousandTwentyThreeCommonWarrantsMember srt:MaximumMember 2023-01-04 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMember srt:MaximumMember 2023-01-04 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMember 2024-01-01 2024-09-30 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMember 2024-09-30 0000109657 GTBP:TwentyTwentyWarrantsMember 2020-01-01 2020-12-31 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMember 2024-01-01 2024-09-30 0000109657 GTBP:TwoThousandTwentyWarrantsMember 2024-01-01 2024-09-30 0000109657 us-gaap:MeasurementInputSharePriceMember GTBP:TwoThousandTwentyThreeWarrantsMember 2024-09-30 0000109657 us-gaap:MeasurementInputSharePriceMember GTBP:TwoThousandTwentyThreeWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputRiskFreeInterestRateMember GTBP:TwoThousandTwentyThreeWarrantsMember 2024-09-30 0000109657 us-gaap:MeasurementInputRiskFreeInterestRateMember GTBP:TwoThousandTwentyThreeWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputPriceVolatilityMember GTBP:TwoThousandTwentyThreeWarrantsMember 2024-09-30 0000109657 us-gaap:MeasurementInputPriceVolatilityMember GTBP:TwoThousandTwentyThreeWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputExpectedTermMember GTBP:TwoThousandTwentyThreeWarrantsMember srt:MinimumMember 2024-09-30 0000109657 us-gaap:MeasurementInputExpectedTermMember GTBP:TwoThousandTwentyThreeWarrantsMember srt:MaximumMember 2024-09-30 0000109657 us-gaap:MeasurementInputExpectedTermMember GTBP:TwoThousandTwentyThreeWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputExpectedDividendRateMember GTBP:TwoThousandTwentyThreeWarrantsMember 2024-09-30 0000109657 us-gaap:MeasurementInputExpectedDividendRateMember GTBP:TwoThousandTwentyThreeWarrantsMember 2023-12-31 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMember 2023-01-01 2023-12-31 0000109657 us-gaap:MeasurementInputSharePriceMember GTBP:TwoThousandTwentyWarrantsMember 2024-09-30 0000109657 us-gaap:MeasurementInputSharePriceMember GTBP:TwoThousandTwentyWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputRiskFreeInterestRateMember GTBP:TwoThousandTwentyWarrantsMember 2024-09-30 0000109657 us-gaap:MeasurementInputRiskFreeInterestRateMember GTBP:TwoThousandTwentyWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputPriceVolatilityMember GTBP:TwoThousandTwentyWarrantsMember 2024-09-30 0000109657 us-gaap:MeasurementInputPriceVolatilityMember GTBP:TwoThousandTwentyWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputExpectedTermMember GTBP:TwentyTwentyWarrantsMember 2024-09-30 0000109657 us-gaap:MeasurementInputExpectedTermMember GTBP:TwoThousandTwentyWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputExpectedDividendRateMember GTBP:TwoThousandTwentyWarrantsMember 2024-09-30 0000109657 us-gaap:MeasurementInputExpectedDividendRateMember GTBP:TwoThousandTwentyWarrantsMember 2023-12-31 0000109657 GTBP:TwoThousandTwentyWarrantsMember 2023-01-01 2023-12-31 0000109657 GTBP:PurchaseAgreementMember 2024-05-23 2024-05-23 0000109657 us-gaap:CommonStockMember GTBP:PurchaseAgreementMember 2024-05-23 0000109657 GTBP:TwentyTwentyFourCommonWarrantsMember GTBP:PurchaseAgreementMember 2024-05-23 0000109657 GTBP:TwentyTwentyFourPlacementAgentWarrantMember GTBP:PurchaseAgreementMember 2024-05-23 0000109657 GTBP:TwentyTwentyFourCommonSharesAndTwentyTwentyFourCommonWarrantsMember GTBP:PurchaseAgreementMember 2024-05-23 0000109657 GTBP:PurchaseAgreementMember 2023-01-04 2023-01-04 0000109657 us-gaap:CommonStockMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:PrefundedWarrantMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:TwentyTwentyThreeCommonWarrantsMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:TwentyTwentyThreePlacementAgentWarrantMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:PurchaseAgreementMember GTBP:PreFundedWarrantsMember 2023-01-04 0000109657 GTBP:PlacementAgentWarrantMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:TwentyTwentyThreeCommonSharesAndTwentyTwentyThreeCommonWarrantsMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:PreFundedWarrantsAndTwentyTwentyThreeCommonWarrantsMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:CommonWarrantAndPlacementAgentWarrantMember 2023-01-04 2023-01-04 0000109657 GTBP:BoardOfDirectorsEmployeesAndConsultantsMember 2024-01-01 2024-09-30 0000109657 GTBP:SeriesKPreferredStocksMember 2021-02-16 2021-02-16 0000109657 GTBP:SeriesKPreferredStocksMember 2021-02-16 0000109657 GTBP:SeriesKPreferredStockMember 2024-09-30 0000109657 GTBP:SeriesKPreferredStockMember 2023-12-31 0000109657 GTBP:WarrantsMember 2024-01-01 2024-09-30 0000109657 GTBP:OmnibusIncentivePlanMember 2022-04-01 2022-04-30 0000109657 GTBP:OmnibusIncentivePlanMember 2024-01-01 2024-09-30 0000109657 2023-05-15 2023-05-15 0000109657 2023-05-15 0000109657 2023-01-27 2023-01-27 0000109657 2023-01-27 0000109657 GTBP:WarrantsMember GTBP:RangeOneMember 2024-01-01 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeOneMember 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeTwoMember 2024-01-01 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeTwoMember 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeThreeMember 2024-01-01 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeThreeMember 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeFourMember 2024-01-01 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeFourMember 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeFiveMember 2024-01-01 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeFiveMember 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeSixMember 2024-01-01 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeSixMember 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeSevenMember 2024-01-01 2024-09-30 0000109657 GTBP:WarrantsMember GTBP:RangeSevenMember 2024-09-30 0000109657 GTBP:WarrantsMember 2024-09-30 0000109657 GTBP:RangeOneMember 2024-01-01 2024-09-30 0000109657 GTBP:RangeOneMember 2024-09-30 0000109657 GTBP:RangeTwoMember 2024-01-01 2024-09-30 0000109657 GTBP:RangeTwoMember 2024-09-30 0000109657 GTBP:RangeThreeMember 2024-01-01 2024-09-30 0000109657 GTBP:RangeThreeMember 2024-09-30 0000109657 GTBP:CytovanceBiologicsIncMember 2022-08-24 0000109657 GTBP:CytovanceBiologicsIncMember 2024-04-25 0000109657 GTBP:CytovanceBiologicsIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0000109657 GTBP:CytovanceBiologicsIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000109657 GTBP:CytovanceBiologicsIncMember 2024-06-30 0000109657 GTBP:TwoThousandTwentyOneScientificResearchAgreementMember 2021-06-16 2021-06-16 0000109657 GTBP:TwoThousandTwentyOneScientificResearchAgreementMember 2024-01-01 2024-09-30 0000109657 GTBP:TwoThousandTwentyOneScientificResearchAgreementMember 2023-01-01 2023-09-30 0000109657 GTBP:TwoThousandTwentyOneScientificResearchAgreementMember 2024-09-30 0000109657 GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember 2024-05-20 2024-05-20 0000109657 GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember 2024-01-01 2024-09-30 0000109657 GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember 2023-01-01 2023-09-30 0000109657 GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember 2024-09-30 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember GTBP:TwoThousandSeventeenThroughTwoThousandTwentyMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember srt:MaximumMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember GTBP:TwoThousandTwentyTwoMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember GTBP:TwoThousandTwentyFiveMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember GTBP:TwoThousandTwentySevenMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember GTBP:TwoThousandTwentyFiveMember 2024-05-13 2024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2024-05-13 2024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember srt:MinimumMember 2024-05-13 2024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember srt:MaximumMember 2024-05-13 2024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2024-01-01 2024-09-30 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2023-01-01 2023-09-30 0000109657 GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-26 2021-03-26 0000109657 GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-26 0000109657 srt:MinimumMember GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-26 2021-03-26 0000109657 srt:MaximumMember GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-26 2021-03-26 0000109657 us-gaap:SubsequentEventMember srt:OfficerMember 2024-10-17 2024-10-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft

Â Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â â˜’ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Â For the quarterly period ended September 30, 2024. Â â˜ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Â For the transition period from __________ to ____________. Â Commission File Number 001-40023 Â GT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Â Delaware Â 94-1620407 (State or other jurisdiction of incorporation or organization) Â (I.R.S. Employer Identification Number) Â (Address not applicable1) Â 415-919-4040 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of Each Class Â Trading Symbol Â Name of exchange on which registered Common Stock, $0.001 par value per share Â GTBP Â Nasdaq Capital Market Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜’ Smaller reporting company â˜’ Emerging growth company â˜ Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜' Â As of November 10, 2024, the registrant had 2,234,328 shares of common stock outstanding. Â 1 Effective as of July 1, 2024, the Company became a fully remote company. We do not maintain a principal executive office. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to the Companyâ€™s principal executive offices may be directed to 315 Montgomery Street, 10th Floor, San Francisco, California 94104, or by email to auditcommittee@gtbiopharma.com. Â Â Â Â Â Â GT Biopharma, Inc. and Subsidiaries FORM 10-Q For the Nine Months Ended September 30, 2024 Table of Contents Â Â Â Page PART I FINANCIAL INFORMATION Â Item 1. Financial Statements Â Â Condensed Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and December 31, 2023 3 Â Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (Unaudited) 4 Â Condensed Consolidated Statements of Stockholdersâ€™ Equity for the three and Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (Unaudited) 5 Â Condensed Consolidated Statements of Cash Flows for the Condensed Consolidated Statements of Operations for the nine months ended September 30, 2024 and 2023 (Unaudited) 7 Â Condensed Notes to Consolidated Financial Statements (Unaudited) 8 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3. Quantitative and Qualitative Disclosures About Market Risk 28 Item 4. Controls and Procedures 28 Â Â Â PART II OTHER INFORMATION Item 1. Legal Proceedings 29 Item 6. Exhibits 30 Â Â Â SIGNATURES 31 Â 2 Â Â GT BIOPHARMA, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets Â Â Â September 30, 2024Â Â December 31, 2023Â Â Â (Unaudited)Â Â Â Â ASSETSÂ Â Â Â Â Â Â Â Current assetsÂ Â Â Â Â Â Â Â Cash and cash equivalentsÂ $6,418,000Â Â $1,079,000Â Restricted cashÂ Â 93,000Â Â Â â€"Â Short-term investmentsÂ Â â€"Â Â Â 12,893,000Â Prepaid expenses and other current assetsÂ Â 248,000Â Â Â 84,000Â Total Current AssetsÂ Â 6,759,000Â Â Â 14,056,000Â Â Â Â Â Â Â Â Â Â Operating lease right-of-use assetÂ Â â€"Â Â Â 53,000Â TOTAL ASSETSÂ $6,759,000Â Â $14,109,000Â Â Â Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITYÂ Â Â Â Â Â Â Â Current liabilitiesÂ Â Â Â Â Â Â Â Accounts payableÂ $2,612,000Â Â $4,328,000Â Accrued expensesÂ Â 1,868,000Â Â Â 1,195,000Â Current operating lease liabilityÂ Â â€"Â Â Â 58,000Â Warrant liabilityÂ Â 182,000Â Â Â 1,052,000Â Total Current LiabilitiesÂ Â 4,662,000Â Â Â 6,633,000Â Â Â Â Â Â Â Â Â Â Stockholdersâ€™ EquityÂ Â Â Â Â Â Â Â Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectivelyÂ Â 1,000Â Â Â 1,000Â Common stock, par value $0.001, 250,000,000 shares authorized, 2,234,328 and 1,380,633 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectivelyÂ Â 2,000Â Â Â 1,000Â Additional paid in capitalÂ Â 693,546,000Â Â Â 689,539,000Â Accumulated deficitÂ Â (691,452,000)Â Â (682,065,000) Total Stockholdersâ€™ EquityÂ Â 2,097,000Â Â Â 7,476,000Â TOTAL LIABILITIES AND STOCKHOLDERSâ€™ EQUITYÂ $6,759,000Â Â $14,109,000Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â 3 Â Â GT BIOPHARMA, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â For The Three Months EndedÂ Â For the Nine Months EndedÂ Â Â September 30,Â Â September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Â (Unaudited)Â Â (Unaudited)Â Â (Unaudited)Â Â (Unaudited)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating Expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ $1,307,000Â Â $1,364,000Â Â $3,868,000Â Â $5,109,000Â Selling, general and administrative (including $0 and $547,000 from stock compensation granted to officers, directors, and employees and for services for the three months ended September 30, 2024 and 2023, respectively, and $222,000 and $1,767,000 for the nine months ended September 30, 2024 and 2023, respectively)Â Â 2,297,000Â Â Â 1,758,000Â Â Â 6,733,000Â Â Â 5,299,000Â Loss from OperationsÂ Â (3,604,000)Â Â (3,122,000)Â Â (10,601,000)Â Â (10,408,000) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Other Income (Expense)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest incomeÂ Â 96,000Â Â Â 216,000Â Â Â 343,000Â Â Â 600,000Â Interest expenseÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â (213,000) Change in fair value of warrant liabilityÂ Â 95,000Â Â Â 485,000Â Â Â 870,000Â Â Â 4,796,000Â Gain on extinguishment of debtÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 547,000Â Unrealized gain on marketable securitiesÂ Â 2,000Â Â Â 5,000Â Â Â 1,000Â Â Â 43,000Â Total Other Income, NetÂ Â 193,000Â Â Â 706,000Â Â Â 1,214,000Â Â Â 5,773,000Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net LossÂ $(3,411,000)Â $(2,416,000)Â $(9,387,000)Â $(4,635,000) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net Loss Per Share - Basic and DilutedÂ $(1.53)Â $(1.77)Â $(5.28)Â $(3.47) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average common shares outstanding - basic and dilutedÂ Â 2,234,328Â Â Â 1,367,206Â Â Â 1,777,313Â Â Â 1,336,532Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â 4 Â Â GT BIOPHARMA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY For The Three and Nine Months Ended September 30, 2024 (Unaudited): Â Preferred SharesÂ Â Common SharesÂ Â Additional Paid inÂ Â AccumulatedÂ Â Â Â Â Â SharesÂ Â AmountÂ Â SharesÂ Â AmountÂ Â CapitalÂ Â DeficitÂ Â TotalÂ Balance, June 30, 2024Â Â 96,230Â Â $1,000Â Â Â 2,234,328Â Â $2,000Â Â $693,546,000Â Â $(688,041,000)Â $5,508,000Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â (3,411,000)Â Â (3,411,000) Balance, September 30, 2024Â Â 96,230Â Â $1,000Â Â Â 2,234,328Â Â $2,000Â Â $693,546,000Â Â $(691,452,000)Â $2,097,000Â Â Â Â Preferred SharesÂ Â Common SharesÂ Â Additional Paid inÂ Â AccumulatedÂ Â Â Â Â Â SharesÂ Â AmountÂ Â SharesÂ Â AmountÂ Â CapitalÂ Â DeficitÂ Â TotalÂ Balance, December 31, 2023Â Â 96,230Â Â $1,000Â Â Â 1,380,633Â Â $1,000Â Â $689,539,000Â Â $(682,065,000)Â $7,476,000Â Issuance of common stock and warrants for cashÂ Â -Â Â Â -Â Â Â 740,000Â Â Â 1,000Â Â Â 2,975,000Â Â Â -Â Â Â 2,976,000Â Cancellation of common stock issued to prior CFOÂ Â -Â Â Â -Â Â Â (13,902)Â Â -Â Â Â -Â Â Â -Â Â Â -Â Issuance of common shares to settle vendor payableÂ Â -Â Â Â -Â Â Â 127,597Â Â Â -Â Â Â 810,000Â Â Â -Â Â Â 810,000Â Fair value of vested stock optionsÂ Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â 222,000Â Â Â -Â Â Â 222,000Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â (9,387,000)Â Â (9,387,000) Balance, September 30, 2024Â Â 96,230Â Â $1,000Â Â Â 2,234,328Â Â $2,000Â Â $693,546,000Â Â $(691,452,000)Â $2,097,000Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â 5 Â Â GT BIOPHARMA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY For The Three and Nine Months Ended September 30, 2023 (Unaudited): Â Preferred SharesÂ Â Common SharesÂ Â Additional Paid inÂ Â AccumulatedÂ Â Â Â Â Â SharesÂ Â AmountÂ Â SharesÂ Â AmountÂ Â CapitalÂ Â DeficitÂ Â TotalÂ Balance, June 30, 2023Â Â 96,230Â Â $1,000Â Â Â 1,354,656Â Â $1,000Â Â $688,448,000Â Â $(676,687,000)Â $11,763,000Â Issuance of common shares for servicesÂ Â -Â Â Â -Â Â Â 13,333Â Â Â 1,000Â Â Â 114,000Â Â Â -Â Â Â 115,000Â Issuance of common shares to settle vendor payableÂ Â -Â Â Â -Â Â Â 12,644Â Â Â -Â Â Â 110,000Â Â Â -Â Â Â 110,000Â Fair value of vested stock optionsÂ Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â 433,000Â Â Â -Â Â Â 433,000Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â (2,416,000)Â Â (2,416,000) Balance, September 30, 2023Â Â 96,230Â Â $1,000Â Â Â 1,380,633Â Â $2,000Â Â $689,105,000Â Â $(679,103,000)Â $10,005,000Â Â Â Â Preferred SharesÂ Â Common SharesÂ Â Additional Paid inÂ Â AccumulatedÂ Â Â Â Â Â SharesÂ Â AmountÂ Â SharesÂ Â AmountÂ Â CapitalÂ Â DeficitÂ Â TotalÂ Balance, December 31, 2022Â Â 96,230Â Â $1,000Â Â Â 1,090,748Â Â $1,000Â Â $686,200,000Â Â $(674,467,000)Â $11,734,000Â BalanceÂ Â 96,230Â Â $1,000Â Â Â 1,090,748Â Â $1,000Â Â $686,200,000Â Â $(674,467,000)Â $11,734,000Â Private placement of common stockÂ Â -Â Â Â -Â Â Â 120,000Â Â Â -Â Â Â 6,268,000Â Â Â -Â Â Â 6,268,000Â Issuance of common stock for exercise of prefunded warrantsÂ Â -Â Â Â -Â Â Â 96,666Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Initial recognition of fair value of warrant liabilityÂ Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â (5,831,000)Â Â -Â Â Â (5,831,000) Issuance of common shares for servicesÂ Â -Â Â Â -Â Â Â 15,782Â Â Â 1,000Â Â Â 429,000Â Â Â -Â Â Â 430,000Â Issuance of common shares to settle vendor payableÂ Â -Â Â Â -Â Â Â 57,437Â Â Â -Â Â Â 701,000Â Â Â -Â Â Â 701,000Â Fair value of vested stock optionsÂ Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â 1,338,000Â Â Â -Â Â Â 1,338,000Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â (4,635,000)Â Â (4,635,000) Balance, September 30, 2023Â Â 96,230Â Â $1,000Â Â Â 1,380,633Â Â $2,000Â Â $689,105,000Â Â $(679,103,000)Â $10,005,000Â BalanceÂ Â 96,230Â Â $1,000Â Â Â 1,380,633Â Â $2,000Â Â $689,105,000Â Â $(679,103,000)Â $10,005,000Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â 6 Â Â GT BIOPHARMA, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows Â Â Â Â Â Â Â Â Â Â Â For The Nine Months EndedÂ Â Â September 30,Â Â Â 2024Â Â 2023Â Â Â (Unaudited)Â Â (Unaudited)Â CASH FLOWS FROM OPERATING ACTIVITIESÂ Â Â Â Â Â Â Â Net lossÂ $(9,387,000)Â $(4,635,000) Adjustments to reconcile net loss to net cash used in operating activities:Â Â Â Â Â Â Â Â Stock based compensation â€" servicesÂ Â â€"Â Â Â 430,000Â Stock based compensation - officers, directors, and employeesÂ Â 222,000Â Â Â 1,337,000Â Change in fair value of warrant liabilityÂ Â (870,000)Â Â (4,796,000) Gain on extinguishment of share settled debtÂ Â â€"Â Â Â (547,000) Change in operating lease right-of-use assetsÂ Â 53,000Â Â Â 78,000Â Unrealized loss (gain) on marketable securitiesÂ Â 1,000Â Â Â (43,000) Changes in operating assets and liabilities:Â Â Â Â Â Â Â Â Decrease in prepaid expensesÂ Â (164,000)Â Â 16,000Â Increase (Decrease) in accounts payable and accrued expensesÂ Â (233,000)Â Â 1,437,000Â (Decrease) in operating lease liabilityÂ Â (58,000)Â Â (82,000) Net Cash Used in Operating ActivitiesÂ Â (10,436,000)Â Â (6,805,000) Â Â Â Â Â Â Â Â Â CASH FLOWS FROM INVESTING ACTIVITIESÂ Â Â Â Â Â Â Â Sale (Purchase) of investmentsÂ Â 12,892,000Â Â Â (2,487,000) Net Cash Provided by (Used in) Investing ActivitiesÂ Â 12,892,000Â Â Â (2,487,000) Â Â Â Â Â Â Â Â Â CASH FLOWS FROM FINANCING ACTIVITIESÂ Â Â Â Â Â Â Â Proceeds from issuance of common stock and warrants, netÂ Â 2,976,000Â Â Â 6,268,000Â Net Cash Provided by Financing ActivitiesÂ Â 2,976,000Â Â Â 6,268,000Â Â Â Â Â Â Â Â Â Â Net Increase (Decrease) in Cash and Cash Equivalents and Restricted CashÂ Â 5,432,000Â Â Â (3,024,000) Cash and Cash Equivalents and Restricted Cash at Beginning of PeriodÂ Â 1,079,000Â Â Â 5,672,000Â Cash and Cash Equivalents and Restricted Cash at End of PeriodÂ $6,511,000Â Â $2,648,000Â Â Â Â Â Â Â Â Â Â SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:Â Â Â Â Â Â Â Â Cash paid during the year for:Â Â Â Â Â Â Â Â InterestÂ $â€"Â Â $â€"Â Income taxesÂ $â€"Â Â $â€"Â Â Â Â Â Â Â Â Â Â SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIESÂ Â Â Â Â Â Â Â Initial recognition of fair value of warrant liabilityÂ $â€"Â Â $5,831,000Â Fair value of common stock issued to a vendor to settle accounts payableÂ $810,000Â Â $700,000Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â 7 Â Â GT BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Nine Months Ended September 30, 2024 and 2023 (Unaudited) Â Note 1 â€" Organization and Going Concern Analysis Â Organization Â The corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data, Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March 11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc. Â Throughout this Quarterly Report on Form 10-Q, the terms â€œGTBP,â€ â€œwe,â€ â€œus,â€ â€œour,â€ â€œthe Companyâ€ and â€œour Companyâ€ refer to GT Biopharma, Inc. Â The GT Biopharma logo, TriKEÂ®, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders. Â The Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKEÂ®), and Tetra-specific Killer Engager (Dual Targeting TriKEÂ®) platforms. The Companyâ€™s TriKEÂ® and Dual Targeting TriKEÂ® platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patientâ€™s own natural killer cells (NK cells). Â Going Concern Analysis Â The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The Company has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company has financed its operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and strategic collaborations. For the nine months ended September 30, 2024, the Company recorded a net loss of approximately $9.4 million and used cash in operations of approximately $10.4 million. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year of the date that the financial statements are issued. Â The unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. Â The Company has evaluated the significance of the uncertainty regarding the Companyâ€™s financial condition in relation to its ability to meet its obligations, which has raised substantial doubt about the Companyâ€™s ability to continue as a going concern. While it is very difficult to estimate the Companyâ€™s future liquidity requirements, the Company believes if it is unable to obtain additional financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from the date the accompanying unaudited condensed consolidated financial statements are issued. There can be no assurances that the Company will be able to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Companyâ€™s business prospects, ability to meet long-term liquidity needs and the ability to continue operations. Â Note 2 â€" Summary of Significant Accounting Policies Â Basis of Presentation and Principles of Consolidation Â The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation. Â 8 Â Â The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€) and applicable rules and regulations of the Securities and Exchange Commission (â€œSECâ€) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the â€œ2023 Annual Reportâ€). The consolidated balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date. Â In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Companyâ€™s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results. Â Accounting Estimates Â The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include managementâ€™s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax assets. Â Cash Equivalents and Short-Term Investments Â The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying unaudited condensed consolidated financial statements. At September 30, 2024 total cash equivalents which consist of money market funds and US treasuries, amounted to approximately $6.2 million. At December 31, 2023 total cash equivalents which consist of money market funds, amounted to approximately $443,000. Â Management generally determines the appropriate classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying unaudited condensed consolidated statements of operations. At September 30, 2024 and December 31, 2023, total short-term investments which consist of US treasuries and US government agencies, amounted to approximately $0 and $12.9 million, respectively. Â Restricted Cash Â As of September 30, 2024, the Company has classified certain cash balances as restricted cash in its unaudited condensed consolidated balance sheets. The Companyâ€™s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with the same financial institution. Â Fair Value of Financial Instruments Â Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. Â The three levels of the fair value hierarchy are as follows: Â Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. Â Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. Â Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Â 9 Â Â The carrying amounts of the Companyâ€™s other financial assets and liabilities, such as cash and cash equivalents, short term investments, prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity of these instruments. Â The carrying amount of the Companyâ€™s warrant liability of $182,000 and $1.1 million at September 30, 2024 and December 31, 2023, respectively, was based on Level 3 measurements. Â Warrant Liability Â The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, â€œDerivatives and Hedgingâ€ (â€œASC 815â€). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Â The Companyâ€™s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes. Â Common Stock (February 2024 Reverse Stock Split) Â On February 2, 2024, the Company effectuated a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30. The Companyâ€™s common stock began trading on a reverse stock-split-adjusted basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol â€œGTBP.â€ Â As a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission and other expenses). The reverse stock split reduced the number of shares of common stock outstanding on the effective date of the reverse stock-split from 41,419,000 shares to 1,380,633 shares, subject to minor adjustments due to the treatment of fractional shares. The number of authorized shares of common stock remains unchanged at 250,000,000 shares. Â Proportionate adjustments have been made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise of outstanding stock options and warrants for the Companyâ€™s common stock, and to the number of shares of common stock reserved for future issuance pursuant to the Companyâ€™s 2022 Omnibus Incentive Plan. Â All share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest period presented. Â Stock-Based Compensation Â The Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Â Stock-based payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods. Â Research and Development Expenses Â Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Companyâ€™s products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed. Â 10 Â Â Leases Â The Company accounts for its lease in accordance with the guidance of ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Companyâ€™s right to use an underlying asset during the lease term, and lease liabilities represent the Companyâ€™s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. Â In June 2024, the Companyâ€™s lease expired and was not renewed. Â Net Loss Per Share Â Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Â The following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive: Â Schedule of Anti-dilutive Securities Â Â September 30, 2024 (Unaudited)â€¯â€¯Â Â September 30, 2023 (Unaudited)â€¯â€¯Â Options to purchase common stockÂ Â 101,264Â Â Â 124,599Â Warrants to purchase common stockÂ Â 1,133,762Â Â Â 304,962Â Total anti-dilutive securitiesÂ Â 1,235,026Â Â Â 429,561Â Â Concentration Â Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (â€œFDICâ€) insurance limits of up to $250,000. Management believes that the financial institutions that hold the Companyâ€™s cash are financially sound and, accordingly, minimal credit risk exists. Â The Company has a significant concentration of expenses incurred from and accounts payable and accrued expenses to Cytovance, a related party, and the University of Minnesota, see Note 4 â€“ Accounts Payable and Related Party. Â Segments Â The Company determined its reporting units in accordance with â€œSegment Reportingâ€ (â€œASC 280â€). Management evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated. Â Management has determined that the Company has one consolidated operating segment. The Companyâ€™s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Companyâ€™s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments. As a result no further segment information is presented in these consolidated financial statements. Â Recent Accounting Pronouncements Â In November 2023, the FASB issued ASU No. 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosuresâ€ (â€œASU 2023-07â€), which introduces new reportable segment disclosure requirements related to significant segment expenses and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable segmentâ€™s profits and losses. This standard became effective for the Company on January 1, 2024. The adoption of this standard did not have a material impact on the Companyâ€™s results of operations, financial position or cash flows. Â The Companyâ€™s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Companyâ€™s financial position and results of operations. Â 11 Â Â Note 3 â€“ Fair Value of Financial Instruments Â Financial Assets Â The following table represents the estimated fair values of the Companyâ€™s financial instruments: Â Schedule of Estimated Fair Value of Financial Instrument Â Â September 30, 2024 (Unaudited) Â Â Â Â Â Â Unrealized Â Â Unrealized Â Â Fair Â Â Â Cost Â Â Gains Â Â Losses Â Â Value Â Short-term investments Â $ â€” Â Â $ Â â€” Â Â $ â€” Â Â $ â€” Â Total Â $ â€” Â Â $ Â â€” Â Â $ â€” Â Â $ â€” Â Â Â Â Â December 31, 2023Â Â Â Â Â Â UnrealizedÂ Â UnrealizedÂ Â FairÂ Â Â CostÂ Â GainsÂ Â LossesÂ Â ValueÂ Short-term investmentsÂ $12,845,000Â Â $48,000Â Â $â€”Â Â $12,893,000Â TotalÂ $12,845,000Â Â $48,000Â Â $â€”Â Â $12,893,000Â Â The following table represents the Companyâ€™s fair value hierarchy for its financial assets (cash equivalents and investments): Â Schedule of Fair Value Hierarchy Financial Assets Â Â Fair ValueÂ Â Level 1Â Â Level 2Â Â Level 3Â Â Â September 30, 2024 (Unaudited)Â Â Â Fair ValueÂ Â Level 1Â Â Level 2Â Â Level 3Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market fundsÂ $1,220,000Â Â $1,220,000Â Â $â€”Â Â $â€”Â US treasuriesÂ Â 4,987,000Â Â Â â€”Â Â Â 4,987,000Â Â Â â€”Â Short-term investments:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â US treasuriesÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Total financial assetsÂ $6,207,000Â Â $1,220,000Â Â $4,987,000Â Â $â€”Â Â Â Â Fair Value Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â December 31, 2023 Â Â Â Fair Value Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 443,000 Â Â $ 443,000 Â Â $ â€” Â Â $ â€” Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â US treasuries and US govâ€™t. agencies Â Â 12,893,000 Â Â Â â€” Â Â Â 12,893,000 Â Â Â â€” Â Total financial assets Â $ 13,336,000 Â Â $ 443,000 Â Â $ 12,893,000 Â Â $ â€” Â Â Warrant Liability Â For the details of warrant liability transactions see Note 5 â€“ Warrant Liability. Â Note 4 â€“ Accounts Payable and Related Party Â Accounts payable consists of the following: Â Schedule of Accounts Payable Â Â As of Â Â As of Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â (Unaudited) Â Â Â Â Accounts payable to Cytovance, a related party 1 Â $ 638,000 Â Â $ 3,515,000 Â Accounts payable to University of Minnesota Â Â 697,000 Â Â Â 130,000 Â Other accounts payable Â Â Â 1,277,000 Â Â Â Â 683,000 Â Total accounts payable Â $ 2,612,000 Â Â $ 4,328,000 Â Â 1Accounts Payable to Cytovance Biologics, Inc. (â€œCytovanceâ€), a Related Party, since Cytovance owns greater than 5% of the Companyâ€™s issued and outstanding common stock Â 12 Â Â See Note 8 â€“ Commitments and Contingencies, Significant Agreements. Â The details of the Companyâ€™s accounts payable to Cytovance Biologics, Inc., were as follows: Â Schedule of Accounts Payable to Related Party Â Â September 30, 2024Â Â September 30, 2023Â Â Â Nine Months EndingÂ Â Â September 30, 2024Â Â September 30, 2023Â Â Â (Unaudited)Â Â (Unaudited)Â Beginning balanceÂ $3,515,000Â Â $2,283,000Â Invoices, netÂ Â 1,365,000Â Â Â 3,691,000Â Payments in cashÂ Â (3,432,000)Â Â (1,710,000) Payments in common stock, at fair valueÂ Â (810,000)Â Â (1,120,000) Ending balanceÂ $638,000Â Â $3,144,000Â Â University of Minnesota Â See Note 8 â€“ Commitments and Contingencies, Significant Agreements. Â Note 5 â€“ Warrant Liability Â 2023 Warrants Â On January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate of 216,667 shares of the Companyâ€™s common stock (the â€œ2023 Common Warrantsâ€), and placement agent warrants to purchase up to 13,000 shares of the Companyâ€™s common stock (the â€œ2023 Placement Agents Warrantsâ€). Â The 2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the â€œ2023 Warrantsâ€), provide for a value calculation for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides for a floor on the volatility amount utilized in the value calculation at 100% or greater. The Company has determined this provision introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Companyâ€™s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability in its consolidated balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is evaluated at the end of each reporting period. Â The 2023 Warrants were initially recorded at a fair value at $5.8 million at the grant date, and upon the closing of placement, was recorded as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Companyâ€™s unaudited condensed consolidated balance sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed consolidated statements of operations until they are either exercised or expired. Â The 2023 Warrant liability is valued using a Binomial pricing model with the following assumptions: Â Schedule of Derivative Liabilities Assumptions Â Â 2023 WarrantsÂ Â Â September 30, 2024Â Â December 31, 2023Â Â Â (Unaudited)Â Â (Unaudited)Â Stock priceÂ $2.31Â Â $7.20Â Risk-free interest rate 1Â Â 3.58%Â Â 4.6% Expected volatility 2Â Â 114%Â Â 119.7% Expected life (in years) 3Â Â 3.25 â€“ 3.75Â Â Â 4.5Â Expected dividend yield 4Â Â â€”Â Â Â â€”Â Fair value of warrantsÂ $182,000Â Â $1,051,000Â Â 1Based on rates established by the Federal Reserve Bank 2Historical volatility of the Companyâ€™s common stock is used to estimate the future volatility of its common stock 3Determined by the remaining contractual life of the derivative instrument 4Based on no dividends paid or expected to be paid Â 13 Â Â 2020 Warrants Â The Company issued warrants underlying 58,824 shares of common stock during the year ended December 31, 2020 (the â€œ2020 Warrantsâ€), that contained a fundamental transaction provision that could give rise to an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance with ASC 480, the fair value of the 2020 Warrants is classified as a liability in the Companyâ€™s unaudited condensed consolidated balance sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed consolidated statements of operations until they are either exercised or expire. Â The 2020 Warrant liability is valued using a Binomial pricing model with the following assumptions: Â Schedule of Derivative Liabilities Assumptions Â Â 2020 WarrantsÂ Â Â September 30, 2024Â Â September 30, 2023Â Â Â (Unaudited)Â Â Â Â Stock priceÂ $2.31Â Â $7.20Â Risk-free interest rate 1Â Â 3.98%Â Â 5.0% Expected volatility 2Â Â 114%Â Â 89.0% Expected life (in years) 3Â Â 0.8Â Â Â 1.8Â Expected dividend yield 4Â Â â€”Â Â Â â€”Â Fair value of warrantsÂ $â€”Â Â $2,000Â 1Based on rates established by the Federal Reserve Bank 2Historical volatility of the Companyâ€™s common stock is used to estimate the future volatility of its common stock 3Determined by the remaining contractual life of the derivative instrument 4Based on no dividends paid or expected to be paid Â Warrant Liability Â The details of warrant liability transactions were as follows: Â Schedule of Derivative Liability Transactions Â Â September 30, 2024Â Â September 30, 2023Â Â Â Nine Months EndingÂ Â Â September 30, 2024Â Â September 30, 2023Â Â Â (Unaudited)Â Â (Unaudited)Â Beginning balanceÂ $1,052,000Â Â $18,000Â Issuance of warrants at fair valueÂ Â â€”Â Â Â 5,831,000Â Change in fair valueÂ Â (870,000)Â Â (4,796,000) ExtinguishmentÂ Â â€”Â Â Â â€”Â Ending balanceÂ $182,000Â Â $1,053,000Â Â Note 6 â€“ Stockholdersâ€™ Equity Â The Companyâ€™s authorized capital as of September 30, 2024 was 250,000,000 shares of common stock, par value $0.001 per share, and 15,000,000 shares of preferred stock, par value $0.01 per share. Â Common Stock Â 2024 Common Stock Offering Â On May 23, 2024, the Company received gross proceeds of approximately $3.2 million, before deducting placement agent fees and other offering expenses of $243,000 in relation to a purchase agreement (the â€œPurchase Agreementâ€) signed on May 21, 2024, between the Company and institutional investors (the â€œPurchasersâ€) for the issuance and sale, in a registered direct offering, of 740,000 shares of the Companyâ€™s common stock, par value $0.001 per share (the â€œ2024 Sharesâ€). In a concurrent private placement, the Company issued and sold to the Purchasers warrants to purchase 740,000 shares of the Companyâ€™s common stock (the â€œ2024 Common Warrantsâ€). In addition, the Company issued warrants to the placement agent to purchase 88,800 shares of common stock (the â€œ2024 Placement Agents Warrantsâ€). The 2024 Common Warrants have an exercise price equal to $4.35 per share, and the 2024 Placement Agents Warrants have an exercise price equal to $5.4375 per share, both are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial exercise date. The 2024 Shares and 2024 Common Warrants were sold at an offering price of $4.35 per share and accompanying 2024 Common Warrant. Â Pursuant to the Purchase Agreement, the Company agreed, with certain exceptions, for a period of 60 days following the closing of the offering not to issue, enter into an agreement to issue or announce the issuance or proposed issuance of the 2024 Shares or any other securities convertible into, or exercisable or exchangeable for, shares of the Companyâ€™s common stock. The Company has also agreed for a period of one year following the closing date of the offering not to (i) issue or agree to issue equity or debt securities convertible into, or exercisable or exchangeable for, shares at a conversion price, exercise price or exchange price which floats with the trading price of the 2024 Shares or which may be adjusted after issuance upon the occurrence of certain events or (ii) enter into any agreement, including an equity line of credit, whereby the Company may issue securities at a future-determined price. Â 14 Â Â The Company determined that under ASC 815-40, the 2024 Common Warrants and the 2024 Placement Agent Warrants do not contain a clause that adjusts the exercise price based on circumstances not considered to be within the Companyâ€™s control and are considered indexed to the Companyâ€™s own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2024 Common Warrants and the 2024 Placement Agent Warrants are classified as equity. Â 2023 Private Placement of Common Stock Â On January 4, 2023, the Company received gross proceeds of $6.5 million, before deducting placement agent fees and other offering expenses of $232,000 in relation to a purchase agreement signed on December 30, 2022, between the Company and an institutional investor for the issuance and sale, in a registered direct offering, of 120,000 shares of the Companyâ€™s common stock, par value $0.001 per share (the â€œ2023 Sharesâ€), pre-funded warrants to purchase up to 96,667 shares of the Companyâ€™s common stock (the â€œPre-Funded Warrantsâ€), warrants to purchase up to an aggregate of 216,667 shares of the Companyâ€™s common stock (the â€œ2023 Common Warrantsâ€) and placement agent warrants to purchase up to 13,000 of the Companyâ€™s common stock (the â€œ2023 Placement Agents Warrantsâ€). The 2023 Common Warrants have an exercise price equal to $30.00 per share, are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial issuance date. The Pre-Funded Warrants had an exercise price of $0.003 per share, are immediately exercisable and could be exercised at any time after their original issuance until such Pre-Funded Warrants were exercised in full. The 2023 Placement Agents Warrants have an exercise price equal to $37.50 per share, are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial issuance date. The 2023 Shares and 2023 Common Warrants were sold at an offering price of $30.00 per share and accompanying 2023 Common Warrant and the Pre-Funded Warrants and 2023 Common Warrants were sold at an offering price of $29.997 per Pre-Funded Warrant and accompanying 2023 Common Warrant. Â The 2023 Common Warrants and the 2023 Placement Agents Warrants contained a clause not considered to be within the Companyâ€™s control. The Company determined that the provision represented a variable that is not an input to the fair value of a â€œfixed-for-fixedâ€ option as defined under ASC 815-40, and thus the 2023 Common Warrants and the 2023 Placement Agent Warrants are not considered indexed to the Companyâ€™s own stock and not eligible for an exception from derivative accounting. Accordingly, the 2023 Common Warrants and the 2023 Placement Agent Warrants were classified as a warrant liability, and $5.8 million of the initial common stock offering was classified as a warrant liability (see Note 5 â€“ Warrant Liability). Â Common Stock Issued for Services Â During the nine months ended September 30, 2023, the Company issued 15,782 shares of common stock with a fair value of $430,000 to members of the Companyâ€™s Board of Directors (the â€œBoardâ€), employees, and consultants. The shares were valued at the respective date of the agreements. Â Preferred Stock Â Series C Preferred Stock Â As of September 30, 2024 and December 31, 2023, there were 96,230 shares of series C preferred stock, par value $0.01 per share (the â€œSeries C Preferred Stockâ€) issued and outstanding. Â As a result of reverse stock splits in previous years and the agreement terms for adjusting the rights of the related shares, the 96,230 shares of Series C Preferred Stock are not currently convertible, have no voting rights, and in the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through September 30, 2024 and 2023, respectively. Â Series K Preferred Stock Â On February 16, 2021, the Board designated 115,000 shares of Series K preferred stock, par value $.01 (the â€œSeries K Preferred Stockâ€). Â Shares of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Companyâ€™s common stock at an effective conversion rate of 100 shares of common stock for each share of Series K Preferred. Shares of the Series K Preferred Stock have the same voting rights as the shares of the Companyâ€™s common stock, with the holders of the Series K Preferred Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation, together with the holders of the Companyâ€™s common stock on all matters presented to the Companyâ€™s stockholders. The Series K Preferred Stock are not entitled to any dividends (unless specifically declared by the Board) but will participate on an as-converted-to-common-stock basis in any dividends to the holders of the Companyâ€™s common stock. In the event of the Companyâ€™s dissolution, liquidation or winding up, the holders of the Series K Preferred Stock will be on parity with the holders of the Companyâ€™s common stock and will participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Companyâ€™s common stock. Â As of September 30, 2024 and December 31, 2023, there were no shares of Series K Preferred stock issued and outstanding. Â 15 Â Â Note 7 â€“ Common Stock Warrants and Options Â Common Stock Warrants Â Stock warrant transactions for the six months ended September 30, 2024 were as follows: Â Schedule of Warrant Activity Â Â Nine Months Ended September 30, 2024Â Â Â Number ofÂ Â Weighted AverageÂ Â Â WarrantsÂ Â Exercise PriceÂ Warrants outstanding at December 31, 2023Â Â 304,962Â Â $63.30Â GrantedÂ Â 828,800Â Â Â 4.47Â Forfeited/cancelledÂ Â â€”Â Â Â â€”Â ExercisedÂ Â â€”Â Â Â â€”Â Warrants outstanding at September 30, 2024Â Â 1,133,762Â Â $20.57Â Warrants exercisable at September 30, 2024Â Â 1,133,762Â Â $20.57Â Â As of September 30, 2024, all outstanding warrants are fully vested and had an exercise price greater than the market price of the Companyâ€™s common stock, which resulted in no intrinsic value. Â Warrants outstanding as of September 30, 2024 are exercisable as follows: Â Schedule of Warrants Outstanding and Exercisable Â Â Â Warrants Outstanding and Exercisable as of September 30, 2024Â Range of Exercise PriceÂ Â Number OutstandingÂ Â Weighted Average Remaining Contractual Life (Years)Â Â Weighted Average Exercise PriceÂ $4.35Â Â Â 740,000Â Â Â 4.7Â Â $4.35Â Â 5.4375Â Â Â 88,800Â Â Â 4.6Â Â Â 5.4375Â Â 30.00Â Â Â 216,666Â Â Â 3.8Â Â Â 30.00Â Â 37.50Â Â Â 13,000Â Â Â 3.3Â Â Â 37.50Â Â 102.00Â Â Â 1,867Â Â Â 0.8Â Â Â 102.00Â Â 165.00Â Â Â 65,649Â Â Â 1.4Â Â Â 165.00Â Â 206.25Â Â Â 7,780Â Â Â 1.4Â Â Â 206.25Â Â Â Â Â Â 1,133,762Â Â Â 4.2Â Â Â 20.57Â Â Common Stock Options Â In April 2022 the Company established the 2022 Omnibus Incentive Plan (the â€œPlanâ€). The Plan was approved by our Board and stockholders. The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors, and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards granted under the Plan is 166,667. The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant under the Plan. As of September 30, 2024, there were 39,467 shares available for grant under the Plan. Â The following table summarizes stock option transactions for the nine months ended September 30, 2024: Â Schedule of Options Activity Â Â Nine Months Ended September 30, 2024Â Â Â Number ofÂ Â Weighted AverageÂ Â Â OptionsÂ Â Exercise PriceÂ Options outstanding at December 31, 2023Â Â 126,265Â Â $40.15Â GrantedÂ Â â€”Â Â Â â€”Â Forfeited/cancelledÂ Â (25,001)Â Â 14.80Â ExercisedÂ Â â€”Â Â Â â€”Â Options outstanding at September 30, 2024Â Â 101,264Â Â $39.74Â Options exercisable at September 30, 2024Â Â 101,264Â Â $39.74Â Â 16 Â Â The weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of September 30, 2024 was 8.2 years. Furthermore, all options outstanding and all options vested and exercisable as of September 30, 2024 had an exercise price greater than the market price of the Companyâ€™s common stock, which resulted in no intrinsic value. Â The total fair value of options that vested during the nine months ended September 30, 2024 and 2023, was $222,000 and $1,338,000, respectively, and is included in selling, general and administrative expense in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2024, all outstanding stock options were fully vested and exercisable and there was no unvested compensation expense. Â On May 15, 2023, the Company granted stock options to a member of the Board to purchase 16,666 shares of common stock. The stock options are exercisable at $10.50 per share, expire in 10 years, vest over twelve months and have a fair value of $150,000 on at the date of grant which will be amortized over the vesting period. Â On January 27, 2023, the Company granted stock options to employees and members of the Board to purchase an aggregate of 66,667 shares of common stock. The stock options are exercisable at $25.50 per share, expire in 10 years, vest over twelve months and have a fair value of $1.4 million at the date of grant which will be amortized over the vesting period. Â Options outstanding as of September 30, 2024 are exercisable as follows: Â Schedule of Options Outstanding and Options Exercisable Â Â Â Stock Options Outstanding and Exercisable as of September 30, 2024 Â Range of Exercise Price Â Â Number Outstanding Â Â Weighted Average Remaining Contractual Life (Years) Â Â Weighted Average Exercise Price Â $ 10.50 Â Â Â 16,666 Â Â Â 8.6 Â Â $ 10.50 Â Â 25.50 Â Â Â 50,000 Â Â Â 8.3 Â Â Â 25.50 Â Â 74.40 Â Â Â 34,598 Â Â Â 7.8 Â Â Â 74.40 Â Â Â Â Â Â 101,264 Â Â Â Â Â Â Â Â Â Â Note 8 â€“ Commitments and Contingencies Â Litigation Â The Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under, and are being handled in, the normal course of business: Â Ohri Matter Â On July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the Demand, the Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing that the Company may characterize Mr. Ohriâ€™s termination as â€œfor causeâ€ under his Employment Agreement, and that the Company may revoke the Separation Agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohriâ€™s breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohriâ€™s violations, and attorneysâ€™ fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Companyâ€™s claims against him and counterclaims for breach of his Employment Agreement and Separation Agreement. At this early stage in the proceedings the Company is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any. Â Berk Matter Â On November 14, 2023, former interim Chief Executive Officer, Dr. Gregory Berk filed a lawsuit in the US District Court for the District of Massachusetts alleging that the Company discriminated and retaliated against Dr. Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act (â€œSOXâ€). The Company vigorously defended this matter and believes it to be without merit; however, the parties have agreed to resolve the matter and the Company expects the lawsuit to be dismissed shortly. The Company believes it has recorded appropriate accruals for the matter. Â 17 Â Â TWF Global Matter Â On May 24, 2023, TWF Global, LLC (â€œTWFâ€) filed a Complaint in the California Superior Court for the County of Los Angeles naming the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (â€œNotesâ€) and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its Complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint for Interpleader against TWF and Z-One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine if the Companyâ€™s shares of common stock are properly registered to TWF or Z-One LLC, as both of these entities have made conflicting demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice and will reconsider the motion without further briefing upon the filing of a supplemental party affidavit. On May 9, 2024, Z-One filed a motion for summary judgement seeking dismissal of the action, representing that Z-One and TWF have settled their dispute over the entitlement to the Companyâ€™s shares of common stock and there is no remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of default. The Court has set a hearing on Z-Oneâ€™s motion for November 14, 2024. The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these claims. Â Significant Agreements Â Cytovance Biologics, Inc., a Related Party Â In October 2020, the Company entered into a Master Services Agreement with Cytovance Biologics, Inc. (â€œCytovanceâ€), to perform biologic development and manufacturing services, and to produce and test compounds used in the Companyâ€™s potential product candidates. The Company subsequently executed numerous Statements of Work (â€œSOWsâ€) for the research and development of products for use in clinical trials. Â On August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and allowed for future invoices to be settled in in a combination of cash and issuance of the Companyâ€™s common stock. The Agreement also set Cytovanceâ€™s beneficial ownership limitation at 4.9% of the issued and outstanding shares of the Companyâ€™s common stock. Â On April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovanceâ€™s beneficial ownership limitation to 9.9% of the issued and outstanding shares of the Companyâ€™s common stock. Â During the nine months ended September 30, 2024 and 2023, the Company recognized research and development expenses of $1,365,000 and $3,691,000, respectively and made cash payments amounting to $3,432,000 and $1,710,000, respectively to Cytovance. In addition, the Company issued 127,597 and 57,437 shares of common stock to Cytovance to settle accounts payable valued at approximately $810,000 and $1,120,000, respectively. Â On June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded 5% of the issued and outstanding shares of the Companyâ€™s common stock. Â As of September 30, 2024 the Companyâ€™s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from Cytovance for services that have not yet been rendered as of September 30, 2024, amounted to approximately $1.3 million. Â University of Minnesota Â 2021 Scientific Research Agreement Â Effective June 16, 2021, the Company entered into a scientific research agreement with the Regents of the University of Minnesota, expiring on June 30, 2023. Payments totaling approximately $2.1 million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work with the Company with three major goals in mind: (1) support the Companyâ€™s TriKEÂ® product development and GMP manufacturing efforts; (2) TriKEÂ® pharmacokinetics optimization in humans; and (3) investigation of the patientâ€™s native NK cell population based on insights obtained from the analysis of the human data generated during our GTB-3550 clinical trial. The major deliverables proposed are: (1) creation of IND enabling data for TriKEÂ® constructs in support of our product development and GMP manufacturing efforts; (2) TriKEÂ® platform drug delivery changes to allow transition to alternative drug delivery means and extended PK in humans; and (3) gain an increased understanding of changes in the patientâ€™s native NK cell population as a result of TriKEÂ® therapy. Most studies will use TriKEÂ® DNA/amino acid sequences created by the Company under existing licensing terms. Â The Company recorded an expense classified as research and development of approximately $0 and $192,000, pursuant to the 2021 Scientific Research Agreement, for the nine months ended September 30, 2024 and 2023, respectively. Â As of September 30, 2024 the Companyâ€™s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant to the 2021 Scientific Research Agreement for services that have not yet been rendered as of September 30, 2024, amounted to $0. Â 18 Â Â 2023 Sponsored Research Agreement Â On May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the â€œ2016 Exclusive Patent License Agreementâ€), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $1.7 million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work with the Company with three major goals in mind: (1) support the Companyâ€™s TriKEÂ® product development and commercial GMP manufacturing efforts; (2) TriKEÂ® pharmacokinetics optimization in humans and investigation of effects of altering the route of administration; and (3) research and development of TriKEÂ® platform. The major deliverables proposed are: (1) creation of IND enabling data for TriKEÂ® constructs in support of the Companyâ€™s product development and commercial GMP manufacturing efforts outside of the University of Minnesota; (2) TriKEÂ® platform drug delivery changes to allow transition from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ]) and extended PK in humans and gain an increased understanding of changes in the patientâ€™s native NK cell population as a result of alteration of TriKEÂ® administration; and (3) research and development of TriKEÂ® platform combination with other FDA approved (or soon to be approved) therapeutics and alterations to TriKEÂ® platform through formation of immune complexes. Most studies will use TriKEÂ® DNA/amino acid sequences created by the Company under existing licensing terms. Â The Company recorded an expense classified as research and development of approximately $863,000 and $0, pursuant to the 2023 Sponsored Research Agreement, for the nine months ended September 30, 2024 and 2023, respectively. Â As of September 30, 2024 the Companyâ€™s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of September 30, 2024, amounted to approximately $862,000. Â 2016 Exclusive Patent License Agreement Â Effective July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended, the â€œ2016 Exclusive Patent License Agreementâ€), to further develop and commercialize cancer therapies using TriKEÂ® technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement, the Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKEÂ® technology worldwide for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKEÂ® technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $200,000, and license maintenance fees of $200,000 for years 2017 through 2020, and $100,000 per year beginning in year 2021 and each year thereafter. The agreement also includes 4% royalty fees on the net sales of licensed products, not to exceed 6% under subsequent license agreements or amendments to this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $250,000 beginning in 2022, $2 million beginning in 2025, and $5 million beginning in 2027 throughout the remainder of the term. The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $3.1 million, and one-time sales milestone payments of $1 million upon reaching $250 million in cumulative gross sales, and $5 million upon reaching $500 million in cumulative gross sales of licensed products. Â Effective May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University of Minnesota. The amendment requires an upfront payment of $145,000 and amends the license maintenance fees to $50,000 in 2025, and $100,000 per year beginning in year 2026 and each year thereafter. The amendment also includes 1% to 5% royalty fees on the net sales of licensed products, not to exceed 6% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $250,000 in year one, $2 million in years two through five, and $5 million in year six throughout the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone payments totaling $3.1 million, and one-time sales milestone, and one-time sales milestone payments of $1 million upon reaching $250 million in cumulative gross sales, and $5 million upon reaching $500 million in cumulative gross sales of licensed products. Â The Company recorded an expense classified as research and development of $145,000 and $0, pursuant to the 2016 Exclusive Patent License Agreement, for the nine months ended September 30, 2024 and 2023, respectively. Â 2021 Exclusive License Agreement Â Effective March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the â€œ2021 Exclusive Patent License Agreementâ€), specific to the B7H3 targeted TriKEÂ®. The agreement requires an upfront payment of $20,000, and license maintenance fees of $5,000 per year beginning in year 2022 and each year thereafter. The agreement also includes 2.5% to 5% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $250,000 in year one though four, and $2 million beginning in year five and throughout the remainder of the term. The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $3.1 million, and one-time sales milestone payments of $1 million upon reaching $250 million in cumulative gross sales, and $5 million upon reaching $500 million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone. Â The Company did not incur any expenses pursuant to the 2021 Exclusive License Agreement, for the nine months ended September 30, 2024 and 2023, respectively. Â Note 9 â€“ Subsequent Events Â On October 17, 2024, the Company granted stock options to an officer to purchase an aggregate of 23,335 shares of common stock. The stock options are exercisable at $2.11 per share, expire in 10 years, vest over three years and have a fair value of approximately $45,000 at the date of grant which will be amortized over the vesting period. Â 19 Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. Â CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS Â Some of the statements in this Quarterly Report on Form 10-Q are â€œforward-looking statementsâ€ within the meaning of the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our current beliefs, goals and expectations about matters such as our expected financial position and operating results, our business strategy and our financing plans. The forward-looking statements in this report are not based on historical facts, but rather reflect the current expectations of our management concerning future results and events. The forward-looking statements generally can be identified by the use of terms such as â€œbelieve,â€ â€œexpect,â€ â€œanticipate,â€ â€œintend,â€ â€œplan,â€ â€œforesee,â€ â€œmay,â€ â€œguidance,â€ â€œestimate,â€ â€œpotential,â€ â€œoutlook,â€ â€œtarget,â€ â€œforecast,â€ â€œlikelyâ€ or other similar words or phrases. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance and achievements expressed or implied by these statements. We cannot guarantee that our forward-looking statements will turn out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than our expectations for various reasons. You should carefully review all information, including the discussion of risk factors under â€œPart I. Item 1A: Risk Factorsâ€ and â€œPart II. Item 7: Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ of the Form 10-K for the year ended December 31, 2023. Any forward-looking statements in the Form 10-Q are made only as of the date hereof and, except as may be required by law, we do not have any obligation to publicly update any forward-looking statements contained in this Form 10-Q to reflect subsequent events or circumstances. Â Organization Â The corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data, Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March 11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc. Â Overview Â We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based on our proprietary Tri-specific Killer Engager (TriKEÂ®), and Tetra-specific Killer Engager (Dual Targeting TriKEÂ®) fusion protein immune cell engager technology platforms. Our TriKEÂ® and Dual Targeting TriKEÂ® platforms generates proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patientâ€™s own natural killer cells, or NK cells. Once bound to an NK cell, our moieties are designed to enhance the NK cell, and precisely direct it to one or more specifically targeted proteins expressed on a specific type of cancer cell or virus infected cell, resulting in the targeted cellâ€™s death. TriKEÂ®s can be designed to target any number of tumor antigens on hematologic malignancies or solid tumors and do not require patient-specific customization. Â We are using our TriKEÂ® platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic malignancies, solid tumors, and potentially autoimmune disorders. The platform is scalable, and we are putting processes in place to be able to produce investigational new drug (IND) ready moieties in a timely manner after a specific TriKEÂ® conceptual design. Specific drug candidates can then be advanced into the clinic on our own or through potential collaborations with partnering companies. We believe our TriKEÂ®s may have the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies. Â Our initial work was conducted in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by Dr. Jeffrey Miller, Professor of Medicine, and the Deputy Director at the Center. Dr. Miller is a recognized key opinion leader in the field of NK cell and IL-15 biology and their therapeutic potential. We have exclusive rights to the TriKEÂ® platform and are generating additional intellectual property for specific moieties. Â 20 Â Â Our product pipeline as of September 30, 2024 is presented below: Â Â GTB-3550 Â GTB-3550 was our first TriKEÂ® product candidate. It reflected our first-generation TriKEÂ® platform. It is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. We studied this anti-CD16-IL-15-anti-CD33 TriKEÂ® in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia, or AML, and myelodysplastic syndrome, or MDS. CD33 is primarily a myeloid differentiation antigen with endocytic properties broadly expressed on AML blasts and, possibly, some leukemic stem cells. CD33 or Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC3, gp67, p67) is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells. The anti-CD33 antibody fragment used for these studies was derived from the M195 humanized anti-CD33 scFv and has been used in multiple human clinical studies. It has been exploited as a target for therapeutic antibodies for many years. We believe the approval of the antibody-drug conjugate gemtuzumab validates this targeted approach. Â GTB-3550 was replaced by a more potent next-generation camelid nanobody TriKEÂ®, GTB-3650, both targeting CD33 on relapsed/refractory AML and high-risk MDS. The pivot from GTB-3550 to GTB-3650 in our clinical development was based on a solid preclinical foundation that showed markedly enhanced potency of the camelid modification of the first-generation TriKEÂ®. This is illustrated below by better tumor control of AML bearing animals with GTB-3650 (purple dots) compared to GTB-3550 (blue dots). This provided the rationale for pausing further development of GTB-3550 and moving over to solely develop the second-generation TriKEÂ® platform. Â 21 Â Â Second Generation TriKEÂ®s Utilize Camelid Nanobody Technology Â Our goal is to be a leader in immuno-oncology therapies targeting a broad range of indications including hematological malignancies and solid tumors. A key element of our strategy includes introducing a next-generation camelid nanobody platform. Camelid antibodies (often referred as nanobodies) are smaller than human immunoglobulin and consist of two heavy chains. These nanobodies have the potential to have greater affinity to target antigens, potentially resulting in greater potency. We are utilizing this camelid antibody structure for all of our new TriKEÂ® product candidates. Â 22 Â Â To develop second generation TriKEÂ®s, we designed a new humanized CD16 engager derived from a single-domain antibody. While scFvs consist of a heavy and a light variable chain joined by a linker, single-domain antibodies consist of a single variable heavy chain capable of engaging without the need of a light chain counterpart (see figure below). Â Â These single-domain antibodies are thought to have certain attractive features for antibody engineering, including physical stability, ability to bind deep grooves, and increased production yields, amongst others. Pre-clinical studies demonstrated increased NK cell activation against CD33+ targets including enhanced NK cell degranulation (% CD107a+) and IFNg with the single-domain CD16 TriKEÂ® (cam 16-wt15-33; GTB-3650) compared to the original TriKEÂ® (scFv16-m 15-33; GTB-3550) (see figure below). This data was published by Dr. Felices M et al (2020) in Cancer Immunol Res. Â CD33+ HL60 Targets in Killing Assays Â The purple line represents the GTB-3650 and the blue line represents GTB-3550. Â Â GTB-3650 Â GTB-3650 is a CD33 targeted TriKEÂ® which targets CD33 on the surface of myeloid leukemias and an agonistic camelid engager to the potent activating receptor on NK cells, CD16. Use of this engager enhances the activity of wild type IL-15 included in GTB-3650, no longer needing the mutant IL-15 included in GTB-3550. The TriKEÂ® approach provides a novel way to specifically target these tumors by leveraging NK cells, which have been shown to mediate relapse protection in this setting, in an anti-CD33-targeted fashion. We are moving GTB-3650 clinically based on pre-clinical data showing a marked increase in potency compared to GTB-3550, which we anticipate could lead to an enhanced efficacy signal in AML and MDS. We have advanced GTB-3650 through preclinical studies and filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in December 2023. In late June 2024, we received clearance from the FDA with respect to our IND Application in relation to GTB 3650. We further anticipate approval to start study enrollment targeting patients with relapsed/refractory AML and high grade MDS in the second half of 2024. This initial study will test GTB-3650 as monotherapy testing administration 2 weeks on and two weeks off (to prevent NK cell exhaustion) for at least 2 cycles of therapy. The design of the trial has been agreed on with the FDA. Â 23 Â Â Â GTB-5550 Â GTB-5550 is a B7-H3 targeted TriKEÂ® which targets B7-H3 on the surface of advanced solid tumors (figure above). B7-H3 is an exciting target as it displays specific expression on a broad spectrum of solid tumor malignancies, allowing our team to target these malignancies through GTB-5550. Pre-clinical work has shown that this molecule has NK-cell targeted activity against a variety of solid tumor settings, including head and neck cancer squamous cell carcinoma (figure below), prostate cancer, breast cancer, ovarian cancer, glioblastoma, and lung cancer (amongst others). We are advancing GTB-5550 through preclinical studies and initiated a GMP manufacturing campaign in anticipation of filing an IND in the first half of 2025. A pre-IND packet was submitted to the FDA in October 2023 with a written response from the FDA in December 2023. The main question from the FDA was regarding pre-clinical toxicology and a pivot to subcutaneous dosing. The initial trial expected in 2025 is designed as a basket trial for patients with B7-H3+ solid tumors using Monday through Friday dosing (2 weeks on and 2 weeks off to prevent immune exhaustion), and is dependent on manufacturing of clinical materials. Â Â GTB-7550 Â GTB-7550 TriKEÂ® is a product candidate in development for the treatment of lupus and other autoimmune disorders. GTB-7550 TriKEÂ® is a tri-specific molecule composed of a camelid nanobody that binds the CD16 receptor on NK cells, a scFv engager against CD19 on malignant and normal B cells, and a human IL-15 sequence between them. Â Critical Accounting Policies and Estimates Â The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results may differ under different estimates and assumptions. The accounting estimates and assumptions discussed in this section are those that we consider to be the most critical to gain an understanding of our financial statements because they inherently involve significant judgments and uncertainties. Â Use of Estimates Â The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include accruals for potential liabilities, assumptions used in deriving the fair value of warrant liabilities, valuation of equity instruments issued for services, and valuation of deferred tax assets. Actual results could differ from those estimates. Â 24 Â Â Warrant Liability Â We evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, â€œDerivatives and Hedgingâ€. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Â Our use of derivative financial instruments is generally limited to warrants issued by us that do not meet the criteria for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes. Â Stock-Based Compensation Â We periodically issue stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Â Stock-based payments made to officers, directors, employees, and consultants in exchange for goods and services, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if we had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods. Â Results of Operations Â Comparison of the Three and Nine Months Ended September 30, 2024 and 2023 Â Operating Expenses Â Â Â Three Months Ended September 30,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ Operating Expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ $1,307,000Â Â $1,364,000Â Â $(57,000)Â Â (4)% Selling, general and administrativeÂ Â 2,297,000Â Â Â 1,211,000Â Â Â 1,086,000Â Â Â 90% Stock compensationÂ Â â€”Â Â Â 547,000Â Â Â (547,000)Â Â (100)% Total Operating ExpensesÂ $3,604,000Â Â $3,122,000Â Â $482,000Â Â Â 15% Â Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ Operating Expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ $3,868,000Â Â $5,109,000Â Â $(1,241,000)Â Â (24)% Selling, general and administrativeÂ Â 6,511,000Â Â Â 3,532,000Â Â Â 2,979,000Â Â Â 84% Stock compensationÂ Â 222,000Â Â Â 1,767,000Â Â Â (1,545,000)Â Â (87)% Total Operating ExpensesÂ $10,601,000Â Â $10,408,000Â Â $193,000Â Â Â 2% Â Research and Development Expenses Â Research and development expenses decreased by $57,000 and approximately $1.2 million, for the three and nine months ended September 30, 2024 and 2023, respectively, primarily due to a decrease in project materials costs, partially offset by an increase in scientific research costs. Â Research and development expenses relate to our continued development and production of our most advanced TriKEÂ® product candidates GTB-3650 and GTB-5550 along with the progression on other promising candidates. In late June 2024, we received clearance from the FDA with respect to our IND Application in relation to GTB 3650. We anticipate our direct clinical and preclinical expenses to increase in the second half of 2024 as we plan to advance our next generation GTB-3650 camelid nanobody product into the clinic, enroll patients, and perform tests for data collection. We also plan to complete the product development of GTB-5550 and anticipate submission of IND application for GTB-5550 in the first half of 2025. We do not, however, anticipate an increase in related R&D licensing and administrative costs. Â 25 Â Â Selling, General, and Administrative Expenses Â Selling, general, and administrative expenses increased by approximately $1.1 million and $3.0 million, for the three and nine months ended September 30, 2024 and 2023, respectively, primarily due to an increase in legal and professional fees and an accrual for the probable settlement of a legal matter where the amount of the settlement can be reasonably estimated. Â Other Income (Expense) Â Â Â Three Months Ended September 30,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ Other Income (Expense):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest incomeÂ $96,000Â Â $216,000Â Â $(120,000)Â Â (56)% Change in fair value of warrant liabilityÂ Â 95,000Â Â Â 485,000Â Â Â (390,000)Â Â (80)% Unrealized gain (loss) on marketable securitiesÂ Â 2,000Â Â Â 5,000Â Â Â (3,000)Â Â (60)% Total Other Income (Expense)Â $193,000Â Â $706,000Â Â $(513,000)Â Â (73)% Â Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ Other Income (Expense):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest incomeÂ $343,000Â Â $600,000Â Â $(257,000)Â Â (43)% Interest expenseÂ Â â€”Â Â Â (213,000)Â Â 213,000Â Â Â 100% Change in fair value of warrant liabilityÂ Â 870,000Â Â Â 4,796,000Â Â Â (3,926,000)Â Â (82)% Gain on extinguishment of debtÂ Â â€”Â Â Â 547,000Â Â Â (547,000)Â Â (100)% Unrealized gain (loss) on marketable securitiesÂ Â 1,000Â Â Â 43,000Â Â Â (42,000)Â Â (98)% Total Other Income (Expense)Â $1,214,000Â Â $5,773,000Â Â $(4,559,000)Â Â (79)% Â Interest Income Â Interest income decreased by $120,000 and $257,000 for the three and nine months ended September 30, 2024 compared to the same prior year periods, respectively, primarily due to lower short term investment balances. Â Interest Expense Â Interest expense decreased by $213,000 for the nine months ended September 30, 2024 compared to the same prior year period, respectively, due to the financing costs incurred associated with warrants accounted as warrant liability, there were no similar transactions during the current period. Â Change in Fair Value of Warrant Liability Â The change in fair value of warrant liability decreased by approximately $390,000 and $3.9 million for the three and nine months ended September 30, 2024 compared to the same prior year periods, respectively, resulting from a reduction in our warrant liability due to the decline in the Companyâ€™s stock price at September 30, 2024 as compared to the prior comparable periods. Â Gain on Extinguishment of Debt Â Gain on extinguishment of debt decreased by $547,000 for the six months ended September 30, 2024 compared to the same prior year period, respectively, and resulted from share settlements of a greater amount of vendor accounts payable than the fair value of the shares on the date of settlement, there were no similar transactions during the current period. Â Net Loss Â Â Â Three Months Ended September 30,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ Net LossÂ $(3,411,000)Â $(2,416,000)Â $995,000Â Â Â 41% Â Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â $ ChangeÂ Â % ChangeÂ Net LossÂ $(9,387,000)Â $(4,635,000)Â $4,752,000Â Â Â 103% Â 26 Â Â Net loss increased $995,000 for the three months ended September 30, 2024, primarily due to an increase in legal and professional fees and an accrual for the probable settlement of a legal matter, and the decrease in the change in fair value of warrant liability, all as described above. Â Net loss increased $4,752,000 for the nine months ended September 30, 2024, primarily due to the decrease in the change in fair value of warrant liability, an increase in legal and professional fees and an accrual for the probable settlement of a legal matter, and the decrease in the gain on extinguishment of debt, all as described above. Â Liquidity and Going Concern Analysis Â The accompanying unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern. We do not have any product candidates approved for sale and have not generated any revenue from our product sales. We have sustained operating losses since inception, and we expect such losses to continue into the foreseeable future. Historically, we have financed our operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and strategic collaborations. For the nine months ended September 30, 2024, we recorded a net loss of approximately $9.4 million and used cash in operations of approximately $10.4 million. These factors raise substantial doubt about our ability to continue as a going concern within one year of the date that the financial statements are issued. Â The unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes we will continue as a going concern, and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. Â We have evaluated the significance of the uncertainty regarding our financial condition in relation to our ability to meet our obligations, which has raised substantial doubt about our ability to continue as a going concern. While it is very difficult to estimate our future liquidity requirements we believe if we are unable to obtain additional financing, existing cash resources will not be sufficient to enable us to fund the anticipated level of operations through one year from the date the accompanying unaudited condensed consolidated financial statements are issued. There can be no assurances that we will be able to secure additional financing on acceptable terms. In the event that we do not secure additional financing, we will be forced to delay, reduce, or eliminate some or all of our discretionary spending, which could adversely affect our business prospects, ability to meet long-term liquidity needs and the ability to continue operations. Â Cash Flows Â Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Consolidated Statements of Cash Flow Data:Â Â Â Â Â Â Net cash used in operating activitiesÂ $(10,436,000)Â $(6,805,000) Net cash provided by (used in) investing activitiesÂ Â 12,892,000Â Â Â (2,487,000) Net cash provided by financing activitiesÂ Â 2,976,000Â Â Â 6,268,000Â Net increase (decrease) in cash and cash equivalents and restricted cashÂ Â 5,432,000Â Â Â (3,024,000) Cash and cash equivalents and restricted cash, beginning of periodÂ Â 1,079,000Â Â Â 5,672,000Â Cash and cash equivalents and restricted cash, end of periodÂ $6,511,000Â Â $2,648,000Â Â Operating Activities Â Net cash used in operating activities was $10.4 million for the nine months ended September 30, 2024, and was primarily due to a net loss of $9.4 million, and a decrease in the fair value of warrant liability of $0.9 million. Â Net cash used in operating activities was $6.8 million for the nine months ended September 30, 2023, and was primarily due to a net loss of $4.6 million, a decrease in the fair value of warrant liability of $4.8 million, and partially offset by stock compensation of $1.3 million and an increase in accounts payable and accrued expenses of $1.4 million. Â Investing Activities Â Net cash provided (used) in financing activities for the nine months ended September 30, 2024 and 2023, resulted primarily from proceeds from the sale, or (purchase), of short-term investments. Â 27 Â Â Financing Activities Â Net cash provided by financing activities for the nine months ended September 30, 2024 and 2023, resulted from proceeds from the issuance of common stock and warrants. Â Working Capital Â The following table summarizes total current assets, liabilities, and working capital for the periods ended September 30, 2024 and December 31, 2023: Â Â Â As ofÂ Â Â Â Â Â September 30, 2024Â Â December 31, 2023Â Â Increase/(Decrease)Â Current assetsÂ $6,759,000Â Â $14,056,000Â Â $(7,297,000) Current liabilitiesÂ $4,662,000Â Â $6,633,000Â Â $(1,971,000) Working capitalÂ $2,097,000Â Â $7,423,000Â Â $(5,326,000) Â Off-Balance Sheet Arrangements Â We have no off-balance sheet arrangements as of September 30, 2024. Â Item 3. Quantitative and Qualitative Disclosures About Market Risk Â Our Company qualifies as a smaller reporting company, as defined in 17 C.F.R. Â§229.10(f)(1) and is not required to provide information for this Item. Â Item 4. Controls and Procedures Â Evaluation of Disclosure Controls and Procedures Â Our Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer evaluated the effectiveness of our â€œdisclosure controls and proceduresâ€ (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the United States Securities Exchange Act of 1934, as amended), as of September 30, 2024. Based on that evaluation, we have concluded that our disclosure controls and procedures were effective as of September 30, 2024. Â Managementâ€™s Report on Internal Control Over Financial Reporting Â Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, a companyâ€™s principal executive and principal accounting officers and effected by a companyâ€™s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with GAAP and includes those policies and procedures that: Â Â â— Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets Â Â Â Â â— Provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and Â Â Â Â â— Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements. Â Inherent Limitations on the Effectiveness of Controls Â Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected. Â 28 Â Â These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Â Changes in Internal Control Over Financial Reporting Â No changes in our internal controls over financial reporting were made during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Â PART II. OTHER INFORMATION Â Item 1. Legal Proceedings Â Ohri Matter Â On July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the Demand, the Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing that the Company may characterize Mr. Ohriâ€™s termination as â€œfor causeâ€ under his Employment Agreement, and that the Company may revoke the Separation Agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohriâ€™s breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohriâ€™s violations, and attorneysâ€™ fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Companyâ€™s claims against him and counterclaims for breach of his Employment Agreement and Separation Agreement. At this early stage in the proceedings the Company is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any. Â Berk Matter Â On November 14, 2023, former interim Chief Executive Officer, Dr. Gregory Berk filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that the Company discriminated and retaliated against Dr. Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act (â€œSOXâ€). The Company vigorously defended this matter and believes it to be without merit; however, the parties have agreed to resolve the matter and the Company expects the lawsuit to be dismissed shortly. The Company believes it has recorded appropriate accruals for the matter. Â TWF Global Matter Â On May 24, 2023, TWF Global, LLC (â€œTWFâ€) filed a Complaint in the California Superior Court for the County of Los Angeles naming the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (â€œNotesâ€) and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its Complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint for Interpleader against TWF and Z-One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine if the Companyâ€™s shares of common stock are properly registered to TWF or Z-One LLC, as both of these entities have made conflicting demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice and will reconsider the motion without further briefing upon the filing of a supplemental party affidavit. On May 9, 2024, Z-One filed a motion for summary judgement seeking dismissal of the action, representing that Z-One and TWF have settled their dispute over the entitlement to the Companyâ€™s shares of common stock and there is no remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of default. The Court has set a hearing on Z-Oneâ€™s motion for November 14, 2024. The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these claims. Â 29 Â Â Item 6. Exhibits Â Exhibit Â Description Â Filed Herewith Â Form Â Number Â SEC File No. Â Filing Date Â Â Â Â Â Â Â Â Â Â Â Â Â 3.1 Â Restated Certificate of Incorporation as filed in Delaware September 10, 1996 and as thereafter amended through March 1, 2002 Â Â Â 10-KSB Â 3.A Â 000-08092 Â 4/1/2002 3.2 Â Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., dated February 9, 2011 Â Â Â 10-K Â 3.2 Â 000-08092 Â 3/31/2011 3.3 Â Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of July 19, 2017 Â Â Â 8-K/A Â 3.1 Â 000-08092 Â 3/15/2018 3.4 Â Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of February 10, 2021 Â Â Â 8-K Â 3.1 Â 001-40023 Â 2/11/2021 3.5 Â Certificate of Amendment to Restated Certificate of Incorporation of the Registrant effective June 13, 2022 Â Â Â 10-K Â 3.5 Â 001-40023 Â 3/30/2023 3.6 Â Certificate of Amendment to Restated Certificate of Incorporation of the Registrant effective February 1, 2024 Â Â Â 8-K Â 3.1 Â 001-40023 Â 2/1/2024 3.7 Â Amended and Restated Bylaws of GT Biopharma, Inc. effective November 3, 2022 Â Â Â 8-K Â 3.1 Â 001-40023 Â 11/9/2022 4.1 Â Certificate of Designation of Preferences, Rights and Limitations of Series J-1 Preferred Stock of GT Biopharma, Inc., dated April 3, 2019 Â Â Â 8-K Â 3.1 Â 000-08092 Â 4/4/2019 4.2 Â Certificate of Designation of Preferences, Rights and Limitations of Series K Preferred Stock of GT Biopharma, Inc. dated April 3, 2019 Â Â Â 10-K Â 4.2 Â 001-40023 Â 4/16/2021 4.3 Â Form of Common Warrant Â Â Â 8-K Â 4.1 Â 001-40023 Â 5/23/2024 31.1 Â Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended. Â X Â Â Â Â Â Â Â Â 31.2 Â Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended. Â X Â Â Â Â Â Â Â Â Â 32.1 Â Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002* Â X Â Â Â Â Â Â Â Â 32.2 Â Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002* Â X Â Â Â Â Â Â Â Â 101.INS Â Inline XBRL Instance Document. Â X Â Â Â Â Â Â Â Â 101.SCH Â Inline XBRL Taxonomy Extension Schema Document. Â X Â Â Â Â Â Â Â Â 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Â X Â Â Â Â Â Â Â Â 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Â X Â Â Â Â Â Â Â Â 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document. Â X Â Â Â Â Â Â Â Â 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Â X Â Â Â Â Â Â Â Â 104 Â Cover Page Interactive Data File (embedded within the Inline XBRL document) Â X Â Â Â Â Â Â Â Â Â * This certification shall not be deemed â€œfiledâ€ for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act. Â 30 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â GT BIOPHARMA, INC. Â Â Â Dated: November 14, 2024 By: /s/ Michael Breen Â Â Michael Breen Â Â Interim Chief Executive Officer and Executive Chairman of the Board Â Â (Principal Executive Officer) Â Dated: November 14, 2024 By: /s/ Alan Urban Â Â Alan Urban Â Â Chief Financial Officer & Secretary Â Â (Principal Financial and Accounting Officer) Â 31 Â EX-31.1 2 ex31-1.htm Â Exhibit 31.1 Â CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT Â I, Michael Breen, certify that: Â Â a. I have reviewed this report on Form 10-Q of GT Biopharma, Inc.; Â Â Â Â b. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â Â Â c. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â Â Â d. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have: Â Â Â i) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â Â Â ii) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â Â Â iii) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â Â Â Â Â iv) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â Â e. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s Board of Directors (or persons performing the equivalent functions): Â Â Â i) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â Â Â ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 14, 2024 By: /s/ Michael Breen Â Name: Michael Breen Â Title: Interim Chief Executive Officer and Â Â Executive Chairman of the Board Â Â (Principal Executive Officer) Â Â Â EX-31.2 3 ex31-2.htm Â Exhibit 31.2 Â CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT Â I, Alan Urban, certify that: Â Â a. I have reviewed this report on Form 10-Q of GT Biopharma, Inc.; Â Â Â Â b. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â Â Â c. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â Â Â d. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have: Â Â Â i) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â Â Â ii) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â Â Â iii) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â Â Â Â Â iv) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â Â e. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s Board of Directors (or persons performing the equivalent functions): Â Â Â i) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â Â Â ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 14, 2024 By: /s/ Alan Urban Â Name: Alan Urban Â Title: Chief Financial Officer & Secretary Â Â (Principal Financial Officer) Â Â Â EX-32.1 4 ex32-1.htm Â Exhibit 32.1 Â CERTIFICATION TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â Pursuant to 18 U.S.C. Â§ 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Michael Breen, Chief Executive Officer of GT Biopharma, Inc. (the â€œCompanyâ€), hereby certify that, to the best of my knowledge: Â (i) the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and Â (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Â Date: November 14, 2024 By: /s/ Michael Breen Â Name: Michael Breen Â Title: Interim Chief Executive Officer and Â Â Executive Chairman of the Board Â Â (Principal Executive Officer) Â Â Â EX-32.2 5 ex32-2.htm Â Exhibit 32.2 Â CERTIFICATION TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â Pursuant to 18 U.S.C. Â§ 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Alan Urbani, Chief Financial Officer and Principal Accounting Officer of GT Biopharma, Inc. (the â€œCompanyâ€), hereby certify that, to the best of my knowledge: Â (i) the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and Â (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Â Date: November 14, 2024 By: /s/ Alan Urban Â Name: Alan Urban Â Title: Chief Financial Officer & Secretary Â Â (Principal Financial Officer) Â Â Â GRAPHIC 6 form10-q_001.jpg

begin 644 form10-q_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@
#_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?
HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-
$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$
/P#W^BBJU_?V MFEV,M[?3I!;1 %Y'. ,G _4@4 6:*YT>/?"C*"->L<'GF3%'_">>%/\ H/V/ M_?T4[,5T=%17._\ ">>%/^@_8_\ ?T4?\)YX4_Z#]C_W]%%F%T=%17._\)YX M4_Z#]C_W]%'_ GGA3_H/V/_
']%%F%T=%17._\ ">>%/^@_8_\ ?T4?\)YX M4_Z#]C_W]%%F%T=%17._\)YX4_Z#]C_W]%'_ GGA3_H/V/_ ']%%F%T=%17 M._\ ">>%/^@_8_\ ?T4?
\)YX4_Z#]C_W]%%F%T=%17._\)YX4_Z#]C_W]%'_ M GGA3_H/V/_ ']%%F%T=%17._\ ">>%/^@_8_\ ?T4?\)YX4_Z#]C_W]%%F M%T=%17._\)YX4_Z#]C_W]%'_ GGA3_H/V/_ ']%%F%T=%17._\
">>%/^@_ M8_\ ?T4?\)YX4_Z#]C_W]%%F%T=%17._\)YX4_Z#]C_W]%'_ GGA3_H/V/_ M ']%%F%T=%17._\ ">>%/^@_8_\ ?T4?\)YX4_Z#]C_W]%%F%T=%17._\)YX M4_Z#]C_W]%'_ GGA3_H/V/_ ']%%F%T=%17._\
">>%/^@_8_\ ?T4?\)YX4_Z#]C_W]%%F%T=%17._\)YX4_Z#]C_W]%'_ GGA3_H/V/_ ']%%F%T=%17 M._\ ">>%/^@_8_\ ?T4?
\)YX4_Z#]C_W]%%F%T=%17._\)YX4_Z#]C_W]%'_ M GGA3_H/V/_ ']%%F%T=%17._\ ">>%/^@_8_\ ?T4?\)YX4_Z#]C_W]%%F M%T=%17._\)YX4_Z#]C_W]%'_ GGA3_H/V/_ ']%%F%T=%17._\
">>%/^@_ M8_\ ?T4C>/\ PF@!.O67)QP^?Y46871T=%<[_P)YX4_Z#]C_P!_11PGGA3 M_H/V/_?T46871T5%<[_PGGA3_H/V/_?T4?\ ">>%/^@_8_\ ?T46871T5%<[M_P
)YX4_Z#]C_P!_11PGGA3_H/V/_?T46871T5%<[_PGGA3_H/V/_?T4?\ M">>%/^@_8_\ ?T46871T5%<[_P)YX4_Z#]C_P!_11PGGA3_H/V/_?T4687 M1T5%<[_PGGA3_H/V/_?T4?\ ">>%/^@_8_\ ?
T46871T5%<[_P)YX4_Z#]C M_P!_11PGGA3 M_H/V/_?T46871T5%<[_PGGA3_H/V/_?T4?\ ">>%/^@_8_\ M?T46871T5%<[_P)YX4_Z#]C_P!_11PGGA3_H/V/_?T46871T5%<[_PGGA3 M_H/V/_?T4?\ ">>%/^@_8_\ ?T46871T5%<[_P
)YX4_Z#]C_P!_11PGGA3_H/V/_?T46871T5%
<[_PGGA3_H/V/_?T4?\ M">>%/^@_8_\ ?T46871T5%<[_P)YX4_Z#]C_P!_11PGGA3_H/V/_?T4687 M1T5%<[_PGGA3_H/V/_?T4?\ ">>%/^@_8_\ ?T46871T5%<[_P)YX4_Z#]C
M_P!_12+X^\)MG&O67!QS)BBS"Z.CHKG?^$\\*?\ 0?L?^_HH_P"$*?]!^Q M_P" HHLPNCHJ*YW_ (3SPI_T'['_ +^BC_A//"G_ $'['_OZ*+,+HZ*BBS"Z M3SPI_P!!^Q_[^BC_ (3SPI_T'['_ +^BBS"Z.BHKG?\
A//"G_ $'['_OZ*/*?\ 0?L?^_HHL/\$*?]!^Q_[^BC_A//"G_ $'['_OZ*+,+HZ*BBS"Z M0?L?^_HH_P"$*?]!^Q_[^BC_ (3SPI_T'['_ +^BBS"Z.BHKG?\ A//"G_
^_HHL/\$*?]!^Q_[^BC_A//"G_ $'['_OZ M*/\ (3SPI_T'['_ +^BBS"Z.BHKG?\ A//"G_ $'['_OZ*+,+HZ*BBS"Z.BH MKG?^$*?\ 0?L?^_HH_P"$*?]!^Q_[^BC_A//"G_ $'['_OZ*+,+HZ*B
+^BC_ (3S MPI_T'['_ +^BBS"Z.BHKG?\ A//"G_ $'['_OZ*+,+HZ*BBS"Z.BHKG?^$*?\ 0?L?^_HH_P"$*?]!^Q_[^BC_A//"G_ $'['_OZ*+,+HZ*BBS"Z.BHKG?\ A//"G_ $'['_OZ*/*?\ 0?L?^_HHL/\$*?]!^Q_[^BC_A//"G_ $'['_OZ*+,+HZ*BBS"Z.BHKG?\ A//"G_ $'['_OZ*/*?\ 0?L?^_HHL/\$*?]!^Q_[^BC_A//"G_ $'['_OZ*+,+HZ*BBS"Z.BHKG?\
<[_PGGA3_H/V/_?T4?\ M">>%/^@_8_\ ?T46871T5%<[_P)YX4_Z#]C_P!_11PGGA3_H/V/_?T4687 M1T5%<[_PGGA3_H/V/_?T4?\ ">>%/^@_8_\ ?T46871T5%<[_P)YX4_Z#]C
M_P!_12+X^\)MG&O67!QS)BBS"Z.CHKG?^$\\*?\ 0?L?^_HH_P"$*?]!^Q M_P"^BBS"Z.BHKG?\ A//"G_ $'['_OZ*/\ (3SPI_T'['_ +^BBS"Z.BHKG?\
$\\*?\ 0?L?^_HH_P"$*?]!^Q M_P" HHLPNCHJ*YW_ (3SPI_T'['_ +^BC_A//"G_ $'['_OZ*+,+HZ*BBS"Z M3SPI_P!!^Q_[^BC_ (3SPI_T'['_ +^BBS"Z.BHKG?\ A//"G_ $'['_OZ*/\
^_HHL/\$*?]!^Q_[^BC_A//"G_ $'['_OZ*+,+HZ*BBS"Z.BH M0?L?^_HH_P"$*?]!^Q_[^BC_ (3SPI_T'['_ +^BBS"Z.BHKG?\ A//"G_ $'['_OZ*+,+HZ*BBS"Z.BHKG?^$*?\ 0?L?^_HH_P"$*?]!^Q_[^BC_A//"G_ $'['_OZ*+,+HZ*B
\)YX4_Z#]C_W]%%F%T=%17._\)YX4_Z#]C_W]%'_ M GGA3_H/V/_ ']%%F%T=%17._\ ">>%/^@_8_\ ?T4?\)YX4_Z#]C_W]%%F M%T=%17._\)YX4_Z#]C_W]%'_ GGA3_H/V/_ ']%%F%T=%17._\
">>%/^@_ M8_\ ?T4C>/\ PF@!.O67)QP^?Y46871T=%<[_P)YX4_Z#]C_P!_11PGGA3 M_H/V/_?T46871T5%<[_PGGA3_H/V/_?T4?\ ">>%/^@_8_\ ?T46871T5%<[M_P
)YX4_Z#]C_P!_11PGGA3_H/V/_?T46871T5%<[_PGGA3_H/V/_?T4?\ M">>%/^@_8_\ ?T46871T5%<[_P)YX4_Z#]C_P!_11PGGA3_H/V/_?T4687 M1T5%<[_PGGA3_H/V/_?T4?\ ">>%/^@_8_\ ?
T46871T5%<[_P)YX4_Z#]C_P!_11PGGA3_H/V/_?T46871T5%<[_PGGA3_H/V/_?T4?\ ">>%/^@_8_\ ?T46871T5%<[_P)YX4_Z#]C
M_P!_12+X^\)MG&O67!QS)BBS"Z.CHKG?^$\\*?\ 0?L?^_HH_P"$*?]!^Q M_P" HHLPNCHJ*YW_ (3SPI_T'['_ +^BC_A//"G_ $'['_OZ*+,+HZ*BBS"Z M3SPI_P!!^Q_[^BC_ (3SPI_T'['_ +^BBS"Z.BHKG?\ A//"G_ $'['_OZ*/\
^_HHL/\$*?]!^Q_[^BC_A//"G_ $'['_OZ*+,+HZ*BBS"Z.BH MKG?^$*?\ 0?L?^_HH_P"$*?]!^Q_[^BC_ (3SPI_T'['_ +^BBS"Z.BHKG?\ A//"G_ $'['_OZ*+,+HZ*BBS"Z.BHKG?^$*?\ 0?L?^_HH_P"$*?]!^Q_[^BC_A//"G_ $'['_OZ*+,+HZ*B
+^BC_ (3S MPI_T'['_ +^BBS"Z.BHKG?\ A//"G_ $'['_OZ*+,+HZ*BBS"Z.BHKG?^$*?\ 0?L?^_HH_P"$*?]!^Q_[^BC_A//"G_ $'['_OZ*+,+HZ*BBS"Z.BHKG?\
[redacted]

```
MV8'/S8X13_=7)^IR>]?-F@^&H?%_Q9DT*XN)+>*ZN[K=+& 67:)'XS_NXK[* MKXMT_3M:U;XFSV7AZY>VU66[N?(E2'6KR62SG694>-<,5.<'%;OC>'/B*-YED?[1H=_:6*JN[=,=.O->UZZN-
+B=C/$^J22AAL8#Y2<'DBO9-0TZRU6R>S MU"UBN;=\;HY5##(Y!]B#R#U!H \4T+39M >SG\3V-]$_)6:YM2JV+<[[ M9MJ@'<. &R^2%YSSZ_X7AO+;PEHT&H*RWL5C EPK$$B01J&!QQUS4-
KX0T2T MN(IQ;33O"RO#]KNYKE867.THLC,$(R<;0,5N4 %?'T^AV_B3XZ:EHUU)+'!= MZW=1N\1&Y?WCG(R".U?8-?&^I:EJ.D?&G5M0TFU%W?V^M73PP&-I Y\Q^-JD M$\9Z4 =%\4?
A##X"TFVUG2]2GN+*N<=LGN:\RU^Y^*/Q6DM--N_#TUM M:Q2^8%6T>"$/C;N9I">0&/&>A/%=YXM\'Q>!_P!G/5-'2199LP2W,JC >5IX MLD>PP ,\X H [>'XI^"I]&GU=-=B%C#*
(7D>&1#O(R%52H9CCG@&NAL=;TW4 M=$BUFVNT.G2Q^:MQ)F-=GJ=V"/QKYA^$OPTB^($-])J>HW5OI=G( (;=@&>5 MAU^8$# ['/MBM+XW32^'++P[X$M+B5M.LK07+,^-TI+NJ[L?
W0K>GWOI@ ] MB?XQ^ $N5MSXCA+L< K!*5ZXY8+M'US77Z?J5CJUDE[IUY!=VLF=LT$@=3C@ M\BO)]"^ GA.;PG:_;C=3:A<6ZR/=),5V,R@_*O3 ]P:X?X#ZK?Z-\1;KPU).
MSVLZ3+)$IR@FC_C&?S?/(ST& #Z \0^+= \*P)-KFJ06:R9V*Y)=\==J#+' M'L.XKR3XQ>-?#GBWX9G^P]6ANVCOXB\8#)(HPPSL8!L>^,5Y_/;R_%'XZ2V& MH7DD<$]Y+"K)UC@A#$*N> 2J=
<8W,3CJ*Z?XQ^"SP[X3\+V^L:)'-;.MPL,D M32-(KA@2#ECD$;?UH Z_X$WUOIGPDO;^\D\NUM;JXFF?:3M144L<#DX /2N[ M\->/?#/C"XG@T+4OM6?#7_DW+Q3_P!<;_\ ]$"L MC]FK_D/Z[_UZQ_\
H1H ]B\0?$KPCX6U0Z;K.K?9;L(',?V:5_E/0Y52/UKJ MG=(HVDD941069F. .I)KY3^/_\ R4^7_KTA_D:[K]HWQ)>V=AI>@6TICM[P M/-=;207"D!5/^SDDD>H'IR =]=_%[P#97?
V:7Q);M)G&88Y)4ZX^^BE>WK[U MF?$#XHZ3HW@S[7H^LQC4KZ 3::RP-(LH#@-U4J.-PPV/SKF_ /P1\+WW@S3= M2UN&>[O+Z!+DD3-
&J*X#*H"GT(R3W].E7_B=\/O#FF_"N>2*S=YM'M]EE*\S MYC#2@D8! ;[QZ@T <[\*?B[ C:JWC7Q%.]U"?#OBNVU>XUO3_M4MI-#Y#>=(FS(8GA6&>0.M?2] !1110 5YM\9_ M^1=TK_L))_Z
]>DUYM\9_P#D7=*_["2?^@/50^(F6QZ31114E!1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !7FWPB_U/B+_L)-7I-
>;?"+_4^(O^PDU4MF2]T>DT445)04444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 5YMXN_P"2N>$/]U_ZUZ37FWB[_DKGA#_=?
^M5';?"/[GB M/_L)-7I->;?"/[GB/_L)-5+9DO='I-%%%24%%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%%
!1110!!>_P#'CN-_::_YE;_M[_P#:-=EI'_)MLG_8O7'_M **>@#YC\/ZGJ/A[5;7Q!I^]7L9T^<<#+!OD/LRJXQW&:^TO"OB.S\6>&[+6 MK(@1W" M'NR8G_B0^X/'ZU\\_[P[8^*M-\7:-J" PW%O ^,F-
\OM=?<'G_ M .M4_P ,_$5]\,/B!=^$/$+$+F&PN9O+)G_/8*C_\ 1LM5_P!GG_DI,O\ V#Y? 0DJQ^T= M_P E#T__ +!4?_HV6@#H8_V M'_$/B3X0>.6TV^=Q;Q2A+Q3MEH#HSW[_R
-._P"O6+_T M$5\S?M"W%M-2HXX"AD@T^*.XVXR'W.PS[[63\,4 ?4R.DL:R1LKHP#*RG(( M/0@TZN(U+Q?8?#OX?:>ZQ!=RH8K>TVVJ*S!_*)Y#,O'R'].*R_#?QO\->*? M$-GHMC8ZM'*,
(,*6Y(D)Z#TH \K_:._Y*I__&"H_P#T;+74:?\ MLZ:/>;;:W3:[?*TT*2$"-, D _UKE_VCO^2AZ?\ ]@J/_P!&RU:L_A_\8IK& MWDM_$=XL#QJT:C691A2.!C/'% 'N'VO1_AQX+LH]4OVCL+&..V%PT3,3V7*H
M"<_A4$/Q-\&SZ"^MKKL*Z>DSO>;,SZX&4I%4,55&4,QPP/ /6N0^,L%S;?!2&" M]D,EU$UJDSEBQ9Q@,(;GCVLC@9QG:P!QGOBK&N>*-"\-1 M)XK,JVMD'!*++( S@==JJ3VZ#O7S#X!@?PU\>8-
,M)W:.VU&>Q+-QYB#>G(' MT!^N/2O4?BU)V/8/$]I>>+I;R]N8K41QZ99GG:7)WL0RXZ\#<. >M '::/\ M%3P3KM^ECI^OPO ^.[_,*: MI'877A7PW>Z3"-Z323,2DIXP!RPR.>_?I7K?
C_49]6_9OTJ^N9'DN)4M?-D< MY9V'!8GN21F@"/X'^)M%\,?#&^NM:U*"RB;59=GF-\SXAA)"J.6/T!KU7PYX MX\->+"ZZ)]\-U(@RT>&1P/7:P!Q[XKP[X-?##1O%WANZU37UGGA6Y:&VMUF9
M%4A5+/\ *>IR!_P'Z5RNI:4?AS\;>RTB[9UM+V\HF8_,$D"DH^/]ERI]0>V M: .M_:5_Y#^A?]>LG_H0KM=?T_0M2^ .@0^(-4DTRT%A9,ETD+2[)/*4+E%& M6')XX^HKBOVE?
^0_H7_KV_Z$*Z#X@_\FUZ%%_P!>FG^BUH Z7X/X?AK1/!% M[)H6MR:K:M:VPVM'A*'@S79;F/3]K$#P]XX@M-%>:*"6
MUCNXU9R6B;>RX#=>J9SUYKO/C]XDO7\/>&]*$$NV.^A^V707(WD!=H^F2QQZ@ M>@H ]1LOBKX'U'5H],M?$$#W4CA$!CD568] '*A23]:FT;XE>$?$.M#1]+U; M[1?MNQ%FE3[H];EE
['O7G7@[X&^&=&=4^']A>:B;I]2U"U6X%PLA4O^8H*A5 M!P0 1USDYZ\ >>_!&+R/C!:0[MWEI<+G&,X1A0!]95\RP[?BS\?C)_Q\:19LM&VO@J;>$CC'(*NY_*0]*]B>^7BD>%/A]?
7$4I2]NQ]DM=O7>X.2#VPH8Y]0! MWKF/V/"YTKP?/KEQ$JW&JR9C)!W"%,A>O3+;CQU&T_0 ]?HHHH **** "BB MB@#%\7_\B5KO_8/G_P#1;5E?"[_DF^D?[LO_*->M?Q?_P B5KO_ &#Y_P#T
M6U97PN_Y)OI^[+_ .C7JOLD]3KZ***DH**** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@#DOB;_P
DZUC_'$_]&+6CX_Y$C0_P#KQA_] %9W MQ-_Y)UK'^XG_*,6M'P9_P B1H?_*XP_P#H JOLD]3I9HHHHJ2@KD M_B;_DZUC_KFG_HQ:ZRN3^O)_).MB_QSX]Y_Z 2,6G'="^>Q?\%_\B1H?_7C#_Z
M*W:PO!?_")&A_\ 7C#_.@"MVA[@M@HHHI#"O$?VE/^1;T_K[?_P! KVZB M@#S_."7_)(="_^_2B2O$=$_Y.4E_[#]U_Z,>OJZB@#G_'?^_'K/\$_&"K MK_T4U>_D/_L'^A_7?!?"O6 /_P!`
" IKW2B@#Q_X&_$4^(=(^('AS5)BVJ6 M*9AD<\SPCISW9>A]L'DY->&Z?XEF\'_$V?78+=B2UN[G$3L0&W;TZC_'LU MJI44 ?/VC_M#:KJFMFV&GMH-G&MUV<9AGMXP"[Q3SSUK=^!?
PZU6QU5_% MFM0R6V8BES%*,22;QS(P(R!C@=SDJNOO=% 'REXRT77?A?\ %!_$=G9N;+[6 MUS:3X9HF5R+VU^Q!9
M"PO+JWCD6SYS!'C"J0>03C<1_M=N@]W^.'P_O_%VD6>I:1$9[_3MX:W4#=-& MV"<$GJNW('?)QS@'UBB@#YA\+_&
[Q#X0TBW\/ZCH8O'M0(8/-9H954O7XU7Q_\%KLS67V;4[^T=UM5!7#*Y*)\WKM49..N>*] HH ^2/AK MXWUSP#J5]I,.BM0_0^WX_6]%% !1110 5YM\9_
MD7=*_P"PDG_H#UZ37FWQG_YW2O^PDG_ * ]5#XB9;'I-%%%24%%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444
%>;?"+_4^(O^PDU>DUYM\(O]3XB_"352V8+W1Z31114E!1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !7FWB[_DKGA#_'7_
*UZ37FWB[_DKGA#_=?^M5';?"/[ MGB/_ +"35Z37FWPC^YXC_P"PDU4MF2]T>DT445)04444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $%[_QXW'_7)OY5PGP9_P"1$/\ U]R?R6N[ MO?\ CQN/^N3?RKA/@S_R(A_Z^Y/Y+5+X63U/0J***DH**** "BBB@#Y_ ::-EI'__MYE;_+>__:-=EI'_";;)_V+UQ_Q3J*
/GC]FC_D(>(_^N4'\WKI_CMX M_M[0_P#A)-/A+:EIR8F5>LT&P44 ?+'[//_"4F7_L'R_\ MH258_:._Y*'I_P#V"H__ $;+7!\S0_M!>(SIL&FZ9H=D+E8UAC?YY2<# M&0HQD_YP:/ GPK\1^,O%
\1>,H;F*S,HGE*V+B6[8'[FP\]G R< 8X7U'TS1 M0!3U+2=2-UFW6WU33[2^@5PZQW4*RJ&P1D!@1G!(S[FJ5GX1\-:==QW=CX>TF MUN8NSE)H+*-'7C'#!U?2M% 'B/Q'\03>*?
V?;;6YX$@DNYXV,:$D+B1AU/TJ] M^SC_ D\U+B+2=^EFW6WU33[2^@5PZQW4*RJ&P1D!@1G!(S[FJ5GX1\-:==QW=CX>TF MUN8NSE)H+*-'7C'#!U?2M% 'B/Q'\03>*?
M*\J6:R.6:X)"EG!*@$8"%<( ?ABXEBT0ZCH4UTRK(25$,X12PW '&5VG!]'1T:K7@C0=<^*/Q.'BK4K6 MR[!+E+JXEP5C8@)@\F<[ON 'T .2#C/U0)10!\X_M*_L ?(T+_KUD_P#A0A70
M$'_DVO0O^O33_^ & 8T6M0+6?[W '6T2T5"J7<&' E_P+S #H6_K\ O$M%J3$ZO@*M1_B6PV+VP(BR3FXN+_@Pq!W$M D[QIW$+;V6Dc%]-4S[M:9^CN$@D[@K-O?@@J5Z=,O:rF>GDX"Y8cYz@0L2wQq8YkE(JuD%Xj5Pp0wHqDjhm
```

```
T'PP|%^)8%*^8MS:3.HQAEN)60Y]2"_| WR/P]3^)/Q"- M[\$-(G@FQ=Z\BQ2X(!P@_?X'IO 7Z-^%&C>'_P#A)/V6X;14#7$,5Q=0>N^. MXD; ]R R_P# J\=|(VESXPU_PYX5D"M:)=NV.0?+;#2\_P"[&
<8Q0!?|<^'O M^$<|*^#H'CV7%S927<^5VG=(P(!'J%VKS_=KZ1TF#4KGX+:9;Z/(8M2ET&!+ M:0-MVN8% .>V/6O)/VDU"Z[H*] %%K( !T'S"NB\?:AJ6G_LY>'3ISRQB:TL M8KEXC@K$80>3U
+!!QCKCH2" <9K/PYT1+&XN-<^*=A<:RH9VC,GG_/Z$|R_M/'./P.*ZG]GSQGJFJSZAX>U*[>ZC@A%S;M,VYT&X*RY)R1\R_2N-\&3_ OM MO S3:O927OBH&14MG65O-
^C^/%V^EJK:@NK1&U5AD&7*; ?;=BK_ ,3OA_XE\(QV?B34_$)U*>XF M\IYU9E>*0AF 4D_=X?IC'H,TFM_\G*1?4^U_P#1B5Z_P#L^Q_^ MBI: (;?
Q%>>)OV:M1OM0D,MXEK+!+*W638V^XF MM5SP-8SZE^S5J]K;*&F=+HJI_BP=V/J<5Q7P3\?Z+X(N]8BUMY8H;Y(BDR1E MPICW\$#GG?U]J (OB;_R<%<_]?
=E_P"BH]J[#X_>!YO;8Q"5-K%%$;JV/< 'Z&O=_CY_R2ZX_Z^H?_M_0J /+O@U\,O^$F^R>*_[7^S?V9J]?Z+]FW^;Y?ER??WC&=V.AQC/-=Q\2?" M%[KWBBYN-<\
<0:#X=V1I;V\UQQ*=N7Q&649SGGDGTP!4_P"SC_R3S4/^PK)_MZ*BKR9K[2M4^U^Q"DNFL5NIHG5F8>7M)$:G;A@@X^[['IF@""[U_"_P 8 M6\OA'Q4FK6NQ)9?*XC?YOFC<
D'(4<@Y&>Q%>U?&3XCW7A3P[80:*QCOM55F M2XV@^5$_D=MQW #KWIJ\)^)%QX6GUNU7P;9>1I$5N$OENOG2;CN;+_ #' MVCGT-
>B_'70+RX\|+^%]>@C9[6VM%@N&&/W>X(4/K@G>RN["WCMOEA:1)%1=JL"N>P M&0<<],UU7C;4X/&'P2UC4]*60V\]HTT?F+M8I&^6..>R$_X4 >&?"OX9?\)[
M]LO/[7^P.P!GS1?]\]FW\WS,Y/7>N/N^_6M?\ :._Y*'I_8*C_P#1LM)\$?B! MHG@Y=K-I_8*=O'A: Q?I]]Q&X%3Z?>!/].OXVOVDK&>/Q?I&H,!Y$]AY'"ONCD M9F_21: /6?&_ )$=0_[!2?\ H*UYY^S+_P
S3_VZ^UJ7Q)\7M UGX3R:8I M82W0@*&(().<2>!UU^?Q$+' MPR#_ &E?0O;*X;:8T899@V1MP >?RYQ7JNH^!=?1"_ QC:ZQ-S2W-Q:RI) M;R,X(\Z,'.X YS[5R_P
_P"2GQ?]>DW\A7MWQM_Y#KO_O_ .E$= '(_LU_ M\BWK?_7VG_H%%>._ #6UU_4/%\|=AX-KLY_<1\%V&.^!C|\>W4>Q?LU M_P#(MZW_-?:?^@5Y_| #_DI\7_ %Z3?R% &;XT|-
^(/A9XMM9M%'Y+S"CZL*_ P3\|?7% M^%?1^BF\R6QL?=+/B_EOW:|\\?9XBK^AXES)^\$RSXDKS7UR, UG7 OVEEZ8\T"PA6TS7J:?8GHG/9*Y4*<(.'KIZV=Q"&"N\*I:;+?
&>\P5S'CZL* _P3\)?'BC3(%/%J>(OL-U(S26N M'\-/MO\ PO'3_P"TO^/_ .VS_:>G^MVR;ON|=<].*]"^" QJ-Z%\(;/3M5^ M7!)?%A&T8ABA)$P!?7:/J]/QRT^^DB\E[F]GF:/\ N%ED MD M)'X9H ^H/%(_
")6N_\ 8/G_/1;5E?"[_DF^D^D?[LO\ Z->M7Q?_ ,B5KO\ MV#Y__1;5E?"[_DF^D^D?[LO_HUZK[]/4Z^BBBI*"BBB@ HHHH **** "BBB@ H MHHH *^EX]WJD&DQ6QM%MY /-$(4AF90NW<,$@GVS7'?
L[;%>77C"ZUL1LMC9V[ M1&0CAI'QA1^&2>N.,]17H/@[X.^I[_PGH>IWFD-/@2;5FO+F*V5Q MP&<.FXYX^4,6YXXYXKH/%FK_ *\1^'WB*VGU?Q%LOKFHFZI\\!KFC0[ MM3NM-%Q;1!-
V)63(&#UPQ[\<5Y'JG@WXM-IDVJZIXY2RG"M+]F747@Z=OD 0 M'T XY'(S6AK'B74_#'[.'A^YTF9X+FY6*FX\]!\T2D.Q(/8G;C/OZX(XKPMX9 M\ :AX'G\2^^)O$DLNKKYIEL3=JC%@3L7:07?
#KPWXV\ WU\GBK7AJEBT68)#]\=>,?BMXUDT/P=?R:5IL:EQ(DAB;RU(S*[CYADE0%7U / MCCQ?XU^$?C:VTOQ1]LNL:7.BR2
M%Y#*3&Q(+HS?,&4AOE)P<>X^D*>1\)OABUW;6D7CF2>YN9%CABM[F&5F9L M8X52>N8^''_)-O#G_ &#X2^0173T %%%% 4 M444 %%%% !1110 4444 ,/_ * *SOB; M_P DZUC_
'$_]&+6CX_Y$C0_P#KQA_] %5]DGJ;E%%%24%%% !1110 444 M4 %%%% !1110 5\P?M'?E#T_P#[!4?_*EKZ?KY@_:_Y*'I__ &"H_P#T_P#[!4?_*EKZ?KY@_:_Y*'I_ &"H_P#T M+;0!VVVO_ !D\'CXVA4)'%$H55'H *
/C3X<77B&\V\71Q^%HHWU> MYA>"%I "L0(RSG/' !/.1['H>C\0>(?B9|-_%D(U77[B>X>,3]CW!GMY4)P1 ML/ Y4C@ CMC(-+\ /^2GQ?].7I-_(5T'[2Q__"]"_Z]9/\ T(4 >Q>*M1UZ M\|!K>*$$_P"]I>+
UL2]ML5RI).[Y>%)Y->.^(_#/Q1\/:+)KVH>),2VZ"9[ M1-2D48D9S@+@*Q]NAP0,\9N?$;Q3JV@_!_P #6&EW,MJNH:;$)YHLAB]01_)N M[ [_*$/VA\;3X7_)!+XA>^U^XM01:"Y0%;AN]^6!O|
E)Y).#C/ M0T >K_"WXD7OB/P]EJZ";T9&X:5T^4SJ$+ GC ;Y2#CZUY9HWB7QH$4_$\ M]I;>+5T-4^ZJV6D W!;X) /!&XEVD$%(" MU62!D4 M >K">"[;Q@+X$^ZT(Q(\K8X(M$=PDS38B526&6
8GCOUR.:|ML-?\ B%%|8 MO$5|NA:M)HFF6N'VQ3M$(@^_#LEQW%<-\/-^"\)^(=1NK/Q1KE'^$/'7BOP:|2E\$^+;R34H)ITMDF=O,=&?'ENKGEE;*Y#'C M/8@@_05>#Z'\|+?
AU#XKTZ/3O&,U[J,4XFBMX)XI* &-% M&TJ2M&ID0$*Y'*YZX/;.!7COQU\>:1:^&;OPK!)'=:G=%%FC7D6ZAE?+>C' MP/Q],Z?QM\|??7@_0+:QTJ41:EJ1=1*/O0Q*!N8>C$D 'ZXY%>:?"W2?A_911
MZ]XMUW3Y]1=B\5E,Q98NO,@(^9CUQT"4] #T3X!>&+W0O!US?W\+0R:G,LL M4; AO*5*Q],DL1[8/>O6:RM$\3:+XDCFDT;4H+U(2%D,+9VD],_D:U: "BB MB HHHH **** "BBB@ HHHH ****
//_(R?\B"__7S'_6NWT[_D&6G_%Q3 M_P[!!%<1\9/\ D07_.OF/^M=OIW_ "#+3_KBG_H(JG\*)ZEFBBBI*"N3^)O_ M"3K6/\ KFG_ *,6NLKDOB#O\ H-Q?]^I/ M_B:;B[B35CK**Y/_ (69X._Z#<7_
'ZD_P#B:/\ A9Q@[_H-Q?] ?3.. .)I M#O^@W%_WZD_\ B:/^%F>#O^@W%_WZD_\ B:.5]@NCK*P-?]\$> M&?$[F36-%H+J8KM,Q7+CL-ZX;]:I?1 "S/!W_0;B_[]2?] Q-'_LSP=_T M&XO^_4G_
,31ROL%T5+/X/\ @&QG6:'PY S*00)Y9)EX P_F:EV\[/TQ70(Q9T M7Q/":"UUK38+V\[(/,7YDSP2K#E3]"*R?^%F>#O\ H-Q?]^I/ M_B:/^%F>#O\ MH-Q?]^I/ M_B:/^%F>#O\ MH-Q?]^I/_B:.5]@NB.'X5'^?;;"2+?;;]T"2X6!2MX
A6UN2OG8ED\Q\ |S=OQD XSCBM M#2O!/AW1/#U(H[Y'X@)N[D!HK))W;9R&=!-A;BK@ GD(N^ G=/BA)_X94) &@/DWTEMTNAUBAIWFUB.R;=^'@^BcB.T&<T[@D
M '(SLQVW-2'2^ "S/!W_0;B_[]2?] M2?\ Q-'_LSP=_T_&XO^ 4G_ ,31ROL%T.|_ #CPGX4<D@*&Q*UCZ?F#:HE=R?)2P4:RF>VVQ? M6WAX:NP%?XRQC&]^:*/'.UF\L&.R!"V1!PZCX@(?XK_AZ=%^(VE>U:E$N)!%KH
M )"V&\S'T'/A&*!/:1AH^E2=0(HX:SGU,*IQ&NG6?D_G3&=,*[C/J-*TV:QXB/UWJ'J#%C\4F<;??4!V,\KXG7/M>/V1/G!?QT*'Q91#R0L$@J_6'8\I%@J:?\6*}U+e_T%^![9)#B6S<0NR^-8W`q!-YH)ZH\CD-Y&Z::`
```

9UZC11SR#E1Y M=_PJ!_| H-K_ . O_P!G1_PJ!_| H-K_ . O_P!G7J-%'/(.5'EW_"H'_P"@ MVO| X"__ &=' "H'_P"@VO| X"__ &=>HT4<|@Y4>7?|*@?_ *#:_P#@+_| M9T?|*@?_ *#:_P#@+_|
9UZC11SR#E1Y=_PJ!_| H-K_ . O_P!G1_PJ!_| MH-K_ . O_P!G7J-%'/(.5'EW_"H'_P"@VO| X"__ &=' "H'_P"@VO| X"__ M &=>HT4<|@Y4>7?|*@?_ *#:_P#@+_| 9T?|*@?_ *#:_P#@+_| 9UZC11SR
M#E1Y=_PJ!_| H-K_ . O_P!G1_PJ!_| H-K_ . O_P!G7J-%'/(.5'EW_"H' M_P"@VO| X"__ &=' "H'_P"@VO| X"__ &=>HT4<|@Y4>7?|*@?_ *#:_P#@ M+_| 9T?|*@?_ *#:_P#@+_| 9UZC11SR#E1Y=_PJ!_|
H-K_ . O_P!G1_PJ M!_| H-K_ . O_P!G7J-%'/(.5'EW_"H'_P"@VO| X"__ &=' "H'_P"@VO| MX"__ &=>HT4<|@Y4>7?|*@?_ *#:_P#@+_| 9T?|*@?_ *#:_P#@+_| 9UZC M11SR#E1Y=_PJ!_| H-K_ .
O_P!G1_PJ!_| H-K_ . O_P!G7J-%'/(.5'DF MI?"Q].TN[O3K"R?9X7EV?9\;MJDXSNXZ56\/_#9M=T.VU(:J(1.&/E^1NQAB MO74W_H!K-^'W_(C:;])/_1C4^9V%RJYRG_"H'_Z#:_^ M O|
]G1_PJ!_^@VO_@+_ /9UZC12YY#Y4>7?|*@?_H-K_P" O_V=' "H'_Z# M:_| @+_]G7J-%'/(.5'EW_"H'_Z#:_| @+_]G1_PJ!_^@VO_ ("__9UZC11S MR#E1Y=_PJ!_^@VO_ ("__9T?|*@?_H-K_P"
O_V=>HT4<|@Y4>7?|*@?_H-K M_P" O_V=' "H'_Z#:_| @+_]G7J-%'/(.5'EW_"H'_Z#:_| @+_]G1_PJ!_^ M@VO_ ("__9UZC11SR#E1Y=_PJ!_^@VO_ ("__9T?|*@?_H-K_P" O_V=>HT4 M<|@Y4>7?
|*@?_H-K_P" O_V=' "H'_Z#:_| @+_]G7J-%'/(.5'EW_"H'_Z# M:_| @+_]G1_PJ!_^@VO_ ("__9UZC11SR#E1Y=_PJ!_^@VO_ ("__9T?|*@? M_H-K_P" O_V=>HT4<|@Y4>7?|*@?_H-K_P"
O_V=' "H'_Z#:_| @+_]G7J- M%'/(.5'EW_"H'_Z#:_| @+_]G1_PJ!_^@VO_ ("__9UZC11SR#E1Y=_PJ!_^ M@VO_ ("__9T?|*@?_H-K_P" O_V=>HT4<|@Y4>7?|*@?_H-K_P" O_V=' "H M'_Z#:_|
@+_]G7J-%'/(.5'EW_"H'_Z#:_| @+_]G1_PJ!_^@VO_ ("__9UZ MC11SR#E1Y=_PJ!_^@VO_ ("__9T?|*@?_H-K_P" O_V=>HT4<|@Y4>7?|*@? M_H-K_P" O_V=' "H'_Z#:_| @+_]G7J-
%'/(.5'EW_"H'_Z#:_| @+_]G1_P MJ!_^@VO_ ("__9UZC11SR#E1Y=_PJ!_^@VO_ ("__9T?|*@?_H-K_P" O_V= M>HT4<|@Y4>7?|*@?_H-K_P" O_V=' "H'_Z#:_| @+_]G7J-%'/(.5'EW_"H M'_Z#:_|
@+_]G1_PJ!_^@VO_ ("__9UZC11SR#E1XYKWPU;0]$N=2.JB80 ' MR_L^W=E@.NX^M3:7|+7U+2K2^&KK']HA679]GSMR,XSNYKN?'W_(D:G_ +B? M^AK5WPM_R*>D?]>D7_H(I\SL+E5SA?|
A4#_ /0;7_P%_P#LZ/\ A4#_ /0; M7_P%_P#LZ]1HI<\A\J/+O^%0/_T&U_| 7_[.C_A4#_]!M?_ %_^SKU&BCG MD'*CR[_A4#_]!M?_ %_^SH_X5__0;7_P !?_ LZ]1HHYY!RH\N_X5__0;7 M_P !?
_LZ/^%0/_T&U_| 7_[.O4:*.>0*66&:8RRB)$A4,Q8YQQGVK._X2J3_H7]; _| 3_Z M]9RKJ+LV==+ 5JL.>$;KU7ZM'(_|*@?_ *#:_P#@+_| 9T?|*@?_ *#:_P#@ M+_| 9UUW_"52?]"_K?| X"?_
%Z/^$JD_P"A?UO_,!/_KTOK,>_]?<:?V9B M?Y/QC_|)'(_|*@?_H-K_P" O_V=' "H'_Z#:_| @+_]G77?\)5)_P!"_K?_ M ("?_7H_X2J3_H7];_| 3_Z]'UF/?| K[@_LS$_R?C'_P"2.1_X5__ $&U M_P#
7_[.C_A4#_| 0;7_ ,!?_LZZ[_A*I/\ H7];_P# 3_Z]'_"52?| 0OZW M_P"_G_UZ/K,>_P#7W!_9F) D_&/_ ,D_]?<']F8G^3|8_P#R1R/_ M_J!_P#H-K_X"| V=_'_J!_P#H-K_X"| V===_P)5)_T+^M_^ G_->C
M_A*I/^A?UO| |!/_ *]'UF/?^ON#^S,3_)^,?_ DCD?| A4#_ /0;7_P%_P#L MZ/\ A4#_ /0;7_P%_P#LZZ[_ (2J3_H7];_| \!/_ Z]'_E4G_0OZW_X"?/UZ/K,>_]?<'|8_P#"H'_Z#:_^ O|
]G1_PJ!_^@VO_@+_ /9U MUW_"52?]"_K?_@)_]>C_ (2J3_H7];_| \!/_ "?C'_Y(MY'_A4#_ /0;7_P%_P#LZ/\ A4#_ /0;7_P%_P#LZZ[_A*I/^A?UO_P!?_ LZ/^ M%0/_T&U_| P!?_LZ_1HHY5SA?|
7W!_9F)_D_&/_ P DC_A*I/^A?UO_P!?_ LZ/^)(Y'_A4#_ /0;7_P%_P#L MZ/\ A4#_ /0;7_P%_P#LZ]1HJ^A?UO_P!?_ LZ/^ _KT?68]_Z^X/[,Q/\G M_P"?LZ_^%0/_T&U_| 7_[.C_A4#_]!M?_ %_^SKU&
7W!_9F)_D_&/_ ,D_]?<']F8G^3|8_P#R1R/_ M_J!_P#H-K_X"| V=_'_J!_P#H-K_X"| V===_PE4G_0OZ0ZW_ . G_P!> MC_A*I/|] H7];_P# 3_Z]'UB/?^ON#^S,3_)^,?_ DCD?| A4#_ /0;7_P%_P#L MZ/\ A4#_ /0;7_P%_P#LZ]1H
1]9AUFWEEBBFA,4IB>.90K!AC/&?>M*K51M7 M3.2I1E2FX35FCR[_ (5 _P#T&U_|!?| [.C_ (5 _P#T&U_|!?| [.O4:*KG MD9|J/+O^%0/_ -!M?_ 7_P"SH_X5__ | T&U_|!?_
+.O4:*.>00^=QKZ&TE/*T:QCSG;;QKGUPHKS#XH?| (G-_UWC_ *UZEIW_ "#+ M3_KBG_H(I2;:5QQ5F6:***S+"N3^)O| R3K6/^N:?^C%KK*Y/XF_|DZUC_KF MG_HQ:<=T)
[&9X6_Y%/2/^O2+_P!!%:]9'A;_)%/2/| KTB_]!%:]4]R4%%% M%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !7"_%+_)
FG?| 7|G_*"U=U7" M_%+_) FG?| 7|G_*"U5'<3V.ZHHHJ1A1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"_#7_5
M:W_U_-7=5POPU_U6M_| 7|U4MF)[G=4445(PHHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA?$ MO_)2O#7^ZW]:[JN%|2_|E*|-?[K?
UJH[B9W5%%%2,**** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ KA?AK]S7/^OYJ[JN%^&OW-
<_Z_FJELQ/ M<[JBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%=?| M'I-
US;^5UBOCE\OR/0K?[K1[?_| 2D%%%%:' M"%%%% !14DS.$BU2RD<]%6X0G^=)M(TC3G) M7C%M>C_R+]%5;K4K"Q=4N[VVMV8942RJA(]LFH/^$@T7_H+V'_@2G^-+F2ZC
MC1JR5XQ;7H_|C1HJG;ZMIUV7%OJ%K,47>_ES*VU?4X/ J+_A(-%_Z"]A_P"! M*?XTX>PJMVY7]S_R-&BH;:|M;V/S+6YAG3^]$X8?F*FJC-IQ=FK,***H' M6])601G5+
(.3@*;A,G|,TFTMRHPG/X4WZ)LOT4@(90RD$$9!'>J<^L:9:S-# M<:E9PRKC5W[6=_NL6]*H1ZYI$TJ1 M1:I8O(Y"JJW"$L3T &>35^A-/84Z6_%#_D3F_P"N|?| 6O4M._Y!EI_UQ3_T$4WL
M@6Y9HHHJ"@KD_B;_ ,DZUC_KFG_HQ:ZRN3^)O_).M8_ZYI_Z,6G'=">QF>%O M^13TC_KTB_| 016O61X6_P"13TC_ *](O_016O5/YW5%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7Q+_R4KPU_NM_6NZK MA?$O_)2O#7^ZW]:J.XF=U7*>,]8O])GT5;*?RAH2>5;[_NITRQ^F1_G M@I*XSHJ*X>?PCK|%I)

~~'[C5K^,I>ZQ=/>N#P0K'Y>.@SR?HPKM:X;PUXH|227EKHNL> M%KN*X0F.:^1=MOA1]X'&WG&, X]/0=S42W*6QYC&?LO[0$HF4I]JL<0DC[^$ M&G5QOCOP;-XA6UU/2I_LVMZ>=UM(>~~
~~^#G:?3GD'IUSUXS+;QYXIL MHEM]7|#ZE+=)E7ELE+HY'< @?F?|&U?86QZ+7FOPJMXM2DUWQ)=*)-0GU"2 M'S&Y*(K8![#YL?0"NC|,Z[K^LWUP=2|/I5DB Q&5]SNQ/X8X]OQKEX=.U_~~
~~MX>:_J-QI6E2:MH%])YOD6[?O8&YX"|D]QT.0!R#0EN@?>3X>QZ;I5E/<&& M2%(X8(R[!%&.BCL*:TLF)ZW9T_AVPMK7PKIUE%"HMQ:H"A&0OW2P+YT-SY$3GDHG/~~
~~)]>,_05Z9I*/'HUC'(K*ZV|896&""%'!K MB/A9IM]I_P#PD'VVRN;;S;W='YT3)O'/(R.123T8^J*GBU5MOC)X4N8E"RRH M8W8?Q#+#^3&JWQ$L(-3^)GA2SN5#P2X$B'HRA|D'V.,5]>+=-~~
~~OKGXG^%KN"R MN9::#/FS1Q,R1_,?O,!@?C5+XB:3KE]XY|/7.BVLK20+N6?RF,2.&R [#H#C M!]C5+H2^IZ5+:6|UHUI)!&UNR;#$5^7;TQBO/OA&WE6NOZ?&Q-K:ZBX@!.=H M/'7_("/U]:EN?~~
~~&WBJ:![*S|$ZC%[;)M663_%".1UW$;2 ??ZUN>!O"[>%M M |BXD66_N)#/=2#H7/8'T_7)[U.RU*W9S'PH_Y"_B__*__/V:2JWPAT^U M;4O$6HM$K7271A20]54DD@?4X_*M/X9Z;?~~
~~6&J>*7O+*YMEGO=T331,@D&Y^5 MR.1R.GK1|+--OM/_ .$@^VV5S;>;>[H_.B9-XYY&1R*;>XET(?B+ D?C7P1> M("L[;@L3.IP2GF1|'|S^9KK?$WB'1O#MI#<:N0V9,P1"/>[..ZCU&>O%<_X_~~
~~MT^]O?$?@Z6UL[B>.WU)7F>*(L(UWQ|L0.!P>3Z5#|1-)UDZUH7B+2[)]172W M+2V:MR1D'*CN3C')&%X-+>P;7,KQMXIO];|):C:GP=JD%H5#?:;P>5Y>U@0 MVW|.F?~~
~~YUU7A]F;X4VA8DG^RL&;VTL?#%]I]MY>Z=[E# MYLF.1'''C)R1U],UU_A?3Y3|/].T^ZCDMY6L1%(KH59"5P<@]Z;V!;F1|(O^ M2>6G_767_P!#-9EY_P G 6'_%X'_P!->F>~~
~~;W7/#4$7A>_|,W[,ET1]LC0^ M0$8Y+%|8.,GIV],5=NM-OF^.%CJ"V5R;);(JUR(F|L'_!;&,|BCJPZ(@FMX MM>^.#VU^HE@TK3Q-!$W*[|HVF7;)&XX(M_P_]^U^M)[687$A|N>,HV~~
~~M#C!P>:;>C$EJC-U:!+?X|:!+$"C7-E)YV#C?A)0,^O0?D*])K@]9T^]E^,?A MV^CL[A[.*TE62X6(F-"5EP"V, |C|Q7>5,N@UU"O-OA%_J?$7_82:O2:|V^$ M7^I|1?| 82:A;,'NCTFBBBI*"BBB@ HHHH~~
~~**** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-O%W_)7/"'^Z_] M:])KS;Q=_P E<|(?[K_UJH[DRV/2:**Y/QUXU_X0JSM+C^S_+9]HD9-OG>7~~
~~MMP,Y^ZJGNI]P#&U33;%;S43;I*ENH)#,V,X .3 M@$G .3C%7]%NKR]T6SN=0M/LEY+$K2P9^XWI[?0|CI18+EZBBBD 4444 %%% M% !1110 4444 5-2TNPUBS-IJ-I%%(8(DBB085$4*JCT~~
~~%/ID+2/!&|L?E2,H+)NW;3CD9[XI](84444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YM|(_| 5^(_^PDU M>DUYM|(_]7XC_P"PDU4MF2]T3_&/_D4;3_K_~~
~~$_]%R5XA7U!K.AZ;X@LTM-4 MMO/@202*N]EPP!&A-8G_ K/PA_T"|| R9E_^+KOP^*A3ARM'DXO U*U M7GBU;0^>J*^A?^%9^$/^@1_Y,R__!=' "L_"'_0(_|_)F7_ .+K?Z]3[,Y?~~
~~M[+K=U_7R/GJBOH7_(5GX0_Z!'_DS+_|71_PK/PA_P! C_R9E_| BZ/KU/LP M_LNMW7]?(^>J*^A?^%9^$/| H$?^3,O_,71_P *S|(?] C_,F9?_BZ/KU/ MLP LNMW7]?(^>J*^A?| A6?A#_H$?~~
~~^3,O_Q=' "L_"'_$"/)F7_P"+H^O4 M^S#^RZW=?U|CYZHKZ%_X5GX0_P"@1_Y,R_| Q=' K/PA_T"| R9E_^+H^ MO4^S#^RZW=?U|CYZHKZ%_P"%9^$/^@1_Y,R__%T?|*S|(?| 0(_|F9?_(NC~~
~~MZ]3[,/[+K=U_7R/GJO7/A9X_,:IXBOT4[U(M(F7E>?| 6<_3CV.?2NJ3X;>$ M4=6&D#*G(S<2D?D6YKJD18T5$4*JC 4#]*PKXQ3CRP.K"YHT[;"T4 M45YQ[4444 %%%% !1110 4444 %%%% !1110~~
~~4444 %%%% !1110 4444 % M%%% !1110!!>_P#'CM7Q?_R) M6N_]@^?_-%M65|+O^2;Z1_NR_| HUZK[)/4Z^BBBI*"BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH~~
~~**** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH Y+XF_|DZUC_<3_ &+6CX,_P"1(T/_M *|8?_0!6=|3?^2=:Q_N)_Z,6M'P9_R)&A_]>,/_* *K[)/4W****DH**** M "BBB@ HHHH ****~~
~~"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_P",G_(@O_U|Q_UK MM]._Y!EI_P!<4_| 017$?&3_)$%_P#KYC_K7;Z=_P~~
~~@RT_ZXI_Z"*I_"B>I M9HHHJ2@KD_B;_P DZUC_*YI_P"C%KK*Y/XF_P#).M8_ZYI_Z,6G'=">Q?| M!?| R)&A_P#7C#_Z *W:PO!?_(D:'_UXP_| H K=H>X+8****0PHHHH **** M "BBB@ HHHH ****~~
~~"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "O-OC/_,B[I7_823_T!Z])KS;XS_| (NZ5_P!A M)/| T!ZJ'Q$RV/2:***DH**** "BBB@ HHHH **** "BBB@ HHHH ****~~
~~"B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *|V^$7^I|1?]A)J])KS M;X1?ZGQ%_P!A)JI;,E[H])HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH ****~~
~~"BBB@ HHHH **** "BBB@ KS;Q=_R5SPA_ MNO| UKTFO-O%W_)7/"'^Z_| 6JCN3+8])KS;XKHLESX61U#*VI*"I&01E>*] M)KSCXJ_|?GA3_L)K_:([A+87X=2OH&N:UX+N7R;27[3:.3]Z)@,CK[J?Q;T~~
~~MK=^(.OG0/" U)#S>70^S6R#J7?C('L,GZ@#O6)|189M$UC1O&MJK,;"06]VO MK"Q(]/| :89]6'%0RW$?C?XI6L$3K+I&APBX8X!669P"N/S7J/X&]:JUW<6V MAA>$=%_X1[XI:9I;*!-#I69R#G,C~~
~~LWY$X^@KTGQ-JFN6"6T6@Z,-1N)RP+/ M+L2'&#EO7//<=.]K0+1&/>^-O%GA5[6X|5Z1I_]G7$HB,MB[;HCR>02<| MG'L>:L_&%E?X?LRD%3<1$$'@CFN8^(]GXPB|)M-KVKZ?);&=~~
~~+:UAQENU?6;CP_P##@:K:)$|]O:0E%E!*G.T< M@$'OZU5/V?[3RRP#6]N'P/X=Z_P!<5*5U|QWL:-CXM|;>)(SJ&@:%81:66(C:_=@| M@'4C##OD="/?@U)I7C[5=0|>6?AZZTI+~~
~~F!S=Q2@LZ2J&/R,#@H0%(..YY[U MV/A|1+X;TL0;?*%I$$VG(V[!C'MBN(U$QGX]Z0$*EAIC!]O4'][U]|8_#%"L M[Z"U+OC3QW=>%?$NE62P0R6=S&7FRC*2#@!,'&3P.0>M5-6|4^/M*LY-7F|~~
~~M.Z-/5B&QZ9P#WXJ#QJ WQ9|(@$=>?|_>-=SXE ;PKJX(!!L MI@0>_P AHT5M UU':5K4&M>'X-7LE:2*>'S%3OD=5^H((^HKDAK7Q)O0;BU|M-Z9:0=5@NYRTI_$,_/Q~~
~~Z5'X'UB#0/@S::K<@M%;),Q4'!8^W;BBUKCO>.V#]3S=E|0];OO$6N:'::3;WE[:W;16B)F-1$KNKR2 ML21QA.F,EN*;|*%G35_%ZW-PMS<+?@2SJH42-NDRP X&3SQZTOPU53XV|>-@ M;AJ&~~
~~<A8A|;>(]$|0V.G>+],L8+:^?RX;NS8[0V0., MD9SC&<]JZ_Q%X@LO#.C2ZG?LWEI|JHHRTC'HH]S7&?%T#[+X?.!D:D@S^%'Q M2,;:MX0CNBHLFU)?/PX3&Y/O'TP6_6E9.P7M*_&&K>'_~~
~~+9:TMC!#J$LD:36]PK,J$JQ(X(/45W%>=? M&G_D1H_^OV/_ !>A6;2L-Z(Z_4M?L]$|/'6-2?9$L2N50HJE|5VF'A#0$2411M=Q;G8 M#:IV'!.>W4X]JTO[!^)/_0Y6?_@%'_|$4)*UQ~~
~~NYKZ%XWL=7|)7.N2QO;FR M5_MD!^]&Z+D@9QG/;|NM8EEXE|>:]:1ZGH^AZ5#I|WS1+=3,TC+G'4$ J^R3U.OHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH~~
~~**** "BBB@ HHHH **** "BBB@ M HHHH **** .2^)O_).M8_W$_P#1BUH^#/| D2-#_P"O&'_T 5G?$W_DG6L? M[B?^C%K1|&?|B1H?_7C#_P"@"]^R3U-RBBBI*"BBB@ HHHH~~
~~**** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH |_| C)_R(+_]?,?]:[?3O^09:?| 7%/_$$5 MQ'QD_P"1!?|_Z^8_ZUV^G?|~~
~~(,M/^N*?^@BJ?PHGJ6:***DH*Y/XF_|).M8 M_P"N:?| HQ:ZRN3^)O| R3K6/^N:?^C%IQW0GL7_7_ ,B1H?| UXP_^@"M MVL+P7_R)&A_]>,/_* *W:'N"V"BBBD,**** "BBB@ HHHH **** "BBB@ H~~
~~MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ KS;XS_P#(NZ5_V$D_] >O2:|V^,__"+NE?| 823_ _>JA|1,MCTFBBB MI*"BBB@ HHHH **** "BBB@ HHHH ****~~
~~"BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "O-OA%_J?$7_82:O2:|V^$7^I|1?| 82:J6S)> MZ/2:***DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@~~
~~HHHH **** "BBB@ HHHH *|V|7?|E<|(?[K_ :])KS;Q=_R5SPA M_NO_ %JH[DRV/2:Y+QKX7O?$D^B/9RVZ"QO!/+YS,,J".%P#SQWQ76T4D[%- M7*.L:7!K6CW>FW 'E7,1C)QG:3T/X'!_"L+X?~~
~~^$&|'Z"]K/+'+=S3-),|9)7 MT4#(!Z 'ZDUU=%%W:PK=3C_^$4OO^%H?|) YMM]B^S>3Y>YO,SMOTQC'XU!X MI|&:I>>)+;Q+X8>(? 'B MOQ1IA.K:U92WJ,/(MXPT=O$/XFR!EFQP,C@9]>.B|:^%~~
~~[WQ'X.CTBSEMTN%: M,EIF8)|HYY_)_2NMHHYF%DJ^ I="@DA6Z>WCB#NQ"94KGD G'![5 M+IOAQ%|#V_AW5-DJBT%O,8F.#QU4D_I6_534[6>]TRXMK:[:TGD0K'<(,F,~~
~~M]CC(S^=*_0+'!Z=X4|=Z!%_9ND^(=/DTM%+[5O'&A:W M!+;+;:?_ *U9&8.W.?E !'YD5TFK6DE_HU]9Q%1)<6|D2ECP"RD#/MS5RBHN~~
~~M58XW2_!+K|,E|)ZG/'YA1U:6#+*I,I=2,@9P=OIT_&LS3?"_CZSL%T;_(22 MQBTV-!%'<1Q%KA(QP_,@ <<9R2,#!KT6BGS,+(XWP+X-N/"_UK?F2PO;7=P' MM@KLSK&"V-^0.<$=,]Z?X1|*WV@>(?~~
~~$VH74MN|6J77G0")F+*N^1OFR!@X<= M,]ZZ^BES,+(Y+QUX7O?$|&EI92V|9M+Q9W|YF&5 Z#_/-:OB?PW9>*M%DTV]~~
~~MW*I8/'(GWHW'1A^9'T)K8HHNPL>>P:%|1]/@6QM/$6ESVJ#9'<7$3>:_BDC>6XGRBR%5()PH//-=K13YF%C&UCPY:: M_P"&SH^H9V&-1OC."C@<,/H?~~
~~6N2LO#WQ'TJUCT^T|0Z5+:1+LBDGB8R*H& / MNG./DUYM|(_P#5^(_^PDU4MF2]T>DT445)04444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%~~
~~M%% !1110 4444 %%%% !1110 4444 %%%% $%[_QXW'_ %R;^5<)|&?^1$/_M %]R?R6N[O?^/&X_ZY-_*N$^#/| R(A_Z^Y/Y+5+X63U/0J***DH**** "BB MB@ HHHH **** "BBB@ HHHH ****~~
~~"BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%|7_|B5KO_8/G_P#1;5E? M"[_DF^D?[LO_*_>M7Q?_P B5KO_&#Y_P#T6U97PN_Y)OI'^[+_ .C7JOLD~~
~~M]3KZ***DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#DOB; M_P DZUC_~~
~~'$_]&+6CX,_Y$C0_P#KQA_] %9WQ_ Y)UK'^XG_*,6M'P9_P B M1H?_%XP_P#H JOLD]3I9HHHJ2@K'|5:&WB3PU>:0MS]F:X"@2[-V MW#!NF1UQC|:V**/,K?X:^)[6VBMX/'M[%#&H1(TC<*H'0~~
~~>9TJ3_A7OBS_H MH6H?]|/_/'*])HJN9D|J/-O^%>^+/| HH6H?]|/ P#'*/| A7OBS_HH6H?] M|/|_'*])HHYF'*CS;_A7OBS_HH6H?| ?#__!RC_A7OBS_HH6H?]|/_/'* M])HHYF'*CS;_(5[XL_Z*%J'_?#_~~
~~/QRC_A7OBS_**%J'_?#_| QRO2:*.9 MARH|V_X5[XL_Z*%J'_?#_P#QRC_A7OBS_HH6H?| ?#__!RO2:*.9ARH|V_X M5[XL_P"BA:A_WP__,^+/^BA:A_WP_P#|^+/^ MBA:A_P!|/_|~~
~~'*/^%>>^+/^BA:A_WP_||^+/| HH6H?]|/_P#'*])HHYF'*CS;_A7OBS_HH6H?]|/_/'* M/^%>>^+/^BA:A_P!|/_| '*])HHYF'*CS;_A7OBS__**%J'_?#_ _QRC_A7OBS_~~
~~/QRO2:*.9ARH|V_X5[XL_Z*%J'_'P_P#|^+/^BA:A_WP_P#|^+/^BA:A_WP_||^+/| HH6H?]|/_P#'*/| A7OBS_HH6H?]|/|_'*])HHYF'*C MS;_A7OBS_HH6H?| ?#__!RC_A7OBS_HH6H?]|/_/'*])HHYF'*CS;~~
~~/*])HHYF'*CS;_(5[MXL_Z*%J'_?#_/QRC_A7OBS_**%J'_?#_| QRO2:*.9ARH|V_X5[XL_Z*%J M'_?#_P#QRC_A7OBS_HH6H?| ?#__!RO2:*.9ARH|V_X5[XL_P"BA:A_WP__M~~
~~,^+/^BA:A_WP_P#|^+/^BA:A_P!|/_| '*/^ M%>>^+/^BA:A_WP_||U2 M*.*^|:W%U&CAU6:%F"MZC+]>:]4HHYV'*CS;_A7OBS_HH6H?]|/_/'*/^%> M^+/^BA:A_P!|/_| '*])HHYF'*CS;_A7OBS_~~
~~**%J'_?#_| QRC_(5[XL_Z M*%J'_?#_/QRO2:*.9ARH|V_X5[XL_Z*%J'_'P_P#|^+/^BA:A_WP_P#|^+/^BA:A_WP_||^+/| HH6H?]|/_P#'*/| A7OBS_HH6H?]|/|_'*])HHYF'*CS;_A M7OBS_HH6H?| ?#__~~
~~!RC_A7OBS_HH6H?]|/_/'*])HHYF'*CS;_(5[XL_Z M*%J'_?#_/QRC_A7OBS_**%J'_?#_| QRO2:*.9ARH|V_X5[XL_Z*%J'_?# M_P#QRC_A7OBS_HH6H?| ?#__!RO2:*.9ARH|V_X5[XL_P"BA:A_WP__~~
~~,^+/^BA:A_WP_P#|^+/^BA:A_P!|/_| '*/^%> M/^+/^BA:A_WP_||^+/| HH6H M?]|/_P#'*])HHYF'*CS;_A7OBS_HH6H?]|/_/'*/^%>>^+/^BA:A_P!|/_| M'*])HHYF'*CS;_A7OBS_**%J'_?#_| QRC_~~
~~(5[XL_Z*%J'_?#_/QRO2:* M.9ARH|V_X5[XL_Z*%J'_'P_P#|^+ M/^BA:A_WP_||;?| M"O?%G_10M0_[X?^*^| CE>DT4;?*]|6?| 10M0_P"^ M' | CE'~~
~~KWQ9_T4+4/^^'_/CE>DT4;?| "O?%G_10M0_[X?| ^.4?|*]|6?| M10M0_P"^' | CE>DT4;?|*]|6?| 10M0_P"^' | CE'_KWQ9_T4+4/^^'_/CE M>DT4 M;?| "O?%G_10M0_[X?| ^.4?|*]|6?| 10M0_P"^' |~~
~~CE>DT4;?|*]|6?| 10M0 M_P"^' | CE'_KWQ9_T4+4/^^'_/CE>DT4;?| "O?%G_10M0_[X?| ^.4?|*]| M6?| 10M0_P"^' | CE>DT4;?|*]|6?| 10M0_P"^' | CE'_KWQ9_T4+4/^^'_ M /CE>DT4;?| "O?~~
~~%G_10M0_[X?| ^.54G^%6O7-_;WLWC6XEN8,^5,|+%X_]T[^* M]4HHYV'*CS;_(5[XL_Z*%J'_?#_/QRC_A7OBS_**%J'_?#_| QRO2:*.9 MARH|V_X5[XL_Z*%J'_?#_P#QRC_A7OBS_HH6H?| ?#__~~
~~!RO2:*.9ARH|V_X M5[XL_P"BA:A_WP__,^+/^BA:A_WP_P#|^+/^ MBA:A_P!|/_| '*/^%>>^+/^BA:A_WP_||^+/| HH6H?]|/_P#'*])HHYF'*CS;_A7OBS_HH6H?]|/_/'* M/^%>>^+/^BA:A_P!|/_|~~
~~'*])HHYF'*CS;_A7OBS__**%J'_?#_ _QRC_A7OBS_HH6H?]|/|_'*])HHYF'*C MS;_A7OBS_HH6H?| ?#__!RC_A7OBS_HH6H?]|/_/'*])HHYF'*CS;_(5[MXL_Z*%J'_?#_/QRC_A7OBS_**%J'_?#_| QRO2:*.9ARH|V_X5[XL_Z*%J~~
~~M'_?#_P#QRC_A7OBS_HH6H?| ?#__!RO2:*.9ARH|V_X5[XL_P"BA:A_WP__ M,^+/^BA:A_WP_P#|^+/^BA:A_P!|/_| '*/^%>>^+/^BA:A_WP_||^+/| MHH6H?]|/_P#'*])HHYF'*CS;_A7OBS_HH6H?]|/_/'*/^%>>^+/^BA:A_P!|/_| M/~~
~~'*])HHYF'*CS;_A7OBS_**%J'_?#_| QRC_(5[XL_Z*%J'_?#_/QRO2:*.9ARH|V_X5[XL_Z*%J'_'P_P#|^+/^BA:A_WP_||;^^3R867>WJ^+/| HH6H?]|/_P#'*])HHYF'*CS;_A7O~~
~~MBS_HH6H?]|/_/'*/^%>>^+/^BA:A_P!|/_| '*])HHYF'*CS;_A7OBS__**% MJ'_?#_| QRC_(5[XL_Z*%J'_?#_/QRO2:*.9ARH|V_X5[XL_Z*%J'_'P_M_P ^+/^BA:A_WP_P#|^+/^BA:A_WP_||^+/|~~
~~HH6H?]|/_P#'*/| A7OBS_HH6H?] M|/|_'*])HHYF'*CS;_A7OBS_HH6H?| ?#__!RC_A7OBS_HH6H?]|/_/'* M])HHYF'*CS;_(5[XL_Z*%J'_?#_/QRC_A7OBS_**%J'_?#_| QRO2:*.9~~
~~MARH|V_X5[XL_Z*%J'_?#_P#QRC_A7OBS_HH6H?| ?#__!RO2:*.9ARH|V_X M5[XL_P"BA:A_WP__,^+/^BA:A_WP_P#|^+/^ MBA:A_P!|/_| '*/^%>>^+/^BA:A_WP_||^+/|~~
~~HH6H?]|/_P#'*])HHYF'*CS;_A7OBS_HH6H?]|/_/'* M/^%>>^+/^BA:A_P!|/_| '*])HHYF'*CS;_A7OBS__**%J'_?#_| QRC_(5[XL_Z*%J'_?#_/QRO2:*.9ARH|V_X5[XL_Z*%J'_'P_P#|^+/^BA:A_WP_||~~
~~^+/^BA:A_WP_P#|^+/| HH6H?]|/_P#'*/| A7OBS_HH6H?]|/|_'*])HHYF'*C MS;_A7OBS_HH6H?| ?#__!RC_A7OBS_HH6H?]|/_/'*])HHYF'*CS;_(5[MXL_Z*%J'_?#_/QRC_A7OBS_~~
~~**%J'_?#_| QRO2:*.9ARH|U;X=^*W4JWQ! MORI&""C|_P#D2JVG_"OQ!I=K]GL?&US:P[BWEPPLJY/? >O4Z*.=ARH|V_X5 M[XL_Z*%J'_?#_P#QRC_A7OBS_HH6H?| ?#__~~
~~!RO2:*.9ARH|V_X5[XL_P"B MA:A_WP__,^+/^BA:A_WP_P#|^+/^BA:A_P!| M/_| '*/^%>>^+/^BA:A_WP_||^+/| HH6H?]|/_P#'*])HHYF'*CS;_A7OBS_HH6H?]|/_/'*/^%>>^+/^ MBA:A_P!|/_|~~
~~'*])HHYF'*CS;_A7OBS__**%J'_?#_| QRC_(5[XL_Z*%J'_?#_ M_QRO2:*.9ARH|V_X5[XL_Z*%J'_'P_P#|^+/^BA:A_WP_||^+/| HH6H?]|/_P#'*/| A7OBS_HH6H?]|/|~~
~~_'*])HHYF'*CS;_A7OBS M_HH6H?| ?#__!RC_A7OBS_HH6H?]|/_/'*])HHYF'*CS;_(5[XL_Z*%J'_?#_ M_QRC_A7OBS_**%J'_?#_| QRO2:*.9ARH|V_X5[XL_Z*%J'_?#_P#Q MRC_A7OBS_HH6H?| ?~~
~~#__!RO2:*.9ARH|V_X5[XL_P"BA:A_WP__,^+/^BA:A_WP_P#|^+/^BA M:A_WP_||^+/| HH6H?]|/ M_P#'*])HHYF'*CS;_A7OBS_HH6H?]|/_/'*/^%>>^+/^BA:A_P!|/_| '*])~~
~~MHHYF'*CS;_A7OBS__**%J'_?#_| QRC_(5[XL_Z*%J'_?#_/QRO2:*.9AR MH|V_X5[XL_Z*%J'_'P_P#|^+/^BA M:A_WP_||)[FWE@F|>WLL M4J%'C>~~
~~RK*1@@_O.AIEE|,/$>GVD=K:>.KNW@CSMBBB957)R< 2>I->H44<[M#E1YM_PKWQ9_T4+4/^^'_P#CE'_"O?%G_10M0_[X?_XY7I-%',PY4>;?|*]| M6?| 10M0_P"^' | CE'_KWQ9_T4+4/^^'~~
~~/CE>DT4;?| "O?%G_10M0_[X?| M^.4?|*]|6?| 10M0_P"^' | CE>DT4;?|*]|6?| 10M0_P"^' | CE'_KWQ9_T M4+4/^^'_/CE>DT4;?| "O?%G_10M0_[X?| ^.4?|*]|6?| 10M0_P"^' | CE>D MT4;? M|*]|6?|~~
~~10M0_P"^' | CE'_KWQ9_T4+4/^^'_/CE>DT4;?| "O?%G_10M0_[MX?| ^.4?|*]|6?| 10M0_P"^' | CE>DT4;?|*]|6?| 10M0_P"^' | CE'_KW MQ9_T4+4/^^'_/CE>DT4;?| "O?%G_10M0_[X?| ^.4?~~
~~|*]|6?| 10M0_P"^' | MCE>DT4;?|*]|6?| 10M0_P"^' | CE'_KWQ9_T4+4/^^'_/CE>DT4;?| "O?%G_10 MM0_[X?| ^.4?|*]|6?| 10M0_P"^' | CE>DT47WGPQ|27]I);W?CJ[N()!AHI8F~~
~~M*MSGD>9ZBGV_PU|3VMM%;P>/;V** 0B1I&X50.@ |SI7IM%'.PY4>;?|*]|6 M?]%"U#_OA_| XY1_PKWQ9_T4+4/^^'_^.5Z311S,.5'FW_"O?%G_$4+4/| MOA__(Y1_P *]|6?]%"U#_OA_P#XY7I-~~
~~%';PY4>;?|*]|6?]%"U#_OA__CE'_M_"O?%G_10M0_[X?_ ..5Z311S,.5'FW_KWQ9_T4+4/^^'_/CE'_"O?%G_ M $4+4/| OA__(Y7I-%';PY4>;?|*]|6?]%"U#_OA_| XY1_PKWQ9_T4+4/^~~
~~M^'_^.5Z311S,.5'FW_"O?%G_$4+4/| OA__(Y1_P *]|6?]%"U#_OA_P#X MY7I-%';PY4>;?|*]|6?]%"U#_OA__CE'_"O?%G_10M0_[X?_ ..5Z311S,.5 M'FW_KWQ9_T4+4/^^'_/CE'_"O?%G_$4+4/~~

OA__(Y7I-%',PY4>;?\ M*]\6?]%"U#_OA_\ XY1_PKWQ9_T4+4/^^'_^.5Z311S,.5'FW_"O?%G_$4+ M4/\ OA__(Y1_P *]\6?]%"U#_OA_P#XY7I-%',PY4>;?*]\6?]%"U#_OA_M_CE'_"O?%G_10M0_[X?_
..5Z311S,.5'FW_KWQ9_T4+4/^^'_/CE'_"O M?%G_$4+4/\ OA__(Y7I-%',PY4>;?*]\6?]%"U#_OA_\ XY1_PKWQ9_T4 M+4/^^'_^.5Z311S,.5'FW_"O?%G_$4+4/\ OA__(Y1_P *]\6?]%"U#_OA
M_P#XY7I-%',PY4>;?*]\6?]%"U#_OA__CE'_"O?%G_10M0_[X?_..5Z311 MS,.5'FW_KWQ9_T4+4/^^'_/CE'_"O?%G_$4+4/\ OA__(Y7I-%',PY4 M>;?*]\6?]%"U#_OA_\
XY1_PKWQ9_T4+4/^^'_^.5Z311S,.5'FW_"O?%G_M $4+4/\ OA__(Y1_P *]\6?]%"U#_OA_P#XY7I-%',PY4>;?*]\6?]%"U# M_OA__CE'_"O?%G_10M0_[X?_..5Z311S,.5'FW_KWQ9_T4+4/^^'_/CE
M'_"O?%G_$4+4/\ OA__(Y7I-%',PY4>;?*]\6?]%"U#_OA_\ XY1_PKWQ M9_T4+4/^^'_^.5Z311S,.5'EFH?"SQ!JEJ;:^\;W-U#D-Y GRAPHIC 7 form10-q_002.jpg begin 644 form10-q_002.jpg M_]C_X
02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7]#A(6&AXB)BI*3E)66EYB9F]*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U
76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;;WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H
,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH ***P_&5U/9>#M6N;65XIX[=F2 M2/[RGU'O0!N45Y==:Q?6"WT%K>:W K68E0:HN)#()4!,1(S@*QW#W7'>NGN?
M&:6>GVE[/:$0RW5S!)M?)18?,^8<?'4K^UU675[\:H+":X*V3+6&C'S88YY]2*N>';G4 M8=1T5KG4;B\76.>ZF27&V*0>6PV8'RKB0C'L*.UHHKS&[FU.\OM>2QD\0R M:G'?/%9M!(1:QX5-
H;/R[02G45R_BZYM]/:=K6%G34I+$X8X(16.[MZ_+TJG%XL\22Q%QIFF_)IJ:DX-PXPC;OW8.WEL*>>E '=45YP/'-U;W5Q#;+ MY[W5RTTN Y6&$10G;A
3DL_T&2:UM2U_4KGPW9WD"'3AJ,MO;!G4^;;))M M=B",<#[N>Y&: .QHKB1;1V_B%=$.J>(5CNHV7,[.5D90'W1S9RI !R!P?PK' MFCN[7P?<:A'JFLRW#:FUIM%XQ8QB[*)G@,5 &: /3J*X+1
>31M6U*WU6YU M&UM0D3P0ZD3+*2=P+*PS\O &,\$'UI/$%WJ&BW\6LP7]I/:RN[-(T@-L@V-L MA\HW6>]1@[%D#LIX$3 /PH MR.1W%6K9KJ?7+;PU+=:I9/NDENC_&@TKN

```
<%M=Z3HEY8)HEW:BV%M>1LQM!@AFCQ][(.<-W[UXV?CCXV&[B MP.%+?ZG_.O35^.GC7<018DGD#R/_KT->Q:AX1\1#39=%TW5;.72)[&.R*7\ M19[?:NQG3'#9'.#T-;6I>'KA_!L>AZ=S-8..1FO
M#;7XW^,YWV>589P3_JO_*]*?CKXN5@AM; DG&=A% 'I4/PVN!I][.) .L=5 MDN+>>U2SA(MK?R#E%QP6!);O#X_C]XI)&ZRL#D< @CFK5M\>_$LDJHVE6))..I% 'HLO@7Q!
MO^PPZCIXTA=9&J+NC?SC^\|PQGMUS@_2N6ECU&2]L_"^G2226L&O+<_99;&1 M)XHQ*9&+2?ZLQ@Y(8')R!6#<_'?Q1%*R?8+)2#C&"<56;XZ>+V=E6"R7!QGR M\T ?1]V,V
M[1T]%%%>X<@4444 %%%%% !1110 4444 %%%%% !1110 4444 <1\6O^2?7G_7 M6+_T,5\]"OH7XL_\D_N_^NL7_H8KY[S@T 1@B]2E%L\>N$*&>)N&5@,'KUJ!./-]
<#'YUTWBV*&2^BU&")XHKU!+M M?J":H:"E@^HI#>+NW..VXK:V.P\/:,H\-+[CX4 ,17KFF7MGJE@GV$$P0L8]S+M (_I[UYUXIGBU2\FOK6W,<<)$+ MY(.[KAA6WU>JE)M?#N/E9S41 <9X_=,.?
I7:>#-$6YM)=1D8?)\L:X_6NLKBRL[00&-HDP#$@7@CT_2L+$GDWB"(6VJ ;0O!S M@<=ZQ(A_JL_W^:]2\8>')=5AM=0L_*\I05=@<@#KVKS]"RENIV@M]KN&QC/7 MG'%.SV W?"6FM?SS2
+B,A0S?PD]Z3Q=IGV"XBE!)$_)XQSG_"O1/"UWI-OH ML5C':26YBDV232KA9G'4@_7BL_Q)?6>M>'[E)M-GMA:SD122C[WN#Z5HZ4TF MFMBN5GDH"%7W*V,,?0UW_@>."PL M[RX.%WG'G.,#;/?
L,UDDV[(DQ/%=@L=GYW!:-MI('KVKEDYD/^Z/Y5Z_KD5I M>64-G:Q._P!L#;98UW1C;ZGMGL:\FEA>VG>"12KH2"#52A*.Z&TT:-K_,BY MJ7_72#^;5F#K6G:_\B[J7_76#^;5FCUJ1#(E+R1(#RSD?
3I7H=UI CT#[*A&-MT*&VXZD#K]:YSPYI]K<.I:F4EI"=X0>Q[UZTSV2HD@-8[MK=S^5 'S^[-E<= M-U*G$,A]'6NL\9^'%TS4&NK5 MM."X4G[A]![5E^&].BU+48H[@8A#9<^WI0 M!U.GZ"&T-%
<(5DC!)[DGI7"W,1A:[A8CU7;;,,N>U< MI::=<7\|(A0.)7$8(YQGU%>Z6&D6%E:P6R28>&%02..1ZT->':C:-8:C/:RD M;D1AGUJC&1YJYXR/Z5ZGXYM-)MIX[QDC9Y/E?
VMS<@+O!V(6'3UK+URT6UUE5-55?Y@!TZ5[#H6G:79^%K>"!>!C> / MO-W/YUQWCNVM+BV_=0E9[7JQ'W@: /,C\PC6M_PI9?:[R=R@)CV\G^')K"5& M><(!D^U>]^ M-M;7P_+-
<*WG7,@/W>JCI0!QOBS2_L%Q'.I7;..0.QK#'5_] MXUZMXPL;"72FC)W+'\P8<[:\PN(%AE*(P9,94^U &OXB_P"26Z)_V$9?_037 M"X.*[OQ&/^+6Z)_V$9?_$$UP\:[F5>.3C)[4 0V\3330PH-SN6
ZYS7;7O MAN*QT)$N58SB,NQ'\/%:?PYT/39-5EO9768P_*CXXW5W5_I]M<"Y,TJR90]> M.F>/TH_^='/E?4TZ/\ U74_ZX#]*FU"SDL;YH'490GGU7L:ZGP%X9CU_5HC M<@"VB.]Q_>QVH N:?
X9270SOB47\Q?;/.*.=&-URQ[*G\Z]#\*Z% M]LTLAX@RW*X;'R<[#_*N_\ BGIEO::ZU]!&56X'S*1P M#7'Z5;+=7 +0M,50G:*.E\&:+;ZE;,\L19W8J6)QM K%UG39-)UG[+*00&8 MJP/!MOA;1=-
L=!TZWD"QW&TR2+C# GGFL#XB:+87BQRI$%G0?(X&,^QH M\2BY:,'_#S73^$M*_M3492R,Z0(&P/7M7/Q0EIRI49!P![U[\ ##0K.'09 MKR8[);HX9VZ8!XQ0!YIXFTXV%WO5"DOK[T ?
1GP>/_%NH_\ ??\ G716_;6NL3> M?*$+P1A1@G/S/Z5SGP@X^'*?[TG\ZZ7P^^[5;K_KA'_Z$]>#BE_PJ4'Y2'SV M7+W+-QJ>I1W4\<-B9(TEB5&V \RL?F/OCCGH,UM445[P@HHHH ****"BBB@ M
HHHH **YGXAS2V_P]UV:"5XI4M'*O&Q5E/]".EVWB>WL)8]*:WFU$6)@AG M:2XC!) D8@;!Z[RZ;IWV*%=7FU&>SNX Y*PI#DO(._W=F/] MZ@#N:*X/XF:?9#2?[28W[:DQ2SL8;>]DA5YI&PN0I
."CGL*^A?BSS M\/[O_KK%_P"ABOGP4 =OX;LH-?T&YC$42ZC%*ACD;@8!&>GJ,BM>[\1::FGF MY6TN6VW9MY(GPAX&2]"RL[ZT,5S;0S1,P8HZ C(Z M'ZUV4L13LHU8\R3TU^\TC);21Y)XWU*SU?
1[::UL[NW$,B[6G3:&##^$]ZY+ M0AN\16HSM;?P3ZXKUSXFPP2:'"DH"@-\@'\..F*\R\):7-?>(+658RUO%,#* M_0#TKGJRBY\T%9$2::NCT[6M)AT[P5]4LFY."#R*M:S86LFE7[ MM#&'>V,9<=P
<+]*[(XQQPTJ+UU<"L9(X_2]%ET/P[/;7KK/$SRM$!QA"21GWZUXUX=>.V\ M312'&P2L!^?%?0OB*!WTR=%&&*%%(["OGJ#36BUTVQ)'ERY![U4YN4 M:W9L?$=];QCEYL#V]:]ST.V6T\.6L#?,! H
ZUI2G[.:EV&G9W,"VT/=H=HL M$LT=LL:E0P(8YYR1VYKS'Q1$8/$<\9<,1C)'K7N\LR_9MK+@8X->(>,HA'XA M,@&/-3 M@S4B.S^'^F27=U-,00G3AMP\Z;B7.22:P?AI9NOAU91QN@,I
M2WZ9/MWH \<^),R1106H]RI/>N9\']=<8H,O"IP"3QTKD/'^CVL/AF[,:A9EYD M/J>U>@V,82T"HNTYZ5A^/K:*3PI>)MP7&": /)_A?>QVGB1H)4#>?"?+ST## MVKU"QT&6\N?
M+3'@G>/49KR+P3ITEUXIA*L5^S_,Q'Y5]"Z4ICM-I-/7UH M\P^*6BR#3TFMU9VBPS!1U6O+-.3S+VS3/RM,H(_&OHOQE&C:/<%5 VQ')'>O M!/#-I]K\1646!CS WZT->[V%E;"WCCA4J
,A<]_6J>NZ5#=Z1<1-&3/M)WXZ MUT=A: $C5['427&3%+M;CMFO?[*SAO-#M5@4+& M8US@=(O M^27:) V$9?\ T$UPA^Y]!7=>(3GX6Z+__A&7_T$UPQ^X: /2/ 5I>7&DVRV
MTHA7>69@!EN:]0.F!;=C*% Z.P]ZX?X86VSP_&[9/F$L/;FO4BGF6N,9R.AH M_^_\.270$?VW<(I0!CIG%8OQ?M&76;25 M-HA(8^].^#UI<@WMR'(MF8*$]2.]
'I?]B:@[0RK*%A)^90W4]N*\U^+6B" MT>VOEB'F;_+DD7OGUKW+3I$G@V$?,O09KSWXMP*_A9MX <2Y% '$_"26)[B] M@EVB6*/*/B]HSGPS)*4RT14JV/?FO(O"TJ6_B;39)'*PO((Y![&O?O
MBVWE^$KA&Q@CK7SUHT'VC5]/B'5IT_G0!])V6B6EQ=FY=G+@97/?V-5?$^BK M>VSQ*A"E_4'VKIM$MV^S]<#..II-8@V1,[.",9X-'RCJNFOI&KS6N\N5?&
M<ID>. 4W#GCZ8KRRXA74O'$RR<@W.T#'H:^D8=L-C:Q!0" ML8-'I0!R=YI-O;V+Q2'$<@(SCFOG[5,'6KI5):-)"JD^G:OH'QI+B5_P*%^4CDJ3M7A' MNF=K1117M'6%%%%% !1110 4444 %%%%
&?KFD0:]HEYI5T\B07<1B=HR P!] M,@\UA67@*VAU"SO+_6-6U4V3![:&]G4QQ.!@.%50"P'0G.*ZVB@#B(_AGI\1 MAC75=4%G;WWV^"U$B!(Y=VX_PY89)ZDXS3O#GAR?_A.=
<\4WVG+8R7*I;V\7 MFAR54#=(<< MA>.N%YKM:*,O5-"MM7O]+N[B24'3K@W$2(0%9]I4;ACG&21 MTYK4HHH-XCXL_P#)/[S_*ZQ?^ABOGSM7T"\6?\ DG]Y_P!=8O\ T,5\_P
M1[F)9#A"X#'T!JH6YES;#6YZ=X"D@ETY88LB5/E<,,<]?RKT*V3:#D[E!P / M6N*T_P .VN@PV]S;2 +<.@WS$\/WX':NFU-)KO0+J*SF$4TR$;VS\I/TKHK1 MHNMRTG[OF-I7LCC_(EWEI?
64<=G=0S21,2Z1N&*XKC_7JEKHMVUQ?M*(I M>$6--QSZGTJ+7-#G\,JJWK19;(C$39+<=?85M?#SP_HOB73;M+]9/M%L?^6< MNW7:VPA1-J)@(,_P@5YY\3-/UK5[F-K>V=[&V3>Y5A@,?
4>P'ZUR82A M"O74)2Y8OJ3:][$^!;VUL_&,=W?3>1;[65I""0">@KZ&MUV\AP4VY##TZU\ M[>$=!C\17MWIOVK[->KAH=PRC#/S CUKW[3%%G:QVZEY/)01L['D[1C)IXBE M0IQ2IRN[M/\
0&E:Y;NU61,.0%(W$D]!CK7@>L/;Q^*I;I)#]G.TB0C ()P# M]*]V>=?M#W$C*L42$D'N*\2N+V*7QE<37\<:QS_ZN-B#CGC([5S0Y;^^A*W4 M]KT?"Z79,%#%H1DCZ5RGC#Q[;:)J
TU+)KB0*&N&#;0@/( ]36YX;U&)+"V@ M:92K?+&2>1[5@>,="T">6[U74T998AMRDA4.!TW>M=&%E052]=/EU_X!4;7U M/-/$2-
!XNO;BU42\K*HQD891Z5[3IBL^D6S2(JS+$OF(IR%..E>/6GB"#5?% M;76!&NQ8TVC&0*]9L]B,(.G*3E[RM9=PLK7$M<_P#"/:E_UT@_FU9T M2>=<1PYQQ8+G3S6C:G_BG=BG=3_
.NL'\VJG9PSSWL"6Z;I=X*C..G-8$GO/AVU MN=(M6M'.)[,JAM@BX=>/F#>O/.?>NDF<10_-U4=:X.P\66>H7D>GRRB*YA16 M;!&&/<#Z5O'68+GS(B^W#8!)ZX%5*7,[@]3SSXG2&64R?
P\*#5CX66;?8KB\ M935ZQGS98HM':PE MTFM\<2DCK502D[-V&E7;KG )QUKR7X M8ZO9?V5?VS.(I&(+@GN._P"->C&\2YT1ZU+$%;^2 MU9SM=K=B4*_.#@@9ZUYS\.H(I=41R
98RIS[5T/Q>U*UCTRSTJW93(S^9(5/ M;U-<1X4UU=)U"(SG9#UWCM3=N@'T7:-(;5Y8V"XR<53U2^$>BW,KC$PC+-&J MNF:W;7,38=8U,2N')X)-<7XO\:64>@W]A:G?=;=OG9&&R>
<4@.2\&0+=WQO7 M^]YH)_/->\1 +;B3&05SS7S[X*O8+;4(8WEV[V4,K' Z\$5[G:7@N[.6)6'F M1?*RT 0>([V*UT&YN."5C+#%?.,DIGGEF;[SN6KVCQQJ<-AX8FB>0":="JJ#
M7B:#Y30!O^(/^26Z+_V$9?\ T$UPK$;"/:NZ\0?\DMT0_P#41E_]!-F,T >U?#NUEL_"ML+A65W7(!'05Z!"V+=-P_]/>N<.%EA@3 M[JC(QQ6H]PPMR5?&%&BEC+X[D4 >H6T5M!&'8!6D
M&2UC;YG);K7O%_C)>1S>,;>R@;=Y M$1+C_:/04 :/P>LH$T^^U%G'G&98B/[H'^->X2W"V]L)<_*,5]\!^!+^'09YX M&U"VD@N%Q,KL5,;CH1V/I7J[JD/BBRN]$FE,@,<0#]RG,Y>]_&N^NW\,QL5
MVQ,X!'U/%>8>_TB;QKIRS#*AF(!_O8XKI/BIX[M?$5E;Z781?(1#2.3W'2N/ MTK5XK*ZM9!:!6A=76:)L2_COSP?I0!].6]X?'D:([7C4Y(]:R-762-6;22G MRY1N8$^U2.9$.2S!B8X[MG/"7!X%>
["\%VR&$8V AAVS7SCX#UX:5KP>=LJVYC MGN37N%G23T_*O!^0!Z]30!]&?";CX8GZR5H>"GN&U:Z\I M8C#Y4?F%F(83B)VQ]&/=2/0:***]4]8**** "BBB@ HHHH **** "BBB@ M HHHH ****.
(^+7_)/KS_KK%_Z&*\&BOS#;B%;*U8<[FD7<6KZ_\<7>BV7A MJ237[9[G3VD16C0$DL3QW'>O,#KWPJ7_)@%U_W[;_XJ@#E8/%FI17$;M)^Y M10ODK]T->GO79W/C*;1]
5OEFEGPT0<]CW_"JW_"0_"G_H W7_?IO_BJOC6_MASJ-@TG]@W;V]E'WC(VKD<#YN>30!YWXDUI-=>*Z=Y1<*"&1ON@=L5-9>)]0 MM8Q]D@M[>3RO*66)<_,?G^-=:VN_"?!SX?
NCC_IDW_Q5.7Q%\*E&%T"[_Z MY_\50!]J:/XKN+G3X]3ED"16_P LV>!NK+UCQ_#K-C=:?_V)ILCS67.Y<>O M8FKD/BOX;RV?]GQZ)>?9W?S#'Y1QGU/S53?Q!\*MQ#:!=D]/]4W-
,51Y@26]X/+BN&"QLO)3(Q@^O/>H ME\0?"=2-N@763_TR;_XJK%OXE^%ZSQO!H-V'5P4(B;@]OX],?Q3XEU&WN9] M-M;QQ'&NR1NY/4UQ,-[/;2ET8,[\%G&X_K7J%%XD^%EW,]UH5V\K,2[>6>3
M_P!]55.O?"?)SX?NOE_Z9_9_\50!C>%%1R%R+J5FC.Z0$$=58#M^59_B+Q)< M:S"(V#I$K%%MINRM?%GPPPPPPPLJ9#);Z'>(V",B(G@_ JDO]2^&%DZ1SZ!< MDR1K)\L;'__///S=: /)K=B@#(2K \$=:[OP]]:-
HC76H8<::RF(LN2">@%:( MUWX4-8'AZZQU_P!6W_Q564\6_#".R>T31+L02,&9!$>2.G\5-K5 M#&?XC7 MH65%MBJL>&5N=OI7(WMREW/YJ0>5U)YR3[DUZ5)JOPNCLX;DZ%<%9*:
M;6;58F(E:4'<.W/)K0U[6[B\U)VBF9(H6(B,?'MG\.[.T\4_#*RF\ZVT.[20 MH1N$1Z'K_%4]_=?#6PM[::X\/7(%RAD4"-B0..OS>XH \L\PWLL<4SQIYC@-M,PP?]378Z+XHM/"UM*/%2^(="GC@9(
M%AF)$;9RZYX/UKJ/[<^'DGAQG.C7/V"*X"K$4.2Y!Y W=.*R'UWX5#)?P]=] M9<-@L>-2O!/N:T M5U-X5+G;H%T,8!-=MW-X%5[
(2+X;W5HD3:'=F&V4LBF(C:">RF>XD:20]2QJNGW1Q7ITFO-"O!5_#]UQSCRV_^*IJZY\*>/#]UTS_*MO-M-BJ ,"^O;J#P?I$$<[(MP)"Y4X)"G&:Y.\))4$DD\$DUZY;Z_\ #?4A:V-T-M2Z,<>XQ*T9
7/)_B]JHR:Q\*-VOX?NBP.!^[;_XJ@#S.+<)8]A(<$;3Z'M7 M=>(/%-]I<@L+PLBQKY\W\18CD5HIXA^%<+I(N@708'*GRF-^*J>;Q-\,=0O M3)-HEV\TK#<[1GG_,>H \^U:5)M6G26?.0N#\Q(
=JH'&.!7I]QJWPNMY6 MCDT"ZR!G-5MT-P"^JA-MWX5YQ-PCJUO-TS;-*H Y+Q-?\ BU>B\?\ 1E-M]!/[R-P#%4 ".8Y% %Q\'2#-2P >ZO-C5^[O?A7>P175ISO$BB)'\M]J@ M=!UH \;\3>))??
$=X]U<6BK*5PKEB2!5'2+NYL3'+;R,K*^X#/R-E7L$LWP<1 M3C2-X]%5-P#XJB.^^$"J131V X-K16XQ"/KFNHU.XET-P-Z7IJ.R-C7$P'7!/RCV].[==-M2^$*C-T*8-?[#?]\
Q56IM9^%NI7:M)HEQ-.P"J!&Q) & U 'AEXH$A(R/6 ME7DJ*]HDN-A"[$2:#-D<'*_\52"]^#X8 :%+TZ[&-\ BJ ."/\ O+/!L0C9 MEEU.8EB#SY:<8_$USLV%B)'YU[8^K_"JZAM[>32I&2!=D*;&X!/0?
ZTD_\ MPJ6.62WN=%>&5#AXY$=6!]QF@#P:)>_()Z8KN]1U:Y3PEI#QRLDDZNCN#V7 MCCT-=RA^#>53^RU7L,A-\:TUG^$&;9X+2V!#(RD#)&>,DU!X(MH9K^^\Z&.3;%$1O0''+^M<5
M2%\3"79,\3$O_A2H>DCI+C7Q#<3PQVKR&&:.(D-P=WX=O\D5+>WFII-%9:> M)/+5661WP'SG(-XY&!W[UJ45VGME/3[9X%EEE9C).WF,N20AP.!R:N444 %% M%% !1110 4444 %%%%% !1110
4444 <#\81GP%)_U\Q?SKP "OH#XP?\B')_ MU\Q?SKP#N: (FXW_.\/ZUUVE0H=!N+66X$7GHIPQ RV1M_D*Y<0!R"20A8; MC6U;W>EVU\)IX)9;97!50_S CIGU'M7K9?EL\5&4]_+;S?
8I)6O)V,&=61IT M<89<@CWS4/)D/M&:U=;_O<:A+*R54\+&<%[_7S[V] H: MF8FE:2)6O,=Q5N2"?2O6;(")+@'KDUISE+G>@0[DK.5"[D]2QP?:X#ZK6 MM%>Z]ANSUB7]+LGU#48;-
29",@>F*Z#Q+IDL$)DECVR1X .>2F.]5O"]Y8Z M/=2W=S#+<7:KM@57"K]2>M6=1\2R7YF34+:.2.48 C)!CX[']>:=+)\74AS* M-O4+:7:.2[#_*Y@U"I(4\U9F00LR9S@8!]JCMHR\BD;
<*0QW=,5YU+#U*E3 MV4%=DG2R:1+'X>1E+CS$4]._^ 68.S<=>%'H/0 M5E84,5!S\W8UZF/RFIA(0E>]]]!^Z]F/'WC3L<'Z4%660JP(8=0:=VKQ=A#K M.VDO+V"VC^]
(%'X5U_BK3W32E#9@&!CZ=*Q-+:+0KI+^>-)I5'R0E M\8]S[5W.D30^+M-O&N(?*524*(2WF97L3TP:[/J594?;M>[W'8\ED.=F?2I[ M4LGD%%/O>8P'XBI-1T^73[J2WF0AD8JI/<5J^%M&CO[ZV>
[D\JV$H.[UYKC$=_M&?#[KHODF,9V!@/]LC..X*X)*N6'(D4&O8/%.MZ;H$GV:)/M5SA6\HD@*O3D MUY3J7DRW1N8+=X()SO6-B2 >^#W%=,L)6C15=KW6.S6Y37[LY_W?YUV.FZ%+ M/X?
%PD>6F;&6Z;17)P1+(^TL%W8R3T'UKHK^X>WO8H[*\E%O B"/!9<\|9)P? M7];Z1]0N5N&-MB7SF-5RG'F'/7';M5(V4T5S]F=0)![],JY\5A:N&J3SZ5S4BV]UIGE1P%9[^GKY(?(S-?]J?0U-MIZ!IKZKK-
LH./O,1V-K-DR&4$8Q7<>-(+>VN[O4KR[AMH!&$5I&P"V:\B,7 M)V1)D>)['])/O"L"' M?^OA_P#T$UP@%0(AP =H^^?Y5UGE@>%AIA:/S@?M00]6'/%8ND:3<:OJD%I M,Y?%^L.5[Z][%PCS7.$9
M5\L8'<9I(P,2\<87C\:OZMID^EZK<6%P./#)^8[&]K:27$AAA7<\N%"_C7" M0=)HEHTMK?RQHD:3QF$-MR5R"#_.N;N(O)FDCPH=,@D=.M>RVOA>XT_1;6W* M1EPGSLO-R??
O7G/C719M&UXAU41W,8=".![B@#FH%#/]T9PW\]VO#UHT]]"8 ME&8SO+$9P*R;2)Y)RJ#+'( '?(KUKP;X8FT_P\||Z1M/<= ?X5^M 'F>J68M
MKY%X;>V0<=RO+:ZV@QMW7H#UQ7%;=LF.^30!Q7*SBYD D;CD M$?RIBJ,KE<^WK4D^3\QZM5[0=..JZS:6N"4=_G([**P2;V)+6J&:73[%I8,+ M'&%#X_AP ?
RK&55.S*]C_N^\3"&ZO6TNPA9Y(X@ 4(*D@9QQ_.N$52N%88 M*9!'?K6E6C.E:G5KZC::W/7_(/ #P[KP']\?^@UTW@F)3J=ZY+96&/&&('5 M^H[US7P=_P"1?UJ[
'Q_Z#73>#DE.K7920*@ACW+MSNY?OVK'DN^;L>#BO\ MD:4/21W%%%%,]T**** "BBB@ HHHH **** $)"C)( ]Z-0PR""/45Q/Q3B2? MPS8P2#=%-JUG'(N<;E:501^(-9VH:=8>"O&^@-H2"TCU
7,=Y:B4B)T2(NKD M$D+M8#YO0T->D45Y3I'COQ#?ZU8V"7%G=-J=K<-"Z6,L4,4J)N4)(Y'FKV) M'K6]X9\:7GB;5 *@MXH4C&GFXU0$$F*;=L6,<\'(.:]\^+4T=Q\//. MBN*J6<@$C Y#E2
W<@]J]&\0>-4\.^'&O'O#-ZF-:E:-/MJLD94*D)DV[B*;>2W-LS:9 '&AAEW,?+PS'&-<^F#6G;;JUMX3GLEECCGCE0 M1,#ABK')..^*E3PAXAO8GU*:RN)(PFYII2%R!QWYS7NRJPE4<\19*+:C??U7
MWGSN#AC9UIJ6D4[6]-4SE%8^;&0!R>XS6K'"DNF75T;LH]J56&'/7)YXK." MS;5Z;^*Z?3_FLW=UF"Q,GRY#LP6,GT!/>O"RBK2H3K1G)*S_#4];$T:E5*,ML M':SO/9*)0H,?4BM/5/#NH:=J;6UW!)
ZGE67@^X/<5>U_MPJ/HME9RW,D6;C/[I?O+\H/->MF;PE2@G)WZJQT4U4;?.K)?B86'^5AMVEMX M('/TJ_"T:RQ_(_,B)&!P6'L'>QK0T#PKJFNH8[98?W:!B9&V]>U>B67PVBF M\,1V5[>.EV)C.7A
*HQ7;MYZC"TK*KG.$5&-Y7OOW7F%*G&G*4D]SR/68;9&ML M22T1EAD3(5FW%3Z$UEQ(&1B>U>KZZYV/6R"&R>:9MZJ3Z2X(93P<8'4=:\P:$ MI]L7L2*\3-1[/H5*H5*4KIM][DXA+D=BW!#-KEZD4<,4Q
MNIH@N54A22.:V-%UP:+;L(]/#SOQ)([8W>@%%0:M>OUKZJO6J4Y2CRKD479W5[^AX&#IXIXFW):FNIEJ226)R34GO3$IYX!^E? MF+=W=GT!TWAG0SX@BG+1^;(A)
8G!XX'%:>D^)+7P]I<%@UC.+Q'?]0'.S82 M>@SUXQ76?#BP2T\/K)L_?2DL3[=JD\0_#FT\0ZG_&@EX]M*YS. N\ VR/0X M_"O7P.)HN+H+H8MODZ>I:EI8\B\37RZCJ:W"Q-&K#A6;=5\I.MU[?V5I
JQH6 M''45@^*]BT[4Y88<[8V\L;CZ=ZZ;X9:1&_DC>./8%%3/&[/<5Y^)=)U6Z M"M'H3*U]#K-9TG2M5%I3SPI]JDB)C&9 !]TCU'6N3\>>$8_#GAJT6.)KZ.W;;&W#D>B@\<>M7O!*
(WK_8I;1K M6;'ER-GW&/?U%%:RG5G0M%OD6K]?\BG=K0\Q@?8><[3U K1FN;B9FD+_Z[68 M@=,?ITIGA_3O[5UNULRVVU6;.E%%RC9K]29-621[EX?TRR%FDMG&#]K02W#D>B@\<>M7O!*
#X,_^5)_JW[$%?XU>L6B3BDS2Z%4(?Y<X(J]#U1D@X!?:!IVn?>5ALuKcaLS1XcOdp+bb6HtJ$&7?==...
```

MTUQUM)8QQ8N+>>9VSG;P4+]/6O9;KPIX8U#PS8:'_P_)/#Y5E(9!(LT99LC' M/_9(^&'A4GCQ6/IYD5>>0++6UT]ST]K=[A()]X>Y4$QK[?2M;7K/1I;_M^TK]9K29_F_3Z8I_@^YQ
MM+QXM5M[=Y(8VVR@$#_JAI_P__#FFWL=S#XI&4.2IECPP]#STIV]>!/#N]7;3R M^*P@_@C66/"#T'_5[6=V[WNK?(?,SS+Q%]EX ?.I6[&)=^V/D'..N1Z&N]\/ M_$6>]CALGA*7'E85B<[F'8?

```
Y/KBO);SP8W@NQN;2X\4>&6O9HFEB34 / D:C "LS\<]|=:Q_"ND_V MWH/]F7'B/PU;7%S(8H4ELUDNN?1@P(YS@5ZZPN'UJPYG!-;1:K^OZ1ASS^%V MN>Q_#G7M9\1>'&O=9@1)/.*Q2*FP2*,
<[>W.177UR'P^\'WG@W2+FQN]22], MLWFJ8XC&$X (P2?2NOKS\5*G.O*5)6BWIT .::BE+<****YRPHHJ"]$IL+@0 MRK%+Y3;)&Z(<<$_2A:NP$]%>,?
#SQHNCQZDQB/7WN@TJB(*LD^&YRP8+@!CC M [UN^'O'FNZ[X_EL(M 8Z)\X64P.A11T+2\ST]BBBQ. PHHHH *R]?U^P\.5)].HR.L$*' HRSL>@4=S6I7">, M? .B:V;G4M;UG5(+9<2,@N]L,1
"Y"XP/_KUI2Y.=<I[=;;BE>VAS4VM^[K MQ %XG.AZZUYY1NU(@_=NJ<>:1GMP,].*[KP9XSM/&=C<7%O;36SV\FQXY,'J M,@@CBO+!H/A*U\565!:>*M171UTZ9&G6^.$8NI]@=C
!!)V]\5W'A/P#?L1 M;ZAH&NZK+:) Y@1+TF&1AP=PQSTQ7HX]=-TDG&5].5MMV6NFQA334MUYGH-% M%%>4=!G6N@Z59:G/J-M8017D_P#K)E7#-ZUHT44VV]QMMA1112%%%%% !0>
MG%%(>!G&: /FRRU#P)*ERWB?Q5X@:5_M,QVAH)9?+,YS@I@=_8KZ&T;[,=#T M]VWB5YS\#&+_"K3 MF8Y)FG)/ ;5]]&H **** "BBB@##UK_D/^&_^OR7_P!}Y;@U;Q!\ YY$FGS
MWCPRB!F6#^?G7(/K3 M[GQ%X7E<7%S:.P7=(SVQVF3 #N/&_H"#WK4@\(Z:7^3PV15TVI/WSD+C; MC|O_QUQ5,>]!/5)9E)>'S9&"6@+ (S$$OG=][X(/N>*-31X])NH4U; M3;>)?
M$8'FJF&*|<'\A^57Y+>&5XWDAC=HSE&902I]1Z4EI;PV5K%;0*5BC7 M:H+$G'U/)KA?' OXYE\0Z6WAN4K8C'F;64*&SR9,|E<>GO6]"E[6?+S*.^KT M1$YD\(^+[.XCL(;A
MQ#)ND\Z219"S*HW[MV3D(.2YATPR29@EEE)Q)V(RP)Z] MB,>HZU3BT^5K4IPDI^:ZBCVFX+M^|S_ !$9P3S@$Y..];M22%%%% !7*ZEXK\.V
M7BVUTN|CW;DVU$F\D'RRWW5W=1G^M=561=>%]&O=;AUBXL8Y+^&R4D]NA\S M@D=LBK@XI^\:4W%/WQP->BBBH,PHHHH ****"F3(TD,B(P5F4@,5S@XZX[T M^D9E1"[L%51DDG H
|6U:UU'2==BT>7Q?!+ N SB#PM ZQ AF7<0>"0IP.I MKT?08X=;\|VL2ZFUU#=VI7[9;1"V8ALC*H/N$=,=B*XG6X+'Q%97GC?0M8UB MPMXI5\|6UBLQN6A^598U;L
SU=_X1M]+M?"6F1:+,9M.$ :"4G)<'DL M?T@N44$=#Q@MS]:T_TQ_,B>**>XDC M. B2L"(E"J !@8% $]Y96VH6K6UY D\#%2T;C()4AA^1 /X54/A_1S]5Q] M)TRU-Y"3 ,8AND3IM)[C@5I44
Y9E.2Q4.H/* MDCIFI?"6F7^C^&K2QU.Y^T748.YQ; ))"Y/7 XJ^56WE;NFI'&?Q MJ5N0>(W"PDGM++>>UTW1=05J/_"6;\;U\CS=NF/.[&W^[BJ^G>$? M$MM\3;G7)]6WZ6Y8A/,)+*1\L>WH
OK[>]>G5A%RG3J3C>*NFKN[TT3N8)O1 MI/4[JSM8[&R@M(2YBAC$:%W+_@# R3R3[FIZ**\LW"BBB@ I&4.I5@"#U!%+ M10!YW>>&_%DGQ,AU&"|B70@5)3<
H3'S(4[DGO[^U>A]]HNU5"@=@,4M%;U] M\]]BI6]U6T 7NR(P4;VZA1116!84444 %%%% !1110 5D:_=:E:0VCZ<^GIF MY1;@WLI0"+G=M(ZMZ"M>LK7O@#FD^)K%+/6+*.[@1Q[.2 (SQ[$T
>7ZMI MOB#5HY+6YTSX?SVGVEKA$>X=?G/9VX^8C&?6O6].$@T]T$RP)*$4WK_P"K M:VC(3_9]/OG1=(\,67A 4
%U+P1]C>*FEE6,P6[LAU\.Z9;W$4%O:Q)+%#]Q&"@%5]@>!0!HT44$@#)/% !7(_$^W%U\[ M@,],&^#'F3MM1?F'4UU6MRN#\>%-?UKQ3H%[I.M75G9PS M$7D<]N*N$.9V_*
<.=V/9IYXK6WDGGD6.*2[NQP% Y) 9NA>)=*\20RRZ7<^< ML3;7!4]1Z<'L:\E^(?CV_%YI\5E(BQN+B,P@ (,&#_#("KZ5W'P"]&U_PWX;UN;Q3<7FKRR32E+2)1(7CRTN+GPWX=|3:/
P7>MSI*E&;/5I"Y(&#@"JZ_=QO2+Y,_W<;HP!CHN.WK73&H[;/WO3]3LC5=KQ M?O>FOWG2Z<6.F2$CP]ID7A[2H]N+"WC,M?SNZR)'T7<@&"P'ID"' =' M;>%)=+^"'|,.=?
'<+9/!'=G((D8'+\%#X?1O%CA@M MS(X2S>,?|MP>I_W1SG\][*31]3NO EQI&HZJ&U*>TDBEOHUV@.P/S <8 S[< M"@#Q<>'[2?\ XD<'_P[#JVWRQ]"ZZ#L?IYH4'?G/(&.M?0 A!+:Z=;6||QG
MFBB5'E/5V +?C7BK>!=6FT_^R#X4\P9C\K^TTF;*\8\P+]I[=WZ].]IT^W: MTTZUMFF:=HHE0RMU? W'ZT 6:**\W\3:MKNF>M=6+4F.;:"]U:P1Q<0L) MN_'.YL9.?TH [_41>
IUP-.);TQGR6F!*!^V['.N!^"GG#P9??:2AG_ +6N M?,*?=+;AG'MFDTKQ5?Z7X&UW5;9I?$ OIMVZVL\LP5KB !2S;\8;:2PSCG&* M9\#;K[=X#N;O9L\ 4[B79G,W<0<9 &@#TNBBBB HHHH
Y_QGIVK:IX:GM=%%N M/(NV93D.4+*#RH8=;U+X2L=3TWPU:6NL7'GWJ [WW[L#)P,]\# S6W15\[Y> M4OG?)R!1114$!1110 4444 %%%% !1110!DR>)]%AUY-#DU"%%=2<96 GGUQG
MIGVZUK5REQ\M%N?&,?B9_/^UJPD,8?]VS@8#$8SD8'?%=76]944H^R;>FM M^_EY$1YM>B****P+"BBB@ HHHH **** "D.<"6EKD/B)K^IZ%H=HFC&) 0U M"]BLH99EW+&7SEB,_H |O*Y-
4|W_@9;/3+_5+*M='GUF:!?]BC9%9&V$?ZWDX^GXUZ]]O:Z;:VJO<&XGBA1)/F&#(P !;3S0 M!9K |;'=:#M4MT>Z# &:1U2V ;/\ 0W@O V]'^(V$Z,/C==0)_"F^?1]0,5Y;1B1KEX MPQD)?
+D@Y&6R?IFN\KD/BE US\_1]Z,I&G;/"\.G64 K&[;F6) N3ZU=HI78KO8****0@]':X6QN&M%M5KD1L8E;H7QP#^3T4 CB_A_=^*[JWO3XFB==KCR3)&J_M# [#CFM'Q3X+T MWQ;]F
||;0$A6A8 E3U'R#71T5HZCYN:.GH:NJ^?GCIZ$=O!':VT5O$,1Q( M$0>@ P*DHHK.R"BBB@ HHHH **** "BBB@ HHHH *ANUWV^ K33Y=,NK2RGM3&UG=R%I41L_*S9SG!^M<1I_PR\7V&M3
MZTWBG3;S5)3O=7FG&5XQZ)EL(/H*].TN*X^@TR"/4[F*YO57LT4?EJSU"Y. M*.&TCX>%K.R:#4+),Z02N8Z!@P!QGOBO08(8[>".&)=L<A$ M&>@ P*!?2Q3_P 57KEKJ?2N#_#_
K<^7!:6]FKIY6T$'<5.6R3D=]]LF#V% MNRSF<&)2)B,&3CIV/?K0!/33&A>44MC;NOSCTIU% '/^,;3S/ NLVEO$1OL MY%1(8RQR0>BCK]!?7 * HOANT; ADOYE(88((V]1VKT#7X#=::!?P"TDO#)
MR_9XY1&TF1]T,?ND^M<+\#8_*\"7,?E #LU.X7RF;<4P1]/?YQ\D3%3($P.N/?.*["BMXU MK4G2Y5]T[VUT],EQ][FN%%%%8%!1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%%
!1110 4444 %%%\>WDN)+B2 M* 4:3[TA P6/N>M3T4 %%%%<_P" K>ZN/N]NBTQ;BTE2VDDWVX&]MJD[02#E%C/M/J.:_\D*"0_236!XADF%S;X[A4#N%"H#3[+'52\*L,SYAD/(/8BN%U4:G>^*,*S
M\_4%FN([2*!$,GEFV>)Q1CN33]=U7XO:%9PW#IH5V)9T@V6MM*[+N_B(SPH[F@#U MRBO__*^_/UX7_[]2?XT>5\8/\GZ\+_P#?]3_&@#TBBO,Y_P#A_\%O+_P!#+_"
"VU8923@9P!GK5+0]0^+VN:-;ZDHT"U&X)$-U;RI(F"1\PSOTH ]9HKS M?ROC!_S]>%_^4G^'E?&#_GZ\+_/?]3_&@#TBBO(;+6/B[?>(-1TA8]$B:MQ'"$W$MK*L4NX9^1L\X[UK>5\8\ GZ\+_P#?]3
]3_&@#TBBO_*^_/ ]M2?XUEZKHQQ=T]\TVV9 "N#?3^2'@)M66+__T]]JEU\7]J\Z0V?].+>,R&*"'5G?9 M1GDT]'Z\L]L.EVUZLGAR&$3Q+((HH5>:C.&&>"*/4]*#\W\KXP?\_7A/P* -7A?.OU)
M_C1Y7Q@_Y^O"_P_P#WZD_P_H[HKR+1]7^+NL7&PFAVQL,@P%KBUE02X_B0Y MY7WK5\KXP?\_XTP@*[_/UX7P%P'^'T^'E%%P{/*"YS^'E5F8Z9AI_[4-DH_ZA8'6+D^5K.Q, \4(P-\LBDT_F.(F\5QYBPND
[4->NT5YMY7Q@_Y^O"_P#KPO__^|A\/PXNNKHZ M#@Q$|F^H[FWFS!$>W/RXSSTH U]*** "BBB@ HHHH *K.A!<7.G7,%|=&UN9( MV6*<(&\MB.&P>N/2K % "'ZAX \47=Y+_!XQ2"_P.
(=*B<@[0#R3DY()_&NU MMXWBMHHY)/=$"L^W&X@/.3QLB7$8RT3'HP'J*X+X)QR1>"[V.64S2]JMRKRD8+D$98 M_6K7ANS\16?PU2VTE8X=72XE\Q\
M(.1M\YN6[G*]ZYJP]X7^*7ABPFL]/NO M#ABFN)+EC*DA.]SD^G% 'K]%>:2+\7XHGD-QX9(12V%BD).!T'-9WA-5%2B[X M@T;'4D70K,2%AY-W;2QR+@D<@GVH ]%_P#OU)_C1Y7Q@_Y^ MO"_
'ZD_P : /2**\KU6[^+VE:5=7[_X>N!;QF3RH(7D2?91GDTNF7/Q>U M/2[6^5_#L N(ED$4\$]NF1G#.##/!%ᏴD=%>;^5\8/^?KPO]_P#WZD_P_QH]KXPI^?_7 MA?_I\? [J2T>XT_D45Y'K'V?%[0=
%XZZ%=K;2_N_5%^#Z#O6E(OC 1G[ M5X7^"]4&^_4G^_5%^HG^\W_EX_I_?^_\XT>TZU,/7_Y_YX_I^TKJ\ T=
/2 M**\W\KXP?\_7A/_P#Q[ XTGE?2_OU\_J]HKR.35?B[XEAT7 M;H1:2W_VV_D6TODK\XVEL_]Y\/^H*V2^_G^TT*_VA<^H>RF(%,RLL6%SESG@<8^M'E?2#_GZ\+_ ]^IA:
/2 M**\W\KXP?\_7A/_ ]XTGE?2@_ ]_QH &TBBO) HKR.35?B[XEAT7 M;H1:2W_VD6TODK\XVEL_]Y\/^H*\_/UX7_^GZ\+_P#?]3_&@#TBBO(;/^TKJ\^G<@%%_P_^&^^2_P#WZD_P_G^
'I%%>2VNI?%ZZUO4 . T&-K-8V.[VTHCE MW@G"GDC'I6EY7Q@_Y^O"__'ZD_P : /2**@QO#*^(5THCQ.]B]_P":<&R5 M@FS QU[YS6S0 4444 %%%% !1110 4444 %%%% DD2&)Y975(T!9F8X
ZDF@ M!7=40N[!549))P *S[K6[*TU"RLI')DNY#%*(.[JKI=P5CV)_.!7%1>:1KL.+>%7R TO&=C86YTR\AEC:R> M8MYU]\:|HS+O/$ ,H3S@@<4>]T4@]ZS_P"W=*MC^R/[0M_[0V[OL^\:8S MT]
MO<(=\,TK94P7"]HW#8#@C![CB@#]=$)2::X@-RME(XDMWVR12H42!^Z^T\[6 M'(/<5KUQ'A[P +I6O0:M/?RR&*V\I%>4R2!2/]4SG : /X>,DG)=G<7$-I; MR7%Q*D4.:EG=S@*!U)_$E8S>*=)3Q
FBM.1=/E57<8 '7&1DC/% 'KM%(!A0,DX[FLT:[]]S?76F65]:R:I"A M)MV?D$>N.<9QG'2@"/7?$F4"84DQY/GY"11EW"CGYRHYVJ#DGL*TX)XKF" M.>"1)89%#
(Z'*L#T(/<5Y7#;:IXL\67<,DUUIU]9VS_C2[7M)&POEQL!^]@ MD"[O]G"!!.*[WPIX?'AK0H].$BMAWDVO@K"N.=B DD*.V30!MU!>WEMJ[G+ M=W/;K4)]1AT MB>!EANY5BLQYA%M>JV
!'_!5WK%I MHVL7_^J+YOVSRXI"ROL7W[X0.(S)_$"6 W.!UH ]2HHHH **** "BBB@ HHH MH **** "BBB@ HHHH ***SWUW2H]832'U"W74'7N.<=.#6-8M_M#L#=W?E.[4BB0O)*V"=J*6.3CV-
3;=[-JJVGPWUC.D]M,NY)&>)/!'^/M7F M^IC5M=\|,6ND7)8G62 M.U#*ZG(8'H0>XKRF&SU3Q9XHOK>:XNJ[MK@>%N]"AS08=-$@<(S-A 0B;B3L0$DA1G !)H V:*"0 23@"L-O$..I:
M9>R^&K/4[RU.# )L GK@GMD9P>AH ?]?2BG2=(U*WL;RX*23,JEPI*0EL[/ M;HFX@@9ZFMFO(=,T[\]9?VS/'>S"'S%MRE_D..!S0W,8P6LL0K @W_%O_A*]'B'B%% -P1/E M5N^V|]DT;P(
=>*|#2^.]?Z-7:3;CG$H4X6Z"ESD+ MR,X|R<9XKUH# SF@!:*JZAJ5GI5FUW?W;O I +N<#/'Z"N8\|7Z]+#H$>H64 MTO\ 8TL9:34]//FR6QX*2;.0!>00P',/QH U-5Z1NK3Z9:W! Q&N]RD+
M,H.&-''BFUQ^PA$P=SIH&W-TD*0$78MHY#/(9R=Q2!NBH^7F!W' VE>((4GOY?M  *022@24J0! MY:/P&1.?J+ODDYKM: "BBB@ HHHH *BBB@ HHHH *P->PUU:[PFUTR
M7=U9.[^6.F)"=H8_4G@=|&JGBGO?::2EU8CM>I;M)++$HD%BI&&EE7.N2 M<\9/2/PCX@5&C_P1Q*'2/EG(V7[7SS]
MG5M3UBTN_$MOI@CL;26SVVN6%XKA0=ZD *GRY"<\UVRJ$0*H 4# ["EK'\4 M:OJNE6L9TG2'U&9@|N Q 5$7)'+(9F@'";Q1&!VXTE%%:]C4%9Z=HNM>)M2U*W:[AAFCGAGGFEA ?
<"0DR]I_2=X(W=\OV'@:2.N:]2CBCBW>7 M&J;CEMHQG^IH 0P1 *\+$$D*N^VSt4E2=2NY+'3+FZBM9;Z]&]G2 M(+|TA X4>YKS"]=>%3 #Q@@:\|VL5KAHV4.I:I<*8R7?QG(%
%3U4 M[QO]'B>Q@OFB6X+U!"KP(5BW9G3"R >9G!4D'VKT?PUH#:1X8@TF^: M&Y"EB8PI)%+A&N]*KD 9_58T+2(=+TJUB7R6|R$WS&X(9'FMS(03SRV: MU: #H*X+Q]P7SH@A/SQFK3X+XA(
VLT$X^U:>FC>0%GM;F98C+ 7U6R5;73]NKJ"(FYGMR? MC1F"?N@ =T@W;L<<*: #Q'_&[VF! )NX+.9I%%#$W$H!\M.<0|W!8G Y].\|[ MT#1=5|0ZD9Q=6A&?3L>O%7 /L+72]@L*!\+:!
D<2#A15F@ K@O&W]K3\\|G^=|M M,OV3#?7\>F+K+O)6X11RP4AGP$NNF209.^5B53=G M"K-F4QAZZOP=JEW.V.]JJL&-5NY#W7G5GB4D1"3,|H8+U"M\9S[T_\(^ M'[1Y
2N;ZZM93?.DFRUB:;N_L 092I/RN^1N XR/>NEAABMXEBAC2. 1A410 M.![ 4^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHK$\[2ZK]Z3I3: MAF<,N,@5HZ7H\>K7D*: M7%J4EE1
M&SQ2.BO+$"%D91N&>N#VS4E%#]&U/ M7;J"_O;6ZV.I&>;RU+DA :00NIQLDW8=#D*V<9K1\:'!>;O;2;9'\<>%@ M?MBK=!1$MP JJT0SOW!@^X.;LD#->DQQ1PIBLB147.=JC H
/)B\\S^6GFE= MADVC=MZXSZ4^BN%\8ZSQM%U26RLSX |PG:!S=%@;6.<)[F@#2] M8OKJ6\3Z3>V K%.|QNBH$\6J3+.Q-[GW_0KO+$2HB.@^62%2 R.1GI[UH>3G(#KQZD]
<0R7&D6:%=*>)|V%DWD[_+"D M_NRNT+N^;"'2N\5510]J%4#_& * &)%X||CQQHKR'<[*H!8XQD^O J2BO__M%^VKWK:=X@TN^L]$$S]!!!]#U&WN9==O+M66_M(AL\DQRRD.O&>;[''@":
M&&*W39#$D:9+;44 9)R3QZFI*1CM4G!.!T%>6:K<3>)+^&/7M-U;3+L+OTM; M4%@S'$@ 9@%6<*A&"< 9H U/%2ZO/]ES#=9.BB;#[+<60#7.GS@ K,5'WDW' M!!]>QK;)|>';S0[2_2_EM'
W<&8RD92!,J Q53G&@X\L1TR3BU/^EW.GZ-Y MVI0(FJW,F6[D&-\AZ^7QQNV@9 X!SBNAH 9W'#D42P_*]*.!.@ [4^J MNI?O]\\<\|-=E+U*W[@$96^X:86>,@:*@ @BLF:P9|ROKUOK,0>WNHXWC)0Y)
2XBQPDBXPP'Y'>%DXU*\]$,(&<=D>X@#VR2.3P..] %#O'K*PYT.RU"*SUV^MI&L# M,F5++L\[CC^<=[X?DU;5M3AT?4YY4AT^W$DRVT[,WF$%?)GD/WV .[*$ G/ MH*@TY+WQ?T]
|;Z(8021MF*5541W&F,#NCVN#^\5L!E=>_M7HMO$8+:*(R/*4 M0+YDAR$8'4^] $&G:99Z19BUL8!#"&+8!))8\DDG))/].CUC6+[+0=+FU+493 M%:PX\QP[;:D@9P/K5XD*D@#U=>5W7B&7Q-
XU/\ 8L]7L=G""VCW+F*.O;[* MS?,/ED1L'D$$$'/' ]F"C#G.Q0X^%Y%ZGZOC78Z6C*XMIC^ZM8CR3>H_+ MB2/J.D893QD9&%K!J[]Y@8=5`,XH\U\/;H^#T?AW<& 1*#$H\8&'L\ 8U=TLX0$\[]$](
|1T&>U*%#4Q8ZN\|X\Q]>\|&MEQCA'$GX(B.D@N*@&D PPMFD.GQNRFBOAA! !>1,CB1BJ\4*@H.(JQ[,A-|=%RX*WUK&.?Q$.I]ZTSE?>5L,?XJH.%#\&#Z.C4WJ?YC3[MSKDQ^`XM'MIXD(J8H]!=
|1T&>U:%#4]@ MFD.GFPLZ ]K%($G@;V]J*$MPMNUD#_+(@2 #%%
AO4(OM&E78_M.W=S&$P3&0V>I0'DA?O $ @T_0+,^+K"[OM<>6 MXAEE,.<".|=LZ1D@2(O#$/DYW$^G2H_#.E+K*6FK72Q&XMIC\ZM8CR3>H_+ MB2/J.D893QD9&%K!J[]Y@8=5`,XH\U\/;H^#T?AW<& 1*#$H\8&'L\ 8U=TLX0$\[]$](
$#O/!"UOHEKK#Z9J$DT+M_.AD"-68A3V#]6 5AG(!|4 -U/Q%>:O9ZWX>U2U_L:TN[.!\LH@E!P#(@ M^9P1P%&.2&Y%%.@@ 5ZFMZ/9ZKK<=U+=322?.!!YYIWA MS06BG@U2ZTQ (U"*
(VTD%<!'AG0=&88YP2EO%.+6[N+R(21*RY6"1<[D1\@>9 MC&>!0!7U3Q'K-Y)XCTN\M+S1;FU3[ C.V'?^*$(O/FL1POX'W<=;Z[2_#EI
M;&SO+EKF\U"",@7%W(6<%LD_*/E!^8C('3CI2:!HT5BTNH);26$U\B(I/$_C$_V'+J+:0AGT=Z8Q@I=A7(9L/DDC8 C((\|\%FXU@Q'; M:IBYR<>J:M !1 M110 4444 %%%% !1110 4444 %%%%
!117.>(U(&&%AZW9Z8R *@>:BB>67(5( M0@<$)@9DD)( 5V0"QXD(06NEF#3)+S[>ZDDD=E<L.N8XY. "Q[%=@EBO"CH,GG HO2L] 6$W=Q%#Y\H[#A4A4@
M>0YVKGU.*L331V\,DTSK'%&I=W8X"@;W/B"U\9;JEC<:$+[25="L,B MLESL=<+=*N7+6TWG0JWV9E^=HS"6 MW.BG;*>'< KMM"\+;;X>_P(3.9I6E!N)#*T>X %58\A3M!QD\U)HV@0Z5
M%&9I/MUY$AB6^GC7SS%GY49P,M@8&3UQDUK$X!IZ4 +7FVO^J[C69X;CP[+ M=.NE7CPZA:HK"5,%$WEJ09D@U_E!PV%?%7K?QK<^(HKJ]'1'.'R.7A*R.-7&DH<|GG.!78
& *6 ML'Q3XG@\Z>?7F6Z09S!<|+&N1I!%1DM^V0-{5X}2@!<9]EN/@$Y2}& #*R_B;(.A;Z^+~ !,GFaJHV*Q
!@lD6%;YJ&9_RZ)XN$=I]tAhf@=E.(RDI!\!#MDUI$#3?eN~ 4h#$MYL#>%NM-RZ\C/gRqIP<*@&3}RB^L(?{N!
<^@8AH!\&1*V^1UpsG2_S#&VVCOQ5B^PV0*F7#\&5NM $$$E\^*#$9?Z?\G(W^3RI@FFHE7H>E(VGQA|FB9%9R_++5;HE,N(*LW25 6L/UWA*3#?S<R#QEF5TJ2XIF7F?O^G/EWD5N|@V%K/PY.?RC7G=>ZD/B6;M]?X!*UP)0;FUF%(D^P!;W&3M#55Y_N7;Q%2:$E$
```

```
3DC\WV19OO&KBZ;[&B-_C%T77;;6H6,?R3+]^,GD>X]17F818H>>IK?\$6%S)JAOERENBE23_&3V'\Z M\+!8ZO5K6;NF_N]#W<7@,/##N2T<=GW_.'/1J***^E/F0HHHH **** "BBB M@ HHHH
**** "BBB@ HHHH ****_,;Q%J4FE:+_=1+NE&%7C.">,UX5?07&I M7;O*[/*Y+.[G)KZ&N+>*[MGMYT$D4BE64]"#7B7B;P]<>%=6P"\EC,28)3S_M_.!)]1^M>QEE6FKP:]YGSV;T*TFJD7[JZ=GW
7P3XH&DRC1-38-I\WRQN_2,_MGL?]D_I^=;6N:.^C7GG0Y:TD.5/]T^AKS^XB6ZAWKU[UVW@CQ-'J-M_PCFLM MN]; M/ASQ+'9&+3M1D"([B."1SQN/13]>U8>M20>%;[R+ZY6._P6C9L_,OL/6O\
MQ5JG]M[!:ADM8SN7/#,WJ?3VI>R5:'+NNC'0=2C64MFM&?2PHKS/X8>/3K4" MZ+JLO_$SA7]W(Q_X^$'_+,._KU]:],%>)4IRIR<9'U,)J<>9$-Q<16MM+:>;&ZDTZ*%;22!WA9F-PQ0JI(*CRP,Y(
M!8]JS+-$^(K0'3-ZR*M_;O<(Q-PBJ@8[OP8=*FT36K77M.%]:+*(3(\8\U"C M':Q4G!Y X[UA:5X(M-(U+1+RR@M()+.V>&Z:($&4LB@$>V03S6GI47]A+]DN MY%+W=Y/+&Z@[,NY8*2>C8/XX-&
[[UQ_B7Q-'$TVEV$H:Y7"SLI_U61G'U(__M*JWQ#\W+/.MP=UQN/ MS,26G3S/,Q]=QIN$'9L]&M[2)'6YD4>8H(#=\'M5W3=.FU MR_\_+7*P(H6OB2]CLM-
N%>1ADH004'+1H77/5TC'\?)%#QOXG2TB_X1O1V M"!1MN)$/W1_235S2]*N_$^ ML)8VV50?-++CB-?7_5W4HQP]-W^;.6M*>*K+E7DEV\CTSX?:]Y/J35ZOF:LHRJ.459'V-"$H
M4XQF[M(=11169L%%%% !1110 4QT61&1U#*PP01P13Z*/+_!%H;Z+=^?"" M;24_*?[A_NFLMU$T>X=:]X4/&XP0:\HURW3PS?&&ZF"PODQ.1] M]?\ &OELRP#IR]K26GY'UF78[V\?9S^_?
BO\S>\*>)UM'33=0E"QLP2&1CP" M>BGZ]J[^OFO7=3_M)E6W!2!#D9ZL?4UZ=\.?&_\_:\"Z/J4G_$PB'[J1C_KE M'_LP_7\Z]3+ZTO9J%3?^M##-LLE!>W@O5?K_)GI%%%%>J?-!1110 E'UH[U
MQOCKQG%X8T_RH"KZC."(D/.P?WC[>GJ.F4E%79K1HSK35."NV+XK\4);"33; M*4&[P!*RG_5@]O]?TKBHH0(V+DC(Z@\UQ>F:G<6^H27EPS3>
<F3QZ_>1V=A(&=^JD8*#N37RN/=:O522TZ'VU+!+!45?;=O^OP)-!L;G6=4 M&G328V#<9O\ GH@[C_:[$?CTKUNTMH;*V2W@0)'&,_"LG^Q]/TK1-LKF)+7_ M $AK@<,K >Y\ICL8 M\1*T?
A6W^;+E%5OMD'V[[#Y]_:?*\/[R^^S.,_GQ19WMO?VD=U:RK+!(,HZ]# MSBN\\\LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% "=:S]7TJVUK M3I;*[3=%
(/Q4]B/<5H4=J:;3NB914E9['@6HZ9=>'-5>QNAE>L_J#W%?.5T=2TO6)[ M#5PZW,#;65NF/4>QKZ+"XI5H\LMSYG$Y=*E4YXOW3U/0=3T_XF^&I-_UIE36
M+==T8WME>^'=7GTK48]LT1_!U[,/4&F>9/87<&HV$C1S M1,'C=>H->IR)IWQ=\)!TV6WB"Q7![8;T]T;]#^N;OAIW7P/\/^_=Z:Q,+/XE M^)Y1*DMM<17MG*T+M+\NA_
M0_A7@J&>RNIK"_B:*>)BDD;C!4BIK6[O-!U6#5--E,<\3;E(Z,.ZD=P:UQ.' MC7A=;]#+#UY49\LMCZHHKG_"?BBS\5Z,E[;D)(ORS0D\QOZ?3T-=!VKYR47%
M\KW/=335T%\/2RWJ"5YAL@M\X,C]CGJ,</;ZXK7UW6[/P]I$V MHWTFR&(<-=6;LH]2:^<=:UF^\7:Y)J=\<+]V&('Y8D[-?U/>Y<@M*W<=OICIBI=MQ?7<&G6$32SS,$C1>I-1W M-
QL"V\"EG8A0JC)8GM7JGAW2+#X9^&I/$6N-JTZ[8XOXESTC7W/\1[?AS[-M6]J,%&.KZ(\JE3=>?/+8G/\-9_PC\)8'EW.OWH_[Z;^B+^I^O'!Z?)/JDLEY M=RF2XD8M*[=2?6LJ_P!1OO$NL3:I]+
[I)#PO\,:]E'L*J2W5R]W%;:>)&N'8 M)&L?+,3VQ2H4O9ISGK)[F6+?UBU.&B6QUAM+K6+R'3M/!^T.WR$=![M[>M>O M>#=,L]*TEK2) MY&V+P-]XR>O^[_'?;WS53P'X2D\.Z6LVH.LV]3]#,X Q&
M/[@_J>YKA/O7E8W%>UERPV_,]# 8 M'V$>:?Q?D:U%'[3Q)I4EC=C&?F20#YD;L1_GFMKM12: M35F5")].\N[4?A1UK.UC5[70]-EO[R3;%&/Q8]@/)K3POI+W4V'F.5AASR[?
X>IKY\O;VZUG4IK^^E,DT-MK;F)Z =@/0"KGB#7;SQ1K#WUV2$'RPQ9XC3T']36:S'*QQJ69C@_#))KR<17 M=1V6Q]_E66QPE/VM3XGO_D2P03WUW%96<32SRL%1%ZDU[WX,\)0>%],"D"2^ MF
,\WJ?[H]A65\/?!2Z#:#4+^,'4IUZ'_EBI_A^OK^5=X!Q77AJ'(N:6Y\_G M&:/$2]E3?NK\?^,EA2:)XI$#HZE64]"#U%<7H-I-0L=0N[ M>QCL6MS#+.?3_CIUI=(\<\495UDQNSN/7'>MF"V
MBMA((EV^8YD;GJQZFIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** $KA/B-X$C\5Z>+FT"QZM;KF%^GF#^XW]#V/UKNZ*J$Y0DI1W)E%2
M5F?)UM+)%+)9W<;1RQL4='&"K#@@U:T_4[[PQK,.J:>V'C/S(3\LB]U/L:]5 M^*'@(ZG&_B#2(O\ B81+_I$2#_7H.X']X#\Q7D=O*MW!Y;?>'3-?24:L,13_M #/"K4Y8>IS+8[:_T#4/B/IEUXLM)+;
[9'\D=G"/F*KU5C_>QTSU]N*X:SNA M(##,""#@@CD&NZ^$-KJD/BZ23=#^$G^#\<_IFH/B]I%GIWBZTN;2/ MRGO8C).%Z,P.,X]3WK&G6=.M['IT\O(V]4XU*/M%N8.@ZY>^$-;34+,EHF^6
M>'/RRIZ?7T/:OHVPU6UU#1H=5A9A:S0B8%A@A<9Y%?,%]_QZK]*^@_"O_),+ M#_L'?^RFN?,:<;QEU-[0HZ+1' M%9UJUI,T-"\):CH>AIXWNIH+>>W830V]RO6/IGG^(YX'7W!K \0^);_QIK-N
M[H>7!&-L%NIRL8[GZGN:]_^-=OJD[:8$9_[)P=RKT\WMN_#I^->9DI96_;>1 M^58X;]ZO:SW_"\C;$R]F_90([RZ2U18$/SMTQWKU_X7^_#I$2Z]]\7_!,9
MES#$P_U'"N?]H_H/QK!^"P].K!=>UE72$_-8Q]#N[2_@>GKUZ=?7=-GN7\R MVO4(N8" SA<)*.SK]>X['/M7%CL5=NG#Y_Y'5@\,HKGEN:=%%%>4>BM#J-C&!J<"]!_RV4?P_
M7T_*N^HJ9P4U9FU"O.A452#U1\K(Q!.*12K*<$$8(.GA_7KOPOJZ7]L28S\ MLT6>)$]#_0UTGQ8TNTLO$5M=6T?EO=(7E"]&8'&?KZUP\W^J'TKQIQ=*I9,_M1J%2&.PG-:
'TWI^IP:CI$&HQ9$$L0E7(Y-QGFO!_&/BN?Q9JO[LLFGPDB& M,]_]H^Y_2O7_I_R3W3_P#KR_H:^>[7I77BIRY(^9\]D>&IO$S;7PNR_$?( MXB7:.M>I_#7P.8A'KVJ1_O6&ZUA8?='!\CU]/SKC/
6F6NJ^,[:WO$\R)5:3 M:>C%1D9]J^AP !@=]G"44_?9MGV83@_J\+[^G;__#'4445Z1\<%%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )U%>> MZK\)M)U+7I-
2BNIK196W2P1*-K-W(STS^->ATE73J3IN\'8SG3C-6DKF?I6D M66BV2VMC"(HQR>Y8^I/D?]>S M?^A5U8)N6(3?F8XE)46DUU"Q2Q-EE(WCRX3;T M)QUQ7D5__P
>J_2O7M!D\8#P+9BT@TLZ?]A^1I&;S-FWOSC.*]3&WLK6WZGF M8/9[_(\=TO&#CISC-=A\*?\ DI$?_7M+_(5Q^EXP<9QSC-=?\*?^2CQ_]>TO M\A6V)_@2]"V5MJ%H]K=Q)+"XPR,.#7
GX0:,^L1WQ;KC_#FO1AZ4N:^=A6J0347:Y[4]4)M.2U&HBQHJ(H55&_,#TKF7U/ M7;^]U!='2Q6"PE\C;2VVI7MC'?8 M^UPP%<2'&W<"02C$ E2.@[\UD:EG0-5GU6._:>
(VMKV6W"H<\+CK[\ULU@ M:9X$+)[2^L4M#;_HCQDL%QT)QU MKQ^V_2O7] D\8CPC9BTATPV7V8;"[-OVX[\XS7D%MTJ\1\,=_F893?VU2_+O MTMY[G8_"_P#Y'R#_*XR?^@U[T*\%^%__(^0?]
<9/_0:]Z'2NS"?PSY_/_\M>_DA:***ZSP0HHHH **** "BBB@ HHHH **** "BDS44=Q#*2(Y4D?\ 7LW_*%79@?XZ^9S8K^$S@+[_CU7Z5]!^%O^286' M_8_]E-?/E]_QZK]*^@_"W_),+#_
+!W_LIKT,R^&/J<&7_;/G?2ONGZ5V/P MI_Y*/'_U[2_R%<=I7W3]*[#X4_\_)1X_^O:7^0KKQ\ EZ&%#^.CZ$HJ&XN M(;2!Y[B5(H4&7DD8*JCU)-5;;6M,O+=+BVU"VEA>01*Z2@@N>B_7VKY@]\T*
M*H7.JZ=:"4W%[;PB$J)#)(!L+<@'/3-6XY$FC62-U=&&593D$>H-$E%%% ! M1129 [T +129']*,CU% "T4F1ZBC(]10 M%)D>HHR/44 +14%Q=06D+33R!( ME^\QZ#ZU(CK(@=&#*>05.0: 'T444
%%%% 'C?QF_P"0OI7_%Q?_P!"%>%/^2>Z?\ ]>7]#7SW:]*WQ?P1]/\ (\[(O]XK>OZL M['X7_P#(^0?]<9/_$&O>ATKP7X7_P#(^0?]<9/_$&O;+_5].TI4.H7UO:B M0X3SI N[Z9KHPG\!\G/
/>_DOU+]%4QJ%FRS,MU"5A0/*0XPBD9!/H,HHR/44 +129']*,CU% "T4F1Z MBC(]10 M%)D>HJO%>6\UQ);I,AEC^_'GYA^'I0!8HHKFO%'B%=*M_L]NP-W* M/E'IP?WC_2LJM6*#G+9&M&C.M
0@M64?%GB/RB>'-8&L:8)F $RG9(!TW>OXULU2T[3H-+LH[:%<(HY/ M=CW)]Z#7U])24$I[GQU9P=23IJT;Z#J***T,@HHHH **** "BBB@ HHHH ** M** $KQ#XV_\ (QZ1_P!>S?\ H5>WUXA\;?\
D8](_P"O9O\ T*NS_QU\SFQ M7\)G 7W_!ZK]*^@_"W_"3"P_[!W_LIKY\OO^/5?7I7T'X6_Y)A8?]@[_P!E M->AF7PO]3@R_[1\/[5]T_2NG^&J7K_$)193P1/\ 9Y,&6(N.@[-BN8TK[I^E
7M+__"%=>(_@2]"V5MJ%H]K=Q)+"XPR,.#7\7[AH7\Q/(L22H;S14C]!$)I<>%^+^#P4"ARTPD&+B-S!C9NBZ<1T86Q$^J3G'6C)!1$]J4%-[JM<2$(!1[J_F\J6-W<M]J>RF!K^1*-R>%G,U8X*H8?^ M7-*
W1#.1&O0#C@9)...M=IX=L[ M?3_#G:_VK2VJU1)7>(%*88YL(K:M_U\,-J@@@9DJ.[#H:BIJZ>_HMOZ6??9;)&M\-W95ISF8'K=+\$1U0V1R/7^7<<!7M.^V.J\_Z8XL+T"(ZSSG\RK0$O)J_X4UW*B60]D1[20
[ TK_GQA_*C^P_*_P"?2.LJ_2M:7$\(NY?ZLT1ZF3HPKFS:F1/.DKQ:DIS87$E_P;F2A7AT*50IPVKTGIP3X8PNOB\JUEHJ8_.2'?Z:SJM*QU]!/GRQB;V^5)7-\FZ1)@@HQS/E1$1(Y$*8;O/BK-0 M:HI[,"T
M=^WC:$6]S;I)Y4G+PEAC'IN%>L73C3/%UW?2L8SSVUS9QQ6\T-LT^PJ6WQD* M"5W;E-TH]>-Z;0Z/E&0!6;<VEJ=2YT,(RI0D=?5[K6!7+KOKC$7&1:<6.%).Q:!DZ?IW)NL3QZK*=K^9>06*24-8W[#:!.4*?
W?6>DS:9<6L02UDN[G[#(H7#J][ M8U<*0H7 W,3QR!W->AT5I!U4OE8E_E<_ZEC_?.I3P>.!!6;3KL%GMEQO1Z;:91*B'KGN'X!Z$\91Q%1/19&I8^]E(N:\52*$^D5+&<R^7U?NXI88U6X0M0DUT%;TN^FNHY-+?
M/C#^516WAS3;346OD@'G?P>B#V%:]% #3R#7E.L65S%K=R;HLS.Y8.>Z]L?A M7JU4M0TRUU*R[B/B.:C#@CZ&O/Q^&EZ?)"XK0ML(SM8O.#V:?)M.@K]1'H"V8_))Q*UUQ"HS>2
KTK0M%BT>R$8PTK'K/2)))8LO*_&]L9 ]!1X@U*?2K M:VO8]GV9+E%N]PR1$QV[A]"5/TS6.7X#V^V(Y@AD0E[(/4ZU%AW)TG98>U/KKLS_TCOD7=&0'3+ZV^*G
"BBB@ HHHH **** "BBB@ HHHH 2O$/C;_ (QZ1_P!>S?\ H5>WUXA\;?\_ (QZ1 _P!>S?\ H5>WUXA\;?\ (QZ1_P!>S?\ H5>WUXA\;?\@[1\[Z5]T_2NG^&J7K_$)193P1/\ 9Y,&6(N.@[-BN8TK[I^E=A\*?^2CQ_]>TO M\A6V)_@2]"V5MJ%H]K=Q)+"XPR,.#7
[Z5]T_2NG^&J7K_$)193P1/\ 9Y,&6(N.@[-BN8TK[I^E=A\*?^2CQ_]>TO M\A6V)_@2]"V5MJ%H]K=Q)+"XPR,.#7 "BBB@ HHHH **** "BBB@ HHHH 2O$ M/C;_ (QZ1_P!>S?\ H5>WUXA\;?\
GV@QN2&4@8!OZ%5R=-E5MP:J[O12D.F ,(^+I)H\_K5RA/]2Q*3;2:G+4F@E1^8E)B1S1;A<=B]9_W)4(T4*N0Z):I.O5?L]?5_"$7UU6.DGM88F,[:G.5;8]R[GJ>3Y1U2I:+2]PZ3B[67DI$&?1;4&CW1*,EK M8DL=+-
"BBB@ HHHH \;'YV_^0[[^,'4C]X.=2].^5>5]N;>HZ>TV*L9FW6TQ>O-5UGU#0V26_MR8L0XUSX>RM%A&Z-5ZY$OH]N(SM+4?4:A5GG;$Z,%8_26+T?<6%BWA3L*Q+H@J>#N2/IJ,V[?<2=WAZ=_$$ M@!HO
R4>/_KVE_D*X_2_O'_KVE__R%< M=I7W3]*[#X4_\_)1X_^O:7^0KKQ\ EZ&%#^.CZ$HJ&XN M(;2!Y[B5(H4&7DD8*JCU)-5;;6M,O+=+BVU"VEA>01*Z2@@N>B_7VKY@]\T*
MLT=W(ZOY>SO%PM+@Y=W_Q/%;3S!]W4VE?>G8[W0=?L/X#KD^(<P>-)#*GF6VW^9DL_NY]B*6GTRHX1FY+JW9[_QQ0_5`DYVJ28&;*<?A>4E)6Q%A#Y89^GV!XE9W2_DI<RR!^5:[T/ER^#J06'2M5+J
<7_P#0A7G^K?%&/6?%D:6%K):RS*:58S]8]J>VR4?!I9UV6*/9^BR%_DF9AQ3QAM\\YQ3^NP1)8V1F)DM=1C8[A;Z5>S5RY'9Z)<5_,1^_'F?JY$&A<+1W6+Z>'ZQ+'ZCVUO_IR/\ =7OI;V
>Q:AH%EJ5TEU)]HBN0AC\ZVN'B=DSG:Q4C(SZ].U> M__"__D?(/^N,G_H->[/#I71A/X;]ZXXW/(@#H7P%2,BYH`"'AYE"A!C>6\C-Q5FY]]W6KJVR'IWV
+W1"9Q'(8\;"ZYPQ&!@GT'I6[176>"%%% M% !1110 4444 %%%% !1110 4444 %%%% !116%<>)+: MVEUJ.1&#:5$LKY8#S 4+X7\L4 ;M%9D.N:?-8QW37,4:.0I#N/E?;N*GW
YJ MO!XKT"YECBAU>S=Y'$:*LH)+'I^?8]Z_NBLF7Q)HL4T\4FJ6J/;_P"M#2 ; M.0.?Q('XTDOB"P_L&[U>UF6[M[:-Y&\E@@22R5JCQWH UJ\T^)_@G5/$EU8M6D:^.6A=N[!SEPIPIGLI#+=2IW$4PIF!^F 2)
X2P5B"0!AN&0/KCM5;3O$4] M_;NNBWL=A=?\>]T2IW#&060'* @<$^V9K2G4E3DIQ(J04X\K/&F^'GB>]V+V.JK04K^3B2_D`
MBVZ6T,4K3RL A\QF55^N5_6DB\5:#,CM'JUFRI%YK'S1A4!P2?3!Z^E:U\5.MM:^EC&AAHTKV/%6^&GB72KAXC9?:8P2%E@8$,/7'4?C75?#KP'K&C^)#K.HH
MD$:O,B1%@SL6[\=!7H=KXET2]GCM[74[66:0L$19 22.HQZ^U23:[I4$$<\N MH6R121B1':0_,I(_(/ID@?C6E3&U)PY&D1#"0A/G39J45CMXHT-+.&[;5+40 M3,41S(,$CJ/P[^E)>>)M(LI9()+^W
RB;Q )!N;@D >Y Z5Q'8;-%8T/B/3) M!8I+>0P7%[$DL4$C@-AAD#^GOVJ#2O%^CZI:^_3D4DGBW MP]$\B2:S9JT7#CS1Q@X/Y'KZ=Z-RBLZ36]-BOHK)[V_7,P!CB\P98'I^?:U MK,LO%^FW
A]LNI$LH6$>WSI5R2XR!@<@_P#ZZ .?^)/A#4?$+VEYIP61X%96 MB9@I()SD$\5P"?#_2W3B$:<\?8O(P"C\<_RKV/Q/;2Z/INII%(T6H7$<$ M0!!(+L5!SZ<9IS>+O#N6'M665(!_?
#NG7#1I:&YB!(66)AAAZXSD5 M[/<^)=$LKM[6XU6UCG3[T;R $<9QCUP=_#_#:OI6O#5=0C6!$1E6,L"S$C';H M*]5[\]*RHO$FC32SQQ:G:;T"%Y0)1\B@X)/T/!]*:?$VB_8DO3J=J+=Y/+5R
MX^]Z?7O]*TITU3CRHYL7BIXJK[6IOY&S16$?%.F+/,)+B-+:."*=;HN/+D$A M8*%]3\III\7Z,NIK9O>PHLD,U><3QR M864HBL,N8P2ZCW?!XPTPG[(+B]NH+,-C8LLRDD;58G Z8WC/I0!T5%,1ED
M0.C!E89!!R"*?0 4444 %%%%9C:[IJWE_:&[03V$0FN8\,;$$AO<8!Z4 :=% M10S)/!'$VY)%M4"@RVIYV"$\Y%V]V%X,0M4 %%5H M[VWEO9DV1\K7BT$DZ:.Q=[0N_&\/@L&S^H\*[(SJ;VG#4$+
%%%% !1110 5R&I^";5Y$[KJ/M M[*>74(%BMGF@#M 1&5SD^YSQ77T4 <))X.U5K>WG@C5K_4HY]B\MGCB MGD<%BYW(TJN!LP%3 7'&Z-4YI>5S71T M4 >:WNBZ@@]^NBI;-
+:3:A#&=92XTB.> MZM?(TME"7$32"6:)>%1DR$&1C)R>G2NGU"]>QMO.CLKJ\;X8^E4 0\%3WME+ L]LI>ZN9R2AP1*P(!]\#FFZSJ>KZ9XBF MOKAKU=&B>**(6YA*,S#G>"""^"Q XQCBK7A_4-
1DO[".[O6NEU'3OMK*44"%\ MKPN!]W#XYS]WWH M-X;=M2GNA+$!+J4=[]WG:L(CQ]?Z5BQ>"]4?[#%%=7-CY M%C%'!&$$5B9%%29)-S9X!(3&.>>]5D\87MWX6UT02.MWIT'+*)Y;1+T3
MFYFMG!'[H@MO'R$9QCG=VQWKN?#NL'7-,+RT/DR),\+H"2-RG&1D X/7D UL MT <2WA+45@DLEN+-K2[CMEN9'5O,C.2]#L[:T$9QM))YJH_@K6]K,*^$E;JV;M.;*+*>XT
M]%L?,>W>)7-SA@'"8<LO"\UI)9L9X3Y&I2WK84_,'1E_^OS#\JZJB@ HHHH ***M* "BBB@ HHHH *Y_4M,U UMS;2P7)8(Z;MP(902&!SV.0.YZ5.0:Z"B!@7WH&:$X8@^0%.B#O[S
MAM9\+Z_JUN(IM3MI&EMY(I<[HE5F;<,,!>74V.A@BZ(0A*E-0/;(G/&;IF2'H8#+RQAPBH>2X"CH8%OJ%?/+%)H%W(RL.:4N5?5$G7V"G(0'1$Z4Q.U;CQA3[H(G&A8/V9VAA*L=N^=WS
MFC^#=3TFZM[ZWN+..Z@546.4,$(\O8QR 2#TQQTR*[RB@#EH?#-S'X>T73VF M@\VQNXKB1D0A&"N6(4=NO%58/!LT-A%;F:W+)IES99V'[TKAMWTXYK:U/6VT MN8(=*U.ZC(!,MK
)%4GM@'1>&,S,ZMN39.SC.!P+=1U;P^(;>YF@N(KV&VGN\ 2$O.5^12N"NWC=T)!QG!H UKGP3 M19%R.X^7!^M5K_$O5-U<^('BBEU"XWQ!!;R M3PJFP $[1OW';UVX/0XZU8?7=Z5-
=QZB56%[>:[81L-^-*L4ES\F1 MM7/// S73Z'JBZUHMIJ2QM$+B,/Y;=5/<4 2^&,K^_MX5E-OB21&SS&"-Y&.X7)'TIEEJKW^N7=K-B-9VT,9,PZM(XW #M@+@_M\"% &Q7 ^(?
#.J7=SKNHZ;&@OF55MMS@+U1@Q,I,>[!Q[\5K7GB2WTVUTYKF*9[B]3'=>DMA#%;31:TK2FZU7SPJW: M$'" @YYRH ( 7&1731^_/3[+%<[UEDCA:=U7]W-TH!4,2<\Y[ XR,XJ3Q%X
MGBT."Z2*WN+FZBMFN2L41=8UY"ER.@)!Z9/!_'+SV!TBRU?5[727I83;3V M<$TR@S2Q[MR*QQN!VX[DYKN-!LYK+1K>.Y8MR4H8I(2 [#*2-N=20>
[<^W;%1IX3T5(YD%HY:4H6E:XD:4%#E<.6W+@\C M!%;U% %'3M-L])MVM[*RHVD.1@7+$LQR2223DFKU%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !6(?
#&C?:I;AK)7>0N65G8IEQAR$ M)V@D$Y(&3D^M;=% &=IFCV6DI(ME&R>8079Y&D9L# !9B3@#@#/%4YO"6B7$ M,<4EE\L:[4V2.A W[QR"#PW(]*W:*,)/"FCI$(TM74B4S>:L\@E+D;23)NW
M'@D8)Z5I6%A:Z98PV5I"(K>%=L<8)(4>G-6Z* "BBB@ HHHH ****(Y(DFB M:*10R.I5E/0@]17.V>D7'AK1X++1]US(UUF1[EN]G/4@'"J..@%=-10!S5 MEH;WFF;E)?22QW6KP!+E5 'ED)L^7(]6I-
9\,1:QIMO8M=-'%"NPAHDD#C& M,X8'##'##!%=#5:[NH[*V>YFW^6@R0B%V/T5023]*,*V\'6EK)=-'6'1TN//8^:C!OW94D#;N#$G./N]_:M MZ7Q->Z1?J\2Z1Q?G:XO+'3GV!HEYV[42E^[?'DKIE'KL6>'N
[,=.M8U[XEUF.+2K)MK&33X[J\NE ML6G168C(R&&T 9/>*RAKVQOQ07VLR7%]]A:ZBUJ]EY!#B,2!,B0-RPSGI@T M7YO ]O-;M92:A='3AYC0VWRXB=P06#8R<;F(!X&:T7\.6[W<\YGFW32V\I&1
M@&'H"'?O3-+\3P-IK$&$VF"""2&>.,RKN=&W(&VDD*25.<<'!YK?7:+H9&6N@F!Q86V>[/%CF+\VOR*+D?F&*+4KQ%$,'M@7^2H]IE:?WV1-^,IPF9MG?I/$I+9Y]=%S8/S)B7+M?!PH+8/[LSQ
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110!#/"L]O)
^=DB%&QUP1BL.Y\)VEQ;PV_P!J MO4MDMTM9(8YL+-$O17&/J"1@D'%=%10!CZGX=T[575[J-LK;O;IM;&P,5.5] M&!12#VQ5*+P;91SEY+S4)X&N#@X
form10-q_004.jpg M_]C_X 02D9)1@ ! 0$ 9 !D #_VP!# $! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P_1" #O I8# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?
D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $"
P0%!@<("0H+_\0 M1$ @$"! 0#!@<%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-
T=79W>'EZ@H.$ MA8;'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_0QJ 22P M Y)+' 'J:1D4 \MSQ]
[^6>XZ_AZ5(W0]>AZ;^-?B;X#^':Z//X\ M\8^'?'"%%IXBU[3_#/A^ZUK5[.Q;7O$$FJRB'3']!'TR.:9'N=2NGP(K6W#2?(6X4 M$U'M%HKM-M)7MN]NO_!$]GZ/CT!@ Q< 97.X@ ?.,/7TSUXXQUS4CX_O(.C
M?.>>01QR." ?R/IO\B>/VYOV2_BC\>/'W[.O@#'H$@#_J]H'X;^*OCW\L,,BW8$ M1M:MW\2:1=V**;VUDMS(RW]Q8%U%Y!Y;F1X#N$@QBQ@_?!
%3J/IMOX@?(ASJE%?1`.FZ\]`KT,13]HX[K#8(=#\AAJV@]ADH%3(OTP2/2TS&_CIZ=Y*!+Q>DZ,LD1YHKX8E(\JKS:5<N2L]O#*%5E
BIXDE\#_!?X=W&O1W%PWC7XL^XU'] MAZ! EG+;VZ%XA=WUS:VK @ZMXPELY1MS)Z+EYK73\F^HX-5$[-T MU=I-IJV]O5O7S\C]T-7 YE^4]CC;@9PV3Q\K ||X()ZU+D<\CCKI[?
7TK^: M1/\ @M9^T/\ $3X.?LNVGP3 _&;/!VH_M1?)?VH=?\ $7AWQCXMU#3_(41 M?#O]CT*/B)XI[\_^*+.UN)/$_AWXA2W-G!\.=839:7_J^Y]R @]"#QG@YX/0_0X *"#T.?I7#?^"?
&7A7QYIBZJX+\|7>&_&_AV9KB" MWU_PMKVG^(M-EGCD'GVXU+2I[FS9X"P0QB4NAX(!! [=<8&.F!CZ8XJ0%HHH MH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@
M HHHH ****"BBB@ HHHH : W3V Y)/ !R23T Y)/2 MD."V 1G'/(ROOC.>?7V%)*,QD;=W*D*#"D@A@0X#@J2A&]01U48P<&OO2_P""
M@W_!0S]J]+C7XN>#+G1/V=/!/B#/]FNZ\9?"+X???BO7_ (CP:?\ $[XO^^?B B M]XNL_#'_ BWP1\#6Z3ZE]?@B.^&N:N:H5G&:'N(A-2N=6I[.*?>5OO0U% M3IUM);ZM+7W52!E>>""
P(RI&>HR.#SS3\C&(+'PM!9B&&#P:H>N7?D'A]\N7T*A '+Y ^%ML5-0>?D&Y]I1[3.Y[_ZJPQ[]\@33Z4I@%B-_+&8E+]%=43GA&]=[M+!;6!!'PUXL.<"/QBS?X;)'S$L)T6%]!S0I35QNEIA*H*SD*R0
MRT57^9*VFFBM>]M;R.!I@%HWX6&=DR*\&L8O!NU2IB)L_@:6TR2M%_&MH$-#"[7&S(_>4Y%T)I'Y]V_K!WB]G1'2V
Q&^&OPR@O;[6-G]Q*;#N1F)R2)QV;,5*,@%RE:P!8DLQ;(4KM,,X6ZV1!;+1B$J2;DOHS2%<NVD@(23%HCUTHI(4%;4!GQNPPT/%E'[!X:F2%V5I,<YXKJS^YC02
/BGPM^UQ\5 MOB/^"U\V5|>+WPJ G<:5\)?2'^KZYI?A;X/\ C24FCCC.M:E$UIK=MIFH MR :+-+ $<>T*D?2 2_Q[OV4/V^OV0ZX7Z_|)?/I=T?%*Z!XKDIJ]YXD\ 'X7%#K45.C&E
M7[*GC[Q%':/X[\ZXF=Q=M.LN(2<*W4=OOKN&ARM@=7Z7K9C0]XKWJ9D06/YLP8D@QF]KLC%FXTH@Y8T&R]7W_GHA;0J2L2Q^3O%S8P72H6ADH<9
X9TS5))MXK)28HY0&N88S]E;[. Q#'^SRVMXV#+$ABC20 MK'O><(N^21PZADW!)Y78$E@1*0R;E!';C$IT*2FN;DC'IL^9=V^]DMCFI/D MG5Y7=SWM?3;?1=.OH?R2>$O^"7G_
4'_9\'/)GQI^'W@?P%\4/BQ\,_*M;>^&&H_LNZC\0_[''\_/X#_ +7=S97'@X>>!?&[6\L.O:!/%+%+(^Q:YOK.XL MBFL0ZG%-%:^2D"@\_S?@%(;C/@YS@!J(%/W'O8LQ1ET(]!V?AX_G5K#^6"%8[:W\K
MPOKU]X86S^*CZ!XHN]_FL##H\MH;WL1#5;@7(HJ_L6[^=,H6$6!C\K[Z?9P?<'])MWDZ0=9+KC9^7_*)-]!FJ2IJP1"X<GU$I]][C=7!XF,:5K ^O0_N75%J%D0:*(Y@W"MYYV5'E;!]+0J0VZPK
Q&^&OPR@O;[6-G]Q*;#N1F)R2)QV;,5*,@%RE:P!8DLQ;(4KM,,X6ZV1!;+1B$J2;DOHS2%<NVD@(23%HCUTHI(4%;4!GQNPPT/%E'[!X:F2%V5I,<YXKJS^YC02
MVSG\>37]*V?8_I_C2-6BC\"/KC^A5Y?NQZDOA/:?A7B^ZW2+G%Q!V%O&>F!3**(,(&F9V9"9-G&=KD7V*P0&!@P"8 X:WJ7]$N"IHO;#1GQ3,X;TLX?1JEB$TA77*JKCJG_V]&%P=0-OYUO"$"26%^*VM%J
6:%@P?]IKX M%,BA$01A_%T)\L%%3>HH2S7RE6K+I\P+@DSS!?:#S6D'Y<D4-RT_A.VD(0%9#K4O@MJ7@*@2L)CUNDL8#1/48QF/%7V>4$
W!/KOU'X@>U2*2@(R#UZ/Y!/ M]/EW?ES4:W# @A5V[@"254X+8+@$G[AM?29W:$VL[_O[Q'&T( M&EGY+@T59PZ0S9RNZ(F@IJ:V/Z6C&TQ1>M:!TUAI/'M(++-5H?IFK0#8>LSVUU5U/NSSB<VQ;2J07J%@;1#2M3YCUTFVA'LJW6Z. M@D3D7EZI3YWO
444?@1^7]"::Q@!%"]9$K:5+LHX+\2ZK.L^DSWBN(U69I0L3TUP@%5R>IA<_"UO/AC\,CX2@7Y<Z:&#G'\P>Y2VU]+06*GQ$M\;@%]H'W%S8M.:CY[,/"7K2QB*2H5#RKY!S9!-G"3U=@'S\MJ5L0!;J(;4!
."5O[.W7[7W];;@C<QH$7#GA3Q7[Y)H7K/P#W#"K6\U=%>'BH=,'DAR0%@D&1HZN%PF/PZX&X('71)'$>A%JO%[Q:ADIZ)V!OX71A8.[;CS?P;)@;2:L=!#P+++ G=-&Y\$7
(?CS M\&KSP:_T'Q,"K/;E&(]\BMH<W0X/B?V4;]UA$U:>V:W")O[2FQ*.@[+V<)V4$G=%.^C/4[N-GMDFBO/KC?EZF_P]5+1]B:'V$F4DAVG*2MXD
M98[^9+1HWD^V3^:VS^0ZVSDD*IDDRNUE;<9"Y=MS$YD+M*"-RN*$8W_Q M9?\!S'"B^%H?A>;9+S96_4*0^AZ'G0V3U"L^:H@$9+PF84$WX7E+0K89<)#=@!QTE>VSF&4A?JK#=+^>C#W97BB(T.?
```

~~$WQ%NM4U4:;<>)+B.\|77JW-OI5MJ<-A>2SVTMU;", MAO[3(FP"WF!R65R(E%T$];72O;JY1>U] M7 MHK[(Y()^UE#3F<>9=K:=?\[LN+_K)/\ @'_H)KSSXP?\DJ^)G_9//&W_*CF MH5Z~~
~~'4&5MRY!0 @Y_^4;?3DY.1G@8//?SWXOMGX4?%%A_!\._&A4]CN\ ZD3 MG\@,<=_7C.*]V+\E^2_S-KIMKL[,_GO_.#5!@G_2WOV/0?M5_M)9_'QT1~~
~~M_6OZ4!*C$MDC!&@[C/3TK^:G_@U8)7_@ECJ14G=_PU3^TDP&,@D>.S@< M8."<9Y!Y/TK]Y/C_/&6T_9_^""Q3^.H^%?$GCBR^%W@O6/&#^$/!UB^I>* M_%+Z/9?:4T#P_90&:6[U?~~
~~4)BMM;J(6!<@F)N6K3"TJV.QN$R["+GQF/Q>'P. M%I-)*MB<55A0H4E4FXT:7/5J03JUZM"C! RG5A% HE*4(N:5TKWVV6KLGN^U MM>Q[BMU&1\K!L M8@A@G3EB,!0<]VSZX/%1FZB5~~
~~V/Y)OCU_P<\:AX ^#_(H\4>!?V ?VE/!WB>.T5/"OB?XS^%+[0_AI!>RA M2KZ]?Q6WFVL:[L%93$V3C[P*UY7^Q[_P="?$WXA?#K4;OXP_L,_%SXD>* &U M!K+_(2?]G+P_J^L^#[Y54,T~~
~~^PTZYM]/U&->9;42.J#.,C!K^J,_]"#Z2^+ MX8K\88;@C!3RNAF>'RB *MQIP+1Q>)Q>)I2K4W1H2XH>'>'C"/OUZN:X6492 MC!86HWIXM;/<%1KTZ%2 9U)\UDJ 3E23BF^;;JK:?~~
~~6L_P"RX7*;@%5F.,\? M*.^221M R2,C&,#)(%*U[& NTH2^" S[$VG@2%F7.POE%^7E_"KXG_".#5]5U+1Y_?Q2T!M!\8Z?=Z/> 9W#W%A= 7 MLY98P]I>*BQRQ!9""I)'YZ_&3_@HE\=?AC\?~~
~~_CS\+WLO!LND:'>VWA[X4W&F M>!M;\1:1X8TV1_#TFK_$OXJ:]%=VU[8VNC_VY,) ATN/3;IK(R6^L/ 6EK^ M9LVR?,#MD* D@@A2 V#C&< R"Z1F"+\SL P .1LP?G. 6"Y#* 5W$]<+C&?YVX~~
~~M(^+W[4G[9_PZO#XB^$_[16@^#?@7H=_J7CC2?$7Q'^%?PYBU9/B)XGBC\<># M_!.G"YM/%FOZ>BV\>I6%QXAFTQ(:&"*XO(VD*]]XY^/7[17[5G[/?[8'A+^ MWO%/P&N?V:?~~
~~#T'@/X@^_A[IEYH'C3Q'\=O#NMZMXA\1>$/ =SJ K?+:>&)/ M!]> H;G6].BU :C XFN+>&2V^Q,4]Q._WM?<6?O))>0Q!/,9$,JEHU9P'D : M)24CQO8(T]B0]I*~~
~~H2/G&%6\B8MM.=K!3C)/S,$4X"_=+95FSA2 .<\?S?ZK M\:/C)H?[:^D>)/%F@^(O%UGX7/[/7A7X3?"K2]>U_1OB;XO*^+__(3ZSK'B M/Q X/LEM[CPKXETZU\06L8\;6FO2V~~
~~Y+J"V]S9ZKI<<$MM=_3'Q@_:W_&S+ MWQ]XB/PC\/\ @SX4>%/#FI_L\>%]3^'WQH^'U_K'CZ"\^.'BF'0 5\3ZEJ?A M[Q&VDV_&IVZFUF>&9U:)@?M*U]&'6 59Y"YC*+QB01M* M4+~~
~~M5"8T:1#*8TD16*L6 4O W$#M8JA. H=U7<6;8 H)R27*CD R<@K7Y% M?$'Q[\9_VA?^"9?QC\8W_P 0 :^%/Q.TOPI\2K+5O'GPKT6ZT76]4/P]U>[A M2Y\+Z9=C4~~
~~1T.W\96FGM!/;2&^NH+>X*03PJSR'Y<^(7B?7?!_[7'[//Q?3X MBI\5/$Z:5^SA\/ _9: L;QA9^ TCQ9X9BG\2?$'PEKXU:V\ :SJ:.3]VJ MV>O:9)81';:W.NZ?/+&2 ?T*M?P+O)="L9(8AQG(QD*I~~
~~+L=RA5CWEF8+@'& M6M?Q;S&A2216=&195++)&"6B*XW+(,O!!U;X'^+M9NM,\;+\,6\6:I87\OPL\.>'%U_P=X@\<^+R MYBOCJNIZE:PZ%9^;:6,C+.>E_9\\?Z=X1_:8_:^F^"?BS7~~
~~!_X%M_@'XD\ M?Z'J4FL^)_$RM\5M U:Q1J/B&U^*>G^)].L!X7\9:7KA3P_X=T[3(V75O#%G M# I]N0]Q= '[GM=*GWS$G. 6E"KRWR@LZJN\QE69%+%7)0;E D,<>H6\H'E~~
~~MNA8E@(G=8IB59@5$K6.L6\ G%;V)TZ:?S6B]$U3X=:#XU_:!\!?&Q=*^,6@^(O'?\ P3X\ M7_&N]T36/&WC0I9_$O1_#FG:7H>KZ]8VCPZ5>^)3:*FIH6TO3VNIY7N1I(W M;1@']"AU&V~~
~~=O,C*1L5=A(K!,,J9?;G: [*N>5RP(8J'*/ [$#)T'E,@D)./ M+60$K(^%)2)B#ME(\MD5G#D+@_R]?\$U/C+\1OA]\0)M0L/"WB'XS6WCC]GC M3O$FL?#[]G_XB:K\5EN/'^E> (;'4/"QF?XA0^'.\"?~~
~~$'74UJY73= T34$ MM1H^FZJ#HS2VGG7';_%_Q%HM[\>OC!H7PO\ C=XN\&^'?B__B9X>^+?C77 M;SQIXRU?X5_$7_A+?#?]JW?Q;\(+9:/;>%/!G@[1Y9_"G@&[\&.L^H7NIZH]~~
~~MQ=W%M9M<2@'])IO[< DS0 8)# <1A2 VTG?RIVD,'V%]A #8W9#S=(69$V.Z M@!@'X1W#&$2,JML$NS"G!8L\85'#Y'\I%WJ]'X_^$LT/Q9\)VF@?LO^(?BG M)\/O LFA_$T>$?~~
~~VWM=TK5M(@T_QMX%U@Z] J_AGQG<@MX:70 8U7Q%8M=ZG+ MJ.G:4]K;RW@]3T3Q_P"*M1U#XC>)H_%GQ \)?&37OA[^T_XM_:3*:GXBUO4~~
~~M=+^$T/PYM;74/@!]7DSV\.FZ;KGF)_>%>3?!_Q JOC'X4?#?Q= MXAM/[,UOQ+X+\,ZWJMJ8W5H=5U'3K:29O*E8R1M)/)YH1WU 8%BH[DGMD8X_7G_ #B#S%8'&%Z\C/;J <#H.N<<'CUI~~
~~P0GY@N%'W^ M_*Y(YR< O2U*=U M?\].Z_004444P"BBB@ HHHH **** H_,&"2,!2P8D],="!WS^&#ZU(2 ,G@ M"JTJAHW)) ?!^7 ^4 D9)SSCDGCG !'WJ3=DWV0' >+O'GA#P#X;UGQCXW\2~~
~~M:)X0\)>';!]5U[Q XEU.UT;0M&TV XHY+ 4]4O7ALK&T6294,US/$A_L%_MG_M_L_?M*_M#_$S6/C;X#M/ MBYX%MO@9 MM>_#*UMAX@@;6]&\0&V%UHMO%%=6HU.YL9;A8 LADD K(_X*53~~
~~M_#2P_84_:AU#XT?!CQ9^T3*+?X87K^./@=X(.H#Q?\ $G05U/2&;1?#\FE1 M2ZFNJV_EWEJMK"LBB)V9R@#5_"[#XL_X(F21AX_^#>S_@H!(0 [8TSQVX(C MRQ7='> ~~
~~$64#"^6?)E*J+B;:S2'"E& 3$4YR;O#FMOK=KLULXJVWW.QK N%)] M&J]+7_MVS6ZW]Y[;KSV_JK_X),_#"[NOVI?^"EW[5.L_%3X&>+W^/WQ6\(Z% M\/O 'P&\<>'_!?~~
~~HW@GX'_##0)/#7PQO_$*>';B2VTSQ#XCTB,2W'G0P322V MLS,KEL)^]EIDP0D@J?+ VDY(';)X!;J&;: Q&<#I7\SW_!OIJW[%&J+^TP_[M'/\ P3Y_:#_8?C+> G\9S_'*'7HU^(:!=8&EQ^'6UDNB1:~~
~~(LMU<7*6T\GS7@ MWMC=[]'9:+_@=?O)Z_F:_X.NO^48.G?]G+_?_ 2Z&OZ9:_F:_P"#KK_E&#IW M_9R_P'_]2Z&L&TFEW_X" 4U/Z+_#*O@'P.6SSX0\,#MC_D"6/\ G]<'I73F MZ0F0 !B/^$!\#~~
~~E^/!_AILJ 53&AV7S M.3R%)X..O7C;FOSS_P"""BW[&?]2O[8/ASX?67[.O[:_C;]C;6_!.HZS<^(+S MPAX9M/$VF_$2RU>U@BL]/U6.;5= N[$Z=)&S17,32,&D<>5(NPQ^GD6#RW,\ MUHX':~~
~~<]PG#>5U:G)B,_QN%Q.+P.60=KRQ6%PD*F(KJ.\G2BW% JR)G>%*I4 MIT)5JD=5V_1[>FGEJ?=WQ'^./P=^#D6DS?%GXH>_AO#KLLT&BOXV\4Z1 MX;_M6:W1)+B+3UU.ZM_M3Q)~~
~~(A<0%R&=%*_,I;T#3]:TS5] LM8TF\MM2TK4K M6&^T_4;.9)[2\LKB)X+FVGC)CGAN('DB,4D7!4D'C^%/_(*)_P#!OA_P M5'^+FF_"S5D_; N/VZKK0M7.C2:~~
~~\1E;P&_@1=8=8YO$&AHMQ>Q76E6*0H]_MM87\BPA[=EXA?[_^'/\ P1_X*?^&O!W@3P^?^"S/Q+\'6OA70_#]D?!^C> M!K&F:!)IAL6?2 +U:YU^&2YL+.$3VMI)=V\[!!'YJ.A8+_3&?~~
~~>"'@%EGA]PG MQ5EOTM_#_,,^SO&YAAI>1OYF M H,6!*#(O[LGY@'(R]Y0@@EL;B$8KUKB7^*GP[CTR76)O&WA6#2(=6@T"75V MU_3UTU=GD,,6C_;7D6!M1DN1Y"V8)N"QP\2,R(V+9>$]?~~
~~7X92>#-6UV?Q/X MA7P)+X5OO%^J8TVY\0:O+X?73+GQ%=VMB)!:J^H,UY+Y3AK,L[PJ!A*_#KX M>?\ !._]J7P'IVF_VSX'^#/Q.\$>'?&'B2/PS^SKXV^*'B*YT;R?&%D(;OXK MWGQ)M]#AN~~
~~4U'PY.7DT/P;>:#!?1Z=/4K6&UD3$=S>%/ 'ANTCNM5U'5 :TZR.I7]O'K/P$8]/FNY+ F\/>(M&M[U'DTY[V6*&V6=Y?,DRVFL>)M7T>YTCQ M#+\/KW4+6'4;:Q M:Z0BZ0SV5I*8[A'>(EIG /L;X.?~~
~~M6?"?XW^ O''@OX?7 M.OZA=^#+J\@DUJZ\/ZM:>&?$<6F7)T[5+SP[KTEF ,U&VT_50]B\EO.Z7 \N M>U:=3*L7L5S\3_AY9:C/I%YXV\)VNJVUS#9W6G3^(M)BO;:[N)%BMK2>T>Z%~~
~~MQ%=7#DK% \8? M\+Z?\2_A9XPNM9\=?JVU+XBS>/#GBSQUX0\3:3=Z%X!U'1 *NKO0=2L=#E MNEU22>1DN88$05Q_B?\ X)0^)/$4?BS7H4\%:A\0=8N_VF 9MO%]]XI\7_;M~~
~~M6\0_%#XCQ>*_A=XFU:.:2V2+4/#>E1O!>65I"MKI"R$Y6W$^]@*\]^"'[7'PO_:$^('Q\!?#*+Q'K$OPJUK4/#_(D\ M47NF ;^%VUG1=6N]"U?2]+NV=6EN[+5K&\M]$\H@ Y#G&!E_&[X#^(?B': ~~
~~MLWSZ*OA:;Q \(OBY_%_B+Q%KUN%U=_#?A!))?$.E^&;[])++?'<6K^%_V5M$@TKQCI!\3_LY:[]%YKGQK MO?%_CB^\56'B?QCX5\265QH'A:X\/P3W U5!'?WNK:YJ4]S:7UM81):H ?6]~~
~~M[^W5\#=)\<^._A]]C^ ['5?NB^)==BN+CP;X@^R>,8?!\NE6_B:V\%2"P+> M(Y]+N=>TJ C3A #(UV LB&)@.J\)_M;_>\4?!SQ1\;QJ.NZ)X1\#ZC_8'C M#3?$N@7>F^)O#_B+[;ING1Z%>Z.Z"~~
~~[74[F^UC3+6T@"]HEO(%4J&)'Q;XK_M &=/VS=>_:'T[XP:9!\$K3Q#\)_AC\3? WA?XAZEK/B'5XOC=H?BVY*WGA[MP1X\^&92VTWX>S6:Z5JTVK>-=%U:]N]1U::U=[06"I;+Q.I?LO?&/X*/!"~~
~~[[Q+;6+:9IFOR6SQ682ZF6"/6)8=.>5KAT1_(= M+_X*F?L^7]C\4 1N/!?QMTE/A)X@TWP1XN MKX:ZU:W,WC76 >L_#7A_P?]J MOL&H:SKNL:GI4%F8B;9H[Z&9IO+#E?#'_9+_~~
~~&J!XCL?"O@#4_#>E_">_P#V ME_._:2\ ?&:'QUJOASQEIGA;7/%.B> _%?PN\;_!]?PW?V/C/5[^VLK[1+#Q M'-X@L3ID=VMY]A!M%M6ZO]H'\B/XQ_$3X3?M;^$_.M?!WB^Z^ 7[3WPP^;_A~~
~~MKPIJGC#7/"%EKO@+P XQ\%>(=7\(;IXNTFRFU/PAK&KV>@WMMIVJ6,(]4\(^*_#WB72;W0?$7A7Q M/HKQ)J>B:MIUZ@D6X@:9&BECW07$3*\+I/B) MX2L+/78K:.\TOQM\2?~~
~~$ND0Z_XPU"ZEM$G=X!86MDGE6MJ0 6;]3=*4);B 8' MM@N7:*1=CK)+)([C:99B$Z>7EVRF.PS2Y^;'MG]:J7,KK" MY4*6X" ML7=S@,Q#_483/RT!T;[;BO=0Q!I;8 < &=ZRA"H#*29 /EJW@L M?~~
~~3A#%58RCAJLG&G4<'R/>VO*EM:[YFK]^G34P>*HX>GC*E"K'#U74C2JN$N6 MK*E",YQIMQ2G*.9KW8MN^FG7WZF&102.>.^#C/IGUSQ]>*<#D?E_('^M0L5+ M8 &20 PZ]LG/3CN.X^M1Y_\~~
~~#_\ #G,O>U7:_P A/M*Y*[6R,]!D<'!''^?S MJ8.",YQZ@GD'_/YUF2?:"Y,;QHF<$G!)'KP0O?I@$$$5/5)WZ >JLP"BBBF 4444 %%%% %0X79' MR1'Y>3@G(9QD8&=P(Z#KP1S7\87_37^~~
~~O[*_[(G_!8O_@L!I/[E:!X)\0:KF)5M]+6PEC$!BA MU#3+%;='9[>2$?V@>,[318Y7GBLK?Q+HBQ7\EK;S2,T,0E) MB5BH9(\H847*2JW5M/=?Q:-/;;IZ%I7IMZ:W7FKJ]S^=+XN_$K]EK]I#_@XW~~
~~M_8+\9_\ !.'4?"OQ&^(WAGPWXVUO]MGXF_!G4H9O FJ>+C3YX--LO%_B#2I MCI6M>)+*V:Q>XCC6X$\[<]M:7$_VNU,4?]AOB'Q3X8\'>'=1\2>+?$&C^%%O"^~~
~~MEI+>:IX@\2WUMI&D:?:W$LA:>ZU"\E@M80C XDFD2.,...2BE&^/_ C_@G M^QA^P!H,JZ!^RG\"O"?PUGUP6EOX@\0VDGJI>+_$ MI&GMM/U?Q1JTDFL7D, M#2/6\C O7.TC\R?^"_UM\4?~~
~~%ND?\$]/@OX(U/P:;>'/C5^V?X=\"> M+'XKQZA#\%=:;;PSJESX:T[XLMICO75SX=^U+]I/7M;^MD?N7J'Q>^$^E^# M]+^(-S\3? AX"\0SVUOH7C.\6Z-!X9U>XO%86<%AJTMP;*-FE$,TL:13J"~~
~~MBNX:1 WE7/B=VN(9)(M9H)87,D,L+F XV1@2037\/O@/5/A!\=?$'[^"/[/ 6?AEX"\&? #X4?#C_@MK?X9U_X9:3XHU&;X,>* CW\#XO#4&G?%#P_B.:.\ATVP_M'49O!FCZG=I=>~~
~~M%)UQ%;V=N;4WWZ;?"S]J+_@H7?\+?^"%_[&/CK]FK]F/_(;-^('BSX>^)/"O MQ.MO&'CB'0M7\(?"!*\;0^'OB"FIW%[##XBG@T[3=$L#8K ZO^IZ1Z_P:I_ P2VO5P#G]]K] MI~~
~~GMT\=L3_+.#D<#@U_2.8"5"MM"EM[HV7&<$#'RD$@#(4@@'IG(_FN_P"# M3^>>]_X)1VUS?0"RU6Y_:5^/]SK&GJP TS5;CQBL]_8QR N'2VFDDB1E9@RH M""P\0^' FUP,[6'.>2^!O[.?P5_9I\$1~~
~~M?#GX$_#GPU\._!\5U/J2Z!X>T^&PCN=1O!MN+^^= %N78'+EBY*D@_P?>'. M.5C9_<,NWVZ$\>F3D<5#&68 "%B%X 9X\JQ>14~~
~~ML]S6MDE;'T\RKY%+'8JAE%3&TX>SH8JM@Z&)A0KXFC!35/$3H^UM+EYHK58Q MPE)2=5X>%2]N64YTWR=6M7?WGV:VU0^*+"QDQJA!S^[P(U/S$L!@+@G[V "Q~~
~~MR3GK7,S^#/";ZCK6LS^%_#\NJ>(-/&G:]K%QIMA->ZOIJ6J6HL 5N&A:>]LQ M;QQPM!(S!E1 $XR.L4\ %2O.0!SP?0>Q]<@Y.">34J10N &C!.[=S_>4D@GG~~
~~MJ",XZ9[5YE.$Z=2;C05.%1||W&4;RFTKRFG4J RLDD^9^ZHJUS9N^BC"*UT@ M[K1[=E9;K[NQRFA^%_#6@V.GV?A_P_HFD:?I]@ T^WT73[2P@L],BG>\CLK M"*UCB$%E]LD>9;4A0+B5Y N6?~~
~~ R+1=(6/5(TTNS1_M26]CV&.>:2"VMX@\F]S'$%)P !TGDQ89 @ 8AF X!(/!XQR",U6N_+0*?+E= MLO(!$I8L0H4Y+$(" P==[8C.,]*UBT[V=_>?WZ77R9 DMMO,YR3PIX8DUC3~~
~~M_$W]@Z(=7>2CK9Q MEU* $S9:5E5([E)8\%&1T)7E9S, MA ^4)Q%+*RC(^F:+W1M1M$D;>89WMXXI$F9H3\JF:T/EW%O#>JZYI.M:AX>TK4]?\/R3WN@ZWJNFVM[=:)]J!2ZCTJ^,37 J\~~
~~MD3R*PB<%MS'()S45AX6\+Z#/XBNM*T#P_ILWBJZ^V^*9;72HK9M>NIT%K >Z MT\4,^>T:S:Y M%K;R,ULJ,!9 +*F8[3:67[.I\GYBI3;P;3RR1J2YB'[PI;K%(J!G$2Q^5)+ M*(C(+E9H/)C$BQ%8Q~~
~~D$FJ9NQ<0QAIHHV6)1):W#1K&^UP>& %TW1WO[T_: E[>OI M\%O]KE3<_EM*6\HO(R$&5RTD7@WP;_:?B#5!X0T) 1\3V<.F^)K^30[,ZCXA MM;96,4>]S^2RW]F!~~
~~(0]71<&4RLRL<,=QY8KF+R8)!&0[V\<7F6[O(BQ)_H]P ML;2 &F[4TUQ;+#AV*&.&[A\V&62$ E8'VRR$9)ZM488O,3*OFR0L9##(Z9CA MD0Q*5$!G1Y+C*O$)/+D"@DD]*B<>9;VY6G?~~
~~I_6^Q,KN2A%ISWMVMKKV5].G; MN?%G[8GQX^//[//@OPOJ_P"SS^REK7[3K&2[M==T+1/'?A_P*_@G0 L([H: MA=MKD,T=TL=O:O#%#:;I![F "2 ?GG_@F[_P4+^,W[=.ES^_$'[(GB7X&_!~~
~~MR]L+Z?P;\1]=^)?A/Q MA+&4\PG*:7/&+5\/! O79Z/]C8CN7#8!(R<<'+\'G&#\O'&"3SQCB&;86= MF(R]#=D/(H5,XW*F" I(WG/"@M@YXQ[\^_')]%ED+9 M**^[.1NP2.N"#U!R^Q\]??~~
~~$W]O+]D'X.>.=5^&?Q8_:,^ M%?@+QUH K9WNL>$_$7B2UTK7K"VU"(W%E=7 M/O6'3;F H]G<%9))8C\^)1N MKW+X(?&OX3?'[P='\1/@O\0?#?Q\#7]]=:=9^*_">I0ZKH U>Z=(T5[!:7<~~
~~M/$CVLLBQ399OG&0%'!_$K_@N9\ O@;>^ /V?_B/J/PB^']U\0?%_[8G[.GA? MQ3XPN/#EA)XCUWPS=>)H]/O U/5O*^U7FE7 B?LLUG+(T1APH5><_N)\?A M=\ ~~
~~_A'X1L_!_PF\#>%_AQX0MY'U"T\+>$ 'L]"T6UN[\A[ZYAT^RCB@2:[E4 M23R! TC89B3S7OXO+L!0RC+L?2A75;&SQ5*,I2HNC#ZI5C2E?E;J/GD[QWNM M[6/I\PRW)J.39/F^'I8U8K ~~
~~,1B<,IU'AU1ISP<8.O?7O_7778****8! M1110 4444 %%%% #)/N_BO\ Z$*B!RA!Z>85_L/I@^E3D C!&0>U0RJ M=BY)+#D@XZ_]\ALY!'XT;IZI:/5[+1B;LGU=K*W>Y$\:M\Y(P~~
~~5*G!!#!0N0*_B@_P"""HO\ P4#_&]M<_:X^+Z?!C]I72_V>OV=_P!B3]L#MJBW]GOQ/\&?*?#\ G:_$SX]7OQV\8:'>:[XSU?4=60 HG@;2],FET=;F(3V&I M(^X69D:5?[#OC!\6_!7P,^%WQ~~
~~^,/Q,UF#P[\/?ACX1U[QGXRUNY+'[!HFA6 M?VR9U R6N)HU:*%$ +W4D,:8[?6I=9EDMK'1=6G M/V[1IQ+),4AS7/23A*52"]LHSBI*F]8\[ERWYK*S:?7H[7 82M%PJ0E><). MG*RLG%Q$;5&L?~~
~~#^D> /"#7NI^"=7UB$F"_P#$FEWUG/ JL,1D^PFY$+.A M!C'['6RE(HP0 0A P,#:",$>F1CKR> 2OY[/^#>?QI^P3XO_&.].C:?M'>!/B[=ZEJOQEL_BW%9I%=WOC_P 0ZFBW>MM<6IF6RDC<~~
~~MV]F_GV4T<=W"ZG^A"T9FBC+;064/A6)^5O\ '>'M@8/')KKJOWU&S3Y(NST[K M;N[LYX_2DE;WW&W72VO;1=MON+=?S,_P#!UU_RC"T[_LY;X$?^I=#7],.X MJQSDC/3/;VK^9_\ X.NN?~~
~~^"86GXZC]I?X#_^I=">O^>GKQ6EE_G%_H: M/2UVM3^BWX?C_B@_!!P"/^$,\ #IDDG1++'7@@>G\L\])'R<*I!"D@@@ \J MXY/H/3&TYP<\UR?@5RG@/P2 "> M,C@\TCH"!X%/)=92,J3D # ~~
~~NDZ=*.(J M4*L,)VI3^K8KV,9)MJ?\)0C.>DFX1W;=EJ7*E7]E#$>VKQH2TC6E%4X *RU MYZ2=Y;\OQ7=MTTI;N6M_)UBX^TQ:4\6F:E<)J PHN;72VL["9_[4NH%*23V MUIM_Q):!E\U(R@VE@P_~~
~~/Q/\5OVQ]0U3XW_L_!_]HZ'Q1X^U;6/A!XJ^&WQ M"\9>,//AJU\1>$M>AUC5OB!>_"SQ;9:'J'AZQB9+"'1]!\':Y;OXAM5L;ZY MEEEB,MPG]"L]M'+%PUOQ 90Z9)&MYJ6EW%S<:;S_L] M[V[~~
~~NME+$B_:IH BI,<5%OEM/WI_S+;\=23\]?)OVQ/V@X;_X9?M!Z5K/CGQ! M^S]X;\ Z3X)U?X:Q_$GX?S_&*_\ C;=>(_$7A2^O/B%X_@\//?\ C?P;K.NZ M9IT=KKW@K6K2WF\/&]UO2$CCM&9.O\&?~~
~~M6?'OP3IVE>)]8^.5Q\9 *U?0_@A M\8O%T1T+3!8:#_PL_P"(4_@'Q9\,;"33[=7L](M+)CJ'AK3[H#5#_98:>423 M2_L#;_LL?L]6?B[P7X^M/A#X)MO%GPZT2T\.>"M;M]2&XT+1;!94T^TLK8 M!~~
~~()#:1W5T(7F4RP>?*5<&0Y\]UC]BOX&".PT;PAX6T?P!H.K?%CP]\5O'6F^ M&K&.U_X3W7?"%U/K/A^RU652/LMAI^MRKJ3V"*EM+MDB5 TE,#Z\TX6LL M3'@+CA>%YR5 X~~
~~!.2,9X/4>M*8D8889Y)YJQM_+' '8=*DHH B\I#D')R2>O M0E=IQZ9'7'?GKS0(8P5.W.PEESSABI3=@]]A9,_W68=S4M% $8B0=L\$X_#C\33Z*(_*0#'S=.;MQW8SQS[=![#L*> M%)(]\G_#^)/U ~~
~~+10 W^/\ X#_6]%V0D)?"DJZ$!B0N?F]/3'3IC/>M&HI$ M0H05!!*Y!Y[@=_8D4^@+:2[MGX_\%V_A%\=:^_P_/B/J/PX\'ZMXUN_V M IOV=_!UWXNN/"FF:AXED\+WWB]4O ~~
~~#.JW"?:Y]"N(P4O;,R>4T1=/+.[(_:;_MX<>-_!7PP\PZ5Z5X\^$?"_@?PS9")]/P]X3TBRT'1XY;J 9KFXAL /A@MXIY M9#YDLHCW,20<@[J_*7_@NFBGJE'X2@C 7]M'J]F=U)7#?)\;(2?E(R"0"P/R ML?O ~~
~~U^SELB?9XGVKN O:.6VC)86R\YQQC Z8'%>UCZE:IP_E$)U9*A7QF84: M<8MJI%X:IAH225_$X Q[UA7=^EK;SW,LT* M1VT,\MQ=NK 86T=O&TLC7#KB50L2 YI7)B&YR?W8 :!N 0I)(5R~~
~~64\GD<>I MZDC'4].QJE1*LT;1RK,F KAX6=&4XWAMN?F >).+ MBGS)[/2+3D[=(ZKWFK\]?4^8IS3E.$4YSI1;K07NRIP6LI/GLIO/XVM4,.H6=RUG>60BV>= /#> M6XB2/S~~
~~^5;R+*KE"^6K^F#1;&PTB MRM +TZQM].L /M(+2STZTBCM;:QM8(UBM[6&VC CABB1 D03">4BJN0*][/\ MMPV5K+72I8^EB,7@Z >;Q4::HS56',HQY?>?*T[W3L^577 K]1Q+D6!R2IE<~~
~~MJ.#S+"8C,\FP>:2^NPI1A4I8]_+*E[*VC<6WS*Z3CK=N^Q;*RJQ8@AB"#^8(M/X^V,DX]K 0QMEF X4 87L,X)]N_:I%_B_WC7@MN_O6N]= MD^I\R]&EW_RO M^HZBBB@ HHHH ****~~
~~*)QGY^(]B8)!)<' 91P6RPSP"2>F,G ?R8W/\ P5[^ M.G_!(3]KG]I;]GS_(*MZ1XO\1?LS?$#QQ\4OC!^Q ^TCX1\/ZGXCM=1\&:S MK%WKOAWX$71@M$CDUO0M.N8M :"[GBDT74+5T;?HTMM?~~
~~O_682J9C;)VI$)59 M25VC!:;,'>VW(V8).2 #T'/\ $W_P4Z^!'_!5S]M6Z_:_9_9J^(?2[57_!*'4/V M=J4^*_B^X^%_ASXA_%3P]H?Q;^'&@6/B&/&@\]'@Y)IPJ:GX<\]_!C]JKQ#X++UW]A'_@F[\'?~~
~~&@\7>$_A9XFCOM)^)?[0MO;Z?+:V#^)=/N[9_M4O=/U%;FWU""YGMK/1!;A)_(FU.!DO'_*3_ H#]G/X(_M7?#/7OA#\=_N MC_$3X<>(+J&YO %U=9HO(U+3)C#:ZCIM]:S0:CIFIV ~~
~~S'(UMJEC/:W44!;FW*:YI?A_XQ:# MXY^/.L>" 'TF46'AS0S9M#>Z[?:/;_8=/TR2;[1>V^E6$'V@;%# 6[9@ $" M)H,%V,+*JE?,D,@R <8W)@IE&8R88E2!T5Z:DJ;NN]M^V][?@K>;ZX4Y.+F~~
~~MN_7;L]O*W?\ R/A+QQ_P3_85^(?P,^&W[?B[]G7P ??!SX07(O?ASX4B@N M[%_"T\CA]5FM 8L[B'6)F\0 N7Q YVH7/]O++'JJ7 D0U]&^+O"OAOP+\!O~~
~~M%WA/P7HNG^&?"GA7X3^)]!\.^'M%M4L)T;2=.\,W5O8V%E9(B)!%:P1+&$" M[DP1(2Y >W5YQ\8/^25?$S_LGGC;_P!1S4*7,[)7=E?2[ZK^OTL6?ST_\&JQ M8_\!!+2 >>1C(X_:K :/:CI=IJUM=~~
~~MZ9J=I:ZI87L;6]I^HV<5Y87<#)M>.>WG26&>)@< &ZX8 D@XJJ2C[12J)2I MQ26 NAEM6.TQ;R3*C+@]3P7[#O_!S!X?\0 \1& ;Z?PM\+4T^?2Q\.E\"~~
~~M>&_$&IG6HK@NE]'>&UM[K9/8KM=MS*KJ"1G(! >[]]?_()A_L@_M=>!M(\! M_$GX8Z%HFE: XAM/$=G=^! 'T;PIJ@O+..1%MGOK+3A,MC N_?VRX#G'..1Q M7[*'_!~~
~~(7]BC]CB7Q=",>%YX2IP7Q'_&_R6C7_+5P[BZG=M45&,;[1LVHOENW[S^E M_P!D_P#:N^$7[9WP@T3XY? C7 5U_P"NN:EJFF:~~
~~MEOI^HVD%T;2]E0W%M<;!$8\;0%)_/SX@?M\?$OP5\1_VAHO$7Q"\(> [;X8 M>)]3\%^&O@/J'PO\4>(_B)<>'X](\.S:1\:I>TB*6"~~
~~&T;P]H]E&T5CHFAZ1::5H]]23*WDV%E M!!;Q%R26*JBLQPV,FI[CPAX?NM3N]8N_T2;5K_3#H=_JLNC:=/J.I:"ZRF3 M0M3O9;=KB]T@R2OG39I#: $[8RS,3^7U:>&EB*E>C2Q &$VW3I5:M^5~~
~~MJZ2 M:E:]MHZZ;6/QFO+#2K5)83#5\+AY3DZ5+$3A.HH ^ZW*FW%V6G35;=7_#S> M$O\ @H;^W%\3/!%WJ/@K4O 5CAZ/K EXPT'0K[S9M O[Z MVU>71;4VBWTF3'?~~
~~1*)I9(H/T8L/!_AW2K>.PTKP[H.EV"(J0V>GZ'IMG:V\1 M2,/%;0VUM%';*A298UC51*JDDD*!H+HMI'O6*WMXHYWD>]B2RMUM]1EN%C2 MZDO(1$!++~~
~~]GB,DS_(ZK%EFQD&O6WR5M/\^[ZF)_+OXI\=?%O2?%W[,TWB:[MUC7/#_A;X ?L^:I*?!GB/5?&.E_$+XH^ YOB'+I'Q.O?"UWIVGR6TGC'28S MHUSK\VKR/)=?\ !DOQ'L=:~~
~~MOO#WA+QKHL'B34[*S^$'B"V\;?&K4]0UGP'<:]IML^N_!'3?$UWX&TM[D:I> M>)#IENUE&SRQI^RUWX7T6]GTF[N]$T:\N]!EDET6\N]%TZXO 'FE1D,ND2S0 M%]+< ['DLW0O&~~
~~HYW;K$^CVUXT1U"SM+[[/]H,?VFSAG5);RTN;*]E@>5&F@ M>ZM+JXM)WB8>?9W$ELP*LRD_"#PW\4?V@?VBM/_&P].\6?'KQ9\ K/Q_\ MLH>%/B[*_!GA/PA<^'_!C\ ?~~
~~#NMV>H:E=W.E:E*CZE<:^UA;QZ/JZ06XN+ M&>Y,P1948CQ7Q=X@U?3'/'[#OQCO?B?#_\0OBOX7^%O[_A71V7O$^@>,SXJ M\;ZEXGU]H]H]<\>&?$^GQ6]E=:^(&62^;5+&;2K(_&7QMII]K]~~
~~MU\(K3P/)K/A;Q/\ %W5[;S8=*T/6;]<:]W<7T%M;0R%+GPY\?V7AS]L7]HO MQ5\$?$WB+Q+I]Q\"?C1XF\9:/KMWXFN]4\?&+P1?ZAJ%G'\8M/U>T72=!TZ M2]1M,^';Z8TU#2:X*WFD5Q)^X=~~
~~[X;TK4;C2KS4 'TG4[[0[F74 $O 3T MJROKO2=1>,PMJ.GW5PC36 [+$ DEQ:21SR\!Y$5C38?#.BV=]J>HV.C:7:7N MMH@UN\M])LX;W6F\H11OK5U'!'JPACW1A+QIF6 C'\JLQH_FP\=^)/#\G@~~
~~M[P@WQM\9>)]Y^)GAZ_OM.L !WAF5KJ:.R:SM;:QDWRA?4 9^&7A#Q9\>_?QYU/PK\2O M#OC'Q= P3R\9_%[Q)#KGB3Q6K:/\3;7POH>DZ)>:O:&:TLE\3K9VZ7ZN1~~
~~EW^[K]N?"7P#^&'@OP;I7P[TCPCH][X0\/:MK&O>'*\1:;;>(H M UC7 5OM:O;C1C]\ Y 9X74=1OY[;[.(OL"3K;6;)$ *]+.AV+)!]IMK:ZF MCMWL6NKJRMI9WLVR3;[Y('=H~~
~~P&+=P8B,80G:: 7M9OHF[+OO9]@/YB?^":? MQ.^)GP[^(L&I^#/#VJ 'T>/V?;76?&WPZ^_C*\16>B?$C3_&*V^H>*?CQ MK7Q(N=/T?PA\3]5T^]BBTSPYI%TU[):6VIO~~
~~IYC97.C^T7\0]5T3XT &/5?V M8O$OB^^O/&/PE\2:=\:= U?4/'VH:]\ =<@^(GAJ+QWKWQ9TJWTVXAT#P3X3 M\(WE ;> KC1%BO;J:]EN (:\T^Y2Y;^BR[L/AI\'M'\2>*/[)\$_#KP[Y?@'>^+OB<;;3;~~
~~M+\5>!;K7 &Y,;PV%@DMC<2W'B1XHG:"VM;I; MLI$[1B)0Q)VI8?$5Z=2K0P]:M3H)^WG3IRE"D_LJ4DFDI.ZNVK)=6FETT;'C~~
~~M<10]XK#8/%UL/AKO$UJ6'G4C1BMW)QBTNOQ./KNU^!FIZI!>_#?X0:V_Q*TJ M'3/V?_$7Q3UKX4_#&YM_B%XD^&?[6_B9/$6FPZ6/ 'BF9;"ZLM#+.#7OV;M4O$NXHM,T]+/Q4+?0?"<6G1)>^(~~
~~)XK13VZ2NO\ M1LGA3PE%;:+I4_A;PM%::)>0ZGX;TY]TA;?0]0BCGA?4)@^R?9=,OQ'+*L M5Y8K!)-+T M2>&YM+7Q'KT8@>ZTFR$*L]M$I) M!!?\ ! +X,6EKJ6GW5WIFO?$X~~
~~MWJ6M_:W,UB]S\0 &[:74;'XDWEL^H6FJ7"V[ZC"%;VVE7R^3=);QI+ =KE'5U.W] M;P7?N&H\"8S,\[S2EDB>9Y34CA73F\7*G"&-A&4L)3DZ]&%15.>#Q.BZB3 M5 ~~
~~22J=1R3&8G.\HJ/+ZF"ABL9&G0AC8J>(PSK1Q.'A M7=9SH>UI4I5O8S<8R5.3C >%KGBWPMXZWKVF:%: M*,%D6XU*Y@5IR 4*97);@ XQ\G?$_P#X*?!7L.?!^#6KSXB M2_!3P^N@@72Z?~~
~~MJ(B\=Z#JM[9WXC$BVKV.E7U[>R3A&RR):MC/SX(&/RD\+ \N%^SQ>W&E7O MQN :2 .C^ 2PQ3/?Z/XC^)^MMX>O$/$MR^^ZUR#3C<2 84DN3++%:!VCB@#*^M:NZQK#X8?~~
~~\$)O^"8'PC/AW5+;[+XR\]+@C\3N>\F\+V>\I0ZMJEIS2N[V 'FK1W]W 9731JQ2W$UN%VHK+RS,WQTL#P=A*F)YLUQ^:T)$I8/ RHP7,U\TL M164^;6UHT^5Q<9*=[I?%56]J,V :VDO ^6 /~~
~~X(T*([.H;Y2:_J[X)@_M M/>,/VP?V\VVO@;^T\0M*TC1?&GC PY?7.OZ?H*RII$=WIFN:KI)>R28M(L+K8 MJPR2=Q8U^%G_ 6;_P"6_6_[&7A#3_@5Z\4[_XZE@!<=?G5%R~~
~~$KVNM/)HUH%A_MF\BNR(]0MHSY#(#(075SJ,RW=ZY,EQ,;R[N6:1N" MK*HSM ?5<6XO@V7!'#>%R7F8!">S[8\VEF$:V+I]U%A4Q3Z*O%SDU&=S;Y96 =G;R^R MXXQOOA[5\.^#\~~
~~PUE^8TM[2,*:A>M)PJ\T9I3:=H))' MT3&.&.*DJ,,D@Y&,,0.,9&!ST'N.G:I*_,'>_O))]4G=; M+9Z>70_%G=/WK Z7MHKV6R"BBBD(**** "BBB@ HHHH *@D;*2 X].W3.#U] MLY I3Y?]6WX?~~
~~^A"HYE8JVP\\Y'<$GUXX'/MZ\9J5[_/!OET:YM7;9:K1=>]M MA2 M27;&_B(P0W^C6\Q1E)CO;_3[>TG7<\<[QN=I.?YC/V)O^"8'PC/AW5+;[+XR\]+@C\3N>\F\+V>\I0ZM~~

```
X*T+X8G^S?'&J>&!/I=CJNA7>H7&D%KKQ M',B"5V@>UO;NY6>P>_|-A,G]E7CKQSX/^&GA/5O'7Q!\1:5X4\(.!!:W>M^ M)M;O[?
2M*TJ*6]AL;9[V[NYH+6TCDN;JVM4GNIHXVFN8(PWF2QJV9J_@7X;> M,[K3O$/B3P+\/_%^K6T=K>:7K>K>%M'\1ZBJ)LN]}N=*U:\TV]N96$0BFAN+
M&1XXE"SQR#AZQHMX>&)IP;FIU*4W==8JJKI:N[YY+>UOLWU6C_P#P4"^,7PBU;]GW3/V[OC7IWCCX M;_!'6M/N='U70/!.B"]MK?Q#]^D36T'Y__M$^H:=;7&B^";?6;E?
(TVY|6W>E0W\KQB"3Y@6]=\'?M!_!?XB?$?XE_"#P/\ M2/"'C'XC_"/3])3XG^#O#.L0:AJO@=]=M[J;2].U4:(YQ_,O_P6<^,O[.GQ_:LT?\ X)@>!X/@9\OB?\ M 'X6?$/]N_]
MIWXBQZ!I4W@#X#_#WQ%8Z]HG@30-?U!3/??$#7A9"'2;*UNE_LQ'CNS");D- M6F+E.7)5M9R44U?16[M)?BK*_D88=Q4IPD[)2=K+H];ZO9;?\/I_15J_[=O[
M)FA_M)6'[(6K?'SX>Z=^T=J.F0:I#\+KK5"FL'[1$+JSTF:]_>:-:^)]5L0+ MS2/"L^HQ:_JMKFYL;"5"&/XH_P#!U9+)) P3&L(W;)7]ICX$1H"=QE?_(2V-MU.X9&=L?.3$@2>;Y]%1Y>YORC\;V_ANV_:
^,'[/%A:R:K^U5?\__!>WX&_$ M?X6.!/I?]J?$_4_V;-"\/^&X?#OQ7M-?N+$WDOPTN/"-C/)+K::@^E0-YRH\ M3/O'K'-!TGHG_!1O_A#-9UO6?%?P;E;X)OGXN_6+1/"UFT]?&=_-:[]\,H MM"
O$D7A+PLLO3(#:+9;\X_NJ0V0.N,8[?"_[?GP_:^ M^/'ASP'IG[(W[4K?LSZQX9UZ[O\ QO=#P]_;OB_0;R$1:?9VMP8YFMG@N%? M>4A<._VYKJU^&SVL'Q'\,S:?X/A\)->(=1N9_"4UA)JM@DTE
MYOCG2>5/,>.,^85VJ#^EW[(7_!-7_@L=H/P!^$.G:7^W=J?[.]OI&BVBA\&] M<\/VFN77@]1?-=MIM_JMM+=OK#$01M'Y9E81HS_,5!%?UF+:3(5*NRG?Z''"MU.X9&=L?.3$@2>;Y]%1Y>YORC\;V_ANV_:
(%)1]T/EAXRO\ >R.AR<] 1Z@YK]"QGB;G&,R M>GD||MR2%*G;]|L!1]WU9SO@ZTUG2?"WAW2?$FM+X@\1Z7I&FZ7KF MO"U>UBUS68K.(ZE]$-LIW6T%U_M6NGQOAC)?20VDL4,<>7|YE
4M@5^0OB__@IG\1/!7P4_X6KKO@OX!6%_XKT6 M_P#&OPV\-P?'#3KK7K_P58>$M9\;7-KKVG"R@;2O%;Z5[<=G#I$CQO07L] MTH>SN$7\W/R4_9\@YA8(RDE@P50PVL
3N!91@Y!9R3MSSR:SYV>-S((RN4Y6 M26/[)(JG)^9'=HI0!E'P#N&->1C\3M3_."H/QYU?3[?Q?\ #+]G3P'JWPTU M5]5TW0]8\1?%BVTC4DUGP=\(K?XR>*+;5= 33KA88Y-#6ZT;2(H'F\Z\@MY6
M>-9%-?2W[2WQN^*GB'G/]FWXY_!/QWIGPITKOY\4?V>[[QC9:_I%OJNJZSX M+^(7B;2++5? ]CJWLZV\<_| M%;-"\|?%JS^$\]*+^:5]0UIM-5KK6GT]L5^(UK;ZG^S19ZSI\T$D]CJ_QC
MFNULD@G/F64V^-%>59(U-/V<:6Z";R\$9W%=LCXWA6(+#'($@^?GIN';!*R7 M3K'(]IL*>7M=U<1.TAP(T8'YP"1M?&.1Z8K\3E_:2_;!\4? WX4_$;Q!XX^& MWP^U;2?
^"@&K?"#XI:5X/MK?Q,VO?#;2_BA?^#K3P!9ZE(YAT?6%DM);;6;G MR)[N]BBA2%;4N)Y<[P9^T\2/@=^UGX^U;]HCXB;M\3OA;\69-C3<__GP]\( MO%$/C_3?/AWX.RZ=-K.D>+O-&F>'H-9TGO'?
1ZK:6>GF[U>[D75+]M&CMY M4(<_-N6[E(+(0B-);Q1-P"KE65VW%O;E9O19#K]!"N#D"!P^.[N]!$QELK MN5)CP8(1.T.))7|DR1A90O^B;F597*3R0/Q5^(7Q]9Z1^U7X$U71?VF+^Q^
M"7QML?&'A'63? |"/\ ]@? [Q'=>%-(U?P/X0U?F"?+\4>'O&20_;M=G\>: MS./#MG]JMX+M,WD#OS_@W]J+XQ>$O@1^TMX6U#XH;OXP^(G@_P#>^^&GP8\"M^/=6FT7Q5)IO@KXE>
(?!UE8^,KKQ/X=2#P_J=G[FDZGK5QI9B56T._QM/M9# M<2Q^40#]R#?7$(I)%V,<%G9U"%[!8+&OS(
M=BN2LYE&WS&$?.8E)&6'%/"/@NYU32_AMINH>/O"^12Z=XWN=?0ZMXBTO5+3Q7HD M-Q%'?7%E>?99K.VN"FGQ%\0?M#_K^&_[:/B/1?V]?C]\0-<\!_M6?"'X&-M>!M+U'Q/X%TZ\T?0?
%'CKP'K=KI6LZAHD%MI6L:KI^NWVEPZG?[[:ULY;=R MDQ$LD0!_1]%(X0!L]/@&1<]?7(-8CD#TX(P:FB<#-S] M,GU%*[2[H3OS1BE?F7W;GX]_P#!=+_DU+X3_P#9Y_J6RU^S=MC["CG
M_1K,>F?LR[A[@9Z?A7XH?\!<_5K%_V7/A)IBWVEKJ#?M?_+.&LMITVK.? M9W:.59^,)4NM2DMY[B.8VD&7W2[/+!3#LNU@/5_VV\?\@K[^QW^PUI=AIOB_MQW9_$CXK:GID4^@?!GX77-
MXM\>ZS)<00Q6*M8:=_.EA'6XD#O)L?RV M!3=J1'*\OS+)N'<+A,+5J59YEG3A>$HQDISPU2#5248T4G*FXIRJI6NU=IO/ MMHY+FF:
<.\,4,#@ZU6KB9+K9'%'%#AY)EE9E141%+$LZK@?.V.FOO*_;>_X+B_MLW_LU>*IO@?\']&\1_M2_M1ZC<0Z7HWPF^$5E+XD-AJDQ'V-O$6J:4ES%9P+_M+,K3I%YDD,2/)
Y4,3NGY_QV7_!8S_@L3>2MJDMY_P $Z?V_7=?L]J/M%M M8_''AN=5E9)D=UNU6X0.KR2QV+1.ZNT?)S^SO[$__!,O]E;_()Y>#9S\)O MTOB'QP%N-7\0_%'Q(L7B/XD^*KRVLYI)S%K%V3=0BX=
[EH+&VG&Y9\A<&-VQ MO)<[JX?BXYOBH9CG::R;#U/>H5(M*/US%TM:62Y6IT_JN*3_'E'VJBIE&BZMX.23:;1_#MX M7_9/_;Z^_'!37P9XF\;_LV>,__"WQ/\$?QT^'_MNW'[7$Q[<*VT_.MNW'[1_(
MM&NY=5-Q%K"2+IMK*C1WEC,_K+#)!AG_TM+89:,L07>.%F"LK*"0"5XR.&.M)" $A5&%P,5_)S;?\%$[.\_|%3?&W[5T[)'[9T_P/_7_9YL?V?[>*T^". MNW'B&\|5:1X]&J7 U::2+@.^E2VT4]O7S&S+
<3$8@?Q7]6'A?5$UW1]+UJ+3 M[[3(=7TNQU*/3M2M?LVHV4=];Q7.=KJ-NK2"&^@CE6&ZAWR&*>-XVKW;O:R/8\6LYS3.ZW"^( MQ>68? 4<)PUE>7T_]^*PN*=J49SG3]JG452BZ3]G&SA.5Y:
[M+I(?OR_]=^_M )BIE_B_WC_2F1]6QTPH]OXN/R(_,5+7YZWIT?.A(H_(7JT^R_1+] HHHI@ M%%%%/ !1110!19V(B?S;SQ(]%59V(B?S;(QJ%5Q(VB?QS;(]%59V(B?S;(QJ%5Q(VB?QS;#(V.C/ !&7_@W(_P"%"?M(^#?V)?VJ=
M!GPD^*.@^+9_&'P?.9_%GC.V\3:=!,WN=/DM]T,P 5>*:K4+N?Q+>165Y_M)=:19F=(!@.LKR;5_MEM!^[#;50L\Y*(X>-2)0I(VC;I8KO9!]UV<#/.MZ/V7?2^#;;]@S]DOX^&/EHP[X<+?
VBM3\>_"?Q ?$WAZU\2_%?6]2T*75A%=6 MH75_=E^W6[QS'S:=VCG7RY)!("N/Z%89%C):1D02L!&N0NU@CRDV]%))=B M,%B[G/"YKLF_=A?LE9*_P"/G?\ 2QSQUG(Q5YQ\8_/A3\3#V'P\\:9/I_Q3
M>HG^A_*O0O/BV!]ZE_U\Q;HQ^_N$>U\-]/B@8V**S+M/]]("\$U$+HY[P>?0 M(+3)+K+;!L;A^^^IN-XZJ]BTQ.\H=BWRJCQ-.\)<H/X0A%ZHQ!Z(:(V?!:_ %N\]?X*]*H2R^$ 6X;[]LN!...
M'%?TKT^Q^O(+)[I=FKHAV"T_48_+.*3:Y[ ?4#(^N&_S^E3T4.[M>3LNB M?*OPU?S8K1Z1@O\ MR#_#7ZLC52",CIGD=".A[XYZ4V0X7G]3@<9YY_+ZGBH$GC;E'1OIC^8_P_*)IH0%9E
H5CGGJ2"H!QS MU.>..Y(%4U?2]M4[V;V=[65GK;S>R3?B8T]=7?M$W=)M>ZF[/KK;WDFWLCC M?'?A3PSX[\.IX*\9Z]?B7PMXET^[TG7M UR@U+2=5TZ[14N;*^L_L+E)(+F
M!T(WK(A4@^/Z'_3]_8D_91L_"DQ_!?>RTG]G[X8VHXS_X^9PNOA+* MGA+33#X)O/$7@;O+]^LOX1M3"\&DLJ]86LMQ-1QW#.1O O%7BZQTZ;Z%O;ZC>:%I%[6UA<."'2.XN+3RM^ N"
MVUB0:_@S_97_."N'8WQ" :P^,B_L[_>^%^G?&[IOWQ7X"T_3M=U#4+C M3/6K_#__$35]M]89"K1:G#IUA?WFH30ROY,UO%M20S/GJ%X/R3A_,GX
MEKY/5A]1HT(_7YU*D*="#*$O:7BY)>WE,9+EI2NKR@]-7^N>&O#"%W$F3\5 MSR'%QHY?0P6'K9BZU6G0PN&I<\IU'.1)8A2IQ;2HN.TDX33%"# MM?9&%R1MP!FO
IYEDW#4:4L@4ZF>0526(S[%4:_]%.NW*L/EV&G3E.G7C|M_P!9J^TO"+Y5!RC;YFGF^X<TX(ZD<9O#A76GHNY2BJ.3X5Q4] M347SJOB?:\<3!?7C6'S(V<^ M$_$B:<9(8Z'?
[1N8CJ4(R<%AC/4FORE_X(1G_C6G\$89/E=?$7Q/F4$@$[_B M'XBM85:V8X[AG\57]8BMB\5F^25<1B,36JU*E*%X;IYB^:: MSBG&M>5Y< MWVM4E\D_?EB>:: JQ]J#C:KR:3LKNUN]KWO\ S?\
_!8GXA?M%%%% + MO#X"^\/PP_8?_:%M\,(?FD_"SXZ"?"#XT$%'PGIEM/X3UNU\ZHFKWWAZ7Z=OM9]ZM4C^SQQHHLT*_V(@?]@]8_$3QK$\$/B+^SUKESKNM:_PS_M^*=M;VOC"QM]FCBM]8NX;7,_
<&LB0SVP5CNCASUR*]_N$B1A"R%BH9HE_UC M74<3*%&_VD]U)3C4E*3A)O3@XM62;BG=GOX MW/L/C\HP&4]1X2RUU7%O1HIC!P<]_T-XX'%.KQ8_"K-272232>KV3;;
E]^AX"T_JX44450!1110 4444 M%%%%% $.>J] (TNYF\_^+]-5H-&MGFGAU[==VT5-MG]*6]\]/[&?"'F-O^S['/A-_MXTUKXM_%/XFW6DZ[\*/&GB:W%S=V-U:P7MS!H]C<7M_+:
M&0?:=3$KRZE<7$SDM]W^.OV4OV-_B;JU[XF\?_L[__Q_P"M0*_:?$_C/X7_M^#/$&OW3P1>7!+=ZSJ.C7&HN:=F(A47.81N.3(W)_!O_(Z;?\ X06G_#3 M,'_1,3XH_'#X@&=
MO\5[;SSWOB>YTOF75HO#2>O ))QVX('2NBM%2M!O16E=6WUJ5Y' M-32YI2MJG;7T3]>OET1YE'\OAJOC>P^)]_#KP/#\1=%\P^%]|\<1>&=(7Q M;I_AU$17\/V7B+[*=1ATA-BQVJDRI!
&CB15(O_/#_P=7QN/^"8=FTR.F/V MFO@9L1/*.*;BNU"%U8,8$E*8*(3@J6.2[&OZ7[_I_@ M:DH)P"?09IW<++R_F_!'WUQ:VMA?7&HKC38-/O;N[ADB$T
O:V.=Q)E7\HFNX=:T^SU[9HXETZ&/29+N:2V\F\*U^R>HQ MZK-87\>F3#M1FM=1^PW+/B1(;=M1\/ZS>^&/$#B+2M"B?2%N+01W4%W!<3Q2H#Z0T[X__M
+&DWQ#^'_P,T;X) 97OB#P\MKP#9:/IWPT\+^O#VL+J4U+Q6+AD M70YI=LMS0T57A6X<:1'AVJ9+!A\A68=X&_G\M#W\#0>*_G_MACP=H?CGP#*
HGAS4=.U"_DMOAAXS\6,Z&$^%=1UK1H[30=5542*]>R0@(/ M.M/RK=_P#!'XP:YH?PU^Q&GBR\*#NJZ+IND^%[6?VA+:QU;3?VBO NBZXBUG M69/A=X\26D<0UCP9ZJ]J\)2]_!F+!
MM,\RE0?,+$]<#0H \M8TWX$?;1X=4L].^'A6UT_5/(^*5W;KI4#V\2V%6YNO'+6WRQ1+)[JY$ M=U-]2B[GNTFN)G;20EJGA#]G[X1>!/B'X$^'A'X7^#?2^Q?\^*2%^?2^ M(L[77-
999O/FCNKU80\:7LNRXU$6XB%_ON5% 'SO=?5L_]S-_P#' MOB/XHE\S'_.H?7QCX=N0"2BSQ?]'AK2;W%_$'ARX3%'&?1>;+]^?IM\S^Q{O ^(A)}F;0O[;L]{_AZ4_: MY
BURVJ_L??!F7X(>*O@'X0\%Z1\,? WBRYLM1GMO E MC;Z2;'6M)US1_$>A:[%#$]1/?:/]^@:1+:QMNACMK9H!F MC?6-% 'S5/^RO M\#]7^(6A?&#Q1\*/
GB;XP:'9:7&/B3]GAW36\17VJZ/9K:VNNSRO0+%_:(8 M&6VE=)&L#+_Y)S' 1L>.?V_!?C#X:^%_$?A7XC:S9^(?'>BZE8 M0RP>)=?M)X+FTU^_D 5I-8T^[MK6:&^X;9;*%4$!:]]IN]2VW(W<\|?
0X/Y'B M@#R?>?U7Z7'^|X_2\Q^"/ X^N;R].F.7?'*AM/[M/M)=1NBAGU/45AC2 MXU#4+KRT$EW)TFQ5%*"JJ^G678%#)F ?@/A+,6QZÒ<5*(*2<6:5*ERKFNU/
]I2I%-%&,;RE6;4$HMO:S]#*LOQ>;9CA,MP%)U<9B MJC5-KJG"C37-B,35DK&_"WP MRGU?QOJ/P]^"GP_\>+_]H$EU]%AX<]>(/&'B&Z\V_:0%K"PUW4[>>V M%I<*LY*54D#
(RK^ZW_!%'@E9\&?@I\ ? '[0'QU_9Y-I^UWXH&J:GXKU#X MLV#:YXE\S1:Y>6^ESVUCJ;W5E9.NEI:SV]]&AOA'(%68E64?!_O*_8%U'|C M+_@F_P##]XE?%;]'BC|K7]I'|M?2]FWXC?M>/ZU+BYU?
5;_6OB+<:WH?@R6X MO7^W6FF5>$TO&X^AVDD_6@#4@9?QY=*Q@P%V6%W.6\21:K+,_?OO%;?(N$ 4)7H@2+VH6JU49AR&A2XNRSOU,SRD&(5J 2GH,L7G%FW7SNGW>F3/M'
MFU+V%6I7KRBE/^%&ERQE?Q?LG&&M^\$ @ %6U1Y}K(T$^&IM|&LLT&8^@$ER[X, !&E2M2; M|]2W+#%NWGNG@*0=%Q3NFWGE1*@.)*T&C$'.Y!(RV@OSO\6OFL)#_3QOM
J38T"X$>5(Z#/.CVO< !ZM 8A1G6E,=.*Y8SYY+V+5W_MX07)E65-T8]9$-%E20*KX&1\795P2Q7#G%7:*6+*R,X"[A&7>1V*$@Y
M9F=SDGC)RV!UR!4WRE_F5B0#DX]3@_C\Q) 'N#P*[VY2[K]1AR>XHI M6O).ZMN" V24>N?Y3D_4GODFQ3Q0N?3Z4*H;NT^Q5OT-0HHH MI@%%%%%% !1110!5/W4&^V1(.#&!
<|&OP4_X+E?\ !4OPW^?S\W M4/ GAVZ^+A(XF?. WQCKOP^(7@?3P?>^(/("OA'O)972:;]M|XD^2&*2;/ M#\!W"S1O2]<;Q*60 [JP->MURL9@=DAYZ9?:><'(_)['/O7X^?\%]C_C=^Q MC\+?
V(?BGX" ;3^(E_\"KP5^T=X=UOX,Z XA\*^%;,QC\0A>:K&+AV\*; U MM] ?RZ:'$;J;_?W"L9%E\|8Y!S5F^?"; >]*+E=7NTXV_+T+]X N=5.[M"323 ML_A?WVWMU2MZ^_$
/^"JGAGJOO]GKX:_#W7;GXP>)?VA_AQ\&?"N^&7X@ M_Q2YAQPUXQ\1WESU\OQZ7KP:6)Y)K)$@<*3&'8%Y/U_:M2\$_LD? #XE?M"_MUYI7?7NRL?7MZ^_$
LZZ!X6T2V"[R[U76]0_MM;6]I ?M!C=Y54K&J@?K_P_$L?\@L_O[+0OV20^"<[*WB[XS[%5Q>M?AGPY\Q"O"7B;7?@M>>&=0U_2]#K%=GUL_BOOQCL+0PVOA^V2.5KOV2(/@?
XFUWQ_9Z+#X5T7QCX9 M\<^(KCPQ?:+X=A\[0Z3KL%%S92K8_?7K6;S6UX]O)=+ZDTGH] M%%??RZ6>B[678QBO> E_76Q^?C.[C\%\I/VAOB_VR__MAO]M&?
&V;X;*+/}/%_H@CP^\[{.8-/TC2F[F*&!M&'45NEOYH JE?!/_PE_;)-B%@X[{)_HE5Z2X^&EQ@XO&K!(_X4M7 ![1/%!1Q@M~.
M&B>'H='\22;%K&KX=ANKJYMHJ3NK'5;2@@6U>X>S'YO;X@]9R"N0OXK^";_@E MS_P4_P_9L^7"]"/Q'T;3O ?!0?8[/7P_@*!=.^?C7X+=ZMXITSP-I&C"]G]JS M76N
(UW1O&>GO;:S<>$=2B@\3:]HUW;?VK=6VM3V-I>11P'Z*[_P15_9[ M\?!_!*W]G_]CC]L"PN_UY^RSX0U[XBVFI^!>U;PM;6QQ1N[#WB^\U:]A>M*6:YOM.63Q%?
6(M;UY+>X6WMF[E%0!6]IB$&M^C<;KF?9WT?]OO99V1[.P: MH.'__."7$SHT%Q[!PU1_TE5GN+9O,@GCE\ETNH)N5^&\BL\AE0MOQ0W(%?MTL]J@9R>Y/@'Z#') MY'))Q1XL_X*(?L2>#?
$7B/PCXL_:?\A)X>\1>$M7N-$$\3:3J7BW2J>|T'5\T^F6I0H[F%^A)(%GOVT^|*P%GU_B?H'!6P=:X4+$1#OK)G
M=>07GB&'"3%M=;U*.2ZEG@U-_2[N(=Q+R,R@UZV3X#"X$$X]G4E6A*GAZ]5] MDE-OV5*=5Q7)$%9C@:W+W>;_!9)M^SP[A$/$NF M0:X>|0Z&&3SGE5&-(!"'|
Q?"7]BZTR+3/AK^*U[.&32_"MEYQ M&M__X3.XT6=^;(Z7:L6FFD@%*OQ)K7#-?L^#7>^!$-.K!K/CX+1%^NRL?DJY 'Q-5P/E\&*\(D$B)D)^)D!F?)S^S:'EYC*KM=
$7B/PCXL_:?\A)X>\1>$M7N-$$\3:3J7BW2J>|T'5\T^F6I0H[F%^A)(%GOVT^|*P%GU_B?H'!6P=:X4+$1#OK)G
M7]1@DGEN[F2%C8O(E]"AD>$HT*F:9SCUEV5J;AA:$W*GFN/JPM)8>EA5^^I MPK)*$L7-1PO).:C*3E!VL+P@IUJ.LSA%2<,/3P
M\_WF'R_:7_X+;%'<6]R^TOY*FN9_X)M?\ M!.]D3PE_P_%%+_VWTT3X>7UM=_L=>+?@?7]\">I5FT_PT/"'P|\2W/B4R1=M;J_U[<6B2W^P(O/-9P6()'+K4+#P^P
MX'T^.UK48=M/S+#!>1_O7?@Z7!\M*_#_G|G7^CC0V^OM'OVMO6'6_L_>I?X?4@ %;>?M7S_:X4_T \ _<,(WV|...
J67T(\/Y5$E&&%%RS#$5HQ4%%YE4#]_42-%H@I]+EPD(!!"H]U_ Z_2Y5O_E=9+WX]_\Q-]AO\%9+A9  SF_E1+8=C1V%\1=VSD
^4_N9'/$'QB^/'PC@\/-TU_W?P^/Q(Q^9DGB^">Q|0RV5O.VI:\ M,LT;6L_&&P!T(|^]_88_#O#R2WKZE|6IZ+IM?#!@&ZE)3
7,DCRS(@]#DD]37Z@ '1EDVJ7P6^@!A\ ML2#@Y0!!@)X4Y_R:9%(I^#P+\L|X3R?>%9|D:(O7%5I<
^$UOX_W0!4KU*D#4=0)|0OXO!=NP_%PYX^ZQ2^|7X&&&@.||4Y#P@Y8
MB=X+^7PO|%?OX=:POB#P*\!7(FE>*O"NN!64ZKHXV^IN<36UXR.H=)6:.02)MA%4KE47YL_T9QWA^_J?T?I/:.UX$J9EF$^J< WT'34X*FW]T_P"&044450[HHHHH **** "BBB@H!KG"[_MC"_?
7']-B9082"=R@#MC.H)'RY'/7C/6I7E4;V&?^*>>?Z5'G,7]5"\]K#KE M<^.*SWU)/F']K#XU_"#]F_]9R^Q/QP_-2'^"WPMW\%W_B:XBZG9/X@?\[207 MOAV.6RM7TM"N8IH6:]O9+2%+::::::
M/@7K'OB 9J X2?)$[416_G_1DO0\[IJ$^SJ?%+$Q2R MI\O1 {'Q2^O\& OB #X9T'QGX~*4V+~
MXE\*^('"TU30]|TZ1DECT_5]QEN+..]MGN[X[RDMN"DD,>#E_P^*+[_@G5_P M39T]]+M+[]D:]EK3+[5+LV&DZ=]OP]\#64^NS012H;32Q]@UW?3CS%F,@S MSR(%;@)ZYTW^^3VDV]21]
/3KN:S5J,7ZK[__)HW;2^R/C/@B/_P1^TOX M2^,?A/\|$J_$GAOO?_@>U>U/2 @/@#9^C (^7BC5KF&XBT+6O&^F]^(_T^M\U-[B6"]>T%FL=G9&)X8X=@9C^[U]^F(NRL?*0$]NT$C.
<9YP.@S]>I/SY M\$OV8OV=^?V3Q)Y+:ZG@#PIIGAU].ELRXMS]C6%O US]D\ MZ?]('\]RJKDIM7 'T/&I54!P2$ 8XQR.G'([MGG..WJ?%%%ZUC^KMY^<#G)XY/?%7&Z? MBI_)@@^KR@H3L_;::@P
3M/7]OCYB021@\']H\NO,KZ::VU#GC&_%R;6B3 M:UZ;"K)L&26?<._3R,9XY(Z]N@*BDN&_@01R@A68X(&2#MQG)/&>>IX_F MO%_C)\>?@Y\!_TK6OCA?2O'"PUT?O]J:@Z-?
B['7;31H=6UNX.;3++!_!+2 MRM^/++G8@Y0!!Z!_M#A2|!_AO|.C|S|E_OLV:Y*IU(1]|S6_>)|\(K+5 M=STROBE%9UW=V4,SS6Z0REEF?"QX+;7Q6L,!BYT:E>G1G52\2YE%4
M4TK<\KW3W2TL]3:E@'O O@'0+S7==U.\E2/RH;:WDG2V4LR^M7;11G!9W 7[V1_P_$S?@9XJ_X*2?M->*O'^07 6AX#EJ.I\%!!!!!!@>WTV;1%)OU%R^*++ZZ
)/?)(T$UNS<_^TGXR\6_!1=4MOV'^?V3/&EOJ/J37Q-T35@NE?%ZUQOI@6XTGP1;74!6RUC1 MH2(Y+]R=KJ-X!GF=441$?U!^#0"VA"'O#'ASPAX9TVTTPT[X7TFTV:+15A;
MP6MG8::]\_G;V]M;VZ)#:Q0P6\<211]%15"#^&Z6LH\)Y0N2N_J8SYXRO4@VD]2N[;0NK4AP=P]LJ+Y.)]4'C'!WKY+D ME7WH4Z4]OE2Q@&NX8]4JGL_CBDTC\A"LFCA"2!N
M3.H^>W4CN,XQ^7_72 M]E'X2A<$#]LS]F7OC@>+]Q\]HY]YSQ^ K]GK7!MK8DX(MK9>>GRP1MU_M'1[CW%>?C:D]\/]#T6:\125MU[6M@82L[W^&*Y7]EIN.K9X&8OGX8R"?E
MBLTSU0NW:'^U8%7]W^"4K^]*+O+KOKK!?!C[ZY]_/UN_.P0..9R3[:KL&!UQSZT$ ]0#]:**!A@#H **** "BBB@ HHHH **** * MS] !Z*NPDCC$$ D#G^$'/49XQU%?A?\MS_ V/OBC^U)^T/_. $^?
CK\/!W M&BP?LP?^J! IOQR^$GO"\$@ U#3]|%\_X5_P$/9AXe\KZY TDU_W@9>*/"UJ9M M2T^SN((:Y)T@58V"E3^Y%X!W94^'!ON8^&>?O!E+=..<@X^O3}K\!K]@X@K%|JS3@T>"\%?0
M*>)%\|3/A'_%#OC%X6\8?LG?%.YU7X+_!Q|*2^*^ M=?U)::X]Z?$!?KK:G&WDE5VS0J^\!(^JY&YDGPD"-1S?[S@\E'12-_9%_2$QD-[UP-[N?7^?>?I@L?W-)%_R?@#2$?#"=B70
M!]H$GAP3LD):1)O['$A@N'28]I:*2<1LO(RLK(6^:<"Z[%._DJ=NPJ,J?YV/ MV7O^"S?]57B_]HKX:_L@_ MB?\|SIOVC/V=?BG\0/$+Z+]'Q&\ 7R>/_@ H4 A MN9QX@NO%
<=H"FEO=VLD(:\NXH?;B!N)(_C;^BJT( 9OG?|WYHYX_%(5&K!L%PSD:N?.\DELJ69P69 MHU+1QL266-V%DD@CS-XMQ);__F^)[("Q-X5_P"-9#YC.VX_\(WJK;2=P*H"-M2 B%54<*!7I=>>-_L_|-A-
ZB/ZFL7%-IM7:VW_S-#^>_-M_@U/;_@EQ=L_M5-MQ'CL1XZ8C&<<$C^\/V<)O%.D=E#'S%!"Y&0VT'ITRIZ\XW>O/HUW54#'&6-M8DDMC'6'&6
>.^F.3W!./D]HS]MG]E[IE6]\..1^T#\8/"7PTU3QC>7'A:3-M=?NWCN]8M=.*"]DM(XXW8)"77S)IG6) !C.>=*=&OB)*CA]7M.3/2C32NYMZ-M+1.[U?]
6IKA\)B<56C0P=*MB<35_A8>,7)3ELE%15WK;KWU/JPS/V>ORW^SQ^V1^S;^U3!XFD M_@Y^+/A7XI#P7 9VOB:W+W379T>YU!9/L4 1,]:Z(B&6UMC#;*
[R.X"AA2R_JU6K@V\AYSS6G#D5#ED\K&\LU525U*$ME}3]Y%_MY[_5_$.NW46FZ?I>FV2LUW>:A>WN0:=ID,6D:?X>)%[\/A!&CZE9SZK:W$_V=-VT_]@L%Q^A?&:'MR35OV5?V%\I[!?6O
G['_AR^N$\?\ QATA M9$GL[GXS:VJ61@T75XPLU]X>@A2X2&66 [!*S'V3X[>$/@7\&_]@I)_P3+^ M'G@/2OAIX2^&W@#P9\< 'B\-P)X=T_1/#:GOH.EV]E97=H&CBLYYF'"OEQK<1 M%OM1G
G=I#^I<%T\OX;S#'8/&*AO#GTLGS*6.P> #S\ QP!!#)[JQ@]1.4J:5]TRK#0I8K 9?]""8BKR M>WE1]T:\VZ;4H4TO..2M.\\F&TB"M12B653*WZ06T)P!O^5?FW..$GW5\Q3K2]R>
(IQCBFY5:*-62ITH*2M&%.,80BE!6C%.]]M_BF:YCBLW MQ]?%8^5>K7KU<3B&J]FL,I5:BCA(+D4:.C"I[*.$8)*"TO]1'3X3+YVZ4. M4"-M8*KJ,XW*JA20&(!QD GU/;:Z39H\LB(5DF"!W58E\!F3>C#! M
KWOC8:_X=TO3)KM(.&LK V:ROWGB6!GF"1.'W#"(&+]B+_@[M\=_)[/[JX<^,Y#S ] MH#MN^_S^)'1POH}i@ON)?O(7,^@:[)... 
PCXKXTX4GQ7POG/#>:U(9MEN0X: M@RA_;6(X\QV~8C^!^ MI?ML_MF:O>R-IWPY\*!"=+=W/@+P'J30B:'4_B1XTLPFFVEC;[T:XL[:^M9% = M9+M2"#\AW#?\%5?^"SHQQ:76M_\ S
()^ZSJ%M;%+ZRF'[5_Q?\+26XN; MF[B^6VM_"%C]'(1&Y@VQRK(BS8 ?\ :[[C;]@+]EW|A/X=)\/__G;XE_M4\\RQ06ZRB*. 4547 MZR?U#A*${?{;!}U?^}\@/#@ 4H*K#Q XKR]<:%=\%%;;
M7M,&^%,TK3S (/MDDEQ+]HC MVH+VQD@8R8\.*3@*&4?/ICG:RZ?@I-^XIYYIZG*7YL}BO}_ M Y^W-0[)}0?+?@\%\$_Z(*QOQ9SFR.\)(=O5Y|]!JX
MC_">'XT'6)M:MU_P!=  M#1]QM A-QQ*$RBIGR7\*Y4RZ5JL?\EKKH@#F=. W>Y\ %
(KUL5B)5,2N7+,+3HX_'I&ML%JK5^VF\/Y+V M_M ...
```

M^"@/P>_X) 6?[(?[$'P?^!/[1?BSP?\_'+XB?$#2[BZ^,GQA^->EZK>.?XE\ M=7UG9VVL27FAZQ]L&]7 C:>2*/^SV1BJQN-S94XQ@8P5(X M)4$X!X) /48'-?RS?MQ?\$OQ^"5'Q] -:+^)?QY*?
M]7W[%G[0OBS69;;XSW M?P2^/'A[P;!XF\1Z6'T_4AXL\,2ZE%##KAFM9#?2EENVF:XGD3S3YAYZEE6T M27O+165M4O+T[^7;2%_8KSZ^B>_]?=UI?L[?MT_\%4_V*O\ @H3^SA^P3_P4 MR\3
_:+\+_M9VVOZ9\(/BQ\#X9_.]9>&/$VAQ2ZC<2^/_"N8[*]BTR[@9 M((WDTY;6*!$>VGF8R!/ZH_A\B$]9&DD+OYPWEXXIE;]ZD.>4C9FWA.<$L3R M2!_5_P3[_X)N?\ !+,]FA
;+!_&O0OVU[W]LO]VYLIO#'P\]??%[XWZ% M\0/$^A#4K"&0V_@O1$U?5'E]#)2*&5B\HLWDE(20LP_HLU_QEX.^?A]^4 M^.?$GAWP+X9TW9]L M^) ?5M0N(+%!5YQ\8/^25?
$S_LGGC;_P!1S4*AU3XN_"O0/"FF M>.],^)?@32_^O/91Z+XQU#O9H5GX8U6;491!I\.EZW6FO1?(T/Y_/^#4W_E%S?_9U?[2?_*G#5_2O7\TG_!J: MZ?\ #KF]7?R?VJOVD"'@^.2!U'?
&.O&>>>>G]+=6 4444_?A3C/,IUZCW^M7IUSZ+&Q67S% Q\P!P"<=MX/<'/ Q]<5?E&488!Z=3@9R,'/;'6OFS] MI;XC?%#X3_"SQ+XX^#?P;O?V@/^G?V:FD?#33?$6F^%+S6S+<+#="+6]6'V
M"U:&+V9YOWRXD,1&=V*NC2G7KT:$)Q4J_9OIR<8\SLW=3DSNJ/9N4HQ5KWW+H MX:KB\30PM!P5;$U%2ASN@HKK=NO7HO2WU;LNKWM]!FZ7:/.8]K*,@A&!8_+N M).2,'D>V1P,4Y:Z) ;?B0*2
QX(XY]!CYB3P?8U^*[%^ P4_:'_:U^*_MB3P-KO[_GC/X1>!? 7C'Q"/B;\3-5*^?@[7++P3\2?=CINH7WA6ZT>O2. M^U%H;35]-F^V6H:!C.8@0V2/T@^,O[4G[_[.6@7'BKXY?&KX;_#/1(DRQ\6
M^) TBZF*IN_MJQ>2\FN'R/*@MHJ))BZKP0N>S&91F.'Q<$8+ M#PA57)]J[BYR;=U>ZZ]I[_]C'\/9OE>*I8#%8/%5\74E"*#IT*R ->).G= MX>=>S:YDY7V=DG=_0\LT#!$0=W!XK?\%T;S
M]G[0_P!@CXQ:A\63_K$XO>>)/"VI^#/A/]WC'2M,O_$>H^(IC%K UX>\'7%S M;2WMM];VMA+=AX9(XXHXR\C[05/SOXZ_X."_OCK79_!/[_!['[0?]:WB.V MGN,6[UCPKX8N/!?
@ZQY>T+"U>V62UD$BRKR3^2W_! M4;XJ[_P#!8__:Z_9VD_%_:S^%_P:^$'P/\ @A>WOO#L_A/9>>+;OSH%G=V M$^C7'B%5HMM^SZK;VU^]9TN*^C,B2%U3*(C?<\
(<(8BCQ!DT\]QV%R>C_:&7 MIK'YA1PN.<)XBI>-+#J-Z>[S1]*2::YU9P/TK@'@3%8?BS(;_%&;X'A+"O,_M *A#,\1.AF,(IN=22A0PU-N-3VC7)*-2T4G%;N)^HEK__% O@9\'OA9\&_V M;_|
@F9\#/#O[1O[9/Q3^'O@V-O#WPM\.66D?#[P1]T&@6%K]/B_XU>-;/3K M..WMM,N/M#K;WK2SW]W!Y44,(_!Z:KWOQE\+> M&^(WQ3\0#Q1]>O>&-0L]?U36? &HZ7;;GX9MM6 MU>%(]J-
HH)1)/I \L64SERC-EC^\D\(9"29$6.0%"]M$SL1R0Q)#]=Q(/ (Y MZUQ\39C@LDSG.LIR+$2Q "O6K2]Y]Y*>*Q]25>M.I2P^(@H3I. 24HR="= U M+2;DU(\/C#/L DF/XCR3@^JL94QF97QO$,
[//LQ4ZE9U<-',;\N P49SJ^S= M JK."C[6)[JYO]8DT^X7 M6Q%I\4MQ<-B&P2)%$:*]C8IK:R4 5"V#'EB26 XR1SC...9]#[$TWSH2P17 MC)7&]>C]"22V.N-RX) ZDDX ?
$X/'8W+*BKY=B/]N+GAZE/$5%=8BIAYPE&I M#V\5[:TX2E'^(E[WF?#9;FF895-U\MQ,\!B\10G3Q$Z,G2K5:=2$HSC*M\MQ] MRYH2DKNHVKZ;GF_P6^$O@SX#_#'P?\
[/A_:7]EX)\!:,FA^'+:4]5O==O8+& M.:2>..?5M3NKG4;]3,KY>Y+$9X<*%!]1DE"8*X+8V\>N"*622%T"Q,/G:2<;6X/.W)#8XP<>PXKDJ5Y3 M4JE5U%*KS+FIQ=2HI5'9RC%W[ZMMG#?
%+XG^&/@])\/O%?Q0\;_P")+W3M/N]6 MN[+2;&(RW=XFG6"37UU]GB5W\FUAFE?!*KD C\N_A]_P?=_X]K_%+QYX<^&O M@?XW:YK?C/Q5X@T3POI>A1?#GQO%=0:
[K]PEIEAJR2Z(&T%?"_AC3],O+C6[KO7]>G6.EIIBH! M=/>)]3A9,_^"OA]IDFH>(0^'&C:[X;UZW@FCAN#H$'B+6KZTU;2;U8]\ MUK 9$56G3\ 2?
@#X(8WOFX:\1\5EQAEXE<89MPCP[E..9;BN';@*H4X8"U3/L5B*684:?\ 9N&Q$<15I4'*1Y&:9K1RNI@82Q-% MNM*7[&4;MQ2E]-_W?1*.CNWMI<_O(DN3Y9&92\A9$!4S+ON.<.%0E=KDR,
MJ!2#P".?GM^V_P5&_8@_8;T4WO[0?QP\.:3KES;W<^C> /#DR>(_';N26P9 M9K;OT/39[E8GW^6N[4I[-&8D(6;BOPDDOO\ @O[_,%5;N.'3-)T'_@FC^S# MJFHS3R:UJGFK\7=?T1[
XHH[O2//BUO58+]"9GBNK!=%MX3]F9WN2@#?>G['M/_!O;^QA^SCJUC\2OC FN_M>_'!FCN+SQ]\;[I_$>FQ7;2%[IK#PS?2&P>/S M29++=4BOY8,YW%L_M^$%%JF7C9XI9?G_$
&IR5_"_P9KX;B/.*69YQU6?^J&1U\2G^_EED_QE%57&C&L1% M\LW;WHTZ;]^R3]S^#?%NN:I_G7]WI_AZ:1["VLM-U6QM!%*FF7%Y +#* M\#$$ABO_;7_P#!,+1O'WP^3]M#]]WP'8_$/3-&U;4?
#7[*?ASQWJ,GBO1__M"5GHVK7|7>+_)\,7!N-)LWU3Q#'?)9WD\"RQ^09Y$=PSC^F;]L+]C3X@_M& M^"_O@7X ?M_$;]D;0O"]ZA']%I\($\ PVWB72-2TV72$T\2[L3'96T*/MMB6U-"I]U3DFOG_
()S?\$N?&'_3WE&@:/^UY\7OB]\($T,]TG1/A%XTT M[0;?PYX?O]4D[CX5K[7K6YM+)+U9VOKBY=(5E-8W&7(Y(_7,7])+[+_HW<=^ M&'A?4X>\&I9WG^7XK+.',LR?BK-
>/9Y]2H8^CFT,X\4<324J^;9U6Q&6TXK! M5KSNO%RE.U6I3I3FXRJ27 %\4EY+;71*WXG#:EX#\,:W?G4=;*^%\.U!(T@BU+5M$T[4;\0_+>XN;
MFVDN!"#\PCW[!DC!#'&_H'A[2_#EA_9VC:3I&BV/VB:=;'1_/M=,LEFG8__M]FLXH8?-E;!D<1[V*Y=F/3< P*VL[0\ (US;39 M(I9Y5;RND=8S_1,^U;\%/@W^T-^SE\9/@S^T#=BU^"OQ'\%:AHGQ.U
^(&* M?9O"5O/!]MW(WB9)(FT6UTZ2S)EN6*V6IH#(VE\]/!X_#(VAFG:]/M_$ VN/]ZXIKJ^VDZ?C*!1TN&(6V)%: MRS#'$BM,.:JA@8Q>#'V@:Q/W)0<4A1YG)0\(F;IKA.#[:S@]
G%*!)%!>+'AL]B6MO6UQR=N7 MS]/+T[_T]#]H/ 7__1V_:M_:0^&7C>X/_G[;P[^/)_OH_T_:W^?QS_;XU M+X4>(XM=\"):)](?@08]1\(_"?X:Z?IMB9Y];N]VP@M?[:U*32[6&UL(K72?BOX?\$?
L=ZM^U9\?A]:?#3P5/J<7Q"^ M(WB_5!U6XU.J\>7R1+:?\(AX7L=.2#3M#@FNCJ6\FHWG[^_P#+BD<+$JA?TS_:3_8[^%W[5^L?L\>(OB0WB>QQ M/V;?B_[OO]^Z;!?
M)J+XLTFRO.M(M;94D\ZR:*YWRP A&PN6!&*O%M]4% M=*5G_BZ[KMITWZZ7]@E3]_3LTXVV!5=?Y^]/Y9_B3_ C;'^UC\/VPX/C\ M1HOB+\(_^"U_A'\@3PK\/[3O/=CX6K^S?],FCZ'<^
CX(_T>UN-;UN#4;O7[MWQ&O6]=6]SY04,L188'_=_P#!0:?KJ-P7F3X3G7XXVU\P_7_@%X MY@_;'O-I%%K\$U\7&\M6>IMHMGXABS]HUBV4"P9+DLTT\9WLN[_ Y-X;$OK?QV-?O?
B%I7QHUWX.V_B5E^S&M?'+1;=-TOXQ.CX;2,I XU MT^U'FQW23 3SJ)959E7;^>?_=2QL?^"84,DK,L;]I7X%0.9(]>-)E/C,V4 M.C>69BEW"H,A638^UEP$116Z;=-7?V;6] M.FGZG*E:K
6O=IW].NWW_)(_MHX_%?\ A"O!L.F]KJ/P?X.67<:H-+'&,LZN=OR1@CY6,2I)Q@=#SGH,^E*4 MXTX2E+?1+7N>A#?++FE4C&DHA3VS>].6G+RO=6UOZHG:<'(&]L;3]UCG
M)&/E!)..3@8SC'17S+^U9^T]\?V2O@9X_^.WQO\2V'AOP1X.ZO3]LNHH M+OQ'](@=M=\ Z#;RR"YU#6=X:.U@FD3TWXG?$SP5\(/MGB]XE?$+Q'IWAKPAX(T34/$/B/7-6NXK2PT[2]-@-Q-
(U:1E!_EF^!7PC^*'_7B_;(L?VK/VC[/4/#G_!.CX5>)]17]GGX)7EQ<M6+?%W4=#OWA3QIXALXR8YM!U'R&E:XD;?-$8[.VC6WEG6O=RK*?KE,68XU>S MRW!3C4]:6EC*L,6HL+2?
+;G^"5U=QYE9*7*?6+!_$6OVFJO!:XLN5M(;BRCM8I MI9KC=>LX,L*M^VW_1FG\O?\$X?V1%M[WP[-XLD^?+C!U:6X;M*;S)6M;X>_=X2%AEN+I&+_D_,U?1/J3/[#G[/?[7'@/PI\?
B_P"%]4N/M_@K4$OO#N@>?$?$.K^#K&"UT_[%-Z%>:>MWI@@*0P6S*T*QQ@'!U^_M9_XD?LL?7L7^)[[QI_!^O>$]>N_#T?A_:CXW\>(_%BT&G*CV'7BKQ/Z'<'&?A 86/C^STGX@RO8,SJ6_7 M_P 0_P#!*!7)KX&BK$(LBE=R#*Y4
(7'2Q8S'B*EF>3XC PJ3HPEF6'JT\ 3;IT*=.AAW15 PIN M-=2UI592IN4I^]*4M)'MYMQAAL\X>QN!C.>7X.6:X+_#@;7N4%AL)A7A** MJ0IRA2G.I&U:I-TIRG4?/+FT9^BEK(LBE=R#*Y4
AF"QDJVX!>'RSX(# MC/ M99V"YW#,XE<(1S^AXR.0<\?7&(;_:YF+O&X8J/GD"#CDX"^9(RKSE59BR[CD# M@FR2/-7D=!W'H_\ ]:]*^4N?WK6Ny>DI1_]M_$_EI?6]VW=:))S;3MZ22
M]!GE/U&U<\XRW&><'C''_"E\MR0Q4;NO+9(S^&/KB\CU'YBAONGZ&BRU=E MJK V5VO/O;IVWW8[G3;V%[;ZLY\LIDAGBF>%]KJ5W;E.X"M,RH5V>:NX M@Y!!P?4#.=W?'&>=H&
<\I(5V]"R5W?751>C6FZ44T[+TM]JW;\S^3?2/"^97[!6!?\%P M/B/A!+[]F/X:7WPD"[$6C_$2W\!2V4_]E0>.[KXA0Q3^*5A^W_^J7%]\ $U MZVUMDV"6PN?ZJ_"NAZ1X7T+2O#'A^SBL-
\/;9Z+H^GP+((K#3].MXK:TLX M_MXP+K5]I_B.\U.:7(+;5XH(TO]+%^_"X@MXXGM6RJU]=>+!?#&A^O@3XO\)^$ M=%T_PUX8\^?Q?@HOAW0]^@6RT[2]*TSPO>6EI9VH(H[>VBBC4",%OO[V M=V=#]O=&%~]IVOV3T>GX_+E\R^=ST?V?=UOM_3IH?@]_P>75_??_]*2V DO=M0=M&TV^N?VF/V@;F)TU6+I97ESXR2>^M!\[K:7,DUN6)+?NCEB1NK^FA? MN\Y'\Z@
]3Z]R23_,_5?M)9SUS_,)PQ.>22'O$GA2:YCU[2[F*XMBUU;2P[(0S+&7"N%W(A,G 4 MFOTDE,(VR.\8Q@MU(X')P>>*^8/V]]+^_>M_!GQCIW[.VF_#'5/BE=QVT&A M6OQ>6[F\!S
]IA6XcUJ]"WMYQ)$8 P1]D*X4Y4T,HK4\UAZGNMM)V:7K9#5IX,/G6A.4)2GA]^C:U=FDFVXM+7_/Y_X)^?W?\ M4_/XG?!?\ M^_]\3_QSX,U#X?%
QIKMUJGB>_P!=GGN;6SNO$>E6]P!>0+[ZVFA MM]3>8FX^P_X_^/V1/"FO6?O!_:9\2?$W]LCXI;X;FY4_&W MQ'=ZOI+7H,CS7C>'HYWTV99YW5H#=]X2.*-8?E\PGGO^"
<_['W_!1C]EKXS> M.[GXF;'^Q_>_";XW_%OQ9\5OBA>?#N35XOB%X/U/7=$T?2_^$?\"$DFDVL<M7A>VN]&@U"VT8.8[;[=<%H8I';/]_'E('!+23N(D41@_F>*$I;M.[!L2!
M)48_=28,!A\U]_Q]QUBL5GF*_LC'9?2PT7&*FY]#"I]56-A"W#*5,!E^C,G_MSBZD5AI4X,WL;M:G]R7ZMXE^(S+/\ $3X>KX,*MYR46HRDI:<\.OA-A'HEMX=^&'@;PMX%\/V:B*WTSP
MMHEEI5DL8B$>#;V=JH5D$:_'+@GH<_9/X^?\%F_B?;=1^"WC+]E;X5? C0? MB5%\=?AWJEC=>*]6^+G@7P'X>N+75K V_VC1_$VH6VH:@D[[,7%]KV\+O%O
M9<@']>/'WQA^$/PCTN;5_BK\3/ OPYTNT2]F(\|<^+_!\,6&R6[2UAD:?5K^ MUA1S=W$42]SAI&(J5C;;_'K_P_""_\ P4&_X)7?%3X6MX?^'|_X2_;5 ;[M MX+WP+X"|9_#_.3ZK:Z?\M! Z-6U?5-
3\1-5]%GIU_9WUW;)'96NE1ZM+*%/Q-X5RI*X9Y]EV>YC1PU7-LNR7,LOP*K5KRCB M\PO^.668!T*3RJ5W5S2$]86$<-2YZSIQ?X!#BBAD>9/B"J&=XO#WK4EF6
M)E*I5]12/%U*U:2K5*C<8J/M.9M&;44B M67Y8LEB:_4F>'_&_C_P K'B:5_"C#6?%%FMKJL^A:5++2_M!!C2T_2KB.+=JBZ:UQ;A[HF%GWL,?I,FE_P#!SA M,11+RM
M+"]2Z>WU/QA8PZL9+K6[&YTZ/5)H]=T2R=8S:RPHDTL;A%E88'WW'GT7\VR M+C3BFAG7$_/A=E>6YARPI>)'&N18/.\8[,Z]&6)P^1<.XGB[ZE.HZ?M5I2 ME"-6/M81G&<3P]9Q@'/9U&)9))'O)
(8$6$*?Q=YWCC52]L/G=(\?>(M4$C^@*?,X*1?&O\9^\O_!17MPK\9^"DO[9\%_N^(!X_&\>(T67%C6.\M^^"(T)3KGZ:6VE$S/NE6]OK4%WJ^%,]O6+O)?,\$E5?^X_LXY.4J"=,5_$J0/>7FJ
M)E*I5]12/%U*U:2K5*C<8J/M.9M&;44B M67Y8LEB:_4F>'_&_C_P_K'B:5_"C#6?%%FMKJL^A:5++2_M!!C2T_2KB.+=JBZ:UQ;A[HF%GWL,?I,FE_P#!SA
M+"]2Z>WU/QA8PZL9+K6[&YTZ/5)H]=T2R=8S:RPHDTL;A%E88'WW'GT7\VR M+C3BFAG7$_/A=E>6YARPI>)'&N18/.\8[,Z]&6)P^1<.XGB[ZE.HZ?M5I2 ME"-6/M81G&<3P]9Q@'/9U&)9))'O)
(8$6$*?Q=YWCC52]L/G=(\?>(M4$C^@*?,X*1?&O\9^\O_!17MPK\9^"DO[9\%_N^(!X_&\>(T67%C6.\M^^"(T)3KGZ:6VE$S/NE6]OK4%WJ^%,]O6+O)?,\$E5?^X_LXY.4J"=,5_$J0/>7FJ
(8$6$*?Q=YWCC52]L/G=(\?>(M4$C^@*?,X*1?&O\9^\O_!17MPK\9^"DO[9\%_N^(!X_&\>(T67%C6.\M^^"(T)3KGZ:6VE$S/NE6]OK4%WJ^%,]O6+O)?,\$E5?^X_LXY.4J"=,5_$J0/>7FJ
AYKKM%%?^(=4TKQ3X^L[,XACCE=[&&>]U MJWN DDDPN%LX+]*;'RLJ%R?Z#/V6XO@3XB^#'PZ\? /X?;/X&^'GBKPM87_M (3L8?;>!6L=&6,VMG;:CH]WI>GZO8W42V^UDO(PS\3(\L,B2-
]*I&&OA2 MO1=IWA2Q (ZLO!YP,\?A@_5_.6:>,G /".8YG#@+P#X3\]V9QPS2I"\L<...Q M?B'Q%A\THX_%3Q52ED>"I\.<%Y9.I4Y*LLOCD6 I4<3147*=_#"B_1HX+_U. MFL=F.97H+FIX9.-MKX7-
*4G;1+6+=D]]_Y;O#O_J:7X_FB\8_P#!0K]N M+_M#U"]IW4U>WU/6]!E\;:IX:^"UI!.R?ZS9M9NG_LWZW\+?#_MKK'CW2=M6TU\V+NL/^%M?N?\Z&$&6D+?75]X+]1EXN+\BV@\A%7!6K]+7K_6Y%&_MDB5_7\+4_AK
MX.^+G@7Q '?B!H!!H!N>"_&>D7?A^(]$%U_^'TV[\^]KBTFAN%%3*9BE1L_MW/(K\R_!G_!$S_@F??]/+_\_!CX3\]?_V8?#'A+^_!VO: XKT#6K76/$"?ECJ_MA^Y-WI
[(ZH1>?O7"!]BO'FC\MI,/G(W\F<E3O1FG!QBYPYQ_XE>)&6TN.M>%L-PIEG#GAOD/"> X8P&&CFM'.56KY(E5')]>$IXMTJ>1.>"PKO+*<7C: MTZE:-TIXU@*3R(RL MQ+1/&K>8LL1BW9WQ
+G>F.(<#BCG'#<#L,X)7/&2* M5L'#)%(NYV!D:0*% +,7)ZC R<=",X!P=M54*.!T'8?F??UK^Z.'HS<*D ML/5H*G.O*%.M!1]U*D).3E1O&(IU$U3Y7.JEB&HONU#1_1\THIWC&/M&]C2
M=VFURM26Z=E]W39E8K(4D&Y][<@CE2#P #T/!'X=>-<0QF3CY*6B@M.9?]O:?<)MO> MWR_I?(AVEMHV!1G@@@@\#KP3^F_M5A5"E^_/U)ZFD4]MI&/7/]:=6M.*C'X8
MQE+WH\NSFU9O[DB0HHHHJP"BBB@ HHHH ****_"BBB@ HHHH 9#"48 $GC@3N^Z/G@(RQ/RC/]O?]:_P+<+KX,:1_P39_"N'DS(M/!$+WS 2*S!E14*X1V^UL/[\+MSS:6<,W$_R4Z[RP3/3J]H)+9*3&(
6UKJ%*)*M+VN2,$#3R8[Z2%SHCD_^XJ[DLQRCJSBS(;N*C^Q#G.$D[F,K^RJ/*M>TGE8J7)@Z^8T(\U]:^\ZNEZDT5>RR#AGB'ZZ$-R#DJSB@T]FL*,)7/T*J* M@A%;K.FZ^#K#G&L*E+#M12+(SJSG3\GT
V@/^"8/[:?P?7*#7A%B%\3_B1\%2T#P1X.T9XDU;O!JDN MN:<+>)V!'$X5%[1X&I]1:ZD\M)I:*@]S MASE9BE)83W;UIP-8FKA:\CZ8I/-GGW#3ZSY@F)LDNMJ0[HT!\?AGS?BD2MWTIG@]A
MM@FC)=RS"V>Y;V[F29HV0['R011G %Q*^QQ@OQ*V(Y:P6$:E"^%["U&FGWMLRN. M@8-1^XF>"^(GYJJ(F]LMSE]1(W-!]^M_W**3GGH*@.JNFN!YX *;DGTTMDNU0+[ER4U@&8FHJYZPXR#W6D!-:(/&FTG(J$
9E639^M<$B21(R9P1@'8R@X R1N4<'L3P>O-14YW6Y MFTTZ:O;O=V7W'3DWSI[!FXIJU9.Z\M;=KZ=":OYFO\ @ZZ Y1@Z=_VYQ^_!129'3//3'TJ-
R^OZ'_"D]MKZ]KV>MGY6[@M=M;=AK%%^]W(/D#N! MZ_7][XS&1&4);&;%MN1P,Y&03GIR>V,^U17C8B'#,&D7IQM&,%N<9_SSUY(] M>*N27E'ER*@!7>P8]3A2/
M+*46HN*O.3TCRWLM6N^X_HE]>'J2UD M>$_!5BVK^,O$HMFC9+T#3D1'N[N1&7R[<*[/M)CR,U^_PC_P""WQGA/XO?%ZG \ M+>X/Z)^Q?^UQK^%QG^J %6DZSI.G_$I_%%N?#RWT.P^Z'B\?|[*\F:W:W2H,^J6_H=+
X[^)UW=R00>&/M"PTBTOKZ?4+2$2I;$X6*GRIM[&_%KOC\/_A:\2?&@;/^T2!~@#3Q5XAT^UKF.TLKQ41(T^Q3=0MK:>XG/V>XN(+9_@,8R1+@Y%%?YZOUW37?4G!4W]K^M_
(O[.MOXUTGX%0_M[ZGX5K_&@?@$?@O@Y:Y=27X?_?T+5Y[]PQX6U S1SP3 M:Q:AK&=DG"W5G<30S,T$[J]_WW!W"]#_J&<8W'8:%3!95I]5:U>I.I?]ASQK5
M+KEBTXN%&4FW+XXP@UIQ^A|G"WIF'XIRSB;XRCAXX+).OIXNOC:^(S"A%'.J:J MI5]4L,L).G;2AZ_M,(4C*?MJB<1QBE>4?MZ]MM(TXD^+/^!?#I]?7 A"X1 07O@S_M_@EY^SMX[L.D?
OO9H6I26=S^TSXLTH2NVBZ>VFZ&||.17EMOAFCEEMK:A<MW#)<3VOF?U%_#?X:>"_A+X%\|+_#;X>>^;'PKX!;9;Z'H'A_3+;6ST^SLH-MEA10L:@_O55DGES\,>"/". MFQPVL5MLCGU#4?
*BCOM7U-OF>YO[^=6GFGEED?\ >%?EX_^F(S1HSXSU;N_M<9#8)^;D@YY[]!7SF=9OB,6Z6 P,W3RG+ZLG1HR3BY5)?%/ELKRG3C"TGLG9 M+F;9\=Q/GE#.O8Y5A("Y)A*5..#PM*
[A6<+PEBZ\E=2Q%64'%\UI*$8Z).Y M62!"T>UU"Q<=I1U(QG<3D9Z'AL8P,$U*'$$WDMNWR-W[_]!O^X6U"N!U M'QTZ*X?23WILK!.!@9Y|(X/MD#&>/7!7S*E"DG-
0DU.3ERV=^;.YI.UKWY950$EX]YVJ45Q\N P &"ELDGY3 MC OUXK".+HSER0AB%5;DE3C2J\T+<\4K.[@FG)*S2=VNHY*HVW:R>]OI\E? MT9H,1P"P4EO0<^JC]ZC/09QOD YILC!E9=RG'
QG#$A<8S]XA@O8E2%R17X MS?MU?\%C?A7^P\AOAS\]3?V=/VH/%VGF#%PTL/Q*\$^ IM1^&U[KGB69H * M\,6?BG<%%OO$UU,J)72+.:;:28^0$$IVUWUW_,%:?V8?"'[(<7]7_P.>[/XB M?
LV>$KR\UK1=!^&WQF\7/A/XT>*=7L606MCX2\3&/5M:37:UL]Q=O>P^#R?!9GB'"

```
M_P#P2<^$_P#P5&^*6]?#OX_^'6TKPI>^!/#7['%_J.O:H=+\;^(/'/AK7.^ M(FC:9=36(AU:ZMI)+.SMWOGM"LUY_H@F(^;^U#4O#'A[7=(U'P]K6D:;KF@:
ME;&SU/1]7LK;4M*U&T<%6MKNRNH7@GB\O%N$DB*>064]QVUX_IW[*7[->F7M MEJ.G? 'X)Z?/IUS9:AITNF?"WP=8R6&IZ:\VFZA8O;Z1'):7MC+#%+:75L\ M4\B*R2 @8]'"\8U,/A,TRNC2^JY?
C<#+#X:GA_9*4IN:FI8BIR2E5JU(IQC M*52WLW5M&#M)>_@O%#$8;*<_R/+88K(Z,DD:Y2$3-N*,I8?* OS*.0#ALGY20"IY.*U; M?"P)NPN1R"<8)&2O/IR.?EQ5,.$<*QW,V Y
(WOMP7"D[$+'<3MQU(Z\5$UP M\!$:*D?WB#(V&?AF^4X(Y W9SC(R!7P=^%8.QP"1D9^;/VB_VP/V;__DK0_#GB;]H M[XR>"O@_HGBG59-%T'4/&VH-IL&JZC%;-=R6ML[12!)8[:*69_\M=JJ VY@
M*\)\,?\ !5O_()U^.HO$T_A+]L;X#ZXO@_2'UWQ +?QK8I]AT>,L);C,ZQ^ M>R[>8+<2S[L+Y>"2/I<%P9Q9GN!I9MD_"G%&;Y:ZE.DLPRO($_9SKTXS:;493BFTM6U=K;UN^A
M]^RRB/<^X(H*Y&0JA1\K,.Y)W * ISCLD65I;B1FD:\O)8T#[(V,4$>^XE/RP0R.=E?S3_!Q_MX.%/%/QI^(&L? K_()._LR>-?VN?'MF9=/E^)[Z9N,\K\(\BQ.$HXC"<)RPD>)O%3.\*X+$)X+@C
8N=7*H8RBW368<2U_C17NE;28?#?@2XW:>NJ&TM= M.U"WOI;59;:.[:0>8\K,.$_;]_X)>?M2:GX:\'?LP?L!_LG?L:>%?V7OAQXE M^%/Q_\+^,M>NSI7Q<\0>,/ &K7&LRZ5XKU)83. M9G!P?
WN_8\NOVK-6^#UC)^V-X+^%/P_^+- CJTME%H?P>U>_UCPA%X5M8($TO MR9]4DD:WGD=762-$2,0QPQ1J-AV_N?BIXL\ \+_1I\.$_3#Y%PCB,+F?'& M$XDSVEQ1P]FGC1F?#G$6+P-
6C2S:EE&48;'Y+AN(OJT,1F^593G,Y9-3P&$R M^>+Q&&DX/AP67XG%9IB*N;5'5I6C&GAZ49Q@YPYDII.5GR]'*S?-)I+5'UE! M:6\:1I%#'#&D<<*10H(E2*!@88H]@
CB3&$C151>X/.5N["RO+:YMKNT@FM[ MV*:WO+:>-);>ZMYXW@GAN(G&R:*:%WC=&!!5R2#QG3$6$V\$XVY.>!DXQWXX
M_*FB$@@Y4X/.03Q@C'^>17^>4(8B/).=>HJEXJM*E)3JXB::M4J5JFL81?O. MT6XZR46]_JXQIQ?P]=7IKZ[_(WW/SLO/^"4'_!-^^DGEG_8O^,PN]2FU6[ MCD\!Z5Y-SJ-
S>F^GNI(EC6.:5KPMW0".&&WMXXHHHHP$5% P!6J8-W4X^G3@ M$#@@] :41,,8(X&.&6TO]^ CFW$&/S;# M8;#^[%4<'A<9B\3#"4U&$%R4(8>"Y$E%)*+SC2C2E-TVE&I\22MMJKV2OK]V
MMAT6!N_X#] N.,?CNJ6F(I4DD@YQTSVSZ_6GUYD$TG?37]$4%%%%6 4444 % M%%%% %+ +$%@74*'523O+' 4YVC/4;B?XNHP#7Y7?M$?LO_\ !+C_(*;Z#XW
MU3XQ_#SX._M+:M\!KOQ5X3\7:SH;65Y\4/ASK'A1[Y=?\'W5WHT]KXGTG4(I M=.NXK73-1*.*2ILSN(G;]4 9&$91U(88^ MB_(:5X\RUC:]^WKV(?\ @GC^W?\ "C]E+Q=\K_X ?\ !.W]E/X!?L:_M'_&
MR#X)>' $_P_. C!H7BO]M.\EN]9U/P[H?BOXN^ 2TWBE=.;5-/DCO-(=UOM( MLI[1KJV6*-9]_M,L&^61 P=4DE59!&(E8"5F(1 S86)W> EL;GA? P,G^2S] MG_X66G['/[9GP\^)7]:7_!*SX(^+OBO\3/%
<:^ O^"F7[&'A.\O? VN^(?&. M3;^+?B9\'[J]N+/X9>*M8MKJ.;6?%FC::^GSWUY/>6#1/+) )_67;,%#A_+2 M1YLDQEECD,B)(&56/ 6,!<@Y+K,Q56D(KN]-E>V5M=7EYX@UA[^STG
MP[IZ1I;S77VC[1-'^Z)]3^&7[:OPC_:%_8$\+?M3ZSK_(=^%.@_'3X,>(M2 MTO3?'OB?2M"%KXAGT36K;5/"^GW.HWEO#?SV>H:;>K;6MH9[R2W02O%\Y480 M?/3=6*?(K^];LKZ;[]
=2N9FK=E\N_8_,G_(-3A_QJWNV!R)/V MJ?VE&';&/'3#\<]>WI7]*U?RJ_\ !KW\=?@IX&_X)F7>A^,OC!\+O">LC]J' MJHR[&D>)/'?AG0M1^Q7OC66XLKP66]ZE:7)LKN%&DM[E(3%)$0ZG!%?T7G]J
M;]FE0-W[1'P,!Z_\5_RX]N==['CD GJ0.E/MO[RYEZ*W^:'U:ZIV?K_2/> MZ*\$/[4G[-@CDE_X:$^" CC7,DO_M/P1Y48Y(9Y#K81%;@9D9%[AB*B_X: MJ_9G*AO^&BO@4 9#$K#XK^!F1W)VB-&.N
/*I^_$FYATZD4=6NJM^('T!4)5 MS("1A<,,@\@88_CNKPM_P!J+]FU 6?]H3X(QJK!79OBEX)V*Q^Z#(=;";3D M;WW;4/RY)/#/^&IOV:&:-1^T1\#PTT7FQ+_PM7P,1(@;RVEBSK:F2)7(^=6(
M.#T'27S7T2:\VUK]P'NY5UP0=XR,JOR]3D$8[\>P/'-2!2"Q+$@XP.@7&>G MZ?EZUX(O[4_[-+%%_P"&A_@=ND("(?BIX'1W.YU\M4?70Y^45X)_PU+^S4%+_\_#_YE#%"1\5/ YPRXW!L:[\K#/(." 1D
\4 M'IJ;]FD+O;]H?X&(@7>6;XK>!E&W)&XLVN[0N<#=R ]T5X&?VJ/V9T"^9^T/\$$#C,;O\4O!*(XP&RK-K81E92 C*Y#_,.3 MP$/[5?[@W_M$_P.L;2,A^*_@<,N>JG6]X/JNW?UPAQ0,]]HKP%?
VJOV9-MMA<_M$_UHU&?-7XK>!RC*HW.ZD:X595&3NC9T"C+.!FI(_VI/V:IA&8OVAO M@>XF!,3+\4_!#"3!QF+_(G@$P!!+;"<'@^M'O5%>!K^U_^S0SB(?M$_PR M[Q%M'Q6\#$F7C*?
V[RXPV8P25_B(QFG?\-2_^LU,1M_:$^")RNY1_P+1\%; MB,CJ/[:R"<, OWB.0.#@ ]ZHKP)V/V]?V9GSC]HGX&%!#XK^!=R;LX5T&N[ MT/!QO +")^ MU/\ LSNKNO[0WP0>"[1_%/P0ZJ6SM7!RI
(Q2']]7]FM7:_MVAO@>L@VL$/O3\$!RKGY,(="&]0_M4?LS";R/^&B/@<)@'8P_\+5\# M^:JQ99RZ?VYN3"C^(#)^[N) H ]\HKP)?VJ/V:'3?^T1\#I%%RX4I\4_!#;V MAR9E"IK;,61,X0?
M4_LS@A6_:)^!FYD\U0?BMX%#&(XVMM&NG;D M9RK$..Z"@#WZBO!?2^&IOV:#_,W#_W_,.KX"\]=II_:H_9F5E!_:)^!@*+:+MG:@/Q6\#-NY(PBC^W,;P_MP8 "N6;[H W M$X!KT+P=\2/
7Q"TU]9\!>_"'CG28)VM;C4O!_B/2?$=A#<(0'BEN])N[J& M.9&(W0LX<[B,8R =Q129).<;00??/3\L&EH **** (Y?\ 5M^'_H0I2@PV
M#M+!@2/5OXCW)'.>,D#%.90P*G.#CIUX.:6@#X\_;M_9[\5_M4_L@_M!_LY M^"?%'5W\.?%7O9^'.I>$M!\6MS?6C:PEI H>O?9G M\O]*U*]AVNLCJWX>?\$O?^"6?[2'P_:V\(?'_XD??LZ_L@@?
L8^#OA3\'_&WP MDUGPI^R)+KEP?VI-9\51Z1%9>,_B?#J<9LH=.\//?V8^J:99SH\L6K3R3*\0 M-?U &%0#W)WDG"Y)?&XY"@@L %.TC(_V@&%46V51F#;VQYH!?YU&28F) M$_"3X/^$OAI\6/B
MCI8TCXD>(/! H/#EGXX@#M<1:GXET#3/(T2_UN&X+,_62RMKR;)$\TF,U]40 MLENBQJN4BB"LZ*0&9.!\OS'XYXQ:C4*H7&TYZ$YR,X[\].G3GVR#4> M203>7Y9 B?M,?
D=".5\6P$CG'KC(XKU'Q/_P6 M;\>Z)^U;XA\(Z=\"_#M[^QKX'_;,\/?L_^*_B[_PEUP?B@WQ_P!?@@:;7M \ M&&P&GS^_=*U.XBTNXO#<27=P';T;Q@X'SW_P=6^/_/_[K_P"$!?QUX.7O_MW9_M%
C6+_P4WB?1QLM=*E\4PW U.7P\UZ=5AT_P"R*+D74M4MI%!Y+&4D!6 M+)-702?*TGN_P"OU/Z:?AVW_%!^UQP?!OAE_\ RBV(Q^E=G7RSX#_:<9K MM__@V*3]H;X&^9;^$_#MI-
CXK>!B%EBT>R#]1_;@964XW*X#(86P&^7!(Y8'OM1R_ZMO<8].I M Z]OK7@H_:H_9I9$F71H:X(>4[LD;GXH^^]DA'8_;0V@?PN R2Y78W- D_; MH_9EVLK-
+17P+5F1G59/BOX%B(53R&#:X6SDSMO9V^Y@>T+' M*(%CW LS##9R><<8.1@^A[D9'(S_#^?^%^?VXOVB/V)?V>_A3XV_9P\;:7X M'\3>(OBK:^'-9O;W0=/UY;
[2&T74[J6WA@O,1O(LZ1[5"D[RK94]#7[+#]I[ M]FIA"3^T'\$#'*NZ%S\4_!2+(F!^\29M<5"@QEGCW(, EP!FOPK_."[?_!2 MWX0_LR_LS^"?$_PP\/?LR?M0?$'Q'\2H="\/Z5XPU#PK\2_#?@64Z9<7"
/L]LY2(&YEC+21MMFC_0/"7AO-N./$/A3A/*9[G^8X? M X7 8NO2P675L9.G'$4Z6+QF(Y*-##5(>[*K/EA=\C<>9,]C()HT\.:=_P3E^"G@K6-4406_C75/B>FIZ-H;\X MN[S3UD/GJ0<$*P4,#U!%?
FE^QO\ \'$GC/PU\&M/;P__,$X? <%S=:O+O+O"OP^\*>(]>BB7^TM='A*^FBO+5[H@*L;SW:L<["$ W?5?_$21\7(U M!/\ P3O\0M$9%C@$?QH\'Q!I+C'V>)U:=UC8[E#1#/).W8!Q_3G%/T9/%[+^
M(,PRJIX5>'.%Q>&Q..PU2B_$3@J5%3P51X>K4G[7BW"JG0A.491E6AAN:"Y_ M9WC*![F;>*O >.QKQ&1^'>3*%27-A98^&<5Z\6K-2G2HK#X1-14O_P#!R=XA$F@RI^RAX1.KEM*/BY-)AN/^$6-
VZQG6(+..2:2\2TC)D1"A M,I4,P' K^;C_(*$?!\$\O^"I BW]K?QWKOQ9^%_BW]I/QO?:9\/X-5^,?PH\ M'7]AX2\0Z(OA_3K"VL=)CL8[=[6^TC30]K] /[U;E)9C(Q8!?W 3_@M_P % M5M6SJ?
A_]@/]G,:%%>-<7FDP:M^U1X L]6M=)E4R6L&KP7&MM<6VHQJ4DE@8Q MEE$@5<+\OXN?\% O^"V_!?7^+]HKX7>'++Q5I7I[)L]S%X?N?#'PA^$/C+P'X M[\.^+R[U%
(6;Q9XIB34X;FSU*^_T2:QN+FS2*UN7<%2$=/>\*OH]^*>;<6X MS)\NSOZ.F0.GDV.CCIU_$OARHJ$$R&G3JO]K%P3I8NO[;$4[1NDXR3=X M24DTF?V^?L_LL_!;]DW]F[X4^!OA7\(M(^%VK3^"?
#U]XW%KID\6ZWXLOK M"*_UX>)-=N$DUG4IAJMQ=-)#>7/EV[*ROQK\V?N:W19U+?NSY;K$R*RB.$A? MF6<@99S]U Q&W ;/2OY'K+XK?2)6-_K_X)N?LRSS00Z;-X.TSQ MOX-
U#4X[:]LX)Y];U1AJ6]B+Q+93R30G3VN8X@\:D(B@J+5W^P)^UG\6(1H7 M[1/_<1C4?"DJC79M"\!^/AQI5U;>*HI"[(D)OKNG276A6P=UBLQ''#&N" M$7E#^"XWP8X-HXO%RXP\>!
[+L1A\3B<+B,'E-+COC?&J.%KXB-2&%KX#A[# M8+$*-51]C&GB*7MDVU.,8>]^*J3S+%2M2J5)/ M]U3GB)U:OLX%"6GWVJ>)O%WAGPUI6D6DFH:M
M>:WK.FZ7;:=IZ!C)=WEQ=7$<4$*A<;Y''.<_D1X*_X+__/!,/QQ\7/'? MP>@^/^E^'M0\ QZN]SXP\4VL^D>!O$']AN$OH_#7B&QL8)5655@OK6.7"J4*L0>"_9K_P"""_!++'X ?M!^ M+OB?
\4/VIO@K^T7\)+8:K-X_^ OC?Q[X+M-%%\.0ZP\2VC^+=4L_%<<\ B9M(B M:1;"26&WAF!0SPRR+Y@^OX5X/^AMEV2\85/$'Q:\2,[S;!Y'.KPU@>$ S?$?#C^Q M<'F6+F'E3-
TZ#G+$2G6]FH^5B:$=25"%#"8 M/"TES^/$&HS37MH9(K;31]HL45)M4G5;:TG93;LT].TFPE]^>-1_MX. ?VC?BF+FV_93_."5O[4'CMQ8P(M[X]\-WNB:9#]E\0UK]NO+2(Q#3C'B
M:21)MRH3O\O!-?L%\.O#7_!.?X1V\[0?#9OV,O!B_9[332^CZY\)0R6^EA);2 MV'VO4))&,*Q#"QL9BX64.&4-7T%8 M)?LS:?;>3#^T%\ K0HQB86/Q+\!6EH MY 78RP)K PXC98Y(E._HZ!6>
<9S5.G4H8KQ#\2?75+372W\6/_5]_:*_X*T?'_\ 9=U[P)^V:2=^S!^RC\,KZ*QUFQT M_P 4^*=(USQ;\0=7TZZ75WL?AOJ^M7,]]X?UVWLX!#=V]NPFNK0SQ;L_*?B_ M_@@1 P
$JOV._P!O'7/$GBS]]_XD:=K&HZ)=&7P7^SWX7\4KIGB7Q1I=DQ34 MO$OB$V;I=Z;HUK?1]CALFR=1MPT[*@;"?WM?%;Q5^PE\;])T[0OC#XZ_96^) M.EZ/?G4=+L?
&OC+X<:];:=>S0/#/=64.I:O<&SF>VD9#+;M#)@A0PYKD?AY! M_P $WO@MK-[XI^%.I_L@?#OQ#>VD>F7'B'PIXO^&6AZG/80H(|>T-Y;:EYZ( MH.!"O\ ,8?-&S'-?O\ P]].I<)_1XXF\(>!.!!]?
A+Q'G>:TLPP?$WAHL%@L M-@:5/VE+$83%3SO%YQG&,K8V$N6MFL)X;&X.G!PRRG1JS>(AX_\ JM"IFU'' M8S&5<30HP:]C*]Y2:NKV<$XW>M]^J=K'OW[O[-OP*_9D^?"NF$?"[X!X?)! M+O
FC1F.WT7PEI<&DK=3G;9]0U6_M5CO]7U"Y=0UQ>WUQ-+-%,#CC)F)%%'MGV M "9Y5 M4L30'X]^"7F$@'!-M;CE5B&#-&88VP1*0!+BK2?M/2LS]Q3-U^T-\#0[OY:@_M%;P.&DE'S%%1M;1BV.<
D@X7)ZU_G]B\=FF;8O&9IF>8XC,\TS$#$5<9C4LC-ER8HF9U7;(|+UC9Z(G[4G[,[!9%_(^!KK+(8HB/BKX&(DDX)6&/&MC? M-QS"FXC'8$XX.:M+2I.M+E;=.TYOLY.\DZU*<;
[5^KLI))N.MHU"T)NIRKF; M=W?75O6^FKNWIK=O7O\ 0%%>!#]J;]FIGV+^T/\ YFW,A ^*?@AFWQXWIA= M<(W##!P3N0]5.,4+^U1^S,9%A_X:)^!WG$.XC;XI^!T=D16+':VN@@*!G=C#
M!3CKQUO1V?>VFHVK'OM%>!G]J?\ 9H.W9^T]A#2"?^BK>!\[0#DJ!K;;F!QA M>_1GFG?\-2_LTX0K^T\A#V4MM)7XJ>!W4MQP637&"/UPC'+-HYZ@CWJBO__M^&J/V9LX/[17P-
4\KA_BKX&CRZD;E:_75VMC.4/S 9., XC'[5?[,Q;:/VBO M@9N;E OQ5\$.9, !O) UO_2$!)S)%N"YPPX.0#Z HKP4_M2??LUC<&_:&^!RL MA4L!\5? [$*RAAD?VV#RI!) PO"FY. AP M-;W ,6&W(PYP%/
>V6.I66I6=KJ-A=VU_87D$=Q:WUE-%=6=W;S1":&YMKF% MWAF@DCPR/$[HPD0AB,F@.B?1[&A12 @@$=#12NNZ^]ʹ4!7XD_%+_@@U^QU\5/COXP^,^I>._VEO"GA7XB_$(_%;XE-LX^ M"_C-
K>A?LZ>//B$=9CU_4O$>O?#J"&2T,FO:PHU#7=.LY[73M6NW>2_LYF8[ MOW$P.F!CTQ2;%_NCOT&.O4\=SZUG*$G6=6ZMV=[_'[?UJ$/T" M%%V)C1CCX,DVU@S(\*@8,98#S/0G>PW
RF:C81N M,#;P<^GJ/;UK67OQE"3TE%Q?1ZKOOO84;P5HM+S=]/N\M/GY'X:_\%/_-E7 M]JCQ1^TA^S/^V5^R5X"\-?&'QG\*/@_^TE^SEXT^%7B7QA9>!H[WPU^T3X=T MFPTKQM;:UJ-AJ-
O>V_@;7-CU+4_#T5O%=ZK:R1QVU[;+%<";E/^ /P+^^W M_!,K]FK]AC]J[3+GXCZY^S?X"O$6I^#8C\8M5T;Q!)K4E@;6X\X M:3:7'BFYTZ**:X,#V]K<0P0S0V]Q>Y?\%B?
VA_B]\%_AC^S+\O@=XYN?A1X MW_Z :P^&7[[,US\6],TJW\0^?(?AQX1\9P:MJ0BC7_"6@WSIII]XH:RT*RTN MYOV^RZ8EQ7BXO>(O^%W?%%;]@+XH?M.?2"C'M2'-W8:9HQX@9"FOQ9BD]3
%O2O@GX=_M[PQKOB.UT3R]+M-9U"WNK>VUEK'RT:2UWH[/<8 MI4W*C@YT':48^^VDD[N=.FGKV]LKK6^OD$Z;]I0K?#'VB@V[V7X""QZ84MH+YM->'[;)&J7DKLZW,CL68??;?\&I7_!';#L?
A/\5E/!.? MC'XJD4$D9VAY6)&>-&Z#&,\$^)?L)?ML?MY^' B=X4\^,?'NI_MJ:Q^UE_P M3@U']N?X4_"?5=-\|,^#X3^-K\0+|VR_"[PWXPLHY3IWP[ETS6+827/B5) MKNU>RDN+0O/*4;[Z_P"'?[3?2
[5'[3_[//QK\7?M@ZU8:C\9O"?[4GQ4^'>H M:/HEM91^'_!5GX6N;<0^!]%NK+!]VFZ"))M-CUJ=(Y[ZZC$LGF3?O&I)IPN M_AC5CZ^SK.E)KM>4&U?6S744Y**G-7DOW4M/^GM*5+7LIV?
2Z=M#\TM)_X-M%_V';]J_P-5^/=6UCQ)?_LDW_P^TO2O"_P)M_%WC"S\8^'_(AVS*FK>)]0 M\;3ZC<6NL:-=P$/%I+V,2VTK,J*5&VD_;T-X-%OV&_B#\;/T?]9&U#Q-\!! M?BE:^++_#E[J?C?
QOXL\5^/&O!UC.'6:5'H3W,8@UK6;20QV&J!W6TNHU9 ME>W,L#_UQ,5:)2<$L1N)')P=P)'LZEL'@$>PJ\%49P!\W7WSDG/U)/YFIO>< MOE^O]?>4M81GMS='NK=_^??PR(&AH
^=/_95U'Q+\%/%.B>/M_#FI^/\ 6O%WC/Q?XVT[Q3X"M+J-O$'A6STV:D_ 4=6ME?[!J4TEP]M(8S M=-*P8M2^)W_!HH:_M:..\|">OAEK&O>!ʹ V;=&\^+=.^(/P@O?$/C#%#6O%
MBSXA:BNI+X5UO0_%QU6#^Q="\/33Z>;W2=C)=O9%9?,>29Y?Z^3&C @]"#D$ M8ZYX.<>HZT,J 9P!P%ST|>P/7!|\^Y[CK3 B\?&*/CS M::EXU\&?
%+QKXA_:!\4VMIXP2S^+OPKU*ZCE\#^"O#VGG7K<>%=6\VL0M]3 MUN-]^[W$B#YK9K?XP^,W!G1\??A_X*^/C'X5_'SPQ\;?%<<\L'P.^%5M! MK_@:[TF+4?&&G3V=WK/C'5M6O+*
[NO#OA:35+9S+9?9KR2=Y1%YD:D?V_?M_M_M!:_P#LL?L?L??M'__+0/A+3+35O%?PC^%7B?Q7X6L+R)GL7URVTZ9 ,N+]./ MM-E9WLD5U$?&'BSP[HOA77_AOXL^*VJZGI7COX7Z=#X=7[+
<_#NS?^S#X4^V MJVIV;17!8L'DD;&&($I\[MRKE6J:6MWY;+Y%.G>FJO,K*7+RV=^F MO:VJ^?H>8_#K_@U2_P[\0_A)\2XO'@\%>%[Q)-QSIɅ'^ [?\"@'/QDXG
M=*ME\27=K)$S17(NM5^U$.G[GRA&Z1HS,Q[";_@U_X(\*G[KX5_%:*9F*I(M?C-XN="YBD54>%7Q/$)"C20,8MPCRCJY#'M+S]L+]N*X_P""Y7P0_9>\8^&-
M/^$/[&_BCX1'O5OAMI,>L:5KGB+X[ZE\,[GP]#?_%@Q)'P:P1W A/3H+S6;3 M2/"?AO\ X]KJT>]U.]DE94\C^@]%!YB*0/F4[@,XQN++P2<88(!X8Q6'UH MU5 MU5 .C"NX ^ACA?^$FN5V4D^>4D^
>FO)S+RE'J%:#I5%)OF52"5HW7+==;NS5M %2?VY M_))^RU_P! 'L^_!#GC;3OVJM1\\|32#Q++\W)N&)X $RI ...

```

end GRAPHIC 10 form10-q_005.jpg begin 644 form10-q_005.jpg

```
)_MH+/$/B+3&UO4!H]MI4,DR3A/,\Q1&2"P)XQQGZ5W]8VA>%],\ M/Z)+I%HDCVTOXL>'=5U&SM8OM,:7LGE6L[A=LC=@0 M&++DCCIR+ILLD5S.L(,:LHS@GK1I/P]TG
M1;FW>SN]46WMG+PVC7C&%">VWN!V!)%7+7P9I%I9:U9HL[0ZS,\UV&E.2SC! MVD8(XH R8OB=I4FJ6^G/97D=U=;A;1'RV9V )VD*Q*$XXW8JEH/Q3M[WP[J6
MM:SIL^FVUI=M;1X_>&5LX"*!R7SU&,>]:%G\,M$LKK2[B.XOV;2WWVBM*N$X MP00%&:P7D\KT Z5TR?#; M21J%Q?RW^KW%Y/9O9-
//=EV$;]0..#]*NR>!M%DT;1=)$#2XX[#5+5U_-O<@G:<<#Y1Q0 N MK^-K'2A;L+6YGCGA$ZRC9'&%/3YW8#/MUK U'XIV_P!C\.:AH]I+=VFJ7[6D MJ>63,I7J%4'DY]\5M7GP^T>
[U"TOQ+>075M:K:))'*#F->@(8$9]Q@U4_P"% M6>'QI=CIZ2ZBD-C=/=V[)=%721NIW 9H LQ?$31U_M--2AO=+N--MQ=7$%Y% MAO*)P&7!(8$X'!ZG%8]_\2[E-5\-VMMH-
];1:O>+#YE_#Y8,9Q\RX)PW/0X- M;=O\/=#C&I&[%WJ4NHPBWN)KZD375[-;7>]:>E\Q> MZ@L;QHHY6/WF*CH3W(QFK:>!]#ANM#GMH'MQH@D6SBB?"#> &W#^+I0!SVM_
M%6WM_#VJZIHNE:A>P6>Y%O?(_P!&:13@C.=VW_: Q6A<^,KS3[_PJUW:P?V= MK]J$9$)W07#(&4>A4]/6F7/PLT&XM;RR2YU6WT^[W/..G MM5K4?!K:CJOAP-
=*ND:&5EBM]I,DLJKM0LV<8 YZ9)H ZB?I'_OBI:BFZ1_[ MXJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \72$Z M1'9@D+?7"6[D?W#EF'XJI7\:WF944LS!5
R23@"O/O$GC+3]85M)\.07&N:G M%,D@-BNZ*%E.?GE/RC(R.IZFJBTI*Y%1-P:CN0^(;[4K,6$6DPQR7%Q,8PC* M"-H0MW90.GKT[5%X?
U6^U*^U%+LP*D$K1HD>W(*G!YW%C^*BM>VN(;V%9XUY M4D%77#1.."I'9ATI\=M;Q3/+'!$DLGWW5 &;ZGO7IV=[IGR_,E%Q:U):A5C; M:[I=TG#-*;9_]I'4G'X,%/YU-
["F:9$=4U^%H_FM=.8O)(.C3%2H0'O@$D^A M(I5FE!W-,)&3K1Y3L:***\L^G"BBB@ HHHH **** "CK110 C,J+N9@JCN3@ M5%]KM]VW[1%NW[,;QG=Z?
7VIFH6,.I63VEQN\IRI.TX/!!'Z@5B_\(7IOVO[ M3YMSO\P/C>,8#;MO3IGOU[9Q0!I:ZCMHEXT2%'8_:FY)4$U#X]\/:+?:??7][9127"VS!9'8CHIQWK7TC_) M MA_U[Q_\ H(H @_L-
/^@CJ7_@4U']AI_T$=2_\"FK4HH R_[#3_H(ZE_X%-1_ M8:?]!'4O_ IJU**,O\ L-/^@CJ7_@4U)_8B?]!'4O\ P*:M6H+MBEI,P)!$ M;$'\*!I7=BC_&(G_00U+_P*:E_L-/\
H(ZE_P"!354\&WTNH>&+2>>5I)<, MK,QR2036_2B[JY=2FZ^N#>6\TEE>D -- M#@B0#H'4\_/WK,_L374) N--D'9F212?J <5U=)6D:LXZ)G/4PU*H[R1S$7 MAF^N3C4M158>\-
DACW#W\?_*"* +M%%% !1110 55U$[=-NCZ0O_(U:JAK#;=&O3_TP?\ E2>Q M<%>:7FOS.=^&SY\*K&3S'*V?QY_K78UQ/P[^2SO8>P=&_-!_A7;5G1^!'7F* M_P!JGZA1116IPA1110
4444 %%%% !1110 4UG5,;F R<#)ZFE/2N?\ $\OD MQZ>_I=I5TX<\E$PQ%;V--S[?YHQFFQX_;GA6_P#9*NWVHR7W@RXN9"NYLK\H MP/O8KFM;GEC\27DL1(8-U Z# %0K>77]F/:;?
W#80^QSNS7NO"\RA/T/B%F7 MLI5J3OJY?CL>H6+;K"W/K&O\JL53TIMVEVA]8E_E5RO!DK29]U2=Z<7Y+\@H MHHJ30**** "BBB@##/\ R/:_]@P_^C16Y6&?^1[7_L&'_P!&BMR@
HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "N/\ %?B2]%]'X8\-[9->NDW/ M(1E+&$]97]_[J]S5CQ=XHET?[/I6DP"\]07^5M+;/"CO+)Z(O4^O2K'A3PO%
MX;L93),UWJ=V_G7]Z_WYY/Z*.@'84 6/#7ARS\,:0EA:;W8DR3W$AS)/(?O. MY[DFMBBB@ HHHH **** "BBB@ HHHH **** "BBB@"&[N[>PM);J[FC@MXE+ M222-A5'J365I'B_0-
>E6+3=3AGE;=M3!5FVXW8# $XR,_6]?CNVU6[\,W46F MVEI>H8F\ZSN$9C..RH588/O]*X+X=:;/#XSBG&F22QM!)+->3I5\94>: MV"6QR0#G:* /9**** "N5'B36?MGE-H3B/S_
"P^YN1G'|W@XY],=ZZJB@#G M?$U]JD-C?0V^C-/_T$5#XB>9/#U^8( M5E;R'!5GV8&TY.<&IM(_Y MA_P!>\|?\ Z"* +M%%% !1110 5D^(W\OPWJ+^
MEN_\JUJQ/%K;?"VH^\1'YU,OA9K05ZL5YK\S%\"#9/J">@A/_CE=K7&>#!MU M75%]%A_]!KLZBC\".G,/JXE\OR"BBBM3A"BBB@ HHHH **** "BBB@ /(KB_
M&5[FYMK$+@JPFWY^O%=H>EV!8 M=B] NT?E7H3F_A73]#Y^C037M)=5^8W0+^0ZK;6S2-Y;6*D)GC-==7!:(DJ: MU822Q-&"GEKD]0%-=X#7FXR*C-6[?YGT>45)3HOFZ/\
1#J***XSV HHHH * M***,,_\CVO_&##_P"C16Y6&?\ D>U_[!A_]&BMR@ HHHH **** "BBB@ H MHHHH **** "BBB@ IDLL<$3RRR+'&@W,[' 4>I-/K"UB)=2UK3M+E&ZVVO=SH
M>D@0J%4^VYP<=]M "KK\]Z,Z3I5Q=1'I<2L(8C[@M\Q'N%-/SXDE.<:5:CT/ MF3G\_DK6D)$;$=0#C%>>VFO^*XH=%EOK:/9-:1L_E;B79GB!,@V?(<,QP/?T MH Z71O"L6F:
[J&NSW+W.IWZ(DKE0J*J]%0=A^/-=!7))XHU"7PUIFIBU@CDG MN%CN0Z2[8UR02OR[CR 2,HSZGIEBUC;(US/(DSL[J%12-I7(')!X M!ZG.*.VHHHH **** "BBB@ HHHH ****
"BBB@ HHHH Y+XA7<\?AN:QBTO M5[U+U&BDDTO;YD P/FY(_P YKSSX5VU@_C!)[:1%EBMG0Q6JP0*5_O2HCDN< M\ ]B37H_CW3/#]WX>DO_!"=266GJTQ%O-
(C=AT0C/XURO@/5O#9\20V-EI M^J6%Y- \L"SWPGCD0#YB0LC 'IUH ]3HHHH **** ,SQ$)SX>O\ [.\:-Y#Y M,B%AC:<]".:FTC_D"V'_%[Q_P#H(J'Q#$\WA^_5)Y(2('.Z,*21M/'(/%3:
M/_R!+#_KWC_]!% %VBBB@ HHHH *Y[QJVWPM=^^T?FPKH:YOQL?^*=9?[TT8 M_P#'A45/A9T857KP]44_"8VZ[JB_],X3^AKL*X[PN<>(]27U@B/Z[&\H?"; MYA_'?
HOR"BBBM3@"BBB@ HHHH **** "BBC-"&N"N'_+5UC4W959HAY4)' M&.HKL-2U!-/A1W4GS'$8QV)[UQ^D6[QB6X)&)SN'KU->A@URJ4W\CY_-I\|X M45YM_=H7;.(P64,3#YD0
_6I^U%%=#U=SCBDDDDB-3C5]-/\ TU(_\=-=8*XV MZE\B>SGQGRYL_H:Z72;YM0TV"Z90ID7) Z UR8J+LI'HY;5BISI]=_P+]%%% M<1[84444 %%%% &&?^1[7_L&'_T:*W*PS_R/:_|
8,/_*-%;E !1110 444 M4 %07DDT-E/+;QB29(V:-"X.>*31_ MB%=:_P".VTC3;6"72EW,;H[MY51RWI@MP/6L?4O!&D:G=/=2&XBGD8M(\;_? M)[D$8S]*T-
*\.Z9HT3+9P,KO]^5I&+O]3GI[5Q+$3ND]CDC[:Z4FK+KU9Z31 M7%Q2W5OC[/>W$8' 4MO4?@V:T;?Q#<0X%]ˈ)$_YZVX.1]4_P)^E=,<1"1UW1
MT=%16]Q#=P+/;RK)&W1E.13W944LS!5'4DX KH&.K&&?^$T.>@T\;?\ OX<_ MTK9K'F^3QC9G( DL)A]2'C(_F: -BBBB@ JK-IUG<745S-;1//%]QV7D>E6] M* "BBB@ HHHH ***;
(Z11M)(P5$!9F)P !U-'$^/O',_AF6ST[3+>*?4KL, M_P"^)V11CJQ Y//05SFE?%O4+-]GB'2A+"?^7G3\DK_O(>?R-<=J&J#Q%XCU M'7<,$N)/+MPQSMB3@?3."?QIE>G3PT'!11Q)
(XQLSWP.:]OKAK04)\ MJ9DU9V"BBBLA!1110!Q7CS3_!3?ZAX?'AN41QI&W;QE:O+J4L%PD,]NMBPG/GNF-[/YDC ,H(/"7=0! M[-1110 5RP\%1I>&X74[K)N/.
(;GOGJ>A[9].*ZFB@#G/$^@VU]87UY)<7R2 M+;/A8;N2-.%/\(.*UM(YT6P_Z]X_015;Q*ML_AV^%TR!/)?&]HW;3CG(JS MI'_(%L/^O>/_-!% %VBBB@ HHHH *YGQN?
^)+$/6ZB'_CU=-7,>7,>-?\ D&V: M^M^MY'.HJ? SJP?\ O$/4H^'3M\7W_OV:_HU=K7#:..2GC.W])+60?D17]G:Q0X,K3@J MN<=
:IV<30V<4;C#*N"/>DFO8M2UKSX@=B0[1N'(.X@_RJQ7K4TXTU!^I\K5 ME&KB)5D_+[@HHHJ@,[6%=K-1&/G\U0O\JW?"F4TDVY.3#*R9_&J14'&0#@Y% M3^';B*.XO+5I
)7G+JF>2,"LZ[;HN/4O!Q4,8IM[JQTE%%%>6?4!1110 44 M44 89_Y'M?\ L&'_-&BMRL,_P#(]K_V%;E !1110 5F:SJAT^!4A57
MNYLB)&Z#'5F]A_@.]4M)\:Z!K5T]K9Z@OVE,YAD4HQQUQGK^%9!N&OKB6_DZ MS<1@_P,8^Z/QZ_C6%6]JHONB>>9-70BJWF---(9;A_P#62MU;V'H/85EZEXFT MW2;
[()=B[WK$)I'BMFDCB0G 9V'W1D5KUQ7BG0M2U#7Y)[:QNKB&6R2!7AOE M@1) Q.95.?,7D'&#WK@C:4O>)-V?Q+8V^JHLMOJ FDD,:2?9&\IR!N.'Z$8 M!..L?
VU9'2;/4]TOV2[:-86\LY)D.%R.W/Y56CT^^GU7[7?M&_V:Q\BWV'AI M77]I)CMD@*/;/K7/V_@J>WT'1E$^H-?6\UN\T$E^S0]%;+X0G;P.@%.T!'2+
MXBT]I;V)OM4,EFI>19K9UWKG;N3@[USQD5;TZ_AU/3X+VWW>5,@151%1%"HH"J MHX X %3)16P#H)I["X-S:?>/,L.<++_(-Z'\ZXS7KR_P#B'XX_X1ZSO6M=
M.A&2#DN6\;0VT43R&1D0*7(P6(&,UROC36TT2^TBXA1;B^\R1 M8[56P\@9" ?9=VW)][J9HR>)/#7A'4Y]9D&IWD >>!4CA:3K-+8Z72/"4R:A'I_MB2UBLI9SB"ZA8M Y_NDG[K?
7K7;UYGJ^C=NEO/9Z"%H-HX%WJL,;$-@QPC[[? MCT_$UZ&S!5+,+,0!DD]J^>==U=?$OB[4=83#6ZM]EM&'0QIU8?4Y-=&'I\|_0 MJ*N[%2.(HUCC4*B *H'85'=SFWM7D1=TF,(H_B8\
?G4]:G@S0_^$F\0QR M)NT_2\7%QS@-)_RS7\^?PKU*DU"+DSHD^5'JW@3PY_PC'A6ULY!_IDG[Z[;N MTK74+B%C:F=!C! M;&YNH]ZPG^]CG^1[<&O./AU9B+Q_T&IK>6RP2D,U
MFT#G(&!CR5&1R#\V#P0* /;Z*** "BBN7F\9"+6I-._LF]PCH@F="@?</_T$5E^)=6FM M;"^MDT?4;A3;/^_@6,H,J]?[S@\?2M32/^0+^8?2]>|?_H(H NT444 %%%% !7+ M>-#_"*/IR?
WKM?T!-=37)>,3F[T9/^GAF_)3_C6=7X&F-!_WB/S_"91L#CQ M=I]4E'Z5W=<%:G'BK2#ZM*/_'-:[RIH[,VS'XXGL6BBBMCS0HHHHHHH **** M"BBB@ J"[D]JTF?^ZA/Z5/7(>
(/$9CFNM+$/+#R]^>>16U&E*K.T4<>-Q5/# MTG*;M?1>IE^'XW$,TL@(+-A<^G7^M;-C,C79&B?W5 I]>K.7-)L^:H4_9TUS* M***@V"J3PI;ZM:WXR'\Y$$8^QX_K5VJFI'%[\DS?
W65OR(IKMW,ZB5N;MJ=K13( MSE%/L*<*\8^N3NKBT444#"BBB@##/_(K_V##_Z-%;E89_Y'M?\ L&'_ -&B MMR@ HHHH \)^)6G^'=,U"T0)4COV8H5] MB[E
Q@X&1^=4W^&VBZ%%;7.J(9KFZB;ST,Q!5,-N.%ʹ,|G-:!ZFO+K1<97> MESDITY1E*3TOT0E8.MZKK&G7MK'::?9W$%U.EO&\MRR-O()Y 4\?*:WJI:CI M_P!OET]_V?9+M;G&,
[\!AM]OO=:SBTGJ;$,.N6:Z=!=7EU;1&2%I6V.60!6 M"L02!D D#IWI]OKVE75Q';PWT3S2,RJG()9>HY'![XK%/A"9[86KZDA@B@D@ M@
@PRJ\JR98YY(VX[5I7>@+>37+2W!V7&H"]=0,'E",KGUQSFKM3[CT)8_$ M6CRQW$B:C 4MUWRMD@!P">WD\R(D@-@CD'!ZUS\_A:X MO+-+>[U))!!:_9+4I;
[=J;E)+\G<<(!Q@=\5T[,68L>I])*/00E,E#9[2YEU?PRD:3-EKFP/ M$=QWRO\ =?\ 0UW0Z8I:]6=.-2+C-71O&3B[Q/+[#4(M0A9XUDCDC;RYH95V MO$XZJPJPZ*Z,CJ&1AAE89!'H:W?
%'A)]2G75=(E2UU>,8+,/W=PO]R0?R/45 MRMAJ1N9I+.ZMWL]1A_UUK(.1[J?XE]Q7RF-R^>'?/#6/Y'M8?%1JKEEN+INH M7W@R7-
JKW>@DYEM,EI+;U:/U7_9_*O3+*]MM1LXKRSF2:WE4,DB'((K@>^:S M[K1_W6_0UVX#,]J=9^C_,SGQ.#^W3^X]6HK M+T+7[#Q%8?:["4D [9(W&UXF_NL.QK4KZ$\L****.%^*?
B)](\-C3K.4)J. MJ-]GBQU5/XV_+N\ST8_*GXG]*^@<8Z"N;%U-5! M$5)7=A:***X3(**** "BBB@#F?B$B$';X?ZVJ%@QM6 *J6/Y#D_A7#_#N 0^)K
M9OM]K+FW;$:75\S=/[DWR#^8KN_&UW-%X>N+6#^TXI;J-D6[L(?,:WQCYCR, M?GZUYQ\+S)+XN+07MX88H&2:.&&X-O*W]Z221V4,.P7U-'M5%%% !1110!F M>(I'B\B\/7[[1P%/?,*
X*HR@@;3SR0*FTC_D"V"_%Q_P#H(J'Q$J%T!I.L3 M-Y#Y$$K$#&TYZ\U-H_Z R!!+#_KWC_P#010!=HHHH **** "N/\6MG6|'3T$K M?H*["N,\3'=XFT]??&J#[MN[/?@RJ_"=V
5ZZ]'^12B.WQ'H[?]-G'YJ:[\5YW= M-Y5[ID^<>7>)D^QX_K7H8'%31ZFN8K6K6#\G^8ZB@45N>8%%%% !1110 444E M$;7I^SFXGT&!Q'Q%Q0"Q%%32\ON%HHHK$[0HHHHH PS_R/:_|
M8,/_*-%;E89_P"1[7_L&'_T:*W*"BBB@".:9)HG:5(2I^AKBHEDA#VTW M^NMV\\I_?0'0_B_B,%B(AUE3V_VAV_$5SUZ?/'3<35S&HI ML;<2?ZN,=_<^@'F
MY2YGL4D7J***]$L*P?$OA6S\1P(SLUO?P FVNXN'B/\4>H-;U%)I-6Y:ZD2_ M*8?'+-U*_2?JE<%V 1ICYAmZ^**2?Q+(<[^YD?&+M,<[@2:'RI?=LJ5#ZM9T[!*]-
+A[0OT07-E86EY6%Z5E+P)(S*|BO:7*O#5%_7+"RB-Q(!]>HZ0[UW+#-+RL+GW
HVOD[KIXB0J14F!O2NB%,(]-O+[,F#@:D#J9]BVDL@J;.#T[-I1*B:GR,2FN^R4VDJXP+FJTP
```

```
]B@"Q5.7_D*P?].:FFOO$MM=72PQ":6Z=(?,A)\J,H V0>1@L?PKJ/MMK_P_$7_?0H^V MVO\ S\1?]]B@"5 P0!CN;')QC)IU5_M]H/\ EYA_[[%(=0LAUNH?^^Q0 VP_
MU)ERXR05(/1<N..>#79?;+;_GXB_[Z%'VRV'_ "\1_P#?0H QM*N]]CC2VA5LRB M$KYQS@$<\$GU7_ -"% M6ZS-1OK1]U6YA))7 #C^\*N?;;7_GXB_P"^Q0!.:XK4/[1M4U&Y%QJ[(R(
M+:&/+'@M=?\ ;+8_\O$7_?0H^V6W_/Q%_P!]"@#G+V?7K3@9S[U M.^VVH_Y>(O\ OL4GVZT_Y^8O^^Q0!8]H?^0NO_7_P#H0IW]H68_Y>H?^^Q4 M$5Q#/J^894DQ
<[6SCYA0!H4444 %>9_% ]NLZ&7O$M5$<^)))YH5S\O&^(; M@?8\&O3*\X^*1D:72X8FEG=EE(LHQ,"QP,2YBY^0]CP?[4M\;IMA^^.B_Q_3\:ZJN6\:G":,,]=4M_^6,_/SC^+^#Z_A74T
%%%% ! M11FB@ HHHH ***,T %%%% !1110 4444 %%%% !1110 4AZ4!@PR"#]*4T 0 MK

16/'XEBD\2-HPMG#B1H_-W#'$8?J_P+%;(@B65I5C02,, M%@O)_&L2\\,Z;=ZFUVMWD_9_)^SLZJ\CX:4KC)5<:2;+^3'+-N2(M]_8.V?\ .*8&
MO13&EC5U1G4,WW5)&3]*%EC=BJ.K,.H# D4 /HQ110 4444 4[)%)N25!/GM MU"T]UY:?W%_*JUC_,O/_7=OZ5;H 84C R57'TIB26\FW8T3;AN7:0IHHTRYP MH'[L]!7"A5 R ?I7>:E_P
@RX_W#7G]RVQ"1Z4 .-R]X4C.>N*@+8?].] %EP_MG@8J6P0"23 '08]I!+O7.1S6AI_+R^P% %K:54D+DU-\K#!Q49) ]I>WL=E-MTKL_<#U- %P83(R"?05&W)XP.:Y&3QC^].
(UQ6QIVKP:BN5PK =,T 7Y .X M%4W3=P0,U/*Q9L8Y']D[1F@"]:+_HL8 '3K5I#M<#;\N,DU'; ?9(L<9%.+ M$<$#% $CJLG((!]Z:64KC(;WK&U36X].(4D,_=?2LF#Q?&TP62;;
<_PG!0!U M)'7&"/2JTP_NXR*(;F*:$2Q,"&&>M1L26R.A_6@"-$!GC; ;*T0N6X; JFG M-S&,=6%7V&,>>U #HGRIW)M.< >H]:0]%.X**C=]]EC@$>]*&K>5D1 MS58 _>- '2N0W(
^M0.#MXYKK7D<:< @YZ4 02*03P- MM;W@Q0M_=8'_ "S'\ZP1GH:Z#P=_Q_77_7,?SH [&BBB@ KA?B%X]ANQETW^ MW=/FNY&+^2T-QW;E]N*[JO(OB=K%JT'V>XD86YE/R$J4P-
P#%@#[5U5UXG\2M&_P!F\+S1 M$"4;YG!VE?NG Z@U\;%%-NBAC'N_M2WV[HBQ^^/NM_#]37552E9;"OU/-/^ M$O\ %,8)N;6SMA^YPTJ, 2O^8?X5*GB[Q.?F-G9?*TX,>&RP0?
+SVKO]FT@N MX_+N(4E0$-M<9$+T-GXTG4?9%1A%]=3 MG_\ A,_$PS)@>LBK1PL(Q]L8)]_'?>R5,LQY"CY3^KI(6
MT_485^UV8$GEQLZ'B12>@91T]XFAZ2[;XX%R"2=KGJ>N:?M/[J)<+;MG%OX^ MUH6I!T^!;A(H9&;)*DNV",5)_P )YJS.42R@)^;+)?IL7(..]=7)X:M&E9U M8H"]]%
Z!3D!Z5H)XBU5KY8S#$R_;WC&+\OK6HUC;>0?.TPG_1E!\L!Q]]I2KI M^C&[.8Q&YNF/S1X^;9]*/;1(7L_PCXCUHVQF,$/F?8Q)Y1OOWF[?C/3&,5 M.:L:PUV%^P0!?MFP>9?
GE=F>WO5]-$TLV7EHUNR_90H78I&W=GH:N#0+07& MX0VI8W.[)@!YV=:?M5V0,%,GOTJP/#FF&QG28 GV9T^4G[L)]^M//A^P6X+:K;W,3? M:$<^?,X^8+@?ABCGCV#E?
0V!WJ9O$D2W05K#65 M7[1"AS&V"&7]]*>?#M@EOL2>[C7[/+&"DS# 9LD\CU[U-_8=O\ :/,%]> B M>A'G'5%P!^ZT<\*+SI%^;,H%U 6 H
$(ZD'KS7#W M7AO5)?&EQ>I9L8WU&&=92L>PQ",*V7SO'?Y0,&NVBU6WGU&6Q03>=$]LQ,9" MX/3!Z&N7N?&&H0>*)M/%I%]CCO8[3S3&^ 70$,7^Z.2!CO2':Q!X2O(]FUO
M+:)-/NI=0DFG:!4Q#$$=(U Z'@C/NQ]M)X:U80Q1-9//>+?M.E\7093SMV&& MH##'YTI\9W[6L=^EE$ MMF+TVTRN&$B+YFP.P_@&.(S>6>G-.]"L;N4>([6R=V2'C
M[]4SFHM%T&]AU#3B-(^O36UW/+=7NY/W\:%\*-IRV=RGYNF^F;UC5].UZUM MH?L)LYHI9BSHYD58P"PX."3GBLB\^(YM)(V.E7!CD3>(MN9 #'O4G[ [D]A M0!WU%
<5%XHUF;7/[/6&V=$C@=Y;>WEF0^8,1\,#@#@#^0GZUVM !1110!4L?^7G M_KNW].5:/[QKPY(* @%@\S@\N'YRQ]HEUSH5\8^XR";V]^>,"P*)O\:[75F1C>/XT
M.'.G>,%6Z0WCR!Y/*1*H(7<<%?1 @. 0<=Z;!HGBBK9*9+ *::10[DXPTFQ% MP!C@9#>W-=UBB@#BI=;\7K=XAU%%6U1@Y\Q'@+D\]8+&[G@:SN0[@&8Z7@^ZU)XY(I&9
.LB9R#<2WAL=F:ZBJ@"K]I\ R#:#<->>7W%DXZ=#Y+ .&W=YFE2K&BV@]!&0 \&H6D(%C0F?:Z%R]VL8_QJ\%%'!GKK3!:R5&H.H2$&@1I'NKGYD4+?>3O*G@8 4
F((H4<]W1(R7@^K8=>.W(G\{M+ 'F.@>!^N8MD>:?>'&!N8&EOVQWSKGNOH+.P*&NGZ5ZSCK M^L(BRA+&%+EWXZ>U>!#B &HN'I&OEK5;U/:0H4&FO+PO0EYV_3V?P>%+
?H^ M;O)8>;+V:H5$=;TQ=V6B[*VE)*AYA)?9S@?@?97EF3>=>"87"
```

```
6GXBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Going Concern Analysis link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Accounts Payable and Related Party link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Warrant Liability link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Common Stock Warrants and Options link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Accounts Payable and Related Party (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Warrant Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Common Stock Warrants and Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Organization and Going Concern Analysis (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Schedule of Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Schedule of Accounts Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Schedule of Accounts Payable to Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule of Derivative Liability Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Warrant Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Common Stock Warrants and Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 gtbp-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 14 gtbp-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 15 gtbp-20240930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series C Preferred Stock [Member] Statement of Income Location, Balance [Axis] Selling, General and Administrative Expenses [Member] Title and Position [Axis] Officers, Employees and Directors [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Statistical Measurement [Axis] Maximum [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Financial Instrument [Axis] Short-Term Investments [Member] Investment Type [Axis] Money Market Funds [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] US Treasury Securities [Member] US Treasuries [Member] US Government Corporations and Agencies Securities [Member] Related and Nonrelated Parties [Axis] Cytovance Biologics Inc [Member] 2023 Warrants [Member] 2023
```

Common Warrants [Member] 2023 Warrants [Member] 2020 Warrants [Member] Debt Instrument [Axis] 2020 Warrants [Member] Measurement Input Type [Axis] Measurement Input, Share Price [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Term [Member] Minimum [Member] Measurement Input, Expected Dividend Rate [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Purchase Agreement [Member] 2024 Common Warrants [Member] 2024 Placement Agent Warrant [Member] 2024 Common Shares And 2024 Common Warrants [Member] Prefunded Warrant [Member] 2023 Common Warrants [Member] 2023 Placement Agent Warrant [Member] Class of Warrant or Right [Axis] Pre Funded Warrants [Member] Placement Agent Warrant [Member] 2023 Common Shares And 2023 Common Warrants [Member] Pre Funded Warrants And 2023 Common Warrants [Member] Common Warrant and Placement Agent Warrant [Member] Board Of Directors Employees And Consultants [Member] Series K Preferred Stocks [Member] Series K Preferred Stock [Member] Warrants [Member] Award Type [Axis] Omnibus Incentive Plan [Member] Exercise Price Range [Axis] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Range Five [Member] Range Six [Member] Range Seven [Member] Investment, Name [Axis] Research and Development Expense [Member] 2021 Scientific Research Agreement [Member] 2023 Sponsored Research Agreement [Member] 2016 Patent Exclusive License Agreement [Member] Award Date [Axis] 2017 through 2020 [Member] 2022 [Member] 2025 [Member] 2027 [Member] 2021 Patent License Agreement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Officer [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Restricted cash Short-term investments Prepaid expenses and other current assets Total Current Assets Operating lease right-of-use asset TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable Accrued expenses Current operating lease liability Warrant liability Total Current Liabilities Stockholders’ Equity Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Common stock, par value $0.001, 250,000,000 shares authorized, 2,234,328 and 1,380,633 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Additional paid in capital Accumulated deficit Total Stockholders’ Equity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Statement [Table] Statement [Line Items] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating Expenses: Research and development Selling, general and administrative (including $0 and $547,000 from stock compensation granted to officers, directors, and employees and for services for the three months ended September 30, 2024 and 2023, respectively, and $222,000 and $1,767,000 for the nine months ended September 30, 2024 and 2023, respectively) Loss from Operations Other Income (Expense) Interest income Interest expense Change in fair value of warrant liability Gain on extinguishment of debt Unrealized gain on marketable securities Total Other Income, Net Net Loss Net Loss Per Share - Basic Net Loss Per Share - Diluted Weighted average common shares outstanding - basic Weighted average common shares outstanding - diluted Share-based payment arrangement, expense Balance Balance, shares Net loss Issuance of common stock and warrants for cash Issuance of common stock and warrants for cash, shares Cancellation of common stock issued to prior CFO Cancellation of common stock issued to prior CFO, shares Issuance of common shares to settle vendor payable Issuance of common shares to settle vendor payable, shares Fair value of vested stock options Issuance of common shares for services Issuance of common shares for services, shares Private placement of common stock Private placement of common stock, shares Issuance of common stock for exercise of prefunded warrants Issuance of common stock for exercise of Prefunded Warrants, shares Initial recognition of fair value of warrant liability Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Stock based compensation – services Stock based compensation - officers, directors, and employees Change in fair value of warrant liability Gain on extinguishment of share settled debt Change in operating lease right-of-use assets Unrealized loss (gain) on marketable securities Changes in operating assets and liabilities: Decrease in prepaid expenses Increase (Decrease) in accounts payable and accrued expenses (Decrease) in operating lease liability Net Cash Used in Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES Sale (Purchase) of investments Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issuance of common stock and warrants, net Net Cash Provided by Financing Activities Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash Cash and Cash Equivalents and Restricted Cash at Beginning of Period Cash and Cash Equivalents and Restricted Cash at End of Period SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid during the year for: Interest Income taxes SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES Initial recognition of fair value of warrant liability Fair value of common stock issued to a vendor to settle accounts payable Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Going Concern Analysis Accounting Policies [Abstract] Summary of Significant Accounting Policies Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Payables and Accruals [Abstract] Accounts Payable and Related Party Warrant Liability Warrant Liability Equity [Abstract] Stockholders’ Equity Common Stock Warrants And Options Common Stock Warrants and Options Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Basis of Presentation and Principles of Consolidation Accounting Estimates Cash Equivalents and Short-Term Investments Restricted Cash Fair Value of Financial Instruments Warrant Liability Common Stock (February 2024 Reverse Stock Split) Stock-Based Compensation Research and Development Expenses Leases Net Loss Per Share Concentration Segments Recent Accounting Pronouncements Schedule of Anti-dilutive Securities Schedule of Estimated Fair Value of Financial Instrument Schedule of Fair Value Hierarchy Financial Assets Schedule of Accounts Payable Schedule of Accounts Payable to Related Party Short-Term Debt [Table] Short-Term Debt [Line Items] Schedule of Derivative Liabilities Assumptions Schedule of Derivative Liability Transactions Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Schedule of Warrant Activity Schedule of Warrants Outstanding and Exercisable Schedule of Options Activity Schedule of Options Outstanding and Options Exercisable Net loss Net cash used in operating activities Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total anti-dilutive securities Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Cash equivalents Revers stock split ratio Cash, FDIC insured amount Fair Value, off-Balance-Sheet Risk [Table] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Cost Unrealized gains Unrealized losses Fair value Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total financial assets Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] Accounts payable to University of Minnesota Other accounts payable Total accounts payable Beginning balance Invoices, net Payments in cash Payments in common stock, at fair value Ending balance Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants measurement input Expected life (in years) Fair value of warrants Schedule Of Derivative Liability Transactions Beginning balance Issuance of warrants at fair value Change in fair value Extinguishment Ending balance Warrants to purchase Volatility amount utilized in the value calculation percentage Warrant fair value Issued warrants of common stock Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Common stock par value Proceeds from private placement Other offering expenses Direct offering Purchase of warrants Warrant exercise price Price per share Common stock issued for services, shares Common stock issued for services, value Preferred stock shares designated Convertible shares issuable Schedule Of Warrant Activity Warrants outstanding, beginning balance Weighted average exercise price, beginning balance Number of warrants, granted Weighted average exercise price, granted Number of warrants, forfeited/cancelled Weighted average exercise price, forfeited/cancelled Number of warrants, exercised Weighted average exercise price, exercised Warrants outstanding, ending balance Weighted average exercise price, ending balance Warrants exercisable, ending balance Weighted average exercise price, exercisable, ending balance Range of exercise price Number of warrants outstanding Warrants outstanding, weighted average remaining contractual life (years) Warrants outstanding, weighted average exercise price Range of exercise price Warrants exercisable, weighted average exercise price Schedule Of Options Activity Number of options outstanding, beginning Weighted-Average Exercise Price, beginning Number of options, granted Weighted-Average Exercise Price, granted Number of options, forfeited/cancelled Weighted-Average Exercise Price, forfeited/cancelled Number of options, exercised Weighted-Average Exercise Price, exercised Number of options outstanding, ending Weighted-Average Exercise Price, ending Number of options outstanding exercisable Weighted-Average Exercise Price,exercisable, ending Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Range of excercise price Options outstanding Options outstanding, weighted average remaining contractual life (years) Options outstanding, weighted average exercise price Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Options outstanding intrinsic value Awards granted plan Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term Purchase an aggregate Exercise price Stock options expire Fair value Loss Contingencies [Table] Loss Contingencies [Line Items] Equity method investment, ownership percentage Research and development expenses Cash payments Accounts payable, current Stock issued during period, value, issued for services Aggregate research and development expense Research and development expense Unbilled and unaccrued amounts Proceeds from upfront amount Maintenance fee Royalty fee percentage Annual royalty payments Performance milestone payments Sales milestone payments Gross sales Sales revenue Cumulative gross sales Royalty expense Royalty expense Royalty expense Upfront license fee License maintenance fee, receivable Subsequent Event [Table] Subsequent Event [Line Items] Stock options granted Stock options exercisable price per share Stock options vest years Stock option vested value Stock issued during period share issuance of common stock and warrants for cash. Stock issued during period shares common shares to settle vendor payable. Stock issued during period value issuance of common stock and warrants for cash. Stock issued during period value common shares to settle vendor payable. Stock issued during period value issuance of common stock for exercise of prefunded warrants Stock issued during period share issuance of common stock for exercise of prefunded warrants Stock based compensation common shares for services. Stock based compensation officers employees and board of directors. Officers, Employees and Directors [Member] Increase in restricted cash payment Cash paid during the year for [Abstract] Warrant Liability Policy [Text Block] Common Stock Reverse Stock Split [Policy Text Block] US Treasuries [Member] Schedule of Accounts Payable and Related Party [Table Text Block] Repayments of related party common stock. Warrant Liability [Text Block] Placement Agent Warrant [Member] 2023 Warrants [Member] 2020 Warrants [Member] 2020 Warrants [Member] Extinguishment of warrant. Purchase Agreement [Member] 2024 Common Warrants [Member] 2024 Placement Agent Warrant [Member] 2024 Common Shares And 2024 Common Warrants [Member] Prefunded Warrant [Member] 2023 Common Warrants [Member] 2023 Placement Agent Warrant [Member] Pre Funded Warrants [Member] 2023 Common Shares And 2023 Common Warrants [Member] Pre Funded Warrants And 2023 Common Warrants [Member] Common Warrant and Placement Agent Warrant [Member] Board Of Directors Employees And Consultants [Member] Series K Preferred Stocks [Member] Series K Preferred Stock [Member] Common Stock Warrants and Options [Text Block] Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable. Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price. Share based compensation arrangement by share based payment award non options granted weighted average exercise price. Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price. Share based compensation arrangement by share based payment award non options exercised weighted average exercise price. Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price. Schedule of warrants oustanding and exercisable [Table Text Block] Warrants [Member] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Range Five [Member] Range Six [Member] Range Seven [Member] Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price. Share based compensation arrangement by share based payment award non options equity instruments exercisable weighted average exercise price. Omnibus Incentive Plan [Member] Share based compensation shares authorized under stock option plans exercise price. Cytovance Biologics Inc [Member] Received upfront payment. 2016 Patent License Agreement [Member] 2017 through 2020 [Member] Royalty fee percentage. 2025 [Member] 2027 [Member] Performance milestone payments. Cummulative gross sales. Sales milestone payments. Gross sales. Royalty expense year one. Royalty expense year two through five. Royalty expense year after six. Sales revenue. Upfront license fee. 2021 Patent License Agreement [Member] License maintenance fee, receivable. Warrant liability current. 2023 Warrants [Member] 2023 Common Warrants [Member] 2021 Scientific Research Agreement [Member] 2023 Sponsored Research Agreement [Member] 2022 [Member] 2023 Warrants [Member] [Default Label] 2020 Warrants [Member] [Default Label] 2023 Common Warrants [Member] [Default Label] Assets, Current Assets Liabilities, Current Equity, Attributable to Parent Liabilities and Equity Operating Income (Loss) Interest Expense, Nonoperating Nonoperating Income (Expense) Shares, Outstanding Adjustments to Additional Paid in Capital, Warrant Issued Debt Securities, Unrealized Gain (Loss) Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Payments for (Proceeds from) Investments Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents WarrantLiabilityTextBlock Equity [Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] WarrantLiabilityPolicyTextBlock Debt Securities, Available-for-Sale, Unrealized Loss Share Based

~~Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable RoyaltyExpenseYearTwoThroughFive RoyaltyExpenseYearAfterSix EX-101.PRE 16 gtbp-20240930_pre.xml XBRL PRESENTATION FILE XML 18 R1.htm IDEA: XBRL DOCUMENT~~

Cover - shares	9 Months Ended Sep. 30, 2024	Nov. 10, 2024
Cover [Abstract]		
Document Type	10-Q	
Amendment Flag	false	
Document Quarterly Report	true	
Document Transition Report	false	
Document Period End Date	Sep. 30, 2024	
Document Fiscal Period Focus	Q3	
Document Fiscal Year Focus	2024	
Current Fiscal Year End Date	--12-31	
Entity File Number	001-40023	
Entity Registrant Name	GT BIOPHARMA, INC.	
Entity Central Index Key	0000109657	
Entity Tax Identification Number	94-1620407	
Entity Incorporation, State or Country Code	DE	
Entity Address, Address Line One	315 Montgomery Street	
Entity Address, Address Line Two	10th Floor	
Entity Address, City or Town	San Francisco	
Entity Address, State or Province	CA	
Entity Address, Postal Zip Code	94104	
City Area Code	415	
Local Phone Number	919-4040	
Title of 12(b) Security	Common Stock, $0.001 par value per share	
Trading Symbol	GTBP	
Security Exchange Name	NASDAQ	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Entity Filer Category	Non-accelerated Filer	
Entity Small Business	true	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
Entity Common Stock, Shares Outstanding		2,234,328

~~XML 19 R2.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets		
Cash and cash equivalents	$ 6,418,000	$ 1,079,000
Restricted cash	93,000	
Short-term investments		12,893,000
Prepaid expenses and other current assets	248,000	84,000
Total Current Assets	6,759,000	14,056,000
Operating lease right-of-use asset		53,000
TOTAL ASSETS	6,759,000	14,109,000
Current liabilities		
Accounts payable	2,612,000	4,328,000
Accrued expenses	1,868,000	1,195,000
Current operating lease liability		58,000
Warrant liability	182,000	1,052,000
Total Current Liabilities	4,662,000	6,633,000
Stockholders' Equity		
Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	1,000	1,000
Common stock, par value $0.001, 250,000,000 shares authorized, 2,234,328 and 1,380,633 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	2,000	1,000
Additional paid in capital	693,546,000	689,539,000
Accumulated deficit	(691,452,000)	(682,065,000)
Total Stockholders' Equity	2,097,000	7,476,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 6,759,000	$ 14,109,000

~~XML 20 R3.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	15,000,000	15,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	2,234,328	1,380,633
Common stock, shares outstanding	2,234,328	1,380,633
Series C Preferred Stock [Member]		
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	96,230	96,230
Preferred stock, shares outstanding	96,230	96,230

~~XML 21 R4.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating Expenses:				
Research and development	$ 1,307,000	$ 1,364,000	$ 3,868,000	$ 5,109,000
Selling, general and administrative (including $0 and $547,000 from stock compensation granted to officers, directors, and employees and for services for the three months ended September 30, 2024 and 2023, respectively, and $222,000 and $1,767,000 for the nine months ended September 30, 2024 and 2023, respectively)	2,297,000	1,758,000	6,733,000	5,299,000
Loss from Operations	(3,604,000)	(3,122,000)	(10,601,000)	(10,408,000)
Other Income (Expense)				
Interest income	96,000	216,000	343,000	600,000
Interest expense				(213,000)
Change in fair value of warrant liability	95,000	485,000	870,000	4,796,000
Gain on extinguishment of debt				547,000
Unrealized gain on marketable securities	2,000	5,000	1,000	43,000
Total Other Income, Net	193,000	706,000	1,214,000	5,773,000

Net Loss	$ (3,411,000)	$ (2,416,000)	$ (9,387,000)	$ (4,635,000)
Net Loss Per Share - Basic	$ (1.53)	$ (1.77)	$ (5.28)	$ (3.47)
Net Loss Per Share - Diluted	$ (1.53)	$ (1.77)	$ (5.28)	$ (3.47)
Weighted average common shares outstanding - basic	2,234,328	1,367,206	1,777,313	1,336,532
Weighted average common shares outstanding - diluted	2,234,328	1,367,206	1,777,313	1,336,532

~~XML 22 R5.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Selling, General and Administrative Expenses [Member] | Officers, Employees and Directors [Member]				
Share-based payment arrangement, expense	$ 0	$ 547,000	$ 222,000	$ 1,767,000

~~XML 23 R6.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 1,000	$ 1,000	$ 686,200,000	$ (674,467,000)	$ 11,734,000
Balance, shares at Dec. 31, 2022	96,230	1,090,748			
Net loss				(4,635,000)	(4,635,000)
Issuance of common shares to settle vendor payable			701,000		701,000
Issuance of common shares to settle vendor payable, shares		57,437			
Fair value of vested stock options			1,338,000		1,338,000
Issuance of common shares for services		$ 1,000	429,000		430,000
Issuance of common shares for services, shares		15,782			
Private placement of common stock			6,268,000		6,268,000
Private placement of common stock, shares		120,000			
Issuance of common stock for exercise of prefunded warrants					
Issuance of common stock for exercise of Prefunded Warrants, shares		96,666			
Initial recognition of fair value of warrant liability			(5,831,000)		(5,831,000)
Balance at Sep. 30, 2023	$ 1,000	$ 2,000	689,105,000	(679,103,000)	10,005,000
Balance, shares at Sep. 30, 2023	96,230	1,380,633			
Balance at Jun. 30, 2023	$ 1,000	$ 1,000	688,448,000	(676,687,000)	11,763,000
Balance, shares at Jun. 30, 2023	96,230	1,354,656			
Net loss				(2,416,000)	(2,416,000)
Issuance of common shares to settle vendor payable			110,000		110,000
Issuance of common shares to settle vendor payable, shares		12,644			
Fair value of vested stock options			433,000		433,000
Issuance of common shares for services		$ 1,000	114,000		115,000
Issuance of common shares for services, shares		13,333			
Balance at Sep. 30, 2023	$ 1,000	$ 2,000	689,105,000	(679,103,000)	10,005,000
Balance, shares at Sep. 30, 2023	96,230	1,380,633			
Balance at Dec. 31, 2023	$ 1,000	$ 1,000	689,539,000	(682,065,000)	7,476,000
Balance, shares at Dec. 31, 2023	96,230	1,380,633			
Net loss				(9,387,000)	(9,387,000)
Issuance of common stock and warrants for cash		$ 1,000	2,975,000		2,976,000
Issuance of common stock and warrants for cash, shares		740,000			
Cancellation of common stock issued to prior CFO					
Cancellation of common stock issued to prior CFO, shares		(13,902)			
Issuance of common shares to settle vendor payable			810,000		810,000
Issuance of common shares to settle vendor payable, shares		127,597			
Fair value of vested stock options			222,000		222,000
Issuance of common shares for services					1,300,000
Balance at Sep. 30, 2024	$ 1,000	$ 2,000	693,546,000	(691,452,000)	2,097,000
Balance, shares at Sep. 30, 2024	96,230	2,234,328			
Balance at Jun. 30, 2024	$ 1,000	$ 2,000	693,546,000	(688,041,000)	5,508,000
Balance, shares at Jun. 30, 2024	96,230	2,234,328			
Net loss				(3,411,000)	(3,411,000)
Balance at Sep. 30, 2024	$ 1,000	$ 2,000	$ 693,546,000	$ (691,452,000)	$ 2,097,000
Balance, shares at Sep. 30, 2024	96,230	2,234,328			

~~XML 24 R7.htm IDEA: XBRL DOCUMENT~~

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES					
Net loss	$ (3,411,000)	$ (2,416,000)	$ (9,387,000)	$ (4,635,000)	
Adjustments to reconcile net loss to net cash used in operating activities:					
Stock based compensation – services				430,000	
Stock based compensation - officers, directors, and employees			222,000	1,337,000	
Change in fair value of warrant liability	(95,000)	(485,000)	(870,000)	(4,796,000)	
Gain on extinguishment of share settled debt				(547,000)	
Change in operating lease right-of-use assets			53,000	78,000	
Unrealized loss (gain) on marketable securities			1,000	(43,000)	
Changes in operating assets and liabilities:					
Decrease in prepaid expenses			(164,000)	16,000	
Increase (Decrease) in accounts payable and accrued expenses			(233,000)	1,437,000	
(Decrease) in operating lease liability			(58,000)	(82,000)	
Net Cash Used in Operating Activities			(10,436,000)	(6,805,000)	
CASH FLOWS FROM INVESTING ACTIVITIES					
Sale (Purchase) of investments			12,892,000	(2,487,000)	
Net Cash Provided by (Used in) Investing Activities			12,892,000	(2,487,000)	
CASH FLOWS FROM FINANCING ACTIVITIES					
Proceeds from issuance of common stock and warrants, net			2,976,000	6,268,000	
Net Cash Provided by Financing Activities			2,976,000	6,268,000	
Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash			5,432,000	(3,024,000)	
Cash and Cash Equivalents and Restricted Cash at Beginning of Period			1,079,000	5,672,000	$ 5,672,000
Cash and Cash Equivalents and Restricted Cash at End of Period	$ 6,511,000	$ 2,648,000	6,511,000	2,648,000	$ 1,079,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:					
Interest					
Income taxes					
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES					

Initial recognition of fair value of warrant liability		5,831,000
Fair value of common stock issued to a vendor to settle accounts payable	$ 810,000	$ 700,000

~~XML 25 R8.htm IDEA: XBRL DOCUMENT~~

Organization and Going Concern Analysis	9 Months Ended Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	
Organization and Going Concern Analysis	Note 1 – Organization and Going Concern Analysis

Note 1 – Organization and Going Concern Analysis

Organization

The corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data, Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March 11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.

Throughout this Quarterly Report on Form 10-Q, the terms “GTBP,” “we,” “us,” “our,” “the Company” and “our Company” refer to GT Biopharma, Inc.

The GT Biopharma logo, TriKE®, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.

The Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE®), and Tetra-specific Killer Engager (Dual Targeting TriKE®) platforms. The Company’s TriKE® and Dual Targeting TriKE® platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer cells (NK cells).

Going Concern Analysis

The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company does not have any product candidates approved for sale and has not generated any revenue from its product sales. The Company has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company has financed its operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and strategic collaborations. For the nine months ended September 30, 2024, the Company recorded a net loss of approximately $9.4 million and used cash in operations of approximately $10.4 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.

The unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

The Company has evaluated the significance of the uncertainty regarding the Company’s financial condition in relation to its ability to meet its obligations, which has raised substantial doubt about the Company’s ability to continue as a going concern. While it is very difficult to estimate the Company’s future liquidity requirements, the Company believes if it is unable to obtain additional financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from the date the accompanying unaudited condensed consolidated financial statements are issued. There can be no assurances that the Company will be able to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company’s business prospects, ability to meet long-term liquidity needs and the ability to continue operations.

~~XML 26 R9.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies	9 Months Ended Sep. 30, 2024
Accounting Policies [Abstract]	
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation.

The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the “2023 Annual Report”). The consolidated balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

Accounting Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include management’s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax assets.

Cash Equivalents and Short-Term Investments

The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying unaudited condensed consolidated financial statements. At September 30, 2024 total cash equivalents which consist of money market funds and US treasuries, amounted to approximately $6.2 million. At December 31, 2023 total cash equivalents which consist of money market funds, amounted to approximately $443,000.

Management generally determines the appropriate classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying unaudited condensed consolidated statements of operations. At September 30, 2024 and December 31, 2023, total short-term investments which consist of US treasuries and US government agencies, amounted to approximately $0 and $12.9 million, respectively.

Restricted Cash

As of September 30, 2024, the Company has classified certain cash balances as restricted cash in its unaudited condensed consolidated balance sheets. The Company’s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with the same financial institution.

Fair Value of Financial Instruments

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

The three levels of the fair value hierarchy are as follows:

> Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.
>
> Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
>
> Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The carrying amounts of the Company’s other financial assets and liabilities, such as cash and cash equivalents, short term investments, prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity of these instruments.

The carrying amount of the Company’s warrant liability of $182,000 and $1.1 million at September 30, 2024 and December 31, 2023, respectively, was based on Level 3 measurements.

Warrant Liability

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “*Derivatives and Hedging*” (“ASC 815”). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.

The Company’s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.

Common Stock (February 2024 Reverse Stock Split)

On February 2, 2024, the Company effectuated a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30. The Company’s common stock began trading on a reverse stock-split-adjusted basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol “GTBP.”

As a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission and other expenses). The reverse stock split reduced the number of shares of common stock outstanding on the effective date of the reverse stock-split from 41,419,000 shares to 1,380,633 shares, subject to minor adjustments due to the treatment of fractional shares. The number of authorized shares of common stock remains unchanged at 250,000,000 shares.

Proportionate adjustments have been made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise of outstanding stock options and warrants for the Company’s common stock, and to the number of shares of common stock reserved for future issuance pursuant to the Company’s 2022 Omnibus Incentive Plan.

All share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest period presented.

Stock-Based Compensation

The Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

Stock-based payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, *Compensation-Stock Compensation*. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

Research and Development Expenses

Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Company’s products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed.

Leases

The Company accounts for its lease in accordance with the guidance of ASC 842, *Leases*. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.

In June 2024, the Company’s lease expired and was not renewed.

Net Loss Per Share

Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.

The following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:

	September 30, 2024 (Unaudited)	September 30, 2023 (Unaudited)
Options to purchase common stock	101,264	124,599
Warrants to purchase common stock	1,133,762	304,962
Total anti-dilutive securities	1,235,026	429,561

Concentration

Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $250,000. Management believes that the financial institutions that hold the Company’s cash are financially sound and, accordingly, minimal credit risk exists.

The Company has a significant concentration of expenses incurred from and accounts payable and accrued expenses to Cytovance, a related party, and the University of Minnesota, see Note 4 – Accounts Payable and Related Party.

Segments

The Company determined its reporting units in accordance with “*Segment Reporting*” (“ASC 280”). Management evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated.

Management has determined that the Company has one consolidated operating segment. The Company’s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company’s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments. As a result no further segment information is presented in these consolidated financial statements.

Recent Accounting Pronouncements

In November 2023, the FASB issued ASU No. 2023-07, “*Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*” (“ASU 2023-07”), which introduces new reportable segment disclosure requirements related to significant segment expenses and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable segment’s profits and losses. This standard became effective for the Company on January 1, 2024. The adoption of this standard did not have a material impact on the Company’s results of operations, financial position or cash flows.

The Company’s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company’s financial position and results of operations.

~~XML 27 R10.htm IDEA: XBRL DOCUMENT~~

Fair Value of Financial Instruments	9 Months Ended Sep. 30, 2024
Fair Value Disclosures [Abstract]	
Fair Value of Financial Instruments	**Note 3 – Fair Value of Financial Instruments**

Financial Assets

The following table represents the estimated fair values of the Company’s financial instruments:

	September 30, 2024 (Unaudited)			
	Cost	Unrealized Gains	Unrealized Losses	Fair Value
Short-term investments	$ —	$ —	$ —	$ —
Total	$ —	$ —	$ —	$ —

	December 31, 2023			
	Cost	Unrealized Gains	Unrealized Losses	Fair Value
Short-term investments	$ 12,845,000	$ 48,000	$ —	$ 12,893,000
Total	$ 12,845,000	$ 48,000	$ —	$ 12,893,000

The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments):

	September 30, 2024 (Unaudited)			
	Fair Value	Level 1	Level 2	Level 3
Cash equivalents:				
Money market funds	$ 1,220,000	$ 1,220,000	$ —	$ —
US treasuries	4,987,000	—	4,987,000	—
Short-term investments:				
US treasuries	—	—	—	—
Total financial assets	$ 6,207,000	$ 1,220,000	$ 4,987,000	$ —

	December 31, 2023			
	Fair Value	Level 1	Level 2	Level 3
Cash equivalents:				
Money market funds	$ 443,000	$ 443,000	$ —	$ —
Short-term investments:				
US treasuries and US gov’t. agencies	12,893,000	—	12,893,000	—
Total financial assets	$ 13,336,000	$ 443,000	$ 12,893,000	$ —

Warrant Liability

For the details of warrant liability transactions see Note 5 – Warrant Liability.

~~XML 28 R11.htm IDEA: XBRL DOCUMENT~~

Accounts Payable and Related Party

9 Months Ended Sep. 30, 2024

Payables and Accruals [Abstract]

Accounts Payable and Related Party

Note 4 – Accounts Payable and Related Party

Accounts payable consists of the following:

	As of September 30, 2024 (Unaudited)	As of December 31, 2023
Accounts payable to Cytovance, a related party [1]	$ 638,000	$ 3,515,000
Accounts payable to University of Minnesota	697,000	130,000
Other accounts payable	1,277,000	683,000
Total accounts payable	$ 2,612,000	$ 4,328,000

[1] Accounts Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock

See Note 8 – Commitments and Contingencies, Significant Agreements.

The details of the Company’s accounts payable to Cytovance Biologics, Inc., were as follows:

	Nine Months Ending	
	September 30, 2024 (Unaudited)	September 30, 2023 (Unaudited)
Beginning balance	$ 3,515,000	$ 2,283,000
Invoices, net	1,365,000	3,691,000
Payments in cash	(3,432,000)	(1,710,000)
Payments in common stock, at fair value	(810,000)	(1,120,000)
Ending balance	$ 638,000	$ 3,144,000

University of Minnesota

See Note 8 – Commitments and Contingencies, Significant Agreements.

~~XML 29 R12.htm IDEA: XBRL DOCUMENT~~

Warrant Liability

9 Months Ended Sep. 30, 2024

Warrant Liability

Warrant Liability

Note 5 – Warrant Liability

2023 Warrants

On January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate of 216,667 shares of the Company’s common stock (the “2023 Common Warrants”), and placement agent warrants to purchase up to 13,000 shares of the Company’s common stock (the “2023 Placement Agents Warrants”).

The 2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the “2023 Warrants”), provide for a value calculation for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides for a floor on the volatility amount utilized in the value calculation at 100% or greater. The Company has determined this provision introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Company’s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability in its consolidated balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is evaluated at the end of each reporting period.

The 2023 Warrants were initially recorded at a fair value at $5.8 million at the grant date, and upon the closing of placement, was recorded as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Company’s unaudited condensed consolidated balance sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed consolidated statements of operations until they are either exercised or expired.

The 2023 Warrant liability is valued using a Binomial pricing model with the following assumptions:

	2023 Warrants	
	September 30, 2024 (Unaudited)	December 31, 2023
Stock price	$ 2.31	$ 7.20
Risk-free interest rate [1]	3.58%	4.6%
Expected volatility [2]	114%	119.7%
Expected life (in years) [3]	3.25 – 3.75	4.5
Expected dividend yield [4]	—	—
Fair value of warrants	$ 182,000	$ 1,051,000

[1] Based on rates established by the Federal Reserve Bank

[2] Historical volatility of the Company’s common stock is used to estimate the future volatility of its common stock

[3] Determined by the remaining contractual life of the derivative instrument

[4] Based on no dividends paid or expected to be paid

2020 Warrants

The Company issued warrants underlying 58,824 shares of common stock during the year ended December 31, 2020 (the “2020 Warrants”), that contained a fundamental transaction provision that could give rise to an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance with ASC 480, the fair value of the 2020 Warrants is classified as a liability in the Company’s unaudited condensed consolidated balance sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed consolidated statements of operations until they are either exercised or expire.

The 2020 Warrant liability is valued using a Binomial pricing model with the following assumptions:

	2020 Warrants	
	September 30, 2024 (Unaudited)	September 30, 2023
Stock price	$ 2.31	$ 7.20
Risk-free interest rate [1]	3.98%	5.0%
Expected volatility [2]	114%	89.0%
Expected life (in years) [3]	0.8	1.8
Expected dividend yield [4]	—	—
Fair value of warrants	$ —	$ 2,000

Warrant Liability

The details of warrant liability transactions were as follows:

	Nine Months Ending	
	September 30, 2024 (Unaudited)	September 30, 2023 (Unaudited)
Beginning balance	$ 1,052,000	$ 18,000
Issuance of warrants at fair value	—	5,831,000
Change in fair value	(870,000)	(4,796,000)
Extinguishment	—	—
Ending balance	$ 182,000	$ 1,053,000

~~XML 30 R13.htm IDEA: XBRL DOCUMENT~~

Stockholders’ Equity

9 Months Ended Sep. 30, 2024

Equity [Abstract]

Stockholders’ Equity

Note 6 – Stockholders’ Equity

The Company’s authorized capital as of September 30, 2024 was 250,000,000 shares of common stock, par value $0.001 per share, and 15,000,000 shares of preferred stock, par value $0.01 per share.

Common Stock

2024 Common Stock Offering

On May 23, 2024, the Company received gross proceeds of approximately $3.2 million, before deducting placement agent fees and other offering expenses of $243,000 in relation to a purchase agreement (the “Purchase Agreement”) signed on May 21, 2024, between the Company and institutional investors (the “Purchasers”) for the issuance and sale, in a registered direct offering, of 740,000 shares of the

Company’s common stock, par value $0.001 per share (the “2024 Shares”). In a concurrent private placement, the Company issued and sold to the Purchasers warrants to purchase 740,000 shares of the Company’s common stock (the “2024 Common Warrants”). In addition, the Company issued warrants to the placement agent to purchase 88,800 shares of common stock (the “2024 Placement Agents Warrants”). The 2024 Common Warrants have an exercise price equal to $4.35 per share, and the 2024 Placement Agents Warrants have an exercise price equal to $5.4375 per share, both are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial exercise date. The 2024 Shares and 2024 Common Warrants were sold at an offering price of $4.35 per share and accompanying 2024 Common Warrant.

Pursuant to the Purchase Agreement, the Company agreed, with certain exceptions, for a period of 60 days following the closing of the offering not to issue, enter into an agreement to issue or announce the issuance or proposed issuance of the 2024 Shares or any other securities convertible into, or exercisable or exchangeable for, shares of the Company’s common stock. The Company has also agreed for a period of one year following the closing date of the offering not to (i) issue or agree to issue equity or debt securities convertible into, or exercisable or exchangeable for, shares at a conversion price, exercise price or exchange price which floats with the trading price of the 2024 Shares or which may be adjusted after issuance upon the occurrence of certain events or (ii) enter into any agreement, including an equity line of credit, whereby the Company may issue securities at a future-determined price.

The Company determined that under ASC 815-40, the 2024 Common Warrants and the 2024 Placement Agent Warrants do not contain a clause that adjusts the exercise price based on circumstances not considered to be within the Company’s control and are considered indexed to the Company’s own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2024 Common Warrants and the 2024 Placement Agent Warrants are classified as equity.

2023 Private Placement of Common Stock

On January 4, 2023, the Company received gross proceeds of $6.5 million, before deducting placement agent fees and other offering expenses of $232,000 in relation to a purchase agreement signed on December 30, 2022, between the Company and an institutional investor for the issuance and sale, in a registered direct offering, of 120,000 shares of the Company’s common stock, par value $0.001 per share (the “2023 Shares”), pre-funded warrants to purchase up to 96,667 shares of the Company’s common stock (the “Pre-Funded Warrants”), warrants to purchase up to an aggregate of 216,667 shares of the Company’s common stock (the “2023 Common Warrants”) and placement agent warrants to purchase up to 13,000 of the Company’s common stock (the “2023 Placement Agents Warrants”). The 2023 Common Warrants have an exercise price equal to $30.00 per share, are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial issuance date. The Pre-Funded Warrants had an exercise price of $0.003 per share, are immediately exercisable and could be exercised at any time after their original issuance until such Pre-Funded Warrants were exercised in full. The 2023 Placement Agents Warrants have an exercise price equal to $37.50 per share, are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial issuance date. The 2023 Shares and 2023 Common Warrants were sold at an offering price of $30.00 per share and accompanying 2023 Common Warrant and the Pre-Funded Warrants and 2023 Common Warrants were sold at an offering price of $29.997 per Pre-Funded Warrant and accompanying 2023 Common Warrant.

The 2023 Common Warrants and the 2023 Placement Agents Warrants contained a clause not considered to be within the Company’s control. The Company determined that the provision represented a variable that is not an input to the fair value of a “fixed-for-fixed” option as defined under ASC 815-40, and thus the 2023 Common Warrants and the 2023 Placement Agent Warrants are not considered indexed to the Company’s own stock and not eligible for an exception from derivative accounting. Accordingly, the 2023 Common Warrants and the 2023 Placement Agent Warrants were classified as a warrant liability, and $5.8 million of the initial common stock offering was classified as a warrant liability (see Note 5 – Warrant Liability).

Common Stock Issued for Services

During the nine months ended September 30, 2023, the Company issued 15,782 shares of common stock with a fair value of $430,000 to members of the Company’s Board of Directors (the “Board”), employees, and consultants. The shares were valued at the respective date of the agreements.

Preferred Stock

Series C Preferred Stock

As of September 30, 2024 and December 31, 2023, there were 96,230 shares of series C preferred stock, par value $0.01 per share (the “Series C Preferred Stock”) issued and outstanding.

As a result of reverse stock splits in previous years and the agreement terms for adjusting the rights of the related shares, the 96,230 shares of Series C Preferred Stock are not currently convertible, have no voting rights, and in the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through September 30, 2024 and 2023, respectively.

Series K Preferred Stock

On February 16, 2021, the Board designated 115,000 shares of Series K preferred stock, par value $.01 (the “Series K Preferred Stock”).

Shares of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company’s common stock at an effective conversion rate of 100 shares of common stock for each share of Series K Preferred. Shares of the Series K Preferred Stock have the same voting rights as the shares of the Company’s common stock, with the holders of the Series K Preferred Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation, together with the holders of the Company’s common stock on all matters presented to the Company’s stockholders. The Series K Preferred Stock are not entitled to any dividends (unless specifically declared by the Board) but will participate on an as-converted-to-common-stock basis in any dividends to the holders of the Company’s common stock. In the event of the Company’s dissolution, liquidation or winding up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company’s common stock and will participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Company’s common stock.

As of September 30, 2024 and December 31, 2023, there were no shares of Series K Preferred stock issued and outstanding.

~~XML 31 R14.htm IDEA: XBRL DOCUMENT~~

Common Stock Warrants and Options	**9 Months Ended Sep. 30, 2024**

Common Stock Warrants And Options

Common Stock Warrants and Options

Note 7 – Common Stock Warrants and Options

Common Stock Warrants

Stock warrant transactions for the six months ended September 30, 2024 were as follows:

	Nine Months Ended September 30, 2024	
	Number of Warrants	**Weighted Average Exercise Price**
Warrants outstanding at December 31, 2023	304,962	$ 63.30
Granted	828,800	4.47
Forfeited/cancelled	—	—
Exercised	—	—
Warrants outstanding at September 30, 2024	1,133,762	$ 20.57
Warrants exercisable at September 30, 2024	1,133,762	$ 20.57

As of September 30, 2024, all outstanding warrants are fully vested and had an exercise price greater than the market price of the Company’s common stock, which resulted in no intrinsic value.

Warrants outstanding as of September 30, 2024 are exercisable as follows:

	Warrants Outstanding and Exercisable as of September 30, 2024		
Range of Exercise Price	**Number Outstanding**	**Weighted Average Remaining Contractual Life (Years)**	**Weighted Average Exercise Price**
$ 4.35	740,000	4.7	$ 4.35
5.4375	88,800	4.6	5.4375
30.00	216,666	3.8	30.00
37.50	13,000	3.3	37.50
102.00	1,867	0.8	102.00
165.00	65,649	1.4	165.00
206.25	7,780	1.4	206.25
	1,133,762	4.2	20.57

Common Stock Options

In April 2022 the Company established the 2022 Omnibus Incentive Plan (the “Plan”). The Plan was approved by our Board and stockholders. The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors, and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards granted under the Plan is 166,667. The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant under the Plan. As of September 30, 2024, there were 39,467 shares available for grant under the Plan.

The following table summarizes stock option transactions for the nine months ended September 30, 2024:

	Nine Months Ended September 30, 2024	
	Number of Options	**Weighted Average Exercise Price**
Options outstanding at December 31, 2023	126,265	$ 40.15
Granted	—	—
Forfeited/cancelled	(25,001)	14.80
Exercised	—	—
Options outstanding at September 30, 2024	101,264	$ 39.74
Options exercisable at September 30, 2024	101,264	$ 39.74

The weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of September 30, 2024 was 8.2 years. Furthermore, all options outstanding and all options vested and exercisable as of September 30, 2024 had an exercise price greater than the market price of the Company’s common stock, which resulted in no intrinsic value.

The total fair value of options that vested during the nine months ended September 30, 2024 and 2023, was $222,000 and $1,338,000, respectively, and is included in selling, general and administrative expense in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2024, all outstanding stock options were fully vested and exercisable and there was no unvested compensation expense.

On May 15, 2023, the Company granted stock options to a member of the Board to purchase 16,666 shares of common stock. The stock options are exercisable at $10.50 per share, expire in 10 years, vest over twelve months and have a fair value of $150,000 on at the date of grant which will be amortized over the vesting period.

On January 27, 2023, the Company granted stock options to employees and members of the Board to purchase an aggregate of 66,667 shares of common stock. The stock options are exercisable at $25.50 per share, expire in 10 years, vest over twelve months and have a fair value of $1.4 million at the date of grant which will be amortized over the vesting period.

Options outstanding as of September 30, 2024 are exercisable as follows:

	Stock Options Outstanding and Exercisable as of September 30, 2024		
Range of Exercise Price	**Number Outstanding**	**Weighted Average Remaining Contractual Life (Years)**	**Weighted Average Exercise Price**
$ 10.50	16,666	8.6	$ 10.50
25.50	50,000	8.3	25.50
74.40	34,598	7.8	74.40
	101,264		

~~XML 32 R15.htm IDEA: XBRL DOCUMENT~~

Commitments and Contingencies	**9 Months Ended Sep. 30, 2024**

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 8 – Commitments and Contingencies

Litigation

The Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under, and are being handled in, the normal course of business:

Ohri Matter

On July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the Demand, the Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing that the Company may characterize Mr. Ohri's termination as "for cause" under his Employment Agreement, and that the Company may revoke the Separation Agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri's breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri's violations, and attorneys' fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company's claims against him and counterclaims for breach of his Employment Agreement and Separation Agreement. At this early stage in the proceedings the Company is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any.

Berk Matter

On November 14, 2023, former interim Chief Executive Officer, Dr. Gregory Berk filed a lawsuit in the US District Court for the District of Massachusetts alleging that the Company discriminated and retaliated against Dr. Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act ("SOX"). The Company vigorously defended this matter and believes it to be without merit; however, the parties have agreed to resolve the matter and the Company expects the lawsuit to be dismissed shortly. The Company believes it has recorded appropriate accruals for the matter.

TWF Global Matter

On May 24, 2023, TWF Global, LLC ("TWF") filed a Complaint in the California Superior Court for the County of Los Angeles naming the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes ("Notes") and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its Complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint for Interpleader against TWF and Z-One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine if the Company's shares of common stock are properly registered to TWF or Z-One LLC, as both of these entities have made conflicting demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice and will reconsider the motion without further briefing upon the filing of a supplemental party affidavit. On May 9, 2024, Z-One filed a motion for summary judgement seeking dismissal of the action, representing that Z-One and TWF have settled their dispute over the entitlement to the Company's shares of common stock and there is no remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of default. The Court has set a hearing on Z-One's motion for November 14, 2024. The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these claims.

Significant Agreements

Cytovance Biologics, Inc., a Related Party

In October 2020, the Company entered into a Master Services Agreement with Cytovance Biologics, Inc. ("Cytovance"), to perform biologic development and manufacturing services, and to produce and test compounds used in the Company's potential product candidates. The Company subsequently executed numerous Statements of Work ("SOWs") for the research and development of products for use in clinical trials.

On August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and allowed for future invoices to be settled in in a combination of cash and issuance of the Company's common stock. The Agreement also set Cytovance's beneficial ownership limitation at 4.9% of the issued and outstanding shares of the Company's common stock.

On April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance's beneficial ownership limitation to 9.9% of the issued and outstanding shares of the Company's common stock.

During the nine months ended September 30, 2024 and 2023, the Company recognized research and development expenses of $1,365,000 and $3,691,000, respectively and made cash payments amounting to $3,432,000 and $1,710,000, respectively to Cytovance. In addition, the Company issued 127,597 and 57,437 shares of common stock to Cytovance to settle accounts payable valued at approximately $810,000 and $1,120,000, respectively.

On June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded 5% of the issued and outstanding shares of the Company's common stock.

As of September 30, 2024 the Company's commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from Cytovance for services that have not yet been rendered as of September 30, 2024, amounted to approximately $1.3 million.

University of Minnesota

2021 Scientific Research Agreement

Effective June 16, 2021, the Company entered into a scientific research agreement with the Regents of the University of Minnesota, expiring on June 30, 2023. Payments totaling approximately $2.1 million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work with the Company with three major goals in mind: (1) support the Company's TriKE® product development and GMP manufacturing efforts; (2) TriKE® pharmacokinetics optimization in humans; and (3) investigation of the patient's native NK cell population based on insights obtained from the analysis of the human data generated during our GTB-3550 clinical trial. The major deliverables proposed are: (1) creation of IND enabling data for TriKE® constructs in support of our product development and GMP manufacturing efforts; (2) TriKE® platform drug delivery changes to allow transition to alternative drug delivery means and extended PK in humans; and (3) gain an increased understanding of changes in the patient's native NK cell population as a result of TriKE® therapy. Most studies will use TriKE® DNA/amino acid sequences created by the Company under existing licensing terms.

The Company recorded an expense classified as research and development of approximately $0 and $192,000, pursuant to the 2021 Scientific Research Agreement, for the nine months ended September 30, 2024 and 2023, respectively.

As of September 30, 2024 the Company's commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant to the 2021 Scientific Research Agreement for services that have not yet been rendered as of September 30, 2024, amounted to $0.

2023 Sponsored Research Agreement

On May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the "2016 Exclusive Patent License Agreement"), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $1.7 million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work with the Company with three major goals in mind: (1) support the Company's TriKE® product development and commercial GMP manufacturing efforts; (2) TriKE® pharmacokinetics optimization in humans and investigation of effects of altering the route of administration; and (3) research and development of TriKE® platform. The major deliverables proposed are: (1) creation of IND enabling data for TriKE® constructs in support of the Company's product development and commercial GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE® platform drug delivery changes to allow transition from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ]) and extended PK in humans and gain an increased understanding of changes in the patient's native NK cell population as a result of alteration of TriKE® administration; and (3) research and development of TriKE® platform combination with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE® platform through formation of immune complexes. Most studies will use TriKE® DNA/amino acid sequences created by the Company under existing licensing terms.

The Company recorded an expense classified as research and development of approximately $863,000 and $0, pursuant to the 2023 Sponsored Research Agreement, for the nine months ended September 30, 2024 and 2023, respectively.

As of September 30, 2024 the Company's commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of September 30, 2024, amounted to approximately $862,000.

2016 Exclusive Patent License Agreement

Effective July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended, the "2016 Exclusive Patent License Agreement"), to further develop and commercialize cancer therapies using TriKE® technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement, the Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE® technology worldwide for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKE® technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $200,000, and license maintenance fees of $200,000 for years 2017 through 2020, and $100,000 per year beginning in year 2021 and each year thereafter. The agreement also includes 4% royalty fees on the net sales of licensed products, not to exceed 6% under subsequent license agreements or amendments to this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $250,000 beginning in 2022, $2 million beginning in 2025, and $5 million beginning in 2027 throughout the remainder of the term. The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $3.1 million, and one-time sales milestone payments of $1 million upon reaching $250 million in cumulative gross sales, and $5 million upon reaching $500 million in cumulative gross sales of licensed products.

Effective May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University of Minnesota. The amendment requires an upfront payment of $145,000 and amends the license maintenance fees to $50,000 in 2025, and $100,000 per year beginning in year 2026 and each year thereafter. The amendment also includes 1% to 5% royalty fees on the net sales of licensed products, not to exceed 6% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $250,000 in year one, $2 million in years two through five, and $5 million in year six throughout the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone payments totaling $3.1 million, and one-time sales milestone, and one-time sales milestone payments of $1 million upon reaching $250 million in cumulative gross sales, and $5 million upon reaching $500 million in cumulative gross sales of licensed products.

The Company recorded an expense classified as research and development of $145,000 and $0, pursuant to the 2016 Exclusive Patent License Agreement, for the nine months ended September 30, 2024 and 2023, respectively.

2021 Exclusive License Agreement

Effective March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the “2021 Exclusive Patent License Agreement”), specific to the B7H3 targeted TriKE®. The agreement requires an upfront payment of $20,000, and license maintenance fees of $5,000 per year beginning in year 2022 and each year thereafter. The agreement also includes 2.5% to 5% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $250,000 in year one though four, and $2 million beginning in year five and throughout the remainder of the term. The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $3.1 million, and one-time sales milestone payments of $1 million upon reaching $250 million in cumulative gross sales, and $5 million upon reaching $500 million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone.

The Company did not incur any expenses pursuant to the 2021 Exclusive License Agreement, for the nine months ended September 30, 2024 and 2023, respectively.

~~XML 33 R16.htm IDEA: XBRL DOCUMENT~~

Subsequent Events	**9 Months Ended** **Sep. 30, 2024**
Subsequent Events [Abstract]	
Subsequent Events	**Note 9 – Subsequent Events** On October 17, 2024, the Company granted stock options to an officer to purchase an aggregate of 23,335 shares of common stock. The stock options are exercisable at $2.11 per share, expire in 10 years, vest over three years and have a fair value of approximately $45,000 at the date of grant which will be amortized over the vesting period.

~~XML 34 R17.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies (Policies)	**9 Months Ended** **Sep. 30, 2024**
Accounting Policies [Abstract]	
Basis of Presentation and Principles of Consolidation	**Basis of Presentation and Principles of Consolidation** The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the “2023 Annual Report”). The consolidated balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.
Accounting Estimates	**Accounting Estimates** The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include management’s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax assets.
Cash Equivalents and Short-Term Investments	**Cash Equivalents and Short-Term Investments** The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying unaudited condensed consolidated financial statements. At September 30, 2024 total cash equivalents which consist of money market funds and US treasuries, amounted to approximately $6.2 million. At December 31, 2023 total cash equivalents which consist of money market funds, amounted to approximately $443,000. Management generally determines the appropriate classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying unaudited condensed consolidated statements of operations. At September 30, 2024 and December 31, 2023, total short-term investments which consist of US treasuries and US government agencies, amounted to approximately $0 and $12.9 million, respectively.
Restricted Cash	**Restricted Cash** As of September 30, 2024, the Company has classified certain cash balances as restricted cash in its unaudited condensed consolidated balance sheets. The Company’s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with the same financial institution.
Fair Value of Financial Instruments	**Fair Value of Financial Instruments** Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. The three levels of the fair value hierarchy are as follows: Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amounts of the Company’s other financial assets and liabilities, such as cash and cash equivalents, short term investments, prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity of these instruments. The carrying amount of the Company’s warrant liability of $182,000 and $1.1 million at September 30, 2024 and December 31, 2023, respectively, was based on Level 3 measurements.
Warrant Liability	**Warrant Liability** The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “*Derivatives and Hedging*” (“ASC 815”). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The Company’s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.
Common Stock (February 2024 Reverse Stock Split)	**Common Stock (February 2024 Reverse Stock Split)** On February 2, 2024, the Company effectuated a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30. The Company’s common stock began trading on a reverse stock-split-adjusted basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol “GTBP.” As a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission and other expenses). The reverse stock split reduced the number of shares of common stock outstanding on the effective date of the reverse stock-split from 41,419,000 shares to 1,380,633 shares, subject to minor adjustments due to the treatment of fractional shares. The number of authorized shares of common stock remains unchanged at 250,000,000 shares. Proportionate adjustments have been made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise of outstanding stock options and warrants for the Company’s common stock, and to the number of shares of common stock reserved for future issuance pursuant to the Company’s 2022 Omnibus Incentive Plan. All share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest period presented.

Stock-Based Compensation

Stock-Based Compensation

The Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

Stock-based payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, *Compensation-Stock Compensation*. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

Research and Development Expenses

Research and Development Expenses

Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Company's products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed.

Leases

Leases

The Company accounts for its lease in accordance with the guidance of ASC 842, *Leases*. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company's right to use an underlying asset during the lease term, and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.

In June 2024, the Company's lease expired and was not renewed.

Net Loss Per Share

Net Loss Per Share

Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.

The following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:

	September 30, 2024 (Unaudited)	September 30, 2023 (Unaudited)
Options to purchase common stock	101,264	124,599
Warrants to purchase common stock	1,133,762	304,962
Total anti-dilutive securities	1,235,026	429,561

Concentration

Concentration

Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation ("FDIC") insurance limits of up to $250,000. Management believes that the financial institutions that hold the Company's cash are financially sound and, accordingly, minimal credit risk exists.

The Company has a significant concentration of expenses incurred from and accounts payable and accrued expenses to Cytovance, a related party, and the University of Minnesota, see Note 4 – Accounts Payable and Related Party.

Segments

Segments

The Company determined its reporting units in accordance with "*Segment Reporting*" ("ASC 280"). Management evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated.

Management has determined that the Company has one consolidated operating segment. The Company's reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company's reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments. As a result no further segment information is presented in these consolidated financial statements.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In November 2023, the FASB issued ASU No. 2023-07, "*Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*" ("ASU 2023-07"), which introduces new reportable segment disclosure requirements related to significant segment expenses and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable segment's profits and losses. This standard became effective for the Company on January 1, 2024. The adoption of this standard did not have a material impact on the Company's results of operations, financial position or cash flows.

The Company's management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company's financial position and results of operations.

~~XML 35 R18.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies (Tables)	9 Months Ended Sep. 30, 2024

Accounting Policies [Abstract]

Schedule of Anti-dilutive Securities

The following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:

	September 30, 2024 (Unaudited)	September 30, 2023 (Unaudited)
Options to purchase common stock	101,264	124,599
Warrants to purchase common stock	1,133,762	304,962
Total anti-dilutive securities	1,235,026	429,561

~~XML 36 R19.htm IDEA: XBRL DOCUMENT~~

Fair Value of Financial Instruments (Tables)	9 Months Ended Sep. 30, 2024

Fair Value Disclosures [Abstract]

Schedule of Estimated Fair Value of Financial Instrument

The following table represents the estimated fair values of the Company's financial instruments:

	September 30, 2024 (Unaudited)			
	Cost	Unrealized Gains	Unrealized Losses	Fair Value
Short-term investments	$ —	$ —	$ —	$ —
Total	$ —	$ —	$ —	$ —

	December 31, 2023			
	Cost	Unrealized Gains	Unrealized Losses	Fair Value
Short-term investments	$ 12,845,000	$ 48,000	$ —	$ 12,893,000
Total	$ 12,845,000	$ 48,000	$ —	$ 12,893,000

Schedule of Fair Value Hierarchy Financial Assets

The following table represents the Company's fair value hierarchy for its financial assets (cash equivalents and investments):

	September 30, 2024 (Unaudited)			
	Fair Value	Level 1	Level 2	Level 3
Cash equivalents:				
Money market funds	$ 1,220,000	$ 1,220,000	$ —	$ —
US treasuries	4,987,000	—	4,987,000	—
Short-term investments:				
US treasuries	—	—	—	—
Total financial assets	$ 6,207,000	$ 1,220,000	$ 4,987,000	$ —

	December 31, 2023			
	Fair Value	Level 1	Level 2	Level 3
Cash equivalents:				
Money market funds	$ 443,000	$ 443,000	$ —	$ —
Short-term investments:				
US treasuries and US gov't. agencies	12,893,000	—	12,893,000	—
Total financial assets	$ 13,336,000	$ 443,000	$ 12,893,000	$ —

~~XML 37 R20.htm IDEA: XBRL DOCUMENT~~

Accounts Payable and Related Party	9 Months Ended

(Tables) **Sep. 30, 2024**

Payables and Accruals [Abstract]

Schedule of Accounts Payable

Accounts payable consists of the following:

	As of September 30, 2024 (Unaudited)	As of December 31, 2023
Accounts payable to Cytovance, a related party [1]	$ 638,000	$ 3,515,000
Accounts payable to University of Minnesota	697,000	130,000
Other accounts payable	1,277,000	683,000
Total accounts payable	$ 2,612,000	$ 4,328,000

[1] Accounts Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock

Schedule of Accounts Payable to Related Party

The details of the Company’s accounts payable to Cytovance Biologics, Inc., were as follows:

	Nine Months Ending	
	September 30, 2024 (Unaudited)	September 30, 2023 (Unaudited)
Beginning balance	$ 3,515,000	$ 2,283,000
Invoices, net	1,365,000	3,691,000
Payments in cash	(3,432,000)	(1,710,000)
Payments in common stock, at fair value	(810,000)	(1,120,000)
Ending balance	$ 638,000	$ 3,144,000

~~XML 38 R21.htm IDEA: XBRL DOCUMENT~~

Warrant Liability (Tables)

9 Months Ended
Sep. 30, 2024

Short-Term Debt [Line Items]

Schedule of Derivative Liability Transactions

The details of warrant liability transactions were as follows:

	Nine Months Ending	
	September 30, 2024 (Unaudited)	September 30, 2023 (Unaudited)
Beginning balance	$ 1,052,000	$ 18,000
Issuance of warrants at fair value	—	5,831,000
Change in fair value	(870,000)	(4,796,000)
Extinguishment	—	—
Ending balance	$ 182,000	$ 1,053,000

2023 Warrants [Member]

Short-Term Debt [Line Items]

Schedule of Derivative Liabilities Assumptions

The 2023 Warrant liability is valued using a Binomial pricing model with the following assumptions:

	2023 Warrants	
	September 30, 2024 (Unaudited)	December 31, 2023 (Unaudited)
Stock price	$ 2.31	$ 7.20
Risk-free interest rate [1]	3.58%	4.6%
Expected volatility [2]	114%	119.7%
Expected life (in years) [3]	3.25 – 3.75	4.5
Expected dividend yield [4]	—	—
Fair value of warrants	$ 182,000	$ 1,051,000

[1] Based on rates established by the Federal Reserve Bank

[2] Historical volatility of the Company’s common stock is used to estimate the future volatility of its common stock

[3] Determined by the remaining contractual life of the derivative instrument

[4] Based on no dividends paid or expected to be paid

2020 Warrants [Member]

Short-Term Debt [Line Items]

Schedule of Derivative Liabilities Assumptions

The 2020 Warrant liability is valued using a Binomial pricing model with the following assumptions:

	2020 Warrants	
	September 30, 2024 (Unaudited)	September 30, 2023
Stock price	$ 2.31	$ 7.20
Risk-free interest rate [1]	3.98%	5.0%
Expected volatility [2]	114%	89.0%
Expected life (in years) [3]	0.8	1.8
Expected dividend yield [4]	—	—
Fair value of warrants	$ —	$ 2,000

~~XML 39 R22.htm IDEA: XBRL DOCUMENT~~

Common Stock Warrants and Options (Tables)

9 Months Ended
Sep. 30, 2024

Class of Warrant or Right [Line Items]

Schedule of Warrant Activity

Stock warrant transactions for the six months ended September 30, 2024 were as follows:

	Nine Months Ended September 30, 2024	
	Number of Warrants	Weighted Average Exercise Price
Warrants outstanding at December 31, 2023	304,962	$ 63.30
Granted	828,800	4.47
Forfeited/cancelled	—	—
Exercised	—	—
Warrants outstanding at September 30, 2024	1,133,762	$ 20.57
Warrants exercisable at September 30, 2024	1,133,762	$ 20.57

Schedule of Options Activity

The following table summarizes stock option transactions for the nine months ended September 30, 2024:

	Nine Months Ended September 30, 2024	
	Number of Options	Weighted Average Exercise Price
Options outstanding at December 31, 2023	126,265	$ 40.15
Granted	—	—
Forfeited/cancelled	(25,001)	14.80
Exercised	—	—
Options outstanding at September 30, 2024	101,264	$ 39.74
Options exercisable at September 30, 2024	101,264	$ 39.74

Schedule of Options Outstanding and Options Exercisable

Options outstanding as of September 30, 2024 are exercisable as follows:

	Stock Options Outstanding and Exercisable as of September 30, 2024		
Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price
$ 10.50	16,666	8.6	$ 10.50

25.50	50,000	8.3	25.50
74.40	34,598	7.8	74.40
	101,264		

Warrants [Member]

Class of Warrant or Right [Line Items]

Schedule of Warrants Outstanding and Exercisable

Warrants outstanding as of September 30, 2024 are exercisable as follows:

	Warrants Outstanding and Exercisable as of September 30, 2024		
Range of Exercise Price	**Number Outstanding**	**Weighted Average Remaining Contractual Life (Years)**	**Weighted Average Exercise Price**
$ 4.35	740,000	4.7	$ 4.35
5.4375	88,800	4.6	5.4375
30.00	216,666	3.8	30.00
37.50	13,000	3.3	37.50
102.00	1,867	0.8	102.00
165.00	65,649	1.4	165.00
206.25	7,780	1.4	206.25
	1,133,762	4.2	20.57

~~XML 40 R23.htm IDEA: XBRL DOCUMENT~~

Organization and Going Concern Analysis (Details Narrative) - USD ($)	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Organization, Consolidation and Presentation of Financial Statements [Abstract]				
Net loss	$ 3,411,000	$ 2,416,000	$ 9,387,000	$ 4,635,000
Net cash used in operating activities			$ 10,436,000	$ 6,805,000

~~XML 41 R24.htm IDEA: XBRL DOCUMENT~~

Schedule of Anti-dilutive Securities (Details) - shares	**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]		
Total anti-dilutive securities	1,235,026	429,561
Share-Based Payment Arrangement, Option [Member]		
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]		
Total anti-dilutive securities	101,264	124,599
Warrant [Member]		
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]		
Total anti-dilutive securities	1,133,762	304,962

~~XML 42 R25.htm IDEA: XBRL DOCUMENT~~

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	**9 Months Ended**					
	Sep. 30, 2024	**Feb. 05, 2024**	**Feb. 02, 2024**	**Dec. 31, 2023**	**Sep. 30, 2023**	**Dec. 31, 2022**
Property, Plant and Equipment [Line Items]						
Cash equivalents	$ 6,200,000			$ 443,000		
Short-term investments				12,893,000		
Warrant liability	$ 182,000			$ 1,052,000	$ 1,053,000	$ 18,000
Revers stock split ratio	On February 2, 2024, the Company effectuated a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30. The Company’s common stock began trading on a reverse stock-split-adjusted basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol “GTBP.”					
Common stock, shares outstanding	2,234,328			1,380,633		
Common stock, shares authorized	250,000,000			250,000,000		
Maximum [Member]						
Property, Plant and Equipment [Line Items]						
Cash, FDIC insured amount	$ 250,000					
Common Stock [Member]						
Property, Plant and Equipment [Line Items]						
Common stock, shares outstanding		1,380,633	41,419,000			

~~XML 43 R26.htm IDEA: XBRL DOCUMENT~~

Schedule of Estimated Fair Value of Financial Instrument (Details) - USD ($)	**9 Months Ended**	**12 Months Ended**
	Sep. 30, 2024	**Dec. 31, 2023**
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]		
Cost		$ 12,845,000
Unrealized gains		48,000
Unrealized losses		
Fair value		12,893,000
Short-Term Investments [Member]		
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]		
Cost		12,845,000
Unrealized gains		48,000
Unrealized losses		
Fair value		$ 12,893,000

~~XML 44 R27.htm IDEA: XBRL DOCUMENT~~

Schedule of Fair Value Hierarchy Financial Assets (Details) - USD ($)	**Sep. 30, 2024**	**Dec. 31, 2023**
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets	$ 6,207,000	$ 13,336,000
Fair Value, Inputs, Level 1 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets	1,220,000	443,000
Fair Value, Inputs, Level 2 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets	4,987,000	12,893,000
Fair Value, Inputs, Level 3 [Member]		

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		
Money Market Funds [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets	1,220,000	443,000
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets	1,220,000	443,000
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		
US Treasury Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets	4,987,000	
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets	4,987,000	
US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		
US Treasuries [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		
US Treasuries [Member] | Fair Value, Inputs, Level 1 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		
US Treasuries [Member] | Fair Value, Inputs, Level 2 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		
US Treasuries [Member] | Fair Value, Inputs, Level 3 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		
US Government Corporations and Agencies Securities [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		12,893,000
US Government Corporations and Agencies Securities [Member] | Fair Value, Inputs, Level 1 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		
US Government Corporations and Agencies Securities [Member] | Fair Value, Inputs, Level 2 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		12,893,000
US Government Corporations and Agencies Securities [Member] | Fair Value, Inputs, Level 3 [Member]		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Total financial assets		

~~*XML 45 R28.htm IDEA: XBRL DOCUMENT*~~

Schedule of Accounts Payable (Details) - USD ($)	**Sep. 30, 2024**		**Dec. 31, 2023**		**Sep. 30, 2023**	**Dec. 31, 2022**
Defined Benefit Plan Disclosure [Line Items]						
Other accounts payable	$ 1,277,000		$ 683,000			
Total accounts payable	2,612,000		4,328,000			
Cytovance Biologics Inc [Member]						
Defined Benefit Plan Disclosure [Line Items]						
Accounts payable to University of Minnesota	638,000	[1]	3,515,000	[1]	$ 3,144,000	$ 2,283,000
Total accounts payable	810,000				$ 1,120,000	
2023 Warrants [Member]						
Defined Benefit Plan Disclosure [Line Items]						
Accounts payable to University of Minnesota	$ 697,000		$ 130,000			

[1] Accounts Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock

~~*XML 46 R29.htm IDEA: XBRL DOCUMENT*~~

Schedule of Accounts Payable to Related Party (Details) - Cytovance Biologics Inc [Member] - USD ($)	**9 Months Ended**		
	Sep. 30, 2024		**Sep. 30, 2023**
Defined Benefit Plan Disclosure [Line Items]			
Beginning balance	$ 3,515,000	[1]	$ 2,283,000
Invoices, net	1,365,000		3,691,000
Payments in cash	(3,432,000)		(1,710,000)
Payments in common stock, at fair value	(810,000)		(1,120,000)
Ending balance	$ 638,000	[1]	$ 3,144,000

[1] Accounts Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock

~~*XML 47 R30.htm IDEA: XBRL DOCUMENT*~~

Schedule of Derivative Liabilities Assumptions (Details)	**3 Months Ended**		**9 Months Ended**		**12 Months Ended**
	Sep. 30, 2024 USD ($) $ / shares	**Sep. 30, 2023 USD ($)**	**Sep. 30, 2024 USD ($) $ / shares**	**Sep. 30, 2023 USD ($)**	**Dec. 31, 2023 USD ($) $ / shares**
Fair Value Measurement Inputs and Valuation Techniques [Line Items]					
Fair value of warrants	$ (95,000)	$ (485,000)	$ (870,000)	$ (4,796,000)	
2023 Warrants [Member]					
Fair Value Measurement Inputs and Valuation Techniques [Line Items]					
Fair value of warrants			182,000		$ 1,051,000
2020 Warrants [Member]					
Fair Value Measurement Inputs and Valuation Techniques [Line Items]					
Fair value of warrants					$ 2,000
Measurement Input, Share Price [Member] | 2023 Warrants [Member]					
Fair Value Measurement Inputs and Valuation Techniques [Line Items]					
Warrants measurement input | $ / shares	2.31		2.31		7.20
Measurement Input, Share Price [Member] | 2020 Warrants [Member]					
Fair Value Measurement Inputs and Valuation Techniques [Line Items]					
Warrants measurement input | $ / shares	2.31		2.31		7.20

Measurement Input, Risk Free Interest Rate [Member] | 2023 Warrants [Member]			
Fair Value Measurement Inputs and Valuation Techniques [Line Items]			
Warrants measurement input	[1] 3.58	3.58	4.6
Measurement Input, Risk Free Interest Rate [Member] | 2020 Warrants [Member]			
Fair Value Measurement Inputs and Valuation Techniques [Line Items]			
Warrants measurement input	[2] 3.98	3.98	5.0
Measurement Input, Price Volatility [Member] | 2023 Warrants [Member]			
Fair Value Measurement Inputs and Valuation Techniques [Line Items]			
Warrants measurement input	[3] 114	114	119.7
Measurement Input, Price Volatility [Member] | 2020 Warrants [Member]			
Fair Value Measurement Inputs and Valuation Techniques [Line Items]			
Warrants measurement input	[4] 114	114	89.0
Measurement Input, Expected Term [Member] | 2023 Warrants [Member]			
Fair Value Measurement Inputs and Valuation Techniques [Line Items]			
Expected life (in years)	[5]		4 years 6 months
Measurement Input, Expected Term [Member] | 2023 Warrants [Member] | Minimum [Member]			
Fair Value Measurement Inputs and Valuation Techniques [Line Items]			
Expected life (in years)	[5] 3 years 3 months	3 years 3 months	
Measurement Input, Expected Term [Member] | 2023 Warrants [Member] | Maximum [Member]			
Fair Value Measurement Inputs and Valuation Techniques [Line Items]			
Expected life (in years)	[5] 3 years 9 months	3 years 9 months	
Measurement Input, Expected Term [Member] | 2020 Warrants [Member]			
Fair Value Measurement Inputs and Valuation Techniques [Line Items]			
Expected life (in years)	[6]		1 year 9 months 18 days
Measurement Input, Expected Term [Member] | 2020 Warrants [Member]			
Fair Value Measurement Inputs and Valuation Techniques [Line Items]			
Expected life (in years)	[6] 9 months 18 days	9 months 18 days	
Measurement Input, Expected Dividend Rate [Member] | 2023 Warrants [Member]			
Fair Value Measurement Inputs and Valuation Techniques [Line Items]			
Warrants measurement input	[7]		
Measurement Input, Expected Dividend Rate [Member] | 2020 Warrants [Member]			
Fair Value Measurement Inputs and Valuation Techniques [Line Items]			
Warrants measurement input	[8]		

[1] Based on rates established by the Federal Reserve Bank
[2] Based on rates established by the Federal Reserve Bank
[3] Historical volatility of the Company’s common stock is used to estimate the future volatility of its common stock
[4] Historical volatility of the Company’s common stock is used to estimate the future volatility of its common stock
[5] Determined by the remaining contractual life of the derivative instrument
[6] Determined by the remaining contractual life of the derivative instrument
[7] Based on no dividends paid or expected to be paid
[8] Based on no dividends paid or expected to be paid

~~***XML 48 R31.htm IDEA: XBRL DOCUMENT***~~

Schedule of Derivative Liability Transactions (Details) - USD ($)	**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**
Warrant Liability		
Beginning balance	$ 1,052,000	$ 18,000
Issuance of warrants at fair value		5,831,000
Change in fair value	(870,000)	(4,796,000)
Extinguishment		
Ending balance	$ 182,000	$ 1,053,000

~~***XML 49 R32.htm IDEA: XBRL DOCUMENT***~~

Warrant Liability (Details Narrative) - USD ($) $ in Millions	**9 Months Ended**	**12 Months Ended**	
	Sep. 30, 2024	**Dec. 31, 2020**	**Jan. 04, 2023**
2023 Common Warrants [Member] | Maximum [Member]			
Warrants to purchase			216,667
2023 Warrants [Member]			
Volatility amount utilized in the value calculation percentage	100.00%		
Warrant fair value	$ 5.8		
2023 Warrants [Member] | Maximum [Member]			
Warrants to purchase			13,000
2020 Warrants [Member]			
Issued warrants of common stock		58,824	

~~***XML 50 R33.htm IDEA: XBRL DOCUMENT***~~

Stockholders’ Equity (Details Narrative) - USD ($)				**3 Months Ended**		**9 Months Ended**		
	May 23, 2024	**Jan. 04, 2023**	**Feb. 16, 2021**	**Sep. 30, 2024**	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**	**Dec. 31, 2023**
Accumulated Other Comprehensive Income (Loss) [Line Items]								
Common stock, shares authorized				250,000,000		250,000,000		250,000,000
Common stock par value				$ 0.001		$ 0.001		$ 0.001
Preferred stock, shares authorized				15,000,000		15,000,000		15,000,000
Preferred stock, par value				$ 0.01		$ 0.01		$ 0.01
Direct offering				2,234,328		2,234,328		1,380,633
Change in fair value of warrant liability				$ (95,000)	$ (485,000)	$ (870,000)	$ (4,796,000)	
Common stock issued for services, value					$ 115,000	$ 1,300,000	$ 430,000	
Series C Preferred Stock [Member]								
Accumulated Other Comprehensive Income (Loss) [Line Items]								
Preferred stock, par value				$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares issued				96,230		96,230		96,230
Preferred stock, shares outstanding				96,230		96,230		96,230
Series K Preferred Stocks [Member]								
Accumulated Other Comprehensive Income (Loss) [Line Items]								
Preferred stock, par value			$ 0.01					
Preferred stock shares designated			115,000					
Convertible shares issuable			100					
Series K Preferred Stock [Member]								
Accumulated Other Comprehensive Income (Loss) [Line Items]								
Preferred stock, shares issued				0		0		0
Preferred stock, shares outstanding				0		0		0
Board Of Directors Employees And Consultants [Member]								
Accumulated Other Comprehensive Income (Loss) [Line Items]								
Common stock issued for services, shares						15,782		
Common stock issued for services, value						$ 430,000		
Common Stock [Member]								

Accumulated Other Comprehensive Income (Loss) [Line Items]				
Common stock issued for services, shares			13,333	15,782
Common stock issued for services, value			$ 1,000	$ 1,000
Preferred stock shares designated				120,000
Common Warrant and Placement Agent Warrant [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Change in fair value of warrant liability		$ 5,800,000		
Purchase Agreement [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Proceeds from private placement	$ 3,200,000	6,500,000		
Other offering expenses	$ 243,000	$ 232,000		
Purchase Agreement [Member] | Pre Funded Warrants [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Warrant exercise price		$ 0.003		
Purchase Agreement [Member] | Common Stock [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Common stock par value	$ 0.001	$ 0.001		
Direct offering	740,000	120,000		
Purchase Agreement [Member] | 2024 Common Warrants [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Purchase of warrants	740,000			
Warrant exercise price	$ 4.35			
Purchase Agreement [Member] | 2024 Placement Agent Warrant [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Purchase of warrants	88,800			
Warrant exercise price	$ 5.4375			
Purchase Agreement [Member] | 2024 Common Shares And 2024 Common Warrants [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Price per share	$ 4.35			
Purchase Agreement [Member] | Prefunded Warrant [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Purchase of warrants		96,667		
Purchase Agreement [Member] | 2023 Common Warrants [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Purchase of warrants		216,667		
Warrant exercise price		$ 30.00		
Purchase Agreement [Member] | 2023 Placement Agent Warrant [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Purchase of warrants		13,000		
Purchase Agreement [Member] | Placement Agent Warrant [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Warrant exercise price		$ 37.50		
Purchase Agreement [Member] | 2023 Common Shares And 2023 Common Warrants [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Price per share		30.00		
Purchase Agreement [Member] | Pre Funded Warrants And 2023 Common Warrants [Member]				
Accumulated Other Comprehensive Income (Loss) [Line Items]				
Price per share		$ 29.997		

~~XML 51 R34.htm IDEA: XBRL DOCUMENT~~

Schedule of Warrant Activity (Details)	**9 Months Ended Sep. 30, 2024 $ / shares shares**
Common Stock Warrants And Options	
Warrants outstanding, beginning balance | shares	304,962
Weighted average exercise price, beginning balance | $ / shares	$ 63.30
Number of warrants, granted | shares	828,800
Weighted average exercise price, granted | $ / shares	$ 4.47
Number of warrants, forfeited/cancelled | shares	
Weighted average exercise price, forfeited/cancelled | $ / shares	
Number of warrants, exercised | shares	
Weighted average exercise price, exercised | $ / shares	
Warrants outstanding, ending balance | shares	1,133,762
Weighted average exercise price, ending balance | $ / shares	$ 20.57
Warrants exercisable, ending balance | shares	1,133,762
Weighted average exercise price, exercisable, ending balance | $ / shares	$ 20.57

~~XML 52 R35.htm IDEA: XBRL DOCUMENT~~

Schedule of Warrants Outstanding and Exercisable (Details) - $ / shares	**9 Months Ended Sep. 30, 2024**	**Dec. 31, 2023**
Class of Warrant or Right [Line Items]		
Number of warrants outstanding	1,133,762	304,962
Warrants [Member]		
Class of Warrant or Right [Line Items]		
Number of warrants outstanding	1,133,762	
Warrants outstanding, weighted average remaining contractual life (years)	4 years 2 months 12 days	
Warrants exercisable, weighted average exercise price	$ 20.57	
Warrants [Member] | Range One [Member]		
Class of Warrant or Right [Line Items]		
Range of exercise price	$ 4.35	
Number of warrants outstanding	740,000	
Warrants outstanding, weighted average remaining contractual life (years)	4 years 8 months 12 days	
Warrants outstanding, weighted average exercise price	$ 4.35	
Warrants [Member] | Range Two [Member]		
Class of Warrant or Right [Line Items]		
Number of warrants outstanding	88,800	
Warrants outstanding, weighted average remaining contractual life (years)	4 years 7 months 6 days	
Range of exercise price	$ 5.4375	
Warrants exercisable, weighted average exercise price	$ 5.4375	
Warrants [Member] | Range Three [Member]		
Class of Warrant or Right [Line Items]		
Number of warrants outstanding	216,666	
Warrants outstanding, weighted average remaining contractual life (years)	3 years 9 months 18 days	
Range of exercise price	$ 30.00	
Warrants exercisable, weighted average exercise price	$ 30.00	

Warrants [Member] | Range Four [Member]	
Class of Warrant or Right [Line Items]	
Number of warrants outstanding	13,000
Warrants outstanding, weighted average remaining contractual life (years)	3 years 3 months 18 days
Range of exercise price	$ 37.50
Warrants exercisable, weighted average exercise price	$ 37.50
Warrants [Member] | Range Five [Member]	
Class of Warrant or Right [Line Items]	
Number of warrants outstanding	1,867
Warrants outstanding, weighted average remaining contractual life (years)	9 months 18 days
Range of exercise price	$ 102.00
Warrants exercisable, weighted average exercise price	$ 102.00
Warrants [Member] | Range Six [Member]	
Class of Warrant or Right [Line Items]	
Number of warrants outstanding	65,649
Warrants outstanding, weighted average remaining contractual life (years)	1 year 4 months 24 days
Range of exercise price	$ 165.00
Warrants exercisable, weighted average exercise price	$ 165.00
Warrants [Member] | Range Seven [Member]	
Class of Warrant or Right [Line Items]	
Number of warrants outstanding	7,780
Warrants outstanding, weighted average remaining contractual life (years)	1 year 4 months 24 days
Range of exercise price	$ 206.25
Warrants exercisable, weighted average exercise price	$ 206.25

~~***XML 53 R36.htm IDEA: XBRL DOCUMENT***~~

Schedule of Options Activity (Details)	**9 Months Ended Sep. 30, 2024 $ / shares shares**
Common Stock Warrants And Options	
Number of options outstanding, beginning | shares	126,265
Weighted-Average Exercise Price, beginning | $ / shares	$ 40.15
Number of options, granted | shares	
Weighted-Average Exercise Price, granted | $ / shares	
Number of options, forfeited/cancelled | shares	(25,001)
Weighted-Average Exercise Price, forfeited/cancelled | $ / shares	$ 14.80
Number of options, exercised | shares	
Weighted-Average Exercise Price, exercised | $ / shares	
Number of options outstanding, ending | shares	101,264
Weighted-Average Exercise Price, ending | $ / shares	$ 39.74
Number of options outstanding exercisable | shares	101,264
Weighted-Average Exercise Price,exercisable, ending | $ / shares	$ 39.74

~~***XML 54 R37.htm IDEA: XBRL DOCUMENT***~~

Schedule of Options Outstanding and Options Exercisable (Details) - $ / shares			**9 Months Ended**	
	May 15, 2023	**Jan. 27, 2023**	**Sep. 30, 2024**	**Dec. 31, 2023**
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]				
Options outstanding			101,264	126,265
Options outstanding, weighted average remaining contractual life (years)	10 years	10 years		
Options outstanding, weighted average exercise price			$ 39.74	$ 40.15
Range One [Member]				
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]				
Range of excercise price			$ 10.50	
Options outstanding			16,666	
Options outstanding, weighted average remaining contractual life (years)			8 years 7 months 6 days	
Options outstanding, weighted average exercise price			$ 10.50	
Range Two [Member]				
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]				
Range of excercise price			$ 25.50	
Options outstanding			50,000	
Options outstanding, weighted average remaining contractual life (years)			8 years 3 months 18 days	
Options outstanding, weighted average exercise price			$ 25.50	
Range Three [Member]				
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]				
Range of excercise price			$ 74.40	
Options outstanding			34,598	
Options outstanding, weighted average remaining contractual life (years)			7 years 9 months 18 days	
Options outstanding, weighted average exercise price			$ 74.40	

~~***XML 55 R38.htm IDEA: XBRL DOCUMENT***~~

Common Stock Warrants and Options (Details Narrative) - USD ($)			**1 Months Ended**	**3 Months Ended**	**9 Months Ended**	
	May 15, 2023	**Jan. 27, 2023**	**Apr. 30, 2022**	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]						
Options outstanding intrinsic value					$ 0	
Awards granted plan						
Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term					8 years 2 months 12 days	
Fair value of vested stock options				$ 433,000	$ 222,000	$ 1,338,000
Purchase an aggregate	16,666	66,667				
Exercise price	$ 10.50	$ 25.50				
Stock options expire	10 years	10 years				
Fair value	150,000	1,400,000				
Omnibus Incentive Plan [Member]						
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]						
Awards granted plan			166,667		39,467	

~~***XML 56 R39.htm IDEA: XBRL DOCUMENT***~~

Commitments and Contingencies (Details Narrative) - USD ($)						**3 Months Ended**		**9 Months Ended**					
	May 20, 2024	**May 13, 2024**	**Jun. 16, 2021**	**Mar. 26, 2021**	**Jul. 18, 2016**	**Sep. 30, 2024**	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**	**Jun. 30, 2024**	**Apr. 25, 2024**	**Dec. 31, 2023**	**Aug. 24, 2022**
Loss Contingencies [Line Items]													
Common stock, shares issued						2,234,328		2,234,328				1,380,633	
Accounts payable, current						$ 2,612,000		$ 2,612,000				$ 4,328,000	
Stock issued during period, value, issued for services							$ 115,000	1,300,000	$ 430,000				
Research and development expense						1,307,000	$	3,868,000	5,109,000				

							1,364,000					
2021 Scientific Research Agreement [Member]												
Loss Contingencies [Line Items]												
Aggregate research and development expense			$ 2,100,000									
Research and development expense								0	192,000			
Unbilled and unaccrued amounts						0		0				
2023 Sponsored Research Agreement [Member]												
Loss Contingencies [Line Items]												
Aggregate research and development expense	$ 1,700,000											
Research and development expense								863,000	0			
Unbilled and unaccrued amounts						$ 862,000		862,000				
2016 Patent Exclusive License Agreement [Member]												
Loss Contingencies [Line Items]												
Research and development expense								145,000	0			
Proceeds from upfront amount		$ 145,000			$ 200,000							
Maintenance fee		100,000			$ 100,000							
Royalty fee percentage					4.00%							
Performance milestone payments		3,100,000			$ 3,100,000							
Sales milestone payments		1,000,000			1,000,000							
Gross sales		250,000,000			250,000,000							
Sales revenue		5,000,000			5,000,000							
Cumulative gross sales		500,000,000			$ 500,000,000							
Royalty expense		250,000										
Royalty expense		2,000,000										
Royalty expense		$ 5,000,000										
2016 Patent Exclusive License Agreement [Member] | Maximum [Member]												
Loss Contingencies [Line Items]												
Royalty fee percentage		5.00%			6.00%							
2016 Patent Exclusive License Agreement [Member] | Minimum [Member]												
Loss Contingencies [Line Items]												
Royalty fee percentage		1.00%										
2016 Patent Exclusive License Agreement [Member] | 2017 through 2020 [Member]												
Loss Contingencies [Line Items]												
Maintenance fee					$ 200,000							
2016 Patent Exclusive License Agreement [Member] | 2022 [Member]												
Loss Contingencies [Line Items]												
Annual royalty payments					250,000							
2016 Patent Exclusive License Agreement [Member] | 2025 [Member]												
Loss Contingencies [Line Items]												
Maintenance fee		$ 50,000										
Annual royalty payments					2,000,000							
2016 Patent Exclusive License Agreement [Member] | 2027 [Member]												
Loss Contingencies [Line Items]												
Annual royalty payments					$ 5,000,000							
2021 Patent License Agreement [Member]												
Loss Contingencies [Line Items]												
Maintenance fee				$ 2,000,000								
Annual royalty payments				250,000								
Performance milestone payments				3,100,000								
Sales milestone payments				1,000,000								
Gross sales				250,000,000								
Sales revenue				5,000,000								
Cumulative gross sales				500,000,000								
Upfront license fee				20,000								
License maintenance fee, receivable				$ 5,000								
2021 Patent License Agreement [Member] | Maximum [Member]												
Loss Contingencies [Line Items]												
Royalty fee percentage				5.00%								
2021 Patent License Agreement [Member] | Minimum [Member]												
Loss Contingencies [Line Items]												
Royalty fee percentage				2.50%								
Cytovance Biologics Inc [Member]												
Loss Contingencies [Line Items]												
Research and development expenses								1,365,000	3,691,000			
Cash payments								$ 3,432,000	$ 1,710,000			
Common stock, shares issued						127,597	57,437	127,597	57,437			
Accounts payable, current						$ 810,000	$ 1,120,000	$ 810,000	$ 1,120,000			
Cytovance Biologics Inc [Member] | Research and Development Expense [Member]												
Loss Contingencies [Line Items]												
Research and development expenses								$ 1,365,000	$ 3,691,000			
Cytovance Biologics Inc [Member]												
Loss Contingencies [Line Items]												
Equity method investment, ownership percentage										5.00%	9.90%	4.90%

~~XML 57 R40.htm IDEA: XBRL DOCUMENT~~

Subsequent Events (Details Narrative) - USD ($)				9 Months Ended
	Oct. 17, 2024	May 15, 2023	Jan. 27, 2023	Sep. 30, 2024
Subsequent Event [Line Items]				
Stock options granted				
Stock options exercisable price per share				
Stock options expire		10 years	10 years	
Subsequent Event [Member] | Officer [Member]				
Subsequent Event [Line Items]				
Stock options granted	23,335			
Stock options exercisable price per share	$ 2.11			
Stock options expire	10 years			

Stock options vest years	3 years
Stock option vested value	$ 45,000

```
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /"!;ED'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM
M;$V./0L",!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD) ^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I( !47BK9.7;=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+
P04 M " #P@6Y9G(VFP.X K @ $0 &108U!R;W!S+V-O&ULS9+! M3L,P#(?(!?>>NLD&Z@ACZ+98@32$A, G&+$P@+:-HH,6KWIJ1AZX3@ 3C&_O/Y ML^36!&F&B,]Q"!C)8;J9?-
M&$Y3U\(5,,,(HT_?!;0+L53_Q)8.L'-R2FY)C>-8CZN2RSMP>'MZ?"GK5JY/ MI'N#^5=RDDX!-^PR^76UO=\],"4:L:XXK_AZ)[CDMU*(]GUA]]5V _6[=T_ M-KX(JA9^W87Z E!+ P04 "
#P@6Y9F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOVI;
[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIA]4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-
*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&XMGUMAVC2/'K^!F!F<-0HACA*FNVB<5@$_9Y>PTG!Z(+[+9OVX?L<VPLCO='U!=*Y \FIS_L,C0' MHYI9";V$5FJ?]H,@H%\;D>/N5Z>
HWEL:\4*Z*>P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^]VE+ZU)CA* M]+'.
<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8.8S\# MAWE[7YAGE<90-
!1M;*PD+$;W8(<7?2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;]\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E,^=?]%U#KG[VW>/Z;L[2$R<><41-71% B.5' 86%S+D4.Z2 MD 83
>LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-;/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M/";EEO$*]Z04 +T? 8 >&PO=V]R:W-H965T&UL
MM9GA;^(V&,_WU]AL6G:I-+$#K3E1!%HKNVAV?6XPC;=IGUP?P6I0$C:T7]@O'Q M]PF(H8K%;?%)DBKN%4B+ZPE$QB!HF^C:P>HM-)EF$6E;'"-6#W@$*ISKN#9X!<*!&GJY%E=AF
[N2@*+6;;%U;$@[@S&N;?3=5H*-('D8C30,9$B<5U M9TS?NHZ3"?I(_@C$-CTX)AG*DY1?LY.)?|VQLQ*)4'@ZL^#P;R-<$8:9$Y3C MWYUI[_S-
3'AXO'>_R^$!YHFGPI7AGX&O5]>=JP[QQ8*O0_THM^_%#]B?^7DR M3/._9%OY8G=4'$8+_+7?3T?[E7;?]BL(>!5"7AU M&N!4]$#ZV;N3P-O;^,CA3N7,LO9UB>H;
<@Y*SL%IG'=!ZO%PCWL'7QN'&MSM MLV/B0S4-^A=C9[V_R+\[KBJYSMB5>N*PIXT%"H&BQW+52KQ&Q'GO\$KHME MK.M0(RB]; K**E"&ENPVUH%^ \!'L0RR. -M^L
C33]/WX\>/XS,R>7#/C,1M9!E:A1F* MQY$=K0M]5T&_G4! ?2;_B1K8_(!_@/O(I-G/B ME@[MYU.WI8P$U!9<@BFD$;V-I$2K]$3QA(.BS[?2B(Y;4ENO8#H@I>G1<'%Q
M4]X],E$\Y;SF=;,SZ-9SN8V-K+C=C,?D#E[U'@S>IKIR<7U#7%8%*(9GGM>X MY6,\57(3Q)ZQ:Q_Q=,?&=8,V4A2K4A3#8\]KT*E,-8Q*?P5)[9O]B..@1VWS
M"DD;,8I5,8KA"2COL6,E>#T8;M"C?2-6&^&)5>&)X9GG@\RG,"L98^GPB,F M#B =[FPC7QMQB55QB>$99QYHR+UR02C[^>D7,A/>6D%+&B%Q\U=&D8S?$/C, MM/2^GI$?[7,
(4"2!F<.&AVM!$]&*)4=C1;21IUB5IQ@>?N:*^T&\)+.7Z$F& M1G[C8TK?;BP*6$5 MD]A),6D_82W6C/*FA%'%/"4_XOC%N";NXJ]FG%4F8B=EHDFLA2KV0;+).-^# M&SEQQSK.-
K(0][(0.RD+91-RR/40#)92F5](N,^#C+O<\P38@(E?&!IYVPA# M3A6&G)/"T"SB84ANUBE<3HV]]HA/W:(N+FN*5T4@YZ0(=_L3CF7V5-Z# R1Q M&"X2'AO;]8AA]>
(NKFL*6B4@YZ2%I-E*0#MB>+A-/5X;2<@YV!(I:1FI&.;W M0_PLWT DG]8:YSNR5G5]L;']D6>=-R6A6(#4/K^$7U?%7G%QHF62 M;[<^2:UEE!^N!/>%RFZ ZPLH]?
XD^X%RQW[T'U!+ P04 " #P@6Y9QQ81 MM3$% G% & 'AL+W=O+U[LV9.0W]2:,8U^Y%FA3@=KKJE(RFM5*>C8CG1:.<\F(PG]7O;N1\)BJ=\8+=2*2J/*?RYQG+Q-/I ^>
M7]SRQ[4V+T;S64D?6#CR#B&4LT<8$A9\-6[(L,Y8 Q_?&Z*"=TRCNCY^M_U:3 M!S(/5+&ER+[R5*]/!Y,!2MF*5IF^%4]?6$,H-/82D:GZ/WI]9+T!2BJE1=XH M X*<%]M?^]-
QQ)X"#GH42*-7]O@-PI^372+K*9U3C6=SZ1X0M)(@S4S]'U3 M;P,;7IAEC+6$KQST]'PIBA06A:4(1DID/*4:'LYH1HN$H=@85N@(W/
MO\Y&&B8U]J.DF>!L.P'IF2!FY3'RO2$B'@DLZDNW^CE+0#W7ZOZA^@BHMGQ) MRY?4]OP^OI64K-^2V^H%=WT35B2IIPDX'$#:*R0T;S#][P)'WV4;N
MG8P=4/5;]K[+^GQ)U1K1(D6)&;#O%=_0#+A;66]-1;4!$_]:>13@B>=YL]%F MGU!7#GOCZ;[<=:@Q1HXL=XRI25/S-8S:&T(MP;"O9FG?A>?*\+IFDFA>/*&-0?Y
TA>9(K(X]>*A=:T/M MM/F&;3/IL K[]\RTI31UN_[Z;G&%%G%\<1?;P$]?Z?*N'ZPUY]=L+>K)_X?N\HWY:<3MMOB%L&T,'<>MP_J[L8G?=_4]EI'MQ86?1+;UX8MLC%CDO
M)/TP=]45N\OK86Z_>B&(NZ4QB"(;W]Y@%/G]Z1#O:BB.G.DFUB+YMA99KJ]3Z M]&%"\/@SNH &K,>_SHK\YJSS3M8.J>^J,';783A&;)C4'[.@EYBQ6#-4]2, M0X.0B22"
W[$%7C\,AN-O\(;6FTK0;E89>BO\+2C&3L,1H"<>/:30D M?BO#E3(9H^Y,*JTT#$Q 4@T]I6;Y S0KST>.6@I.$=PQK5ZS;B-A%Z_W^ S."L80G]NR>.A/_&&
ML+%?'NSV&K8@[$HY/+CK2+"[)5FD*3?W!) VZG:6%W"P*#FD$2M4 M2X9?4)/&4KGG!K+]A8V8=P%$UQ M$%K<:Y6%Y!WUUT2RZS"(N\/8IN6W)3MBZ3B\Z=B"O"LX#L;]_3?
9NP)P=QS;M=O7]75Y=WD1H\6?YRB^NU[^_N7ZZOSB-FYL_'5_>?>/E0;I'IBM/:U% ML*>I'>W=XI@KM*^H?.2%@CYC!:K>1A<(;>W4ML+KAF%);! M",#WE1#Z^<'<%;5W@_/_
%!+ P04 " #P@6Y9MF*?X?0" "7"@ & M 'AL+W=O+ G00 M::6:MHM*]&C;Q;0+DQR(52?.; /=?OUL)TT3"!"JBR'3#U9,9YBJ;I\;8N< XZ-**6VYSB!G6*2 M6>'$WOS<,
(VD[,YAR)39IB_O<&*-M-+==ZNG%/UHG4-^QPDN,U+$!^S^=< M]>S*)28I9(*P#"%83:W/IO7,-0(3\8/ 3M3:2*>R9.Q!=[[%4\O11$ ADMH" M]\L69D"I=E(!7PI
MDVA!9M*ZQ1*'$\YVB.MHY:8;IC9&K;(AF7Z-"\G54Z)T,IRQ+%8O!6*D6H)1 M$F.I.C>8XBP"M-#& KV?8PZ93$"2"-,/Z"-ZBVPD$G573&RI.+2;'95CWA1C M>D?&7$#>0[YSA3S'Z[?
(9Z?EMQ IN6OD?E-N]^RK$GA5"3SCUS_B-U=V-MZ F>"&IA^A>E?AEF4'^&- M3!@G_R!NPRT\!S42=^"8WQYRA| &=K_'[J_$GK$T5=.U2VD+HU&S:@>U/1?5
MH!Q4E(,+*#M5=G!0,*LV'YINT0Y](.*.KBPSC7 M'SF![I#3#BO:X>6T:F<1$#F:INN^"/C,;"A=MSU*?"RNH[=J01_9[C!?DTP@"BNEC,4% !:& & M
'AL+W=O='BY]Y\]2+#,L\]]7[1:B<%.R&>U M8DR3ESPKU%UGI?7ZUG'4?,5RJF[$FA7PS4+(G&H8RJ6CUI+1M!3*,\=WW=C) M*2\ZPT'Y[E$.!V*C,UZP1TG4)L^I?
+UGF=C==;S.VXLO?+G2YH4S'*SIDDV9 M?EH_2A@Y#40^VV*N\\FJG7@(U B_N)LIPZ>B3>EJ2L3S&3RD=QW7 MS(AE;*X-!86/+1NO+#-,(^_;]).H],('CZ_L?]
<&@_&S*AB(Y%]Y:E>W75Z M'9*R!=UD^HO8_9*O^378UU.V2^45KDM3#,(.=%]4E?:D<<" / M+N#7 OZI0'A&(*@%@O=]"&N!\+T:HE]@--VI;"\=-Z:#@=2[(@T:& S#Z7W
M2VGP%R],HDRUA&\YR.GA2!0IA)VE!)Z4R'A*-0RF&CX@'[0B8D'^6#-)35P5 M^?!4T$W* ?.17).GZ9A\N/HX<#1,Q1 Z\UKM?:76/Z,V()%H5>*3$!]BLB/ MV^7[+?
(.N*#O@__FAWN_E7#*UC(!9L[_TS[Y;NU'S@B: MI A*ON .7QWO8DDF+VN3'>H6"W%%$N(DI+=JC6=L[L.E##%Y)9UAC_^X,7N M3YA_+TDVOB39Y$)D1Y$(FTB$;>S#+\!
(Y7Q%:)%"_=M"85^;98F%HV**2R:S M/VR'7N FKNL.G.VAIS%<'%]XL8T+>G'/PDUL7.2Y_4/E18WK4.OH4-@](
MP2Y9L@+2,2M=0%.H@5QIDYY;1C[P8IY!.8),O7)+P%44)EW03192Y 3*Y_R9 MS$5NLKBL8&0I:6$]G!90V19\S]3]DI1+V+B$>30D+%]GXI4Q58Y@-R8FKH!5
MY4"O&/Q)QDA>%2%FBA"!50@U<\9DLY)+<;,FN["GJC4K-\7LM5)RY?M^.=-R MX'63N)YXK:$ ?WRG K0@5]Z.#L+D^WTD/6RFQV]"J2K(^]T),SNVU%\'L6NG^P@#>KYO&XX
/3=V/=MT%!FZO;/& M)XWQ27N!A@21Y*& S(9%4!=I-.K)6OT)0/65 NR99F&V;Z[AV5 M9&K&\RG-7'WC@XD7BMWO@%
MCK<$=FKV8EK0#5?"LEHQO^!OF)9.SRG\IEI.LL8]#OSC>2:,W1/K:F^A62<38*RS<;A>RD M""IL67G[@X[7VKT/_Q0:.LO#[;1+?F=XD@7V1/MVW1TAN,1%RCC&YWMV8S)!
M@%&2M%B_/UQX[:<+L)28/@HUUV[KKX/0LV.SPI^B.U<&+(?].PF=((APSB(_MSAN]/U9X]>>*-Z/)(1\N]*2D6MR3Q6?HVZHR)*C'NXF"DY]@,*2Y-0!""RZ
M\7NGUB.PX"9,SIB^;YF]]IX9-7W,LXU&[V#N:[K_-!Z%V<8C,;QX!-9B_+YMA99KJ]3Z M]&%"\/@SNH &K?'7\LX0RAW=OQEMM8[7"(LKX01&QUK@T M7Z=FC! @'+,3WXU/W8(_$UC?
7G#]&(PQB*/^.:?0/KM7>PW^2:M"5?D X6 M=XX-/.,_'YN*\]O)O=TU>W[I^I7/)"D8PM0)5[D\]L976170VT6) ,C$G< @ .@@ !@ M !X;"]W;KUWIL0(W'!9LB7,TM\5,
MT8:ZYS$%A,G(NNH-I8/5+A6]<-WIG#?8F"RE_V.1XUB$4&!G+ MP.BSQC$*88G(C=\UI].8M,#=]9;]4WEWNLN";1O+]9W'}ATY[QV(,6$K86[D
MY@O6]SFS?)$4NOR%3:WK.1"MM)%9#28/,IY77W97QV$'0#SM +\&^$\]P3. M7@WHO=1"4 ."EUHXJP'EU=WJ[F7@)LRP<*CD!I35)C:[**-?HBE>/+=U,C>*
M3CGA3#B6>4Q9QQAHI:7@,3.TF1OZ4#D8#3*!ZP(5LWG5<'2;LU7,2><8CF9, MD4]*AD=,',,)W,XG.@;L$GMM'&\+![^^"!*<7R9?GX.X!55MO2 M4S'W2V8[C=:A-W37NS'?
US@+SCWOB=ID?\RW_3VUZ,Y;]|S_B*X*@;O3##-4 MRW(*:8CD*C=5R3?29M!=E/W]B?RR.QAW6^03&HS5"N@KZ,]%5-+3DU28$*F MO--
SZM6JFE35QLBB;,4+::BQE\N4ACL]]T#GB91FN[$&FK\+X5]02P,$% M @ \(%N6<&'!-OP" ?$@ !@ !X;"]W;KUW)K@R3 WB:9Z1HT;]],W\MLNNV'3C\HMA(SB\$%
MG.S^^RY.T7GY+G357_8G9WLQ//\D%6GW7WA3J: M'5'6R59P99)G3B&?;B<_>^\Y8W6@N*W1+Z6%>^=E0>\_Q+??!Q?3MQZO])
M5*Z]&D*H'R]R*=.T1E+]^^L*%G1QSU@U//[^A\^;DUQJ0M@$Y;T!Z&M"V 3UK0(,>!]QMP,XSA#T-_+-!?]; HST-@K9!T-3^ M4*RFTI&HQ-U-D;\Z11VMT.H/#5U-:U7@)*M'UD-
5]+\FJEUUM\RSM1HG)FM1]8.'2OU0 Z@]G?Q)'>6K+YL\7KM@,?#AT@/1VX5R-)%D634V5Q_OA%;A]E\2> MM+0C+?/M5HW5BS"1'>;GM3HI->A%ZMR+9#U-
,FK.98OU(/3E23OH5ZH#HG_1E$1!Z?BLSRG,7;LCF9^6R]^^ M+PO=V(E;R?]NE+*XD5.[K]AQ>X/T%C%.(X%IO+ C+\S*RW_5)3?-RO*[ MO4[4EW"\6FR0<"(DG)@9(V;* N];DV%
H%9T_UATWUKTCV6Y;Q8,=458'=;: M=EI4N5/*[DJE\R*S=5XX_%-/*82HL>:8P0]2#B1;U0K=,UE*T9*QR^FTZ@) MCM0$R-2\+6D01=9<(Y>)96":0VMM"*1%,Z+ M2/<-L2^RK&_-
RN;^)M_5]R@@?5;,$3,,"2<*S4L=I7-SBB'EXY?S:63,CV3, MKYQC2M\Y=8>2%3R?K+@C")D/N;^:&V?/R,(L-E*?.)".NKVU7AQKO4"HM6T-
ML^*/7<,6YHCRPSDY]SQFRA@3C".!:51Z;]);:I9<<>.[=:-&UR M$5,-1]A98U0TCH6FL]GI>,\NY*'5LKE)]!=+^546JZ1L_JBR/^VSM;])>!5% M(;(*YM>:;I
MHOZ=SVE4=P.5C6.AZ31W!H=G=S@^9DF5B=0IY"I_SAI#LB;U25,$[2QVTD0\ M)FE2?0.9Q3)$\ B#W H_#D%5#=62CXDIP3$UEWLMX^\SJ3P["X%X*9> MKICI'T!V*A#F*-52G
16-8Z'I]'1F@V=W&TX&\G_VV05:PD$#>4A4 MY)F"/9C/&8-NKV'8'[$W'7 V1@"(LH-@S;8HI8;]] MYM08$*EO*79BG]C%/LXF@3W)");P@"B:G'/@S8ML<3_Y80Z0YWV)W;MC[M7
M8$\V5C<0R P(&#O?0T;U E#1.!:.SN]GK]="[ANR\ ..F:^84G^%D@WELW; MU1@K(;^<4&>D$^QDO& ?MF]@!Q[#"AWT9 ;P3(+'@)(C=8N#"?N%!NG$,[D@
MGO_V]H$]P>AES52?'J6&-D%-&J.B<2PTG>P%.9!,\D4T&B6P@"A#99+C(!D)[ M1380:Q?9!/!9!%|DDV$B&PB#1,;!BZ,'.JK(QD+3Z>E$-ADLLD^?)(-I&22R M!T5%!!+9"Y]"6]-
Z#28$S< GC4"8D,66H1$]I'):(U]N6##-#80UC..434V M*AK'0M/IZ30VN5YCVVN.6_!TMA80#$!E/."0O;3D$C]F=1.8]/Q&KNYPQ=9 MM[/7W.JL1+D!GU"%TML9*R&_G%!G]%/Q
M%/L- NL$O.*9?,L$!"0Y"?W%^9/J]%EC5#2.A:;3VUD/U&X]7.<]VT"3#@D MH(B:/@!V9V&"T\9P04S M70!H' -A\#BV=W'L.$9%XUAH.CV=6\#L;H'U"60L%P +*,("BIFY3SZES(-F
MQH!(O?:=CF>#WLL?M+2S(9Q?R *6D/,J-XUQ SMO1:"R2W70G;RGKQ=@S\U[S M+62F_/7$#.L9PU!W=9&1>-ß =Z9B??PU)_+||OHGA.LM))Y9."=]^%JEC%
MX:MN#@=5OFN^FN4QKZ\VWS<2+&611V@_OZ4Y]7;0?UM+\.8QO29SF5XTEYZN+5BL/EC0A M^5>VHJGX9[EJ6(WW"_?18LGEA=;PM+4H8)33-(Y:B
MC,ZO&B/KPK>5@[+X$=&7?.<8R5MY8NRG/)F$5XVV!&-:< E!!'_GNF8QK%$ M$QWXNP!M;-N4CKO'[^B^NGEQ,T\DIV,6_QF%%?'G5Z#=02.=D'?-[]O('+6ZH M(_$"%N?
J+WK9V/:Z#12L<\Z2PEGT((G2S7_R6@S$CH/ T3O@P@'O.S@".S" MP?YL"T[AX'RVA4[AT-EW.'33W<*A]\9^_UAJ]%W"R? R8R\HD]8"31XHNI2W M&. HE4_6C&?
BUTCX\>&8I.%X3FB(Q%'.XB@D?7)S,N@G'B>(S9'8Y(OD2\> MPAR=:9D'4;*YAPUT>,16>_GE^VN.B*.?)1(D/YH/ M-?ZNV7_PD;]O]K>P : EQG [D/A]
(*^Q$7%&5U^1W?Z"P/Y'_ _7.&_/O;&W1[Y]V/ M'B;3;V@T?Ic@T@F@Q,O)GNF=N@.GI4F.O\A4)Z%%$%).&<9L^T,?SM%%O;_EW' M%R28"PGF08+Y0& 5GITMSXX)?
3@5,V?,\ES'Y<:S]SSE]/@\;-J.9;7;[ '9"@GF08#X06.5QZ&X?AZXQE&:MW)!N, M JJ--2/TL61@KDG@"$=SQN:"NBS_ M@L)(!#IG\I"D(:+)*F9O5,^]L;EC684$9 ML<;,Z=?
M7(V=FM[VQU6'UQ049TS?>.LG#NQ@.[ #X\! ^(W*Z2A)E=/5.L]7 MN&ULC^N0K*?E).G6 9;L:Y4
ML:CERMC"T5Q!HKD%6F42T5!5MVHZ=4I]]+Y5N<(E5]B+\E91E>\5\BJ&5#GP M/MD<*NH+>"BB(-%<4#0/%,V'0JO27JHAEG$1+N653.5.P;MH8$4B4?F]R@+Q
M0#R"ZB"@:&Z!5HDT]^MH0K)NJ%G4^U"]]U)3"AB66<&8I 4U9^\DG4N62!'P MM5R9K\B;2J R.L7%;$T_H Y(4BBH@T1S"[0*==C637QU0\O1%>Y0_ ;N25RHH
MEG%%/JQRME^H&"MW._+1/($*) 5:M42L%QZ>JY7X;Y4+VKLE0*&Y99V9 B MH7H"\5AH6+=;HD9;#4O#+$:BL 8KF6G5!HFFU;N>X3R=:;??ULB14%VL$EY
M%U;O*-5^,OWAS3ZAVEN@0@4HF@N*YH&B^5!H5;I+X<,R*Q\S(N:UL[MU%BQ5 M"A4K\RA]HH4FK24:2$\HB(9$XY"D3R?WM!9D47/T421]8DT"]0D%*Q!HKE670TYQ)I&-SG
VO^A MG.!2.<'MH[*H/YF.IN,/LR@&%4Q T5Q0-\4S8="]J)=RB_8++^(V PH#7,T MSUB"HCQ?DS10"G+ DH2E*%>O!>3ZH9"4]R_RM9[V$0#584#17%Q76/"@IREW M-(9=W-
7H9E#]]Q)7:C'8N.C79U<_2@5]'^=4,_;13($*,07:)YBJ&QY@ZO^0 M3W IGV"S?"*9.K!.5P3*V%('WM_KZ%E4-6DAI]V+^3&+ KD?2OZN)1)4:@%% MDXMF9NU!@V[3:NBS(^5
>K3)9]"S:K+4?1A0A'UW01I:F,1Y%0[V@6 M,=U>L6MSLT>S"%*8[V8TN>--"S6"#3O=GF8]C^O[6_8-]_R4@@HV"RI'\^.) MRV9F.K6=<CNZ74
:0]QUZLG(Q7750XOH:0RUB+ZFZ7V&JN-92A^X:ZP%9X]W M=!^]&V_Z,/J.W,EL_/UV]GCOS="MC[9UHEAG^[?W-Z.'R>U4]_IC4!T$%,T% M1?-T7PHM"KYI9R"S?M!)BFG E=?
Z8%*)]!H[BEHVC?=4$ ^U/U5B2R%$FP6 M2D3MP1**.'D]4 R"RB*@..XI:'HR@8!\J/NKDEF**GAPWDZ;*BWO*)]3 M]_,K>%"A!13-!47S0-
%\*+3]5O52L+'-6UTF]5CFD5CMP%W(8]%H%S7-"=O! MS T=O7\=5,(Y4V;"&S-YIF^7;^_?*C*5VDMA1G;+,SX%?X]B8H4:401RQDB
MZ)FF(X6SSW=KFA+.5^L[JB7'.$G6XI"2DF300O\9X^\GLH'MUX/# M?P%02P,$% @ \(%N6>@S#SE3" EQ0 !@ !X;"]W;KUW)K\/-$TS;=S8N]V9 MG?T D5;STX5.LB9+ZTE@7
M3P9U2NVK\3B6-34ZCGQ+#D_F/C0ZX38LQK$-I"O9U-CQ].#@^;C1Q@U.CV7M M*IP>^RY9X^@JJ-@UC0ZK<[)^>3*8#-8+'\VB3KPP/CUN]8*N*?VUO0]X&V]0
M*M.0B\8]%6A^,CB;O#H_9'D1^)NA9=RY5FS)S/M/?/.N.ADAS\4@66!AI?B*FR&]H9QT&Y3@%;M#?:ETP]AH9WYM]XN$WM2#T]&*KIP?3P$;RG&\N?"M[3;[|'\R 9';TVU=
<15H$@NY04_5S\9IUUI MM%776"00,T7UCI-93 '4^N<*^#V4%@Q]!]ZO]FT]43-3WW[V83B:OU3<>?E?NI].B]*U ->Y5
MP*ZHI!A]8.^_O5'GQK>U1B8.U3M7M6ET0OG8S*E8NK+ZFBHECH]XS9 %6Y4 M]DE%CAI#76AK4,VOE-78E))'<[6-F8K&.97'(*HLW,NR@EC]LDI4UNIZ M=#;:U;G8U?
G#W]]=W\7K,:#?+YU=]!'@$0@3?+6]TDB+5 M8,OOG0X PQD"9%([I"4NS6IR\.3WH00$CYLH-)P>O'Y[ZRLG[AA^HFF/=OD/]' MAZ^'XGZ/4X$1=(5&C":MD
J<;Z8DU2_L20R$KFU)TXXH3X\]WGCN9 ]QU0% M>M$&M/>05HRT8R/KN&_;KL,5].95B2*UA\AL3 1P@BKZ#<59RMD5L]M^B= MC2OE/$-
Q5)O9^\#BX0/8!U!.8[&58'!OFKIGF@G BBW)%*!J;RL*,<>B-UK! M8]W*/C,XMQ>D9FO?KM.K5WFEYA]M&6KY7%XJNL6$TW),R+GC&V0@]XMU?8,> MSD-(F:;I'#U!.?
2(_(HUK;HRQ8+'"P%D0K'^P5#*"J,34>,*ZFSD*U'MC+;ST MQBV@8%_[#FQTR<&X*'OK[ALH,9-QKE(;'?=O>KUNK$HQX"*H%"45[."2KX+Z M!&/X*#TSUB23R:15"Q_#]1M%_=*!
(*D+T.]3MK_&SZ!?5#(S<_CG)7*AYT M)>:$+OLX\UF=TUEEN}_[A4FTGS8%PRXF6]FB=#6H-HLV(^)>R5C.%=<3P MRXBIUFDWX5?FK95D,]XCR,&DA6A79NV$]1OIRL-
NYU,^@U=Z#K&7*E%*,B. M;]".ZX:V)"ZM==ZY#DHEVP/8RP?@V^D^+_Q>-]=+@A"Q&2*M&>VM@S*-ED? M(XZ-Z)3$]1+-2D8K"#07SCS>A_[2"R:_-=BXQJ-"5\P4I&=0=]XA?
C12/Z," M^_#)9U?#(MU3)?N^[R:]-H@-T*1[J+:;620!:P'RW3(/Q2CF#2-SPFP^8#EUX8./L-G?: M"5=6'\?%;M!W]<.5A^5K)E6$*H!>)/RSV>1/D%SL1"M)9<9!I^0Q:N]9.
M+FL#$K,4-5SD>@R\$N3#R8L8C':E^9,VF>!5K=IG>H?VP"CY(1YH M%*?V44FY[*^9GJT(HNI!Z.Ð'$,)QSTMN:1[N"*X;M)F(K;(Sg]@ MH&TDM7JJP#$M^3OO73FI-
J&SX]=MN!E_.LVS BL/9\*<#R3WDV2)S>]@[B;B;4+VG#,8H14ID5VE;]ɑ-YTBR&*@]7**QC MS=;'8HD$R2SCK$+*Q(XUYM8E*F=@(S?SSN6(LM=*TT]$+8\9\ C\]K'0>962% M84BJN-
3):FW^G]#.>*[BRD>5,#!(1Y:L]Y)+@0D7'W2V0]R%V-IED4KV_9E M:N,RR=&2&T<6YF%^A)E6\+A#W>V9FR[X".1PKR[H,F6>-BH0>\5C)KH=#7G" M1K31H]5-
^(8S$8.N>)PY7!E8!I)#0#=,6*Z20]8UH;.HR16X&+D"Z_D<76\? M_XIU-G.CE:F4N\66]I)4UKO%%$W;"#DT=4=4/P1S6/8FR)<9(]?N.,-[Y6"3O MB!&PO=V]R:W-H965T&ULK5M=
+]LXLGWG:K!\]I[!2K6A^,XGU6.V:U"#QF[R@HE9C$&@:CBBI*VA^EKGW,DKUHM_M=#;:U;G8U?@Y*
[IR6Q2#:#1'2?]MV@7^Y,||VNE6K%S:;]|;NC==MNGY^+,TS4;V+59G=AMHV3)DS;5R70\/CO92%T?O7]SZZ:UR]-UU;Z5E>-L-UF
M(YO]&U69W:NCR5%X%FOUBT]&'G]M=C;Y6=!%L9]HU\^E*^.Q]20]E3D@2) Z[5I:HJ$@$0U MOGN91W%)FIC^*2_Y]UC+PMIU:6I_M!ENWYU='XD2K647=5^-KN_*;^?)R2O
M,)7E?7]7.C3V8!GFGI5X&'J#EUP-$QZTJ&<2*1&5MT*?H"TUY(/#0IQ_K&)8=4^RM![.K+:ZWD7K']R;FB+ZSU.2FB/KJIOYD(.$TA6DU^(@K&&KX&=&BY:
T=:OKE;@RE2TLB]/6]Q'LTX*+_N-DSV]1_8S\=!4[=J*=W6IRL/Y}] S*CL- MRKZ9/BAPKK8C,1OG8C]>GCX@;Q8W/V-YLWOD#>Q2_/-B8=L&SO*OH0T[>:?# M\BB
GMNM+-2K(T2(5$7"ZE:Z"*Q+/-!UH;<5!N'UI.DMYI3N_9>U MR@H#7ZFM*D41W^&7I.XEYLE*6 A30(76"DB]NE*)=JT0W:P%2Z7?+\]UF*^L] MKZGQ>+P8J5HW$"=![M?4;IH/Z6K-
"}-F4I'\P4F\-[-LTM+=1=]F: M%CD@UQF Y>PX]\KZH-6F\QO'VKM+Q-4B:W+7_=E!?(T8V68C7@"@%=UNIO6=+W?V$]KW&C]E+EL79K.HP&N[IH(;
.K;'/J%(.78/-!UH;<5![T+Y+RPR!AB1|70FM.Z+&Y$@R+&EYA8/QGWT*IM
```

&@*B,))BMKNE@\'(C:Y N&IY' (U(TP/%SSB#/S$!;Q>R M_#?(BWM>8[_64NIH3;:4ND$P;%UB&#S87OC66!TC"S- M7AGX*2-#_9PU,%[M\4;:TA)A).9'X(?(!^204U=S]F?TQ#+2!R^$
4H:L@S &E$] MPL$_I(SWNZ"+W^RA?.B2!Z<)K'JO(#9R&]*]+@*'8*TH.];MUOV+[E< MPLR\:X>.<'JYB;D8XY4/[TK+A:YZ0.Y!D@;2&6!3M/)]<]PJY(!XN^%$KS,
M@CHB4:=1UZKNO +J9DNNC4CK^&S[/7#VXL,C@[<=NX [\((!K]38=A-"T]C$ M3*.4'66]]0);Z4T<'.X?1 [D+-$IVCV.!7$(B$9X-E##C=C"C3$&6B7VR0 . MIK...!E$R%G87(@]
<2VKC@W(KYS#'8BA =&-R#%:6\@;V>S&X$*%-C;MC'8+)?Q-EH*DY/ M9_EX/$:F"_Z8]2RM5$!34%.7C]U\T#FR5%'A#-F]PP%K-DYO?V]7^#3;%90$ MS,L"-/^(L_>192EALT"[W68S"
)-N.*/?1D)HHR&)H8 T6'26 M[&9'!SY,B%](Y!#"HS:-Q,@\NMH%#]4)4S$#72$K\>%F $I"]HAIGA/]G#,F M('F0M^YS2#)72E8R(BNY]]/^K Z#[Y:W'KIE<-25N59-S7D&SE<7?
^JO8S&9 MCIY1VFU1'5"2(001%UQEWE4!/R@"UQ3.WFW))IZZ=:QP-NDYHYL(GC.;SS93Z""T%:W760^:U51YL68 E4LED20,O[B M 8!5M^1:&+$"R'$@1Y^R_A@]GO(!N_CH
|)UL>G65+FHU:K2RR(MJMG0NJ&*>G\Q?Q/+J,'QEZ;LD2-,NYCWQ=?Y='P\&?=\A-(<8SAZJICC %2U?B M'S0EFXC? W&P'I6Q(F*'B39^^]X9KE ;)@HZ=&1]
(G/.!JF]YK9*.#;*UB28NP8+K+U,T*.HF#T=5!-![4Z5(46MGJC*U2)@\OF=W4/2CL.[.B\ MWU!.LPV5L1BX[5J;Q4%F042)'8:(GJ0304PWC5F8QD')/AT$>)%.O6X!\&;.
M5^W=R73(8XR^_J@&-0]FF V:P:G7[Z&K^[5SK+GUR69!-*MMG=:U"=2#MQN2 M;11BD]X@CN/0B[*'E>4.(+(DI[.$M@]5B<["?> ,QWGNNB"!S]';VP0K=ZE, MW$YEN2NI=%
(HT'2W[FT:$ON/6[EWYF/&KOK)>9K3:$>P26\8G(HJ)/$4OUVG MDV>Q^RQA+!'@!NUUG[EV&$9'$FS#?=Q?Q.1\RBQP,I](/]R0[!]Q2,]\E:L+ MR/U:.XRXC-
!.0]]=+9/!Y"#]'4'.T#H&BP5E],>';^CV"&:B(.CS%Z6R/CI MQ('V&$'M%[/5A3B?/,E#MP8#%]Y_HI&_9/:'B?.NUH4@_7 MLQ9OY%@C+?8'/,0U9 QCQ88R"O?&
<+Y83W+3RI=;1)A:EP.(L3:*"Q^J[-^U!#U4MP>Z!C;))??),.2C&-+,D(!4?#2[DU. MBP_R?,CT^!HC"V2U(WX,#<6?!K MVOUF8:K@FK]^>7,U\M2'F*ST3880P@/*Y8*>D2?
I!G[R:#9^[,S"..F]CE$* MP$ZTR]T;)$;8*76NH9UVP ^/]PC=:6Y,9"MUA0;R2:];DAT71AV'L4[[' M[LN3_ACC^8W$)X-BR1$2+B-8>V(DE S=RKZ17*M;?>0#BPBVR,@Y)%5,U!78
MK8U#Z!T59;O(C8@N5"Y($4J*0_N.$K=VE@6EAF8[>@'S>4I+EKY,IA4K2& M;^!=H118KUGX[F+?R5VMZ)HA$GR+3!3 (M X+HRXWN<4>D=9YRMT+%'L4'@]
M0H'0%0Z+^(#X3IG\==&8;X PK+14E]Z*_EZDSW,A>ST>59 "&#T"$!7C?'9=A ML,*P20_L]/KQKC M3P/B#O]_=W)]18]L)/HFMBL:@KR&^9YH9'XYYN*K0#X2NAV^)Y$$$D)_""4
MG#6V_?5@S!VAB?P0EN5..?-C^OD;W9)3S+*C-,N!QKDSO3$;6A:8-A6_;6]] MZ"Q==5(PP(Q7[(SXUC-SMB-]>DNFMV(4O8P'.O0ODH.(8,NAU3;&<>A]'QKX
M]S]#C,Q0R:9"+FPSU[+MV^T>&X]?T'EPLHY:1X,&8"L7\DQY2*= MV%+6 ;V%/CE*4L!!:^A'M=E69L^!Q"03QXKPC <:&Z0-W4,UK!N3(W\,-B/> M&=K2NE&>WG#V,.Q-
N4\.;JE1C9:AR1:/T=WSS'NU,S#1R,I^5F5=]SA$Z]^, M\5W&L)$\E,*^K;URSDLM8R,6@ZCW\3S2&%]B/W0+&BL4A[[LVZ%#RICOX8!/ M)^>Y2_]F*UR>/Z?
X2)4S6:NQP6/,ULF7.\"U[\T%]4;MM=Q\YJLT/A)[OHB MF>3 8^M:0Y]_3S+D1*@N_48 '2N-2M-SCUP-9*DN6M,QT\T5+:]JC3U!4, M[TVJ:KKJ/4P?>8>F.K*=7CK?]WX
^9&XBNA%50I8:64/6"L%+O0OLL+;VE-D M!RC<8R6_K:R)Q]#Z4UIUV.,/M1)7_/B_HC%#QTG;6W7:/:%O ZB;<@]BZ:5^ MJ+._=^ K=WAG-(83[4*]]#AK?;>G5CO2\)-"R6.L%5>
KSG#%WV_4F0P5HT# ML.(1=5\?I_#&:(SBF6#>AKNC'7\"ILIC&(GS:@_, 8X]/B>)(+E["C=.;W7% MDL/ZV?_W^B&QE;00':%+P;>NX>XJFPTH>Q7NHNC6(,B[(R6@!1+KQEUW)AUB
MEZ08R:CI<9 W^_=)KLQBKDP^I;GQCA[94.G-2,9+; >8+_QW$+'F=C#CK:!I MC58?A]VX,MMUN^[0Z8.+&L4P9L'HF3J?/ M\B=G$_J(C$B)O_KFB\7;S76J:>]@G_IV[S6-
I[;QU7NZ<>W?+%E]]SF9*N M$ZF)KDKNS;]UBVI\ZSB4^PDLKMN2X7X)[#:Y MJL/*H#R@#%GLB ZJZ]&;]J-A3LE-L2:9C="T0&?&RKPG(?29T$;7FKZ&\'<. MC;;?7(GK.U'I=8L\Z
,6!T=$'"'%DV3Z_4MARM^-6)RT\/&BFD5TN]ZVY)HOE M7,A7W&.@CO8^SP+"?:TU,4??[Q]HD5LM_"N'1Z&DIT^U3N/WC1=AX.MDX<]> M[A7)!;]2J[MWTK'EY3XU[#\AZ&IW-
7HGKX7>E!?G/R.B*[* M--I>**('XNNY3/9(^/%,C]/OQ&U\6Z0#C%R/8=:1#8YN?N]4H[MJIE^0L4=MQ3;DRW6GN@Y+NOI-
E@'_B2B/P]HSUXQ/67+TQY9>E(MB7/,O6MW;P]/E'M(3%-DY-21;PU_V#C_5LV^/W;2 O]67Z2_$' 1C4K_K,' M_G.I;MW?!L2G\2\K+MP?%/3#W9]E?)3-BCY"]-
024\>CIT^.@/S\IP[NE]9L M^<\+%J9MS89_I*)&-30 [Y<&,.M_H07BWYN_E]02P,$% @ \(%N6=.:1 M^9+\ P $ L !D !X;"]W;W)K&ULI59M;]LX M#/[N7T%XP[!N=JQTS9-DP'!]6;=
(1KX7>1"C_S,F,4@"'228<'TD5R@H)V95 4S M^&'7'5V\4LM0I%7D0A>%)4# N_/'0K=VI\5"6)N<"IQ3HLBB8>KS$7*Y&?M=? M+WSC\\S8A6 \7+ Y3M#<+^X4S8(&)>4%"LVE
(6SD7_1'5SVK+P3^,%QI5MC ML)Y,I7RPDR_IR \M(RL0HVN6D M9\8WC"OXP?(20<[@A@LF$LYR^"*T425%W^AA8,B0%0^2&O2R HU> #V#KU*8 M3,-
'D6+Z5#\@@@W+:,WR,MH+.,'%$<1A!Z(PZNW!BQNO8X<7O^[U-==)+G6I M4,-?%U/RFA+E[UT^5Y"]W9"V> 9ZP1(<^50=&M42_?&[-]V3\'P/X5Y#N+TU[0W93_E :]&-Z]Z4?=
[CD<8'BSZEUHC;3P/4-O)G,]>"IF8-@T1RI@ M9\/*FPP!M>%44YC"S%I86@O.FK";5[)8,/'H.)R>:Y@U9OG&I F=$.E98X> MJ7UL\%YG[%$Z&2RF]+QU3L'[>*E!/ !^]>T/66\W\
(K#6TN-Z5U 8^T5VG MX5:2L[]RY$TR],NY&G7[ON!.&(4UZ_7]P86'WSV*[W- ^7.60U-@Z_29!(..HF$]R1Z#G M*+AHP:K_5 S_,L%*D[H$X4A76,V^/M1+F?@*%L MH,N-
T[GW.F?]4R>[EMQ:>2$K!L^0UOHO_.N\V#];MW#2B<+3'=0W1#;D7?:Y V M N,5 ?/J@'EQ4PA>4P@'*-DH>Z]'N=>+U^2:T7:$=]?I\WC9#*25N5S626V.
M@#H>"@YMMHICC;^]5(74VQ'2;MR)XY,MJBV(#>^?3"E&]]\M9U.>BAH4&]@AV/7E!JTLI4,U= M+Z8AD:4P5Z/E."/5\.CTV =5]5_5Q,B%ZWFF MTE 'Y889M:RHK
#MSR2Y4$^L@:8)'O\+4$L#!!0 (_/"!;EDMW2]B\0, M *8) 9 >&PO=V]R:W-H965T; MI.XY/)?W@QQOI7K4!:*!;U4I],0OC*DOPU!G!59,G\H:!7U9254Q0U.U#G6M MD.4.5)5A$D7#L&)
<^-.Q6[M3TI'ZCM%LI!CR7F%0G,I0.%]XL_BR_G VCN#/SAN=6\,UI.EE(IV ME!?;'._9?G>_DRY)IO);EGSPW MQ<0^9#CBFU*UCK<.LY9PWG,D;G!=P*X4I-'P6.>;[
M^)#T=2*3GE!'4-I3GY2OINN1"H MI6$PO#AW^)@D6NSOY*RB)O,=0QPDYXWA<)0ZPZ^$+KU7AN\A"89QTFH:!&GB M])'65T?5=P[F7)9RS3,=P(W(3N'$!B^)KCH+-
X^O/MICV(M=-)I;AAX0%HF=3"D9=2A%-Q0UU==-4WS5U"L*AR#B2"PN^%GS%.R8,S$@).LM3^%]@ MEZ-AO-1O"!]],>.*8 M*LIGW>:G/IZ=EFOO[%Y2M.M+\&H]].Y0T?6:(3GZ
MD\!>>XI@RT![UDI7.LEI\NAY(VS6[$D^29/5-!5WL^]S3WJR\>#-SXI=*\O4K[_[+H4"L.>W=GA6KM7@@:7/R;:[1;[1XAL^;N M?3%O7C"W3%%T-)2X(FAT>DYWOFI>!4JBL 7U?27*S
MG=@-NJ?9]%]02P,$% @ \(%N6?R_-EE\!0 V@X !D !X;"]W;W)K M&ULS5=MD],V$/[N7[$3H'/I[GMO-[KS.6 @4ZA M-W>E?%;L3:(YV7(E.2'I]=V5'Z=$KF>&O
EEDFS':&2F\N.U%GUW$GERO"?VKBT(L\I[=^^+64*O? M>$EEAKF5,@>#B\O.=70V&[*]-_A+XL:VOH$CF6O]P(TWZ64G9$"H,"L0=#? M&F#!0*79$,/ZN?
7:.)7EB^WOG_96/G6*9"XLW6GV0]5M==J8=2'$A2N?N].8U MUO&,V%^BE?6_L*EL(S).2NMT5D\F!)G,JW_QL]S50A[E M"^'$U871&S!L3=]XPX?
]9Q,XF?.FW#M#HY+FN:L/PAB1._A=BKE4TFTO^H[< M\F_]5W,*A?Q%UR'\/L%L,4[3+/XJ.-[+'HP"+L0A_'P MB+]!$^/ ^QQ\2(R5B^G'7; TSFPA$KSL$/B3/^B"L% (MXT
OP*T0"B/7PM&_HJ5(FSRP0"/S9=>/W^BL$/D6I+4EH#H+"/I$8N3ARYL M=@LY#45IDA6I"HD\VIB=D$Q\'5BCVOH]G),X//?S=F:^+SI_WJ4P]5JF"%3T M0.!:]!(A$2HIE>!:$G
->VDB*BVEP'?-".0#W"MJA;5F(]^U(M,E M K59RQ\Q_;BAK#8W_"0=1.<9.T#1]D:=))H2AK!A-M2. \0;3!4?LIC'K31RY M-
423MC).ZTP)F,E<9^29*95P5Y6]C70K#W1!.Z8WWU:XE!4^,6><6$Q+Y4GR M CT;:5,;2DO*^??>_C"B@ J+PVR.IJDNY".I>Z**L')^UR4]728/H?6=W#/ M)/9HD>*->X.(_B:].
SNI'WX=6&0L^4H:=.!89%$,.B-IO ,AKTQ/ M>?BR(M@I2"UB[%$$5#LHBBT]ZD;:/D N&$-FV+PMCG,"!?\8A^)B-R-]H;II+90#+8 M2E0I#"NUQ^>[_^#5?]8HJ&-
NZO*#,W(X(87DN2.66'1O8!(G7=J.N"QS0YMP>%@8/ D=389D51(L MG],.4+KGCLRM,R7+,!CNP\]UDUH,%$)2IP'<99V@SJD*1)MS74-;)T5P M7R3H?
#1]R[!&T^Z4V%2^4Z9G+),1KWP*S*9GAZ:/%9) M2'4HZDU_ACYVAA1%6QO!3AOP/=H(#MG\\]01?$T;00WQ![41?*(-.*:-FD?!
M_L;!C$^13CJE6^EN\;YJ#E9'$%U!*FJ_GXS/!=*Y%X(7&*;A]TTXAMW)Z;AJD @@OYSQ4]/M&P 8TO-%URZP8OT#QGK_X%4$L#!!0 (_/"!;EG:1'BV MO@8 &H1 9 >&PO=V]R:W-
H965TC@OJZ4/1^4SC4?QF.;EU@+.](-*EI9:5,+ M1T.S'MO&H"B\4%V-T\GD:%P+J0879W[NQERPF?I7KTO'$^.*L$6N\1?=[+_?\(?$ MC>U]
UNRU/H+#WXLS@<35@@KS!TC"/]YPVNL*@8B-?Z*F(/N2!;L?^_0Q->V MDRU+8?%:5W_*PI7G@\4 "ER)MG*_ZLT/&.V9,UZN*^O_ATW8F]*)>6N=KJ.P
MC6NIP]^XCSST!!:39P32*)!ZO<-!7LN/PHF+,Z,W8'@WH?&'-]5+DW)2L5-N MG:%527+NXM;L_$NJ]P*-_>;-(IT>G\)W?]72;<_&CO!YUSB/6%5*"]^I HM#^3'IU2F7[H2[2E\$O,5F!-
ED".DDG;V EW7&9AXO>P8O& ;__MNEQ:9R@>_OV4C0%B]C0$Y\@'VX@4!!;-'0XNOGDS/9]?!;B]CH^!#W47/%T,*>M="3D:1W44\#XG0]EHV2%0 MW04!#=&@"[;H:
%V%]:KZB@,C<,EU?:\C=MX&:O"5*,R!-1+4M#H%.)Q=) M#3:'A-9HVX'\%E*Z5;EZ'%X5O" %HC(1EMB>3\9#O/NOBT%!5D V(*F>:K\
MF+=&.HDVR;6Z(^/DLD)__I!WXCV:7%K!DWY(3*DU^C&9/00;05=]RKIHS$.D M6(Z4$<=K1RH1#]*R.K)[P&%":%HA;%&89T@L*%H>,@F1R7?RVQY7#+]G#T/F
MT$*!2]=]%0;*FA%LBB.(_= T1BV+EHV?G_;8A73Q%.=EL9%\-W%%D> M[9TDS@Y";[N/O2'-Y57+*B44DY%"KF4>S& A:<^&P@F7VX/,8?4"[SVB/5>K MUK4&WQ=
(1]*52:I[8T?]F@:]55>26$MWEH'+VVM83.?O*8[$K40\E]28FE9?% M2]YE#$FN&EUM@I71-=%HY)W@SHH:K)PJAR-/CN"2O@T[M=H&(E="&K@357M8 M-F+]?
R6UWTY*6"M7D@/3QK@9L5R6W'B5L"=/1Q[>*RKY2:B6NE"8^1LE^^H; MY2T9T$:7^&IBF_U6.L.S_*4^>LB+Y.BLV^"@M!+5A?I4]JEC*BG(DL/:6FI;% M8??U[]?2<%?
>4K,HN>A\;'T?P62V=Q@W"I7X@Y>FF3ISM+UO\C)6B8G?:.)OL]"92':18[3((1 M%*V67FD<=@;Y&L7H/-L0)9:<39&-=U)3*%?L(^;7H]$R6"#=AKZ
M9V##PG6]N\$#.CQ&C[6_:S_XAB3G.'I9#R&F=6>/>^[=&L_:O?%:.TBP\A;O9[@\)E^] MO-\>_@KQ29BU5!8J7)'H9'0\'P07[P9.-_XUO=2.WN;^LT1!A/$&6E]]>F+% M
1_0_7GEXA1Q2P,$% @ \(%N6;S2?Z Z!@ "!$!D !X;"]W;W)K M&ULK5AM;]LV$/I.7W%PBZ[QL(!P(.FZK]WVYBC]#*E$>B5$ N MJK+6+6D)Z.5.*SSE:BX[F4C:EQ92%5Q@X]].=:-
$GQNC:IR'-5!.JYX48) MCZWL4I4IT>R:1:412TN%>BV]KBZ/Q>E7)^,PE$ON"J6*T."\>EQPY?B6I@_FTN% M3^/!R[RH1*T+68,2BY/167AXGI"^5?BK$&N]
<0^4R4S*&WKX/#\9!120*$5N MR /'RZWX*,J2'&$8_W0^1\.69+AYWWO_V>:.N&]R&E,=YY_+<'D 7V1M5AH^U7,QW[8?8WA# MC%$?XWGTK,-KT?
@0!QY$090\XR\>_]]+>M;E_H"_2B-8!N->3*.P/[((7M*MV(Z&?61K]@&_VN>.P.<[F!6 G1Q!Y5#B2"4 =YC(Z]94,,2GKA50 CC9E#@Z M]"%QMNZ+6V:U0.'W8$/VG
M,Z'R0@NX5$6^(<>)I@T[F7]1+X 9^$GGG/+3.8]PE\0[2"-Y"&OMQP'XA.]QA M&DV]:1! XB<9PU&R$ 6*QSFOV%MF19KF#IR:T>;!>%?D*
M;4+C.,:]BAI].4"2;=5+P[Y4;,;!;M7D>>QHN-KUBC-EKE)X,A5WQ>FD3 MWT8C= #>]+F+9+@21,:T]'';06'KM;R$WXN%@/=_"Z[TA\RQK?*FT;)6_0WN\?F4' NN7(-8.&ZDN5<*.TS
M,FI:U4[!P-SZ*#08B6U!(!(Y:6%O9I8)+)2O.%FA]^U.L)KH26$1J[S,]Y MJLB2#$35E/)>")3,"X4?2%)ICY'AC;A=S5U$:'7I87?&T755E_/XU.OL%DL M>#?
WIOXU]'T/,X$IZ!8+@("JUO* [*)P:>>%2BV-:;>4#2 W#*\]\87B4-+ZRNY9K'H3K,;RYN,(YXS;REGIWB_*"8 MC#2XY8(7"FYYV=J-A\XC@'?.YZVRL'PESFPP[$H].R&06*/(#L70B^.IO;NH
MV1=LGG#B=8J;4ZKOFDW4VU' H1(]_C S9K-&=$-Y3"PHQC_)FZN.\Y<%U@X M,%A>266PL7!ZW"9]29E2CHU0A9S[%.!OO&[Q] 91]EU!#A/'EL$%K)^.&,YSM,.(!,D.)-#]:0(6]; >M[
M>]]A9[QQ,]V$6MHSN,;^;FOC#]]#=#CFG[G3[8.Z^XW@"U?+ FM=B@6:!GXV M&8%RYV[W8&1CS[HS:?#D;&]7@B/-D *N+R0><;H'VF#X>/T/U!+ P4 M" #P@6Y9N0U4K:$-
#O)@ &0 'AL+W=ONN<':^^K)X> M+EVK0KJQ52)-TMC"^EQ:U>'KK)*9CRIR]GD\G)82%U>?#B&3]];U\\,[7/ M=:G>6^]HI#V_]J*S?:YP?2@>?!!K]:>'AR^>%);E;II,L?
JO<7=82LETX4] MG3:EL&KY_.!B^N3E$8WG_7_7:NMZUX(L61AS2S=OLN<'$U)(Y2KU)$'BST9= M]CPG05#CIRCSH%V2)O:O&^FOV7;8LI!.79K\H\[\^OG!V8'(U%+6N?]@MM^I
M.;\QR4M-[OA_L0UCCV<'(JV=-T6<# T*78:_\B[ZH3?A;/+(A%F<,&.]PT*L MY2OIY8MGUFR%I=&01A=L*L^&\V1-V_MG;.\^6^Q5[S2+LV-JZT2_[Y8.&\!FO_L\D)8Y&CW
M(I1(3UPE4_7\ )GBE-VH@Q=??S4]F3S=8\)1:\+1/NF_/F1[Q>U6]GOC57(F MOO[]];#:=/A7[O?96>[V2G&0_K%6"P4]L[X5V0I<;DV]4A@N1*NM"\B)7*YF+
MRII4]0Q"G/!KZ86TVBFQM*80'EDOO E_,<.OE3 68\$:(C6UQ4"S%+@0B]K! M'.?&XNHN5947H"E,24VA$B_O,+]GZ$AL%8@DA2RP06IKF3N>,!C%*V-%=>=A M;U".EBID"98B']#X-
*\S%55G_=*TMA82%-D-ZQ9RD2MR5M*.L2]7'LZ0A:G) MD[!8',BE:58T&OI3(EI]T(YV$YCQ^(MNTO=@84=%I3.F52SF*WV:Y.;J7\/ M-ZIF,!:B"+!>V3A!:"PK5QH1=(5=5F
H14'D71"A%]7/Z56IEQK:P.AV,<5^ MCL/H ?3TRF*E#!(O'NLNB.N#;]9RHT)L2U&#$^PH(0"1F(M%ZZYQFS-"1BRN M>]*-V%N0OQ$7*^M3M[Q!.P&(3P MBBW8$1?@&
['.I2Y'$/GT* M_"N+JA*< [C0\]GD*2>%K)WB>Q AX[5OBJ]W-SSPAS3//Z4<(N=PZ!%!R?R0*I[QC'M!"SU">NW&B3LWDN^ - -;94
M]RZ.2)8]1IDA:FQ=A+L>/FD(Q);D+*^*!9P^,P#>88G1O3#(2"F0]LH"I,@^ MPFLRJA_]]L0ELE:AZ53(B)EX]M/,;HKV#QQ5RS'XH+BCVD(""%+3>3BMX>\A
MW[<*)LQ'D$EDB:AD*@!2-9- HQK4=-\8AKZ2R#W<8G)@'R(R*:P$"=*,/I." M"U-B2V):*@&:R6TL7BJ[VR.3]\TFN'MZQ/Z&UR,;;/(0_!58X>I.I34UD@TK
MC,0KQ.5;]\$(+!:L(_(Y=;5VCI>7"0;R)CW%S_(W+%G\?4 M!;1Z;C0<8V]'6*!95M06#B+'K*=RK3:0:V! M/:+?:BQ!N8[ZC5Z-2FR4]=+ $, 8!.M6/&_@@87*F-1
)/8&J6WJ)W(^)*]0;Q3A%. M>:T6B 16A7.Q[^QA65$YH1QN CB58&>YZ=:9YPD>(3VN%E))%T(2[B)8/1 M6;""^9F;CXXK=C0?HC!-K8GH"LUI08B!!]$
+!37V<%R'!%>:D0!B8N/@#JH M:QFL5>U#IPKLAO5@]O?8_]3>V!B7L^])^I)QM6!VBELWMD5:,F!!M2R_+Z'
M>^I_NE@O%-13R7YT/#3D[/81:"8@AN'.>3]A8,!*!1YYZ.;FF+9;"J:U4:)8(2)2@:V"G&RH7]E..'[K5Y% X,W8F$K@OP*C\2E!DB%&_D0>':-M0C#";:#+C,.C_MH/]^-^2F>A"+=
[3V07X!,5YD5Z.' -&)H2X25PQ: MG@YZ87-?Q^Z82G,_I6](,9!&@_*;=N?ND[8]![W?>[.AW7SR$IV=6>D4!>9- MF8[!/^)#U.L](--
F5RGWI!]L&TR#,!@SR:I8Z6LOE%V@Z1QO9T"'QJT]XH' MJ[;=0#NBZ0A&9"R(DSKP9!%GP?J-RDW5[D' @/42&*\Y5BXN' >BAK@7&^S(M'LK1]4U1@?
O!FK4+!7,7BBM#QSXZ'%%!@*?CF8R[!.>'*+L+FN)I <26-0*(MX(3*$QP/O'VDTM,URQ^I[]?IT2A%I<7>BQ3NVXK9497]]">NO.4U((0YP);VJ86GL*V=
[PW;#"=]Z\PT:*.!# D"Z8#QJK><7'MK.# MHD9!Z6U/A>S MG25RZ$=L@,DA?6+\K9[596]YH(E/5$]^274L?0[57W$R<-]6TBZZ"*?Q(6*] M,X5XH,[Z?
=K!4KD#@_RLLL=1V9Y((D1_$M/1_.1X-)E,Q'QTGHJSYO%H.@M7?*X'Q1L-1STG4.^,OD"V"]KJ(M% M:Z>/Z+Q2D?7'XL)19=SAA<<@UAQYZS(L&1U=E^@L\KCKKDO>]Y%
[VSQ@%P85 M+]=*'%-K9$+!T<=#7,],VBS.RZE;<^]HB93(IR.MD]*OY(B IF,U'D!C/D:MN@\! M\H:.J@+?6#^;#P57W\U/3UZ.OR3]'S8_WK1;?'+!NM47YT+1]Q\"/ X83_4 M Q_#
[QP/!X.P^;80/I0\[M>DJBUQ;&M;%%:Q'PQ?'[X>)89BF=R@97?;&)NY8 MN=DNF?PR'0O7"OK\X/?T,M8M&>3Z4ER=9?FM;/CQ_>2/P^]A3,(&JVR70^C MFMR)AP7-60$%K ?
J_MOCS\'T='RZ$I_XL\?'_2SDSG#^_/\;Z'.Q%VY_.X_M=5-@@\]\$U8""2UG(YZZOS%1K=PJR,VCW-^1$-(EL0$,:>20_R:Y("&<=O<
M("I^D"C0/E,)]Z]5_.F1NV,K*SH,H4^!]^0'J_]VM1O8L\DD^C4V%O'OD3A! M-Q??H168HRY,Z0FNC_&L\R\1S73^.7U?TPB'LW<^<\N^C,\'93KTMI]M,N,I M(+4:HJX ?
_H$&$@CJF!H1,[KI@"E/WN>#+<4*GPB3T&!TP!B'[X>]1N-SIW>Y"$HH5X5R%.I&UDUZJ8#GL,0D(.K_BG M5BY\8@R_1V]%MK_FN@@_8N]&AY^"
0DK73]1]R6F3L:GQP?"AI]7A1MO*OY) MT\)X;P]^7/-),0W^Z?!+C[>T+M;]Q>_]02P,$% @ \(%N6:"#M.!: M @ +P4 !D !X;"]W;W)K&ULC53+;MLP$+SG M*Q8*D)-AO>P\\;0%QF[]H
EBM#T4/=#2ZH%(I$*NXN3ONZ04U443(Q>1N]P9 MSE(<+K9*/Y@2D>"YJ:59>B51>^[]BVQ$6:]6I2\DBO=".)0%[YI-8K,@9K: MCX+@V&]$;UDX7)W.EFHCNI*XIT&TS6-T"\KK-
5VZ87>:^*^DJR"3]9M*+ M-=+W]DYSY(L6=6@-)62H#%?>I?A^6IFZUW!CPJW9F<.MI.-4@\V^)HMO< * MPAI3L@R"AR>]PKJV1"SC<>#TOBTM<'?^RO[9]([.7_*FC2O5HRC9-
UM##YV* FNG_AK M%CXQK5WTTX%BU5-$[U"X=?EQI#F&_'[K79[MMG;;-8EYZ85*2X]MH%!_81>[3.1]VS?>P?^Q_[*;XIPH.S.#H\C<+P O[Q_E8>W*:D-Z+/E?>0)4
M(ERHA7R!0HM)&$&?/O2!U"M]8\!4B DJ#RO4D9U8Z+=D1-BV*0F,A"+D MHG@2QW.(IF$(8<#4&A%>4&@#L_DD"(*W#LK?N<0-ZL)9U4"].DG]?ZSXVMP MV9O@;WG_E-
P(752LN,:*S[#_M(;:C&)D\@=02P,$% @ \(%N60W3!VE8$P-E#H !D !X;"]W;W)K M&ULK5M;<]LXLG[GKT*YI]:2*E]]YY9=B3UZ-SXVMP MV9O@;WG_E-
P(752LN,:*S[#_M(;:C&)D\@=02P,$% @ \(%N60W3!VE8$P-E#H !D !X;"]W;W)K M&ULK5M;<]LXLG[GKT*YI]:2*E]6Y$@SL3)2G8;8-0D,BF
R:'84OO@HUQN+7YR\ M>M'PM5@(^[FYT_#D)#%GTE]*@.0$==G[8E7B).!?T0!OF!2.R#C*MIn#N?M^-N?
\MJN[/6=K-RZ/+(U:%*%6\K^U'M_B'\@^W4;$Y6MN^:L76NV8QK>!&OY!1Z75P]RL42L+ MJ^@IA'7U<)]@ZD56RFY8;LBVJZH@JU0Y=1X>RX+5UEUT4AVMK*>LWN5%4+^Y=)$#CCF]
MX*3PV]RX:&8!KEBKFV+@M+M4&Y,$QK\K[:MFJ^/=*%_*Q]('G(ATC+YD& MJ^@IA'7U<)]@ZD56RFY8;LBVJZH@JU0Y=1X>RX+5UEUT4AVMK*>LWN5%4+^Y=)$#CCF]
M!]I[;GL?O#&1.[4[^(%$Q(@/!%5^1'(C9MAM!1)%$%KK9A6:>F78CX5WVV!1 M._;6Y7%8'6&YW%'K[&9D(NE22;.CJ/[(!1"SC=.9%+]><>?%G]^N,E(T+:N
P$P<=_7<Y<$$8E:VXU..C4L.M@XKMB#*R.A9L_)@%T,@VJ\@V1!FRR P]RR!:=
M_U>/0^%CS'C[[)*2X@V1!FRR P]RR!:=
&K@N]YCSH@9W\PXT-+C<*/*WV6V+>I<*\G9@-N5K/?X<-(P:2AHW!D;9E97]:H[.:NM>SL#GE ?UCTR7'$(8BK'T`MN8WHR/D$CZAMAU0Z#TEQY(@2^3
4%.BG#V]U-,1>+=TF2$C'SBH%.G8AA-7@8V'1[=IWOMR/I)PQYCUH$$UXSIEBG'(B%(P/>PK@DQBH2O'/YR.
Y3TL+TDV+I7<LNBYS'3^YY4=LG\HJH+&W8KV?(8<(DPKC6UH@%8A^/%.D
!:7=%SVZ..'#I$"-0FFMH^ON=(/+,E/4^^TGWEEWN4<$A6AKQE>MOV)N;0
DQ%[RF3LX[A41MT.UL$D@>W3@]@/V/X7+.E!$NX=ZBQ$D==G[G8E7B).!?T0!OF!2.R#C

M?+#"(R=N-@-+LW$G2G"^'GTKRI:RZ=-&%<'P1+00.A3L?6N-V0@?<(">A@ MH(.'66"')>QH<2_JQUC,@OC7H>! '6K*]J@R46\FT,(J;E@S4F6-!X;B4<&P= M
H;UKBP3B$.C87$!9&!W?.J)0'2(^<,/3+X0C0C- R+K@,8O/5&!-M@ M@)&2K&T]$HT3EG$-,@K^7^1!%1G0F["M?Q;YG0[ZF07TP/\ M <-1\8L-J,_XDX
\|:Z^%S[^#/G>*/%AW\,=LQ_;D5PR0&0,]!+$#< 4RE.(M1$ZQ(-7N?7+&+<8^9^UDX5] O;B2#:0-,,1%_"*(40#M:),A$)A]*EI7_M]X C6 !\ "Q=8O5%'X0)"^\]VG>WD9#=Z>

```
&H,,J@V.(/1Q0?X$LO6KKTDGO M\P)@O. 0!9P)DZNBK2@&*%2K;^08(+)?V,5DSL[.3O/I= K@(3A1U@'?4D"" M K3O((Y;#P@9)5548'CDD\$J)0FGD[^7*S@BR150'H!9
WGHS[AZ'V%B6@(EBE_(P;(U*#1]+-8]B['NV6BL M S!DH6;#?3 (#<6S40+#\:RCFE$PO::.PF.9YKV"?X-QQOL3*LN7:10"8@7. M4>V19WJ&I1S(^KL*]S0R O3&(?Z' /81;03SA&5]89?
$,,Q=TK81Y6Y$A3@& MWBE4!>4:1@_*9O %I"EIT>;AC35$7XHPT=@-WXIAPJ,)[3(J^7)4R6_1O_X9 MTO/;N,^[+OD.*7Z4Z+#B<.:=L?*?NVRQ!LPL+$@3I&':C4$BAO'](O;B)]?W@
M^[>J[.)O6':]Z+H"E_/I\6S:05%$.)0)P;$\5!0#**:O#L\\1%B%G9)A( FU MA@*$AC'+%\7I5\H%J7Y9B>;A@H2TF<1Z _M.KD4"_4 E_ &X6EQ&PX%$"BF MI3[[#PW5'0#-
DR(E!1>,O6YS5X:%M[(BM :$[[QXVP_I)FF0P5MVASV-G:PJ M@K>0FJ1P[I4YI%$!.*YB:,*(,8P /!QRH!8!44[\OJ T13Z(U2EW(&!F&"T,D
M(Y<\,XR_14$YS'$U"^2JSPIN;.165EP/;YL_YCTP[54-=X:V[O;.8<_&I^PE@E5K'=>U"@".CAL@2R1BDMD%J*-O M1=DXL]2:!JQ!H""IV(;:%T["G>,,^WGNVG,!%>/3AS U=X"
/00$N:NF95(C MXG*W[T,P%QOC#=\[\5&Q)KK%>8H,\$0@DTXPH!51<$1[_KB.)U\+[+,$]\4 M-RBO0^+:P6NHDB ;FC/]PF:7<\+2L\EL+'M=Q>QU-
9]]_O2[_!YV&>L"31@M*FQ]XJ"*3GS5 T>8K(_#"[U#_HI$ (S$UUJ(R "@P G1CO%_)6+'6+)1.5#!\A4&K@TSU<-'"*X>GJZ!8'>@:T
M;_;#^[(_ZJQ[:PA_"^JXM90S.'6TD(9!&L<&:83RMG!'IB@@RWLY\+!X*@G$482F3B#Q'H>>U:[C7*9;XAFO<:Y8JSR#&3X$.D"/*:RG;I1!$T>,>ML!=42R0ZYUQ.H$MO"
M!5)2$%T007M=:O4%XB_LM!*8]HMN$-KAAX *GDZR3\,*8&$#.G=+M3A(85BD M/7/RQ8L+$2C3M%L^=!8\:'8VR\]F5PX,Y*>7T_SB])3-SZ?X#7U[IY77!I#K M#7:Z8>F6ER*@OFB:
<%BA"[0;PL^A-__]0\5&%=A*Z,7YCED@B<"HYTI.&DUW M'R FOC U&HMEN6-._1A_/KZ7E!]7+6($&A;B&ES]L>VELO6X-T& M= 80XQU4G'3-(7.R0WXZ2:9CB@:F(-U\;3P;)_>=9J/9F
+,\0TI%:4##G'P=LPX]>&LF]#/4OH] M[.C.YB,V14GCQ>'*I")=:#$U0FT#0LM9*2%F685_BFU3J3UY.U488'L00Z+5 MQ<&(QNFX1@$N"'YZ6S$9%AUA'"6U\ "24IRBPH3F0U!82+-Q?
5CJ @1;<]/G M1<=V!F5(Q+T_R[*LNV")[*^5\HWZ<) \]$'\.&OM/ Q'19ZLC_3>$?,(%'U_ M9>QN1BQ/72H@VBZ$I>72 93];':9]XSIF*32U_^8]/+#IO1$<[<0X18/?
&$02%75PVX(RIDY937<]4)1" M*L>EKOA*+^X<9#_DS0F[BPD!"VJH4BK3JV(P%@(?C%?PM/8EDXO1-%1!+ZN, MBL(8#VK=Y<79Z&W#5[\+?DCW?
^&:HJ/6"UBQTT#],OB_PG>&_$EOFZE^P:O M?&$O\@S*"4_U79W]5PNH]%%U$?7C2+N85/IL:GROM!:[[PFMNT,Y&[]$^0%@ MW>_*&'8'F6Z!F6Y0@'_ABB10SOJ4&=Z:+#
(PKQI,UK G.*!ZFN98@@1-B]D3 M)V+N3L".+A6+\AC,BL!=APX")O @(4$CR9V"<)/@M:R(NN<) M8,LB8$LN<'[SH2%"\M*+$867R [2>.%OW\6&FDLC7@H2][#R.)S&]=!<*_M1
M3=>;90L*G/V[A4Y/_&&%\H"I'V+D.5L4D-K;BB#M=?HHN6*9#D<]. M3_-G%W/8_RR_NIAGGV@ VSLX@(IX@10V.#W/I_,+=C:_RL\O1GN2L^XBUFS\ M)M:M(GBM#Z/+OW
'JT>4!K+9PP$DEOP')H6?NNF2\<-(ZZ#\@9FEI5L))I1# M#J/A71"OW>;9.\!RFJ+^K=*-TOUYV]O7[[J!FXRO4]^0R+4-JO27 M4/PE]RQ@9Z@( *QF<1 SR*[/Q-@\&"ZYJ!>OD]40- RD-
4HR>0=_\=KL5M82 M;P?ZN:R6YHOK /D&>#J2YKWQ0]%3$:+3@)@ZK(0!A3J9#QKXX#Q_EZFU&S\JM1"K_^.C\>7'BBO/+V>$F*/W?T>H+M)U];N MLLTCE!*:X9ZUKM#X*^)8%?
T3YTC2!LZ%\+ M);(;+6XY: ]'>5F8_8+];J18)?1+ >D,;0PO2R+XOL>?+,7K@O[RCBIH1@'? M*@B7XN"MAH?L8#^>>,EHA"R#-0.X?71$!YB5<"BM]].-I#>&%Y.QR=7@2.\A
M";Q48UALFM8*8+/&IE46]DB[$#*]=^O2HOF!F^CC-MW=B)E][TH,.GCO-U): MU?!W(0[;^H^0S Z21-C\ >HARJO^6A&(%R\_A/[N]>(S>/F$GAY/G^4C-O[$
MC87FE].GS]F[+11$]R(6[NXU"@IAY>OD)P]#8Z+D[B[Z1)B,NP!N,2689[^P,3$^QMH7+&B<"$>JRS":/[LBIJW.+2),R8239R)
M1VK'1EBBOU2EF^UKU:XW/JO0_82D<6E&+OJBO6=X!I^>_("<:CU>.FSI'&;O MYGY-7Z/4CR:TR6,Q&6'S\*\BAB_/9X.7YR=#IGZ2_%!P*_2:?@Y)-XMKZWXS M&+^-
/[F\=C\T[%YWO]=\S_4:;]M58@5+IY-G@&:T^PFD^V!50S\[7"IKU9;^ MQ&)>:'P!GJ\4I"3_3>(/T1]]?]02P,$% @ \(%N6>C?5!SJ @ =@8 M !D !X;"]W;W)K&UL?55-
C]HP$+WS*T:I5+42 MW00GT(4"$O1#[6%5M.QV#U4/)ID0:QT[M9UE^^\[3B!E5>!"_#'OS7NV9YCN MM'FT!:*#YU(J.PL*YZI)&-JTP)+;*UVAHIUC<$[V6C]Z"??LED0>4$H,76>
M@=/G"3^BE)Z(9/S>RU=+=Z M]Q7W?H:>+]72-K^P:V.'+("TMDZ7>S I*(5JO_QY?PY'@.OH#(#M :S1W29J M5'[BCL^G1N_^&AB\X/&:H,F<4+Y2UD[0[N"<&Z^;B\#=
YKL54B%RE7#A9I MJFOEA-K"2DN1"K3PYHYO)-JWT]!18@\/TWV299N$G4DRAANM7&'AL\HP>XD/ M27"GFAU4+]E%PC565Q!'?6 12R[PQ=TIQ U??(;OE-V?BXUUAE[-KU.&6[[D
M-)^OI(FM>(JS@$K%HGG"8/[ZU6 4?;B@-NG4)I?8YVNJS*R6Z"]M0:K?94+6 M_G'#&M/:"$?R3VF^R'I:\UV!O5Q+*EU_-JDN2ZHD>I3I(^#O6CQQB%!\I]4N*NHS4UD*%U!@*3J@-
IKRVZ+>% .[1LW!8;HC[\#;@S;WB=28<9F]?O[IF\?C#_@/_!_E%?/5 P .PL !D !X;"]W M;W)K&ULI59-;]LX$+WK5Q!J422 &\F2'3N.,2!Q MFFV!%@CJI'M8[(&61A81B71)RF[VUW=(R;
(2*XYW]V+Q8^;QS? ->.-D(\J M!=#D5YYQ-7%3K5, MN].Q7;N3T[$H=,8XW$FBBCRG\ND:,K&9N%UWN_"=+5-M%KSI>$67, ?]L+J3 M./-JE)CEP!43G$A()NY5=W3=-_;6X
>#C6J,B8ED(<2CF7R))ZYO"$$&D38( M%#]KF$&6&2"D\;/"=.LCC6-SO$6_M;%C+ NJ8":R/UFLTXD[=$D,"2TR_5UL M/D,5CR48B4S97[(I;?L#ET2%TB*OG)%!SGCYI;^J/#0Y4&6
MY0W5=#J68D.DL48T,["A6F\DQ[BYE+F6N,O03T]O*9/D!\T*("(AMXQ3'C&: MD2]<:5E@]K4B)_=TD8$Z'7L:3S1^7E2A7Y?HP2OH%^2;X#I5Y!./(7[N[R'3 MFFZPI7L=' 28!PKR;
<.X0^G6-5QD5F;^N3 MT@QU"3%Y^Q;;XCAX4GL<]RDXBX$=E&Z?S+*!W4AX9\ =+9BH2&1L!CL69O\B M-,LU[>-=R %Q]VMQ]X\6=^.R/S.05$;I4^/.KS!@K=I4??"(_ZSJ/>'6VB9I
M30__(PG335532Y.<1%2E!'X6#%TL)N5Q\W9.GVO^J."=AM576$-&NM4WJ+[A MKAY(:ST<@3![P7SDX),.3_@?)!^Q9T@*'EMM=8+ K^31'.]K_&%.- H9'UJ& MDNUU+H8#:
[NUW%MY1="C%TA;_U>^E:3WKN8].>\$_J"%^H[(CKPMO$;"G"IA M3I4P)ZQKV*EK^ @GDV7G[2SW>N&67#W:SW#[D_4R7T:!N+(4ZTK4^HQ@&X;) MPV&G3 \WZ/:@-
CQ;GLWO$9#DX-]3;U: M=X9794.T,R_;RF]4+LT3F4&"KO[9 -\'6;9JY42+E6V/%D)CLV6'*7:W((T! M[B="Z.W$'%#WR]/?4$L#!!0 ( /"!;EE:):8&PO M=V]R:W-
H965T;O^^0ND39.$;1%YLPYDA.=M)]:0+ M1 ,_JE+HN5\84Y^'H,[FOB0;;6151M,#"HNFG_VH]V'0< T^B @:0,2Q[M9R+'\ MR@Q;S)3<@;+>A&8'3]]+)G);=*Q M728'
>^Q/H$T"B")DM$!O+17GSJ\] .\5K1VJFDKU):5&OZZ7&FCJ%[^WB>Y M01SM1[0]=*YKEN'I79F^^M1B@Q6*U1> MER?XBEEKB9TE]8X>!=OFG&KLV.O1.A9&PM6+D<],9!@
H]9OJK&VU>C%\!DF MZ32(HHA&:3".QW:\%^914,,XF:;.\8&B2^^=XV=(@DF*8#N!;9 M"1Q]^31-DNBB]W#S^.+8;L.;I@Q +%I]>:(]KO24D6_1T3FM# THRI;^JZ*"D,R=
[.E"LX[Y8Q_^[6&UVW@C: M5[T'X?=WVD.!7HZ&\5)_(/Y]F@^E)( =*CH4==L+^G GO)/UV@[]L07O3*GW MC;0-SDI*QG\,'#02#)MJB1NJ=IO4%2N=L$&ON'I-
VI*^%L^29TAZ!3T!XB"= M-#YI,#F+G0=IHUN81'(!&=,%'*7!*&VJG5:-@],X:B9O70?51/5K8,VX@F=6 M;A&.IEV(C8^3+K[1/N \[/1X-'+C?:49#F[ "M7&W?,:7'::R["W]D^)R^8& M?
75OWB$W3-'>:2AQ3:'1R2F5H6KN]F9B9.WNTY4T=#N[84'/(536@;ZOI33= MQ"[0/[ 6_P)02P,$% @ \(%N66^KO[+2! .1 !D !X;"]W;W)K M&ULS5A-
;]LX$+WK5PS4;9$"J2W)7W*:&*B3!BW0 M+HHDW1R*/=#6V"(BD5J2BIM_OT-*EI4V4;II NPEIJB9QS?#F2K.2*F>&'M6ZKPN%+'%.>=:/@F#([F:_%%
MT5._04EXCD)S*4#AZLA_%Q[,P\ Z.(N_.&YT:PPVE(645_;A8W+D!Y819K@T M%H+1SS4>8Y99).+Q3PWJ-VM:Q_9XBW[J@J=@%DSCL6+2(S_V(<$5*S-S M)C<(,FQTJN0%EK0G-
#ERHSIO(<6%WY=PH>LO)S\PNF5),&/C$V8)GW-S MW@5;9*A?'_8-X5NK_K+&FE=8T3U84_@LA4DUO!<))K?]^\2K(1=MRU\%*Q-N,'D-K;$WQS47 M@G"HF3,FE@A_0+@?C*+](
CL.+8#[Z/6I7N[RX,&9F#%N()KEI4(KU[$41B] MA=%^/ B=TW'*Q!J!B[;97CP)'#;Q&.Y/IN/JP7O_W1"+DNN41,XT:/6O5P7; M)ADW%(GNP(T[ZFS4U-FHL\YLLN!R&^&WSRZ-
=W9#)\XCNV'>.GX'K MI.$Z^9W.Y:CA'5577MS;NMWXMDO;N];J3ZZKHDN@U+9Z&,RYD#EG&12*+^U4 M+A.T'QF3@DFQ;EYGN^/T8"O_$,,M.G=V]@DNZYGP@?X\-
W)YY=C:HH]Z@Y!^ M)KTH\,ZXOGJS4F@;S)#V: .*&800!KU1#"]AV!O#2^JK@K[XE()KF1%KEY<( MPG!(%F$X[4W:-AE?48=2P]X@4_HU# @K&M&?R8C@1CO#A%_S!$4"-QRS!(8_
M]>OIKN/;DO%CWU9"$<*<3A()V),-A: ]"H:^NJ0%-+FX<3MSB@DJVKBSJD#) M0UQY$7S@=":@[-";78!VFZS/LP/:0\HZ'4$:BIY">^ZSQ;,DA5:D["71[HR[CIR_@AI0M^3>DZ<1ZI
M'M.&Y?1)E6[Z#%S#8'=Z#)Y9ZQY8H!:[X/\E=D&GV'6?1AZI<%.K<*->\(#" MQ=/;)C\+7-"+(>S%3R%M6T.*HBUKWE;6X#&RYMT6HJ>3->\A6?-JBK\I:]X/ ML@;_4=;ZK=M)EJP$
"$#P &0 'AL+W=OG(>^XYZKD3.=E4XD8N.5=P5^2E/!HME5H=.HY,E[Q@ MTJY6O,21>24*IO!1+!RY$IS-C%.1.QZED5.PK!Q-)\9V(::3:JWRK.07 N2Z M*)CX<<+S:G,TMX3);+)4V.-
/)BBWX%5>_KRX$/CD=RBPK>"FSJ@3!YT>C M8_?P9*SGFPE_9'PCM^Y!9W)=53?ZX\- MYJ@+J1VW[UOT7TSNF,LUD_RTRK]F,[4\&B4CF/$Y6^?JLMK\QIM\0HV75KDT
M_["IYX;1"-*U5%71.".#(BOK*[MKUF'+(:%['+S&P3.\ZT"&Y7NFV'0BJ@T( M/1O1](U)U7@CN:S4+^5*"1S-T$]-3ZNBP,6Y4E5Z U^9$*Q4$E@Y@\\KO6P2 MWGYAUSF7!Q-'83SMY:0-
]DF-[>W!'L-Y5:JEA+-RQF>[_@[R[,AZ+=D3;Q#P MBJ]L\*D%'O6" 3R_2]XW>/Z^Y',F)53S-G&H!!A9PK>/.!4^*%[(O_H2KW&# M?EQ=2(=RQ5)^-,)*D5S<\M'TS2LWHN\&6 <=ZV (?
7J%A3E;YWR;^+$6=Z9^ M]'$=1.OG:N1 -@VXPG_)TEH.V = +3G([ Z*^O5R_7H!7PXNUS47W1N"#1<< MF/;)L?CE(;3420]U\DDO^;9B>B#)I[5YUOZFX'#6\2T7V#](I]ZS.R[23'*X
M$%FZ9<>>)!5*.RL7P!2\YVD#[AIP'Z,$UCCRX#5$ONU3\JOVPPB)EU@)I1#8 M04RP&*[WKKV2EL'CD7UD>E;/M5S?MV+#QZ-V&-\[ M\QI?%^9SG6%
>6&GO/#9RFO;PY#R!M'ZE?=ER4DM%[TPRF18?S"RO[D$:?I4 M96+WZ[+4*GI"F+M"?)C)?Q9B"_A AZWY21FZ7F1Y48AO+J"V&W8R?*BE/B6^ M]4*+4A<.P WLA
XH<0^=/BU1%_D$R,3Y#A;N>0QJ,.@U&+];@Y^T4 MMCY=9_<$^^0Y&*A?G@TRV5DT\PGIR9YA]]M9HSV=\ 5ID+HS[_,XVXW62XM< MLG)AXN[J$QI%;V.VTB:-M.&2ZXT>#I%3K
^!Q;=F.7S,YAS>_LF9D >/?=HP MI"Z#UZ@*.Z3@1E8419#8$30FXH5Z(*2H8(H#/A@#B;'O4O #*QPG$-OXTP;2 MBFM 5'$GJGA05%UC_79N%JOWFS\(\2^_^4E',/E).Y7D)[
>=ZS'+]VI#&JV MC_]@A'[^;:C_MTJ?DP!YSJ0G*A->5)GPJ#+AR,[(L.?F?(ZNU(YQ=R/J,U_]H*J5 M.6==5PI/;>9VB<=D+O0$')]7E6H?=(#NX#W]!U!+ P04 " #P@6Y9RU8' MKN@"
!2"0 &0 'AL+W=OL;)I:J6M^0EL&D2C0;0_M4%&WAVD/)CF(5 '[ M%[;S3%A3MRUMK&(NWRA*&$P%D@N\AR+QTN@?-5S?&=MN"7S3!F#
M&W<+/(<)J+MB+/3.K5E2D@.3A#,D8-9S^GYGU#+^UN$K@97<6"-3R93S>[/Y MG/890-2<@+D<.[+ "?2AZ6P.238\)-GH0&3/3C&J3S': MQ1[?Z"E#N91-\I?
(MD6:4;*,P\CW/<_KNLM-9;?]@DBG]])ON.UW$9Z?;?F- MMOVB=MC:]'M6:JLNM?7'4A,L,[20D"*BF[( >76;Z MT0/"..CO,\[5>F,"U,^H^#=02P,$% @ \(%N60Z-"",8 P J0L !D M
!X;"]W;W)K&ULS59=;YLP%/TK%I.F36K+9TCI M$J0D[;1*JQ8UV_I0[<&!F\0J8&:;I/WWLPVA(:5HE7CH2V*;>\\]]_B [FA' MV0/? CTF"89'QL;(?(+T^31!E+,SV@.F7RRHBS%0F[9VN0Y
QSKI#0Q'KO?H7W7SLIDEYC"CR1V)Q69LG!LHAA4N M$G%+=]^@:FB@\"*:/E1 '"1*G/<&I$ISC M!.^5!+=*<'6C)3/=UB46.!PQND-
,14LTM=#:Z&S9#*12@&YJ)#4=760QQ,]^4I&OFSI[YU.D$7$!^AESK!#F6X[7PF?U_NMM! MQZV%=#6>^PJ>$J]-NZO'*"EDQVC%:(IF-,T+@;6#I>)7F&4D6W,T!X862EET
M_UT"HVL!*?_3IG+)PFMGH5[Z"Y[C",:&?*LYL"T8X<%'OZD B<(-SS':]W:6B_Q!AI/?9ZVH>VX \OQ1^;VL*N7<9X3#'R[#FOP M'=1\!YU\]?6<3N4G(T9S_"0_90)-
&,/9&M3Z!/W(];7>WT"Z!-9Z>9T5WGIY M/8$UQ/!K,?QWX7:_3\%Z FL(-JP%&_;L]N%+MUNVXWM'9F\)<[Q!$+2;_;RF M>]Y)]PXK9XM.,W@)K-
!O4S0;OPLQ!GX+U!-80S+:>IP:K9SM7@ VC MVJX[])TC0[<$NI87',25G,V#H2<%MM:S($<1+3)13A'U:3UO3O24=70^57.H M'J:>8SL-_4$L#!!0 ( /"!;EED,9NF@@4 %TA 9
>&PO=V]R M:W-H965T%'M!2[3-C4XE*2?9IU]24F0KEK5VP>8BUH'S#4?_B!I2&C\D])YM M,.;P&(4QN^YL.$^O-
(WY&QPAUDM2'(LSJX1&B(M=NM982C$*EDG&0\)#&>4V!9%"'Z=(/#Y.&Z8W2>#]R1]8;+ ]IDG*(U7F#^ M+9U3L:=5E(!$.&8DB8'BU77GHW'E&7UID+?XB^ 'MK<-
,I1EDMS+G<_!=4>7 M/<(A]KE$(/&SQ5,4\ZPAO3L58 M2?E3%^:A3"<4!^#\S$@J!C$./_X0S>$SQQ'[NREO"K;=S)9C\Q5+D8^O.V+P M99AN<6?R]K4QT#\TB:X2-
E,)O>)OK&WWM6_U=*[V*F'.802V;1T$X*KTZ2F"U53M M5ZKV6U5=;!+*+SBF$9!XBQF/CFG;RFGN)33=][_..:Z]2IA3P/I[VAOFZ+)! M?95>/46PFOJ#2OU!J_K?
9<$@!OZ0H"4)"7]J$GYP<$L8(_/PGF[U=*ZN*F%. M0P!Z_S "M['=H?Q>TP79;U638EA),6R5X@YO,64@ZDK_'E@JQ !9RR5-BK23 M_HQ?B9J'9K)Z+,N>+O -AFD2I2A^ KQ:B?
E&AC@. (EIBW2,"\\7A6=1=!+. MP$^B2,Q*\C-=2!$%,?9G&-[H/5TW0%02P#:(XBX@+DFRO]+6 #$5>V7I/?BZ M<_OV]<@TAA_J5%CB-8]!4Q3(DE9.@9HZ=(&"?T3)+?
HK9C>$R7:2_ 6Q /V$ M*4H)1R'<(GHOYHCB9!5_O_M*Q@^9*&5I?A'P(V%Y^?SLDSU%2U'=R^Z9^@?O MZ\V\EV\;C55+ZZ4_-\M5PAR5,%E MKY"_Z?
8:'3P'3-.R+7/T8L1K]7QN+JB$.8<1&-9('UC6BQ%/I5-/$:PF\V4E M\^7Y,J.,B^J&_/MR$ENH?'FHRMHQF]< M["CAJE)()6VFE.8HI;E*:9XJ6CV%S%T*F?^[Z-$%=_9Y*J;'+*.R8H[D FQC
MQI@'$X-B.'[Q/&GW>78NJ*0Y2FFN4IJGBE;/A=W2J=&ZO/9<8RSR>4OKPT?I M.JE2VDPIS5%*K;L5DL-^W<^?%0N,$Z5TF9*:8Y2FJN4YJFBU5-H MMS1KM*_-_LKV]_(W
MPG2=O]>7RU^B?"C> U='JV\'/N9OS+5=\^+#@UM$UZ+^@!"OA*G>&XJ.TN)= M?K'#DS1_E;Q,.$^B?'.#48"I;"#.KY*$/^]((!]47%9/_%!+ P04 " #P M@6Y9QHS;U%@# #3#0 &0
'AL+W=OJP6 )M\SGJNAM]!Z>>K[*EE 1M6)6$*.7V9" M9E1C4\Y]M91 4PO*N!\%0N_"TW$8&X =\9G! M6NV\$R/E3HA[T[A(AUY@(@(.B384%!\K& /GA@GC^+8A]:HY#7#W_8']W(I'
M,7=4P5CP+RS5BZ'7\T@*,UIP?2W6'V CJ&WX$L&5_27K\G$6.1FGL#PA<7!$HB!JU07DAD\@07AHX;$C MG+@J3VSYX@-\VT(<825FQV>48RG@>&JW^#53]^J(3)A*N%"%!"Q0N;/-
#KG] MB&3D0D.FOM:5IHRY53^SL8]3M:0)##WT!P5R!=[HU8NP$[RM2\LSD>TEJ54E MJ>5B'XV%TG4"G:CZF$B=MI*G8WF,+:YPW?5:[2 (!OZJ)NYV%7?;&?=-CL;+
MV4_<<',T7%6GP*P#7GX):!4Z*!@J>SK.GL5MI M[#HUVAVX,CNP3IP3VT!<]X_RX!+KQP?0&9H#2M0VGBW M(K>7D-V!K+4%)V%36W@FLCWM_4I[_[]Y9_\YD_1,9'M)"H/M
2#X)_=TPQJL M[0U1^]'^&>X<7L(G.ZB;HHF.L(F'AM%61/1T%W5S-%'Q=*)]G=NC3.@\!/S% M2=W@)@+CNK_K.B_U=X[-&L";UT@S0#\/A-"/S3,!-4];O0+ M4$L#!!0 ( /"!;ED2M7SF?
P8 #=" 9 >&PO=V]R:W-H965T=EI20>!IXW&B8\2@?3 M2?G>9SF=9&L51ZGX+$F^3A(NG]Z+.'L\&_B#YS>^1'=+5;PQG$Y6_$[<"/5M M]5GJJV&E,H\2D>91EA(I%F>#
<__T8N05%D\*4VRR[+RX^SL\& M7M$C$8N9*B2X_O<@+D0<%TJZ'_]N10=5FT7%^NMG]:O2>&W,+<_%11;_'2?*=QVM!/D1"!PMFWV_:;9X*5FQ>](4.\=";R M-52_@*M?BIFN[I?
5J5U]J!U0>2&HO!"4>O0%/6/YNV3HGGR)^&\61BD1. MK@7/UU+,B8Z]+V*VEC)*[\I2?V6IK-YXS_,H)S\^Z0;(1R62_)\FYVQZPYI[ M4V3N:;[B,W$T*F9"_D@!M/??O%'WA]-
KD(2LQQ'*\=12'WZ-5,Z,A95C/#2 M>4TF;W1&I4[QW?(P'07>L>=YD^%#W9K=%"MK&&SWP8T*ZS5#R1 M:R[O]93P:IW.S?F4)*BMBJ=G.,[3H@TSEDB7A*[&G MH2#$/;X!-!\F-"#
(R7^D+?G#C3H/)Y*:[2+#AOYQOW(!E2JQU&SG&:[T0?IR MR87Q:W-AMR"8"P;E?)CEVN8"/$> &W4>3B0U>ZW'(&3@]2H7 E3TQ%*SG6?0 M,P#IS"$78"$'>D(0LHVM+0O"J-
@VF>"I"-RH!%28=D:D&#S^BY7)P/!L<-*OK$$E72PU>W/.D"Z%%TL=MN=:4&7C_:6-T'Z+#9Y2&$\/ MR2IX"@0W[!H86&JVFPS8TGYM>%-4Y,52LYU7V_-
&V_2FK[P7P2VVM8RVI'0/MU((#A'A[M GZ9@5^&=2 %G))IBZ(E1EB M93"QMD@F>#($M^<<#UW0+3-TR_IUHH"A,C*6FNT\P\@,ZT0!+.223%V +3-@
MRV"PU39A&6T.86P_(E0/F37"GG-W3!0B' M!H3#?AU+"%$Y&4O-=I[AY!#K6 (LY&PV\MF$L/9LU-ZS"9UD'#RY@COE[+TN M:#DTM!SVZWA#B K36&JV\PQ,AUC'&V A9[-
W#TOLN8D9Q WWGF_H)*7@*1;< M*6?W=,',H6'FL%]G'T)4J,92LQ_:-% ]PCK[ NYFMU&K?$F-JP]U5_\I,(U MEW>1SIY8++2R=W2LLU9N?J5@"SX4L"NC/%UFFGB^* MWPZH?
BMB^C]02P,$% @ \(%N69TY-C9(! YQ0 !D !X;"]W;W)K M&ULM5A=;^(X%'V?7V?7E=D>MU&WB)"24 E*!"5MI MJT7M=N>AV@<3#$1-
[*QM8/CW:R=I2D@:P:?)PC1/$KVF*B>Q94I8@(:ML9?*48;3(0$ELVI;EF0F*B#'L M9VTS-NS3C8@C@F<,\$V2(+8?X9CN!@8TWAH>H]5:J 9SV$_1"C]A\9S.F*R9 M)7 N(.]*704(+/X.\
([?E &:BIS2E]5Y7XQ,"PU(ASC4"@* M)/^V>(SC6#')&%T#+/ 2;6+Q M2'>_XV)"'<47TIAGOV!7V%H&"#=*<"_+@9\'*U[&),:!+&=$,$!S.T1W/9=C'! D4Q
MOP2_@>>G";CXY;)O"NE58<#I-7"L*V!;MML G[3#)SB4<)C! MG09X<+KW)OCT=.]V%6Y*I4NY[5)N.^-S/N1;RI8%&&$B2P+,8D3 ).)A3/F& M8?#RA^P&]P(G_)\FJ7-
VMYE=I:T>3U&(!X;,2QRS+3:&W[Y"S[IM$EXG6:"3 M;*]D)K!(BIPR1T\8^_%.L,9,ILE@+:;X6FH*1\W@9CTKYVR&T?=^RK+ZY/=2Y M;N=UG9I9T#JL/X04V17]2YW8ZL%,C__Y_R ._
MMLDXT'5KY-.ZG6U7=Z.*[-U2]JZFG-^MJ="%5CWEM[H[]^ONUG?J;)LY%D>3 MTXJ"-Z6"-ZT*J@,J^($80TK MD3?RG-N%M%)%N@DFVHBJP0#6N_W(NM34WU!
MKRE*6MD"K6Q376S50!U<8.%G)OR"O7(ZOVDXQ#?80:>>0H+VT9ZMK2:VJK;J MMEIM>;\@TNOGWMVK9U6UID=7A[>040>,0Q M$G*1S1 3^RO (\7PSD5WA(,5P]*& ;&6"
[#SJPJHO*&!,4U21/:*#?JW_$O$ M^48R(;( =".XD(6(K$!(DX02P 4-7YLD,0^>3A+,5MFK& ?9#/,;3]F:O[R- M8&^U-H-_8X;X]XYKOK_ GP ;%5)"470-'O4F5,A:)
(5UQ@M,%,&LG])J7BK* ?EV^;P/U!+ P04 " #P M@6Y9US5)>*,# !Z"@ &0 'AL+W=O]7#-3=(@'DK;KO]^A M9"N^R&X?^F*3HSF'9T;4S/0W4KWI!:*!'WDF],!9&+/LN:Y.%I@S?
2>7*.C) M3*J<&=JJN:N7"EE:@/+,#3ROY>:,"V?8+VQC->S+EZPOV1SG*#YNAPKVKD52\IS%)I+ 0IG ^?![\6^9P&%QS>. M&WVP!AO*5,HWNWE*!XYG%6&&B;$4C/[6^(A99IE(QW\
[4J&$+E*ZRA#D#!Z21*Z$T3!F6S8EFY'P M@ADSF)))F2W9G/-$PY-(X/49\RFJ[^3R=1+# MS1^W?=>04GN>F^Q4C4I5P05577B6PBPT?!$IIL=XER*LP@SV88Z"JX037-Y! MZ#4@\
(*H1D_\Z_#PBIRPRGI8\(47^&*GK)$APX5 LTJC4ZPT\?_99W7Q?Z;R([2D14)2*Z MQCX0)Z@8(-'5!E?#FP;E^V#H/*C[W"UM=_Z*^5J6O M=54??>)4O>E;YP(2IA=U$EMG1W\.HS
XUUCCZ+>MQ@LBVY7(]J^+E'E.?8(* M8O+6 &9@QKB"-F?2ZIF=2GKGJG0J7#^YU9VSB]<* M.^>7^OHQ%R[U.7?H1]"%H+K.B<'WWMN']S,!IVWC [6-FN;0L-WA#FX^?>P$
M@7=?>11[__Z67NIQMVF YI;AG4MNA(8YC3<&%9@%UU[_8%KO2(F)E*@<4<;5KZ0PVM45[_<@U::HYH7(XF&(L+RZZ^LU=CS4#3[ M$_O(CD-U]J#W6.?
_T.W%W3J[[^WG*O==4#F5/3-%Y5-#AC,2Y]VUZ1ZK'_4$L#!!0 ( /"!;ED5 MB'-ED@D /1E 9 >&PO=V]R:W-H965TU'-16@-
C=BH&G>W^O83UZG#W%S^ISEC\6<=BXW=2'LI=ECV6+[[,SCJ]LD4\YE-1(D+Y MXXE?\C@N2;(=_]30SCIG&;CY^RN=5@Q MN,F>_^#U ?5+WC2+B^I_\ESOV^N0Z;
(065('RQ8D4;KZ&?ZH.V(CP/&V!+AU M@/LFP-L6X-4!WIL U]T2X-K<:FJM0 MA.>G>?9,\G)O22M_J<:WBI8C$J6E%&]%+M^-9)PXOY7:GBUC3K)[T*F;UD=*=UILM5)G=+)H]<
M9ZF8%R1(9WQFB_L\>-=\
```

```
!K3SH(Y/*G/-[,_B6C[W $ &%3!D7 M6#<;N )*C2? \;MVZC4QC>%A?^?]BTU>)S/'$JXXO2.Y6HV]@8=R6. U5;=\ M^Q7JA"Q@QJFTOVA;S4VZ'LK64O&B-M8$!6%5BQ]](0X,XNB$050;1):["F0I
M/V&%TY'@6R3,;.W =&RJUEK#$6969::$?DNTG4IG>IGS-07$%^@."X&90A.C M%%&/Z/TG4)A0^6'D*QW+6/A9[7=:^8U.^!VB:\[42]+/+(?\7WM?,S:@T0YT
```

```
M&CD=SJ#LH#BX0%$0==%;Y"YP@)DW3@BQ(T4L8T0GXAPQ8M"?RZZO*<_MH]YM4F&6$[:\0'8$L9T5W^M%+,,T)6C2K^*D+/1C [>)/&0?28CT;^IH6L MUY#UW&1V,T"\:$WMP('D'D1
(J!*T!=L^ZZBM_1\> M&V$8Q\FIPS;<%Z[066:>H>__E$^('!^=(%'0Z9TX0L]]O0]?6;!J/CRG;7 . ML-.RY99P7[#",RN6&_D)/8^+5YN>_L$UK@"QM)=5B3*^9JJZT35/FPOQI+H&
M[J=7M^EK+'2!E8C"0IL&G403B.J"6@T4+^VE<,Z5OF+:[DI?ZD&8"?K]@G.U M&Y@ S=^$]"]02P,$% @ \(%N6>Q\M-M=!@ $S, !D !X:"]W;W)K M&ULQ9OOC]HV&,?_%8M-
TRIU)+&=!#H,J;VV6J5U MK7K,^J+:"Q^8(VI^,"? G;0_?LX/XB3 0\CL(EX)\U'-IGM$_$U M77.>H<<32<;+AL?QFE8B(9?)0/%CI1G"V+#!%H85M
MVI,B%L2C^:SX[*.8SY)M%@8Q_RA0NHTB)IY>\3#9WXR\'#.LL_L.:S M#70@=SS[8_1R".K5ED&&$8_3((F1X*N:T4OGO;U;="A:_!GP?=IXC_)4[I/D M:W[P;GDSLO,1\9
OLER"R9<=O^5AF"O)9G,/4OY M;1)^#!;9^F8T&:$E7[%MF'U*]K_P*B$WUULD85K\1_NRK4]':+%-LR2J.LL1 M1$%R1R%M+M?Q-M49NBM\PFB//3>)
<)^6T@^V7S.SDOEMN0HV2%/C,A6)REZ,.V2S,6+X/X _X9HR(_1QA&1,3X[F%N[_F"IG=*:H3 M8#BD+BPI].@9O=N0I6FCJB@1+A(T)=?95/T+N 1^M>INI6Z]+1N?EF_2#=L MP6]&\KI-N=CQT?
R'[QS/_OE4TIK$6B6@=0DHI#[_;1O=OQNN!XZ_G_Y3W/1W[R[(-2-MUYX=36*M;+TZ6\_0!/5TED"36*L$?ET"7_,$]7M.4##NP*PF=5:3?M.XD8.6]^#\+I];_$(:L9#WTRT+41BLL<_<2;29Z<*(>FJ.B)
M,(I*'6U!I8(FF=8FF_4K$U9WM1(FJ.SG;B&#!3Y6C#..WY@.V MQZ[?F0W@8 :FZMC]#F]?9VOH'_2)O3*_#_(RA[P.%K[V2M>EUBY# W0<0WY7 M">LJ@R:U=AFP*@,&9T
YYF49+D_N2JDYN^F8N)W)#<<:FH_"+ =$F $>7@DV M3=RGMOSK)F:"G1P%3PY,3T9M_$+L@X]/>O@X+#6T3(K9G](0!J>IQVQW>\UV M$\CF*&9S0!X"O/SW?0)[N59]TZ76+H/B-
L6:R*P]@PG..HC.G)YX9L3XX]L'Z_(/U>>>=SP378<5U&.:Z*^[DE9)# M&N?='5/B=^T-#CDT)<5H&(0??5Q>O>F1L D:PXK&:$QC@)^O!8?I'):^ULIT MJ;4+H3 .FUHNPUK7RW2IMBF\TK# -
:\&T899^ M(3:I+'U;T^SDK*?#4D/+I/@.PWQWC:>72EYK$;1[TDU@&E:8AN'U-7UVJO?(-MU02+8<5BN.>]VY&3OTVV C9R3;15U<$$NV'%;GAJRL@UX515!A-P1A2<$1C. MKC?
R2K"UMDR.5R7@N$/S4H1&>A*."1^_$/O@XZ2'C\-20\NDN(YH6V4COZML MQ!]W.16.-S2?QF8FO,JFSR-4%A1%$8Z;GT=NSEP0Z&MM9M4EUJ[3(H*",PE WP=UL(#CLT+45GI">=&;%R.'8? M%
(X:"Y\$X7!#TU%<1K[1EF<5YT*R)NB+*OJB0[<\M[X)'T+]AX6N-2Y=:NPP*UJBI+4^J=5TV MA<,-34VYD/9??;R*.P@XN*A>!HCE9-S M&V?
E$PCUI_43'R^+YQPLU;Q\7.0]$P]!C**0KV17>^S+"U:43V"4!UFR*1YB MN$^R+(F*MVO.EESD#>3W]R3)#@=Y@/HYF/F_4$L#!!0 (/"!;EFRZ],: M/P,!P,_9->&PO=V]R:W-H965T1:+MI^]-
%6W]:)(#K"9V9AMHI?WXV4Y(4A'<,KX0._$]M!]QSMN\8[QA_%&L-B9ZRE(J)LY8ROW)=$;\APZ+#,/UY"RW<3QG?V+>[):2_W" MC<8Y7L$FSA!M)4(RD>?TI0I_*I#9OC/?I7$[P*9H%$W+#T@21R
M/7&&#DI@B3>!O&>[;U &9 C&+!7F%^V*M6'HH'@C),M*8\4@([1XXJ=2B(9! M-SAB$)0&@>%=.#(L['$T9BS'>)ZM4+3 O,JL5;D"-59F4NNOA)E)Z.Y2G.R M20&Q)?J9:Z$$FFJEB'Q&'V]!8I**3V-
7*E_:PHU+W.L".SB".T)WC,JU0%]H M LE+>U=OK(@&>Z+7@15P#GD'=;T+%'A!#[U'+A)KS$&4#XN';B5%UWCH'O%P MP[).[9.Y9/$C>L"<8R]5'"].F0@'9:X?41^]*Y#B&B;/.C "^!2?Z\.X/
MO<]6PKV*<,^&'OW89 Q@.G.LS)PZ=D)BFA"ZND +6!%*U1#),[H"*PT31GX0!F%_[&Y,J/4K:GTKM0=S&B"YG&Z!J],.OCP!CXD-,.DAI?DZF2V M$2P<#1H$>UI'A
(OK/B%ITEW@58ZWY!8Q;*"MF<;61(]]-@.SE.SYF[7TNKF M=/[#BO_P5+55/5D"49S=&-8731 MP8;U>YUA.U'?J^\]I[U0-H21K5\Z.>WK2_49I<]3MQF-75.[I_\((JB#",ZY M9,$\[0D(#]]83UVRO2-
;HJY7OK6ZO$'?/;E7O.T>[-CN]#.XQJ\N3_X9J6F? M?+Q0S8=5O]8*99.O+E'^>36]0?#M4AY6JS8IW4;#E@%?F;94H)AMJ"QZM^IM MU?I.BX:O7E[TS7>8]THJ4
I+9>IU!HH!+UK18B)9;MJ_]9,JF33#M6K?@>L% MZON2,;F?:-25'X+H'U!+_P04 "_#P@6Y90NJ5<#$% !*)P &0 'AL
M+W=O49%THZC))L9:R$VEZ:9^6L6TVR0;E@BOUFF/*9"WO*5F6TXHT%N%$;3_D=GT_3K8C"A-UQE&WCF/*7:Q.ENYF!C?V#^W"U%NJ!.9]N MZ(H],/"GYH[+,[-""
<*8)5F8)HBSY=@9EBJ1RQBOE 05'X\L4\LBA22[,>_):A1^52&S>L]^]_YX.5@'FG&/]71 MWV$@UC C,*" +>DV$O?I[C=6#LA5>'X:9?D[VA5M1Q,#^=M,I'%I+'L0ATGQ M29_+0#0,L'W$@)0&Y #
.6)@EP;V@0%OCQ@XI8'S5@]N:9 /W2S&G@?.HX+. MISS=(:Y:2S1UD4<_MY.Q"A,U41X$E]^&TD[_'^3,"[810^D2W6X4=OFZW8I_MT"0(DQ62'17SQ3/C?
IC11]G\9X\)&D;9!_01_8A,E*TI9]G4%+)/"MGT2_]> MX9\<]3]! VDBUA("5C0MC?E6*H!D?V KHD6\:^(.Q>(&(1NZ,[G_36O]-D M@,CH]+FG W]@FP&RK=SQCW5&D?+R6ZRA
M=_1%KF^!KCBGR8JIZXN2V8L]LPS=\=!GZ%ZU0%__D'#HLV!Q]D-'6*X+WTZW M;Y7@+K. ]=G,D!DL8_R)&?.??L!#ZY?>@*N=XSME!N-MVA7?[[;TM)9]IS406(N8847.$(
8MD]*&Y64NDC0>ND[[R'IO.]LU\C0]F0P M.ISVKULYU@ ?F26C*K@C,7"+Y'TK4_?7&Q8_.MZ9O+48?4,'">9!@BV P%I$ MC"LBON^X*XXA"80$\R#!%D!@+0(G%8&3-
ZPD61BS9_]4*M(B]:4#$LR;O$HR MV!JX!YD(R&,KS-BJ-8@%4>;H4?H&&13.*]%:)B&V,/O5A'I M7?=F!Q+.,Q&6<5%SH1&*"S$Z1-%]Z:K!%E#];A-(:@+)_U(YZ=WT)@L2S2O1
M3F0L*)]M(FIEC;6ZK]P;ONQ2;96E!^D=9E"1#(JV@$)KTU'K9.R\8ZV%004V M*)H'BK: 0FO36-MVK%>_?2HN/51O4B#1O!*MF<*(^S]%G4.#XUJ$X]XJO#/- MH"H;%.TKT9I5EVO)UV&@@9RV
UT+MND"%/"B:=R(L^2K+WE==>'R\ M[#]'D.>UDL=:G0E7=H&J=E-TKT0[E;/ (4(5!=:S-8"WR2>] P[^K"M.[Z*]J?50;&K_B463*&Y%N\I-)CZD0:9Q?KAD-&%<-Y/?+!7[&^6@.CXW M-M_P]02P,$%
@-\(%N623I)P4/!0 +Q\ !D !X:"]W;W)K&ULQ9G;;N.V$(9?9: 6Q2Z0C4X^)*EM((DL-T73&AML]V+1 M"UJB;6$425I.WI[DI2B2+;,C0,"S46LP_P?*L<8QR$=9$/)=GCS$8\N1/<(ICKA$(/&S MQ?
\B*1,_8==%>M8$&T8)UDE%CW(DKS\1<_5BV@(7/^$P*L$WJ&@=T+@ M5P+_4__(>A5@MY;!?U*T#\0>*<$@THP>.LS#"O!4"6K?+LJ-0'B:#*B9 =4 M1@N:/%#Y56]1D2275GSB5-Q-
A(Y/[DF6"4<\<1)]AZ^(4I1S!BB/X:]">H7! MAP!SE*0,_I1W17$^PB?X\A3 AY\_CFPN.B%1=E0U&)0->B<.=.&1Y'S-8)K' M.,[03_5Z_T?Z4*^_UNAM\?+J_^B]O.$[3PM\1'MP^Q?@.9[?T9U[O?IWE%^"
M-SPI#_3RVX)>@N\HN=?U.O7R)US4\][6P[?+>QWRV;M;;V7"K[WL*YY_BK=& M%'^Z$P-3#,+78K1F2(UWM]+6*RQ&4 Z+/33CYFBO+M_N$(WAVO\""0\<9^R?
MCN>Y*]OO=;O=I>/1U]\C(@BH+.N!@ADWP%2%J]\1,TRA IEB#7BBJH,(6FM M"R#E4'.!^!G3*&%HD>(+V*EYM8A&6TS%=X+X%) ?&W(AWF> M=Q0V.PYS??^J&=?
*X%6=P2MM!N<,&JW%2"&^S "M5A2O$,^<;928?K/]@?AK M]_+^,$H&#=M1*_,*ZW6=UVMM7]?E^(ZAH$G4F=!2/VPF MU+GL'^3S.,CK'P8%VIZ>JX'C-)"H[29*5K;!HU5-?
>-%;[Q*-UWCHK)?5=<-MSSD.#/2].3NO)FFA4=K,%*V=5^\UKYY^#2##+D\6&P4,>B>EZLL4P%U]_\.T1-M9PM..]>.],1SYU%&:8%1VM0H+31*FYFBM7WSNC+I_M]+DZ[1M4FCM,_H;6J4
M%AJES4S1VC9[7:%T]4N4:UR9TE/.]HK11]KW.@^NAW-U6VX&OF'(K^1'1 M52(FHBE>"J1S.11/2,O=V2*$DT)M#BX(YR13AVN,8DOE@+B_)(2_G,@&ZCWR MR7]02P,$%@ \(%N64T$(VZO$P
C4P! !D !X:"]W;W)K&ULM=UO;YM,NL?QMX)RCHYVI9[&X'I)3ONI#?\I&'5ZMY] ML#H/%2,[J;O0%FDTVIX[X!8>%YT"P[I_&':^+*1UY\+^^S M;&/]7'Y6Y8=S^\UF_>
[\O)S=9\NT?)NOLU7U+[=YL4PWU9?%W7FY+K+T9C=H MN3AW!H/\^3*=K\ZNWN^^][FX>]O-XOY*OM<6.5VN4R+7Y^R1?[CPYE]]O2_M+_[^TW[C?.K]^OT+ON:;?Y8?RZJK\Z?
E9OY,EN5\WQE%=GMA[/]CLUO;P'M[+;XVSS[4,[XNU7ORK<\_UY_(6X^G WJ1Y0MLMFF)M+JCX?L.ELL;JEZ'/]L MT+/GFO7 EW]_TOW=SE<[\RTML^M\\??YS>;^P]G%F763W:;;Q>9+_B/,FAT:
MU]XL7Y2]_UL_'K>=5AO/MN4F7S:#]T>Z]^C^(%P/LX2L#G&:-<^R M83-@N#]@]_1 43-@=.R<3 @?.R 23-@LC]@_J.3-@>FR%BV:-O;$5+IL!-ME\=6L-=/S]S@Z"'/3W;GV7YUR/3;7>>
[U>'/#WA]M'/N/WTE-N[Y_S\]==W M]OOIIOTZGV1_["*>OO*]_^RFT"[\=6O-'Q5S_6OFZ+ZUWDU;G-UG2^7\TTU M>3>EE:YNK.M\M9FO[K+5;)Z5UE_<;)/.%Z6ETJ)(ZUGY5^M_K3^^NM9?
_ONO M[\WU0.HF?-94RQX+..\4FQHR8]_+RUO=9/=](P7YO&7AO'GU8X_[[WSM/>?M'".HTU^6,WA3->>.>A[.]>'1]O#5T:YY=+1=O;7LR6ZXW3/<.U2\>&LYKP_W M#U5?5-4QZN'VI.^9
__FJW?6L/7?W+A\<.'?;\'?ZYZ].>JOT<!<&;JB7GX MQW7]Q(U?2[-P]UL5E6W7WWPZD#U[5U5?,0;[AAFT/"Y?PQWWO-5+\G+5>NTUGVX:PZ>"FSXB$]N-J_[(G@_K
MFZ$DYI*81V(^B04D%*8(+&(Q(&(22TA,DIB",*V5CY;R23FDUCPB(UW6+VD?+ARG.%HZ%R\ M/W]XV2^(HN+(HA%9-":QA,1D]\=A#R\&D^%0_W$HJ*@VK\?/WILG-U.M;
(JB6G'TS6HC=>JL)C&?Q#P2\TDL>.0F+R?8Q'8&@\'> MK":+BB,+1F31F.02$I/='T?=X3H_#@45U6;UY'E63XRS^FO],MVJ/%LWVZ(Z M_K?
663'/;]Y8#^EB6TWSYA)O\*]]\]G6=DWY8UU3]WR).:2F$=B/HD%)!9. M.K^MCWN_J*2<+\UV#0G?%=;C3L:A:3NY"0F"0Q'6';A)\^3_BI<<-]<2T MF-WO3A/>9
_9(E_7YPVM[,F]+O=V!Y<=NU\9CW/XX]W19;M9O_9+;EA6]9^N,^*E3F,1<$O-(S"">Q@,1 M"$A,D%I%83&%)B4D24Q"FM97+Y[9R29-XOR1;"8FY).:1F$]B-8F%)"9(+"*Q MF,02$I,DIB!.;R7VH
TA#,RG".^]8Y&=[=)-9Q6^L,LSXJ8T%U=O&TTYMV3T+ M70\MZZ-;@@&HAJ@E4BU-M1K4$U22]*4K3^]>+$). GYLPDR=W#5)S4PZP7:5SF9%_1Y$NMR]!=G;!XS@R7V
U%Q4\U#-I6(6@T0QS+40+BL.%((1@-MC&H)]DE44Y2FMX VD6@:XTKU"<^A]76=K]]V;^B><[S?C]O#-]Z*:AVH^-MJ@6K9]*.0+4(U6)42U!-HIJB-+W)M%E%>T2?_K3)Y-3GH]@H%6%W#-
H4]'TH!FI/K_5-ML](Z$O^SA;;KL-FO9LM,F! MWQ@7K>]AFM^S#T[/G$/4!6C5$]:K%]):@FD0U16I42U!*W#;5F"^.?.ITOMID M[IW0URZS;KA/8_UX.MWH8!'.ERTJH=J?]J-#NO#@%8
44V@6H1J.:HEJ"91 M35&:/OQ;M*=C3GM^R7^EB\VO>N;7UY^95;N!]*Z_";#)3E1S4_;P6B_4Z"13503]!:A6HQ"-.)5%.4IG>*-K+1&(.5Y^S8G=M_/HX83E?
M9.4F7V7U1>EV5[_N[1ADKNRZT;2+1-0?Y!E/53SA&VUR:"<^M&R(:@+5(E2+ M42U! 8EJBM+T=M#F+!USSO)K66 8QL!>EG*1NNN'S]_$U5HII_[$X$:-D0 M0U22J1:@6HUJ":A+5%*7IG:
-3#KFP&10U.]7EG4[ZV[W]:#;2Z>;CG/&@7 ;C MP4=4\X_?C0 M'**:0U@(U6)42U!-HIJB-'W^MS%)OQR3??#P0*+*';+7M/W& MIB*=GFLCI]!_/"(:OZO.Q@@94-
4$Z@6H5],:@FJ2513E*/_C87Z9ASD=?; MY7:QN[65=?7@0 !/S9;SPSJ-@(TVHA]?]_#N]&@!8.44V@6H1J.:HEJ"91 M35&:W@&K:W^)C3"\]OY5@"A.A.<5&ZQY%S<_(&(:CZJ!:@6HII M0C58E1+
M4$VBFJ(T46U3Q4\U$M0+40U02]!:@6HUJ":A+5%*7I6:7-4+ MUB-8%)@M036):HK2]!:01BN'YFCE[ROM MYJO#2QLTA8EJ+]IY]:C6H\H]J(:H)5(M0+4:U! 4D]BE*TSM]F/E^<<3O"E#9KQ
M:C&J):@FD44U3H_P6V>^F:^#G^"U"2/B^U"2/B&H"U2)4BU$M036):HK2]!;01BN'YFCE[ROM MYJO#2QLTA8EJ+JIY]:C6H\H]J(:H)5(M0+4:U! 4D]BE*T[M[F^<<3O"E#9KQ
M1#47U3Q4\U$M0+40U02]!:@6HUJ":A+5%*7IG:7-4+ MUB-8%)@M036):HK2]!:01BN'YFCE[ROM MYJO#2QLTA8EJ+]IY]:C6H\H]J(:H)5(M0+4:U! 4D]BE*TSM[F^<<3O"E#9KQ
M+_+MW7WUA3,PKX70."JJN:CFH9J/:@R\@&JA:@F4"U"M1C5E$23]8H\/#/5T_7<[[O-S5HU1!5!!;!:)1]H:C6HIJ(:H)5(M0+4:U!4DJBE*TSM MY-V1]:3F
<>%C+GER4T%OVXY]'JKYJ!:@6HAJ M4B5(M1+4$U8B6]*TO36X[2M MQZ$7/B,T.8MJ+JJY].C6H]J(:H)5(M0+4:U!-4DJBE*TSM+FYP=F2\X^G&U MVJ]8+]VC>'S)=
LPLG=O1T,0LJGFHYC?.H<]%!VC5$-4JDGH\N@.:FH2U12E MZ,VBS<*C$&[WUP C(J+JJYJ.:HEJ"91 M35&:W@&K:W^)C3"\]OY5@"A.A.<5&ZQY%S<_(&(:CZJ!:@6HII M0C58E1+
$%$)]O1347U3Q4\U$M0+40U02]!:@6HUJ":A+5%*7IG:7-UX[_MUTL]YIT?.$_.;:)VK&^S%W]"B'JKYJ!:@6HAJ M4B5(M1+4$U6B6]*TO06T09E M1^:@['GG2-"D+*YJ]AFC_J7H&U]I0
5HV1#6!:A&JQ:B6H]I+45]>K-H ML[*C_T!6UIF:3Y*@&\5A4WJ]I!J&1347U3Q4\U$M0+40U02]!:@6HUJ":A+5%*7I!#<9I&PR> MAAVC:5A4+-8+P
MRL2'RT;H%]J(:@+5(E2+42U!-8EJBM+T)M(&'K@&K:M) M)T/(# XUJKFHYC7:H9"[CU8-4$U8#&$X:K'6#:AFNJB-K%UXOV=.ZK&CX%&Y#8&N$.UV@DU16IEZKWVSUV/SM6,_M9\5M7BQW!Q3+^2(K-WFU3C&V#&2VBFHNJGF-
]KE#.W>XPLTD8IJ(:H)5(M0 M+4:U!-4DJBE*TWM&FT@=FQ.ICW?P/K):@FD0U16IEZKWVSUV/SM6,_M9\5M7BQW!Q3+^2(K-WFU3C&V#&2VBFHNJGF-
M"/3RK;@6HII M0C58E1+4$VBFJ(TO46TD=2Q.9+Z>$;!19_9:MM_3A/-EZ*; MBVI>H[UL$KTI"Q@\B&H"U2)4BU$M036):HK2]!;11D2'Q@#9U?5VN5VN5D MFS]]?G?@@/
C**.BVI>H_7TBFZW0..@]!:@M$MM036):HK2]!;01BN'YFCE[ROM MYJO#2QLTA8EJ+JIY]:C6H\H]J(:H)5(M0+4:U! 4D]BE*TSM[F^<<3O"E#9KQ
PA_.;H;QMH"A357%3S M&FT_\[W?=.!T]ZJ%]"90+4*U&-425).HIBA-[QI.VS6,&:\CX^/U33;3GP=O MLFFN=?(O07.?].:AFHJ]ZJ%]"90+4*U&-425).HIBA-[SEM[G/R&!D#$^43 M_>*:BZJ>:CFHUJ
:B&J"52+4"U&M035)*HI2M,[2QL6G1@@#9B?<9.,G=Q0 M2,U% :,_1]F\..MY?]Y!%U0+44V@6H1J.:HEJ"9135&:WBG;J.C$'!4]MTS M7Q0U>]Z Z4E1S4FMHHVG3LSQU.M?F_QA]^;P_MIWF^R_FL]
(2]YEY?8,F5E'134/U7Q4"U_M1#6!:A&JQ:B6H]I$ 45I>FMI M8M3(JH$S3?BFHNJGFHYJ:@&HAJ@E4BU-M1K4$U22]*4K3^LNTC7?+F=?&'U'\'!J)5%,4IG>$-NTZ-==K]/RWOA9??/X
MDV<.FFM%0_5?%0+4"U$-3@_'MYH&'HZ'3_N]I3N_N@QA]FJ2513E*/_M?J]=_>-43ZG6^7.8K]I8DJSDL^JOK(^K8J8#BVH>JOFH%C2:
M]FKK3,>74WT6A3W;C:>CX=YFXD@N.HZ+T7U-4$VBFJ(T?>ZVZ<^I^J?'V>S M?%N]:->OWO6'4MY8LVU15"_CO3,7S7VBFHMJ'JKYJ!9.N]AY_0M[MK/M MGH_FB2/!Z%@P1OF=I0UI3LW7
_VJMOK0F";JN:CF MH9J/:@&JA:@F&DU;R?2_U#=#\I6W&M\P):D!5%.4IG>$-EPY-8FMI0UC3B_P9OR:Q40U%]4\M5/1+4"U$4$JD6H%J.:@FH2U12EZ9VES.S9<8!?
ZYG6]^6ZC^7^POMGN\+^UVT^-YYRU^7U<=0:;%W7Q5 M6HOLMBHU>%N?E2GF=_?7VSR=;4'9]W?+?]E[N W?I35;4&U3_?!OGFZN_@U02P,$% @ \(%N69[_RN"I P :Q4 !D !X:"]W
M;W)K&ULM9A=;]LV&(7_"J]GJ;$!0?:M(&DJSI-Z'T2=#,M!(E[Q!_G]I-;A1Y>;R5*$"].*H*"]Z?&F8J!Y>J_Y&:YE<-K]+WPJ)5VN5VN5D
(SF4%2'W\N)#MK<61\6$4 MD'\P).G#S=@%XR;)=#(!%(ZOC60]VN3RD\G^B_P.SP@O=N2%ZR01G'-'*N;U^.]*?M!'%H+MI5I\IQ/7#JF0'TYJ&M)7-'!@*RIJ &$J%
M=RKPSPC\5N#_!]*PA.!>$90=@*U^M9NS*N!AS'.TI.2_J6PN;/%'N*[7P M*Z_D'V7J7B:"QV/EKL5@=J#A*]N+(T)L8.,X+AO[E&(9XUOT,_]RC&<MG]J[.;2XZE5(I;3M(F@Z].QUODM?D1NJ
3^@#K6]S_B:H*]V5EYHI>%WZ7G M*Y[_@^FAOW]7+=_'#B7J(EA#^=8,+AG'RHW3%:IS"PA)?'09T#U;T^I4[=7X9 M,MHD+2BB+BP2S!>ID$72?F(]3;M(F@Z].QUODM?D1NJ=*2
M%\\"0)H.PBR$<$0\,$USAE<%H)KFJ3B""F"ZWF,)0 %KTV&A,PF*3L.0%,%TT MTRZ.Z;AHZGPX!2UE; KZDEP'0*F:,CR%RL30P/HF3SK3)[I3?[U/+Y0KH M5_0/^K1>BU>-K>&S-?
2QYIO3A:;A"6&8+V+KJ[+LS.WA.=M\D+3%ZOO M/;OOC7!_#XR?M?'Z.RA?$X!6.3H D[3$%*T?P/.BV=6N_WH!*^]\A0WM<[(;? M@88U/?K8!*'C.*=?8?.+8:.TQ?2ML=L^VFPJ@6[4+A]#*=E5O
EWZNYV.XGO MU?Z9 =R\V8:\O723BW>@@+60.1.9F\Z$YIL\ZVK%%@%%0# #.%0 #0 'AL M+W T>6QE_F>@OPP_NO[EFY4I'3@/UQ\_#,OU/4'SUI\/!V=M1XNKW M%P\X] ,G><
TJL6SJLQC#H^C'HO:TK>W2:OUVNJE2OFV'.XGC=^YYA;U)B+NM ZNTOTPH?>BLTT;&,#'-0.1S\-MZWY S1KXU-';24^^1\)(\$_(IR_M)0.OC.2,+ZVY#89)P0OI*7T7Z' A6"HG"X=V!C=
(S9,S44@3VT:PO\?U\AU@ M-0.!C'-&8-NWAF&_-)I1*6[TQ"PVOA>05X_OEZ56.)5D&;8[_MK!7'20<2%3 M*ILPH:)R#?N<9B]'LND.KJHH P"5*G(]2!F9%H(8#2N/>]!!D]Y3S.WAZ_ZV MN!?
9QKZ9IA# 4 NJAY;&3H!_D\UR;])VWL3K>RQ4_F.AUAYM!K]%;2C"W, M?)$U C#V$&2\IXNU*J=%AFNN7V"FO]MG:=44$GXIFC=^]=%1B@SJX]K&F7#K M1-A8/3AY#_Q?
<([GZZ#>>,ZX8]*>S5B:4O'B8*CI%1GK/U:W^/7ZE&9DSM5] M P\]?@G3=D\3YI5MU">M5Z_/2"^/C,9'2!4U'51.QV,P28&.6G_M81>Y,1\W@OE8S(T AL7!%&
^U@N+\S_ETT/SL1BFK>=$>JA/#_6Q7BYD9+Y8 M'+=/HC_N3),DBN8]^AHY%0PPNH6Q_#C9L.T@0<6!R]KM;X;N.=LK)/L#W=_MUR%8IG@G8IGBM0;$73?P2!+W;F-QP
/,!;QW(+X[#O24VR>*8%C6.D.C%\W?N#W251E"1N!#"W@BC"$+@:<013 !HP)(K,>W#G?12L MWE/!^C^XPV=02P,$% @ \(%N69>*NQS $P( L !?3T\$MP>:4#M,*2VBZD8_1!2:5K5N %(MB6/:
(7-2>=I3W;+T]!;X"O,DQQ0FE(2S,.].W2?S+W\PPU M1>5>Y%5%;&GC3Y?YVX$G1H2)8%I%R=.B'.5_'N75:A+CK%B_Z M)B!@G_+?IM)0NFP8"&!]E.BW'I_+> M?;$.']P)0M6-LTI
BW+HN)$N0/LN4Z0W\3.]RU!S*Y%!]D6!^XP#DX'_H1 M_?%%9%S+.'C8ZX(1O6D.Q%!?G:V6X%9L/$]OBAR^CCL/D=@CCD_B>.=CZ'
M1I[8IM/2A"&.3]H$;/P25KY@1F@Y+3[9M73I>N()SMOAVD*$0I%R1Q [W'G; MX^5$,:TT7K8L,GFKH(T<+?LHE#"9 B2$Y!\AY_(*L",A]Y!UPHE_19 3 M G*R0\BM2.X3D/N[A*P0Y $!>,!+R F"?
$M OLT+>>D6PL!#W\&$;=EG&W>M(FZD,WAV'Q*0AWDAZTYKX>Z9G;,%@;BWX0]+AI;&<"(;AW!.2[O]!G ARI-M$;J3B?,3,P(!0[-SZX3N-DJ;R-?3@OYF/0/+L2]R*>NK_IUVED?#:O!,8D
MI9/9,M^%<^D>?P4QQ"@,$HT96;3U,$VMTNK6NG\#;ZLWO"1OFES"X8K>,T M[A'98P1]?X,O5W$PQ]0,4V97C-80T] !+B:;$)..C/-%>@&:,K)BZFWGY
MLXN#V.DZH6(PRBIE9]V0R7!+T"7EE3*S6&A,K.B2,DN962UDUMZ.)N66,K-< MR*R]AMX3K7V%"RBL\>S5#I,CM0)+E3&;+D*]EVYB4<'AF
MX=3Q&&VG^KES')/XZQ94ETJ]5LNFPP4LIX3#,PN'SD72W39Q3RN&YE8.B>>H# MZ'YV_\E0&),2$,\M((2)TN<7D$ZX9HDQ*0'QW_+"S^;3]+EW@C$I-?'2 =KT4_S3:+'"RR4@*K_B(QM]>!*
M5+UW=Q =2!@'*MLXO8A3$I"U4[J'40*<8DE]5>T$*;R!ZGE=T!%V-2%]IR6^@YF?>778A-I@6\M-_%=1%]I>T$)]V6C\OZ)6:AZ00MM,A&5S<3OQ
D1,;8(0NB>CMQ^C"_W,+&9C^EN1,D+OKAX(S+]\7<9# M>PK5H0O9N:E/89%7,78?SH5-Y9LR#-K.GZYG=FW?E/&Z[/>N*S?/
M01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z%ZAW\4Z]0]34/CQZ M[FN\_SNICM=K_>/VM^5]$Y\7Q0UG!_\EK]02P,$% @ \(%N69C$(26B M 0 IA@ !.
!;0V]N=&5N5=%]4>7!E&ULS9G ;H,P$(1?!7&-@F,[_M37^4Y-OJ@VYH#*PW#_85AQ8E*OJ:Q*V'0YSD_-X'U.]IJ0U2J1B>QA) HC[[Y?IH9C5C7%%B%FK%JS8.2[XGVQXZK7:9XG"1V^F^IF4=1N4
!$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ M\(%N69E&PO=V]R:W-H965T&UL4$L! A0#% @ M\(%N6<<6$;4Q!0 )Q0 !@ ("!+ X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \
(%N6>@S#SE3" EQ0 !@ ("! ME#$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ \(%N6?R_EE\!0 V@X !D M ("![U0 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ \(%N6;D-5*VA#0 [R8
!D ("! M"&@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ \(%N6>C?5!SJ @ =@8 !D ("! (P 'AL+W=O)EJP$ "$#P &0 M@($]G >&PO=V]R:W-H965TNZ ( %() 9 " @2"A !X;"]W;W)K&UL4$L!
A0#% @ \(%N60Z "",8 P J0L !D M ("!/Z0 'AL+W=O&PO=V]R M:W-H965TM !X;"]W;W)K&UL M4$L! A0#% @ \(%N61*U?.9_!@ -T( !D ("!UK M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
M\(%N616(&PO=V]R:W-H965T&UL4$L! A0#% @ \(%N6;+KTQL_ P ' P !D M ("!.>D 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ \(%N64T$(VZO$P C4P! !D ("!5?< 'AL
M+W=O&PO=V]R:W-H965T7!E&UL4$L%!@ P # !PT ; 0 $! end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange
Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show=
{};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=
((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-
11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a {
display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; }
.report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-
size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font:
normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align:
```

~~center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html2132161true680false5 falsefalseR1.htm00000001 - Document - CoverSheethttp://gtbiopharma.com/role/CoverCoverCover1 falsefalseR2.htm00000002 - Statement - Condensed Consolidated Balance SheetsSheethttp://gtbiopharma.com/role/BalanceSheetsCondensed Consolidated Balance SheetsStatements2 falsefalseR3.htm00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)Sheethttp://gtbiopharma.com/role/BalanceSheetsParentheticalCondensed Consolidated Balance Sheets (Parenthetical)Statements3 falsefalseR4.htm00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)Sheethttp://gtbiopharma.com/role/StatementsOfOperationsCondensed Consolidated Statements of Operations (Unaudited)Statements4 falsefalseR5.htm00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)Sheethttp://gtbiopharma.com/role/StatementsOfOperationsParentheticalCondensed Consolidated Statements of Operations (Unaudited) (Parenthetical)Statements5 falsefalseR6.htm00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)Sheethttp://gtbiopharma.com/role/StatementsOfStockholdersEquityCondensed Consolidated Statements of Stockholders' Equity (Unaudited)Statements6 falsefalseR7.htm00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)Sheethttp://gtbiopharma.com/role/StatementsOfCashFlowsCondensed Consolidated Statements of Cash Flows (Unaudited)Statements7 falsefalseR8.htm00000008 - Disclosure - Organization and Going Concern AnalysisSheethttp://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisOrganization and Going Concern AnalysisNotes8 falsefalseR9.htm00000009 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes9 falsefalseR10.htm00000010 - Disclosure - Fair Value of Financial InstrumentsSheethttp://gtbiopharma.com/role/FairValueOfFinancialInstrumentsFair Value of Financial InstrumentsNotes10 falsefalseR11.htm00000011 - Disclosure - Accounts Payable and Related PartySheethttp://gtbiopharma.com/role/AccountsPayableAndRelatedPartyAccounts Payable and Related PartyNotes11 falsefalseR12.htm00000012 - Disclosure - Warrant LiabilitySheethttp://gtbiopharma.com/role/WarrantLiabilityWarrant LiabilityNotes12 falsefalseR13.htm00000013 - Disclosure - Stockholders??? EquitySheethttp://gtbiopharma.com/role/StockholdersEquityStockholders??? EquityNotes13 falsefalseR14.htm00000014 - Disclosure - Common Stock Warrants and OptionsSheethttp://gtbiopharma.com/role/CommonStockWarrantsAndOptionsCommon Stock Warrants and OptionsNotes14 falsefalseR15.htm00000015 - Disclosure - Commitments and ContingenciesSheethttp://gtbiopharma.com/role/CommitmentsAndContingenciesCommitments and ContingenciesNotes15 falsefalseR16.htm00000016 - Disclosure - Subsequent EventsSheethttp://gtbiopharma.com/role/SubsequentEventsSubsequent EventsNotes16 falsefalseR17.htm00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)Sheethttp://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policieshttp://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies17 falsefalseR18.htm00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)Sheethttp://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies (Tables)Tableshttp://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies18 falsefalseR19.htm00000019 - Disclosure - Fair Value of Financial Instruments (Tables)Sheethttp://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTablesFair Value of Financial Instruments (Tables)Tableshttp://gtbiopharma.com/role/FairValueOfFinancialInstruments19 falsefalseR20.htm00000020 - Disclosure - Accounts Payable and Related Party (Tables)Sheethttp://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTablesAccounts Payable and Related Party (Tables)Tableshttp://gtbiopharma.com/role/AccountsPayableAndRelatedParty20 falsefalseR21.htm00000021 - Disclosure - Warrant Liability (Tables)Sheethttp://gtbiopharma.com/role/WarrantLiabilityTablesWarrant Liability (Tables)Tableshttp://gtbiopharma.com/role/WarrantLiability21 falsefalseR22.htm00000022 - Disclosure - Common Stock Warrants and Options (Tables)Sheethttp://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTablesCommon Stock Warrants and Options (Tables)Tableshttp://gtbiopharma.com/role/CommonStockWarrantsAndOptions22 falsefalseR23.htm00000023 - Disclosure - Organization and Going Concern Analysis (Details Narrative)Sheethttp://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrativeOrganization and Going Concern Analysis (Details Narrative)Detailshttp://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis23 falsefalseR24.htm00000024 - Disclosure - Schedule of Anti-dilutive Securities (Details)Sheethttp://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetailsSchedule of Anti-dilutive Securities (Details)Details24 falsefalseR25.htm00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)Sheethttp://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeSummary of Significant Accounting Policies (Details Narrative)Detailshttp://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables25 falsefalseR26.htm00000026 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)Sheethttp://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetailsSchedule of Estimated Fair Value of Financial Instrument (Details)Details26 falsefalseR27.htm00000027 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)Sheethttp://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetailsSchedule of Fair Value Hierarchy Financial Assets (Details)Details27 falsefalseR28.htm00000028 - Disclosure - Schedule of Accounts Payable (Details)Sheethttp://gtbiopharma.com/role/ScheduleOfAccountsPayableDetailsSchedule of Accounts Payable (Details)Details28 falsefalseR29.htm00000029 - Disclosure - Schedule of Accounts Payable to Related Party (Details)Sheethttp://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetailsSchedule of Accounts Payable to Related Party (Details)Details29 falsefalseR30.htm00000030 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)Sheethttp://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetailsSchedule of Derivative Liabilities Assumptions (Details)Details30 falsefalseR31.htm00000031 - Disclosure - Schedule of Derivative Liability Transactions (Details)Sheethttp://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetailsSchedule of Derivative Liability Transactions (Details)Details31 falsefalseR32.htm00000032 - Disclosure - Warrant Liability (Details Narrative)Sheethttp://gtbiopharma.com/role/WarrantLiabilityDetailsNarrativeWarrant Liability (Details Narrative)Detailshttp://gtbiopharma.com/role/WarrantLiabilityTables32 falsefalseR33.htm00000033 - Disclosure - Stockholders??? Equity (Details Narrative)Sheethttp://gtbiopharma.com/role/StockholdersEquityDetailsNarrativeStockholders??? Equity (Details Narrative)Detailshttp://gtbiopharma.com/role/StockholdersEquity33 falsefalseR34.htm00000034 - Disclosure - Schedule of Warrant Activity (Details)Sheethttp://gtbiopharma.com/role/ScheduleOfWarrantActivityDetailsSchedule of Warrant Activity (Details)Details34 falsefalseR35.htm00000035 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)Sheethttp://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetailsSchedule of Warrants Outstanding and Exercisable (Details)Details35 falsefalseR36.htm00000036 - Disclosure - Schedule of Options Activity (Details)Sheethttp://gtbiopharma.com/role/ScheduleOfOptionsActivityDetailsSchedule of Options Activity (Details)Details36 falsefalseR37.htm00000037 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)Sheethttp://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetailsSchedule of Options Outstanding and Options Exercisable (Details)Details37 falsefalseR38.htm00000038 - Disclosure - Common Stock Warrants and Options (Details Narrative)Sheethttp://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrativeCommon Stock Warrants and Options (Details Narrative)Detailshttp://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables38 falsefalseR39.htm00000039 - Disclosure - Commitments and Contingencies (Details Narrative)Sheethttp://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrativeCommitments and Contingencies (Details Narrative)Detailshttp://gtbiopharma.com/role/CommitmentsAndContingencies39 falsefalseR40.htm00000040 - Disclosure - Subsequent Events (Details Narrative)Sheethttp://gtbiopharma.com/role/SubsequentEventsDetailsNarrativeSubsequent Events (Details Narrative)Detailshttp://gtbiopharma.com/role/SubsequentEvents40 falsefalseAll ReportsBookAll Reports form10-q.htmgtbp-20240930.xsdgtbp-20240930_cal.xmlgtbp-20240930_def.xmlgtbp-20240930_lab.xmlgtbp-20240930_pre.xml form10-q_001.jpgform10-q_002.jpgform10-q_003.jpgform10-q_004.jpgform10-q_005.jpgform10-q_006.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024truetrue JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "GTBP", "nsuri": "http://gtbiopharma.com/20240930", "dts": { "inline": { "local": ["form10-q.htm"] }, "schema": { "local": ["gtbp-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["gtbp-20240930_cal.xml"] }, "definitionLink": { "local": ["gtbp-20240930_def.xml"] }, "labelLink": { "local": ["gtbp-20240930_lab.xml"] }, "presentationLink": { "local": ["gtbp-20240930_pre.xml"] } }, "keyStandard": 178, "keyCustom": 38, "axisStandard": 19, "axisCustom": 0, "memberStandard": 25, "memberCustom": 40, "hidden": { "total": 114, "http://fasb.org/us-gaap/2024": 89, "http://gtbiopharma.com/20240930": 21, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 213, "entityCount": 1, "segmentCount": 68, "elementCount": 404, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 564, "http://xbrl.sec.gov/dei/2024": 30 }, "report": { "R1": { "role": "http://gtbiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://gtbiopharma.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R3": { "role": "http://gtbiopharma.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://gtbiopharma.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R5": { "role": "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical", "longName": "00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2024-07-012024-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30_us-gaap_SellingGeneralAndAdministrativeExpensesMember_custom_OfficersEmployeesAndDirectorsMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R6": { "role": "http://gtbiopharma.com/role/StatementsOfStockholdersEquity", "longName": "00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R7": { "role": "http://gtbiopharma.com/role/StatementsOfCashFlows", "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-09-30", "name": "GTBP:StockBasedCompensationCommonSharesForServices", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R8": { "role": "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis", "longName": "00000008 - Disclosure - Organization and Going Concern Analysis", "shortName": "Organization and Going Concern Analysis", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-~~

~~gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://gtbiopharma.com/role/FairValueOfFinancialInstruments", "longName": "00000010 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://gtbiopharma.com/role/AccountsPayableAndRelatedParty", "longName": "00000011 - Disclosure - Accounts Payable and Related Party", "shortName": "Accounts Payable and Related Party", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://gtbiopharma.com/role/WarrantLiability", "longName": "00000012 - Disclosure - Warrant Liability", "shortName": "Warrant Liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "GTBP:WarrantLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "GTBP:WarrantLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://gtbiopharma.com/role/StockholdersEquity", "longName": "00000013 - Disclosure - Stockholders\u2019 Equity", "shortName": "Stockholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptions", "longName": "00000014 - Disclosure - Common Stock Warrants and Options", "shortName": "Common Stock Warrants and Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "GTBP:CommonStockWarrantsAndOptionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "GTBP:CommonStockWarrantsAndOptionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://gtbiopharma.com/role/CommitmentsAndContingencies", "longName": "00000015 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://gtbiopharma.com/role/SubsequentEvents", "longName": "00000016 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000017 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000018 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables", "longName": "00000019 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables", "longName": "00000020 - Disclosure - Accounts Payable and Related Party (Tables)", "shortName": "Accounts Payable and Related Party (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://gtbiopharma.com/role/WarrantLiabilityTables", "longName": "00000021 - Disclosure - Warrant Liability (Tables)", "shortName": "Warrant Liability (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["GTBP:WarrantLiabilityTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["GTBP:WarrantLiabilityTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables", "longName": "00000022 - Disclosure - Common Stock Warrants and Options (Tables)", "shortName": "Common Stock Warrants and Options (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R23": { "role": "http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative", "longName": "00000023 - Disclosure - Organization and Going Concern Analysis (Details Narrative)", "shortName": "Organization and Going Concern Analysis (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails", "longName": "00000024 - Disclosure - Schedule of Anti-dilutive Securities (Details)", "shortName": "Schedule of Anti-dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R25": { "role": "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R26": { "role": "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails", "longName": "00000026 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)", "shortName": "Schedule of Estimated Fair Value of Financial Instrument (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R27": { "role": "http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails", "longName": "00000027 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)", "shortName": "Schedule of Fair Value Hierarchy Financial Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:FairValueNetAssetLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:FairValueNetAssetLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R28": { "role": "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails", "longName": "00000028 - Disclosure - Schedule of Accounts Payable (Details)", "shortName": "Schedule of Accounts Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:AccountsPayableOtherCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:AccountsPayableOtherCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R29": { "role": "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails", "longName": "00000029 - Disclosure - Schedule of Accounts Payable to Related Party (Details)", "shortName": "Schedule of Accounts Payable to Related Party (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_CytovanceBiologicsIncMember", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0",~~

~~"ancestors": ["span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-09-30_custom_CytovanceBiologicsIncMember", "name": "GTBP:RepaymentsOfRelatedPartyCommonStock", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "GTBP:ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R30": { "role": "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails", "longName": "00000030 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)", "shortName": "Schedule of Derivative Liabilities Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:FairValueAdjustmentOfWarrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-09-30_custom_TwoThousandTwentyThreeWarrantsMember12662468", "name": "us-gaap:FairValueAdjustmentOfWarrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "GTBP:WarrantLiabilityTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R31": { "role": "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails", "longName": "00000031 - Disclosure - Schedule of Derivative Liability Transactions (Details)", "shortName": "Schedule of Derivative Liability Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "GTBP:WarrantLiabilityCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-09-30", "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "GTBP:WarrantLiabilityTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R32": { "role": "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative", "longName": "00000032 - Disclosure - Warrant Liability (Details Narrative)", "shortName": "Warrant Liability (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "GTBP:WarrantLiabilityTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-01-04_custom_TwoThousandTwentyThreeCommonWarrantsMember_srt_MaximumMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "GTBP:WarrantLiabilityTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R33": { "role": "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative", "longName": "00000033 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-02-16_custom_SeriesKPreferredStocksMember", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R34": { "role": "http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails", "longName": "00000034 - Disclosure - Schedule of Warrant Activity (Details)", "shortName": "Schedule of Warrant Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "GTBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R35": { "role": "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails", "longName": "00000035 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)", "shortName": "Schedule of Warrants Outstanding and Exercisable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30_custom_WarrantsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "GTBP:ScheduleOfWarrantsOustandingAndExercisableTableTextBlock", "GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R36": { "role": "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails", "longName": "00000036 - Disclosure - Schedule of Options Activity (Details)", "shortName": "Schedule of Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R37": { "role": "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails", "longName": "00000037 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)", "shortName": "Schedule of Options Outstanding and Options Exercisable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-09-30_custom_RangeOneMember", "name": "GTBP:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R38": { "role": "http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative", "longName": "00000038 - Disclosure - Common Stock Warrants and Options (Details Narrative)", "shortName": "Common Stock Warrants and Options (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R39": { "role": "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000039 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2021-06-162021-06-16_custom_TwoThousandTwentyOneScientificResearchAgreementMember", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R40": { "role": "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative", "longName": "00000040 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2023-05-152023-05-15", "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "p", "GTBP:CommonStockWarrantsAndOptionsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-10-172024-10-17_us-gaap_SubsequentEventMember_srt_OfficerMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://gtbiopharma.com/role/AccountsPayableAndRelatedParty"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Related Party", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r43", "r45", "r47", "r699"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://gtbiopharma.com/role/BalanceSheets", "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"], "lang": { "en-us": { "role": { "label": "Accounts payable", "verboseLabel": "Total accounts payable", "terseLabel": "Accounts payable, current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r43", "r571"] }, "us-gaap_AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"], "lang": { "en-us": { "role": { "label": "Other accounts payable", "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r43"] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails", "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Accounts payable to University of Minnesota", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r14", "r43"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://gtbiopharma.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r45"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r110", "r111", "r357", "r358", "r359", "r360", "r361", "r362"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r110", "r111", "r357", "r358", "r359", "r360", "r361", "r362"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://gtbiopharma.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r50", "r571", "r734"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r440", "r633", "r634", "r635", "r636", "r705", "r735"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [~~

```
"http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative", "http://gtbiopharma.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Fair
value of vested stock options", "documentation": "Amount of increase to additional paid in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } },
"auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://gtbiopharma.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": {
"negatedLabel": "Initial recognition of fair value of warrant liability", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional
paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r8", "r27",
"r69" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://gtbiopharma.com/role/StatementsOfCashFlows" ], "lang": {
"en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://gtbiopharma.com/role/StatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Share-based payment arrangement, expense", "documentation": "Amount of expense
for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r303", "r304" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description",
"documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation":
"Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information
Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r599" ] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "lang": { "en-us": {
"role": { "label": "Total anti-dilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per
share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per
share or unit amounts for the period presented." } } }, "auth_ref": [ "r143" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"presentation": [ "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by
type of antidilutive security." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfAnti-
dilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": []
}, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not
included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r22" ] }, "us-
gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
"http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative
applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r320" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"Assets", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://gtbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to
economic benefit." } } }, "auth_ref": [ "r82", "r91", "r103", "r119", "r146", "r150", "r159", "r160", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r321", "r323",
"r356", "r412", "r477", "r543", "r544", "r571", "r584", "r668", "r669", "r720" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsAbstract", "presentation": [ "http://gtbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-
gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://gtbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets,
Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r100", "r107", "r119", "r198", "r222", "r223", "r224",
"r225", "r226", "r227", "r228", "r229", "r230", "r321", "r323", "r356", "r571", "r668", "r669", "r720" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://gtbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets" } }
}, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements",
"presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if
it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r599" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" ], "lang": { "en-us": { "role": { "label": "Cost", "documentation": "Amortized cost of investment in
debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r165", "r206", "r411" ] }, "us-
gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleDebtSecuritiesGrossUnrealizedLoss", "crdr": "debit", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" ], "lang": {
"en-us": { "role": { "negatedLabel": "Unrealized losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in debt
security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r648" ] }, "us-gaap_AwardDateAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ],
"lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r673",
"r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698" ]
}, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": [
"http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is
granted." } } }, "auth_ref": [ "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693",
"r694", "r695", "r696", "r697", "r698" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award
under share-based payment arrangement." } } }, "auth_ref": [ "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293",
"r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [
"http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Principles of Consolidation", "documentation":
"The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements
(for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting
entity." } } }, "auth_ref": [ "r64" ] }, "GTBP_BoardOfDirectorsEmployeesAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname":
"BoardOfDirectorsEmployeesAndConsultantsMember", "presentation": [ "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board Of
Directors Employees And Consultants [Member]", "documentation": "Board Of Directors Employees And Consultants [Member]" } } }, "auth_ref": [] }, "us-
gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr":
"debit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://gtbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits
with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both
readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash
equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r16", "r102", "r537" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [
"http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash Equivalents and Short-Term Investments", "documentation":
"Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed
includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk,
(3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents
approximates fair value." } } }, "auth_ref": [ "r17" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [
"http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Restricted Cash", "documentation": "Entity's cash and cash equivalents
accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts
entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in
legally restricted deposits." } } }, "auth_ref": [ "r17", "r81" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://gtbiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and Cash Equivalents and Restricted Cash at Beginning of Period",
"periodEndLabel": "Cash and Cash Equivalents and Restricted Cash at End of Period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation":
"Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is
not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not
limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value
because of changes in interest rates." } } }, "auth_ref": [ "r16", "r61", "r116" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": {
"http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://gtbiopharma.com/role/StatementsOfCashFlows"
], "lang": { "en-us": { "role": { "totalLabel": "Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash
Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted
to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other
accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known
amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r61" ] }, "us-
gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit",
"presentation": [ "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Amount
of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of
changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r617", "r730" ] }, "us-gaap_CashFDICInsuredAmount": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [
"http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash, FDIC insured amount", "documentation": "The amount of
cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "GTBP_CashPaidDuringYearFor": {
"xbrltype": "stringItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "CashPaidDuringYearFor", "presentation": [ "http://gtbiopharma.com/role/StatementsOfCashFlows" ],
"lang": { "en-us": { "role": { "label": "Cash paid during the year for:", "documentation": "Cash paid during the year for [Abstract]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label":
"City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfStockDomain", "presentation": [ "http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": {
"en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock,
nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r97", "r104", "r105", "r106", "r119", "r137", "r138", "r140", "r142", "r148", "r149", "r198", "r222", "r224", "r225",
"r226", "r229", "r230", "r249", "r250", "r253", "r256", "r263", "r356", "r435", "r436", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451",
```

"r465", "r486", "r504", "r526", "r527", "r528", "r529", "r530", "r605", "r630", "r637"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables", "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r34"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables", "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrant exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r264"] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables", "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrants to purchase", "verboseLabel": "Purchase of warrants", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r264"] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables", "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r34"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r67", "r214", "r215", "r532", "r660", "r665"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r574", "r575", "r576", "r578", "r579", "r580", "r581", "r633", "r634", "r636", "r705", "r732", "r735"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, par value", "verboseLabel": "Common stock par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r49"] }, "GTBP_CommonStockReverseStockSplitPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "CommonStockReverseStockSplitPolicyTextBlock", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Common Stock (February 2024 Reverse Stock Split)", "documentation": "Common Stock Reverse Stock Split [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r49", "r465"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "verboseLabel": "Direct offering", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r49"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r8", "r49", "r465", "r483", "r735", "r736"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://gtbiopharma.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.001, 250,000,000 shares authorized, 2,234,328 and 1,380,633 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r49", "r415", "r571"] }, "GTBP_CommonStockWarrantsAndOptionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "CommonStockWarrantsAndOptionsTextBlock", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptions"], "lang": { "en-us": { "role": { "label": "Common Stock Warrants and Options", "documentation": "Common Stock Warrants and Options [Text Block]" } } }, "auth_ref": [] }, "GTBP_CommonWarrantAndPlacementAgentWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "CommonWarrantAndPlacementAgentWarrantMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Warrant and Placement Agent Warrant [Member]", "documentation": "Common Warrant and Placement Agent Warrant [Member]" } } }, "auth_ref": [] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": ["r71", "r77"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Concentration", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r41", "r94"] }, "us-gaap_CostMaintenance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostMaintenance", "crdr": "debit", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Maintenance fee", "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered." } } }, "auth_ref": ["r622"] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "GTBP_CummulativeGrossSales": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "CummulativeGrossSales", "crdr": "debit", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Cumulative gross sales", "documentation": "Cummulative gross sales." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "GTBP_CytovanceBiologicsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "CytovanceBiologicsIncMember", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails", "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Cytovance Biologics Inc [Member]", "documentation": "Cytovance Biologics Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails", "http://gtbiopharma.com/role/WarrantLiabilityTables"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r13", "r44", "r45", "r83", "r84", "r120", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r549", "r550", "r551", "r552", "r553", "r570", "r631", "r661", "r662", "r663", "r716", "r717"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails", "http://gtbiopharma.com/role/WarrantLiabilityTables"], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r13", "r120", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r549", "r550", "r551", "r552", "r553", "r570", "r631", "r661", "r662", "r663", "r716", "r717"] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"], "lang": { "en-us": { "role": { "label": "Unrealized gains", "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r194"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": ["http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Estimated Fair Value of Financial Instrument", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"], "lang": { "en-us": { "role": { "label": "Fair value", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r647", "r648"] }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized loss (gain) on marketable securities", "label": "Debt Securities, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": ["r423", "r623", "r624"] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": ["http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails", "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "DisclosureCommonStockWarrantsAndOptionsAbstract", "lang": { "en-us": { "role": { "label": "Common Stock Warrants And Options", "verboseLabel": "Schedule Of Warrant Activity", "terseLabel": "Schedule Of Options Activity" } } }, "auth_ref": [] }, "GTBP_DisclosureWarrantLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "DisclosureWarrantLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Warrant Liability", "verboseLabel": "Schedule Of Derivative Liability Transactions" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r598"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r596", "r598", "r599"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd

~~quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r597"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r585"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r598"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r598"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r600"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r588"] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://gtbiopharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Loss Per Share - Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r113", "r126", "r127", "r128", "r129", "r130", "r131", "r135", "r137", "r140", "r141", "r142", "r145", "r316", "r319", "r334", "r335", "r410", "r422", "r539"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://gtbiopharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Loss Per Share - Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r113", "r126", "r127", "r128", "r129", "r130", "r131", "r137", "r140", "r141", "r142", "r145", "r316", "r319", "r334", "r335", "r410", "r422", "r539"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r22", "r23", "r144"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r591"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r587"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r587"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r604"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r587"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r601"] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r599"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r587"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r587"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r587"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r587"] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r602"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r8", "r98", "r110", "r111", "r112", "r121", "r122", "r123", "r125", "r130", "r132", "r134", "r147", "r199", "r200", "r210", "r265", "r310", "r311", "r313", "r314", "r315", "r317", "r318", "r319", "r325", "r326", "r327", "r328", "r329", "r330", "r333", "r357", "r358", "r359", "r360", "r361", "r362", "r364", "r365", "r370", "r420", "r428", "r429", "r430", "r440", "r504"] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "auth_ref": ["r195", "r196", "r197", "r312", "r606", "r607", "r608", "r701", "r702", "r703", "r704"] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Equity method investment, ownership percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": ["r195"] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "GTBP_ExtinguishmentOfWarrant": { "xbrltype":~~

"monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ExtinguishmentOfWarrant", "crdr": "credit", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Extinguishment", "documentation": "Extinguishment of warrant." } } },
"auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr":
"debit", "calculation": { "http://gtbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 },
"http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails", "http://gtbiopharma.com/role/StatementsOfCashFlows",
"http://gtbiopharma.com/role/StatementsOfOperations", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value
of warrant liability", "label": "Change in fair value of warrant liability", "verboseLabel": "Fair value of warrants", "documentation": "Amount of expense (income) related to adjustment to fair
value of warrant liability." } } }, "auth_ref": ["r0", "r4"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and
Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table." } } }, "auth_ref": ["r337", "r338", "r348", "r560"] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"],
"lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring
and nonrecurring basis." } } }, "auth_ref": ["r337", "r338", "r348", "r560"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
"presentation": ["http://gtbiopharma.com/role/FairValueOfFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value Hierarchy Financial Assets",
"documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders'
equity." } } }, "auth_ref": ["r560", "r707", "r708", "r713"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
"presentation": ["http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation
Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": ["r339", "r340", "r341", "r563"] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
"documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and
liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r339", "r340", "r341", "r563"] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [
"http://gtbiopharma.com/role/WarrantLiabilityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Liabilities Assumptions", "documentation": "Tabular disclosure of input and
valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } }
}, "auth_ref": ["r339", "r340", "r563"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"], "lang": { "en-us": { "role": { "label": "Fair
Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } },
"auth_ref": ["r239", "r267", "r268", "r269", "r270", "r271", "r272", "r336", "r338", "r339", "r340", "r341", "r347", "r348", "r350", "r379", "r380", "r381", "r550", "r551", "r555", "r556", "r557",
"r560", "r563"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-
us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://gtbiopharma.com/role/FairValueOfFinancialInstruments"], "lang": { "en-us": { "role": { "label": "Fair Value
of Financial Instruments", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as
defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments,
assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair
value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable
to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum
amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or
security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a
recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value
measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups]
items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all
other required (as defined) and desired information." } } }, "auth_ref": ["r343", "r345", "r346", "r347", "r350", "r351", "r352", "r353", "r354", "r409", "r560", "r564"] }, "us-
gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted
prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r239", "r267", "r272", "r338", "r348", "r379", "r555",
"r556", "r557", "r560"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member",
"presentation": ["http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]",
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for
similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r239", "r267", "r272", "r338", "r339", "r348",
"r380", "r550", "r551", "r555", "r556", "r557", "r560"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueInputsLevel3Member", "presentation": ["http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value,
Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [
"r239", "r267", "r268", "r269", "r270", "r271", "r272", "r338", "r339", "r340", "r341", "r348", "r381", "r550", "r551", "r555", "r556", "r557", "r560", "r563"] }, "us-
gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"], "lang": { "en-us": { "role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r239", "r267", "r268", "r269", "r270", "r271", "r272", "r336",
"r338", "r339", "r340", "r341", "r347", "r348", "r350", "r379", "r380", "r381", "r550", "r551", "r555", "r556", "r557", "r560", "r563"] }, "us-gaap_FairValueNetAssetLiability": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetAssetLiability", "crdr": "debit", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"], "lang": { "en-us": { "role": { "label": "Total financial assets", "documentation": "Fair value of asset after
deduction of liability." } } }, "auth_ref": ["r707", "r708"] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": {
"verboseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for
determining the fair value of financial instruments." } } }, "auth_ref": ["r6"] }, "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information
[Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinancialInstrumentAxis", "presentation": ["http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"], "lang": { "en-us": { "role": { "label": "Financial
Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174",
"r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r201", "r202", "r203", "r204", "r205", "r207",
"r208", "r209", "r247", "r261", "r331", "r355", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r392", "r393", "r394", "r395",
"r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r421", "r547", "r560", "r561", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r610", "r611",
"r612", "r613", "r614", "r615", "r616", "r655", "r656", "r657", "r658", "r706", "r709", "r710", "r711", "r712", "r714"] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": {
"http://gtbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 },
"http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [
"http://gtbiopharma.com/role/StatementsOfCashFlows", "http://gtbiopharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gain on extinguishment of debt",
"negatedLabel": "Gain on extinguishment of share settled debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished
prior to maturity." } } }, "auth_ref": ["r4", "r28", "r29"] }, "GTBP_GrossSales": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "GrossSales",
"crdr": "debit", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Gross sales", "documentation": "Gross
sales." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": {
"en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementLocationAxis", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
"http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by
location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r211", "r212", "r213", "r342", "r344", "r349", "r425", "r427", "r489", "r535", "r562", "r731"
] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"], "lang": { "en-us": { "role": {
"documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r212", "r213", "r342", "r344", "r349", "r425", "r427", "r489", "r535",
"r562", "r731"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit",
"presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Income taxes", "documentation": "Amount, after refund, of cash paid to foreign,
federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r18", "r115", "r308", "r309"] }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDerivativeLiabilities", "crdr": "debit", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Change in fair value", "documentation": "The increase (decrease) during
the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [
"r626"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and
liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": {
"label": "(Decrease) in operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r609", "r626"] }, "us-
gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": {
"label": "Increase (Decrease) in accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but
not yet paid." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": {
"negatedLabel": "Decrease in prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of
outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r3"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": {

```
"http://gtbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://gtbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount
of interest expense classified as nonoperating." } } }, "auth_ref": [ "r151", "r625" ] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InterestIncomeOther", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight":
1.0, "order": 1.0 } }, "presentation": [ "http://gtbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of interest
income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InterestPaid", "crdr": "credit", "presentation": [ "http://gtbiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount
of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with
insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities." } } },
"auth_ref": [ "r628" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of
investments." } } }, "auth_ref": [ "r452", "r453", "r454", "r455", "r456", "r510", "r512", "r514", "r517", "r518", "r519", "r521", "r522", "r523", "r524", "r525", "r576" ] }, "us-
gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value."
} } }, "auth_ref": [ "r452", "r453", "r454", "r455", "r456", "r510", "r512", "r514", "r517", "r518", "r519", "r521", "r522", "r523", "r524", "r525", "r576" ] }, "us-
gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails" ], "lang": { "en-us": {
"role": { "label": "Issuance of warrants at fair value", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged
claims." } } }, "auth_ref": [ "r4" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeLeasesPolicyTextBlock", "presentation": [ "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases",
"documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r368" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://gtbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES
AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling
interests, if any." } } }, "auth_ref": [ "r54", "r85", "r417", "r571", "r632", "r659", "r715" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://gtbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label":
"LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAssumed1", "crdr": "credit", "presentation": [ "http://gtbiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Initial recognition of fair
value of warrant liability", "documentation": "The fair value of liabilities assumed in noncash investing or financing activities." } } }, "auth_ref": [ "r19", "r20", "r21" ] }, "us-
gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://gtbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred
as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r46", "r101", "r119", "r198", "r222",
"r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r322", "r323", "r324", "r356", "r571", "r668", "r720", "r721" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://gtbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": {
"label": "Current liabilities" } } }, "auth_ref": [] }, "GTBP_LicenseMaintenanceFeeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname":
"LicenseMaintenanceFeeReceivable", "crdr": "credit", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label":
"License maintenance fee, receivable", "documentation": "License maintenance fee, receivable." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number",
"documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LossContingenciesLineItems", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss
Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": [ "r216", "r217", "r218", "r221", "r305", "r548", "r666", "r667" ] }, "us-gaap_LossContingenciesTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [
"http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information
about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r216", "r217", "r218", "r221", "r305", "r548", "r666", "r667"
] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLoss",
"crdr": "credit", "calculation": { "http://gtbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://gtbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Unrealized gain on marketable securities", "documentation": "Amount of unrealized gain (loss) on
investment in marketable security." } } }, "auth_ref": [ "r58" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember",
"presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails",
"http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label":
"Maximum [Member]" } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r274", "r305", "r341", "r407", "r424", "r426", "r433", "r457", "r458", "r511", "r513", "r515", "r516", "r520", "r533",
"r534", "r546", "r554", "r558", "r563", "r564", "r568", "r569", "r573", "r670", "r722", "r723", "r724", "r725", "r726", "r727" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]",
"documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r709", "r710", "r711" ] }, "us-
gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember",
"presentation": [ "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]",
"documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r709", "r710", "r711" ] }, "us-
gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember",
"presentation": [ "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]",
"documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r563", "r709", "r710", "r711" ] }, "us-
gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" ], "lang": { "en-us": { "role": { "label":
"Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r709",
"r710", "r711" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputSharePriceMember", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" ], "lang": { "en-us": { "role": { "label":
"Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r709", "r710", "r711" ] }, "us-
gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by
type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r339", "r340", "r341", "r563" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and
liability." } } }, "auth_ref": [ "r339", "r340", "r341", "r563" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember",
"presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails" ], "lang": {
"en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r274", "r305", "r341", "r407", "r424", "r426", "r433", "r457", "r458", "r511", "r513", "r515",
"r516", "r520", "r533", "r534", "r546", "r554", "r558", "r563", "r564", "r568", "r573", "r670", "r722", "r723", "r724", "r725", "r726", "r727" ] }, "us-gaap_MoneyMarketFundsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that
invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit,
and other highly liquid securities." } } }, "auth_ref": [ "r672" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://gtbiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by Financing Activities", "label": "Net Cash Provided by (Used in)
Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources
from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for
other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r114" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://gtbiopharma.com/role/StatementsOfCashFlows" ], "lang":
{ "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": {
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation":
[ "http://gtbiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used in) Investing Activities", "label": "Net Cash Provided by (Used
in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and
collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r114" ] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://gtbiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM
INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative", "http://gtbiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net
Cash Used in Operating Activities", "negatedLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash
inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or
financing activities." } } }, "auth_ref": [ "r61", "r62", "r63" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://gtbiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 1.0 }, "http://gtbiopharma.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysisDetailsNarrative", "http://gtbiopharma.com/role/StatementsOfCashFlows",
"http://gtbiopharma.com/role/StatementsOfOperations", "http://gtbiopharma.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net Loss", "label": "Net
loss", "negatedLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r55", "r63", "r89",
"r99", "r108", "r109", "r112", "r119", "r124", "r126", "r127", "r128", "r129", "r130", "r133", "r134", "r139", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r316",
"r319", "r335", "r356", "r419", "r485", "r502", "r503", "r582", "r668" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of
accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
} } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [
"http://gtbiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol."
} } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://gtbiopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL
```

~~DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NoninterestExpenseOfferingCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoninterestExpenseOfferingCost", "crdr": "debit", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Other offering expenses", "documentation": "Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period." } } }, "auth_ref": ["r88"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total Other Income, Net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r59"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://gtbiopharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other Income (Expense)" } } }, "auth_ref": [] }, "srt_OfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OfficerMember", "presentation": ["http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Officer [Member]" } } }, "auth_ref": ["r163", "r733"] }, "GTBP_OfficersEmployeesAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "OfficersEmployeesAndDirectorsMember", "presentation": ["http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"], "lang": { "en-us": { "role": { "label": "Officers, Employees and Directors [Member]", "documentation": "Officers, Employees and Directors [Member]" } } }, "auth_ref": [] }, "GTBP_OmnibusIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "OmnibusIncentivePlanMember", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Omnibus Incentive Plan [Member]", "documentation": "Omnibus Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://gtbiopharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Loss from Operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r90", "r540", "r638", "r639", "r640", "r641", "r642"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://gtbiopharma.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Current operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r367"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://gtbiopharma.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r366"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Change in operating lease right-of-use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r627"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://gtbiopharma.com/role/OrganizationAndGoingConcernAnalysis"], "lang": { "en-us": { "role": { "label": "Organization and Going Concern Analysis", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": ["r42", "r64", "r65", "r79"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r598"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromInvestments", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Sale (Purchase) of investments", "label": "Payments for (Proceeds from) Investments", "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets." } } }, "auth_ref": [] }, "GTBP_PerformanceMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "PerformanceMilestonePayments", "crdr": "debit", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Performance milestone payments", "documentation": "Performance milestone payments." } } }, "auth_ref": [] }, "GTBP_PlacementAgentWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "PlacementAgentWarrantMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Placement Agent Warrant [Member]", "documentation": "Placement Agent Warrant [Member]" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r592"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r594"] }, "GTBP_PreFundedWarrantsAndTwentyTwentyThreeCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "PreFundedWarrantsAndTwentyTwentyThreeCommonWarrantsMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Pre Funded Warrants And 2023 Common Warrants [Member]", "documentation": "Pre Funded Warrants And 2023 Common Warrants [Member]" } } }, "auth_ref": [] }, "GTBP_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Pre Funded Warrants [Member]", "documentation": "Pre Funded Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Convertible shares issuable", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": ["r251"] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r574", "r575", "r578", "r579", "r580", "r581", "r732", "r735"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r48", "r249"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r48", "r465"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r48", "r249"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r48", "r465", "r483", "r735", "r736"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://gtbiopharma.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r48", "r414", "r571"] }, "GTBP_PrefundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "PrefundedWarrantMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Prefunded Warrant [Member]", "documentation": "Prefunded Warrant [Member]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://gtbiopharma.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r621"] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Proceeds from private placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock and warrants, net", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r2", "r435"] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Invoices, net", "verboseLabel": "Research and development expenses", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": ["r15"] }, "GTBP_ProceedsFromUpfrontAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ProceedsFromUpfrontAmount", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Proceeds from upfront amount", "documentation": "Received upfront payment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r369"] }, "GTBP_PurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "PurchaseAgreementMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Purchase Agreement [Member]", "documentation": "Purchase Agreement [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails", "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",~~

```
"http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r266",
"r274", "r299", "r300", "r301", "r305", "r341", "r382", "r391", "r407", "r424", "r426", "r433", "r457", "r458", "r511", "r513", "r515", "r516", "r520", "r533", "r534", "r546", "r554", "r558", "r563",
"r564", "r568", "r569", "r573", "r576", "r664", "r670", "r710", "r723", "r724", "r725", "r726", "r727" ] }, "GTBP_RangeFiveMember": { "xbrltype": "domainItemType", "nsuri":
"http://gtbiopharma.com/20240930", "localname": "RangeFiveMember", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-
us": { "role": { "label": "Range Five [Member]", "documentation": "Range Five [Member]" } } }, "auth_ref": [] }, "GTBP_RangeFourMember": { "xbrltype": "domainItemType", "nsuri":
"http://gtbiopharma.com/20240930", "localname": "RangeFourMember", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-
us": { "role": { "label": "Range Four [Member]", "documentation": "Range Four [Member]" } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
"http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails", "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
"http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative" ], "auth_ref": [ "r217", "r218", "r219", "r220", "r266", "r274", "r299", "r300", "r301", "r305", "r341", "r382", "r391", "r407",
"r424", "r426", "r433", "r457", "r458", "r511", "r513", "r515", "r516", "r520", "r533", "r534", "r546", "r554", "r558", "r563", "r564", "r568", "r569", "r573", "r576", "r664", "r670", "r710", "r723",
"r724", "r725", "r726", "r727" ] }, "GTBP_RangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "RangeOneMember", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails", "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" ], "lang": {
"en-us": { "role": { "label": "Range One [Member]", "documentation": "Range One [Member]" } } }, "auth_ref": [] }, "GTBP_RangeSevenMember": { "xbrltype": "domainItemType", "nsuri":
"http://gtbiopharma.com/20240930", "localname": "RangeSevenMember", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-
us": { "role": { "label": "Range Seven [Member]", "documentation": "Range Seven [Member]" } } }, "auth_ref": [] }, "GTBP_RangeSixMember": { "xbrltype": "domainItemType", "nsuri":
"http://gtbiopharma.com/20240930", "localname": "RangeSixMember", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-
us": { "role": { "label": "Range Six [Member]", "documentation": "Range Six [Member]" } } }, "auth_ref": [] }, "GTBP_RangeThreeMember": { "xbrltype": "domainItemType", "nsuri":
"http://gtbiopharma.com/20240930", "localname": "RangeThreeMember", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails",
"http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Range Three [Member]", "documentation": "Range Three
[Member]" } } }, "auth_ref": [] }, "GTBP_RangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "RangeTwoMember", "presentation": [
"http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails", "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" ], "lang": {
"en-us": { "role": { "label": "Range Two [Member]", "documentation": "Range Two [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
"http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails", "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" ], "lang": { "en-us": { "role": {
"documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit
of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence,
or ownership interest." } } }, "auth_ref": [ "r163", "r273", "r371", "r372", "r413", "r418", "r460", "r461", "r462", "r463", "r464", "r482", "r484", "r509" ] }, "us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
"presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
"http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information
by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee,
principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership
interest." } } }, "auth_ref": [ "r163", "r273", "r371", "r372", "r413", "r418", "r460", "r461", "r462", "r463", "r464", "r482", "r484", "r509", "r719" ] },
"GTBP_RepaymentsOfRelatedPartyCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "RepaymentsOfRelatedPartyCommonStock",
"crdr": "credit", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Payments in common stock, at fair
value", "documentation": "Repayments of related party common stock." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
"http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments in cash", "label": "Cash payments", "documentation":
"The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates,
owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r60" ] }, "us-
gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit",
"calculation": { "http://gtbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and
development", "verboseLabel": "Research and development expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer
software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation
or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [
"r307", "r535", "r543", "r728" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "presentation": [
"http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate research and development expense", "documentation":
"Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired
in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both,
used in research and development activity." } } }, "auth_ref": [ "r700" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": {
"role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense
have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research
and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge
with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or
process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } },
"auth_ref": [ "r306" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit",
"calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://gtbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as
current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } },
"auth_ref": [ "r617", "r629" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 }
}, "presentation": [ "http://gtbiopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings
(deficit)." } } }, "auth_ref": [ "r51", "r69", "r416", "r431", "r432", "r439", "r466", "r571" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://gtbiopharma.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained
Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r98", "r121", "r122", "r123", "r125", "r130", "r132", "r134", "r199", "r200", "r210",
"r310", "r311", "r313", "r314", "r315", "r317", "r318", "r319", "r325", "r327", "r328", "r330", "r333", "r364", "r365", "r428", "r430", "r440", "r735" ] }, "us-gaap_RoyaltyExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": [
"http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual royalty payments", "documentation": "Amount of expense related
to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r56" ] },
"GTBP_RoyaltyExpenseYearAfterSix": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "RoyaltyExpenseYearAfterSix", "crdr": "debit",
"presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Royalty expense", "documentation": "Royalty
expense year after six.", "label": "RoyaltyExpenseYearAfterSix" } } }, "auth_ref": [] }, "GTBP_RoyaltyExpenseYearOne": { "xbrltype": "monetaryItemType", "nsuri":
"http://gtbiopharma.com/20240930", "localname": "RoyaltyExpenseYearOne", "crdr": "debit", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ],
"lang": { "en-us": { "role": { "label": "Royalty expense", "documentation": "Royalty expense year one." } } }, "auth_ref": [] }, "GTBP_RoyaltyExpenseYearTwoThroughFive": { "xbrltype":
"monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "RoyaltyExpenseYearTwoThroughFive", "crdr": "debit", "presentation": [
"http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Royalty expense", "documentation": "Royalty expense year two
through five.", "label": "RoyaltyExpenseYearTwoThroughFive" } } }, "auth_ref": [] }, "GTBP_RoyaltyFeePercentage": { "xbrltype": "percentItemType", "nsuri":
"http://gtbiopharma.com/20240930", "localname": "RoyaltyFeePercentage", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us":
{ "role": { "label": "Royalty fee percentage", "documentation": "Royalty fee percentage." } } }, "auth_ref": [] }, "GTBP_SalesMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri":
"http://gtbiopharma.com/20240930", "localname": "SalesMilestonePayments", "crdr": "credit", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ],
"lang": { "en-us": { "role": { "label": "Sales milestone payments", "documentation": "Sales milestone payments." } } }, "auth_ref": [] }, "GTBP_SalesRevenue": { "xbrltype": "monetaryItemType",
"nsuri": "http://gtbiopharma.com/20240930", "localname": "SalesRevenue", "crdr": "debit", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ],
"lang": { "en-us": { "role": { "label": "Sales revenue", "documentation": "Sales revenue." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [
"http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable", "documentation": "Tabular disclosure of the (a)
carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an
entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due
within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] },
"GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname":
"ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock", "presentation": [ "http://gtbiopharma.com/role/AccountsPayableAndRelatedPartyTables" ], "lang": { "en-us": { "role": { "label":
"Schedule of Accounts Payable to Related Party", "documentation": "Schedule of Accounts Payable and Related Party [Table Text Block]" } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "lang": {
"en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per
share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r22" ] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ],
"lang": { "en-us": { "role": { "label": "Schedule of Anti-dilutive Securities", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements)
that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss
per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails",
"http://gtbiopharma.com/role/ScheduleOfAccountsPayableToRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of
information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value
of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements
using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [
"r7", "r30", "r31", "r32", "r33" ] }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "presentation": [ "http://gtbiopharma.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of
Derivative Liability Transactions", "documentation": "Tabular disclosure of derivative liabilities at fair value." } } }, "auth_ref": [] },
"srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": {
"role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r195", "r196", "r197", "r312", "r606", "r607", "r608", "r701", "r702", "r703", "r704" ] }, "us-
gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
"presentation": [ "http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, off-Balance-Sheet Risk [Table]",
"documentation": "Disclosure of information about fair value of financial asset and liability not recognized in financial statement because of failure to meet criterion for recognition." } } },
"auth_ref": [ "r40", "r80" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

~~"ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r5", "r369"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } }, "auth_ref": ["r35"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Options Outstanding and Options Exercisable", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": ["r35"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Options Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r11", "r12", "r72"] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": ["http://gtbiopharma.com/role/WarrantLiabilityTables"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": ["r44"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Warrant Activity", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r34"] }, "GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ScheduleOfWarrantsOustandingAndExercisableTableTextBlock", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Warrants Outstanding and Exercisable", "documentation": "Schedule of warrants oustanding and exercisable [Table Text Block]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r586"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r590"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r589"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r595"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r152", "r153", "r154", "r155", "r156", "r157", "r158", "r161", "r162", "r541", "r542", "r545"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Selling, general and administrative (including $0 and $547,000 from stock compensation granted to officers, directors, and employees and for services for the three months ended September 30, 2024 and 2023, respectively, and $222,000 and $1,767,000 for the nine months ended September 30, 2024 and 2023, respectively)", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r57"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://gtbiopharma.com/role/StatementsOfOperationsParenthetical"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesCPreferredStockMember", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": ["r618", "r619", "r671"] }, "GTBP_SeriesKPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "SeriesKPreferredStockMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series K Preferred Stock [Member]", "documentation": "Series K Preferred Stock [Member]" } } }, "auth_ref": [] }, "GTBP_SeriesKPreferredStocksMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "SeriesKPreferredStocksMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Series K Preferred Stocks [Member]", "documentation": "Series K Preferred Stocks [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock options vest years", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r559"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Warrants outstanding, weighted average remaining contractual life (years)", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r78"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Volatility amount utilized in the value calculation percentage", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r299"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302"] }, "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"], "lang": { "en-us": { "role": { "label": "Warrants exercisable, ending balance", "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"], "lang": { "en-us": { "role": { "label": "Number of warrants, exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": ["r10"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"], "lang": { "en-us": { "role": { "label": "Number of warrants, forfeited/cancelled", "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired." } } }, "auth_ref": ["r75", "r76"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"], "lang": { "en-us": { "role": { "label": "Number of warrants, granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": ["r9"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails", "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding, beginning balance", "periodEndLabel": "Warrants outstanding, ending balance", "label": "Number of warrants outstanding", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": ["r73", "r74"] }, "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Warrants exercisable, weighted average exercise price", "documentation": "Share based compensation arrangement by share based payment award non options equity instruments exercisable weighted average exercise price." } } }, "auth_ref": [] }, "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Warrants outstanding, weighted average exercise price", "documentation": "Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price." } } }, "auth_ref": [] }, "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercisable, ending balance", "documentation":~~

~~"Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price." } } }, "auth_ref": [] }, "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercised", "documentation": "Share based compensation arrangement by share based payment award non options exercised weighted average exercise price." } } }, "auth_ref": [] }, "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, forfeited/cancelled", "documentation": "Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price." } } }, "auth_ref": [] }, "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted", "documentation": "Share based compensation arrangement by share based payment award non options granted weighted average exercise price." } } }, "auth_ref": [] }, "GTBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, beginning balance", "periodEndLabel": "Weighted average exercise price, ending balance", "documentation": "Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Number of options outstanding exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price,exercisable, ending", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r282"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Number of options, forfeited/cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": ["r679"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, forfeited/cancelled", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": ["r679"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative", "http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails", "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of options, granted", "verboseLabel": "Awards granted plan", "terseLabel": "Stock options granted", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r680"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Purchase an aggregate", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r284"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options outstanding intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r35"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails", "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options outstanding, beginning", "periodEndLabel": "Number of options outstanding, ending", "label": "Options outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r280", "r281"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails", "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted-Average Exercise Price, beginning", "periodEndLabel": "Weighted-Average Exercise Price, ending", "label": "Options outstanding, weighted average exercise price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r280", "r281"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r285"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails", "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, granted", "verboseLabel": "Stock options exercisable price per share", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r284"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails", "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": ["r38"] }, "GTBP_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"], "lang": { "en-us": { "role": { "label": "Range of excercise price", "documentation": "Share based compensation shares authorized under stock option plans exercise price." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails", "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": ["r39"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Range of exercise price", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r39"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "Fair value", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": ["r37"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": ["http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Range of exercise price", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r39"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r35"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Stock option vested value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": ["r295"] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": ["r36"] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [~~

"http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsDetailsNarrative", "http://gtbiopharma.com/role/ScheduleOfOptionsOutstandingAndOptionsExercisableDetails", "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Options outstanding, weighted average remaining contractual life (years)", "verboseLabel": "Stock options expire", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r78"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": ["http://gtbiopharma.com/role/WarrantLiabilityTables"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://gtbiopharma.com/role/BalanceSheets", "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r86", "r87", "r620"] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": ["http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": ["r523", "r524", "r525", "r536"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r64", "r117"] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r593"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r97", "r104", "r105", "r106", "r119", "r137", "r138", "r140", "r142", "r148", "r149", "r198", "r222", "r224", "r225", "r226", "r229", "r230", "r249", "r250", "r253", "r256", "r263", "r356", "r435", "r436", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r465", "r486", "r504", "r526", "r527", "r528", "r529", "r530", "r605", "r630", "r637"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r8", "r49", "r52", "r53", "r98", "r110", "r111", "r112", "r121", "r122", "r123", "r125", "r130", "r132", "r134", "r147", "r199", "r200", "r210", "r265", "r310", "r311", "r313", "r314", "r315", "r317", "r318", "r319", "r325", "r326", "r327", "r328", "r329", "r330", "r333", "r357", "r358", "r359", "r360", "r361", "r362", "r364", "r365", "r370", "r420", "r428", "r429", "r430", "r440", "r504"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical", "http://gtbiopharma.com/role/StatementsOfStockholdersEquity", "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r121", "r122", "r123", "r147", "r365", "r408", "r434", "r451", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r484", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r504", "r577"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://gtbiopharma.com/role/BalanceSheetsParenthetical", "http://gtbiopharma.com/role/StatementsOfOperationsParenthetical", "http://gtbiopharma.com/role/StatementsOfStockholdersEquity", "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r121", "r122", "r123", "r147", "r163", "r365", "r408", "r434", "r451", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r484", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r504", "r577"] }, "GTBP_StockBasedCompensationCommonSharesForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "StockBasedCompensationCommonSharesForServices", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Stock based compensation \u2013 services", "documentation": "Stock based compensation common shares for services." } } }, "auth_ref": [] }, "GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "StockBasedCompensationOfficersEmployeesAndBoardOfDirectors", "crdr": "debit", "calculation": { "http://gtbiopharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Stock based compensation - officers, directors, and employees", "documentation": "Stock based compensation officers employees and board of directors." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued1", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Fair value of common stock issued to a vendor to settle accounts payable", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": ["r19", "r20", "r21"] }, "GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash": { "xbrltype": "sharesItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants for cash, shares", "documentation": "Stock issued during period share issuance of common stock and warrants for cash." } } }, "auth_ref": [] }, "GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForExerciseOfPrefundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "StockIssuedDuringPeriodShareIssuanceOfCommonStockForExerciseOfPrefundedWarrants", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock for exercise of Prefunded Warrants, shares", "documentation": "Stock issued during period share issuance of common stock for exercise of prefunded warrants" } } }, "auth_ref": [] }, "GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable": { "xbrltype": "sharesItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common shares to settle vendor payable, shares", "documentation": "Stock issued during period shares common shares to settle vendor payable." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of common shares for services, shares", "verboseLabel": "Common stock issued for services, shares", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Private placement of common stock, shares", "verboseLabel": "Issued warrants of common stock", "terseLabel": "Preferred stock shares designated", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r8", "r48", "r49", "r69", "r435", "r504", "r527"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://gtbiopharma.com/role/ScheduleOfOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Number of options, exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r8", "r48", "r49", "r69", "r285"] }, "GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable", "crdr": "debit", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common shares to settle vendor payable", "documentation": "Stock issued during period value common shares to settle vendor payable." } } }, "auth_ref": [] }, "GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants for cash", "documentation": "Stock issued during period value issuance of common stock and warrants for cash." } } }, "auth_ref": [] }, "GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForExerciseOfPrefundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockForExerciseOfPrefundedWarrants", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock for exercise of prefunded warrants", "documentation": "Stock issued during period value issuance of common stock for exercise of prefunded warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/StatementsOfStockholdersEquity", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Issuance of common shares for services", "verboseLabel": "Common stock issued for services, value", "terseLabel": "Stock issued during period, value, issued for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Private placement of common stock", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r8", "r48", "r49", "r69", "r440", "r504", "r527", "r583"] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Cancellation of common stock issued to prior CFO, shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": ["r8"] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": ["http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Cancellation of common stock issued to prior CFO", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": ["r8"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://gtbiopharma.com/role/BalanceSheets", "http://gtbiopharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders\u2019 Equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r49", "r52", "r53", "r66", "r467", "r483", "r505", "r506", "r571", "r584", "r632", "r659", "r715", "r735"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://gtbiopharma.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://gtbiopharma.com/role/StockholdersEquity"], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders\u2019 Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r68", "r118", "r248", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r265", "r332", "r507", "r508", "r531"] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Revers stock split ratio", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": ["r70"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r363", "r374"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r363", "r374"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r363", "r374"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r363", "r374"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r363", "r374"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://gtbiopharma.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r373", "r375"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://gtbiopharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://gtbiopharma.com/role/StatementsOfOperationsParenthetical", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r643", "r718"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://gtbiopharma.com/role/StatementsOfOperationsParenthetical", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative", "http://gtbiopharma.com/role/SubsequentEventsDetailsNarrative"], "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://gtbiopharma.com/role/ScheduleOfEstimatedFairValueOfFinancialInstrumentDetails"], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r247", "r261", "r331", "r355", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r421", "r560", "r561", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r655", "r656", "r657", "r658", "r706", "r709", "r710", "r711", "r712", "r714"] }, "GTBP_TwentyTwentyFourCommonSharesAndTwentyTwentyFourCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwentyTwentyFourCommonSharesAndTwentyTwentyFourCommonWarrantsMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2024 Common Shares And 2024 Common Warrants [Member]", "documentation": "2024 Common Shares And 2024 Common Warrants [Member]" } } }, "auth_ref": [] }, "GTBP_TwentyTwentyFourCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwentyTwentyFourCommonWarrantsMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2024 Common Warrants [Member]", "documentation": "2024 Common Warrants [Member]" } } }, "auth_ref": [] }, "GTBP_TwentyTwentyFourPlacementAgentWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwentyTwentyFourPlacementAgentWarrantMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2024 Placement Agent Warrant [Member]", "documentation": "2024 Placement Agent Warrant [Member]" } } }, "auth_ref": [] }, "GTBP_TwentyTwentyThreeCommonSharesAndTwentyTwentyThreeCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwentyTwentyThreeCommonSharesAndTwentyTwentyThreeCommonWarrantsMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2023 Common Shares And 2023 Common Warrants [Member]", "documentation": "2023 Common Shares And 2023 Common Warrants [Member]" } } }, "auth_ref": [] }, "GTBP_TwentyTwentyThreeCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwentyTwentyThreeCommonWarrantsMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "verboseLabel": "2023 Common Warrants [Member]", "documentation": "2023 Common Warrants [Member]", "label": "2023 Common Warrants [Member] [Default Label]" } } }, "auth_ref": [] }, "GTBP_TwentyTwentyThreePlacementAgentWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwentyTwentyThreePlacementAgentWarrantMember", "presentation": ["http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2023 Placement Agent Warrant [Member]", "documentation": "2023 Placement Agent Warrant [Member]" } } }, "auth_ref": [] }, "GTBP_TwentyTwentyWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwentyTwentyWarrantsMember", "presentation": ["http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails", "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2020 Warrants [Member]", "documentation": "2020 Warrants [Member]" } } }, "auth_ref": [] }, "GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwoThousandAndTwentyOnePatentLicenseAgreementMember", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2021 Patent License Agreement [Member]", "documentation": "2021 Patent License Agreement [Member]" } } }, "auth_ref": [] }, "GTBP_TwoThousandSeventeenThroughTwoThousandTwentyMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwoThousandSeventeenThroughTwoThousandTwentyMember", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2017 through 2020 [Member]", "documentation": "2017 through 2020 [Member]" } } }, "auth_ref": [] }, "GTBP_TwoThousandSixteenPatentLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwoThousandSixteenPatentLicenseAgreementMember", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2016 Patent Exclusive License Agreement [Member]", "documentation": "2016 Patent License Agreement [Member]" } } }, "auth_ref": [] }, "GTBP_TwoThousandTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwoThousandTwentyFiveMember", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2025 [Member]", "documentation": "2025 [Member]" } } }, "auth_ref": [] }, "GTBP_TwoThousandTwentyOneScientificResearchAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwoThousandTwentyOneScientificResearchAgreementMember", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2021 Scientific Research Agreement [Member]", "documentation": "2021 Scientific Research Agreement [Member]" } } }, "auth_ref": [] }, "GTBP_TwoThousandTwentySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwoThousandTwentySevenMember", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2027 [Member]", "documentation": "2027 [Member]" } } }, "auth_ref": [] }, "GTBP_TwoThousandTwentyThreeCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwoThousandTwentyThreeCommonWarrantsMember", "presentation": ["http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2023 Common Warrants [Member]", "documentation": "2023 Common Warrants [Member]" } } }, "auth_ref": [] }, "GTBP_TwoThousandTwentyThreeSponsoredResearchAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwoThousandTwentyThreeSponsoredResearchAgreementMember", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2023 Sponsored Research Agreement [Member]", "documentation": "2023 Sponsored Research Agreement [Member]" } } }, "auth_ref": [] }, "GTBP_TwoThousandTwentyThreeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwoThousandTwentyThreeWarrantsMember", "presentation": ["http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails", "http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative", "http://gtbiopharma.com/role/WarrantLiabilityTables"], "lang": { "en-us": { "role": { "verboseLabel": "2023 Warrants [Member]", "documentation": "2023 Warrants [Member]", "label": "2023 Warrants [Member] [Default Label]" } } }, "auth_ref": [] }, "GTBP_TwoThousandTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwoThousandTwentyTwoMember", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "2022 [Member]", "documentation": "2022 [Member]" } } }, "auth_ref": [] }, "GTBP_TwoThousandTwentyWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "TwoThousandTwentyWarrantsMember", "presentation": ["http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails", "http://gtbiopharma.com/role/WarrantLiabilityTables"], "lang": { "en-us": { "role": { "verboseLabel": "2020 Warrants [Member]", "documentation": "2020 Warrants [Member]", "label": "2020 Warrants [Member] [Default Label]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://gtbiopharma.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r320"] }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": ["http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"], "lang": { "en-us": { "role": { "label": "US Government Corporations and Agencies Securities [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": ["r729"] }, "GTBP_USTreasuriesMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "USTreasuriesMember", "presentation": ["http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"], "lang": { "en-us": { "role": { "label": "US Treasuries [Member]", "documentation": "US Treasuries [Member]" } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://gtbiopharma.com/role/ScheduleOfFairValueHierarchyFinancialAssetsDetails"], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r538", "r555", "r557", "r560", "r729"] }, "us-gaap_UnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnbilledReceivablesCurrent", "crdr": "debit", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Unbilled and unaccrued amounts", "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "GTBP_UniversityOfMinnesotaMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "UniversityOfMinnesotaMember", "presentation": ["http://gtbiopharma.com/role/ScheduleOfAccountsPayableDetails"], "lang": { "en-us": { "role": { "label": "2023 Warrants [Member]", "documentation": "2023 Warrants [Member]" } } }, "auth_ref": [] }, "GTBP_UpfrontLicenseFee": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "UpfrontLicenseFee", "crdr": "debit", "presentation": ["http://gtbiopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Upfront license fee", "documentation": "Upfront license fee." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Accounting Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r24", "r25", "r26", "r92", "r93", "r95", "r96"] }, "GTBP_WarrantLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "WarrantLiabilityCurrent", "crdr": "credit", "calculation": { "http://gtbiopharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://gtbiopharma.com/role/BalanceSheets", "http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilityTransactionsDetails", "http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrant liability", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "documentation": "Warrant liability current." } } }, "auth_ref": [] }, "GTBP_WarrantLiabilityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "WarrantLiabilityPolicyTextBlock", "presentation": ["http://gtbiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Warrant Liability", "documentation": "Warrant Liability Policy [Text Block]", "label": "WarrantLiabilityPolicyTextBlock" } } }, "auth_ref": [] }, "GTBP_WarrantLiabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "WarrantLiabilityTextBlock", "presentation": ["http://gtbiopharma.com/role/WarrantLiability"], "lang": { "en-us": { "role": { "verboseLabel": "Warrant Liability", "documentation": "Warrant Liability [Text Block]", "label": "WarrantLiabilityTextBlock" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://gtbiopharma.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails"], "lang": { "en-us": { "role": {

~~"label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r574", "r575", "r578", "r579", "r580", "r581"] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": ["http://gtbiopharma.com/role/WarrantLiabilityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrant fair value", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": ["r709", "r710", "r711"] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": ["http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Warrants measurement input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": ["r709", "r710", "r711"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://gtbiopharma.com/role/ScheduleOfDerivativeLiabilitiesAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Expected life (in years)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r709", "r710", "r711"] }, "GTBP_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://gtbiopharma.com/20240930", "localname": "WarrantsMember", "presentation": ["http://gtbiopharma.com/role/CommonStockWarrantsAndOptionsTables", "http://gtbiopharma.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"], "lang": { "en-us": { "role": { "label": "Warrants [Member]", "documentation": "Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://gtbiopharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r136", "r142"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://gtbiopharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r135", "r142"] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://gtbiopharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r603"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r63": { "role": "http://fasb.org/us-~~

~~gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)",~~

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-

~~50-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297":~~

~~{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)
(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
}, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-
50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r308":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r310": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r312":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r314": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" },
"r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r319": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r321": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" },
"r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r326": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" },
"r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r331": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r333": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r335":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r337": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r339": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)
(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
}, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r344": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r346": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r348": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r350": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" },
"r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r355": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" },
"r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r359":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" },
"r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r363":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r365": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" },
"r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r370": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)
(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" },
"r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855",
"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" },~~

~~"r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",~~

~~"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX~~

~~210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r605": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",~~

~~"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
"Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r610": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r611": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r612":
{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" },
"r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher":
"SEC" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)",
"Publisher": "SEC" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c",
"Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402",
"Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r618":
{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r619": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r622":
{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r623": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX
210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r626": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph":
"(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-
28" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r630": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" },
"r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
}, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" },
"r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r640": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
}, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
}, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r647": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" },
"r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" },
"r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r654": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" },
"r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r659": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r663": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" },
"r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/450/tableOfContent" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r667": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
}, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" },
"r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r675": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
}, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r680": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)
(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r683": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI":~~

```
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r686": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)
(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r689": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r692": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r697": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)
(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-
50-2" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r701": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic":
"323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-
50-1A" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r706": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r708": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
}, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r713": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" },
"r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" },
"r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r719": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r721": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" },
"r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r726": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" },
"r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" },
"r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r731": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)
(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic":
"205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-
45-4" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946",
"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } }
ZIP 65 0001493152-24-045892-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-045892-xbrl.zip M4$L#!!0 ( /"!;EGH@U<;4\; MN1;^7JG_P1>I*Y 2 FW9#TDV4D+"-
A(++&2OMA^=&0_Q,C-.;4]"]M??Y]@S M>0':PEV@278J%#"V;" 38=B9F+)+E?"TXB]4V)70 M,MI!152]>&J]!DNXOI9IG5'1^?\&L^+65GDLKW'KK\Q8&$K^7UR#XG^&:GU;L=R:&T M;]]\.-
P_;-8ZK=<92B!2*_2F+L3SH\=*'/_OFXH_+JS_: M:'YPSJYZQW21?3AXS\Y/V.!3CUVU+SOML]Y5]?S/T]YGUCX>E(OWPTB@7WG[ MYC<9C+B(64<+@1J!T-0+LR-NZR\UL)=?@D&
[<]ICQ[W3TZN+]G'_[-=?=@YV MW.>+=K=;?'[R:*8RM",J>O"NP89*AT)7 Q7'?&P J/AKQ_F8YN#RZ1U,:/H# M'A>+;M5X)_=8S4'W_P9\L'\DTQ><]4%W'4'R_6<"^-
*/H8_9VIB/TZ8!VIQB.N$UYA_3387UD*_+A<%Q-<4Z-; M4UBO+?M*8WEM6,-X:0.-R+T\_^R8S=I&H:B_!:5%:H*51H-E46SB^U7*:, MIS.6I59G@AG+K4@@NHBS.*0 U)?D,8MX@$N:J41:6(PO=Z]
*@)A#- M"(TBD286/)3I-;R2'6&49BP"0IFC0.-C@%0A!@SC!U$/9\L34CY;6P&K).)U M7)7GA!5L!1$+%LD4+$>LN6"U"E@X9 JW]=)]F480D=Q*M"/3(,Y"L!>8J>,9&X/XB+B)T.-XSLP>1TZ*YD[_\ "AI-
8K5"*+40!TK$"7KD_C0 7< MC%@4JZDIN%J+:VFLYNB-TT4/'E K2VQK"D0.MN%ZR2===Q59X35K@A MK)N'Y#QQ9 ?RDL-8$"DQ 9H=QM*,2",24R50O:1\Z7,H31 KDT%3DA[6*O:L M-]8J$"$N&
[8+D@L%6-.3;^\V&/"T6K V5.9E%J/$X0=>/3S:%7M4U>,X/ K] M)7<-]4#'J:=Z:M,HP$(QXDT)$?G"021NL9H;V.1;%B6Q5K$W/$F"J^27R67S'130MD" MD%&Q#+EU:
(=&AI)K2:.0/BOAA'I*+66&D@1.CAN/A7(+3GDK(X#*0C93S3&G M!SJ+.4EP#-A660<4,,G,983,/AK**@@!#+JB["4-R6L4J*7-KQEL.0&^[Y' MZ_5[+O#Q2O]KGK"
L7"'5!0N=")#I*0_'!5*W^=#&F1[##QJ7; H""&6'PN7? MKT4J-(_A#G%'C,G94I$LM=[EP2G+,<*8DC!*6*73*VUXRV#)C?%ZO0F/,PJ& M%OND(HI$8.4$%&X>R/;_I,V73#7,8\(\_W&Q
;!Z.@;A'BHB.C-^FV&H,OL= M&(^)1OF\M*#=E.C[F[]L2)LUM$_CG+?P+M@R=%=/",DHSZB"(-/D*I;R>?=;]7 292QNTCEU M-&CP8+ O&=?HC^U^!4T$[XW84OH!WFD-MW#$ M9NV
NT/I8<&:E87")=6]S%<+L4N,\X2,U[VMECEY\"R45A5[)D62R5U%NTDB MK17B&X%%1W'MA'M7 B2UQ';!:I#PAN($_*:=GX*4Q9=,8@R.>[,T<$>6]LI= M[JVFI'\=^VP$R$W)>4 Y=EU]"
C&"FX@T[;!%* YO*\O7RC>2KX#>4@?*;; M92%8X?5<"6>) K/AMB M, ,F2\!:&+H;4:Z6'SQ96F8Z2EAEI].TX6V%M3$)>9[F+TY%&HJY E?-0W M,B9%JN613FV_E-
Q;*KF/#MX]:RX/)ESWJ,Y@3,D0]G3XL<+>'[S_^+P*]^C= MR[_F,ZM_$W.^S$-EK4KJ;!CSX(8=8@3N%*)O\$EC^O@*@VKV6S53\V-9^9Z) M9JW?*GWK>CF,,YZ(;]O@VD#-;X/%(
MBHCU;D60TU[S'8WFL%5S_F"PPQ@/]4J^Q$BCBLLPM$L@TT\"43:4 5&^Q\ M[/9UZNR4&\NJU6(MN_W_%JC\<.9*^^>QG0=9Q;7.JOK&L!:1WG)D=S?R6]7R M]T.V.Z'=?
3V]8($'GNW5*8]%Y&K,C?3^-^&M=+>8T<(R"JMHUC [Q40M36^- MYM?/X3883HV^]K/EO@>4OB[T?U!+ P04 " #P@6Y9ZUPME@X( )4@ M"@ &5X,S$M,BYH=&WM7&U/XSH6_C[2_BG-
1P,S_KM5L-_XFJCN-SJ7O2^L.OAE[/^[SN12FV3'1YD ME@UE(@P[%[?L2B4\K?D3-78MM(QV4!%5+Y]:[Y@E7(]EVF14=/Y[S*SX9NL\ MEF-<^BLW5D:SG7;K].)\N-Q%/>*)C&?-
GW7BRAKY7^$Q[;3?I2.3';<:U" F MX?(EX6LYGMCG!-_JMOO?)G(D[=LW'P[WW[<:W?;K#"40J15Z4V_$\Z/'G3CI M7PT'IX.3SG!P7GJ^O/'30_O_1,ZR3XP92F/^!Q><>MRG8*=]4:]OYOP ?
[1S)]P5D?]M81)-]_ M)H O_0QZ:!,^%4R+J12W(L0#* V.,J4M4RD[53I!\?J_F8K8'T/6E2J;<)WP M&ANDP?[*K<"?JW4QP34UNC6%]=J:KS*6UX8UVA!.ZG(C0@\/[)/,V$VJ;F,1
MCD5MA9I"A6939>'\4LMERG@Z8WEJ=2Z8L=R*!(J+.(M#"D!Z21ZSB :0*L2 M8?P@ZM%L>4*J9VLK8%5$O(YWY3EA!5M!Q()%,@7+$6LN6*T&%@Z9PF6]=%VF
M$40DMQ+MR#2(\Q#L!>9<8J\;J%?J>,8R$!\1-Q%Z',^9V>,H2-'()34 M>HU*Y#$*@(X5Z-+U:1RH@)L)BV)U:TJNUF(LC=4V"5;'N.MZ5YX05;@CK%B$Y3QS9@;SD*!9$2DR 9D>Q-!/2B,14"50O
M*5\Z#J4)8F5R:$K2PUK%GO4RK0(1XK1ANR"Y4( U/?GVOP43GHX%ZT!E7N4Q M2AQ^X/7#HUVQ1U4]CL.CT)]RYU /=)QZRJ5.&$G1)2;VI$B 'MU;Y%LN.L(1 MC765GHLI02G*5#0??
HH:+O/6KI*%5;)PLY*%&P%2[FT&??:$0=.E;G4Q]\^I ML48Y@8#GT+N/K4)9@9$ P_GNBDA?Y1H-0#A.I2$Y.D\@B-0U1FL;BV3#LBS6 M(N:.-U%XE?QJA62FBQ+*%H",BF7(K4,[,C*47$L:A?19"2?
44VHI-Y0D<'+< M>"R46W#*6QD!5!:RF6IFG![H/.8DP3% AV21<4 -G\183L#@OY&@@A#(J"_" M2MY4L"J)7MGPEL&2&^S['JW7[[G QRO][WG"$L;"'5)1N-"I#,G!<:-23L$- M-W".E# GK\=U6#H?
^$3)1S*6=D8IFX?Z)J?L_)1S0=Z5KA1=I*8\'!=(?2N& MEN4Z@Q\T+MD4!!#*#H7+OX]%*C2/X0YQ163D;*E(GEKO\N"4988PIB*,"E;E M]"H;WC)8 M.ZN>\0I6Y:T M+2O-Y^#V/+0)-
_,T*$58SE&*L,B7(D1S,U,$B#,6RQN!#[<1ZTZEVM^>K./O M.\=J2:E:4MK(U1JQ68O=;O]Y6!)D;2%F26 O4]-"UQ*Y/"&Y=6]597R2)E/ M3I2/"/B*SX./^D%RI,RJ/-*I[5>2>TLE]Q'A?
>E<'NRZZ:&>P\*2$8SL\&.- MO3]X__%Y9>_1RP^F.VO^$'-Q[T?*6I4TV2CFP0T[Q C<+D3?X)/&]/$5!M4: MM!NFX<>R>,E$JS%HLW5UM[] ;:POUG.>B!^;Y=I )?/RZ H;J\QK[>_94-IX
M4^SK9")%Y.&=SH7,1015!*_SCB?9,:H&6EBN9Y7Q;<-W22LNY=^HV/Y!=Q[ M%KCW6D+ZU[R4#@/X1[V.88LX;+)+1"WTM'W-11I0Q6-VD;D MR]
[@/R4J/YRY@/IG9N>"NCS77155&-9"U2^K^+LJ?U6BW9?G=V3\?9FTH(8' M'OC5*8]%Y&K,C?3^V\U6NEO,:&D9I56T&IB=V9;6_;-A#'WP?(=[@96) ?LQ#T=JJ 3_(C0'7=FUM6%[2TLGF2I$*12=Q
M/_V.DN7$3=LA6Y+&10(DMD3>\7^\'RE>Y)Q['P?-_3WGW&UUZ1/LC^/UO8'; M="K9)[56ULU.>]2]@*EW,7#?%T(E31UJU=B QR-,8(C7,%$1D\7L1A&FJ'E8 M($,R'3_4K@$1TW,NZV"
[;GX;8/#&E)C@YD8'JX*3::3?=FP6?<;._=W)< MKCF5=O-Y0O%1&M2[FHC'5T^9Z+@3K]_K=UI>?S3FK4F[-72GI=%?_<"6AW/MAQ7J\>ON?MI>\!XJ9,ED[2(C(+:6_BC/"UW
MRG"0H&\:4#LYJQ:!)>!K9 8#F*W(DV^XDFEF50AF@3!E>L8D)J71C< 5M'QC M6VQFB] OPD?N+Q@*:&M$4M19< S!O4%_:?@5PB@,N8_:FGSP]O?:7,4+IB-& MMM(OPZ$=X4
$ETO5Z*@H9G)UH-.KHR(L4"-I(G,[,22&F2)0)-9FADFJ(UK! M9ZFN!09SK.]LHGX"9^N;7 9HG5?+9UP^9DB'_(BPHTQ]6C)-RU*L8(*QTI0U M"3VE(^I7^I1#MLX]N='I=<@3GPFXS&P!265
0\4&HQE=GQ"XQ]7CTRU^,O+GD&B.*.['CY\S73@[9$9" S8VSP^ H72$L M)B<^FPDL;I8%$:ZY(==$.RT!.<=\;=3>G9QF9E$JO %,!J]LOB0V MCUO=;G[]X!"O>6 6MFOU]P;,E Y0EWPE!
(L3$I1_*Z25@.-'C[ E7WDT :4 M3YA1<6%=5SA>]S\+/K-ZGS@17:*RGDD=JJMLNZR=9MOE)CU>]S&B>?I@VJOZ M#S6O 90+7E+T2]N+3YG$C\FU\-Q3W;>W- MHTS@]ZI
>PYZY6\'LKE+6C>8Y>S1>9WL\D*MK9@.7J';@43NDM;#L>94Y<5L M_6B]M]<=?1NY2EH2-7>^M*, ?BN5H,=1!'48LSDVR,'E$J5O#1LPBFV!F]1A MP!(#I5*>RV[_SUQ5%L[F]/XF-
IMJ+K_7WC[14UBW)>7=$O+K$G.[/KA?&WY5 M0]X_H]]N#=]8\M3+C!,+3:0WO^?]-9PMS.:DY%3X51H=O*)NC.]%3N_V1S^ M N#8-W'V#5SV2LZ^N?L'4$L#!!0 ( /"!;EE&A7*,0 0 )P9 *
```

```
M97@S,BTR+FAT;>U9;6_B.!#^CL1_F$,Z5"1>^[*ZA2Q2@'2+Q $+V=/UHTD< M\*UCIXZS+?OK;YP0:+?5GGH'W7)]0I^FWG&S^_A3*PK]_=1MUBPKAQ[@.]@ M_BOWZ(ZI/!
DCXBBU7>I_@K5[7N5NQ M!=/%PMEI_=1]]+HO$XI'A:.]6(G8/WIDHN_,W.'EL&^[P\FX6' G,'?ZYC.\ M;[Z#R26X5P[,[5G/"COSVN3/D7,-=M\U(Z?-YAMW/R\'3!,5)T3@(=(26K_! MY_J\W]]#..:>
[D#K[*)9!1*#IRC1U(?%&BUYFDF1,BL#T"L*3(1F8KF=@28_NM!C,EH1%1(T+;PZG!@-9>[?)++3EV%$Q+]LTE:E"BNJ-M*$+&U6;?$"O156KZ&&8VD0M8$7$H5XKS:IUR#&^[1C$K;-8L]E=-
MA8H-MHO315:1IN,#V&>KZM'EZ_D_F?E;-E^3-G-Q,H&*"TE*MX?3"!,H-"92BC=Z#@0SZHT4C8UD-M]F:8<([QH#1-$L2!""6#(YET\^2(!GV6FC;I$68-]PNIM0S;L,#$^P(MC""6G/F9P6?%
M=/X"05G#;B-N9+'LBBNK,>S"_6#QW^SU*/AET\=_T^>!L8[Q;_W'LGPU4(V\-M,G0;C;W)Z]5SYC+-CT5?Z74P@_?X3E@F8=0Q=;*BF]CUF_B,@-!CPGIR[P>'-M)Q58>5IRC;0]I1Y_=;TO^*6=R5]I-
]D\K.C,4Q;S=^"5[W@$,*>ROP-4$L#!!0 (_"!:ED<^?W@$.!_W?#@ ._M-9F!R;3$P+7$N:'1M[UI+UI=]](TS_\WI]"E^]][FOF'"'0O.ID_\PBT-B-M-S'86=YPA-2-8B$126##!W^ZM8
">T@X9XS26S04EWUZZKJZNJ]3__O;2H0-M"R-KO"3^^U_R*O=?-HBLO/'B^___5GNU5NN__^_FXM-$A9?!2T7EW\N)]LZN-M/WQX?7V]>I6O)'G\@:Q4*A_>T#67^D77;[;74;D<^>''PWV/G8
ID^5%165$-M%JQO$GCQQ?GYZ-OUI4-9X+7/R@?[EU]6]I:4&__M5#4OY14I3Y&E0W3H5ZQO>'.ZED0TPQ&""[>/JYO+5?OK-Y=^4&5&5$;2/&54-M*$+TI$(V1V6IHN4A606P6P^"OU^
I87K<\I9FC2?LR><[9&BKX>,LN8X!W;8-M;;X3?@'OH/+FA7-5=GQLY0/\=GVADATSS&Q\]8A1AMJ%QA?;SU8RLB0-Q?9]-M[9NMRSE5SJK+&5#L28%??T!?HWNH;
(ZVL(65YJ(]+^W':GRY]2I%5O>)@AJN-M7737O^VNKQJK0UZ;31@HFRM6FFH7YBIT[A)-3,!P-Q<$^N^3RJL"N/GT0?_W-MXM,4]-R!GI$%?^;\XM_+FB2]0%2S?3B42X+5?_OW4@5OZ@=M]GZ
=WW0'_GI-M/]DLT>2!P%T3/;!^) K,%%P3;]S;1Z)5UWX8Y"CZX*GW%U6_JU;[\!]$&)'_M>KR9+@W0,_<[PQN8P_/^I'Q.OXG,D0'N+E0& ((2T@__KTZ!R,$_:E-@QH,1-M(RC-QY-(RY-]0&4%4:
M5.#?]0<,)6Y)*.I2-/J>CN!TOR;(W$PE^OP44MD&K\2C-&7$C/Y!!KY$YD=(-MJW#\PKR-XY69P"RO"S$2-?].?]M&&@+(4.UHO-_5,?P>C?
RZ8L3=',S.9(^+\JZ3]7LE")$3P'OV=8%:$L1U\2(APE?"_@K[7-1ADX$]&4X1.A&V\$\S3#0UX]-4>&%*N!]C#(QN'RY16I5Z8P@>;3.9YT\-MB'.*1Q,$<@A2/!=Y_5HX^:"]5*Y%7H!&3)X#9+_<:..A-
)%GM-WG:$A>0',1A-MQ9:$+0Y92:#"DM"9-1EZ6>+X'D"'Z9$?3]3.Z$D!544!]NQPH]5(1DO+/<\_M>0%)_8!LG(@I5<(2TX+O@OI3;;S-@*B-MB1*)GF7#H-N04-[TT0>GR9Z31/M-M0%,Y-
(8#\,E^XENI"@VE.P:NNNXE"&*E(S;>$#5S7IF@&=89U<%0#2C#59"R[_U)8(7*-Z/,FNX%Q[Z-K@Q&-*H3KJ1+[\@"F-M0R#ODD@53DIB39I.)?$@?;$U?1CZJAS'HT="\V\_P7$NL,3-
>900G6NF@M*(U-MV+7&AI:BS-%7G\L0A;J_\!I-J"S2#CD$FYD$C:-MW:=SN9A(POW-\W+@&1'K(+SBOGQZZ@]932JXK^&]<-R-:A&"O@37\ZH-GN'Z-M5I*[S)
(9"K%,UDI\9B']\A/X$H^_8/Q.!\JH552E?L]-U:Q?&>CH7>![[\JM#83.TF0U#H@<$A3:D8>CSY;+0N=#K=S<__M'G#06SW"T05^CF-Q%SFPCG''-JOX(FCQC]-5??E<8/.6@.'YTFWYX/&9-M!
S5VWS,!X_$G&Z,^X,(O3KUXG(91,JCC4%SY,/"7.(>A@?U$#HN$_<8/$X,-M,IH=RK-1CS!X(I,1M-DIAP0&;<((A4I@T";P;*<2&+0)!S]-F-M,)#IM-=MPJ&>/D(0)@PVZ>,$;8(CZ#A!FT@6-
GO$665[,+8];#>OP$,F2KZ4-MW-S2?'19U4A<0<*QFNBZ]"<#!MB$"H[S-O0$%TM'?/-/CA2-2"\42,-M,U_RH?%K'D;@@5*%3M(4<&1@QN3#)RV&/#=2*(;W+A8,+R#?#^D71@!H#O<
M"UU'C4=32"""_0EI)4;%ZX@^2MU:==N.RUYO%\.[A#L4[XWD$C(-&@!27SXP$-M/Z,(GW-U4-YW,E2Y3Z)L#"9->H6?P82.-QP6R68<2"CQCB4")S3"";)/7F@G-M,1KT')S13K\^BU*4>+(!
Z6Q=7_,@B6#YP,@O0&W.-M1!C&$G42[03L<>>_MI+LN0X3&+?QYQAC&@M"XA3\('\-8]HW;G;0-LHC\O)HDSR19"T[J59&KCH'(-MPCGB:B7*Q[9Z0806R4"3.__-[-MS-]V-
;5_5>I/Y'F"GQI_Q7>MNQ/9-!,PNQ'-M7MK*I41ED4XP]%W)'6OHE=,//0:INXRZG(!1QR!PEU%O3?!@HU]KD\VN:V=T-M,(EL/T-7E/K0236;O#B;D@OFMEE'K@D,/PT#3,&-M9E9H5^;9P,4+*N2.2]?
U.^P8!6R../!^;V4K%^Y4-ET/(QX!ED\M0&.8=YI&-M;HEZ!D[-\9"YK,/>L8U%\368&-1'YG;M37#!V2<%ZH^SYD]%G4]D+I2"C$PX-MYCCBE8\?S?C!6M44C5Y+T(*+3;!HWZ-2U]>*5L,*QQT)EA?
L_5D_56*.)>_\&+M+]PU\;@]6*=SH,V-M"D&;=P&M@*?YX?ICY.>]_(@'.J$_MB6!]^UOF(7^MR!>?VR#W9Q,]XUTR2Z-M1P]TT645552]V8S$?,[FN]VI@%Z%]68SXLVI,>L=YL?6MYN?&;QT9.]Z-
422-M63)%+-4KWJLW&]K7SS>^B9(Y*,G,VV-4#A-M_)IM"NQ)&+A146",+-7F<^,;#E+R-A-XEE=U.@F.AQ=]_3,L1AQ]RUD*3"*-M8]YTWWCE\F9]B?((WVP?9&%Q_^V-*9D9F#A)U#X\
MBF.IXG0REP[_7/H(S"7/A+F^_>S8F>M<_]@'!+AR&M\!$2X#!;3?QTUYD5=4-M%$!;-*/VN;(=C.^,1G"5*"L-N,Z2ED_+NM5Y&;"])"QI-RUZ=O[;P-Q+K+[;-MWC$N/ACG:FZ\D*?(ZG4?
-1W]C%HBAW9*YO#%&E%;V,V#5(YI]E*H$_&LP+/B-MF+,BD8;XP"D#/"OPK#B*K4A0I-+U5"R>%7A6',=6)&A=L0DT%ET/V:<8QVL$-MZ_OL:]-
$M%NVS:2$Q1A,B02;VQY2^3[10O.7]Y[8WXOPCY<_>+\!7]P__\%-M![E7LY?^O8#/W.QIR<,>TSF[&ZR8.P"G<0]JCJWW!DRV(7"8/$,%NR")<0%2S.(L-MW,A;)P/<&/?YO3F*I&GFYTA@WT;
M#!;/8,&^31)]FY2!"/LVR?!MD@H;/YW,SQ\T2?-M$G0;/T!G^?/'2Z)\FS2!-M!?LV"?5MT@0BI_LDQK=)$&PQ5Z7&.TG)230^NK"Q1Y$0C^*4-M(,_>01(2C8_0?@#;]F39=OK8(L>V_1T)&]OVY-GVHX,
V_8DV/9CB3V5XAAB-M9P[TK"CX[:""'"""ABSB%G8!"SLQPB[@OY)59'7PP+SQT_DTO4)&-=-?4==8-M79CHUZTOG=VZU#7%U*SV;FG[FU[QKMU2^%2.%^;HDGX/L',9.JE.;;RQPIP#-M':
()FM9S5:0+WQF9_DL7R'H;X:7]-[8U@"/G3K;=D=0T58==,@R]\X%>LG;:-M7+7>=P8U#UC\RG/TH)V&28[#?G]..X;-"2&08*/DU-0=PR41&B/V!NA6-M;P1#(#$0B,#'V
).O&YLRDJE)9BY#@I<@R2"Y0,COP"U.1>Y,YB'F]G57\[-MJA2T'^W9^6P.LFXRO/S,"'/0$N$22;D'"R"0^EC/&__K4=\NUS]"AF]A9':R
MU'BPC9$#7'(%"L9I7#BE,$X]X)3".#TQ3FF,4P\XI3%.CXC3IUY?!HPREY>;-MB&?Z<7A(WLXC?B\R]^+KG2O'],%Z3XO^]7[RR-M2OL3',,69.VE8[F.4.(MU^==(2F-KB-&>"B-$B,!]4XG1G@H
MCQ0C(/"N*D9X$"_EO;/TM+M9B4-"WLU*P&Y6(I"-=[,2L)L5.Q)V]E-K2U5:-M,"(+;GE)D,8\]I1$-OU->-0"HP*NR\CJLB\SHL*PFCMPNI1^8TEV.<"'<]_7-MQ$A(.!*.K1.>1!ZZT@HDM3-
ZX$41*)+*O$,D'.##.]$)&-E)14+L.H'"UB$=-MUH&*NYJ8?@5"C(DD8B+!)0D=Z^1B)"4>28DLAXOQDV3\'+DA$X1GWD1"_U7]-M3Z2YPHA<_Q72O.Q/9-#T/BU&>6DC_'\>O4S6-2X/-ZS1T.&=-
Y%LVR2TS8H!-MF!.CF/1G2L8A7%X[5XXC]&'7?>#(4(,HN2!Z]A=")K[9+;CA,9G-#^?F]P-MB>.SRP>;@T$NG(IDU98Z77G2-M
^D8NQB[484ECI1]XH3=1UYY:4)NM."=,E#41ZCV,8H/H]B99^\>SR?7Q1C/-M&,_GI)\U8_DL"8S*"W-&,J'H6S+KG>/XI-K98QBC,+TZ^+&VPRP*N!0:TO__M$,;WG'GQ//:<_8-
ZGWLI0K072NQVOJWB/E?E?XQI$FE9+\$&]&K$#B]BJC?7$08SW.A71^OP;T&4(UX6*W63NOBRU[,6%@-MO2>6%@8:1/!R"'^'$E:ROBN#T5SD-(=]20LD;)F"$7D41%]I&N>.'N\;H)YX
MA/%Z&KSB-;IGV.)%^]G1ZS!ZBWO0M%K"-]@.C_,+?MY?$Q@%BL)@;$=^Y,<3-M==OYL&/Y>\$C5IY.3BG6E4FS]-?B<=AS]>6Y^N,AQONQ8@/;E@ACW&OX(!C?-M,*Z/*S?$@*4T@$;>^Z@]
<$*'-SWU)CH5F)DKC.]\S)@54E6&M.9("V!9N9]-MDJC,!37=*RI4+[']P)4,RV10XF\@GD4&J"!%5)8L;GXR-M0=6#SP3*5Q2A!K(,.&W"),48VE-1QO)8&Y<%2X?&?3+H&++Q!9V=>Z+?;,2
M211@+'[.CNCC.VEU2/3O5/*GSD8YSN$D+/AD"3[V\SR.SN?YQ.O=XN4).;23-M2#>2@BL?'1[;3QMX=*8B/YPK+9%%-UZ@C3@Q_5"IOL(%Q^;LH08/YY&>#"]&
M5'Q!O9#?"9:O&"I8]^R%TPI9LK#YZ31-B"*-NT',JF27^19]XDI2SE_+-W=0M@PYV2.MOFIUE6F(X+T&\](-MW6]?ZSVT*7S+!*(!#.Q;P6T;EUUO%9H>^1U59NEXTW
M(+.\HM<2MC3YT8C>%@^V[@>"2!C?&-]BWJ%T,G]5PEC-KF878L'Z^1@.AGC-M&^,[=3H9Y4-AU"88M1L!8;T<4"]CC&.,IU-WH[H2&+;)A>U&/E@S!]/,&.$8-MX2G4R_P"NQ-
)1NU;/E@O!]3+&.$8X.G3RSW^#8,VN.!=BP=KY6!:&>.;XSMU-M.ADLP!FD+)XO;C<"PGHYH%[&&,<8/_$1)'P$Y3S%ZV9ZSR<9[!PSLE)GY3"<-MD@RGY&B3TX@25"NM!*K@YJA:FEZ%[_!
77$M<_$7=_M%*>S?@I-FYE:P7"-*R?"A2&V6(,]^2Q5P+(A(%RX,L9W-4SG-BW4#HD>@_$9F-M)U5HX\_""_),8_0;TMOG8(T>@0-M-]>%!G_9EZ&-85AD;]"IL7X3$7]\$-:?-M*DW!NH[1O<1]=G*
[%9('X6"_RJFI.9X*>"H<9RH$Z]>_O*CZ&T"I!'4Y^PM-M%&.-:Y#H!68]V.*E/&C-5>I/I+G"F"7*.R+HL;PN-W8]_\ZG@/NALNB!F'$R-M!61(TI<"VKGGB&7$,.!2"
[1T.7T8;*D%6E)=*@ROM,+KR'M'A2S\=_V3(V2T-M<'9O!I=AD@RX]XX93]PXI?%#LO1K_*SWG_++PE!+%=32[&=A]*4';JGTM##-M$@VP(^Z6D\5LKI0ERS90Z?
%O*@!B%T)35.]Y%D6*WQ]$/'#A-_P)1>;&VZ^-M("Q(.Y"1SC0?7#]2?/Q9&]*8GCY@)8+1C,.6E@A59'3PP;_QT/L5@BUBUHKU42ZXE^G6+U1C1QW$JS.;0-M9W#X(&$(]^@\[-@
X_Z8N#^(D]I!O[I"Y6]3^2?2<&&-$,_65'$H,]32"V-MD"5IO"!,QX)P,_"*)!?S)C>)AP4)=@@2]Q5/]Q#LHMC[GOOFGECVW*_/H8U
MAE9<2E6+E_$BCI<=*5YF935&=&R(QA'@=O4!3BRB75/NL/E/@?E/9XH=AE;2-MH96LE+K-N3\Z2Q4W/IE-]VI)WG_G^/+*BI.!S)"B+Y#MW!-]N!!#*Z70L@0.-M=T-2RPGD'4VTMUI]9P-*O:)\)RA-
L(C&WK8@ICV]-;$F,[(=C.9\E145.FF)-M'+_@N3DC;&;3%HM/N)S6(.%S..UU3TC$SD5>A^M3K[Z+M"E@E+D,;GA%RE-D-MZ1!>8C[*_&KK^>A9]@_7"UDZ/=\8O'9-P!=-TKKV+]%$O\]0=&=
[/@4RHTK[-MR/(^]EWR;)YI>6,=B-*4%UW>ZGALCRF$?4^/<&*GCTHTAS-MF04*_$3[8-(8#CDNGSY-O7]S<7'Q:48HZE*-WN-(6O]K@LS-5*(W22%:(-7-MXE&:,F]&_R!#]*#3,/I(3!EYS(O7!+IT_>"
PU\3@70+,+C-&1S=Y\@K285+SRG#!I9.3^NMSZ-M8BC)D/*L*LVNB5N!85^(/"RM(@D\JY%-M&<5?@7@G3/U(V%.*(B8QZ/,&-'ZANR(F?+"\MKM'58IEF?0-M%_@TO'EJM_]-
^D6O7^TW>I\^#"&#T../P[1(1)KU)X>6_U6HW=!;=>)QH_:-MVYK[KD'4.@\K5ZOU6FG'K!HS0C7^^1@H/U4-MH7.#U8]BA0ZW]'[,8&/@X9#E$1MZ<*SA+%,A*9G=_>E3;;N9=ZD$.WG#D2
MVF^104$"2."U]?V7-W"Y^DTS3IMW:#!S3O!1F:$-X+L$-7[*PLGR]R5D$_I]-MQC"<^;OO\6V93&3Y5=G_0Q9-5GF6$4R.0#MKK,4^]5Q@FG)75($7H^3K+J1K-M.Y#^-
F=D*$IA^0AFD]S:HYN=L[>_O+^;-TN!T3V2Y"FC_GO)OZG70TD2_"..J-M\ASLP#YO!_L=&A%8*]5\\/C)##^4;G-$HE4!..;]0@T>F1M&-1<^BMSR-6(-M'7BO5@:;(&E"D@FR\#?W#R&-
"'4"T%=SF5=Y^,[&&SM!,66BR]KH:[)"Y[>F-M/!PQ_$O6_5EM^MS$!0)^SQ65'RV/XBFMWQ6[4]]2?($8_,<4#$/$:Z0Y$AYI&"Z4)(\1.-DD\LUR)NQ)"_MS?.WE^=1-M\W-U^?
[\55\!A(;P_09P\JN?X<:$O!($1^RAB5>R;V4&B^B-M^#M*:SAB!&77')9LO<_=*@U[F$^1/=P,-1O$Y!E$=2T=TR*BB!HO6/^'!#2P-M_!>C6HU]W"E=MYHRJTG3*:^@+=]+)@\
!)S[R+3O:K]2H>D:VLX]NE*_T%[#-MW7W]]3!5B[^G9#D:>UZVZK%=&M-&.IG-YW(4?>)E+8;7:EADZV';VSC-2K(6-M:[\FY]A_HL"+8_^T%K<_]PC&O(+4BHI:G]B#KKEZ^G97K]Z-GH5H0%?9!]TV
M'2@EY^*VU>E^KCX^5*_$]UV[KV9PD]"P.P42(JY4W0.MKY1$X&/G;-T.I:-VX;M)<5.5E3>(<=$6]5W^DY#*>]50INH"PN>%8!-M+$H64L%,EA9H@NRNK*GY,J"B(
M3@+^^LO;R\C7TWN^'7*-[A>?V[/A5QXEC$1AI2AR'U@.!%W>5/):SZQ\KN01-M5.NU3S*4CJV@U^9$-Q+ZCG7.M!GK/>E(-RQ_;],5K2PEN."1H>,G\PK'ZTM.
M;62U&424_YUDL+Q53VECEL>,R*^TW_^QC#7DE$Z\DD.#EM7CU>]*Z(QG0G2-M$B7.GA/PMI68L33=_]RQXC.ZH(W/>'!1!HWF5643&'S'Z[WU&]"*<3)0E-M1-M@LN"&1D+YI,QG-R0<%?
SGS%8$;;'=QHTQ=Z1]T&>HRH!Q]I>;3_?SYJ_J-MY_G/B+P6RNJU6_]_>9,G"P>279W-$UC-*C9KM"=_2,+!J%2I__KTTK]^]%$-M$Y6BMG(L=FF-WA99R>;ALW5VN19_;\(@__<_98HL?50N5"""&1H]
(6K#SQ#0-M;1#F:$E,P$4,-SG,@7_2.=[C3?L8-HB;W8X+/6(#9,#9:Y50?P_7FR155KW&-M&YT)#-$<3K75>>1K1'3Q&$MH]>B7-A8(L_;#3HB:P"A*+%$,0\YK'I%7!92D-M?.KU1>22(\M'D9S,
(&YJH^DMIT-)P$(+(;1\_'$V*#2T/6'-F!N5R))PY,K%@A#E-N^V$=DPQQDR.TT_)I%#]M&5I*$Q=-M5)IC!_0>Z\6Q^]4L!D^(W<+.5N+>%@%ZW0_B-3H$S/;Z,->M6MJ*E11WFB-M(MN70NK?
=DNJ.*=OK#1>0C.B<,P?!_!H8]@Q,UYE!.*!D5^_>M*\S@TZ.F-M(HO^;_(?8L(HQ@7X+*0$00CF4Z-M__Z9\VBM")>(0V!<+_]+[/NPI)91W#P6W&L73]3-0NTZ-!)$5I.LD+\#9\'
MT4LH<^BC*!,)Y0^8&63]A%%W:7]EMJE$).HW&V/X\T.P(D?\3?US@<8XA'.-M?C_\#4>-KM-]#,]0VB)-M?CO3>_,;:V@('R3L]ZB@+EGRO'XW5F.L5Z
MF&B4!O[M)V'G6LHO%M]$X2YX"O;6!+1)4+2G!T_Q!/O;P+R"L$0-B04$-S+-MP@DH,V@6(U0EA?"L%1P,TTC@PXD4M^5!!LQ8%Z*G<1R<"M:-)C^9ECA=<&!?LD6<2
M8#X(V5OC6@=2S2MY45,O4&<,LY3I05@3]]P_/F$\>=HSN-4M+(2D?'[*L%8-M(VH/J7L:.XK-9,3D5S=&:Z0Y$AYI&"Z4)(\1.-DD\LUR)NQ)"_MS?.WE^=1-M\W-U^?
O72W3+8^WEFB18X^5[*V6;3/-M:N%">5N?;Z3K8N]3=K;JI^MWRZD]-MBX]?6P'EMP2HW7FL[5W@1*X+'[%-/E/W=_WGU^-Q4T\'P6F;?-LM^OP<-C_/-MV=@PS+-&R[:)WA-
T;DO0YIUWVDTU_1Y[@.?HS_GY\^OGK]]!S&<=:9M$6%M"-MTW;<<3_^B2-K)UH8C"ZOAI-51&2+R&'?,$KFB\D,B++,P+RD-!Q-D0I-M]GW.,3*G$.A\-L\Y)8#0?
S/_V'KB>#F;JN6H,H&KC;4R_QO"35L5ZH>S#B^Z-M_KDB?D+R#'FC2(33H7?#]*)7F2:-&S;MS4!Q?7W.OXC]N-M*W&:-LC'\%AH]-MV-UT@235"*]%Q");6FAEQ4AI'&!YZ)U>$L8/RK^7K7;SDD
5=K5'FK64]0Q%YS,T-M53;A:Y*[7ECH98K1U&8U@]&$(.6$M"$VIK@*OK@S\1^)(<.^0(=A+G(H;B/)-MUR@5!Y73T?*R47;\A9X>;\W(B<[7'XV-O@'_:#X,A>5!&F=9H9ZO!@"%IWO-M98C1'.T@R&
J08]F'67\#@A.TIR6*<.+*OP#+YW)/'0Y9M#G-&^-G6OOD;1Z-M[E=$$_HFT->824+(PR$YV/#%Z!/%]BVSGX-M*.W94->MZ?8>AG%ZPOCG'IILTMZ@YEOBE^%G=OEP&]R@;JFE_+[9M""F\H8F
M"\0#?,%8F]*]I9X]-[3M;VM+]ZM#D2ZCI>Q'6VB5[\FR5,@MHMFNH0M>1DNA-M4HD0HDU!DISB./M#I.R&B$XX=.2^]K.!#-W-R[9*WE<]G@8E(G$7'-6Y(N;S]-M0M+^D=CB!T?
XBSWJK"3V))!K@?NR:MMD8-MMR?X\]8&E3]\N.@S3ODNGD3=E2!%PB]^YGR:YF[Y.)K_67)OS6$TTK;9?;2C-M!AT-)G_.)<\R:!D]UQ@-:G8!]2IFSO$]THMH7QC\?V-UR$LSZ%U.F2OXZ7&]
MB'CJ6MMF\OZH;[U3!SLA=;TWWLK11;$E"S30C_")]'T.BSBHC5]+H.WS?YNE-M%A'L'"@M;AL'FSTUZQ[;[A[;]AOV-]=V-M'V]R]1]I%*0*O"&G*0X-HQO.,YFZ21./DAMG9D7;BU-M5.!%AR-
A23U:8#L@#X?;X@^4O7]]S?[,ET64FB3CG5#((8ALOWX_4*>/AW]3-MN7R&HLL9]E#XQP[)>_5Z[;^75(#);9L9$"%7]H]IC=-6T6RU]^U;JWI/M-K(
M\%%7[6O>3.&!ORO_89X(BEOEW/3@;]3](=%,0&G>_./(]1O45LYY]FGO5Q]%&-M5)U>_^T8F4&T4=)-&KMYC;ND-4_,9!2(>Y_>TR"7(]$97%3W">59P)T6ZDE-MH-XR@K:CT9L-H"K&'HN-
!_[WDZ@%U0#WC[:;]@/6N$+?BZ$_?6-B.I-Y&O33-M]U@EGQG:*4>T;Q0U@GEG!O3*@)MC[,0I8>-TAC.H:)U!;4F%SU*E[2FQ7G!;)\<9_;O\CNW!.B)$-MI3@BM_/ITN7-
R,R8PVIZXRI,J^PT_(;@*.IH!^?0-<\-M-F4N!U]"M*.=FR$]OH5\^GR07[Y$/5]1)A>CI^U"$,,//!-W_<$29FC5._]-M4)]K1@FXI%77E(/*S'X7_Y\T%S17-5%D2%-W)75EB-82-BZ%Z'CHX[.YT
MG/2G[OP^BSWE-M'FS2>$V*_>%$-M(/'H*6))S@7<43CTY4VO>==>N]]!>&[W4]OSR?&OC'#Q?17TD.C,MDGF-WF)4-M/!K?/QJZPR@A9,F#S\2_>4,OK]T.>_4B@HN[(-MO$L[:HB/<27P&-<9E:"
(N0&@F=!H#&6_CSU1;=>)WM-MKU5Q51];R$RD];P-M'/AZ8_3B0-YF>D=X^$31(95B'F;G<\T!29*#567.OY+LG^ZB5H$*9SZ%XUEJ-MEUQO]HR)K%/.Q39#__A!WG3;
[H$EKXV'[*1@55O;3D-V%?*CB8H>)W-V9WFL-MG+?Z359'T.1OOE*S%.#H_H]__XOIC\[^5VM[FH$8;2BR&\Y^"LONT&S&8#?T
MXS&FC!A#D_#_P>J1__:\8[RX4TH@;L;8Y%]'Y\O^BN((4'1GKK.L[%Z[E0#B-MY]WP0]^DN_7B;]KH*V.G,E,N:8639;512H8*I#5!F,50?\+9O4(MO,C^3E-M9"A<'I9&\-B"!VY6>
[U&OW>0/S8\T=TM>P!8KY/1Z[U<;/?-!!%C*^#RGH"_MI@D;,>=(*&GI5[O;RT^K_;]T-$D[I#CWZ35>3C_.*0ED8]*(L94H;9$HRMRL
MBASZ!^5"+O@!I9]5U1HCRZBDJ;9LA1*F6H,I4ZVMZ"$-6)6I8]LC_,HO?N1C-MF=2&4U'_;6__E8-O2;Z6MI";AH$YM%/X#-2';9M>YM;;^OMZ\B;=Y_>?__M#L\D=UNV&G*S+V%H2,#;DP
<*AG;5!W*%SU6,LO9ZA@^]>]7-\5,GBQGX"-L-MBAC:C]>6_,8H/2.VTUF2R]*ZUEML+P5E-YG)E2K1LMUVTM]-)OTC@)];1\7O-MT/C-GCP]DYO2GQK?EKE\P7BT^?VLWE#GS:?8].KAX%BRRL?\
[$2%!@5VA,J-M3F2,MI;)].1;EG_+3G@.KC^O"8@XBG\;RD(N5\BAAY8IDMJ.^HM7?!;]G=?.U.9@/?6TMP.^,80"*"/0<\VE+0ZZ:RM-W]@\7_0?W-+2GB%-MH9_G>(*!R%Z-
RF%0E#44GEO#IZM9+TR[]T+S5[5!/;+R_FX9&:K>TBGY3]2-M,GVH9E1#S4!]L_I5+_]6N?:BWICWZLWVRTFL*Z4IF;Z$&AZ;T8'J.:(#A^$3
M=':7@R_@2@5O*XE$FO*@$RNP@TW"B54H1FO#PUK;Y$:2$D6,K>;*6327<9Y.-M'-\#1@&/Z$V=T1/4X@AD*-VNBO2>^7,)N4[T0$K2/HK\N;-77P=TB>SHFL-M-
,]BAD.:*Y2054@13.6]X*#TO:N6(A54M11B6QK4]LPS0K-NEW4X_RX4NXN[-M97-9B<[Y=]EEL5V4'I9Q6UC3>O&NM.OWA/;FS).C@REUY?TZT%]MQ&<_!!*-MP%,XT>=3?-@T[\;_F(_?^#N(*;A[?
Z;BL5<(@5=>T-<@YX9\H+6!->^N22=^>6OV?"11#HHAQ-=X63-COIZN5-MSW6V\R@TI^4CN;7FXEG8D9-SB;*&%LQ5ZP^FM[O4^DR2Y3ZMQ.QO:^M_C2+-M@]589FY]Q]E.
[X$Y]EZ;22#\4],P&)/WS+5_6VS+*.^N4REP+)_*%$GJ'$3-MH_+.UI\I'!78WM6Z'<:UOBMOS1YX#;E];[DZAY^\MOK:]91>$+,9U1Z?0>YZ-MJ^.T$34GWOF858'#UF2F7(P"(:G@G?WL"I$30E8*
<:=;Y<"A6[+LS1=\WWODOJ5DKRZ"Y]]DI!>$.'0&52[356-M#?-R6+&?5S^?ZV5!;D>82.DK(N^\3WY_M*7^80,4QDM@Q*TH:UKM@2!UCKR-\X2/Q!;9WN@M?
HN/@Q6T^+OSR2WN"_PQPDI.ZSW)%%[*3HMO28;/@)2G8$W-MR,0"T4[\[V]S]YSC8+N,W)@UP]*<NXND'L31H;C;PUF/&?T!-<.-A>GO8;Z-M?>M(1Q1DXE'(MQR&3V0X=WF5KQ&
M#EOMYK8!Z6IO4F(DV-;>5;S:.V>"2S*\_9X/_^=-7H?2K,-U\'CJ@M#0M&>0S#K^TCM!K&("_.9BV*U.NM6?ZBO-MI#\B?-A\EPP?R/2:/]DMZ""H]$2D'1K)G-HO%0VW[!@U868+"Z
M[746M;N]\]23WVQ5LO$;./MJ++L/HS%5%941DA&(="UU\ZG__MT>+%>\Z%FE#-MT_Z-G$VZDUST]1OA6):EGS]?EHTZD(3-+)0_&V9OT70EHQ\MVS"$8%2G_E%[I6^]]K,&!^.=G?
M'XU7ZNK&VRP^OW'8M]\_<.;QO*5]2O7]OC-MQK/HX?6'*TVX$^!Y:I.DUQV3H.ONH-3:+G-(KY'Y@XON]%?=EB%Z6'*)]]__M7K_>_9EV)PY(\+#>KOA_O1D&>BR^/PJ0BZZ1:9/0#]MJU>K:E[MW
=O"K]O'W_M=^E.:P4.O]O'$LEAY-YA2'GU=2*!H<%%SPZ)P53V&H?0B=:R+7VC$#FYAP)_M'F!G*"%R3N5]LV6^\LH%@UTA .R.=[/%SI_OMS/N;G@:V-GJ%B]888L)=O8D
MAE/09(8NY)!.;U#EYI0>TUMQIVI)MNN$^S"5@9/B4IR;X(E=]G;[I,M7UY/E-M54[O8,H(78;G6F*-F?$](^RNRD^;-M7&W/0Q\V-7#1AV*%SA3R451]2-'O;.<7'5@=%(/IBA'J%PS=2T40YYJ)*]9$U[]
<]MRZ%-M^'8I$;D$G5!^Z*'BIO4RN4L("';^6DKW2"9S+7,KD2]Y\P;B.$11\E(78"I8-MZYRW\10(3_3O<2?"(WC15?>A+-5]_>2<.;)UFDO,N,G8ARXZ0F%7!LHG.#L-MU5.8"H5]1]]D=F5,=V^VM-M-
^BR;_I3\-%P[+2%#X3=1L@1$E%&T8R(%#<'+YQ-M+&LO&UE%X5)U-A0-L6$T'$+(,_I\L=8^7R->9&26ASL-M=@_TAV3'JO^=]O-W-O[G&^4-G3'=&(M8>G-=[2>F1ROS-0&LA/Z>L"I=[?E
MM&NLG=D/K!"/U-7>OC_WOGLM1C<6O;5G$GB8-M;.G1:^G1NO2$=OOI7E'5GZW?)Y4>G0P>)E9ZE#[CR.VY)W6Z2[);;(TF-)Y[-M"99>09]QY/;
<&XD/E&/3K$*;VIP8BF3_/9ZJCCA(Z^SB]H(WTH;AGO8BCMLK-M//D#3A9-J*CYE=P>\]&/Y>*\"D8)Y9G(J:W9XYX'+$EC'-TLXR)3"&1H2'M>U[#EZ?X;MLTBZI=D6.CDZ-
B;=QJL0M:P\PDZSKF/.*4U_>#!.3.-7H$2B-MD5GA\KX.%D"09BCB;2-/Y1D-ID]G=;^]-5X']V516E;G#_W*YWQT249&T]LN-MVK2O>^P"K]&L'0WB-E3OLL9X,O67O2K?OH]T>;U-1HEY-?
57@-21@\S>SAMI-MRM)43_@I97.D4^I/D05?CKG+0WQ('_L,7D&C*?7C*=M&1^BA#]=]-:X]WTR-M'N*[T9X[3]O/UM,ZZQTQ'SA=K>-Y6\TSXW&18$Q,-HEQ;C1A
M]3KW)07>;3N0&>9'1RO'R\KNO+<*Y'\#;1;R"7&&S1A%-MAACKX],69K),3?O,@*<^UL]UX9(,L]K"H$HL2+K03YK>,-KB:-$5LT-(M-M3(ZP-EO[FS)^+9&5IF"=L7&/G@AOWBOVYX7YBE'^;Z#
(:C;;1Y4%,].6R/$+-MGIO#V]1GFIU#,J,1SZ+8WA5&U-MT6:';+BHPY]6B]*U31AK\B8G;)##RP8MN@%-)]-MKW:&1-NCTS".P!@5Y';S$=("N9^C?F&E4LS#.%&0VW.KCPVYP,YC(>^T7-H
M;P0'26C%1PC6PA!BC+]A0*:K$B$9%&<(S]0SHP$6F$/0?H,T$@]0%_!:1?L%-M;8V]VG;N5-\;!6AOU*9>QGH&D]?)R-C/C')094RF4AEWQ/;7M]]*-WDZ23,C
MOW:^3Z..B\&+D5!.!ZI=5'(C]$HF4ZF21^OWZ8+>056A20!;5V-5=VS@A:BQ-M62IZ4,]&]A118HF+\G10G&D^X^]RNM:3B(.$)@N!]_50&0]?D#Z.#%VBG(4P-M4]-CXT8LP_#S\'#
M!"XF5XQ4_+8T0M+.?O,/!1[+01NR%V-VC3826%_E0QP-M%!83DQ1B,*.PI%WFA]YBN)<49<#W!U/5C+A.F3;\J2@\#!U:OW/.OW*C1DV\C-MW/3V%'N]O$&$Z5$%Z\F^U&I/EWI3-E()XGD6?
>A*AU)3=*:8\[9)BZN$>96:-MBZ]9]%%1R5%]I&,H-DLM\%P[\%T6?03Q'>1&YN!T\U;C%0O.QW0[Y%-6?22P-M.(LMGXMTD;=?C@]E9B8I!CZU5;6]6U)5'GIW&BB]<7G'PXFR7-QUU-F1"
M)X,XVR#GGP0#X3;U^?/FLYX"UJ5,+'78-BJ#3H."PGLP"%U2-E=BL#5:UU]OY-MJL6NE%0%X1+F@O]@LQ154-W"25XC=*8>7W8IMLP+#8*;7VE-M519Z_BATEU\?IF(LR%_C*"9K6(WML[CAH>UX$16-6R6?\M.>
(\%!K(1XI_M&\H"E'-%/;1,D=1'AVH6I\*WQP&450Z4.4-M,9?=<28E3%3L](+SWI-M=@NM]')_0E;Q.4-ML(.;Z(S@-(S>]I*?>-4I)P2C9/!I&U4=9&X0?[.+=:,(9&FWS\_75S0-M+
[\KACJZI66PT>GRZ4H"*S4L-3->H2/&^X87E10@!PH-M;'QA@SFG%!]E-)^X-ASBB9YXLJV$P*_GOD3_*K*3($OG,"ZMZ]&_#?'$V-!7T_48"64]-MR!3OOA[&L3>)!O&E*X%CMY%F/)QY@F8(^;GX]I7
X>-(&]IA^05.9*F$]*6"-M)7B<&7C0'0@<0O>X_Q!5II>:EY0!K<6;)0UUJ[X=!/)G9=&UN-W&](8G;O5&-M;OI'6A,-D0;I+FG[6$$.XHLD-D/W@*L@D]FQ"6TP[:>R@4^*EO*Q=94\MT+-MS?
9KL./@WO6I=(O3#M.4L7$)(486X_36F@!NF.[-MAYI61YU^L<]=5^*%U&4L,LQ4\";"ES>06-+1Z39?D]U/UF5_?TLB-9Q[$]DB
M.#]3)X,M8QW[R,]>P3ASH;DYD>$W>RDHM&#^)!9;P"@1E0N_H5SJT.5@]2VP-MV-*%A]A<%)Q613!8I-9;-B1Q,0DD)@PL(S1$R2Z0":T(E=$EKAE%]5;C;5
```

```
M>6&N[O<*2Y<:W*V/5K&X[0U&%N%(%#A\L\07SPYF/&=;&'6UF-W5IZ3(K$J; M6F/.+(0Z56 417_O;"*J@R?Z<<+=/:N_OA=RK5IN_(VJS'_=/<]9ZOFEU6@O MAB+\|_/SQ*/RJW?:YNV;NUW=2&
(J/J]9=9=I]5%Y__?@"GR' :Q_&7YO/ M\Y\_GE\8[?]7ZOY@FP<&:TC7>;A217J0YLK3+TNU2]OA&D\ZQ8!=C)RM@ .M M!KR&E%OMIH.YZVH4*&YA'@56@;:RT?8DXARR:]^)Y'2K)
M>%CE[#7JG0B5+__OS_DOGW^G1.70/E3.WG ?V$+K!W]_]^UN=/XJQV4M2WJM M,'94E>-&M-<%N">54RIAE1._E[/373K7N+\G5\J"*@LI43F'!KOOY>P,MSUB MF_FW5NOW;>G\58YK)
(;TNJ@_MI_C0G;$[EGABBICM1_,[11]>#H[;=$;W1+U M0U9'H)*6Q17IR]/9&>XP]YA;_))7RH@[?[7C$DFD(ERG1.KI'"0Z0O>,OLH? MW=/!$5),3 *)25B$]+MV&^ (!I+!C
%J03*%:D719BXAS55%942M'U,64F1& M3KF31DY])"3YMO#6HX FPZKP.'L\?2C>MOZ42Z0OX.QASN=!W'8&OO"3Y *.4K M&K$VS=Y\"9\"#D2_K]78'OT4-
#Y#'W$Y8RW%,P4JKU\:+6W%^M<]9?3U]^% MI][G4LK57CD"M;?'GL+H=9Z[YVN-UA"K/7]!6,I7 .0$:L^%?MK7>G"/?M0, MNI2AQ[)0O7W4"X5 M;P :A3-6>ZYA8-
I73.8T_I[+",)YK&2F5"IE:/)X6_5GJ_JH"#R^G9CO%[5' M3]27K_U\(>6]KQ*)Q[?#GE_=AYG0E2O=/E[H^@Q&T^$6BD?Q^ [2'\YCA1X? M7)2FC)C1/\@0/2#S
MHX^HY,N8AX]'EZ[_;+^9!:AFY4Y9(RVX.6*FO+"\=GN'=JW"KX!9>L8B1$O,B++PQL5L^>M<@5Q=&/ETZ?_9+-$DP<" M=TWT9@*O9GM@C"[]2+3AY(&\R)%$-GN3'G[:8&%KE%TX]3_"N__,@|
[Q"Z_G7_5!KK\O:C+5:QZQ0!",F:B='D"_0[)8\_?M-["2 M(# S!1)B_O21>.4Y=8)&EOO+#CK.FPNJ-+.;[@[;%[H4MEX'K[5"PV#71Z*__MG,'W5V5FR+,F1A!+VQ+B7MYZTP?S+O3-
1L68^N73!\AE&W[+@'G)#@%4H_#1 M,TU:!H_AH,Z)P;NZUXXQ5G8B-FL0C6LRHB*0_&B) ;,A_:'%7^P]#7(Y^M)4 MGG?]B]M6I_NY^OA0S1"M=NV*J+;K1._IMM>JMZJ/K4;OTX?
A36H'7NNTZXUV-MKU&_@#_U.O>M>K7?@./KPW\>&NU^C^@TX6^=VM?/G?MZX[&GU1TL?20:WYY: M_9^I'GM3DB^@22;Z$QD ;1NTC;J#/^C=P1M.W<'_?C(M\C_7Z1V_W83UIFS-
M515J5#]VQH;DK@3#JVFK;6WQK54P=/=K?(CSQ:BHZSI MF[(JG$YH.<<(78;G6F* F?$J(YA4"BWE5_>+(HW?\J>D\A&H#-2 G)EU9I+W M7"$[J^??KS]67'3DU0>KE])X]NNQR"
[:Q8//]9IC<[C,J:E#[8-P-DDWGBOQ MK =8W'5%'5<3+CD^)JWKR;JG5WJIJ6KS['2-69_%L0S8__^BHRX-OMK71:7$! MH NTT4L[G@R1IE$@G4KPXLX0__H_ZHGA AV/LZ'*LO/I7& \9.>=8/)3EP<>
MYUWY!AE):HP"%;6"3*PIB'RDU:DT%[T4$4W]2+%,SV^DAI/_'H9.!R.>Y=^% M5+5*QZ.[H[[;KBHC?6N;1 \L2_= 0$Q?O0_XWF!U1TZJAG@'$']9?]A-R^BOS+0WK,.GVC;"T+ MLY^@ ?
GA=!C!:PC$+3Q6+!55FJ3$UV>P3O58LT7/[;C<&6+Q+_NTG8.I"R[) M"56E,](SL8I9.#KCKH$=S=OY"OEP^1:5(H2*>]$S/\*-#C5[1X-#"6!OND4E M@1!UI[T4G#L-[QUG;-X,]8FZBLQW=
[]\TOS*TCB=-TC>-+==OR\4W'\O&KFMQ<3(7; MW&T7'* CZM8BVZY#(:I+(G@H&)_@UAI93Q&&H,<;$CQPCSU0J0*I,'.?XYB;:11Z.=C5BCT]S MPL_;T8^?WWBEY!KP"GC<-)I 6,5?
U+08[H"TQ[AU.@X/1U4",Z(UK$])%@(W MYHVX(U62#H!I[CI='J4%LXN5/#,7]60"JE4^3^G")XA;#E2;P'D=/!_22K#Y< M)%DHQQN/QP(,*T ?T/^%ZQ%GTTP7;:'ZB0F7PAXHF:
M]C+E$-0\6DI?'>$IZ6*MD6H74]+25^D'^]\,OG6 M?#G>::DZ8(U=:U+;M:8=\C%C.7]1\G[^8L/+8H0[T]]"CG^=/'4>BDDX@D%G M22I+DS[V*TM'V7E.1?IY) %(_Q(HQKQCG+
34U20&1O9#O!T^&5^7Q3JQ7DQ M@=/597^P%+8(/5W.98JT71'Z)$ F"=/5;:\]\ YMDN=J$ACO8V>U&'QGM5S) M%.C*^8@BFAW175EXV1$M1; C6J8RN6(!GYC:D<,.HP/O9)8R^5+$IP-M3TQ!
MB\[.%;BH, 8E+469 ZX^ER%VND#F)4XK2(X^1G:V,[(HV:K(?6=DF8'&NRG) M-4:9#%:TG*LI?^H/S4*058S#,:O]\U-V8S5I1"5:S8X6B$RM:NZK02@2!\%" M4@\N_VS"RC[;M.X=>W%
[5DQT>#U942HYGZR(E?2-Q>E9,=_W;[G4$'#K43,E__ELYW%]TE,]YTG:GFD:^ M)>%';48KB5+,?BX6@2^/MQ38XZ4RE9(W#ROAQJ6<.Y%Q22*:G/O4E4/DO54\ M>HL!7,3B;NSZ$7 VDVN |
]!6V,Z:S-NK[4 RK45L] Y"2YRRQ1[O=@5QHW.S/TH_((H&%2H$?4__*"9X'.V$? M2F-1>^)@E2O55\.?0KOQ3)XP+-)D>)E8(($CZ[<-"FIQJ*]6)7THV-.RSG Z M=Z".WXE(3QT+#U2Y2Y22-",L1]
()L=EE.A>X-C%%>3OIGG3(I<6[2Q#D'(TX MG0OLYD4#)[_U?D&OP]#2MQ]_ED%V($)$-AR.M.!ZO^D=N&>-'8B;OQ=>15$@UL&;]) K3)/A.=(T(-UWLSU?>D;-E1[@? MO;SP*2K9Z7KJCR;#
[9[@BK^^!1E3Q5^:#!PD>1<5?VO'TR VV[;+,O>E*:Z^ M3MXJ*5(?AW=>:(O319Q MQ=^$S]$=@07.$#AVQ=_4%-$T1V$M^)L6VC_Q__T)N&!8%G]+C+B$8B-$287/ M@$X0
5_"PS>.948@9HRLHB0&=0(4 *'!S*'&!ZA^D\@!4=%_TH(QJ-PF,>)% MZ#WR\$;%=$N5*XB UGZ8-4,OK\J,T.>_4BTH;;36=J6$/<*UIL^F'>A;S;JP]0;GSY M+MOP6P;,2W8(H.J#CYYITC)X#
=U3@S>U:EVC+&R$[%9@VAX]#7(H><(8REW_XK;5Z7ZN/CY4,T2K7;LBJNTZT7NZ[;7JK>IC MJ]';J=.[3?@^/KPGX=&N]\C.DWX6Z?V]7/G MOMYX[/W?_Y0ILO21:'Q[:O5_IGKL34F^@*:6Z$]D
+1"!6WH7!,/\-*)0C2@ M$>7V ]TT\?>3:6G_N4[O^.TFK#=E:T;(Z!PY(,G\8%7NRG?LK 5R# U5\7P* MQ[/4+H'VQ/0TB"Q16[LE-:M;LKY$0;Z,U9'^+Z&[TE:.)Z8E@Y>Z0]M8AY;?,S%^G"[:5CR?
CU[9#RI>Y" .:!S]TI M$&>O!9?LW4VOA5T^1I6]6RW\^,,M'B:Y6RH1[19R17^YG=11LG1346H^H@KG MOB40,D>I2+('BT5-M,T6/)^C>27<430X[C [>/(W,E(KT$=JC%'97)0?
J@@.N*,G,+07CF0^V)Z:A\BGI!^!I?R=\Z)!5,ND,[:%A7R)K$?E2 M=A%S/69/]-WQVX<#2@=V0$DRGVCN>[4":2GF&2-P=B-1PDN+HGN-4T^2B"J@ M5[]/O[2+DW&-C:?M-BZ&?
I1YFS]5B&;^9OZR^=B;=J MZ+;P2UXM],#^1MZK@G.JA9XIYO-IMWOYM-1GC:F(=23>4S[X?L=9E$*G\WF, MH@.N5#Z$=QU;(?3<*0JA?QY2Y?MRC7G^PAX[.(:KG_N=U(&;%V$6&BPLI*4!
M9A)*44=BB@N!>VGF:6\;"TF'7%HKZ93@@7M6/0?ZQKX77F&0N('D0* =\VJ'5[BO0/BZVDH$(Y=%(0E7[9&(8H C$8W!JJ'^:CZ,9B#/ MY:./HWBN?+YW+B(U=8OC.CLQO:?JN7SY ME7XE&3A
\BXJG^>.IT%L]FA;DGC_35IR7^KN1Z^2HSY<]EF+(;/I,G0YEREZ M2*A+!_22K#[<)$GARN?)%J"/2'DQ<'"S6*YDR)RW'*]W)=+(SJ[X7J86?>3. M.IY=05+U%K;&E<_]RW-'8,%3
E!&0(R3[[Q*G_LJHGSJPIIVNT*XDE\ZQHPK M^>%*?KB2'Z[DAROYX:IO[Z;J&Y;I^8T45_([QZ'B2G[X[F!WVVY;5XT]$-)? M)3_E[8[L]B=2_YD[7B6_.F"-76M2V[6F=J=!0]KYD;'L2,_5*EDK?OOUN2XD
MH#P8E26I+$WZV*\L'67G.16ED2*)1@:00,P[Q@FKYE+GA&L" M]>EKY7?]M5=Z>$G*1')Q0\O'6@BSM\N M']??/N!D)QNM.UP[AO/LP6/>+C'@H1ZQ5BRI#5ZU;Y3!JI&;]OLYX77U)4B/
MGE"%?;HROX"VE8!^.:LWW+94LT/41^(,.*,C;45I*J MM#;_1G\%+YW"VL-RA57,-;[70WVI,D'3+Y]PN9'3 $[U83$1AL"R.1WFI#FS5O.R.+IFQ*M"TZU[02)K$Q%I8.P+I(?:Y\SJO"=
PJ%XON+>Z2/=7RN036PO1* M^JE63!&0GD!'UROI@1LSV;H'%9_UC@U5H.N4 =\>@!H=V_MM3!VHJ'8BTE/'PG+B6.@2 M]?8]VV-;1T,M%'3I5,B4Z:"[.0%#XY%#ATR>"W
:Z&R#@@R\21X!*&QM93-X M^\O'VE0BOY3$YJR4R+Y*N!.F\_0\?2?,'1@8.;N>I2]*Y[]4*O,M. MF ?]L\"=,/-T;.V;*I%UPJ17;].ZWY4?"P>/::!VU^&FZS4Z7,Y\C&TOXS!
M@YNW[F8S>3DJ5?/GUOXRF)-!A4L$*90R>;J4=F-')3 \?N3&A>%=)BIP CL$L=#3YL_:?&*=I?UF]'\WGMKD?.^1,&QW G3+_S M&W?"#,M".GFA_T2W)0QOE>D01^]H^AQ2-O-
T6KR[1()N!T[!>YQ'!"=;,UYT M[H99$.^&3.'/M"$.CQO7P"TPO1&0HH%[UCBX!28&B2M(< M,[[S"+3 CZ9GH MX$]Z.-F;I\.WP,QGBG2PEA6X!:9_3RU\"\RXY&5;G:<9H#I/8[!B'WXNGN:?
M7_*_8PVEI+<9IDOIT4;L!8#8;KF9F]Z-_KR-4M3-SK6H33Z/FV&N7Y[_1DM^ M)(F;81[2(+?'TR V.[;?5L/%RVSV]6;6@K4>;,%:>:47DU>NT_W.QEE. MUML"-FFN)GGJQ>K]XNN=W/[\.*_S*?
(VW9ES=$=@R5ZLPK]1GO[-Q45J>J&;8UCW0$\1[9_XF_X$7# L"YU%1EQ"H<&U MO J? 7T@ KZ$AV\J7*%<3-S3'Y9$H&O>KBTW^R6:+) X&[)KK,&,Z['O@S!]## MO2:*'PGM__A$*I'-&IJ
XQ=>TR1TFM;?%S76:D"&M B",1VT.85^AQQ@S=^W MW\!*@L#,%$B(^=-'PFP>E,O]92=!YTZVJC2SFW,.&:LZT[9>!Z^U,,UDUT>B MOYS!]U=E9LBS'XDVU$TZ2]L2XE[1>M,'\R[TS6:>F]/\TP?
(91M^RX!YR0X! M5%3PT3--6@:/X:#.B<&["M"..59V(C9K$(UK[JQ+M6(%J4E_:#P,V=#>TP!: MP$M3A]WU+VY;G>[GZN-#-4.TVK4KHMJN$[VGVUZKWJH^MAJ]3Q^&1]5XD0Z\
M9JKVBYI5M:_##_JR!S5&F1!-07I5TCM6.X!Z4RYF_(:.508D20U6MU+[;57\ M51X]C*#JF4_A>);:))=<;OA%98LU:PA-KB;^?3(/[SZ5_IGK3?9<[C=$]!??W M__>'#/&VEQA5J_GUUD8EA\)B^76
+*\%R%8D\Z7:-;KH%K^QEP?>[9WP((WG MXQQVOTB5TPW;L@-U,,LQ4ARY\*[HEQU-22:@FTRTX6J8 M>(#W3!2B@>HM^Z/D-,P(@J[BX6"OQ?/UR,&M=-/4XBK@1(V6E4BO)5,A13Y.
MUYSDQ"+%,[,\,L-B_WWJG%00:7LVLKY]-A)Y0UU96O!0[]XNGZ#OU!([,R S M*D1$E57Y!:_R0*D.%16%I0;\;2R)]?O+O5JU]YEHWG>^]XCF8^>!Z'0;C]5^ MJWU'5&O]UG.KKZT#8CV6ZW[A$<|
(!R'&%@"4X^%8'GHZ4Z9=Z]X^K5ZDYF"E ML+?M9T6]'_X(4IG"X;"LV9(Z9]NVV>D\;(S-L^&Z+ONW^_IZ/SA(XETC8%%* BQRM!M&0 MT3=#-K03__<_98HD/QZK<+?7P\FE''HH)
(WZF(8J(YQJ7U[1$43WE@*GJ<58 M+76WR=8>-SJC$1RPK#2F,T%: JA$1>Y68F2N,ZKS4)NIDFPS5W[>5GL<^?+G M1V5\%#WK<]ID">YZ?.\V/SS-*&/ M;0QK$T8<_^0EG;:%DXNO?I"A
2=J,;3W7BX%-25Q]\J)G)UN<]\'\7+'I5"I M4HRARXPU/'"\**"5CE Z8B--[0FF//*1!]_'0S18H;2>K!-%C2SDJC[!S^PJ"QG,83-7'EE\W!+%LY@LA;C>A)E )^U AS29T9$WL:\ MD;_F#V]-
N7#_Y^6$YFU#K1[)^WL,B?X'&;PI([\ /=%'60_NI%ASXW/ >1L^ MGISH0O4 =31^4>U<&,X;G-JX5O:^C'^Y+Y<[+74%M MDR?4T2;-""DSG6JX'-'(CELANR@/-
ZX&T\B5X(>AB_F$A@9BX*.+$J[X\$>= M[%K0R(#KU"0/JV1U-N0JR\+)I"I&^"M^ KEH=3I1N&BI\!?)RL#H6_LM9 M;ZTHO&?
=HERM_F"J;C37E*G5&H^UU0MY/UA)K2]O/Q[RSWTN2**!;Y]E"X\H M3U,[2?5D9&VMR2 Y:(B]^>%84X64YV%55C/Q$L8*J!K-+V @8IJ>T%S&HTZ8TJ MKS^;01*U(EK
F,,@ADOB;V,U\P^Q'LQY+&<">;\V @VHKGPTG\):*I:5C%=9 MNF@K,ORZ] AJ"Z]D$N'3-MUM1E,O:)>
E4RSU:ZV:W@E$^U*QNHG*591A_7[()6X58PZ'&,'Q$+PQ(+288;6C!#+S[2&4JI4B#GJGW%V*1H)N;$#B/ MKYBABI%NKT51$,7&2FVO;)#BVEK9_)G]_'G+5>2OXTDR5C;K(;SC]8R-&-.J
M)Q];CU@]G5"2;FHJ\+KT6&H*KV02X=,6+38"X1']0=9Q->TD=/(>X=):YED5 M<.B+JLAM?V"YL@MD7N+V\R)888Y0TGACM=SN1T8%C=$(H%40LC(6RU(8JA,V M7_ZB+DMQ+H^0$7%(3-
1L"_)QM1\L@],^W Q=^_ZD.7/'%54P6T(%SEDN9/)T MHDL0N$2J$B =%_M A<^$IC-0[C$<36E$I9$&?&^P:A3F-?D'QY::0BQK;EM__MQ)<>(1B5N-5C7D0]4]"*6P? V3H^H63]T+>$I+
(TN8/P$,4Y%3+$4VTZ+ZYYB2!W6&*Q^W]5^_NPL^_R/"*NR./0W\JVZ&O!CSTHK MS4V4HH>YO=<4>->\F"F0Y]3Z,J52M?>W0L15BOE@ZW&_'9_QBCP1*W)K0GUO M/IL)6H,/1D#80\T]6J(.)
B!^#84(2-E67O'-<0CG'4"+]I.TMY3MWO?>&BT M^]5[HM[JU>X[O:?'1H_H-(GU1B31:C<[CP_5?JO3QN>V@X"BL"GHJ$4-&9ZK
MSV4XVW\"1FY*\C%KWVJ67SMQS6DDH!9OQ!+2@30<%F\0\>:V#O^I0(86!\E8 MJVZT*BXJE?IB6JG]^!VS_^=TC%>G*.5^@+=2806ZZ%8J['VY3U[95HJ%;5ZJ M6$A3T&?>@()F3!NH^J0AY)
<2YLH8ES/_+W.^VL-MYOM;SE"UZS@/,2K86/-Z+,4PJHHRGP*.U!(/5R_?7G_-I@^=:H\Z9I[.0:,' MR60$K5G&&/TLB2ARZ+'<\YGK^0(VCYYC=C:8#[('F@^?C&L0Q=IQDC:W7VU0E0-2&-MT3X3
=!H#\Y:VX./] 4$O%%9-PJ_@L@YG[;K%Y_^D\T231X(W#719<9P+O? MGSD067A7Z2.A]9: X">R64.[I-SY]@%RVX;<,F)?L$$#%!Q\]TZ1E\!@.ZIP8O*M3[1AC92=BLP;1
MN"8C;J["CY98XQK2'QH/0S:Y]S3(Y8J7IE*\ZU_XYMN'"6>99SVL-H+#,#"D_>0ZVG=D"=(%W6F#(8T8TNES4UAX) MRE@0N:X,?1=1-3JS-4T7I;?V4,J\P@J2,I=1S=<>Y L_@NI95(V"L-"=.'S
M6+CZ[T.Z;P7HB4..S=9KY?)67/78I Q6J[LOLY98']<>-[VEDZ[,T>2 'N<% MN>X]^DE'S%I+:IRE\H-5(]=HKV:L7/H^OKRQ;.7<2\EXAHUD@BT159(2E MPBMK_!G_'&FDT8N/+.H%-&:+.,V-
1@F2P1)U1]4^O,L0K@[I0K!^D%0)%>2[: M0@H]J@:' !U9D6?05V2E6+C:>]8%>A:AG]>-3U"MCT031I6VGUD' O.*UGSP MNSHD6S-,%)F!CR]1VO2R/@NI7/2(>KU%=+4AL6"N>;**/@KTF
=&9B<7I/:, M,B2Q(UIL7@E]6LEG#CP"V@CTOE=>G1!:'HBHD0Z7E)"1-8$7T<7&M8A_^.G; M4@7LA.A=5:^L-%]8:>[\:/6VGV<\_]+W92XL";*$S#'ZV_%2.U[L"?CJ]%,F
MC=YU+'-0EN;CB317+]0)KQ#?YHP,Y0?%^@@@^%4$S*8D3^'EV6\9;0[ KZ>* M9GRHW$?4RS6C_0P-D?'9*]C]9*[L?B+-Y=V/T+/_?_;>M#EMI6L7_LZOT/&Y M]UM)%?8&,2?[I IC.Q[Q;"?Y0@FI
=E"PAJ,X=>_O;I;(Q(((6SD\-1=^W%L MD+I7K[G7NE:+IE787W+_D^X7 G_E=-1#^I:5-F7QH,ZJ)\$I6E_#W]+ELT.\ ML5KY.QWPK,'(_,[4!0G!E"Z#PPJ?C4_GV"]"U#]64*,1$D@5(U'PF%E?'&;5
M*;."0L9/SXUTP*PW)RP!9S/.'G<7^C4OCW-8H6K$TX9YCO@3?=F-FCJ)KBWO M73CLAOR3*#6R;KHYFAW$ON9>KJDH,SO.SSQVYE'N9O%7$4SBH%OC-EN3=?PL M8X2@!1UQ-TV1D&YLV?
^#V)_Q&8>93.!$9G+!:>@CKFNSLVVW&9=,\*-$"Q+" M&O5;)/2*%&U$!K42HZP-L6F':,?VWO'1JQK^$"6WE-B;JO8GZ13Y=4!H,KD@,_B_*1SSW@S9&B9?4,_M=!6X$:8Q)KVS4&T,-
TJF!4G]9[I_DN'DOK3/Z$]?M_+V,3$7B6!SLQ'L-QJ* MJ:]\]UB)[JBPD&&[TT6(#7<#BR9 I0?M-A!,K_W%L8FB$-LJJQ8,U\7BUB=G M*-(S! /M?EK2\(94S:3O@-\P_082+)%%$4.I8UTHP1TM9PAL1-5 H-
^T%89$ MOJYCS0HOILAI4*W G@??\^LI\@0#4QU[ :!)W1$X9,(S9\API0+_&8%*IMH2 M!F)A[8N_AX,J]D%3]PQ=@@T'0R#,LGGS,!2 M*.U9",56@\|&/XWX[]S(ZBI80<,JL&)\!1U)-A4LX\C[$.-
&Q(4F9\8,S>SG M^!9D3VKF)#WPYX*>%>OMYAS-E$V0,,$C@S3% M@MQ7)2L+J<2=%+P+X[(QH^#75R-!'QI[Y9#* Z(6N2&8/I8&)*X'U+-Z1CT! M9RVF=-
)Y,HN.H7=P=WQQ^DM6KF3?,9!%6FS4BV?HJ N_E S(*;6!*96X?>^Q M#K!86'R"1&$:6(G@/VLZ#E<$&?_+L+I8<:FDA!/J9LP<%DC+IXH=]X;5;OKT ME*N8.::8258)]*ZR_C$66($.=M5\J(&
P(76CFW=I \R\|DLNZ01$RH3.!MJ M?P4)5DC_3$Y]"!58V/QC!0VI6W#'95_(#:$0?CTV'+GY'+;'P4V-#E4$V/Z1 M1Z3FD("FXW!()!LYLFKBH(!MCN&:.!) %4',K;L1#4,(2IASZ!3IYW8S#,% MV<"_-
'I,&>$_>:8BYVR3*S."LK0UH0$04L2QFT',=-?"[@8F[U: /CBN!T\, M07DL83]R(>#<-%*/BO(M9AAP'$WP8?H"8>I0Y>LR,' XK;/';* CQ;EU '^/ MZ6B0H"'"AI#X@-C?ZU-
3G6=\":LC!D":M0#HRD&M$;U>R/7LOIL\=KYE.BN!N G8O\;B@W42%6Q09%TPC+!B"._) MDNF#9?*/GJ72$P6JB?*(G+_"J1B2UIOUN!U3"-%$SF,,:37TBF&5QVJ"B==)
MUH(H6HVH+QT8SIB)L')DM_AC-LD,) +E79)Q#LF(6A0A@*$?AK3^'G="M1!$ M2O[8S8G&YCPR'[H6[!*)-",C8<:>0/831UTH#XE??-HX5"3A"K19XM\("J$X
M\+@D&Z*.R$LPNQDC'#:0E]AJV%)P;"!A7C3 /Q4(Q%H8_^5L!0H!'TF60M3B MLCT1*D53^[M ! ^;J@1H6[ Y(T107,;X3,KY7U_=R8_TRU!JP3*41,4CWE[\ MN"4?6]]BG#U>W#U?5S-7\L'[2SX\Q1[-
SE0O#,0C#N93A;-)\5*%'QNJF&D&&W0=W\K+GK4M*6_-5]L;1JSRV,[VY?[LVSU[. M7RTQ2\P=X.8JYN9+_D^C56C4E%)QYPVT,FAVU=T)GR)AG'4'^@* M"O7 W'#3<65(?
DKT\N)G\@TRL_@9BX#>"(O]F->(4M\VHJ37B%+?-J*LOQ&% M..LV:V=)/C.M7&9N3Y<-[IVT@)W"=_,$Q/+(PV4>F0O)>LHDO,?,3G)3I"Q4 MLYT4M2!4)HD@YP2VCO5;
(@4F5/K'&3. 0"]\4N_VLVKU@YWE>PBSEA M_,)>*1%'W8*@['44=]2W&LE>/(M)!%HU05\PH9*!U,_E T#_#O[';>'+><5 M;CK-)I)+#5K,A?^VEVO1_!O^D / 2%X#K9HDJT [!2"?@?\,.V?NA[/ST';
M1UJ@A,<9<,XN!^7,0]D$.HXL'>Y42;Z)W!&'DF@V$VZ@)#S!&0.2(>F2!+64 MHT[)DZ72;#19-2F'6F:+2,]R/78AW)/A M"HSFT.B%L%-(72KF:6-/3U;LDF;"-8@+_(DQ"_F6[^4V[]#: M
N]F<\R)PX2"!)!@T,+NX!H+3@'%L0F50=0"D!\5G=) \B:C(A$$R2 M,=SZAA^P^!.59&RUD:RRFQG\+6Q0X83R:>5PF9"0C*;WYLR]*S.U'&#J*%#9 M0B+;!;<$(\V0'66&OV$I-$CRI*=MZ;(5QHB@?
4,A:T]!(K$W6-EB+<_1$ADD MY6&!.>\"7>GV%)^2XCBJ+Z$RP]))=2JIC$-[_#<^9S%,U.VUL,WZGX_7DK,I M(Q.-+&%#0LI: 7K(51:[R-W\9Q*>=2==JS.]?_<&#-AC%S=&("OEA:[R?[_S M/=+DD_:-
_.ML*&4YSW38F0IOC4;OYO?D^GCGAYM:RSE[W6:1/MS-IEZ7<[L> MD3T" 0%G#RYH7(>,W3,:'O5.+GR$9^3<6%+_AM0$C.PK/B@2<*^3J&>)'09A MZ.2E/)?
\GDM]\F_7P:35=X2E2#5WQ'=,MY:&N<>1;AAT-]C+X3S+8:6-AE.' MJ$+QH0?UV?&.F18&+].TB"ZGFIM>I\&=+M)MMT8S/&3:\UXEY%SJV9D[E\2. MY7(_!); OC23W!NV/-A9'2^#?
F*$[1&]M/;0)^\[&[O^BSA@(*J$7#[8*O(G M:CE\CZ$7]XR-$)DKZBUDM!&N8"&DR)$4<-#&%-M)]]5Y2';QI"F\Y>C9;NW1 M$O:H%+1';(A#<,H6W',HBY/RH'Y+0N_WYE>2;5G??QBOE;K6;9>Y
M/M65AG*C4+#W7'_,S.T-2_WN'5QK4[Q2PNI;J_;A5LV^TX-P0H:F+6X@]P?8 M[Z6Z$2LFY[2H/1N"I^WTJ9@#'3GEU%AA*:31Q6](!!$_R0X8#%H7@SS\(=,@ M:/5(!]L2,PR?P]1,*&T*OM>IHC-D
S"RJ6B:+4'78:\DS]^13U@ULN@6(#>')]W3ULN!=%ER M"I!;@5W$F583_=KX0X:JR6J*_.&]OC%E<3X#&>3'W&.$&YF9X]PJ0,+SC:= M?V!P5*4B_E]G*AN_3A_V)[>%ZKL>5>@5#EL!M6O7R!6Z
M:K(X"#O3G'VQSNKN0M_OS5BQFN9)+KR:D]6%"_BA.O0BD$@"5N 4,7L=$9+Y M$;&XR1#.F%Y'WDGZ6BKUNR%=I"DD^=\GO=EPW\"ZK)R0B*6CE[-IGAC+E[^* MLFND7]6C*G.@$?),5[IGY;?
A :/GMVZVO>MKKTA7:>LOYCIQ%<-'7#_P_#ST M=LV=]';N-7GHSW59?BD4?U_W'#UZ&[J3;]]^'?SZ]FTW/F)VM;'SH^#'%2+[ MG5E]+?;J/19@<',AG*K*&3^I+%CY0J38D%?
&U_ZUN#.4YQGJ(K_7B+(".6:I M\YZ.?V7RF6S#NB/.6LR(>XU6H?PLBSL_W.WGZ%!VJ@DR'(3B3=MLG-D]-$EAY:)67&@ML1T!.,G'FV7_+2V[$V(V\)S:%
MM)YL6LY=V0!!JP!!Y8!B'Q/<.9+HP[_0$5X:."'X$WT<51.7S_$^#("K"GWP M5O,NH7DK0+ MI9%"29W'13TY/+%&!U'?UM&]"%S74-MN6[;Z3^8&?A09O!S %UDO%;!#W\M/.S+&/S"JWBH)5EC(]
(RS%%8Y35D67: M>!!0J=&%JWYBD:!4@39;BYJN:UT&*]R=>#^$XQ:!+L]MM550KF/'_6(I9F[<$]+)I_A0U4U^^**+01%-6*D. M>XB+$6'.._*NJ63#%I^H;ZRQ[1M+KV^LL>T;V_:-?
4[E0MJB67F!MWXS MK.Z?.BIN@!L>C^=I*Y%=X$-0I0(%$'EZ*3#)S:-738RB)1L-RGQI6NB94U37*>NVRSPI$69S"[J89?1OVZETW;A2M0-Y%SI/@9?%76;
M"Q,)OD6\)W[952UQ+4^QSL^KY0F_^8Y'HIF[[QZZ'E^\|D=>^V]5UR,51JK%(.CI1C>&_)\#AKV'!>?N/]ED?*Y6'] .7EKBS@^V[YRS M\>U%S8>;._N:V\9V-,BM=>C="(6Q8U6 %)
(O"_O!R#D=UM02$AO=X+V$&F7 M9 F&%PL&4TW =0/])4E(RGF_&-)E#I&Z-X-MN7_01:7AQ>F:<;>=\V[:S&

[[@60%=VV[KOW->^NW2MQ%N^."9>[S?B]ER? M_'5[13[]_"OYF71),0]S7AC:>-6%4Y OZ6(I"A*FL^K-L*J#_^73>1K] MLY0BG_PI.>2+X$GQW:3M55+?G+2<+TZ*13CE9QTY(10\?
^*=\U]^<@:]WTTB M0,(")(PB80P$TV3@KV7@V^@K&3Q5,I"5[3G,\S 5)N%?KCB#BE-.W$_G_QGW M>[W>:?=I<\P,N_FC]_L%AOU&P]Z[_:B)-QP/WNW(K,>Y9R_VU[W8M_9B=9K^
M77<>F5SSY([GQO/#RFE[?B!A 1)&D3 &@FDC.UB/[. 097* E $2%B!A% EC M()@F@^%.:!D-0F;1RVHXL$A:L8/V-2NJ,W/<%%YF3#=]5;Z?7=S:3:L,Q6@_' M:%>][36KMU9.V^%
P@(DC")A# 331G:\'MGQ(>KM&"D#)"Q PB@2QD P309. M3WW>[H$JKAW4=G"AM& ?&C&-++19K*9MUF5W:U%V-CP2QSIF[\[8W\AM^7F5 M?,VC*5_7:?(O:7[!;$_9>G21M !*HU
:0]%T*;A*"NXAZGB=%:4&)"V TBB4 MQE T70W*:W*L'L;Y^DQ/-K00E5J0M<#JMUW6Y/%FJ3KVG#>N@SU_ZY%LDI-" M\K6YR"2%D!I%$IC*)HN!651.?V#5&2H MHP6E!5 :A=
(8BJ:K0=E:CM4N^5!%'C2JR%!7JE%."LW)##FW5V1E)#EV)\E0 MD6^BXI'0G,O3+!5[T,-:"@M !*HU :0]%T62A#RQD=I#I#_2\H M+8#2*)3&4#1=#G]J[C#:^R[>G;GKE06@"E42B-
H6BZ+)0%YCJ' MJ.,NU 6#T@(HC4)I#$73U:!<,-?]J[2LXSM@$]MMA$\|LC?[[NS(< M_VWQAKIB35)2:$I6T[1K<,<9'P^W%'!E8[EV&ZM] 6]Z^0V]0PM*"Z T"J4Q
M%$W7@W+7W.%!"CC45(/2-BB-0FD,1=/5H$PUUWZ;6,L";H=-?+,T1DT*.-0X M:Y*20E,R0\K1>$OQ5BZ7:S>F#,4[^+'@4\%G\N3,DSTOO:'W>D%I-91&H32& MHNFK492?
YO4.4;D]](T&I050&H72&(JFJT'9:)[]3K)U'8BC>TX^12EYX6%N M7$YWL0,UZ9N% 774H+0-2J-0&MO1V_YJH,B )-4B0IL:E(WFV9VOCT\4\HWK M*(V296*=.^SM:"T*J.
<&I5$HC:%HNCXVEC(>9BTC=C$C=C4C=CDC=CWC_\/$ M\Y2)Y]GO>6LU=]A1V^8.>Y17UT#/6 -K-4!-O(\WB$(;Q% T70+*N?/L9AMF MP@A_[)XPH'>_06D!E$:A-(:BZ?
I0MJ%WD%6='M0TA-("*(U":0Q%T]6@3$// M?DM>JPG#CMHV8=BC7NOSV#9A0$W#CS>(0AO$4#1= LHI].SF7LL)H^$?$>Q) M6]<#J(D(I5$HC:%HNAB4+^D=9-VJ!S4FH;0-2J-
0&D/1].]'4<:D;[_1K\WL ML ,U&1B%88]J*PPH+8#2*)3&=O2V4PW4>@XCSHC,PA>;(^4K?])OO=(5,%_8 MD[86 M23A-(HE,90-%T,RI[T#[+6U8>:D5!: *51*(VA:+H:E!GIV^\I;#5?
MV%';Y@M[E+W@U6J FI$?;Q"%-HBA:+H$-KY3S>ZWV6:'J^@IFG%9$_9?XF7/ MWKHP0)U(*(U":0Q%TU6A3$G_( MP?:@%":4%4!J%TAB*IJM!69#^O@MPC1.%
M'389FJ6QAZ]F^O:9JWU %E6 FD6AS6* 9NE:4 :DWWI-<*/YHNG'"NC=BU!: M *51*(VA:+HJE"?I'V1)L \U):&T $JC4!I#T70U*%/21RX)W@&;C,S2V,-I M,\|74',2U2P*;18#-
$O_LN'2DM2W*#^JO^,F-^?[15C(Z:)\|(&<*(HC7HCP M+HZ*N=QX]T+$G!/*9SP/8W*S:@VY"-/"B;L*/"(M_KTF(4V3>-__B J1Y=%4 MOO.T7HQE-U7,9=9L@C3EU]^&KG.\/>"3+-$?
F(D,F+Z2**"+,LC$UF9+DK* M:;_,NE\*>1ILT,KO"8R$'CWQ-S*W.D:=BVMENXXV'%'_^Q47/$^D EX[_4B6 M@S!*H_1![IJ*/)R*I>SHRH"H&S]3SRR(TD+DR[)^3 8;K%8-JP=
[W[Q#I=8T M(]/Z$JPEUDT\L?-.)V=UX7D3"\X?J42#E M<"Q3L?IR\/76]>-&+]J';+S9?NF<7#F&[8%S0DW;/_=[)U36 ],[,F3U1).N M:M+J>2C78?
X@.YG$_%XVKW<\E)]P\M4C1E8O1+:HGG!QEPF1)=6O&PO=V]R:W-H965TW>2VL7#LS'9:^/>SG3:TX(9-VTMB._<5 )Q;4$G], ABO\2$>>G( MCMV*=,1K10F#6X%D7998/$^
\O78ZWG;@3NR+)09\--1A9

^30Q\3;@)X&UW&DCXV3.^:/I7.=C+S""@$*F# /6KQ5, M@5)#I&7\VG!Z[90&N-O>LG^UWK67.98PY?2!Y*H8>XF'@? $0;0&2- M-LJLK4NL<#H2?
```

```
(V$B=9LIF%S8]':#6%F%6=*Z*]$XU0ZT]LBKRD@OD"7(,@* MF[2B[P3/"27]&?T0F$ELCWRE91@R/]M,.6FF M# ],>89N.%.%1%/IL2Q
J\]-.'7AQ\SJ!)6&,L*4^312S#%QN&XK84IA[997V@H&^:(*1O]HUXHA+ M=J/V% Y:A8-.A==2UD:8V>+K9FTDP@HM,!%HA6GME-S)ZF=NQ]1U@PB-XN@+]SV9<@
MEK8&2I3QF[GFSFQ'VS)[8:O+J_&)+K]-M7RA:6KW#1;Z4$M$8:$I@].AWA>B MJ8=-1_'*EI0Y5[I V6:A?R% F #]?<&YVG;,!.U/2?H;4$L#!!0 ( /"! M;EFOZ;E;?0, ((/ 9 >&PO=V]R:W-
H965T7$RY0]3GQ?IADP+'N\@%P_67+! ML-)-L?)E(0 OK(A1/PJ"V&>8Y-YT;.]=B.F8EXJ2'"X$DB5C6/PZ \HW$R_T MMC>^DE6FS U_.B[P"BY!?2LNA&[YCNK^WP>M@ MYEC".:?
79*&RB3?RT *6N*3]*]|\@#J@H?%+.97V%VVJOG'?0VDI%6>U6,^ MD;SZQ[Y6?=+)?13HG5J>HV%P+E"GPF>$TK4+_0R 84)E>B+>616 MY15Z@[Y=)NCE\U?H.2(YFA%*]:+)L:_T%
(R1G];#G57#10\,=XQF/%>91._R M!2Q:].=N?1@Y#'P=>P,@V@(XBYR.EU#T4#]XC:(@&K1-R"U/(-7RT,J#%GGB MEG_">0\% ROO.Z+I-\O9MWZ#!_R,#3KGC.DM52^M1-]GP.8@?J
_:(9O"2M9 MJ]9& MQNES*)DNS9*.S/;XQ0V_V,GOBE.=9&WFQ8R7.A67IOD;%B;3J@S0&M,24(II M6IJN>F<7(%+(E?XNMW&NQ@O#G84.FS6NZ#FG="B]CLSVZ!TU](Z>LBO1$A-
1 M@6HC4GF$T0Z186]TAXESH$.9=&2VQV34,!G]QXY\8O)W6A^Z2;LT2SHRVT-Z MW" ][B3Y.UT.I=>E67)\+_F'_2 (VG-_&/P[/0:/O6O!T[*_V^A0-IVZ)5VY M[4/<.8*'3H@?
I2QUNM]L,?(E2]LCG#[^IS>M-)V.!],,[[T=P]'('(?7>Y@Z M&K3"Y.\4+0S$RA9_4D>NOX%5_=+<;0K,4UM6^?^Z5]7I#(L5R26BL-32H'>D M(Q%5P50X '#3 9 >&PO=V]R:W-
H965TB<3N=W9FM#1((G#]>2:+SK^VVF6;:7G1ZH6#99A:0*\G) MIM,77P&R#P?D@Q1_A[W(Q@[Z_"!Y#$=ZD+CZFA>_E/=95@6_+A>K\NW9?54] MO+FX*&?
WV3(MS_.';%7_R6U>+-.J_K*XNR@?BBR]V6RT7%R$@T%\L4SGJ[/K MJ\WW/A;75_ECM9BOLH]%4#XNEVGQ[7VVR+^^/1N>/7WC;_.[^VK]C8OK]X?T M+ON457]_^%C47UT\*S?
S9;8]Y_DJ*++;MV?OAF_,9++>8'.+?\RSK^7.[X/U M0_FYZYWG#W]T^Z MW#SX^L%\3LOL0[[XY_RFNG][-CT+;K+;]'%1_2W_JK/F 8W7WBQ?E)M?@Z_-
M;0=GP>RQK/)ELW%]#Y;SU?;_Z:_-7\3.!L/HA0W"9H-P?X/1"QM$S091UPU& MS0:C_0W&+VPP;C88=YT0-QO$72=,F@TF72=,FPVF73>X;#:XW,1A^^^W^<=/
MTBJ]OBKRKT&QOG6MK7^S2=!FZ_K??+Y:A_U35=1_.J^WJZX_5?GLE_M\<9,5 MY>]^,PV'DS\$XC^/\^I;\$.25>E\409_28LB76?RQ^#WP=\_)<$/O_WQZJ*J MIZ^-
BUDS26PGA2],BH*?\U5U7P9B=9/=M&RO_-M?>K:_J!_U\T,/GQ[Z^] + M_IQ^"\+HIR ;#]O^,OV; M?\H>SH-H\.*=E]TW;[OSZG73]>NF&__F23:K-Q^V;>[D('K^$8@V7O2"]VXV
M>UP^+M(JNPG^6MUG1? A7]:O'/?KI_0O66!6LWR9!3_\.2_+'X-__;G>/#!5 MMBS_W7+?WV]GC=IGK5^ZWI0/Z2Q[>U9/*+/B2W9V_;O?#./!']HB2&()B0D2
MDR2F2$R3F($P)^2CYY"/?/IU'>EEO;8HUT_W/P7E?5J/"-+'ZCXOYO]M?3I^ M[P7[)IG$$A(36VR\P=9+PR_7X7BP_>_JXLMN3,FQJO-838XU7<8Z 1L_!VS<
M.6#!0UH$7]+%8]:6*Z_3-UK[QFWUR16$)B(C[X"1Z.6Y^NR*FJZU1-3C4= MICH!FSP';-(O8-XG+*_5-U@DEI"8V&(3]T=Y__F*G*BZ3-3D1'-DHA.FZ7.8 MIMXP)?,BFU5!?
EM':KZZ:TN0%^B;(!)+2$Q,#Q<7832*PNE>B,BAJN-030XU MAT.'T7001U%[E"Z?HW3I7T3=IZN[+)BO@MMTWCPCU<$*OJZ/P*RJ8#%/\|7 M\^I;6\B\=-
^0D5A"8F*+Q3M_];^_'!^^^K7<;#0]O)UJN=UTTO*ZUN9-+N.# M&QKHP3KY&0[LX;Q!]V7XO"P?Z]>XV[P(UI/FLZS\Z>67.;_<-T"HEJ":0#79 M:+O1&
Y;DM9VNZAM"=5RPU%T>#M#/0PW:CM'CH?>J'VJ7^[J1?F'P*ZF-D>3 M@W_]G"T_9T7KX3&_V3MDI):@FD UB6H*U32J&4IS4QW:5(,#I3=9JIT9GF
MV$PW5K9M&/KKAI>.X&U7I*W10NL&5$M030P/C\%?QF&TOP.##E7=AFITJ#DZ MU$V7K1J&_J[AI73ECU59I:N;%X["^-7>$4.K!U03C78T8FC[T&VH1H>:HT/= MB-
D&8NBO()]=FS_M[]R4_KT;M(- M035!*I)5%.HIE'-4)H;:]M[#">GW+M! MFQ%42U!-H)I$-85J&M4,I;EQM\W,T%_-]-R[06L:5$L:S;]O(-"9$M44JFE4 M,Y3FQM2V/D-_[;,7TZ?
E[$U6SN]6Z^?JUK2B?0^J)8WF]&,MA\0%.E6BFD(U MC6J&TMSW3=N2*3Q6,JV^9$4U_[S(=G?LT_KKMJ3ZM;Y)1;6DT9RD'L04'2E1 M3:&:1C5#:6Y,;4$5=BJH#O;AO+MP?K-W6-
&""M4$JDE44ZBF4^-7>L4(+*E03X6%M"E(%8/BSR;UF=K7>KF_IE>E4^+NJ$ M5?X2P3^G=]#0F@K5!*I)5%.HIE'-4)J;=-N-A?$I5Z!H9X9J":H)5).HIE!- MHYJA-#?
NMC,+_2<+'7]+]78!T1INM"%#M035!*I)5%.-YIY'-IF&^VL,M/JB M-#>UMOH*_=77*TX$\,N]0XOV8*@F4$VBFFJT8V5>,WJUR_W3B/:B*&:0#79:,[IK89AIKI9G'G\G*]
M&JQN[^[RF[U3R%Y(CKV2"LI.?9:G/_/MH?FG]$XPVI>AFD UB6H*U32J&4IS M)==Z"5 M&ZHEJ"903:*:0C6-:H;2W#S;9BZ:GG+=@99UJ):@FD UB6H*U32J&4ISXVXK
MO>C8R6WY+,MNRN"VR)?!0S'_4B<_>'C:HVS-].'%]J*P97WP(3H\SRP>MRXD MT$H.U22J*533J&8HS;T"OJWD1O[3UK9/MD_7:0VR7Q_J9]SV2F)T> F^<-.^ M[P6P[7:;J.
[ESW_/^N8/U22J*533J&8HSJC=!:#M425!.H M)E%-H9I&-4-I;MQMS3?RUWQ/G4CV:U;,YO6S?+W4G;4VS'ZH=Y2WVOY'<$3[ M*Q"TM$,UB6H*U32J&4IS,[KS(5#^:L^_NG\YDO_E-
X!1JL]5!.H)E%-H9I& M-4-I;LYMM3H=^[0&@W5%*II5#.4YN;.UFBC(]=V]*YEUY],'+CO9#MR. WMT5 M M036!:A+5%*II5#.4YN;=]FBCRU.N:='SYU
M036!:A+5%*II5#.4YGZ:L"WK MQOZR[OGIW;Y%K;6I&Q]>P+%U;>$?US>BJ"903:*:0C6-:H;2W(C:/F_L[_.Z M'_%MH-VK-X_.H_%^1-$.#M4$JDE44ZBF4?!=5@D?\^Y'?ZI M?
5N..O=ZQQ?+H8+$\G4X/U\IH(X=J M4DJBE4TZAF*,U-J&WDQOZK8_98 M*V^A8;03TO'Y*)H<+)?1(@W5!*I)5%.HIE'-4)J;4ENDC?U%6O=CRI^V)_&O
MK^O:^U"S_T[T7DZ@5[Q$-8%J$M44JFE4,Y3F_AC82F]\RD^)&Z,GY*%:@FH" MU22J*533J&8HS8V[;1+'QSXEKEZ*! ]US#>79FG-\."K[4=P$-;/U03]"91
M3:&:1C5#:6XV;>LW/G+VW+%S1FZ=4T;\ZPZT\T.U!-4$JDE44ZBF4:]P\X_M7>:T8X0U02J2513J*91S5":FWO;$<:G M[ ACM"-$M035!*I)5%.HIE'-4)H;=]L1QAW/-CRV5$9/(VPT]Q-
>#L^'18<* M5).HIE!-HYJA-#>AMBF,7]44?L\:!.T+42U!-8%J$M44JFE4,Y3F1'YB^\+) M*?O""=H7HEJ":@+5)*HI5-.H9BC-C;OM"R?4^89^J'>4#\]>C";G>V]^2M"9 M
M4DJBE4TZAF*,V-J"T,)U1AZ+Z!NE^/Z+\3O>.-]HBH)E!-HII"-8UJAM+< M'P/;(TY.V2-.T!X1U1)4$Z@F44VAFD8U0VENW&V/.#G2(QY_[5?Z)WAPPKQ MH)U!)PI4DZBF4$VCFJ$T-
YFV/ISXZ\/^E]S_O@4)VCVB6H)J M4DJBE4TZAF M*,W].; MY20^Y8($+2=1+4$U@6H2U12J.50SE.;&W9:3DR,?&=AA08(VCHVV
M>\'<\/+\|G+_/4WH5(%J$M44JFE4,Y2V3>=%>9]E59)6Z?75,BONL@_98E$& ML_QQ5:V?D7>^&Q39;9W>X9MWX=G%P??%\(T93^G MQ=U\50:+[+8>-3A?O\H4\[O[YR^J_.'MV?
L^)Q75;[<_/8^2V^R8GV#^L]O M\[QZ^F(]X&M>_+)Y.-?_!U!+ P04 " #P@6Y9(L@VH44# R# &0 M 'AL+W=OV@5;:AY_MA,!&[OV.?&6VYN)"LKDV%LI55[ZOLQ64
X24P_6;!18&5'HJE+TL!.+=&!?6C(.C[!2;, M2T?VV8U(1WRM*&%P(Y!<%P46CU.@?#OV0F_WX)8L5\H\|--1B9"

.T^7Y0.L'"> MY;F3D6%#,DN3N=#>%,W2D[HG%8HD8PM F+ODEU(.?PX)T#'OM#%!X4">4H7> MWC@(JIZ'!>L"(RO],LJ\GT7R'(^2Q0=A[!CHU?+ 5@#P$JN/9!ZIT\S5G?CJ
M6&C7/04V)JB/! !QQ_X?0)!)F!]85"::3HC6(#O79;UL3RIWF5/A,6'+]CQI]1Z[Q4P-#PWZ)Y7.].#N]F!XK1:*37GG!Z5!CFR<^W*$
MNKH%A=_$VV9$X>@?"5F^;MV7CSW1>374<$QL)M@AT6LS7!T^@>%)>CR\UDYN M'A[_\N%1S+H.&U2TBTL1-X;H% MTB0-[$OVL$OWP/HT_+-
/1H+M0/ROL%O@S]5T@;0AE'UA*BJ!L.(K;]3F,R[&J*=W3C'O,"9[1U8 IPMF0BTP+=-'(" M:\JWTVXA;)('A&XR_$R&88!?2H6OE$&)8\N<'Y+,M4RXGI8H1IF"<< *BY8
MV.X))ITZ!'_O,E G4\L!P'G$@\B;9D<+@3,.*/.DKY7B>3&_VQ4H1Y+VN+;& M]5BVA_3-D-7;H.'TS0RT2D4!S"H?1:@VVN.\*@,P0FDB>PQ=2&.GU$LEZHSX MBMBC0\3#G%E$8&
<.DGG8MVF>>Z1KNSJ4!)#PA/9_D:E'6$KQWT0")$[QZWVH M4?T^0)HY=VJ--()1/ID27 SLUC**W LSF/#%-T7BKI.7&)R0,3G M B\GB0VIR0)]C
M,8"F4*Q+/9_S//^"Y!X[T[L:,NNOK:9T*;B=J#[QL"GA+F5A9^J<;43ELGG\ M/WNAG9EU!LQNW"SW2?O(D[.E:]GY42[FR\7&W&PWVS.6E^!Q'28\KDHZQW4R
MZLH'+\WRX7'OHX^K$ONXXN;:PX^KF"_5"_EJJ;3@M.!&L?M$P&\T;BBK$*QZ MT,$D"]EE+&Z4#*7$0EV@6YV-L*,DYY M'N,TG7?X^8:XM<*T^"!-
#@J_R\7Y9^ZN=.DC=Q<0_[*I$;=U,/Q<^4H!9#"& M''ZF_$)F%G^E:\PIP,K*A[/GPH4.8?(S$RK'0\(V%^;^&H@6-SIS2!;:5]<% M&[LL=I<$-'0+)-K!P?0#_I[]B-0"/ M9K.!G+&47I#4L-
=B(>*YRZ$J=RT#T-K!)\-DO%*$3]61E9G%-Q6%JG,Z?-1A M7B_V+IL>2(:VLYGK+N\[ 2]QJDU=$]C%K8U9&>D&"D[I#!)T14:&F:/@9B["
MY&=BB75G5!NS[=%8]K#73P[Q!H:2(:FE&8L@N:I^ QWG"9UI^^9:-X[YWO@@ MR\G41F?Z;#ZCIY+0/'KH[?P@C@$,=8&F9P\IMDG33;EY8G"(+ -"L@XLR;E+
M2T9$S[&1(70P0@ZKHCPGR3HB8U?S'(R#U"8D>J9C'56(R1WSZ: (Z@!TK0,( M[RVY-F9&S\A!39Z-W2BS6U8V-U"CH]F@2T[H*K(QH&XQ:6:SC>862/I#%O^=
MZPKBM,UK(Y#_+>*9NB:2[R;)]>\59V1E0JU(KU M//>?_,.K^>BE1$ 9RC]8]HZ];P6"V=2 /;HWQ"8^10YDC,!=XS^QZB]26 "; M#]T817-%;.Z@G:9R1G4"XH&AB3*Y77!2D_
6\FG6UX']:"GOUR(BMH"<[.VD MS9'K !BB#@-U=Q6H+=$(N27W)N"5Y?7M-]A KC?T,7;:T?PX4XH \CPY(PWV.Z@7<5F.4[$.!H9%9@;,<%-A_2<-_?G^L/*PB1$2GO ML%M^8?
ZX#5%+FB)V;\6!IF"-2+^T"Z$/?&"H24BQ#]>"4F4;A,*+#JM3%X.X MDK+QO-N#+E$"A0[Z%?]X@'G>1@0)G7O58.2"0G!HG5\J<@]1KJ*124Z285]X M*K$-AH'1SJR>;9GSK9Y!
[,*V=5H&PS"&0T_,J3> NB&Z$H:?_ID4_=I]VIF+ MQ1L<&4!K<%.5#J 45!N1!"*E>BCL1,7CS\;X=F=Z-6B__CK?OW@ZSS3H1+,S M_3FQ*H-1[?[TKDX ?,C>
<[3HUMD]Q[:_A9SXV,63P"J'W0"+H%*#?M;9D3%+ MYAX932^-*!2/0$"\R;>HCC,$A>R;Q1"[?OHW:XZZ<_):M5PU?E1?D&? Z M.$'!?U5921E-.1'T0_"U%4-
SB/&9E&MF%I^HY;)8V/9; MY;O-3 D_1X:!T#F.W=""'*3W=GG.MSK3_KYQW>";TBV?Z5$VYPI+I;V 8(S1RE'F28K'/ M&S(IGDI$+V#U>(!()8]
1!,NB'$@GL^Y[2G@Y+&W0UN&"E/""#+\#4E*:+U= MXC'1+F0=S1M9IL,W7(1I6I2HT(Y2^+YW,@UY8PZ629U,N@(_XMB\=VE=?(!. M>I:,]J&/<+)(@$3MJX\B?
P_=5RY\!8&,&28/_0Q<:X*9)$ZI!W*;W$DY*0Y[ M]4Y:Q%))&B6P3"?!XU+$?Y@D[4%1Q47:N2@H7!\2:KE1,V=6BJ:K85VY(6>'KUGD-A5O\%@ M_%0T_EPAT-I]E$;01SD4=! @XPKH$
G_OBB!=_L3!^$YK5Z/SPX,/M9]E6: MG6FKVY:OU)ORX[FP\Z.-S-RY9A@S6 =G5/S,5E5X_P+[..) 5\F3[_;FTWV_7 M44GP(L@'T<+CP+"^V<7F0A9[94^L@^$@]O-FGF+?
6XQT[!&0Z:;>01#TCH1< MY8)U]I5IS=ZAP- +IS3++:)A,:6GM%QB9 3B>6B'XV"139IV %GHW1ZC@@SO M,.5=>S>?R1JDK/VKA9F1JK?B $F6@BY[34Q$FX;NM/-
#=D[POA;A87(4E[V@ M\H\P& U??U?J+^M,"Y.S\9_C7_S14SDS-@;"*0KP.M/EXAM:A4C2VS_H773I MXNW9"$A-+$G9@LO.+GY]K8[U_6)G>BWPRN!A,*G6W9LV239&BH"?
CT4="C&8 MD$#%:]-[7)PK**'M;DOE*9^PA.2\_*8_I>E^DFW=29(7O0R#/^H\&2\9B/?_=O@=YXC*C6(GK+WT MV>H>[5>1^JC6@XG>R&1]V)+7)&+.X]-
T@F>QBP+>+9>EW7RYMR=Z?(6XLM3X MSOY?8%/+LE-ZG+X7OE#.\Z5ZG]]4OLY:&F:_RO5_PJ[<+NV!ZYK3I^)SWX*' MR)[&_Q.N"?R?*H:^,ES9V__F
]\AMG91#U@JC+$S)QQQ@Q&G4S#R2 ,!2FFU MCL%",<]7RR%=9:'D2T+QO^4H2\Y1EA(>97FUH^3+^4HC;+A@PJ,,U9='GT)? M,H@^6T?JM^.BI)SP-S ;[HUL/+?
(W%SX:2=Z2NN<;W6FS8&V?RT>R74Q,V<14LV MN6IP7U5:=RW#B M#G.5G8\2:&/R.&L$,>#,Y(AR8.P\/(>\"4G,=?/-UN@8NKF[>P/MQ#3H)?^^ M$-[DH36T
]YVMU$#I='92.49NR""$I;%'SL)%@21W? MB@*Z*6XB9&8T!P-*B@))VN-\G!=98GQB%M20! M-F$XE Z9W*-[OJU,<.ADJ:0^+^^B 2B3/"!RP0;MP>70YTJA/CV5F)F4UDRK
M&F])]X!,FO>._1.]1H&TYML#E]QV/2C<(6#C@4%+]B]]LY9 %[0FIO8*6B)/ MH&1IYS,,)I[D[*\V(&VH)_AY_[F6J!UNY"56=J@U ?E,:-/<* UG?.KP\]\);[Q/E^9SH1
ML7(_MUH3J9=EO^JH,WU4GPYUWASW?Y=V?K#=;WM:-D?/.C&S:+,L)-237300 M]]D!9'1G7^9 ,_S+"^P(?VW"#3$K@8MK(Q8SE&C?%IUCR!$&()L11B.LG^C MP#$0U-
MDPLAET,&!(UTF@P,U]R6<)/=ZB,PAG#T[_X8\G4YTS3GGC$FS.Z:W M-F0P3\Y(:7"N8(:/1I\5PA^D0=S9\V3[$'@0W&[K0 'WA M549C&Z&;%IYC_M-$(G?XMYJE.\
YBY<#$D[6D@N(>)A.((@)&J*-/38T5!!R M"]Y"-CA(R6,]_>X)E6N!(M>U;B>I8-NL@7+UUXF&R[H(JNM-0+G$ 8P]9D$ M:NT>93WH4>+U,J<=W$$=:SB+M?,9<9Q+WN-
<+ONHSO1,..O?Z,_"_D\^RWYF MHS,]?!+XVXN"KEY7 .4&(K6<2PS.3XVM__FABS]1UO'LB& MJ&B0R3(\#FO.=5CO[??:3JL+SV<2F!M0R7BWNOML6YU*SK/Q7U\LF0TG]8*:
M>7,*]M?LE$".FA>*98-_-I9Y!VD^AW)->>A:'@9XAC\AD2^3,1CL:]S(ZF*% M0$=BR#0AP1Z./:\YRW0G"6(S9&$O#/MC0'990@Z"] *[:H]DY9AC4],J
]XE_)>@2Z?,8>B=1!,"OH;'Z5%#)P!TZ;+;, MB"0QQ#?20^)Y9$Z2)0>("%M3&Z6(D_$#1=/NU)ZU_M1E\$TIS'M,*,DIDQ?J M#(Y/T<:?RIQF9O%A";).1-[C.D<$I(5]3T Z]WN=J5B[
M+/5KOUYUK9(9]8RC3[ARRY6<*[= ,,J7L-WI]R^DHT%MQJ,??:;.L>2:!$/JDQU%ZBIBIK;L '5-3S.3UI.FW@H+NX..C/X7#^]\'3Z7,*!_T $UR@XXFA% '?,"]$< [X8.*]_" M&'SX&.?Z?
J4S[1Y,;H\%]>*H)<;!-CAT#GZQT7A/O(/%WF"CY((;4%B$PEY% M5H/@!O%?&1<&(?X3U]O6'.#2U^VO0>/Z0MMTB^6HQKO MN\%8;U..Q]M#3S9D(SAPGF;TR)UG_
2]#49;0UENOYE,XI_-$)D/1 M!0QNBMI:.H[1]MC6L+F?,#/AL\9]GVX?V>:U.$9N X=0DTO#NS!V80!#T8 &, MO+ O MC-S[H@ ^'F&1.\PA)RYSV-@!/Z7!R4_I:G)Z67:Q__KUZ
';8I'(3VF?#G' MGK1K("%7?ML=R)*$\-OP0?#R6U=7"E6^O$,JPHN\RW/1K.=AF%1\_*U@I2A8 MA=AU!32Z=]*?3FB-9;KZ.ZT,TDF4I8SP55]:J MR\A: F[;""G:2O^'2'\QMEG]J>/ S)5""-
,Z7^G5(3$8CDR1,Z?-JD(?B^ZTD^I;[6A&J0W^.]>+!Q-Y3- MY,+T1=2;DY_-ZD/E:8FL0$(:;8].XN/HJ/7<[VVY/#:7U].+]*?RT]AHCR_; M9P_=A"'Z9K+\.W)K[6DX;-FRF?
ML25S34FS#6#V3"TVJY)YD'9$/+U7+M"9>BKT[HM+A[(9E\4UI:X^@+UGYC!D MI^\NK&EPTQOATI_R2\@R1G2P<%=3I(AI9'/'KT9W=LV@>(2\+VRQ!TAD@TN+
M]N#2&/.29AX>.3 I=7HNG$^;Z$GS#FKQ2-SH(PY;A;MDS%0%/;*F+:F)TXAY G,GT?[/64AX=)(T7UT]XO^E=U'W?/E[+!I*N5:/
ME?:.I$&R8<9+TB!T*$]IM\CO8I+80S*CM^M'>2G''1LW,Z6GR.?KY4K$H)[( M8<4KC4W=)"Z.?^L\DX\N.=%UNFQ\>- ->WQ1;&G\R6#JMG2Y+QR?(PE&'"=F: M3\K6Y?I?
R]*'*25TU\7?LO98>[QN#!HWC>7SPDLS>,S\4#GD%N7SLPJ_:H9Q M73S2NGO2C :ZDBZJ2R0JWU/[S1)D73HP[BCT4-/>*+V#'ES%FXXHCYDWBGI1 M +"FZ<-A
E1+S0F>'AG%YV&U,-#/^DMXKZO..4[1:0VP;?T=/-)LC*U>%#VM MZ'=._R!QW_QU>53L)W485^2BM/U$/R=5$L1F5 M%.TI]8^VF*=BNF:5D,JNSW* 1VD[8-.?]_UZ\
[S>Z+6[2WM.:U4#21VF@#)( M/(YX"6\H$3\%;V7GCCQHUK'![U_>7EWNUU#M.3.0N.^!6%R9&>7J@)-3Q.>F M*IW+0E=6")]=((&,NKY4;X#W='QP^ -M#;,;^R?Q7.;B&C?#D-
!3>UEG^G8F M/MS5CR[:E]F!3X^!?CP#<.SH&6X@(UW0Q<&$SCHRO>C' B$L]X4,TH'Y1O@K MSE033_;[ZQ8;>0.PD8\ZTY/KLW;EL7K_^ER/@XWL040^=MC !4:V8=O]53@? M7
M2G:T%X4.*07R[CH]-]OY7QO;YE1M'GOJOM[+*7ULG/Z\;W;2OYMQ#W\R+ M2)<@K= 6,5OK[T^<'QWF/4>O2 EDKYQ/G:@CRS3(1XIV^NIX*EK7TDN-5TJI
M7_;"B[CBIA.YL38B\S:1=5[N\[IU7[NIK8?(_-]+Y))-Y-[%V^/HS^OYV;ZR M'B)O?)79AE?M.5CI$3CI?Q%Q4R\WV72;]A=9EK](O__56G85BJ7WENV"LK>@
M]9;TS>;^6H'LQ;>Y9>F1CPG?;4CN=?$'PQZX74P&%N-A7<>Y+_!A.>!\SBTE@%&F 3__0E/1Y$+0GY%YA'G?13J[GO2G_<,".G2#U97O M[^.5P-)4"\T[D>5!#@:OC^O!
B,K9^;>S<0L@@E\.E&%2/2QA-Z3L]RW4P$2 M?B"!9'CR:_0\SQ>6+?Y8NHCIDQS%O&S.4L?5V![7[U1!LH4^]WV)J^PTU M&ZVTS<;]
[9U.;KTF[MVN;3I.&PU!_=U_:.FU!*9C>:\KW'+F=GP9?DC.U!+)W?BIFXC7O/#:IXOQ'/MLU9SOW%'%B?W&#C6Y+7OL9.+VV-]AU@]<*SO
M$(C_7<<:U]XN#/]3:@3)3.UW6.'ZQM=DQW]GPNKM9%"7V\G2LZT%76AXWEX\+M?J B]Z.ZD;/ Z M_^EYY+/L8TZ'V%IXW>FK4:M#T=>+WU6'J%Q7(K#P;:!Q28(
M>G0'UB;+FXW-3D7.P6?_S)*7ZF"^K>QM@NQ%-C=MLNAM(_9,[B/;3+>-F[.W MC\_"<=OH-2O[^"P_AX* M][L:(VB-3P;]EH7]8]2H$0N?@ P#B^S7SYLB@'(D?0EF\F)::XJ?)[W2O<-
MZ<_+3K/D.3C2)@Y"1BTQH$FY'(7>OEELL)G,N9FK^NM%)BW@F5IBX)FM6'V^ M565"K+Q/FM.E40_I(]TL:F\F#VSFJCX59X;TZVX6M><'1&N]D2@>EH\J:80D MOIN<-(GC JN01?
K!5=9V%_7Y13S--$%F\AD9.NM,+78S5[5ES+]^L9NYJBUC M_O6+WOI0KC\U[,.K\.>6IH\T78!4#\PX;/:1*LK(F,5XW>>G MM[?7OQH7U4;6[C BS]*']T;&#N+?]+57-LG0W.,$1H_L\=
(")([$%8'97'66 M<\,)Q-6?%*XGQH&:.RPWHTHVTXO=2O$F)/S*ZTCX;01_96JQ6V'(JDF+!V"^ MJME+#*BV-7L;MMBMI&^"V0O!R!Y;J^D96,&R$ F5KL5EH_F;2&@I;QYVIHU:XZ'VC:
<8I\-9^)_&]1.&IR!$-?63,15.*(QBM\Y=IJ<<>GV0I'G@1CPB=VIK?WK;/;RZ)TK)8R MHQNQ>@'^S)4=_J3/=DC#5SK3DYNRM'\G]-5&?^>'31Z.T8=4Y]P@13"1A'^G
M@WIB+/&IM%3JK%P)LO*M.$"2I:#+7AP6O(._1/!SPSL_;I7'=J8/3TKK7/Y3 M%TIB9IC:WF=NQ%@4GY8A&R;1V*# >YJB:&/L:WW[1 SZ+HMW6&R_T)F^[/?. M?
DO7YU:]ZO!&8(3/2KNT.3>'CRVH=OQ[7],,)-]P(\$RM3ACD>H%=RP2B5'H M5Y-/14H;,3DK(?:[0 /.V4#X[ $>9@^4"XT2%@#Q=-2Z5I\*Y3])+/[:,0^; M!MF+ULLX?./?
QV1'GH%:?]0_%_76\|O!A;QELO<\HXV"N=_*TU^$O'N+1J9G MG$2!C),H9US MK#/V6"^[2B3K8Y_9Y9;7IXV:/%?[E7!DF0325_3DY*/)GGF
M%KS9//))J!U>G3LG>7ZG"Q)J6;J.U^CO@V498Y(POO-Q/O'^A_;&B96"] MNKO;FIC:JZ"*:%_6%*TOB\:)*MIML).#:_F\W#\]+B=)5,8O_-7[W2]\H9SG
M2_4\7ZE\3;LCEF61RO5_/+EV.Y%I:IQ#A#PG<#K+NX^ 6'0=AN4F@H_*E<[T M[N%"F?Y\N3"'PLZ/(CY.:[0]^_V=F, I06/9Q%L['/#\ J0YDAI:@<2N-)@P M=N;(8N">HY:T
*F*)6Q]U4=9@8W>"ME?)&1VF=_20I:XB+Z4KQ0KV1>SQ0 = M:_5,[E49>Q"&;$XN>Q>RJB)#,P7;,[EI5G[>G_PZO]XOKM4S>5P'R'B8"^+N M%BY4G?U^0E2X
%.SV#U\N_I5OY&3))$V)X40T;=-]LL) 8.> MO1[Q+0;!.^HSMI%EM)I7KN:Y! &5E1P+*\_7UF?Q-X+%,[78K3QF3![#^O)K MA7)B_[O^R1!ZPCV+5K1GX74JNF_[/8L_>)%:ZP4D22WZ?
P6FX$2W:F>Y2 M6F^GCJF-OL'&V#_M8ZIZ"BN*A0+<1;GU?D$7"S\C@C(Y#\_83YLI7DQ?UKIN M/4>AV9G>#B=B]Z6Z/]*+\!IKY!9U!*IUW-7&Z.@Z*I8ZT^OKQNB\=M_KE5W
M4E,4/4TS56B")C+._D'DO+[#O0V5;XH QX[4W?O;V?[2G+?FA7,N0O/ZSM+%]<'T=X<_HG#G M*C\8W<( MMK0A)LZ$X#[( M^92O)/H=#]-9(.DX0,FR/KF5%4,YV^Z$U4+ F?
XO_9W>6.9*1(WS 7 M];$!OD4O%L+<@[_*?^<(! \V ]SN+K,JDOP:8<_W@QF%624%>FD9_;BX&1&T M7=B&EU!_D%G>B5(FM/@PJ%P]5+/I]9V#>1??N*8N=&7Q.]?&'@.E:5L#ZA5Y
M[[?^M;\&?W+-H"U"__V+R1Q"<"S+S[M=A'T'_.P1.2^O8?@\%+:E;1YAO.0$ M.E-2>I@[2Q*::?5RBU".H(#4'90%;%^&,AUF2(Q*"W\'LQY%S\9/PDN1>YAI M5)-K8A.%R"<_$U)(RG
*M6+!AE/X>;=_-1=+P5?@,P]%H=9!=H%/LN=UIO?3 MB=&=B -]DF0XS\<AEO<,%ZGJ 3%0K'CQ2=X/GL]KZEZ_4R*ZD2<\4I# MUA:V,:=%U=.>ZM]DR(Y"GOY^)*
(]]0Z)2I1$;V<7KY?/;= MV5CDLK?X_A:!VW4V+Q;$"_.@7.M73YYVYC-0LGI"MZDP+/.PC[!#I$(^LRLH ML,0@83VM2&&'&4B)A[[C?U'/C.K0V82^FEJ17T=?
32@APLD6+F29/P\^Z7DD M+A+D\WQD65+"\PC5)P6//KG2-1$AR8",AEIYBTCD*%L46U"AZM$CYP"U4#ZQ3%;2* M]\|'/VNMM\*[^
.^N'FA4O!44.0YP>1Z@JQSKW"O'B,NG^O_+DH8Q.7_99XS M7S[(U50,9EB3+N*7Z HT\';^W\YN4%CJ,44EE!?FZ*GM&:>D!_DE(M:(,R[F M\0+6<,JKY5\.UZDAE:OSH^']TX-
```

```
QN1YG*:)NE&:QH[(N$5]:5AK(UYP"XAB9 M@"6?LI8$06(5E[QK*1)M*,:IQ%/J4KY8+]_O6(.EV;D%M9V5 MSO19U9Y?WLYOAO)39@I"LEWWT/WAPB;D_'@UW1\9W52F3V1;#I?
APWO7>5\U MON:KZF.STYS1:5'CO'@W](|\2F@9].Q]B>P\@3KDR+ M0O)0KPJPNG8)[$B77W%HR8VPYTSL#_Y##S].[>>]);(;+ MWBW6>3J9X=82% 5)^Q.;]]@'#<
C$%D17+G3<1Y[:^)WPY8.7RR9)"E&F@H6 MUA]!WXVUNX%F&=A WXWQGR=W VR*:4K#?A4+J#N&;N(P7< FG#Z#_/M">).' MUM"YIKQZ*A>
[Y3^\AOU[4S;A%!]#"+4H#%F1*E&A"K9393M466+K>*<=WT8# M%BUNGOJD?>2)9FX'@HZ,G1]\L9JO5FM1[:V<03X75;;M94KN"WR"M<_!CCFZ M'7M J>'IL,>F-
PKBW.!819B6FO'+YL]DGX$&3?;93P02TD83J%]!(XPOEGQWV!TGV$ MN>05*1,N>.:S&FJD:Z^R!(,]=4Z@MT><*"BBI0C :3GX/3S%T5J6 8E7^!7- MA-V*
TW!6QQJ$E+@7@K^A%ZIF>=$I)L"_F7/4B4!%BPHOCG/>]P=3!5U;JZ\ M[[;79N3HXGJ*AO^_1M_PJL&'R-QH80BY-,Z"?TZQ \'6,/L\P9S1L%7ON%<0 MIGVL>B00)(37"-]JPK[[A-
C[$_DB'>'EDW[6)O9@AB.RL<.W$3X% M)#TXZ[S!BK8SDJ6.-.I85Y:.B#X.=AZL1S-/3_OUZ_K=I-TN28[6?4A PA'2 MH9P46[)%^OD=J+G<95\<0@5T=]R:.:*[<2@.5-WE/6HV85-,1R)
<"TBP"'>"O.;G\+_IGO%#\(] M,;(23&ZB& $&H<M2,NEC"58QJ[CQ'/2 M)DB :ZGPO_\7-"<5CSFQ'PA]KL3EO'3A+\_;'ZD5M/H"\8WE^H-Q-
:0O<,?:&NJ;O\3.W*R\4#L'3[8.R0.5/G%0L9#(/GU3@&E6Z)!7D"MR^K MVA#;0XNWS*C+;E[N9?W/;S: M,[@ZHTRT.7W3F5ADW#-:M7\:"Q:YB !78KU]TDX\7C^,&8\S[Q+\P!-U9!'\
M>4C56CB(O*)W,:&1>O![@-1'']^J/UZ^"]]PME1P!LC(7U"T YV6VT5P!J>_QZD #6U5Z7 M9HAX(QO/NSU,9,P_V.PBP^1T*&WZK[L(3WJE=E)7GJNKRK/GXG%E4P;4.,+$
M.&&T@#NY]&6Z=W'=@?^;_CXJ-NXL-+Q8SKAMGD&;0[?DDKW4767@@K*T5PE+ MDR_JX?TG9>8^2HVY4S!3[\S<1\/1KT;U46B?RIO-W(N,U5J8.^Y54!ASE_>]
MR7E[O<'1.DV573+AK92QS12_;C/5W"0S13PGMW)D'4+5DJGMH\ MLY0V1R?+)-@X+[+*39"@&U\=:U1:CS6:PXIK M@@9O^# 9YK'T'=*'H!DD\W=:5LXF,SPZ?
8404=HOJY[2_M[%F"]-VA!=73,QC%!3OS6A]C6JN0K2]=P>_=B4^T=PTD?I,L'9;KUP&58K""8M&10Z3% M5V9Z/UD]DJ\OT<-4<<.BS\)4OGX1AZFFP\M^ZW?
Y>=SN9H:I_&TA\9BJE(2I M:E%,%6.JV7MB(28LEPQR=@HNU'HYV^':@ZLCY0ZO]N#R.16N7>3FK,:U<7FT MLCR/EO>B630A=F16 W))AJX65>(F,&/*<8/*ZP[*#S8I*+>I<<"
(L:;T6KM) MY="Z/7E\,AKZQ!RL&L=X&0)D9%=^VQW($M[$-PX3FI??NKJ"A:0&1X$M.O_] M(Y3P.G(Q*:K==SKVU\'YK^G^4^_H_MV.O;':L:<8W/TX\M6>VQU\R=@K['+Y
M(+1X5X+J1B"JTYQK+.AT6_W:]W>1_VTJDS*"Z:OLG,-WGSQ%,7>'Z;>BN37< M7M-;70*(,H!-6$\*B;N*5@ICF^92;..9.Q10/ZNSS?U9LZZUGU6YLDELXX6R M]
(']+Y^FJB9&_2_F"Y4TL;[=$;Z9J0>W'3.G+CSHG7V.L=SNB&R^,ZV*8=QG8G>I8[E9G>G$_NCZT'A[,1O\=QG)7RR%CN4F#,_3(0J6( MD4,&<(QL#* ]E7;H'R$)Z8+"W2 #Z:^(VQ?
4969B9YX#E^(SEUV/.E-!E(;M MTS^_;QY**1WOPAO2I3GPX-JZ4JZ?GB7T'AQ8">' 8QF;#QT.Q',9G(L#&B(# MW@,T7VL3 M&_$#E6CTMOM>EE__HI7;T:G>1:BBFQ MIW+
[6'T:*8,G?;_Z'DQ9FV?9559Q=Q\.LEF&\>&#(8 MON?'/Q?RT?GQ(\I,YVFF<2)FVK?1&T"$X%/\/[N[W!%D/>+&0 M*L)72]\Y$OM]XWAN=Y?%RYA5XO9NS2H'T ?
+Z*7%C92@9<(VO(3:8:GR>=U; M0:7FH9I-K^\<)!"_<4U=Z,KB=ZZ-XVA*T[8&U"N6O-_ZU_X:_,F--6T1^N]? M3.80@NM(>-
[M$@R:;U@FX;R\"OGS4#@8A(<1QDM.H#,EI8>YLR2AV58O!,ZV ML(6SW0!TA >K8M\IV(Y5R;@<@8OLDM>&#F(?4[(=P\L *:X(E@JM"\&KX3\ MB>8V"TYNLQ#(;<:& ")I0/+?
8')3T&^F-\V:>/Y2=Y*;)X$M 5J-)V);B.D6 M:VNA2YA !'7,H 1UM\ MH]!+CJ!2B(8TJLT4Y&TAC>97F6+N]G68FI&1@1H4MF-%[>F'K MJZ"N[Q!J26#.(AP^A%*S?=
M;BYZ49#M>Z7F[Z/SXQXZ"1F+LZELGQIPT5RV3P;^L,4LVA3,HN(F]9VD#^L2 MA>C2[=Z.6K];1X8H;G;K_!K@BN;*\RI@$*6]QA:IZ,-8NGW!W_\9U$]NE/YF
ML_0:0(KFLO0J:!"5O20U]EM\HLWHB=LT?*(H()?AXVW[/!='135!X/Q>&&>U7I A+-Y>-5H!_KC8\R/W\1 M%-'RAF>SL%PBBXP&V1%<:Q<*]]"? O2BX M \A6G-_)K$3QY:
MA5NSV#J\7^KB;H43;Q3_'JR5PD=@KB- MP2H)DKU8:1RW'Z_;5D_,)$S)O."U$?=V;P:A) TXF_=')_EWM&1[V?H:BW,> MQ1>8,)FX^[W0F8[/1%U3C.
[U23OWNBNIC%)U]U)&$"ECX3MMM07S9U\95=ZA MS[@1UOQ.^HR)_HK[?S;:")<2VDAZK++(+/C:T&\?#XJ7XY/"I+B1Z!Z'G:ET M63N]K!XBZ=>[<$=8%[]+[K$4B_BQ.])#
EF.3Y='#5F'UBIUIL.I]GC5+XQ> M6BBV[]),!WUSO3@V;I_[C]/^[^Z[\&+];DP'4NQ =-,:X+T^"#E]70GR^*U M6KF"&[Y4NY7>@V,::=DV+]X&MP+>1BXFX$:M,WV[
M_/DV.5%TZ2UR+/=\_ZO@>I[9ZB3";,<<^)S=7S/Y9.WI<;L53X\IY/Y/KP%3L3FI)+9QUANU#LA6<'IY++X\#Q^JC2%_M_:>.:2Z*CCS^!1 M$DGURT:[_%0_40;;+K7-
;AMMX[B#N\"?'1C<(;EA^:OHN>T=W4KEMG=TA45Z MSLBQ"H5:!]GW-"P*6;MS#_@5;M/PYJ3]A%V M6$C>A$'CK+4];Y7.LY]W^U??(N@XKXHR$%ZMA&H?[]
[HHYL@WY7*?"B5R\E' M3:1+XE#!](Y:!-PQX/O+'FG-;JJ2?>5XI.DX('B5161Z7>2UM JG*!M%(I1EGY\KU>J'YH-4W2 M:^RE.&'AM39+]/BD(F[WVHQ45/+U4IH3-
7S2X"T/.5%%'0D&.D#T_Y^HH0FB MSO0$79^>O/0;74U>B]6*)Q(M!WGMW83@RP(FBD? >3-__)E"'P/%[16#K => M-);2("?5:X6$?/0UNX1=()?%PLID+>=KC>IJA V5S2/7A3Q\
_!!2S8&O@*; MSK1=&S^9^\6K4K>R7I,4&F'YEQ4CWIGKX2P*Q.+RUS+/6=*Z%?E%UBTTR(N[ M\L](L87%>
DHECCB.NQ,+^_+ANU&9BXVP^[X@MM,^WZZ6)^YGX9HB<)%&Q1RO*V9 MZ$ V1$6#POV("VG?!._8S^A,#WX;VE ?O:%>+S,']5_W!^PG5R5 W\7B]P *
M?)UO=J;Z]*E1/[R]NV_T&4X<(PBKJN,H89SC_E1E%)E9O ?EWZEV%"QSH.GX M0Q*'Q48&5':!E!K,7H-P8_R7X @ ;SZJ1>H9R?%3"*JF\W"[R<=MZ)H.U5>Y M?O.[?'_K5/>W/
61>1NYM^%^0S(5P,E\)^J5.AB9(I.3E"NED(2'DGK3&+X7"=4]L]R/H[;Q^"3I' M+6 )>O,KXYP5]@J%,'P_2NT19F%"\3S!S ]2UML??*6C'L)NA!27AZ\.1]?2
MI')^6I$=HCH/2Q!&GCIK+#6;E86<3).9>31\%=SV'F9B3)E^#GP?GU M_KA[]OKRJQ9-^M@L'6\92Y ^KG,YEZMC,/5GFIZ0F<5CGXCJP-PMK=W/K#^# M=V*?Q+ON@?
U2AIDB^.&%O8JLIC]8JIQC%HY"%U_VL(R3^IAWWNML(F9,4Y=; M>2*+OU1S%\*$XTO4TB-=.$ M]$,?S?:U7EFZ.! ,U.SKB/S9[F?]?=)[*8^/Q;I8]E@LMIL>7A=@:\-RN)&]
MGL5F*\ZNHFYL*KM\R?W)[F.-6'_ OM5CVK==2.R+ NRU&LRCE/;X2 .'&4G! M_\YS=&@A?J)DB72$D;TM3NC#?WL(T6E(&IDPI#$AST%CA&I0[V2&-;S@K&U-
MM2%B#^EW;$71T@QS3!9!A:./$P%$_#>^[(!)PFX+5COF0XSY(&+YX4N,[$OG5?G=YS]K+M@ MV%[8HV<@-)*R_\^R7+.ZQA_^]LEA_P/_EI>.]NF.HWQTPN4V>M'LEI;B_V0A
MJP/+78Z;'EC4GCHWRJHD2QG,SDS8'*X9G-1*5_OGO:[V%)K#>)<41IJ,E"Q M3Y#["(Y]+'/T ;9JVLO!S$/8,1V7:,[Z(GZOC$T))0I,4R1[!*.K]-PZ+YC4 M:&O@N4P*(Q.=XH!+G2
'M2T@VV7O%H;#D3*)EJ H2-IWX#78!XT55%T8Y-^1 M9NGT= .X)*NS\<$I_OVT5__3&[B.H$TA+ZS)(B9>C6!S&3P$/#"2(DNQ?++$ M2"JZ,^=K[9^1"*9)@C-,Z3A029)-XH^&"
(&7T^'/00]UG@#4-EH G!"B"1MA M+TQ-#AXG2D5H(K&Q[\F>^FFWB3(PCRA+B4+<&"I<%.KU?#U6:G8^U[L$)]LQ M0OC_C@ZXG9$0;B"\@@_K3'6EPZ$X] (
!ICK9WR2HT71&""720F^[B* M*7DI[ZSPC?/?O8.2*ITWGH(8<0':)6+W143[$$5?3G:/YO5MRGNE2B1_!ZYU M3)M'(_EY>6XMI\6MF='(UW=5ZW1R>3:8A1G?5$9-
2QN75[^'K.R52[5(CO5> M1'8U5JI0+U?H$98 X_8))AK+;"2LJ M3V'I-F^5@#=8)XR0<@0Z7[>SVU0;HV_MJO_HK#^PU'W]6B]ZDKY )X<=%HE2
M),&2Z_7EJ+"4&*T>TLY3^YZ(%H1 $$7JB@/[A3#K]G9TD^ZH, .!!C-S@62! MFY?UAUFF((/U%A&=;YTG^50!6$+6)- [U0+699.@OH,Z//B9
M!87.!8&JD=",!'%YCO31PJPX#72:FVZV/P%82X*J8@*)R)_$Q7\8Z=I( YPX MV=/H9@84*GG A%U3&$YH@J-2E51P@PV ]^F@%CW>IAXBNAC]( MJ&MZML_-;#^WQ/;! K$G&*
YB0G*!UT\SQ/8;S!OBP.NIV@"@+]B0J0N2 M8\ARX4=(OSD4)H"V)1#46,B#]0CWV*=OC31Z::")-)]&.<+AX5?BF>*G?9$Q MS7RL-W%Y+X]_)RH6+"D'?BLEH0)X#_ P'4DR_LP8LQ-
B4'+V(^W_K6_!G]RB_'M M2OS__L5D#B&XCH3G77I/_8T;D?/R@N)]'@H'NQ3"".,E)]"9DM+#W%F2T$RK M%T^Y-^?1]^8 &P+LYF&3T[QMAQNP-2;;3&?RF-
K93H_!=A$]#9DX&S14Q;Y,6Z'B 6"'T ML%2H2-GCFOAG'61:F5!"]GPP]0'2YI8D+=D/I%/DG@RNAL$\@:W-WJABPU*. MU5UY3A(?OK<",<.%HIG6A)=J[E10+4&?
<&4*;A6[Q'!N4GCIHD+ V2MW.NY/ M*^>7>./^:/1++NV7GC>@J)"B%93=GY;+'<6]&YY75%C=BTX>K5Q4Z-3DY<)8 MH[E<46'ZS&#>_BKS#]-F^W?I XH*5SS\N+>ALT6%I:C.Z?
A%A6X!X '6!=ZV M-SZZ"A ./[00T"[TR\T6^G%)"OW*RQ7Z!=GI(TNVRI67V[)1.YVV*^]1Z&=S M7CKU6975>@&+_+L4^AVF4^BW25QC2_,J M\X)&-9P$2W'E:OVAC6J^6JVEH-
W\9?.8/8_(QIPXV>7=.0Q++FWP;OOL@F*S M&=A[[WHWP&>TKE)3X>KJY.?S1?.QLND,'8\D2_'W:K6F?'$M#$Z4RQROIU7%5%FMIK0XOSTK$:L[ M6\LM*C
MK5Y@VEI7@>F&Z_E?K8N)*$Y_W3X6-Z9P;^WZO;IZB6D)W.I8T"&1 MQ7J<6ZR76U^QGI-)<(OU7$_)*S!2;E9>%B6K5BYN32F!U9F_HID8X,CK #MS M@U\.7A_^'![44.L%',$2L0
9SM*QSFB[W9=7+U'"1IN0,2QR$IMJ*M-RAZNK5J*7:7B6. MAVGY?SE7.7/.7G.'M7 B?;DMZ/JA. M+E1G>,JSYKF8K.8-'%Z[ZBUA^=I>SENI'ZS9(ZWENO8JDTIW'8TP,T*5)KSW
M5=!EXG603\JT@([<3X\LT^Y+]U>E"7:6IB>_(6D7R\0N^8FE97(:K7L3#+R0 M'EG%;-$@I9!EN&1:AH;^$K< S98JVX/OIE2Z%[:+7+Q=$!OCK]039D?V4JK-
M6)L#C[5Q1A@W2>&D;VB&$:N<**:Y\6E3K&[G^=W3QN_JK_.W7R]-J-.Q+V5# MIMB$#BI>9#GF;GFY5O?JB^B,[CVI[[K[\]>.8C 4C MMY"9N"\&0AP =',5!Z#;MC@.-
O[7K5W9G%)1+W(H1UTEHK+L,5W;(M&/6?R! M1;H"03!5:+%B 3LB3MSL>-10))B@4N>#=-779&>.Z_+[!G6QCJ?_9.K M.X9N8O\>5.]E[T25Y%=9L@3%K]/W-
4&7+GNTR$K3C8#$79]G6\DMM,Z#G5\-O M*U;RM7HT"%HNS:__PZ[MD+P0N"47YN6290.C. OWW:^2/[O5,5)YEY)U] MT70@XTSBII(#(![^]0@_'SO'.6^#KU,?:VP=B(\!YW9PZ3./-
/X973GX M$S)R+'%:%1!_. X@.F\<1!J]+3.YL M",YNR58S7@\O!PN$BU.C:M(PS:H-NX](RH>42 M$B"^>\LB_E^:>[%^&>C!K/Z\JPL+]Z*Y:THR*64^##!Q"NRB[CE+#O@ JU42
M+K\)S[G,&Q"?8">K%8@UJGF^%.;1A+LXLSZQ01;*M98:&%-*-#!F+4(Y;!V> MJHT;?2Q+\<;.S+DZ76XKJ:]Y76;,,5DUBWVUX(*^0/C3H-0I)QMN5)F0HJU/P3GHJ05$0IJ/I
ML'ECZ^)Y4:EKN;?I^.+ZZF)T\=B-[T6EZ70D5P0KM^>$F^H@/O"M;9(#(N[> MRE%(>&7BQ>K*TY(E5>->-<(AE#OR;#X&Q?IX92 (BOQBR9+@(FBS\: VQE;D M$L:DJA
6@0V1*8OR"-(3T$,+%Z2R8>IREW3?.BD+PT 46LNP])&"N1RZI()= M&C0?XEE$- T(5-H,(?!_@94DCF%VD=0:@A?)/4*!\0"I<$2*_,]B\%PD7[/' MM37/Y_$#8A,#D9YU]DR\14L="3)
(KZY9_4%4X$-C'3?%HVR10S8OAW"VS2%L MQN(OU=P1ZNH$+*18)6)4S+O2B^4/L *(Y0M:NVK^8-3)V-;@9E>LTI&54=65:[])##/A ,T=D@[LYB+&>'I.\ M?9O%*M?8HYAWE:<
JW&:=G.LL(Q4T*%>C[I-7IA9/:+)/#IKW'+7[$8,4+&W M5MDO/-X)PO3QPKJI>RYK7>IYXAY8RW+"'[FE=*6_L2((R]*#V$GDBP1QP-(A
M7CO@K'?/@02.8EA6X4.B)/B$@4GICY6@ILMT[V5CX< X6,6,K:/?3P4FYXU4 M7J%.#&HZH:QSEXD1DG9-;=='@*Y@R%#D876? *B'E6!VD8IZ. 03%*B^Q.\> MR",9B;(VL2U&P]C%-
V)=;W1I1 4J^Q5Y X[FY2@/' M;[GHJ.V+I2K(P_%,9+< ]A491(>OGWE<,")=XB7Z@U)YU%UUT-5K(5R_E>S M[07./$>['SN[*&G+W@;-M:\. MNLK(DJ]^'TBG?
\J);V@KR]W0KFDGH^N"\NNY^)._$)>\GYT#P!#K3)9(^,;: MR<.9\334WFK[_3D7= O.9-$FPL\D[9WP@M5J_7RZ>S.?-^#.?)[?%NJV^:^Q M=@TD@NLVUG0)V_6/N#-
/O)/R>^\DQFW"TINH;MIQ)-Y)?;6=J%JSVVO3C%Y]L#$=E.X8CQ3$T8CNT8CD42:N^;R"E3R&UKB+\D MVO:)_7-.;X"IN:[ #H<,41@!S74+^.'UF' ,7?:;GH^YWIS2\#:2<73\9S=2AW
MJ/'O.M/R_N'+\]O!"ZIV=WYXAR+X>X4911R=O+T$_: 3];4IVD?TRK9T2XT MC6UW/IOXOP;UP0T;9M^+KQ31KEFF&23!!D\ROGTB-GZ7Q3N\N+_?F;[^UI_Y
MXUI_6FHX?"3)QD@1\):P2"&V\L1GSE@<4H5V-WL3;N$PB_OWOI0_MRQ]=L$W M^\8)EJE]YQ8[@W7P!=DWR0T/_>H.N&1S/$(: NPPQVV>'^AW_=Q/$OJ-$7UE M%^N#[QRCAA-?
%+W,@[_MO SO NA)D QBABXAKPM;:QNZJ"^H6!Y&B&5P)R'+ M#GG?K O\[A1>0$Q^9\[9A!*+X MS6F^Y-[_G$A_))_Q-C%]<4BQY$H_Y)B2 M" *?MB"XWM/JS+[I>W6
5@G\UWN*=]@(:[W?_<(7RGF^5,_SEV_U/%?\+B_\ 9.W<1]680A6X?)B;"M2;" MCA#X01ZDM_V)^Y$K84) ;[#G)+4UE096U$L\40WLO)+&;D^6EJJ@CGSK:6GT MXPE,&R_'?
VX%Y>ZZ_A2$#O51#68F82NH @&[@@*PE#M!8O$!.A"+&0M@;LT4 MF)>M#OC[JU7HES!G-JIA2!*A[!6+<=+CR/^%,&/936BL?A)>RMNVA9D6'X;L M7(ZLUR\.7ZM'XUK#;6)S#)5
GQ9 M4V=.4F"Z/WHL01_KH[<62WMA3:1).30 M593YXT VT:P&MVT*]=5I_/ 3-!*2[&7.DX$E5'%QO:J8+3J:UVOC0?OL=7RJ M=-TF:L=O=,9;Y+D^?=!.V!8_2LO^M-<4-\OBX^/5FI;K?
#U?#RT#]'/Q(E9( MB8WX5)4H(^Q3US>*X,/4Y9&F]Q!6KM*_(EA#F&N3,L\?K%=UL@U8% +[\&TDZ^2A1C3K MC\_W%;G:.OY5'LQ5IKU9VLSE?
&^F#VH3=N6WW8$L20A_!M."E]^ZNH)9C0=J MU?DB[R;S/D0;[:>JC2(/(IE^FC:?+H8/1Z^MH11?/ZWKQ,JKG=B[N#X1.0"; MW%)PR;$S!C&S!$LP7FN]*L'9.<;S+-
\N>M>#5L']]>%TOQ-HJ:"F6Y=\]^78XQV/Y>35H%/CIZ&1F;D\@ M^88HB8/)C25IL]D)N5 'GE^Q5RQ?+)7RM1@IN5#&3*Z%U\37&Y3"F\/7M7IU M_*;=7;?'M254\?
I9?!/2>N%ZDOI"^[EP )6$@BP,&A4@'Q@9;/(_2B.QF";P3U=1EU9!% MTALTT[ [K8S.?O]^$,J6Z%[AL:?XZ";;SXDY.6%=.UA"I\1NRYN9DQ#:D4<[ MZ0)T^$S]
<7&+SV<[5X,CH:,+TDO^)A:WL?.W)'_1!2CESQ. M0,(G=@;+C/H.3OB^D,]^:>9O-.BM5^&'A2AC&J*DQQO.D#E?=HQUC\ZB) 2F M#'],1?
N[$";3)C*D:%XX/RH^2\+A\'=XS7QHV;O!77K9 AM-CTP%NX\WKB*^ MEE)%?$B]:ORBX$57'FG7U!9G&DC3*B">QPN1*N.#2NP3E!B';7U-$N\\/LV6 MN1LR"Q-*^'U=
RL]]VU@!:6PSJKZK+,\O:#),K-X5.J69=Z# MX+-M1-EEGALT%&122-["?X7@U1(4[ESN(>[+;YBN\'7+4UN>2F:!N53,V+MT M3RUJ( DT5P0_[BN,"*X!8*$7(2
M%^U<&R.=_@3HI9$WTYT57*K(S(S^?:_6GXJLR/':G MG=AN:2#/FBRGF [)EQO>&B M^ZU_ZX&\U^HWY.6]4B4:]6L3&K0B;Y=K[UZU M%#T%,3.24R@=\
(T[I=&3&R"%H%Y\Q;CJ;*/KIE:0K=5NR6OEJ*'(&RA3,;L" M X8KE6:'V>,%)-R[@;"XK,CQ2CU.Z1W,].I(YN_/8NE.3V13.[OY=5V6%E1# MCH-U ;KCM8L>KUTA7CN9B?
9U)SZ>6%*1"MZ5298.[P[(6G4&4&B3^ FL9&WF M=GZ3;&2D#QI3E OIUKO,4=G+%>_ES9J-@Q M0/+48D=GZWZ!*Z_>!%S9*Y=JL47N_1H]MU'ALC*Q;UZ]W$_0:;E?F=,B&!H> M?
L:0,$IDDJ5;''R!GB&].*MOH;OURUSWO%E\>;I[EDT5 4QL4W7FD(U9T M5RYO?'17C1G=;8ALEM8;KB7N5\B@!#Y8THV!WFZUN_J"-J%-"]=2:)=8P12N MWEJ1IO>XWNN_%"5W,;;6-
F"C?#?0D9-3:;\=E%\?[WNO>OGO"-G#M\G:_D:'0S2LBL8*WRNRLCTWB*6S/]NK9"M[6?-?V M^8,WKQ2^_IG*KZ/6466Z#=^6LXG)REO6Y$EN]BW;-FB+*9I'FJ7;DOE'O6Q4
M3M6!7*_]%3&;N_> H*V>*2G5]BJ;%K(=;D.V!$*Q?_>[>7#:;EI'I6W$-D=F M5@-"+Y9BE5YNB#^8"D3'-EY;('DW3^JY5FF<3$Z4[(1K7OF(%:U5"QL?K96R M%:VE.\7@[XO6O#(X-
(7*S;-6_OW,;X.U)776JT'LZAMNP;>V")Y\;!X5C)"L#(4-AFT<\XH5M]0T/ MVPI9NV1K;<.VU&2P]W+W-CE\>?U3V]ZQ+6,-:ZMWV*3I0F[V'=NVDRVF9-[* M;
[9@5@:M^YMJ*58KFQ>JO?](]*Q:*X],'-[7DWGS+O^:2"U*9%8#-ZE6\M5R(RN16BIRM(W4YLO=4<4\'56?W]I72\,> M?%R@YI&.6'%:;=-Q2HI[Y6S%:?5MG):6!)KG;Z5:?
="XJLK;,&T)4[AZ2TV: MWN/[3BY==:9N+'"ATC:TBRG,Z!6IMCB7>LWVS]KX\->#]'<$=^[F_0):7SV- MPA>J>WSL5M.L#I[>=M$E$K2IUB[T>\)U];*V;,289"QVYB/*2#E=#1VEEJ_5
M%]=LOJML?HBUW):#OHO4BZ.+QB_Q$-T==3,4KWIE+U;$6M]T[)7X$>OG%_V# M;3"WW&KZ^XK#J4*E/_/T-F)4= M&7N4,QU[3+4K_JY4?WL^&_53B0$23M+>[# @H"96]-
':W"GR[Z8)@O:_\5>Y M_M-IUR@_]06Q9Q0WV@6/Z6HW-KWWJKS')W2U/Z_(U3ZARSUM7[=_H^F5?#8, M017].UW?@*BN7C'$%_8J8;7JZ/^2R8=P\CCH/!ZAI4W:YUIH59"Q=?#
M@\%Q=3WCPM.? Y?MV=?='YCSAYJ:(_$JQY@Z,,HN2SO*]'&^PR_(C\7O7_>XNP'[R%@P.&$TTK57_+SN!+LJ.K>O8<5&9E4;P L#3<%! M@;&7@R^-+'VD&>3>SK2?(1NR\*7U?
&64_Q3:+H) RTL<_^[7%N.%;C?T&I;?+92I?TM^## <,*K0 MQ^XP9E?\8"PEKX*LD"GR^ E,^LAWCV=?FW$BF M]Y4T0JVQE:P M)*?9VIH"B28)"P1H!$GTK]\3NA%
(,$F,,E[MSK5(HG'Z].F30]@%8.!'ON2W MK'[H 9"PS[3N$TTC'3N6 WH"+-L!$Q*HV\Q@D:^?$9W/"_@!.$W+!^8*,,(E M$A*41]L?
*2&T_[;V[Z_@^^&/T&B$[4;GQ5^*UC609Y*D=473T6:3>V:R0#DK M#=;_?0%W%_^&7S75WX_$RS9:N*]U(PS<-[ITFC>!(HV>#SM2_WJCR\EL^\4_
MHB?)=\./OI@J[#.^4DV9L=F^)$(S^T5P.=M\H\\^DKXV=8I0QNNR8#W'ZW?& MU^]XQ/6;*JXV]+['!=;FBN$)R"R_&',VFFTONY;52Y/G7R>R[S=CTLNEYQ[=_^/Z)B281S="/0CT90\
MJT0\JS*XJT7.BY_EOYL!0-E4^/02T6]PI MS9$N%YC3Q*HW6PWOV,>SCA-\LAU@(^G:+G\K=;Y]>5\7K=%FAX-A#-+J)@OUPJO]F@@4G^3/@>RV9&GL7AA_[G
MLX?.EWKOQ_0\9IXG4WO:R2RG["YY#T^4#_M5Y-N>,Y',91*RI!$);8BYNHYY M_-"S/%HAOJ;6.5&':8U0@?H?2I5_G'JODS5A.+JLK6&LC"./K<5*G8F['N>V M3GM
4[+G::ESY6H!5GE$]X672K4$U'].+[TH;U_)?;W]]_O&]/SI1F) M<,4T.+T^-"U]EN;0N&IW9XIJKC50B$98^@J+YB#(*ZSO3/4S1H?]*44]CT(/ M &):8/0G@QC11D;?D?K1M\[[SYW;PR_-
<:Q9I8:93RI_G%*>E\J3Y/FF5NG. ME/(P2753I_M$+EDO&KU_;@ZZWH4Y/9=<+CU,U+R77$4R>Z\%F04[PC,VNSM_ MV24>T^.Q[C/NOR_^8F-$]P7TFUKA(8R:76K: ?F*?Y6*I4*[M
MKE_EQ:,(-LL%-[GU_P)<<&,HN/GK\\?:Q^I-]Z8Q X/=*!I^;+[V &7/8<#U MP<[>@FA[666'L91(9.MOAI38G^/-2U0#C*KZ^_7QVX'Q^:35['^J32<;DBA= MZ[LUM/OI;U'YB2&79R\?
#A=#I;/5^/RZ^W@8]C^5KK\7FU-+A53YS@9(B#E4 M] S0]AR&(2U>0DQ7M'/R[Z^+GXW2W=7]MV+9WIADPHTN$QE*9Q4/33LTQ5]_M_M?
VMGYB"=M\K5\"?;Z!)7Z&PFGBH[4W^A?##N&?97U[6S(FT[];UO25F6SJ M^QI!,E.^W>24N5(1<^:&-SQ:6PG<7A9!CTT72KWN10IK"E]O=,Q(?ZW7/:-A M-=_HY\!1&*?
G+F*O5$L^]4H]AE_%MTA=H3]? 9HS$.X)XW:[(8 5P-H].B^) M9-C5<\+P('O)0DP2G8AG1F6"N#?IAFXT>\%$ZUG*U4%)-6P[VXF!I2[)+^^$ M'\@*F)1=,*)B1<-
"M<%*E:&YS8W)LKTQLVP?585>&ME)X-??9U6W>A1<_ET6 MD3)$;]^FUV-E4 2B;L0P8@6>G_A=C^'DRJ#"D/MZ1-US]@G!9>S.T$@@'5&9 MHFD :#/9_;F6>R@O_MH?V1I
IW8*._I)Z&']4Q?8;6$4Q3Z58/6.@3\>*$+7 MVL#J RJG@>\"*E?T;D7 WZJJ2EGK23[BO3?^0,GD?<=J=N"0L>P1 +) RW7A
MOX%G.3X5H'=C%MPKWXJUPNCQCNSNP*#WWHJ$LK.NI*=-05/NK*S<_/X7WS0_];Y9D< M=26JT:QD'O2T_MRA@RX5*I7]<4==0'[>$UC0).P^5[=;/M;$H\9+3-X'19\T MJ;9P0
3:+*#,+DA!/\ TBCOL>(+8$/ASY"Q&L\F2!%E-Z!BA277&L',3?T;_M(IO.X&."_R'$,],2,C=C1QM=1DP",B$T4T?-Y<6MT+;[(Z6G8ZI29&!K(,=" M1_XRI2+)?>52;>G 9WG_[]G[?
^%H9T9?+U4+4C(EVU2HZNLT06!;!;TKE$<; M'^!F$\DF$1.U_+FEX[[S7-^/')F58K54E0P.__7KK&6%1ZUR^[@:CX^^5% " MB$8;M+FV$3RR9_V3H![%OZK;I6K\KS3_JCS1DXX-
$&J3*L@'NFQP3XX4%6CP MN\%8T)"4VYMHVCVRY7_"I)#8'>?*+2E/=QC[7!/$\NL\V#.O;Z__/G3B6"@] MJ
/[9)1,11PKVMV($H,LVIG#7+KB3G6TKA/A"ZW;GN61$!NDBJ%4\7GA+1'[ MS<;;*'NS'#D!AMB'VSS^(4K^]=E=G-)/*8]]W"PFW$YAC6=@8V"!HP, :XAZ30V*/W#<'+R]:P_<,
M&46",7S]5&DY9WZ[?[>;]@ I38B 7^JPD]&PS\ &GIBL4RV.-7C0&Q:06H J M*1RMQBU(E.HT-XV,?2CW%JBO#:"GKNL%B$E)=1T^)51H^:;FBN<*@ ?]\F_#
M"0W@E^6]F73,J&,8L0S6-_W1"F=2E<-?#7*3\H(54&E=E_>D],!__2]_K?V\ M_'E7,;ZU-D;Y+&V7]^)_#7".I]6)C.^^%2N?V@3E4Y]&^1PJ-EH[Y9-(Y.#T
```

```
MTT>XFF+OO)I0,&8>IK5FNNS.86A6]#XJ*CWD'J%7?>P59^?-]1;18+@0%N]@W]_60>]JU#4NV=VW.0IUQ4!JA/H\P'=*A><3B] M.-] 5L]]M8=$E_W,?FREH"?
%+!""W3_A_VVDR/O2"D;M">E0ZZZ?N0S2)3 MFWA6/.#9[2-G.Q)/[.S8] N8D-?Y-=R@?>374.))^81G4@"B/M:;?7DC!SA! MGO""ZQ]IN.1W&BZ9W^L-VD=^K_-
['6GW!/BS5Y$78"8_K@?6]&^-VB3/$T'_MF0]C4YVO!WLX9_4PFZ/K^:!8G#2==O:HXL@>1?_.(_2:%_X6_>L';&(C"Z*CX@6 M+8^QKT\GP6DX5W6152\;=MMR?K4R#(Z:-+(P?
6MWC?,5UT1?NV[].G'/KO_I MMXQQS'CJ%AO4!&6+4@A?SM!J8S(_FRK?LKJ^^9;[.[41"9>_&1=8=P#7VF1= M.@M=D$HZ6V?%%?'&_9KU3SOHM/N_RC/R1C%["<)]N_9.I44^;GK\|
[1_E^22 M&]%E> :']EJRVJ6RL-(S];K=W+N*4_WSX_3JQ]7IW57E=F.];M%V!KC.X\IM MIZY\F@=!K^.I9WS^LA.7/%^V#-?2-)5C45+ZQ M6G&-?6.5!?
K&UO.ZYU"M+6NL_6X^KP3/VZO]^/S#^=LWW^W^5CZO$0I?[>D] MWS;<^MS W+/,Y+UUY6Q39!KF'K+'\K6.)R)O?N?S^UJD)8[O3&-S?63QA@;X MU--]\WN[.
[L+]LUO_L5<+K!SS&M?KL_MZ!G[W)()Y>3.:O9ZYF'5M:?RNBVF MOR0+G,[OM[^V?K^]G?V%YL1M/H/(@7TFK'WTS\NJ&45/>) :8,?IZ[@QPX?#GP,[F M-RKOE).3X]?6=W2P7-
_1KR-[_Z$1?KPYW=][O_GDQ@;V@@'R@>78LG'=<=$QV$<-3":5K" M/[+\INWZH3=J<$$QJ2C.MM"_OVX_&<6B^34H_MS?F"$$V%'3#82VK__W_]DO METIO!N;S[)=W__TEK'Y]
[^'+AV.O\>*O!%:HU70*+]'9ISN!;5!G_Z6/)9 ? M6C@[&A??*'XRJP'^IB,T-5^/!I#?N?8=#R!O"B\PX']M MT39LO>>Y32%0.OEZT#$"W?#04]D"Y@B&9%?@A#WZ7SF+' Q'R\%9?
DTW]'S* M.X)_Z(W0MQSA^SOZ\4-3P!;!,L*QYVY7:('Q0(PWNK7H(M4]T82U<+:Y%X*9 M1_^D?D5O[]#W- !*9>#P5;!]@VT[_#T-5I>@$WS-9NAYL(+ ?
SV[0"'B$R]S1;FA.ND5CTAE6V)>GPT^IG;X=W1V$ M"\_/!R*Q6A9 !YN*7B8(S_)G^ ' &>!\1 LO-OP>WML0MGO/N.%I5WBV#MBB M8/SS<'H$LR'PO1WXTR8*X>F,#IJV=N*8U1'G V
>QVF+.U7+F7=?YXYG:6=T M\#FG7=UXTQ!81;G,8R[2LTU;%MXI>%6]7M?K7L,*/+[;1Z)+]Z\-K-@/]#/# M"74\S8)N!<0,06'5#SN6:.DGP'"!
()EO&@!&Q#>CG[*S)@7H3=&W!X8$S!X M8&:V877]^_7P%*Y/?+8!+*[9P4O= 3[4LLP0E@>>;H8!,EX$+/Z)R@.@CWTA M;N$'Z-
VR#=B*"T_]",TVL6/@MG<6,K&8U2JHN@9(C(Z!ZP@,RT7PD!JX]P8X MN/"ZL%%"#O!+_+Q(8\A>E(GZX3X"\B=A@CNA7!26\"5(RSV/ L@DQ)*_<(6AD>I M$X"UP?
UIC%#AT^&A/4COERMDH3--2(QXT^B"[/.)D>.+2$P/H?+.H[H^_(76DO-U"42=;VPRW\EZ!-_ LLZ>F*0BR+PF):(NL&J[0!)@-P3 M'A
I<#ND52F5)/P1;&FRU#H6O[J)DEAX\MMA<Z;'HPZRQW]#]>/SP&!P)7 MTP\P"BL5F+3"$P&HD4"&-5%;@%,Q!1.D4 ^!'F&!;.ZKC;EA@-H-_PD/L_A% M26[HGDK)3JH2H PT45U
50,9BD72_3D-%MQT:?I6>+>Y-%VU-#UW[YC?E';5 MM' I#BUD$< P6"P>/X@FR"M0:Z58+.A'P)C>>:*-;!0/4XE?W3;N_= *%_X M?*T?67[@62#5#D'!97.%)*K\&$?FG8$H!18$PB=
WX,-!A/RW"'99EI^$\!" MX46RWH1K'P"*^$\I?Q$T!@G>))RV06L!/,!: F8,]\!& ELT0&>GN5I-V!PP M' U^%'%TQ7VN@5<;H(WK%P^VZ.MUV,B6%)G7%]^DL'S)@[,5G'<6(,8-?6!&
MIFB!N2',%.LBL2]L2]S!NH LDH-D< "OT]&!%KS1.^X]?.^Q< +62PH#&Q?( M?L'*KR>^X7F#WTYM( M@!/8'- M2$1T#S )8AFGO"JC4E/'RE#DO'85'K_!V;-@N*+-_M>?
_[6]#;JML,W7^B4( MZ#>PQ,\0+7=X=.^-_@4'&[_6R_KVMG2]F];=B #VV\$B!#D=4GU?(TAFFF$Y M>0QEJ8AS*(XE/1#&%88=YZG4O4EA3^'JCW_1[\/ZZ
M!SI*\XU^;G0%X_3<1>R5]I)/O5*/X5=QK$ %"OY\!6C.0#BH,K?;#0$W"M;N MT7E)),.NGA.&U6T;AY@D.A'/C,H$<6_2#7V.JMS-UQ/MG0U*NZWG"MV*%;HS ML+
[+D2X')Z/SR13TCQ\/([4%/E=J2Z2VH= 'B]")%+=# !0X$!B8^G5(D]F] M 07N$ U),M(^NKY>!SO,!G@=@)[<$@ESWI=:D($&HU(Q^&VDZRFO,@)LL:;2 M<6WT/J .=N]B)(K8#
[*\2S#$06M!Q1/C6WZT+?HKVEC*#1WKCR:9GB:H-CA] MWJ<,(7:]=+LNGH,+TLT,P:1TT!T#/_)1%P2DG(@&:#KP5D!N:8=@O8>=H;= M#J^'Y457MZV?H6621BI]"!H53^"*"
L:N_1*WKK)NR ' 'FW8ET\P[NE=UWE MS)#:&[O_NZB1 03L86@(V' L0#0#?E] ML&VDO^\N:--@V@?DW==;PB3W SJL Y]1<>?:0 V&9]G]A%Z)#K;XK%FD:>.I
M:X".H(O"@++V'\*;NR(&CCXD5, ?$7+BNZ ^0BS?LA$SN$K2YZ%9 MVB\3)@]&K 1>5XT1"4P2))XL..<'FE]SK$/W2D_<6K(OVE.-;I@1^X($6K-9"" 3>GY-(#^>T#.Z(G# "/8B 9F.BF
>8L'0Q*A -U)KSS MC-/PX<88TB'*#C]U O(N&[8FB8!S)Y%OP)9\X021H1[C%4F12 SM>9L18GF* MQ>CNG=PRT2.#/^#@'7D/-'D/V,B-HGMQ+9UZ2>(.T]E$V"B7QI%H"J$1*I&$
M\!N7>("&;&T,+2$GTHNK MPJP2B2P7D5>D7 HQZ7'X-)3N5Q3-29>%8HS,-"25;ZA2M-$:'0Z$CR+2@19Y MW?U8G<>8,/#O;YIQ4=
MG[7)F6"GCG;1#%QDM,!DBVE)D(I.&NB:1O4"EKH#Z>TG8F*4'Q(=O3YP])%9 M$OU"F28%Y+J@P:&K76O(IX -WPG;[471-MA'V,+R9Q(:OGR]C+JZJ 2:H=0F M@-
EC@DZWAR5KOA[ZK+EGB=.>BQD^%FMB&=95/H3SVIER3LA<1\"D8SWXP$$<>N#.B1T)B*/DMNW>HRH.=-$*X2H(2J^C>\AFJE(P+3+1#;P%#97:@#JCX3/%
M@0H;TAM'Q@T3LV_9=?)&6NLGT6$,XH)Q3PHA[[PC/[U@],!*Z5B"S M*X*!I-N#8CF1AGP,IG?0/Q.@HYDQNB[42I?"0[>IT8YJL\T>E:*5BYB\^Z_O M!=O;U\V.,$-;7+2R5QO^5
CT6J=KL*.M15P,>)@JQ_[4VJTUA?'PPZQ$)6^\ M+.B5N"Z>BGQ=(8&(7@3_I-JRJ1&163-6WB[N;P-"9"GUF+T,))C/U ;(!VX$ M(&^7$Q5FET"2+_[:W3D855OVAR(X)$
9LDQ4"2;,FXE4N:%,9.,Y8,^S;+V< MZ==(,T!'KR,G2UJSCV6)EM/TR NA#_$<;1+/@56KV#\1Z+N-B!D9LXSTV" T9SG(.<\SY3S')'>3[YR!U/C
MX#2"CJ^SH1(%"PR7Z+C'8X:H(NQ[6!OEM$*>)1G#Z3PGW&F>=Q=\:K25B;Q%_&(6VVCJ[C\"'?]N\4^TPS MHOUI&\L4TVUE7OQ5*E1JU7'S22@"-
T10I5D(JA(15&43">KNH'WZX2!LB#MK MA015B0BJL@R"FK95PQ!!50JU@](X@L*8@X^Y;!8 TI=.$@QAH9'7XX83OJPT
MHJ"$.\S/DGVUKH1ZZ**U8G[VZ\M#HQO^_'R^=_K=2GL0[GGAXR^,=OPX>KL7-D=,K'HHE'=YC[O3 X4UK^V8P_KW2 MV,%4_<4KF$$5:HB(UU,(]74P3.O#E1MNPXUF./6+]?
TS+C&=7,_:SL,3GY6 M+L*O]^WXK!/*\!C1Q_:B$R)Y%W%/]B] MBDG>7+X+;(K23N\P81BKG3@7_($J=^&N#['LY/6MRU4N>9%#+LA%.EC*S3T] MVF^TS/<-PRE%-% ?
V%A!E0E/HH#LOIBSRE 5)V+DU;+G;1K!GS=QZS(#&_L*)>ZZJYD.5RJDR5N!D)IKSW!29@"WPQUO5S MJY1,Z O2A\+YA!,4O-UD^U4D1%:%V7U]B8G=)E67\<[;H<5NGIAYYZZ-P?
7YHJP'^N-5B*XB5\5*- M9%5I;$*:'Q]D'/U,YUW@TU>BK?(8J6-!=%OUY&TM8(3&DAG\*8N@LJ-?JNA# MX&([ JQ<&2\VTZ[L,3&68ZIRA17K3:K3 NV7(D"^?^CZ04*(EHJU4HV$J/Q7
MM#Y6+%^T$HVZTYK]S;U[TW%#'Q2-FWOXMG_AB/@*1, IO"F=OU$N6<7[^_N[ MNT9LI+?A5VVLC9H4;9[L$7\T3C*E= DM@%(M_I>R!1ZU^Y2 +Q6G]=2-$_#E MG=(D
4\%'52:J.IG:%:4JLN)6_)@^F(O]'JN/_PMULL L-KTA(]*8%0OV%)=H^G>6HX( MP.;3W5Y@=:U?K(4#K)T0%O7?D'MLJ_)2VJR)#H'LPU!0W[_ .5 MWNL]MQ=*O3XJ^K0<'SLFPPL;V
T2-51]^8C'XAAVW[>B(R 0=-,(#(U[/ 6Q MLHL-&=_=O-VN5*O%@?1H/G)&O2QM15\7-65$*J#F@WP,F%>F]G-Z?@0L$WY) M=5/P4E*=!]&G,?ZP5BWP*$T[50Q%<,WYI
"#>*%TTPO;:D-]K4F6#V7^4F(P M[!W.*VKN9=C_.5QI![4N\*0U:#4X!)=+YNJQ/'NB?,XXO3[Z@'6F2. MNZT("-7B:FIRP)I;9(M8ZPA8&T'R6--F]/H[^AEP,A"$6=S
M=%Y_A677@(2FA9WCN.N$SZ>-?(974TQ0?,XF%;SF) "L1BMHMS_]KD>A+6]MXVI M4V:>I$O,EALQ#VWAT6&=&;,EWLYTT*/3)19ST.^^=>]JW:,#HS9];M3\#WID
M'L4\#OKQ4:&#L3)D?'?Y9;O!)-8=V1!CPAR6 QO.WSWWWQ_NJ] M73J/6-OGL=B?Q-A&;VR:C(-Y\+)'9XN-Y&(Y,]F8#H'[>8? .78(W,\[!.8= M
G_'R$I%N^ZYCN^BM,\#*^L"O.H:6)Q36 M]]%]=FG0')J/Y)=*E.+"32$"@?)GGFJ91X[^:(X3?+;ZB/"-+MS#]/L%JOE
MHG2HT+\>K8O2L/#H1HU41K]^.WYX7W1*YQ\V(4X#JFMU&WNRJ'^-5&*GVOZ M%CN?3(S16=4+"-3,Y_-$>%A^F/VD)C-MSB8S!:)BPZZC+81P&&.==G1"RF"X2HSTN$B/?
-3(2D]GPYPE' M0ZF(EBDFT-TC8CGZF%@.-UZT7BK+Q;\MIA?[$]$_Z='$1 MO>&"@"GPVI@[%KB.,&S]_YY>_K\"-CQJAH'A"'S%_[W^]/]>:B-#1H3"R=$B M?1[1(DW1;T0M(U"]
').]M/1B'FX&*'23X[]+#IQT-T6NGEX'MKFSQ@(USIPN5R<7G%2K3 M\E#9LP^5E5<4*IM2L^M>5_ZQ$;&R1VALI4>W)]BO568O,*ZM*&0V MY8%_N>V5WHNN?>_>;D3,
[#$'/O_H:&:XK*(/^R*T/%JV\;)AC:-E622WV M!/%67&KH;$H>=]J_/KE]?'*_'^RM9_#L,4SMT9D ^[6QF0 YBUDW)_=4;LP-
M=G4_HR;0R8H"=!+O(PO%NH)Q'1Y%=+@]/EQ;'NX3_."&K\D6N/SNA$])Q:S:Y/\G2E M##Z:;T" %X#,;D4!?0,X7\2V.5A@==%[-L7^[UW/-N_1&Z9TPP ]!I$IR=,I
MT0]4X%$Y!9S&@D!9:6=E>J2#Y5.%/PX"P6@MKLUIXA2=0*<0SHD)@(XEI6$+ M\##HN)[T@OJ%U*P6V2$SL[8=X(#S:*1O76HQK]-#) MR$$TP"+9X!36( >4"1Y'.) '&R_"O>MV8]
.<:RT B4,V%:3M@#Q0^G;W,<*;-C(MB02@=*MFK[S(_626>1.A4P MT;W2_J-TJFO0(T C9*8@><*0+N7^4_U0%._*-_NQO:A@8A56;8A5J5&:U+N;
MMY>O1VXF2XLJU;:+>]NPMV$M:@K(![2G1^<>E8L3>FL@!2D&CO-C "1JZT!# MN[,.]SC5U\@/SN*'D@>Z\*.-UZW?&YYY!+\=O1[P/P=7O&%WZI!&&[5=\:L? M[/=
[O>O/<=7U61HKDQLCI7"2Y3]0I/%4(LEZ:KJ=#I#7M$'!6*!@ MC(.^ZLBITO0)9<-2N,@ 04TWH8)S7] M']G31?-BG/AJZJ,#"K!OV"Q7I,PQ(_VH0'X>4%:Y-U#6T(CUI EN,72%:_$Z
M]/>9\6!UPZZBF^]GIRWO\.?IP45MD^@&]_)O:BL#E#2M6V<")=5&4Q)''^-1 M/,/FIH_*O*'F#OCL;P3=/&%!4:-<,"A@&[HBS:A=+J:I1),%R50$9BV56RTV M'4?
3+AH"XVN/^)6)R,E:JDG2NW?O1N&UW>Z/1B ^?>[$3:WJCA,",@:Q.#'( MDD+!DK6B@8T-T/#CE>OJ>&&9DI$\.VB(3"JCR:3GU#AC;HV)Y<2ZBWI]G_1[ MW;,?
^_;G]\^!6N*=#9#+U!ETM3&M#B;FSPW23G6$OES=;/HA>T41T,/W[]:' M<_?@W5'S&1!08FMI"JI,W2QC# 6-[*RG0H-?C1B7<[+'*^K1
M[#LYNX\L(7BA\#&/+#H=+79>15T:DH'YX2?B=.2QWJ3XK6=J"970'"<8+\|: M\-RC\.^/C:_UBTYL(P[M;;Q/:K3W;U[$?I-+8'KT?L:BP=9&]IB10P MK28_CBE-
/'_6LSWT$$RZZ^\|U_<)*ZLXU^!OS[ZK^^?E=U;Z7,<>8@SS$@]N M6O5UK#Y2':W%JJ/#B:1AER(;=T)OXU;Y H_03$H#]_4*Y6&X"K7DEW6T>[W__M]MO-
WT%UX)9Z#-3DJRFA7^*YSD//G*PE3+B0]?@0#\.N.OW5WLV]DXM3[TOW M[N V'E)UF$F98X\UG!I=V)P^KXH'U9L#[/&+];'LO(CM]QM"B*A!Q] M/#"61,54]X
M0C@9,;AWX\IZV.D(Q;4X[OSKJ +!3E=Q\LT[KU?_%)Z_]X>SB1YW\FHW2SSS M>?BM1PJ;P3/7?>LA$?_4)L4_1RBU4\8_]6GCG]H4\<^WL\8_ET>'Y0/[9T_< M'I_W:LN*?RZ(&.?
1%FE,_%.?*O[YE.CHV^FCH\NCC_/B6='8-]Z??FH]ECZF MCXLNAC)J\W#33YYK,B$,4QX?%UW>B1X>'9U^_>>=^:T5-]QX-V7 97R494'' M-W5BPY*CH[N3HJ/+.]-B\?)SO?
W.O;D5"XB.+NAIK^6$Z*CRSO- MD_#.:?^M:/[_=W"XE.KJ@\YV+=CC&\LNCHQL#_/R:766E-RRYO=54=UB<&R>- M_J=W9S]+:][6:O:+_>A:PVG"EUE)@TMN9S75 8??
2S\N;YNUYGEUS=M8S7S M>X^N/9RI?=68QA!Y$ZM1/'^3P'^.K7'*I41KG.?4$V>C]8MD]A7RW_(4@W63 M;7#FT/\FU?,F1263>]X@IZ+Q0Y(WOMU[7Y']9@#
<[$XC,W3XT$;H34KTR>0G M">") !.V5^P5Y4#>2ED-Y*5_/4*>UA,C>R;$0P[^Z9GW5?\?$9BB,QI3 MM4]FS]!N1HW2K6R7:_&_,@3GM' /2,\90EW2[,EHRC!^=-K,+3^.XM.6>TAD
MP ".XK9R*I-O&<=]TB]]Z?V\:2>[^G_,WE9!MDU"$,<>_X3M9>;VS9T$'I^E M-58_'I_F4WYY^7TZ"QS W&M7F9#E4=X9D^>1D?(S:T>/:^#3W_OO[?;2VGA,(HL
M4CN>&UG,*0]L'LD_B8X@CV[,;)2XHTV;N%,?V[9AR1I-9__CI\.O??^^:RZ^ M('J!6LW^HWT",R3PZ-@ECT8EA-XCFDO%KOKEGO&7@X]?1/_KMV_%Q@+[3"WR M<.
<28IOHJ!_66C!S1W9 G**N79M#7?O4>1W3U+7OS9S7L5S"W-TK^;_"V]W/ M'^*4Y\NQZ)EOHL<"*7;JX.$3LSVTQ^=S',^0S[%>]V7WQWMK627O MBZ2%>00:GYS?
49V0W['<$_8_W>_^N*H>E<+VO),\%GB0<^G+,SK38W+$>(32 M49N8Z;'Q!;NU9![G5I3]'F\YJ*EXG M_QR3Z!*X<:K+"UT 7^D!>(&'@B[%G0S__[:KXF@>M[>_=JP7VS*0?
S9^.O<#81V0'',4NG-@ MXO[S_M[Z]O]MO#M[7K#U^_EU_\%2- 9PQ$I[BQ87! @B+(C=W#A:-=- ,7>49I+ZL1 MB1J; 8*D>4O3B.4L4P.'3+0LFJWB(AMK@J 3U*LD&K8-
0G%Z5B:8^3]OA?HVX@ MZF2LAHWZ1:I*^ 8UK(O6*4C6.\L,#3L1EKA@-"C-K'+XX6OU]._FKP]Q.M]U M"GL2IY,YA,Q+0_$ZJ_"IS1 M(\PZ#L-NBV.&1%R"0!+K0J779Y6W-
_^T;L[1DLZDTB0">P@ZQ93I$)Y,N?/# MYU+(>J9X6=(NN8Q(>ZJ"%TX?&Y;;2JHU!_/*[ZG)6DC!IU!2= M*6/UTC8A(&:X"VQ/X#O*_*PP]>'+LX1;P9 6#?"ZY;_-8/OZT+/ M%_
E>Z6]^N&/9*>$;4OIM(0GTP^"7+9]D7SM1EZ&,5(T56Y6!Q2+=?C8+&+ MS)!B+8F5:JH+^AV8ECK.T,H*_C]=PM-_O@B:0_!7@M%#>^2@*0K\IC7HU])9A M>3I.+1-33"
<_FL@!AX%NC! P"+8PE8 Y 3"^(!2E=:&PVX/&Y[OW;]]6/F53 M&!$8J.6$NZG$\0*0M0396RX^.C]N? &))J)3!V]T(H[7>EG?WOY+T^'__@1Z5] TL*#+ MVVZX0>!V7^MO;0-
HN@1[\5W;,M4VH^]K9&@'I(3B+,V>8:(\H^.FV9H]HZG^ M3K^AZ=JVT?,!$/6O-W"P9M#!K17_R++G T^M <<=8+Q?839P>VE4VZ)%3YCJ MB>27F.Q5SI(/O5*/89? M_?
DJ,/$_'OX'T0/_"VC.0+@GC-OMAH!+!&OWZ+PDDF%7SPG#BE;'(2:)3L0S MT>@&^6LVVB6.LY23B]'K3*SQ)('TFH,CMN4(]5;DG]>?_RT6]Z(2H=- =+7R MCGYF.$8[*HZ@\?9'EM\,?
1\%(.H8=<>P^[Y%'H,3"Y.E,$'P,!I0B[^Y$GYH M6P_OGF].*\?O5=.[^X.3T\U]^.W]6OCD[/W^DG M%U=?X9_;'R\N/N#?US?UF^.SX_.;Z_S 5@/\M=L5F@R!4D!3)=#Q;+9/H>$!
MOP:E_DK@]&G,"#X!I0Z>WOY$WCI9#@5""O7.;=MU;U'-BM>2%5!4;"7'&'>% M01F"ZKU&2X!=X8%TTJB_LVV!5+6Q_J#K W;\CL\_QE_#6;R':I^UZ(9>L / M8+L?X7_;/#
[Y"L5E5Z\W*;VX='!0W4& 1\"F,@N3'Z$'W$-!JKFAI\,[/ Q] M-(1MB18@LNWB?&HJPGC L)PA'9<-3&L$93? 0>-JAC2NP#\#^%L1)^NY?LS( M7.9> )?'+*U CS5PVKGP?8W&98MVGW\
<>FH=U&7M:$CW:/Q'9^GQ">*A84B3 M; 8\3_@N<#U*DFP9E,_=@*W 2S%>[8F6#>!3(RZ%B]3& WJ,RVF?^&+H06Z1G_PHW9H MF9A=.00;W.UN!@P]%[,*@&P&OP""0\0-
0L(EA8,_1OB:AC_TN6W=@LFN/L21 M[G3LO@7LQ/!T\D3@Q[V.!_0"YW;-W]C]0O*X:,ZZ*?RF9S4$71RW\8.#UD!/ M1*[>N?:=T&\=]YZO4NCPOSW+O_4+6HATB /J MB4G0]:'-
(96[G@0:@6@:1$L8X2=76GP3DWG&V*VTV4&R4BG#2)>FU6H)NA;$ MNC#REJ;Z@I9*KP+N 5[<-7!D#48*W M0$QA-)[(* :
('(TRKPEJRC=!'NG%2T@61R#R0=&3^,)F!QT.._K%$(I@I= V M<4FP"_K#V#"1A'P"U$FP0V8>-'?ZS@"#/$3V9/BDPGUW0]WOT+)-()56B%S M$W<6"#7@"'#N[%:@/FUQIC?Y!&
(]$C@#DD%TV)R^(ZG^$J2:?KJCDTI:JK_6 MK_"G)_Q3=1D0^-3OY0/ZWNNYZ[!:K,-&=Y&%HY*V'Z+T$4JJY[R1(]&4:2,E M"@%7=N"]_8G"0 S(\*X!(M!U[+YF1#70Y%[!-"IT[P$/I-
:^H)+ +_C>JF)D MHE;;N"_H]_"42_3"3D* Q 7A+24SQ9KASR:<9MBCY8VQL&KHHX+;2\7<+,)B ML&$U*9J2/899N"!5-RVO&7;1B]X4>3N@%9D"%UX;%+U?=/Y:KN&O+IT-V'T/
M;76,!PNPVT'@N%1V\^Y&?VNY/5"^NT9!/W6:!>!C1MMQ 8RF?F0$_.D.7&Z# MM&6UD*DX"=U77.H0M@"7V;$,_*IT4 /->W M#=>2T@16"))+2AZ16O-( &-! M#@7?
1;P..SZ4#O:X$CJY%OK.<8FCHU/]DK;4%"'YJGS>!2Y#O2.T$JVQ#R!> M.(GLNSW\]&"W,&:)KO#P?=0ZXA1]60Z!#KP=$'DHJXWD;Q%_^/2A'PC03J]W MZCM)F+4DS!??3J_3Z\DU
+Z_0V"9G.2#_QWYTRQ<#!WPIO+"YY"SA2P1U"34 M9#9X%QO-#;\*#?F)$1<&^EC9K3?4)5'W'5.5>JR@@%K'EC+I18DZ0KK,406S M%'3(MQP7?@3:?#=TW&TPAUW;!0-
>Y:>SZ:VYK!##ISW/$F"V];$+S';4)^8# M:-_ DXZ=-@#HZ5O9+6)>Q>XCBW/.#$S,MY*J.MJ( MP#M##P"\94Q1P*2@@50\_\!_(.N%U1MNZ)@R;5)^Q0Z:K@O DF'IB12,2;BB
M)Q!@D+V8YV&CF436ET7F&!4AX'JPCCI ]'QH47,@>30I8Q$LB$1+H7Z/Y*5$ M YT=FE:6%Z*(;;$#BB%APTT6Z%+9K7H-?A_AR!1&T-D9<;Z@F[-7)KEO7H>4 M>BR3?
=B!$=05SYNND7.-79(>&3 N[B%6R"AD8R3 M?!5(>H$'Y DW@!(AD,X25*4EJ.J0HBEY#Y5'#6ZB$0:NY'BFY5-X5#HG(X#! M[L3:)8Q(\O-@Y^*6>V' &04X8M#'DA"X4/
47GU7PRP$C,RBV4O@XX8I":&M M%$8'D&QZ85O?.CT_>HD.$+,?LQ4+;S@6) .4H1>V,3D,C3!?<9F1]!M-LP[9""R>1KQ59*2NA15R#?)"<$C.2(\ MLBR M[Y 2#'29)#2JDQ][
PV\FFW/Z.HVN[&.O!WM;]%]>:(//T;%H*!?>FXKLI?/ MA&DU+34" M]P)( /P),DT=WHQ0S&#JXH5T(^8E!CY+9#J4FW\!*W!WN&W=AP M]_$G+)%;F.>
43FI/M#+3C]NEZJHIQ)+E*^WO*2N%-](NFATE^+R1 ]32'UE M8T]BT^2H]H0F%332JDSV71HV\6X;O6^HXZ'F)KR ?'DQ;U*,++]-*^_*.B;M
MJUS,T[[FE_95+N9I7WG:U[/A(BB351.VGM43F."EQ=?,OCY$&NCSX:)&G.XNVW=]YKX,J];*F[__+=8+.W\Z+5? MZ(8=_.^+Z")*\M\O%WL/+UYM'#TLG9B7T.W[W8%OIK:!
<3U!U:0E2SM&'88OM9L>PG((6 M))VQ?O/DCI1WLB4QOR'M-05+Y4=(I=-H[+KDHN- .N8WD+#V1%ME3.'G'6'< M]6639U#,=7HK.RQ!A=\^/"K12&]-_E6IT.<-UU3)+ :HV";/4R&-
'9XD&X%T M?S\(3?R&PN;1@MOT@^UXR4'4Z(P;V!!]S8EJV#M=A+>B:QE^03/8 O?2SDCV M\Y'^09Z+9@BHZ/9!"L!!8'J'6H$R?^IG'V774/R%V??A+"A*Z/<=TW.[G!]T
M=G2]PW"0:+'@O1:Z;/@IR]2B;!/+D#D5Y&9DVU XIMOLDU7$]@GBK>&YAFGW MT[ #-'H# ? YTP%V[5L-RG "4!3D !PF?TC?,($%,%Y;0#'-[8]VY6,(H D[
MMT#Z6=S(Y;2]C0E6.E(G8*4"U^#TW2B3#P#,?O@FR% M_Q74$+N'=F4*8L8S'+C$A(Z2&;2C'8U).?1#SIT#>K-,ZHQ. MHRZ+#4S("ZD3GMQXO]OKX.IRS]29<9 :P>KSC#:%0\@1
Z2HJ=RED&@5+S; M8)$#![."R&HO'53U3M@UV!:.EZ6+QH5F<%S8?8>6!>QUT6W=@XM$CR4#./0> MNL;10X
NV"ZP!$QI,91O6J;01/9RXD:Q:\GIPMB;3TL9S4YN&*]:W'B"W+7D^C$X ,,>%-U! M*!(BI F&'KJ1@?6[1/39,J6@T_JU*NC$Y(X,HO 7,PSL6$:6E_D*A)9'"6=]
M#1D0D3P(@FW*6B/61UYHZ\Z5R70*= [K\VOP7E":]1U:!_)VX)$>RI,>\V5?$K[#!\J<9A3W9=S65],7= :/" M_V?;(>7KAZQ:KB@Y(YRJ("0N7V$D*U>Z"&3,-W M?
\E!7(_C4Q'^MAI8MDH_D&#@W;9,P1X]3_KG!:4G]@P.;:@&7@.CRJ)%29K! M*A@%N>/6*H!P"O;Q$YS9(M"E.8MRLJ'W;*.9Q/3>LU+N/9NC]ZR4>\]R[]G" MN,AC/#OS8RE9/J)RTD?
T:E[NA]7N3!Y)DIK2!@C!CM"XO09 M]%C$0X6ZO)F MV&0P)MI9L9-.$6?"9M]R6V"7H/M/>!Z;^O)!^/8E)>GX +5-+4 ^>PX8 2U M;;
<1VI8CDS@=W_()ZN#>E:XY=LB1&>:+Q,)QCDJ< $.IB=2:6,!^/?5N86.2$HN8KN)QYGY1A1B*X M9,CP4A2&(K&F_W"IL)(XY-?+)$1P7,Y(Q+RPAQ@/$A%%]RQ?H0VRC,"-
OX,N=%=A#JTLE6*S!6>/)ZOY>I^^K<[GMRWHZ3G-.X)E&1+62T+; .]%)M M^SXH5;N&&4I@+L+ M40 W^I#6P1VM\E!K>1[J2A.# /\:)>%1MDZ4L94L7>=&TTJ]4UD]I*.%7@N+
M/Y-I>2IMDDUQG+#C.A9E.BHG;E1B[R9Z;2U* /0C0K081NH N[HGV4+ M/-2\U$)2SV2F3>O(ZK=[RS:Y4IQ+R:1+GG+KXK0EQ]5MT(MA(33696,MK1L&
MF/0ZXD'D]Y2ME$242G-3R36(5NZ+<&^07SQ9ZZZH=TP6 ,0E/YEAQPF%PYWV523T0?RD0 H*/DJE[2=" 5&&'B$ =G4T6V Q4)RW2JK.PDM;U[
MSC'DOH2RRQH&>;@5@199$P(JL!NP&+J5J#)/5^EDE$2FZ@"CVMY(CD=EO(F, M,&7VX.,MRZ;,3/UTH&X9+]61%[8UKEN&@[95$EADL'S>N<;F?:[)K2 P2;)N M=BTD?
NDDVSHYJI/Z'S?VH09FIXYNXY;_QHL'FMUSWFPY!%K A(\GK@NN^J#5TK>H2IVZIT7F MJ7CH&,AF7>U.^E&\_NS:C:>X>0*U%";DT#9,N2T0C M<&ZYFKC6,:=*'G.:8\RIDL>I'!"
[@EBDM_+2F#EE!=@! MJ6<;?3]NXB&KSJB^PXG2QDC+]D(J.4R\,I4A5L \)+:!4!!EY:AGX@Z:1TTN%!==@0H-K*[FO\S-+I8TDAO:AH>2%0X]0C?' \I
MH/7)C4SYN8*.PML/HC]="J$[T=]MVW*I#-'%5IU4&!HZ;?FUMI4.5[V,[%,^ M?&6B5JM36'9L4A!Z]'=GEUCW%F*?[)#J:IH&6*6HR,NH'IE#7.&C@4W(I3=D M7$7M:K!B-
V&Z5#$;$&UB_!%H'-C3"XN1_+#1M8(@CD"AY0:+J$'&: "R>6#H M]Q[^TB&;SL5!ZE'I(#RD#9N-:(!0< RT*K):4@_H7.XE)SND[?7 ?;":<5<=
M0]97JX[.P"A$;XD\T!//PC\9%'U+VG2:M.G*"8LN8=#)]F8) M>TX&1Q'*GB Q@[<[307835!A",<2(.AY7&Z>'2)J8SI$[!7GTR%BA4IA5MRM M@08BCY-:DN8Q?U7WN>J#>
```

```
[D^N%)]$/&O)74_T@V"TK11R"1K4-54".J(J5+O M[;_7)B>>9'>Y5&_5!]^;;GT1*5C)SA;&<*H^]628B,.A!TI2R0Y>&%SEKR(6 M<>9,Z8 %$:N%H):BZH7#/FS];?
0PR6A.Y>=XA*||*0T1W*.O$5Z_Y,+99::> MSC>) T=H@8S7ZDU*PT31?PEZ2%3D<2S'$BT[E6-3<4I9%)[H&9Y2FKE 'W18 ME_M!)">!I2>SP(]0/T!SA;7@^$QZH)0UL?M%">M M)
[OA1$MB@K- ?G KXY#^&+@I3*0:GA#.X|%F&H(#5A^.W:*O<$Z4+4PN?L+0 MB]NE=B"F:D&LQ@;A1VI"4<;TJ/M$EQ"7A^)@.U+ROW*/4>J7D!I&
U1F93.6F#Y&'Z>9]^B/82H8\W0[/Z7#19 M)9? S]N<[, 6+(>%8!W:F]U7 [PTM)0H$ P[_A&:;7Z* M!WHE)GCE"TJCO[9IX&.J^+;2]!6-WX.2(;,F%8D($./^7DWGKKX>+ZN#?'U
M03[,K?AGX]WZP)AV=A1E;%*F$VI98D9*%#\E4G23/13Q'A)SW;$A5\1,8ERH M.9_ ,;T0F\:0$R8JWTR*,2V),]5[BNIQU$M;AH5CZS#]$=-J#(\FT*=$(7X;
MG2V>5H#L#NLTYSYN]) ^2%= M7FY23N8^F[4.L>_F(?8YAMAW\Q![F)_/ERD\==7EB[:1S42>X/5GHT^BZ]" M$RR*QU,D?\+ H&F&.LY%UV=X.;:JH'HX4M9\A
MSE/L8_P(PUPFYMLF'M2HR6H3& OE0I)N6+\^U&_<'ABR^Z5J0)>-3-)C&$]OT(?U.8$9QK/6A=EF@W6L\_3":<)M8+-(L MDR,K>4-HMD:3=W--:47-
;.0D]XGD9R6=7[;5M60H6:K@D5K=Z).GBV:2\P"Q MKN"D_)D8"R35&^IF$>NAVXS=OMMYBZKQVZ7;0IZ?KG@G5E@I5M=UE407<85L93X@*+9N*4 M*+94R-|;N1TI3HC
#XPEK92SV MT!F^[S8YF2TJ++GC$IBH5SOH!_#.%!MI8EC#\A-GH'&3;!#3V)IFFPJ;78\K M=4Q$"OR:.SLGWJ"\CE>\C/+XI5XE_99$-@Y@/T(<:\.LDN*X;EY,XR@4#WST
MT8BXQ]Q&/!%LQ6_XG2CFKTB/HT%IMR31FR[IC7$K2*=6CD%3HCA0N15VKYN M=ERJZZ&'MGL>CKIK:UW7%+8ZTQ =L%$SCX2G5(7X@%RP@_EVRQ,\XM-#ODHC M?
@MQIMR=BW58W,8C^A#L'3E8KQ52-SO3PL)!Q_1W- IW93AF1T&O2^AU@EYZ M254>&X9.V0^>>5"1]H=&&4/"1Y/K;"O2V:[8V8T^\8O(7,L5MM5EC5#AJN5S
MF(+&27;PON/=/4?&>08/=7S]V,%KE#$KC-)5B^7*!I_A_+RLYE[C&::0QN(P/FC'<-1S@V [_E>:,76>X\4+@!^ZS\#OO\CWY( MENCOL-<_YKC7:5E
EE/!:S>VRL7=0KFR7RA7JR^'V<2$#46<(Y*XNI*XK]7F M,G&;P84XUIM]C,G?D7"9YH=9"^; ; P3R'IK^PG&]R!5%(JM3]&)/BIJ\=*
M#VM>8*$)PT.G#_EKHO]$P=W(Q[C^6(6>FOI/7 M@EIQ%I03EC-"$VV![L2".5JY4#[(/X5<=A2H5PJK14\Q?W:&L%S,
4@'=S,5U)BH,H[E)Y,TV&D1/_725T%8WJE2G8<;@-0=MO$L>;\GC+7F\)8^W_)Y1A1R8 M/-[R:(]_I,!?V]_<@$6U4"H>;"[X6Z5">3?
3Q[TA(9=AU2F/N,J%@[W,^[TB>/:'Z#V/N:S$]5R>SI_W7(,.I<)>[?>.NI0* MU=WJ[QIWV=_+PRYK[6HO%0NU8J9@WPQO^_S0L%O,-"]^+S0<5#87!_,,O)3S
MN,OSZNZH/!M4!WN4Z'3]#.J3EGY>\P0^=3#)%N1Q8T;!,RZI \M_./&3#6 < MI?A 9<M=G!/NPENC!N91!:&#P:DN!Z?$B I"3540%M341["L[3Y. M78'7>+!!W0RITM^(P*+1FY[[
PM_HY$65 D.N^X9GFQ+Y+9:O@AP"X:3&MOI M-W%F!_5$]Q0NZ.F\+'@MR9%+TM4T4.Y8&HKTC_%AV6,_T:V;FAY'4Y62[?&' M^O'[\6187"N:P6/@%-
VX)0$\UTY,4N)6TO!AU_)YYHY:[A$#4/7! :C:(P:@ M)@:?XJ/ <-XBL<)14B&=9*71!LQS!1;&< N>K9!KY:XI5^X]SC]N)":29OF2*KIPM5_&]W>FR,=7@>GPA.:!MV..:O:@&ZPU;P;[!R[
MP5;S;K#38W@PRIF%F+P;[/K92RKBI+WCB!-WT*FG>']N.ZT8^.B0VLE#2@OH M6*=2(I[LJ"';J:1L)UKC/Y6=XB1C2IM@3.G3&U-I_<,6[4@W=%NLWN*$0Z'& M#SBJXWX$&?
RP0=P2YVW:0FE5AEP+M@FL2;_'(2"-ZM"P$868;)!3U0:&89PSGP*Q/QO!P*E:DLPQE$3- IZH1JT6$O09Y MJ@>9?0\V(\>V7-I@X+=*Y>
(&IP=7:VN8'IQU(8=A83E)787'3I#K+YB+'60F MN:V(I>[NKQ,T6Y6#S,LQYD8L"I+]:8!87&+P-"0]0O_\['@"?H5][6E8[);M M^OY+GNR-
PW6E^Z<9>C1598.S)G_KA.&GI,IN_.:WID]_>XZ)PK7-Z<^2S:/2 M6<*9YEZ>&[KI^;%[Q4P5_;?"P5:U]#1"6-4]F&=^\-;>1(_CZ/V/2A'>G#!/ M5M0TC[&L:XQE8]JRY"&6-
=YG'F)Y9GO-0RQY("$')@^QS.@KK^QFJO^;$::H M%6>/4JP-\%OES>YZ/Z1!;$R,);J%,IERX=PJLT_WJJ(7Y6R#?_G1BZD!60I> M,GI*#Z^VVE#*^D0']_>FC(
M)SQ8V,O.%%A9@+!P4)X2H,6'"(>*W]>;.;_# M:" -VL6^'*E=U3ZMRD:P8*QM5ZL>D2'_U51]=3@+)RFI^+5>=Q[M4' J=K0 M/-?0;[95];OL?FOW*4D/&QWY/MA_[*
[SR/>2(M^%&AYUN+-?T"]]$ZFW;O8=E_8[K!8 GLCF[W'._T8$,&N,B: M?*!E.7!A]7D8-G;"L&/HX8*&[[M-B_I"45,PZ4#VL14#]E*@GPR[E0NXJB?T M>_R/X^J^!<@"0 +XF6]0PRP?
WN_A&^&7&KT-%F! <[:Q/FR#(PD@EO03C"1\ M49&$K_+(/\:1A)R?K +X&[P^TX9[TLQFH!N,+%=2G6 .HM8P4V@:VA,TC0&V M!'^%-
O7:HZ$!GR@.BJBQS_TLK9%.@GU"S2IKZ!0??$.$0BG3P[[O3<^H!RG M# 43=A)D-F_QA^"G('F3\GQ*D'/&=7Z,"J,!VE (\=#\: CB@?EW&D5P*M3 MR8[2#3;YW4U;-
K[UL!C5AUIZ,I^!)XG-^!U8)=$2RN=&4FT #WM(Q9VC[@ 4 M6%SJ/[]>,_K$$H*.(3MQIE@PP81K^QB[(09%;5%;B7<5M)FT)3W7EE8./#"< MVU\TIX4AFN4_8W*1!3"!N
M=1:W(Q*;1S[YM(C:;+G<,RPX*F&Z4MC-GKF8@.3Q4<=GAZXRH&M2!Z4<75&[ MGNQ^/8_!U80"B54@[-&Q[@E8VRW- V'/=$94;D6LL16Q,47@N1&QWOO,C8AG
MMM?/KMW"7C4S<3\W(\;BK50< M5PO]N]L1&P/\]!/8:OD$MCE.8*OE$]BFQ_"@>I:%F'P"VPJ!Q_ QUG0F!G3] M1WKG!A*N)]1 +'2REC9NLA8/'I-)5]';*$,A(R%-
RTI(@R5L&U.N3.$W/:N! M^:0-]T[D20UK0I*1KC=31G(&34XF$VUTWF)A]23='MMO(*?C-0+^S\9?'ZV? MH64"Y? @;1=3IPY=4!<\1Z\#I?1]*Y]?N<*,94R?H\10+<4C^
#S@_KV/<";TAA(.SQ#D'T/#]L,M96F)WU +3 586INC^:5 US(?N%]OH6:+?ZG%] L M3GS=/4_UQ(7"9D?]E":-RPU&L\Q1O_6%(#VV%0:A)W;T]Y8?N!ZJF9AE?2^! M8-0"Y
"H@@/3#4'U<,-V1^^!96LU):>U[F@X.6X#&1\<(<@!3JDNZ!8@G^>P MM_!$6H(+2!QSS.\ RSV,$#3]9*L:/[NA Y3XF M@S8!Z;[N&99/8]WAR.&P@)+19Q"@D @#
(A*5RIX\3R18+46P5(5#@DAP?JM, M,:6D4J+Z1#E/^KY@?BOB?MDC37.N%W&]QS$ZR9^ &]BAR2S*,!%"_H.O8L> M)AQAZX@F:$.&U]>M%A(]GGKH<(9R3%E:!BO4ZTV\'_"1S?
5;\^/+>)7TA@$R MEZ$E/BU\;0H.+5E?QP*.AS\3W9Y-+!D!Y!8Y="'I/@)##%C_\^%#O\6YT_B5 MTB0MJ1\B2[(8@9I4\&COB+@F7$>?V%,C!$8,Z,POS J_RHT(B6!9@&1&]<$
MM!VK!5),2A"F4Z 4%*4!"M^V041,3#4F4*1@2Q41><)FHH$K,TT4&PA7!::.X&K"5XX)-6C%4IS"7'1M'IT3C9 8N/A9.@3D> B M[2@ANH0^DTZH39)Q*
(#A+SG9VW&)Z7A4EIY6#^%;A2GJIR4R,44\K(GZ&/]8 M>%U_1SMEUH$*7Q"M*OGUF,4*R9>#KM;D^A43R)(*X$!;% 5@2#J<*NBSI'1A M5P"L.[$9LT 4I@6FIJ"UO;
[F]T#YX;4ELPQMG H/E.6C>F*T6J@ZXH.*K:%B M2E4Q< L'KX#M.NUMJNN/B"G;-&43Q:):H<+^P>9"4.3%EU8;_O";G9ZW$*.;A[M-DN]44<;FRBC;_D&
M=48M%P[VIAJW^%R;XM8*Y=K^G!"PL@$$2*E1O'9+Q5*1^S !DP\._X%^C#O# M9NN=NS($GM4,I--]P8R@"H)HK1A3I8#1BHUC3(>SG&E!;P@PVASRJK1D%XL-
MOK"E0G%OJMZPSY5C50NUO7E-+U^;+OPRS7A&RA;PX=0TO=X]CVN%:G8=\F_5 M^;E_'BM>H9=* -9JR=4YZ5F!2UAE^KD-C;;"?,2)SHV]'O#
M3^=@S)BQ2'%FP\_(HW213"%-9D@P@\90[F"$[HPTC+%N,%B'BM9;Z*J[>P_ MAJ8JT]/4[DXM05.STI/.2^RGR;)G>!B>MO'KE@]O:_0Y!8MZY@G'C_(F_E/: MJ6B)G*?!9-NA7G?
T&TROA6W+-L:^7&@W)^KUDP"GRN>7R[EU)KV()47N/7+; MDM&T30_Q:E)N!J9Z4B+#5"[UF!UTX!>I= MB6W_MP?:_N]!MV45'_1?5>.'!3M8#GDH="LKY!>AWX@/4F'W!_<;_"
[&2U]4YOK:,7:;[9F4])Q9P>G9/>\H0TROD! M\92LTRPH%L0&HN7G*>_2C&Y W.F;M!-.8$[!/S,UKGORLI(_.LB?/QO>J[_T MWZ4#Y:ETN[_:.E(Y4\O,XGY26O)N5EIRC-4X_>+%7X0]
M3@-*K5"K9 Z%7SXH6Z7"P5YFFM*:9$R^4+:V,L46APN@CNQ+M/QCV2OLEM>% M0JJ%2CF3-TZDD+BUY@;9O,_!H8FY6:W6]EN>(ZY==[ DN8YNQ#:7C&WPWC;:
M.:6:,C@N9I5LRT'OND\'9"0."#L>N*T,!U/N!5[-?4HM1J\SL1\2)0&]UD'$ M"0_GYJJW6N;_OKC^_&^QN!^%F$_A)+7*COXIQ&8/@8'#-,E="!_8ZN\CRV_: MKA_BP,LZM<0X,[Q;
((XKR[^-L)=?WE4 ?Q%ZFIR'K/_$,VM1.QQL3>)W#=N& M6^J)GNMQ/Q#^88&;&K:P3QGFH93V],.=DYVK'1U1L?>F7#[8*16W6B^W2B^) M&"R?NE_(!B74UT)&I>#QENMUB>
(T]D?#CY&JPMV+@N397 M15QB?-!$%I!?^%4?\3%W3\(KAZ.P(^X\^L3RHUH5;[[T+ =[*-GZ\8-HAB1/ M+[#U$O:EC;\\B3H?R2_E$:KOZYRNBTQ<_2#=0TM0*R!8G9H
R6Y"__U_]LOE MXALSHA"MF:207D0A],/2&WT+! ,UHN0TP)24N JQ162I8FR7JEN"!4.I:L]_ M9-NNSXX5]8'P 3'-T.,DA>,'V1BXW@R0:DL'E5V20T:7PI8O"Z.U2_TM]2VF
M6=M&H#9.2=&JY24VX,).>B;_1+52DO=BQ*XU&LX=82Y7;Y^> S#L7;EG9]Q< M&>"9X1ALDR#AEO;>^-H5*3E((Z?H=>3Q>6O
D^#F]ES'IP:SJ'(*'UTZEM^AO"BXX5UL&PC_G_XV06G%9FN6(@O) M#'07R2+N.!=IR3LQ!4WZJ3;,(16#;+W$%&O)'^$/X#K=T&X3OR8EC-CE" :I M9S!
(_C=S+Y]ZDL,Q4%9808,WQ6OZ84]X=Y;/A2!8>B+5?G57,$527GH@VMJS5>>I).<16QN3F#.8>#/]BS.2IK-;8LVTC^).N6HYRQ;^&:[W M]87\H+9W,"?0%PSK)3>I)?
ADGW:2/L)1S6RY0[GL3TI]:B,N9PIXEIAMZ'&_M<>0J6!AH8S?8EHW-/6EF#/!"GQL?,Q\&W1;8DQ5U+:<6M3+N'F,M(RJV,N+? M(&K/01T-:DY2ZPGJ!G%,UO8(ODR-
CR<>I#B>EQSTX"?ZX:/V*+RN%;.GA[ NM@W M0P0BFN:!PP&832*3;_X,+=9O"]C, Q]*Z+QIE9K2[D+)&WYV(\'XR,J5I9[ M@3=E5PDOL.D*3DF0P]-F"/H@*\%?
3NT/YJ$>DH$1(R*VA5,[-.%YKG2-PI]Z MRS-"O1VOZ?1^X2@%3JW@6I=YQ[_5[8=L\,L:ZD^/4N%$1>GEQN(GRB))" M&7/6 FW9: #_"@-1B!FM%DT)N]F 6]>R CE@3AX+
MK=M@A@R;Q;P2GN%SIV:+6AY\Z0-'UM^*IA'ZT7 @2UYTW4Y<=%2\Z??;441/ MRSB'.']](JTU/!]",>PN.BVX>D(8W/LF,8 M:-J-+UW,.)*HR<=)"Q1P'A E\<1#N6 1-
7F&B7.Y\^#&W/[4I)&5L:#)?53V M\SXJ<^RCLI_W4=G\/BIK?ZOG69WO"VV$4.$!C=%D0HK5$L?^$9KMR)5DBB9% M7+>[QJV2%C@'S CMH!^[DXBJ3?<>5L9?L AHQ,+-
T'RKVP.2)J&!?!U$2F#< MBD0V'CYHV+Y+LM/RFF$7%1..R;)P!+JQS)#"N"QS:= 8!UT!#8T^47XH(\1Z M<._2F^"FP8]<>#U%E.%G"1<5RD6/=)*46N'33+:D^N#TE>*0%/:6C[,B.4R.
M30Q1+9<#_GAR9$^Z^BB]&%]@6[?"MCJN:V*Z$_+XZ%LL6*1/0M."E2GK\ B MV>B'36QPPOZYCB7N\)A0)R&);>IM%Y JP^@HC'MN('@6H!S4%TT;A#V#Y?M#
M-..AL?"NM%X1;3R=ET73]6@GJF<#*D]^2%H;?NM9_BVL3RDK:"47$OJ2T4=2 M@:,$4HW2&A+$P_D#1(XQK$IAA;=)[ZCL/VF*MB?DP%X@.2MV5T9Q;-=+Z,VY
M0K$@J_60CPU'EJYKZM)&VZ9S;G%^6M9-GE0]7J]KM>]AA5(+?=(=,DKVS;0A::?&4ZHXVD62.?'FC60?8=@ M![2&:R\P
YC>PHO0&Z,B.XPY>;!$TS8L=*>J%\!3N#ZED:*9U^R@;HW5<"TP MQF!Y' 8>1L/JXY^0-$:7*LVX%^+6YV[Q-J8SN/"4,C2E^Q&37"-_KX(*C0/0 M3'
=@2&T")XHZ1G!G2K%;+0F28D1KQI=(TV)7: -0\OHF:80ZB\LUR> M-2\M4> /KN>(OB]_H;6$/&4B4=<+N_Q7@C[Q)["LDRPW400>TQ)1=\/%'!*]
M#2:DAZ/IA8.T*NWPPX'<[C19:AV+7TWIW,*3WP[3:-9ATX-99[FCUP,N](0# ML7$" ;JDI%W9B\58$D!-UI"JL>QDDW:Q8ZE\J)'(ZZ9(1A@T:3YZBU\EXR10\!Q./>$MI5XTO
MD:*/C$%@#BP",VH3CX )O?-$&UDF'J82M;IMW/NA%:C[_GGG>@=K4&EF&MSV MT M48U(M^A@9-@A.8#@@:@),I;-MG!?8UH_M'M@&H$M&K+GJNR73/EY$?]6O.8:.+/A
'(O'FS1 MIPJ<+2D@KR^^2='XDEV="LX["U#CAC[EL;2X]6J249&0%[8E,!9KD7.OP0XV M]'#"$5C!&XP&P_#'G+^"S-;4T"4H?->^$S*W/%H[B3/F?LY?UTQ?ST#Q;<+
(*$)NU+EF2@KJ;N M.[^-&*\*82' %K.-CFNCXB_#08>N0Y%.5-8N00<&%H)RX-S%JFZU+?HKVA@6 MO64P7)#APU$:VKK)NR#=FPS+6#1F&)9Z
MUU5VA&2E=!Q6%]DC>D])N5=!F.3KZ$3H55RYR2\O]"8JE,X8(CJ94?/[8-M( M?]]=$&T4E^**(&&2YM]$N#=0@YX]%3!YMV_BL.7JNC:>N 7)2 JKG M"3"40!5("PP_;/@4S@_L&$?
7(9XE6SSQVQ%/%-#H@=T&&]"4\$;P\:?_;%^ M^H\7A0%E41S"F[LB!HX^)%3 'Q%RXKN@/D(LWZHZT?0J27-#L[+MIA&4B>$Y M/FK*Q&J#3B%D!QS69/<"TQ1
MO+:74DNR82+*C2Y'=8Q71!$O*TF!1_@"SH!!Z_^R+8%M;G8"\RX:M M22+@(ACD&[ E7SA!I#7'>$52)!)#Y=IFA%B>8C$$W+O, 8&O:&%I.4D2' M1 20M]X1!D?
9',94M,7$2H/VT>X(]5AE%&C2@4*)BLP&(C9/O"*EW\>DASX^ MRPFEYP-%<])^4(R1F8:D\@U5BC(TNO&9=P=YYMT<,^\.\LR[S<^\RRVLIT=9 MR^DH:VU'/W[H6 TK>
;!U7GUWBA/WF"Z]\:T+3:FG8,RS8"%F3I4U/Z8=ZL] M)IH4L3RI)"]STD.B._\RBQ[GA_[,]#DU0F)WWH=R)-!%3!FC"SZ8,2+D>1S6 MP*;VYWU4)ZCFTU;>@_&
VG%^8G,]L;ESO!/7Z^9GM-YG=!ZBT9J?TEQ/J52< M]S%='Q_23I )ZN?N3GY@:R^LT"V+>SDR C%X7.O3,&,]>V.L)U0;U%QD/:%: M]/S#YXZ_'*H^5:03&JU+QH%;=>U4L%DO%2KE<
M*A;+\.]JI?C*% \58R=X""+'[C8LM WP8QW :UVP\_+%7U="%CD?(K&U@-PX MG>+4:;I>3Q4&&WZ YIQ>GJI6-!+!PK9!'K)M:-50E4J;G^X?KMN4*TGKBH[]74#::X= MRU%
<;F,H#)9WW'O/Z,T35&# V\7]XD'Y^>)PGE#MOBJ]8E'P&RM-SYA6UEII MJI8JL,\2Z$VH.;T"G:F\TPFZDW2F 56ICBI.,G%N.IT*/GAWH[^UW%['\+I& M
;_>*>BGSAPHUI76#:3TQ]:SY=JX2K8ZN7E50)RJ5 M?FN=J+)NQ_*;Z$2UZNY!=;>T#QI1]:#VJATT>O^"8E1:N6(T.(R3*[18/]K+ M]:/U@/3Y0[6__>'5,_:/Y-&
7$%:=W157I6JJ"#M___VSK6G;20*P]_Y%;.L MMFHK$L=. @E0I!!H2Y<"(K#;;ZNQ/9#9.G;J2TO^_9X97^*$+ )RF.O76! RF)(>IRL'(-(!5%:?E4MC"$A M(BT8D?1*
WS2$H<%%JG*T'010S+4CB$UB]8LBB!2HUW7FX91K]7:+=T0\VJ5 MYKQX]&PTBCDJWC)%;"Z:4=&7R&5$KTL6PJ5'!5%:?E4XH88&&V%HS1-J-0%# M=:5A:+=HS:
(6#,%X;31;>Q*&YHX5S0]#X^!0O+L5\E QE)9?%<:&,#:$.+3> MV) 6FWR%:6BO:*VB%@T9M;JNU]O/IZ%.\AZ9>,,LHY_CD=C2?O9\6(YULJT\ M,?
93**7E5X6L@ZR#K+/.X*NNM;78YBL+.XTRCZW_@YW7(TJM76_OM5MZ6_RM MBX"-1) 0KL<\EST'5A9745/QG1.9M3R+[EQ!$45B>DMRT-..EYLVDBDX/@F6Z<
MF_%OZHOE0<@MQ5!:?E48XL'8/6++&E4U-:.N_"(@O0=',)\,(S^(:+*B.7+$RUFTHC?B-3[R<].&SV_I MNQV1:7L0.?2R8'U=KT1IUB/5P]5 MD7#F4?JMO%6'JE
5JBJS*O7@IL0!SQ7#C8%P4[ F1[A!5:@*5:$J)>'&P,C- M@N#&F#MRH[?(;;57[58%L,B3]7JS%I.)[0T%T^0/#Y*#VK7=] 7U'O5-ZK*@ MNPUU&OAU?GY,S-PBI:S%RXEF1V FPJDK%
(D6@ M*E2%JE"5JA31ZWXN?KML!$7[20-&5*ERY M4A:I0%:I2E2]. M3C\J\[1;#V"5VY>WT\XL+^(O;85\<6OL#4-#S M;>8+#'3H, YZ5_;BT3.UY-E)K=6-9K<7625O]\
(H+OI\T"*LR8V+PGZU'&( MZX7$9,1F; P]^;WEF'4#NX \6SYMRZN)W$H/IV&Z15W0(R?R.)Y57 R?."N MY8$*7^YI:XY(EGL1?H$CJ#LBH!OZ].P-;^5^*7ZF(J^Y6A+#->R &
<]B,2C;U/ZJ#E+^I$\*=!*I5DW-G\9RHC,4BF%X;>8)\< M.^"K$AT*$7@.M]/R9;_ORKN/+67>,DY;SLD[/#9Y4Z;Q<2"UG"F6YVO8X?= MR3,R@_+8VYBX'1R;J[6TO@[(S6@(]^_X,.JL
W)!!RRNTPM/U%Z]EC]+2T\3 M/XV'0SH6#C6HYAD5[C/ZO6(RL!1P[:%LKZ22H51EJN%TA#U5,?GJE%ZTZ*,; M-!!79T46[S(?FLG%N/UANW?[3TVO9Y:E=_;IHG-
S>WW:.]3,,D'>4L4G7W)X MI,J+5W59SPLKT%6RZ=E63 CP5/\1<9^)T%&0[7PV?HK/WK(^/O&>!Z%(.DCZ M-"!VY(R(1:- \ , $/P.[! F+"&R.,,/0#$<;F,R8(X[8(HM<2%)#\D!@F-8
M)/!"7H]&8=_S0;U=74X3H#^P"G]@M6,T[QI 58AO/VP;KZCE90.8>?3I1BH] M/KN\^MRY_MK9(6<7W>J$N5S";("7+NFZ'CK:];7RJYOI.K&WCIDS]'KYNE@
MT_TU]AH66=03X=#N2X47WD\QK^(3'1YJT[D4%U>&1R"\A 8\'NT_)7[*1S.G M?;1B%^Z0'VF!)LOTE0.0,(<<^XRYAQHOK*7<(#N#4E.I2>^*G\IQ#\/>5>PF M6^@$S<;XI7*E
!_(HC[W7[?/V=V,;;.I:^>]%EE[172P,N7QGA1]RGTX+75: MCSWJY\N!0Q:ESB_U;;;??#*+,35XWJUF*@/C%"MQ,_+^;3E=CIPK7&KO(^\|
M+\D3Z3APS5N1(P+=D$TPY1LD570M*2[I7MBUBMU>&R15.@%2W4?N4D ;ZF2. MP!LZ&(J9?\MG(?5'V.^*WI@;)'4*I,>=3R3&[EB6%[FA6$NT6JY>]OSX#-9^ M>JV-?D
NAV)Q5K!/SFD0XH*;N1?P=<4]N6]Z$9D"8=I 2E&P'IG8!(M2 H(#4](@C21"34($B17@0$$5! M% 1$>N\$4*2#TDGH-:$&",D7[[QY<^^;]^[[9N;-S#?SW<-O_W[AG+W67FOM MM=?
ZKWWV(7XGS@"G#'3T=0 R,C+@-ND/((X#6@#UB1.@$U34(!"(AH;Z)!TK M/1TM+1T7,PLC*^]I,!_O:1X>?D$)$?ZSYP5X>$05Q,Y?D)*5E06+**DI2JM*
MR,A*_V1"1DU#0T=+QTE/SRE]AN>,]+_Y(C8!3-24Q2>-*,C. N1,9!1,9,0V M P 9%1DOUS GRXR<@I*JA,@:IJ3M*0.Y:<
05%)66M2]HZNGKZ!C=NFIB:W3*WL+UG=]_>X8&CQV//)UYP;Y_@9R&A M8>'/(Q(27R0EI[Q,37N;G9/[+N_]A_S/I67E%955U34MK6WM'FGU*P7X]^4--,(R!ACV.X^ZC_)+B@[
M*X3]J=HOFOW?*1;T[]+LSXK]BUYC !T%&6GR*)@ *+!_*)H_NK^79AU563F8 MP]X/V.@J4HA0[/)?ITJ#O.93PV2+"MB4-"^F2NGB13)8B4#6<>SQ,>M:^^/' M-\U4B
#-8@AT"6I+!!#:8$P&_8A> ^ZOV-TGT-76]NC\5=W?M.5_%11R3][/+X_RD!_R#_[R(_BSMJ<4YW&K'B\1 6+:7- MSGY;/8TS5!4C II'X*-#42+P;+LEJ%$^!WG]FWNQO^Y-8O#V
M#P;_"QF(,<;6"7.9'?E\$7DGB-Y>UWYIS;N[E_??GVJT1,3,0B8E85 MDW<,6D-L+F436'I/(OH"D 1"Q/F6I:7W15Z_N@/]EXX_22/^(/V#]-]/>@F[ M_VQ2B][G"V@8@Q#X(Y;^0?
\_@'X9NQG"IJ^\&P-2U4_3QNZ'\/BP2-7P",_ M 87R_S1(\P>#_W\9=)#<]Z2GWB8K [_>9')*#T L/33HJ5(P\F0F1GC H MR1+)^G(*(D)@:021.HZ2AISI !/.17[ZS/^[K#+_DJ*2/X.[
%XD/A_C(*2! M]>(^868L32T01+TH:QT2_PW14HN)/08*&[&;V&P"V_0SQ!*5,Q&(140_-E.X M8#[6X^EQ3IM2=$!?(/V<*)=@1A/9K2D>;'&8G\4H[9N5>!NYZK9\MOB4:3HR
M@0EW[>_F;(V_,E<_$3BYV0+=(:\@ LC&CC)8.Q]?Y(W3#],V7J8L:)XJ=ZIJ MJ^TE>V*OI,1C6P^KJR\?7!>LK:\.'1N32DE[0'XV)KUDQN@)NR[TMWQB<68! M3"1/8*LDJ!'D/KS#Q6J-
W(<_KK>_UI#$X2%4.H]],?&IB2"V\=EL/#JQ M_?0YO6<%$$>Y@JFU==CR^8$GI%_?2)N2UP?:8'7,F M7Z:9Z?[A6'_(\6]Q+!3LI(,I@KE.+L]R^1/2_G'AXB69L-
71M+USVZX(;P:$/\$5W_D.-_FQP)-3C?6=FRU%&M"KJ2$M#"#'K5 M*JQEFGKI]&@P8?3#@[B)WKV4JYOI,V1/FXM-ZDF2<,<>SDUW5QD&0[?.@@^/
M$@_$C5V3(KH7IG]_R5[]OO:?K%#YKIJ7;KJJ\;JS:4?KM]Z4O=IGD0%2Z2X" MBIW+*^?N#7T4'+R6DU+1BL;7(!:_+W.AN$K;X8GB1\YE/1Y7ZM/%/-C* M)Q[)]P_-
ZBO.&:_8"/4]=@JI'):KE^]XHK'*.SQPJ?V1CL9=!FGJWI*?,O7^ M3<8%4KCIED=5>GBCM[49$37/+F7B?2J9!FZ-Z/VPYCQA>B-.-.LO7JYV?W5MQ+$[U% \,['O MCB8TEY0M[O_M7
##3$<\=N5X, !;\LIT*H^Y00M]@9UMHHQ2!&4S?JOX^T,C MGOOYSF:")C1/U'[P3] ?JG.:TQ>>8: Y8$5C"U("Q/K/J\J!PXLVT6$&R:RI M$KRW7,R (@[NY_PQ4IF.)-7?_%XVR-
D/5;Y8S]-F"3@!-)2G MJ!7Y9V)0Y?\UH:34$WIJ*>U\/#)_];1_<*?"V4FK'.VP]W0Z#]3A(;_#^ITI MW9L703GWF/H&_OYFQ_]EXG<+$,: 0];PD())RZ41;"_]BP$=M)(IM9Z:OY/*
M['X07BD?QWVEOF'@=L:"D? !M])#O2:O'?):* <1Z$PJ(@+?U1"[,-)F%J" M?D,\8:WQ4&ZEZ$#;[M'?&?H_/X#]OY49_I#C?ZPT6ESE6;-^\":TQ> @"_!K"^%8$*D$9T!A&! MW6WP;M'T-
2(09Y=W[&YX3&FBL/%&_(NLD;:FYF]>,)6/F(E@%0CZ(R5$P&J0 M".B(*VX\VY/$21(N13,2ZNZ0I*)R&>$@L9S3ZR,"JQW@8\!TG='-DHK52,]> M!>U*/8X;;XW-MIJ\
[,S2F,TZ)A1.;)M0#P\A..)VE)/8-67_NE MNR/( ZL[V_TM;02.#!"=E6\1HR1]EUC)>N"@F=!4%!&@>G"XWE'LY2H^FEHC MVF]0[(-+L?>HNMB\3]5SID?:"4QEN1I]?;'9[!KUWL
'2>8U)>=:Q+/M])M0 MRL:YN"78'I8(Y#*;]9Z.2?(LPCL-/RZ )#JK355Z4+]DEJ> A*HR9::H>BUK M@/6FX(W-#5)]?KJYK84TA85K=@H#S=R9Y\3S)/)1)/"@@X24T?DS!)2W!_3
ML"CB-41Z#%U'PA:2 2ZNDFU^)TCV#%G4I^? M![;\6WVQUDPT]]<$Q?LF5;>]%3@H9VT!3]IXY!,U]>M.2=B'9C<(?2RMMLK- M7L*E)YMEZ,
(G/E/=59F9&53G6C&UHC(7//Y^K\'[GXGP?*K'|C7J% M1FEFL1SPI\$@F]@)E)BQMI7"_$DJWQ]/>WMBF SWS416'OF.]J0QAK[!(MI3 M92&1S\51-;4UD^=OLUN_U45#-U -
W<61CX]5+(8;A'OM9E=3*H;M:JNWA/2_M"KG757Y3 HO>P:$"U48U<*!\.S MO9-UCW3"$_NYM=66GTR%046/<[R^*P+%$'B,;!!#:++&5*#Q7+K/BOHR\^_M]
```

```
[*L)!AP/KRM;NSF?;8^\?K@QW)+D=(A\;O5E7XN,29TTD]@[\&=:H9C*Q] M93_*0*69;7L*H_+TLU"A^]7EYRK$OQW='\OB;0WDEDS@2-]>)7"$;HVW6,B>
M#OH\U6Y+;@4YI1>G\^8IDM?C^AA.ZU)9582[L^PF+:1UK[:ZR)3=:EWTLPRE M@ BW1KO+=3(8V/#-."X1_2XWVUK_O)OUJI=1;9O.,#$Z/2I(Q>R['+8A]X.C MLF['\OK \[:D\<-
Y8\Q3;8/*#*E<&,Y+!T^UT':6-U9.G7R ->?RUY+&&:B) M;V?B10!E*$@%[M1NZ^NSFI925TN^;O"W@GW4_-5&HS]P$UF=Q>3,?=A[L/AZ] MRWZA^XPW']>I38$S)@:AMC'P$S7WG]
K#FL1XQ@)N4;>#YC-E\ M*BXAY*S-+HHW'#D8%\5 MF!1L?R(C"CVWT[1_H@H1>%A(B,:RK[8:7^MU4K[R^5*>J' LKL/_1:Q?U XG M<$C1IB[>IPHAOUKD&&?^,?5[D;X7TO]]-
)*OM:I8$-.AC' *V=3";W#;VH= M-E&2G'0)HJUT:]>Y^7#MWOB]+;P1;ED\](VWH)NA]_ES72.*9^@N%L$I\$T[ M%*045R!Y."2FM+6!!5/*J]65ZZTL*55\*]
7A$G,\.M.;;*W2R&QIFKNPVI MF(0]PI:AQ,C("NI!Y@,5(Z/+/ S7 #5(+68TUD\&3?M\I]]!]G M&$T35#F*P#:?28^8FZB]00K%KD1@1^-C[(\"@M;AYK$/D@B\.0WL29[R,\#$
MAI1KO5M5KOSAT@*2.DXS.S#42C*&6JR\'A =T^B6&;APD"0#AE9 W:%'O!H/!D@T12=7QGM MIZTR:=7#\<-4[_4HKK3L;-(UO9UCR-+)@^P9LR
_%52MLPW:4@QK(42MN1+U&:]^8+52!OX]S:VA6GIQB%<)*EJDVBC3,F\M@PG#3 \.7[ MER?_$=RG)(A 0O4LXS[L<#1G]!6\EF"P^ PZB5@UX>U*1N;T;[.)_:+L/[)Y M5[9
JU'0(QHYGZO_\MOX1\*^[G_*@*=L2)@H&GG\R'7>2]0Y\X")\=B_"Y[< M6SN-PU81@:*K^()G.!DB #>9E1-_\U'@>]V&$++>>YRO23GV1&:]3>XY]:_Y:-X.IW7)D[B8WO8,
[L\C"\.9)OC%^=9>9N+BCH*1]S!5/ -F M/3:B;)K#82R(@KZ]#E"7MO5K&(6Y>9, TDTB0(?7]L>TH]BFGZE>7."F3:W[ M;#4K\&)&,/LXF9/RD$UDH^\$8FV;" @)PXY
7T@K6^C6<?,CW)ME(K!W,I.$ MP;Z8D()YYH&8[,_:'W9,"\W\SM7K*NCL4XGNUXOW' M9OQ;;[HOR$[$-8AD*X(;+X?*(5CJ4)>NJBO=^-3;!VQ;;#?MZ)!TC.!ND1;Z M/(?\-
-69H#TMH:&KCHE*=]O3;TMUS6UG.(7B9#"]E["9H9OEXFX3ACQF5UTI M:;2THRL$9+!#K[NA,VJX+$9/S'0T7@&%%NW;O54T=:8:/=8Y8\\UUL1CWW"N
MHQH53=MJ])CVK<#I'@]SY/E F:>CCKMJ-0R[VXR!MQ'T?M[!5\]>CZDXZ_@R M]R!?!OL\ O6!B]0@0P'B^I@]1I8Q&WB-Y9?QEX67W)>3[5_G=DVU2:.+*=QF
M^,K(QDA%"9LJ2]%T;DQF<B;GB8#8RB,0'K1L592;"PZ#);5/WU['WI!GSPA-G;/ MZL,NJ,*!HO X%S$'?8,8_9AY>*IH%#:X(WYYAN$I8[B51.! ?CJ%]*2T^GM")!.O#8DE/3P;IG3<_3S
M[M2@&N!9S'BJ(?Y$H/]+@081G(SEL-F5P=TEH3K[[^&=2[SU;*D:K@I9TE8D M7&Z75B0LK,!@H0D!3]7F6CSZHL$0N9<(S.8/V%$8OC+^FT4;#YD+Z[4-L;.R58CV"$NQHPK\
<<@BNLJ3]G-*RSEQ.0?%D^)X%=;LF( M!M"0I\/.%]@IC7UCQ4LGE-C,8S5XWAL;CKSK;Q'"Z[8I]_7OU%NN/+K/_I@:%>=%?>.,S\X7%U5/;L,^BM&EMQ& Z)!:.Q.!?VZQ>1Q,
MR@7]SN8PVL:Y5\O@#5)DS;8I]X.1TH=I+2G4')!"C:6I61IPS."GZ-O ?V52) &DRPB6) $R*"%BLJVP> MG+! C+*22GQM=S 7=$X3<7@0>SCJFH?HE!XD5.41@LYEMCQ?,?]%F#F",
E-M*H] 5],02^U%GZNASQNWKI7"BYD'DH]0#X6*4$T(I8$'1"[:$9"(.3)]S]. MWZA5Z> ;])TT6UHGL>"Q&P3M>A9"PS01T"AV^46RF11\ B\M80]Z\]8 R\M" MN&8,.V*
<1"PABPO>9S$@D(@M0]7+I$DL*#YF'49!2\WP8;O3A[NDI'!1;L>3 ME6PKH((B(AQ'(>M(W;NFGEB]V>Q=>5$X%GKE6>OPEF%L\+KZFQ#4D8A36H! M5GSD:?L&HA1(P@F\MOJ9
5"8G'ZD8[+8RWL>7S$QZ?MV2_Z?O)7D9FL0S^]C M$&T_=K^+#Z N6]:F7UK35=_(]@NU/3UHA MR=QEF&M?2KCC1OMD_X1R_++?(KJZ+_\L^HN/.7=W/5D!LTR\,RER:!41@?%&
MP@M=FZ?: #QV.91DKRF2%C!2,LPRR8QI9)1C9-&T+W:HZ/7TM><*]84W26 ? M-;U?T1-J,$KPUI0]*6]\\FQQM(";Y"2E)0X+=].C&WM[KY^#JHVT:Z
MWW.:%!]9P6U/GK@;!@9E4^<31,V$Y$]9OBC>A'D$>/=HX(D0+$*;8S4K1X2 M4;+')\<\):433+T[^8$VNAF7F<<;/F;#)%[1?FR#9N8X\?SEA_/L>TX%C]#Y
M8=%FT$)OR6!5;10X1%VB)LB9P5PB+[(KN<-.M"^G[!+G9= M(Y11+HW+1)>,NOF,;@/HBH=-?8 <#(QGKY4Q]W]UH[',R]*$RJU[[JW?5.W- M>^@B>+$&R<1Z.">TOT>3(D/$](Q-
%W,=B\#'N$^*(->N.:C6.N[859L5 M,"(ULU=^]D0@WLN !-02$$N,/PL#;"9!>Q)":-$GS:K:3?6S=B7+LD;:^IK: MK-?)_KWM5^7&S^KFG^N0FQ7WZOO_$=Q1FP>0C%-$P),(%/ZL!"
(;YXK@6L>C MA'*CB=2'/[E=9C8RO&_U)YWJ4(]E:X"A#@&2Y1#-2O?/G?TS$4R4?_Z<,24:U MB8=/($;%"28M/X-P/$GCT8G,+J?:OW%L &>N9GCQUZ%9'7'\KG'!E A4-AYG
M6R?'$P'A<9'CR%'PH=CJX/LLQ@SH_=@#:G@LH5H3/U6#B)D"'"%.D+# K.#@K M_N%!U,,DGYX3C^"[5LF'+JOMOE2D,(;\_<(.9MBO 9;1.M*$1RU->E!S/^R> MA*E?'S^X=,
<9Q,Z*>0E0P%9<)K*D0@[,>=7>#,-!*+T5$. M^K3/.3VA!O5'B]2Q]$?#@'9(4M.^*HS*J?*!TW:%@0&R0HKD:"^^/[\T2!97@]4;-LL MJM!@],NGRR]]JE*H;&^_I&&V5VF8 ?51)##([
J1$D+L.H0(G#FF>@3?(V75 MD,?@4XBYL1W)PQV2I78L1BN--/@$,#(@$O?UPQ.H&":WHHXM4]DCU:$+8>\3W M&$]
MNF^8M.&O8R5]9Z'T8RLU]"%U29(F+F<=++2W#-0O.\_KK*GV;H<^DM?) M8P;1]F;8NCT!3[1\6BB1&]Q55A'GUUD89#WZ7A4XH7GT@R(";*U^GNB8R-, MPX)EN[QT'UYZ",S>#
[".<6,8HB_"?+O%;QX?T3I+7]OX5!]EZ^S,W,[,T)U- M7G?4C*!A:>63KL/]O/D8;4I ?[43[KLDD*#SI>K@50(-;Y7MJDW2;W87.!M( M6"<>8DV*(GY$X%"\ #+KA4_T%SC^@=AQ&BF.)
)S!].(-3"4$.G8C2-U$YS6 M(_D&\D&A4S=S+R(/1_=P_EI!&-!S+UV F^($*(L^C'V^.>GPRRZNV3Y#\XE9"R9.)_=I:;'-;;C-6_[#A% M X;:?B5')$S:I9]":-XB@5=]ZY@\#!]I
.9F:3O50P289WUYOGCO9".&8?(BO6]NL_DB<"G;,%I.021ABR M.+0A18XB#Z0Z!$:%,UZT."+CKDYJ8=W)CZ:\6'O_JHXUZX;IQ-!0?66-V_"R1 M!+9]WOM=^F([X/ V(B$H0C2+_)
<&:5.7P1M@06&J5]\M97#5.WE_Y-KLH3/ M2\M4,&G8J4;G8(]G1S^!*OMMM#%:*+X"-'6Y):\/UL5U/57X.3XGZN5XT(5
M!FK>TFV"3>WO[_FQ;:L7HV)/M1]IZKY#%]T\N.U9"X_,G^P\^]V:S#JU@\&0 MVG[H%?18 ML\#1?:++Q8[I]B2%/(]&AUE-S8$B(&(>3X56K/.:/9"#/\P8D*N"L_%IM(4 M)C?
JX]MFMI;\^<&RC,@/5*+$O3B6%&,? M49)^4Z+Y-3P$#51OL-[K'FUK/UB_3!TU:;6:2T:?]B+]"*THQ M)EI,@X'AQ<$XR\\(9X0C$;#S_GR.#,%;_&!9;-
R&8J)0#@>ASW8AI9ZN6Q[X'V5Q]_\#WSZ M0"7]Y@'7D3(5$+^>'-F+RH6,3'D'4T; LAIB(_X_6!E4<$M5;1EJNT_6+/RH.
MQIV=S>ZOK1]U*Z]#DQXXP'C\S&8W3T5#.BJ^R!IUS4\D!VJK]AZO2;_&,KC' M:'"J=8(&9(TA)ZYW:QI+4R\],6;@VUA"%C"@2?-6ZMTW-%)'T:3#YIM;0B?NFSCH3T3XH7UKCKP(0*
(*+-]82(@[M=3BU%P7L[_98%^L:_-RP<213\1"/F> M>9\P3.@X>NC[Q'X-83_\QEY;XRL)-NFG[-/ M,^Z$OSYC67AM*=[5I2<06%F?=MA;@>\*=)2-;T;!F)F*RU97.\\_'1,*;+G
ML(G0H9T)3I")"1O(R5X^A#3@;/]K#!$(*IL>,1EE[:0SWQOHG8R,G<\"!]> M;#28?K+T2&NUIN,Y$;!>W+M6X']GT3_OZY%0:WLCGZE,611:I/A#%]/;VP9' M' 1=Z(
[EGWM=:NA+NQZ)>14;8TWN1[@*>"NV!VDGN,/F5:U+,H+]1/*=Y(P MDT]>6^*@N!^!B\8[H14'1!"L3OF?BW9$C%(6N 2@OD-,.+.A M3([-3=G>D)]>^9")O12C
V[A("WN(OLHG@MS]YBAIX$-T>(7?KQY?E>Q/2'# M"[&H=2V[L@S+CX?A[- MDMN]NCYQVC^Z??U+^$SE\ISXKB83HP3$&0V6?AB[HPT4&[T^WY&3P3_BG%53 M%9\=
3FX*'(F0IO2_.QX08Z'T\T>/9XS,$8KJ\N"@U_>6:HFZ+6G?F_+23 4 M3/SF0/'HS]GTEXP:@2M$.6W2X*'U0X];"N!?XY "= ->^,;1D$T_3?='%%\G& M^F'B>%DXWMY6E(F)
<'<_&*MW78I9*3? MQ08V3/E>U4C'O#/;K3;PG=NW)*W 5GTGAMD6,VD#SD[B+UK?]8VD/C];EB 7 MJOB]]DXP2W6,3-]C\G]&/^T %EFBY*,+X,%-:PP9BTV IC8,%?
G.LVC3&4WC(5WBZ$HX,7SX9P"CQNCX\[8 M?\&^*]8PFJ"&50C>]1>FIS4^$O1HVCQ[P-15%=H$54X/8"5;?VSV=1.U&5WA MPV/#G[]0:" EU/MJ[_)]T_# IKB"#*C%08@]1U4'X_3
:O@M4-=PU0TLR;7*UYW1Y?4WO#67PB MEHN6)X<^!PT\C'+9SN=YB'_&C4$!:?]I(DJ+/K)=/XOA- M>>2!7R;M9;3TI"74X36S>0YX()Y(M_(K?$648MD1 FJVB!XIGHEF.6I(Z;FM
M+HTQOS?&X<%&F0X >(C/WJS-59+\IRW7?9:?T-H!)_,K6&WO=Y541GI^1%1E M'DHYZ39G_GDK]EQ#E]K5[K]M:PPB&L&D:C(+YC+_[N!3_$/WN# ?2/+75]65/66!$S?;/4Y,E6Z>=
[JB[_%K6:;A7R$RB7A,OQITB&]G0-+QE; ML=C(\W9QMK-EZYE($-;@5+RKX[0<\:^BL&@1+2HE6LX5M"P/>?M@U?N](\LK M^,T")=/Q^&<\)=\4"9YSARDQZK+P1V-
JIF:A>F7'3:OIW;R!&8!SML_VBBXT M"?";:+!CEZ/\SCS@]HC98(1XS?C4^>)51Z 7 M 7VC"6-XN1C.'T&3CDQ;_'"NZT4X];HL? %TSVVP\"XF(,^#2(^GVG*H5FS- M^XB;"/0<07UX
G\%DS,EC1'?2W(J7<\\/S+^CCF66N(6?+IQ_D.99^TS%5B!8 #F5<%/%D MRU:(=;9\1^.5&]$W#VP'!3]O#/U/XQ8K9UJKG *]]7-!<2L'"G^6L&FW+B%C^ M$H])?%?-0L%H?
OP",T\4NYGN0]N^O5Y5C[4 ;]S)9B3"_CA@VRCNLJKWM3X M9?Z5^3N"+)OEH0CE;4FN7DP#E"*C^%S@K^I$?=EV0*Q!$I*%PG+>2QH ,RHLRU-"6#9LS\\.'TB1[8S+Y!Q.1URP4]
M.]G>KY;C>3;M*9%%># N[]RU9BY<,,;>X>6SVO M+3&UYCN]6@E,6N7,\,_ M=WV\"/6VI"F,]B "8-(4YI'BH$T<$1#0X(O&;B+38L/6SY?Q"GN+V]?KI*%0
M,N4C%]S8])83T^._@:J+M+1Q3_+N#X>H]:Q>Y]@ M.*,)2Z;F;KN7."#!TJ:L4QXJ/VCQZN)%3%%,;!?NV6N@(Q',TKJZ"MP'"C0S
M)GD(5U4XN>X)/0MY\&2]TT5G8GLH_4D/X)99VHM_D8I8 TL2GB6=^/7[DILD M*/^WGET'N6+WD6/)21Y.L]'""Y:&\HQEUCTL;/>-]6[2*5',"Q[,,5[WGL78 MMQ/ F-S>O-<
MQJA6OPG,!7@LR-;;]P'O]'F$H_+W-<8(#=>7F4D[F26_FU[+T#_Y67E=Q(O_ MO2"&P9 B:@YXE%GJBH\YW7@,1ZQK%V4B&TY6C:J:([Q0"#[+I1H9\ Y$J4C' M8 V("TG2T7-
)%6'[&M#3N*5[JCQV9XE ,7LUC 'F8%'<%CD>^_R1M:PTEU:8 M_8'(9$U0#UPM&VW02 /]CKBR:CW(5.#LT3@"S^3S19,#KS>OL[O:S):T0";T) MX*CI$.RX$SM&VPQ[6*8N3>C[L:
<"+U3OFEL,L'-]%; !'7E,=*D;C?6[6(79 M[8V@A9M^61N3;BF@>&BW_>G:(G,2$%N+V1.]B M8]7/0$/>CMSMEU64$"SWMG_5'1TTI]+YB,+^PO55
MK:&TQ[7U#3]5/_AFYEO>3>PI\>(6JNJ]!]#YCBMMK:V%LMZP,<_T_Z_*/(H^ MSW K^P.O>YP;HPD$*4N6_;$M@,U)^.M66L_I?CGOT,9V M6X?QO1KUB7H(B@C$>NHU\.
"]G42+K.."IC;)2@NOXK[J(]&W&=LB=F*Y:."K7S@ 3P$!3>7C0SG%8_4 MV0K'9P7GS[]?>Z:#FC16H D7!(;,=]>BKZKP7&<%"C>$\*;ZFD=)O0+Q7GKZ] M_*]XR+9+]8S9\L'(IRO-
N1&LNK[SS@S.]_J=)WZ)O^R:[\+TNSZZ(*A7]^) MX]\>C/HWGBB3-C>FMC&_==XA-S56 R0X^M4&]!*O>9R5:0D/"M>53:FU>E32 M(7_1=XLQZ<"LV,\1"_0%G':DCJ$\##V?#5(-
^T8$\&Y0=&PNW+!U&L M6@Z\ M&U&5S.>59W\Q7DI;+3YV-0L\RU/"\/6\RJ=4U95?(4"F+],!_2K]8,EE6XM(* M%5VC5_*SPU+,VD<9]!:9[7MA]]Q+F$(M?2V]=$U!H,+@>#
8R3]GLAEH(]6O MJN#Q\8>30MP/[F;6N%[)]KS[^_\NTW FW)&I;@?LE 5\%,6;CIMUI1P'-0 MNDG744T%W8F%NK!H+EI:LZLE3L8\@-Q;U1*+^'6V;<$MPRTTT%)
MS2)]RGSU5/ZTJ*OR5V^T6#2D/&2S]RE)FSK31]Z?!/]6X((#HYQ56M0O#!5Z M+A7?N@H])'54 $3N&OXO0_WB("+HZQ'\PG$D52 MU+]J[(-FL/NU%-
W[S3->_MFG_D@XU?MI';G<YS]5M6L+@NVA;$&AJS$6U2I7 MI_.D/-8H035_.PKXD,'(RUCX!$I)...H+CD@1ZOFJ)VP>6VKL[H])BU/Z3?Y M^61ZQ@'?LTSQ03]]#!ZOE-
)64QP^5SMZKS*5T.*21&OE46Y@Z[WH2!GM0$%E#G%G^G M=&W\"\Y%"L[.%7?KRD!5(:RD)M:DCG!F-(,(Z(OQI\DW>&,,\'D,;NX#=2FS M"N'G\118=EN48DZ9:=!E)7.T4]5_]Z-
+!@E>*&FP:&[;8Q5,Y:AQ=Z;?1\ MT<;"Y&>(MT)B&;-'3#"P^_EM[.7YQWLR-Y6-YF[EVM^^_E3<7KQ0Q],T$.! M$%.3W@%$2 M+A7R*]YX%P^^>!PX^(PW,6P#]!!Y> 8(EK
!D1Z)(@X8;B#XT[YW96_HSA(3T-3(@/6([C9VD_=Z-G.0XSF1#? M]?.3OZ;4] E'B'X0_4O4/Z4]1B7MNCV4T&Q67G::VD!
(YH#3BO[QX9X"@\5T<07+2I>Q;;\X1;0Q1)5CT!1]5"V1!=Q0[3&S^_ MD]&IA-I3@3'%Y2>;)CS-R=2(P+ V098L'LN",JV>(0(T<(_6D5)]QG#AP3.) MUZM?
+29+QHEO*7TI?76I1OG$Z0A5I&(3M3%S4\*)-VLS;.0MJ!]NN/+I&\N# M%KX'H $OOQRF&%U*4ZJU1GMW4)NBQ+T%[DA.?;&J\OD4'4$DTT>"ARISI@Y
MV[.S=_B"T=,#"X94CMA[?7B8KT=>4V(=BU5^H,EV MR/W)=#&U@]6,]#[0FREX))(D,I46X;&C_]%#U*@=78)]U_]U9TXV;L-8:!> M[UQ--%-77;98_\H$CY8S]E-
2?"I0HL!\3\\DA@A(9IYLX!!H"D9& M0R;T2MKBK#4A*E)-328BQ5S+UJY(<=E;>/Z*T@H&C+F5);(Z?/#L!PU#0Z.# M/A -QK:EX4(CH7>D;-UW]9"^G@@<:L>."QO*N
Q,UQJ]FF,:VH9='@TC+>]I_M87:SX#7+0AU.3S$Y=B;+ZE;]>K,'!M-ON^+Y;XA_Z!3X'_Y_K@AL_@EU&'S M0-0'<1R4303Z/_>!WOD9#Q7O9
;+5UIXKO>\;F+/%ZI,RG;CYN(RIO>N#'(E MB,&_M(RF!805&,YKN?7*Q_%ZTF%V(H)2=%'(/6C"-GE%99\(<"+FPL81XWE; MK+7 D_3]A3=$X(XY=.?F3;(/U'<4U2D9+@1SKZ-
8]3+W?!\\@#2^TR"GK#5 MCFWB?NB 3(Q_@3T:W,[K^*7-:19*=U601>>450_Y@EG\P:W!&$5(YUQBS 6/ MJ]7,K4<)1.![P"HL*G)H"@_PUW1^^.X6X?XSHZT%L"F"QZ,(L#
ME*U.:>95EV>/@>7ZN74FB9GDI8DZ+OZ@R_8NG&1)@O9#9C>.9!&=,FVPW3'& MN=T\+ QE%N)*X)Z^M9Q6QC%]-BL0(WO"=Q>5A[R\AV,"8"KOG5(R>2LK3C56["?7[]/]8.1]X5?
33G M8A3.CE1A_?Q,$.;,52 ]O8=:O\1S8+7]#T\]DF5@3IV]FR2*]XJYD5(%B/9&\ M@2KUH&8PY_GR5[P7M]L>=9%_BW5W%GZW9;=_]5L7MF^_@D18!;'^WZ87*ZQ
M#W8Q_49CK%-7<_>4R#E6U^8[$_ALN1)06_$):UI7@;8GTFI?SK:?KI9F?TA% M)57%ITM)Y]4.S^Q ,,,@H^Q7U?%( MCPK!VH7EF$V:?)?MCG9=!\M?
#&6L4&UBZJ)GP9!U2"L_4MQ<4I=R/>5W$6?T MSJF&(4NV9,];PO4MA[2.H,8S9?KL!2Y0**HN$^4:6D<[&ZW>,MUR6.KH-:AG M8ZX^DD@9Q2#SB8HR00T#^1[ W2Y(JDCKKK?
EYB1T'YCH&E]\!$0I6M2YX5YM M!,$1B76\^$IZH@'C\GCO1C?K\<0NT(EZ1K1+*0I*WQAZ?KU\\N*8 M>]YZM9-E]:G+9V?8!4]9IFIY%WG,Z#Z7C66
5UY/N=40\8WKHX'@YW2QVRON MF584L7E%$-N]]*J(31/,?$_M\S-I73G12!WCIN"#ZZ"K(/E;IV%^I*+U7B]K%G1_Q=D#8UY>7,TLC(CG)] M1K>
(UQHS]XZE]10G<*]SK6WP((S=:IVSX!/3BD+U_M?A?6151_84!$][-VLNBZ=E]XU@_^]^*4^J;N[V7WPCVNUSL,*5<4CFP6V_0<6)0X$G, MR#+*>.IAM]
8A2)@_]U,2FT)N[].0;\7$RM>-_;"+K827/V,_\$%]Z<5TM\5 MU4HR((9[,3_/IN21EM\YZ#&W.&".56UD=_43 4<*#4G('HN=U;WLI%(18Q>. M*3IRLU2B3/#XY@:@^QI
\$5C;,!3A%/!5Q?)Q\LWJN=NU[G06'^?B3,)]9?: M528HD/@*O$=\%X/NL!6K'JGQP_#OA.&]Q B^]+ZM:ZIM1MB M'0]2,(MF+.%3(TN#,"FI4*_G)'BOLN56V8T-Q'?=!
[>0B23V25Q3O*UJQ)!8A&?60-9@C+ P:TV+!)CPO'T'V,N#-B]]MR9 M:$OWO1^HZHI^5U*(N[_=6]%L6OG>_.WW%XC/$ZIG+^;0Q;W+Q]W=1X5%>B+H
M5K!$P%$DK/!^6:BI97W08QWM9%VJX,M5H8)QDWK9>Z3*+([P\SS[9\32Q?K* M)D>.V<70H$#0GDD)FE M#GB#H@D"\)1V&Q6^DYBKK1;.]>L9CV_'0MZK?"/D
M1I!5VURC67Q[I/O M Y9[9]\TSS#?;<#)5,$W4E=V\YQ^6717RD'<3!#U[F80 M)'2HS)<,%LEQ"(LHDOBX%O/F0@9+Q2+&E1 A,"7XQ;ZD(%>QQX46V;(8\*:$! M(X^_8=#-
VBXJI$G[_7G;)]]\!&!W)4+CH?:R7G.=993&BE,KIS.16]"=8OH M+8NA6%@+SD]JAEZDYB[M.$/SJCS M7,P4Q5?***"<5NIEKI;U[WSQ5VZA#!]9)-<]30> =C<,'SDM&,9D\#3T!?"#
M3UFV+=L'V":+]?E]D X\N5C]5UN_Y=Z"L)+8<=;THI26)P48#]\@K*VW\(G ML\4GL@'X9G"O&C8-V%4^T)U-P:>S51[[3Y$@V@>G)2B]GPYF.G+7NVS]Y(IE
M7BA8:6[KM"P%O^T"L)AYK;/]R\B/S""FT;%GEJ&,MTK'_2)4 M+7 EH%;#MVHZY'&JD519);#U@.+U_-1"=;2M1;?^MFYE9ES]IFE^B%(ZRA3 M\MA'"Q_M
UH7^WF"^#F)M2L1R+H.DGS/A;7O4 >"G 6,JF*ZO^]];9^XYCP;)8#N^NQC(ZF0W"=/86G+SS[FX)B'$9(Q.HE>8P MNO5>T[_YO#H<#_P)8,L*\/'"B>"Q$/Z
MV'ZDWYJ#QNQ.XVUQ>1XSY<&Z_0,T%@M0N07/"7%T%Q"H0\O.:#7#H'NVKL#R MYYF_2$+K7N.AU+G-=:9WD\WH+_X7+\6-6?UXVR[,T-=]2]I^R,V=T)=%+Z[0 M
N7:K>7T3,+R3E:.G=*+N_J^B]L9R15%GRV0SN,[,_H15TE@T=V*$5E\>D5^S.6Y?;;-%ZJ87%]KNGZ]TR8'3Z(P&LU=/\$]Z@#OP;$W< MJUEQ/M=3,-Q.W2?I5/&[0_?0[L
=3BHU7<[=#]2FA/!?&'5Q1EUHWGM!9A5? M=^"H($KA162A_[C#@7[TYXO_K!U]HO!]Q;"9LCU.YZV4!2S*3XC(YM7(2M&50SQ?9@M!&';*L@ K1UI%KA
MP3Q_HJG)MZ4QC"K=+>N*2F.(VN6INLJ]9YBKRT-OLFASUT[1 M3+WME%I$K)$'H+=O.3*,+X\)3Y89%?SE)PK^[F0?E#4"?]X\OI/NER]BA]$
M+1%C9KW5$6#ABDO;15<370B+@BCC2J:MM/UQXA8(^O[%2 MHUW;?$<50YT-'Z8>"\^;-];H,D: LF0MN(8.!/5*P$FL6L3_8>^] MPYKY?K6WGCOV?=\^YRS_LCS,,/(?;
<<V/DU,:GHO0&>??&+K&<+,_3A?'0P,PT5ZC-S91 M)<:H\4$@+70O:AU^N(TSL.OC;!]_L&H/E_;98V;1]:,>++&#UT2N\!= 5R7LK M#7B#!^P&CXTW3'T,LO"+Q@.WC_#_O:?
EF]0X%2NS 4= MVPO"-)?\!'P6^.UULFD"0&)QROEG-XO?5@K%BH89)?6V&02*044C?HCY]P46CTD<\QR.\_@]S2LY H+<]5O+/-_/)BY,/ M.5:ZT(WOB.%L\9+@ M0HX7U:X15UN-
"&)'+C014*U'O/;#:X> KKUZ5%)5-2YY_ZL^A(UZ@I\5MG=" M7@<7=XOLG*^!?=MK=_^8+YF.V%3:W,KTN^YH,RRT+%W%S]78">0[8P]'FN#,_M9[..>-C]4-T0E4--P9EB:BO8*?
E$"LJR0'_Y_7(0[8.+L/70Q?0UX>#6E_JT M25$9"GBL8,0-&A+R)OS6!FDUC;),NUX23#]S80&MVT&8N\@P9V_F$;2,T_TM MEMU4)S/M$!E]'W75:<2),8,_0-
(L^GT6^!8CO,;P88I/U)$\1\](CL0$Y+@ M<[MRAV(Y&&Y6*'?Z)*K;->%S$T?AF$]X3]>6 X3R$!>VWF5CID&'Y?I( MP;"3Q(W1_(G)>Y8I7"@Y& [ZKR?OM2F0JATGW"Y57=&3.--
QEM:)N MH?5D7Y(%U>X4ZOHA8F;I\&OK794"M4=6A9%V>"\ M=FZ\A1NEV- Y#]^$ED+-K'(QH8?6&-O$[YU'1V'FS])TON+CJCNLS90U1R%< M-H+]=-)I*!
<32UM;P8X;*=6>_(G':_!#3C,-3.?F=2:=* MHY+!8'CK?:ZD-IN/P:/O@A++HFE2]I[[1]9NN)OY,-:.D#;C,F"];@20@]40 M4G(WL6M>^+C!8NJ"]!>U+R+4&
[(>VNVJ:XX,;R(W7].P4VV7:YHIAZ<=JP'X MY*T[/"+H59(6# EPRV87CGX\CL4I+ O5GI$WL8)D7W!%3C] M*Z+N2"(4V-!/R$,/(NN'" 2Y5-U^N.
]G0MH]YL.'%D0:MWH+#V]6R>>YOFGB M'-ACY ]*57_WY45;()BH^.X8/4.*R)@M+@%0G0Z_5+9'G$J%QPGHJ=)^V%A MB3.^T>CK?
B$WG]<=LA[FOS\MK.NV4;3!N5!Q;&1Y0U9VHN#J\B=J KK]7B=# MH9&YG: F3F.-H82'MA*9*L"WM<^R;!.>+'\FO]S$0\"N8JBAS1Z'W?V;T$]8
M@'DO9>>AK?!/GZK!>F3M[H\^!3_5'X8\KZ-\,UQ%!"$J!MER=:ZZ^#<\C]Y7 M44C"7(&/X>%$TKMKFAPEA4Q0;1$4%10P\]BF>V0:!]S@X<'4W_$-/TXV&: M0K?EC6XL@%_UK
:Z:06^X6DX( A[O6M1<=_AI+XM1.80HWB',\WM=:7,A4#& MR,?V?>1_4&* &ZOO.!C6*M/1PH@%6()E#KL0%6\' W7\3;P;"6#=[[7SUB0O
MC;*)D*!VH9K6L5)E1WL(FZ(MTP.FOC"Z+<"RY&CW'X'0G_WT%TPO=)=S'7IP M"#NYY+K=HF< ?;+CZ"+B0S"^QJIC*]6CVYU;)
E=K"N[#6[,/)D"=C_>-1[("G@M355X#U%VLT$Z/Y&]+%EA E8X)LS=U&FF,^#\]0U0(_B?OQVOH ME'C<\%?%Y=]+TLO "6W,PQ/E73T0;[AHFK1K,=T+0/_]R$ :[]3$ M2)
<\Z:RVE\:W9]3$!PG5J=_);$]Q*+!."G9X]TU0?!\/XRHOH>4,3ZE]9,(4 M&+T3 Q47(_@']%.0XG-;?MNHUG3UUR2']HZ.AI=W$VHCKOO+/O"CNI:ULY0 M_4/5X8*R9*]"LM-GA8495
H93_+NX2]L7MW6^8PJ96Y@\&493=I=8C>U;S2_ MEASA>OSPUG*$R'P-Z2TK+."F-] U9,(+W*K-+=C\CNF;G4FE'0_A[I>KO!W( MB++^0/"NG=;LP1$.^&1\**H]3,(IOAX&EZ,3(G*1
Y D ;%RL4(! M?;U'Y,YW3;Y02=AUP.FTH]=225!E$R831;D+<9_?LRL?FHX87DMID"(#2CU8 M=.#7I>D(=@(1>_"F]$;2A(!$^&G9[,1; WSU C+Z?/ MN:&5YVUO*',5-
5@FM$[G\3Y_W#8A4<(!$"&@BT8S#O!DH*^A0O-0!6"+DRFX M94U9F-I%)Y6YC-W#Y\9^" 5[0Z=TT]5Y!&NAW$N(_]C]86P54&>YB7HQY&C5( M/G6]G;1;BGZYI9@$-=DB/-
XY7^AJESO"+R<1[+W;GDX+ MP) 9P=B'2"=TDE8R3>(-YD"6W9&PKBU)HYBGE\!/2!TUO2^C_UKQ[;K,&Q- M$U5CVM7S-O3U/N%IQAT:VOO8?RG";Q9E"';9'Q]$@[T]YZ$U
MX2!4:[G@06>.+X"WLM"&$43)+T"LN=MH"FK:$T4Y8BBCNGY[[< 5-LMC>KM! MW*6!]GRZ/,M0),8C^=VM!R\]JP.US%X.!ZB[?5G< 4NW407> M#%9D"
```

[EI7GP3#ZP^_/(@7,A+$G-=(FO}|-.1I[|A:3C_D.?@7TX*8Q$QU*(M3&>R0 ,=]9'/X7WL",RQUXL;+.X]A 7LDB&7SQQ@QQ\ '@0MD<I$< :)@NY?-
Y#XG_N8"YC'>W!V]\D^%G!Z21X+R#0MSEY? M(OWY51)E>),0+(!:G$&2;LHR03O<"RKTWOKBA0G9)[T,+56??UC7-=#E]%F M9Y?W3LV?[A#)=9M4M/=213 [OW+TWR
S/T,88(*1OHW61L8>7"&F\8@(&>;] MN*)YO-7:Z W78MG2THKAC?FRTL](F0F**W1]]S355@!I.&2= :N@9-M@QT(MBTPOPR5*OUM1%THN\/4Y=@#
(^^1+5MQ!9*Y!\^8MT%LR@@;>\QY!88]SCBY[MN#UY?_T34D3] 2#BZQ6+GP31>D?6UF3. +9HN1W,3:N80&YD^-%;FYU[,C# M8004S7P#%;!=?AKZ1#:M6DH+45.
<QP^]4)%]@N MA(/9<1D3Q^Y7.%7>1.O:)2 %[P UX^ =+_$!=B#QX";.Y"#RAFLI8CL,+7:WK7>W)7NKG#O1;MEE]\5) MK,3GRF:;W2RI
/<55)!:3>F.7"57S"1%H>FU8%IC,7_^./PC^V!QHS: ._BU MN-._#):"7P15;&KHG0E6]GDW63/*_A+7E!*VN1=X%B3>,9Y<,2=/1G"@G MTI#]E?UMJEZ/G+8'2>RNK"'Z;_MV:5^D9'[?
#CD* 1C+TBK%E%F92,E4TQ6Y MSQWVX9!$!YC!\E8#=2VRX(:\4^[T39U,0]F:0.UN=][&1K07?_9.9<>X-^D M9\&KW$>Z"5D&CS*W'][PK0[*O"%%L!XAZY;=/,V*.(M36Y_A"]U?
$#Y8D?G MM[8$KKHOA,=O#SJD.S0&\ ^[.=0^W;!{H._"VF MU>/Y4;%.02%YZP1W,%.2"]VZW\'MVR8\%H;S_[L80%AL%U& M^)EGQQFDAK8
'2%*V>_^B,91[T*FNNV8]XSA][GVZCR/+':Q-J MNA8;6'G 0:)-K, [I.@WOW?*&D"'"_^!IIHLED/!6X-6OKA]*935C3!&NUDP1 MCWBK)YJDF
(*:5$ZJ3B53YL"'ZVI8EB2OZMBM42[V'&Y5L"[N>T3$IP=>F=A M ?,6?_["T]&AI>:7*"V^>_FMK-\K4L7<,O>'KPA3GIW@?A2<^:=A_"%19D$! MB4<3_6.V#O!\%M#:R]]?
VMS[HYH<4? =3_@,D7^IME]VE#.&0[WM@[^>=QU M>FE0O7|-"_!Y:Z3CEPD[I*^X&;RSA4+,/WJO]_V2O0H\!68?(+(*+B=WBW MKY_7VZ3_8OZUIV>$!;"?
A1#Y\S!"^RO7&P1*>R]9Z\ZR M9)//GK!MN]2#O@>%).Q-DO2#XA(>:983T-B/8#>8A7]?=.6V5/C>+0Z^M&NX M3426BM/C-KH*OCT"0ZL ?Q[2%7\RN"4N.,=-C)*<=]OG%-
Z(>9S.;"NI* QP M(.CK 9H|Q"T@ E1V4]%$T]SSO(VTAZR3IBJQKVBTL+?_[,H_T*RZ2-EW?0O MFI?IE89H:W7D&.Y"\<$>D]I_/2R"*."6EG(-:?#5@NQ#(Y"]DR,F_LA@PQEF
MWZOX"S(?V+Z&?H"$!0@RY:PD:7^SZ3%C8IVX"XV+4FCAI0\0@@8V7*_>N;=S ML^;QYE-]SB]5I[[E'H5(:TW6VCYYT'[OUY1G>G3?@!]\/-.B]3EP=S3B-
XUG;3BLE\/.#_Y=*PG@1!FKF(8?WOH;"X(!:>1 M"/AYS>U120!7]TD:NY75,%^MXF5B8=DQP+@ZM =@3\-'1]: M7DE_]&1!3&?5<,< M&@5<;1'W76/+2&EC*?
#@I,#E5OI,\H+BQ9^V(CZ'_"N%8![A3;_]#5)F'K5U MHF(JXU(74[RN&6]<0%P8PIOQ4;7PI:MY2P(#.?*@*/3C<>#85Z&Q>'^Q&VW! M+P"=G1+YI.?OYFQ8'?
U'U,)#&AQZNW*AIY1]\G-^/D#^DB\]543*>OBX)X71 MG*J_).NPP&3MM\VLX*6VRTTPS;X MFZT+=81<-T#@H$X)E#_#[?(((C4:#P!1G"(RT,*)DO?THRF)[%.,C\ZKF[: M?
P#P(UR=N8*9H PD].2[-4%ZW?D?7IM(\@B>IG35I&$W&W MV 9A ;:8SIV[/;.VN^C^13NM#0FR-[[F#TPW)C=FL/JK>%[/G)8>SGT7"5">&HB@YHE.6MB=K?Z
ME)6_B7@DL^Y^ZW.,(6137&8..]W/GSTW4%%A:%'W<9&6Q(H7W':I]Z!5_I6U MQYT].8+;?@'X3)7 0]<9)N1,_'P]@PK[LX]]3?W QA]Y#%8468;U#+N_6K5!]0M=K
M=WQK&0,E%\U]1.TUZVXCH2V&Q&/DFI]BGZ3NX+-)]'3)!%*)L^6L>(S!SKV MG.9XTS:I 0KA]7-WZ2/WV*Y8$TTW,+Z>D-'8S'XW @L(MT&--^G;1@I8O*I7 MJZAZ'H*PH2@TT R]9-
HT5<-;)%'/!C]_%5@ H>OCEB;W"Q8GKRKY)K/"&2&! M6IXEG=^E@![LQEE_1=)C:OKGKT9>1];A;? 1#;^I6VV?I]$7 M;H%26= PZWX=<;KI,P46*#&EV@(;7E)_W),P.KA1IGT>MR.
[#6VX2YSG4G\/ M9DYQYT[WKUX\K3LFU']>_*1?*V;^LP6/UWX%;Q&R==^_"@M E]O.IRO)L7, MGL4Z>@E/UL'Y-VW"PY-+PO/@LQ*.$UF_YMBS%X"O,50]Y5C Y 'A5N%VR&M(
MJ*),J>\ 66,Q/7\81N:SC3<^2G1!MGR8R5INFC$ZRS+CG6?G6Q^^[W$1_CYI MUU3IQF5_!=/U/D3T1>>Z?IMLVM.?Y8+9D#&_6;DK]EA.4=\[WK;)\.JP)T&F
MRH=5Q^G>BY4D=KVOUG]H\HHNCZ]%,6ZN:YX;R?@;6!3G/-X(G+&V%RY^F$TZ M3'SPW-AD@O9:VF;?SOCW!\MIQ1QC^[BE7AFT+2X[Y]Z:,9.T
MG$53"LL+'KZT:\/RSG$L^KX"\T!I7M>07H'Y.E9776B[2S\0/Z(*JL@/.<9[.9*7.& GP=HO&R8C@!USTW5)5VL_[MX57OX1Y_M#'$.+R\[6* M;%M3>0:XO9E=;34J1]25Q62-
Q-.I+O9Y&-NJ/5[LS/QF<0ZSN=^]0OZM%S^' MAB"3I7>62J_EYAFL/>FG]DG,F_@2\N$AO\F6G$AW*B8^_5=\G'EK*M%PG0;B M*7)S?UQM@C4QR'=$37V2
MO$PJZ5(RCC^7F)8P(8SY/6-'M&CW3SRH=J M%;\UG;CN]SLI;Y]D/FA7BO63@V< M2&!0'<0F>EWH]O>P%V)O^SJ?N%^FEV?UCYZESOLSH/V+V$ W%HDD;Q:5S+7.
MN=N>;\]9ERL $5^M='@?61/BOE!OB^I'! 6B'44-K*+U95W?..DE6PI)#CCZ M$;*YIV:*CYP/R>@V8'AHNHFK]VH5F61["99>XI8IG]5%/\==VX0I?3U.4CAYS.,)OZ*%Q5: 0&>%-#
<^OEPF4'|!*&Q M8;:V&,4Y"F:GE6N7"2CRY^&O&X [[JO!'O8YDQ]3;#C3]"R?D/A3]2V^4*7X M)3VM-,W0T4$YC\M8M/6&U^?IOJS6A/()JFR#Z/S[;4;)1F0OZD7A9MI6-'X??
?VJB[PW/EI:HJ# MK 6A1"J(]6!6/47KMEKQEQ=II? 9H^1<]PML+Z ?#&* 9_!3E]43VTHW;_;) M:5I:86-:36B#^W+YKQ1;_K4X[;\#1!E:(R.W7",QS2IZ\)]YLILE01NE6>06
MALNK*4@.>@ZUQ1E7>[E2*(KQZ6G+?QX\9WJ-KE.*_PI$1VIJ#CGAK/PI==W\ MKNQ1U>,@P$P_.+E!V\JX!COWYI=1E(CV2"06L(D%?!,6'O;J[=Z3'%OYD95. MY)_MC4OD?
-J%B)-1&2%)99$J65=6/6I33F@XQDJ#I'-=^N)RRI?1D571EZ)" MX<8?)LO"+\?77.>^4O;[%%G*3W.>RG<0EQU^P&H)0#)VK;7LO74UY)E%.HV:U M;X5BF?EW5@*FU/GJ%/8Y4G^!
[I6ME'+V8=K+S[,:#:H)0(UYJLL&PO\]3'U2 M%)N]GO2RQCG7DF(T*Y/TIC_C0I37&XDVM\+EC;VY_-P)!=-1ZYLQC^ST[ZMM M[F4"QVK@YX;?0!0_HC*H[NJ>M& MYJLLQO@JAMIS
U9;;HN@(<;M&+RA.B]3B&7>E.%#^K+ 1T)%>8I,=%M:\^]^ M18]S$;8DWU#R+0E]]*]C.R$0N"%?8_74QC(S0+1D4[_2'T/]ZM&DN[M.8[V4 MS=GP14^O)K\EG4/G1&
MOI@*5NDK^G+-.],N614C ANK!9&A\%MF6 =>[GLIC4[,=,I,BBIH*7Q*=Y5 MX1?)_DK^,MCW%4V = I,\;[JS.GFG/+6J4DPY7M4?%UL^KNU+O_"1QC"@F2,X]?W-U\
(NKNK_IK*^A':C=;$S2Z]TQ\3'3) M51&OV+3I=KK#%\!1&%U^<_F>V,FXV_;/EO9 PM@$ 8>=,+C[6"7H8N/0 =' MK+NZ@S6H6,053A;9L7F.P4_XW;&QD4>0*!1X
41]87C]E"$[]VY]QX3!(1_O MG*]_HV2\HJ2:@?!X9,N31\V.4()$GL7+("P[E)._[(]HM;$5MDEYA(6T&!L M"OR@SK B58,\ MC0_!FV>@39CI["+F1.%PJWV[JD5DHMZ+
[1KXZT*Q5>&O)->N M_HCBUYX:>?3*.D/>H\Y/;L=N\F5WB1*SXYUH+55F6,XP#2X/.4&@9<_Z*WM" M/Y<@<_V!'Z@HG)GR(KLR M?VT!K"@(@A9V(_*Z] M1@(SICQ
N!F&KV^5K1[;XAPX]SZ*B+#S*(P>]D'Y5W1WD_!]+\^(PL_G0DZ[F-88'#'-WD:C9YG46SSQ\EM\C[A3%<%/T5V[;ZW47_;/IR:2>>H/WY^'?9^PS77"_/+
M_=!K,D"15L>NT'&0TS/2%HKQ9Y8)NH8IMU*,(72WI._#:#\#CB@0]LXGI_2 M48PCN"TIU4[=40[3YE-4>,R^>%3MY,Z#PT,U[(XM$_+!KPX_C;V\75?!>MN$
M+G)XK"UGVS#1U44],25N<[4&D$%A#8'OE5O:29X&S72'F8XF@A9M!8E3./1%EN MR+O;F2P-YUWA7>YA_-=/U'XE+AJW-EQ]H=Q,<(,AKW'F:^]"^TM1EJP,GN& M\:-&;6]937#
[H$DI)P7:|P>?/]L(S_-EW2HI(Q9IL0,TB9\,_8EY0=6G.\4M MFS9-&T[*I\]UVHQE&E(;N$!5.S[S8RW#5QGC* VY;S$T(/ M"O]%3BATNB\7#]T2-ZW^IYF I3IX! MN]B&8,_)]AU:"'YQP?
SX"P'CEKX#]7W(]U>1O1(D0X)].7=FIV]$4)E5[V\& MET9)7;W28=V*$1PXO]GCF)"'/G/29A9:RC7CGQ,U7.N-*V)H9)T/HR$>(8
M1W\&N;9PZ(K4'S=\Z6@UM@H[X]VZKXIV(_(N'SM_\F?(1%]QT%RR&]/@RQX' M95^.71$WYH]?8@<\B*]V[]@VVUY%M>_/@O54;-U;2.TM$#2/>8A,R!0Z]#7[
MS]6Z,#")05DR.5#00"]Y*R+D#\V@NZ:G0S/BEU(&D:D6.[7E(B_T0B8 0L M->7*=X02Z>070$VC;]) [7-AA[YZ*@O).6T-2^QE_PP=2Z%BIB;SJRVT2M(O M\GCXI/!!
>#_Q0WL7\89^3_ICJUO'BGN@DC1:Q)-"8_(IOOGRW@=)C=70:]] M'^$S.DN$ED86!@4()"NGO'BP'#AT;_$A;4K!S0L/=/-_9#/[;+^PY-ISE7-?
M.Y:_REE\$VH<9Z@+O6;T&D]K1])3V9TJ->=?PS@T42BSRMZXV8M M!IJ1M)BE]N9["[X3*I^Y6K_2.BR\=UJ@VR\"_X8BG=ODHRW7&C%/F*=\K2K> M94BVIAD"2'?T-]9]^A+]
[&#)]ZZ@UJPRMTF1V/[^]-..@HY],&=+SXH=&YW MK.N=7]>^Z0E$QK8P$(UHJPV/;7F.,FFFKCUO>VAG=_/>:H?25OXOVGWA0F0@ M#6MD,2>7DUZA#&5Y6+O?
V*,GTB++#H(.,&2)"G.MA.]L0 H#CHN:$Z<[JX9 M+J,\LE 7B+Z^R@_]EK 9G27\.$SZB53[*%AW_=_5&?VWN,DP^#\Z80)O3H"CCM6^S_[17(!_'+B'WW3\(O(WQ?\Q%$:NMHTJ\S?
KC7+>2':+!+UU ML>F UQ$:3NMSMX /=&?/H(*"K$8.^>^_VS;ZD7)IVXN:#8"7(B8P +FN+$ M<_F?AX:9LG2[U_ZF^IQ]7*IGNHD^DZH[+,F9*8\4;*4E;6/#W_9;3^T?%-I4
N%;:"=]7K!#'K4%VKWQ]'?W%'4 H+V*<%HR]A 1LK/P_71RP^]-_>S>R&(YZ MSBZ/8P%XT%-1T!\'!S3WEJ,<_],XF^+?C](9.>LSV,JQO& T74N/ M0!9Y-G!2;R7<"D-
N%=%\:M^WI+\>3;&Y4;Z;P!B_J;ZF^]_@4];NUDX@C7V MU/+O*"O0;!\+\-62#\ *X-?15:&*^A%\F9^-9H=IENV.R@VJ\$"(A7AZ\E0 MM@4,+H7\DHX%V"*C R3-<0#H+?1O_/0WU=]4?
T"%\@%9LK_)M;6_3L3Z#>'F M[6CK2T]^>BVY)E@LE(LL/.-F&4%;KP(G;.CBC$7/@#]M:JH4!H5^B<[& *M@) MS>@L$?1+=A9T/ M\0IC=L\&EZ1CPOT;&LWT0;D9/,W/?-- R[/;Z-
M/>IXM MTYE/E,(1;+&8@#-;'!7HY.!]?DZMD--0HU;^-5>Y]5'O0KK(?^IQ#%S0=]6A M_!"W)@5"S",1"EE80'I4#TLH%$54\]=T $_.**!FKV QNY$8@';#J!_N#]. ML\AX12Q
!E.)&\/.W$%_9&S?RTP""'RBN I?R@CI1'5A C @0]904"Y NQUT) MC.F+_&E4L_TS"'?IY8L9P1;0Q%M#Y/[9*H$XD='V+=*-'==>;_M%PM8C)#'4.!C 0/64"0E%E";^=.HJ!9S(Q>T A[#
I#DN"7)_VGJWR5&<&C& M>@RBP@)VY9G^.:C"8:XK3V"[W.M0U!7S]?\J/SD:%@8]9HK^ MY[I:A 6\SE,]H3R HR]B >N#?YIJG7?[S*OI[%TP1K4=A([&I?K_;"B,0YLU
M6<^(3F8Q%Z_*W^.]N#M$:9A#M/3B@6P+@ Q"HO0?ZBUZS^IY_Y/LY[T>.!R M+KO_W97KV?\;Y<("Y.>,QJR_)]S[^+KM?O#".YE/1F$[,/>A?$U:]=\6<^6> M?
D0(FD5RG>>S\I:C86SBM?_D4L5]&1%N!+]&HXW;:=+D%G>1D6M97(!HC>?^ MMH;'4Y 5Z]OBA33MXLO6=1"8_KUB'A0.W]D?]G0IM-\ M9Q9RKZ#
[ZB*&!2=5T3'0>A)TI:WHK6(?A3]>?5!U^O#X]\%_1X)ZB&.V.!42QX)@%=^)VM=Q%\]_?/'4A M_[J5DQ$2'?#/6H6?]&#DT!'(= #].BT-A%R_$RK\D?!X6G%"X^4T9MJZCQ_
MW>WRUSY_+.)MY0?L<*/CBDF@-;-C>6+!_^.S_ 45$<53XZ#UX_R;_PS+Z%' MU;$F(X1-[E^Q,7_\R#IA 0RQT'$AC&8'FA.G"P\Q,^#CJQM<\(4AVY.EV:X] MG ' =^]!)[NQ@-
M/*R@URO__8,,4E8R1-0!CZC[B3(3$#"V)XX16Y03G/#)I MRNI4<+I?5(QS !K0E0K$)6G9 MFUI!A+]W,%#KM2WD$ M>D-:TM2C'/ZQ/A\1?%#B(6O.KC!64(#P2C+WH
*A*7$6F9PT_=KJD_9W$/Z' MJKDZ+6P+#HJB^<1ANU?2RRH)FS6<0VP']6ME-2I'RR8[7PM-]&3M1D=%_U8 M9;0E Q=OY*MM[T8ID>^'8:^F6S-FH M&Z:5+#9
YW)WL4"AEYPWE33??^?C6*I=QYB'BUA 44[6(#N :<8 M1CH!=M &VK]NJ>/_J.RX6NC\Q^'"_[VX/I3/,A#*O\8]_Z]?PG3W$[
F.EZ5[$7.'8DGWBES:DKZ/)9)\2$VF:D>B:7E:7HMRI,K&5?9,@L.>P5N[JL)_O TZP.CS5RSPL M*K3*_*)GEG=-Q4S1PUF27=;,Z^/I_<]3S_>N]>SUS;S[\+P:.(F#-(B79Z&;
M&F>)&\EUD3P;?3.U[F:U5GO'I@]2/.*?/RD,M9;RK@#T8]7U]*V\A<>TEL:6 MME4'.)_EN&99S*S6[C=U]ZDVBD]G<8G39]WT$5;"1G2#;Z5]W!.GD$<[JZ@ MOABIT82N?
RQGF)L&F;B<(E1H/@]9K[8.2D).E5A,RW.V/P8UQPBT17-^=%A]'E>W[K M!!:FLQ0C@+M^;7'MDL MC%48P:0P.Q)$5],F(MI0'=;M6_-P]OA48!25;N3?U&&U
M*EBKHG38*OT1'$K]KOTXA. VCP- XL3=RZ+BC5D\Q7+-3'"1]Z-"LG;9CF2Z MHV #14)*)1.7G%U6E(3W>VW+3'"*ANQG^/V2HMLZU/)2"HND+X<@.?KULC?5 MJ?ZC54UE>+G
SKL7DV6D%5ZAK_5M&VG]C5EAR<6]S358 ,4:[.L.54.=UN2] ML"SY!V*3/O+#(FCV^.26BVB66Y\SDRG]A**T#HH?;8M;K1]6M$\?3P9E=IV M?TAZ\ &*Y4FDY4*"N0I]0_9WY\G%)]
(C+NH'+ZP/'(E>KOH/^[9"XQ+/O#T P M<'NUPVE9TDDYA"9NX50(-.7N^NDEL*5U/6//TX(^76O%>9>D9X M@J=9CIQAVFF I1,GBQ$;3.]$Z0'98"V1F31:(RX#L8BMRKQUK23?
41OBH28> MZ;>CSCM?C]7R=9U+H*I6%;!2C->8UN'*CFR)W)#F%9%VU1D)%3-/P1>;Q?QT ML>Z*9U8&3!BE&3@NYO]H*L [#-&Z^UG,_5Y&VG_I7?X/\1*DG69S/&C_;=$F
M4\"B6ZN)TA4JMHX2.B1[\(_C9H70_L*@LU,HAJL&% S;Y9S\|<9MW*5(#34, M4V^%BPS7Q?<3T;_)?US)<=?4Q!F*+!4L/C[XA 7 <9E1V^\'"6Q)@>Z>DA M%H
VL(_35AU=A=YO.^C" OKZ^C&WS*#Q0K("'>+2)!:!]0 @S"'AO'1=1O6>Q M@- BOA#)8N?CA^OQ6$!*"@S-T0O!>+T$;>.8V,%EBSUC\.6Q%LP9;OF4^]8W MO0P3=X/&V;$
.3$02B=I"WR%3]+\Y#S*S\OI*KKWDD]|W?2(FV.\R\PK';@ M#NX"ZA>C-S9^G-KI(W^9?V)_X5[FVCX\3K(:?/SMVX_3LG]@4/XGHW:U>1Q M\"?V1^GE@5]?T"G_RW= M_Q.DR^>I-
&82'C7YS,B7X#IN(@J="8+0 I)KJW"CLL!O\S-@?O9;G1V9I$K+ M*W]+[F^]_%NZ_[[2%>W>?B-:D9X]]4W9UJ1DZM&@R",[*2/_R.1BP0;E%V.P.?Z'Z,KF&6 MFB'INXO/ YRVPV*_8,
/#>75)_55+!WIV^H"13*??VG)$21O'H[35>H92A M M,WN?,KA_ER(24>|-)+.$.+5&?Z>Q(OFQ!#@V-6M8&%/TS=XM_\IZ?W3S%(1 M^#\LD!G^].LQ:?S>\$$PO^&GRH7\-
Z"&80(5T:PY M658Z=?5?&7S\H%)69A.A%K,DA".%A,IF0U!W\=/')2-H:(&]O9/3=[TVOU;B MUP0+/5/&:#DVW G9$-/LW=GSN.8S85>O#A8(S'I7N]#9,,N'LE!M*E.=T'(ME>^)5
].H+K+GAH(($]NZ*KT#S" M5&@Y \) ^FF?V^$[=7XOB;PJ&>2 M3CJN_2OC,L6Z* SM5PQ:|\5VK4 Y6NVTS/J4W6-@'V[G&;L#EDG2SZEN=D(L\6H?)WQ?6
M5>]7%W*E"'UE'OZ98["?B.(&D./"RE>T-%!?V[%@!O691#9689B3BU,H3)$= MH+B--C[62+]+6%M42[5\TSPX7TDMIC0BQ]HLGX,(W?PO:KV<^K7BD$!:X8-MJZB&
(26:7I##1*,O+QST.LCX>T>_//+3B$P5L,J$#BUUK7H:U M'|BF0M:MG]853_; DT7>N:_TWBYQ#(TOHNRS/Z/$*O?Y^Q+K R?9-Y<": M"]2L8NJA@H'&5@[
9&>B1C4H:7\B/NN0O(/F+.Y^>*43V[_Q6O\L&5MVSK\ M+'"O*TNE>SMED_L07GXDO>$GJID?WQ;DYE4SM\#2;44Q#FCIU'-8ADX:I#>F(MJ2L6-4[S;[K6^^/,%WR.]PT3I!$
!RJK3=O.G&NA1YV=W)Y-OKQY,S= MPV<=GGE=_T&8*M^*//> XQ7D!9O(?>EODP::":EZ[T15_= BARM<&X**12:5 MT:9X7$SV40[\ :O1FMXL5KLM%$6)1#57I&->VE>
[X^WWN1Y2]$'&@,@@UU32 MC>Y<:K]@;9";@*$_3BC=SETWM-&<%*1]*2BX]ID>C*H1\LA/K?KOLZ!Z(K1 MU,X(VTC.FNS'!2?
S[,1YX59#HM!'R.EZM$.7S6"4_F6CLAN@((8@_$(7!I*1 MI5%/06N)%MMW5*G#EXR7#EJ9\N.Y,K$ EYS.63Q30D8D1;WT!Y?C43T] # M*-Z2,:=||^K
/_;7DV&C]#8NCQ0FUW5]7SPQ/];DK+H"C44&O%QK&=[HZ8F1$Q\]>?\0XC14KA8 N8&I**WFQ '=8-Q:@^*9, M3=;*[C]O#YBWD1Z3)V-J.\X@(V7;QY=UH>,WL8 !63?;?_/X<^7]LU"
[N7\ M9?^SKJ^V?0#]>WF?[CCH%5OXJJ'D95@PM3?^3&5WC3/0$OMN4GU: ;7V$R MT9%5P!$K_DZ>1^Q ,7/P3=-%IT>&!1T +=>=6V_S\<$=F>G3]7-C\ 6=
<=#I8:1CY_O295;7Z=,CF MACM%7[IN4TBI78"4FKQ4HR.IF8P-17S')(M&\U<0WIV>7\6?55UIP"(DO8> MG:NEO["I']M&3K^5/30I(% LO]$&^8ZVY;=TW> ;S/= -M^ MDI&:>'E"
HJY84" \7>WQ5QB18T)PR"AZQ9)S-2G^+B. MF/0W38:]40U;ZYU]]4 M>Z*FM*X]S)"%.[TFE+ E6E":[_R2E#2Q.W8(XAM;HAX^'?Q@=!R"V/*FTEL3 M#=\|V,KDB9F?5]1\H1:@WNH;.
[+ $-^.>CEE ;RNH51I92[M;)TUV1CM(.\T M65Q"X9F[H?)MTT78>>P]5;1'3]&*3XEQ%-OEAP7A.VG58_OY]WLH=5/BR+GXZ2]O%O!O]#Q%C@F>0.=HX\MGPMZ\^>94*BJR?
ELKR^PN]<>FZH;1#S?N-087/ &,J9KI1 M6' 2>D(K_%)*5CMI:*6("3-/N/MP/H!D9)YM>Y?^R M=?O",V&Z3<,PB4!]WRW+]GR+*T<2+#_,[!]UG_F][5L Z@,6P*@BAH"8@'2 M5EOY?
_HB9XNU9/JIMC"/3N/PM"H=69&P(GN 6JOOC.N:E>YWS!WHE^|EWDWN/%"8$%K2M?>FI#0.*^>ON%DFSV7
M>%56O";,%1_P/M4U7W"'!DI)OG4%XV*F#4=H^K^-2WC)&I[VS#S3W<(>E_FU4 MGLX; '&,AX958TI;1G5GG1OB#2M/0R'U<_NX\&GH=AKA&<1A:'<"\XV+DU4Q
MW3J^E)HYL_45=<*TD$W>*#$(IHNH?ID6ANZ.E:\ MG2(/GK)]T5NM(M[?E'U;9#THZU[+?8;LS>]]65-@.C)W;+$%$KRH!@E;R9,6 K=.)SIQF&W\.VR"CXI.H"J.IL>Y&TQIU&-
[U$+'T=T!6%7 M=)2=VPHD>B\S=)ZZ,-"79]&S907'AS)8<< ?Q MQW;\3^QB@"=.5Z_Q*?F6W 5V-QP561R8 @:.*$)U1PKFIYQ M*5FM5OF58\!TC-X* S'1E6C+_;P&-^.9C712T]
<([GUHKI>]NEP MN3*]]N3F+4]U*=GW-X+2]YER0+I%,[>'8M5KAV=VU)>&N$6=3)]?Y[FF?#UR MGOYTZ%.O*/N%\?8&NOHZO6>""F$]DT_Y/E_PPF/$/QX]4]8;+G/CC,'.-=N
M3<"U9L13]E&$]/*ZSB^JTV4I9+IU/XW8VFQRLO+U6DRR7A#"HWW0/L^C2I"> MQ?7V_$>U>W/R(K+2+ALY%M.HCS,:8$3Y&J[4BW>@/ZF,:";6.34 MR]+G[+?^]+.?:?
O*]RI9H^CH],?N-'K6$*6ZV.[RD8WEV-.2QP501DA(J%+) M*(8-\FEVHL.>9K)UK?CK1ICY06'H=I A;5VPGTZR)>&\@HE19&,,2(G#;V-M
MK7PFT_0Y7EU=925!>I+F;QBS*BS@LM7184WO44"Y9=C>A.? ;|\X.CLT]AG# M3A:&*K<]IV=:Z88E'HWY+;D\|>\Q+I?. ,S"%QP030V5P4OA,HVLU>!RTLM\ /;/>;
<=G#7>0Q;!@(S_V MSJ(I9"*O>'@T8@\NQQF\E0C/VRL.OE717V#!OR86^-X@(V5@MYH1^^ -8[! MT.Q>((S?R3CF8C$60&Z ;^L:*&<.4U07?&LU>W=YV7Z:UY>]Q]C"7F+[BENX
M2439,Z;X]GTQDI2F<%VI$ 7["'>1W.[NX]S;R&I E\@\8%!].H[X&)&65C>" MOJ4R^)#0MYZD+R2DHKAEQFEI6]D:VR'B53&FSPKU&4Q%:'U0&VNN6>HH/)AUL62\U ME.
[1.G982X[:]I'U).ZUQK-G7'_-IHV\K*U1)S,[0]942G=8BJ?]H3C_\7> M>\F.7,BEQ 32BA;51\>?BZJX0+/(KFW
M[C/#\1C]M35=P^V@45B#PFGU(N0PCZMCI.QURYT!VIXYI34/RH&#SDK7=@-7 M:-L%#NO7,Z"@MV%DK&,K%<0T MOQ; =]_->Q7CG.GM1N(59]Y!55$:5I.1-)[.[VK-
^JL&E&>P+-3P>P+6+KE MSN*7Y8-O.C(<(2D%W2)Z PAB7BT.6!6 /F;SV-6^]]9P>*HSRA_/%YB\0%(3G;DT*2CL9]>X'GSG>!3C^!34AU11QS K.E=N[;/ MJT6M-
1524"X#4H/\7)W.;&;\%]U&G@1<4(T \P)SBV*VHX&ZC8CH[L2T23U9 MX79XYV(3\S,"AHSC0C(0^TK0_F:>M:[$%Q0S;S5 M,UT"30Y9A(D4%->?VC!;.+6O>:-(2259$)Y& 3LPGZ)
4..19]2PSVGS@%O^ M:>:2LR/;(%XK8\]LJ/I"I9')!GC%6/32"SLS[7SEU:2MY.&P 1'8OG%W/8 M\6QEY$H<>'VS?W_E89VE/W*S4BF @(D36(U]T5SZ:R5:RX+GH4U 56LWL_N
M](8.A.KA P7A 0'1&1/"9W6ME2L-"-I_E3WI_1AC$$%+@<'#"0%?!;)3KHXEU$;*R*?J%H9$19-987".ZQ9 M3I?:3 %77KZ!I:R.%%9PQI ;5NN9P(\GU)W*1>UI4ZFTS5F=: 7LQKA<) D^X
M'$6/ZF]"2%'):MM%N09@%,ISQ+K2\Q3O+KE%?Z/&!'#4KC5BN+Y6;0_%+7W(MX6_DWC'0Y1W:'3YOW4-R0>Q+T)UFF1I0D2%Y205+S(8"69BJU4B0B)'0'"*N M-
]NFYD:4VXTY>7DK89% M?4&S;7OV$(1Y?-G/V;!]4K1#^ 5!7=EDXDT8,/,I;"[] +.*N=U]><[JL7^H M5.)5RF?L!, ES5Z'P1D/6ASPW1%;"VY)ZP?/YZSA@(,U$-;T8X.Y&LA"CZL
M+905.0G'A/[-;S?956GN41T)(N].ADW M-)R].L] SK$D7*_3@F]0SYH:W1,Q4%L\.3W7IK7.08/.*?0CM42<;:N=BQ.)YK?(;Q$]VR*&_ULKG0:0$7'? MC#Q)2K4]N2;6>-3.B-I)S$?$@VU&?
CV$BM)]]@X^%=R*^NMU]P=$&VD^E)6 M$WD2D1]QG]B6$%(0MT.6KE'H/"D=?UV/I95_EC2H] 00ZISHE]".(CCO"SPO?Q5 M7E+H"+.(^J/YNW4E_Q[X4SX,IE3M4,X(-<8*C=VHV
MMS0]VO#>UK<0C@LD]5IG+]035?-0GJG#"R[IT\@-G-Y$#;#CQW=R_'H.@P6>+,X%9PV;KJ3.^O? MKS;'$KYLU=N"2.;HX--.BT.ZMUG>@'[DF'E,($O/Q)8FT^S<'.PI"DFKK(Z
MFQ$(CK8(Z9&#M_SW1SD4/[T<>/GE:4/)M;L^[CJZ$VS'L==#IXE]AB*5$5L] MBY)6)UR%F*6K@:E:)02Z2=81X2HK&"W2^H/?@;_@O315K>0[71-P0'WPK9; MO52?5&)
[*\M.%#9)^PFI@W.[\HRHE;-^/&# BUU]8]LD,KFT5!3VHEB%&)P MZ(;F)@4;D1]H@3=$)7+7VN%3D?
%/NB@HS"Z0W9U>%L1:S:#GEO9\I&CY)T8AW&QZ+O<>IY:OHWG%$1MU)? M(6R.DHN+Y/M>.S?!R(IC$FXAE1!7AA]/)$R97+E_,B05,O7'$*TM!O-7GO>

```
M\'N<&0S9R5B&7U)^W]"\2+4CRQDLVJ<%^4AA;=(Z."#_TU1W MQ="*7J0O>)XY!S8L9[FD;[Z?GKS-MY8E8@LZRL#4[G_Y*$FI 0?^%&,XT^*F
MA)=,H=JU*ABB6EX1!X28P$^M(:?G-",P?^<7557C_E9D*SC.[R]%P9S'OPTKBJ'6T^."J\CJY3;ZRI"S1!P6TR M&W4O5B#->L![94VJ=,Y=MUD#-
!)H1(BP0GDRE#.G"8$[BDI*;Z*U]LE\71:3 M7(\1"Q9" ML](6%AI6!\]8>ZK@WV@&\P(L9T3(SN& MJA4O%8"K4+?HL!1_P-[CAC9F0DC@/ QXG@:^ WZ6[T<[BU1GIV-.*#Q7?
MG%2T4-1* =#&):TIY5I7/52*>HE;B M8A\4SZ"MK3M&U#)#(A=3,"#(@-#1JE;D:JZYOJ.1D:W ^SE=EBIC_ED!G$L9=02U&3DJ#H.^ M-;XIJ-;&<*<$>:\6CO[+X7[:PQ1]6L_(4-
0K!A9Y3@2JVUU^0TPULF'D D7: MTD]CSXI)BU>O]6+,CSU?'(>)>\UYIZQ0N,GD_;MVV,EEV&=JJ4^J?K1@. MA5] O%2:Y:X$"Q'
&3R/50*Q$I^#!F9::NUSE@>:79GEK:%,AOP5A:&A"1Z7 M3: PDLUB]Y=[2OIR-%7'Q-DO[UJO=$,=Z\098AI'F=VSSU>6/V?Q)W4@L:HU MJ(VSK0ANTC=Z,K25O;G?
%,:>RZ*EWR@E]T;$/9BFGB!47K=&:26CDZ>E>)KL M*O'+,HMT]U*W^]-#@&=7Q PS$?-/C!NKEG%X_ST*! O*:I'\#./ "+<'4 @U()RME MJ-F"-B_5 @>\(^^$C6._!SL.=%
M@2YZXK])6IZ>UA8 ;]_/=*BY.[2!P2/G MA7$-H=#D5QH*.8L6+/,6!_7,HY66[R?IROJ*CK2Z;Q6:]V3?>)TD5^OQOG6W_YZ;'U\QW?-9LZ@"3@";6M/_IH[JTM5C0:CGL
M0\+N37/#PTX<()5J3]6)>8*'+ H5'%!BB.;GD+9RI1%G\E(0D-U&^EN$1'&_ M>"^T$_3"I'6/!5:79=0RVBUZ[W)-;(MNH%;V@Q913,F]P6=A9"?%T-VK M8+_[;47ND+IH-
QJ.\XB)X9:Y&NX2L6[(G$[M%7BTEET<'8<.ZV N@E8;5AER MYS@?[*.Y,X4)-"#%6T0#.""Q6<= J(_/7D$TO79@D:+IZ^EF5&O-0[#G M07*^XP-
N##A%:R0GA:YJ8PB;+_:&N0MKQG,CT;.S M@NUM4G,8R$KL;+;D#M?3(-8@;#=Z$D,B5AH>,;%\5QJFIXIA@T\9K#EBV0SN%%EP(M504;DQ17LO/#'UQ#8!(W7< M(G.W/2J 9
M9Q,Y83/@>71 "!1.L1(\/5 FEF#G( M0BV?$PXI$8L^CSH=G@O7KA'LS>7O.D?,?5J">"3*Q/"&V0O,'+IYWE07(U-0 M6BIC_U%D3%]2:N3&KL>>7<<):&]-7J,(I"]S?TP+([
CM#_&G1J1;/YR]]&Q MLN>;A*-.V)2:X? HV4<=O9N(JU?S7W(L!*9@]V+5$RZ/&D(-V,MV%!/-#WN/ M#10^W9T7--PR*I&";24?9$YRE0E3!^TG7-%K9-8B=BAUE.QN.4;C@"F)()3X
M)_3'1/@@-=7^E.T@;_BC&5=JUU?PB-5)(=8P8Y*N MS^=X(=N>;XF^9HKS#5D4)[P?]5F 1\T7!'#8CRJR*EJOZ).]KYU7[P>O=8!. M ;73T ,A0Z*'T8Y!5;+P,;>(9&CV,RNX$,U^RRS7-;
(K9CVS&YK*0_MK&X]E M4F_K9%MQ^U&:0UY(D:$2=*:VMS"?>LA_&.3]&:F#V+,[O$E(C<+.9'-RVK!7 MFM9^W]K$Q%P/6T2&
[*^&YZTY""!'30X#DPU'IG2ZL_5SWIGW'1&9B9U64.B" MR6^XQEDV]$K?"%PHM],$-<@_.9/S$<0X8HY$'%:8!!ZTA]8YN^5DD"^=]SO$ M ;>^N?
VT9J%42NJK"D:%DTHK^+94EG1D9[Y,W)8!ZE]:0X>72O+NXNT]!4Z6JPOJ$I MV&CQB'.U1:!@LG37OE*,V%UMG&@_0:T(J*V21-$-03&^[2LOC8.E9@HAW][,082<__N=\<>9U0
MTJZDHI::?7J;J?[%G0U/E/=DM9FZ,M75QYD!YPF 2]??%E_[<[R(RP<%Q6;I MXD%I,7>US/!]I[6IQ+1IKGOJ-8OQO[W&Q$F=Y5DOI)FPL".$C$!,@G\JUUC^P
M%;^W/8\^>$>AU;E@_@"R.%9B'=XBY7K]#-$@'K?OI265R4,^]&DW\6 DX ;: M!O .U$?V<7O:>=.!A!SH*^S=4J3]D^*"@2TW+Y_ [P4;CX(5JV&7A+3T:2ND
M,9^K8=AJ([PU:90[6=5M>44+Y3@;5&KM87RU_=RK5&I'$69P?[$Q*O#R*DT1 M#^\A>L-/C5 LG50X[*(X:FZ5HV@X_ GM78SI:5M/N.G)NFUP9"U\4F?%_D3,
M86L=!PQ7I&B(.#K7&,N=[ 78$]$L[65>O[(]T?WIS0&/AF2D1HW%;F'L.Z*X MY)VU($' ;J$4*U+0S[=4-+B>9^$O=+5SP835H!ER'0?,20PM,_+?MJ@9F@%1 MU-
O/2LHOU9Q^UPD)"2=[;<%DP1 P5R :+^E"-0MA_;0"9?>?27Y.^WQ M;"6(=.U:]**?I;,)Z/.U!S1.IWT,%G/Y&QO^2W!4H)'CFYU7)9&1D9L/FFE\
M@3O+LG@Y%C_(F>ZZ9$F&LN$2"4N;^=+)KAJ2Y)Q"*_YR^3Q]\Y:CFK+>TL;1C.!:9+7&']5;;7R)IK7C=IJI+3V-A.L6SP90*,R=QPI-3"@(#!M\RF6*>GW?8Z5T2J95S
M<+VTO+R<>PM"!\U_#M\VV6V=2/Y43K!,7H(1F\T1: JM':&=B[]STNDLQ>AJ M.NX:W$JI[=-7*FFR-GH:[&NWY^BR%%XBB(P(K29"(45PP,62LI7%UNG.PW?Q
M-.4DTKD3GUB&]3;2,UWTT:O1^M6K33L7(QTC<( SY#'9G"8'R3^*P?ZS]D,6 MC_A[\.+W(SK[I\L?DI@P:XKYZ( ##@YKT03(3\@LMZ=XJ^?-%+8&^>.$^MWH M@VU8PTE/[/?:H-
,KRI)4P\[U_\C,^A_=J(IG$LBZ9B\_?5S+4^5D-H]=19/9 M=H/10W?#_"MYKWR:3V89!B217U8C14KI5U4!@'\$;A@$L;;GB; MYF9\* XP"(4MW_Q696%)E?
>6_P)3H)&_8)\ZY;,SU5#IAJE=CA7PP0HUUHNK M/H/UUOSG8O'"3PPWDR9&)2<>']]?H\V=%&+1BK360G)[>.5S'W39&GSH3#8+ MX:9M3; 59 +9&TC:W5LR:[:A=M"DL]@SI[N?
8%(.]A#UV#1\2=6N#'&J!E,, MUT,NF](5Z$W05P8GRTUYU+P:,219BZQ:-6!R&CSP;W\ FYN R95#I^,NC6#: M>10&JR<7OK\[E8;TQWQ%52 U0G3TV88/KM;
[])!M^M8.'".E56D>ZVRMZKLI M\GX\M-B%O6_GGT>L=:\'T=PH"9 ^I]SDG93D PK)8$\J$46,.?XPU)G^N!"[ M*&HV:U8E8@H4!]+-SN=K6(>\-6)C[+F99J.D]WV*S#?
C0V:&ZD2<&%7#\J[3 MZ,HZ7VI%:72+8^ $$'"5EIGMZSS)49=TNE.PAO?L33/EB8W">PWO^7C(2#(A M@CVVDX6"4BS>*^.3.$P^,7FHA@'R[0UBVZT_UR5>ZZY,/<#'OBX\RT-*_RP
ME%CC$1H1-/J:W7I'0OL(6U-\D$E;7\GYZ / M1UJMTZ@A+]J9,95J$5&Q%%AL0CZB58!TH[C6*N=EV M+8,_[G# \=(6.3O!=[VY$!'OH/BB9(.[9H[W\SYI)BNJ\U%W',A.Y*GF)U7! MG^S
_(N)2XM*C:OC9;KKEC\P'[P!-E9=C[(=YB5.* MCUZ4NE_[2\8O+IIF!MH[]%BI3C[T(>24YF ,%63A3#[)<^E"O*S\1980L@G/ M@.N*8JYT-Y3W%-'#3K&, KZ--CJ\LA/5#S:[.KBZ
N'Q9UVPCX9'. MZ,OJ7*>/#;EHV^;K623UC%YO::UC,74!"2NC/@8\H]\SH\3,K9<^)4-'UK[M M]4[V8U13UX0#(C3N5N4QO'Q\F^CR,3KR2P%W8$G]ON:,09K'O>VATLKAG1H-
^9%Y*B>$@1LL#ZL7UL5 MW-(U8-OY,G#_(\?^@73TL6C;]]ACJ&<[0:T@VAM)Y3'YP&+%*'2!ZCB1SD)6 M<>7^_H KFG[T %-AX.OH>C99_M(;I>D0YRTOKGOU-3#IC62$R8V@#'$
D^L4&@5" M7\@>TN3,X*'"^[1V["8';+S:LK(L [69V- )/((CW/KJ?T[.FZ\2P@$W&*'8 M!E68\)IFJB3($Z:O/?8%!U1#%G! 2I,.>U*QX)]U,NF]65^,7Q<.T)_#%J_J M.&*\>;6KF
K0K*3B0^Y_?XGQ]L/M4)>HK %BN//_W1*P&9>RAG+4)5MS/G MC*^&ZO^4J*#,6+_.Y\5B0:\QY,8E8CPFNS1V!^SRH)71?1![JQACELU(W^A( M!A+0)&CSE%;I:I'N-
<:>+:RRI*Q0A*>B,B?DZ06NC =K?<$/\;>K!\^59>\Z M?9N]7'4G/URA_R9%_!EMEF<7L$;88_&BHT$#*>GW17GKAA\TZ)R56#\J?D]A M6!B^9CDXMYU32P=KFY@A0Z-A2XP2.(
_!CN. PYU8EH2=@6<)+ U"<>MD/0* MQFKGJ<"<%K_9'/JF:S$OG%_NYMZ^30]G6TWU1%_:E]O# 0R%:P:LO1CP&T7!Y M\D;_P?*Y"O=^F3J365%A=\V\N8')H@]_#M58>
[!L2R:$/\A*OF=6\>Y2O_<9 MSCS/V&=V/>G)TLF7@Q#^]=L.W\2K9[*@8Y_/SG&'72DC>=0B/6BTTV6I5OS\ M]U8#^%/16/S_"_0O#^ M'5N!D8EXLOOEN$S+:
(W19/0IL%A=^K"/J;>H;..%DG'=/1DBWM.>@8'1@BJ* M&=@Z%%P\^20):Q UWY(P@49CU1'(8/^\[F.C0O&/9WP.E9G':+LF58RNN>;R MW'M7I1P).6J%Y1GFV.WI<@5]#G1-
>Z]Q_A%1.G]LQL3$J^Y1P5*:$\ZL:,9* MY^9]F/=J4,7D+'TZN:NSBE:LB3[I(RI69Y^RP2H!JX$5GHIK0F']$I\LX8EX M?VYH;-F M0!I=//:'3TXNM-,T!X'7-U2@>=Q%YFH-
^0:0B7W)'8,9PTS^XYT MZ2F5)5]9_V%"VAKP*9 N=O;6#3$GD,FO)J_ K4B@BC M)X,\&E91(V&/].8$F;R'U12$I-I6&]0#.?MB8V3M@W 5[S"$MB7?YFYC]_; MD:(P?.$L@?
%IO]"Y;2Z)IF^Y,3NW#;KI.V2??9JV+>+TDLZ3,/"&HPPE^YD.O5C.2)P^QU%NU M1KJ6(5A2KJ?;)SN5&_W*>2KXX!2L?4*IXY9FXFOM?#;D:^PSVREOG>MX'15F
MD0@;J\7ZF:\:;WMX\F0[=,'9/M-R)^H/SK^]R,(0[YWS'"/EQ65X46NLH?*% M_^)]R79!9?JW0DEV\Y\6>-.S>>^1J:31DSWB[[QU4*IV3 MC;-CMA\RQ6*J$[0Z$YM"69B=#JG .
MFP[(D^#!ST0;)LL5;WT!2**'?XJ+G+YXWB]8OW>2PZ2HW* M;,B4W)M=%*-F)MBD0U/R"V52GGO-1[QV,?&[69"JJ,Z1/B4?'V\4V#B]TY_5 M,:&HRU-NKWLDB@-
F!3"!$88'ZPGH.ZL]39=5YJ&'H]")+HMG1E+AG3W?B1D* M"+:>D<8/C:X:,/3;NQ95U!3MO92\D+,H/'U69OJ*<+C*JLNMF.Q,WL17X:]/
M4L(NH*\|RDF5@D3WV'8D1L],IW,TU\@4'4ZL#YTXQTO.ZKH3#FW,];U)*W]! MT\42&#K&Z"L&3=H9VN(![',?_F!BCIK*=N.O@LE[R>*!G=GN)6X"F-CC<-(
M(8^08IQ#1[[[U7+]DXA-Y/?WXR]8]V@L:%J5;)P85SWRN.0M%";M'W4'5"^U MC5F,;J[D\:$(:0$,U[SI*0%:GLCS*L*T/4$49.1ZW8%^Y/7BNE%NO4Z M^T\AO-
N*R="OJ*"98@ZWS[L&Y&.R9THY6D&;T<4[Y%?L.^77[^F,ZV9H$-#6 M"Q&(;3_"0*NKMB-\8$Y'CL(N][MMOC-&6A\P7;FG(T!G'S?QI:BLQ%_7'K@P M84-(2"A&*H*
DO%*$YZ2'B_=%R]ET'NQ!94U&X-C*+Z/R6S?"/& 6.:K0O= M=5);:0_LT]WLTV[%1S\>\],9LJ@J3QDJ8]SJH*KA=G"(+>6$?X>T,6D4S PQB-2,@R[T'E*-^7?
5_+@$>D5!O^H5_0^L5V3KP;E].EG^ MX--A_V.O_GD%MN@F8Q*[.M$=?5;*\/R.Z/B$:UFIX\.*8$=1DXLMULLP F^4 M!MA;].XD3=_DI!FY?)0Q'U>BB#LEB>>PAS%26I*ZO]XH"@>\
<]C"7B,Z/(HB M&O'H67@]][KA$LQ)@M)..,9S9T-2JZ>>[G['Q(KI^\NDX14#8.Z-+MD<*]FK* M#EP,JF;QX++Q,*B.\85.K]X6>;(T5;Q7[5O%8?KU?NE9;=[BBWM+^M]E'<\M
M,3HQN$,6= >5K0JZG3X^'K+UBL*S7KX M^H#'IH->FM[DA-OX6\:T]V[0Y.E:>5+0LP)IZ?Z. OZ2@A#6 M>AS>(]X^AX>(D#;P6N& M^Q=J<4"=*0ZX=.3/CL;4?
@(7)F)ZMD5!V*NG4*PG-0Y D> ?(HUA1B-/S_+A M@&U:'-!0/>LOCK\QV7HZ[!Z&#*\YW\%T\!-?$@=@"< H91QP 8L'AH=X8<00 MPK;SG)*"'\SJ/)4XX0=]Q ,$_93IY;1>K](OG7SS_F_
F&$DLZ6N/CDK&6[Z_9]Z0]S'/^.RH/DGWO# M8$<29!BYZWNH!H["$GGC[_9/&)%&+F 23S^3+<(\I_'/_ZG?_QJSE ^.8>RP M7SS_XOE_'L_<%;=RSD&X*_37K9,B'%T=SSQ6SL1
M)JC]Z7#:TV!@UO*8RAZ&WHW!\|T?LWV"?6(AL,*"'&7S.>PXS:< !%!@R MGG\./I%X;I/_FV'@OR-N_^+Y_UV>-?6G$XB^(TV5AG+H!&=Q@#I)VZ.7V!VB M_*,UE&:JLK*H\
<)UM6PS>1[XQ0P!5[P_IB>=9NOQ#Q8@U:K<<51%

N866HB2I,FP.1W<)^'UF;S[XQC$IL>KUDS0"@Y8 MRZY>MLS$P*;CQHNL#2\GBD^9H&%\,I+1D)+Z] M04.).K>B*P1-+ZJ&OQN*_E&P^(RDC>'5VGDU2_1F B)F&MJIRT% E
'<^4,$2]\WZ& SSMDA#8;M2=;Y5>T[<$:(S)@G,OF]GM M"WXREYZ4S;)'0A(@=6$7;I3X//=B\6<]R:#S4=X_FY)9:*YQ98(GN[2DW:KI MO%^JTGS\%]H>?G.?-
UYA80C9M:F\X\|6=EWB+1*LJ8'%E?GUKY+46%RL.(";MI_MV&)?VZ@*9$WZ=Y.MX/5F%R"B)W M!M6A.8\[6D'0RM+2B8&ND%NP>Y#2BM*JCUTE\1QSW0)/9MY[)*])#JV+R]KL
M:8]5%YVTIV>JKM&99+\7"93JYSA3K\VFSKQ]*Z?UHSGG+V=&*WBHZ25=XF" M647]'D_MJ508-17+HI+>8Q'::N1MX5Q7B/3>FB'0@8'C>53%&U7]3)TL-EE4
M&VV$'W/G[#*Y)OD@;%C):(Y"F= ;SHS*1!I&;[D^[P0EF[A/=SW1,= =M]@] M^%W+-+\MUU#6 MSE^$PY"[L&6>'S&EO_BHSMAT*)+)GI3R#Y.Q_UG[[03:'TM._'C0RL$!R#UU
MGB_Q2_9_V.CUN\*^ORT"56;.N,GC %:N1L/-TH/,H%G3WWW[_U+VU>]?._L; M[:H^K#5EZJ"K]C-^0A/#YO%SJS02^[B2. ^U'X,M+]W-!<]88OQ!A[MX]TR= MQV=PX]7_
2YH/6[AY[2F)EYK<-3N$VC7DM7.2PUXA,&66W+X_MX98.KNH?;" MYK]W^OR-1B0PMW5,S@\^HL !$CJ5/RVBRK=.[;*8PS;9L.^+'?\B^X"SIJTB
M>E]94J;A1^:#USV\").$^#)R<6[679&A*E5N>YL#6-W3+8F:9;R[.A)-:U(5 MQ'&)@4A#U$L$F8Y,0'F>7=6Y ]J_ZGN,_*IQ1R,V9]Y%*TKH>7J'XM:D(2NK M91E^:O3N=C*4-0TA-
M#2E\UIBM_XLBH"=X6AAL$ ML=%K7KP6G4&96[(H#ULK +U70_G.7D:DS]UYW,6YA[>*'AW;HC3A2([M$\43 MZOT M6U-,L^FKPGD?V&2S^FMSAG:EK5FD89*L1I]"W5<)9'IB
M]^)^8#E30$B3.T2QVD7S/H6*.>?)_A#HD7^&HI-31U6Y14>Y6GA IZ)6- ML$FW#]OH+>3[9&M[+G(Z\C):[$W9<[%+H\48JMS.--VUJUS?&JFRQJ5R/'W/ ML:--
F7>SZ.2=LAJNVT>_ZK$G":YZ+15BFO;(4#FHYC/"C"P+BO9(O59J>BCS MTI"39P>*Z=EY 9\R()>WUXPX1+*SJED M=?=$M>*+S_.R1/J)X'*&2\O%KG>F@XD- N\Z?[._FRD26B$:Y-
PJ2A#\%'$K M 3J;1VB@QUH2_68V!O@4F*+18B4U^6@-B>'Z"N6!-L?35 >KE>C*>]^LSC9Q M\/2<$A*=#S+/2.WHA\2HDIAHBSXQETLQN+[3QU^:AA;#U,S1-V )OR'L6 ?Y
MWMS:8^-9^-!&_Y#5QD9(B/"'Y51]KUF CD+.8+S*7VV?-.K8%RZG\."HY3I# MD06OV$W94-G=L7;3BV$N=[>EG!>+JZAGH"<*BS<&JJ=T]&,"$O]X.0?^HEUFV5@OU!7:
[[H,JM]'I6>MNS]T,\>M_<.9?1:[>]ZT_:0&"K7-F>,+ MLM-#,L.+A_(L>Q8%9L7VCX2;T\+I/W_@+#\W?:^ B6(?]+T?%5Y_+9KM_4)U M<4696?+PK5XWO+=*L0QK+
MYRIW_#W0%FRNAZY3F 2)1!04;X!7XK&T$Z_'>NKV_=AZ<1-[YMKC>:(9-7VXK%G<"^(N#%A]RJB=IU58"^WV$63 M=:;G^,*:X2%YS#%2IYJ3'4.,7NT>;SU=A?&=WKK9)TF54??
GX)!U B5X7M$2 MO04ZR%,9J)VG-<,!>JH_X'2A]N_\0CG9=FTA^D?1^5SI65N"I<:ICDNV#N>+7Y[,TN.O$1@& 1=&-Z".\(*1S4HLGM M82=XS$+Y[X/.XW59:"*^&P+ :"!G%,[J[B=
[).J+I7"WQ+Z+,\2B8-B;P3__MZ6"5?5'?M^,D7@('7*PIQ0&/%?-P@!L8!UR5QMQ"3YU>%*X]W<9[>I(N!Y2V
MO/6_*']1_MM1ZK4&5DFGKU98I&@:,-0,#/&J(V2'WMIZ[P:D+R7TU_CD/4#U MX %D\S,.>,Z"]QRNQ^K4-$ 5ON?]+"O@&0$$#EB6Q4O>EB\.F.5"IJ=^KR3[
M_+\B8MZ_J'Y1_5.J\@0BIV#E 0J5:Y,,-;5[N?+E/EK'IB?P2\YYB5Q=-5=A M&3O4I^^BH\U['O'G+FK^+ "@[9@UV#[+*@XX:L0!.U1K@RJ_H/T7Y7\?2KWN M@EDQJ:468?[]&H8:+U2?
2+[A?=_YMT3ON3_(CHBY0H+@TE-2\Y, .L7 \'>+G)9YCI$(WDN G MTJ67[CGWB=X[J-MR_6$&D M\8%#!)9JT/)%P(.Q#^K^-7KQMWW3K)'%+EL?<<"\'!*V#@)C/YIWH/1Q ,N4 M#
YP,#REV]\L=Z J'I__ZW6('RE.4[HX()%-$P?4@'# ASR#I,B[Z^*:X[N@ M?[J$D1SE0/J+\!?A+\(_$6XG4**RU =%^5VAUC/Z MVF]IV$&H5P^CJ7RJ#*X,;C+
[3UQ]&0AZ_?;,'EEX8M[#_SB(Q1J\_P(1[ V> ME^G% 6LMH%- M:*DH:0RWO5_ 4C*(Y_OUBR%X("_J"5_]-_#:HE&3KS;7XW ML8I 8'$VK.TO3/4!P\V^/QHCKTUSP2KZ< #^X?
LI/_8\6OT(K%^9=)[M ML#6_9[U0^DGP9'@NCQ':'=-XG6/G5C(Q=+- MW&\|+J(S\5Q=,**_WX%%\> MZOA6@]'J!-_QN!CY.8E=7[CW3JYJ>5"Q(7Y/]4YY!FOQ] MI5O'*3)(P?%UX-
2\)#E39R5:+SI@7:$"& EXTRU# /J2,JH;26<3(\=YU.<2 MR9[=16;P;>=\C-[(UAF0$3C MS")\@ W/,=_1P7>&/_]^MK&GE@^^,RCW6M=TLN8LH*#=WTRKVFD8"HT$KW,( M[.
<>BV\H7"N_EC T,O8E[_/F3'QTO]\*E#EW5VW^OW#^P^(>[#\.[RIF2CW MG-PJ?AB\Q41C;TF#.#1>2-E@+;7_6:[_^=;YP3%I#NX_%'M.. F,0Y ?HTA5J65
_"/+#C]_\FA@^V=TB\3J7__+DG2<2UM@Q]1V>2<7V;!O M#U;X%Z=H\=I5O[]VG24!33 D,7M+]WJX)*7:I]^U0VQQZD+M(.HCMD'!(-S M8OOC*>0#_@%#\B_E)_X5=Y_DQ0%AY3-
D1X9H9 HRQJD2*[?T#CP!6U-G;(]H M3<'W.NN_,F7E3QW7 "Z?!9]4D_[#_5+_K=S92^3^FN9TV_2@7HO/#P?M- M8+2G_BAOFVS8 )V^;5.,'QWHU
F//E\OY15"5&W\V3/^X]PBCKPCLT'D2=&9 M.M0<5KP(?'))XA0*SS5J!>T<).* 8170FKZ8*2@(#^!;>=@-:>PD#N@/434) MO>&W$.J5Q/'2J/?,X$
660O/32=YE3L%&KOY,H+3(60KT1DBDM^B?R#BJKG":ST M]-(6K;&F U3R M*3=YK]VB[M1P0%0"S/47%T.(4 DJ%>_7E(;N(Z)NAY:SDNEY-I#LFIWH!)9> M#PA>7S_/:>5CQK)
/[EYY*K-,E3C*&!?RW#++S?P@3SCRNZUF.ZQ(@'50#@< M\6T!E6 >:?XQ3=$"CYU:_<#P 7$ J+M U/@C7Q.-D3U)P',-HD0BJM(=<18Z M@_B9AQQ#WZWET M[C 9C5\-
]5QUYPJV]'L6&2%VS>&;QM@2[9WCP!2"C>A.Y-/DF7B__3V-H&Y MY>&>-4C??@*E>3RU/[&88IU983);V.I=0L5'IR-"W1"]@<_:Y3IBN::^G?F? M,H2+UT^/&'5E63;ZQ-
SMA$^"J72"+[7GZ4B9!MX63;,(N/@LY7H9LQ ..$ 0 MN$$\7X<9KB/N?;OR@F(]\TZ[1?7Q'&-F]"CCI,_VB4YI>7GIE_M]A1\8\E48 MSW0_K)_V4(=O([K'7PE0BZM$I4:%Q@:$?
245CXUV.V!EI1]][)'U-MDW0[\U MCF/$?&A 'K*B5YKE-&%W4F]JD3JN/_Y.TU[5Y\Q;YG-G(8:/(+UN%A;9AC'$ M'[6Y9S@!1/:T MV",C< "Y101Z4Z2RP)8F0HWF7
BA,*EW<$,J(NSS0$5UR7UXA-)GCL?6RM&^ M DUCH^@LF]2]LA[&U7YSG1&_#8/S1:8^\@^>?#':(R6\%^RRRN/VM!1[=5!\ M(ED@U)2$T\A9AN*L-
=*2IDYLC6OV+7@T@HC!F2T!164W>9,)(Q3B'6+Q @N5 MY>#H&A]-2>^Y^"Z8K:E?IYI?\P0'$"_S>5G:K>S3;G*O4RAZ"47I/TW=\SE7 M8.0]5?M4PV*IJ?+59CP7H[!\D6KP[?
9OCF4T;%3A7Z.H9QR*7G#3]SRS/ITH M6-KO,G>[?:UVQ-"P3VO^Q@'5"]LT,-(-C,#YH^?4T.3+Z&>B@F]N,/_8C&9 MB]5QB$=W?
&1[*2#;3>+&6V9=_3,)',.,C34#4U00]9UQ'5GD,FCT$W;=^D@*F[#-Z5!,:>NFJ;4@:0?]0L!% MXO6 34>QZ-@1<<@K]))B;*)YM^*-0TT&#M#O"M\1'[)\8IFF6'*\*,$T290[ M#M/9G
LU"326**7+__0>M^,OX^;]L_Q!JQ]WU#7Q\?%L M?.\JO'$_,V:LS\99O"$;&>NFCA_UGDNP8058=+_<9N.;MGT7]K1V%JNFW8[5 MT*0(4Z.W7^U9#BG?"_O/(V=-O>/G=0/?\,S/W>
(XB[>9)1VPQ?T3!KHCPPKN MHHHD6B7YIS@#WV3-A3FMU&XK?-9_LJRO<4_V&N+]L3WRQ:DW;\TY[4>Y#%CNF MZU\'B0P&J WU2<;Q5G=
[TMX[<5WW'OWAL3'$Y_=L&!9A0PP+:-C0' ?X148N M.E_7=1\W%2DH/<@1WN,[QIOFAWC7M% 3FHV"2VUC$+WFCO%/D6Q76@I$ S!S M26==8EV'^(=E8RC572O7=(EI^=XLR?
DZV^Q)+ K;R4LZ)U&-EE>-*?.,+7( M;C)U&$V6$@KQ[07^=+/CW8%A"3[G#NX M6DOHO M%%2&M00[OM.+5+]E"-\(")8+?K+CZXN1Y&I,-;>&< :VW,T.#E;*/@/V+4U/ M^L[[4:>E-
G7Y2B-OEBMCI@)3T-WCA>"!THQE$<1G6X.[EL0\<0D85@[Z1X>> M\Y:!8T=?5G9)YA@?31_E5$NH%O1;7$8D.E[.)@C<+5-2O.<9#_>N6_QXQMQ_ MP4*"GQX;*N1$X#"QO!]\
Y0TA5!]&:OOIE_K)-_-1A^D,ELDQ^$8+T.%%# M7?IH 7I+?K>Z.[$;W=;^T;-..1:I95$-DN34#F*?2,*/-;V^(SL:9\WO?WV0 M_[AU:GW*,6/U]B4'" IX(V\@Q@Z0S;;+&25&-Z9/LJZ-
F=1J9@DU?.4UU8C MZ3.;#VN@M]0JK98C40BTT>.FCKZ>FVQ->0$O;S9W4E7PL_8.JA[(0UD,NW\E MO8,8(C1*6?[.F8?M+-OG35_15>D<>AIE/M:T^/ZHS7#F34"M]UGPI27Q6U *
M+92-V-TV[W3SW8^"%((OZ-\S[Q%@SW&PYGBA]5:S^17 :M+NXEC$AM),]*1) M",>^(!OE\@$QAV5J0=#NQ-9-I7[=[*]M;^?.Y=H0,>]1+8$(+9KC:C_P>/M> MF?
S02#9;Q\QOB4>=L(59&'KW(QZ+_#-:-5@.Q:[]K6,N?R2>G/9]\4U>-!8#0(,ZBHN?MK3 MZI"5>V [U-3O1'-]84YGO::3(K2\]H-K4S;S00#ZW6:&CZ\0<&ECP/RW7 MFB>+:\81$^[.?
#H"VX;OA[%?;?:C:&?]=#[?X'JZ7J[F$N M,9^4)64?_7D'BP*L4C&M=N(K*=%/#JOM=<$?]AT9MB$$!*BLK EB;(X]I-UA M1^;@PR[L!/Z_$2BVZ;OMR8.S+L!S9X[*E_8R,PI;P]SLR=X-
2M4S3Q:!2UI(C M:NAL.6+8@D1PE2\^1Y\!76KT;!,P ,ZIO^Y/A2X45 W M+H)]D6%6<^:!2V#Q0G>!6,_(#GGZ]&[PO9&^G%4O4QLPT]V4 MJ]T'Y]4@E_Y4;S9 MKE2T#G6,O9#[&G-
_-]6R<,VV\:+0R,(\EN4V5GVR3T[M.9<^M?3=9F6;^82F MS4/ST_6^;H%W2887VK]*.JSF2CAW>WX0:;1KVV_5*9W)(<9>W>#)KADX#.@P MGOIFJD1X)WQ%EU*=TUKA?@
\,$_8!LZA+[LG5KHK1/96,9[(,N7PT_+0Q*D M'R)=>>Z@OJT5UOW1TC=$>ZT$[5/S=9;=6/8I31-*1@ M(NM2(BWOY!:-X3Z"*-U94,+:.5\?!]!TU827+]RG9HN"T7:?:3HG% \'7*?V
M;E>)S!3U%OGMK[!1R]X/6'_J2GC)AYE6/"'GV83;W1*H-VM0*G\F:/K5T=RR M#5=E4G@R81CT1<:B4X4J[\:]:Q$GT-WB(;^=2#!=(!#/A&'.TF[X?6&"80WTER
M"8S.:ZN^UGS'9JW6>T@N]MR M=*1+A] [04] D-SX?G?O_;[[W+O/O?><,;YQQCA_9(PD(VMFK?F; M:\WGF6NNN>+\>B0PS.1#BJC6M=5L.S!40N=F%MH(5?
PY<2#QO6!N]FAY_66" M4Z^@ \"*KED[C>T3:5*JCKF8LOYX+)6DIZ"-+X97:+EE0(/0@+4]H]\1^7Q MEO7KN@X$$"51-WI-H!HC^.H#R;RKR,OQY]-IUZ+:?-"
M7M7+^Z:H=G-4W?S.\LG=6HQ'>?J[[AA,@@?4%XP&G/T"GI4O_^D I[9D*-GD M[]]WG_X/:M^^10,P,OZQ@N@*(+_:RN0Z@E%G1PA9,7ZOLH*T TFKV>L*7LN# MD=(97*"?
N*C6)_LQHZ,0,7W<&'?>(AFLA@1FZ_SW[3E MZP!R&@/L8'S4NG'/D+P/LAR9TO3>ICB)6GT:)XE/M1G!PBW:,^ZYQ\>.>4KR M_SCZ1R%K;*X:HANBF+AS&[EM(B3\;
(!WM/)2E67\/9>Z'CW_#*>_X"K-@<$P M@U\TB,MV"%^S64;S(Y[XPXO2*XK3YNSPVL67%C(IN]-/;QXQ2//<$1KQ[B]T MX&0_Y<-@.^E_6Y.%A%Q
```

PZV+E)\S>Y&5R]>>1+)#/M(MUUG2T1%?,R5+A,.CM?N79D#M9.A7D6%B0[:5@!:PQ, MN32[.W'+!@R4H&I=*S?E/DM8YC(_S[GE*?X>.;HJD_7=
MW5;=Q,,#SJ4]7C]:AN!!#71YZS22.'G8Q;I"V]{Z:- M'@OZ5A DFC3VOS#L?Y<%_Y7LSN3.?/$W;8H;19&T%+MM=($V!>ZHW,%'-4D[MIT +9CXC#:=TA$^5Z5>.!:
(JG];5.""D0Y7B(6NN(?O[,YA+<^1 MF/"*==MC8T'4_0,=(7K>A[.%L@17]Z6W"OW2\7\JO@I!\8AP>B#C9V?8]":/ MYY"E;S93N1BTS_Z2*X8:NQM[=M?.$W?4MOXZ ZC2B-
*>V"0B\Y9P3QLQQ'SHR\,RK8/"T]TO%+/'-$E(/XZ MZKOC?V^UWRE?]>'>!/-FJ7?0"B"$KM;JJ\DL=..L7]@K)>4"#:#=K&F.M&A(
M5^;NBQW[5(!7H&\|>EQH(F(,3W.Z:]*^9U>P/E^U2R1IPORGT]2*N&4+H_G;[(CBOU\'1^,"=JW]XVIBK1_@5I; N# MB3>7G*Y?!).#>$7C9J=Y?3]*2 MRCW"KB66TD8QO[X
$GC@YX5^\V%L(OL_L:3]YCM,MZ 9,30"Y-0-.#-'NCF M01W"=3YS\>8RD9A@X? :,8F4^'5VZ=YI MG6;!;M/;RWHO4DX6%CXSGV@]LEB(_NDKWW"MHOG[%'S"!!1R3@*\XK&58 ;U
M[:QP7>-EWU#=T[XYVJN2?.?4"[K$L5X^0TF>DAEG1V9WP7>B4(P"$/,X]<=@ M*)N1^R4HNN(U]9H$AO[T,_OI-5:E7,M4):3MLJ[= M)4L>?'[ZR"5+]%?6AMD][.H+/2]<[@-_!
<&2WHZ!_;C\5S'*^WK[{$GV,&1_Q M'N+0BUBV :]K*KBL9#[0-VI)%SJ!%G?T.+<-AR^8,!_'?;/[JK M11Y%CBLTZLGTAKCXP+@A2'+]U9CDWIAD,BE"RM%TAO_#C]KI]L21DP/MX,_[
ML%_ +$0?K F$,'@ .N7P3L4P"CDT@-)XBH*@Q]8EQ90$[%1Q<$#9A7H469C\ MEE3)DN)^%?8S+^<[/ORS8S)$'PLQ7E_BU;_A3HQ- +B1! MY29<-R'S1C>
M;S7?;$@F0)%WBG.8LND.2K['H6N3!G*J.+YVZ,;:DF;@3ONVI+? M)@7%;6!\.S;0H(D8F=H2?WV'^"8E#AS^ N&_U97%(VD$7TNGR>H0]/"G"/N
M<^A2NW9SI&C\C/@!4]MMBFAKXI3BFKI]X1+_&.WY\K6#$*55E.";8Y7VK.!J -_/!?G_]92H/L<0*[3OYCG87N:/!'Y]5'W 5K+8,1:("TNI/9L;9[7)V943Q:J;N1GUE M?>+>:.-'.?
IM>9IX;!;^PF^(;W60^WL&]IZB'*]..+)[PPM,@:X":S%OMI+T M3ZH/XZ*B6//^4O,3XW_E+L3D_NZ,__:AQ)#'9#M[#8B,$L@^0V5?<2K""D*KP&%C;&\
[O%S#*S^0@VR,I?:B'IB&0K8?+R.(,=9))E=7B.R3K*G*_K5KZB;RRY[P3P+'_KGY MW-3]'7#VY^CE&5=3IL>_WZ.Q QLT@(=X?]*>96Z,-(* H;VB,D0.B/D(2X/?6&[%>8?
L+HHVGFEG3SUB[FGK8P?XH*N,]EP]:7,_;_;82NR?O<$MP@\9ZNHN+U9 MJIC_U'4R6K7F=[T 2[/_0"@]BA5,!, H-R(U5<<$&&RH] 6\+JB8G^/Z(3:^ M5\[QMIM+8;0',7Y!7EHNU
"!>>O+Q8)6HEZ#9H_8LCFES-8#%-4!)KVS;H+ M+N3I$[8-4<;];3=V@B#))HO*N3I$L\K\I?F%X;&1QT:!I,OA=ZX)"W?5F69KN8Z MX.\S\\.L;@^[;L.*G6HX^DT"GN-
1(5G/EW837U07L_WZH&C(K"]>#3+='KV M[29_>,Q<03G62G-9R?#R]3)S M^.*5]IWRFXAYI-GXPF1$X;7EO@$K?CK0V%;5 *//1#MOBH,3W;?.ZVIB?W\2)?
U1,#5!UMB4<8&0=S=4+.L MFF_K5INOGLGT*;&C0IME@DKL2EVE/B$FY4::+MEOJF3LDRG[-+L[A"MA6TLW MEU:AP>=43' HAMG\\,@$?4];\)S+GS>9E\>^
M/TXYD+6K^B@D2W1M1W6/T,]F8?2:J.+[*.#2[F0/=-*TRS^"F-!L?'?>7<"RS M/"GXI>WE<._[Z%N\,BX:[SO4A\H]H/SGLD2V5.OV:UY@LM3!3_B>7OOC"3&% M?
&N]R3,L'QN^Z$:^6$99!).K";17I2VG0TS18.F$&$83]8GL*S%INY4'98I[Z MY&5"-.EX9DHDX^7'E2X]&CS_\IB8%G#;:29-7]ISF;!G.':JFVQ>\603G\]+ M\^@S+?WGK6.P$X%W@?
6Y<2KD\TI7YT]CIS*K6)(2)\EUG >ECFKX!ZC/)9T M)K=&ZLU,'M3D;'BVW"97UW&E_>^@UO]U4,L%0@%:3]M=/L=8G!RSIW8O M4ALS#+M2T#SPAO:3G+M@U0!"':)*"J_/=
(12@R)J$>J4OK/@\9XQ;:%0Q-(F MF66V'ZV;Q9?RG>62'4@^QJRYT."G6I86+JWX9+_3G&#\LN"&]XY@C[",Y$ MU1R!*2KB6CHF;3"RM7G3NPC??F1-
26@39+;OU>M#D[8O#S&N1:>X=%=YWXU$ M3Y6H>.7 \A*O?88_NUZ8)<.VTNZLQU7'[;%/\@.'-XKQ(B"^ MJ/ZAA$HQRM!)<"!"Y?#&UZ8&6^ONO"G<-=*%*<$7Y&>WC]TUOGJ$!
MM2&J+8">.B5TX"3L7W6C^^1R^!+:(M_]D9PX7P1$ M@\CN\@4G>M89/((4W0IGB-JOEQ8)< MT:6R@W%%^ XWMD^(2188S"H*=G*],V':1 D?)1:BZF?
@%>*R9PU5?)]K=8[5[VQWQ5L>)]>=Z*.6R)KMM>;PY/1BX M-E4QB_5$_/E-C?7.157VB.20QF[VB8F[ZO7MAE]IQ=:HE[[AL1O3S CIXOJ6 MV[6"U[E+*=V?H%F?>Q4.CK1/.4
]J4L4$Y2=5^)Y*??USIV.7:D5&;M!1H^# MA>YR)SH[VSG!*I!)QH:HGQ@HL Z.QRVI"*Y]!]!7K)AMKQ8N]W,9TD:Z.5XQL MC4LZ?R/X^60ONV-S7N3UK>HK*:+7);\87
M/*]_AF%MJ\@:%(E(A1UQ25YJ3PBZBWPA(JPO,&E&?-60B\)6Y"(**#/S9F+= M6-8UGF186D,W'#*00837(\H>M;\+]K> W6,TJHH- U;3RWT)NJ=:\=>, M/3C6IOQ5K=S(R? 39$J^W16?
DCJT62:#*2"-5_3RU,;:+G4T%Z@8<-0MG%NJ M&E9'[WM7:$]_GZS%]1IS9+#AR&/A">:.10,$J7".M0(S9AJGVQ^9&_Q08AV
MSNNK6MC:D#UI:B+WL31XX]8:M\">J5[<^OJC7](.87AS6(MY5Z!?(VQG/'3-N[%E"?-BTSE6-_ML>)RZ9J&F1M%+F3@'X4HUFZ M$-&6JPHNX>6/X]>ZQ_Z&\+N^^?
M>#:666?;PKS+F$<< NN?/)0E2%?54#[#+ MJ02.'K"][=_R[/U6_/:4QG8U_5\MDO_# X-U[R6,_K!=\F7[\PLX$K&9.N- MRQPAWF*^DQ$+?(8.%
(XWOP"XZ#B**_MSY08VV2D)*E_KGOWN6\PD0_CC^F+ MJ+PX+CP[54X!0]]8M!'N%%VR*G3P5'PI)SV=U;'-U^T,]U]+\O5][;Q-!4, M7?:JMDD4DSH3>
[_G>MPM$PWIXQ_P9NF^"HI:GW)BBEH2YZ1)"1[*(6%Z[Y;" M'+&M^W4WH/13#=PH)?MV>>ZG@TFPH(V)*5/X=6F\<_A,.J*]_3CN0Q;M<5W8 MYJ)(QA@^:/#KV$%7D1-Y^@X-
VSXN-|>_Y>W^J>I'VY/6^57*JVP2T#]R+_Z4 MW?OW=(TA%/.@1 V,BQCQ4OBNYT5U9'G$2C5V+W$EDU.G "1H0H7H3#5)"D\01+U]553=A;U9="?2H/M032DV$68S$
MKZ>B9"S^5H*6O(Z9W@,#>_M=X9(W/C*_"^V:1 R4Y^O=RGL3+/2X]>BOR25M M#TI>=9] [F'X22<'/%SSQX&\L@2*6$+H?8=F; =QX8@H_J?!E51@-'1>5RN
MC=6FE=4";_6.YV;9.D4H)N" M@+R.7[TY3P!]V]>5#+O77SQXK,,]1*2Z*'S*&/XQ?4S>F_B!2'<HV^K@(F?OX3V-*]2#AH;Z&C->RCZPXBY^X41HEN6+6';M@2;:I]^KZ 7:%Q"=F]2=):
M2P':8!??=VX)5^-(GAFN.C3@CK1+$7 @Y*XE;'S0?M_Z/)JU7^C]= MS3\>R73!:J3D75AH&YK .W>T/&?2D:LHL'*QY3R)OZ/&&S"RQB B>Z(;K:A MS-
5Y=/GD2NZZ&N/D9LKENNAI6\?;:1!)ZBT\+(IKD./!*V6YA^D(QOP"[M\K\&K59T8MI.QOWK#7#'>J]0C=TM&
M=K[*9Y">&#M^I!*,8MX9O.7L46BK,U;9E_QUD8I^B%@RV7)7EG,X\U.E4%3M M3;[0HL,$2&GAH)@FR.BL,*Z5WR>>2[=!PT_Q->CJ/D4-Q4;=I-_!X>,O >:.
M7;_Z:3"'\^4V)UBV#&[0E.M$QI05"8YW5#/E6Y)\ ML=>J^@?,S^6[1T/*"^+K#DSWNQJ4PAR_P!S=N?2-TC2CZME&J7]^MH$ 093_H=5 M'/-AY &VV5P"]:? >;:G/?
T%IXE^!A<'$$W(^)B?TLN'3]4>(1(E\^4 MK.<3,H^\ L33'^62=IU6O!RO>^@1P+F$ G0*3SC?F_0-04Q-@ EB\YOZ8P:Y MA>1E\Y6$VM)L*CKJ_C%TS5*,DX@2D[8!*YOE6D-
LY;65%,V]J!@ENV(" TIV MM6(H9D<_=&KW]":FZ]:=V7"U9:9THW916O:JAQ4;1EQA[8^,;$4Z=T3:HN:- MA5G+@C[A CL"%N)'P1XBATU6]S?\1TX//O)-QKHTS?^P+*#XQMI4F"/0;?
&S V8A&(M/"-@Q\'!*7"86O1W3]3_Z)1/;: 87.?KO9$OJS_,.^.3F;Z<==W"0I:6 M3_(/1JO>1@,<\'(-LZNA@BDKR7<[G.5PBXM#O14$FGVH9P961O6AOKI*PB"9(J+_V0RZ:IP&MU)
MS@+].S%/@DE2;!AM:&A/7B;$%X]SYQZ'QWR#BRB1=7(<,="D/9^]"UFBNSH. MS)V.>&LS8E2<'-%?U>C+62>_#0[0M+TVYE"?^$.=LG]H=O>7L2ETJ] BLKPV
MG9!=.$K1//*UHS'D"16_AVUOHHJQBC_1K781C5@Z_+#@V\[-'_27:*_XK3[_MWAA14RZ3+2B4!.8L+@MSN]))C4>]%MGH7+VZXM^.8Z]+&,2;"BF_7WP9A((C M](C
FANNQA*_6JX)'Y9VQI0U'5GY064"ID:,_]&_DCFC<.:=!YH#\WF).%[V MYDQ%3%/-.P:E64P3'S),E2566_[1"9&H=XNQ_S#6XDDURG\QG3-EL#S=U"JC M81$=V"
(ZF*6CO&ZQ=]9@A0:EZ OZR84&V.KZX2Y09$]TEQWVH@&&#%<=R:(C MM:G:,7#G]:W2 M,\B+(Z@I8R/$GB2+2X]]JDUIH2^K&=!(EEV9X555T-],K+$KR"260&" %[Y M_L9-==.6.
QX0MN*&9K3S1>[<;#[']LT#R]KJAH9GSWL?)O.>=>353?!=4]U- M21&8/NRZG1.IEK#341*+2V_L*0RG:F6[]I-"P64X:AOWGA6;&1YDURYN+>J6B[IA2;Z*$7KIEV M?S*Q#]
[\Q<*^206@><%0^=Q'^%:2VGCA>.!#)ETV#1O'5V :(DTQK$L B/J4 MW8%%I29UN&[BX$W2]=C+$M!S-KMT0[^^UM)2[\)XX5FV.U17U'14BH>JAGKJ
MP];C:H4OT]5BFC(7YT$)FTL4<'!6^#="T4&[X-VAL<\=#-\EULTS)L2P"Q9V M#::62GF2W^<6.S^G6BX"OE! EHX9RDU0XP35[DD3D.KPWCHP.NOHQ55LH%7O MHH:2LCV.82OJ
$JILE;<^[(=;BB0.ZC[4],E67G>:Z*?7F[UX!6"]UM0S=;S MY(#-_&UN0LC'#GJ,IS(P]KQI=8&)6O.-^KQDL[_=,<*;8CX")IN19W9E;(K M31%ZV=WKK)!Z9M:!W'$H.
[#//3EP^!8DV4)Z&_@Q_\S',!&U4W$^Q65SEFUQ M/6]P<>%9M^\#BEE-EX6"%N0Q6(7Z%\94K<9X]XVN2(JD]K0_KY\YU:JK;LAT
MABFDO0"H"0',*UA.*Y2SEF@^Q^C>ASZS*I'_%H2\ITLM^YDCMG("C(-SR.W# M7IMM9$Y5R$9Z\K0RCK6>6T@:@7A-BL&VGNUD8RG>SS3]?[W$,^M^0Y:4
MA5OG0JT,7HY!&O'[I>M$]3SD1AU2YF O;%66/!NW:?1$#49/Y M7J6FI%X*/ID78:=5>=8/4M(J^^[S08ZR5!&!%*4R% N)BGV7U'7,.HYY#8ZK M,N2:O,+QV&@
=+H)#3!3@.1[]5_8!1U+(@/LLL_)TZ!T_,.].;_+_N+C@%_#B MBS_D]'/2WZ]?:,#_[@!0MS\&;B1@'-#>IN2><7LF&O!H4/4*EGV%5P(B M8"FV_,W2V)/^GNM:;O-[-Z-YX*_W7!;2_#=\SFB
M:*\2XT2&^I@FJ%+Z(+DF)RS;X>$;]>KH3@.3-7/7"J8,U;(>ZNA4:TBXS[F MIN.#IW-JT*<-/N1/:%T$@)KP7YL$7>#L*%,^RF0]^T?=6.=*>G
M+V8V2.U3!')Q;@1!!NU:#>}^"5:+]QQI3>QSF#>W0NH:&CZ^3QSFR>%F?'1+ MA>C%DR(,GS->K;AZZ)Z-O!>/!D25VZ$H(/.20)OVAQ#(SVFO>\)IM_OL:S_<
M!=I(*IXL1P3>KC_6/7>:/;)HNC9-;OEZT>)IOO-_ 5%D)#]M%!@[1 ..4[WM M4&%T+&@ -@;UPT]&EUIR=U'Z\QZ&-$[\7M MH\=.IND)?1<5CX]G.FGHO+I2 M1/+2P-VJ;O0GT=0?6]-
X3D+!K;4=)5O.VFXGG$?A40):WJ^%LXL]T7 G<)F MW],_&H\4 W"9;YV!]?+CO?E_09':49^B1CO3/0 (+.^F,<@U/JV"%=.56E
M!OW9US)1=QZ]N86K)BPN(]KB<7,Y57=/T]\^@P,)*_R8>*C&O9/0LE?KJP8# MNQ.HG%O5C\E0?+$,V.3T>?QS19TAC?X=G]2%QR19&60ZSX[VS_!:Y]D;.'L:'ZI,<]
Q>.QY>&7K14Q;+]/3R_*<3ME]]] M%+GC!YQ9\M.791MSSLS*/8%F!S,_H\9D^',9OX!'!P\BNS.9\H)Y3A'V"\>*#/VR!X/T^YBTP_\P%:<8=V8. MC#2%_=&?C7\]:?
)Z@](BW"?;>]PHAD@]GHRC).:_&C<;ZG9SR,@T@TNT:A M;&=/4O5I^4?!C8SI9.]]X9T%K8C NJ MW;P+WP.^+0PR13N6\K>O949G\%S?/7CDE^;(-O-28T9S!K,*#%7^]^/C_Z;,
M\.^(S9HD,KI9]^9#TN_;Y8O\7V'XMAUV;S/=:*088T=;.M3%Y>- YM(H&^ M,M<7+#E94Q 914_6_/Q9_JQ("W,)]+5#(B6435Z-V&1!]^D*)+Q_51RD.RDV
MZ7V(KR3S>E,HVI%MELZ5W-E/UT5&M$IO?H]]Y>= KM%4X3V I E*/A0>-3>;79,CK>M(.SG1'0_C M(K!U^6DZE&<$%>*@712/XXWSOGC(OSBF^B4TH6=G3C#.@\\A,.#=W0?
5\WD&QC.90LF?>3D1\QL=PD+2 M,W2E%3FIO(3W3>9DBO2,]%7PPV!/(COVZH)P3_FWFN4^B+FM_B1*SO<.44$-
MW(Y1Y6/.CV9A*EF):XN$/FEJ$D56R>\6>EP85"$FN'9/3BOQC!-<[C"%$[=O MZ2/Q09Q>"""#:4(I/?&Q]XI]_=J;EPTVN;3.UQ\O"ZB7>G[/H
M_-7WEF'6I;@0=GZ.RDIR,.9S W$]L&ZZ_V/,^@KC^EO(BNM, O-%99(VQQ;XBA4@0!QXL/<]IB-.R(!TQVTSD3BH0I6(H+1:];UZQ9P',K[,^OZ6H- M-5TN.D;$OY>W1Y5;LM-[%'LK]?Q
'&G"B8("\CM3$_+!')52.G.P/]Z/*]Y[MU4X!/VR@JIU&JMLYO5N_C"SLE>99*_LAMI;/=Q+.S5@W7R]PFOX+>3YE0VII>N&*\SSG6P M(H$?S\O'HW3IXAY OQO4YX,-
;9>>3SV&^(GQU^57'X0)HN K5A^)51:.N0W; MF2?X6Q .ZS_J@@J-7W2OKBTEAO0^]+Q:05&TR%":F8^R'!]UTUDN[GN8WK>I M/]=8M13@KDI(:EXOZ@V$Y'NF<<9;?+5Y;E-
/JGAPYMWZU6["N+]8E-7K(XK M"_]76Z7_?IT.M*H=8H#S*?GGKZ7KG_H&*,?;!GO\@B C^.29))@X@+714F* M/<4LWOPHNU=>^/9.2,F9Y6Z3^W5-F5_*5X?;^LWZ$USZ+QZ%
(&9DO-PHDC,N MW.I_OHG-\SS5IF(YH=A*>T-_'U'CE1]<7&@W=I-S&^>V@]RKB$LB3=!NG1O, MX:"G)S,\]/2B9[/F>6SE0IFBE/GISAE6]$!YYQ5M15"K MC.E QGQJOA[<#)
MT*P]7PG#DTFKOX,E_IF8*3&,B1"[&G!K&UJLZ^IZC.-MK*A#[\>XJS$K+%4 M@-4]]\.5$?-V9O9X#77CTZS?A1E>OJV5>(3!DK]65*]N,+[G953I =D/=PC1 MV?
K<>9;$M([,%EF+?.'Q,HIOF1A183C6]@H,%3,R3X&]N9>)?(/%Z?9^460- ML$(;YY8QDS.3BC1[%:5Z;_GQYBJ[PA-<)F>7RZ#+R<(*F5#+7ND%%P@/[_] M2\YV$*7FU#MN*.]IQ+N[-
ZY+B.]K^1I (N1+^%$2]*]QB87IFG#_GVNE:/ M5?Q6)2<;KT+C@%3=B85^.ZX7OG1YY^NWB)UZ*T^(BZN.,9MLH0FF"K3#\&G MMJ[=/?NQ&9?9Y,_)I^?
PCXH7M^LOIM/$P>WYK@VZ"06S5L!>.>F)"8K =-J$ M85(ELM+>72IC%6GL'R$+FJ4\G?^1V';K_"IP 0[\V_[+_WQ?;-_OEP/Z;Y+E M/(H;H_!
<#+HWW4$#NCKR+2+#!C'66\EW4\$^Z(5"]3,;]- P-3A0"BY99_SK0LA:$!EZ1UR]>X&"25,U?=3@G]%QR77$Q% M V3;?(#OKC@+3:5RHA*C!$/<[95VL!.ELZ-"3[Z3')*Q>F)?
LSU"0"0_\5@;? M>L]8T=S7/\-TUN>K4&28_SDKW][?<5)*]Z.<[X==O_GU$ZW?]!WK> ,KSBQ[9NA91V+7I)RWX)]75M4GBZ195MOJ.3*$LK&-Z?RZYFJ;^)T#<\"%:L2X5A,G.($T<3S.-
Z5/\]]9C^^F=NA_ MU\805<+P9,;%_LD.<_[+71PDN&:0/:64=\J1?^N MCQBI&]0QN<-[N3=-I2V/.?D33VNP&LH^@IP5NR'0+6K'GWDUO_%83(!ZLAQ$;JXSX& K%/9WZC
),IBQ2JMA5\=0\(-V?C0%5VVZF MK]XCE&]3&J0!LJUB$:#>S^3L3#QEYW@6]0Y[#R9VS!9'""N7/O*D97 M:XNU:]F6ZP@YBDL8E]]+@AI6T7Z;/.<9?3"V]RI!_MP[&@]
MI^8EBM6!$_,&:R^+#11U\7IN./2+%4D>O0T GO*6-]XTI2;'$VI5+53!ERX8 MQB4A;+1R]R3/T1,*0(D'[(%@*?'.1S9E7< OY H;KP6VK$>TLM\] %/!/E>M M8@?
E+1<2WQLUARL/<^M6QL,;&@]R(%DMN[I)4(/#!#O;G57$@7L&F]1F[THR M%-L+F^DNALO&=WN!89+AKD8V*;^&9LQNR48WA3'1!&%/X.@^A2W3SGK'OXCJ
M')]>=61*T.*"F6LA"YMI=RPYXU;.6%[DXX]O%R<33,>[\W@<6*AI5\QCV.W M5CE4VVQU@)@/=:\FB[B[$ 2'!@8P>ATQ@Q?G]V8JAC9.T0!R[Z1.$>6ZY)&H M8BNJ-V
^E3+7GHC%#"_QTJ)II Q1U?'TM48M%_TIB8B7[+.2P:PUW!/^$-@R M<.=J.E3@BYF3LXGKU]8B ."YF*NK-UB2V/OM#HIZR>87M!IV6KM#Q??MJ?'$AZ;D]K77VFR*F6*.;
(GYFG/LI4C%"X>"Y:*C4!+9@K6SUQ' MJ/NY@D5X>+5<1(;Y3'J+?X R@L8"KO!=ZT4L0+; ! 1?*41&'EB%)Z5=3N0%"S MKO$N,P[;24QXQVUY(:B4;CN-3:I@VN)R!$M,'I.0](1?
53^T"%LRDO[I.?F): M_L/#!A%NK1*SC?@*0WEE9J# @1U]K@F'C\^=;+B&84NQ6./CUH6#8&?N;>$* MFPK*YKK@.UA9?0-W)$/*+[MOA]S&#^?G'AQZ+_
.#D=LS2Z1@)H@Q'A+OJ;LW$;[FE]<)+Z/+'=B64XV MFX'QT?+F&>?N\9Z(<6UJ(@+VE.O^'8&J17K5KT9HP'Y.\SW>7L$9(-$1?WCL MN_9:<<9'PLRQ>;F&>XQOBMQNP@7 A
[56#8 M\A/4S.MC@2H/T=!#IW5!WKO<5WKI\2]Q=W4%7.WQF;YKAJ<6O>@9H^/9X15 MT]2+R=M^0K^8#':.Q.\?.U1];G8.9Q!*R@FPYF]&&X5
MR=7*L;HH\5,QT;;F%%>E,'8T92+XAM14Q>C,U<*?:685XCUZ^7 YZL M6QJ5'VW1#=LA*EY/"HI1?=T5Y!X:-^SN=X&DJ,G_5 T,.2//U5#_,.EAX^1W
MQE9/&FLO@S^ER+>0IN:L;E,T7;MH"M$@C 8[J8S#IG+A,;]4+ '9M:4OX5#R@ M9@5RPFQV?@ZR)]/8IDN1 M%<*MO2[ZF)_.&K7%=G;D# ME%5"-FN \5,-E\241)
<8[;J)1=_RD=X>[LC2"=D.Q[SJ'&;#FU K]@>;2,#@C4QG4 M\H*6^"]E2S?%?- H,'_W(:>=D%LG"#CKM" PTG0P='-4XQ7-J#%DM&>K%@= M/YV/WAD]7'W9;56\C]LD!
(SU\0?.H\0G+1^[WQ.3GU&EB4=H1WR.VQ"-8KG30 M@$@D)1] 3Y]/MW4>/GO^\O'L^M$(OO#(ZIZ"BF?@8?X@;DBL?+X)W&LF><>)
MB[W8RY]+5*D/0NB,J3HV\$*5F'SIS,-2$FT;& MQ>8OU#Z(4*QAO_^0N!7ZC?%' +N5]#&CM6]/W:EO0K+Y E-,3X,SFUSQH0Q! M:=*%]HQS<:KF-P7%-
FVJ.@\:P1VO\2TK&1]0S(%*U=]\LI@\XR*YB]-\9M,S MM[@;.U,%A,=-:LF*>EM%9=?F&?^!PX!<->"G- MVS[[VMRQE_&1QV6X.AJPER^"!.=5.
QV6=!/9S!KY$]G7FJGMJ6E36EN3[&*UN8]QT3# H8$\Q"9=Z !\+-R MT$!-IQWCDX"Y%7_BWX.]=1/Z!)6\S+)8MN/_^SY#)/1FTY3KY@EC44[4CY6_ M90J]H0%K+,@(+@R#P5
9@X/3H\LI!] 9\M^7*;L]237I4!7E_%7,TZ%H#Z> M"51C(2]8+,LS@QEN-3;S5V%E(%)$-LPDTL//A6]B?]??N9\\U@[?N"5N M@:X5KA>?CVA8#8^@/IS#]6Y?:=2+[A(ARP3'-
ZN(O".9GXXG\9>91MH4Q#+4 MSCN4P5X;RNZOQWU>1P/8IF>\MF5.JS"H0-?%,EX:DM?8U MYP^7DZ]HQEH_"6&!RLH0$V.A??%QG5QOT%O6Z^V7!4-3;^8M27'1^LO;M6
MA+3#78,B!$'K%!SC#4MTH5^7.]T@Q)+KV=N0LZ,;99]"].0ED8WIV?]R%86Q M:=?II)]IF/*Q6G)'2QQGHK9DTR4Q^ANC*L[2\- MC."GL0V2?
7P[6Y5MJ\&!M/7SK%D,_I7+NWPV>BMOKSB9S-R6TNU=@:K#< M+Y+39,WXLE%)?!7DMRCD17M";&+#[?QL0;)#/I M>*_G/;',0QA Q5(O]Q97*I%7XZ>-B&-
*.=^!Q/200C!LB2+>4\0*8%D]WINV M\.N(UMNPM[FW3>R*LYB)VN]5\3KA3 PW=/@D3KB+)A]QZ^4XGYI8Y >(]= M\GTQ5_[20=VPV?(AI'(MHB2SYVB1Q,,ED*X +X-
C>^]#Z6]FY&?32GY/-.O,M 98[5=5EGY"Q;+] M%OVUCT.AD>]RCK4(Y.>Z5!5T"_Y<\I/OEE8V'MQ=5O/D8HS^TC,C,-K,/>F M?$H\]Z.C\XN"^IV ;^@*L) \9SZJ4M14LQ3!#?,
[D')RMYM=\FB0XKN]]2Q7 MR(*EL?_AZ=;QF,QQ\(71S-&9S-37\ .>VFBJB RB66%4LM,].(2KEK6\SD&# MBN.04TV&G.CY0 :IGB?36DCP\P [01U$186WE_%D&9>
[]T883;$&/IW!$^N+ MS_GC[(/7U#1_H.:1W]Y&NX)-3=#"?N(J:(EFUV2*AN_0AEX%:E.I>8I>J5 M&G8WI64FW;T2922C,;CA@BV"DBWT;40N>K@POLQZC1M%(QTQGXN
MC'F".NLF6D>;;N+ICPH3>4U4CU\-$:^/5(CN9*U)GH^+?+-8N_&%-$)AE; -6ZEITH/5@'!P\1N#2U@<]ZXHJ:K* M3_K3M V5-94#^@09;?Y/JKG\IO5ZG;X_QPIG9)SM:C:X=\"4H#6?
G5FGY.9 M;MBM9GC67;(M8UI_%\W[#-NPIF%O\NR#3#_%G!XI<@XY&-N=1_0&Z(!=V,5 M1YTG^:[(+-S-=,9;D&1H0=UBI^SO5%KCHEQ&#.P^JC+LKO=.J$0#M.:E_$'+
M%DD"]()·I] M*BLI$%SLY6X0I2F&FQP71,- -6B O7Y X?YU:\52L\-BS,TX]X6< MJ:+_P*H#OJ,_TC<#V7$CNP5KZ:$C$E_Z*R1((=VC=#^-#:4?'2_%172? MJ]+Y<4/KHC$6[1?
A]&VM$\&VS=^!#;P%\P8*(#Z>76\G0=;VHW:\-8=,484NL MJY%"6K$OBZZP%'?L'SBYL6C!36)S=C_;7&7"Y@9%G&(W5HF%>@]#X!UE%=1V M@92IG:E5MH+3FGF536'\"
[-SY\A\@+BKG'B-83,DO#;6ER]>JS]LFV614]CT M&VU<7;S5\7+G [+(KV,,G'B,PPD;P*0]^QB"9&Y^I0.T0^9* M%4H']:6;7011-$=[!C)(9;]7GV6/%%" ^IU\T.
[-4,E],55*>D^@'4.^"BF M$M8G=O@9?,&/K'B@:$/L7,'UR4 NA\0*)!KA%D!9-,A"Q0^ L(GX# MJ?ZO^R@WO7U!O(^4.T&QGMBR3X/^+ ,AD7WV'+2.00SVN7ON?N'G@8R7(*(? M?
HH]R3]+^)..U,^;O;NN)4F0D"BQM*BS[#]+^//@KO;I5V^R(U"F/?3*,KZC M?Y;PE[$',8[_J[?^_LOKKV3XV+P_6 '4*M*R7P_P%ERN0QXQQ\#Y#^T2*$F
M4)/7+$=I7%SI**O7;IE=,^/9TT5'+@'2OJ4@%/6_UVD^1EG0_T):^&\K^F_] M_1_K3VNZOF9I4<[!@4Q)K(R"Y(X2]9GDG_I1'M\))+)'<@5>G!BGSY=11 X9 MXKPY=N;Q$>?=2?
NRH2U@=+36*RY)5%#QY11]GL@14CG"%LWI6!-2=O$EK!] MP-@^SXORQ"CVWD\9Z4D2"W-8R4?MXC].>0YO[,(VV@PM&5Z= MGQSS$";4%^]}' 017]\%I5Y",&GVN#8?
1MX]J_VH3+_N-.07[SOBTE[J M5D-LPJV2K.TM?EVXZ%/18WUE:!NUUBH*-K*0*?U]>_+_,<6+ PW@T+TNO*GX MM9/56*S*>L=19K++NA^IHKC : LV)86NX(6*RYU)C6&^+.
M;RT3^W6WM=MJ&YJTA=7YS#HD9BDLHYZE5;&YQC0EU1Q-QN$QU(>:!3-%,3W$ M *J2^#=L=2.Q^4M#EBT3]EN?8BA3;EM")Z-;9(B>FO)IV:KP;,:D!1P>77YZ MJ].,TVB;%,
("S]RGYAHFHNX;$!P*(##E32F>FPO"2 T1G>?.GMBB81;G=^2(M M -P5%O'MA]X-L_P6K#5CJ\EJ/S3NTZFVQUG\QF3;K9S#G4_ZK/5CJ)6UDC$ M!LK=)H+=AI_
I@L^QEH/+BB+FBHM+7,X(,@,#>9GNQ_7!;,RXHH^?I%[0L'. MULPC$J;S\%%,\%/;MIZ;S+P$J]L7#A=#YJ/$V\" "QIODR635L<_X.]]PYK MJEG[A8.H5$'I4I?>D2:=B$H7D-
Y!!46(@(#T$@&ITA&0KO26T'N3WGOOO;>$ M&B D7WSVMXO/?O9;OKV_<]YSKOW'NJYDKAK'(MH2K=T M*CT_O:!.$D

```
#!A06M6U[\2NY^8V>#JE0*])XKCI>9\@1NF!7Y"'!TTI*%]9'.T=SXABIDI*Y(^\A:_D;I'QZG?G?/)"HE0!Y+<@:Y!C:>O, M7I$[%C8(([&!+%F6UVFTR4]?4U1]'9W!88WQ=/TQV2;=)7-
Z!@.,QY8O=9C@ MC!#./,:?9RQ]!/RX%IL_9SHU^4G$^;UA@*BFD+<(@TQ*V;&!CR.G ?Y!R=A5 MCVD3!6?]J5SBZ4 %V&+:,]_I0*++^/QD+F0=JOY$<9^]7[V1R^KJJ[9AW\..
MYU.G,UR@Y/BIC:>%E5)VD1TRY]IY[)925.D<,D>R4^=O97B2"TY3S6.G[_(4 M479]N/%_%:]Z ]D;L6%9TQR[USR;MG%'>LO= !#!(3HI&.8A5X7A&2-&?1=O[ M402XO
,8JG@S_B4(N\G6S)J0UQ[>09)7? 9PT,E)CY7R'L\[B[YNQ%\9?-+ CAF;2(KR^:5^P9T49DHI')];->$$:^TJ!EP3R1W4'N_D,(F(+ MIQ\PLSY_\0;&X@:\P)].#291-B?-%4/:VXY5GE?
\%I_3_EVDVH@ Y)]:IV(L&;%P[HC"Q=Q]+?O+Z03"]#WQG^'KCZ(,M.".\0 TX*4" M&/+AI-?E;[8W%*S >];.Z4[0@+D<# @N7&C@_XQ]$UET;.\M7D+B?YCSA*NT M7"R7--#%)#:?
G9[NDNSTO:N\%_(-WP'!T%T+^NP"WJ9!IK/8>U,_K M05KXMN:SD8O7:IEUU- Z6V3.&@C+C' MFI%QE;!8 [">3%6.QUI3(B@^NA'\G;U+*)U@ISRA>K6!;*CR3*=,:PK42BJ_\%%)9,H-
H-R0 M!^A;4)M?,%MJI:LEHTU\A\Z9\/ 'RLP MZ-O'RK%="S"I71/.D&1;D 91H@'SU?K>VL;LIG JB97!F[3Q\7FZVH9 =L:W MGU]L5.*"DRW?NL7TY[^PX2W;>L=,I-
L5)W8/:^">VX43A#.]0,;9(6.V[25? MS(<>#,Y7XDB7+UBRSAVL>EB4I6O'\5LEDFP5=_LS+P'#1]W/G70-T YGF Y9P M_/VIW:R.J,5T41?_M8LPS&Q,N0VK1#+%EM[-U+?98.KE.-
;B7"0,.=O Z RC MT>6KS.4$8QMWQ/3@Q>=, [LOT&I7H*&^YT6*XY(UZY'1V#Z/!APB$U+>^ODL MWIFPD#Z;?E:[4W; !VE)GJ2K)D2XR8Q?=72G.#5.2MXVTV8[A7R\K-Y+1;?E
M&= S:FA-UT95H>6]KF2XV@_U=(2\;L/$A!Z<%+KZ8IFGZ?.=08\Z@*AH00P' MERR;^\%P1[KF@W1UI8)M^2DEBK5+H_'CQG0AQX-K6;7YBEX7GV7KM1_C>O_
MIG,P^J22X\+6%JG/LI1P;:N>+**$B7YGJN:*JV!\&9YD,-9;(U$0JV$]=?=M M_RP[3L!6IY24E7_HXIS.D9&*6:L@[[$=6UR5H 11?$ MW@LFHMX03[QS5[-P4WB:^A>CY9ASOP!(
(106%]+_=0PNS&F=G:K[EI8"G$I MK\N;B)QC&HQ18GH$C5FB_PD)'AXC+ZG$<# MH2^E]OB/&9#_N8O?PQ0-8-2I10->G*,!QX8ZNG^[!1QB2HD&=,9@<'M2&GQ% M,18#JT4I-
D2B=ALOA+<;NJ14&_[,"(';IU5=21007*EB=SB(DX"HF'T"3GLH MAAKYY)55*[Z&M.%W_/,F2-D_W@3YFBZ6]+UET49&O2P3NZ=GILQ MI=9.-&J:I"\VGI.6-5ZL7*DX
/\FW>N7K"Y'W,-EYL2&@,EUQS&/E%"%)AFQ M>HIMBNCF=BG_FRQ3S[)U>6/[@]DYG,_;-]A0A4]8X7B1B%>7H MTJ7"?MC0.-'9XK_U,D\K?
R_=*6U!V6#Z8*)42J;.^'M65$*ZZ:NNM4,=4XYS M#](0ZP&SZ6@4Z2WL*U(4*T=BG2OGG<,I"3DY 3$ZN%%'JZ?XB#+,$5+^A> Z MT$9GLEY ?
1.FYEM66X\_H%TOG[(UTQL23X7;7/P#0._F?)*]!W)7>Q,U=;OH MKEN3I[U]@JJ&HB68#P'T'K6BYQT4JNZE=$M29A*Q^G 3M:+73X4$J@5S"KL,4?QBTH>/FIJ1F%#
MU&&T43,>CV(7NMQEV!(@[_":S9@Y!HS,($IMRLD\U#;3ID>3TZ[DP+S^M/60 M)7I;]S@3U+9'3U>I?8OR(.7RT^@62/?$NJOI[BL<(T5_;H)C)IJJ@QV]>4$,
MHB:"4%>-1V1[3"AE[M23$[N?&"72#C[4M 8O5*)>56>-9.Q"#NCGZ4G\Q?$U M[*_:3BH2K--,U]U.7#?"R_9N[AB4Q6F-FS2_Q-7X;#-L^ZCC.QV1XLF%[O>)
M2*0>!LFOXJ[N68W8PXY2(!78 M21F.>LW;R(:G;W3L6XD0-_.,7 9:QB-EF:>37BA]'[S^YMV=""7O2$3PNA\ZM3-PQGL+QVBA_3O5;T]9D*FYBH
MG)T*EU699V7I@9GX0(=#8YCD3I]Z>W"TTFW.VPTF-&^T"%/R1RT.(6 :M@#A MUA$^J&-%J3Z3&2F!181"_,9'+!SIQA@':NFXUW9P<96'AA_<^1WM?4A'K )^ M(!\ .8<1Z:
;T5L4XT.!2V$X@)I9;8 M".;LIV<+>Y8]U>0OG1+3WYY"I+;EK8H999D/_-^3F14RKR1DOUXQ)5J8Y:EO MR+T;&4:F$$JOEJ6'E= "E\[^-K7I)FG05E!IPZ3XRD?PX_NJ'MHP,32 2;@%
MD5$P7C%Q!Z%?YO+Y=@EMNUQ\7$]I&SW*1#X>G06@ 83@I5M1P6_[8NJJJ M3LQR;.ANXGI<IK?: M<+!^HXV: !O ="?DSX*BQ MY6S+'G%,E8..N*8'SMTA9W0O,S<)X(R*2^-
KH"/)PE-^;"AS"\6-BSNAL\X8 MPT1S7.B*GCSN>6W8'-62,[WA)@YK78<"9@WUL%UY&F&4O?I\JX:^L+/)JQG,=J,[#MM?YI";T\^FK?BRLQ_6U/)0K#D,8 M@X;*!:Q5;>BNHO0P/A_K,
O:%<$*UKGQ-I993 M3$5IHU-144OB;HG\Y;>) M%(\GL(KXM*V*RHMW#!9F#X)BC"+L\7"2C@['3"GF^W)<"%HJ=8E,+'CO!G6]
M$NTZ6X;J)41HA$35Z!Z*O5VM>O8L1SN=PUVLJRW;QGS8UC'[R2"OI,72CD): ME+7J Y;GF]<$'^)VLCSJ1,J"IN:GMQ_F.EJ(JV"'Y'_OQ-A5#%9'FDMT7"CR MW-&Z6-
#1.U[)PXU[)^WB9K0?(,2?CA2FI9 L0:%LA'];&36.V^+!@LK:#JF4 M,4M,GW)-B3E$5(V@IQ,FL5(W@]FA(^N/?YYS^J_WC;N1C^)YP"6\;UA>?58/ MFBM2!70)\R'94-
08=/,%+P0!$0DM*?Q)T$OZTA8=B%_&EDSW[ S75<:',EUA M- /#?!OW+RW<+;\&Z>IVD_Z<9F;:$ C"1@N[#6>>L24^A?.U,RTZL)??R$$ M;@8O%5[@BEPA_I[TE8>\
[W>/4:1HP"WPH$SC0>OO*5.WWD)!OSYF@*4B0"B? M6VB %_/?\[T]RSJ8_NX':, G-*#%]/BV[27\[REK#;@2_NX'OTKI5\+7X2&C MB5^? Y> L(FKZS0HI.+?\]7&!J\W_OK\][+]6\
[7_USVOZ.K_1\D>K/?95L5 M2L&N=SE>%3KIU^RKD %4+4_'1Z,JLY&A1C8S>'MFOZR MI;P6.J^2C7#7K*\ #-A:=.;]P=&4+N!3AC9K>]91^HO]P<;> M6#0 ]'
#)^FZ!O_Q.^IRV$C'15]'$&G+Q5Q3M?X39GOE4'B-SWM#1*F/V(9H M1Z9S S]\/'Z)1HZD9B!'?)WKJ>W7"PK4]N797L*1VB<47>,84F.>H^YQQ9!0
M&%3WFJ7AO46W6ZT;HU@[H;8N%4,T4D2E6O#3>A <_ZS%S2GZ!B),^/"./52O M'1)K/_/81\U6YD#'@WBE3]YXW)&.QKC(O_^B7Y")ZC#O6I'.=1(W&]J-FSG3 M6VX^2)>&48/F3;TR
$^77UV:QQ>J6R&.U[W(U>0'RW$0]85J4GZS.B(/!JAG MZPB9K&?D;X707VWIZ[G-1LTL6P26)\OMKSR"[3J["2=ZG<0'QD2/TG[$:W^/ M_2H>QH=Z=-%XY<&&\@$)-G.LJ-
U4]OQNZ&*E'&W'NPF=X2)AJ*VJP(_\2"1 M? @Y\!4W^9ZY99!F14&I$W+T7;O*+YW[X27&Y$LTHR^BJBV2[X$Z+SM=.6*5?3(B^.3/&?02RZVZBTR73^D#-SF
M>Z%+=9TPR"O!*95P_FF4(E\L=*%U6.1,IA^GPNVX=?S#,8RE+^7[4BJEH:F@ M-)UUIG&W/)-]_NUNUYTK2_9;G1?2P7#,TC3H.$4#FD-)M?@+K!U<:00X.G4.
MUZX3MU)OU+$LH@&W$2W-;]@=M4J'EV(^/:_856'3T".:]4[Q2LE]HEQ!.SW% M\&C(!!L6K3\J=$"=%< <9@W549BG>)(G9TB,-''(B;:0@2F+=-
[17^=GK7X&'CR]DRO@'1M8Z6C2Z!R;?W4NF<*9=P;NUJKZ)#3+5,Q%U^58EAR7_U&
M0)U!Y9ELIX/M88E9TOYU'SPZZ6304'F]N&E@*F'9WBOWL^%U#U=S3W:&4UD*>,V>_%BX8^/Q>IFF1ZU(%F1YJS'!U]69S3Y,#9LV92%4 M Y&]Q'
'$76I&J=@*CW/S#EXWO10VJ%Q_=Z''RLI7#UUMQ8/$,].E#_S55Z% M=P7T+:R>QY]_;!4,21JJ?]D0XNB],=X?8MZF<,7]& $L&.19>M
MKVO;/>N;X=\V"W%A<8$GC3<0JRX6VC7NG^62K>-9G+CNFAW66.S[5C$\)EY1 M][#%(-_P *H)@\+IS-E=$#_,\'NDU6&WFN##628^Z;;69&5%G;]/A\2J[:>) M_C"9
AQ?'*J9M"Q6U+OG;EZ$^JT./"B)I&:+6/-I.(B3_I@+#&6CX[/+!9F- M;*8%^_C\=6OA+^0 QPE'P-"@QA:#%X1RCC=HW=./M(F#2'G"GZ75^:)NTQQ< MT#C:7B(6D-
H,L(\+X,&9?/!".T8#Y1Y"EYPG3RZX.H%+6 UHP/=*'8P6#$4# MVM31 -Q;9U>W:BJOD+8HSC#M6=Y+^D995QSD/9&%XX?;"V?P1D3>WY7JKO5; M,)O8++R'P8&;ERC_.4,42@0-()?
_I9B8[OO:7;X:;_ M<1=RUHR;#XIWCG4CP,W8GFC $QL(&@"F00."TW\I19M?97PJY15\2(QX9-NX M:3W6>+ "AFO]7:$89X*&CL(A$YE?!1#^2RG[?XOM#\7VM]F'YACT_?5'4(NF
M>:KJL6@-?E#EN)=*5TB@7O@#-,#E4"PKJG14I3;U\7\B]FI=N[E_C^&_I_Z_M1&PG?YO).J[VR^O6'<,)C:9=6N2+/)TN+'EE9M[O.K=-[!^IW5J3B(5QO:Q@IMT 7] M=LV(K2GU_
[QE6<7,K;ZO ['(T*AHRTA'Y"Q6.O0<3DV@&!KGC!H]S[- M<=RY)#^*]\BA\ENAA8<2Z,-4 M]K("P/8HMM%U/C&##!4@M>XS=EAGOU?:FUN%9Z!.AM_]TQ#Y&-A,1K
]#M9RJR$(RX&,7J; M@_@$FE(794LT^_9B/%)HNF\-!MJ,8-Y58'CHT"4)OYB C!/\9%^7PE_8+P/O MH0'_[[;W^[)DSW'NPHD?CY;/T+ ?S]A*+4?&MY\870-.,U9Z\+^VRW:Q:A[>
M!O*ZI$]O1;RW=P_C,@CNTE!*SQU+/N$_8?OD?R>SAV+Z($G1_(_*&<- C[6#BW+U9XOG?^GJ7^YHC:F_B-FOW0 MY5"')J?QLPCNZ9^< ^0KQKGE'S?
N.0(A'^8I1VRX/5@LL^?;7\6;F4<^P0XI MWA<0IYY-RQ+2>CW@:6VF=)ZL-"I=V/U%*ZE,I]139/(0PM6,$H3-ITL:Z$[U M"D9 ) 1V?[ 1:B%_A*1\/#G0\>!?DG)7@3>-\GT_ND?, 4IG]
()%O)^1&6#> MR'8[[N827;J74.HFD3PFZDNJ(:CQR5;TL-+:-/D #<#N/()(M%"W,I RZ,8. M6'NG6)"(T5ASO5D9+Q6"C%:^WGV8^[1]=Z:Q<&C,/%8&=^)XD,.#L5 ME
_=>6WB;FMLCKELHO/HEFVS-&,IW*.FWY>Z:UWAC1S1Q_0' MY]Z$<@[1.^.IRPNW$'%&I<.TTY\_5WVWL]=1&+W);%9%)\4UPI[KHB#,XOS& MEA -(+VKFSPC!X<@9=J:#].TA
M2;/O5G>FR[@HOH[8IFZ$>]]<#U-L6J*T1VUH_^:X$8:.J&K4N M&]N=.S$X3W',=C'3\UTVVSZ4?1>W,=E8W#BN[KR=M&:W5%C[YC%UTP#X2A=]>?E99;.SPYGP@E<
M>MI$'O#6YH /[!)5WT(G3XOZ$NE"A,!HG>!2;8;3 M(0S" MU6H(WH?SK=5&7P-]TKH-@/JH-H]&\M,!_*K<&7#+!H,'@ M1!X:L&#QFYHFWSNXNN56>'4*_DT ZQ:Z5Y]1/Y Y?
RJHW?UW;?^U:QAEW-M? M>$EYY7VN_EO!_"^_;WKXKSU;,VZ)3S8]Y;O$/DS_K9PNQZ\-9_BU5]VU 8+B MC;_)5?ZW4E#-7QK]=UWZ/V X$,?OJ3Q\#Z'RO^N)JL(@*,7;/-+UG#]X M7-
W;Y)$DE@=P_1WF!14_76?P[VP S37CMM[_/89BZ#_F1U^B%X)!QB.73FOB M3!OKU3D+HR5(ZC92LNHGE(T35*)6DQ[Y,A]ZJ3^-B;I^PC,D2W[CQB\YO1/Z M1JE_.@?
VRD'MBJILI89TLG&Q\9Q$"'@!#T #'I&S!9\4(N3K>'*LOEV#R5X6 MN=F^(G= ZXQIO_R7_?0V(=\'EN51-71ET<0UG;$F<#&]0=K"E*/TG,^2(-@ M)Z>?
W9G#QP%BC)ON*]*XY_VD>\K.8O;"TWH3 2LL6< M6NM'2/,<((!#=_.&!(I)='"9 MTJ1HQ^-69P@+>XG&VZW-M.#.WWBD"Q.1FAE6IL3(#S5^-7>PJD0H[/?.]16[
MGNP+EJ$\VSSO:Q\4\ ASZ98W5/BOSZ&.[;^]!GKGA10\BQD09*!$LGG:TM;$ M1MK;:+]_WD3[C4'VE9S\(I9RZS0,W^>35:>\#!CDE3 M_J:;2?V[BHO,+
[KJN=T!M+FG3)$(';K*%B".P;.2CK2GO1FW6:(4<59[9;+[ M(3G5]O++$+^4.%B/0NG(\EL(4WUXC]RK5FS:["C%?9#MX@8RD/]G_D/J<$V?
M0\N%:1!WU(!.^:5LC0*+UM'=!S]N$VGY#H4"Y8:$#H@G">AX%SHK"(U83VW4 M3/2B-?OV)_-!#DU>#&A UTO,.BG\7'A%R:(%3_F:P-::V#&VQQK;OKP'#4ZW
M%FC=59SV+)%?,MG(1I"VN.D4U93')JZ9<@GB>9S3W/"^U?1*G'2ZK-R36'D" M$KN@51*\+2SV?"5&NM4>B ]U=(_N^KYR^$<",5@@?\=]W.AO()N22BIK2;?K M92!
(<8]J33)*S<'8\8^D DG^Q_WD??U!6MM]>GT*G"[7LPD M^KA%CU<<0SA[GHZ\'"G;]$A4<'X7[O!00)E>+WHTP48Q_UI8I;0;XO5RLD1S
MS=58?];KVRKOS&Y1[]^OY*!U7T3%E,-3MB5VKO#WZ>:U3DVL;*A$S2)3^^NE MCY86/AT%,>_'3>#:K MG!]W)5-PW#;X&FA=Y)]7"0ZD/:(].31>9HBZS>' I1_6?R8?-EG>$=[ #;G*
M(,&EWA>;+6H*HSK]:'@7L/=<.IL\: 1T?H?&R? MMN:N"<;:BI)WQ*B43V9=9'8+>#6AN[LZ".>2DI*]?Z\0!KFW>_ MH?!?6!\*VU//*8X;+W&S41]/MK37&ZG!JX;#&)^2,?
4">^S)\M,>L[2TX/Q< M*XH+G62IDYD]'_+9CNIC[-DDK)-O!%JZ6&9H )Y:R(I[B]T;?F-=M^F M!4?^A;."O ?Y% V()-5 RI,+X2Y-%M,#SFW&$[6B%$?.6:4@R\2OJCKV;LX M],(]Q-&
F2QZ+5:^4C!>)Q/4S2')+*??DG#VKWRW&\?AM_MR$8FZ(]2X*_ZM M.3K78U^Y1:O^^$"F(Q)T3(Q0%,HLOC2/K8HQG_<5:W=A8F)*NGHD#"'STN*@
M/_7,HW1(B@Y;O1C&.OZC0*5 .E;&T\U*@31NV #7+V6?_YZO_XE?Z-#D88 M/%V';O_U+/786)L$O4 M4VN1+394B-4P7 097--XY8IIY3?J/@3&Z6!\F'@M.46IFI05SROTV M'4*'8R-
KGN.P+ //<3<;3TD"SB?03!+J:<.'1%6YDV@F XSX"LKFFKTZ1X090Q<^9/7T];\YM>Q-4CF,JSI,=R9LM M36]';31/7/AM_XBKR'X;)$#Q>,$!$.6V 7QL98W3.KV?O@11,ZBK+ VFNA>Y
M%\-DMRZ0RYQ4.=?90>>Z^BJA5=.I4MO>RGRRQDHU33E62;Q^IARRX%">5M?Q M#!$)V;ZC0B@N8#Q/2$:Q>:GN'KL:/>ET,1[@+PEVS &93HGW)1@:29"'M(?4
MZH$)N$@PCJ!H;ACOEP3%@U5KPWL=&B%K[(7..E^BG0ZL]\[H3LC;$>GMAY;B M49;4VMDSPJSM:R^4JXF- M2=*<84T++C1:;8@&\-6UIRB'Y,IJA^CD;1D["-7D[
]MDNDR+0_0MBS-?"JI MK+C4W@&T*7+F$#^#=TG[E H-4"*@[IU,#8.Q[!:$)&JEG:D/A[7,HT>]3]+T
M@JV,ZCVOQ:I\SI71+5%WR^]BO2(=2P[MK\Z<6I!]+77,X1.5R'M+EYE@-015!D)K9!L%#OYH/(VE&&Y5NEW"^E M.#-Y&08F(L=<'"CU>U42O<&$M\>U=A9FU+[ AZOH3
M'4X.M@;*0;2R8J:F4NZTPH?OC.D-VR0:3!VS#YR&A-5S22P! MD0$'X)T)-."-0=.RZ[:,S"8R7$>,J6413L[/;S2D-!ZS>P#9/3NT@/Z6^MN
M66AX;*>4D,4R!)LTE&L"X0B!N1A2,R(U$;I5K4? M<#)W85<:$8_7X'S9CI:T+7U?*S^:J,-L/OH@@3E94O5]R$'<'!A MW9EPCJJ9U^FV8[LA?30=TZSE;K%V0C 5-
ES>V^QFF[C,;RK+Z90&%$M!M3N? M?&Z(_4PR5/%CEMK!:_::CQ%?J2'L66\]>6*$CSTZ>K( M6$;CP.#F"T3JTCGT^C/>)8S7R&,>:'V%!\S\4.-?^#++_8O*Z.+*I M=
(1J)V&YSG8I%*@&>VIM;4VB;&[6V^FMWR2ANC*Z&N%5;M84ZX1B@K&4IZ0W MO+7>I[+FEG-*^JAFY#&68:6M^6$--+VY6NC3L^8?)A NX)/*';._-^=V>G3( MPD!61BR4'>-
!>8G26$0#5J:NN(K*:GTNQB7R]77T6(P[MUT8JTP#=0QN)BY% M7W=RBC IY9OZI.[G164CZ=3N=M;A5@_K)@B49*EY_[CG_<%MX.P/AE[J#]M:
MVIY)TVZFC_F_GLZL^)RE@@'XKD!SOZ8WS(M8 M*2?*+0VL)7 ATI[7Y*T@@ALO!3XJ,DF^2%BLT\[M6Z'9R;<6ZQH^[F1.T7_B M42*0>V^ED0D;+IP-
BT/)U,1=.9FN:103:8\RP780U%I=6X,]+":%<,VPN"EE M\PFG\D,IDF!VZ,I:/YL.QF+\S'#E&X *$1YJ.;OAD%")_**'L>IH@<2@NSEWX$]33=30 "D<##$YX_IKG;F+X
MCYZH['K;Z/]VR/%_DVW4J:B.$J.=Y0+0 ),';,#FM__&K]F6BN+ 353/C5J;/&FX%>,A.0B%JN MV$\QI83A;*FP'C^VZ[^E//%>&/Z4.$E3O#WZ7V5[^R_9^%#2Y:30*S\S&R(2 M4#EQ6 8
/+!D/.?@)3:8,8$4X:;8I-^F('TL$27*!+^.BE&?53/[[D^UMQA& M]87;+N>I^B361XZ3+H19>RQU\J?WIK,=H-Q6R>JTI%WNEI"0DPM"\DK>Q@Q9 MH0<5F5:O$V3#1,53X)F2I
M&PWXX/9>?L)Y/1HI/+)4*6"IZ^PT'4S8]GXX.I9VK7AG3[N8[E87+Z3"K[7(&$DMQFU26UMVYOY_;B\.QK9-F7U$"\Q,] > M/.$*S!3)W*4+CQ&@Y;F@1 M'H7A-
B$MK6)]MU^_;03!*D,U6T(=6?H370E4K)C?E3TUCT0#PBHK[YWTL0P@ M8T' BR/@!<&P87\#$R+]UHFO:X6X<77HAA&9\XN5-2G4&4K*A?@ ;L M]&(6))\:\I,67$LWCH'L./
=ZVTCQ==%2G).'$=/'IP11$G!-5RBFR@2=,+M M\KV+VT-"/?/(HA;!CFBU<=L5%8(K_*6 M-[EL4+"!QO'\GIRYK52Q1:(9/',W"XM;[5[]N)(^U#_>YY M[5&*)[^>.*6O4.B3-K?
U5/&^4_>'ZK?U'[@.:,Y72E-$3#OE/7USSQ8/5^XA M3+2CG)Z^RG]@F2THK3KFOO/T-K-H]\G JDRVN\A+)\IE[1H#%_KI:\T?
MB%VWMOK^H8T(6"90@,Y/3R6*\)&^DC/ISJY0W)C42F$=3(>)3)[, MD8 ^S;S/E>3CU9'Q<;U8]#U9(4]?LCWGH&=% K_F-G"".]-23XY3NW(7M/RL MB>:#V0MZ_K*=?
LF+&@W(&\=,L/-\C(>\5'@!L44U)N2^:SV3R&-/RWCYSR@P M([X@\&JF"^AJ'%4^ITNP;'K.88)YG6,C1,N9%%-]#B^?-7?OJ_5M*D)(!3^W MMW.J3$I6AODO@0)MXCT(\-
+BDFF/8>M2^C>A0NB9&O!%Y>F5U@[W2!H&.5T2\*IY*XJ<%)K=:VQ M]X(U^'PZ>&:;81Y)9+MGNN\%A!&GO2U,SDG_>0O[4O$Y8'<8\;^K^D^J^O0/ M@BFNQF2>\LH.7EA7^85-
_W/:?\0'0&3O#O.&>_+>=T"%[2&YU>8NZ.\&P @;2<&=^?D81?IEX0*K8"%@X9#)LE$1 M>&RF$Q?4N*H]AD&2;MLKP+AMR\'YG;*%#(REF=?069,L3*:N\>!G0#'#YDM9
MZ/!';X[&%'*RZ(!15^_;73BW7R:,!].DI4\W,T0/P 1/Z3I(O>S_;, 'B* M!J"^^%2I!1K'V?';?8:Z:*@;FB% MA&#+*]U2[[\4C-Z")L'06#@&1*6?WW/4#KR7B]NLN["Q
3"M@*7&@I:XR(<5;!4UU M[:\(8H%M269,V+1.Y+'S%&6P ;_RM9*:VBBQ@DP>VOY,&=S9$/:FW.R 9*Z& M4(F+;>O0OJ+J &;RT>^BAP<%MN30&N!.OEBJ7TU*LOETB*[S
QFA1/R[>KR+ M@A%X%V&<,:MP$)#B6T(+2<=IE>J)A"]N\_[+L$E-!+ZSMR1_MDNTVJC&N;EN ML
*R^M4[@0TQ6A^Q#CN3H&\N\HJP'5CQ\|5!3*^"R_GZF@%Y3_A(U@!^@+#4#_@CVR4:EADCGM-( M(M.];8%T/#D;TA#KU[BU98WQV]$[Y[2J=3O9'MJ7JFE8E9=/-2A>1I8"L!%@
MI1.A":%X5G^JT>,A,PY3C7AS\[H M.X3CTY' H3+CQQ*;)MOZZ6)JXC)^HDQIWCOSY7[B9>OG[T:<)7=U!+%#6S1/ MH>JYJI(5BD)[%94CO4O(9SL@^!N)H$EY_#E#!>,JK$?/4K-
Q#B'AP1H=KAE; ME0]+Y85K^C<':/R-VV2PPU^_,LOE6$O )]?LCR]=D4<\HY5=.%EJ>)%I)-61-B0:5]8G!Q-&P$,51^-^UY M24L4_XW.M 4FZ+*T4NGB4U\0XM3AW7W;O!UGT"
[8MU6[DJ_5I$]&&YOGL+)X61ID@8=]KXW3CXQ0Y<.LOMFLGX0T;1M: M65MHBL4VQ :,-A*^+IDOCRA*&)R]&X>ZRI&_%'>D3>_-6.FBF@*-V6#@HG>]
MCF^9CF+DQWL\**1C:OEU[,U[@@\5F6P]-A;$H*"_#8SM\$A3([S&SVWL'!YH M1I*57(O?&[P&)M6MDUKLDVC1C9J=ZG-DZF*(?=J;87;O5'U+FUH[Z=MJ3)J9 M[H.>I2>D^ +1,
<:.!B9G%:B:TK1"\L827PU$IG!R=ZP_J ^*U<2T8S)F-(&\ M3VV+9$Z=:?!4I6VVS7H;GT&SLE*_J.^K<4GGM[Q69;95% M-G[HM"QGH^AU=[KC52 K8V* M&Z5_.FP^YIKEAF
M>P"'/TCIT,E-+Y^L!SB-10[F=L>(-8>UI\6(#Z4*15F?-*XZO:&:K:A@F'R> MR][.I9"SN> J,3>7;.R:'5ZGZWR5?>6=-8N+-1U'$DL0-=F\#_SP(B0%F.QF
M;$^=VI+,H#T*YLIB.$MY':6]&LFCMNA.SOKB66JIF#=S\C8@ M?8*=J7<<(\U/XH!O/4=@<@KL^:H&<2KMQ8LL20\;QY]!ZPY)!'Q=WPO6/AE(+(I)U>^%0W0RC^]^C 4/^-
:)>BU"'W\?:9'D;"O8ZP#V%,(QE8,.<%LRE M^?%78_Z?NU:DV<&=20LG\| =D\R_GM;#U>/UA_H34965D?DFU*1_7 M98.+H!3'B]$
HQ$T0(Y'=/_3*1_B;]GT=.&GM2(!'C2>GN_L[!\%4Z!V^-L/ MWNW4//)24D1R% 8:$PL@M!=[@*3S M\U;492K"F;G:>CVWF2-6C\(4L"H#L4/N::987$!+!]_3!/%KT7(#5GYWCW^
ML7@9? CVE68M&GG=,&P+I;A9_3H6)V()#^!_/06KG7_'=\]DAKNXB4:1^S,M MJ,M"%!N>E^A,1E+YGXK M%6]=,'R&(&67[I[44IU**MYS,=\P#Q8LBPP)>0&?G$AZNT M#
K:"#M3KDCN M9=L=G&I=6HUC D3U':[823KEHDCXI7'A A9K6('TZX*H:\72>*U1+M-+\3+\ MDPJ=GD3'=Y%!R*W#S/>U3L+<7L+;$3N,=!9*%<$3O3.,K="25BG597OYK)N>
M>2IF*[RE9,V>(D_#I(23 K/J0KN^N/G@ F NZT72 NU!*^.OGQ-,M_=ZJC&= M8YE$PHGFJ5"WU:B?>M_WGY3C/WL ]PY7%4T;&E%I@]8D>MV"OZ/G@BV&D2KP?
S#*I<$@YA#9SMQ=/ S;@O. MIO8(>R^:L2/T5_B825"FHJC]EMKC/G,/\8 VS8$<-K_"/9XWTYA%?M_"*(E\ M%O)#RFY;<#L.^<\)2##!;C\*:&BX@./5QNW,$G;G3C.S
XMSMGOO$9(KRGNMYL^'7_9:RB=G/4;:BH-G9:>'%>N%N^J=& MLH2\\ZZ$ O:AZ(#;4IU*(0,)HO%29<]@7)Z?.2(ZN>_;!TI[&XCMU8,&X*YG M%[%-
H\8EAW'Z2E],16\EHP&0]Z8DU%,-;/.>7]NU%&^#^:@6RITMZ(XFYO,> MKI<\E9C>&,9XZ2_>_=YM_Z.+_-?H[T2F;@+2$@V(M%7&H%HP>)/X-V*"L."? M/I.G6G,-?
2%'[*5JL**:KE$Z0ZX&7DZ!!\W2GKC+1L7PLK[9B\Y^_>[(P=#6 M(\,RS5KRX+/8AS6AI8;SAAV2/&/,S^4G=@[TQE$W8&.0'RD\K(R+J[;.=FB M1S'3,=0_F+?
C951K]&.X@D!8H[%71R(]O!Q(@]UKX$ES/7!39Y2=Q&V0N9H MW;<9-XAWC7_&4DQWT8"M2\E&$7?/63.J?J"24V[&%.CAFY'GOOT?BZP3IUSI MQ*Y3U\I27HM9CWX-
SDP6V"86Z,W+#7LSWO1#>%Z68FB8H,.M=(1'K_RF#(GF&]R)/2FIUINCJ'LR(*^ MBC'DR"MHK:!VQJ^)JMUN]C3_6./:IYJ'J=*E-PM9&G8V;W?0UDY:FR:&6. < MB-B]]>18;G5!%
SOFTY$F]]*RWI]3BO16W71E= M":,\=F>^GJTFY.>Y&#X=AVIL/"]2S%+_N!2O2'^I,+!B2*;N1"%8>,PCHCGR M:J20YU-LI/44E9.1-16M#[%2_9K\ZKD$5KC-7':$_#/-S0P<";Z/2'[ACI3I
M9S)'24PUA5>'N S^7$[3TP02YI45?O?]^?V>&F$AM#"#2T#&\|%8ND>C>I1G M[]38& R-=J=;\!9E\./-3Y\$.?E,J&,&0?1][93KW0U.F7VK$S+H[X)J?TZ2 M^2V&].?
L&6V>KRD;CK)D6B'_C$[D\H\S(;\4W@+7+(S7YBUY8"8S"U>+Z7[E M25[8LH6CD4BK&N(<=G %+CPBGYVX!2=%27M(8!SL'63;G5GZ#@>5J*?!#Z/D MM61OQ']=!(A'68[]\%
$S9[[9 STH\A#*RD:.SK)$+9 MT4!EB8S,EV\4[0IM1@,6]#IV#"LIGT]/]3@+>;\(%N2JNMOL'>6RTY'I>C(0 MY,'OD-6%,1QPV],BQ=_1O'M.?GS/?UM\=)XN85WMTT62KC)C&
<49/WO$;:== M9L>+%5B>'7G_H-.B)BJ\ ="FP]8^8!5-+0N0]/ MZ)FG0XA7>]\=UN2R[1U%I0E(EQH4%*0JB$B- M@'010>E-!:1$>]]1D-X$!*1+1SI([[U([[V&WD,-(21?
```

V*=L]=ZSSS[G]'// M=^_C'_,D[_6^]XY*G)K_EU_N7Q"A_. M;4>W%,-:O;;-(L8)E'C8Z#*IZ,[QMYQCP*%M$FF=]E@;8G!"(X6?%W9N^9G$X MO'*U_5HW-S*-O:[MTDR9FCH+%PQOXW-
NN&:,(8H.==-("[&W=Z M?HPI?#'@CNE70ESA-_?I&\)#-3R[^%TDDAM3.=,0[\YW>:D\&.O)QPIU+8A^ M%3YO2J,9DCR0!XV6H&(156G-N'P.M#Q7J(0^D9%/)N?O6XE\V,A[7CFY
M*O1DFEX3K N75J;FNN\H&#*QO'\LI:!7GZ,Y<2(O,#]L]ELC@-U"2 S['6* M%U EARF@1*-U3]V(%L"?1V(DY2ZZ6DR5S^^Z*T0";-87PHO$K^E"5]O M5%4]CU-
LY!'VMIH.^W2_CFBX@GH7#2"#>S0*Y'F;Y=P]P=4>(2#K'3=]QA!D M9?GVC=3CJ%QH0V'5-%E_2H@_?\FC@C6'Q"PV]U?-Y%*]@R/2^7SF8%NK1/S-4M*H@-#__
CJC<81ZCP1DC54WK.[PF]Q4[C2W-[Q8N%*Q> K8XK; MNQIOLL("PBK?:DL0J-E3W>V:J&?]SU>#*FVUYF,QC01]-6LD K))WQ^3XKZ
MZ#]=G@$U[(86PT.R"7@:^C6SB(57=U6QK^KDNGV$HBZ[<\.]&YCKF1]0)RUH M'#_C5<2]N.I#$<=\5KV:44X.5DQ%:3X3(34&3"6\2ZXW2LIBVE5M1ZGH*2P
M"YFZV=?]\&\7H\':UA+8*FP2X;9BE1A\L<;M.7+*6[&$*QLH0_R/<-:H-!7] ME;AQYD/[\IV2L_N*60X"J0>>^ 1^:;GZ%LG1YSUK!<)KA&VE3*DV[-W!I8GQ%VXBZ8NO0D"-D:LV:
#\L\BU M*1-L#H/DX,MTC8O&C\6)]_D/4*2K$MD-"(4Y0..Q&'31C-B[0N7!:&,O(9G MH2=+\S",AN"N&Q+U @Z#1E\L<+,.'QZ6OX=405#6&I_3]I1T]+Y$RER!3,?@O
MF[\6M01N2QA%2+=+>^C7_\]*7CJ'(1]AY+[9#*IFY"Q$T6[T@;EOPB['!.;[MXVC 'T'.4YT:(KBNXUY4)&PF"8\E]9+H_A]IQ_R]\D2:P<-=@%BGKZNW.,O5_E'0+I;'D;
[X$$U9#NM.M*6=X6"+K(RLX.TDOUMDOT=E M^DLQ@,>@)+1U455I&)H3O$**8,A'(X^000.2J8NJY-& Z[F8GM)Y"EFY],4- M"&D+3#MEPIB)@:=+?SW MY<+R0O#U9T]]O"&
[KR$PWG)K\R7'\%C$<^94_=6I*4&Z09C?7>ACF\$<9YU3 MVY4^!11EP+*B 4S*:,"[O:=H0*(S&G"S%0T@?3+E,'ZX-@P&!Q;:>>D;+>@6 M0UDE<=[H5C6
8WK]T3;OG94.S8\3YE#B:E^-IQ0#3PW0@/:K3B ?57%UU4<[M>>]O,)2=6+Z&ID]C#PZG(YFC$T[Q9X[O@>#1L<8 NW0T (-#-I*U$!)Y3/X4 M2%UH_5F6HR:GJ_:4)0L-P%W"/"!VA)
(/_B6()"(05G["]W F(8KGD8(LU;'MUD:A@ M2PZN0GH^G&+:WX%?[+9F,?FR/2FUA;^H9!.!7:,#9]\!_G&[",6<4 M?^]]%HD\#I[A0DG_'J@L?R*3Z$&%[MX2R*7V^'K>M]0 S0D-
8F:D#H9Z&&N] M:2AOHV!5Z]R+QSK^-[Q6NP3Q/L;^)WK!D.N???-_:?\QB]S/\VZ&?YF<-+IV M[;%ZS2 A?ZM!>CT,_TF%._]<+Y;4=2^5DR=4V.D[P_:!=^> [WBQ6R5T3PE,
MEKWV>Z>!!VCH3/5 \)7DL4K=L^9SY?37[ORI]23C\VB &NS)X!9&"!5*EM1(MTQNYQ(UM'IRRY?MO^26:&BZ&-!M[JLM\YZ@<<(=\RO&6.AM3J.J8TTS9&DM2 M]O(?&0?_?H\?
<)>9[]0^&#'RV?C;4*>[,W_KCKD^OE47F>*3)S^N6MF&_Y U MXK%@HK_ZOL(IP&9:\IO,*R)T9V-Z+N38[YE',$W8,SU:N;F!I6]VWI%ZC0W MA_4%*4? A
\.6Z%JEBXD,++"ZU,F%4Y-R8#DMD6W-QDHVZU!9>LV+9]9(;V= M,1>I9&.[PQ%_@J4XG+=,(81CSP"W+1Q6XP^ZF!MT22:-"C5,!)#6CBP47P<5
MV,2\&4.EH5CWSRF8@<=84MJZK9)[D 2SI@J-(O3#=T_&-IDB]HFI/$/F:\!&)++6HQ48/2NU?36K35 3=3JL6\../3_P:S Y_MNS.B#M/UE4S5LWY!*R(F5>)(>T]4Q$*HK&.5)\
[[;:O.Z*^D?T^M=.7Q#O< MYU%6%OT#Y]3XH7Y%*9Y>.RF"G>UZOAKR_@,;8>6-+8K-^@EU M:A)WI)\6#$7O-8Q_'>>Z(=2NPQ6D5L9>'BZT!"0,Z@L68UCQ M/E+K.CD2M-
U'A,I@6]FF!&P3^COY!1X*T<.W2\/C ANYW7%:KSY5V2?"/HV9 M6]"A'+YLM<@DHS$5)&),5;_T@)^KB+H8%A1+FJ\L;"ZAQ@-\,29%Z03C9$;
MX4A^$XOKTGX]S+SLB=2ZQ$RIO(:P+%_^X.O44GG/E#)[=;J*@CHE;/Y69K_# M-=;]%,\V=S^6#);?969VN6'&6%LIA]N,2H#VL?-D\WCAF&%X?
1HC'U^>U24460$)H)2E%4QGTH(^,)R<) MHXI1@4E7IND=PIL7SFPG]:<.I/=+C54[[P M-184!15TZ.G/=P'EKFFD>QU,O93S&L_C&^UM2?XJH97'X#)EV7-D'$TWXU,E
M,9NE&:.M9)]X>'M%PF-6.2!4\WG*5;D.R1<%=]>9O[7O&/!Y*+"W0 M3*Z92E3A"]PL9Y5NF\^%KRW)@6B-**_4[7WUDWT8I_VE#KF6D^/I2B255*:M MB2*-
$V@PU3R1;0XEYVY_]=X]TR/,BY$9]-A?$8BEHFTM5C08?L]Q3>;1,OB\ M*/ C+P'A4CB9HO3O/NGS#R] L/(O^PU/RRR'Z/GQLF^UGGNP92[[BW1D]D@K M38(;_7YK!Q+Z=>
(@.\ONY6EA8_&%!A4N8T45JP(D![F^$QH/+]LB<+GG"_MJ-7GHNJ8L>;[O))Q[CG^A?&CM!L*2;]C$UM@M34:L\4E9("]B>>TS'%*YPR$;K?#;_ M'DU=?+?.SM$B=8%^-
JBED#>89%IMC<@@W4C5*2 DP]!&D-AZPH[H_J86R@,; MR3A#FK+GY'N7(ND2,)MA*]UXVC2IE1[-]XGX6ZI-=?UB@BU;=_% M\.'[?7*"Y75/!$*=\>C>TBJW!O/2";X>3_?,XWA]=-
$8.37AN#^.O:X=F#-(M65*@K2E;6,_]):7SCGH1]3BO?=V5<%VAJ-S_2665;Z(7O@I):"<.=@"4#H(W MNM,2PQDREX5/!5N6 ':?Z[X:*HWD\:.O*^7-^-8?[:]&5,T-C(@)G\L[TD2,
MV'Y[/$QO\M%6ECL\2D #PP"T9.)"=,Q?V];5\T[WROC>=HHU1[*C 800MW44 M$M,W.T!R4GAL)VTVO"75X/ *<8!/QCP55+24$4_/5Y]'PJ.2[MSX5S$)-
O]S1]K.H0MCG(CCR'5P:APW+\7!P+P>T)U\(L6/GLCW(T;FG;8'55 MW9E?]>)+R_7,U9C2G)P09-)\P=QY(13T].T:3MH]9:23=_/]/,Y-^;RX5UUD M[&X&P1VDYTR?WVG6I 4F*?"-
-4].2+:TY? M4@MP+"L/Y2YH2HXUK"1M 354U.) VA)3,+RA$,(ZGN2UGZ_&\N=!04N6_1U M8TZY^#!"0XA=6S/&%* MTN0/[9R*U!^0721" S9O
7>N'63=@:2_C$%5@1HJHV_M70RBG+]1/.13"+L9 MMSNE'D86<&[IWFK"?S/)9+AL[6(0&6 ?1+)>O MQ@J\%8JG8H:D74*:0H4;^4Q\SIPX%83U_^Z(FGBK\SL@5..$ .3?WZ5^X5
M>88A;-6-^$8(3EK3P5>!1&6$[5GKKFH=X<+/*NSV+D]E$"?Q2$#L&0 MY,>6O^?^1SHU_HY"T(/OX*5+M,9_C7TXU.5+"W_; =:@:E&]D.IM*2%.^EMD MW-S[#",]R]NU!(:#.E\=#
+B^ E?A 1+];*2T'T#O) 5!*\FQ3+>1'S3*D; M\3T[@E]9DJ]2I_\1?9@;^;?7#C1T;F(T6555C"9[]W8?2[V6]'9!&GR"98=W#\^6###E'OCO MOTD[$OR,Z()9(L9Y55LW]
&FB/MAZSW<.T*@1C?Y4E(*B'9O A;>DI MD)$4703.63O %\]'_,6?\@\LE@EDH(7'YHAMX$&>TG=Q*Q9K_\8=LNDVBL5H
MEJ1/G[Y/K]#.%@:/00.8UM4P)@GFX62*5'LQ9TKD#YXG8/P?[0O,B$ZY_:M7 M\C]?_HN]6WJVA)?A(AWUVD:YQP'ZV%2N'O&.I3+E(2DS M%;]X&73RC114F^#;N0]9-
&K#$=1<6_V3NBD4"1Q3QL.QRYRF-;,6!%[\>6U M53G?7ATA>&9F7CMW%6->MSY2)R>O*RN^L'V(32P&/)06# MO/>S*FI#[MDQE0YXA>_LM\PM*;76T@2SGO&'-
S,1&+4ZA#6"50%ANDE4]_F MY=1,I$^.;X\M-_5MM=@M$,>Z\8HW:@"1C!5,&O;C(GT%455=.3OA\5&@[C0$ MX7@LQK:O/2;31=4D".(SR<[]].EA M,^?
R&::;1:52;6M0YWG5%B%ETDS0 / NJA$-8*^JVEX6MFY=,)[2F2^)N,O; M8<>Z(B?H-0S-1]E,H,Z0@ M1DX]-U(9-TQ8/A:L=?QBME%@%B524\$7ZRHORY+T_G0F9O5I__;#(N'U^<
M+J/G>B64$CEX^-R96%[PSEVM"]Q>2CB,#$'[Q0T3#N8MU.P0@W[;"?7L0=0F MUY5%20$;.^&WK?DYVD Y&+>)KWWV^AUYDD3@J])@$_V364/ZXW3SV^4Q*9!V
MS1$,CQ\&G5X2V%SWJ=V9\7T)%S,WNXR%4HL$"A9T%MT4)COW^%#UQ06 MNCGE>S!?P+7?0RD!$:IX_,5HN+_";0@*%F\/HP=<["DYJ0S_YL/FJQ F8R MYS9F4,GB%PQ-
Z"_V+A1&;D1D&5B1?/K+G%%Z]SGQ>'^%WY5R*DJ0W_BO"_Z_J:MF))7J^]HO*-/-.PG3S< M4[#0Z^3^>$1RZ1P#HE]VJVX]:,UO&4F575(Z%^.X^'+DCMN\E=.VEI5K&P.*
MM]3:DBXGNY3TWFB2V)8K@.HN;Z]^D6H7YJR%:7'M?,+%H+< M2@Q9WFHR#IN,#,QQL&L9>5)1]%FN'R19^B%1Z-.%V;V :)>*4=7^94L)2VX' M9K5*PJ4!Q0_6NV^\L@5Y;
<-2^EPD,E>=$ [V3:E,T8HQX+:6"W$61]/;+ 9 M8Y?O:N9K;:[D*K1$'QS&#U.K?" SH?;_V*^Z>K6-"K& \A[/O/ #TAQN\[6 M[_>QL:&I[D1P0@3')*?=H+(P)WZE*>F94+: I:$&S%#-
UB|\8=E5:M>:\(=+?#F,+'-8BL$8^C.1Y MH"BG798,D/8K&$&1V]C]1R>=_.WRF6-SL:),FB$P)4*\6%%2YNYYU;MW"4A< M[9\%]3,\=+QD#)@C+4<@G$=*U-
0F5DON]{^GM;V\]AA[$G;0PQLS%TS4/'?* M\1) $_7 >&:HH->9!*T'CB^94P.[PGJ9DET@-/,^O:&;,$(#LC1CAR0=X7\Z M-L.?
6*S=SO9[&#"UA*TSYM50X&Y4I#&=*UT[3[QLZHS#)+IJ'G("EC5A0-S M$1^"40I"("O7LS;\/^?]JP<<_K,'YE] +A.<-EBA 4=M[:>L MX9&!5?P94S>*2](""
[P:0DR?;3,K485G0#GPA]T*PW80VW8N8OEGSPWU+-VG>.?$R%Y-+;'0UI82VA'WVB'O #Z)M@>WB MX=]2TGYU1:O,_,9'+3.B4\&ZXE\=EN0-\$B4K*I7[93YNO;0MXQ^2,J2IR*7
M9IX9Z0*W1]6.'/MM@;W@OABC6P1C,^<=H%[Z;!&I8 ?LC#0Y!PI=*1%H<.S- MF&7RX*>?]%I=*S9L';%6 !O.G=@L'O[.(N[QM85?;Q^EQPL*+FKGNDL_9?! MK!;B?Y0]] /QK?
8@+Q56T3'%L\ XEOTX&<_?U]/4U ?M=LY2M"XYHP%4Z4M< MU]D$U;)%V";&ZG"\9A2(6W"[;*54(6?[IK&"M= 0G-@/SY3(J2P_1#_V8= M8DV[3F[#UBF:GYD
M7S:C!VF>IH[4]AI?:H%N(,+#*$O#/@G?9RYE>(X&!.J/.2SMR9;)$5&,"L?& M46Q2WJDMOSH..+UH@_#V*:IF>^+5C5HU78CB2Y9IH+<<*86]U[.N8"8OT".3RIO&\K0^K*#FF: MW/
**6G*.?OC?YR%H-7^M\0L:<==1/25F].H33X;#XYRCN5 M_F'"ZV(CN:J..SO@VWT8#-K>L7\TL_S-4,PFXD#4) M'4B,&IUW^._!_W@?L#RQ8,: CI"]UP@EFDB;F:.^4(OV]_9K?
JZFO+._VK_JW_GP9L2/(3_T.TFCW=0- N MQRKDD%CA]-QZ?]8/FS:9WDV^$:T2:O1W1F(:I^FBMQ@(&D/(^%=HEQ/[SD/P M9G*]V]/*^MB9<5KNY]9;";JDQ2]/QC?/7';@(.\?
U#?IS=GZ;"74'K]H_YJC M'4"/2L_3F Y[T,\4SS_QJ(CTX?IUZ8*+S[I:\=,>9,':0EM"&Q#G'] N M ST-X%Y?9Y[2Y,TIR29WHV;LSB1I*E0'5!A^:VZ@"_8TO,.44AE[T171W+-L PB)N(V(
@E"%QBM]+ EMK)(M5-NI,,$3N=5-$:*<)[O;']0OJ/2PXD[4'V('IS[9F2[-6A4!?BDIV'FI*Z9' MM,S1(M3?> .U#.E];I?XD-.NXF;UBWE\R;*"]W&!)=*3IC8B\U^(@O8-$IYX M*11)W?B
!A@:W"$W<,D_/A\J?4RD99=M3B"1)0.M[%)R)=&^-[YUGDE2,-)A MHOL!:2S]5!=/W?!^;:"+]DW;Y3YM;D:G2Z%BD'UBB??;,16]046F2O.:+CW&
M=Q6CJ#BAHW9O0QV8+/@1;KS***:CD)[BQ%J*DO+_O"^HE;W!,XKI(\7S2RI@ M(,]AM?]31ZB'Z94W]Z%H +UY=T4/J>:#:;(AAMT/#R.LR![0QL;] MGQ""3FVR(Z#EX(+LFT:
<@X8;1[<*V@ZI&&]_>4*OB*.HM2K=Y]= M:=]/MNQVE!)+I^*.$SJ>-+H+4E?"*8%F?MYVZYP;/!]IH?5&]2_!NI6(](C MY[V1_H? PRO!9VL^)B./%/3,16$2I3XWHN^S;^=TREX]36.
(^;+]@O;;P?9Y M;<.%)L94"C/NQ__[,K-8R!QF@7;(+A'A&1.,]??V841:.SL@6L]\ER9@>BQ MVJG#?]J)&IT "V:]>PQ(6..3$2H+\3*2%MK'GBC^!?-2X-Z@=2S MZEF;>YKQ5?0QU@-
I4D[L,?C1EDB9OFB)/8[BJPPO 641 .;Z%2O<^TBVE$%; M35,^Z=GPYPOGZU(U\?Y#"&RP>,GH< M"7CTS"FF5F^F-^!G:8M1>CF\M!V%8ILA@WO[]"EY.448C>Q6]34WV8]D:25]
M4I,OS)HO8ZW@@C[FT-DW.QEZ+P;A)PM%,)3MTICFJ1VWV +?RF[GSV&HIEX&[.(XV612[%U>KPMWL.<2T !M8^13'P?SY :9\W)) M*4%C@*>+]J+6*D?S%,&&EDS&!
>#EJ'TSD;BDG=&EI@,Z9-*KHULF.W?XG6^ MZ5SIT!>;S;A\[,AX(<@U\Z ZM3HG2:,>3\K,OT!/L8X^O DN2M+:*L(TL.FF
M^4!%]"H_WO1T@@,J_D.1WN#Z7>V7(SK]\X/L1SXI3*8NEY0(<1A(_=Q/FE1* M!#8C@OH4.*9F)[T94]]O1;P.>5LO9)B8"ZDW&;]7FP.WK"=N91[/>5M_.@8] M?
GWJI#A7UET.-374U?O(.3]FB;K:CJK=867WM"[%2 S9_VC\AN2,E4/]+Y]\ M&_3&)6&=_LL&X]-5Q DM>8I*=ZB4^T(&N?//#G]FCMO%&*>,W8@+N$YCPY1Y
M7H%I8==QS62(]SX":4":@PU<@)"N/5P=4W/V%JMX0GN3QH6$DP%HQ0.X_(2 M%K9VT0""CM+[/5.,O2]I9%O8O)1OA+A(M[1OX:(!)NI7W22RDKRNYLRK)08R
M!KJM77^#W8OG2]:=7R#^M,]FZB6OO%@WVYM:F_P%5YRE+Z8N^'-9_.*C.]0 M8#-VVK]W>R1]YC[1_* E_@, *C#*N8@4_]78B/^S1V<<6WU\>D6QLH2+X?Z M28IGA.<.ZK?;,Q-
V@F=]]W'RT8 Z?30 KR_)\V;)2PO_H61!%/$I)>HM!1!^ M.6%."LF(X#H]SP[:H0(U%!DEQVLW;\R-N78@ [;A4ONZB MJD%ENB"?PQX\% M.=H3&1)V;.DN&$(:0$D8
_1Z(QIP+@S)@@:\@YQI2!+>*"QFN$H@F75'F?-] M.UV,(4MC)H699CK0XM-BH641)VG];6_"W;3/JDQ*]/[B M;7#$M+F.FI,.]W7/*".@\)OM2(_7;OW/-_@_-W 8
MO?!,$]6>^U[W=5N33'SF"OB,$335_\R.\T]+\]R28'/:SA'E_(4'] [I^LXI#<0$]Q;E@I3*?"9Q]VTTN)TNG(.&71G39)- M-;*9>BO1U?
0R/45%]>>BXMV1A[EM>WNT5_A;G%'8O".*RI'K:O,';#3E(NQ& M1[Y@08W65U_W?-HE]D>Z3YU;<'M9ZO+T"<.U^$:NGS##_UC]!/6#G@ M/MDYO8]]17]N.[LS,M6!L\:F
:\+KQ'0Z,_.0M];6*J-ZQ3,EJ/#[]?-KK8VNH.R.OS7GI^/N1@UYN^E%P MH:#&MX-.!SW4.B+]G <0PHL% 1V6]@*3]'I9;W 8G';&6HMM[RJZBK7ATD^"2G@K]^L
M1V;]TEZ:>4VVFF2W-(9RF$DW&<^>2FV]H=BS'3$*8YYL'^RR_='T MA2H94X6)E-+C3^_CPOO7^T&)V/J:F%^QQ]T:#QFH]82"E%33]$MC V_M-^ M[JLE8=U&$?[:H1&9\L&-
O$$69\N:AW6TS_5G]>@_M@J]K+[DQTDAU-.$U21P MF)@\+9<\J:G>;!?#@*W3H"A5.9)@<]%L!+ .#BV]..YUW18"@NVRE>./IZ+^IY MNV>/?'U]G;"EJA#PD_9]EN-GDU1-
Y4&@2]W%0[U"=Y'T^]#T-'!ZAOE-9_"M MY2"*>&FHH5I8UGMN,N?X#[F"M*FYK(^+ALT@$1]]:/^]XK>.$L:PY%Q39%8P7!/# M.[U/]VIWR4>U(:TL,P==M>&6:^9.$)&E ;B1+
[_)HS'?SO@-'Q&UM^O@Y_MVR_K;/-M0%&"G/&/WCOEK_V;YYET?F.C\,P7;.3?L3WYKQUUDHIW9-M95F4P M7 C00XUSV []-TX50>*-TX(PNDCONO.:D/-KE$\:3:F95GI*)/ +WQZL/,T
M^M$ 3__Y! 2S4^3I(1] -*GHN8@1ER&)&#TI (0 Y(RG#1V2)Z(-\4,&4]_MW"]\P'6RB0; AX [!6>'.!]N*Z$!-3-H0*]2I_L>K]ZD= $BH++#[(2MZ9[M-($&P#)!0?]MB/9]G8H"#MN??
C%X)_J"*KWRCI)\B?('\W MR*SW<._Y:K!6/_NG0:%;CJE2=.-MH9V=XB7#-))/K-M!GL[-CJ4MD&-*F[P3 M7&;4FP-%DQ,\F0EK'A3)#!FDUQ/#;: 89&;!<#D7C#DD1I&.!@1C$%0?
9%G2]HCLW 7]> $=@S?Z>]YH(Q2U_<3$O)WB?5 MB$K8B8 GH]YQ** !0 Q\&TB#YGPPXDHQ" G!R("17$6Y*#L@5!0"Y.])\6] M05MC&([&?>C#PW-?
<#K8@-8E]+!]#X=,HE:#ORK8[CI7Z\(X6\4<."9_Q M,5*H%2.1HP6R:PYZSN6'(&_W@%^#\9V_8-B9R7V3Y3_=U%:4W=7YF@YM$I6
M)C3R11P\\5@8%]G<.UC=]4!0(PBK)IG=E6%KJ'6T0 -R]":![/.WS%YM3KR MC_ 73O.?*'^B_/\19:YN_3A&_.2F_2)^'$MO+.R6N]W65EBD)WRM>9=W#RYU M)"3U4_[\1/D3Y?\
<2N@>_$O3Y@6_Z0N#X;+OU;;A0;5KZPD[DM4Y]]/ W;MH M /ZTR1/'SFD7P9+E@* K^XB1]FG,)P-;3ZW,%[68ZQ..B8E.7=N1$0G<)0TE ME1]K?
T[;GRA_HOSWHIROZ/%%2EDFKEWIF3>$/F_1]B?*'^B_)]#62<$ MSEMW"O..QL?HRS]K^8Z9+L>EIFW=V"P"I^"INVE<*>H\G/W/ *%:Q2;+76I M0 NB$,1Q,&+$_%?
_/Y:PB@<1]?]_AC:X!=PDNM;X1CCG.F7T 8W]R:=^,$=MX+KN[_A39XV*!'7;Y3D%_K/G-?Z:ZF:F*-$)!#1F6R^L%=-<20SS#*TW?1 MGU^W.R?_$5__9BEP/WK/G!+2KK7C?
9)W:D&0V@YP,>M->& M6R1<@BP\!!T<.>]JL.X4.L5[2!]^_!!]W]_A->B'N;8H^KW,$.T)#O/)7;??Z\@@L#/40,Y?S/J(!.78(>Z0'!VC=#[)RO2PX(&&7H?;4I?447/K=D0&%
MN8<'['UG8*P@I)"%.##PH NC HRH?^3%(N'ZL[0$OR]1[=]-9/O=YN@]]I(,%1]PH-U?N\'TIT2V-S7IPYX=:*MT M/!QX-6A+514C?5DCGSW:CG?
_B8(2ZZ)E+3ED(7IMYA!C^TC=8,IM.1209U0; M.-CDY]KO""\KL7I@D>J(?>'* T88N5-5PES*]ES/E8ZY2B\VXSQYHPQ,]3U M-OQSQ)0]R#U0<*:6 GE.42GI?
>DDL:W6PK>A$%8KE>=Q?>&0^6I2N6%3&_^. MQ2#4RB<_8I]"EUW%5@\8]!$AFKQ[$T*(VL"[0#*M4%"Q;;.F/N-5KUN,BA/8 M&4!ED8/M$565PWN%VMJ/WM>3;#DRO68-
MGZ8#,85#%/4PG?1ZE6?G%!;,[); MF9#OI/C4BLAG#'(D'UIQ0L7,"POIK$:RW=6^:J/_VO"R(+7\7<$TXSZM#S/$ M-FS:4L*R_ENB\2*M75=O2XI3'Y,ANGD[9/5!%
(;83DU;SD'\PTSPVLO*-_C M-+W;;\%=G[C?+4&;S!G4!:<_(&%^(4S^N@29B?;4*&OFVU 980!YHPP.+,HC M&V&G48R0M,@?'_=2.&'I[RB)3_;8H:->O?0<-\+7)(QV-
R>%ZEAR'..'JFJD.G(M!2WBW<;&R"__CVO\G_9O\N(H#[-E*.D3 IYG MJWI9QEN /6 UI=@^(E?6G#RK][LJ>"1KM+]>L'BXP@^(UA:<)PQ.=-"3^F)D MGF?&,& ;L&I
%+7@00*U9#IW?)0<*;K[M(\E&T+HD" 'D_?07@V+Q)G0#VP9 M"3AL.]IP4H;0./1([U2*DZ]W< Q,MH)?5RZ^Z+G?5@>E$G;C[6O)BMC]SD<.<7"8M)7L].Z1RS$!#S*\A*1@6>]->
[7O+/L M5Y1'-B%W+XJ'1TRLB\Q'&4OG012CB\%]?(2RYW!Y2ZI\>1*(6%MDW*7SW,[].9+;ZP,5>4>+'B
MQEH((TS\K#':*'2V/1R6)DNQP232\H=YD3^9K;+D]^(+@)+E4>I/N(8G)F;3\ MZ_;P'R2Z\N[!])\A/3B0"C1@^$RC^$8Z9VP]*A&^ZDU;/MW05:+(J=M^N"_JD&@%I MZ(1!3B^B
:L:7*CKU410(-+O7L(!*@'!*0O#.[#X,.>].G(2^F%1@K,:+>Q MNJU #UPI'B/E/M6BY#"4:*HDO@\S6C /H;=MQO5POT65G)K]12.5270 I7R$/!?$5X0B])SE4F(W#N-%G@P:4F'CYSY_:-
PX#7_1OU_285M7TW N"3]6 ME]E4LU'Z^2U<:?+ZC]"^:%E6G%DSM20KS6SB&;S98CC\/=0@K]O MER]S!'U+PFY>F4B!YO',M&W"]T1,_KY9Y.U]4@7IR*PMHFP5E/U1G.$/1&3Y
ML4^L?F+_B?U[[(&ES43DC=9D82;X0K)U5?(73&CM]?!#X*IE*O7-:94]1EC M-2NI6K,'DEOID]3'=I5$WJC;YI?7IN4[PM*F;L2U]BOT+M*7M/O/@Y)=]
5V\F5;X*_-T7I1:;NB%_4RSQ.&%'+M40'\R,Y:N*$C7Y'-^/* ML9!OZ=)Z\VR^]WW]N,LM4*G8S7=THE?PL% MDA+A.K@>B!N9E;05^%1U1?74$.WF"6+F/@P-4)]!*4
.*\@T1\UDS)SIR+OA M;,VZ.Q^-Y#^[^F_$O#*]JN7K7#G7;2'LRA8)TVU.G LFT3:"2O#=G'EE<*+2 MN?5@ZAYPVZGOZT2^ML9R]J*.3#K2[,0N%8SI7IS#'A%]?\B$=:DEUOW=XW6=
MF*RU0P&*J'O)&9W72OQI8B[$AKT!T(9%TVL,DCZ]EG D1=H54PK]];XR M6._M,/"E=]A4%#=U3-KK="!13CVME0_Y>FD4UE:I^JKY]SE<$_M_MZE07 @/ L-8!I100-*0 A^ML)5KG>Z]
<]\!.YF%=5< KD:%^)5,$%E#6['0V518#SHO D:$%SU@%?W M\F]T2M#)EHN8'O'E-QW$]4P!L%%:-*!X5=LL\N47N%B'0I6O>_OS]UTTN3B7 M,F?C@'QRL>:6/6SE!9LCGZZMLHFE,
(ZO=C$PW'ZE5RU([&6>AK2;']"UY,"' M!HK,R,"(&@-%AJ3=QW<>1K5($P'6ZT'3X:]F\5&0N&&#PT-B@=MF60.8_7/ M)P/A*+=/SO*NV*ROSU
ZL((UV7SG2VNY!)M)N9M]])G9'\P^IZ_Q*G:!S,E4 M*2:+'U*I<#S^]BB<%?9&P;;GI8[U&G8U[@;%Y.IFSJ[!QT;';XX(98NKKGQ!@(2AH_Z7HEL-
68'I#&XT?!F<^K!4$P+^<*B8G>M]]#%QP OKGB38 M*,MVGT;[I/&-8IT8-.LAAL>1>00(6.]5G2C][TO("$?%*<-'SH/Q-70?],R MCS^TN_#4O5REFVB6:),5'->X='B&%/G47CB\4V4
^C5:.DI)X;/K,"/VSF<4 MI_%11:2'GGM#]_S:"[O Q7IBNY;A98!-.L01?Z,0Z#]"$DPX:@QKZTL]V+>4 M_0KQN_"=B04V5&;1T&C?:Z%A8R'-U)];?EIEFAOIOHY?+MAN=F-QOF^MEZ5
M9I-P]V. Y6B"&"Y0BW[H+1BJ2[8:43!F4G-Y<"LO23M0.(.+MFSVW@,&TIFP M]1FR4@VB5^+D10)$K2RS!1)^=$\5C T#';3']&*=EH10-].&0 M5*PF'^.;+
MO)H]7F^S%.8%,9WG=75S.S=Y-V?S$DU;<%#Z"(!(YI%E+%X-3]%042W="HIM M8+_\@.5:*5@]L52IN]89&RO>/MZ1UCH@H"9IQ=A%&2,RP%F0"> I;7CBK+#(MR.,=D:"
(@@ND&JU"[VP-;2\WQ2,3VLZ-%[B\$$FHM M4M.;S2DG1#^\VWS_:=:,F:]U*'A9C9]P.K,5RD6\-EQ#F:!>#DY[\ZB4QL6G MGH'A:WR=DTWNET8-UPT@&5+1D3>NR>[+=9PTAX],"?
9;!5=!GD_B6W5WF/VY M#C@8'T6]]!7S<7>!S0CANOQ,A*X*CXD>WV;-^WQ3P<^L2G'><;]\I%[5CD^% M4HY;ZSA)#,#/2".Z=FY]O,B-72/GR%>(TFCCZY=I(8D/LV]Z<-H8US7'[?VK
M)++65/)%9T\Z!%_3FKI\D46\'@42U.!ELGEY@GC7)WGMR_*@PTLA52.%I<= MDEZI17:^6_2AO8PUTMNO\(RO8%+(! RS9Z#S_HTWDZ MCPXF>IH=5&JF9"BYX^O-
DL;:T^T1)B=5W2SU]@RCD6%F4492W,FN9N6187O MB>:B]W1QP?2..Q$!\70]]=&>74V74<]Z+*L"=M6.#VVV_UY6?O,B2O3//E%@T]T
M61*.U%7&8*9,33C5L_=UAPQ^4)LN;@@Y$K>T^%]Q1706(LC!UD L:3K!RZH MPM#!-AF\5B%2?,"%RS4-/V]*2T>7P"\DH3H@R[;D*=5-!1G:Y^#G@!+O*@_MQ]%RTW08
MDDU\KL9KG-(]&_]A:7Z=S]HZ(;JN#N&)1U3&NSPBP-$(/X360,84QQUZ!T.1R^;-KG91[HK!UE[G$ZZW>TO>VWS035.RT5RI&A_M[X#KO G%H7\84SM?5#[APFLLH!);X8!MA[;A
VU=N:XF!1H!J2.U_)XV5T)) M4(M7-(G10%(9#?RQ$$8A?WB(T3^Q0"?:4J8PH!]$Q'C\QO*[FT7Q%!W4T6[O* M/"LB]ZP %U"7&M@(]9W,Y+EWL^ZHP)9]VE_#VHX*FE/:*I&!>\R%-
M^YH". M+2GUA2=YUUH-&ZH3YA;RR=6_"I6G8@[JFEB$@AH]XN.3A+\V_W['DAL; M3=,T\T#?5K=2833'Q]@DR:>[=TD_D4^?)Y-?^>T5P(B;%()E(VG\IOMQVIM
M[6T'$XM+E=]43^4-I8H'E:BND:9MLRI4>2=BP\C&C60F:R7.0M]H07R$5%U3 MX%"Q/@;_L9QBHH.$!>=U:K/&U-6WA68R^CE*W^N17. MW]SS2_A^V? 0#0B

[+*,0T80D)5RMB:VL7H(_E)/3&?M-/_D-7Q]Y2#/,]X M[DG2QM)=DLG34$FSF;W.Y7UD-=O0^B+.@D.*.J.=S!4OE:?N*38,([TZYV%6 M#@G28W?P,S0!7_*.3FE=G1' AJI8
T+53<;2IS,=!5H=8PJV!<,8*V69ODY1 M@M'FTV4@F8.? M'8A,S%A/&E\C)-&__.L0ZL(O7._!A!>0-D5MH0"*&I,P# M2%8B.I%5FQMH0$8V_&(E-I)?YA]<;:3<7^R=SJSO$Q'C/.^L8U1
QKP+KT9 MM(^QR1<09R%5/L#349Y 9(+"3LXX:_D-9,\.&L (RE%" Q+NG"QB['':DKP< MAV3EOKPBZ)PNB[9F^R4TH/3:1+ETM^!!9LW5:IB4%U+0.(7H\NDG32]ZXVJ)
MJ0B.@5C;@]QN/WZ#TK/4C+H:OV:WNUT[=PNF<(H'.A8Y"[[R;0/8[/SX_U3_ MM5.3OV2U^TV\+ N1>Z!&I,?ZL]KE3K=CR*XDY7=?9/G^9;,^*:9?,BT"_U% M#
(@AKN,]8(TN,L03#RHI2 ;R2_K*XK^FKWP!:7@ZGX @@^RZG@6)^>9ME4TR M*[D_9>++_$LF/GP42<)9EH5D-"!L]2S*T*_OEAHEA^IVH@%$NT3?].=5W6]H MF/S=V^25$K2A?
THK^+,#_FT=0!6-T2WS#H[Z>>F &Z3XUA;IF^X9854,#VL*GFJR2_$S'9LH*"MP_T#*"FP7!E;7.ATQ)?FSB M[[YE10LU?XY',WD6*CMYMN>;%8RX/X7-/HOYW9P#O
3YU=,]\X3I@(_E7SU. M\M\4(A"\'6,-XV/JZ80,5[K^&D)'2ZI%X?B*+JI&#U4\L?IMZL3TG22GB%_. MMGP73 ><_?TI(,LIW W='5VD+S7PU*$1\R)>'G33SIP0?@^!&)U?>$O&<3JL
M%SCSA!N"5_#=0DXX3$X^4FF' %&7W?] R2*3YWWZ$O(M\TY:S34;H8XY*0]3 M(3E7^XRU/JI-#G6QEJ[=CFOMQY7O+Q$*+MA2D:\5]LSBU)=$Z!*P!+.\M'OS M>D-
2T)6MQPW/P:^_&[Q)L:;O)Q>I;MKQ']MTBBWAZ>ZL_=(G>.#.VH#8@#DO M/&\Y0B;WRZ(X-(ALU]J+@C9,ZNN= *A6JB:_.9,2M/J>DP%S#UE-S/S.M M."7S#9E&/H
0,*43M;.'DCD+5*6#!@R.1+M8HP'OE\(QEUV8^:<(#+BQ$[GM M8C]W2^3JQ"IWZ41>Y..@F0V4.$$H3EWW$N#R;6R&P_E@=]3500Y.,]Z3C&@: MX\VJ&
(LI_8MO.8(^N7BL1P_UHZ["GRKMZ,39\V9-:/6\(.N?XFC<:;DM]\)7 M2W\YC4M_(HU#@ONWVY*NGQ_XLLFQS.#["CE+9>D6 K?LL MM#L^,XH$&\-,#%&B-1J;:$ PI#HX9ALYE#.K
'_D$K,-ET.A%DY B/C8+31 M%6Z;?6Q3GGI0L% [46$6"+-6'2S6=,PUU:LH"VCQR95I5VR\<@>.4,V &[:(M7(:1+UBH38B#76-;R0[;@]27%QD9A0P]HH=%"'9R4"=A*>I:5&-Q:2V["[%A
ME>7=CGFX,'+/4F_43=ZT-YN%TVN,>%E;+,O&M^+A+Z7R]+J,4WR&F3^[@",[M=H38PDXZ5D:"C[3VCE5YYX_^]$0#=PE CP9MVJ/GF=@X&L=;UF/#1@1]ENG8
MAHNUN62'AFFTE7 XG]T)O6_?^&MN]A1'<@+W.-VTX&G40#BL<5+ V9A-YO3 MOU*DR_51#O L3Q+*/*@GS/.4(N=KRT!UWXH3;W>D"G[M_/15]DM5;)K#[#8]@7S1$>ED
^.B_"22?ME=/B5OO>XSWM_NQVC!;T,G[_EG M-BT&5FA="Q;&(C\N...PVW.0:J2.'=63U77ZF KC;JEW50B_3KAB2C]:*O) M77!C$:8 ("%\I)^6K6?4&S_!K&=BRZ>AW#R;L0A57MB
TON;8:F? M3R,-RLZ"N56B M2>_6HC*]/A'-.20G7AAF.%KVZ#T+E>?6M#-:_W_LO0=45%N6/UP^420(BB Y M* A*CI(\$>??;9^[?/V<$)@F\A0>)FI8&-(PGG\38U=@* M1-E9'WC
MBV/01Q;%T(M-.;)UR%4P$X1D2\O79XL-^"A,M"Z'_OQ*QM",M\I>N8]TL?F_M6Q[\UU$]L'18O)<9!A#AJH !%$="-H@UB .^6'LH_?L;\AKQJB65=1^/:?- M"[%W:Q!&YM8G[^4(_T
.G]"T2GO#L8WUQ0]/YN;ZW4^#&VEF+XH"/.?&!W] MUW8Z%E3.1X;4%;M/%=D^E,8T]XI^#/Q@,_UJX3$W"/= (G]#7TVYQ9R-N*UV M=\T/AT3'/#8N)S]M +GD]!"PE5?]
[4JUCONEE7!IC:OR9\GO?FF9\N68$,_MHSNZE^#ZMIQ#SM(C.&]_*Y[?LGB8[^BU34LLZ2+L8-0 T?$Y^OPPCB*7XAR;C&TOIC\@?,K3V4H]?L&0I3Q:E@-[AE"FYY@ MO^C:0$
Y07R.3>HPEUCV@T^K03'V[S$ +[,B#P_=)]LY\S-_$SFU($$OR1(@ M$*K6415QRR;]\0GK-Z_B(IPP\9)DTSP@685%?CU['#AM:5_CL\Y76@7ZAC-X MUN76-C^8]>8=F?
(1#O^]@K0;Q*=01V1" MC#O3]]RO_,I,2>_]B)&*]0(8@!01=@6\+<$ $!J=7HH5[T[;Y_]:@)-WEGE MJ#ZS"4EONU$8A29;_P#9N&9U1H_(W#6Q&]_K9"FTC/[)0=BV1%J9!RS&
MS9F$/VJULU-F&['A?%56Y1G\)>W=C0X#>3W6[&,F.%NO@#Z!XF C.U*3@[-' M].6*EMG+P^Y60ECVW*2NY6.'R;FG9;H]C^O!0WXDE;ZU"5QA**6TK3F:ZL'R MNH *?
1D4NUVS:8L>[;>I-T((IC(MKZKOQ-L6$PP?Z"ZT6%W]]M2G-D+R'L_W$RA)I%98HX+BMP/ZU"<-Y MXQEN8PL>*)\5V>RYCWO*
[E>.8Q'+'W'!_W%WOGYD*;%@K#)M$0.X32!;7S+" MPN%($K)+J9:<,AUR0:QS5"NCX:"?'1T'TOD5QYY MP95Y^3&.H4S-RC7GA!< MV6OP/M0P/B&[B &CS)8&
[L@SH4D'=V4^AVC85) S]C%>Y%+?S82HF09/!4+<2Y(OO]9#ML4926KVH[*^Z]+ M"YE]E*= +^HY>.X^W-IE9OZFE--K&3G]][JBC3=C(Q%";2W%%1= MBOY@Y=J&9FL<\M)?
W&6>8C.K&LV8Y)/+UY99D%"]<;7(SHJ@ W*@67\/B0%L MR$#I(=T*<*U+5PQ@LP$/PKGIP]%&AKG!VLD]JDY7_6)8\/!;UV92
MVGAQ1Q/B>L]M2+;;*RBRV\?]547X90KCEAN[Y"M18]D7;N%Y*'-XKM[M%0)W M2D&:F\@H^K"GZ.B-T7(YSR0+N(UQ]8A =UI_M\!UYX&4%U;#VWV-Q*1@H+YY MS^?^U';%
(\:K%"=%\AGB+;*D%&%VK2)V;S!VCSL(BU-GO230&#*N7=%V$ MX@_D:LL21G5LD)BJ:EWS%;\!+'"<8]&GJ5<@OI;_AE&\8\[SY!\@]MU.QS$ MP?
$V]7L7*UT3=*;TK9]CJUQ4(S8MF"JW?]4UUU;6R/(:YG%5+22KA>;1D, M4H*J#=8#C4^D!:]7A^\G7.F]?_V:I/ W86"B&A(+RIAB!M"S34=4^T8#K]\L?&
[#KDW1=S,L)1#')O0]WP@ZC>0MR^FFDZ#2I.JD?P=0W$"O!V .TQC M/V*&__R+HJGB[!V4$19;R(R@FT8P .EN@WL&\P@H6IH:=(X!@"])'ICY>0IQ M+7I-
'KK'7K0>24J3:KU>_Z\^=O^G+R<)7/0P%L4W@=]&(#AFM=D_VQR>QUM MR25;\C.+6A72,IYO+WCEB[ZB.X961?%85%03A5*849[C&N-/'0#_'-Y.Y M=C
7EX5LA0],,F6N5M&Q=LTT0VU?*V28B_>ZX>D9]Q\W\2!7!XKY8:D;K7H M@8&W_'6#_M81CS0(9Q45[3&,#-%@C" M<'W[4./^_O=XX)-FSNLD*6)FK$LO0D0]
(R1F1603N2%E47.W4K+ 7 M/,_J*(E&#<(7?2Z'4W7D3;@";?H1 3.YL0+G @G17ID>0<*L7$$[[ZV5B/1L MU6=:.J/<7;D*FO4FD(B$=4GYE@(ZS:KR.!25&>52])GRF(T3L'BN69@]@2E7
MB(DP26Y;O\ TF=A\;4WT;:9._E"QLU/ (QPG,>8&0U>Z>8_[T&PUB&-U%X>UNT,C(S0 MH#^E[\3SIUT3B7B_-7PQ)7;@K::+Z"@=KR0Z.E&+ MT4>WW6-JT\%"N*L/7WB^?@OL24?
J,MW75V"$BN5R+^>&K!\S'N8.,)4@)/SP M&K![/U/C>S7]Q^4Q?+*,SX_FT(_F&D,MVP11T:=T8A0^[-',-AR,J%5%.:[4B M#8XM?&[^H.'EZB9N)8O;VA2=:[9OR%F$:6''14*-
@Q*=2^V#Z)$FIR'I=7>W MBT7WZ:3I!D^M/+>G[H5>;*_Y#^1+2RO7(X)YS]"J5N_'L2@\'ZO0#6.:>D1] MX<$A9N
=AU6A_&=I&JW"%M<>EV_%G^TY2U##@2C&\Z)I2+G/T$5IO%AHHGV_ M*[W"X3[^!MX2A[*N,(OY+T],"/.2I!YV;AO,&]Q;! NJC D(,XQPA29LX[F$
MRW5'SZ11&GA$G*GH)+Q9)BV/>E!1.>-M&GFJ-Z7>V^#FYZ%4K^&+!I226?] MS,GSOW$;BW# "9I8*&(4LMTV:#"0^+C>+/$HM.(AQSZM;U0?NW9EL,PJ2\K" M,?VRP?O"[=,I]
<&,F$#[[/3 ZFX\;ZXJ?,L->6F%RY,=1S-2LX A^V M] SPO*+7L>!V9_DN %G4-E5\\;**@#UR[_9>OQXB!*IS%'KU9?W8L$O],,M(MB,G3P++#=7'>M$R@SFJA! 7>\U+._?YBC<'7]W!
+PU-(.S4Y<*&Y=I2O/M M5/.4\[^8AN6GXPO.]:D-R.$0%*.KVL#)?OE9]AW;]#*.]8N.&M#MS4Y]9.24 MY?=[G+EU)^LVC+,C#2_AUXN\B:HX0^U%E:[#I@AL;O1 /IS3N16$FGTCR-\Z
MI?H0%\_X7'+B'JXY/H!R0)Q-E/53Y+OMDHG<7EQH0HFSL]VPYGE<'$L[L+2M?@?.+U,)RYE+:N;9+Q..411!5 M>SIUD0AYC%#Z"WE-XA
:N@_&D/.\$@37>UA;;'C_;1\@2/SM,]VR;N%^:;Q'_MP_;ORAJ;62-;UT@1%+GU0_9@A5D1\_K)0-P6#(!Y21A2R5?RWFAGU@XR7P"D MWS[&VW'+3NY2VG%R!"FU/S^@,&<@/;!1(^@=-
JIX6FV MR:+M-XGS?D5'^T322_>\!:?BC0O36+L*!O?ZY5=\?,;FD((OXW7@1XXS- -W M/BXUQ#SID=AC$H,5NWEJ!QL,+34\(1OH9B5>L!_U^8H66*IEMP"VJ2(? MO!A2%!B6RTH-
!NAJ]W$Y8LR.(DETE6N[M!-L&99A>0>$"_OOE2->N_@*6@T M\3U;BER9_TV3.X6,8I^VO@^Y%)H<-^C2O$!7$U_BE\0KH*<1QWN)Z^X2SJN= M^X_W.@@$GT,5)I&&&,_]W?WS!>
1:U$JI/ME++]]L^E3-!Z+,MZIB*5ZM)@- M]]VLFI+/?4OTK;%Z+AMG:EK)]"!;_;7O-C7?^GD=A(\+.YLE]L<:CC"1/Z.N M,;Y_.__^3!,:Q'F_$MZ1?E#\8GR?HGOK>_J5LICEQKOMG+L*-
L^> MR32VUP"_HIT'TW:V'W::NHT4L+MH]U;>XS07,+,27/$0_]&\LK/>'S:/)PP"Z M0:"+:QC KL+^UXMWU=BQ128EGO!@ %/1\Y*GU\Q 17FBB*:#;=1M#& Z$.LH M#R[\JH
KU[]LAOZHC2[#88[D^ZG?H=GO!N:Q-G:+*_7\-R3571U \T*ZWF$ MQX?TQX7SRAA N$G6I3WH$D?K]N]%Y>6@'B9E_"E-XC^5T$FI,9H'4_^Y)8NC M2?
^W[1WIE)8,WPT:S(F/^[G%O)/IU?F>W!'5.$[S=O?!>Y+'[A:FV-/Z]'F M2)L1,D:>B7$#'[INL"VM)>;7%6;63$<.;:Y]%F/E.3+@251U[7MY[RDI9PP#X.C1$[^I 5[T$R^%> M4$^.
[OI1)]4DTV\Y%,OW9%DDSE9<:&#VTH*/CTB")'JD*KKU[;<8DDI[.DTI M-_VB.\ HUV,20[-RBG]#H&*AZ0-B0R3.LK9ARD"_;3I%[K!MXSG:7 PX3, M;_^-
NTHGZ@G<&1:\P[YT>/6Z^2#:(8]]BVN*=) M*>%4QDT+IY0%AG]"23]-#=*H\=:++EYP$6X,6<3@S^EX?=]Q&.,9ZIR!Q5L! M\5'RS$W96U02=3@\<4V0@ZR[VG"GL8:F:CV--8+.-
>P>NN#=-0+TD=U+.TTBV3.:8?^CR<60 MA! CK(BQ:5O7Z<7*=#53C+]_5C.4Y,J)5,$4OWN:6O\HN"C/^S-8MIM4BXL/ M\5!CL_6:!6U]=Y9)O>S_2?D(P@ /.
M3<,3$M#EE:T4Q!V.'R$:WQ'7Z\P6&^XNJS>P]'P@9+UK5/[)A9JULMC_PVW"?1#-72E#KS;:GN4&E!$OG-Z>< M6PK*#[H;8A^4UNR?RBI?
P7T;MJX(!P4=!WM+Z934O9<4B0L$ENVN>I?F$:YV M"6D*[X@F)9X;^I_W)[\VLU^<3A3@5Y(%]3WXSME]_9ZFMSXYWI=7?C.$QFEL MY_OXNF[F=IQ-
D:.WK9'#@Y@.HVLM.R83"Q%A3P88#GB%"J@6?"@8YW2WDQA, M'L95IC!%/*(_Z)/O%#]C%W$I/"^S_%Z^%\;6Z.)Q1-EA.JNT\^V2)PE<*%K?
B"7.M[AP@9KC#P4VQY2F7^M<)#3YH6Y;+:)-![(+$$R",T,>557; M-,^DN_&-MGH3"9-R].3(^F:64/MQZI:=<=R3X.2+\%T202U[IC I5M#
M7W3%B*ZV=BQKP'4B.=Q"_/42IO5!CN/7E0%'\;1FBF.4L:#!_+U)F9>Z_:6W MQ.%*BNX0LRS=R]3S/8*7DE>_)ST)CAHT1A@X+C==LSCG#$#?@V]!3+:HW$G>
MV]B5';*-5G/%D@X95=<-1%B[]D]+@Y7I6A M[6YH-;I3@!]D CY>5',3O]&]EE736%Y6<:$Q-GI+%^XU:8R?<+2"T#,(@F^W MGC;25GDKC^RZPKC9^ESZFWMYH74#/;B *QVX"BN-
U$@'KEO!==XV[ESY_.XZ M!+]R0B%\)-H!M-XURT %]G<]Q0]M8+* 6T/O:$^Q*(<2%D\>.\(2W(,0"O M/@#!+V^*1,PPIHQ /)R@:&1G?':$&;AW1%1D$H2]'#D6.\T'IEEZ^B*H&\Y
M&8\E!O.GO?HBU5GJMB-G?+99DIH]J4W/1Y.#SW997WC,D ML^ZG2Y?WQYU]%I/,*]B$[U>)FCHE*G1X4ZR_/RZ\NBB+\D-AS3WVYX(_VA_+ MOKM)]YI@3&,$(!-;MVDP[U/^#\E?
2F" 5T0)<6!;![4=C]VP@LRMMV')V3KZ M?A?S9E^,.V$X8UE.88\C932D<,!^)L!58-7@_A"'&"T"MZ7]G%#1M.K4T*3: M#V^B1UL=D>!DU/GV6S])MKTCX7O%5]W%!W@0&8-
G'ENW;$["^UN+[M90#47VXZ)":"!E:-S2&NUX:3*=]6/V2ODYLORSF3ITN:7*LQ]).@'+*I?V24 M!\IJ.]T4+>UWK";S$3UIESA$*__2BJ]'8H:CJ;$)K2&]HZI?LRD1-^!(-"\" M;)N_.:+
<^9%0W-MS=-*9=EZJV%5NV8+) M1/V%(A\- -1=_6--NH#_=$>.I.?4I^).-8A+(KXL!$;VX&VZKXYTS)F>[S&I M&VD[*=QO>(G3O72Z#6TI1M]UDP*-US^N.F_OKN3_CPW]?
S,WBA&B-XMTO.$ M] SLZ7=!5V22K6WYXFQ<..94Q6D>)W?Y\'H^+;'P@XINRSN%Q8N%GQ3B8].5*Z_&Z%G9IC MS;+X5;&J&BSXW89%;__Z(9*X3SRIG53@?
]2@L&GW"6D];YR82-RN5RIC9 M>\-[5-HQ,O<^D_BO?A,&/MH.&QL;DB:G#5/4A3?L92PW$.A]U'6N*-8D22O# M%1Z8!1@U.,"N!QX-W#(4R.CT/_Y4G#3O@\R$,CGN3?
O.VH=F)=PY[(L>')N M-^K?$^-83O0A+K.:8RCQ!X4O.1>'[#LP=;M@E8.PIG[_E\RI32IP8[()>2SX M%VOI?CN)A@&/*NF,,R1_/CCZ#Y6F6$%I+3;8]C55C);3VI=O5ZOU&K]2D*MA
ML]%93V]CRZSM><3RNL*QG[.>!T&@6_F8]BK@Z,+S$;GQO%%(; 0(AR;W9$] MS*IXN%XX:U."6@E?"-7+:P:?T8_2Q"%W<=#<+'<8;SM-615*YU)E9_S
MMN9(8F]!X]:!+Z.Y9LV5NY=0PO8=::RS2[-&8Y M6)LLW^?R26WMM;$]F@&><5*P'$]@^T[7I'($ QC/#VF>3D!]_07(^Q !]..J M*"]W\]2LC)GD.)IT_5[*=_UU-?TG@.3F3-
#.PXSO+9U\RUPWLH(*.'38LLI& MK=,/"SBU@(P>WGCXCJ-@^K!G$O2(M=3DUS Q:>.8FVT#1G=9OH@6*OC6'-,7 MN):K8.^_MT",I^\FTZM261,Y&^.9QGZ?W'3J,^!]-
9';:6%CT$.;\W>.;,%MW M]YTS9W4[U,6*:Q_9^(;+"O@O&!+/(HU:BBU<2Z68$'4EYB^CF]_(OB#>U'] M:JA(U$F\',79(F]DJD*P^#M3Y#O+C3(%\T9&^O)T4^YV\)S=UL;: =]ZK:5$
MC[9*Y^!'7$93"%_]'713!K]ON*Q^+KH:QFLULI&9/B26O8S27U3D7)@.)]\')?[82WPX77H+?<5"\T$1U^!2S4@GK+O9\\QKQ^-M.>'%^KQPT=/4N"@"BD9R>%^LGY-S<3G[
MCO)9%]2!+2G?6]S?=KS4"V!1<1_KUUE=5NI:2$PZKLNNE-$0>:P0N1>V!&F] M-DI R,0N44^RV]2+YW6:B%=]J,<_9QU,\2FPP._/X4]HQ47]B_O3T5[=<9
M7*$K#+8V.32]*EZ5X:BV93!PX..V6$U^#!%_FNQBC3IQ__03C(&,(:$HEN4 MU"N-&X. '< S4C!P^Q)XI:)+!.+ 5!@G2]5PRRM=]X'42F M_NHA!'>J'AGUO62"/55E'09VG:O";@*
M81GB%H_J^$SV-E7VG;79(VP?> M_1ANOA$@%]-"DM5H=]&9__O)#VI C2F(E#+#^HV.150R*A M1D$?7VN&:HJIVEAD'\1SBFIHA'8]*=PA)B$\;_#S:2=73
M,T=L7R\NP>RL9)87ERR^J\11\9V&8?(H^+GJ4&MB;G/6U9FJ-#KYA UK2FL;92M/G 7%7>VYM5?"6PG)7F M V[4@&,G5M0%#-7].V]9ND(F;4]GY.^9EPY%?CTY.Z-
7CIX>4MMYDY].&-I4 MOM53G]<18CH78[FM5#"Q4"^Z,/O,RBI_.S+O><':C5;-\B%$AK[W4T='R;_M=BFUL&?)<]Q<.AMXXOI^
1!VALK'EH:TO@AZNXO0'QY]K4%]CPNFO)%SEQ2 M?:EPGZ:EFRJ<*%G>3]I79(0901B \U.X1./E=BY"ZR.L341'\DZ^UBW:P9*+ M!F[UY9+E [(F+"E5*T_O9';
(N'9!71*D9J**^[OW5P[7"NY-V#L@:_O LPB M;GS;[.JJ)4ILF^%ZSAEQ/3"CW>@*>TZO\-9WC[C!U(1',D1+[6L:]MSJ4RJA M^\8%KK.?*@(>U YQ[2[J#_>"]]?(2Q1!:S50
'F(C&!EVF7:>"5LSF#@41= MH=GD6E!VX7"039R#ZHX1B%+$S7UQ6#-*Z71PQ0E*9#G>"*P>72N?-CWLWV:Y
M['^ORLC7<<:E\'U[(ST5.FQ\AL>5R.!]4E9MLA$*H3NJ]IZ:NCPSGFFBXYQB M*/V0*,J^J4"9^)L/[9B3_M,]_:>P;OG[^%G?-;L'2@0B"!>+2*?=4O?51\"/ M2VJB%Z.^!Z#R=1-
XCL3;/1+)Z+6@K*$G(C'.^EJ)9A15_%%*HMI> SS)K1(\ M",*APB*13I*$]XR9N-7]RP+SYE/BA?Z9&=(9HI(SWV?UH;J0 S'L%?I>F5 M9<'&$I'S9\YIHK*;=;2M7D3:W^_G@BR;V7U),?
W0^3+M;]D7Y]_VMLG'\G=-/0 M."ES],\CI7<=_C-XFML ;\7N*F.)@6I]OUX%RV6?PDHQ0#T1G[L23I'_T87 MIF#TK[-F*_Q^G54K-7.W6?]?[;\YZ[?Q5Y91!E $8DHZ5GV= M\AC
5W%U MB?LF)9L";5Z:0_O.T.N\$VT'O6"[]NO\E,Q?N<5<+R8[*UR.5)?[ERW7R3.\ M5. -)[%D?T9M.FK$$^=C(/0]7:[I.>?D>BC63I/+Z48JD>? M'+3E#'X=F%L6HNPFE&&#V7@!?
]B$F=NR/UQ"CU]KD/DOE'F#NJU6^*VVI'9M M";Q_ZNB9]ZJHSAP_E.#_P1N+/6S1Z\V7-.N=/5S>]RI:RI9 MJA-)CWL<>_>K\XVC:?Z&-_(U+TGEY!=0$WWZ.2X;_Z..XPZ)$W" 3+%[-
*^<:2 MU.ZB_R1M+5+"O4-X\?.=44*Z&0N+)M)Z%HAY9'<.@;Q)T;!/L$^X_QUK>XORMNU7E28N%UGN31-U7OJU 7Y!O2%YO
M4)C]&>_&UYF6^B4IC_2U[*;T;!FRI5W)^/4G?6[P\Q;"WT^'G\M$UOOF.,I M1=.!%80 W8!\?(H=&G4ENG;&Z=/BN1(*N9BWP*@NE+6G&Q0%;K/2%B58KS>_/
M]43WD"'ODYLBMC$4%B>V=\M6TX<=,4N[2])N_^VBQ[^C+I?)@@6QZW-XE[M.V)P 0'ZPO:273H-TD4,PL]@.09P=-L G^/-OUQ9(X!4!V5/PL3"!/0D :P M9G\#N)
9#"B5C*#F2[1U==T+:D',#Y361Q<<+&W3:*%BB&I4=-$-'^#Y[5Q# MDB*3D<;[R#61X^U.:7^$6\@4=XY5/4\=7VZR75L:L$1^KR9.4
M=:*W;T<@51['&SFZWIPYT1R>:4;G6MS7=,_9M_P O$S[O$[G":3>CT"9S2L MZ$2"&*.NJF5)T*+'G8^#:S$?NZBO8'XBYMH$5F)NMRE+%M/IZG6^UV'U-'HLWQ_L_">^:
<]DT]>#!C ERAT M$P;0T4 THE12[)[4WS,UF04>+N=AI23.>^7@+NYM7C9B[80!".YH:H[/6=E$ M=0>]N1\+T<39:%5""H$"Z0_XW>C1+5C?-J53'K$6$^)WP&$8Y9DP:].%6:+H?=-
A>+[F\(C6R$565QWW8=Y7!R?*VO M\O3\,)2$=YU.^_5O\1$#W.*1SK>A50E>&(H1*Q->\F+=8J4^\P!D=8%T<IX MPK0G?0'V'2(K2W7T!$]/@83\2$9 -
V=\B:302LXOE4N#1P'LJ^7^BJ5A4S9, M?AR#C)?JA%15U^H?%S/=A7<2\H3FT%B2]7L A$@%,]YR@/B0&DOZ]T=:3]8$ MQI8DLX.S G2[;KB86H<0=]*K@.HQ@"C?8]S-7/VA-
UPQ@(DXT'0?5O.;Q$[+ MS]A(]#>^E]@K26I)%P$'6Q)D"T27-&A,53$_. 00 M7$O&!H_B*!\.<VV%WP/^(PI(TD=H_O#)<=>0P*H]],H&WE073Z]>K!LQP#4EK@N\ 0\E-RK6KB.):!_*
(Y2T^41'\KD5Y&E_QGND@:_M@)?VS]B2;F'A$090\.,)P4TKA6Y2ES!TA8P-Z]8>;BN6!$1ZU%(RABR&D K5\2. ?B9_:AV M@@-9^6Z(TO MJ^.MQ C_$WVZ_?,S>G%(2QD"
MJ_,;WK!]O%=\X1)K=!(,7A4]ZTKFWN+^3NQO+G**%K,!;D=!6!=_E,#I"H!L MJX%6RM$-JK!2\A-]ZC^17$^&Y_^PR$^@J"]8(QJ/$'\? 3Q.FN6,&;VM7T96G&"6SO<-
]D&Z#&H:O69$*3/5$] MCK)*V=0\]XZ]%D1V56AUP$5BO< PM;@@(%&?R?D(DU_/&X^4Z_(>I-?W%/PHR M"OL15?CE6/3>?ZO^R^,=6T]V:0AO'.#@0I@%'H-%;.
[>K&A[\]BDUQ&U9">% M)S7TE$\9ZX=N[.>THO]=ZV.:3ZP]QE*O$(/_M)4)E8/S8C5^<57=S[#/S+ZG'IN+7F(>U3$:R6*->O*OS8'P:=#AM2([,4_$K MW'&2>U#>?=6RC"9LWC.YI]
MKX,]QN]!4+.M[9<%$KDR1I*"S68R:)5?3:T' M7?*)!,M4+EOLEWEEDXP*UQV7,=F7HY!2I^!X#("MJT#+I6_:U7'IO;]8=(>'> M)AT5>KA*+LXV:C6^H';1Z_..S^,.QT'-77?Z#Q6[
M4DHC-F#^ID%Z=@H]WN*K(2OC(GMO-FRX56AF6/"CT>?14Y M]4CA"I7@YOD[W+Z0]+ 0 B^4E,I.6MG8W_UX>7Y8W*W-7+138L#,OD0$]O>Q5EN X$Z4*TDA32X/EQ9?OUJT$H%?
0!5 M0WVPX_7(G,PN>\+8V\6\O'KOP[R%459:!@C6IG>[%>;LNVN*@63/!>77'EY, M+C,*LF-,^/?YP:= XYG][,AE\VK5OB-URUP M<-*'!V76LVU+4>+!E2)EXG
M>!DS*GZ$P%,0OF>$,^HL]HZG4X$?;-8N2%503Y4)L;E;NO>]).WF9U49'Z.0 M<%R)"H-OL9E,-HZB'>^R4IVI7>;=AEB5$_3CCQ RB8!Q5>8':A_:#V/T, B M$1KG/F>-EI=N[^0;
[W5GT0)!DFN]E-5R]CSX^3*Z$BWE8AK+_(.FN]+FU]JW M 7+6?D\\S$:3)57PSX4 X@U7("B9Q2E237]_Z@^]S^H4/D_6P__QVE4TR@R&-VB]&-C#AY\"0IH
M^M>TAO*ZG_NC;5+!*?&I[_2,)TJT,KK'\ SD*V-6B[8SK3A_X,1.#:3OZA MUH_$SS\[BZJ3D:?U_R_RW/O&7PF]WFZNI^J\G!&)=?U.@1ZW]5"&AFTVR6FN'> M(.[592CR?! #V'E$?%R85
.E@72.8T7UM1RDP.DXP4?8]XFQL>FB@O["$P-0 MD/S5:M8$!>R67\S2]@10CL]1?MP:(V%,9ER0)MSE7DAA6E3VUKWC1SH6F3 MLTY[]4YTM-N
@WH1:QAYHRQ8:F<]Z%Y[$I4L1)'&B'Q7TY5;MY0YPPW+]V>, MF#$]4ZMW=IL*T7EPP: FGKF$^V1RG6X&IFT+GW_Z[L4>S-'7L53[.A QR&:E M!3])+-"6M7+&4P^^5
G8Y3E9KE*>.:+> P]NNM[H>R$;#6CH:1"H=(IOX:]1U ME72MMHUB$#X56?INS#>^U@7)F]Z.#J6X2]$L?#53?*LP"@-@2GZ! :#C '"C M,Q"BY3=DJ%
MN!SEGCC3U&1,=8IVOLH9#*525AY1'7-JF.Q&"8ZQL^_8IM36?LOC?(L!>"PZ M5'>J:;L0Q26W(03"9V_76EPE\E.GJ1I_-UA"C MO67:,[*2%*25$OP<.+%LQ!C"7TK,+YM5?
*X:2A4JPUL1D6'=BTLY7B3=W9-: M$5=JX(G&O7(+=ZFY:^!<%[+^!G(G\BGM2$=@I(8F%AZ$N! N7XF)2EY7,M1>@ MS\;3-2[&(4[3R>.)16[*K6U:MY5/?]])+S.,+@Q$*FRUT)92/MF
M8PQ\T$%3I%S)4^\!@"M]O0I0O(N+PH&)VF-9E@E#-X'0?0.!>1N/.\=CZ9(= MF;I)>(MYPJE]GVP1%ZA"KF\.+"/U 1@DY&&_PF\TF>NQW"1(F)CO24"L=Y MFM?
4'IW(P]MR5ONR.:)&+ULYLN]#.3EER5=0S\>7VV/WN"FNC28I$9CEL;__M>ER,Y$UDIW:0E07-KMP\ V(L?,5!- 0#8#WB0DH]GS;I\9?]LC. 8 ^006O4QWW>4A$ A\-
:ZN(6GUT8NI2P_B^ ME6+IX#),T1F; P3V'8O@KX[J]&8F(\3TYFF>LH3IKY#\LDL!_A4V .C&+.F MW0*V+02Z:SCWBTMW>G\AIG:<'R^PD[=<5Y1\;QNK/(AF@BFLIFT/+$66QS+
MIF_K"-JU%BFBM%S:S!87,/#G0Q!KC13R4^R^KOOH/F=B\C+A,0"7:3E+3_-N M%F$QBGVXK=ZF?BY-G#3P!@9 WU';"_3W(,MOD24G%V+PBY.L.GC!AQSQ]/F]
M8W5R>W*FQ]2+YIWT@1PNP^TPR>6X!PH.:U&S>7<4>5I>C['RQ]N'X.!=>^$ MZ-\F17%/R?98KW>=[^=#-2"'=W*@5KP0=XF)$VA(\KN,H.X!HRJACK>;;B8<
MAI@E*Q1\=7O3VYIL?D%31;R^.[O,FP#NY_$%UEN."3M*GLBREQSI$R]UO5K MZ3@U&72,D:KHL[S[V:0X%&$ #\2!,U@37\'6^'X/?^&O$$RB1&/^?@<&T%L$ ME\4_;!
[\],;B^W^F&HOLDL<>TC$O).) QNTDPJ+3B:4D[=>8Q>!>JAN>;3D; M0=-NGP*7"$Y4KSQW7C@1;H4AUL^T:SKBMFPZ/>-)AX6T?IT%Q2IA1V&U/4\#_#R<%6_9;]D

```
MAU0+B@&T5!N>4P@87IS)HMC\,("4]QH80-,GA\)%UXD3?+9.#. O9']^FK"6 M7=V.YS6R90P 7DB._GA3"XU6P0#P%R$;K\8@^ZLT>=7Z)^+O@A 8P,\/_NF% MPC1F."_HFJ7=,("?
GPSYRPNQ[I'_G6$2-'86JQ@ ?WHN_5_>IJ?.[P\N_*-< M^*NB'.,_\R'Z.Q+6(B4U4L!,5; +BW<_&-<^"GR-_]G FQ?X) /"\OH4I7S/,$K>E@7T $YO^>]F9Y_ M?,=F?7#T]PG7:-
G/_F_ASA\R\@]QX>?#RHB?7L91I/.#7W((O[?@A>:)I!/> M82+:#9%<;_%#$4T>"?PN\S@U9ES_WQCY'_/_?X8+6$T)V4+)_HZF+*V-$"G8 MK9K<>PZI\;
(]E3@:UO0(K'+_]OS'T/P3@_P@7M@6;$,OV&(!> M_)D6'MP,_4P* S!T@#PH]+#U5PB7PP"FSU.FTA>Z84'?X%H?R'4')<:=K;8- MYWG=[23(0QS/1THKE^I]CLC^YVAVY[],IO]O3J;
(7R:S]30WN/#Z+UR@_2TN;/V%"T3_Z[B@9K@'"_]I M''+S1*3$9W]9%&'^G?2(XQ0,8$*5?EM?W)VFD9R*KB)=68"MM^!TB'ERFL%K M<@ 6=-S3[.5PYB.;HGLY#KULP@
R&/ZFNNR?KT(I-43">!*GO]3'OAM\[=0] M>\I2NV)71J[D%66'C,8KIHP8$FA^>,T:--.S/8B]H^SSP]3ZZ<7QK&Q#*T&5 MV7F]F?O3*^RE9;ZN1.X"";D/NV5K9OV;>RJHHJ-*_1I=?
Y1='P N,H\#%U]! M3"[++HEW#0QC5[-FC_KYSH=$@NXVJ;SF=N;10X5ZYNY=0J52<[<7A>[)DW6Y$;11958X>\3YP1)*4C_1Z13BL0SB/U!Y]/ 4_Z5(M-UA
MFW3>4]A^SLR0'GE@O:=XZ&Q_U8Y<'>_W[V3L8\X@^#5]TGJKK:\S I*9=/1M9B,FA@PLB(-1DBE6]E-N M?E(=WVRH7]Q*A_=HO<< QAG?ZX."ZY]
[";^^(TW2ZRAZFZK1Q55).K.BSDI) I(6/7J,%YY=Q,/_[)JGV^*W=2R_,,S*#+4[25-KZX MU1>ZO:P2B0 [@0QK.RY)5723Y'O^ZIRP"V64?M.J SX5G[-;\J:H\<['Q0FC
MX\Q.^*H"%)DM((D!@%D?,>UO]<\XHLF1C!A %5WG[R\R78?"]6O_OR@+EW\] M\=MC08?H#,'-?JIE&T=3$-VMGH&9QDWMR% M'#(=]\G "8\E)O*U%@,-L:6+YHR6JWCCOZ-
=8EGW1/]0D7\8BO])7'"B_^U< MDV:4Q0(BUY'+,,PTRKB&Y19#MUCR)Y4'QF]M=/_4 M,F4%_:^[ZMMQD(WVPM)?;4S_:1_ZRZ+M&>D1]/PH^,>A>Y$V'5;E1("P\*Q(
MKNGHMLXQR.'%W\N=_(?/G5M0JAA .',B%@AV8]=RA:O&7_]%W?7.Q%YV:E#$ M/W56;]=T$S*Z#3E&CWE^""[4IZ*;D-KY\5S1P'^>^F\_<;%H!@; B9 M[L4
[JE7DJM5_)>]1NAP3$3M"]P'2\"S&QM-)R3^9S!//?( #&"%,16+R13H MU_5WWS3^."X?+$!ORZ+G,8#A<"WA97T',+'4(4<\N&U_E=%(U(TI>>2X,*PF
MF69C9)N*:%K]D.6=).M7L>)F'&*U?@@^ZWS$P1ZE1SI"_;*JU=NV:F#=J!]' M1'U*;1Y4I'A9.@EA[UAG&6P49G+M%T99Y0])(0>:M1YK%1HW5'A)B3L=JA'
M0L@DYHZ#,Y#OE89WAEO5X6V\LVT*L6[JHHXHR5CA77U>9-"\'#QX2SYC>D)O MIH[]\=#7IVTTU\4(%QP3("*+Z6EU'KKZ&$!>LCXTVN73:]R^[S4/W-!W83'S
M']=I399T&ZA;SV,"-GKYA)^QO+_KP$2?M29?^)&8"/+&2V*TD/,..8S[W4*8 MD5X(U[$$!]"PG@*?74M;#-[UT8K()+%],?/EEIFGXW$_9%*@R6SI:AY*=+3
MS&MVZBGI>AZSS/BI.%8[&40#]UU<^#MT9?VK$(R['/.S**Y+&V.D8BLLB6%D M+Y4J:DJ;Z;W#_?7O;T0/1 B=C_/H[M;4P?=#^H.9^IB([_F-.K'0LP$\7% 7
M8X;XR+CUUCCOWD3Q0C!3^,W%2K\H6KSF+6"T(;PPT;L(65)Q$: C:A*=.>-& MZ#Z5Z[DRS#Q4B'NI%)@_HZ\"22[(2F* M,"29E:=_[D)6%>0XAOEO+F!_7T<"O?8+7OVKJ! 5 E
M:XYDP6'!S$W5P^.GRNZ4WYQF*36[FYENW3@]*@AET1MV#M49G^IMJR>O9U)#TL$K>O3O5VV<+[4I'[IU!'$ MSA.CNMJR8#](Z+BM(Q7==Z&TG](XG[4<0L%C$U90EK\XTL.T
M_*Y&A6;-$#V2%!7$'1DXKT:H!N;ZV-\S A9N\^8Y4SVGS;YRGN+H@:,[SP+D"(9)\G<1%W
MRVC$:RD0*Z^<)O$C^$\$;_6EMT6(61?.FX:#5;F5%3W4YPD@RZFJ#B@YO!/I.0;\"#S@F(' EB$;>#H2HE@]S?<" M ZB$G/-8B2Y"4<&N],?(^?-?-
*&7BQXT=N"5$=LSV$K8<,Z61T$2U!0F6)9O M'^9[;+2!ZZC%UBD&SJG8#S91]#.KK+"GZB@HCZ:8[2?"$UZG2XK.L&SL%Q0J MS<>%61T(&D?/0Z2W=_^*)!C<4FRD:SYV,-
Q."+O++=\L/K$"%_?.!07V*S=9 MT;^V)#;4LH7GW4TF >^ (^=@3^12)/TT:CK1W>?CR6U*OZRKO)M_41:8X>G\ MB/5A+YG8.UPO+
(3O&HX6=JAKS!I6RU']*!%41&RFQ$*1EW5:M]='3]=^"V[2 MU9(=FG8P^HJX_CKN@I(D?'4 =?]#34OZ_CL/(P &$.I0&QM8P75GT^6<7<0I
MU(G2:^WIRQI#;_LMQTT=@_M!MH1N)+WR,G3@WN1RD=.];SZOS 8]QRZ>K6UQ M1 I+9 @MWGN;/9RP[KUO7(L!Z/J'>*G&U=+BRDHYKQ63R%/,5K^[@1=6']8X M-
F0N@G,N^(&EE$%\IINQ]&K'B=ZU >5O9AEV$M0(_61_<)<^#;BU(5P,XE^CY]\P;V!JVH?]$B9+^I34N6% MW^?%[<7L#C\*G;C(L0IWA7/!PH"E7?XB2N2;?GTC7DKM,\5]
%/6E='33J/MXWR"@< [,]]*%G210[-=?KS&+!:,V10# MBSJ&Q%[BKAFMCMZ>=Z28%ICLJUNOT43*6B?X]*M:*+&"*T;KO1ZP,VT9O:88 MK5VUA$&":T4]'J;60:%"B;IH!7;
("1'].3=,EGB&K-]R_D#%".MFVF$ 0Q]K MA7P6LC-@8XG5^_^6S?U)1=KRU]G<\]"F%;E1#& &='G3]_8&A,X])&JO/C'$KE#!GX:1X%'%[P*%>0A>^DA M_8,4+-?
S1[3*WS;8^\]APZ58U%O^_7,TZ/+:#WSXTZ^Y:=5)G<[29*%+!3K> MQ*U:'M&Y,H=2998]>&JQ&L+-N"G'.91ETHX^! @V9*Q\I%7 .^3XL)-= C/55A>Z6*SXL2*_B:\5:A-
/^P3R5>4FKK*KD]@);5E, M*[[UP7+LWTUZU.-J-3P6F;^$"/SP*@0P +4"# !VJ,'Q.6G=69I4/>2?Z5K' M]A/.K\M=]%+$ !ZPM1KN51WGABV9_=/D?
_N12*M3@8%SM"76R_BWCQEE=V9V M.8LXK--(]&=:<8QW;[)]P#DW/ET8 R'E^ W/"28@"PJ04,>F.\ 57:S34U3Q MHZWR_\?>>X=%F65[HZ4HB( ( @J2% 0DBN18 I*%(H-
$D9QS#J4@.8. DDJ2 MY"0YEF00D)QSSJ&(!1157S%S9]:=Z9X^<[O[WO/=TW^\S_-6U:X=UMY[K=]: M>ZVUZS[7,NBK2CEPN[GF.V8/+2E6[U+M19I"#^\6HP!?WZ.1$W">NA^\QJ:/
M KQ]C.2:.U1# 10B#LAG)TJ1JO 4M+J-C7FI'GK@(J!!L'0D(=Y=I,\Q%9P0 MLJB++TZ%+HIUC(94L=[T=> F$314[]-M1@&N*B-,48!WOI>KOCX >2T+/NK; M+SE$@VB\R
,NZP7]6B<4C]#,Y G8O/=4?<&C'4%+QG9Q?0NX]PC8%O'3P;H* M$7F) KNI_NSKGWW]K7TU]]"1;SK]IJFGI:E?" AGX5QS"UV9>#K^LK@#01'T$JUAM> M&T=N89Q;O=9/E=2U"'3
[1FS1SW06#L4 >\A$9]E?%(T5]<(OAA(K*ZCZ0$+_H^F^FX B[A&ZCL] MZGU::L..6A[C3F'2N@KCV/9C\X'(][K@+OBG8UZ]TPNT*)5%]!KF@XG%6-K] MV>9]Z./4(FX&9@8M.5ZM
A6;ZQV2#:/G/R?,*/=6PGUHK\@.=9#?1\8V PE+T M'^=D57R:E=#K/Q/*:CUUX)% MOU)0\;<4O*3MKY2D'^-B.\,SA\ )AQPN*?G3I>.H'N?E^X^)D?S_NJCL/[I-
M/HC4:\4J;D(!>G<1T7HK[K'$R]!_#%J!\^(YY!3/'/HSM5;G@3O%(Y"-:$8C M0;8V?^Y3S4(C:>J$7]'CXN0 C%_>29&#:Z_4C/D3J2K+T7LO&9@K)Z7EU&:W
M,DU,ZF5U1PLZWZMSZ4+2=#:>VE-',.(["S(@I*]6;YM( M\/^,1;^,+'WQR MPW#@C&:>GJ(END4360.@[TZAK0T7B^2V_MF5YN*R9K#$5T]?70#/R%5V Z-9RG?]=^FQMB)G,3^6
M1&*J', Q$6%"6RR%LGCQ$44/[RI9D*C)H^5QN0;&=)K4*DK.".,%6W>C'R =G'O;L.D\>O'\:*4)ZS:7POKQ-A:?FT&H%7_!,
MGSC'+;\&7:$S\&*Y0,3K.F\:&$5OJ),566NT3K[:'>97DM;I>>P8],6 U1C9 M[(T9^KVPY>21$K!-MEG,-YK(C =DPAF+ .=."H?*=).G74D MG5Z@&LF^A4+%YQ&_])I]
(D;ZWOWM2=_^6I>"$WT/F ^-54=I"9.M!'_RV-G% M$7H-)6>#.U\-0+%LE3Z=[.7P^LP5RAXE(H\I M0N/C[CZD3H5/5Z>B!27<<&$(IU!R9DT-\+RS_^:/:/_$$RQ(F7\%\] "YS"
MR%EE8: L1LGJI:%C@6]><:=%JCSD_B?K)]AMTIM3* "COP6(7$_[VWK.V'H? MICXA[4,)HRTM6][MOA.NP9GI1V%^K5.0C;F@3$MW!EIT\84R)QA;B./AL)XV MF55^81.3A^D5
3&"KCN1]NRS6?4R.Y@!?DX7,IOJ0XY"1@8\%1KZG#(J4@T9 MWHR2V< 4G=4@IS$$.'NMXH$U45.>Q9W8V)3S_F?NAX)#T,7+#YL"[+ERC$Q9I='XB89QE+CMT0"R5KWXN(J
M9_%8'#<_=<3?_H9-\GK+ESA M6MFEL% A&:V(3^TI&.((G+3XD(%7=D;NR"7T6X4/UWG"ZM^(\==7I?&@'1", M RE>"SX[U[NXLOG-8KB!#MQ1:8,62!:76;?_&>NW>@>C1; G.
M_5ZWEZ3M101='D<]HAV7\_OHOGVHOP-4A*M_:7\H2R9]'U/R2FR *+Z8GJ#Z M)P00)MRF0W8LAI;<')3MYY#Y4W=U2$AJ=_5B]>8RO%!]*ZMT[%#@Y[0>=?V? M/W<\
(&FO'=HV_:TGPG][,(,9KF(_P!_)2R2FS]1+>\.!;$IY[^4GQ"0:#%@5 ME#3,FP_36,Q,:DV,/0_<,KO/N($""'WS(-]8\,R? M( (G; 9 %_>&+S&537%6)M4KD$Q?6H:QR[&
[N]+%V[]4VGM^TUWQF.BPX"8# M!G#K\;KDF/) &<,G7!3@\@_ZEW_XH1/_;Y=_5O*7(DR2UG?04OUJW+_NH!6$ MUV7NS:S+Z#L+]:+G(XH/NED"JF7_>EE.G&(7_A%V8-:ZS(P
MS^?7KTDW=OWI($QU9T2RQN7<[,\?^.'4>N!OOD3^@#LU9N]0C#8Z^'TGTVCV MXC$Y?:MN\<6=G*4-NF\#;KYM]KFL^.M4X&NOX*"-[5G$G&,>="^7*_):2,[+ MTZF8 ]
[5S8AU3>B-M'<:YLH P0-&)BKQ1IHCNAQS,$&==-:LSG/'27'_QPE< M;M21AE>?=4YKZLSTT\CJ)+I0WAYV E]9GQ!?'FCWLN&+FE%_:B1BFPZ4T/M6
M=]"J2U"U5S0N>)Z==2Z/<'L5:C6YB3QRSWI;)^NV8,6]LG#,0./Z>2R-F-H M.V;%I-T^($PVLW$F5Y%*F6I#)I_H\R4I&+(0 M2C>Q*?DVD$Y [ETXG+=(9_^$"$K0N[!#?
JX"A4#V20:AF[[@-16ZJ;=Y#V,0 MO-64I"&:%4-J$MQYCOKLEM3$N,\L4Y[UZ@]4")-L3OA-+W^/=6#JM8[\&)5! M^_[!FZ_" 4)"#>5AG)1"U7MU[$]?G$E7RH7@Q\:0S,8+>+]F'T-
RU>Y5*@]< M[F6_=M4E8077B>:Z)+>TB M_8][S:P#@ M%&"D4+()0PNBGC KYA2^LT B36^ +!3TT1*J!IA<.VCG*G#*QQ3.A0?01 ,S71HX!ZP1JO.3O([U 9Z=PNM4IN,E4'BJ-AXR?
A&$ MK=%N;[-#\OWAW1.>1^D1@@ 56"CDA5+(0(>-PT =U?QI'4];>>B!) =IPK.. M&_>H;Z$ ,@L8>GOY9$BHF;3K=
MN/TI3N_F[C;;=J%\NF43J9IHJE;2;3L=GA9\0M#\!0E7J6U\/*B$*C0M_.4; MX!N$A6\I3"_(\W$ACI"NVTJ8MEN_-L\'F92-:7?'QE8]>,7YD1 '[DTWW&;*
ME>1$\WDG*]QL3]+\&5X)R>,9:3(PD$? M;#NHK36_Z,)G+-;8N>L;#@)R.9+)T".HG65LW16C MQ^RL0JOWF7C3 OX]E.WB1&KB_U;$V$*)H$O86>#1?? :B\[P#Q]5*5J.!7*[
M8"01%]!4[?44<-2JU<5*SZ1M8XVAN_M()C$-T]BD5PBHHGP6VA%D,!UJ_16# M%\%$);(7F_(VUYRGC\^XUC,MMOU]QE+V:A1DB>E36O+7QM$ZGHO*W+43J,4^ MN-3DH,+-
HZ[WXRV.J(CJW9&R#2U_J Z5QDR5L1;9$MLR7B;29['.! MN6EJ1:L!ALS>Z+%)$)>0WK:WR21T.3X^+&FUT WA)[U0A ]NDLM@"9AHZ E2 MDT/J(M^$&M",5*RE[9S@$)?CX%@I-
5DP=;1$OJC5 :T ;[L5*@KB98\7C1_V M$NMICE]U;NJL*_3 J#+8+QP(OF/*; '-SOK4E9&675UV;%/<[5DL3TX$4X9 M5F_Q)B9;GLX\*D?
$W3VNQN9GW7U_3$,S"W48K107O^M2I;%:Y,GCD.TJ[T6R MJQIM]IE1HR#QNZ]+OHW!)8[8"G:<@ 2S>C?(I:+ >.:)?]Z0Z>[3_W<149J=M M,3\U-:CRD3)2Z._(I #92MPHY!
[]ZN+N($CF$E14X'A"^X%88AXBT8LU=7/; M-)7;IYTCU95_]MFHM1..EH]^PO5WSSJ_S;%J5+C1YM"_':G^R!GH! D^&ZZ+ MEL:-FL@H[KFCGQ;)S*M_"OE>_[38RI/GV(94S]5WVZ-
A&!#0L0^KO(+I8@*I M7I])B$QXB@+,7Z^J3V O@/L<*)6'-1=4Z[%(HP 6,9!!:($S8V[@WW+Z*XW( MUV;J;A0WQ6G635C0$&X3[LQD52I&%##-VFW9'4\8-63"S'<\C(PK2G&XVNG-
M(-98B]$@Q/6\_CR:YAG*\KVCD$:,ND&9&<,30OM]:,[Q(24R(V$TM=9'Y&]) MJW_BC'>Y@?[FI"=K3%\K?AS)[T+P@S@#J@^"J!_ P4XQ"J3W5J([-X70$=QAZK?$[G-
\]\N(TM8R>>@'I&B9@FGWDD6X>E M:YKRNW[YN66$DBS^G%X\^'CH1;?A4[S&X]?JFO-U\O(&317 M\!Q<)^RAU#/]VD%+[JW: X_1 A-\%.29[V,U3,1Q<>8+OM9+XR*6!!:)&2P< M.
(27%3".-!&^I ZE-A@N&4+2)X"L1&Q2K7_V&J!_KZHZX67"QS5#!RR"(-+ MI7.DE*3;5;7?OCU%IAQ-J-T-%N3 "K(T",LT9?WT^OB@2 4X9PM\(&V3+11J M U>=N$]G6 UU*XUA_V!-
CSPMS)/]8L4C6UEJ$5#UI+"7"WEP:QS!%!S1HDNS M%\(L_*B\A%AZ]7C1-90CU?Y;L[(H\O1:+^V6U)4WU%>2'-N!WW(W^#UU<6#.,6Z?.<0,LF6//4(L MHWUY23%@O264
43Y%13C/,'@I0Q7$QC2N/(HF>EY_:AC7H'H\NOZ2J^1_H]- MI%+4;\OV;>T&B@65T32C:09&'""Z=B$EH3?1BK3-1;+9,<$,(;$L.^!*-,@\ MZU9IYA1H223G91>W\ZD9?ZG)
(&"E6H^LTRYW,P'D-Y\\%WS@6,F<_!(@Z"TS MY;Y0EKE"%3#3+88761G[;'_GX6M:"8K[?$NP!#4=20>V^2*$AP7P"#G[K39A M#GF7Z3,D-R.B?
N30WT;Y;8S.,N$423M!#H*_[WKY\DQ7!"=-%[(R;(RN1)!T MSNN^]MX4SV@>W\?IQG$ZS"M?%^JI5-"876[WPA9\<6V4;V\0^3S/YFR='OG.
M[$#@YK>5G;@$9PBAZ8@+>^G$IVXZA8&'1]<#=!U38.4F8&BU902%&"-?1@2!-Y_I(VF!AJY'SZ0F0@_H^ \&8FK:%I9 MV+CQBK?EBQ2QO+N]ZV=M\QJGK/CCQ',-SZ\WW6(8=
[!2205'[R]"3^F.HZ6]=:1]ZC$X58!Q_3X>O0] MJ^T/U=HEP.1>IJU=OHV\Y @]V<#HUO')_U$<<3?!X?<48 :[S0(XYBZ$%DI M"E!99B/0B1PI/G (@YC)C9\95T-(>QQR-
A/4_;9771_6XSWJRIHQ!,!.F;PA MX4%[^/YA415DY@R,SR+96;%WJU*@F4RLZ=4#PUS#9:,^9J,*94^^VC'[&#&1 M'AJD ,F6$5@.#C9V>7#OC?DL?D>XO\2&PFK$(.])H4-C
V4E[/I(;DV02;'/ M]@>MO%A"*?NG+>2(]*SS]G5)-COM(X;"5RG3U@\2^*CUJZ1";T9M1K6J^6H. M%'Z^/;GA;/]-GEL2O>36\.QT>08-!AQ9R+XQ[-Q_[K-YP:(8),!1BX4"4+8W
M\!444$GO.7_JTUU_\K*3EIE6(BC0D7J)D"/J\&$(D[8+?\*O'6%<&I6J"\&C M!^I.?W^]M"@MH0#_Y!M1K[5@@@AQ1BOVQ] SC-'WHT6^R+LSGBM&")/'O[(&.P?:+IH_,!9M38B?
PV3Y:TC[C2MP[1SZWXD'O MV%#SHB^L67)_A&/,_V9[!*C03''3G64DF<;JY>"5^GODOJ=O%7XH83$LU+GF MJI:<;0'$=UHW2)D,N&(8U(G]U+?
Y,6+/K0U$D8L"!#=09P4>&F1]3N@S%G>@ MD:N]MQVJ7CRE.3G=OCS52-2_*F#XK!DHIOJ@S]'"[5KD.C=!U5JGY9N(EIL- M1K7/]^O#Q>8%G[9_TA5HVRBR>\^<@7E?
DF:D%/D$W'T?.8D";/,?SEW-5@4 MG@"V58LX)_$D328M"PH]Z[8.%M0G4ZHZ%C\AA@J9)G;EF1$"I7!( MUOH,>6FIS[<-K2X/TX73IGRCV&??1>A)*2&QAIY/^W<*ZZ0I\Y:_3$QB=?
O9 MYG=G.H>/GY9NZWX6Y$F]>]/?<4Y2E$49P22MJDA,()H;>AT#<-/SV\3-WIR@ M'+B8Z(B-W/)%1#*?0B9B51=+'N.*&F?1+3--9H[6K(G3Q\*"C2L>E$N3>$M$#3=\;;[Z<$+$L
M&-8/I09&YJUN#J7H!O M4-VFNK9>HP(V.5?AO'A2Y5'2MMD MCHL]3/(/GR;R/;J:R>D_R%?D7T/\/2JU2VC*BGPTG%RB^;K"+8XU>3FE*GCZ M=?\L#P.W+"FY\I8HYL@J
9\20*2[K9"<.YY2S0!GUSANO+M39G-* ?/-U8.' M(9]WVJTX!8V7B[P?P.N$RG/".M6_(N7"/.%A0.3PM[]/."IOP?,X]@XML M.^<,'>F7+8NR7^[BWRM<*:D5!0@_3!3HM-(/
MWD=JN,9OV>X20.REJ&+-UVIV($7CB59KL*]"@-. M<1868R9F/$_O'/OQ-BH)P ;1@BG,YMJ8SOT+_^V4\>T'0YGXN/C-5J0"'YR_ M[ZYN8%=$/4X.(^Z%NVC7#)
<+64\L\*HR6X>RN[+O-.H*IE#GVGO B3D9/ALNAU]?&[M(E3&IXI6D (1F\!6.;8@ M00.C>:.H@T[4NBTE.;5Y,22.> M1K<@V2B T9C&E+E[(*DI]9KOQ>?&=L7)
<'BFQ=9]:\>@G%/^2>L85*I.8E MTR@.F@QR7:T=>'S?UBYTSY.O#23?5HPP<;H>'U$GY.#PL!U71F>Z!H"=RF+9 M6(\OEE;5B;#+;O)'O/*P?
C>)+"^E&JDQHI)M6S$<:TH/V,6UQ=Z'60K M^?HQ9Y]V*IJ !"B ]=2&PH6_A4V)W+(Q:'%SNW$QZOM3OI5*)HSFE$?(V>JA
M^7/ZJ&/2NOS3Q,K]9B%,X=UZ0TU/4:UF!US^Y_LS[8_#F4QI9[1OYHW#QI-IT98Z>ZL;?O94]1V-Z;%^/6LF_BO I]@&L4\EEEXUTTRI M";0["/T;KT])HU(Q([?!C8]P5X/3S+@V[
+7A*FLM!,(I.+?:=)-/BRK%7S M4-9/02NFTL:FP"D:'M\%2Q*F/*?S[/"R/4NL MU;&,2]_OYP,,Y2Q;3@1R?PZ9:DNVXI_>W0)N/:!"OCF:'+JKIE;9G^_BW#?U ML-CH<$M#/)53"%&A&
<(1\79O@L_!M8*_-VDH_J64R M_6G;??TCTC53^6[27L_G:'1Q!\V0*O3.N!XG2(9Z"F&&Z!/5Y&,_U&K+S^*[ MQG#-
L3!A90*G@PPGFR:%I&UM^=DW6_NG^!3B:%SRSD($S<'HT+CM30Z2:%"M M%$<@SG%;J5VMTB($YWU5D':JX=I]P.(1<2>""=V.. JPN8X"1(_JFQF8Z1,$ M?Q_!,>VR?HRK?
T6XB@).%4M2H59Q^Y3;N6^R-7GR0>C#U=&KL8?%Y,(-5(TS M;+XMMQ^369WN%[TW]+-<=1;R0.)MJ@EZ%-QH2\R4]*ZH./.]8V=;%QL0'M"W MA%0=FYK0TOWZJJ82K3]?:V?
$5(:3%7 '94S12G/'&SU\7DNC7BE*X(4I>35Y M5*$DZ+-K2..94/#+L0WNXJ9D?WM0#N_2^:A(UH::>T'E!+,UH:L+\4SR4P%5 M/;A$&=7953,H_"9D7MW*LL#RP;
[E=FIEB$"%V#WQWL+K]*_4Z=."'^/^AW8) M#;+9$$M!H6RMR0UL1G%^ZY?]+HQ)B]=N><%[;(:4)T69>CAIAP9 M!]1\Y#VTP1!(Q2 9M8/O%F)_%X^T65@)M2MSJ'92
L#Y\4N7H]9 ST, MRK=B-0EVVWX59RK_.FH1MP,\3A\%5^PFX=TE/:T!!CGJW;F18F'AU:=]G90A M@RIQW_BX@[(\ARW\D*H4JZSVW'""?HGA2-&Q%:MK_QN*&18:1NH2DPK?FZU(=
M#W.US/BMWK=9R D/8(/4@XG5@(%$.DXXY."F11JSLYR/HM]LI)THKGSM<8F] M7AZ;&6EG88%[56)J@:%I1SB+0@XD75OKH\9H#MG'KD=+,GSTZD]8%28#=\1: MH0
ZM)>Y>YWR<]]^"I=A[9C\-[E2I57M;X43-T'G^;NQ#)%J9V36E7Z:-LEW5PKHV67HG8 M>5X]=V<#9&.@&^1@9N6&[;\Q\WB!7N#1,S0_0?-H:82:;LGQ8:EYB;7*_
MF'J=NVFGL8AP00%H9T:18V#&K3+HZ;5Q\.BU2V@O['%?-D_?RL[B6A_NZ\R4P M[IY.^]!B3IK6?>F=U]4)(]CT(1?:1?>8(:)N1*?E55IBX;!\%TTU: 8\[8:N M*W-
C\#R182[YP2D'[C'O48$D# 7PC^Z>PI/6PJF2R)[LK6 ?J='\5$,9&7.Z MF:D1]+;W TL?MW=5SUT=T7:^.:W[65X@O7J_U'CE>$_%RFN2G>3>0A=7=GM M_N"#2R[7"RL\SONY_J4GVI:
(:<)NQ:?U6%CE5(>Q8?@Y:V=UA?]?[1P6XJB3 M":;0#]#MO?,]EY!& =Q9KHR7AD;SW^*(&B3M<7?JR2Q?HKN?YYH5F+05BX'? M,>2<8!6>2+A14]1;OHAA??V7;,**]#U=?D+;-
MC5/*?9-+0XU6W%KMJ7[-3UT]JN^,-YFR7ZJA(Z8=; M$Y:AO_+T4P'R7("0]JG3S\:&3:98N!H$$"[J7$9H'IYV6J2BZ@':A_JW)RF:Q?ZG?Q(M9F:V4[O6HV>X2 G.%)!6
M>%_IIQG4Q)FT*9_Z=B5A09UY&=:IMH$)/CO-%\O300C51S==K-8/&(6EM*E3 MUQ23[G4-.3BK(*("VS.Z$'"B#HDG?T^I +09#9FV4J[+6& L@UQ!9FT1=J?:)? M[QU*6+>
([EN"Q=9/D7EGF5EP91CFS9Y^*LTFMTN*&8P6;B@?&1)J"[\J@>R% M=Q39O9.=5"@N$;Q3296B$.H1H;F[B=$J?#>@Q3EJ0F9@9%95A8#[O#<9(\@L;[9AI#;AHB5L
M*O0J4,U\LD^K96"ZE[6:(NFVY54&]^]2-DINV[L:@ZX>VGO'E2XYKI9:4UJZ MW.OY1E8?K.55]OACI@QX&U.=\3E [7V-/#[E=WCUHE3[*HVGV".\9\,%1OD6 M/AI"YEF3:
<=G.FVB)77YD5S.F[(PR1#-^W+F,WAL+R3Q.6T[**7M^@P) 2C MT4&K&7Q6HG98D.D"\EGK-)HYJ.+)O&WZ="#12-RS(^Y#UP$*PC;>(4:6&L G
M6V%%;;WF>P\E1REH5/6=BF_S,WS'&JA-O)%"P3_Q&)/BH;A^TMP;#NW>MV4Z M8I+(D7,O:,SJU&D48F,R/L65GBJ,-=1+4:P%#@KRON\$X+LNW4YK"#N#?$^'
MO2.80HCM#2EE&](29J4VFYRII4#3-NXV-=54II,K)\9,7Z]+7%#"(W;+575 M=?Q9J657V#_-71F,^(K_+3-EM;V2G2O:K()DJZMX)J@-B[R8M .1Y]'LCJM+ MT9]>$M8=KM')F874Y-L
/P/>3(X\,>'8VT2*>M-="L:-PUY_.\E5BU)+/9YM M+9[%),,DM7B?0QTQZ891VH;*_>B-U>YWNVI3U=:N]!22FH)X:1MDP./*R6T$
M1'BU.V)5;:KNH)$789XX)9NJW"X%W8MVE9%+!T\VK4YZ.M4OL!&*S1]6*EMQ M#0\/$E7Z/.B*"D5C!Q5/]?39#NE3 C+%%RXP ME!J@@^7)Y"VC%=<@=,IOJ3NH;\W4M^NF$Y4-
S$]UPN1V@XL$^;PK$Q[%9D:] M:#AM"0=0AUKQ?G^VK75&CXA)M#G'@EP 1KA+31:I"$U/2$:YU4;8K_6.+W[@ MC"E>XS$QU3X8K6#*ZBM;?[67F9+L02I-
,B;.B(E%_BHTG,'CZE0",VD'JI6 M7CBBQ8$HE^@J4I8+YQC?S5+H75-2F@I>B95%'27F\H*0@TM%%5Z?RJM M6F XY67[9=1!NR(]?;87=D=JV,#7*;:^-N/+KF)9K"TF1\Q)@(B.''V?
Z65@ M*3)+"[V^5@HWJO3\H1M.T#.D.4DWY?^_XF0A_W2L4VM10UP4R!P]L",=S1DI MA?L<(_+&#CYYPBH*,/]R#7IP!$8!P'=0@,!"A/##9'[/+X*>QK<*-.OV)N6S MWO?K%J -
WO16C D#P4XAT,0XE1[^8=ZIV=0% "*5MA;U"5''X.EEI ]1>-> MJ_^-\HI'W_0&\+AYTJ_V36?"7A_?',4TB'0X5O+ ."LX8BNB4[#V[SV[:AO%FMQO^ M9VFL1,<*_]1D_M1D_GA-
YK<>0/_''G3_R?-3>7T)#0A1@$Z9O='S@@OS]*J/ MO[W^GVW3F^RBQP$)34##A;^]YORB'?TW/M?4]6#K/!<.-LO:X*;94R+@]C(*
M$%G8M(D40N/M0BM$7L1/G"]D]9TN_2E^]UY@Z@5!EU2'48#-;S9H)&S3O'M* M4#:; 3ECSY/]=S$F\@E_A/M"#_P772:4?CG"N.@+Z^?Z/R#9(48H/!4] 0[@ M4=?+J^OCDE$
ZB[0V0+D[$81RR_^]/GX6>7E59'7_^6JR(B68^R]575ZH#U[ M>UWPX\M(XN0?][^N31I"O4N_YI16VV'[Z-@&NBB8)1#CP_A"!4R?-=))W$;:%[9>@&L,S! M)^M >"YPWFR=ZO#6$
JP.P"&J=@7UPCD7N8#]4-SWCX!-$>#HEE^*UK,XEQR MJ4_.62B -UI !*?'^OUZ>ZQHGC(/_K$%<-/@ '"- LWD9S-0@(7L97U"%Y7+ M%*7_W "2Y-)SYMDV"'E!CP(02S+AI->D5>G]T
35#V/AT]"A&+[,5?I/3?S+ M:+XUK>UD%][]YQ9^&$NXVMT_J?7[4VO>^S&XXXX\6N MH7>QYH\T<-#EA!4$ M!')NRGI8:'4D,,6^_QCUC/KJDR<@P<%0G9:)DLW#_\;896/#_YS>/S?
```

#?TZM MOT.6H7]]*2]A+R#,DI-V2&UA8%^O3/NC>]VTM=9)OC>/"K(U9 M+GUT[5=(&,]$\3]SU'^ND3^]]0?R^?\Z*?]Q]-5%-UQ'FD5UI+0U9Z2/$V,8
M3QFR,/J6PLVR:]EUM(_,_CN#SOS6_N?4_KD1_O=1R^+G;9I%/*UX=%*T(ED; MK[Y$6QEA]*(?Z2GO/ (2IN+#0?*R_03>E98,_5\?_\-7Q)[7^"&JE@7_IBH,]
M&U+X*FCT$+,DHJP^6(RQ83U*=,[KWFCMNCSM '/250P1TL;-$_"3+0$[G%K M:<$^3;\:O*[WI_>3F_NF\]FNHP =4:DHP&@H\ Q0,$$Y5W&3(2VR*9CAT]7? M^M1-
+@(1(37]%^]B+KVQ#Q,.;$)1@'W6=;UC0M#%E8U4V!V6".FT8$:9WW1> M^9,[[HNDB[CAXLBL%G0+YIFECW9^E^KO@CNU]P+.BRXL!BQZZG10@$<.350[
MT*/<|*4N@P'3M.#+RR-^.[E^)-T\U1F4 48D\Y#-]] ?LN#45V\2\BQ]/1(M_T/:O,$&7FQ;1%;S[!?>F>M%! 8@&Y:0LCK3NPC7*? H'5*UR9,4C;QNHY?*
M%*33/+ZI<\.=F$A12>'W/OX,64 !3@G+9\^Q>E& M(DO#6CZ\PP I^-1 (EZ M07^V92?O37&T8N MX]M;"Z@PP?_8,?F[?]UPEXF=)5A,X1QH\8F/K-_S.ZJ/DZ?4RU.I/+^]_;0
M<$,!VD"GM_60#0;(LGUG[*,!>&GX Z?2[=>]J/"V9\$N*L"->X,E5[VAOB? MKD?1,?KAB'8P? WT&@5 U[$DU8<";+9170#4MO5=V7XR,NN^D^O%OUMRYY59 M],):TAF
;M%"SC!&,T83/4W0*U%!@4HC@:OX;OB!WZT=)'D2N^NU?O81RW0OSC-+, M2LWY0V?D,GAGZ48L#?W(&>ASB+F2I^X>*^AJ"9]!(YH0*Y9]Y%B844U[CZ[
M\ZMN(HF>:!BEO,!VCLWE+N=6V<1V)(S^HCA&E>4CFR-Z=+]Q)ZDGNM8B95;? M .?!F[HQNE8+NZ=,*>C-ZH0"%*BXT&E1QOP1*Q$]=S=0@&%X!+))[K+5O8@+ MO4 48(MV6-
98=AK=IL,,.TP2\5#SN3H*8'"N_I$WP"1Q>9&QG:\1N;NI+8E@ MA9ZA]_6^"PI0/E+C!YSI4Z*X"RYZ@ #UPCA&&(OI_J@DX MCYZE(2@*$.]*(S(5=NBFK@'7D&0;A*IHR7G#Q7MU:
&WHH0.."->Q3,U(D"_%#-#^38B*W%.O:G.H5BNK<2+Z$ /U3S SV.9*9]?RM1 MA^)FR1Y$K]:6]9/=>_G&C63337%]\57O(&<##FF1(Z%_^DR/^E#2MVH=O/LHP M6/Q6>-
:#]Z$^CX^ZG7\MI^QM712@/:S]PMYF69N^$7)*@'_AU8F(JZV=A<.J MT%Q0#I'W#LZ! CQ\@ (450.CA]G\8H8.&1G2,C[]WHXQ=UO1XWUD 3W&AZ MXN5&GJQHMF]3 :YE0X:Y#\/
B"#-W0O?532/M7]IAP-=2ERGVNE" =)U\9B MAC;7_@ 9?DOVKWCO4G_K#]$4QKUT'Q1#$^(>^/#*R]E?O,&YZ M(V?[G$H#] MU@"F3L-/?(=RP3?IC.B^\DU#-V.0(;+;.6%P?/0(QE5
M0P$]@&=\#.%K-@;)<&47U@@OMWF/"E[7]"$6'%BU#E$Q9;VD_'S]YE#R .^$ M-*DJ$6%W.^#*U.A]>,J$#LWSO8C0K?
X$*VX3QA46";0>+/C.@8>Q10HH2%N*%LOK.49>A6/KQT=M(B1]-B?YNEL#Q[M.W\4N/^=B73B)8P=K0\[K:G=VYH[5;0W*5O9&#YQ8+QE MX.$6&6?I3!L-)IN 9]G9<34$?
1+C$$VHWV_DR&E3IC98C\/:^WQ4S,)]W@OC M:!P9I<,:66"]A1W.1P'>S50":JXSVVQS,4GM;!725/F(Q$9S=P!?![(UX'IB M@_F$WV9ERFXS /S]-*#WN@CYA%>]BK G)>?!P>[M
98A8=PKX]9I[RJ>V^R? M76AX75WE]9&+&7.Q<"@19NLCV4$.'S$L)H)(]PF9J"-@-%AKV-F<111P$ZT& M$DWO])*VGD#0T=FM_4]W,-M,:] 0UDA$S2Z#,+;=^N;E%
[)Q^NV/OW*S$]N MN#A3B- =V.:\N-6L6>S#I",ZLL].WM<8-8.T.+SK..0\<;AZDA>K@Y3;7F0BJ': M[@+H';,U&79Y54A.XWZZ&Z9W;H::36N8Q,IH,\DQ2709*$>')0_-BU(,*9IA
M.Q2\$E+\,:XWL M@FJ"5Z:#KDI-TM!D'W.M\$#O.+;#@[+D,"L9]A#.!:M^P<\^VR39U[I0YDP2 MVTA]"6G2NZ%F&XT/1&A@Z0M.=22SN$ZFV_/AM-WTEN9$)M_E MFS[O\?
@[YME@K@](F^%UG\25R J6ME% ['V(8A".3SXY I0&W[M/K1W6:S9K ME6CU<&\(O#H_V_X"RM-MM[@??<>6MH3"]A,AF'%> M\+IE J@E@F3=^8VD82;MQIMY>7OVI;
6=:#50A@CB,+"O; VTYP_H[A[9,2, MN*:+G""/H"]2PP4!*B"O"> .R%Y+8=]# 0*S3#D+9/A6%#3:5*.*V3MPK]!$ M]P4#;YNY"VW[)5^,QMAE2R]KTRSQ\0^A2D*YQ!F._0FITF9X/0K/2
$K@^G7C\0DG.&9;OFTNX]P9\ MT[,F)%&LIAAF])=KP6%&PA_J,-.4F<*IUG8%,%]2=D2!?8&G-.3]P%59IIK[MQ'WHJBKMTY8"U@%^WV)R*@/U,NC--7/=R[)[S8T"D!T* M;?
9ZDT]KR<+86O3&*TY(G.]\+64IZP_LX--U#@=T<0LEI/,_]]B%K6I4UNL] M'6$R3-"0%C"ZROM&C>+KZX*(8W%A5=N5ONVMA@=PD$*#%I.5^1T![M9;X6\C M/AD#]*S=%D?*CL
$9I]X<5$;ZA*8M6#6.\L"F-;\CT0PLC$ M[PR):30217X]$&=6S/W"GT,3R6_G(Q"\8EA>#8OXFNA&-\VU14!JP#O5K>^L ME_/H"F6UT-H7?6?
W9&.S&>]!+AW1X[;V^<]5)0X47PEX"8II#>SNT5,?"N7= MD8,YVNQU"DHSY4D3?WR*D<39M;\X&D]5M*B 8.LW&O"D(#]11<9G5]>^C^3P M/Z\&[LPMEAC(3)@+)&?
^S9GV)S:%2QO&WZT-N5I/==<.$WXKM"CBAKD@8GMO M@-&8;*2>KFZR=79??! !$@W[-+-W7E0(T?T1DIGDT:%RT;_;F_(C>N.KZ&' MMZ.%6EC6!3@+&1)=)UH/7:1"!'-
#CI"0,U89V,UC6[VFT]*5 [:3@/\P(Y^0 MV+Q-:$//4[B'0OS)T\]S^R7G^6#?-1#(6P"VQ;7O^DB*.E*2.GQX%W@+82@H M_ODB_%@5.5AQSW+/2+YWQPM\=K1L\.3X8LG;I#
[^]4Y]*%)OR1FM\[ME??EW M>H](!PI R4-UU F-M85@@I>> X].Z/731X MB"U$TUD8?$$R*+M7BY1NB$)N0<^X-M7_'9R\]&A%O[F6]7/1)VR_;_P\?PO
M0T'5I351LA&R3VL*/EK$1[YA;.@4DOOV1X#]7N0O&##4"6 QR.=H^A5]0*NT MSF<WBFP$]!ZUKA] MB3CH:$FR!HI*;PY^=M"M\R:%\[:4H "OQ M=M01:!KQ?M@ZW.HWU?
#"^X6!]TTB'ZZD:"BPQ4'[!(%>&WC@WO "%, ['058 MC!T1F>NYQ79KTE1IPNMSTX1$-&URY>V6DN\2P(:F.L@B?H!C&-;YW7/&)B8] M@=X#P3K$V#X,THUT%!>OQ;
R=X+LU5Y>\R+,7WEQ%H$"A*NM!C;0K"%)S_$G MK8HRS@VONB+>B_D)A6LXG(Z ?#SOS!=(-B;H+]]$V"'U%.^XW2,OZ3PI%%MT ME,8L2F\E\PMCN9D;_I4;\/F]=OY=,^V-
@+9=W#C N/DGRI5[<+3^MEFZ=Q)4 M5D3TDFLDWF$EEWNN]^ MNT[=JNVJ2X/[L)X/F>K91OQ$GN1##2YH=/Y7OZ@NWW:#L P/XP!B"Q_K8Z$O M:=55LEK2A;2X2K0FK^JE;
15RCI?2\^[9BCTU\0:"37.!7>4]]#U91>X!=+3 MR>;\B H%($>KMV!_Z&H[&])#%5$ V+>UV7D4P':F*@BR'(0#+H9B]PW77S]R\3[26KS)$L@X=ZN&)% M4ZWV(Z7,ECEDOO3?
G_+2XA=Q=8*;=O=&$?"-V9,-())/R=/8L'*/_,DG%8FZ M<"[5>_=NMF,,9]UKS[ZS%B;C?ILUN4EER)]2F>F'R6Q%=-E8//"(4&&I22S91T7V#&[R?"WJD3-#UBMTI^9OD&_[7K2G&=&
PDMC=3*1SC9I4M;8,DFOXT?P&>^QV"<5/Y4AC42VH.%M\AXR'Q=Y FQL7I6%=ZD0@AZV M9:9% $J^]O;NZAQ-+Y?]9<2K0[1?KS-@HPTE5O&(T>9^:[WJEFCG"ZB_ZC;
MD)\:G_Q-N#UQL3S[T,UF^&)>)[%_8H9$-XF+V7*SP0-7!2\):> ;! [=EL\V M4ZD.DM/UL;5G*N6G=11 2.WZY%D%6&;[,%D/-,L>/ZB1C;1F/?6Q[FSVVY8 M8Z.)9F!\3ND&XJ#,,N5L[9?
W2QS;5]4?5]M*[ATN;LY\$<8T5RK,RUE_OO*8 M^BXU^=ZW1GGA6G]OG\3@4HM/=+LYVV6*XL8:OV*^^\$F>6GL@D&0XM-,R";I MR^M^5(0?&I6L<[4A5-
$LTR(//$EU01X[KB@M(!"V\6K]S).LZ,W6X7DL'EY; M(KE55!+&/=*S\/)5X*U#(9G=MNM.L2Q4_ND64D^?X,194KJ'941ZQ<".91[G M.,X,] @_
G>LS[&=WX!$KM[:3FKSNKGTG(9V5^9WWPS!N^2.VQ])A* M5(IQ\\G]$8,#"3@318Y),_1S-C6=6T8-;IU9H,3M<<90LT:RXQ;O"UP]<(6BV5V?GP9\ M$,TR.
<%'YU1(GZ.U,L6>@E8K9GLJ @2/TP(0[TI6S$6]">/49#;OC(2(7N$M MR2KB& N8A7QY>?BL;O$0<[F*SI?&8W!=N) M\OQHB>]Q6:#>^=8KE\;#
(KFT<"MQ*WPAV$BY61&"9I@+AXUG:Z?_^E.Z ;NG M#KX3-9 ,;(D;GPH>XY]%2]4"RWZ9,PWGD=4D5V4D>BY#H)M)X',6!=DNB+\N MZ[#N\3>W0SPU9=N8K[7=+"DBZ^T]'4)O:
1'\Q1!'11XZP46Y),+-M0J-(43 M#W? M@\#7$ZU]HB>>^U7-?XO,@GBJQ\+OM&FJOSMDVQ(2DX'Z:H1-9P0+6-8WTD:U M8_%^_3_L??=85%N6;R$(*DER!A44$_')&40$!"3G#)+!
(N=4"@*2DX 2E2 Y MYYR3($@]H@44.5-(**#"*V;>S'C[]>WIF>[^WKS7]X_S?>=4P=YG[;UKK=_* M&[$H?Z$Y*QY;\KRD[P9UR]^0]??<7G0F58M#%G&F+$^$+C'&Q'0M3?:9A\-
MSO?)\7<&'^R5K#4'<>A]6W!^;22SUH7/MB\]YRR&;=)O8I>-!@P&8I><"(: M(%U?I')VOYADJ_WV2YA/.??'N M,:XP<0&+W#!2.O>[Z38$/99P*WF\)1>7Z\0LR"@K.,ME5ZRP5A//8*5
MLQ;+]#X>5/4*\Q]9M=]WB/B/A.?Q7H<&N 3 MZX;RU3X-94T6,6&Q8Q[I?WC3Z*1S+147-Y^I*$X?FSLN?,]167*T1%8]Y&P MYM,;3S9SQ)-CYE]-R!7BT&^C\5ZX^2^]S\N
H7A+).I;ZK;@(Z,65OQR40=M MDN@&^%@X%,RUUNZUZ-Z6@L1H$Q OV37?Y:@$*[*W2*#";?>Y> MB?"?D'7"_R9>2/Z<=V270LLWP6$(05GMK0G5*5[F]P0*6@H)#HRHC&!1(V[B
M3=L*3'HG=H!1[&"SQDD/_&IS] U8)'^PW62FE#Q+, _ O\"+Y M1\F,[$GLHEG"K>[E?-7"B4L_"A-A#AZY;F]J:K!5QV<"&8DS?-J<&$* &7^ MV/F&(I%A:/L,;;BK%B_O6Q A!K
$:,=&Y#ER(;B_& WH=/U4UVZD.PWZ'.<: M&&5W= G&WW*=0Q@?+K^G#-94>CI#%>UP6?Y!'RFFZP)TN[Y6HRLXGENA^'G\ MF0@!L;-=HIZ!D=V!.6<+T!9V+L?08/RACV?F90-
W)DJ,KA@Z]7P3CZD2:X' M#<#:8/I@ 1^OLM\4:,O/'I.EN/],F)I]ZB/;5\N\99#3]-HM@77(%1AO7"8^ M,[V8DG>]XO2C\/S>4TG24+#2O%\C.N)NC$"=K/7H]X]RH)85:#DB$,-@NAP0
MX'?%E?66*NU4",GJ7"]/@]8$#.(S='EU+78P'|'BY3G]V,10U@WX4 FGB(%% M)]IC#+>BQ]1T$NR(4 M:1FC80P6$L1Q.O^4Z^-0_9WB]0]7: MD0].D-
65H/L]_U/F"%O>.'9>DHF#9]MYOUQPV M2UFKIX",NC>^0!>P$H]?>L7\V-]H1@-N&&R*\E/]]%W?H8H=^2Z?YZA1/ > MKV(C2Q-N49Y*77;/]DOX_>BFG
(S$+;JCV?;DA$#,*IWN^(!>;4GE^ED=6QQ M5FN!7W/ C0]!S-M@'F2YY]%.CMV7(*$%&M>!W"72$#G1X]':^Y1]<_*:T%8_ M%$DLH?$.D_6EZNQIX,[P;+-;T4EG/V149>KZ8GC;T)
(VC'OFS'I$K+SZ_-E M!T-SY;R$B]XB*3>PEBF$-F0M=TB@91"[_]ZQF,5BV)50IF)"OEG"B#/20L[; M.:*C1-MHP#R$J6K*/Y9YC^?@]'Y_?H0GG0"EG6\TVCUZSGK!C<0HC9K& DH+
M#A9)$)Y)W;"_*(_;]14B-9?VPAQBWU)\^TN@9B=0?>F#_=]A]#R+"\@%/,DB M@Z?V6,_(3;^(PNKDX8^A#C0'77. U%QN"DB[S]%F(Z5=2(=H))SEY *VX&5(:V4NO$^ZU]
M>\6/L4+!#UVQF(LR3\$;Z<1A_O+"L;3B51\W[5N;YD_,WCR\8E/)_;G9\" M[A@0W;Z;NB5U.H\&R$L0"49W79X"VFTA5)9VN6ZW*ID M^K$<3$0,4C4 '^9'E?
JK.>ZAAB22/UO/.W*R7@X-TC#F1#'B$B]_7+-H(AW] M;7\%0^4L.U7L7E(T9.U).GJMRKG4TX-*=A(G(!E"$8ARAGFXQ;7@TCEXW:D6 M#0!TL'X1=8G:*,2F&-IL/S)MD4<#S*
]2((${>6F]$-T>?!!^0)BD1V/:GJ23 M"O6*X^)I@-\4/T>& ,4(O+Q/D)$\B+B&I9[*B[,. B9)B5LE[BY ;T+O&>Z M!?N(&?_FHEURK\H@8I0'&W-$7MAYPQFP>V94[=;1RHQ<-@!XR>
M=2184KK]T]RV#HK$+I/@R)09!LLV2]X< IS=!*@M&@:OQG\2"D=UTE9MK#(9H1#5#*4I@R5UZ'>(ZLC5]R;PA(8+'?$1E?KSLC+TP(<<\ VS|+XM+DOAZBG6]H9U%8ZNM5
M;).TK+,K0J:M,7CT>PM'0%%'^,<'"H)?]K?#[!:#^Z_5M[!#B[DIMY1];&/) M^N_&V+)IRUP.OYA6F J-SI\QMK^H-$IS4.\"M2VL M' G3IVO6,%':IR97\/_0[18RT&QY!1LX"B@MZ&Q'Z]-
>^NO)&(RG0@SUNVNTV^DOBE-,;W%'$U/S>$RKZ996\VJ- M4^I&*DFPZVO@TN,,D$SC&)_XQA139.8M+, MBW57CF]BQ]B*4,\NA%S]^5\.]LD&18&.V.9 TQ>@S4:.'HYY%
\&..9@5%!3 MC/Z1O5I^N]SF.H([3=*)%PWP_]\V]"Q.U2GTRMYVM]?4>)5)^77C,T/G"8Z+ MUF;NN/VP7$2/F<=Z)<*&H]!'E/Y<:'Q::LGP.]#KJCD@ 8PWH(5/C>
M6P7.VH5(\N]W!E\=WF#,$3@6\-:+D/S]:&=Y:1RX-&@+DLQ[/F'X_0/ MQ^E_SW%:8AJIXVJ,D&RQ/7^L0%\B\>0STT965UW+,^UE=5!"Q=ZQ!%D2DT>H M3QZ;R=W(JU-
<=L@9D,3=KH-RJBIX:3=PU9,4;N]\E\9^H?I9!NI?)"HJG:J MW>)>2J9Q'-2;NF'>&DZS9Y!ZUKEG]CJFE_V^P3#(R:WU]3_GGJ^);8*'C7 M=PH_"P>A#!X#>@@U^OEO4
EM#F9I8#.M&7PI=Q\^]4T5+7_3?L1E;WIR*H79 M(#2 46K=% VHCT7F&:=TE]_XX2WS+'7N%,INTY#RS>H=/>M77%[?XV,,A2;D MX!959"PRUNHT]_HQ@XVB9%)U
MD7Y"J!"3PJ4?DCL*AX$>?S?VHDMQPQ"R5.^O2,YPC.BC:1ZG?!V(/>GW,]K(HEK M^LD)8OQ77S#,HAZ09R.7$LX4?;TZO[%]'Y.&($1#=H7J=>)'O-[;=O-B1UW MHY&L33F,[6U*-
V$.ZYX6(G:Q$A4.-ZX_?Q1AN":R()QKYC*>*RK4VS]^;UQP MD""B6441"WC@*58-X5 F,B]93/F7/'62.;WQ.4;JD#.KQ MW17Z!F5@O93(MKP=6ZU >>B6U:;B\F8"W'3!(59LT)<\"97D<
B3.U3N<5&H M@YZ'5)E7/,TT0@,6[\3",YF_/VW=%UN1R:%7R@2?V,Q3E@4.KL&Q^T M/51< 1H@KZK\H&-!?]ZGISZ#EI@GEIF@XUC[=&/'^"#DN#H;;OIBX].@PO6F M1Y%QSO
A]Y4#,FT_N9Z#N^(RRZ5BO90N^ML.S/.]W*DD3(Z&.->>;^30_I1B M0O!\KW"'-]]>LU!VXBP;5U^%)%SK=!F]\[_.+<95C.F=*<[#T/#FRU"KF;_MM?$?(X8MK#7P_?,,=+0EOV?G6@
F;_2FH$#[^,Z(N*#,HN9_,M>M?05UEJ2 MDYN^#$*)P=ESOA-0QR(T]?"/XLELV M+,E\/Y3XV5(4:K47ZJX-R!&+K[274K6D]71632ZWF.=POVEY=7=\/]><.,4%
MNY$N[@2P4LY\5):_X]MX=G%_HD?=JLX92SP4AU2*L*L4;K-L71E0'FW1.XZ< M)JV1DV8>]JXFB:-ZL]-/KPM:B<7K?&$@V_TB3;C_,@CDH]KVVI^S]EF7D%Q4\<#Q-
7DD@=2UW$"*=2GL3_$MNB!GO/WQGAPF M3W=F#-OA'V@AA-WG7]RE>)1]N$I^:>!C9IGY\4>03P?#S@0">ZGGT#&.A?=Y MHJG18]]P33%O>K91\\3I222]& NBKVQ.]"M;=A7_?
O)H^VMT\,Z5A/XUU*(H MK.???6'ECPZ1;:TPO5-@T88 RK%WMIV#UA"-S27TTPRN+,XL$[6BDZ']F1LJXHJL/]QD^0!7PT
M@$2Y6'^0>H:+/"RZ\XR5&8,F0SS(WQ7ER5__:\LOV6H#W2DTW(7CN&Q1^3H'GZLV*OVH]'R=I:-Q#YG86B3Z"N, M ,O%DJ6XOM8_^\B1R_/@Z*6=X 9-QPC?
$[(QHX,@<1D7:"Q!=]%"-SFO G/9 MP,_7V&8>N6E=F4XQ>PA59)ZS>)H;\:S4ZU62:0F1$9Y]%3/?8X,AE\K<)D
M#R.1[N_;=UFF,+KPXHWV27@DJDM9]ZR=6R+_\]%W)]8KZ2@AN'YRQ(Z&S> M.SK7^0 4];?=-G$/W4Z.RU5+5,GA+_M[4_FVSAHUB.#6I]UD*T$2OD=BJ%IU MSY?VF_/9+>
A%*53V"?*:WW=1O61[_9IG6-TZ:_IIPB?X5RFSG^W@7U;KTIT M\$P-B$DEJ<;A;GOZH\H5])3-!?^C*!,BA9L,(]3>FU[@:&_6K@M=>$7Q9X6+ M]C5G;ZJ;&AIWTRN.&_6]?
AV_NE0AH14C]Y^L&GZQ8/UI=FN.WO&Y0\A]A7ME M8N9IC!\J)#!\F>K)B*@C1-;#YDZW9^OGMSR_L+L! HF;4V["2&/""9V\+HR MR2L/DY/!R5%'0QP^B0L*T4=U4M*;8I8G@
(FMBBHKSWJRAS =4<% 2! :L#NN M.PI=O#4'KY<7Y!LP2Z)6N-Y59L#*@.PO&"B1"H,P3O%+R/>X;@NV/34Q/H[C MXC'T7!LU""9]"A+Z>$LE<_[R']C;ZU-@?Q<%^_63]:
<'U./IA/DNQ)01<)? M!(9K:)&_S?BP6EF8:Y;K7NS9[H=.FH<\?8&O-B ?#SV_"KL##?9_Z!D8F5;4 M_4C_,&G&&-B ()1<"[P+3\6=X*JYY"0:<4] +EN3#HQEWE"C/AW--\ENCF96
MJ/E^G ,D[;UE:/AE$F.#OB(?Y_.6C>81C%;=COZ2\ M?/R O1:+[K5+G#.AKY5S%FF-A(V>,]TQY8#Q-RN/C2H:;3QJY@.2!<]LL;=U M'.]';D_4]NS.=$]UU3/&A]M"_?BY*7>4/@MY[\
[./E!N;^HY<*YG^4,A)A) M@;F$62=/=L6\OMG\L >1 M0G(]0\U#6Z&*;1.FB0/.'P;LI6-O\(27+ .D!R2A-0[#0'^1%5,<(V7B4)-Y M[;%5#"MS7'3H49508/K+3X)XE]S\(K4U@T2!
MRV]7NFKLZN0Z/&VY&,@+ .]O4S/Z>3M6KQV.%9V/"1.=S'<&(P-!.A-LR1W2@F(2]8@(EQ4AZGY*.-X].8GOZ4H] MZ[11 :FI^S]8]RHWN.2.-/>P]5>=;-M.V.EV52:K+KC
@QX2Q+K'PM#]&[S M BB" 5^6]5PE:RN+, @3/Q;5<0C:O&G R#5V4FJZ7#N24B?6:0(LTNO]4XZ* M>/W*9@ !-CA:YMFD#5PM]9'G92W)EVZL,-_8#&UINN]8_G1H),K\Y6]-,.;>
M0]I-X_Y,7_1,>M>,.HEFR9R!^:P-+#I[,@MYE>N!V#5!:(A#)GW%2\(*+OB MP2QR?8V"*>@$#8 _JP'=MC5H)N-ZO<=BN>I3R7/N+-*GP'0&\L"&,LQ+*X*(?*
D'>4"E2.VFP2RY?"7U>_"WG7C M#B9D%_Q@U#4%P;37SOMIS;0\['ER&&T.-'9'RIZ&U#FY>' 2Q<7V]N&)$>E&> M]@MPTX?
2A]TODN7P:1_M#OMA<20X@$PJ_+)N;OMZ1'&T*=&8!=WOBOKPM2CF M-5'P>*7X?0>_(6]>X.THN:-%*[W\!:87>+$(-94B F(#91_$(&MZ)SH=U!W
M"85"Q1_;5!"I&4.'DF_DWAZPKR5-5XE3H+,00/PG7I8=8+_^.O5][;9.Q'K(YX>EF7RTP&9E5MJW[7'>Y]A;7N1+D2%,K.M?Q[ERC)GC307ZL2]ETV_8W9IRM^JPC
M9T]FDR70,5ZI,7?W15Y[YZ#&@+YM,4U'?XDB M!5C0]+&AT5;F%V,2^A]NJ*$!L0*9=FI\ZX\SKX1+X^U* ML:(!]$XCS4!;7ZFW#_3SR@G(Z@P$;/4NF]],T_+\W'OH*%>1MH$BBF@!8\"
MSL+]+D^\?&$6^LP/G3BW/A?61Y]\PSUB>#D^)#,!AL@U)XB\3!CZ6>%A \O# MS#")ZF,,/V(S^%5WCR#3BPTW-*!:*PO7+$(*^Z.&@/[]QH!=,/XHK$3Y;D,? M&_B+N]$W?
9*7+?"B>Y*Q$P\,L@C=E>6[421*#!]+ XUDS>\AI9U[A]R(AZD MFQ8[+MD(C\/)B$]\LTH-,7"%2D,4,^S=F(>A,N/0BRS-J,(4?YVQ"NEZ%D=K M"5SIO9DI"=VGDV6!#S<-)@7G;RX-
]9E3@=N"E?H .H7!R^Y/!UHMFLOMMPV] MQ^=[,^DB(/M6;V4$R SQ;KKL>KMCP)5E M85F=O-257T'B:8(1-QG3\@U]ILVA@Z1X=$/HCW]P44[MTEZBJL2=%/5A[C-
FT1;1P)RN@@XFMC+6Y4D[JN@6S_@";:K"UZ+$]08'J@.6 M]>,ERTF>@_0WHOC2;W^B7?-G^&QOH!N!T/?S ZX9+OY@21YM-1Q6LV19(16' M,+B /TO0&$>-
OE4O_1;36#PL!%G85DEX[L,"*,%;7V]E;%D'X7O'=K7=:YM" ML' ZJG&G^5*X[U43#G]-Q.55$:$>>>S@U7W6OMLZA>_@]YR<859)4FE-JCC: M=^/A\WX3]B%C;;O/W^"&*"73"-
#.:Y0+F"F4R]^0]1U"->"3GIT7\?W+W"C M?8)//%UEU"ZH:TU(].ZYO)>0I!>0^VLN=<-/:N?Y/M2K&:NHHS91=LF-#"F ML!9=CW*X@EE3#!K Z6,N]I9@=D1Z@&8USJV3M4!
]VEE"I20#LH4GCS(7;-W MC]O*Z'%L$'B7Z,;>3QYJ-_#+F"]JA;_$V*\)*=Q?XA&KYL18S]5$_T*2BC=C M.A_VP/9C?IFE6;XFP)]G>RS%O/NQ>3.TWC??EIZX"49D>*"!O=T_6EHDJ]
MO??*\<64951MKTF45#URK-IG:6"EOZWE(4&,W=3,T4+>74,#]WQC28> MC N\'R^]*@>LD:TR"\+;RM[%F]46?"!*-ZYV^:#P_N\:QK>F7@FG4/3(,3 M,ZQP.+?TLQV_V^79V!->?
V>\8K*[A_XZ-;KKS\>5Y1U6 M^6:&_",2;E[^A?PW@S9N-"">X.U*OS1@ O.8HYE+T1B #-R%G3L,!60X)L1 M\(_(UQO\W2@Q#K&_8%6]RM9S5/]SKK>_\6($_5Z@6$/L[]G45)>?
G3SZ%S_@ MGY8KS>I9/&Z]2*I:U:R&;:E]K/2?FE+F/A:,_3BF8]$_Q?]3*LD>A\ MA=FHN_]9'LM?=?G4]X'.J=S++V^RHEZ?7*E>OV;*3 MT%PQ7R6B1,=$1Q>@]WF8E-ODF.(/<=5?
&/@B_T@DX,'\4)_8&?4(KNA]!]#M MG?'J5]LO&X)U%(3L>2 ;HW:BCB]]HS9B?O2I]D$SO&ENQ-<:6FNLF'T!??AH& M/OP;U5C3_^_&^A,<"?>) M#%#DJWX6L_=D(GC2DM8SM_
$'RBCZ4;!4EM!I+\-#3#Y-/U)EV]I3]4]ZS!Z MJRY5X)COR9-PLN9 GR;?(4$UI*KLG]'_8,#V)WN7!A5B\) &C MS3DI^INONX'^/[<03IX=\X&9EH=XF MW&+;%,K4VAR.J#V?IZ)
(K2,I6M>I!RQ W23]V1_^ZF /CLC+RP_B8E;.P*7: MNH V-V*H113CXP"Y70(PB/R3_+*"&S9FOR2+=Z?5/F_<5[/'9==42L)PDB'T4 &
M^SH4U>1;T=TGX[U_IH<6[VN>IK@*4L*PT)M[VG8X\M_!66P[]OG*APB]>B;%$->;^TM2C0!B=1BM>&Z3@7/>!B&.A]&;="%NL!M*)R@ MNN&/#+MY-^?
!82;,!O%ZYO5O6OHZS1-#+LS\+I; 7CV< C6@X%,#M[]-.D%8 MY8F9"-)-J\E(M3129Y%P#'].<[8P2 .D?HVCB.'9;&Y?N!4'3&+]WER-;Q^17,?.(4564)KQHBE]BS;WF41-%>4M1%2,Q-
/T_MD]68]UFD@7.!S'!C]^EG+2Y5K!X+MU/ZH&(K(HB'&U&8TUW]+0.]ZORF"4\L MZ,WUES]L^RQL08#?HS#PH52;<-5759V?'L]R(4BW?*Z7;.B,1E3(K?L_S,! M8F,\|:
M*Y;@?!.UB2VE;8S7%7N.C^8[6C J1T;7!H-X$.].@)$:WHV7]K(+M[77OW>B!HS3;GX*N@!\9.-)@=+RMC=5#Q; M=5H6\5^IC%82VTK3EM=0I+]%-_98R9#> MJ>I+
>_/LXD$6E.8M&N 4L9RA.!CR58C>8]]&26IUZ9'43L=5=S:=-A)[09F. M.O">UZWA%-*[T>FX"X9WS$X&[A5!0(,=>]#I-U<)5FFM,^ZR610FVX',L%Q) MP@ENR\I:/QI"SA,'<;V"4S5TC]
(*Y]-='&6G]BVBQ1]R6XS0SFUG7" MK83>H-CGO7V_KOO41*O,YN]["8!H O;ZV]1B<]P2.*8X1FI'S[E,,/RVG!UT M?--AS-Y]+/KZ+PG&NE<)U?^>>XQO3?P_+MO8C9$EK8^RZ2T?
W!?<=SKZ=9ZS MYJ!R:*,H_5@H%@Q9B)C<*_Q*6N_[GJSTX-+=BU*ZV(O5 MQ:\-]L%21_>8+BX3SSDUX/H2]D__$6D)//ZF&)BMTXP&FF)VC <>&.KI=!^+&^]K.O%Q!P*U4
MKK2<&62L:E4H9&&#+?*L+?<(1-LN*U:I3X_,?X,0,"\E-)E6C.!8Z@TN%IQB M,8O['."=Z2O%=799CP<*8]/F<"(4^]>VOW7>"9Z8Q4XQV3KOO5]G&<_"PO,M- MX#GG '"49*
<"7W'0&$B%U@ !C>/'FYP&3[^KB#^^WE58CW;H-N!^9Z$]Y,[I MZ'E8UA&FODEMJF8O=2H[LG*F<\R?:GF1>"$@Y\4X-#30A8/O>3EHNP$PZV'IRD%]]>^I5/E'_UL4-FF
M/*$C2*Q.A.Q]-"",/T-5]V;R@!.GWC/X=J,GEOSEIR74'7->^?Y7_Z,L(O$[M*>T.M SM'/W'O5*'01YHI(F'Q:Q:0/8] %$@+SLT'E\FE35L)I6(H=!QW3 MNP7+/N"WG9]DL5TUF]G+
M%F(:WVM^F&SWK5_?TOM4Q>H=K*.<<3QK%)8G!3F5%C#%DS-2[=5.\'J M?QB@%-U&?0025Z&)^2P1(RO/[M@T]G3%;_FL+.M?;UL_(^M8H-'< OA% M3]K*ABD%>
TG6HBL5EXZ<;"87+/Y9>5(_Y(]03=FKSD?L+22WI0I;L *<_ZT MQY1DBGE+5^\@"8]2MT)YIN3]^BNI2C@"&2CUFY,=D.?PH-0=$B[QD'I4L\1 M.%_B^LD\R]3BP
B9WPVZH6^_.\'[^8O7]SX)XI$[9_KOD!Q%V9$5533\/ O2 M++QEFZL:47Q108_MDZ.S[2!,%92BQNWQKZ@;E'<7,EL]'[2PY?*)!N K-TYS M>A26UMM3%EB$ G<%"W%

```
(:NB96GQC3G+^>0N%_/F_"/I[X^DO[\JZ8_#,ZR! M,^A?W.U_!X+^CXH05\;1W\BW O]G?X_"82WSRU07622@?PMG!!7"J/Y^)<)^ MDX=\)9'_W:-KG]-X5>'B'W 0KM9.'E7>_JWW [0-
D+^[YAJ_6>N/VR[_T2V M72FR3BDB#V(_QRKHB<*RX4U W"Y#5250-6L1#.+AU+1ZQ;S&=;%&A@CA,2H85?.!S+SG46'Z[0?!*/Y?[@5FQ^0?ZZU(58@# MT0"9DL6S3C2
]K=/NYLY'QZY9,TP"J(!G\%.ETMH0#33;YX\W=6'*?\B>?CT M-J=XT>V;'FDHN-2*_"_WQAGD;M?_(/ZO)GZ:>R6:KT?'%YBSW78W42V\+$E# M4$-0DHCN'.6QX]&%T, (QP<9:( I1O?
[5"O<^@S\%@,L_M+K:_QQ^/YIB#=J M#^9O)S'N+V3@Z^'5>]O$P:;-.@PZT"V=_H\NEP4 MN$S=0(($^(]?.FB ?G="=C>B?Z+U^J<^+/_SB.?;E.2G/**"I0]_5I'K'N@' M-
QY@;P6RM!RB 6EYWC'*DO,CYJM%"4(NB29Y?[[WD-=WG4FOWU^"QK_]N\/ MXO\O$2]^:3 F;DH94J#@ =W*KU>RH]53S(*P:2;M++AH(5ASO;]L=%-JVD'8 MDK^.!9]
[;N>^/9^70+J":/>O[!#WRLK1 !--T"9N=2 3:"#Z"Y(%#1B+5KFX M-?>^_2^^7-ZPV/_G*_M/?:S^!Q._GOEP#*$-7$Z;K24F'_*Q+VJS),C%.P\5 MNUA"4=C(C/F;"@:;NOB7@RER=?
^5.=M#UQS#W M>U==0TSB09OW,HXI:A^C 7^<]_^I6_Y/3?R:B>!XBY+-\GJ*%HPEY11B'XS/ MCBV^--UH9QZ::$E3__@-KTM41G9+.S0,$8Z9UG@%5;MM\!]FW/<9XS?V]?\E
MI^RW">ME5;^)6+#K=V>M_+CL=$Y^"MQ"EEYRW79Z3$H*"K?COES]N/20Q. M5%W5_FY-*O[4\N:E_:>?:'F1S>P79$?$_TVAO__>CGOJA^Y_V&RTZE[Z94S] M6T';_^Y51M73?
J31(H#: 1GL%X? N!'ORPE!38O@(K'POWWT/S_C7'3O]\6)0^KNC5E_Q6A6?_52_;/(^)=KO:5<:>+]<6O#6A 2/L1&VA^" VX MJU5'I5G[CW@-*_CO-RRL:?E](*-]*CNY]3VKFN-
2.^/<2!QM;LS\\85H0$/6!>W4(CYH(#\7-)UK>G&CZ/+>ML.8+ 7S MW]OW+#SZ>^VNCA9_[QLG2WS7;^3J:FJZK/\:9X4&&$U) MJ-%?Z"CU'3BL1T3XRB-]9:^&FB[R2_B[N7K+J*
IB#?\!Q"

3UJR/^RV-1 M3D-FOX=^X#VP5 4_1X;JP$]$1GOS8KVG'K<1DZGB9)DIE!7Q+C4%685Y[T(% M1^*7!R$M\L3AQUEU_<1Q.W=CGD1IQQMDR1>LHQ)?##<:+[PG 10E;Y7%OVV^O2GYD_$K MG]M#)FHG+7S[-M3R6
M]6F2&,*ZS[/^A2?!3TM4KAHJUDXTPQUV/&137U\7P2PQ'[_>5$! (DU_C2>Q M'S?2EF/,JT97:%F5;+ ,639^.FFP+>A49_MFZ4A./C '[W C-5(7)K$U-2]W M>)+N50\K.X?
H]*C%/G7E]06=G'=5MX:Y%68WS(/('0RL2^VLH$!)R(T#.DLA MRMSWQ"7ZA002%2M12^$/:L[-32:E@5W;E_',"R.5!OK15(G@)YG)U5$SVB[ MH,Q4!NPO6[#=L6@[9)>G3.)-GSY 3+TX2D.S].9"B\^^C:^I,>52ZEE5?;V<
ME4Y+7.(=AAN ("D22.3UD::(]18>:'AM9/,/(;4:0V/% >@SN842O]C8%RX[ MDX$T]6T";=6PF,_9]R.,SEVX9YG#53^RY*E7] O?PG]I(GKK]F-@*T4WQ#NQ MM^E>0+/.V&Z6BNXU&8>[7!'>> D!S8'ZQ6TL,-
F1M,\S#KX&\PMZBCL;3AJ& M%NX<08]]@S-7?6G]2[@\W#4MXN]'L\@MQ&"S,W26>76E(@_>9:DU>2\I2[(/ MZ_1JA3F+##'TN#-_.MA3[!959,N.^R>2R:X'/6)#Q9S7;G)R60?)N!<9L+(]
MGT%8>B[IIH*ZI$M!WTVNLAZNF2(^%\ MM\]5>S?KF2T:\)M_P#R_#3;_&DK&H#":8>#/2BF!QG[L_98?R /$-^8X,\% MRB_P%]& ):4KP'L8YV!Z3-6.!G2D8##Q2';,\U-B.\F# ]#Z?SXPN:M\A9_" M&<@/#>"31Y$2.J""SM
."D:L"*/8*&=1EX_0 ,.[Z,!?=4%.0D2P7.JS9>+ MYZE2OYU3:OD.N'V3&X0&O.%&"63(TL?O,HX'+$+0@.&Q/YD2\WP3MQ;]+\%F MB)L@6,DVVVJLV6GB/NH,91W[VREC?TNHC;H\BQ]>39;76?M/?M"O4_+_R8*+
M1H@PSTCD7K9C)OV8\RBZU*3N/; M>NR=9$*[CV$KO!BFTQCS_2HPB:,H0$#NN9_'N/F M531EE/X#N 4V=\_BT<-M-.!D30CUVD%H^0SQ;LYI7!5)/94'=3JG\ !='*6A M 4\$T@XO4<^
0ENL]"C[\BJN?.6K%.&_=P3^.N+W[2*%O]^Z6'>62M,D@JV0 M^N\='M7GKX;9 9'VG180N%7IU[C%9,3O?*/I=\?P*@(_Z#^/P+?V_I4(![#\ M+\!=)W="W@DG<7@[7B[OQ\P2&S9+:GXC6P#%JFA6[,F>G^8E<5A. O6/NK[*
M3W9&OHD(R1;WDSS,[\L/RON&K;7ED:LBR-;]M&]7V]6+2LABVK:,$CK:ZUO^ M^GAS)1-*:&[SP)/WG$N-"D#*DRD8X#M-6,X=)2YR"MHC?'GNCYP7-!4+6+!I MOWP:0G>"Q\&X(>L-
RY5LM="PE!@^>Y:08&HG$:F>W>"HS]<%LU7?82Q>^83^IIR,]U5B^ M03@@[DQI]L09NA:P=YVD^_:TU6;+/>X&Q#@YDIQ MNR!5QSDW\3M9KRY'[> ZN#]OS"@_!J')'5K3T/:UR(E+K\2J[^EKD5>^45&Z
MUX96/KC+PLCLA8)F ,LO-L04.H 9/*-KHXKDCH0SIZD<28=,X7FP!_'LS6Q. MG(NO0N2$L,\,&9I(X+H44#^DZR648B0ISS[%Q='R>8Y2:#0629 OD]'WG-*P M "Y?),5:L@DM;%?W=%RUT*B%_6%-A-/,FC0-
]:BXKOF**FE]J+NZ^(UR#[YW MRP2\>*ZJWP-SU8=*XXPV-\LH%?22BD03YNB-V;CJ/HSM9(8]%A?>"""*&^ @ M:',LB=Z"3.# ='*/U>3UG^3'P@Q'1"[]BO2O[C-7_:?!Q,N![* !,LQY+;^J M[6'07/0G'V!0R:Z7]A#B&>9TDVF@
76F%P(2:!1] 10'9.BUUR)V;4ZY-92-E[;\3]XFQ MM3C]L#YHNCMU),]OG9FE)Z^JS#4^,9U1]!#/9$KAL]X(K,>.*KR%AMZV(-*G M5EL.@ 7MN)8+?[O9%!OZ;(.RW0G7"+EPK15TS4&WIXVQ&>Q1BGL$>4XI(;GR M[?
WS'DJZ.$0#7M;[DW[[\>EC#E,2.U5SKP;VNV/318\WY=?EOZ=R5QBZJ30X MD+5#3W.!Y]*6Q<[RRC,O;!;SS[\I4,:NI DGC\\;523_P.U)M1U-I9]F>\[B
MEVC(2'>X8(!#)C8RK7O&V;:^=M%XS!B<]7/VE<2(7U<']&L0QMXQ6HZXH;5( M\422-"I.N/F%GW^I@0%WF./Q >4.;7 M=F9V\);B WT^GKO.6 QO3O(]AD. !+'A>]&L+_2)+T3:5(4D>(*G#[]Y 4+5 MODKC6)) "G8,9.N:\Y3S?
P2O#0A;;>>ZWC@K>TE(W-=DR6YE7CKSS8YZGFZA MS[_7I'L_?64!];Y>9EOPE50?':C:T6Y266Y^B ;J58'>'!N )OA5/ MO+ 8 Y'?ZP!5Z@V)RJ&FAA+N'M5S$@'N2RLT($>C!L%[#:[['"0[+VY@NS4 MGRN++-EA)&B6]?
4QK&RN M-[4!*_,1QH\D\^\O=^#UM),N6:RJ;NEE,M3""$\KH;CCM=ZOTDWJ,Q.>E@U[ M"1+?66GUI-4-V]_U-RW>/AJ\6=^B35)4N< 3DT.]MZ,MX'1S\4O3W&*8T_C(
MD7;/UF-.^E:)&%&W_@D*W:>5605PF5Z#+AG&G/*Y47K><+6 ]+L$$E/2!THK M\'%34KBXU*+=]%%'KS)<,?'P]AQBA/JO$>8:[KC[$OZY XH7:OM M_N$)I+K45BCYZ$GEUAGCJVRY.Q4+86L=XHC\,C&-ML]
HJ!UJ)BAON,#8.6S MD(4+_*]#],0)B-([<\'4SF7K(B!81&]NQ6U@B=XF1LRBWG?7<2^GI3H3;/9" M4VZL@?&M&1H@"CU>)(#7/WN[->=9:X7,O'D$T0M/$/_9M<(0H"+"GQ3Z%4(> M<\0=+CKI&S)G;
(RO]?/!LULWSX4!O@3$7;D3;^57),LLYQL,V&-9X76R$X?? M;.%N74(&5.$'M7A-AN]8WZB)5?)6(_(^OJ&F,>LOW.;(2E/.TH!7EN K]=Q<6_W4VT+7TGUK=TGN5_-D64VBM7"+=]=Q&O/8![S*W;E'3T_ZN
M!OZMJB_>>;=&^&K.H[16OM/3 OM#6]3+WMB5[5 6YSL1LGC:RBABC=R\8W&" MO.ZI(+>.@IZ^BS5_\NV-8 M=)!:B\MB,M/"\A?Y=^]@...:M_\T9:=& 0C :\&^*TT6&$ZH]M?!5SYE8$5MV MKOG?TF3:B#LY D-?!BFOH(P]O,
0F/Q9:X/C\E*#)44TH?H2'^ FXF>2 38*BZ- M=$6LHNY!C&;@ZNLU#:D04Q%<>'J.12;T$ZS_]&T@:?UD"3?7I\QIB\8(';K) M)88.1I_.#0FD,G_0AHVLYGCYA-8XD#MGV2;,6BO1
'K3BP)@3')GY@M7PY5<'!K'%:76WN*1CL_&2\I93Q..:!4OF M^I>_W>[VN^HK*#SKB',>#9B>NTHF-]$T*87QH62;01>7IDBLG:\.TYUH /Z! MI!LO2NR_E*C[%RXO22R8T$P9U?-
F,\YUIX5&*9=1I\\HD,%R0XLLU(&&#^L++XN M'$*NKF;_AQ'[#R/VGQJQ2V+#^5H8\1NU7HK/DE 'SXN@DLI_]7V1M]T?EZKW ME_#)#Z)85;-@<3>39BKH7]$]#=]T,;VQNTS9%'V@/U1BNE_&=Y%XH5DN^2@@ MX0(Z?
TD%2N20;][3&R'BBT[Z"C?LT36Y"78$'I1:\HC<=""&F@SN)CA9RN0+ MSFSET.R3Y/XNT$JS5W,IHK&U1F1EJ^WK,8@G#H[VFXL/(+KLDF3#(+DO?7Y9 ME%CL)E[U6BOOD%B!OF/EWCM+R>@Q_; MHD ? VUB"LF:*63H"+
(C*MH4GWI__1PTTRG"P+?XIJ/8D^FVN$2^MTX?;L9& M8^BX,.3'2T>].SB641:8\Y[ARD2PQ\4E;DXQ_/"9X.8>.UX4;Q+V3^:CHLW> M*<9VCY(M'4UJQQ,Q,9\G@PHV6]\";A:^.]%C>")2U5K?>#.ZCT;[=..+LW<9
MR/B0,@E*]%R^O\]-JJ.6^VR;"GO[2QE&BM9)4L$+3L.\W3788AI+R4+W88/HI /%N1\D2 M&J):L\YU\7[YW&'9LCV<0I+S>7]/'48UOC5;3%SHA<'2)F$^M]I?6X/3 W]V,M<>#\6!,L7+]:;N=.;W^MK9;@D2X,!KP&ER,D!_C
M/"C;/;C>0V;X L9S=,8!?,E[XZ3/AUSP/.-IX"(!"M4L#[?OFNTYP9+K+>" M4@]S K<_,]_A2E:"KH;Y<' RQNH'3)#["H'BBOA]-V%S_?9\P]Y]32;QS(G MX.DZ24\BKWN */CMZ%0F#O96;)34S)/"6-C[Q@.JB"6AF>&?
W6UT<[NBE^B$ M7V.9*AMM9%;^1.R,2I+Q,+(V&QV^FLFZW)/J*]?W?UI9?WAG8O6GH4;,S'SV M[KDOA6;6DX9ORH6OW0AG\DNO7^Y"M;TOM=R7F),0C6 KB?S; M]2PM==GG71&]DPCC3UM4N) SC1B1,
(BLCFN[V]<56"D=P]-1S3HJ05V>A:2H1FOJV7)-3!RL],55A_VZ,%1_I0Y1/C>G7&+;2UZ=8S43M@WH^29G%\28#]H5K51XS H.?W]IZZ8"/<"7M&HR" MVG*"!TKM!T"D>O)0O9IK5I>6\1^Q;AZYL]*<=+!.0-[B,%(?;GT'[K,T-
@9 MA*QF H?A'=;'V-\M4:#7D.P(Y85K_Y:WV& :VK[MT7Z!LM\O#H$[H/(-,6NZ M7F3((S&R_;?:@'Z#S+RTN^ I*$7=T/8?3CO:##TCVPW=WF% BF(3&M"1A>]J\ ": M:DR)&R_'[A%2&O,--8F)#WJ=?
V3/[*;N0.Q,"KH1]$NT)R\^;2AS@H(0X:/_&EP!UD<#^I/: MD6ZF:TK93)I1W8I/C6F9 M25T;/*?A=EG1R78XI2]\E;L.CWKT?DRF"H8WMWRR?+>V>CT%['UUKK* M%H%EN+_$EQOD!YDO^,=!/JUX%7N&
LM0AX>)$Y8!]+L7=VIKZJGI#/SWF4(K-^ *UAS&5RS\X3(] -7O^: "K5\IEGW%C M7^ 68U M6YY+TFY)Z?$.6\D>\]%2N&>V(ROVMD\1;7LH?X"O[=ID">(LVO/S M3V-GJ246G59R(R(S?_'#@CO1;"X[XNT(;:=9/0,
[S),KRSC*8RHY\0W\HZ^'$0M97)7LOR=T\KN-4()CIC3@?Q4"&^X?(X'0^ M/F[DD8]4XF9!OB57V9 M)%')CJ-?.F0*I71Y//YR08S*M?ULQ.5"5YJ Q[ KKI-6EI3@X;T0;<;71.\O MV']45/Q'#?_?Z;0= L]#_^XHBZ':K_HO_HM8^LT'!?
NLE3_49UL19YH0P806/0:I+)<'Z[89QWB2#7])DI$\ MO];$*=8U]R#%MN[0#KP+Z!.O#/.Z2!!!:0]_OI3]\Q'_KKM'"6H:N)Q1GT"= M.WUMWG92QHG0:9),LW_$_1\;/AUIS**C^%X'13OU-]B/'7HC_1SU7Z"A_W=?P9Q';^93@#S
MFV.THYH>LGEH_+_8>^^HJ+8M?;00E0R2,X4"@I*4+*E4)(N(Y"R@DK/D4 J2 M,P@H49* "$7..>><,U7D6.0"BJI7WMNW^YS3Y]Q?]SOG]NOQ>_ZQQ\#AKK77 M_O9:8]^".PTS+M%%#3;AIH,C3)UA6J;F4 M,?
LXRN5U<+_E$IFONJ_)GB!6B&7LCQG YWDD;14.AIYW"ZL_Q7#Y7%E.6H;% M($;DQ?!WZ#4;;I1:\K>ZQ&/9KPK<6#&6:"%[V+D7.I:82F\6=VY=MJG$UEDU M$$.(5RW38?@11M/A/CC$M5@!WPG[;@^)YAZE8&%>=DPM4%
[3,VPADAP72WZS M9&0H= ?Y:?)_<&B=VHLU:/\/'6]FEO@,5-8\JFQR9.EA&'63!>A,@ MZ!09;V *0[2LFO2USY\6 7A=M^-;W[]$I"Y-P>A?1>'S$\.X0%&".&'?H:/B M;DLSVJ,"?':;X$";+F"$@CFGKV 6(BJ]#6/$9$?
I%D0N7LR@MFC;'9[9(S15 MS5ULP>:48]_SN,@*EIW$21792LEFZ$V#Z*[4$+]>V6]@M 5=1;SM]RF9UIF9 MA7N!Y$G8'8:-:NOCOILV"+#VB*!NLI+ A8R/'/N,71\=Y!,R;)8\M69TC +Q
M/KVLKO5[A=Q@KQ$I39.;EM,TU@.DO78]<<,R.]3V'(F"]*/HM'7+4!7N0[YV M%=<%'QJQ]OIEPBS ML#CO"_^3\F!KN=V>59IFVS=&ET.;_..QY8R]9BB6]961':KIL.\|=B4#MA_8 M-_$D+SEE6^>9 V2&:P?N;MJ6LG I6Z25)]?
>?T##!*T"4R+\#S7@<\=5\/8T MRJKG\UZ#!RB! 4_1 -'UTA>Z2V-%K#&7R>'@V>S7E06.!EC[KVZ8Q[FK MC5<7R>P1ZMK,$5](TD$#CFA&R5Y% M0NONW>[#"+V&=B!NOWI8=>]$'6R!(. MLWX7'OXVQZ!] IEXY> -
EEHW-F.RJ5M$G%BCBPPF^]\AV+VPIN]^D/NO2N-< M81C^0#P+.^Q"6MCZQ6GLNYKO#M_CN?TY=J&*8-!+%/5V.[;-T>7AOLUGZ)W7 M_H-]E*U2O%051-$8;$)*!+IYZ+. M3?0'@3M*5DV[_Z:M_A0S)<- K "?
N,B_M*S^91A/SNYM%W59E:%MP3?EEI/B M(];LGZG[>\K]7%E 80;IF49[MF\]B&1V^S]Z;=#;/*]+Q\E6OP61(G2&RQ(J4(F,WN+8!C12G/^+HX7^/UAN=8]_5WO_ MA, H3S^-6O4.:0;)L9G'I?
*!Y&K5WA57TXL7AQMS$D6U/S1_W.AB-L[0:2AF69$6_,)&[/ MYR4'=^;E_3C)9N$53?A_5<*E6/Q7X21EFRG+7]*#[Q#^ M%7$K_S4*]$$2*H"SS_2>[>.S7-'*N%LM88U,$L5XM/F;=U4+^YEFVKQO%I6' M3ZC "]
(DH#SC<;,VLJ>L5["E\_'N)4?[>.$L_!ODG9\U7T<;FT=.,<"LNXH M=T4&4*Z7JCLZ4X;+/MZ_7GF]<:Z1O;3U:?7Q"]TRF@" UZ)]1",P.\MI5$4^ M= 5IN.3FE%71,+)Z(*C+7XTC09^TB)( 772<$+%I2QI E[ 8X_B\2*'=7)?
M&8N%7@&IZM=1[,UJW!-@--0>XUD3/NV]Q!#E6D MKT*",>]N;1J-VS"N$!6=V[4I>^4;8N;96 %2/WT@:Z9S ']9::4HC$;HH8,H M]J7E($=V+Y5(+E(32FMLJ6B(;RCKW5,JAP9LQ@9NU= P>UD:-DL")9F&:C\G MR;N)?
2Y@99P\86HY6S[-W[RCQV4O>:6HIF14_/&$1DEC\=QN:_MV6%8%[N?CUC-/!DV)T;A$E\&VL+F_'4+]VC*DE4+[UK2IK\;L=& M^.V X(R*\B[UB$F?88]"L$(;;*K"ND5?AD MSSS;50_\/GZ8__.!4;'>YG6G/YL>!KG+T)U M:
[XM>2JB 6R<+8:[%"_]8V?S[GUDEY+/3^_Y^3E"B MVYR*\C?ER>QO\D5?OU*X32(>#'4O:6\9'AX;H0%@(!H0"-%(+\\.S'TF7O3 M\N6&>KSXZ;%X-HHRI0P- &D 3_?1 $0PZ#_]I/1\Q7"#!@UX,[B-.NS^39,9
MO_GYL07'C]MQ3JR)!_;^"XU"%*BC(L$_F_[9]+^\Z;B%I;BO-C?TYJ:Y'ISU M6K45;>._3SBFN^/E #GR+]YD3)V7,K?Q^36]<[^* KYUYS]8M= T;",EPV>. "O<_]P7[_XISIC MZ\E?$7348G@LNG
)%OR1S"](!]CF8Z3&H3KWIY3_N_SCG\_*_9WKIWK\OUD] M>CY[V4#LY//L>F?'VJT)7;WXUD&2EGP3%M"M?SL\O8/RB^MA2YPDTTB^#6^W M$E$U"R3J9LLU0*A?/A"A-4^%!GS!6,%&-Q B8;V696F.#-8T+3!B=NX97??Q
MZ>Y)CG:02K0\0\(T&O#!I 4-.+HR H*3@>!Y-L)LM^W \*):C"%]Q((&O#L M[PN F]OA%9=7(U#876A ZX0;&H#;$8 &K%_["EYD!2_)(EF8,.[P"]5GS/V8 MI_IQMCJ;XF!&)7WSPA$9"$'"C@:0RR*Y; G
@QCYLBB>BE1R286'NH)1[W1, M45=D413@YOM+;, YEGDJ @^(4"U^]R$!OSJJ4. :4]_[;=/!?Z]18.;;_[T M>U ':B&WB+_?Y)Q" Y9HX&C ):!T 'DU LDY4,]C-JWO[_M5WO3K MU(S8)N[WP<8E9,AR%G#(''6XP&1.#%H0%
&BDK8KV&=%0QG M4D;=KAE R(B#,$R7FQ\-P,*\,S[H5\W?M27[WD_RJY]$_,8V[_WZ%QR_,].M6+6M_T_N,W[8:TLKU$X^?>/S_%8\5<5)H'[5LA!KU MQ!L6B:EHT)S8:R_7ZW6IOVVM]F+I35C6@C2$ODZH?[$CAR\
[\4K]T#]?"*5\ M'I^.RT^K]'/4_<3C)QY_D542;* RJT@1'A*DX>G1F?8G!WV$V3A.AJ8V_YYA M:A,5BL=IX\6?;ODZU6'+5_&9[&$:$/+\.I&:3A4WG^&?Q?KK_MV?'_[G1/B) MQT\\?N+QK\+#\B-<-D1
G]%)Q16#M$2L%K9KI#=@]')=';<3_):"P0]2;3_N-+4_M 0?SS00KA.\?]!/HG15H74',C@Q1F,D$_?T$3A'T($>C@_>X\Q+PC@[X3R MTM[ZMMDZ-:O\D\+_I"0_\?B)QT\\_O?@<:CDV%%/7SLH2*\E>.50R9+5'A+% MW$/)3!A[_,V
9+_@?9:K1GOW":+#_H;7QG*-"4^KPW514@-?*(1XW! MD5XY7*TH.6IX#.O%C44?G.O%*HS48FUELN[T"WYHA13,IMHW;=O;.?O+4>E MQ&I[W.Y?=?E3CD[5-?;_%G_[DWG\1.(G$C^1^!] PDTVI-
9ZZ5*U>6)U2X3[Z9I#A\)3Z@=$LWY"!&RB9P:UG.KNDARTW++$3(E_7Q M%*PQT_)AJYN?286Z&(LY>?OK<&DIPW@F1.B2;E/?P M$ZO/83V!V5.NMY<*QGARE^Y>&+2ZS]'6C1 M>Z6.7 E@[OR.$ L?O'XK2*>
[L8);19KRVK5?Y:!.:.NEMBZMT7#H]7]*4 MPJK))QL6&\[(!$#G^QC7^)"R1LN V(8I%" R TX",LW5*))]N_+,' K:(= M?$;]%G*!QXYZ=[PAN+I BP8LZP\W;+.FGF./24%OZS+%2%.H??Q3YV:M+N V MC")"4,U*!C$&UO"02^5 S
/&%-\HSOT5K<_SH '154LDIX;G$YD3B:XU*(6U M#Z Y\)8Z8U=<1^8P_]T[;Y@Y:%E3 %D0 42VB[UD!H8UD"16E(R4W>F>>YI? MX>"302O^TH:="38E,[RRFL:\<$*U*OC6MTTF,3]_9-/"57R=P@]62U>I[ M*):&:N2C7-JH>KP?
$+5B#HZ3KF>8UQB$%U-.B)";I^0 MB"<63-D-F2>([#E6]0'=Y6I>UUVXL>'N#3'-TM=W;/+1(^I[??6D9HS"SKAYWV#@+:'H&3.^[/CPX([_:* 2,V MGL<5'UON'$PY5^X<8J4VE^;U2Y*".U(#0=NW?
V1%90RQF;Y\MLXI2>0A6U5S MP5:?;\(]@-P/7\(,L[U(1[WLMJH"8[@Q%[^XT,%46]+F.N>UKP8 MO,/W+?A*65LIU?CI38K) 88 S_S(1U>!]2RY:P6N6THR4*MC!L22EN!WG;XGE['VWWEV:6U&FZT[T)Z9Y97]8 M95R@]/<*>?
^]M"N($$(6!6D%GY!9'"4'B@08P"0./NQIB[5*O@Y>? M@(Y/V0]TLN#%[BE^?W9*_=YEC&A /(W\*!TE'$Z6LT8 BB M4\^+,5&<^FA H2>&CG/G<2ZY(&.\6"ZGP$>68U[1[LE>%"HOGO_565Y=GO^6 MWE_Y(U%+MBGU@-4,?
PC0;WC%/M[SM:/I+.A$!U)PE]:4/43^4T;C"EF"RMS M<'Y<3.#]&-03:LQC/J$!^<[G_Y%44AD1FGK W'#IV7%I63'2L$QKC@;HJ?]( MB%%>>G+,-?2C,W_2+^B(UJ$!)QHAX)PS ]LI[N74GKD*YS'NT,-06#Z)G2XU
M1P&PL8$4M"107U..ZKX 3D');"YD/]>PT[0/!<_L@P,Q_I\2?C1=,24YME+- M&[MJU0\+KP1UAXA-\N0[.@>OU!+!>!%* C.)#85>$9V)W5-K;HF5. ^F)2QS MT_+,!'8Q@X09GP/"/N3-;]D3T7IU\$W9R/A80>:':IFEDX)M!T/:1>>O,
<8V M'=]5#'1A$<&B$7Y(]"Q^R:$[W5&*7 M^>.>" B,?TGN^/L9CGJRK:DTFTS$A46IRO[C&I6Q47[-)0# (V1$F<-7@UC M'>7[Q7R'M=84T](Q"!E%9>6A,!>S'_VKUS178X9DW19#?>L@CCY9W,^6:;CKP_.CZ2\M?.\H?K\
<38W2@7 M!BT! ./M[#, Y!E^]>B3L@TZD+"/^;G?Z\"1R@AX28 MVD>K(;T]7W%MG-"W_#G26!51;&99[^HO/S@\:.QD]AT9=2X(3M0 I%=Z64(% MZ#3#N9#\5"DVK E:QG&V8J8?ATDCXLW[L7!RMO3;B 0X,:Q
[C\RNBAE]$V4 M?35]%:(WKB'7#40><'7S#Q2>*;,/O^-5T6(2G.#Q%%ZBW]'IN^D1 N:UZ,53 MK996C<25H#G-.Z<\]DX-*)U[_%HZ;G/\3A+S32F^ZR+]KEW9UCR<1P(%U']JO/M*<2 MI?.)-
\R@@($FA')QUXYW'P(\/2X44@2WDC/$W$VOHIB9 M:D?$0;!VN'<,<0!T1_)D?+773>5ID8V\"0,/B2>Q2"(#""B).P3;.[MC@(]Q M06C A>@0#'3&:7 #"3YBD8UH6,YRY435H ';6TIO<49C.H] -US76KPIDN>L
M;B\XB>9V?"Z]CPUZ8H0&7$'6T#?@KVLF:(]D#>=[]ZJ^5 ^\8W_EB72E6&" M>Q];>=1*L(^^[5P];ZXKFRI\]>I**"M#Y/UU/?(99ICO"ZE]F0X-Y1(S49LT
MMV_R!UDE+:4R7]^LEM1<'N2.91EMN#A$-.74AO'J!MB#>9^_GG5/X]"%*$+X M$0+%!?'YW[?IC'+N104\GI%17C/XK "^(6OBL^^<[Y5OV=(D>N_]ZP1L[N/> M?;<@"N]$N29VS]YCH#_10(OE'JZ\=8&9,-XW^9>)|\-
G6/T/WD0P$CL\W)20 MW_)H)=U,(46$HCA]GZ5<*-;_?UFC^U(;UJB2Y'P1+&N3P2)HC^)9+XG@52@: M=2(HOVGB+^*\RWHT(+(W>?1-L]QG)#<1.D"M@ZAI'*>B4\3VR-?KL+(^C_, MN^Z9^M#YP-
U_8&3$FCNCI,1GG.O,KKVHP'V1D&3%X+YE]I8W_OX5UQF-(6-7 MGMZOF].#9.-&@6?5B\ .AJ@.6U7X0M"VN+HI]WQ2!=,3!S>/E0@;V+MG$N[# MT2,/0W.M?RB0_[9P<*MH!AU[8V1288SF#R.'^4L3"KK
$WPQ%7TJ:_]]*\$V M8'MX3ZWJ@-GMJL4,;7$K>2@'^Q?!(#2 @+\9>(3QB%WF8$1P%Z(#PV#"LB_! MV:B0Z-K'-7"$EEH OVE,2(=:AF;T'5VI=4.$=LH-C-1K0"DJH@&M*K]IX6PS M>&%3X*(D_N)%Q>M+SX$T\-
(;5RF4#QIPQHVA(*2R2*X!7/"@(<889&'$)N?: M-X[S,,EM4!FGL^%$[SDUBLKT V@= !+-%-%M6CKR/:&;S>%.LOA1TIF^^9:E !+VG7 M'1,7RU$\Y "91$5@8!/ONI1=6>?$1PCB'C[<;%[ER3R[JVUH,I:3'GP8\?*_
MFU7M6RN7DTH".LX]+!=D6/O2GUC)3DTJL+ M&9?KR962G?:O8%@T_XQHCD-",.Y880*\#02A0BRZ$9C;6!?DT !GPTNZ8\-7 M*=F&_PIB[&#X=]ZVRXX*U1F"FR*#Z("7KBV808S?CTC$=&%+"PVPQW"Z\0A? MT++
<(!JPU0Z\!*AC:"B1Q5I^4=_=?YU*O(5!B3,R-M:!6WIUR>C ) M8[Q]01%XW;CV=+$@R]H4FIBG&Z0A7%,Q@V<2UDO#F#$;BE*?]7PU:FV-I+$R M>$4MS,\>S^1M3+&U(^7HG>3/NW6/;?OET"8 M1H[
81;JLS4_C?)46FE8B[S0"H!,N[(=-B*./XS0-&<%$0GF!5SEVKNO;%?T M/G6 !5Y@LIATOP?F-C?(+VW"D@9J=DE?]B:4A2EEY1E//+'4]C0?>SFN060K M7^$_X3U%)> 4QR:!,G:0Q:&AA3S?
%P[Z7LO[I>O;'/DMN\+V@,]ZH7XX<';) M=Q-A2.LGAG33L>K7MF\48>TO0([FMG 1G%>NJ#?A M:MMB979EB"ZH;IY_"I!D9L"$M#>/3$Y;,Z4 #SM\Q4.3?S$QJPX!>>T0Y#G-?539=BKA]) WXT:$[1X?>.M54 MN/A3;9'?3$"
[1)&2KNY-L75G(&FMO6,:HE'G=EB&_F4*]^O7VC(^N0\'=C/^ M(/P=<1=8(OC:9+-G1.G\[.Z-EAHS@ E7Q^ K^X5#ELYZS)?N>IB*JH.BU#>! M9.)XO*' '$V+%V<\[F*A2:9I7QO[@V\%$O8G[&E M=!U9:NNE,\BF]5"C530_*?
ZX<2#'9[^3(G%G@7HO//O;>OQ0!G=9?SS#O@T: M8/XIZHPRNSOQ4=\K"_:V!6K#!_'*\./:N$4T@)"L&[SWI=$[EKW-6D9?MTF2 MKB$!>$O7GV??\>'"^2M1 G7O A[9(>'BTP"%M&571]IW!),=4SS6)PZ1#/9P. MY3/L#> Q'&-
^<#,35H>PG[6?MB1N>0DO"?KMS/J(,,O/39YUXE>OF,W+XY_'/K[?=2Q(.8"9DX1KIBLV4VM 8>#.C_U M?0-&3G]P5)TDWP%;,IECKTX56G4=];.!XR%LSLU[3WC])'F)I-0B%/>O?73F M[YRA>LO*
[!C*R>E0==RU,Y)OZWH*O_1C+V*&@^<53"@'V@,YX<%[(1SEQNCZQI0@@ M8-Y]8L1EO0!:<--_I7;/8!] "H>G*']$0 B^C*PRG_68\_D]ENW5*J)IZK?O MOR*- =G+FX MH;DM5;;74N?U6$ZB:-S,"%<)@(/<.HD(1&&D5C?
+0I)2\I9\N3:KU8'_Q5#L M9J;[.?$9S29G/Z3VP;ZP_E!"]YK&",_;BP^J95>-M!\I9E)&9 -"Z;)R$:9: M\/AF1HUV9&NS)6+E%A77E>0,UD47]+% ME)VT8G+8!R(#[DNU2A @&:+A0FE'9USV/FMD3/+W+WR
M3Z/&Q8=Q^DI>3L5L8+YSOITA&=U4/?N\UZ=V-?D;8%Z:A3(74\;#B?EO0JO% M3VJFUX8Q7N2EU9]1F/8-E.#EA,V%$PR_DF5S5F]'8I".MLP#SP O&3[*OA4N MZD:H-"R1[9-;'C\A^SKJ%0)%(&R=\M(LVJ)>:S[&1CK4DC
M0V'VC#A0.Q =5%PEK2_/DWMX]_LIP27?-$$G_K'8A2SYYE?5,-7YY.FN0=UG&C2@42,W;U-IVY%42YDX=W'GS1EN_81@:OD# M]G2WJ&V:TUFYDUMU>:TIMXK@]6&WL[S[5G)Q QO<924H/.#*@W102199!DE> M!)A"+I?.
<$=-Y=T7^>L 1C_%?06Y"77XNZJ77&A J:]RS>XBGQ.2P+L4Y-Y8 M6L5%M]<:)H/E8;XTQS,]_53 3E]AWERU<\VN XHS7%[+".- JC".E9Y$F'S3 MOE$A5.R$\U76\Q7I#B)XT[)?8'QA?T;#TL!$7T)C/0?F3 ZX.-I8]]HPZR@< MV2?
1E+P_=D1@S4/0M>3(^-%^]W%'C5QK) 5)EBB8'I':XIX?[5]B4!B@5!,I MPY//D,]14E/<(;*8@@. "9+X M ORKHX?NH=O#BXVS$*!9<_,D[N;K0"-O8 MC0T/+9WI-X_=1QCE-J+NS(14U:2RAOH'M?93U&UGW5
MF5(0;N9]9<*2N^Y]=+Q,#-)"W:\74+KY6]3,6EY\.^)C6/X$O,]=M+C:_P5^ M5.2CQ>#DV(Z:!R!_S8B^0=LFJQYL'UQS#NKT> #^U.QIX>#G! M3/:5GT9;$G%8&K<&&FO8LK9=],:=E:36+0Q7)_H
86.0*:S;$O*E];M=LPYL$2=I\KW?+1X3P?K2=G:4M%(*,T==% M36+XPG)^!,XWB$\I\Q>LRU2L19?[!>:&]VA;3'MN5 M'X34#F0T&Z]><#]92_#5VP__,KUEQD19&/)\-$W_E._H#_6^C,9W6Q:9+]] M_-(]:NAIR#N 9Z
K&O!N0F))EY?20O0T&"@]\7)D65\:-1RCFU?"V.?;G42, MVR;&&;R]F>_Y&DK$HE62/;^ *#1)5GGU5&GNS\0NNO) M_LV,])8NO>+&E$V*.FLZIVQTYCW 4F*!.W[K6"T>3-^)&S;FJ6SJ2$&.%R7] M+>W'X8"
[Y@OD4'FD_J)6YO.ANC,-U5G:FU=57MO5%%4L#=QPA:B/-XV67BT: MLKEISIW)SN=S/PP-$*:]"E?S3I[H'*]G-M#O%6@@WC@I+Z]Y6X=L2W@N>@/K M!7\XK'(MWSG>Y;ZV]H"+F+4_[K2LK;1*-/BFWO7X HP-%LIX,90^?
%1W?R[N M=O4<:P%6DQ56> 9C51];03F](&9RW#G>VI&2&^/2Z-$8Z6<+ S](].,9/F5P MD7@T\/59QCZ!2N'^2?;2^M%R+>G#!N-@"ELA[6 6HT01?"R'9S@$9X/PIYIP M3]U]0O>L;9>*O#_= ^/$*6LH[V
6T0GM4=XV[UIP[W3U@ M+EO/NK?CJ9R@W+7=!:5>RY-_J"S5I^3U-PGON/L1N+(/CI\&9X;RXELH\0@2TQ23@ MR'V]5-\CVYT]G_%I]28.FY>?U9,=2\\*5(K6<57E=>VWBM9)%6*:H]N;,IP(
MOXOY=@IVN[*WG@<$+X_9L@;/2_#0Q_GTII.ROG.,8PM$$NH0(?/T[ >!]$# M.;&%Q:=O(XVP1RY''^K3-573PK.W:>^_)!0=[MV9HGZ/)44/"G_+:XWOEKB M]C_N^G]=]^]72V_%MSV79"Q&$U9C2$/W\1BN/^");
<_6.7]QR[(WU;Y_K$_M\F.5+PB%41F=&>88N;&!!JOO0VY_;'^S E"71 VOMSJK[;E<.F=.#^8L//3Y MO4).R0P1%"&L-EVW;G1WVZF%?Z"SIL ZXGV'-$BY,^S<_WA3J)%KJW%A?=&= M"14 +RBN-QPLR\O'UO15*35FXC^\+4?
&ZR397A\Y)!BB[R'OJU)B;/S1:R0T M;3=[5C,H.&U[I;?<=.2EO<&T>#$B'FJ&$:[M[C?_&XKK*G7#/LP>(Y 2SS3Q MX*:H)U*85W8 LQ7L_KYL5EQZ=2R!_V>_^.]=;?M@9)#.WJ7O&AHP9*UM2-"P MG+@!W,50DPR#,D]##/8:&
(7U\@P-.-+5T&S>.[M]+GM1C+&[$]\N6(]%S_\% M6UC8T?]$!&NX_%UK7@1A>DA5ZDG[*^V8MQTS.ONO&+;B:, ?"F%[("UH^1'X M_"SB?,(V&]S)-X*]S$;YW$UM#MK4_EMGEE&W,7I'=!RTE0!>;RLH_E6]0/.. MM^Q%X";P?
VQ%.1?6_EH25YAY^$P>@"@\:2Z<,]A6?5V(JKO;4N9ASJ.@[4B\ M=L=VD>\S)#YTWR=NEED;C+%TSEJ?RO5*\#79@45/-N]6+?,\>=V1KJN%L#ZR M%F+SIZQP37_Q#(OY0+GJ ?M\I6& (7$9&-?5'_9\E,?]=;"BQ@<"%V?KMJ&:
M'!B^Y4A.[JH'<>7V_68-FR&/UR M7^6HB$_,T8_U/+X"V)F^EHH+PS,T!VO-+;\EYE$55B1//9=;5?IP_2.\$!L MHF!(.3DDEDD5MN"O,Q'LJ7([V\3)B(&(C%E[V6X*.R50=DL7)0R/JRNPT$CP M?_\=#3 =
(.0FC[@/F^>O=*C]'##FK$B/YR=6"/A*WAPO) M'=YC;-X#<+M(W0?K2G#PKV9K)(&/CPEIMI^&!P(+N M+=KY-;$S+/2*^_E$IHIRH@":Q_R9(0"-!XPR;S&V?5_ M*13Q!2DV802S!6@AJMNOR>@]]AS7LWQI0=7MES4IR3!
<@<,I1EZ'ZC A!8( M:]W,\:<>03-]6NW(.+L:5?H?/J_<=>US9XOXL*A\-=N_#"]EDY^%HIL3F>FLE@ M_%-DAE5P!^L5]SL[ND=JV<;!.OHQVNMQ&OS;SOY3-ST=,OT QSMM#BD$",\4 M\HEC+ZD^V?
#%CZ5J_2:!Y=#\](F;LCAE+A2J-93A4FWSE/432*FEY,?CNF]# M%*L/L\E*KK]>H/>LQ&''=8>566*HO[/!W:%7(]8N=^-(&()., ^R' GZ<#SZ9 M'E)8M!:Y#B+CNJE(KTRZ$:/3+L36UBK;3S#
(8,T<*2%_/HX1^IXL)/[<\O)K\3A$CCL6V=8PRI*785%'0AP<_RTSVG4>\[C79)$)],MDL#@>[2U>;GIH&E4]O&],;1NRRK MZ2? MVO87Y4K%(X4.)XU#O4@%)NVEC9X('N\P.?CO,]L;&9-PFO4G(&+HG;7
ME*E=%=5&R_K$6NFN'5%59R70!%;BF*0-V.'!'.U]DTXZ))(I',5FN?)-(L9K M09 M-(!D]\ACJX9ZS(:6Y%-B](VKP9,;*>_"DR8>I6GU?'7U4!I9?65N;6WL MUTVF5OQ%-106&CR8'N(7KO@$7K>;"*MST4O0=2YK4">]Q4]-
TS%_U:3"V"*\ M8M%+25P.=0O^-9O1#]DMW>OH,]0W,@D368NP]]6?HSC[I,U@D)SANFJM,&YM MV2ID;HD=Q#3?#CR>!#E]>O<00T;RZA2A>_@+EJB;\/XT2^YJZ:PYMY$@;5^^
MO;!Z/>R8#Q+VT]7G=QSO%5W;R=3Q\VO[N/C)YI99$G&-U@VPE(%'I]M4AR3C MNPT=S4"!O>TO6JV'CW6TBAT4"G"W)I,<+(?-TL2P-44,\5WI#EN\[XTZR?.^ MV)Q>G7LNM]MN&K/,TXO;V'-
=0EE%KZX]RC$/:3L1UWZV;9N?SU)9_EGFH5UD MZ+W=S/M7/5"4V^J=YBC*^E)$USUEZN'[7HF6?NR%PE_F=J\-)__CSUJ M#W?KM$]F.JVV<(&F?].R!]U>7B^*5YZ5O>5%"VF"VB@VZT.8&TWC@-51NMB'
M<@F^2A##)G5Y"A]36N-N)@<4+8ZVIN/#H^G-RU0,?!8A-R8^S'5!.^#[Z7L=KVI<'LT M\.G*:ZV42_L41)\CF%C\5CT[_#UJK*Z&SOWI!E%6[0QIA(;+L?BB.\#+;&67 M>MM#D!):7FU0DH68WVL>%,FKJ/>_7W>Y#Z?U
W]MN='+]Q?>0 M2F @O$>+ M1*(+K0;T-345U<$K&B]L;7'2#Q;#D>^;%GW,#XX]'9E:I%\OS'1!7%W;;#TD M0O2?A%;Q#SX\+Q);VWI4]>4N\L!RK7##W')(N?FHDRR+N^*R[
M'UHSW%$QI(<3YL2MK+8OE+S8=VM[2G#VC4=-*4CTB;!G!B-_Z472^TB\7E4D M<.C%4)C?:MKU]&^>>>VI7/1%(MCALR;YG#P9#29#G'V2N.#.>#>,],'0NR'[
M\8Z69&\T0',8PE7F0I)K[L)MS7]J)TJ^%]D"_V[K\S1W,7'<^$K8X\?RXE@K M'<_&E?!/S8ZZ.;L%O'A@T*13]_$2+T?B"(8^HF2_FIVK +Y>^W['8W8)P)5$ M*
(BH#SY/4RN[Y)$[/$Y+:A)5^F4+&+NA5C"T0\!PUX;UJF5H90S.JPBA[(V53*>\EOV&&G?AKN M(!G A"0VUU62]>Y(TWQ XB<.89QU3;U06#P;AP*+P8!&[ )W^R237';!#D\! M_Y.%#@/.@.=)>OKM*JR?"-T^4-$7S; DI R@GEU!
U"U.*AW'WTN3L<2]*K(LA=16=:)^Q[F/U*1^B[O/%^B:,8\JW]$DAT>]U9!^2_A$C7G$5\*9*KW CI6I6\^%3. M])D;(T*29P.XDG67>7=GDR)233Q!I2=%)QZICUB^!Q:$TFJNO?@JOOP\"TN MLYQ@2K67'#0
]Q<3_;DO_SM;FH]^/JAP=P\,:X>AJH0/"L@7!Y"! :CZ992B M6CV5LNI@3GIP].]]SIQ$1IB9E9G; $;,"D)OJ0:BX77H.3KHU#;#>>"6YIM M&'[(9MEP0I**0;OLM>Y)_R@6,1?)D9+U MMV#57U>VW^*,^7>E7F#^0X\GN3SVH/[-
?FZ%)<$OQ.U=,+EE(<*VI2+A>T]# MIW(4_^EL$@=2'O@H1FJ6JC6AOB%S_3Y7PM>T:SFVU8SU;\ZQNKYSU',@^#0G MJX>Q4:-D.Z=SLPB9A'@V)HUU/96A,&<5;1F(Q C_R$T2
MS]6J\858G]*KIE;_)^(GG5.=R&^SQJ56B15%&Z1=#$.L1:*U-FFQH\OW)' E MVD2+;,H8A9OFZ2N\%/9>EY7:-J)RR#M08P-,8X*7T8 E)X3AP $R3-'&?O7L M3L76Z>&Y&D=%D::BXU#.MQN65,+N=\;R;U-3>>O*08#
[U_KMDQR;&$X+%)\B M:I;RY0L<>+G)YK'Y);HYKEY7GZ[1BFXMA#&5:A=6BW5S^HY(\KB:](ZQ%*FZ MV Q+ML9!!;4F4Y+\64UGB[QR]-CJ2]6X6<#,.*P7Q&;F7ZI? M5T./@$'5O(%ERT,
[W+;#2Z=+66%7/+_$=#IXN*O32/(A-"R';)K/*=B9/"/# M? ^,%[+<&I]'Z:%>)7>N L5]Q)!A&FD953PZ>4P5WY *<%0$]%':G.# -/9= M^;LRA/9Q@-"DM.S%8)A!#R*33&2G/93P T M;RY%!.D(!Q_;;L_06R)6#Z:51MK?
```

```
V]U?;ST]^EZT[]M\NJH+.IH!\PFI)[B^ M>QK5*&(L.QJ]B0TW0<#'*GK909*W7,'-I].F'@+# M^M_\S9@C' 'NKY)(QK^9@2C%A2&;I)/M$T(EW4W&U"I^9/>9KUW3"DTZS5GQ
MB'WK/*J9BGR^_]']>O3Y*VXWX@R7&QYNBXUX ;0]KT@;); *<)8F6NF52>0Q MGM *#3#3GS64I]4F)V,(FYK5?H_B=<^Z/M:Z'%.T-ZH!#!+7S4"\F&(;X\$O M3=U<"G,1@Q7@9%N9/6B Q-4[%=DU M:T=IMT^N#TO0!4.,,-
W-UC74C;LWVUHB6_ERYR5NYSE=T2]".']S&5COIZ*D MYSA1S?(_3KQV5_IU!L=S1%!ZR_D)C[/^=B?.X#G0XA 4H+HN^BSQ>Q-$WIRJB&C4_V@. MY@')F>O26\MV'(E*!OH+U92!2#?+A?:LT^;U?%_3RQ897BONKHN/%
(%5P!=U M@Y]\=1>D'$"XM*(!,]-?*XS'9>9*:S)L:_H65D,+B09-=H_6\M]2$FE]*3!Y MC@A8DN #WUK3]>VEO?HXGP=W6^'*-<=ZB8:ZB5HEHT5K(9<*W1G'G#M=1+=:(H3!#;$8)*E0LV?)!A^-
M1L1.4)5!#TBF$IQH\I%C%ZZ34B$'=\Q( M+O9Q^L#+:B&. O;GB.RE"^R#-O!;:B;'F4=51B)=&L8/.SO[^8,KW/;)6\:K ME;ZF,;96&.])/]$:BHO=/ZU7#37!*>!8,7KKY.27BRCHD-^G2DQ7INS1VP1N M)@B^".F7-
)8#10I]M]2(#]4]NK'%5E:5UTG/6A? )E>\9/!P($]7]\ ,\@P@ M2D]VKH)4-5 MNWU23)(WY=3D@LZFQKWYJ6438C:?TY\[&([4"G]-O'SV)IAH!DN-2SN0 M%0#8\YT(UO"X-I0M,1?EJ3U(&'22IZ31C6.=Y^AH&=AU[J/\S%VC(E1 -
:N-Z@!N-8;D6F M,C=REZ;J77$W61#'6*V>]I/Q>U:;/+69-TU6@O?ZEP;W0U7M2PHACAGIQ<<+-S:\Z0N%$[*& M6VB7]&E-)8-QV,]="G1X0]P)Q&4\&'7&YQ\+S0Y87-5B]XULA<$S8TRJ93VD MU5%#Y=9__QNL1R+
MA1:6CR=$+6LM[>A-L]\? :W*KBCF;W$"S+'5=5^UX_>QPV.T7P@-WN"P:/G# M &W+_YFLK(DD3W4T(&( 'SRI!$Z8R!BWR?NRD3 S+9EAO2:8F6Y&\JFGZ-+[ M!?]('4?-_;*WYIK)GH\P]'JM,?
7X@AWE1^G.;6I!1Y7X;4'+8'[&K8**^%6Y MUW:]+@.9'2[.;GC5QF/GEV/]+-"=*$L):HVXT3FM28/K-7Z/>F0F^[UP>BI M._@5YNF> G6%NI-?AL7]]5MKFYS/U[C;.6NB15:#H+&4,*>[G2TWWV_B[G)^
M!!'6,IB2@XUE*QTCA)0:3ONWO6,5=+24+.1-K)<0GFRY/4NM[ZU6@O7[L,2T M?2+=QY6;!LYN8.0 Y#,HRSER(TYHVGYD9\?8?S!-BD*Q\&4H4VI_^E"IDEC+ MR94.Q8H#;E]]O+K$F(DXUN%ZW_+L:VB
($:AS().%.KV(U!/:$%_"^4S1;), M&R)9@3,_PH2"XN-7SE F7K,F](X51]E;HK>3H038)M]TST[:?#_.]W1N=$>: M'UI\RL\0 0;JE*TF+C(2<[]ME/MOMU"VM3[QR5TY]'4__"]*O7I/D*XI+FZ MZ^:DE]5419-
Q#TP3'NC)R5"\CR9^)DKH!)&N&K;B%6CZ.J2_UTDUIM"."4KE&IC?EW>6XV9VT>\8]6,FWY6FUO%+"6"#]]1B MQNQ=XQTD)JT!GWNU>W%6U.YK^)IDUQU-EWU^K^K]XK5Q
M2_D@">M)F]F\UO2F$,3:PY:RE>0T(U8*&T&WNH0P7T3P^#6;V<43U9"P5)M> M#K?9[P1K*MN5Z-(:XN_PO"H>%[S(2: :Y]598N%\7\+]S]1:A 0@QXB M<7+:DFOV,O5@(KT]P494M*!*TBH@6)1"WA M5Y/R8",.D6 =FZ
E(NR68H$$C<]$M=_OO6*M@8TXDCT\Z1/+F^7:,0E#A!C= M#LIRU525]DBTQM\$BG"T\(5]DO1E YP7%DQYJG^13'"Z-FX5EO.\7?F!ZX"Q MJ._.1/G=]B)PUJ0V=EZ?+65F_\W;,'J:E'=KH7;N^WI!\-,6?=;Z;X,;[Y]?
MYYJXKKYY_\.L;/8CF:WG4Y]!1) )M?VU$-Z,,%BXLZQTI%%Y](P\8_$],%W" M+U8.8D$M%#%]HTAI]+\4 UW8>(\3"ZTT>^HH20XHX$T*TS!L_VK"YC3L132( M._N0/K:19B:Y+L#">]](+:UQ??
HCTPU$!I2>VRANGMMH&#]]TC_93W ##[07 ME:K>86\0<%F6E?B)NSW+S+2258KFLZ*DZ*)IRL>$\]"OEG$+IF-<1M6!#NG2 M7:J;),^]8^,S$20M=(R;\^;G3^WU>.>B,MWP3V#V(EO36:7M,;*D;[D\5?9U M58<]E=
[N3TZU7\OZ&']=("K0P &WZ\'<.\=CP+ARR Z2TPC*>*6C)>X$]K67 M8?GYI?&20XM%7-H%'E-[!AKP M =CR>'[XVK!1N)A\+>*#5>>3U'E6AJ)%K^VQ.S<=2](1#6@ W\(E& WP<[=^ M8\G$-'R\5P(VGSY# ][$] :3_:3%C
6.)I.F5S]$ Y4MJ-E<_#Q'>)<^I0[?XBY9_>K;S MBW2!\)Q@[4^+'+2L@]?]_=+G7'VU*D:L 8=LXD7KP0^XO'V1G!M$Y+)E@V]# MO$2"H93 LH?..]VS*98DC2FD!CB;RBM,7L]AA$)A"!9BK'702^\8\P(S./T3--_KG/\7.?
X"]8Y"NMYFK@62 H2F.6"M5*> M I?F(E:E;7X5]VYA045U_C79WLB%)GH>RL\0LHE[25(G-JU)H,^D">U).2%CD\ MT)S^LI8-FZ\V#)(DFBCSHI>]*0_6[M##L";2M6Y)=V(; M:,
"MZI^/1["1:41Q>QXHJE=@!]5]C@F9A*9%P["MR][OVN!O%WI L<)S.]B M8^'9VJGF 1_1P5"49D),S/L>4CG-MWWFI]8.$G=KKJL#+CRGD)P5",.,37?P M!T]IHMUD%VNN+V?F H2A:$ -RSM9\7'#IAT"S1%Q?1>AM"Q#G2?
CQ.]WN><% MN5=E[*-Q1' .LL&!_T][WQG6U+]M&P5% >F@U( @(%6Z2%>DBB @50B*TGL- M-2K22X (2#$((B!5$1)]D"Z"(C5(3X)T(5' ""$Y<=_GGK/7VG>MYYYG[WW. M?L[A__R^[YW)'.\H=4)
MG4!JRJ[E*+BC>.O";)Y/1Y5J0U+? =@W-7WW5\8*SP1)@RP(P253T5E1H6R3 M9T\CD6$<*KE"O=KJ"]"/S4 !XMD?W7".$;%7C_CU>H]9Q<9-9!C56(LU"A?] MV!HS[3/;.Z*M:(S= M";*H76]39^+]H3HE#[?
3(';G45A7]J7@#_5"U]PU>EXF]YN'G;T,V(PR?:& M*8Q7JE; GJI"AYN0N A5%2[9GX$8 M_$6+;+PCM\ )FWE3?;BQEEP-=._3%X5&@4D-.M-:I67(<:W%"*V=5;'O=BTO M9DC&J&&+KHQ)!WL[*4?
#1OA8=S_+F;?.*80^&D6]WVH^_]:4^&DH]F1^]FO7 M]O0@_/-P8!9.Y$X]K(6IHKH]E2.O5!E8*61PQ7RS9'!)E<4_+@U(M=P:O+=6KCU M.;R]P:B2FK?#UO:Z,2+)H!4!/Y9>=FI4..UA&Z_E\+T)E$!_R9$O,\9W$HK(
MMPPX6)C+!H]]]D5*^^(H 'K0+;O5/24L0[:.7(3YR@6P$&I+3X,"R&'EOS-L M&C2XQ;%F B%H[GE.VRJ=P;2Y'7MVIU0W->G1&3H [M5F1!X2N]\4: M:L\2#VLV<+[#;W]'UG.^+0BE@>=J9F$\OYGE>N
_E@$C[*986<1/DDHCX<0Z]S1_1K75"43%M M#FN\;L5F["MX5M^,6Z=CL8#%?P6B>:73479XFQ>TT1;1.1']OA2)/G4T5UOL MHE/74I_/U?"ME!UF3G=EGN#>!VZRI5:2P:>S6I6M8Q[$K<-Z-=8'(W75O7$_
MO9T:\1F(3/9O@]YPX9C)E@+OK:0;H7:I*]L:R,N-HYOUO-Q!F4SPVS>1-.J" M9VC@X%[5[6KZ+GQT ID/#R]\883Y\E#^KG#I[IU!NE=2VGM67^[^4-+Y(YD& M:KXZ1.7KS2Q]^BI")6.!7RV5."U2&2UU@C5E- M-QAJ.^>YIH*
(.QIY_LVXEP"NV_H',N]#Y_D(F*@Z#-K\/%U;#!7NGQ1_G>"P M_*"V[).ZK2I\2IP1<7I58%Z5P_4VOXKS@R%'^8!3QJXX7XY5A+^MQQS#V*8L MSJQ:J7R>[^D#]2, .*G0D5CU%=2E>9Z8RMTT?B=9OQZIKVR5TO+"54,%_HP%
MH*73XTZ63MR^)!L7'CPH &P!WNX]1AIFA7D];E;E?PMX\+,0[PVZ[14N'5;;60EN.*\TS^8@ M#C,K-,L$RC6)WY=T$J ^0)_H5T@*->M['W8ZQEK5]VYF"LIQ@P);V(G.4-_> M)G#05PAFJ;U\QMW.,@_Q($HL?]$>N>7D
V;HU^B[DDXG^"E[!1@8B,W. '^Y Y.2\+\T_:%M%OB4790P)"R<8:AQ9]^X+/FF-TH>;+YT MCD&JW#D$V"W?]5.N8IY52G",+ HV__CE2H<,;4*X?'P_W22.\R5V5GEO&0N) MK5FH:\]>8OSY1I]=7O\
[L/6M4[22,5845@,"+W>A+TE758LP-+E^>]*=QBNH MQG0?1SG,W:]K+>KNGIM9D M!&F7W=2#*8#[4/3$BR8",JGTP485B;V\YV6=M^U="L L3=^AVUL0"*GV ?-V M?L5XT[QKS+C7WI@^%"RXGMMBJ7-FUOG8A-
>I8;V#,!ZMR&VP(O*5=Z!D[]SY]@G2N?*I0CJ/=#O.4[OY'5_" M(FQ8IB%,N>3@<7!4+HICBDND<*,J(.+$1\D\@MYK+)0+[+([TM=U>BH*F=,< MVG1EJ3]-U[\OI2 #/:]$)H),'Y.T1NOWRQ>1656ZYI)%5I>MZ01_E.X>:\K M)Y,-
OY0=!.=0 %>4+[5SO^P8/G=(Y';M%4H@>S-&-JE/4 MU-93E0*=N=B_.CW*&;)N@O)-X[KT\/.M_'-U$NBSHM\ZIDA:5TY6]*! (G#&.>7X[[5; QX*PAN*HSA4B!U)30W',#HGDM/ MJ[+MK&.4U.Q7K>\,!='K5#E1GX6K< M-
6<3$\ELN;UJ@3#B& 5P;'O?)E+HW#?=XB4L)MM0+>N64Y2JUE.?%4TN:KP! M>FO-<\U[>:95OK6:Y^ G=P13V3.:IC[,34T.&T?WN9/&$>N&7UU.LP%EP.^5 MF2[XA97.I1AZI,S:T2*)A&?&+.)H9?.PR8OSCQXS[FT#TVL-
:YAM1[?N$?LP MTRL;FP(?)0VMC&,3GGS*R@$@+C +?^>"2HT!TFCNE^FF(F*\>FSO6HVK.2FI(%M MR!))>S60Q:^L KX6U?&.)'$@%,O9M=+.NH!6]]6*KZ[_=C;A'=?&AQ^[P3^5 M]_;1_B:E2+90>O$:4-^<<"N^-
H[7XG7:25'VL]Y/#6_Q+1?1[11)KJ@4C=VP ML2NM?-FQT#NN.,W9.F;2;)2]=I+Q0\H"#>R^X5O5BSV@89]:V2![M:>71S=R M,KNKI;CW4U>_;JNG/;:1<2Q..O\W6CX6YB,;2LD*[N535P./""&,F@![T"M;
MMS:T&%OY:;AG9Z_'9^]#]Q=? %\$-0\2NFQ-!4:P^0=(*^WH;@PG#WBY3 M\.I>LF*O=C^&T[NWI3]-G;R=-,<1=R)3//WV#0Z)\FV Q6IZ/9365RK:,N59 MG<]L/2X#3BP;^?_Z]KSU7[5__'KE]N^=
(3>EN>;9G@Q*I8"B'7%,._10A8'VTD.0'P528C*"5!2+I4IDI^OC^U?( ]4ST) MPLL5DBL@HE7T+X4%??*U 0J@9_AW@#3;3-\P_^OMO3,4"S\E5P%..N#8,I<^ M>^\+E?YLAT:ASH5&:S ,\M&-
\;AT^3)A%;:,GUQ+S2574SE9+U>D'*,!,!MU MHN2NJ[^Z]*HIL$PS/%7-2YKCAJ/_QG^VJY#%\?\I==#2\@<"7>.RL;"Q;8E_M1BWD])]5A,;_9 +DUSS%^LH_H8#%9/PG_'?KX]?%WZK] W>5=1A$U34_1V@-43W7B M07]U<[-
%FPQ.5*IC_$?AT.6TN* M!EN0.SU)$PF;;).@>'/4@QI/1X:FR'S#Z%&WQ8.5)XQI]#4(UW;U?,*EGY_4 MA8-%U.<Q5S7KQ)QJ=[UO9%AQM)*'+R<=W*AIF>Q!QIQ\%@8CZ MJ//N>?;B[%=>N 0P!0H?_?"3'?
JLUI"@_++&YER]'5.*$F_BP-$AF>[X,Z]^ MM[[/!&W=BB>A*8!]/PK@LV1@=[3TF'>DL3NF^NC'J64+N);28E/ V5C5_;>! MTUK7_+$P^L9=)WGB-,]<,X(>RCG*@]D-[B[6%@Z&;$"%4LW' (41 AX#/5R
M61.C!TLX55A9=!;2/)\0H:ZX$ZVBHYY3J,)SKY\"$ WQW#[^WUF8^<@W/T5: M4AGB-O-!4,Q/"T.'"RL?OH)L&_$40->#BBD14XVVDG-<9D8%7_GNZVRM6RL6 MLDC-,32@=Y236":*L7<*)
BP%!B1<0*80@$L0F]!T(^!'R3I0&$6NY#Z;P. MB5T,7BL^G&I?EB^"O_-ON$T2D;US(BEK/,=C;W-EVR1,'4R]WP\69E1;#!*> MCS%W=]0<#V86L"6&KQL9'W4*#.5X]]:DX@PIA8F>A2,F;1F^,TF,U$7QCG3S M1A:YLYB4"?
MTI$3<:4S5[8W66#U"G\WC3#<]!IS;^=&KQ6A6M?6L088XVA?J MR$F0R;K]ZLJYIX/WEMXK&!E[,1YT_,+X1E9)$CBRY_I/?NNU$\)KDID\Z.[\3S[2D2]E=CKC3BT%
M]64$1@!)>_4&$6@3HTU4<*^8>3AL+S)HR<>E&7B?;BQ=BRZ<\$RTD>\H49M9@IOFCS:,^7U30/YV=?][K<:P=E& MFLF8E3 <@GGL>PB(9:=EB]4SC[\4YAL6X1DR;'?618E5LKDU\[6(_Z/5E&QL
M/K[(U034LQ[HAU1AB*9]4Q'+IKP]_Y;IN*EZ^ A)Z::F,@'GY,,3=Z3OXG\4\I%PLX14 MOCE(:_#B-1_3U]@+]CLO[FZ<;N@O0I.%/?RD=Z#QB@/VKAT&,E^<)9E!K8TD M[4I'24)
<-88"./K9T]B9]M*C.CV8_8RD?)%$=]H)C:NAG,L@'LBB'I3<[DRE M/,=8EY%7V[I];=#+=?A7,Y]:FZ(FF,Z0K!*Z]&0]E M1_Y1Y[K@[\(/PY@+^L<@+(",-8F]@CA8X?/7M>H M--ZGPYH>,%E!B,> %
#K92,TN\]2*A87P0_JM+ZT^+]MJF'*U;XT;U_237]KK^:1? (_2 M('L%ON787N'9T1 VR=Z,4IZRW[^:'"KR./TZ^#ENZ]OUV#;S-3@C95F0M^L M9Q)]-+_(MH!\; PQ/R=?178ETU?!37_T3-].#-P64?>B^5$Z59CS P=73*B-
W8K47UC93E;U'L'8R=NY.!6*+Z>?/)"L+DYS MX=)7P3(SSZZACN9M=^QL&B_[C6B$"T>!HN7GX](]B?LGOQW="RT<'1/KHRL$5? M."WH<[-I0M!/Q89WCV9UKV4PPMY.!1(+(N@'1A5CRDB>=0F.0^6S?4XC:Z?-
M&=F%&.7UK_)>5P0S61? I:?3!K'Q\=H8?CRMLS: MVF$WQFO]EV<:>^E^6*.TWOI);)HDM.I@C+_:]_%P(6D1_]YE%$"U+7<,4O6G M-FWT76O#2CM#R'.0;;>EH;^OB)$-
GN$\C>;,^'L)F9MI*L9XX]]N"B;X=FC5QFD]"N!19]^TLB*KOC_?U1HVN;8 M*\0 Z>?=!(0(RD7!TBT]%0YAGT[D)DML9:"\'L3$4R_XRW1DG:HL/YCZR.'= MW>])M[],$%PAJD_N::]<8%:]Q$).?0977H69M,U4V*@'B,VE]ND!\D
MR73VP3N*(O5'%^QY35G= Z>>?>;OZ399EMB].*4C& ZSC@1AI.V[HT^\&9[8 MF_,DEJ1^:2P4K^,T/]D9,Z0T-6R:&YOB[=R5G43M4C?J2_R'=A M#VBW6-6J00 :-4!-ZPE,6=(EQG7GQ1)3DIXY,3<'0@,\A\M+\AGX9GBX$.KG
M0\MFB'&VP<8/;X$DO+X]P<4"THZK.==>'Q_Z@-E*R(N%K88VDQ]GFQ]G;2).B_$HV0Y$#0]%ZM^*2 M/VSC_C^MW/_1?_?NW$L$7?;AE<5_PG:@(=*%7\6%?R/4ZKH(UC%S8G@ MQY?2D5HNGO>?
&;\)F;G@D\OO#^U%B#]CED<2/;$1]F[5"X2O&V:]16R*J9WE M_!5R,8F7,K66NER /X@^]("^>^W\R2:ZCR[]=#?W> Y(C;\]QX"?7IWZW7^MW^M894E\!W"/ 0X-\/L,(#2-_PU5P< MBR)4]XRY8<9=8I]
(AJ>T.WJ.BS]_^J^$]%_^ISP$^%\%\.5M?*7CJ&[G0"^2 MJ]-Z7@S&(+.[WQC8]=60+>% #]CYJ";;,&YGT,!4#\ L371MI22[(\.4QK2VJ>\,]AG2V$5P/.*2OD(D0LJHC M["^:,4OSOU]^X_<'A)MP!%[XHI__V_7ZO]T]BQKE#!
["^U\&S[(08]46"/&- M4$GU.=<4HVDYQ' :>C#:GK1C)+[\/]I*#P$> OSO!OC2^3\]Q9SG%]P_-B OP' QQ'\1.KQRHC==HE]$Z(DWY]GZ*ZC"1).)[CN1L!Y+TU MU=6(S&&4]H3-'UD?6SG,+@X!'@+\1P*4A,;-B34ALT^V1D1(F1?
H^("]D]< M8O8_QN7>PW=UAT>5A"#@EUJ0#]6_)HGGW@P(\*.%EZ#+;^BK_U=(/:IZ:N^=%#? M.TE*)S)*?#BU5P#?+UF7#A_:WB&\0WA_K^WEQ7<.L7ADET[M]_Y0,5M4R5&\ M-I Q?
VQ]U&M!&6&U^U7LR9U4,Y1<"PUWC\E5T6D>PV,<-PQ<*9__#5!+ P04 M_"_#P@6Y9%Q?S7%K^_!7"0$_$_&9OTNP54 MF\^Z+_SB%"WN#H5"<7O=>YD_5;R9N9S#PVC\R:()>0/X"KQ64%0 4%!3@W<,+ M0*X +P%L3$PL3
QL+"RL1X^PFH&>CI]&EI&5EYV!F9 MG['0TG*(/GW&QR\D),3 +BXM)B#%(R@D\-@,>^@%T(@QB)O[GF"1:[[&874D%@I/RL5E>U/62 M:4^?LPJ:NX4\PB&GH*2B9GO"SO&44TA81%1,7.+E*WD%127EUSIOWNKJZ1L8
M6EA:?;"VL;5S]_#T\O;Q_1@:%AX1^2D].CGEO&06%1<4EX-*R\F_U M#8U-S2VM;=_[^@<&AX9'1F=FY^87%I>6(9O0K>V=W;W]@T/8Q>75K^O?\#\W M?_&% J"A_._V7_)%], 7*CHZ&CK67WRAH'K_-8
('8.)'Y/XN1;6>U<29H%@ M;-(72?EUO8]8!+7/R)X>Z"7K3/R7*R$N(B5^M,CN:S7KJ) M/<4";@!&U6XS:N.75,S2EL1A-CG55[$_N>CZUES7V_QRJ8IS:L9$S".[2NFFDSZX'291S)4SY6[O6&#=6BNA"/T19O_@V/%S6@JEG0=D7
MY!Z<&&#/WXB[(#VK@GMEF(S7=\JMA/0@10H+3F;Y4VK5?V'VU?4@?,9"D.CP9GA M>[G^>@*0B&80>.E0C[!,Q<(9[-R>KI'-/9E%^>>K3HC!"Z(&@](IK.)I4W]/ MKEL371/3.[N0[_8A3:K-3Z_=2OAW(F+]ERQR
I0]>BVSCGQ4NC/ MYAQ:IM.8)_HZB+SSKXC"']K-(UB(YAIWVIT[XVW4I][L#FYCOG.\7&=OKG!]3>]1"H$OY M2C.[14Y=17;*,F-AKO'^]5Z?EWY2#1@9\")*6B/[9H.8KY&BDW3SOY$ECI)DD]?CPU=A3
M=I=GE8(7YYB"O5@+*?T4'R-B0.3U&/?'U]_:ZY5FT!Q"+1PB1VFW:\UR&70@ M09*'7&,G/(U(H%895:T4_Z7VK*Z?9\XO2DERN6-P,_EPQS&\[4UFMUP-7N3N M$.9>*+.\+4K;1P(V0M4_F;]]NG.[,V.C.> MP*J@>
[C):HD7,*R5^W$U#S6:X_\>RNT^>G;5E!@?_'X>2X%M$1 7&KKO][:- M RU;!G?6BIBF]:QZ;>LB=-6X_LNBBSE%[8A6RF*T&?S%E;L_3S8/*ZY0RC-" M22&E&4S",'8&D:W\3BWDQ;%; MI0CX_)(&[21KL
[2!5=;_):8V\P71:Y_:]#]D/0^R_M]%FO=9><)$\DY8D]8 M3"R*8"PC8ENR9E($M6VD:L<,^/WB:LD0TUY?RO[SX=(K'+UIW&^A/';MBCV; M>D^I7M2+ I=^L%8Q?NW-YEM]0$$F2%?S7/?K+I]O35&37ZC+0IS;NK+;RA_3
M+6\Q];>MC? %Z(*D#[U/2:O(F1@C,UW1O8:JZ]F!YC[B2>0;7Y5*EU> 3XSR M6!DK 39]]C=)3]+.SR=^6 )+K>4V7AEEX=M^GYZ$1\7;&\2]MU*RL)3*_'I^ M1U$DI#5 V19"%C.<+.9DHNMSH;XL_N>;BF6.NH;4W *"
<]8)';\Q_G-XE"R# M7-/;VIE]+@1KIMS8I]RF"KU0-R9/9:4BO(F M-S?OP)3!Z".\,;M9_F!+%IHPWQXQ]I4N08T9?WZPS>(3/[,&P6<#+_AG34P81&?6HU[9B%886AOI%^XTASPOO6+Y.\X^I[C*B^ M!U-O)3>
(;*\IH#^\$\5P3/HMB_RB'K6VX26ZOI)A^M8R\V[.PBCAR6;(]Q)R MPB>^E#]3C"17I1PUH]$-*C'+/$5-B>VC'[CV6IXST:B$_4 CZF5T?\LC1?+> MNR(*O.Z0_%V2-?B)!QO9EU0W[-6BQWSN6;IAB">S5=EI'S*D%"S_%+Q/!%A1
M%L6DGU+TI]4_@T)HHJRCZ,*>2(="TPJ$+%&AQ\Z[?6ME6U))P#D0);"\L(K0 M>?I9Q5FR__!U^6,J)4:RMY2TKKH$P26-,4N=KX)=Z>_%U-VH[/'M;\+ M6K?
%B8]I'6'$RY$^Y(7+7Z64T6PY[8R76%"ECIN^I^3=V7,Z]AZT:_<).0E< MHZI]+IQ'GC7'H@LXH?G8Q'4$/ZIYEG5EV'E58K[/O\OYA3 MU-!BC.)B>MMH-=6P&[SC]?OUD[U!W"BK9 *!:G?
S75KK.*"=?]S?!KM(E/GL=6:'@LQ+YE2G0T+1;'5?6N:=Q9[=/<'F])DSB\RJO%CLUDDWPE =\8V^$ M3W,MB@3D?;F'XZKEOQ]8BN0H:%OP,#QMP,.#]9]IO(+KL*ROC) >H16HJS6P-^[T*-*8U+XKN%&(4TZ^C'6/
MS]+$(K'W=B]Z]CO#,WS[D;/EDXZT\U&!_3=M?.Z-7R-^XMS<4)\U&#B="OG9 MQYSR/#$3*EEUP',K#9A[3-A2X=Z+/_[D*539PL&*SHV 0)&,#2#5DO\;+&3# M&\"M#:TVE!.VGFRKO!W;RDQL77DI61X_/[Z-
;6&F>=]WHB+D^I4M3:G9RM*7 M0%G\2EJFL=#4;_,WK";]RN=7. RC*R-=0$E[N]%GEXU8($CYG09 G[V/5H($ MPG34228D&D=77_=V['R)U.C\K>'I-0@,B?],TH(-NHK7[''=^VX/ M^4/O:R0 \P"9^ZP@(KG,[DAKD "%HE25?
20G#SQ2?>HGB7U&Q[>7SL1@"#\+ M]B]7?_B<9Z\3EWR#O;)0NQ&K0)%NKW^D,K9'3P]3IXO2G7WRPAT9M.;Q_F\) M]?PM2K7B85SV].+R)A2LT.XYG(XVBKC4%PE4AC_Q0,-L#Y))RE#\3]VC>B'P M8Z_^:UQ#$T6F
UHS5+@\)*E:?KLR,3D.VLG'Z-8R1@+_D%Z-KZGC&SKV"*(U M*65ZQ[@X2?/BCA' D69>;A9CPC!S?XZC%,.3*E%EO81/;C7$9=2M01R MQE=4E;+'&C2@]1U])!"2B@2@^XA^6/,]@6XW_*D9@B>FSB1CJR_-SB3-OI>I
MQT"^SRE.P:4\0%Q*RWWSR+:@-IHWC2W?"]UZVY/S9ZZ+>ZXF%\L_-*\IMZF MB7M!Q89IZ-=G29]?O\UT)]_1TO1$ E;DN44'6Z]S%HT;NWS/3N&#>Q^>#=&U
M/FFU.972R8<7*C3,_;+Q5.&6+XZZ:R=Z%)X]RF5)TMM+N^BH]%R>5!/E?P1D M&EIS)U=+>"DB1G!-3PLY\A' ,A&K$P@1P&:!M.Y[M)_HWX.ULC<5=AC5^S:D M9;/U6B(A3 M10.P*)]$1?>2"Q5;>L"']:-)[O>S>-
UOSRT""*+*V9-((M8HO8?0]%@QA["2 M%HO]3MP#A<\_!_).)R^9C-EZ.W*T-K3$(H&*U, #EI;K/(+D:'"QLB]/NA,D MEHOLM.>)O+C)5LCS*VG%NHK/@)8\Z=^@BQ72N'RGLDE#9[I+N9FQ-;Z:M&>S
MPL(Q&)#6Q,N28_1T]_'+]Y1+OLIP8#7B?F>':C]IB NCW*> 4YWVO#U22# M D_%I>W'5;$_;Z M&Q$9]*UY^Q1>D./]2^FK"X72(*!R^W3X]"5YO2=8C][X M/=S9*-9CF!%/&FVCSX/ M#*\YR'D&>WM:X9&\O&
["8A@>]]R%%!BBX^/KVB:1HZMRO_G0[>]WI>;]RL=" M7VB_JBA>3GU7@(LDMP2RSQ4U)43G-0:UCO+T&_OL*'#!00ZP %U3+M(*]TEG MN7; 26E!-/!]UG/DS-^DVI:0U)X@)^V$)O;4F5]9_;\K_5/(VN6_>5A(F4@
MMX22M2(N!W0[W)^TUK1QA2P;,O.0*2Q9YQH-T03G!C12T_(G/+-,[_^;-'UDD7,;=&+2"+QO.A:# M06QDWH"L'85KI'YX.Q&'#97PV;NUE#5(!W3Q]%8I>H3*4[\/'TH3M?:1,?UX MX;)\S=QN"/1U+8 ;88%)A45:7YS?
Y2BZ9X]:K,2"-MZV&NLVYL-#C]!>P>40 MDX(#D2G5^K(X96W75*S[FO2#4),JX)U]QO:#U#:/L//CMN:]6:,5''90!_6) MX-$;U>P#$/+.,OC8]_0VQU%%"RN7,S=]83;,&0'!1<;4ZV'AE?^A[4FJB<86 M]20*FN3-$E(I_;RH_12
M%N'<@]H6=F)LFI=D]]2>T_;\A.."I%+VTC-[@336GRAG<&A9GRM^SQ,]+=BB M[8$<^K1O*>"8_'2-)KYTO;'*POVZ76R7Q9ZOC[>0 /NNM_*K$V/S4+:0ZU]) M-9[PMP)39?;GD A;D40_)]E%(93"!P*QB!BB.S3*
[0PK#=DCCZT;:CO\!+DG M_L1E3SUEMWD9?.DZH7$/WD("-^17KDC ]<&-;WEL *!]F/-]+(7L#9[GLB86 MPWTA# T1?D\*6I5' O U!F=X,!*0X\8#K=P^Q!"R)2TY6M!*%V/NGY#]EXB- MH@>OS27EDS*$U6_]$C$X-3#50.'7M?
QD+?/:XO37<(U<]2O0R#OG6Z &D2 $ MY-K!PQ\FZR9,N/5+1P)1A2<,CQ/N^CHD9$]VG1%/VFXXT!(O$4RY?]S.EY! M)*B#%M#17_[?D0/O1>&\!Y8UL,(K3WO8Q5K[_[S^TY&(&V"H*]A3S(TRP) MQHL =3R3/8& $#SIQTB
&+3/M)EPAY'[$+:]?T0#6X$3,!9$B"D5$NA1[H:W MR8S!:! A.33_]GC\(!7)XUPBR<-UNH>OQ!]BGUG=WE"Q[B:N>#%M]\K[WCD<#^^QFL^[Y,)!"O9R0/ MN,DNYT@]) 8)R@R_\9T1/"FW7$.@*T%;"\1FY%\4=$4#V[+?_+T?
K)ZANPI M!1)8GKY/V*]YH1&"(0&7&L2/OZD?,0B;O,>_9D%LLCS\]N@A(1BZ)Q!YF.1! MOP.+[^6!!YJ63,4>%I]9 ZTRR<+;:O"'HJXT*&P@@6751H=I;8E?#>0_!0UJ MB:)B6^2^/N5*@E'<)2 ('S1RA@3D-
;%,_H6MCZG0291,X[8=XYDBD+02_^AZ M0EM%3%3*%C:%@P M#,M#*7 )-']$M>.B1->;A^_U+:HHPW:%+=[;:7#^F!,13!0]]@GFH]+_[AI; M0YO@L-O](VQD\E+7%;]_L8DMV1H/M;^(=S3:B&KD3^8L:GN+Y>5[O:61I-]&
MI7E8T_*D*"-PYIG=&6>2S$Q?)A+[=.*!3M=.G!+*CZ&A$YZ?M>0P2!_@CCIX MA"'/;;O/T?@&LL#V/_9OOX-Z[2W2+FK(_WN%\?=P0P)$W$Z\_KBE*Y!>UDOQ M& ?7ZEVQU$<]-S@'BZ>$Q=RD_Q[I_PXHXSXB@X,?
ZJ.U;D!:Z/]41T0!'P3\/^S#^ MVA0:[#_-'@,Z&7T:]K8%K?'LX2OCKCQ\TC)!7J52*M8\^9L!NC^P.Y:M&Y.% M$L167R?%7E?SG/49MAF:&$U:2^^D=GC!(.8*L(;8Z-,>(>>^SZLH6#01A%IR M=%,-LU4G55#Y"&RMX$]/<1Y=T;?
>VUV4RN/D8: !!/.[W4N&(89H?IL[;80V M[YKBQN^[DP[0 M(,G_J@#G\]=S]P,?:!]]VDW;7E\G-:2D-UR.Q?<&6NW5_F)]FX O4L,>><*V M:,A2.MR^HU^X1"(5/]C!^([!?\8GYI7$K]3._!:^_G2720XT&?-"S&5X(I?I M?
Z[RB\L/%ZB?Y+)=%WO2-3: /BH38-72@R'5BT]AA&I-G>=.Q5)-4=(#G0T1 MJ",MA40A;S]>3F$BP!7Z^Q"/])NX42-(B:C2O8 Z\)LUD7.),4CQI:DMC+// MN.-;9^ZM!&XG#V1,Y.@ZI+*>H9-)#>R*%KX7F[)(MM^D)KC4L_BX4I
48TMO MG70KJ1U-UE@3_>K_LWETYYP@?>HM[4:VU8:48Y\8C3O"/-[2E[3>$I*M5>=[ M@H\,K9=Y\NLI>AV+!'<%5KQ^XIU-4@Y)5WB_]8-?98)GH-%&,*H+X@^0\%O+ M&SW)GYVR;VO]TN:O.M/3 >G!O-\Q@C^VXMI?
Q)5CNF !@1XHQ9O.CW.)#Q8I M(D:-9#D/C4"<%I=QD53OEVZ]]D9[SZM3/(N,[&R]'@L/%KNZTP].#I^D3G8Z M_^OID-:J!EU50S,),7,4;BN:&& )T]:2H[?Z:49[9-@=(TQC\F'0R(]K\5)H MO.8FC\AH#/1"*_7/6<859,]?
JO#6>P!_$?'DT4.!"-.3_U_NR==]LE]:FS*AR_K/S M^6_"-S?A[GV-C0QS\H9*$CED0]5H$1]'8F_"BFV,C\E%-O))D+1 ].4??]N/ M4D^A8]LMC;^H*4=]"^0/\]!N!-JH?B#9.@P0:3'.R4-/M]V7Z5K:[*%_6(?DB,C,9?T^]M2XKF
M5%$$I=0.-]WHL&H4M7(#RE)%C72\G[L70^F&NLWE^C3R[3ZG34;L7VK+!]..N-+R9B(7'8B BD721Q7?].@?3M]7GGZ]N M7&+]B$>/,%$WPHQ@-Q QQTA5 U<_;,';T_MO$_>DSZ1=)=*>5W' MC(D[\HO]X"UBHP()3)&"?
FHC@7#]C9L)041WRA_],1A!79F^W?K;%' ]?E)' MLD!0^IO4ET&@5>X$%PXTG9.;YGL4100&+USK^MX($52(!%#3][B(C_HE(N^8 M/Y:T.^Q/?PVJU2S53W?ZUZDV4:Q?T2HUT5Z W\,=,_MP YKP$_)*8P33FF[][_UL]\^O_?
S8I?C2=\Q>T]"%=_Z\L]"[LHOYQO4A#L< ML_-JT(,9UMC!I>CY&0HJG7R9KXFI4)FUTLFG)[;CRZ*AI/I S<%:\^B/!^I M1&5CM'Y"0RU*XI!I?;=7HQ]KB?7^[VCEY(JST*R/G&R=P7E!]?:K$]FG,8P?
M_).&P_22!NOKN$9BAKM0RNWG;%.OM >-*YIFFU%9XL79R2HJ5P-JOG?;H"A^ MW6XBZR,P^4C4>S.%N>,V@038M&4=R;JO7*I+6BT>GK0"&LSN]^3HU$C_+<+_M$Z"ZV:USS+-9-*SZF;BRPF%-%-
LD@(4&]_P%]PZ]SH07=T=3'IL*)?O2O7+X MT1ZD.RE&%\!Y]LE#WU\^;^U E+A#RSA/P0-(%" ,E-03+/<7F#V;N%@Q4P/W M^C%+U1H.QE"ALM"+;&W(&@('.OT9M!G!M6]&(]5#^]]&]?W;VZQO.^[%*X\]
MNC$.%Y6EMS.XU_IUH9[)[VF^]FU.W5;/C_V-P$)1[1H(/_M&V5 \;8URE!18=G#S'>3L*H/RXHY N2AK"A.'9XUM7=N9 MOUA*DG8XYU1DYX$:!_2G_;'H8[S!)HH5)BILF1H7P^5ODTU:Y63#4/-B&"$XS]5V^I4Q0[Z9F;S$
MCB"L'=@=3\8T*V_$DXVE8QXB\.-NEU]KO/=';WF-A19"YH" ]Z&;S! M@GO64^VULOGAJSVQD/>BK&,$KDU5C4A-)DI8'1Z88: =CQ!==P&\J55]7VLW M;:<#&6Y8VVWS-RQ-OY1 MM/S2_UTD6)'T?
XWN6'55Y(F&F_4)&C4E+A'<>%35)2\Z*'S(?-^5BC43COBK]YZ5/@Z;CGP&$LI,&O0 MR8E#@YZI(DB,P&U9-DC !K364%UWZC#0;BNM"?%R?SW55[-01FZEEGS.F=== 8FMGKD1*9C0,:?FE28K P))OT<9?+5.]>Y['^
M6BSZA++P@^.X131??A82\,GN?R@*IO[;-89N,Z+^H9:LV48H-,3R"^58*(1? M?UY5E R024V%/K((LOTVP3Q$O3Z49A$D)GTX>;V>B@2>TYC=WG5OR5&E2>RD MGA9XN((I3]Q9O4Y[_5OQY%\&=0:Q6DB[V//JP3
*5$KERWT<+6\%Y2\%^S?7 M5NS0]KVV+Z>(CG0+OTWESQ5W1AICG^Q2)]IGOK?%YM%CZ9I>%-M; /M<.3\Y M>;>(3F*\>E\&5@E;I;5 R\$) GI/Y AB#*8\:>SM#68@RG=US[SLT/N!HK@6 M2A;@0NS$X"%
[_&P;&U7*$\G^5-E#/IFR(+%D;R\9^\=TRE"C,O@@D';6 M$YLW;P$$POG2:Y_*E)ALH'00,N3Z>V@FT[7(Q\E'FZGRTR)Q4;L3R>_I$::D MI,YFDEDLJCQ<",N!Q$[COLF3==;+IN$X8L0E%E,"@PY\?I*($QRY\T]SO.8Q M@ =
(#919S#?8-/MZ+RBWG#I^XQCY)9P+Q3=2SU5($ZNI6E=(9B2S1,]=Y[4# M]BL>ZN2,TH &+210&.=)-E9SEZHLW2"/!*9/Y.CD_P4?^S\%?)\9>L M "=O'00)3#;(_NXIV\_#EAFR1P(R4TA@ S7A_Z^CH"WZQ\R"?63CIR(EX_!8
MRR!!/<[X>B3 J')V\Q,)#$]A8)\6I;$F^0N*+&KV[8;F(X'@V8'^P]IT/L$0 M<70IACL3^?*-U26;#(-&3\4<*&2USF1)[QTX8;#"!V3S$?&;A@@^EMN)6W'["A^ M1'K!6$0"D8 JD?'9';OAG*&EBLM[HUEK5Z_*I!WK.-
>ZH./G;$]_>L],\&NB MA#'/%QHKU!Y3I!7#P&1_]IKBR89WHBC-%2FE-#$GKW,>B):CF;R])_SK[.(_M/NKK^$0H]_NR/SV+'256(0,N M06&I:*72+@KV G3*PB B&\1+;(70L"MC7FF>@/Q8#P9T1S?#TK@.3T4
M'+].::@;S:J0VCS\5HYG"8U][B<*7-",@,]W[ M[%9( +1X9X,FMK&O 7(']G3FO>2J4P"^D&?M^R2Q=%_TKK.I)F Y)NZ:73\ M3(R4)5<'"+0*/[FG[VL8$]B5E-GFVTT&[-E['=']:C-2C9%PIV2MI<\,9I&N M'Q RL%&SMK
7:45/@AB-.;3F\!F*FK2(G9*B9 #%SA5PWWD/>(=,XI G+EA\55^^(V>WI.DDC&B:#69^4*NAK(H%T4T.NG(;2X2Q>9IH9XS MF7IK/Y?Q<*L,I5ZYF+H7P;-HW?X9D/_#XHS4_3&]]8(]!FQY+7O!7B 2$Y(
MNA(22.2.O/<;0@)YT66E1Q(&LSP]<\ M,"F(Y@#^"M7L_1BG;4P/"J:\]W/PFIV2G<'Y,HB\NB!E>O=]\Z&)Q4CIYXT MSIAWSMUSGJTR$^ C\J=TG:NYAWW5JQ6BSNTWT<#2])UK35>S]^:)>]^!?26N
M7DL]WVM3W%C"]G8&'C4+-1C%D.[-K^I(T=!C/>VVJ)((AF9KMVHW]UB"B-+] MP*<+5O#,)Q/T5-042'&?.[O3 M8H^XD\^/X]6YE868$XVS*:K^O(2T;$29]R)X,0Y*C[1M%H9>FR_6]>RTT5V\
M0SN;J8"_WJ5AB)JTW8RS1Q#S^X);,Z[/?L>AE4IB?9&-%!O^G4=H #/[1--G MB-<6YD5!<>FD#VT.5GXV[B+@1ZBC+T,)6SO-KSB4X/WD 3KNU!Y=.7&(XDBB MYA&?
M!@N)8RZ4]OD%MG2@76(:%AUB14ZL@HV./3OY'KQ=8I7RZ]TS9[XVT)Q M'4DT6Q:NCM:>],0<#0=E0#'WL.-]6+#"?U_G$63V=1-+/8?29+*']C:S]+:F
M.Z_HOGNKPTI^,!N=\A8>5_42*]WS>E]*7::RS:_2384TSW_@I07E[WNN28\1 M(6F>K=[?]-B+C;C9"KL'3"W?,AQRV>&A@P0D:-)B9]H^P5)L-/"V>^%[\[Y^ MW45G5DTUOK"O[A?"\K(2.4$YKG+T,5!"AL,TT6L)F;C-
Z^Z%#_44Z2)G/+U. M7[9)UNH?C*^Z318;GK$QT$7;/%\%]?'_/L+*XV;A*68E&^<;GUH5AP4U*:F# M?EV8:"0DD/_ZY,]+)9$T^J$=J8\9!X$XO4.[]OT#G*R&3@F$14D]*9=()N!LL,S/Q?3-TI@V/ MM R/#*V.')*AW]>2JC0J0
]N9K$\]W%>QU2'?1Y\@4:\^MAA^N1,&V,55NCA M(BTN/'P(Z8$1QAT[2;%4^L1?]V0.;[+^I;?;+QAX]6Z?Q,S9]Y9HL5=D;&7N'&O31,-T2L-D2Q)=.QK+HN_)4P9IE^%!@EZ:%#Z M=,T.4IO&0?
U,Q.)T*5)9ZB>_VC=8$[OYG.2>EXML/)8RJS85R<\WL-4^,#_) MB_AN$&)B7) E6*V/8B!"W91=XR\_+@67V:1+F#S$5OY#% =3L:SL]D5;75K'00TH!]K\W?LMY\?+/KU"
MTBA"M=H33NR."AK/GG('H5E3'0Q(&L"\HQO6)/L@&LL>F] B$\"I_/>^'M+H[\C3GT$2&G^S<.DU\E0?[E=:%B/N1@8BF72#M MC!0*E,X<U&$]]6/G%!4&"W9L,TZ!]0C 2^"D "FY0H)W&%]G%=QE@H]?'7,C9BD=1Y:RFHW?
WK/TWQ0G1/D;.63P5%6\RL@A.EG#>255] =S ME_+7UD*9#X5.=]O<'=/>VFI+KG]7K[;RH]7O[S#/M+%(43+!RC!9Q1<9S]$> M1L+2KX@X]XXBRW*UX/5LV]X)FVI,U87:9?QQ*]727"X$$9\Z1U.'57"?A7]H?"7SBLP@<\,]4?$
&ZS=O9G]'1#SG9][Z:QS MN[\LMYJZQL9;=$$7@;VXHMW9TK98+=4.+\[.8"=6.!7)W_0B RQH/[1-?I+A M:CMOCJSF>5997=QZ\5M1X/FN/!4>U@\W_BR8'*TEI'O@Z(LIU9U@\1A)K(!$
MA"Y]&$5YFT,WJ9!/CK1@+X0[0WSL&1'GJ0P2D!4^7) HF_=0=AK(WOD*Z1MK MCQD+Q#*VA)F*OX<&6&C W_N"[9HO&Q8A%NL'>KLOZ%K_;')GG9D6SC'8 8TV M,FQ+IB-^UC^S<=9/-;J%-,O; R4/>/2@;W=NS-
9\V%]DP&2.+UX4#X$E#P/, M!B!=J5#"QTLK$YZD ITA:F5M7YEFS7W>4 S]CI)5W^TT4]F+?#E5V!RBDMFR M&=O\E37"X(.T\LBA&N K4BPZ@&_.&J-S[A7C2TTW6C]827H3V_DQ(6SC+0AO
M.=ON!Z[D>9$R.@X](WH0@+X5]TL8>>?N7@&OUYEEF_ZEE!<'U5=-R_3/*C&: MD&P9.3@Q&?@/A]&^>]$=5%OX%OV"I@?T?)EJ]1YR::/CJ(E\&K1N]D2!-/YR M(RKZ7GJEU-061Z>&5Q/]O'0W1Q7PNW)@6)?[B<+
M$&G.RL\<_BIT=+A5M+DN3/FDKCF5=UTA.WVF4V5[O:;7, M_0*WY"KEP)CF\K0P5LHQUPC$8Y\B2.9]\QY-/LQFC;"C&[]_OLH]KY9A DV_ M:$$"7>M-0D\;'6G,SN?T/L[O%M.W6K&LLHV@*PH4=.V?8\YOQW6_7H!UQT'/
MB_@*GDNE"ZAAR^[/2#C8HC:/%]+49>'MB>41R/F+PH.*4N"! FG;B<;61T>* M=UR@3QBA#)](G-!0OOU!.S)!5%3BU]#9?2P.U7A$KM.AQNI(4\'91$")2B#O M>P*.%6X\-S;\ /:"'35=Z(\V8[LXG5@E\?W\+
<9FM'$D1RB+W\4H(NHO][76 M391"3*9C)C>2X;'^XXW'UN\^AOQX7]*V9:+UZT2OC_SWS(J&9Y6RG;#XU)?* M DZ< OH(A5X<0C3Q&JTU\O "S RCBD\GYG^*WLV,PD]=QQB* 4LXUXN%!GQ.
M>T=G0T==KR\=;DV!KWI0% (CV@RWI%BVAOU5RNQ$U)Q=:1/71FC1(I?MQ(VZ5I-YY M;%/BZBK_W))P8WNX;63RG9N<3$?.',J:EJDX-,!/IVO>2 ]$0.,C,%?0 3)=3!]< M?Y8\IA#]6W^V\@K&%S]Z#N'-&'_N-
H3Q!1"I44W1/CABB//$=GPR[RG^[-D5 M935WD> 7*]OLKZK)#BS/VOD/LJ:PJ]:-SX*%5:]L>]ID\C_>GGYHQE1$P&BM M88/V!7_G[2V_81?XTK!I]=#BY7#%3G6Q&!V17YHIETPXEA2WK\;42(B_*/A% MS)DUN'&<)$?72-
9S2"\|=^HO6+;Z) I4G#;+VE'7GEA8AN(F^BX[;EA2S<+' MKY^C.4]'@]@G4B]G8:!Z=W:WD:@HB&,5C7*1U9K1.LL[C_#YC =- /.E;FN$ M 5VC9&[#*&TLER-N\$DXV8_W?MVDSU:)O"#+KPKY8!XP1OXALK
M*&*8YWAGAEXWV;=:SF+FQ1MS ]L*E7[D>^>8K9129E!\P>\R_'/"MB=%C_S06O'X,[Q%[D9Q M%V8-51C&V+Y)2> G /AS>B[PS1;\ S.\BMUM+8],[:+L/_"6Y*S;]-N3*[$2 M^\H^_>F9]\@C%S"P-
2RN&I[C=>)^9@#Y/JBK0U;FOUV-J8$>G.Q"2#:SL61X MZ*6];-J3LO*:#]:M0#5Y56VO"&O(&#BOI^:>]$PG?W+3,\D,A*"A,H@*5MQ^;L":'LNRFPAA=(<3TU ME>9*[H:[%]]98C:
```

<5XVI7B|$^T==2,V]"SP7&_1EV;=G[Z7>KO@X9=^V7MW< M;6X 6=%MBE_#V<9,PD9CI.=35U"P6XSG_47I8&10MUCGX='?K):**H/LBUC42PVBEHW^B8X MB>[[IO=7(JK7]TR.6)H(WRAQTV,:Y=L!Q?EUC M<#^C7,*8.&
<5D9U:$E|F/EPVSU\8LZ25H0%LE4 ME]=!E7I4M-Z]!R;>$4Z_:&1)[1 T<\)4GJ1-$329?E]37V6:N7"NR&%A^(CM MVZ#5%+3:=],8&=I"[K<,?HP5&N/ZDA)]?,0RB@0V+&J*M>813$C@0U.A%#79 MR6XF6)6[VIG9
|5*;!A'78DFB+T1|+K21DO%FOO0:D3(8'L3GT_*KV_W8M0[M63) ;B67^8/J:2]M\$46,2)HXTJJAP=;NP?@-]R8@BUY\M/E'GRL=GU M!W=[?KS9RN(C4]B 9H4+ZN)I1A2,\IH!QD#"3VB312Z>A**GW:_I6VHQ:B;.VIK\+-L
MBTKC/XM6]&+,\)EK.>. M737>W)W;W5:"[4N614OH.RA[61Z_H*7@?FZ,,^ZJL&^G+3,_RJN:@[&I]G([M@WRN\S#W37$S5>.SWA_??U%!#;B<,<)>9WN.0XNJG]"QI"DXA-I&IZ+;,%^5 MMG[-
*|*6^@0W6<;RW:C/%:,>2X'/EM;"+[4/DHX$!WG-#2'0"59CFT"=//R3)&PON>QHKF^QGD0W6@XBL+U M@S.F.*<\'Y7@Y/S/L8C&"7M9@JM[>_4IQYV69,DXJH*+:BV%O3>#;R/S(81S MVCXTAIDZ]E?M,![P9?
U'B2V&Q;)>'O)X&2:NNMR>NG%QC/"/S>?):JR4V.5 M"GXLK?R9\./?KA])P@B.DJV03/70+/]+6':#EY7NGQ9L=:Y0@M.A:)2G MHE.OS50Y/?HMS=J^K,8<3>,@W5/5F]*ZF&.QB@9%'.GB^+UW6-WJF=9|
MW+R&>T9J*!T9TM.D'7_$6.Q^^QX-6! M'$T3M4E)QJ*:+46:TY[]UU9VCUB /3>O(G5G%KZH7YNB/<4R5R7,K<93Q7WR M"R/J10WD$96'3FS)HYZC)/1"&$3C5L_?K.H_T9A% 7&4'BM: M5)RD(0=-+#UY]]#!#-N9P?
R=55]%+<3$8&^NZ/C%Y6*)W_RC+I:#.M-*"XVY MG(DS^3#O VP^J8&F1 +W(#?!6!<;-/ \ID=[W1$NB,74[_S[#%OGG E4P2.> MN?(-<4?W2T@G\9VU1@M]G>A%-4./[CL][WC+U-?R1)#]%\V\<]XU AU5<44=
M11_LSG@V_QVE<:,YJA1O?C^#__DMBL%JEJ'^WT7I8[/&6[FV"\W\<8C!V"F M_ M+[8B I\J3"=W(.2[.8'K-JX]:WCG%Q<R9D/F>3$ N+6BH%@E0V]V]@\4X(0&E;W_D MD$#Z>X00RI7)!
[L,LNHJ4/&ZL5"!FLC/U1=$01C1J7]:MM_'^72"^||H5PV- MQYV.0U]ADAKA9>W=<<;J"/ M7.Q6+7=M[2$)[[NS.|V$:0PLZM4."4_D14V.ZZY.X@"_)]R_DV(1+G6$;WW*;/FY>LB808]T*&WGL'E-#X:=2FUW_F4L;ZK9_H
M_D/]8XB:KZ"_2QYF.)$Q#CWSS7#EF9"+#V_I"+$X9OZWT0(!&"!]8UL#3T[MP[-><-G[+(A->6GR<4[XW]K"S 9)5@=H5I?#O7&4FDE-/5A8:(DS,8&GQ4Y M'S53#=]@[7-R[2G^[8PW/"N7Z$]_B4.,'C@C+
(>96_IH1Z610*F03*?"CIH M].#%T'::P7C<=HK84JO['E8_^H_SA'"C+G[N8%>K*0;X;X8M.8:7KR.4LM&^ MD6N+\FJ=FQWCOHR8ORF7/FZ7>B5\ZK*P<,]W9H,U2]!JN#:[@NU,

```
(1\Q(^4FCUV%/#\2_C@8,;&\D$F.ISAV;^C:7#*_MC&W29HXG9KK5[,W2['%!_TV4L?V<6+_MG=N5Z.QQN]X_@YO$B%3,XAS[I$A|@+^3;1:_PE:@@5&_WU84[LS=?-:7_2)]_M@[,;KV8@M2HAEUL/TE)A($M)+>(I/R$_E2._1=-
I35K>43$I\_I_//Z,-P(K_M71]8D.V&_>(B$-D=+#62\W[WE7#."LXP224L:JK5];7&[MHSSX":.]'P4GV@C_M3X$K7>_NQ.W#[7K@Q[[\W-7O6$A%XS)YV,'^0\8])9NK=UF*TB,1]4MB7'HR_M6:D-,JDO.V-;@$;]1BZ%"T?
&.]!8=G^2KYU^,:@0+1HT,;ORXPV@.%M8'WV]_MD=8=B7Z[)0#*'&X/PI18Y!&7DF;0=9.S-1[,("G32GC%NCM]&CMX_YBN44A^_M=Q@P&""V-EAL37#,?\[5F[UZE!)WWNR1O'I+()>-EL7>[22!2\^-#
[=6VM8U[BJF1XIE@KA)]_>X]15L7-V-+#L>5_M(2(,$P%)WW..P(LER?@)\OKV"T;(QR^K2-Y;7L>.AHW6'|V1:#5I!BC$4ZT_M0@5^2K2V(_*_4=MP"4CWBV.+9/<:YHI+,'YFSN9=3I^SEU;J%$9P5+0++W__&_M"%|HVS\:=B).U?
KW]](L8!OUZ=K-!QN1[AS,M2,RE-H8IWCS<\%/G;5$1_MCW7??0?C?>]C/Z6EU';E-6H;\_3:K#X]@1_-3*@H4-T!%O"K&_M5+]S=ZYZ$_M#KGME/G]"=EV1F?,G^GTNI]J_N;9:.|!;#(J5BV,5+L#:SGO/[\_*;XENI5&
ME_KX53;V_A*NX=I")<*,#@6'U%4JXQ"M?YG2.M+,;>?FSCUF%1]OD:C('VN*_M[NG"S9'S7*6,(M<0&7&AJ(*6CE=\K)A"BF7/'B%N-:[W<.N1H4S$1"*$3ZP)_M%O-RUC(A_"*!?%J+TL_F4DEI'N<-G"J+AS[9B!87J"?)
F^W%=0=*Q_8'(E_M=(UD*_7X2^Q^HA=TX4@%F;;-AF5M&Z!.Z#E>PP$>3XB7\?\YK,=78UC>EED]\_^1GAK((J4]2],;)Q)P)7/G_M4YI\T?"'\16^O2%](I,N_,1F%:"]8TF:[O$)-H;EU\!<>^SYR0@Q-2&A%Y#)_M
.9+S2VQO,]1EP"#&;.WX%%/^//8$N]*@_M_J#Q=K%K6$W5ZSEQ.1?'P8A5TND_X2[,_;$G=+*=S:+NA._AGM*V2)K(F>>F_M$IQUA9_C?[_\#T6HJ0_"NRC_X.;'E;KSL\MVHPDI_L/_B?XL]FXD@AC?|L18_MIR0^O+V0.].;>1Q1H^];
<&>@-Y8-W_G>0YN5G.\B+QG]H>;%S&UYZ6R4=+2"_MFFYXPA]/4A9<4#&BY"U+B]^:7FCV9GM8;6W3-(>D+>,\KN$NBV(L:/Y1/5_'_M1CACPY1R;D"K%?>A<_M[XR].HQ*$F>_PD;U!/C16"6"F.I?S'F--OSD*55S4_$BN)>!8
M'TD!$NBRH\KX3Q^_$N^]>A8TA\L54Y):RA#&5G7"_F,HLRW-!#ET/<*OC[LD_MOD\D]0QU[9O6?NM,\_1-)/)2,2E%(54-^Y7,'J3-61235C$=[RZQ_R;]#[MO_MR'E2K$$?%SM%)<08E7^;R_LEY@V@;]]M_6CS&\O/^E\>;<]7-
=XM2M?=IE_6_M__U/,Z#R5!EG*G7MS/%&2X,17A\;@I*$;)#]=*=&O(B_#RRMO0%S2X>V/5MJ3+=W)7U=243&)2T_V)"P$!_M.%6W)EN=]$F#9(HZ?"9R_4WK*_ZZ>YH8;_E?>7)0F8?5Q?+5_MYF%/4)3[_(#7F5P/N84A:
["GY6ZTNMSDWDQ!O&1>-(_AKF:!#?T;(,KNWC(7_MD]I>WWZ9@==GR:_W+T2@OOR*21M,AD;JASIK(]X]0:&GH_M,$;!E<3TDV7A);H==08*]IF5H@.1RG()^T=T28_F]P:V6;O7#]3ZARY"'VDK_M:R_W34ZV]%*S*YLU,F'?B#
"A<=QW@._^@P/'G5GMZ15XWE.&I,T@<.90*U3_MYQ5N>4A*!=.-K$!U]3,9]>"_4/W?Q<]+&IVVJ]8DQG4E1!\^"CA8.32MFOX:_M*1G'R&2SE$BQK@2-Q=R*VIR<<9H-JCX:[PV_MVR4D00;I*S.W6#3
+O3=D_'R6O8^Q^:@3ST\_MWC\9C!RFVU1I3//!VOK0)N$0^^WZ((6'11EKBY^_"9VPASK)TRV2[$E;@8=L_M,8S!R8X"OS\*Q)3,S%LLFI;G7VKK,#!,!"=(0XKL;$?A.\*BX%,2G%2C,)M
MMWJ&6'C968F('I4+Z787EAWQU%X2;,X@E6-]4:+H(85!O08[4OVMVQ!M*EO[_M!S>&RA#PXY1VFY#&MLK@Y>^'5&+)0LOF^A++<\W5/@>2N1]&+%^X604)A>Z+_MG[GA+YH:K"4);90]C&2]6]-
B!ZJZ2A>30U"$:*5:Y_O2DF$&B2A$7NM/1ECS_MHWJ-V(ZU.FC-?,W.->)%T]BI-3NIQN@$0N%'3\BFXVUK>0%#JK/"0"FXKVZH&;#_M-V3X?Z>LD<)?X@@];3]K6%E_]F"5\<[WP<';6ULM6%A6'%BY\/!@BP!:8/6Q@FT@^W
M'F_D8,\RC[I52L=AYSKY?WGN8U2[U8ZHO:57\^;\<[_(_#H].'XO_/&D'/&=#N?B"M_Y937K[3,0_MV^A=^%M3M=Z\3H'#35AN8&;W(;M=,FN4[QP7C-WN%#/_G+*(UC!WK_/>;<:"_M#_Z9YL;UQO[.IYG::=BL;+FZW,[U;2?
V#+YY\8LRQ9HZ$>ZPXFG\+Y,9_MP[G0Q1+-_U^7Z\@[.GLI!;JX6&LKOR\'L?NL&M29U/L('Z@G:,G_MP$K>LA?,WMAYG:1H=%Z+[E'\8_;%ID/5?FE5+=N+9(@^B2[_N68G]G3$U_YP8BO0'F@'3\7S(&
MB.)]Z&WM%:9/;4[(IVT7]5:G:B"4F'V:DQ77N^?/M?6]9E!'[&']_MC?EA5[I'%5N7U2/1\L/'D�^47'(U_M]9BH<%N3G8TXBGXG#3'=B>!35]T@;4$@YI?GLDV$C131&;,S%DFXW%SL[TL,_MG)VQXMEHHP0WE%
[@G@LGO.&ZOLBG!%F\[=''NP>=J7;SG_H2CV6[:EF[N#C$O_MU(0=M>3ZR,2*V&9]6U]4KYM-0X1AEK'>&Z$TG<4F-CDX?)2X+;]1&C:AQ(?:QX=>P_MV\]SEN/;0DGOO!WNRD*]UVDF2*LP.[3,EISGP3IY/+_,=!B7:@2Y-]
MMWE-7][6S)32M5_+E#>_U7+^@]A4?=!?1B>14:<3KY?7,1BO+5RUNJHM_MN92Q\-SVPL:O4FWY&/R,O%]-ZQB6I,E5Y^_G[%8D*K7Y[8I<"FKO;;%F!+]N;1*$\*BO7<:NMD,WSM_F_MTZ.A<7R(+!VL^BH06\.HN?R9K)
V]_SY:O9=>)LL3+^7VGT?UV"T2E6GH)9>U_M3(;7A>LH84\Y.>!?Y=!=I="];8[@6EC>3#K:'QNN4N/[I3=_N5[,!:^MZ>3G_MWC/R,*(;?W>A7K<2822[\HKKB"5.&-.P,],!RHD9#V6@@FM#:#[>"'-3I($3
MO,E\N6FF2.L"'0;/%.^9MFMU71QEX/<[=AU@M(!4B4;CM,WU?<;".O6F,B8+_MKP"@IX!_=C*7;VHGY_W@(,YMGN3-59VLRUNB48-E_W?N!GDI6CPW9^>]P%3<-BD5Y/Z7ZV8"R
M6QVR,Z2HSZK6'ANU9)I&&M.&WZ*1K@4?H9G/A=&AQ<%Z9:\[J)V"8];624N_MI["%RT]]W-VI?MR>4>XG)[[;$)U-7H&MFU$?*HLL1!O4>R.^=_&XD=9A<_'_MK?RA2A*9X1;N78;<:N#C39Y.WU+RJBL*!@]_(>&83URU@N
M"%A*U)MUJ)N&I=?\&H2'^_MD;;]\Y+>]+:<2WNNZ[[7>.%NB^64C%N@I_X#_XM=UA/<69P3-ZO_T/=47_VX/E_M<2%.?HGS0S.U1;$9'N%S^O,6PEFC]A'RRZ81$I"^FI66;DBUF2TGH61%^0@"_MZW!+,D5VG_$;HI!MV@]'X%?
U$F/2F5]TX>9>MFSM_,H_&U,S[#6#H9_U)YI[C_M4A);7L%'E,K7H8.@-^%^OO3/?GCC)ZYP)6F),CG@W@$_MQ+&D-X,*]CG(T[,@*\#(RXA5C7/7G8&I[#Z=$BC#:+Y\4!;H%P\$S3Q$?RE&T)E\"P_MJ4LF"N@-
@,%/(BX\BY](=TX:C(V,AG:P\7&(1++?NN7;@"';H?=?*SGN%KN3_MN%%>F8RZY;7,@VWO<;BXAS=_DYO&4X)_3+[TZ]>6GVF?#OR3SZ)?,]-]Z#,0_MSNO,Z;+FZ6Y_*7'[/]-
N)YV_9DAM]Z+KUKL'C'WTXAS=*^)*@P9DU>*&@?:_MVAFF"+G*15QN/]Z=9/ZV*SL)[DB&V*8>8N1:5IXP;A>T7GD#;,"<9[Y\6O23_M]2O&VEK71XX+RM(PKGS,UC1B]Q:B1\8#TTL>)-[I2*$?E-1"=HR[7&(PY:PL
M)@3+%.S>_+KT7+)_]SND=]=GC*4U9_?#2A,!H.O*(K2_9V;CR[%@(^7I8;PB_M[8V[7Z1G[B!Y80UX8Y0Y/%\-0[K+[\Y7V_0*N2[87G=N?EX"'Y8T6]?CDH8/_MC*.]6<5O!K1F@GHC2'X[0Y,C'+W(3R2'#8KO;N\J?
YT^F(EVZ=D:7!-!OR5_MP"9P9^AA;-$6K:;_&TC@4Y>M31-8^I-_Y];6T[BK_M+S/E*QF69TNC5%L01&P09]I/NO380>.U1_M+0>._/FD:*UD2!0]S:X2+ZS8X/&2869.@[PVU#-#L9ZX'M$]'^->]3M3BN9$
M[]H1,=R1N"6A^H3F^/17:TF)\_0%'N):?07A_&ZKR/[."B.T898:_FLCIR!PYN4C'WIN0'UN=C]4'#9?+3C]@IB]]_MHLKRY"XA/!E-)O4?U5\DNU99D7K0)S+'?,6?O_APTZXFA]]N(TZXF3GI@4[@!>W#&[TLQ9'&3[
M$;GM..MI;Z!N=CF?3<26(>:CCACDS6VI]ZT%_E>!K=.Q3#=/D\UG$&V:#&D^(_M>#KL#5#QH0TWTV@92_GFB]J?_?@-GN5F=S^@FF_OF6+R'EMW0R%AZ=KT1'\#_M2;I9VERIF?>:9;'.08C&B=T<)OU&J..IX%'ZW#?]OW
)7KY.AGY(G$?AY[A_M-W@_?MLX$?S-._1+67_C?2L_,*ASKNP!89$BE&CK[7X5'3;MX>M_S)HTG^<_M_FN]:K>?=',LSM/_QMXB[?14%_7;EL".PC>=2C&AJU^4XS96>$@?UQGP_M-NF]Y17_=!15W_DY36=GF$":@GM!&*O:(;")
<&FOV!**,X5>0V_IM4U5/+;]_M<:'9@UAWBNXS+$>N(_,E@01!2D,0%)OTF4P(8^^5[D0XHZ,)^P@HT#L,#IQ<_MA!Z:[$_MW::5IC9=.]O#;Z3+V,&5;F>_P'*==]@W8?<^&_!C
OR%*#QCX9844%?'Z2.Y]46XFW))UMO_]+6C)A9:N[_M>_.,R*^S/$(G]CI)T&EH>IK_$S.%#K1G\E"&_\3,_A[@E$%ZD9\X6P9B58&P_MVE&EGD(<;RJL-]%B-FLF,$:_KM81N9?-UTM'X)O\\]!0I8G%BBBS*@R-?G*\_MH2-%N?
683\N4EES!!D<8)R(3076>R("'\8V]B*]3G_^GWZ@&P<21>_[RH+3;_M2M?]"^H,L_";_;=%C)UV-=$T\PIK$6_!$L+I=XS0@==O.&\/-@4$+DG7_MAY,YH5,_D_&;K3*;2\2(/6ZUBY!T-UJ3,+)E;E1^3_4Q.7[I2(V=H1$?ZV,\_M;Z9L]3=
]52Y,J\_3;FR'^>6@I_K6<1Q$Y4S8(J!_>A$+4'HF#(]U0D\;Q_M4Q+EV?]BC)<3T5&,RWULO#]MJ/T4S=+_CC24B.D0,LUQMZ7Z(-]_8/K[@TCI:B6&5[M=[+F'!7-K^FUH>W97[^B=C+Y]:G"_\L>7U^E'OXFV_MPC?_6IS$?
W+M#9#M)?\&Z"#WYJ$;X!7"G^F$B5GD@5L86B($_DA_'M<*7X3_MH[HN-S>LGW"SM7V+79F_#S;[C=E7H-%Z69C^KRI+_5BNGX6B;,DJTC&?!$#9_MLKGO]]R6?WFQXIC6XITRF2C#^0FO$A'4R;-UZJ5V@P4C
80T1FL7GV^C[\6R_M_/3I$E'@6_?T5#W\/JW@^?_5!B_$FJOQST=?ZVY/!H<'T*H/,;8/%/YEH?_MOT5"?Q?VE>JJXVI_)E=$4V<,R4M(HNXD2*,_GGW8ZG(SMBX^7$L*U0DRUHYX_M\33,[,E_-]<\/^?K)K96SM7RRH9]_PQT-
'4XMP9PTH,9XTNA,8-;_&6VXH>(2_M>;US8?A-(6V,X&U*(%\3B_B"6503MGKT=N]$6EFQ#82DP_MC3'HH"D;**/VD=A[]ITPN;\@1Z_=+(FW2[%>?\#QC0,!20]_=!(P8_M=C!H\X1Z6]-EFBH>R#
<:.)^Y*SOP1_]2A\E(Z+*02_(4_)^,8_M.Z!?.!"@H]+&G+P9Q:\\7=AFYH4-21YJE)D@M\@$;-0X#AI("!]SUW-/9+R_M3=T2AM5&G3>ZC!>(_8#_FIYP_V?#CMLD)-97K-*VI5"58Y/P6UU^()=_7]\F
MHX&IC99W%"&X5@^W:M8/XFB,OU*\CZCDN-+E^.24W!>6*+ER6;(./SC4CV_]_M]";:2YZ[TQ*"])7OI@Z(L5+>>=]]48,BFK9ZUU\F/S?U=@>]>.O1$..MZ_M*9ZOZA5>X-[IZL*%RFX?.^R&*,-
H84YT\0E2=_[&LW@YM_J19['J/TKG"-7F_MG^O[_L7W!(>O$2[%37/_C#\COP'B%0O>LT;S#7!MK)ZGGO;]F5_(V_+P.Z%9_MVA";_6@@,Z1?OU.[FS'?\A,@\O*]2#"$XRMP)IB9!M82NM.G]:HD_M7@Q,TCY<'JP-
AX!/!4@"YM!\O\_G;[W_J#<_NDO2HA.N"W>"CBC_)"-.0"Q5+!_MXD_%[)=?YLRJ]HX_$G05[CCWCKBTRXXS'3#'C+>I55E>&_MS#GE;PQPQKO)0@T,IV_(MN7<30?9VKM0Y4WU#R:C^VNQB<.B7,2)X%C_Q8!$
MH/UR;K3K2X"0V&2S96'K?>?%1SP]I0!$\W:6H=VKZU&_7+BRM^+S"I^@'.5&GY;&"0\7(]'W7,]&LRD'!X1E]\ZS4.?^_M7YCU[K<9.#K3T90ROO]/_V1M]P[Q=[SAN(FG"7APYYP_&W@LYV]$5])DNK#*
M677O+M_7P*"*HXN/,.B<)5D$(^<.QBG,H;JK/A#T4$F1#%A=_)_MT5ZM^O-XM!-982]),-S[?U;:26>N$,M;L;_#&%^U_M1A>3/7%%!?I=_$I86&?_9T59_M=?.P?N,%BF3VDF-35#LV)*!."VU,/ODH/X?[4LXB1<'HO5LG'3V\_RD$_Z'''
M$Y-,!ET];COV+).LGD72PK1!BM%*W+270X>RCD1G6&M,Z+0HQ#ZY:"S5+:0?_M"6]P_44,X.GR?U^]&S*-QEN4TE7$C?_G@+@E0_2,T>]BN9EET)073@&VZ#^%
M];0Y,0_R:#1!Q@W2'&$T(Q=DDLH_,W,0_TR%]9]A\)PN3DG-O@+/@K,_NW@[3_M[E-[/4=Y*TDAQ$LA8QHF&6[&A-+H:[O;R,E=KVPD#%XWVA]/^NK^92_3PH,N_M_=_IX\8D1O;E#-!.L@^MWJ+SO:8I*]*F],4CWX\A_;RO@%*
[T/+:_#><=>3G_M?*C\"HAYDWH>:#WCZ)07KG9H+@-B!IH_LI8%&2:>_B>&@H3HSOL+*X'VS]F;_M41+BZ'3],@KY)G>\_VD*\[^\A0K_Q]D<>X+&+(==YN#9&1CD9^A=NQ#1O+'_MQI:B_5?>R_X,%95==?NT4H"H!HY%**9X?
=._M4_SI1C>,)SNQ/VMX>):_DYF@\I'4%\NY]"M59"=/1$X@_K)8_3S+B70FU.>U_M\71=794Q+]M!HZXI>RHC0X9/WZ5]]:&M].=T1_4U,;_LE2WF^"80H4^"F\'BZ>V9B_M?
3+P%,W$PK9V45&ESD2(Q.-0E'W/9,RIZU_^]*X,1SAM#!I1&I=TFJ9@PQ>(ZF3AX$ES;!_AS=_MPL"#>U=Z\"]LH_MG=EGD@\?NVV5%HLZ;]#[$(X,#0*/O"(<W\$)#U4_GF,$6E@NO'%&I<',5V9:.ZYWR==D%]!A+E2#B1P8$.*
M@$C,6$G8PB.]]/_MA=;_DY$_MSYSZ\T]&'L4Y*E#"&0[S]-OU7]VOG!-TN3(].^?V;:I=VOD6YC+VHFN>F\2>%/F#8!!:_U+_MDTC_/BX87B-[I*17O4I+S@7G-QRTFGVEO+EULI=-LWLG,$9GUY]Y4L_K6Z^<
MQ!,.0Z/UF3S\M[WF+41.IT!Z;3Z]_Q++T,_M=&JPE%^.EB]L<=?K)I?=^5[=TP2M/>W(7&_MHFJ-7+?9W;CHM9>>#EE@P,Q+%C%.8IUR;W\[N]5H@R2:N*_|>%M$ACBKN)6[,(E_M2U_FO[Z#NU]$3-Z&F#%_^)OSE>)?
^%6ZX0OB76S[75$A5[I$O5]K_2HUC,F_M@>R>A3J4=^R*FI^U#]U"R3BLN'>X9>FX375N(]LXG2(4G\NK1@M:+*Y\]|;&=_M78O&S2,#_T\HQQFZ96F1I3]"EYI1R2Z?:!PT!/":F*M!U/4?P)0S5R7#_?P)
M^#.7KF=]@=N507Y!4FGO4W#(Y3]75.5_O=:D3YE$Z%/]H"I&?>-*C\RT*-\?_M&OF^;K_./&_3;7,:"C;G=.P-T7U.TK_I?2:C;Y8#)?'Q.*^B\S=UK19/9YG._M;_ME=Q;Y(WK1EBQ1.S/U&-3O2.
[_B+5$CP/Y3#=U^':63AB=Y%G@0H43G:43_MTE3CH'P8CN&1?I_?_)BK17DZ)X35::]PK1V>_WK_@6!OVX-5F#=TRF]$E!O5@_M2GN40D!(I^<5U6_=3&?V-.LA-?]5>P;U6E'O".$,P9]O5M\EM&^TC!^F'B[
MMR*/=GP(0K1'[*=U[?EPVR,RFSM;3]@P65<-IRA!AW&$\3..REA63PS]);KZ>QQEX#L)@.7#)U>O4D.;=K"%L_MD1/>N?L_8'[H_]$#,911Z9P2M++F$Q*;PZ3[I=!^C$BO_L_X_;[7_S@#M<,_M[#E:TDZR#^=+$-F'38^W"K7*
6FW5Q25I%_M-)"+NT>089[U\ZFU+A8&X&HTUX/E"$]N(]K7.2QD10@MU'@V*+:^\_&V]\_MVLK7U[6\9+%HO<;+]8A8?%A76L#@-X_L_CO)+[G-14X8_RJ5>]"8!\D)AG
M#=5:B4Y!X8N:\UY(%AS3ALT:VMYLR@PD]^Q^(M.HQL4%_)EY?6?\M("'EC*+_ML0'D7,I'9!T0L35+L,B:VM6E0B@KMR&MH#?+(_Q_M]UL$7QC68F9-?R4\.%:T0!]&%N>\TF+25:3WZC2LN,#IP6TW:4=,:=V(OPB4X#=#^LZM
Q%<&+V$'91_FIQ=ZG6R?5%9L*Q<5>]'EA#-$SOSW38=+(-]B_MP]'^%S"A.R;LX/\=Y_C>:7T+V9!N=9]#X_(]=/"4Q_MP.$)?2+PU$P'O*_MJ-\.-V-"YZO/!N#_2I7-=.Y".AM?!,;;.!2'N<>;VC8G!O[Y&+;33L+T\|>_M$#W3N6?
O_/!SM*,6B\R>():=[Y\W_M%/$WIDC\_T+.?:\[S]_VG2";A-5R:0+5)Q"#O@KE]#P#N\_Y.V*E!(%5$]LN_MHP1=[U/A?/AT3CY7O1CU=#/O9^!&?X!?X;@]?(N6#]?.'&$M>G0:9]!@]7X/
M"6EH#P&IE@FFP'#DV)0P7#6O@"MV:I[[G_M8-75D"]N7[8D&A4(']VZ+H>5G\Y/'8N?6^0AT#]+5/CX_M[*C'?-N<'A-4#X1?N?^D,F-_6D$=N_9UQ9YC,(UR5[!W<\?=.<)_7'Y:'1_MH9;>Z)YNERT12"KMS$4!;V\Y2
3WB+2/C\^ZG6"&X\H>Y5(&-DS-\/(W5VSA_M.4VYS3OW?.R.M_32X#LV&TEW0TYK?NY5+.-+W87Z_XF=@(8H>_M_OA!D,S2E7_M_0<59#;?0&0B$O5>9_6M7T5?"=\E4-^UQE:RQ5^O6QAG#%H_U27J6;^]7$R
M#KR0Z/D[R3&^D]6>N-+9VQ7##X^F,-_]'\OL\:<7=QR@SC)P>[_OGFTOG6B_MN"A!7!;(OY8X^]M\$?F#KP(.WIZ_/NX.)XN0S-9P2]P_MH\VR79HMQ1-6T]8F_M<$X-M
ULG6#HXV9^9AB]G>CC/GY9<&"""#56Y+26=OMB^G!^>R\IM",OUIK_M.@<0]P#05GJ]X6[)ZP4^;1VMF$M%X@I+@8,K5MD>\NW#\]3#.'O7<0)9E'_M;/85,6F+*;)F;M@]^BOV]W?]OR,'>!8L8)?:51?_PN)EP%[,%2%M/"*
(*_MA0=;/*K<>!$7<@0/X'B@C#=Y_TC]QG?KH?O8P"SY$"9FH%XN<=X>#3L+95W_MSZYT(?_HGXD*S]!]3/6.UQU@Z/_G:Z:?Z+\LP3GCU^U0(S!B7SC*/!"&&2M0_M;YO[;9R4E6]J"C=Z(V938]-A02V%"WL(_
CK??]+&'GTS^7U2KAFR).-V_MX'5-]KUF62^>3T*?#QM),'Q(OB"#&,N?SFM_M*TDU#]7T*.IBI",+KI\,8$2$^1+V%]ZI+#+D@GF@GSLIR>\\0B^,_>:E4AI_M4P@/K_T&T;87-'Y99[DPS,:8+SIV$-.FOB(H&+[YJ3A6'^\H1D=-
Q>A.ZV4@_M-S1H-M_GB52]CD$@D7O/S<+^?M@);0M827_O4N3>OZ6+_PW!W+C?]&/F0ZN_M(7'(]VUSU"O5D&9F_K>;1D3\5U$,F_*_1)^R21QYU'9=6@3&Z'P-9L,7O#.B"_MN"_SF?'R8K]9Y0YG%ZF@>2:/<<$91)H0N],*+ZY?
2=W"1+VY-+"&EAU_.]^%_M4&BE9'?7J,*#RP0_ZHSE]AG?FQ549_^8@OY+<'HZB50@VI+<'HZB50]>"TE_2QOU_M'K!UJKQP*B$]!D&$S(*UUF+==L".%K:7V?F(&%9MC@PR*^#F96[KI*W07MW"_M0%Q-
ST;8&HGPD:)!D&&%48MF^@3\$>P>*:VDQLON\41[XZ3OY#7'_M1D#*!I!R,3>YH_8W]]]%08LXV$[6(06?FV+LI.O]0&N/LBRWA3YE16NW/$'3&2[EX50(Q_41/##*>QKX27>8;GEIDSM21SS?Q7WE4%Q=MN:+^X:K/&$)A
:">X6@KN[!_GNKL'=^6B"0W!WE^#N_M'AIW=PV03+XS=VZ=>^^I,U7S9ZK_>Q[WK+6LV0_>^W(&RR9]H6$R*\&2WL_%NQ$C)L+T"RAE'34M]\*]_M1H6D--N5T-
R%/O;LO$YA3=73]GBW%O22ZK@EC*6CIS=D'$);I\W<L<8-#:LWE;AFV.N'!H];WJD,1V0+MNNI>9\!N??]9T1@:T:J9)]_MJ3SRT],<=?;(1^A"]_]()>H=+(.:1:Y.L]2D_"!5_ZHW70SK3^O+U6*^*Z2_M:2V:BL1T+
(L+F"HBZ2N=>B(9,*;?53?CCM3([G(-DWTC=U"<"2FK?C5MP'IQ_M/1"5-UC"$GY[WXK%$!Y8GK39,H].X4?RC=!A]^_]F';6MOUH\V96ZR"'1UL_M.X3_Q4F70M'>Z^9H-[EDO%KB6Y5O$LSZ[/9]C$=]^Z3,GV!TC/L_"F.W3SA8
MEBI6?-'1U;GH\%U-0<$[HPE>G31/@C?K#_O[RPT9*I@F/5%!Y[;L.+"[S"_M%_YY6\"LX#KI[=JXE7R;.RY?\=8.VN97!"VMZ.G"Y&WNKFP\=K]/V/I_Y%5WSH/,8K^&!G2-84Y34I_/U'+A_M89.D-9O%]3T<8F,!?
Y@\#/"YA.>?;$%Z5D9TS?Y/439F4)82@.@X*L!K$,_M+]O@##-?7EW;'];%_P2S*N>64'B!\N_66K&3S4HFBV%:HH0[OX'CM^]]_MW!4E7^)\]!?9S+G_7OID?:0B_M;_QKWR%LF5AD7R3_\A]HDYPCP?W'3;/@\V?
YOKI85!2W]E'\$:@R3K,VYWU_M(WGE(7QFSA7[!(^_$O)?K_M7KS\%&4,'R6_ZFU^39Y1>;)UF-]/M[3._/?8#/Y(%[4Z*<@^G#WK*6L%\=14&L%GP',3R$_^>)(@^+#68_M3CU;VW1SCQ4&$0;.%ZQ1SPRS]/:2:4Z*+PU6-
U;_FUO%<CSQ+>|7A-@"P=!L49_B\FJT^F6($,QU6/#*ZJ+]1<_V=+]_M5\_MT93+(>.QCNH?!X^,B[<_9,Q_Q34\]/;UE=]35-V-W(@Y9)_)N=@/T!JN"Q"@J[@=LB_MF@"7N#[7R.V7Y4291:F!O4$N]69&D'I]U"1%DRU[UI_@&A
M_4A@;G\]GPH?77E>^*<)OFH32]"DBIQ]R$_=3];#S&-RL0M>A?T%W[[O)>*_MCDZ0F35A/;H&_)!85%"&K^>;9D-RV,;>(>ZA[6:+S%*T9[KVA]#)MW)7FI9_MMQWH!@L"[2/I\1$_4]YKB%!S_E6W;;NDDU1,I-B%)0S(A;J2=
[5W'X*[V9*\3F"2$_M6R)D_P:A,S13CG6:*PYD_=P/;<"PL%T;LQCLTN:2!2/KV.(>6HRW:"\Y]V]M/H!.;2\*H49^M>4BVS_M.F6^C,K_,5?A](?.CF,6I9JZ>1;3D(;CKU&%@_6!NP1X4Y>!*R_68O*SK^0B_MMB*](VAX4!.KW]_"0"E
0D(\B;W)AKM;_8#[Y@59EN'I*5^O2(B(.ICA-V_MXURB9T4GU\"=PNK)+F=,E[^0+GW&0UCP]^E9)BI?WFU"6TQ*I01I]2"JN*1_MO*KA18_\?@.\IL+'=X8OT+9)@M/?0+"FVCI3G^R=^1CT\C&1A4+=.]MJ_MRP\QA_IG#W6&
[S=@,1F:X%8#(D]8>E)"R5,TLW;]+FH,U4_ADF,4;;EY+D&_MWA%NUS9*]L;X@<*DZN7OEN]XS_HPJA!)K"VX)TR@O/G(+0%-<[;Z@9+Z;_M7J!((M_G@@MHZI>\!ZN90=66)_$YHS/?_FHT,+,B'C;#HR;3^15+LL.SH<'
MJK%'7$^;?:1)H*!X94]OFT53BX=S&VABAGVVPW:,V^_+TOX3\W]]I^VNW6$;_MN?EEB6Z\1\Q@C_0ITW]#K(N^Z"KI/;N@K]81$6&K9YS;/_56F61(.GM2]'_M68EEVGBP58ODGP4(U&ZBDD/>]N\DCP-YZH0]TZ9?
=OC$<=N=?+>1?0DK9.C,_MW*3"A_G(MRS2S3<=VFD%7Z,QYOO4G![_WSR7BS2P'/*Y$N*V-L;VN:_7AF_ME#Z=?\M?Q]U8I-3']P22=)GH3_*!70-"R2=67G15S&N_$.M06(E&D#0'YZL_M."YNA-ZK$W7-
^1*PO)&'Y60EAO(9;U^K;"3]>O7_(%5:52#&CV%?$X"88?5_M5>FW_GM77<7%MC?OE3M;_R3=6D0$_U'E^%[(;$ZI6K33BEX4R?GI]WB7:6!M1_M0FU9K8^M.(_8U#:<8UL*O:V1%30:X6_&ZXN,E8+SIQ'P?B5":5AFV4D]GY>X
ML"_W]<$6P:%EG$^^,PI_YV=Q.R)@U6^>VX]T41YDH6U=BN*H7]#=0AF(OI'CG"M*UBV+SXCP&JV^2(F/M>.5\H=F.;MP8[45DO,Z%;C0T,;9+'0&3U%G+?.V_MFG7,X8DZ$19+,RJ]]!GE$!H:]+#_Y8D3X:J#
DIP>G%]3XZN%^NZ_L.89!N#_M]?RVXH]AJOIZB?F.=6U_:4'$'86]D97[=I\0WASXXN9.DRW98FKUM450;X?_MT93==P&[OK,_;8U&N=#OS_/#9\M?UOUB/-@_^L[]6]@M/]5F8U$/5<**=-=>;_MN71GN1^YL":]GV
2RH"S/@^%!_L'MTB-FVX6.4=&Q_0AYCS\'8_MC"F5TGMD'L]]AF1*+6ZF\0+1G60GA=]_P!&'LKAS1CZW_^=\QA3CC,;V5&_M<\S@V+P53:2-#C+#B_70AI9V54?LE'PS%_U$1]#MH>'U4E&A:0'?"%3!SDX
M&)V7B&O$]"))Q7_=M?@A/J!>^4_M^FMY:'P(K\FDQ//<=>0=DWW/Q?%MG6+Q$>O'Z4=%Q>%;G6&\(]N=UD(07^*N_M<\R4UI<51ZE.N?>K*W;1<+\%1L6L-LZ2QR\+>LJ?\-&\H:+EW[WA=\|9PY'(@\N
M\AU'R:W1D6*5PY0#_->V.[3S)33%78Q&>]F#XL69G,D_2MRC]>5XI&+6PX_MFUF-?NF&!KF@>%^;2#HV*B.[FU!$DY-_)X[XF_M#R@]^)+UQY(PC<7BCV]37:U0%KU,3WQA.,F?ON6O@M>S)(TM
M)5)/FI$JZ(QQ\S_!&4,A01!:0O?I*#6Y(H0<_\V!5-HZ2!QSDG?ED6_M2N[[_@&Q#3=8P?C+APL+UV/F:?3)E*K$S2P"&'^=6Q8:^C]WP$_6#:K?#9V(_MD_Q,FRJ2:_B7T]6?MU66LZ+LPH-C99I,I&T8A!?'X"]@+0_A9Y_>65U?)9
MZI:M]_'P,*7V2_\U1\CV77KMDTV@I6;-I"Q!P_M6,UR.U5@EL.%V?VR#:@WT%#ITY/MTKB9X?TY2>92_5?*A]V]>].ECYA]X6KK_M\B1CM\X60%'G!T!FR<@>ZQAIW@6K:O+_WCO_/"FLVISRV;G)$0?T;($P<_?
M#GS_V;S(:KDHM*AAVDX@]M&%UNI-F@DE()=Y4%F4'76A]/2NES/\[X8^WZ]_M#8$.0?#B;NNB_IUIX"XSH=]9\<'O&_'^""V#RRQ<,,Y+'E/Q#.99@9T67K_MF1?ZMBXT.*50X=3K9L,,;IE?_UHH![.&O/?\$H;3T#(^G+,?
Z32O"WB&60NQ94BFV]_5YRH$/QS6(,/>)L52>"S5;_MJ4F9T(I]_K.=HZOVAD]D1LI<:[Z_*<0MU""X*\E;YUIN\4W.\0<2'KS]RL_M+1<#2?QHO=+FKQ(<8(G#(GXFJQV^QR,[\P+.I6OK#R";F]$7EI$7S]O4'.W_M]#\[$QKQ?
C4EQ15M&W04P<:M"Y=A*WWD$5LA^>)?C8:Z_-U+@;]):9>-&=-+SN3P6[_M+/!4#*CX7*_RR#?PM1R\=KPT]F;6E2ZR>]+WIV1""?SC25:/'I!:#XMU#MF_MM7ZIE5;;D+G&&LB1?=?$/7(5EX2.H6A]%;
MI"UF3=:XIQ7/K%BA_RUYJ?+NSP:%!^9T6(?4-%N+:[3@U43HYOHXX&RK3HO0_M1#U\<=]]*..>W;+(=&N^DDLHY7X20ZC>3IN^5_R\62=Z^;HN<%F/&&*A!;]V
MBT*J*"EN<21D9W%X8'74Z>=O>"!IC^C6.*W;QTHNA8>2@P"?_RUR,.A?L4D9_MR!K6S?F^+LL-]!IG$&WG^;(RZ7]Y]H&]$BIA1BS!RUM^0NY+-QD8UDH]SN7_M>V#T<3UEF[Z5U]?^$6<&-TK5TU'5VV],?.Y?
P?'H,EHF^^Y4SM;<_;6E,IDP_MA,LY@ZK"D?1++POQDK7]L?Q6)M>UVE^7KIY%(/6@U0;ZI_H-Z?,D_..(9]Y_M,^.6#O6^.G$].*7S'+,"/4+HC!"6A\[$<,X<(_2G*.3K'IM4S&Y2,E9H-[5C_MUD.5:"#)Z48L28]-8_%'T
'0544U_ZSZ&R_T:+$N>19KGAJOF$@!*NA(:_74_M%45Q5(4.\U*4+=!%0QI8]QS,%9Y2X.L('0G^;*\6:6E'A-6=;$[L0Y3L;U_M3Q;W,#_J=I%<9VF/1W:RHR9EPN@D>I!7-;5)<8!,%;79)M$$*OOX5R@)=4R'_MI-4-
EA^":XYA%Q.XG4UD];YC%Z(^E>UQATZ?0_MMO^]Y(BBDZ_%0MNBQ#<7LLW)-9*PQ'5SIFC[00]/RB^;RP^Y+KS?-]^Q>?YR_MO/K8+Q?PGF[(G:>R)W*-LT)Z9E>G_MS6Y638\;ZE\D]89*3TWYHL_%O1Y-X6_M1F.)NH'IJA8K?
]]M&%D9%"(+)0+?T9G>;R"FXJO2_M@*PT2A86:VR+.T"^AH+.$7I=X6RDL#UL'TX'A@\TF+|G6":O6[%8)"%4@\$VSOIH5=^>[VKKK6Z2T+7ZIG[[LGH]_;#DZ?G.B_[2Q7_8_M.OWZS%]Y(2>(C=59?
MV#B/N7>4V!).B(97%%$T*/IG%T*%R+6"LR5RMH._MF/]:&PH9$N#>_)]I0#A,^-R_!V;S&)U5:Z$ADL[BE"/TEQT=4P:IDP@QL[_MC7_ZV2A)D5E%?.=KV$#Z)SI\&W(Y_QI^KHJFN;S>_/-W2/4SO_OW(8W85OFJ@
MO41XP%_P3>0U[V]@T[[;GG'@"V9U#(:MEAEXPQPPKU"9NL6)6MZ+L2^AGV+Z_MN)&_-=]>\L8HX1KS\U-_[R2(ULL_F.S77L;<6_&,8__QYG2NGF_M=V*7LG&N'TD?FKEG'UJO-"9#6>XR]@/.12A;Q#V_)U\&_?)K9_D-
^.7_!D@5_M_WDL?S=X2SY*,22N[V_X>LGNG8WR&_NEIT[.O/PAX?'_YF?1LS7RN^=!FN46&_M15T81F-_T]PVS/ETR+DS+D;_MZP3Z:[(K1N:8K6:WG!UQ2X$*$5.VHGQ^6"_MOUULL5T.-U=MUULH%:0,8P(YWWZS8
P@7@*3]RU8U5E>$\R_^IO_&ETOY_6>_M\ELS2Z#C,"@N0E4E2.B*51I_(C7D+KQ6HQ].19W/QBG]D^.99"GYGVZC=0_M'Y30-&&GVS)R?^G=NT;4+_9A59^\U2%35+8G+@;??*?V7GIZ,(Y?=QS_RH
M2S_Z+#"S40\V4_&\4D!4[[::U3S?LP/01)A*N)3Y7A84GNMHO.S&CD@;[%_M"(OT5=Q7G>_"3"Z&,_.Y["W@?^K?@_WD9"16]WO42@(_M_.]]VM+_M,_J1=S]Q]93:V+6U>S]WF_N=D_F_#
MD[4N\3%HT;C%>H^%%S66M31Q-Q.^NX,6P^5)O_Y3(^5_+CM9+V2+S'.<\]DGVI_MXS)>9Y*IK>3WJ*Z^L@OP_2QE[FKE*31\'-O$'C]1SD-S5/IQU]TM(MTP'HDZT+)O6<&\!WY*G.;ZPTU"-EIRN$<<8B/+?]3LOG,VU;
YC^U2_M0_0S5V_CH!_PJB_(6OL3)C6Y5)W&G<2=8GPYQ6KKG&RW'V"?723?G^ELW!R_M0\92OYI*Y@@C?Y_K26MCCIH'Y4%\0=*>O<60U^@.A.P;~>%O^)>#T>HCF^.Z*_MLYVT*S'T;9@K6;@VOQPPS\!D1D3/*=73:%Z]P
S8,/I9$U:)A#N9=E;)_NZ_MDTDIF]J^+Q6_E]N%Z"_-RI,RV$)7_+BX#!=&KI'I18G'TL^UM64@*;%)"X:H_MSG-VL'^,Y'7E/V#"EUB*@6S3/=]'F^]+2K6U45-1M=:8:CHZ*&X&(>8R1%C_M+'-C6]$4VY'
D3=W(EQEW6"1T9O#&MM%3Y%!(!]!OY%1'ID_,REVKTZBK6AE7=]2]KE0:Q6?^W8U.UZRDG?_,<E_M!_5V_<_$*$+_WQ,5L^,3)/1]HNV<\C)+L:5/(_IH6RV!O!L)M*'BF+%A#%TW_MU/>%NPXP]RS&2L,5-GG7(D-M&+M<#/-B?
4)UIYX-RKE1//YG6,WXE;;KJ'_MCX?UAS@%?,BG-?F;P\K!YGUC>&ET?M,IY%51;T_;\HA^C[NYL8HABS&<.?Z_X_MM*W_DAW66VP(@TD[N/75-NL/4G]A0[G6XXZS:T"]7&)V#_+/5./:,UC4H_M,_%Q:F3'+!5U^73
FI0@0M$85]7U$#A<:9,F8N),7CT60AL1=M&:I79?P;?S_MS+UQZ"+Q=]V:K0P]D\J#LW>22X*+YBC*_123!P:"#3,&ZSI'C4]Z:Q/QN@-L_M5]Q=!'#&-14"]@4&Q@F'N!-^_Y:&_0N&;$PF%YA_+O*2
I.?:W;LIOY2Q9^9P.J"_6U&LL\:V+NHZBJE[K1R_^C_M9,3KG;@\TT].2ZTK@[<"64U;Q/_M80$L<;)8W>MKCY&LS>\B<_8AAAE%Q]M3-M+<\MN>99EEA?K6A-),+FVQ\("_M>+^$YO=^?!UO6"?3.21VTM/2*
[&4&63&PV.C:6=]O[";Q-'8@V1&%=>?$E_M!-9+I*G0IK_GWMC?8-_RR:H$?ZD#*-Q^K/G=FZL':9]C$3).8S/]\@?)N_M21N]Q(KC1PYD5_&4VZU%Y(]QO9GT38VU,?YF\3\OXYRV
M!XA][5L*ZO="";EYO3F.3,\$A14[#_@D-3V'"Q=?2CD#D,[!2],'_]([\-6P_MOO=!.F8GG:1IDZKM#3SOT:K1C@.]3S;C$R*P-7&WD)S[&5..3G_M7[;5C=E%-Z7]]'H\RT'V^?3%9I+BI(>*U7;$<(=CPV<<:\P$];VV#P*/
M1N]$6ZAZGQK.6O.Z49/@^!\+%[5_8L]Y=V19.PX-+2X7+P7_MK[<;ZM#BR6V));.YNLW.\?;D*1_?4@RF\&,3<.,#"E4Z"_#F_MGC]19%FQE8:7>KK^"\[@/?PH1DO?\_DZZ5?R,?HE?(7S._1-9D"6GH,!C_MK2XENG1=_.4.;I=SW(
_\YTZX2%I9850]K6#?)]U!\8]#+Z@4_M8GK\'V(6S_MP<[+]+UV?17M?F_0]F,/[B%"]MX4%Q8%47Z&-KF%\S'M,)Y!PH,K0B8@QGU$+]*M#1P+S(HG4QHH%)9K5R,]1B/1I$#X1+Y0_&_MCY1^<7:
MS4]4"NA5G^A$@E2FGNM_]Z5+(;9,_8]XB!$&,PT3W0_1%V1XD)_MP[??(<.3%^6>0E]X#5UF33]R@,/$XZ@9N!&,3,>*==8RRVS]_R%D%A:M67KM^Y:G0V\RSFV*_1!3U?_MAUW!YR0_+6Y,Q_I8H^I
8R]"#NLN;D/5?"$46X2\T_2!Z._9V]WBNA=U>3%_M@O^R9"CUC'T;Q!1/0]BP19(KS*D\2R>&1O._T1C<4+#(-42?0BY7@==9P_M4(\N*+L>!7DTQI\SD(,94X6RAW=.(3OI9:=SQ1-ZZ[5_;!Y+X1^<1O^M;R+-D
M6MF6K=Q12DSA0Y!,1_U4^U6-.ILZ2/-;SFM_$C7&C9))=5"%(K*%IC+M^N]=_M/;@N6E=GW_>O4FBL^;7ILLS+21SO@6C/G_J"'**9XD-WZ/D5&4ZDNW-/X%7EB_MPE"B8X9G#D6+05Z5U:EQ*#U!/FN^E58-
:@YF4J+'F;RTWF_4IZ_&L.;BX@QS_M94[B&SOS)KJQ&%"@WP\@+L5M-TC*+@<+!^\W8-7X]95T6^#$YP2Q%1FX]E,_M4ZQN8P?>VRK^*9Y]S3Z^A_Q[=X]{E*N$ZUBY*18#/(I:0(6-[;;.3OAF"UW5(06^/I:E(P*IBW,CH28_M-
<*>Z_M7Q9H(6=542KL:P%*9[4/;VXR$]AZ%RX*]?F?F\CJMS&J*@#U_EE_M5QYKQG>72EJ_%(%5:3N&XB;]VAN9H(W9]]N?0EZ'.0]R$]Y;M_K??0FK?kX?X%&[_M4,:Y]_F62]NWFY(+NCGQNM3D>,+09U$,'!A!#%Q&1".7XE'6I
],0.6EV?U_M)S$O'G]17!FSO21AN5L5ZVEL$CAU2^G%V41O!*56K7.'LQ#-]I%]%!5UR5:F_M@D\N\;]W.,H=M3ZI"HYAE57=RV:K%='WR^4D[W8[0C8S2=9M.'/8-A5*,8<_M"VBR_V#O$:+]G-
Z9]J2OK##CGDBT:8C(BZY&!,DD7;7MV"%$QWD=?@]@>%$#I_M3.2VE4,^*@&47:H"_\X_O^IKK2D]T!KX]?#7V2NS(*!>:M48XX]N1_56_MVSP+]Z+[#6]C]LOXR.EA!MLVM49L2MY@F<&'-#V=OZ";;.5>IXTYI<4R4#?\_MG?-
K/L!(176C,A;]=Q(?]_B!&XGMV+0]0A*_IF_"A]D%>)/U]1E9Z#\L6MQI_MC7F!4Y>0]])0%4"4.O\]O5K#19V@^7'$5P#8%K08%A!R+O'H8.-:LG\Y+DF*,_M-5=/T\K5-HUES_A+@HU_ED0[5R/+NC&5E&_-
?!Y14>W!E;@?/'U492P1EU04_MHV1@F/O3U_[$%1!A67A8&!UEVB9.FX.>2W5.9"+]$8"C[R/[=P>@I"-N_M&'SD+6?_%TM6$UOWRH:'1#XVGXM#,VRU^5SW-;:YXL$(K<#]I?XDPGSUW_M2=_PUV;<<&8GW
MP4UPZ.>,DC3DFIP;%-AG>\<*BS1H]#9;)FEK!$!]%:5.>'30;B(AC1,KZ/!<_MAQ+WXGBP5]VCTW/DL4'4]9["3)D_"Y.O_Y2>546Z>-XTQ;O[HX>BFA2!=@_MA_X8BQ'8TPR20H;
<^1G\M:9!0NWHB9'77PC6&ZN\EMW#.=]!7'EA!&K,]_MWOHTL&-4]N#4D.LQX\+0L_<]>WW!,^C!N+G"H5!.PG]-PI(U_FOZ_MKE.SX8NCW-22HM_>]]'D]!4Z"1YDS'<"9YA36]!80A8]N8-<^(OS6MH7*M9D
M"S\AM2^VZ6S_*M$CN?)SSH:WJT![;>A+(EQDWO\7T*AK*TX8]1-%A2\H[D_M5,5!_4740+MT17Y+]L%DL7Y55ZX-XN[LKI(6.[D4\E.PZ%8_JT+E(.E2,A<_M)53BC+6@$/DVZ*2)2(1S(IL".^??),?
1*1<&VA\IMV$C6//O+#LUCN].WQ^_MKR.A@CCBWZ^V3Q;.*F7%)G4_5-_[CO/<_DOU+0*6*K=#LGZZX."RX'3%-L_MN_E(@ZR.(%#?\+'R(0<].(.)$#X%2QM#5Y!KL6#4Y>*&&0*Z[=!^&BBI.HB_Y:@3[;$[X4>_E>9?>41:5?
H_M1RJ]>_RI;FEY62^X]C&3,G;ZRKWD]_M_<%69.#2?02A9&?169H9#FMOM:90-*[SU$_#]A"G?;HD*%V2CMJ_+),NND1R_M4]@1V*PLW6KHF^;4X6HEPT/=4+6,0<*,HBIS(@^<)%9";D+GW/6<#.*ZS_M:.<_U.?*Z,T^!;
(.O:G]+$;=;SP4M=7[8K5S;^H6_M[2ORK1^8S&29A3&O>'ZY3CSXR>MJ$&U.W_+N2KD\.8)';?G9/8,]K\SC7^Z_MLQ%H0:OO*8^PT8CZ34_.C!L+AG_M-M'MJ'P9O\:!?K2A%$7$=1X$B@XA?%UK%
(<7EIY/\V?)3@V?*S"M%9M@)1KRM_"2:H^RK'2C/9(]\?:;5M:>):FD&8"=?YEAN@T2F'5APE\7_M:X"2B8*5Q*(4U!,]Z25)B7]U#Q46GU#@)@]V6L
M6\4+*RHQQ95AUB(UC;'9)T")6;;$D0]1#O!19UQ4T]PO3KIS@&6M\S1?+UA$VR.11UW]\/_G@._MHI"4K^.DG^;KNI-;>%S-@2_@6]T;A6#-*UIFEQS1#2!4*PX;]ST2R='J*E_M(LZ'YICH,!SM*R4=B(Y6IS(^>F4.]?
L;.8CR4EC[J7T2_6=@FM[GH-J45]0?_M\U0PO=:RW2)3LXAU-1:Y#B%7X9D*FSH=C.._@D!RZ!6TSO*_<@.QA]%$L8P_MJS=0D^@-[(:].8_8IW[2'22.)*L8ICEIH)_Q*_DQE%WK\-UALKD,D@D>H4)__M?-
```

```
"S0LIQSA'W#U^)V]%QR]?<\-C?M"8AY!Y*Z8IC; I.UITUT_4O7'M[>PM8 M=2L9HQ!^?FX#MKX-)P]R9^D\2UP++RLMG5%^V,#@B':V9XST)IS *06RMT8( MP&:I@@I.$PN.D64=\$!XV[ZO?
LF5Z\@A1#]U2Z9=_^IS#PM/M7BV0-[ =WY^ M!Y1[!P]PI(#[%D'[_$D[?Y%5X,33)-Q8>K 3-.[=JR^>Y/CY01 MC;.=E3\]9ZJ8O^&M+/7R>$BKAOC Q3R)@"B:>?N!MS$YHH+0U.*C*'?GXIRG
M#^D_V*;:KC0M>IY;J!W[75S^W95=#;^&LN4#/O&! J]^HP G![ZL7A@= EV< M#E!491VO/4H91_BLD=:9BQG872B7&X\M6)?(.NGG0TUREL8,QWQ010Y?@--'E\5^^L7W09]:R N;SJ4I,42F-O M?2L-
]W)4#1=4,F27R7,C*X55D<&U9_F9E5J12S7%!],LSLE["I'4(,DD3R?= M&A61E9AYG=5XS"NQ+U&QA=,MLO]2.)Q)0+" LW_TU!(G&947&%([Q13A%Z7Y MWPK+6<+@\\T,M?>5?<4.S-.ZJI]'-C_! M
=&&ES]E3T6407)NL5@)R1L"L>4:(>/GT2#S4&-T+!(G-([<:]?=TG:Q()I4 M:+*N,-Y[1[F,A,"O9O857L2)[P3EK3^[@%BEWM&UM/EFQP>6>DM-DR>%U96^ M;M;X'T=*E%*&[7! D.(4XV14.?-YPR!T"V3V?
A">?]#F$$0M%=6+^\B[HE@D M$]?+IW+\SK),GU%B:]E$L++"6"#)*VXT@N:(30*D" *15.[YDX871X;GJDL M?^#;E7#_-X KH(C(9/]-YQBGT I?'N.EV!1U_FN(8%")$6&H$QQ= \"M>DFX
M5R68U;1YJK+X1#H['GL^R1B()MK%1OV8@=?U#S2R/B"5L?82S"JK&'1EFIOQ MK19U?@U#(,VUI@$,&*/--HQV+,PDY>\E9H9$)@@E%*E$51>S/PKIQYYK6TL3EGUMF[5@ID0^I?"ZT\%.X2HH M'C&N#[/_^B0-
2R1P$!PJ*^^6T/(7E/?47PS/OQ2.5KPCKUDKR'^=+=EJ0KH: MX@2J[MU)Y *B U'/_S@0.TX9 M,I?H:"+/RCDHA!7:O(>,W=L\%NB:TR02?DCP)PTX)D6;SG(P$6'A+TA5!"?T M0AZ_+0VW4-.=,W@Q.SF>Z]3_FR-
69TKJRV!2RB;S0C9@1L*.#JH7(B7:C1:0 M"@;[$SIY9_T :K84<74./V.QR4[6K!U)@]U2,%MB>8&-FM-ADDG5?BPVP) B*Y*SOHA,1E>OL%$CAPQY/1X0U=ZC3-K
ML]"ZNRIA'RX:TS>W'6R")SXG%R!OB4$DFP%UK2N"4Q20P%P:5P!V,L%G2Z%5 M3WP2Z$^/Q4E6\UT)![8E$I"@8Y).W\:KPT,1# /;JH>L;>TLLCCL49?C @,! MOI!2")HJ-H'\;@FR*9GA+@I6MHWZ\1?2E8=
(2+&+K$5ARH8I;4TV=!)ELY&#FJF,LB3WGEXGX=P"0"Z2."AU3ZJ6QX" MW$4I5V:M'0D4%:=&'\Z>)&2-G!L\P+&!_NP^G[8N\P]37EG6@>/,G!*.D&BN M#>9!LO"J-"7+; J S5WYD O,,/R>>%$GG.@29EL?K3WZU.
<@!GU5TELRLF&" MT#S.W_O3V'JQ2/L*?U 9/\+T>XV0666)W8;/=V[E$*!DE\1QH:U,EU^7S+6I MKBET#>FHB> P!?8\J>PM\7*?T-/HS5ENJF&F31WN9*65V6]8$ V U.>PPS\ MH8\7;=DYX1R0D>%6V@FY)'VPEX_\A O=VS-
K:M(F,_4S<6$3_J@<*/V,_M\K:ZTI7"67W^1O>8B=/NQL0Y"&P'6(R<,E\.P2%IV6GH[9@O^+..9/B!B:1J-9W[ M&3M%P@&NX,BDOD[F**5.7^Q)A3CE!MO1]U^391L_8'1CQ&)&\E)?.,;IK$T] MLWXR(W$-
[TAU;:FM:PN1KC9F^V">O-]D-P>''+!AC46ZRY)OSW734\)&W]]Y M 6O*EWR-"MZF+%IH+?VWQ?VT2[HHG;AX]6E9F7:+LO\1!5U? (:3W*SE1TD MT43IFQRT9]DM?B9<71V]53+I6XH+F%[M'D_^(-+DIT1D11#GP
'N\7+!;F= ME:YAE!1H[9)DN+XVH8F]YHW%SC_,NO4!>3S@]"]VJ5L8<.WO(-[-Q8\X\TM MPW2:72,*C'>][RC4G/M=6VV#^0PR[4WL3-]W!;P:=SJM=T',D@?>IA?J6!+A M:?V0,/F##P,%4;9Z2=&)"L@>%*6KA$%;V:]Z-
]NPMM#LSDTUWNOTM&4&1M?A M\B[G)7XI(8!+WUHGSF18ZLSDL&.R@S*)SPL,-&"VZ(\F^ ]:K'@ 21,0KG7I MIH O'*U<:J.]>:[]=B MH]Z??49M55 HA&QV'80.=U&W*]PU&AOO- [M+>T)V]'NC2/@&5Z #26$W$ R
MBV"ECPD2;!^^A2#0T06Y<3#Q A[^=KKZ#$?T?/S M/TD]#G6#C?W?/?3VO;(2MIMV(H!3?^U8:6U/8$Q[?A(GL@E%12WO?Q MW8<_LT,LH [RCKOGR;9VHA9:\9?TQ@(M0DH(Q8)#!'#9Q0\I:G-5%3Z2FS\J
MF3E:;*,MR@@27Z!&)"=01.K,1^7V??LM+#<=E# F)IK&N;W&5%=MZC>;>QE# M.RUKRG$2Z"O8/*>1#8661 FKE;50B9&?>\LO%3W$W\2Y&EZ68) M]XGY3IMB.-6K6Z<6GB2EB7&'0,S]IBHE+F49"2.9&&0Q09
L^E2(W=++:DW M+5CC4E]?/]VR?4D,%3WFE"HY;Y])Z!F8&)>3]@K>/_M7RB9_TW873NL]9I43T%=6EP4O$V=5 M0N8_U47 +5U4@Z[=/VEQ>=]5?9SG*&/ZW']RGA-KD9[0@6#[:3I4%(@=2)*>
ML771%V0LGP^VDB5R8YSHVZE[-9YHM_N8O,-FW/)&[ MQ<^O[?+V>[C !'1]0%EG!QXNVU*8P\I/I9R/%>RH;Q_RS$T45"A&EB^Q ;\D M^E?3:N!T?Y:&8%=\R[;0US)2]Y ;6SJ5;*7:6BV[SZLM0:P8S;N-)3QZ60I3 M[#HW@";A-
@[QH"7A0D+!&H/5XT>]9,0:ZJ]339268LDHL1+6#>?\OP$TBY^Q M-40ECE;?+3Z [OR_&3?#]HS,&K>I7T4"8Q=9L9K*;8M"D]Y&]X#(U*3_HE7 MAW&VNR3^ 0DVUK3C@V_^;+?C=A3X:\@69LU9>Y^0.MIY5B'Q"LA2"/Z*=
V> M+Y4!9=:_F*#2#1@EY49?AUB: 'QQNG!47@F-,9OF974G)WDOKK)\K6,W)O-B MW8@<1A+,9(:N';;J;A5!T7'I(LN%-/5H#0VE W]$IHO (X3O)<=W?K"C59=V?]D6N(+."8:3573D%) 3R] M;O"K@<3^-
\DNCLE&7H'T"..N%%Z&A$?<1'=$B4>MSLOEAD9D/@7)2Z'$AGW? MF4%2/"2"QU,Y#*+,="2M,] E*E- M($40"\UA1MJ]1M[C(-%TBUKMJ4\P\K9/3MJ5N40XY9E+81NFC?^[P5P-KVC M(!)SG*XF[@X]8IBE+4-/B4-
Y#'2P7K;;;8%K_89_WZ82V:^N0OM Q[.]PPWO M#+4TC_'$BYZR8;^'/X[,BKV_4?9%2'>:];,$\7CGQT#0+]O1KKGF@ =U]%V5 MQ-S-J*!QCRSDV&,_X&=Y. G"DK\HB) R+F_9 OIF9EK7TOCLBFL_(4[#9.5" M^+4(\6N)2-
1M2U()=:#-A%'DR'% 7BB2'H%%9_'-=%XC\HU67])3[]WAV.K M1#=="0# @9.6F\FP$#06GU7!3<2+[)93,F;R8AZ_2ULN";]Q&"*H0.)&>(6 MWBJQ^1M;8?U:HK28YC3]+?%>0M-/T\D!2(K-G)PA(96I)EC)?T&PVB$->-XX M1]
[['8 L4CM7]1\MD220G:91RO'[FW4+[ EH;K4QD8+*_=:Q"G-IVSA4QG^5 M$O&B3GC#]R)4F'IHBK>WSU?B%GC<#?Z>=(G B7?#^%'\6 M'H5NR];;88XCBG>O,6T-*7'O5J94M/DY7"LCU <7%04T;O9 UK-H13MW6[R' M+P?
_DK7SSA,^7KV0/-35Z$/3&BSZ>K9XSH9 ++T<,G[99V(F]]^O,$QJ;7KN^C),;L%'U,%E=9!U*\(VWK<D?$G^Q,D9#&R\?C5:* M:=A/Z?:C'0ITR5G!+I6#O4)D4:*SQA'!MGR!$M/)_EP8DGC";(,)\?F7*H=K MQ-
/UF3*^'P;Z7[>DN^UA]C%O0Y?S-YT\^47&;?X?V]_^_Q&4WS_^%U!+ P04 M " #P@6Y9NZN5-:\U #A.@ $ &9OUNG54 M'.^6-=P$]V#!W8.[>QH-&MP3".ZN:=PE>'"W0"/!W1V"T[@[01H/^I([<^>= M>^?WO3-
SU_JJU_ZGJE=7G5/[G'WV\_3S_/,ZX+6\M)PT 8&!F#\\@$\+P&D M $@("(@(\$B(B(C(R$@H:+CH:*BH:(38.)BXI$3D9*1$)"04-*ST%%3,U"0D M#'R,S.P 4#"_L*#A8>'@[NY:KORW4 '!8\-B6'! *.ZD=$*D=<3O^X7"1]R>HN/+7)
M,QJN3TX!R"AO\ D(B6CIZ!D8WW+S\/+Q"PA*O0-*R\C*R7]0U]#4TM;1-3'] M;&9N86GE[.+]YN[AZ148%!P2&A8>$9^0F)2<\BTU+2^_H+"HN*3T^X^:VKKZ MAL:FYNZ>WK[^@<&AX:GIF=DYR/S"XL;FUO;.
[M[^P2'T_.+RZOKF]O?=G[A@ M + P?S_^,BZLE[A>P<'!PB'^B0OFE?N?+V#!P5-R(&!+]")^=,2AXO1'PI6, MRZWN0J;F4CO#^^0TB?*&AGN#%OHGM+]%]C\++.!?BNP_ON_<2T"T&!A7EX> M+!9
#'!SQU"NC.U1)GV6E67/D][;$'46/KLM&I&?($[LHI5,'RWLO5G=TMU. M$-'=%SKD6U9ML#6KXOQP9-VC2QX#KBMHA^)'L%2RU.-9,WD;A\?S4U8)(/@)
MGAZCVA]S%7MF'TB2BYEA+]\T"!S,9=H[DG9SY=@PU9I[)6V3D'6,MQD;T>6: M;_',Y$RSVMMF*[_9[H0&5.Z^V19BLY??Y4FW_W6K<57FL1?\M K5'7$*TUBX MH0ET!L@:\@NE",.. ;Q(!(-K3UWBAE%U.U)XI7GK)]8&
(R)\/W6O*3Q-QY]P MF*H+CF)(P4X3'&5$P\5M3D3@HL+-=Z_'\W^_B72UV]&/$U[ M,UW>]:^&$=_G2AAS;FX(ODH@'O)VS'-E(*BRLK).SMXF:/#,X#'%)\>?*9%! M?!PQ,'!IL:4,+EE$<):5:X]9EF9H:,4_R_M"_$U)7@2
X0\]W/N>6*>%B?/K MGO)T4F,&6;9VY=9^E#RUE>%WXQL*S5Z)'=MZ,8EPR<5S4DU+GGPS/ZGA,SD^ MG5!!=),%)$QHV@CN9HJT!? M5NT3O=737Y4IZ30:U;%'!=]]5V/5<(XI;Q,T\Q/A<^@2(""U7*AD#^W13=1, MQY%-
__7KK/SZ/(P_^_N":Q2[E@ %]EY6(W^9&QGA7'!6@J4C&4L%E;8KT-.? M(4[VIY_Q12-I*"GBE)\(=M5TG]>[YH"%PIYDS_?(;/%/"K*".0G$"@X>8Z8> MK*N*>YJUIE2+OE'?[X/B$):-1%N_@Y8$W4+)&@H/K@6I#]X^_\P2]5>Y
MP[=K)6K:Q(4:XN9C,_7Z "YS?'-W21GN;C_L0R22;+"R'"<>&3/A1PS?$]2KRN%R'!F;+A;E*L/XM)#ZI*%=BY@.''>LB/N$@\;+\2/_Z* M+F6_H>@(=I4EFWK7D"DI09C,W9TZ.X@2BGQ^L]Z"6!* -"B 6S=FN\&L14)Y&"]Y:4A&2-
1! Y2MPGZH3#D_%"H7/0PZH$TCQV(*M9Z MUP>.- !53^1>-2K#>0CZ?CD6MM\B&/M9['H_PB0@$/&3>GA#&6]2;0\6V[Q] MFFHZBPU5YK 2_$&8>&FJE/,,6-,XZ(17R0$@ E KKBJXO R-*K#@#B\3@&8 M$ 09
7L0_8Q#Z)M/Y^[Z[YAQ^O,[J#QQ[1\*N&(D;N2O"]5A)"]AQ'T8; M81 4\P/T\^V%RPJ5\^>"[IX=M ZO]UZ78F&7>$<\NR#X5HZ26^_N>-'*/=K9 MT9^:JU*]L@0Q6>5.SLN?VCC_(U:B[R6YJI(E^X#.8E4@ /<%>$F5%FYD-)-V
M+F!Y+):Z;EN*]P\+H;F(7ZTU(P 7L<&"X&VWQ MH7V>YLT%*WNBW ^<\!QPC)-!P*E<7$4(EB6-]OCY,6,/;:7$. M2\BYA"L,MHS=V'UI]G/4,\"UB?_CT7A]3$+I01,:.645TL17$47>YQQQ;V&;I M&
[MJ%H+W7IIC9$*MQE!B/IZG$"GIU:7FFUW+6%*_0T4GF7YW5*^6#0G;#$X_M=Q,(CWMO!7U5R!WLGAX>'*<3NQ=Y[F:3]IS Q%=1$\,8HB@2@8(*#^UE XO9 MG< ?1N$'9\IX,\C,2F2\A'#NI4)NU.;2EU"AN4
MN49L'H8%C$6N]\BNBA4_HQ5JOT+]0FP#."YV1"=WWRUW4]IR\6YN[ER<_^Y- M6HH%$CX +?=%:0*-9ERU;-)R(H *S;V^I-.5?T1;5/ AM"=O4D(:+?0C7M4ZYEOKK8GX1HC-H(A6-! MA58F/%T>HOT;=8CM<(7-
C&K*,C0N3]+-Z;8@A=86W@FC[@O8Z-0NL?=7#TQ9 M;60Z=>AJ#QB_Z!A_)AIH)GB[=.2"@;A:'/OP?ZKNWX&L7D=#])R6I0M[73' \ZT15$9 M@L]P!)PIUFJFD;S/H"H0%_!W3,< .5)543E@Q ^]8-1\K?V@YF'M$V-%.AV#
M&'2N3]2/D\?ZMU'O+"1^RBCAHPHK*LD^K)GJM$/+(HONB:C%H[28,?36%AM] M#=R6=(.C0#0C-UOT<2-=22*"Q MQ4\?!0DVDG L-6@9_G7>Q'RR1]<>TM@0<;)PO"=!H\:H^6$BT)!VTQY3WT-+ MLY.--
JKW&ZWP,Z!3[HH<[$WX6=?JS'K5?-SLDDGN>]R7PX.%&QX?G$W_@F%N M1<5 RPN?ZI;+]*R!QX2[+ZYU%1:G^8:>$SM@&H$/C]/[UN,G5'HE[I6&5TL> MU+V3A[QK9S'6+$W#QPUQX\Q"K+XR)@9X!\U.KL:UAQT?
8H*!8O'YJHL*&Z#\ M904PP>? M;S8^VMXSU_H,Z-,MOE[MLB)D,7F9Q;CX2B^O"W\E63B=-'-,N#+,]2V "2^K M\EK'-T)CE>I>[3>7=T"Y@D'NU.2WMQ+/@!J,IS9?ZVEXCR3&X8P,4]_W=,5D MIE*.CGC@V@8N?ME/DB=
[>26$].?E!#Z:9%S"B]+YMC83PF?#^P6RWUMBQ&ER MJ;\2$X)]M905M>1:J^(6L'?QPYJO#'H(\8*O,;$-+7?[#Q4%&32G9$DWS$P< M^E!**4K..W_*PL=:C=:\NXV8(.7R&BP#V=T@]:)1?4<0ZD @?6N+HUL']=WP MM?
@1]CZ6X$(EG[1$$>(2(O2"XVK9LE%BH682?$PEHY>*ZQF! MA+Z&6&2*KZUI!-E%/Q ;/L(L<*LCR,J:IR0G' M>]+,CK')MT!%[Y)Y%]3)N7]LA4$@#_#N:E$.ERM/-CM@QLTR5HWM%'O]:5%R M:XC@28#BJ]ZWI7 ^Y1-
'5.!51:L&*9M"_63M;3F8&AG-A.R7=\*AHF%E:AG# M<'ZB1MPU-R7#ARBSDRE2(*ZF61<05P7F#]Z[Z&#%S7!6=<$Y $4C .?/ "P+ M^[R5WV9N<_SI_;DYF+17Y@>QDY1/#)M2;E7)%6] M:^!"I(5?
>3'>75<\M5M#7,6.Z30:X"FDXK+*?16]W'NRB9\!UIW-HH7T#^^I MR)OC8N]VR._9'T&"5YQW4]=6>'Q/M>QC/X8DO#W8-.Z> :D'+UKO53SVMV8M M,Q=SU7][U._H8:)\GO/V+FH][.M%%,=_.!)74
M0^9>8I1HZ<3^D7UE?'V7/=58DON*EU5V\!"3I^\@+;.O/9=VIX=[U7&T+Y;9 M:T^T;N$@8:!R5<;\(X7YE^_2*!C;D.&M%:LK-06ET"6U+F8\/-\&^[L'9&YB MXDQS=2*7*1/C9;-G0%:84.QU"];M9:5>;7W(\ ++NGAQ;3O(!U
8!4P1'U6Z0X?%(T$\CSQ M*1(B@&+7?L%K^/UC!T_O^*MORR]1J\?BX8O6]GNN]"Y EZ6QY&3,V M6GZEU$^FUHL1[O]F4]+7'9^]++.U5DH>/N8#4CRH7U,O:P:3EA9--].IJFEZ MD\&7'*08DLP:]N]_]AJ@XX_SQM*YBT
RN7]OHQ'*H+Z^5\^TU/IAHZ15H4"D MVA%]ZG-.-N'\ZE/.#=Y%TN1,;=LG;W1]P>7.)1V](A&9ZL]\[LTDB_,1YUU' M 9=2];W(&^4/$ZXB8IOV(043/$7]3W4^"LNV/W]R?#$V\/WMOK!CZ
M,JG&VDR2=T%J,%4LLTRO\1VL>+&YG=]U;;D>HGMEA!?[&)Q]=5FPW43%ZSH. MN;R1?L0\2F\G"?1!;)STH?\_\1'N,I?I6P=81[S@#3#)9Y;$M%5#@PG-J M"(#6&K)./30-#WS7\V.E(K$C7U/=!TG=:@7D9@T?6]/>IC%N?
HJ7WH*7+07; MG7*3:J)_4$P<$%9LDMWO:8Y;)H+@A$9[&-A/C& :JIN/L,1^9Z@ =7]A]($: M1]74;]-$GH\A"_<_92M+&2!:_1X"]IVWC;MRSTYH,6U58ED^D9U=_EC-2=HE MIFCXB18[OUK.;N.X\WWI1O\1
(SF_XC5LUZC]3Z1:[=FNB* M?1PZW C\?W]2Z@1]6(:8X: =R9^:.G]R1$GT&4;P?C172WL&J*?N-3FAR]\_MV!<)?BI<**4LLR,K?;;%X40;\S36Y,R]UWUO<=O2G+-^>*=^6IMC42*B
MK9XC5@!_.B<54D8\QEBC)$5L\?:"5'KPO:^9JDVN#>==E9YO1;^)RNHX>0:X M+ZWQ?.C\@IW0TZP[5B(X]ETI9W0=35]L4:STQ-I94[HN8.]#30..49?=$@ZM MSX3
HB.DF"SH'I(4W>>MX]1C/WK)3D#^D]33/0,T3G3I$NA:_4=ALXW*6*%A?%-O6> 0>I)%@(TT9!^NK5IN"C_ME3\G!E_L::R]D91!M$_'1Y![W]'*(2_VM]WP'TC[,@Z^$I4Y/BR;>D:XEHRN MR$MO'V] 62;V9Y<\*Z&5QWA9>Z.
[OTVZQQ+P- M,!63G\X5]Z7%WHCXW?!,K=29AQ(T\1"4U:M!M<+!PFP%;3/SGC&:!,XC#;=> M:;_/KZ^/=&:*.MH3A[C!3>'[B,8B@+(L"HB]L&]YR-4")>((FLXF]R7YS)PU MQ_4;(9/P MWG]H5\N5-
'E@;4?'QB'Q$:PM;@60,M>%!ONV:*#4.?M$N?R"LK M=PS62;0,B4*I=I/WQO<(\WL5%CY\.7P K:,EXZ;11[S#B"G449;$5-4W#+1T MSI=S] 8SR5@72%T3RV4$[@);Z)1:'7S@6G_KQ,1Q]5ZX_](>5DJ@W:35.*L@-
VHW+8*EQLGY='4RTJ M&=BN*?C.,_ ^^A'3Y*KB)*)$224^T?U/VS8?FIL:POVAL]{_.4*,Z^(84,Y/ M,0L6^]!^UE^#45I<3\9U02G&'+FB7%VI<9N[3EW:_T0Q1?4," ]2>(K#QKS: M%_)_7!?C,)2Q?
[O2M=.P2LIE)"==SH'[#.#]!BMI>V6,F-1W3/!@AMU]AD2R MT-3?FX)HW!QBOWV_TA1;'7A_=;W9:"V42\$^BD2Q'B" T%(9Q-M<(,]:L<15 MD;F=X"(6E+W^X'QGEG/;5]!SL,I:VU0;.^P]'Y40O#^*P17[8;6Z6&<:_,O+ MY?
RV!28E8]NCF-X:I5V2S^]ZU#/NU,GB95G,)W-QLR%:"9"%9?,UI])[' M\XKH;<-7L46>3]19B$8.UK"]HK0=T*(JUI/0%#@3FS>'3M4Q>X?>:9>8T6YW M!<=%<.9/0UW+9=-CQRUG![>0U/ADS<>&N-^:_/:KE=8BSP
V:IOW;>G7*M2M MS0K[VJ\?CJ=)CR!/^+> RS6MK*^9P .80I[;\^C)-G>8_X=9G_5%Q(?$<$J M V\=+5GE,1-RJ9;:#O^#(TBQD<&T>1.(<_$*J 7/?=<-+GBP5T&44P<0OZ;=]B]M/HQXOV>E8C0V(@]]%G9
M_8^AXF[9$*ZUQ_P3D/S+_(H"&A*9?@8"[B*R:X)0Q?I'O8SE7? MT*K,2:N98+G?)RWM6[;O " @_>Z0^.%FH=[WFQ+FX=G4_9W;,X!CYF5TE1GX M]XS]OX \HY5UV(%1.:4R7"MJ=N7%E M\H_IRN]^22K0L:A7L#9!BN
8.M&^2UB&?/6Q?0;$1 M9\#@0 $(4@/:UY@-L-,.6DN-H:4%%CC@/P.@AQWR5RNO('W@=6N^NAEFM=Z% MS]0>YQN\E_2DCH9 T#. K.RRTG#"%.IWQO*M-E!!$#3_13HN?72AH8/_)]-,
M_^KPW%KIKO&U]T,LZ10T,"9CZZ5I,CX#XN/('[T5'H(=[PS9'3..D^ER+ZP9'FJK&'FH,= ?Z#82HNUYW)P-] M.2MPXR(_'%^U7>,S0*!2FBRQJ3(SV.JK(G!QK^ZM2KJ2@FI))-%;JF - @ : M0(0IU5?9H*-M!E]& 2^@VXC:=O
3!!L>K?.UN,0%3#RF2%EIA=MI#Y/(RG;] M8M)QE/O\O3X[7F\HL?LK"89> +*:(,;#G'1A)]Q&MD;,8W$TM;7U@FUW[CA] M3/O#W)BQ91:)+]VY5MTL:W!!#?>8Q1"A?ER4W5(+"<95Q__SC9+Q0=.?).^T M'AU!CTA:&6-
/);Y,D^U_\@$N406_B1,;<9".8V>LA#2 M_6OI>]N#?\P3OD&^5::'],F,4/&Q3N'\=&K5.S.V^QGPFYSBY5:4\E6 M_W00^Q7$(10[)+H)G>]A3V[1Q0D]@SP_DUID1=Q)/SZOZY!OR"!!]?]];!L MC+]38+"QXP?7[E]#)7D1N?^?-
#:DA#8\28M0/[6E/P,D*^TK7]\N/0.HR>*> M 89C+S%KF2'>'NTZ?^H(^OG]_DE$Z\!(XE;O22XX]#&PX_J#D:@1:.#[(].^ M&"IHB+WJ&5#E_C1L/3':3G"700A:%'6?:C^XTS+Y3X0:L#1R>62]NOWP#* E M$[N]3OF-
2BMJ$$=K,\$]L7&V2QW?AF#.5M\,^R8EUDQ;[C5BKL/"D:/QN60401 M+LVM.+IHT^C9R1"-Q&VL0W2 W+\9[538-@ +;BI97E2L]C@JD$ZF))]Z1N75 MI%S<(?ZCB*?%$QR=9=^RNI T-6^MOR1WRZ
M9X!C;/'A>$[K2\'1W"B_%#W;OO5>BV'2)7VPV';6P3/@:N<1W>?&>]JA[P'K M94ZA_CG8L,9FX[9RV-&E4/\N>L\ MJ:"+ M26@[3];A#:N?,SX*8C_E'A4H.C1.?'Z(@KLK:*< %_-R,AW!V:LZ)@
M158#^Q+QDJ/P,!'#:+YSX(3_:O,X7-M?)$7-U"N"4P3X;YDKZ_.TY^E-/N D M-+F'[NV2AQ8"M/,B=EM5-_&FP$_C=ITKPZ*]CUV/6X],;^M,Y#&<%HC^.'Z5 M@-E$'YU-
,7I!UX18;BA3X(U,\5P3M;M(>9DP9ZL3A@1"7K@"EP(C<^]VPDQ: MUL]AWT^/+,8D9 8M5#=T[=(55$5,KS.^R,Q/]$SV].UXLRP=>M&'\OB76P:8 M =X7F_JYK!S=SHVI3=?N<[5-(%-]*O+>V:0Z73,)16#B M_1?7 $8+^"?K\#?
[\%^XWP )^UN7CI7]>Y>N@7UPO1"H-NHVA_']MXZ;\\#R M\D]J>YZZUNX9*[/9.K9FOR1=D@=W;'_3!LT+/0,^\^R;&:'Y*]%U'),+'?QA M?_&M54HE%!F8>/;NQ<$E(&A'Q@16435%,YUD%[]1HX"V\P=>GF#]&4!IX!&[
MKC#1@_G@/"QT1?G\H5N4_=.P1L&BDI$)V@8"@K9)MM5I2>4WD8LQNIAG '#N2] ";.>] MT%3LI[LF]TF7'^0B)8!5*_FG YP7)/G4&>'Q>HBKOR-S3T//\>]]5C M9A. WD[]
[\YRG/CP%"XOU5+-4]%WF9)L+5;,:^M9SN6MSE&22&5@./E:K?S' M,CO,%HBP8YNM$ 1Y*8:)8,_1MY$ZR7S)N- $9=VMC\C'J(E<^%_X5 M^;C94'GX,WVCU?UXRP+8-M8LMR,WTJUM0I8>[-4W'5.UV+O.-%$>KJ0Y*O$ [
M%PM7SQ%6_F:!9NT^F1B&XF()=9]_[ <-G_NGV:[@$C/>:KPB< M$+7(D<98_OV> -&0UH=FW-$^0FZ7".: O:LU'4-DB=[ )1+ M,"HP4N8'5A0W>#0VMA74G5K@X34N&R_W:63XP=[&%%-")HR'\;+,VGK^VC>5
M5=7N!BT.A[0E=")]/[/V=8_JP+M8N3'CX,^8]EU0)/]N^#^0M=2V2[- MG\2!]O;^(S8$;N-%O_R?CIUYVP63=Z??QXXD&NI;@3XG16<$L&29L&%(+Z]C M/%K/">>W_Z5P1C#_,/WC!'9\M4E.#-HVF1([6NBX?/NK\QE
ZO/31NLLM?.O M5&]OY/3VR]C0%W'#_C?=&_)KC&? @](784H/^8= MGN9GW=:*V+ROT1?K-N0 M3.Q36^&39./CGXIW64.O0S40V\262 )8[B(/)2J/ M)ZC$LRTXFB@3_?V<8Y!@.PI]NDXS,_%Z@!6'=W6[M?
6[U_W$O$'EZ!9%VZ51 M\5AR_0HF"5DB3'EG*Y=W*:$V]JP&1)O:78G][+ 82 .?D+K(FG+0O?X;-RQL M_Q=UE^_S5R()=13K,]]OXKN/\A73](7?4/Y-GP9Z] 1)&8DL7E;F_AE(:2[^ MKH]E=MG!]A&WU =/,IEQH%;-
JT>=^8>7G,2=8]YMT3\%&EZMMGOP]#;FZ'W-3$PV>B+6\!B)_"G3H!ZYSVM<^%^< MNL#;YAB$5Q1]K4)!%3)*KQ1$&6*FV, MLF(/OT"?A>%A!+3OR\OF.&.=B5C'#Q/^\" M_AT:UDO\]N7F-9GN4H($R]Y8$35 @-
-4C^_&O8*M$+ >9['+RFF:@Z7%88]2 M:9>BFCKJ[@QZ:]?-A"]$=]&:KE!9-Y"R]^7\(6N+V0/\_2]I^]]0=^7_1^]Z MB?VC6&6_B%5W*3RI#DYW;I,AP>\[+W%3/ QXD>5 %]Y !Q9D :!#T=AWP7! M;I[1]%!
(FN7*MKERHP)./.+'J0:&/P*%?=HCZ+]SG!)3(^-.7?;[,!3:G*26 M#TNP"DF"AR/KT/ %KLQR]:BHN\MC0Z&SCB>90;&CJ.P[ M=.^) P,"Y8TL)=#3S;E1:9S]QMC;J;G#N=49(/PR$UQ)N3@#O@5L%C]](9_^ MV*64-
=XLPBAE9.5U:J\3 ;2]>0]-&@'YDBRI!>B:A?17)/QK?-3WB%]<-+ 2 MP_JT5&6N3(8=A4?= #&K(!SCI6(T%8^9D$[K]Q$)H$@U_C:RVRQ>QK!])6.: M8/T=)(AWQ(T"!+#O;9-6/=[\\U4=+/N-7<$/[T=\JOXK5[--UZ%LX7;D7;)
M$WU,RDR T%$S#:,*K:N"R#Y=M,%C,K#9<)QGN<]DL+B#W&77T8$NI$^IKK(P MRN)COORUL$8[D4>*?*-'=,JB"5QP,@(<^]6 ZBU$X^RHTZL_=E.]_)#AJW0U M)PTP4.C-Z8"$8:CUI@'VM(DF4=O6)W[RL!R,
M@(B>#BA>8=*2;@F.;-48];$K#)I5N4;XO]SC7'$#%"')U8?Y4T>#=3>&L0Z, ML8SJ%5DB3-G?MS3_WB1WZV== Q[BA?F1T"^;PE]"ER!LEV &BX' 7[8TAST M[TQ8PC(?20MKTP(S!?4"U"7<)!N-'7RKLQX%
<.,]&GHFA=^XYZ,-,@HKVBA%W3/1M?OJC,#%L[)_]#WY?7Y6/L.$?-/"2VS3',>=^ M)%L3U!ABY41 ?/'5=_NPV;<)&^@RO6R6GL7P<>N:FN'?&/_0K<\!^>P9T-N@ M1$GD/##?&O4]=D!LN"U&#&=)(?^@.0U(#2S1EX$3?
RW+VB';B^' [;K5;&A*T,SIN@IJAU:-ZS2%7R6F++V\KU*/9K!^/Z 'N M?7_(3T\*]&B#]&1C'4#0B72)O_E3?@X/(?#:$L#[=2-*.\E]'U>\8]T^R55]:-U?;1,'5YVL'A9-AI2% V4,!X6BH!5G19$N1D)GK(:M] MB%!.]\YR?
WG^SL7VI$IT+95HXW?2&E%5S+U1;OM,L]X74S_RH'31W#4#;XHM MQE[A)R++#.:L)UP*D\M;0GDCKVG:!#-+&CR%ZYRV3KU\O1^9Y%UF^<_ST_$C MLMY6UI5VQ-4 /Y+C'D0*=RN$32WR4V7:1<:R2E
:Y_H]#UL6]]UQ'EJ;W53E M#:$Y2W%\M?DJQ.DGAO=H]=/D2\18XURY[;&AH[#3Q\\,$3VL)G#-L8Z!.F<> M/7+W%(UMS0&CO+S,-8PTMIKTL$5\47I$ M5QR4>8(L[":4/[Y.VQ4FZ0_")EXV?]%:,1"(-B2,-89C)XA_P4BROC
M_H>>]$59>DLWK=$*]:@X_E68 M0]]RD.O(T15!E:(Y]$'OQLR6".7$FN(RGKQ#1).D5,[4;^K5.FN6&+W+4H<8 M'-Z5(R&NP:;9U90>WIF'%;4W6L].YGGDA>E]D^=BW_.@:$=]S=_/7V9(/L-# MR/:+N]7-
NG#&Y;3^1Z(*I4\EJO^-P^V>F/N]'PM?R$H=XTE0-0QK(>GIRIY5 M-_4 Y$Z3V1!UEOP7AX'^_.\W'#)P'_'"X]1,$YS-_63?FV1YSYI"@X_7@NLF MX6(:O%R<[9H=\)_E^-\B@M10>!S&1P0GCVHTWL&H!XR6HOFN1+8V:(-
VNM0 M6V0(LC&7#6<^LBO)$(X!WC_ASQQ?Z1U+#NLQDIV-1I,.U\_(\9YS9&144N<2 M;'^]TNM)BRZ3V!AAR-)[UX:3G@K.P+K/0[4GIR3L%UA9(CU].CNIXPGWI1XYQ_$]+6A5B-^8Q(W$.6K[HL\+'1>F9VB#
M5.G<5_+P\'",KC5BA_<=P7="JFC\A*&!E(3.(ZWR5C:>@F0;\Z#?1(D-X& Q M=I?/L$<7F,/-?S$S5H#4IGE@*H#EELHPF;9CM57ZR4@'+0Z4B=@$)-<"",TH M#+ AIY4*4)Y&F:V/3">KK#1Y3+O+S1M6TF%W]1C<5_O
M@//:I"DQZ9R_RDQW@-UP51#1VE&;])9_)Y]W4=9[1L7+HW#+Y^^(2S:LP.%, MBQRD@0)=1>@.5^]6-W]:E^"IFB2R2PJW13G!4%P.D'(RM>;Y"5CX<#F3A]8: MB!0%CE6W1&Q*OZ,D8$]FE+%KU=
6)N;FQ=)+!8_0I3I_S@P]E=]H\.7?K:\3 ML:UM"B!E^M_^O@H93^[8SYV\DT0+SW6SS6S*NFS]XC&UH#F&FMN"9;DB%9Q,][V M]LZ?MPT)1DDH%=#O8"(B$ ]@.T@Y 1_2LF[(JGJS)5$B.MZ<:FBBH8P9QYT?N9_CX)C[ MC
HB.F80#[]/^@=7RVLFHSI/MA#.CHQRA),>^!9ST9E'L2XM7N<1FA3>T^9% M"RTD#]8X5M YX4.?VXP*/ OK9+E+)!.?\9C]]W/"03DU%' MMORD>4=#\&?>V_AW-A<$U)X$)_@TOHS)NF5K1REN550\F;4<">R'4_S+@&._
M1K$S2G%BO,[;T![!PI6?+24'U3GMGS7]E]=91LU(X]\-5(U39$7!7)7I=L2R MN'BW>%S07>LHCHI:U9B=WYWGTY&B-ZG#CR2+\8]J #[\GDTYJUN)
M2NYFX92K7:..6=.581CKC2#AE;#A@,L5$.,5VFPPA487@OMFN(#.PG'"X/K% ME7#9K:7&>F751I $\":ZG#+B YP[9XQ)Q+KD>Q;6[@U47T21%G-NF!%R]$-4 M1^$$"RV<<++"N$(!>TD9[^)BH7B\Z)S
NPP6/.8L44E#_NL^66W>JMNA(XZ(; MO/C:P2\PRRGG%4#?5$N1/)K[\IY92VA.ASJXV-5HI7/*3YV#7GBOBG_PYUME M+(\L%@S4@HC5S=U#)K,F)ES@',\VHY/@*XF#A*Z7NX\;NT2R&&G531G):RO6
M7CLH<@9R5Y\L^S&1V"':"26DG7 3"Y376GN<:->-P#+_\DHE.+&?V3HK+_7Y M7% @K=>X]UJ:,+C+[UO6.[71$N^]KH$*#.3BKBT#T4THBV)1+FJ]&AWG4I+V M2%2_]I[?2H>^"](BT.G\MGWZ7E](84K;+-Y4_?X]#;)*>
[<6(G7"K-]1%E!G MNE7#I'25MIS#@#)1;D>.F5;M [&M0_'\,^"J1ISX\B_^3H6G>_US3:4V?NZ0 MDAD[2A!;6F9#TR('+=Q']%"Y%&0A9Z78?_7U"5K/5=)=_?Z8&5%2VG+1+;CH M +NV7K.?[_-"
K7H])"0EJ.0%DT&&LILGA^'Z=G/6&X$_!]](8R4%$)H!=%- M,U^]&T17JE6+@R[58TS?Q.BJ!1=:AQ.I].PX[#2P8E+#:5[APL@H3=M*$]:E=Q)RHSXW$\21&]! M@Q./H*0,MIT4)UPTBWW)?.1G8OIO$FZ>1-(V: "=
<'Y8/ZZ^#^G=NK2]"VT M*2-$QXKQ@]_Y3DD",-$'+\&+#+#(PHSY!9+<=:Y4'_C2:@9I6:6GWJ0FS:R0]C)^P+6L M$WM"6;G:[JH?]RR;H+.6:]N?[K]X@BB4I%-Q'-5_Y^KA!$-(X>-"P#=,V6
MYICAA1.SM9V<(:3@^4<\"9I'!EB4I:ZYY!\&W.Y\],>O%6"6)2CD&NCYMZ/S MP9\4UH]NVB*5PG="911B16+3HHAO/LO!V]WW9FR=W%R##WP424_B?$6#\DX. M9S'V][2"](T?CT>R.*;!)H:W*3HQ+&^/Z!;
[%46%RD8*]RTG=<(&!S_6PB0L M;]4!+&,1]&@OG?M<]M,_8N=&\'(2=**XXPUO S $M^ITYH3Y'DN%S_M*EG6( MTT$U^F$:RM\"^>\[CZF=G42LT.U[#_*/FGT+HHB$YHV&HA%,TPP&\=3W2 FR M/,IS*ZVA$K[E0XY6UV^:
(W7;4KY*A?7Z<]*@CZ#M%:$#C-([KR_TZA+3@B>G M0[]-+/DTAB^_UN;E=&P*0_1/FP1AZ+4M7Z3NKG#7G\?%^7V\SW%<:^-2@ H3 M%57S?].()]R*&F]))'9"6)1#D?N0X>#@";X#;+&TPEC;@^S=["M(P3L7KSTM
M4+^9A7VMO,\ JS8%TP8%'2T104)H@11 (@G3I2H>HH @( M41$($@B"]"8@H%21W]47@1 Z*"""]0Q(4I">4<(00+K_[[G??>&.\/]ZXWSMG MK#^RSSXG9YZU]HS[O/9<+()W__/IO'?]YR'_W M&13GG2#V2Z
]RC0JBBL@2G8**G:*\QX0& 2BH/F_)H#^UT%!245-0TMWB9Z! M\6)" QN(DH**BI*:BH:&FOKB:M#%=1 U.PV']/Q=6DZ+QW177G$IO$O*NR2F M78/FMAS#B]]Z\C]4GH&'EX]?X.HU"/F]\_?SA 6_#WH='1$9%QR2G?$Q-
2__T.>-K?D%A47%) M:5EM77U#8U-S2VM7=T]O7__X-#XQ.34],SLW#P6M_K[S]KZWXU-PO[!X1'Q M&/AW\A]<%""]_PW]_Q47^P4N2FI]*F]Z_^"BH/3_SP1V:AI1>5J.NQ9TCU]Q
M7E%X=XE+.RFO!DTO=LL2S_WD]1@#C[@B]BKA/]#^)[+_;\!"_X^0_6]@_S>N M>1 3%<5%\JC801 0^8S)@T+\&U6RL1#%ICL_%]4/G_YELMVN&EDD5>R-QEN1 MK)SL2)\-9]@J-+]#"O!K52>K$Q(C$:+N.)E ,_QHY&Y#I?-
(;\,>AT=MU)LS MNOL)[DF[OE+%G3'3BX]YHMY*/P]8G#BO@9%"$C^):W- MG2@0HGMF0@.^*NQCJ0EI"\M'].?<%7I]^S)XX.35OD0(Q!LV)X=+[$\$!__L M )U]"18$RE=7NMV]94@N^ F]Z.>G^YEG3#]GE MH*B) < DKE'B
O#NE!LA"SPM(]W$Z[]OLU@=C3L'\9*4\)'=.:) *1#FCD7@$@T+$#I= CKM/_YFYQ#?S=[L2]K^I M'X32;UG^]AE8K6Z:&4=EW#L'A4X'_SH'L6NR!/]HS*4^!ST;I?. -/#V7STK M\;T8A_OW:Z[NS'RO9. M/_<=5@P;I?
S!52MU=#OM^'1BR-E'\J7@R9.]*-(=O$LW5%!=A;;.I0!A1+!^ MATV?\!W0[:U]PI8[G%EOF36T9YJBOJ'VQO<'[\SW>-N!%O6VF+"L7CPMXCNN M$R8_'M;Y;<[DFYDOGP6>=*POAH3]"NN#]V(.
(3IA1I@12UIA/Q.Z00))9MI@7ZGC'_-%+P]ZO'57?< MR@D*"A?/ET]J\K^AU95\Z9%."*944N^(VM!UKQ\EK';]A0?BSU:B3DZ!T7AW<]!G!URP SN.+:")'\.NM2$!E,Y M%!QLVN>&BG4(K-5H;'+G7"
(U1VD9K5L7U\4$_8&U,^N:+7E=[:B4"8(>_O N%1-*1:E0X%8R@#D8AHCQ#W1N^O3?/P?)!F?-' ROR@'2B3THUN#I MX"OXI6(TDAFU_11CMB#5E?N--593Z@?.;@;GFBN,L'D,$X.'|G?]LHMZA/>.
MK'*^BST^^.0T^M(MX(HN?>Z"C/_J*!I*Y]D4+$!([*L.=^8GR-3I<'4($202 MVZY_V<+7CPS"4-J3#0Y!NM,;7)[6/-M-1NBOLC=-&K$4^< M5:^\61*]48>_>?.D@N_F;?6_OY3*3*?W&22_O@OGLM"B^3\,;OK'B=E]_B =
MM]2M2?8^%GHF5GY+!=:#.^<@.I]-'$6\?QP$D[O2(+S2B8HZ!]6;=4+FTG'K MB>HV!$%L=;>D'*PA'H*C+<>D3P2S 8WK1M\LE(N+ &0?,],QVP^AXI^+O'\6 M60\[?/:E7K\LTTZCL4L<3DD*_?>"[<&[12$!L@#$
S;/2TP9AUP4P3RCX1@* MLP:;J\94Q3XF('&FT44(EID.5F'G/7XOXT,RU$: MN]J>MHES2/UV^GJQQF,MN=U-<%[*K8HXME'|V_$A-CCM[760'G>3T4X8%FIC_7,O^$DN%A)KSBXZ?\C[0M$;>( MU]>WF73 V_OSR\L,-:(QBA\J
I=?CLO^$W^YR:]"G6/SR/#1O0(%;W-],_GK MOPJ*6EK$1#(UGRYU$(U=,E)^9SO;^&OL!"FOZ$Y4YY&2X<9D^H!S$ W=6:ZF M$'DP5R 8# =W0KDTI1$WQU%>>Q$"B=O?2T@ZY"[\"AH2<@YJ6!I.[0\AB\!Y
M^W9@TFK$1+PEN;<*5K$K'>/)MNFCZ_F[@(%N^62&Q.Z#8>U! E?3M\].A8/G M!(+6>]Y7ST'1;U$]C"8V72='QQ$\H[C\OR*2WZ>+OJFI-T8X]OP*2\@1]NWJ):18>+ MKTC+9>R05&]B?BF(/0?%,=VPH95H49/+C M-
UQ6*D+OFJH1<2PDLG#I8:?DUQC0?R>NQU\)E];T9@']3KX3_;WDI4:[Q,6 M1NK?@*: Z_5)/,9$E;,,DLFI,URB3VTEN@'"1>X#7U)7(D!Q(YE?-EA]7O#V M\=9LY'#AK5/+?
FX4C^+.O$]P8Z(31<_'1%LXZC1%;]1+ENHQ5[E#4WW]:OU. M9QXH9IH4[ @Z$3M6QEM.VL;KY$ B=QUAW5R/%B@$@\E+GR5@/QGI',N1$"C^ MX>C<#)F!\=0!R"-3()0 &;Q$ST7A-WBY8&%QFA>\.P[/0#(CG,Z2R-< LU[E
MM\4Q)-C5\-G) @+-XKS&]_F_4EC4ME>UJ/%D)GW3CAEP+9?$3849)7'-8)OB M2%[X!70N6PE^4,[*^/XC+!:XB=Q(#3ZW@**RV.YF)P+I=2I B,[#CZ\@,$CC8 MO,AQS\IC@DEC(2:1]:_UL@S@4@+03B$&V^[BH)Q_!ROL@=
[C0V]/;6#E$/# M5Q&]%]_%(F^Z,;/F"6P-,?DSF=)2[W*]3M0D&S-2"8+WC=-C!:X>9? P@8D9 -= 'COU8Y(3 M_3Y:UP2CO+IV4W:.?ZT\>[_D34PM&8610LRV\-Y*MX&A'4Y(9G]7L4,W $:T MH/Z/"PKW#^^]>6(ZEC<+:H;XA]
SAHNG06XI^:7V(>Z(P^DZMRZ$8B\8&Y=U M> Z*OAI5U?LI80YL07XU<< M4_C=6.]H3/8X4"Y3U[?)6BWF&2'$#&J*"SDS MM 0=TU6;:FRHBE=7?B]8.@=UNRZB=B;[82,+E63"H<7=T<>YWJG:##>:6Z+6 M/;UGT5#8'<.-
HQ%6L>9^1ZNX6#Z#(9_#G?24$?_O,/=IST?#D< MRNVW"TI^:,KXJ)$?O3%]!&K2M3F]'YADB$[1=#;X-R!QHZ,8E'/[LN\@U]1W M/<@-57XQ"5!\F]RD*9XWP>\@*0;4H"LOI&E 3?$K*609E_M?S VP_T-]>SCB
MLC/]=]R1]2BV"R50IS5_&\H MNR IE+)1KSOTI3^(A>4NNGK-@QG(,PJ:BZIIV@TQ?D M61$(H:$_1)T3)T>_H68/'X6.*RXD\B!T"-7Q)'U_0?5ST-.)K[E6'8FC$0%K M"C0MS/(N9\H#.E=2?
U!6:%%3!C@K!)L'NI+R2S$V&#D2UP65FW6>@Q8.5A.[ M<^>@&+>=:$\\(YG!__26N[,H<(#W..@FQE<[_9"[A&M)X$B$<3&P>M_1SK@ M7F?4_);>RB-X@9E3!'R=&([WSEX]![UW9H@UK@4D"*R8IFB$ M"3:
(=]7;ZW6ZRE@NA_USE:]/$\BN]<^7S1K-UAI'MTX65,5!9:XI4@VI3?R, MZ5X_35UEQT-!B[4WL/=%^1]IC9+X+/S1Y["Q/4.EQ]+1Z*.#5'RTKUD;PW5Q< MV+">SU+F31[UDIGZ%A=!GKCR@G+YT6N[09E.G:8
QZQ&_IKP9T^^4'QX3>=\ MQ>(-Y_2,$7'S#V_#X8+-UXZ!WZ'!T^83G_L_^S5F(T>VFU%;XN>@$.3?:VT' MJW2DY.KH7**9NM52,_R8$7=3)%2W^! MKPGE\BMX"EF?A@0+LY]YGIASY',B5&[B>7]O1-
W>%B]5DQFMKV*Q*2I)5GZ M(]L?D,?OTRK0B]RY+?0(D^7V(0!B=/8;. <1TB:(2$"48+9[FH^%)?)#WZL)/3M)C2)8G&NGS5EKXLX^T[MY'0=I/&]?+1!\YAC[QM]_O&]],_MZ,,];%]9[W,AP!$L/"F&-
V:S'MJ:YQD^R(P7<#SRN*O6L/DKGWJQV)K=Y*OE MQRMKJ>/MQ#F/[9R]AH;MP)@E/?TA]+<%VU_^"5/;.!HZC07-9O4'SS:O:LT- M##@-YZ@#N--MY1AWM2.ZF3$^!7;3=?9.4Q#:&F51R/PK_1]G)0K*TB"( MBH-
```

```
|&^T=C1:1'&N@K;THS%SB:SRYN@+0_/=01U%E6W$K,PAB$1^0-FFP&79[ M %V]&:?R*VQ#+A8;0WH<@8GCVF_ESP%+QM]8=.^L?P7/9?.(J8IS M4"WV=6;(PV>W1\&2>\F&@EI4XG%Q+E3B[XQF:N*_&W$
8C[;)L7O1)\Y;LM] MA*;[L.^7#B-@IYSD&0'_G3R\F!:P7DBZ >3B$YBA#R?K TAT!&,M+[H^M:#E M1/BT/^NKQV]^\=:EV7;/.]^0?MW#H\V0K+]>W6<&2*;W0R,@8+(Z22Y0CO9' MP7/_QF41P.I5$5S0@<"3A(U7UL6-
MBKBTD^Y.>WORL^%:1/^581^A%!7T.\8)"L:9G5B*L43L^^9*HP5)8G!MH0#;ITQ722/=+T.\7Z'\C%(]:F+YP M+QIER>:S !OWLJF\^UQA"X!C(5V?VIP M!:)Q\'Q"?QB)LY@QTXS'\^2M3-O;U/#^]&<3'(+/'\7@]I4_5
>MYB9"ZVUV M[$XU+IHP!WF98-;IF3M7W/T+SHICC2.+;*1GT,6KZQ,6NEN7*W%@=KA.I[]: M?.7^//R)&6UQ2%[+].'?!HJ289QG+-RU\923ZX 3M3RS:'/6W//4!/]M0 M8;[U2Q$M@:M7Q?](E\9+/I0EA^2)K?,];
(N.]5*=1YLJF/U$NNA3.26VFAZBL M\ASTXL<*&!Y%$KMHFF&:7'"K[HS<;0(VR Q[W)<8.7/2G_BE#<#B/KUAMNDY M22O&[K$WIKB!WU6X7OQ3@HRRZEY?L7?1M%N$FW7TNU.CF;%(VRF[W[(NDFU/
M[@H:F==Y/;BFZ,XVY&+(;EO.0V$\O*BU\Z3$E#+2UZDW\Q$#_>#5H00MD(K$ MY]5SD%L2M7A$,YZ% /"]':J+0!?K=LZYMMN3M*8 MVL4:YS)NI+N83[ZY@^2W=]^A)HX+;I7([#+<5;\Q*OK/!\<;?;1"1YX!UXWV
M'@(QN=SJIADVVUC\@Y![2#?U:]2\3]$^W=[8@6:_\5*5]-9%UA7!;8ZE !. M@IGI!%D.(00_@/QI:ZLZH#?VM6RU_&CX$=ZIE>;//OO_K3R M7 V)7GKR*?49S;W77G="+'OD'2F+/W3FKF7VY]QHS.W2Y/P.C.+VN. QMR^H
MOYKN/QN!=4<)#02?'NBE0S,^!(RP6U@%E*]R)@H_5]/L2.M0Q4LWJ?E]ONC? M])O3:KUMRJ\<9K/5W$G3L6-*9I'VK/'(YV *Q LG]56>BSH7/@>A-=6AA*KC M>]/J7JO::4B.0R2+^[QS9/G6M'(B2VH@SNIY:6F>EYR99^F?
P*2"^&$O/KI# M25_!1\)M T-ZO4[O8] WASX'MXLU09PTCM2+22I@))#P@B4'II=W)>+NC)5]BY.*UI@2=8. 9F99 M6+YB8XYO/XR [+&7V>NOCA/@[3H'Q2_+XF&1P7(D*N S=B\V6&D&INZ^*@/% M0GN@@#%"Y:SPC/W)[?
J2_I86+3W3#'OX9>5Q__UB=R;PXZ#WH-FE#P=OPC]SNK2&\-%AA;OY M[L65+5!_OUE,$ZO^V*+[-_(Z[]OXPV 08*P(X4%(N'\)_D$6!8HENOX0+,FX0UL&I1.<3W'I8Z1&N,QTBY FRS%D!Z7HI$.LP^0;U_A=)M:%A
M4A/DX7R?B-]H]1HNCA99N#N^8OI&;3F>:X;WEZ-I\*_(I0,_JA-HHD5CRK-I ML9].0PS-8N 1ZY_KN#%0?'C\IPG2+A-"@),4"Y?!8>#F4E..$&S[6%83P%@;T-O&EXE3UUR#GE>"N% L@5X:X-GZV4]2X-5LO;-CYR'!"ZY%MR3:]
M1*/>[;,+G7D[[*[A6GQ%HIX*$F/A?.[AI^@##H:"J2B+]% M0LLYB*%4]*5")=\/SE'5P1%-?+_C[WTZ[_HMOP]IBV,U-#YUZJR9I2.W)@DY MD4I&(\2/L]T^4F>][B0\:O^@R@OYO<4[1LMG8R;N;>#I^&2Q+W+4=.N0S4*7
MZ_^QR(7W*8I.(UP645R/,]APZ='O@_G&DSP3F9SNC] MJO=25HE1E3O2L#S"UM;4VUU[<,MQE(-7U&=$'S]Z^HK\H^FB12&]6&,[N(%7 MIZYD-"_J&W0G]_0^>72EOGJ'E7#+%EC W#&+S:%I!/@I%YQ)"@V-(I??-;0+
M]M#..CUO).CZ>BC=R>3WYH'4\HN3:R&80BN2XK>S<(B'L,ZJ/CJ1)W@,PB!# MYG-&)6C2P2]O4ETX=XXWW).'$5Z\W?ON%L:E5>4P2'J 1^.WBI@K?FZ25#;X M[ZRQ$$QTLIX(!%"I(S-0B%(%NMPG+(2*_>!>$EZ]9Z?5]
<]M\&-9;'1CG<'+ M0K[)'JNLS#;5RHXFSSJ'V^5>QW<$AILM/03*8]&G?L/>3<CZ=S.!T^F +PJU)"V\G0Q#6^(1P_&DGF*+M%?8"K=),-[W4O]5PES/+L8O&)2\BN[@WS$CY!GU!.Y9U1=3?F
M9#U]D)O2DE.316/EUZ:B8AFNC_8FI(#E,^&T6#(=M"T']];D:4-LB6X05(^=^ MD.C.09.M N3/GO\R+B1#%>H/GYK_61:J$WEFG%" MJ=)&-=GPG3N)_RAMST&Y,W2%;]8VZ#]0#'&OC/BEOZ 1XV>.T[P$E]*TI>H7
MQ3R!8"GP-Z\">&1$Y@V*!WV13P]4U<,EPA+:X0L9I(,+IQ<;W(>\*)TP[&CD M-+2N>]=Z%3:[X( WS:]8!$(/ND3XZPG*F02.'S8-H5(:D(<)7C8FWVO4WB35 MZ?IP&J +7OTQ^,X4G*,;]L-'?3]!3G7T999*ZE3I8-0HH=G15(X]|>
[\?N_C MEQ]*HZKRV[(EF[@F/ 8^+W.5/2C6?EBF_Y!/R>],9#DCP"-HB0!>342OA"6Y MWT+8 7D82 1^]W:8-H:L3#!-P])V["K'Q)MCS9Q,-U=VS#@,PGMH!MQTI0ZN MP[0FCBIOV4R\:(B_MK]@.=X@90NK/],;<8P9KJO7E/%-
K_K^6 0 M9ZF+MKR["EA=X(Z^R','&/\ &9L!ZQJV@[Q@3%PHV]*>&HF_%D_@=^B$872G MA5TR>P0$9'JW;>P?QF@G(AO"2;&7 OV<19$H\G_JA V"*28+X/W?J6LB,740 M#I*P)]:)M9NHCSY1":&M*7K.X1[1FVLP?
N29'B,&=4^=$]V:^?0 MVD:9UKWGM,N2'$LI(1=M2DHAB&"5GYNK5[6K67&/C120;6LQ:XFW')Y(KVOW\SAT8254XX.DSUDP5GW70._K/Z'QD>9H?VL'+>N*,ND MOS\Z IY*A"EY^2$Y@7 $O5PXK
U:YF+20]"MEHN7RV5WR)DLM(PR;?F&;IY3 +*;.)]SHI@PFWK&-&;5:-.[]]U.F7\@; MDZ'QT%=-@M=VE^,+?9\M+U7ZE@79';IM5K\_!WG)A9-5@)E5:.BR\(4&[[G> MP$H!9!R@@R4)4_WA;C6
CPLND]%8<*X^!1>89FSG!C^2LO5RO:_OXZ/^2DHN MHTJ#%T>W(X6'8I$)9#Z2 B$]_LT6. K"2S()P)]!X-[C=RIM+*:4*M4&-FV( MQU(NU(,%A87)]3.\ BD.#OKA.I+/F()9 :\+Q+B&\3:94Q./CEOPRN";)%<"
M+,9WA1Z>VZTI1[#_*R*4L-HM(E*9T\TR]@U5H:QPF/UFMKU4TP#YYY$S+D% M(.:%-DBWS^+)2N[_/;ZZW9C1'JT0 M)+)N0&!"L5;[,MKZ"GIR>GD67-E@(EHG?]IE7[YB[P8Z%<2L[]CA1\6VO M,*C(&35RGC_F1_F
^'15&Z3<'N[6\]H]7<)T2D[]3K7A,\5AO06S*9W9MK2# M5D=6V4#K[/OEO#6.)#,@X&G):($S?*'+K[6RX:>RO_T;\I7Q)^V-WYN3GC36 MYXSMAO?8V+ 8]5+U@5\K&-:0[4F^9QD03.8Y2)#,#B1:X(FY!"M+0/Y"L3("
M@<[XCER"'-8M3K8A5QCQMG&RX\KPJAD+O*[?F8V@G.*?!Z>S&%,L+V^GLZSY MJ:?5R=+PMVM+!/5=1^3%&L9\U!0G< 5+S^29T7B V7QC4?,N=HV$H.,8!)2X MX] #X=(4Z\6API>O3:XE&+O&FN.74P71
4_=&>8W7@]RMT?[IKW^_JY>X8*X MLX:=@RZI.^$S.YW5"2\$5.(Z;@-]8"]$/!Y?__T[BB"+DN9TO+1]'.BN6YC< MR^@]"7-F%%5U>*5)I&P[QD3NO,*CB.^!=P1()Y3I*T&D1JZKTM/\H@"CU2T" MBY10X0MV8[Z>[8PVXX??
&WW=O;<;/ 6_&W(.759DTO#9(9N"N>'J/&C0"UC$H,]RP6QGP9^A#!=I5 M:QE1!?9"A&.@LSZK=L ?W(IP;SD )5]/71YOR^MA.*H?6]G"]]B M2!A-((,]$E<#A6TZ6^6B?6>K9-4%<:RU\#XPW8]"!R!C 6W)2+DLEFO<,E-?
MJ573DZ?/071M%GB?7K!@7W[5WQQVO&;^V;M59I6>5IKE M3!R,%8C=:?7.%@D/S&]E;)CG( KF+I270>?BTWL6:&"0W$BA15 I$WLJE\D;B&781D>B!91!YY9+I@ M@4H9&_;U\TWQ;YSLB7L64T4-
_O4\#&D_>C:AM<=]D$APS4KOK)(UIG)8IZ^8W^OK 'SJ29TEF0^ MZ:W.2V@R-'N?[W!WP P E15^.1V?1W"19 @I=2E)!NJQJ.)/GAT[O?2,(+5^N47/U]PP@LGGQ M3+6BYNF(8D_@1.KL@/#,JO-H)?E6H&I4S/$36 46\W@D7-
S1EWT:17 V+DL MC[>)\D5>\LB1'7]1-$D2K? @OF7>:KQ0W2B'\9 RA@=.PZM*4PA]'O\E^]9IFB=6AS/2GM;8Z8(IS!>G="0T8N'T%=1WB(C=[T>Z[ MO'2@!/U8]< 2$A]^NNG"+T/8Z_?FZK SL05 -%:*4<-/ZOF>(DH084B036)!
MK3)K;SK.SIFO.PLA3$ YMOJ+(M41+=!$41T-OVK_MV'9X!>!;D=EZ0]M77^TTS"796K\?4)^ZISI<4)D M*,8Z%F*.S7M_N-)"X&%QOPD3B>LSMWLAH_%=!_$]OK=7DY+0HQ-46U!6A.N%
M$@D/[H>"V@+D+FQLW#FH'MR=&+G")]-8V%Q)VXSZD'P8]JD?\C+R$KM7N-'%,E:BVK$P5'3.PFK6Q;KYR#6 M"^[RD0M\>"%)1#7'6Z0::F_]&#G01%.98/_U!]G\!MR5$LUP?N;T4^[*%%IHA MA%^P]PRP<"I%'LC%VZ(
:=J4T]= 4S>4 >6!$B;_TKQ,\$;1$6Z\8.]"[L/'E32K^X&[2=VM*9C_+:GQ 6CZ;%7%RCM]-87+ M[U;OF/"H.L,K*DG&7Z5M]NT7AL44Y>D-HVU+7!,E'^L.&55.U1]#>_/-O%K? M\]1N-
!4U.7ML'D.RY6)1'*BGU?,Z9!:5LU"2VP4@["1"BB"(4XE ]*QZP8AS M0";>S3("1NF1 VJ>6 \SJ24@HQ1+$U(KX@Z:72#3#Y_R!7<*L)1_"1Y"4K9)X*>#7MH[ &$]RLE( M=SBJAW)>+^="<) LR@VOU00P,8LM]GNN!
<#$E(]&QB$*2 QJ>H4+X5" 1&MH M,@)B5GBOIDA-I> YLC!>(EXZ6*]_1 =O8^_>=]O,$? T!6KG77I]?; K#3+# MVYJ\_QX3N!?9M,:=+*_9?MX?>_#/ 3%DL^%9>><3.7#+V\C>O?GZH6S!7?]I MEKVY$+=.UG P"P132>:?(?.
[:TI./@/D<:A$)!4./RG@W\L*@D2M)>P+ M*W>?ZEMDHC,TB_W2G;FR7W&W9[XT<@.<7QUSQ:,#XX39K3!1W91C[=YL49V7"X]?A7(I'DEA_F.R9@T M<\RPSQT=Q?M:MQDGMC/R3!%#T\Z[338V*$\IAZF-"]:J36[U]V]%;;
[5)PD4 M'R#1,M4VH'5BV5D!_22A&CB86/,=[W7\-L2]A(Y[:]O8[)>C014W3A,-;A=:IKU ML732I]CZP5,/7[$[-SZL)4^K51GJ&1$\'H>IRT="Y8C3[Q:V<^/5N* L)S#UYDOQ71&0"^RUAW:)-T%MN+QODD/[H
M]9_8Y((0]I=!V!%5V[FS;MD5[_>$C92D7AW^9Z!+MN$8NALO*>A E/+; 7U] M+%*3A3ENB3=Z?S^H6YQN-'0 FRE4)QD+Q^1]?- W$5F7%U,9EA<=S@!DW+1Z M0.#,W_&2=7Y>:2W?96GIZRS"+>=M9_IF1<*ZP?
\X]UGC%&N,M+1K7\G=T5V\ MF-4!1^>)-:^*9DT"RS=* M/=*^=C]L?FX?N" /$WI9SW&+]H$69UQ"C1F(6VI$2P@?1%=S-*!Z6R+%LL"\ MF2*?>G=I]/AC,OUZB=CMC9RI-:OW&Y.9\32FW&#UQ:>"0UY20^Z3)8L5R6:?
M3\MNS"A[GTAV23E=WJT/]+-VJ/Y>,_0\F!<_'>92/ <@NT^N)15O$*E,)G8. MG33'NQ@U%*XO[]^1NE3I$G7W*7%0Y&F#]%9SZN^%-,1BK.XXCX:EXOCVF-*/ M_LDC^+.&)DHBX6O,LB',9=8EQ_UR8U.4>N9B/YOE2Y"P1
H/OS*(+^+1;>HP M]*I0Z*V'5:1Z!D2+4^T^!4>:M':X]K0V)16=TS:MV.U1HVF9.W,KR\C@=.@U MD^0%V*VLE*X V+)=SX^D="WK+TN6I>5-8V'O0?;CY/N M(^2_LK(_/T%DB"157]C+N8[B(O>4>K.K1;EO76XMS/-
$7!G3^UM>(Q_R76]3 M\FSLH>N'[]+2!">.W8"LG^]9/T]P&TM)#IP\BUT2M*@W% R(\&]*N,[Q[+G9 M4)&GSI^E(0%++++.I<7?E>*U"Y:XVG8?=D;*:(4'$CUM9FLHV M&IN:["7FWQF7'):O&M\E]&<5)54IXOE([Y M]RR-
IK'9KLK554'1>KK#T:92WOQIQ.UD_7WT ??=1:&9*#ZFLR(EO\;>5LVO M!DFSHFE2#U38!M&&KBUL#GTV/Z1''D;1I0#&&-ZN:CJ MSN7Y1'^67858-.E M-E)>#MC<)RC%-
W:0!5%3#9D[;ZV*34]N#BW8.SA[V'#85;#PS,]];=)EUQ7R MW$S>R'!PIK?O-@ME^\)-"9;R7>]U> M04M4,+ZPM??*%S=VZ> 'R<.240.RUL_5/_7$LMOVS%%G%'GW]LA'9$C./;&X M6MFMUR3K%X(?
Y9+8B0Y@'^&XQ&!DY#7PPIQ6+CP8#/!VUFYN87+IX"Y=5$YP M6_,:&\]K,K9,/CS+?[]SM8%W.*MZL$AV,'(8DA,3I;61$7=FQL.(N5%*=[', M]$I@SKGN(B"#;,+RF>AG_>S]]X5:4-RXLN:^G@!
[\61]D'UVUH;K8Z7IMT%/*.XQ>_"A.L, M]@>2N]5!SWP3&/US-J>P3$60ALJZQ71-V^PX*^3I1SWP3+M$5 MZX85ON>1PS/A,B;MVH#?+?AZER6_0._R?OU"96T=?Z6V04%8]I#R/I1-DX&D M!J3DP?N[@Z_B=
[)X4&R/QO,)2[O1GBS9I4#1]/[WF'WF6P^G1&VK8-*%!AST M,CEZ+HR&G-=MQ$\JK/J2"FH-HOC[/TXX.DC?]I-TB=@%*_.[O]>TIEN0?N^: M4VD1(2>O4)TI+NUZB!EIM^\NH- KUZ"V6HH<8-"9&G[2WV_AMG ML!]%
[\GO[7V6ER]KVE,/-Q9:"&X[T835U='M PR*Z75@9/%'A^KUA MYHT,9W\P&"\%2&C]DA9K%0A?\/PP+#S>#_/ ]S(7;5!'A]!?!N<@,9DHO#D] M;]7)-!V20+I[>@6>CH&A?RPP;I $"6 G(!T+X67EAK]K%9Q8YS]2C&>9%OS.
MKWYJEW2__[EXW)^[U1/5@M0P&F L=2]7S&[&]1=":UDM$AYEK.0>&Q.(ZR9O70.6HFRF#G M2*\@9<'-\8%7#>O.W!Z6O4\!>U_9B=A>RSZ304]/_5GQ&8<=GZV;=6CC\+H7 MNB^$U8",V]O55'KYL)SW-1\/Z(?
8[U2OC]U==%E^8-EGVZ0F=5L4,]-+?YU:^P MW;WJ[R91LS>*$LH(3].>DZS^KBKXS6 KE-7\]6OY43'A5PA8QQPXFF]-[)KZ:&B-5 A\=UE_&F]KGMJ;:O2XN>R_9FO+'W?VZK/,I&(PP M.6M#N8+#NJ0-TEDL6VX1< MZ@
O(>X2D#O1IVIP:*_FS6;\G_GPU164VW5#<[N-LH2VW5V M/\3N/>X*=_8YC<:G8_V[D>^#V>OPR"X8%1R*[7\O\SM(>Z)KF6UL^U"&9W]7 M%-G1$FE6FR#)X=GRP%#]G8K![#/Q V>RG&RG^9#"=I"DS<.:NE[+N,(;LG&:
MI=:*A<'6FYH!=_H#*[>G$HM_*BQF))BDK %O;:=BAN7YLA2R]2,?N(_2\:D. M]G$0RVY9'G,F*I.(#8DVH%9!WL[FS2:G[)93_L)&\.:'4'*4\MG;QJ'*]LY M--\>SZ".9IQ"8R2+*'2YS/\KJ,1/43'GH+_:7^DD[VZL<9- TI]?-%-507'L
M'P(?*)2 0'ZRAM*JEU>KS_8%5:F#%;US2I\?!BD M,. @D+?0+":]]7-: 64Q^4HS%>IB([?(\TTM%?MN+_.0N/&WL/X]K'$03]5/ZG?PQ]C$][Y[_, /AQ;I M8/37Y];(%Y\GF=*:,Y2>Y]T#M4]^Z,MJ @_1]:S,(8E,%Z]U%/QCA1V"*5%;
MWQX\-42&\W+#QX,ZFX4+@@)B%[^^*O0Y#<)9NG-#FN#1-%TX_39[O MUYTJAGB/%7,,B_>*#ON,FW*D&LB]R+]=>@-F>]#R>B5C:+AX)K]A^+&4;E?! MU8 NTZR*BBQ'QY2M,H_I!7_7T5G8K YQ
"@G;!&/+MZB,'AD69H@%Z$.Q2\0 MGP"I^*YN[+4&K. #3S#KAH@B/LQY,YA^ZBC*,/0&5.#:*2UJ=G?.7T"*?^;8&]\91.:. 2FY?[C>SV'.02_MKN=E8 M[$Q\,*=GL#!A+=_]5!_.B=M9+BPC/:T#FK@S=/T#+TPCV^;SIK<+CO:?
TX8, M%A?F4+E/%5\M=6TB\QCUGL4H+-Q]RAK^)-CZ' 0/?/2(,%C56KUB46>6+#M] MNN6].UR7PZQT_2HL]&_I36-[O5/C::POZ>=%VF>@^W$R=\@C#AA]A&,C%A!S4>G$U=];7W9PTZ#KOB8"& MC%\#Y.M*Y"I9$D(M1
G!,N%_;20;CDG7S(32%>^/:B@F[;\LN\M@<#EDY<9] MRE\-^?IU.O49"8S-=0R$.NL;%7]9[\7E?Y^$>7]\K))?):7T4TED_/V=_?EF M[V16F$#$,XI:\PA0B"WW]+I0@M1U=/VFS\.7<8O/2GXDZ7O#W,W2@A?T]G<; MISYD?
GQ\O<^4:[)%PC++L2!C:ZCZNOW&:4T0SY^0RL0,]91WV9@(T'K-"!R4 MHW!;?5R-\K6651;+6Z]17PI^$5)#9T%:U:H$E5YPL,BEEKKQ-K?5O4N OG5S M71IQP9A@$_,FB(&\9V]<\OSDO?))^*2"XX*. I>=B]-G:4/',"?
3Q&KWX"OC M%4]CK!XG?BWY'A2RTDGGV4%YEO>VYL,/WQX6W% MBH;U@NP_*+E>?Z\)(Q/O/Y6*V4]6=^3=S7@^ESI>RW_Y=6W&V/,.?>ZIY2;- M=7'B=*9)3]][]&&#(>;";-9.""?)^]SFB-E]%;E]@$<2$R)[132G&A+?B]P
MO B,?9MH<3?%C3 MT9)F]T1A4>)02J/^=:\/$SZH:'KMNM>NU],8%4ZTHI?0X)^#CNMLM:V&BXZ)[D[QI<\[H MJ<:>]W#KG#&'W'Q1R)6"?FZ>?UZ0M\B?C21?<1(BD]AS]@6+ IZ>WMVP"TU
MW#V%P&&=:F:AOLB(&I(A@(3T29V#XIN)]'@)4D?0Z*L@+H>G.97HA/[$QM"\8:7U.+C*@__:*DC(SX(XMCV+(=->VE:$78([Z.-IP\H1MOCC7IBP>X= 3<(, MF7/)OXO7:DL37#OUU%+SQ^/BK==5!
<1+I5ZR+%V]]=DV$5Y1\Y/8I<.U MW][-ZZXBW:3S,YDC.7GLG\?@IPBQQ)_7!4KX!"BY"%=?_N Y[:^^FZA5'FY^ MDS($A"MS/XU]<7N]K]1=5_K @I&-=6[BAW3%-[C^1Y'!$CDOFK:[P?Y"=\PD]24N\YR=W!0HEK; MQKV_2-
_1?[U:\9(+C>GB]M5T=6S,QZ6PE<>NH\=VD3Z68UKL41_\1]E?FX&( M?)=!(-"CE[0TU^/-JH5OFHFLXE<)BB>2E)#KH/[A"<$FX=E1H=,W(ITL73E< ME 9[@^<@2#3$RE@7I )<]"7(=(G3AP_I7"=4.^AS+[5%U].2?-
"2+"H@\OATWO$HK-L MDK_;BN1P3TC,MH5WWX<.R6G>*ML46)^_5>5&(W<=LYL M_ZF5F,,%E3A7'\DG(IB&QU+Z8]0];MMT-;L+G<(%7L1X% MS@)% AROO?,W!X=?V^^('\9ZGX.,/SV1?WC;^/W-@[+V-%85'$-
BV]:OB^KC M#3WF]DEA>T1I_4<7*;OZPC+;$H1/D_?MP=^I)%-0?_MCIY7"RK9CA6$&?2^F M_46GUCI;!WV8H+&8HQKN(2.'2H;--=&6P;-9I2_>% R&HHXA=F822?VEFP;]
M5A,U9397Y@T%1FSOC3GV_1H5?/?.]$YO;*CN&F4SW&[LXRK+%^3$V7Q,J.,U W@LP^%2O^N:VK.O+1H9)F=RB+IS9EO3;]QO=ZU4P_X#5 M_()V"Y!H]4.TKTCQ*93$6*,6=#05OC6ZZOG@YB:/OXQ;@.N5N743=940AZAD
MR*W@ATW*%*<372=5Z3AA0;.9>F$]9BO=F1=?I@Z]C):F'0)W%$[X=J6K\]N M%EW')KG&977TT?3AM,CN]8FAD&^'YR"\_9XP<,L2L#F],XBY?6'^-:YLLK)Z M"$#>L[R#$9X:-'^YT'^I.@@R'QE:,)X MHL+K<(M9R%A]2_W.
<*V5Z;#J:ZN3C>21DG/3HM=%GQQ+, M@?0UL5N#WP(*.KXS6(0;V9;O#Z77-L;W-OVL2DEH\C[E&1]]L WE"V5=NP1) M;%0PU:B8E&^T"\%]\3EWWY980'DD(6//5IT9OM#F&_H/?TX&FOZ.[X 11U],BIR>9%=RI9]9^B43],8)
[S3 M)/:,7O4RU:]S$"<2;U7]#HQ_.+I@O45,.,OH$"5/0?%&PCI$_RE-*.!C%8N, MU!0E/< 3(PDP;-\[%YS@&.9WQLO24L"G7TTY[L6.4I/?0=]9]X,]H=+^SZ>> M,E7U9D]]BY?
R"I!AWKEGY>2,8"BDY$)Z]<6B\#9(0$IN)Q#O0BPCL(8>KT>N3&48D&[VO='$\MALTGIMQ3QT+=!3 M@\WA?8I!IM6[9,(Y]. <-$]%] '$3FT0MV8ZV$C^>-E$ B>V/THVKZ5MS-:L^*77R$XKW*;/\'6^<9U507O?DH*BH"
(M*;2]]1 MJ0(2&R @1$! :D1$2HQ(#Q 2!>E-0$!I47I'I4H+O2-*)P@A04!*2((8KY*$ MR3MK_=>:F34?[K?<=9-S]M[/\LY9]]Q>.!9OY!GHWS/(&]] #G!U /0T7Q MF\9%]P X:0ET,O.%@2[ZB\O1STW4DL_% &9%,'(%FZ([$*$1+F?
I2AP[-5^O MW4*FI_C0)2!WTGSJ718V;$^'OWMR=XSY=/[YH<-RD4?GNH/+KG%6G(:AWJ8Y+13$OD\8^N223\W9'Z2UUM\+=0O#BP>@0K&!<3F] MW)]1YNO>0I"%$17?
S?)G,C=A1D!K=X<8%=SI(X2$=H6]88G8DT@[(B1N3XH' M"#-L,..6-YH(H)Q:=)R;L[>_<.&Z0!6?BNOAG3M\Y]7,PP)#!OIY_\K"^"'; M^^-&6S= M:ZO_6N^)GBQ?['-[E.;TGXZG*]3$^_ !TK?Y_..H% O7N.(59B MO
[SG.C7#X*NS^9W)N9S8XRSD[.\*AV=-[+SBFO*7_Y)R[3*%GEU& M(->;\F2CD6_$-9XV/SAQCE21EE)O5?:ZO$]>AY!)LR KVL_CF9RPD16H:+%=" _9]@#]\5IWH7MP M5'_.&,8U I\8_1^&"Z5];A"N@M*%'4;Z]
(J^G2EH5LOZMB3F&%:=/ERDYY5]8@I&'V17W*(;;C-?(6L$]5=IH./ #%M*P5 M5WAE/VZH_*F;'ZE6]!87.F.7E?D/7>AU]%M]>P9W7T-_%U^*V#6K:PP&\&(? MA3*CVO5B\*)@/M0-:LQS4C/3644NOK;BU@< M6^Z2I&(N;-
YDD>'0M&K>6)/F;=O>F-R"<*-E[_;8-IBX7IRF-H=86&2HW"+J MQG/O5P_G^ 8Y!$PCI@]_^DMGV),?S?H.X]?G"RX#E*VH DD#/2-Y9A:SOYG! MQ(;OOQ@6;@D\#DBO8 99Z#GD-=[Y62'%\^_,49'*)E]5&B3],<
'B!$S+HWQ:4FA]3 MN*7E,!]^&[W=.'X&ZHMUQ00%]Y)[G9G*E(,SEY+.)G8RKE?C69 ME!R<2GEHIAS8-.7>?']BTVSPUC4S%8)'[) Z([E2T/[C*_@,018!&6_=?(A1 M8RG29OO:Y?L(=1I+UO8-2W/U"R([NN'V*6&ISX[S>SFM[?
Q&;:U?W=.66QI???U8:56X%<>F:4.N:[ 7].CL>] MS-V)M6'Z? M'U:RS9Z*'Q\X 'V*B3)08RA3/5XRSOL3#T#"#$W]3I-'F;==L*YML9)!L6]M M0U1;]$'-*\>$!)&=.UV"]Q[]V_4MG9O>&Q=G]>"$*>AS8S0N$BZ*)::6O8-I1Q;@[M#
MB]$"+K#CGBF^I=Y0+#@_M@1U#F)/"9C3]2A]$:R)Q^!X/68!*\W;I'2KB-#U/F+>C+>#CY.\QP M(D!"UVP*H4Y<^-FO,:61HQ=Y$CFJ6K;QQ^[XY/VED=/SLGU%]>/@0S\,WG15\^BE97,_M\<[%.XVQFJTCX7)?Q!:]VMZ?]:EV-
C[B[]TM_,?H#*W$/2D1HU0G"F(]T0\F M07F'EBG'M?L)(DBL4U,;,T9?@#9"1\7T2NK2,"\8\BNU21W@]0:*%,K566I M4K*NN>DS\):XM4_6'>]:$LFH*4D>]F*
[XD<$!=C=&;0(\B8[CAB@0L$B#!>:C.YZG+YM=2'#O(':$5/T,RN[_7WVQ!#*HC%H(_@0:SQZ MD[035IEZV)FU@WN*DJ7R$F,B&&+%*+T)?>G")>!F#[[Q8RW2WY0FF(,@*6AP MNSE-^S14+B0);U*7,!Y14X%B?
\D=7R[L'[9HG'F2"E*>^!+S<(@3CZAF?\7% M;8?-S6&\_=+8)_..O^>"/3D.)00?NW#II;Q7H5U#SL^<3Y1V[ /(&RP@A^VE MQ&%Y6!>ZR@'U'GSMP+<5Z#Q]UI[6U%/[G'491Q/(CZ-)0VGQ"YN2B@"M&G7[
M\^0>YC@*.AVP/UZ2?K&^;T;V?^%6C_53OZ0QHX M@5*K[T;-ZLT.[L_3MIO2#R^#$[@#!PTN(+W!$EL$P8#*<"V2!$>7 3\U:979 M]+Q&PS">O@F??ZH1W3:Y8[6**QAIY8W&]M#)"D1>"/> M-
D)HSL\|>O_[5H<M?,*]#@/M\>&.BC!S\U4=B)-4R'O7V-#B^"E5S^C" MW=Z\:P,94Y4U>AP;=$_LADZ6*-]+WE:Q,BHIV:O"?G!V\ KYVK?B>52)] MF--W?F(@2N%WR)0,E#92#I87KF]A6!BT-@ BY9NO7!C:P/5]7&^UDH0Z'4,3
MZKL*)T)[Q'(PL2XR@,>^(_!6W["DIS@%A"QQ_]#R:5;MW:_Z!>XCWS>U,_F= M1BH=Y\,36VN+/=G56Y5>1U.'I?1B3]/4.?T48A/99$4*G]"3]8=U/GZ26/)V M>41'DS+?>]_-K+E@4F.OCG:WZ2M*7C#OC L0::(=_PWZ-*WE
&0T1(2>,$04 M;%@#CMW?'#RS7FVBQ2:QUR8$"3>G+B0C87,T,0_5=EE*A\=XF]Y MI/)26X@F1?3IP<3F"])L8U;:U:%-7]LL?4IYQ9UU\9Y9DC(3>R;$S_4--,EV MX1<[]3GG3]8M."W5/U[29GY-
"9U5>:_[,=%K^,QZOS_(KIDMU#"T*UM+IWAKE4UC]M-6& M^=$>FJA8[7RE$1M1DFOWQH\3D"G$\QU3CKVZ4$U&%F9PT" M9I5.'#:R]9)Z_/LIYBIF^65V)O:__>H3P"4O>+G7'[O0Q^TTG:7B:F;UZ S8 MG\;AU-RD?O-
LU,HOTAMGA0>F\]"+W;.K.(8@E-Y&_4/>IR[T83Y M@66H;&P M^MHDEA2 [6)=!@I7*)%!36=0>M3'.=0M2X2Q);7*0*4QDQMB.RVJ8+7DZ*S[ MSZXIP'UNX:S4%PH@#67P*]._,0L87#1E$C@&XDE)D/HXT /?VM)ID]6.)A=/
M/4'++#D:O/>]<%)MW;S4YX,HAH'3 S)I177.-9;34V2FS]&N9F_]$XFCO]HF M,F_G>[R>2I82LO 14GH6K<7W^L/K'UO?H@RM\WGY+!+*TN]-I96/[ ?9$%GW M&&K]ZT[&><8R_0_]VPH*1S8?O(_O-\H[[O:P-
+9']ULOD>@\X_^>[&65X>.F M+3QDG9[R)ZH&V=2])%XGFA+'<"3Z\.+U1XYHMRRUEWC:)BET/7),,ET[ZC5X M]*2[G^-SGDN[P6S% !36MZ]0T=S>OTA@LAG5NF?KG;,:MBRV+?C=9E-C,.G2 M!7Q[&
M&%3P:7=TC#;120TZ4R*?HSFP5K]G>E__5%F7OZ;VF(JANP$"X3FYZNN;EK>3 MU6P+!;&;8\6Y#L4:C%+52]@?)9#,G\#"K JZ>N3&1@] M')6MVX"J7!QMDI3R',V/'G8X /40$K"'.\2VL*=8ZL:TDU\D;MQ!V5.#ZMA5
MPK/;+"?,"ZS1EZ3Q"RE](W9[4VQ5#E>) ^1XR5=7>!RURJ*L3R8)MS^TS%6>2@L6U 383S^:PS:\CJQ^ ME].3K*,H:ZI4]\^VHS7 ./TE($LUZVN!19[\V2&)[9+4I"GCMZ!R29Z"4N2< MP9K!E+N-B7]//1^\/@29\-ANVM=':3-?
HSD!WF7.;CVN13VV/^HA*]8?@'CP MF]KDOWLM.]3<*1[E[AVU-"S-WC[ ME_"'S.(]UC\K^[Z8&^EG54T]_NONX>$#_K22Z!/3@-);9FASN_]-$N_6^8X( M>>B[R]S);0Y=FKA8\CYTXEGEF$BQ5MZ[-.-
OEY*%U\_G/+LBGU3!"WN&+%?2 M&3KWP^W4M1418?$]R952[S3,7C_]>!OQ-BBN=T]LB3.E?#Z[ ;T"RF(UKJW^FR-5NE!5[]'\%'L"XZXONA MM.P,RJ^N#F?1M>D%]XIO@11$E+Q,K? OB*/C^&.4$'NP59BY*.B^$[]3T-"T
MO; \|K*!EM+/&V%PB5H:Y6(2U,^ZPS7G&*6%[1 M^M]$9AQNF42)P'RPVVZ@YM#UF/601^/X&"*,++NO SSDC9I$*M\ 'F+J4+X5 MR ?0XKG-%H&E][Y%@BTT\<$(.T_)&?K.]L>'L .0%K\\W6:E5AR $$M?_O:1
M0%VG"680H<<]3SLL;J'E9BCDO6IETWC'N2>(?/K.CJ9D!HZ&J$1/5:5O7FDN!7E"%9A=Q(N]RZ MZ72MQL+"V_NW+F2+)8A(ZKQ6H0WJA/8G()$/O;H^ET\5:P?.*%6T.+1VA*B2 M?>K";9/&6BZGF2CDHKD8O'8"H=\&)L.,-
M/O-_[C!;.S0WEG0 'ZJQP^1.0+C=-:I%+!A1S;A9N<'O:*R:^;[2$:8R&?*A M1^93CWX*E[1/[3PL$4:U!,\UT5' !$\O[7"23Y/W>]$">F[R67Q9"V/V>YN MAM\8"USX6(I$8_@W10,;^A.6<\(?KZ*2M-;[FD+O:>^V/3QA\,!Q%B6Q?
YTA M!,31I$BP;EX.QFU]3"):FB$]N?<:P"Y33FV=]A:M?4%P;FK),9MLL"S5H./# MF;V"?U00MTB[,_>2'C?%KDN-LL7#?P6\O4&KI%=].P MOY'DC%SVZ '"8#] M#P'V-%XZA5F*OC#PSLL:R;$,Z2'PW=_"R[_0X,;H5/YN&W-?
6=M\<6TW02L,L(^%@ <5NBR$3_$CAS+_V3 +U M'\;0 4=>V)?SQ-1GQ&Q'5:)00%@I^AL^^>VQ])1_0WTZWU$T\;F>N M)<%)X;:]7&/2W76;E^#_JFN>/GDB>T.8I7 ZH.&Y)G\(MV:S_)8)88'#%Z
MGM=O=P!ZV3BU(R*R('7ITCF3M;]E]T+"N :; M Q!#]&G9IQ<3E7WD'XQ>VLN$TI]\;8,0FU%Z-)=)6/-'[32&1C,U*7'7K+KD MW;][W.M*^G?V!ZHP71.A\HRS/JS38QZ.,R@[ZE,8(/<7:*4*]O)WSR"44!X8
MB9+6TIZRAE$_>V/Q%I3#=K"50VSM(W^.(>FH11'$O?#>)7H'#KSY8U@M\,J] M]L$&A"]Z9I.I]1M2A^.HXSV$/ <^8T@$T0082&WG:X,9R52T9M44"(@W77R93F4$WAP*]GH#FRNT3'XT*NT1QE*(A^? M=[Z:GALY_DKI
[CQ[KW4KP+B?Y;%$^D;#L1*?:T+R7)\B166V;EN&L6F05[X M:JU<;U7-=];&57$>M1)87&%\H:AU^0UOWR1OW\H;01M6KR<39X':VA46!D:U MY@5DH0R!@3YVJ/.'U6ZZZ#$_UU2CQ:Y62?$QU+6PRP!*AC,V4.PM0U;S979U
MA+GL&K!NL@]]M)+X-RJH#%),^"3$X+=C<4F\8QP";I9Z89]"2O?U%C9$50L@ M7>W^/?3LU=G(*9CF@E?3O^KZ)I\]_:]&W_X^MN4KO'CJ'A]LYB'^3I1IJR)! M^L'ALSN+*9HK%2 P7WD\ $H3/K]T/BU0Y+OUG W^I$Y
MN6Z70T/T=[^GG2U?^#-RR'"HJ"HMLJ20$Y'K'D!!X"'04=3C\3]5M$QC1R7B MG%7QHTI+(N.4W)3;8$;&D70S'#5]_\%"XC%9:WRG?5<;:W;.-1]$W !SKI >-OPMV%$+TWNK@ HZZ8DCM M@NRHP7&W:7,.<.MNN>"H-
C$O&[!B3O@M_+-/+^IK!3HRB@<|>%*E!\X*U7VO MFHBI:S9D?&>|9F+/K0D>'S9YT"7O(KZ3OUG0,O*5_9">_[AT&+:T9O@R_H>MT=(.IVBW:< MJMQ'0%&W)]<,U[VHA8?R;UANZ?]-
US@BIVMKZIGAJ+AS=8W)83#M1MHX0Z#N M!E6HKQ+R\@_A)'AM^C>W5_TTO-IK+VQ! $B"^Y2SQ@1#OV USD#=*AENV>0G M:2?&W[IK =]<;-(T0)LE;\H> M 00$+V^W!."_I)
(H(*]\R4AVGAB'2U9Z>93FM+OL&$ZKU")$]4+NQH"8K9D[ M5ESGCR?)MED>@"HSW(.^.SEFO/9Y!%&N7*[AN=[5L]+:_.I6AZ/R9RLWM,SM MKR03V-!E(\&[N)\Y;VWME(IVKS%L@"C:G_Y08[+=LKF=(;,$O(T^@4)\I,6\
M#$S"(".'X#HG)T4OD6D]>UI!B\1 >V4'Z$9Q[0]>L5L=<8.9(^N]#1BO)LB MR.HA'#C(,@&?L"+TLN,(>F))<,I P9MU$8A;/@#APXBE72F'@3^V.8:T>]D^ M$1VRR)BN&5N#RRULOV_%R[L9%%]27KYE)VH?
9U.OMT\VF+GI]X*V!#$'M6?Y MAF._UKDUS]H,0)1L2AI0.XK5\E;"\F"]NDVQ]>U6DWVA,MI\QN&^[B%T^RIR MC7A(:2_L]'\]8$ZRQ%AX ^EO&&]L"N&TYO@AUC3V./H84LQL"@5==M;]9?P5 M9;E2RV%#W;#-
XG5S]9;?)+YU-)!6&,O]TF@I[H M \<,OQ"^?Q<\N">G;^%>4/03)/9)Z;."V_2'W%I3%D M0/Q7RWJI("US /]<,CH=%]/P^63Q";P)Z)FQ?.ZI4\S+X88:-1,[+RECPL5H M]S_>:"6VWPC_9C]X#\ S:^S1@G_,D=@=4%S^^+(=:;HPI4-
;)T:<>=8*%H M>,_VV^/353"Z$V!2HDK/;(E$SQZ Z[(_X0/PC5B/H&P;;**L6;6I6_01]8_I8ZAA9P6 MD$T#+:-9IV\*Q#=$YVD,N4J,%IU8;7ZE;_*1T7A4._R67]O Y:'F8*Z7W=/E MMB&9
42DZ:6T7.KTN6D3(PTKOQ)2;D4QO"$H%]]8;);].%>OY^Q%'=UI;Y*_MQ?DH@1$%0UTHA[U%@TG91*%%T;N5$U\]VNQTU[QZF29>Q;LR]:AFURC[-;/] MU#[QN\0?;]T?W[MWRZJWKF(9-9:8S3!E-
N&6FW%UF.UI4GD')T/J6YOQOA5K M*C2I5]]7K MC" 8]?XXH&(^55UA]M_?(1O,1,U@6!T^I=X1Y48;B%ZWR4A[%.S8X/B2IU;F MXUR]Q2992I[MFSY"&/Q@NBU[^$*06O[4G,X)(&;@T%--S&F&)>U"'PD29Z#4
MUEB7;3+]T#>O?3$0RI)'YI+O2USURTJ M2BWO%6Q /,1T+.PR6^M;;J,9N-]L('E3G@7@EB 3;Z5L!^XHT%EJD N02U:S MZ]7[WWY!]?&0\Z'U^^!OX*]L4GYPUM(0]-]EZ?'P0GC;8)F-[R_E7W6_W]1Y/] &^3Q@ M)>(<8]LLQV-
@E8.$^?'P6CSWJ,%DIR2P81'.]]S!*Y !*!NGI/1-JM%?0S$I M'6J,FS0L>_X%OO_$\/\6.S[;FZ]+._:>)/%LXY>Q<.O'#^F64SL&8V[B7S)G M^O60PWUGE'X-[)\ 9"9.F_$#V^6B'JP0H;T] M*V:V]\8LT)Q6:(>]Y;ETUKYGC\^* Q-
:7#K")..Z$@8+P MW$7V](2O! P._DWO"2WXL"X5^(*SB6@/#VRHHBPQ#8QB?]VRAZKD #2LYM-^ M /+&X:$'(.O,V@V35YGR(I39N2#YW3TR;,R'(9I_C1TG3BX>280&.[+\|U L M4)/KNS4N;K=7"ZT(Q]6>^Q16-
/NX)C9("CKEMOM%4>OS-N?4]90:,08KX^I9 MO587BY$"5"5UFC%7+9D:<0!].G< TOSW2=/]^.!&OK%%3),\8Z]U];FM[XZ]M MDU=AR:'6CW1<=--?](>L[_[+5S]2K[4](;:1L@9BZ[U<]FF![&OO[Z_G%T6\ M$_>?
6D_62SMJ;3=!G]:;;\\CNWM45RT-:2W%)2G*!B/X@TT:=DJV_VW!0^26 M!E=0P43H*>!/CT-I1)M'@1=:EMH4%[#?+N_R57-$6%-5WF:RYIO5VO"_[E69 MB#7.&]I5L?._V'IYA,F,@[B+00!%,.-L_H@)$]LAO.#(&F<9,'/5.LX,
MYY^9O&-PHHTF]*+-K'(+3!2SYNHJJB/<=QCQU2SR_:Z>VCZJ?":%0$GNT/H, M!%-C2+"4O:B$NU.,$\M@ 63+@$7V3\>%3>ULP=2P<(3KL^68VSMJ]OK5 %?$ MPOU7<$"=F<$&DQ]H1NU>,+YGI8#UY0#$V2&T01##^1 $
"[HI-QL(/>-E3M4 MP5K] >C6])Y9N.NK2L/RGM+[L"5O_IO*?R^.^0A.O1K]RQ2*\+MS -(9 C([ MH+92EH4W(+ \TU>EQ]?>@[V0GV7)]SK]9IFO:VH5KFIB:I#P'G'GWK<0@?'S M??W)L)M'8ZK?M$Q[?
>TFEOL/!XIOFLO&6I4*3A2L:*2__)X.]82/*5!=EOI!K+HHNS0#E\<090MH"2IK/=] M&;36E>0X@=D<46#A;N-N()3[)[[MQI*)QN_L2S+0^MZ_0_N\=##[)B- CPCI M%6"6'H#@4K$M?\@O]EVW9KIW_Y"D>M><_;MQ/+4[9[F-
!HB\48'"CR91]H+3 MHB'3U=4%'9F=Q_V$0C!SS4_:9(%6U\7E/T [ 24S U_50!8 MQ-BCC7Z#+8PZ2I69R>)DL MP[*F-;>HZ/E*F).>QFRPD+^)1HQ]]Y4+&8YZNY_ASHT6$[^I<@4/SA/,@]2?2;"-(4K&YRSR^3:=X M0.
<20V<$X(]U=D3&:3:;#Y4?TNP[3.SX8GMG*JU*%"M"$M9R_(+OK2CN&BKT M\V&53-44_:%\;]P XUC:FY8W+4#VWZ7KCGSQE2Z%U?8M5UK;?F#;WHOM*OM- M1'J?O.0E]2%.].;JN;_7*?&_DWHX>O!4;YGLO-"([7Z?
M66690M&'SG%.">7U4AW3JFGO-&^_E^=RU]*RZA+SMDFY3\DA+DX$^+VL(0CZ M?KY7R\>*=RM>8_4KQUTNMV5;#._,4.!+!Z"Q Q!#4)XD1!:@F?4:' ;XJ3UT M*>9[M]P7A,M E\VGD]I]4B8[-.]]QBU.;1=O+*YNYK-
_S9:#'D,=*$7XP%>XQ,+E M/$E-,VK$AM%+755QI^A=]W>2Q7\/UF*:;Z>^5(F*C_;,8KHY&_,K6.+\#-NU ME;;3/1,S%$R.-01,)TKKUGU,K7LK\2A0^*_;KWMIM/Y@)4'Y(\V@0RXSZE<* MXX>I?
_VZE:#@W&G=W+$K85Z*4Z]7K*S27^9:1R;8FI25!H4!W_=Y4X8OBMSR MLG[Y:=:FKV]LZG6EA:9212ZY-DXNK4G)+',VM>!-5]<7WKUC6//KST/&(5]Y M=,2M*_M2N]NFLDQD)D+;TQ%_O?])'I[\UVQI*'#M?^3CO\L8_*^1
=D[;_[X MWB^]Q*=/]&?Y.H=6\DN_BD^NBAAQ3$)2C[ BWKV)CC;O;(E2N7N&ZZGLJS/' M5X0'MZ^0+8>G:G*F6_\Y^ES%C!=P-M(-7)D?,!Z8:%P#;GN(5D=_O0$JF&I MDRN\+WS:9$G5#H2["68YM^O3PLQ:)5RX%F)NJZY/-
,#UE'^N>4USX0M^](,P ML= XG"AD^<,!Z"/;HY_ZK\%9F^.^%0,,V%!35H1BP?H2U)NLDWJD).>=ADI* MA!#K:5XI\B(R26W-AP? F=M&&C6&E,:X+ 8C!/(+,DO'H=L>K)-N/OL&W]&= M!Z"&RZP9_&PB0V]?
IZDGKAAH+4<>AAD$P;O/"\^V_?K3%S^E$ MR?PB97NN'H-<@E)UEXX>@"+-?@07"5Q;Z/MSM*M6Z M7K^1/I;J%LV5\*8@^8+]S;H"J4P%V(*%&ED+"S-HA=$F\-(FRI,).*,6V/9? M&*SURS9K ;*<@:6RG+5MH(Z;_.3>9R
MGTDIHLCL[TZ+X MN)8&2EP;9E^/P?N_&W@>QGG1((DL(4"]5Y0YV264=:0I]$MAH9.W&F(^-LKP MBZM8XIVD(888^P>&(OYK9B7(GC(VH5PR4& \ YY[8 Y_1]DU N-A),6=@'[W
MZ0+]=_Q9]'D.U&5R1XIE2\.#"1.)EBM<9WUK]Q9]=OO+C$2N?3\T/AHB7PM* M\UV(X#3]62V@?+U=H#@0\?NWB[&FQN=B9>^\ACWH;&W6K9#7&,X.T=]D;0.Y MVIY:CAZ:D"F582 TB?
(5B@Z(HCW%$]=NV5&96;$=PX'" 2_G/B[@BX9?71/5 M2;V7B-&'4 -13R'+;X(0EW7=Z-F R$?^8<^2@7CR#2';4P],3!\4\$<4)YM] MK-T8_O]U.[0+:C)SW-/\M/??62IO C4".$^/?4'UB3H ^9^&R5W6,!/O3XIZ M;-,_+8O>
+F!>$C-E!CL[CE FM7'RP[-C;3N5M%K%TM,KFSZ3QZ :DU6]UG8 M96_3$YWR7Q_G$9ZUX7*HQNKAOG"X:[AO68W&G,;^0FOSHUAS[O;JQ. S3B,J M#W3RKY"./GH1*7+V]:.>AS@Q:#)[!G+] S)ZCMK6/W^EBZFEUO9[@.
J&1< MJ)ML\Z&Y]4F"S>\A_?8[0VT8!?#FP':#<9?YPKB GVX3CUJSS7SDJ-7HH9_ CQ_("5>O.VK^/"$I>N\]5,7BZ_[YB M;<\!2)*=:E<.0)[@>$EEFGR_3ZPNM-/8[= M#D*Q*"E?
```

```
TGC<&;&@*12D:@EPZ^6Y,%&O@+WMF'!=8DKHF1/T,!EOD08EA9W& M1833+"G&J6|=)S0S*+'ZO+XTR=VEK4XM!X,|ZF0W2XE*_TALM[:BW6]^Y,SC M%:"L:F?O5\U]E$*7% M_X09?
1&>+=4#B\Y7:0/T*GZV/$TGAH5[T%\V?IRN)^"5.UO4XDBJ'O;IQ.!( ME(F7^,W[5-G\N/*!Y3S1$?OFY.,HG3]?34Z$9=S_B4RA7P'V/0I_BH*3V #% M V]97:JC:B]#>ZRI79HR]5_1 @Q-($$H)1 3+WEE*M ]#]&9$Z[;SU$R?\-!
MV=GHNS%M5_:%_6R6H8X#)>X;U3(>.)X0;)5W*N$\3Q#)3:P \P:0A 3;U MI,#+QK+6\D;7U>YF\QMT& MTX3Z#21:J-@$?5@9$F[2/LVX3AQYN:]*3RI;-.$ M?[YS^L*L:@5K@'#,'3A/JGV./DUU2:4.="ZI?/XTY=%
(E4V]27L26"WO](UA M_![^|>:9(FAXX>:_8ZF]58@687)U]J$W"V[A;H8@U#1DNY8*L0.BWJ,>T(R[ M4PXC:SUE*SRQY>Z*VI+[3M=[4_8V6:\K)+ V]KY9EY7KE-7:KQ]A&AV^H2 7SS(R]WI\#5Y
M'<85S91RG4SQ6\MK@4Z[O$@[88==F,CVP2*/WO9+,JQA7V/'41:?'%YRSZ*TY(]0?@OZ^/TOL82<[& MQNG[EVG,V-K]NE_0T)LIZCCH4QK =?IX[/VZ'X&K<_H6'DG%+[KZ3-OM_6K@ M#4?
P[::IYC]6B3Z*MHCK"HWTNKW+53BAG,J.JD.>M\%'X56]1W+]#>#7&DWEOE@9;X>9Z>Z MJ=K0J*"U+#*O39]]\V#/6)6T6HY5G0!;[M:A6((T2A+>17] M9SO7H[]^E\ #^$3ZB5HFBR9[Y=P=6-/(^&C?
*'\4QFM4T4UR&U&P++>M#B+K M_+**DBD>0<-3':M,OWRH4"]/:JM2<15^,/PQ38#GV')L!<^SVR*:8HYFN_I( M'|5/7,]EG =$$MR6!4#IF=5:5_Y,SO(V^0GO7V\ M:W/R?I3(S.MU!^5,]?4T>O!\6;F.A25\,6QAW\:"@@/8P
M;,U6AB,]Q3H28/2^XFS6/^GWP>*0;!C'[OYZ>@JL-07MZS#LE^LF A^!FSTF M(\B%?Y=FO[H,A1G:##^U]UAXG5M3L1O6,E0L[!<6K^BP:[&1\/0X-]9R"SL[ M]8-I0DE[8LW7LY[H)M&UA846&[ROK-^'T6R9W#?
^CR8$1ZW_W'W0>"N2HWRA M_O35(6$I)R]<:LWBRF 3NQF5L,VW?Y5QERH?\[1#%7"C)P-OJ=K]NI1.0]S+ M$>I5MM@]$Z7.V#O+Y900D.F]T8KU*;S#32=4OG64B@VLO@+Q;/;\]9Y5%CGB M\2@F_VUX::
[X\Q/;_A18"I;]@$LB?$SI)LS%D+#/<0A(7-8!Z&2;P+XQ,M@1 M4"]$QG1W"#32L+WG0RKZU23:%-]IU]?#1DH&3K=DZ\S^.=EOF#5^_X?X=,YZ M-X)BJF9GUVJAQ6CG*EK(N[=#/]&17@? " CRM'(H0&"/\&>@BP?!2Q($N+-
<65@1]CG$=" \C8KF1 [W!6=JZ@:Q*(AEU4S*K]EBF M3+))5>]Y9T7]$B]"(-88.!9OU@7Y9-S)&P>K!RW_#2BSB^E_U:N?7;W V_7@ M>676B?%]963KBG8?1LH++4)=[P:?0.8X ZHAQ+R;MA,,B$=P&"2>X5;6_;4'
M3MQ_E&S;%F0R*F35M_ZY)760^=\[5%^A>S$"F"?MO$0IAA(6+V\#")!X7[#D M9E$8CX(>HC-;RT1HX[$U^I?""X @J=,;NMM"6E;5D3"7AIPQ!)*^ZZPZUMS4 M%G]%K%1DIV@B]*K G]F1XOR$ABPWX=I0V*RC5)ZN-
D.PD!X-Y.QKL+K1"L#- M?1TDAQ6S%/($%WT JO?HG^|0 ^H&A/[)1^@?HE;2W:=K']#NK%N)!OXFTGQB MMV>X(;R&&/QWS(?Y 3&$SO'T0-I,"]M <*(0C$=.@PA MFL1J9BJ-HU=4/N;]1)N)7%25%[XVQK6EY7-
CBG7+QVD$^-P+A MIS5$GT^_D M#_"R1[=O;6Z2^73\V,#+0(5W-*WV0N<%C/>B(]QZ#N]B*,X)*&93/U3P)% M$S[GHOCX<\=D)I0/=C_!<39MB8@@[UC>/2K02E=Z*3I1Z-NR%IZW%P[V:<\, M,6:
(OB.RG7@6OZZ&T&E,SSWT!,RCN='G\HF5K 'WB5CT?=4VT^^ M^OX"-C&<5'',+RS]>WKZOVR6)_O.*MQ@>C;SO4;29769 M=/W0H+R5Z^[>:1])XRTZ[[GRYG2X&_QA$S\'GN9B1W^P&L:K_TPL!.*>"?X_
MS4C8UPRB4.;1.HBW?$"^5*KV[*%K!L<EH1]^4,A99!WK MY/G],TCM7A=I:DK"?^\"?9DO21-ZV1"6Q-^+MR@F+:HM4:Y/DT4RUWHL4\8- M#$=/5:7U$RYK'_'0I*-JE5K^/G@%G.2]DWMH^)5=>O[Q]\|Z?
|'&YD6M.)_;@JFV<_Z[V>#HN]G]].6+S:,62GDFMB_+B5O3WFG6/O-6>78" MXT@C]\3P67!P-F/&I&F;NB,D,_;Q?I66O_YPLMB)&XT7-"]O6A2'UD1=F?YQ MU]?7
I7[P;_^;$/9%+\'92!'"TZ$QK]<_8KR64:$F=*,7^];E5RO0H;UZL]. MVN%=:DN=#C]L[VM]7N]O-"CR@C-QWRZ6-8EKD._$S$L3UXII'O070.1[)'\W M'O5451[7FK#OX3!E]^T9@.'U4F)3T72@6.FMB"4QY*-?^39&XFF0]S@X+Z 8
MW(69RW3FHCLRW^IS" W \ ^W[B3< >#[F@SYNFAS<'>CBV_])(:HWOS-S5F] M6]>Y4C#;4U1!3?3X\,[+IC?ZD717=HVXC[H!S-+D;S'KV(%3*:D$36*GK7A= MGG\G[-",<"T^._CI<^'BI52P-U3#2I;ZB_OY5[T[V=B(JY=4
M]N?X96B#06'@!1B+R[]R8V(K"'L:\Y "R.5UU-'C GJGGC+ M 5Z^D27VUE_ M%<$>&RHA0I-?Q238?.U/H]]]A S^45[CP3K1P*ZP,\Q4?5FV?(&939.W@)!P M1/"^!+)IV0E[^!+IJBT"TG-S0(I7W\R?
9"UCA&A)G&T2C%,=;/MEXG$T5G8, M8XKE0SFA!5$&-'""QOAQ>+YR2K>D>,N4BK[$NTQG' MM[*>I$?14V=3Q&QN;+,15^< ]&&=[+N2)$;_QZQN"V1# ;8A*(<(7> :P!S% M$$%3OR$Q8S3B;K4'K[B+G3#7')&C.STI>\"HY
MS)N5R]_QF; ;^I ,H]>N42,7IPL%CEH4MS?8^UFT?)AJ;HA@M:10\\"W)Z/;.H+Z/21SH]9M3^Y4_[PTIML]I5_M>%4 M?'K^MV>XO7T0U^57 K%Q+U8\$S.%[Q_BX.K\RUEB)R^S^"RH,L-Y])E(:]JO M?.XC]?=
[6_&E(%>Y&8PV_T?N\SPV AUW-DTHN?5_!_.M/U MYD>:.GE2AY)_S/@"#I*G5[9OWU^4FTN1R6OP\JLNH.^09V_N>M!,!:2%;"\6 M"BG*7K&8HHPK);GX(1A6;?F4<1+O@C+]$O4 1(XACI]"^O=*"7?HHZ0C>_"3
ML(5%!C<0%;;L./;8A(24_T@[U6C[][&XI.WRF)C#>+\8*$!Z .>: LA!NBES MTG8S3PT$4-; +U+2X0/035'5K!=H&901CN;QLDT_;:FCN-P[5"W"]\AI_*;= M[.7;NZ.Q)WA,KI]CWQV?_RVU(6$>?A_.N;O"(1K_Q494C2HZ\-
GW#.8DR.:5AFLA?ROZM\)D_$P/% M4-V!GA/ZGRW,.+6%'+)D0F26B\H;R>%72A%_PKR0),/CPH*/OUR3UT_^V[DU M*R%6;-,2__6^;R)B7,R84_S'RJOP MT&1.=-%4\P'(X5[9G$5PF=5]8WK4*6'^'@'0&2B'B [->
[C(:SH@4[#Q@B7" MNG/M\L;%U+ZC E;]*2K6Z>D6BK71"\%P<^WOK$?L MTM#HPLG\8' :#N.&>/]\^*\7&YYK.2O& ,QX!LA3>3 12^+IAI^IZ B46Y5! M7#BIG;OH0]H.MZ?A9><[G]H:JUQ3%"RTT&36(.1(QP76..
[8'B%&2@#CB8DE M-' F;C<@'"T[@#K:[?G:>$UE9Z-G]-!'K[RHCO8#7L5&20*5-P^'5*S.O_W M2>1DB+_8MV7P I!EZ+PRT2/I]SR)ELZ:@APWT!HG[G/)?_X<223TI)QU^ Y4 M]IYQ,HK[(2;P5N9#D^\:3/^,4MF
U+>4+DS<$A.Q+VT4Q*:.HI#N[_Z[=!CPZ:*-3:?ZH)LH3"KQ#2> M,'$>__Y##(,,6*YT6"*&X(1QB'LM?/N^1-FGANX,JL,-!GGF#D'( ]P(D023=$H55?\7 M6^\=U603?
8U&:8(@TCM107]3WB0VNH#T#BK2I0L$P>05!*0K56D1:=*E=T)' MJ4HG"$D(O4B"$!XAA!N_N^[W_=:]=V7-7UF93,Z<<_;>\TS.:1$7OH59HV*. MET5B\ISQ1GGBA^V&^PM\1+LIV4;#^B=%6ZB:/C25K4GU&+590][@]_*Y;
[<("=SXW]I=MRN^C+W"1&[N5$474Y7O4B1L\&U2? M)N;*A$E_\8;$IV=Y;<])=(!([X(D/T]1?;6K+!^%+/F+G9HOK9:3'O\QR MXI4F%C2WR!/\$_+EK>*-_G0_"&66=_SU[G#C^)-S S6:PL:]7R*X'-M.VL-> M#2G=-
G^UA/[5M0^1-R"[(3$[-7]UKN3]VW \^!QDMNE]XEJS[DV^TG8.2G^| MA28&GH,N4&2Q3,RG'^0D+4'XMRA,RBF[IL(Y],208=<[^5]CDQO,D9#=1_@) M\DWF*3,?PB6=5XQ7H(.EGH(]'FK=3 M#D/=,-
,+^-7MKYOJ2N>@A,9%(UX!>_L6M:8IJ:])X2D3 M&?KY]-QWM"B,%B=L%E%?.@1FV8%Q 8:$&NQ$2O >Y_=]I22%7]<;=3/!CO*# MXMH5CDL+]Q7&?-\-V[IEX&LQ37,#WHR",B^\K$MU@I\8HGWE0E+732W,#7X=
M=$XM24L=*1>_'JWE?OFA7%4]M4!G*G MQ](L2^A3\8C'N/&D6>>>M[2)-G!$ M:.\&US?WIO"1/(#B:GMH>'?7A1^R2DNAYAT90@<%]1[U@?,!(F3_C<L1FQ^%MQ0DZG, MJRYLH0W+,WWP /X(=@7?%(NIH6!_KR#/E(\B_
K@K-^)R84V]CW>+L_*=G" M][E[^_GX^<8Q=3S]\>/79_?BX+C'Z$*UY2V&SW_4*@$YBE7U/YFQ"SHCTDE4 MUASQ! Z$:T&'CZZA4LW:F_9_;T_'TOD?UR>LKCPG9M E^H?6I*YFO-HT+]88
MM*CE'FEY6LA>'@Y)%E=,^68"R!B;[&;AH=\8:L_J(&])5U-I]WD?;FL%VNQ1 M7PP,:F!Y'W_VJ>F13U7Z?X8]7L:JW^0&Y4VI21B3X.VZ43I"[3-W#A(0Q/VR1B25 MB?OO,W^YS>G=;V:U%&XWSVTP?
@P\;75>\&S97L"XR2)BY!FRUN+'%&8N-WO M&Q];;]$QZ37[!C(.UUM/7K3OYTXIM[]1*A MYA/6MLLM$#!114TU377T.9Z6F^K_#N3_,1@F?HAO5GQ-5>V[2D^%P-+=UH$.
MF3I'4[*?.7+^="5E3__T_K_F83!U$C\^M!>.,\YXSB,>1=DIU]AX&CGI8^>^PDKG:=$ M[:[C*1P]2V9P.96,$&@ZRX3Q1(#/W8/(W_Y"Y\/&M4[E/M$_KR+WH?YK&1 M,G#=;I"VQW]D(39.G^S',0?9=HW<6A M?
YN8]$S+1<,7@D_:KFK(ZRZ_J'C2%-:-(8\P:2S&1R 8G)XEJ]/[4D3^HF]T.WW@X&O>[&G MQ$]9$!)5L@0YIX)/FY/W;1]GXB\O2 LE]SQ^E^4L[YGW] ZM0OZ+4IVN&P;) MO%D-_1,&BI/M.2^EV=IG*#0\&XO_D&OI\:-GLBJN?
X;,*7@KT#SSN[:VXXYO MYY%6I0+$7?B9:XSRA=?YK5]M?UM**M=,$\:KU08Y7JNIT?%0"49]T68)[CQR%9K@.GP]]NW[A*[ MBY:D)DOJ76%!:V+762L%V2'S4=BC_12R&H":T F33B$)Y;,T/$,22A,;/1D& M7 L ZS[E]B-
HX.#O<+F,!^?1.7A?:$6!FZSD3\2,UX8/! VH51Z1?M^I@DS M;VU$O:69M=F;]/2SM9&1N]UB_GKEJ@]#$@519?9@WK1D%:;AI83+^/5B'#,7D*.+'XI6O!RV?P2_NM-LZMD&RRI9 MD%1:6B\
(#U7JK"JR6E=&:Z8^!_D>C#/,_1V%]YC ?5+>HOF1F((N.>#[J53$ M$Z"OG*0\N?^B\S+&+Y[$+-A*FU=RG_-]*1"ZHKW?AZ7V.,G(/:FJ^C79E26Z M(//YXKIMQ,=[-8>.6,@"FCA%R1P]7B=<@^#%0"-[HN59](U\M!U>=!>.'=EY
M0S@'#0IHN>:2?758/15&][YC1;-OVL+ MD:GP'GFR()39 /#$RL8L@_#N0TR"LDR>>"#4Y*>F2FE75/'B@]TCBC994FU5 M1'!H>]_ .3Q#3GZ7A55XS?UH:'OV=)L,79ELV!?A MTXO4%LNTE&_>.N3\D7L!N>:
<$W1Q]*6;#DHEDUMTR5KH6G9QL:%/T!,?I4IB M,V?-56^UY]D*'L0A<9;F@X\XN>@[M=SSG[11'0%V[RY>6IKS!I.@\*-S4)87 MJ9TKJ=_M0VG*@/IDA>C;4NZ5G P[Q4(K@SPQ<4D==ASW/?&[=K>,C]OA\6ZM
MR9(J0W,#+FM.52^/ E1C*A8]Y3/LXE7U9+1Y7VSVEM8EJ>K0BTG+EK%,8>7_M+A9?>23D\[A\6R%IN)S]'?=_>_HCYX/MAEE:];=X$A]_'K)ZJ;HX\>WWG93 M,09^\A%='SP815E8>17K;?
%\%ZF<3+.V7]@I1^]&OZC]MJ%V=RH((52ZFVM1 MS+Y58<>@,Q+T,WD*"K7" QJOAGB9SREK$? M7B=SN][=O>3 3S6]]K28U\A.EX.%XK]W#?XID$I['\O59W53X.74;: M2V[<&T(\N,1A6*X0'>%!8_Q B,CNGO#
[R*]T]T:V.$MG$:/- M/IIOP]X&;E1OP?]1G(DYHD.&T7$Y!S3]VI M$[=X#DH4O-A)2(I!8I=D'V;O7?M96;F4/7RV$??8_8.P,=B_ES]E4'8^@ LP]IT8;A(%82%!5A),HLY!5#_^DD8+_APTL.?2OWR) MX]IZA2]*#.[S5/6/0.
[&939[Z5YL8"*GN3W-VSX3FJQUFUQC9=M\-OHWA3&6 M?QC=KM"C$U@HZ7;&Y5Y-PSI"H<%%4#_05BLTO-I.['!]TO@84F8:0BA3&&&\ MP4U]S,74Z%-HTZUBWIJ*M>.#_I685+U.-[X7Z8U?)'ZC!/4T((O-ZM='NN[/
MIV#)Q:?/R0O9G;O9RGGXC>Z$T"",[(5MHTO9 B8KNDE2O9Y-F-9N=@ER_9<*B<.:?%E==]!QMIE"HT(K>\D2Y^\Y>)CF=OR *B?>>@A47L MJ!;8^SMJHU_KUIQOZ1SI%>[VD[GCD]*$#D?_U.VYM.6L4PM"9>U=W[JWA4FF
MEEP[HKU=/("&6;[" , OJIZDEAAW0-UZ>/I&UKE$50R8*C4O+/241Y0X&A: M+.$T%0.8*U:IB%GUN:D16=1_A-VK>CY84:JCY/_"A7-6")N;WZ8C;[+4V+DE MN>^!&#HFL4^1Z4-/]0%<-X0:\MP$$$/N,0?A9%$FN-
(]*CP$\QQY18O',]OW M(WX1,]$'!WL?A[QLCE9,2&.L\VI;?^OW0:OD0.[CW]3H]<-[GB(R&NG.' EC M/LLATY-4 ";\P>U[D(L1(OB86 SRLDPI!%6S:#BYER#<7 ^*VDO5#Y!%"1U, MC2SR4+E< X_KDKCFB'/ Y>>PR[#1==Q0*
(2+(K:FT2 M-6C.G^IZ)/)]+:U=;K@)XSOEC%0#'K^ MUW[M9M?ID)8<(3R!Q($/B7"-'35Y(@>4YWMTDY;6[ "2V"?9\9 P!E3W_S_ MHO&R=#Y&"#\N4SS)YQ M@;GELQ%)SFGH,5R.KC3B=!VA#;),1;&V"
($NI%Y<34Q,-4C5WR>U;0":%">> M(T\C\>:W3N$4=J;AHY0R7]J3+9B![R/V$VCV=Q.TL@ANAX:G1FA[^+.%K1.N MA.="N3515:5O[$R4!MFZR)Y/A3]-3;N$!F/I(%)[H!9?0\U)F*.G42F*@5GCVT[LG\/ MZ=<2+_^;?&B:
(@5]YG9GCP^N-TM5I#]T9%\A1I=."*9&_/ B>SH-[X2^4I[1 M\N)X.H-:6_6#2AH0MRH:?^>_)7]$NNR_132$#C#_U\5"0.PYXOTHD0;J4MU& MHF('T(R:MU9$"5896'2MLY&/VP_OU#@F'-J^OSZ=M:Z\>5A_]\>XT]Q MS9%
(=W2*DQ+>NI_>I)_Y-4R9L#?0&!NMQ'P5]F&6&G9D1&?=.?."&$FX%CD8 M?E]QMGE23]^8/,@$/(C;RQ!-#HXWU$G6H=P:/LP>"QZ'1><(U'TQDR?AWK/ MR4 V3U+T62I2(GRKF$R.56)'*_J-3OD5[]8OWG?
[_VVYG#;X>4QDAJ6.C(^1 M(NBY&&NN-D/S2J(_VEK9K+H^U@&)!L,5D?A@G\E_-]CDGB>OFB$:YKKGEQXU MK-#%#LSV9.HFRGRGQ9 MXKE]K[<]OFGLS+&4W9;0V(3T:X6YB@_N.5OLGH.$
M3B#_GV.B:EGLZ7L,G.;!VS6Z] YY]PA0U3F(-5R)FW]57V87;-I#I[10]NO" M%N(/&CP<&?T_W/9_C@M7*$KVV\Y4*HU9YJ.6"-^^WUB\.U9E8'^A%'<)],_?]R"N"N,1?1 P M$-7+A&.^8N>MVP>
[$=7'FS4??,;I_4$48=A>E_[@Q[*MHC6!@U:R2"AE#6X ME!5$7#O[#_+$>2&(R :88_*$R RBIT$1-/CF6$U+ EOW"6TT.$E3 /-QU9U0 MDTARK;E/M5W&/EMG(ITW6P,]#M@+R_>,Z #/PP%5;^*;Z:XK\!Z(IB%=%$S"
M(4(9B,7!>0'G/I2PNDXI4W[-2B?MJSLHH$)G"I-N&"R#D$F1.G#\|-FB1>Q& M$DZ>GVQ)VE8"[8'?+507IQE1+!>+2,^DTBAF5 MK44ZDV_XYD2+CRN;9=6F60IQR.B*R7CH#X [_>-3"YC,[T'U9(E C(M^Z$,
MJ@[51N%2SS;>!/B:1E0-O>%,F942TKG,TGYD]W&Q)^[3_A M>QPFK?D7V)U%C%69[+].!CY.OY KN\V]+8&[JOH^\5*]*ZO95A[ MZ.:O+*VYFAY;QEE.4-WV16W.VCF6HSQGB4VNO\-.JP<6;K'9R.:O:W=$,FTIS1:I_-
^<5&G?:TS8]6< M/^!.09%;VO%=BX^7"#?V].+C=7UI??&W(@1G3XE67.^Y61(S6B#XS$'(Q2T M4;;Z_MO$IPF>HZUNC]1[)]-THSI7_$$3_KI]@IV7=IQ%'&%+\-]JQOZOA]>6 MY(D
$S\HD8OE.\&Y9V1MJ3!=V9IZ>V3U%Z/\KD^U.]]%YRK7. M\TMWX4_"V%6L0C.KTQ:7[!T>U-\-HB;4#P10$_3]]FO*KNF]X1 PTM2YK-2M M#D?9\/==D'I@L?G*3V84GWZ+G;.V)]8LJ>?)EVESAZKA:#M\NE/RQ =9>MM!
M9Z;?:7:'LW-'6TUYIL4L3^T#Z$ O)B).TK8FL.;F%E&YC#!NLL6V::Y;C6 V MQ'GV[!QTC4'L\Y?_?6PGYKPQ?E_#+ZGEYH/81-J_@:J::R^I!N#<,%8 27%% MOK.:<]#S&D",N67HT VRGVD!]SSF(O^M&Q)W)WS)=\A35/5>\
MW9P-CXL(?N7N[E.I'U:PPUO)6SR6-)]I'+(^:RCG*YH==B/E]/;[^$I?%64+ M'#=WCYG]S;N]=)%W;NO0*9'J8;^<\8;[P$W=(31*=L5Y",$ 0UNC:]WW+]^,
MN=G])1[#];LTH>$]7Z$Y_2]M7D',!*7P_6WIC_]J>:]>J4QFVC=]K!9]KSFU M+O@RT[)!/WQ$V]7'[.!P?VU1SWF^1]LK;O_LU9(G;!S=;$+B,"%*4*#W#7D< M_-6$Q#[23X%WB ?
R,GDV!$7^B(]:&>H&GDUUN&)3V#P"#+_\,L2-,:QK2,XW MC+3P7$M:G>PC)D_V4GU1*KL^W[^6;*;LML MN:S]!WK@,6L26RF9OI5"]9O./IR#/)!72-X_D#[AZ$598E5K74X?F%G3D1".
M@T43J/I/KDY77G^W",@^,+]W=7WF2]J9F.O3@P255#/6>Z.0SV/P0:/FMU".'MS\+F<4SUMYW MFW^O+D._MX?/CA36D9O=-6%] FO_WQK:!3/_BK?^T!0O@>[; UD8(]GNDS\+ MNI^!H4<$MVAW;)*5CXXI+>)*5M6O;?
$2]$28 DUS\GB82OKC>9QZ+GH+(^Z\,:YS%1$F_VUCGH2FNG(PF!JB"^ M$X]49T[6$]"-<*GAV24%[0UYMZY,CC@^H>= M,:*;_V+ (O1VSP05V,'RKXYIS(6M:8R[$-WMVMFNYV?%74(1CP 3?'U_ER]@ M@O<])OY'(.>=96?
K]AFI]-OY1.=G ?V 0<=9KN?W0F%'-[HP$UL^0I!4:Z!G^.YD;8! M_^_(^)V0G;E"]N:9=IF:\%>TOEF]?[C+ZQ(C65Z['/P67DT4U&W2I6)?ZTH1 MID7'74RE$KR$0]Q-^9#60U0""D[9*5!L O& H^96D'&:3-7D[GP%0!OC? $Z MU
^_HB5">C@#$PO MW7^6,LF'5Y?M M3MU.A#.[_762R*3BB!]P'IA.%V)057\A*;LLO+6$W7 :*VE-RR"&Z"^=,4O] MD'L0:'AUN!*AGGIA_!+&Y5IU&%TH]>.YE682E\X?XK]"'H]3$NUB!]+PVU,K M='&:TF6
I:V"B<@^1!)$"Q<$4^T&YN+[1 ("/*1WFL](3:Q+L7&Z.'B54>^ MG=XU_X-,1F(PR(O CB.B!_*5;K?L]"X9M2S4E+\^NV^#KXF1T>3"[' Q"W/. M69W4O-W#DI<:P[,:I*2=%IXUOM.KJQ$F&\)[3+LN4:SN0OFU-0LH$Q07L1YP
MQGMCZ;HIZ8*K&7EUE\RV *T;]^/?Y P-8=N<$[PV\WD1-E&^N.CQ3^C(5RBA6<%626U?Z/Y9=1ZH?%925+]1EN__^A\ M3O6L#G:G.JR^@'EH!4Z0YR69YF"@A@Q_&!6_W%?H-XYQ>5NR86; +C>]F&3B M,2=<:/93?
|!W!?;9CK)&HR[:"$' %N]']*.LS2V"$;^_QW?ZC&0.A&/F%_O0 MER/47(LBM/ Z5;2OGWA_ 9 XZZ3GASN]>WL-(RD-Z]CEAGKT4L^:KD3M]Q,^ MHAQE#K/M)@2K-"7CRP)BL7%2<$\$ZH2\N=,F-Q.Q.!$#H5Y^U,M$U:U.\RW-
MA$OYHLNESM09N9^^O^Q95=0HV>W*64S7=?(0O%ZP)IR0U;M\|2S=O"V:#6#U?M=Z/$IW43DG6:MJT*6V%@FI".MEX=> MY('-*@U#Q8/Q_L#[K/?+?NEI7E3;<8@P^H"I>[BA/APH]:!647*V2]*U(C5? M$FQFN6-
<+*5U@X&M"&=FEIA'/Q4L+;(ZG<*G2"*G:7E,O'&;1F ]-";7U$+?[3I3:%LK7/8LGP3# ?SZFYX8VR^?RI'COH\KT"X^: M&,.>ZC]6_",>_44XV9(HR9!9)& M)"3^A@AMM[1BM\W[+:QMXC^$]9]6,?MQ[%6I&IB2;S@=?
\0O^'I^<#4//OCU M$,_=H4T_U6^,[$;'"L=.-MJV/'SLA!M:)\50I\:%3DZ6P_'/X;GMKO'LO #C9- M??1!,G)^<:B:?F@#<"M7_[":>E_*]XCN$;.4*O6&,"M[X!VU:X\%Q9^E_;\!3ELX\:__5N'D_6N9D;E9F.6U6,=I:-C#]I=AT8?A6:"!",:WQ
M]])4].I-];0RLV)/>Y2*]KR8I#/L%G]3*M& M$<;&"UPP%%?SF*-8/4[VQ9[6OE5[W>3SI_)+RR)YC].<'5_EWPP]\'F2;=TC MT0I*&4'&HO&.:$ $.2 K" W"UKPFJWAGHQ-)EBM,;+TG3M%^SLZP.#4Q-+.I9=NQ;)>987N5V;.?+
M9?K"&,SF56B"75?#3$/.3$K$[%<>%LO2A^<@?8 *$Z,RZ,M+ '-D JXKUMQN MOX3Z6HT],U=:@OA>?SO(MOS#3\PT-8Z!2RU+1*L^EC;7&G@][L;N>0YRP]:R M]%L6WQW6?9_MUA#8]H';D$V[;3)+TY6OF;U8)"UIZ=!
7:.Y*0O2$2=CDJGC M*LL7_?Z"N3RA9>,*![UC],E7_-AA3_NCW]J4K!>S5]4VB_[*^KH-TXL@%VYFY,RM#AK@W1? MI_0F_#*)IR9F17,E]\N*N]':QPT!*_AVC*XS*V)_+=,$,FAJZ> Q&%A]+.&)
M([0,27S@ERR,73\'O>S7/AA;7$Y2]T/7&0W_5CQT9(5"/1;1'5?YO-&/B^1+R*^ 1$785WN@X'GPT%+@I:=@+VK$ M:..Y#[59R<> ,,6OP_A;U#&2YR#:N7_'*@U^X @MD\7[Q"]\0$K_;06=F48P M$VP8QD]8+A2-
/X33VVZB&KL)H0F*"$8'OB21L2.3]T,1F:%IW75#]SRKNO[C MD!*_Q0[>ZB 91.C4@Z9^\;9!F]"P0+//%1#_"[RLLW)Y6DE1VO M*VKTM]?>6K"_E])TLQ$D\6I&3:0+3MFS('B/3,032N0=IWOP0O;"".$KQ[W4 M/WX?
YK%AN9(4]VC1??E@Y(SL;R7OO9>SZY/?9:U"NEI:7T2[7D@:=$C6.POB M.DS%["(WEX9@W%!G\Z@(WLQ0Q!I061\K/X](KW>ZG:]O$*.5[,.(&^ WNBGQ MMRG8GB5S*K['9[F+^JRU)>)^.
M=!.Z_XHWS7C\!%SM2;W/KQ%1>R'QDG2B(>M]UO\^JX%Z.4VCDRPM)*Z 4!*; MJ7#QNE-[-1],_\#<2_G&]Y)+U;AYNE=L0F7FOTDWWA$^4!4(A+\]W ="6R\- M!XV';&ANK%+05]ML6 E?7[#'OVV:^,2NZ1242-[S%T9:
M94[&8;?/(B(%F MI-]SQB.0'__C) M5)L=]#^'N:$/X]#O+Q/\N8EI)RY')2/]/BE^Z^(WGPH]C>?_+ZWR//C\4#7[ M^TZ2WAIWSD%"#K\Z O:O6RA.@==@/C(IOR[XL%]3D2=13"#XR->PGDN6%ZF$GW\ );?(+1\@
F75:6]9Z<.OK1UZ;:2D?'5=>+ @[_^E^H4L+"E3P)OJHS)]9&H"' MAQ /31I*Z(6<5< ]F6.<5%] [Z<^)&8 02@D-IQ5D2^0@LZZE&2C!842'/$B MZ]CPP74KDTU](JT]>?.&4F1S8N>DVLH2U2BV.0.-)1,?QN?,A0R
MY\QW#L(&DMR!H7/0I]>R#E5W=]>5E^^]? MEF$48!B)U[W,^L5Y"H(R(6H C]?6.^#ZH;==PBIQNWX0-W3"B=]@3:SW)^>F M_)&5,9'A/\8-"7:N^IH[(O$;$5^56;ZV/M:1(/@<%-.\*'8GR[17HUZ@][/*
MZL(59,!I%)M>19"!_DN:J60H1.PHIL+P20AK^!/S9A M($$:"+?G 3MD/:Q0)*7@%W )$#H3G,79SV*F?8].T2R='5E6QU]/'HVP/'E] M#]+3I6S^W8:*?=KMY,U9'DQUT=GC',1%O@!=9T8)_KG+B:2N&1AL="]K M2G!?
X:XG)CU=N//U6:O4E G/\DA[$/P^ZIC$*DITF$-Z(X#GACMP@238\0IG M!J'0$=#P6[%R?L,[-R3-N:2X)XOC+,06)18M*TWMZ>8(3#ZD_O,ET]+-H]F6[BH0Q1UVV5M68=J+4Y MVGRFK.%NLX>+QMFP4@FK"B7OI5*X??
NKB/9\_5[9W4A'AZ3 MZ3@D+/?SN?ZOD71T2Z94]T/MM7SO)C.#R#O41Z#?0RMR3 '.S#]:S)C2[Q:4 M#VKTW=&I2+?DE?X(A@B_']=P$?@FVE0YUOO_NC)V,5Y<_K;NNACH-O./&>V\ M$-J_9%\Y_6W=YT<]W4/\
[X)0I6Y)KVEB_,-QS0ZYC"]Z1 74UK\HU@[*CU>' MD-Y':EFI2>@/TMT??\EX8I:.,V9-;_XI#3OR:W=ZHS(BXVF1Z"EFDL\4/I69 MVU$3[..W'8?R#Z0E#DX=VVP(NZQ1IR4;TRHD!KUWEB?/(!].>\$+DACW%+)&
MA!]!.C:&Q(+9X]T^/*O;%I,AZ7YY*]"PS[2I?/!-)IC)W2%]P-W=FSI0*G#8 MO<5C[W'V@T-T')I-DP,?U9TO V00+O>_#(WIN(Y)8GM$8'Y[-&;W6]*02<-P MZK$*%^7%FO'@NO5(M([C.G12R9/G+MFVBR9"Z']58UPY^RP%]YI
:4T\PF^0 MV JQUG%''&?Y,'HG!P>;YH$EW?M(J/E@_O7ZQ_K/X+!UXN]X_@B?G+O[A7: MA[G;'0=6ENZDKWW 6=>/^)LG&63;V0Q_7?ORM0$AW4JF=W0<^F@K'HBP[_VE M6<_
G7BLT]\K_BW0\BC18=MV9O1S:IXF)T_CZ([%/M=O'>N0D.;K> VB#Y!R M"@6"*&*'Q!%$9]"3256LH @?YZO5^HRO=6G?I0,?W(V][C5ADZ)OH&/N$H]?C\B:C,XPJG5V 3\,:A M_TCB^(U_NNO(,(4*D'QDN']E4Y"%<*4&L\-]/
MY\,_*@/^$[H]-X%\-@&(Z.[6GG(!^:>#"! )7 ,U<6K"\+8$KVT5 C6;Q5M M&KB%]:V6%^].*WGN5A71&(C;X![+A XZ0AH Q3+PE[/MF?FIZ7 BNI^TY?G* M+V1I-
NZ/\E1S4>HASQK$M#%H7/Z7>Z[@K2$]?/'!KW<#.K_[F_0FL"G5$A$I MIG_C*52ZX/.(M6MY?8BU]T1GFX-6^#G(&=)?E4O+!^W>[+YZ1S@H*O(N"('M MF:!22]KP?.=%5$&%%+
ZSF]S_MDZ;D*':.0I$[F:VNH14B5Z[O'NT<2VC*56 M8XSDP^'HD+"*E]AW=WN.J-26YOC=\SZY:Q9%AWP1%4YW[,:LY9E:,/['77LA ME,/Q5%_UEZZFUTRIY>E-SA,#NT:WS@WIW8REHQGMS=F<8O:INL,F1*C?*-GH M, 40L=
[E*(/W^&L)D:B[SCZ0>9TCA,&UG"D$5G2WV8+)609=\N^NZ_?9R>(V ML%]36F4!GL(_E79\?-(>9_9NG%3@]V.+H,[W)CMN84]5*Q69F3V;7LJDE';7 M7:I4/%-?EO0V5"4M%+\;\O&-8W^NQ\<.LCF I\L"4/1N#A8)]+8/AJ1!)\S]
M_,8+1!.5'9TF^@[9BJZ3Q@%UGM_2_,TQK@F>KZ3[D5U?>':)2QE)7(Y?CH' MV;VG%5O]QI,>^5I?XG6K!!^D@R]*[K%"0S2#' WL%/>;+<4?0] 7"\@%9M5@ M+E@5VHU6R17>#\U1%095C(O,=C8,E@2.)X9,IF@48$=4V?
\_A9)D&P;$MT6>'B^&2"S<_3_],-H.]?(+]^$%QV7EEX,RU,:Q M24.Y;-^X)Z9]8!]K].>@8A@SC7?@EP/[X$[27BF):C*DO;$*ED/#;FKWO_]+ M4BHN8>ZFM<4@K^HS?/=V0&[BT?Z0"RGB'TO#WT//3^A3F$ :U)G8 L1YXM5'
MB"; *3A)2195WXWFZE*U)8F^HEH1:0U3KF$>V(_-4L^O*34]7]IN*UHW"C>* M'FB@-2S[PVD,_W]'(8-Y?.4.-QT(\_+P&U4VF2*S7)WGP5@3$N&5;)I=))^6D MR!M6,-V@;4WZ/-IL-CK97JOM9-,H]>#Q8>+F!,OM8+-
(8_'B\H[6T*:\%[5% MD#==^SW[6R>(>D3M,8FEF7SI.\8O3NOB61G$I>8"5'+ 20H(*'_5W+NL"<) MF<=#V5H?RRJMZ64*_#.[KDTWM.=\K5?T36:H&Q9^YL!5XT^Q2>^.\]?]UT@W M)A6<[-
XB=J3F[3((,490MA)&H"">]EVO)82R;VEJ65*4P!_X$=KTV8+/?AC MWAX?EFP$%X$KSD_S+C8C[4&=C_&<_10KT44IK?.'3I+6X&?:N%F1FT5V MY *(_-\.-'EK"7B%@9-0YYR9I*&B0*AW3 Q03E\4F9IZ!<; :'^;W6])Y76
MRERG55N 5 MWMUI[G""$8C"BO;%R9H=*2XBKT: ?S3R*#GR&35GAN_3H]'.]HOW^6OU"@]S ML,Y])I3-OPC\4Z6R9_'D:[!11!T%]91E^^%< %M_/CV0XKI2P[:\&:K% Q@] M<<%)WA9=8:P)))]D?
SW8:C-.\$I0]11N;HL/BU(H\Z/([:L42XK#'Z,Y2!2G MV?VS4O.:%QX/XP(@@R>E_7Z,GG;$^A4!%TO\:]W"(]Y0Y$B?$S=^KA=^=;-+X,/*P2]&/*S,S,^3=M:0;RJBILYI.3ZCKM:S$H@'7\Z2$L59 MG!R
[Z)=#:QZ*FTHA^]*K4\-89MK<7P5)Q[.[>.ZHE] 1U]YKVZAD-D(0$DN MC3))<^=WX7-0GR5LTG;"X1S4Z]^_D:H_KC\1E!)T)F4MN[BXN_]GGL+7*BZD M7F5)\*>E)UU2^MM(L;P-(391"_RO50LDD<2T(AW4*RCS
\;KM.TD2!"-%FE- M<9K\_;2E23K84^K2'N,(CW\U5^!U>7_V[#/A]!7E;Q/<@Y>#KUVA$Z7+EZ2P MY!I#8*.*Q$-(SCO5\$0R!IO$6PLI(%-LRJ6-=JF>:_8.%DB(";_C\W+ M_!T?4;>LJG$3&V1ZFM)_F:S19 @2AZ8]![GOHX[[*<9:'-
+BF]82BG BE+0'ET/S MST&.^>$Y]AHU+%M6QR"[NRNG.YX%#0CSL+B6TQMZAC12R!EP#S.@@B,^P)=T MNA/HB!\)HOWH1:&53,#7-\*[3MS].*K&%>8<+F6%+=E0AU:RJ MA38P9[G\|'^E'L#P'AV(:TWBLD8K\+&
/'2,I.]2(=D3W ?\XKD05U9G5H!H MS)F)XT_%5[)D%HK4TA=)\^9WXFI]__EI6KKA\;]&7[,#9XRX0/T9*$R/GW72 M>(7I_8/'%]WC63/W%+X^U^.]+F/7/_(8MN5V!K?%RFR(K7 K.WZS5;*GKSI#D.)H0+DCH'L6@) MUL0,RR\
[W%8UE,H4F"&^V-3)"1SU;]BR]C6R-0]P^][]9=C SA]]I8LM0@G0 M_6P/#<7&ONZ0QC@S+WR)1S_$-\6Y%MM*/;TNR-295Q[]C*4P5H9^TY_6!+=! MXO1;@0\NZ6*:$Y&N?M'.%Q7!<:81P4!HN5'7F6/2@T@-V@$EOT]&*9S:
(?88LB+D,+!_;9H-82$>*#843'_'5%_YF@ MY^TW1VL/Y13+9VK$5OXPPM1R]?H[1 M_:AU?>B+.[3C]HZ9;::(69E5D;.FH\%,487%EU]/"_?4ISZ*CSN[#.]1 M1GH@$B \'=S(*V0QTN5:0-\/C^CI8OKQ_$B,+ 5<7N&82%3BDU9&&
[>W1$[U MV&44 3FVTG'SW>7> M<^ZE^]?VA"$7&S]IF=WU?,![I%]Z],!2U&:O\^ME(RI?% M][Q__Z7A:]'[H&M>WZ] 1 MM[*[7*R>C&BT,TL7LM*:9F2F:*IWE40KD3.87-H2BGM MD),ONA4++IU%X^] 4":XY
+I<]#>OVQ\]ZQ 2\+PB]'M,32%[L##L(ZT?$7W MF:+N!_F%NLOI2>.KF!?ZC<2H8_CG_GP_M2%_1^+U_6*=F^9ZG1DB%&8A7CN(_MU_K$895GLZ-QJV0/MFW^9#FZ0X3_,GZ^/*4T4\E)L.^7A]K(X),E7M0*1#S M^WN-
CZ.A4F7^@Y_#<)^3F_ZRD6JB? 0&1'R$\XJOY_W_6MI*%,3PR+YMEF\' M'<%2Y<5VW"\[C(: AP\(\RB%4O'5=R/0IXJU84G]](C&%&D5G%O+KPV6V#?^ MMG"*((]?KT@N^67N;>+*HYM3F.I+;/;ZAL Z)"EQ2 >;6&8
@K"R"Z=$)D#T M]-^CT+N:+I@DD;D>7MW$57P(\]+726.<\NSQLN3LD23[M._3]K]NIQ%77PO[ MBE+K]"0/[+^%8U;1BZ)C?LP &\:=Q:,76_;8['_I>K+M=BKRGS.!DM*<(F>,)YEK@!L*[)1X"L=K_#,6&(*QB\V7P+?
M&'T.>K/[!,\+9;.J_9FIX.WN\V7S^*43HF)^Z4'3]:VL$"/I88J4O'#28;D. M'[?9 )?G,GLM*+FR7]!?80C['PURM"^7*].XV-B@;@3WWL73M/^G:6">F"I2)_GR MK2KC["$WI8Q-
&2_H,YQ14Q>78K&H#^NL],+M8[)]A\8YB';;$P;)EN6FV.T> MTE<614?,FY[9.[KM=S=K$%4:TP6VN^LGY+RC[!.D7" P:J=X,.25='M%6Z"Q ML>Y2Q->#UW^L2:Q!1(&S_V!,\!YKN*^/=<^R*#ZFM)0\=H+N13.31YO:AE)> MY-
D;-,$3M#CG?FL^X7S7/&?-"FTW_RDC_>EK(S+:5SMW[E8?8]=+O8RS()(Y MX(W93\BG(:CT.;_E52%N1)+KL0X1: 8#L01&35CJ][!IG->]D9:HC M8W\;+:>%"W5]T5ZM=9 HBR>LIXQX]O[]Y@<7.;$@Z'CV=,GX;X"!C!4=>\-D
MJ#U3[T?W*U"_=_A\JA@Y;H_UA]"'EEY_M2QU14K?E":\*%LUADI]D\.!T!1 M4V5VBDOB.&NA[GM-5!PQO?\VY:730QRKI_]/)BVK?$ MROX&$][F#W7]3Y?R"*#6Y0^]_$S#*F*'4]$<=Q@'DI4W/B<'1/EK,&+2YC2? MQ5OU]
F;R6P\?N9Y,1I4SR7ZI?M[-^B%D"H=G8_EO62ZN_,P=_0L,FD3NSG6 M6_3UR$,BJ$;,O(]&-VZZC%Y-S;3_J?BTD?E:4'GF]2^#>_=U#R,FXT,37?9X MOTR&>C8.3V=N+;Q:4G9]6L?^SO?5WC>AC&MXT&UF:I@ E.[JX#-7O#?
Q*7*9@\SFV4W% M)\*X!\V.2T?J1 MF)L 2!"X/QP2H_+(!E@_[AUR_'DC>;'WV"YQ=G:V#8%:?6,BM6J?$)(UH2$O M^=< <*3 7-0_^;4(S2&* S[8[Q/!U0]@=:5/I5(M;8[ )\02/!(\QN 42;U/S!LP&\V#^UZNR
M%.^,F7NC!'GKS$86CN";F"FABKH0-.L"+1E,JV?':2KWK6F+HN\N\\X*6$D M9;IWEW^".P*!&]"_VL7)Z0#]% 6UP<,@4DL^RN,J91 5X!Q.Y(4*6_'ZL8= MQB:L)*I71ZG$5BOEW1W_//%Y25B%6?/>-
Q.B;G^._IW&+G"J3,=B0UID+VB5S>N0N"";'&6_@' 7'/ZP![.YC M9?MKDN L$P-//LE\A4D!J.,!EJW+6%-H$WWAS5_UE]U;O;^GNB7%?J=X]Y;(9EXHO M_0/1U/_0;)F=)HQ-NF)#"_;?(SH++;0#"(=1WBW-6_K;K?\M\8\_M[C?U-I
>ME**@5-4G)T\[T<-3I]>@M"(^*/$5[_XP_=TJS_]_($##S6IJ(Q M1= ; !NSS'G=/Z-SV6%_]8GDZWKMO3V-OO7PW.ZXY:"@E4 >CY[UC.DW.K%[ MQ_V'J2.WO9D?>S*T?WVBFOG&\EE8C*?
^(N_V(XE!)7_^2F%C)=9EK3A'SEO#W3?P9 M]U*2 Z-'A$!&-08Y7U!OX0_+E7FEB+$U-Y"<>RWN! MK?H=Y6N)DT/O5\M\Y_Y MGOO[][D!U31+\R"87@Q2W0H=(;O@4VE(PDL]"+)Y9N. MN6R/E>E,A*@!"A63-;R_?
0I;E7I@HHQNQ&LI'&?0K* +L!Q]ENH,P!6<7\O M9-M-&FT/ZNBMQ#B? ?R 7$2MD'Q;CT0:D_@C[QYSR 9VM58UT>4.Y"NM\_4] MDE\L'IKY/$7_J_%D773@CVJ-X(B&Z*N$NWP.QKDNBS\MRQ4?3@LM*G0^FD])
M$#3K4$Q7BG?'_VU,7!=,Q!:U)#41)S3!Z.:[O24*O>]]DDJEU^P"REUR/DXR MWP$_H\[Q%%4>U$@S&Q<]RO&^"ITG?K-* >$\.%!P#Z()!GC)G:A*98XFZ8#W M=X%Y;!7Z# MV< N4H7 BAC%6(@B;@WS/?$Q1!;=R.B?
UR46BZ&H3 4]_D/2N9;'8]U4=;'' MP:O$26I2.2O,N5.:1K)]%%<3,8K[&;B0?B2]/AO8?7I0C F77BBBWN3Z./VY MH;+=-77>Q.#WVS(OWM:WQ) MS!_>W^^60E\/=SFSL6WH5BK62ANG9]?
DFD'L=IH1E99*K27CJPH^J_AUJQ+K M+SWI#B_C![Z^O6._'3\PUYW@RSK@W'7D9#ODD"/BH?:A5.!'=N<]<8/9@PA6 M3K=R4=.1*.[,DL17(TI*%A8BMS2RUCK&-DAT6S\9@8F8((-@=(0(V]-=*M#]
MV>,Z[MC8$C/)^(,WRB5ZSYRFQPVRPJVS[;+SY8M/*TX_' 1N3#X']7X7"KZ! M759L;H[SF!2]_/?IXNFZZ5]@])TU"TTW=_CDQN5A^GVZ.>S8UI?5$"*0M^P^S7NO5P*>*!U3+T.G2K@0B*56 M-T9,QTC(Q?
M$JVV3Y(@8OEN!GAA%P%W/Q;8/RV'&[\*#?.6[R?O>MXJH:1Q, M"(O:%YAU0@:#KT 1/"UPD&& B)#"1=<_/N$/B>&('\?=*Y%6^H")RS*H)_@ M*P4FP$F8;4$S;SEWH>*%GW,IR9 )N]3[0>5KD6VH]L.8*[/4PI_:>?"*E?L_
MGY4OYA57^B]U.$45)/R9[:]T7D&-N,?4=N=[I?,DV9^FSDG8]4ORDO'4V3, MSN$,D )O/1S]\22H_Q.>1-NU;=BPF7S#G\9D>%MD&?TNC@,M7WU/OC(+R#7% MOP)QP@:J_&Y+JX\?VWI\1&X!98I[L'W$29-Y^*FL[ZI<_^'\
((PJ)0&$+N#< MJU?/QRU;Y=O,0/6HLU#1CA"5*81-QWY^B>!,&U/.VKAHWTTN7W!0PY<94.GA MZB$AD'B1)$&6G=/G)3/BI!.A D2Z0:5\1/S=5U^8@Z'3P=Z=2][&M1.3>HN? M2^[G.T5U=+ ]>H,HMV'E_"NOFSA(
^ZJ$23W\B3" A]01.U(1.NR_? D"L?5 M+.9WBJE_QAT7BXE/7W.PKYG#! .'3*1>_JB)_@7B=U@A MC-<:6ZUG@+YBG3Y6$J.?.X.5\"3>=8 9 R3>/.!>OA4:C2F/??$;4=T]C]D2=K-H6GJZ1]&Q'_BZQ[LE;617(I@BOR59=
M+D']_/+M EBAOD"\:=YU=%2R\^H]@?A1I[G\=(CM]OK\ 'EYB"TRY.WL -&J M_T_S9WV05'4.^N@3-@#/)ZDR>021E^N0&YBMO&/?G/[LQ].,0 #0+H%I1$VD MG&\>N9*P=7E+T/'3D MUK"5_K'JOC7Z_3/+CU17NL\[.=]A"SR-
Y;AW'&TN#]_H1,4G!:A=_-]LJPU MR[7W+_X=URRNSKR\(!UJ#1A?9](:N;6BHIN]NN$K\?K4)G^%651Q/I_LR^( M>)PKS2-P-B!42)]'6_ZHO-W(5NMH.O0"68&8();<9=&1'-%)OE5E7]7^SEM$ M3ESH_?
```

```
U[J)]AXS#>^/[9\U74B6PI]/:)D:3UZOHYR>AMTH;JFEB1$SZ7UL0. MI13F[;$20V5EH#4%Q7T_V,%NT4,$*1^@UZBS](XT?5:R,[%'2NBVF )1$!NX MUXUD(;T4Z\O; <&>L'O='XLV;;JZ$S?F%/U95Y[++^<)YLMR)*D\]RV_KKK
MATI&@4J8Z[&CQ6D^7ZZ^4R]AN>4TY(B4=KAB0F7^5[&?PTV3>0:$08E G'4& MRFX[ZL";Q AN-C]PQ?"/P/@J6I?"U_WE"8?[_$L2_%%=#CT-9<%J_+-K8[_S M)W-4;]\#-3DK]:_F[!2;Z;AZ9;YD8(N6ZPZ5P+A>&13Q*J
J]"F.6"1A/4.%AZ$C;2WU6"*X?X M^)8(+K]:?-[+!B;Y9OD#8EP-IKYV@E8I'V(,'T8J'&VZ4P9T:RY="G_A"H:& M]KCZ#3_]PN7L9U0Y]:4\2#'8.Y(2M%=F90=_]N4.@>#O4?YG_FOC28:S,79E
M(D'S_IMSDHPOC&^-0HO^_NXCNUG#6?2O*@LRXWZ/O-.2PF/6"(=9X+M'SS*> M_7GPX;R*%D!,_[^_4&@G%G&XS0%BIDHKGO2*@=?@5L2*8XDS0(O-G&QS!X;Z MN.I]8P0E *9'\Y. 8!AFF7_U#%!60_F
/-8,+BGZ/HFKXKY%?PYW/8H-[,'LA+# MA^%-' >LP!0("&\X7,"7@+:P&FZFJ75J1S4Q9K1@<2E6 -'4.J?XQ__R@HWC M-Y1.[7"<@[^<)#P5#9SE9\B)35NX[+W_:->ZOE6F'Y';V\-@AG J_^;N@"&< C2VB M5,;P&6 -Y$+<:-
BCO5;I/F RO/5D%'G>+UA+!.K#=H- MYD<+W,OKKN;66@2UKOF'!J@*3[<*OBN-L!VGJ&:L3%/9N2AU#],'"7&4]EX1 MZJ08@O1]<\=(>REX*6E9;YGK_(R!ST),:Z_W[>;M9I M9Z&\(['3P)E=5XO$0O8-205RT!PX!,4ZQ-?
5VQF!512%Z"R4X7K?H9%)0CT; M17D9&BG[?PJO>2.3SY\! CM>J SE9TBE?@CB)55>*,E,_2_-*>;C.9YK6-[('*J8].F+!,[C!4*U-@][5-3% RY[#:83 M3LR24>C"8< P34QT-X\KCAV<:T_JP*G4E195.@IJ.U0[54V M8\.D
MP0=S(]\$DA=KOMC5,MMG-^?D=$K].ISHV9 BY]N=UA*?GP$N+%(_=[UJT4@% M!2(S8*TF\_1 VL>+Q6K?#5+*55HY8M]*6A,#-/X[%!5X#>[KETA7B],S4UD]%RV9].GNHQ7'YV+NMXWYL[DF0R $7&I'XF0 MNVX10D_J#
<*>E-F^K+:O98X12"VD7N%&8;?!3\BU*<;0%_M@\29;K%#9V LO8Q&.&GL&6#?'Z.XRCT 8GMZP'@'5^?.@\_1OY(Q^K=^ZGUQ MS)!3J!%39S+U+U51^Z?Y.[>W=YTD/!T\EC6,',:%!?//Y4!^*O<[2F7."P |
MYP')3;QQM\/B;FAY,TC>EN56]C%"E>D4YLE9V4:/JA9&2$N+*O_4^Z0;$\/. M* (TX<&?^>ZE?JZ=J4T><:A-&K8$(Y:%4Z=\ MM=\F+_K:.A[.G-FU_5=Y7 M+#)X.D]]L%17UKL S'K)F?!PMBD]KG.7+(HI;%2Z3PPZ;?
HH_5I9&L^IOY#4 M0UY)!^M;#\Z-!]:>=#^?G^_0 TWO% M_A3F,C<7=.?.$1)1;FOG=-)HAS+36JS;R"G7B XWZU1?"^]R^>0*/GRNOM7X M0\6+S7Z?S3ATC4W)1/<8+<9!5UJEF]DMAU!GM@0("(QI?F'?9&S<=BS16_DN
M($7U!95?'CJGI?5UNZIO7X5#X,\N<4FWN;)>)LB^X= E8/-0?K^DYJ2GM7?Y M(?(89J%_Q"/;XT2W,WU3>6P@8^B2B=[K[X*UYC-1V'<[]=^U)"M,-N"AUMP
MS]2GU;*F!C;/)@ODG\]U412DUA8WJ;"EK7H:%M0;_Y_;H.0+WU_1H+;];.T.B'\U>U)DN7)[,1WN#5C8C4V(TX;F8R0CWGX M@?P %S%5G)'<*[CA.AE4-8BMESFT'LYZ'KN_77#:\.XA]0LII&"2CWP&D &U M*8Z
4/!A4,M6$O0"=+%7&Q=RT(33P9BDZ5[!U01@G5!HZ+:9+ M#(?I';[4#2690:?453R*W-%XT_L^3=5JD<'5Z(WCKQXW%8$5]C/J4E%HI=_']+XVC.B'@8H M#.[&6AUL-?S[XD*F<1"&"\1)/&N_OC#Q'G\:5)0H/ !DJ=-
EQ)T,9K=1.EXA M#''3 S/.;][@,.5%)"IT1],] M='QOK;DNYT-!U,FCDK\Z 6V;RUI5(S:I.;F%17 +N]55/MG__Q+=YY7_[Q5) MK]>MV3<)CH#LD@$1O!:5.0H&P5)/+LR.CP%^KZ,C_RZ @KA.1!$B=TYC>80
M:1AK+BUQRHA@RZX6G#QM[T :30;['MV-C+0ZS9W[N4R$*O0\ZG;YEBLA.-HT MY25];(-4/BHT(Z3_]!\[- ;92[>0R24VNYMKN2\]BS!]%+GVF MN] O?@D@]+:]*4_Y0&4D@Y85(8K;6ZF@BV1)K/GU^J7MFTMDI_*5/263:!&[
MU9Z18K4!-^.689EQD?I+)]\3;6]>[:*AFJ7"A^H'N$]UWL[S#FYR"D*]5X,+ M+:JK,+L.P2Q3$S"V&^$Y(<(;0FJA$0$/6+V\SL/#]*$-;T]W M4&I>%'WXZ1K) =;_,$@-* I<]:4R3Z"88$9]#('BXYL<(!LCR%&8Z!6RXO$
MB0=FZ'H$(%??#/K+3$I%OG'3/PU:N:M$5$=Z9A"ECK\EX65 ]#4]R[GM5DH- M,I!RQ[E--O ,P%VY!A4AT%LKAKKPWA>5@^ MD$+'REZ4F:M@6:;/&?D9I"!8OQU$N@9RCU*'L(BAA225%N-^?BC[7KE.'&\:^:_O,#S97? C. 2S
M0(ZN 4C-Z*H]?^3[[H!+"AEQA F\*OP.>IUVR4,_&KDWF_ZW,K%]2+)+Y2 R M@RH:)#N0WTN/6]X/A57MH4KGR"%8#A%BX/WYWLM^*.^%I!$0C7EUF72VYYRXP&@:G%I.O0J6?>!WEEE9!S1.G*ZA&;8<(ZH]9$O#LO
M6V;^LQ.J02>G+U0"7+U^)S@@P#FY*"O7I>URD>=U^XZ6B" !';,8HB*/LL#C M2M#8TXV!7Y[$M+O,+6$A0AZ#ZYTR#::B> 0 M#KA8T5_S4]E5;3VO_=I9_/T%]T MKP3M[[,*8@DU#LGKRMF5&Y0="T^%LJ(<:ZKF*O":=
[NYC=5D' )R)*Z/V%6= M2O+-M]L-83 @7^T_V^]%-CG80G/'1=3:TF'IR7[SZQ-]=#++5R^9!*"LTB^S M]?,O*C7WP^\[9>C"T(VOH#Q+B% \ZS!*,4Y7N-
1UNBK070KO6!98OLOGF(T1];&::/^74%)'=I[+LWC,;S16!HC!4/V9\86P=AH3VC)?5SB1JE M 1+CXSV_0RSYZSU5.6C!]V?RZQ6RN70N84-[H?-=X_UW\PT"B',=!%+8XZBZR5_N(.@EC;>,N)WJ8W3[ZA9U5LS#NQS;)
M^N>E76F-HZ,#_R?'YLJHMQ&24!MGU(_W,OB@;5!;SSHT(6#+D[K7_;UL>L-S\L;7NE M6^7_/:&EF'_3-4/7J0M+('8DN@*)LP5Q$3,(290/^I+$2'D8YG#0(XEP7C$1 M>?Z&4Y?CW$/<5]R"AO]>C;"YFXYU1V_>HG=[^L$',
<^)SYI6:R?_OFW8!D"% M<%'[_:1SU/&MILH$F/=AHM@5HAU>8X"]LMSP)1N*ATGR=/8#%(S\E&5(LC4<]3^B -C4P <5#E5G[. MK1]5DL46#X\SF(PPKL[B%HKC0+419&=-)XW#< A M9RL'+;EQW!R93]
(E6=_A1[B35%'W;097*],$X>RA?(ITCFER]#R;G(=-IPK" MKWOKV8Q#)G>VF3CFE@F!G]D4/?C. M[E61G0M7-)'5F+J:M0B\=\L_1,@XTU!$^4/H0*9!W!73_QX\3-9[P82]^U#2 MR-X=_3NW^V,SHKVSO;LU+C!FI:
(#T5YR(V_SYR9XDQGS*6ED_'T!/WA#X)+# MN#B^6)F/.X1^.]@2+*@Y"M4D5[_G8M*RB_]R2_=!*]S$"%9B_>]R;G;QL^1R M;.V=G)R?V*L%;7=R:P(%C$A?9H.UQXUZJ W*E?RXX\7=1AJ32SL!Z2B"T#E MG
5I5SH/MH)$LPTB1E_4@ M4*D1V9HF:S7[6*ZU1^'+LM5\G=Q!*TE6^)KCYI>YD1'Z]M:VCHZ;DJ^$8\#8 MY&MEYWAY $H, 6\U(C3_/D5?TA3_;V6O>/* MY7?T^S]4!5!P2#+L8V\9R9[L1APFJ4'T*0B0%S 5Q@&]^O,,P*XO3R/;
M=T%>\ MET.F\,P#/8XB56/PV)_YP0..D&6R%C$6AT/0[\;U K"\A;D1^B@B2>^S=0CY)# M/0<=0;;"1L;TF<&P(5J35"4_=UE*Z^&5[J4($/L/J"RQ&\TU#RY_^FWQQJDD M8DYTB63:7#+;4)]W;2F .B\GO)-)QVB?
Y7"/_M&5!U=\)"ZI/GP4!69^' SV MH*.3/I6CP*E\+M!14+OOX'221_LRF:L%G9'2*TN^B[\?B%8D7L_??XC1F=RB M"^R5P*=;(%.@5R' KIY/+41O;/TCU$^M-CB?'RIP]_>6NU7T@UG=9@OIX_S' M_8:)1W,FA5(C]SS?
C"6)>SOJ,J0RC&DIM"@[^#,U_$P+4RBJ.=@RSG?;W)+4 M'/ZMT?7CH@$FBSYR*(,Z=]ZB\Y+O6 M=1QD6;A@IZ;F>2MV=\K<$Q' 4)Y'OHQQ>*9'(1QGH[AVB-W:7\,KHD/V?Y-4 MR5=P(<.'&5L"9%9\XS8C
38$XETGF@^X"Q&-<$"C^8AIH8"PS557-W=W<+QS M#$E/>K#KF7'>;[?G90?<)]3WSZTP^0>UN Q" B565YYDMZ=]!DB$\OP B>JS M@5-LY_YLB1'A=V82&E_[SJK5!MD-_'W^I2PZY"*9\.Q5X;/VI?97,>/R,W?P MD!WC2Y
_&\Z58XV'KLV]A8?S;G>^W9_0,6OC*2GH\#XZ7"&/T\2372(Y8/,@ M=BR;4$TI%X@EJNG+]-=+DNV>RL *@8U>E[QY% M^6V(]K'V.B70'(* M5:B6X"LC3!6215M?,.3Z2&Q$^YB$1;Z>3?]$-U%Y.%3X]NE/(QI/K2?&_F$P
M=\*:7Z3",U_6Z%V/RX2%E@%UNB*W/K MUY#G:];D3BG<-)'6_=("-6"K21]NWNC;$!+7!F&[_5IXTO_1E_8*T]RQT\77 MFGJ,9I#EV:N(-1=*7TRGT_U+4:FIYVN/CK7H/9%B??@I4YZXH2;Q;;K_[OM6 M[IX^6XY3/+
BW6@R.@.\2B2*=AFKW M!K4I[J\T2(:@A-%A8Z;G5?%V_:R2W$4,:6U(I3S -DMX6U.1R(V-MA1D7NWA MC-.=S1BQ4R.P-%E-<7^!!TF^ >K[9CW,#.3597\RF=;?U$"N4QW3%.=\P\$# M1!42_%E[D'ZPV-
>Q47DAR9L7;#]D@N50OV8Z^S;&&&67X)B]3QZ;H3_S5?]0 M$?G5AT^=8N&H,H+OS5[? P[<+;K4D4.\>?^U="5AF:GZE][>XI*R;\X @]E] MAB0'ZN?X)Z!6][Z^/6'3,5K"$%%B+:F)Z$'_;=B@/$GD83M!R?8Y$6HH[]KY
M_YVVE&8,6236H\-2:S1TJH4PC@Z".F6^-\ODT#X?,@@?* 45G&^1?B&QOZ[2 M#TWBK?K9I/I"IT!DM#<@%OR'XO$..H!,8N\Z$"2'72*#2M!NDUF4SGD# +R M(MC,\E/
ZXA/@WZ*)EY8"4%*V&#MM2IN\9;*&YTTL0O&YIOF?2[OA][''6IO M9AX$(,'I-]%HNLVJQO-6]$]"#V2;D$04,.U_H"]+Y \+_L([$]@]@PM%G%_? M+ATL]>XZKC%!;HQ3W"0D&'?3BO;
H+\%BM=RN#T>7'^A=Y1,@[TSQLK%1@/N"*!4JWXZE\C;&$H572 M?->?>RUM :[&;56")'D.2/?3S0(@D54@2_>0MHR<'6=Z#[K2FR;NH"Q8-6;I6!-V>M^5HW@ MJ_D2U9? -JO]+TR.E/?0"\%>O^V!R9L,;(\T46O&79%??66&-
'_%O=#[FXSS M^->]_\X 4X/DBS1/J$6'DH]1_I0:D(^W-^._]\A:7,4Q'$)W_I?IP#7]QJ06 ME>=^2WCL,"!FAQ?=2*+9Y?]+,T"K1M^/25-/HVQL8QSGR35'KTQAUXO"+R8B M/S(&RCY]:+K5!M]?2.4]
_C!8ZM&I60ACKAK/L+)F'/+MQZ!1]:SEX,O F(V M>-%3)%OHE-\]KW\!+BESHQR&\2>**R5![21E Q^\9'-23'L!XV/WA^/^F>BF M! Q3VLO$'\8G=09(J$2G':F?8^6Z^+AU^,A9()XM)NSFO_?O2*D&^7S80A)>
M$27>CA#HL/#8$SF(Z#ZHXP* 9:?PUPL-[A>!,PA1O&2?QZ76Y24(PS:,"?S= M+"ZR[=," HC5DQZ*O+0N<0Z;=VC6W?5**_/U!]OF$W:LG@<3]>;]9]U5_8 MM2/0W_)>Z.M2NF&^2%[](JB9XX"1I$64'G6"L4,<\+Z8+^48>
<:1I0Z-I3!_ME\)Q?QA;E)-V^&BT6%K=E0\HL1Z"[V_@G87&AZ@]R5]H&*Q?$8;.@[4F]G&@ MU@: 0*H4] NRF7'?$WV8 &(D!^&R[^$]]Y,4.I_BQ\AVUV.>^!I[$0[2*? M"5&=P:W5C!K_O/"R2;YZW6S9(8 :Y:: /=UZ\=!+U\-
VCR%:K :MX*A?1'^^)3<^[D9$D)HZS^ ^W T\79U_F#(!>F;DQ+7D; MN83Y)#?H:"X;.-Y\^[=9ZO+BI6;7]R.U.+A] M029A9+[DY7=)S<-IRV(MPIB:F!G]ID?>S; =;\'5(]$/2FR=/HQ \+41 B/C M#>;[QLC!YM=NN=SA8TKPP(R-
U#?F;%]3?0%4T!2(+.I_^=\N.,@F[Q_PUM&^ MS)ETI^&/7%]C#2]:C39X$)DO9+1+^L 5"V3:W3I/UHDA"1&!A,^XDWTZ+#(% MB,1=*'2?AP@\O@ 'O7A:;XF55\#BULVBGHA,"8^P,T[#4/3CV+<'YZ
M!FB^ULEOBS)BS!]QO>DHEVWA1@^7-?MU!FAV(?7WOT>Q^?#5P+38W M9SOL$UNBS 1+P4]70@6EP-CL7Y*X'/NIF^R$DWGQ'R9)L:%&)D+LX>,+IT], M=V(/VT20/]?6/>>KZ1I#ZL'7_B6'O-
OO8'XA<6)VW5+!T&M$1:^7D1JQ M9 4ZJ4ZWM"EU*QKL>*,F:*G!J:_-QSCB'BT9\UWFM9*(#TQHR1Q;ZQ9)D"P0 M^[*VNO;K08S!Z+58SW5653;UL.A1 2T!_<1.09'4,P (CO. KZ407E.2:*&2 MH*].*=(-*B<"AS8O$VL#,5,^A)-
;\|<[O7/"1@N_RCM>L7XV/I+;%5MDL3RJ MSY6Y")WD0,40 AXR@UJ!_70BM5W\(!XR3\KE!U#\U:!0Z_]&[FVOQP/R 3Y( MEC, NAN&LJUZ"6I1W)]&P[G)2C0KCY.L(;?PP*&]IXH,5!*$/.
M;CY_&+C#>N9&O<'N.W2:_O3CGW(PTQKVE/B2\J M^F)?]KZOWXJK+O#^XRWTJ4A4L[ISIN*T9]!(="XL+M)?1\?OP!<')',/4EG_M39U4(1;BD$.1(-SG$D5*"\0S:EO/T'RF]ZI?5P3RI:[H?VZ3CY$^N)/75]]<
MW[G6=YZ\V_;6>>:"256;'[;^$L/>)*6);4C"ZY$I?MB24% M)6FE2,UNQ/R2X?=J1GI9!C8.:R.H/W3D#( +E4XE]^$"K4(X:*I&$\+(,+74 M&-8KN]3+"NX>0'(@KF/UGEW+)YF[B7'U%LA..G6)RXS\WJ@5V9<_;!Q[D&]G
MXL/4Z/\M+TXVF!7DTZ2'">D"+_DK*!/ Q2Y1SBN_K&?9CBPW7H12M(9!QE;\ MS53QSRHU);S@\(1A3)/FOMH=Q2%+EEQ>75Z3Q%I;Z'+*DYIB)DN;'&\7@6__M!9@O>(*QLQ!#QSR@HI^G>"],I60IR\X
P?,'7G:56=/J<:KV*X]:M' MDBSI]R:M(^.;$EQ^*I7[H1CNVKRYC)1LLU?;5$[/R#W!)?&6=+,/"'/3\XA1O/0C!4/1'D"-FJ6/Z$2U]<[=F"%TO0#UN.;D>4KRG8,]X::R6M",Z+C8 M4DV$$>@H12,)X&7^@KM"0#2! -MQ7/$0\'>V\@
MNA=L^4+XP!52"YC.EH5&Y.S5ID^=+:;UP6[]MISSF[C:'R?8D]#A3Y_A"E^H MZ>_H*K,]R]*+85S$L/>E(OI<,.?!B0:;M%$LI:ZG++[:R+[RCKW73ZW-K))3 MZ0QP+WMU:G4>+M+&:/O'EP23EV/^\[7 0'[ZW4=[I,=&.L:
[FN,:8#.S&^\H MO=_^4/-T?\B]!B&8:(<.28 QM68DH%]IS+CCD[3AAG=,^. .[.0>4^,Q!FL1 MB9%:BKC^]C;TZ9QA=/C.6G/S]!!YE52PP1KQSE?/C(^X:*D3 MN*8I#7==% AP]4H9:K<;OR%M%?@6RR'TYO5_56U1I//0)1B?A!#_
?<9@)$S MS60@]VK99P;!N&V5*.2PV)'\_DWW9:N0AMTY-S_'_HU'+9RC;(%QG-&&1 6- M_O2+92G#DZFZ,;@8A:&'>,TB!4G&G+GM7HV1*DP@5M)6P(7(+C;XH(E%S?YY MJC_V>HS7FEW]PT-H^-M07LAW_J214?G/30Y-;;
J)U;J3O+*VU;96)_;?7Q>[ M]'X16;*QM2\3&,UC.0 N+K^&^&-@S/XGJ,HDA!L&?M'?Q>A#P:OZZ/H]|>#\ MH$K_'P+C4=&A$:$BU@:EH;TF(FCV)QQ?3>*0:"0M@.^"1"#W\5O]/_1!NU"Q M!5TZL883?26\1=U?
DUC$+^LYYOZ_+1E'PZ>Q/G.7_?D&S!YVO'I@/+E]W@0E9V,;9!OA&FBV:M%]H^K@ZH!++W@!AD8#41K8MYWME!P: MRN0BVQC3UYW[4F*VMRYN_BCPTB['7PPD[$V:IAI:*F/]I0!XZ /)14A@/1MG3?_\??
[@/5X2/G+O+F5YXW66<9*=8:LPH(I M"3F:WA<];CE3YSQ:U.%!7P=)MR#G6Z^-7.4#<9$9_/V^,JQ,G@^D8Y?T3C?- M_1QX NLRF42##W_L#GX!K90P^!;YJED6WQ%HO$0V^XS3C*XTMB;D'EDR3>"< M_<(F-J!]Z1Y M1
#E/1)=#P2> ;PW8OK@[2'[&R0EZ 2(K?%]T])C&K'A(5::+NNZXAF=YAOR MG6* K_[VMH7KG20>K\5HTFM$$O:O=K6]#G>#KA.15"9.&CNKH:2? 4)$PX=*
MY"B55"E_U$C9>S=!"#])C^@Q+%L!SA\6!%.)"8(2%S3P]8MSG2D=XA2=KN&= (4871D5X58FBC]_]R MRTW<=(0W>WGMNK!6"/#AF??H:\CU;> K%[%*O9?7)#M:-?)0^26O_T.;B)T!E!.GA)6GH#1%M659 M/@ S2;^*2XS5%
(*_1)@4?VMM80-R@_T^.LNI7\@%^9MSOARVTAG^+CBBT][. MM5-?, !^',Q>)*(R\31@"BNQ?0:HF:DNM!GU5,X-O7&MO]%3=M,VX"?AB:7& MLRUH-6H4"9U&MH3T-:YF8WZ]PW6C&0<562$*N*MI@NE;1KB\_M9'7;%%
<\- M'9!MSH?'SPUV%M2&#XZ'YC[S:8X?/3(26R4 KD8[3+2F-W,))B>BZ.!RF9?8 M:THS':*4%/;GN$:')2B5,)^V)UZ4,GW&Z!+;H1E@W IO/=G_\H&;9 BYR'ZX4P7B1; +F9E\MK%I:WVT\AV0QR-
TUEE'*6)BU&3"^@7N*L7!P*._:F_\M*NHN(=[O MI;CU1..OH]E[9;>E'C2_'M#6J-ITRA.H]"^CSTAMB3:75+__]KU/A%NSCJ*3 M5*^&R)%]O+LZ*(!CM7[B@%(*959^@+&&V.*,]R4HO[X*S8\+6F+R!7^L_DBB MB=+/^WQ&E/?
Z%[HF)9(OZ\L0!9*DT+D90BM;&B(#A:]"UAJ:M6:W\FN5W#< MT+&T;LE&9-??"6U8_-M]7:HPO3W-8*:P>]*S,"I]V?&XMZ"[HZ(CQ/T,<-/& MG1Y$D]_5\$?4F3, W;L.E4OZUXD2A1#PYENW)VF#;"+TWNM$4=%,WA31^H:X\
['%*X,,FGNCKK.K)^T%:;5B)".P(*7Z M#. 3W_&O[',C#O:C%@S4N:DE[UZ($3294/!?)KC"TLS&'%._6S>_6=0[Q10_YY25\TSH?N M'&1GOZG_XCV"A[H ;W%>%Z:)$Y&Z!/-S>*>^?8/F5X+ M0="[AN#IS(]BH M"ULM9@X1E-
)>IMS'Z?K7P-<[-5>>]/7T*3_LD&1_PO/;?=6S^EZ 8V176L)& M&R7A*^>ZR]8]"][%X@W$+'-I9WMGPJ;@?UFZ*KJ6/P9N2[P>_T];>G;?S\:4 M29QS9O;.7A=IAB<\8>SB&(NFUD11 Q,C??A$ZE=?QEB/)! /$AWOT;0\;)5.
M52).5X,/"7FXR@3H9;(!B+?W"O6+/BMQJOZ'1TMEAKZ$](\>S!8OUH/[R>35 M]A*(&D@S=)NO^]XVWQ;8$:VX_\U'!QFJI/W \UL M*2*X?I7&4]%;2Z4<8? 6IY:4E-^6NU3V4=40_R!O?X:TE\PAOO2L(0RIUD/M
MZDVH&DK!-4F_+#](X5-33R9ZY8/S/&Y):0+;Z"U);8Q7)6 G MQB?YI+R3M#]<3GT#$/%*7]TM2'L9K*2."]_]]=<3>"\&GR/U)^>^ATG-82^! M)X3!KQ6Q\8>$:#T]!;ZBJ=8SP*H3H0IOC0[O4"HX1-'8"SZ'/\@ M*#]-
GQ>%%V9$EU%+9PZJUS36B\/WYLH4V$(=1".]F M;:!4Z)K[FIS3^6 [JD@V3A';0>:6)0107H$"#E2^8_4[21K$<&M\>GP-6';( M!1[_""30YB8\Q!5HZRSLF]'IKYXO=KUS_GUR8#S=6M>Z(;VJ83_^)I_,)TU( M)/;@/#
9^Y.X2714>C"4![Q%Z*+4Z0M"/R^#^/Y,R6P-Z4L00S% P?[:@-YK MR^0K_VUI^Y]L7@N49]&15_A&Z9VLN#(\M?_B-0[B2I"AM%-U7*#]9X"._)1> M17 *E3]].&2%%9MXH(4K,\=/;;QZ]]]/.-^?QCBH*'43-]*-U7'CGIP[4"LV
MV/RYN78O$"@O9.[V8_]$H-QB(IW]]6BY .G@0W9WL;_WM]:;'U(XQO+0D*. M+$29D'RQ>W6\)MN,QAG>26VY/NT\I4D%^O4S0+P]S'L5Y,MO1;SF-#BZ<>?
M]EXE&W"'"XJF*@4J[BKB%GYL>+^)&*WC:XTY;EQ,/FHVKHV5;ZC^G#[]]3MC" M!3B1.=?81S&@86]=;G@J5";SEI2O7[1S9@D@.%Y@FIZ8OW^%]!BZ"042BS%6 M%XFCHUWP@^HZZ)('SO*B">$[T0X'=YB']*+I,*
T=>2E&TB.25SW(%2I.=VN M$]*3?W=)_F6^_A6SA@/W"?,4@]\3-KU_:7Q/E#H/:S,Y )%TR8'X](/X>N< MD"!"FF0+L2=&5?G]O=*6 P7B'. )#4%#^HRSP77G^VO]NYBR@M3U IZFQ^Q5 M#35'9T/QU5>+%*@"BQF-
+76[9@W+.<).2U,1/%_?5ZI%*VZ86_V-N:-FN]Q< M##>O#.*8DI>F7N2G) ;! LX O,03QR5=,QA):HNL/_>GD97,W(&/2I4C>V+. M *\C/U?7@N'6^-:_-"'25.;69SC\H2?5/$A6Y7VNL#\HT(IXPY4@3(S'#5K-
MG@&\@@R'MLY!K[L0D8/Y7? T<@AVFI?XVQB!BTC%D.^5FY3]?7YT,?!>ZYO1 MAS6,$:U=:?=R#SY_!!T/#;M,R'@D2;*F"=4RT,?OZ;H::%$0P6$! M8HZS&]:6SB!K51// "ZT9R%[; ?I#.N?I[6'N(5QU5,/7 6U'(NZK'KL"^7,
MW==K?:7Z=.[CHX5>:5C_^ZTFT&N8W^%Y\!HFKZD1#"0$S2+HL!LZ6(X!UJU+ MQ$$7O$F*OD2 ;+5B0D0/Q_"H0SR)WP#W9W[WVXG9RG@DPUY%4 M)ADF+7K/!K#6:-6>H*0^A5%C];!SLYX]:] M#+;LEK8M3GZ=<(F?
UA=L;7.D;N%\34:W$]DLQ/EM8 (,]*N,[Q@.'Y0#TO7R MNMYJ) H=FJ78X%\5ZQ5OMFR+NCHBFKN[<(<)'Q;EBR:]"8'CTM&WW;T"3 @4 M$HPZXW(&V&\B :$TH[9RO&R=M' =AC%1><'P82C?1T12R?#Q9)"VU[R"XGQ&
MZ^]]S7'>Q:GFKM/9 >LB;H]L.,Y\&J5*])H[ SR^Z$FPH/SW;W.QUHIL?#A! M@,A+>@XV&1&3P_U*P;C!,,@4?=F KI+<;63"WZ?ZHA[-ZV2=%MC^(,:JO38@ M,HBW_U'_U\RF5Q(3-64":N [D%_KM;D!!2X;IX]
[C;2C*FI^RUX/.UK=]NBI MKSG]*^:)VZ->M/VWVO\4&D1O@>? 2 ]]0H!U>3$Q(2*W*B#^>,/=\6W-I[7> M^"L;=9FJ1F$*;1YME\9)\&O&NT*]JF(#(40U#2H3KIK4F #C??_N;8TI5!7<
M.=.9;&0/=L#K&ABD2;$]6I>86Z^VPDMP& M.+_E?0VT%3MXS9)2TP;DACS!RQ\.<7 &4!F6R!+8+5ZB^N M8FAXWHRN]//* MZ>@(OM):?^4"?,<\L/^!5SP"27GM-]LNQC<75@R5_S6Y0J\
M]/%:D]:IB1YX[\TMT;Y2+V$OBM=,;@Q5)9+]AEET]RD#R)#73@ MC5%\7>!>BTT!KLK>(4;7_MA4)/)&8>'\5M@S "?9M#,O] .QU@]_4TYIZ\W$ M3.FCG.>V;_-Q]1P,G7.Q:%8.$>BF@8&N/ETAQ]K%&ULIRWS+
<"ZQS]01VW4+ M[#%L=3YHO 0'/GY\_$F>>KE\P7?_$4]"\^4MA@_W4ILS#JPF,DCQ57HZ+^R! M?5R,E0%L?L^]?E;&IM\:TWTF!M,&4(7(YF> "X'@\S$>HL,8#Y3QM%G/0B\3 MF'NPY$+7PM,,GDU7L--
VVTLA&V(\GNOOHJY!\T_]2WC/T>HTX<$TV2V_D2.- MP-T\IC*/8F[J10YB&HCS0KMU5&BUD3<('&!"^^UA*1I6V0D'V>\%MQ?OCMX]\A%P ME!'B&@W(4.+UEF:Q]_+<,1H35".3H.NP]I"#4=P:E26)1$]FP'7$[^L+44>V
M.*$J)NA#'HAI",+LQCLO&+H2.7_W3]I$]=NWVBZ,/([=?^=Z+D_SF M7V'-$WU9W,OQ"(BBHU[\-S@SF%B)_IZA]T/2]:/]$FWP<(?9*>2+7G%B-A:4 MHFM1!@YW4ATX P0LW+C:;;\0A-JXFCH T
KZXDS/3+%9E67L7&=:$T]7N>WY M.8FU->SZ7>\GWRZQ5'E(LRA/N2-:)%UDNPQE3UCILB^C"5$,67?)]O( M.G8AV]K?;V><]_7)6M$GI_$ M>=@<[Z\(*QRY"8C7?O/Y,ZP])N$KN,D1ME^CK52?-SL<1FK..):G6Z@BIQ">
MG<7RS%"X.)CW$.11(PP%9]CH^$XNRE)#!7/62+=.]](E-&6)O;4]ST]XMY-O M4MJ)9SF"IO+$'T8=^HY[I*F;]=IB]1#D+VU/*TJ/'K3=W9S,^_1>@L/N$CHG MAO=%3_;697:E%[//(3'I_PL!P_,&VE+,J9MF55_A=X W-
4#Z0"YI7GZ:*>+7 M"D^#]Y*M]H=(]_I1"7"E"D;&B@.%P[+!R3]?X-5?*5DU)OFAD0%L1^4LKRK%/Z84=UYA/F)($KWH$G3-2:-%. /9:4I MYM&.E L=/N_"H$3^V$;4"3\]; ?%V'Z8NZD*Q3-_#_N^]&>5_/5?=F*V0^=Z
M]N00%S8@6/[M?-I5^@F6V#MP/K+:M@8)<T8A3AW% )N":O?@Q*5H ,BPV& MBH6U]>&.PR4]*@'W7E3IYKIV; X1(^PGK%6@TM:4MB&T7B[&7?@Z]WC MWSG MU7QPRZD90N)$L_ZH3Y/*3\)2!3.4&4,7K
\W;N,ZX)0I=2H?&$S?4LL3; MOK$3FT9&QG49ES.*N5;@BND?$W'6[BQ3].KG_%ZR]DBT6DD]356*-3.7%=OD3DVAL=^PLSEVLOG+YI'NI47['Q4B? M!6%:486A?IK9GCQ"L;QX%[,_1T>1C&C,$UN A=(6:AD7-
XN6+F3IU&]19Y"R ML:0'T-TH*7,O]@]!<:HDZ85- O?7L!.;QV8=D\)\K?2&\7NK?]_T2EH^GCN= M<2?@$#2((WO]V>K%T.\",R0P)]QBIEV.C.X[!+$[]:"/P-DB(E9X;9P!*&4R MXIX<6*AI,7@_SC^TMR)
<=&8$>&I^)#N_2$W^;!)T/BX[]\M$P=$GZV\1#I>K M71[L^>M;S,"V&]>U5:IDC*C4!>M8JQRIF-'\]@:G=?\Q.Y<X,3!"QHJFL-^Q!*[K7]4S&+,^HV-YUH/!/F@R,J7BI M0.=#;DV[MH] 3+O:TS/9X9B:_O[V0U KA
QCT5#:2BA=N&%9?%N!'+>B$[L- MUW4G]>%S!A$]@)F?>+Q]7Z@]^+B\I0NDQUZ\_HAGE,6C&F)K-G=MK9)0^\"/ MC#4$0FP!&5'2[)IDV@*PW8S')6*-S ]-;V'CYN8S M<,]/@V"W4#^BC'U?
Y^D7]S8+SG9$,)3Z94]],$TXT]ZLIW7]K/Q=V8B5,> L M>'N1)@M 5I!;,R087O,FL$:Q(8G'(=V@PG!E8'<%=QP(-;;H]&P;4]OFJH/4 M$K(I/_6.(!^Z^KAR^ZCMT&5@037]+PI3?:3,>;!&\SX['?"Y"(1GZ]L,F)4H MH01#:";,X?
MS$QEW>X&0]\^=_]O61A[\;.[+5U_1).//4C[H;K"<^;)2%T0 M:HT9"$U&DBW!*3AIN@5I=R&::@%0*.!;P"()_35S91_5"SY!#Z HOBE=EU4' M4,MHX3#(=8IG4N#*B(R@O8E+X'^9=@7'%FZDBKRQILGGV X^=>':]I;D[!ZX
M_BWM7E07Z,;WR*5HC.W45*'M#]M0F]PM3&E.2ZYGXMF*_TV*+=T&6Q_C$$Y_ M>PA*T4L$^8#8!K9$-YXBR+I#NG^?[?_4&/7ZW"V?%F6."C1/MI,X^$"2F\NO M,M;T3M")>P%RVB6SY=]JM[M..H1]ZN[5L*H_QYYV\?-
'MOHR>8&PZHU A\;? MV$7"7_^Y:9]Y](A9*G(Y^Q"$Y6NAW8.; BZE@%,W%]7D?\W?SY 'Z2*9=P$] M4\,<;O]NA/CI$6P5D"N#0RP5/UI=LPJUQEI&AN]:)6?7]+?&K#QHRF']:)F5 M)7@ :>I. \5L6X6F#]>9UCX$+1CW=5X
G$K\_NBM]QN:&&Y4ZA?]GO?0HL+7^5//5"I8L8T83Q.\0=)PY!<5]04%&>][T M4^0XNG @]0[@1K/N7X[4Z7TF'O_;!B5[#GA!XDFO#@LE.>=5^Y7C_W6-P3;? MQ:9[[_RYZ2O4_Q@MUSI'0))MH?@_I+5>Z-
<(ZE,*NCLEP";N$"2 ]",D0!K$ M>Z3!TH-EQE6;Z!-!:!3DZP@)+/)3[V[M;ADT#&?<-%U["*H[/>.\[OK,L;KK MO,<0EZ_SE]VEC&87\(\)Q)E7'G:-/E6*DZ$1S[1Q9HBX3ZU@NA1+)1RQF593 M2"Q"%.Z@5RP5D@LK/\?*0>Y?
X/DX8<7OC>+58!2=L6;A88CI\O;9^ U&F9UVPU17J\\S%X M?9_%R\;5MH17",)T1T8]\B$AT9&[,$=5/M44;?5*.@IT3Q [F>M*,?G,F!@#\R>+>$Z0(1^>_'D#9/ M(-03N]\PYX^L0H^I,;$,?C25VH:3=5+!H3M_2F>FYP8)C%%R2
M@6!AY=F+ 4JBK"V3O7%;ZH2F@1R*V*#M MW"&(F#9%=*%&5]+9VB@ZB3L&?I!^Y9W $H"T,+CGFO!N\E334N9Z"G>!Q:Q\ MRDK\#?#!YNV;(+8PB4^@8)"0H2:!*^^$W]#QBUUB+BTG^&5RR&M/ZM MPK
H\@NSO=/%_S F^,-^\[9"%=UD)A@JM,0<$H9KH4S'.]E8V/C^DDX=\#K@ MG8ZK6N:@7X7QHP,I//=*\[BT=4L*3]RK7%$/&[96%MPUZA3]2C_-*-?REULQ M;8-[4)I3'\RR"KN-U.(AJ,?JP@MR4H^
WZ7FIV'N@U*ZTV)@"6=7[X%?-W+L M$B\7OS1ON*[X,$R!^=7WULN)[?*?B). MXD3-<[9KH4>[=\Q*K/FU1Y_"0[BDQS- ]^"&.1RFR8*X5O[[/5( 'LDP6#BC= M; :Z"/P0'Q]!!Q]6:0TX&O$-1I:%U5/"NEH[,UKO
4WEFP0WBDS%7#7:! M-P#P_RZV_W]*>!40I]GU04#!]086$3]%#5OA3C/@F@U3]!F1YR%[/ MX3SE0.W&7,^LD5QLY&EM5:>;3?4;/([K-(5A9*!K- MG/ ?&V"$HM<#!M-]@' 2+@7);7 KE!CA%,EK=#XL;KDL<1_-
^]5/REGH].1O MVB%(VFF]]7YK@2B-L_3]$Z1"?4R*6!LEM];O[4S?ZM]4KZ2!!W5-Y]KOR@DG M#HZ)QQEE"A(TQR^C(4_O.5NU+>#R2T&SEC4&39I\^$Y.V?-17-9'X=5 M[V^7S2T.G+,,_\NM&:'=N/BY427KM5>9LSAL\[8"
MS8)EM!MP.9K/NA3D>=-8-%@4(;6.8 ?DB Q+"\K1=')HCZL".9]9XT;\V&Y9 MTNVGE*#MU.84H<] VN)>FFM+*H@-<;9WFB [;-]=OG E-^G2#W#7/2(7=N:D M[,IEIE0OK]/%X3)3-\WSGOP9^S[G%9X!OIFM_@,=]^X&]TR^]?
9"(1/^/ZQ M$-:JM)I\!9.07WB2B@GVUW(J"_S[##!F>>B[?U/+X#KDWBXC,#!#1,6C!3O/ MK[ORC5LF*#&'RGF3$P=4HF=3G%/"@RI@PW0+0(2V&7FUA%"# Z[(ZE-@8$B2F M$_Q!?
+OV:]B;OO2EA';K8/N\+K.,$8Z0G0HI%3IASL2V=%7?_K3MU:Y/=RY< M6ZL 99\2)L@?>:RX-T4KV],.[]VLHV[T["OI3E<21W5O6-UZ&1P(GWQ5IGTN MX^F;ISYM+HOZ>35"B1,7AE0.?
J)6Y%@TU&MN:\+C7[M'@@T%W/>&X60/)%7Z M!C*'I(K%"Y1C(<_U7'I<+,H&5[P?3&^;]:FT611,/! ^;\O(4W2PL^!V?_,> MV8V&-.R@(5N/\+A^OQK/*6);V N<_VT? ^A#I/?W:;>$W\+D@WO!C^"&D4A-9P"RFQ7.&3?
RK[^9'A50L*P+GTR M+S"Y8EA4B=.ZT6]O\D>15.9+#XG*B9>>E?V!EUZ]\E?U5WWA@VTFO'$Q: O_M,\X\$8!;_OR5#U/N@L)OFDD9=E91GD:X*,)X@'H_*GDW_GYGTO*7-Q5+F/@2 MG6>H] "%]=K]3>_&
(G[?)^&0NNG4D/DUS8F[V4R*@;BBTXH$&(TT TKX*RM M:J&BF/Q3G6"Z";FL+P7:J[.D!GQ1JUGH?U;_4^R71:6W'CP;\0Q_;^2)@4#6 M<&O;)ZX_1MNG?;Y>Q&11/;1*V;+_%M] MM/N(;T@IY'(-N@G3#ED]*TFEX, M-Z&8Q?
_W8IQN0O*3#E_:-&F,U9=V"GUY5H''7'[?7T%9=]BYN6E-V:(D\E%+ M=596!G:(]^3+OY$*%4BRF07?+:)2?_$I3OPA2++=]3NG-#+5/>N4^^IYMB$) M)30+ROG8 %KVU).4V#+R#9OYPG]-XKF"=D_0S1MF$9?P0-F T7D*_!
D9"1E M=DR\DX_\>]*U&B$U6ZMTU#P8F^I-O'9[8+0!MC_XX,[[\QR)GY]2=)5&GG0? MYS]U,L#@;6;>QSM.NR!$T?AWQ#MPC=C=IL8MKE\R*V! FX?)K5,1=JO/$1;5 MSDZQ])6]\)&\6E<*P/J:(6+M#A6E^23I30N^S-H-L;%
:5_!]6;8\5&?$^.J MGP4LA4^?14$OPB^PBJ$)TMV&'S$D!#<$RD@N7@.XIBWF28I5(3U\PL"8M"C> MGV.M)X?*Y/*W7K7U)Z;H6>DM,;4*CD[#$Q1>]6=H0;?4*]\^9(]R M/R@X!$$1C035R_KB8AP6K*C(W)I6_1]W-^U%61,
(!FF/+]BQ0A?09V>6"/VP;AVNO0&-=A28@ M']HZMCD#4BEK7;B$@TAL%HOD(U/IX4%YWU56MB'0@@'&H\9-S=+!TI0'M\\. M2'O&T>R_%H'/+G^/#).D/Z?'E6A/&KZ4Z#U[5SHD.DM>\RP7ZO6+P6M71A47
ML8[([CUV0/U?8\RC'A?>KQ".;$+Y#D&^-2K&9+YH(I0;#0;D;,?AMI&UP&;_ML]O'#.R1[UD%C9QV!@A9Z+?7&,;&[BW]W7)\[.XF]4)\'$FV.@0!VO94'_3R M719U)-\|!+U$:$*DW[/T=81PE?4?9$6LCB]3]:<\V-2(\V-
64)&$7VX0U:-- M_*E%V$+H\)(/@[!N0Q>KHG8SVB">#A#/;6G]$W)-613S*%!$3684P)4I8]2T MUNF@-H*HL?O*6,)=Q_,0KG;N9=KK7$^IQ5<;!F:DEM]\-9LITL?&>O.EZZ_A M5308DX#&BD?
_:YFY@%X9[&'1H[DE+L"6!;%'@#F:#/PBBW_Z-Y)W8BK#Y%:^ MQ%%H_:W\<#%:PH4Q?SR>^NR9[-7NNH_1_/9D3L-C4X#V7+G[43 MV!2F.*R)4#C%E*CH<")8KC.04,V?EU@.R<*_RZD7A<\"5I3_Y$3E/@%C*R+6
M[SS5")^&Q74?15FPZSI7P7%>+.4G(7IO(F8=UU"[VE"A;XBA4#"O?Y"]^+*6 MK#+EE:OF%%-^)PT:AH?&F]WAT<[K<\_@O6AIE5&6N- MS,W!DU,;@]]R+SDQ3B"_+=EI0JA!EM^<%D3!_[D\_^@A3!9,(UPDQ M"%W!2(2]
(1U]!5=R1TCWY85/P6GVEMNWK A4JVOV!2:Y]D]X6ASGMB'_H#BB MQU4/4 @D(N<]:7U(#B/]?,N>P'Z*33\+)80F-TK[\7 ]#RN4H*M0?Q8HSFUG MW\6:8]S#%%\W9EHT/F)^-&C\[B_Q*NE]OH4NI*2^KKD?
U]/=0V"+P\:M3^Y M,K:RT@R.W_((I4U0$Q3].Y.)N!0@N$^)&WS,GH+QK!+@"_G:DQ2[,VE7?E)B(88^$++GGU[O"T%>LSCO(J1H\[8: M"2.V,?OA*]G*/9)V?D/*-=>?B(H^XUZM531PH/VCI'^?D'+'O;D-VY$Q5#TP M$BC^AS-
$\$'F:?NG&;5/F T_0"2W60-)'-J'?+ MBQ6?WHDI>3FI6I]]Q7LP'@XN]\-:+>?S+?3A4SLB'VJK\7A#O9DS:-HEO,LU!W&A M3^N"2;3/C#PX;S5=D_&6R0$WI*B^DD(FP+G)H5VNHA0QM(J6SF-'7[Q9;%"; MC.<23X5X4)>OF"!?
QJX?#T&:3,E_;1$?'8)0AZ!_@VH$BY:MLVC_ M^8&/,U68BZ[LC$+$63B,41H$/@Z$WJ.8J-,YIHXVL7)ZJR7[$<8+'ZX$^M5: M'[W@J6K%B$C^&UDWJSX'KNC9TT4RJ1L,3#O[\BA[]R$(O-/)#FQ2_Y=]Z2'
M,AH[Y8"&'@3/A'8=96V%OPL7W]OM"B87X$I]GF:Z*\4KFHM)A6W=C[$^Q[X#$_M MNY91XZMC1(1N^W/YZ,IA;DWA+H.M.47W"%LL)[O)*,1Y\,\35G;JW&5BZRB!
M1/$7[;#]=6K%CP7'3:F=:)_@RJ1[%ISGBZ<1MS]@YC\I9=!T>6NU_%W&NWD M KPP>!_[D-Y?,L4?CK]O&6#374E^&U@00:KL]T[;.5;4;! \I#A%I. M)RAX$+*W5GGK\<5G1[C79
8A<7;ZOZM5[5VF&ITB&)9WIW\S5"RF'D3D6]Z> M@9V>"F+H28SK6X2&!DUV@^"1MW4\0W8Y*]E+]);@$"R*WK6'PRLM MXZ*0/FI1!!$F&_QZ8PBY=.0Y&_BT_KC%=;.INQ;AI#T@HVZ M\T*"IO2(A#V;
(T[>B!/9K8#0@(M/=EX"6M468'T%IQGE[>YD&%%I:X@<2'T. MC2F0F) #%&B&])/3]G9DW(M'!OQNE=]\F&!@ZBATA&9 M]]>F%W6VN)XSM>@R0-.3"E/R ]FY%QR?Z;U#\54'P(.R8,KM@XA2CJB=!;/.
M]@B',Y+ZQ:#8+@/M9Q9[>1]]G2?]-4YQG.9$CUS$O;[VO?[B4/H];Z6XC[Q$ MF4WZ**/TVZV-C'I:R2$(U E[>K-IRN= >X$)=BU;PR0CW=I0DHAOT'JU[9I: MNF-KV]PAR)/_.4[$B,^W0#SS2OT+>& @19FNL:
M5[4$W\2$*7*6F#&$FO]3=XE^>K'!O.5F**CO^;V,HY?6+KN/?:BN&SQ1;\F= M!,L6;-9/B='1K$R7KB],V\9>YY,.'_CF>:_DBO%>;9W /8WT2[%?R])E0P5 MRT^OR%(GG_SX65RR[IEW=PN'T0U85ZK!
[OU]Y%/QZ/K:^>/3RJ:F^'02<71 4ASK!,!M)_;IF&'/W M(+XM?0.BYYR:NS;9(+;)]?A.EO]&T?UZR3M7-3CD +S\W#W%_%T\&C_F#NI$E:8+*F086]]PIF;]?1& MZRX V>-OG+-&X3[-
I%^UTYA^CKAY_2+W)\-4#8(DEZ3HW[\T9T0?%=?X9Q#V M-6+E!%IP!RZNMA5*B7,"NOV)"_Y"A-M0&>W=6"_RBO>M#>'1X^N/%R++OFA> ME[*X47[_BO8?T\XF_PH'IPTI__XF1LI^]_/Z7$BSH)57A>EY/]6&^:6>W1/C
MWT[SBTSH#YX1L,V]IR&97,PHU9#$RUT(]<_A]+A]ASWH6+W^Z1")K"+#L*[% M3.3<%:U'"'V'I"UZY>U6O_YI(%Z>?6E*O'4_@HT)SU)(SN*M:9(M^U=ZZ/?N; MP.LX5+[I&)M>N)[V]UI$_HT]F4L]NA?
P[%BN,ZP1P_\OQ[UV/7FX:\<0AZ+OO&XI^=AIQRYV?RE.Y]]X\Q3746X+9= M/?_N(:>G1Y=R8Y0Z[^6Q<^D20>>),^I%86'QFKIW5/=B+E\^S[;\-DW9Q1 ' MW1-JLW^FO_W=]_NS_?7=]X.(?-
T_V\!L*/XYV^OG+R_6/Y:ZR/9@3,F\]X(T M1Y1FZA7Y0#T"]EV.B_',WE/ "8V&QVD#4M-&,N1:=*UO*R(SE*3Z[(?#\D30 M/;7:TSFVT]]-,DP;&QS*]E9"]\@OIR0_P9\![N(#N"BT1">?S+V?@G![P&L% M&?
=T,^E1CG_Q(:C'@SAJUKMF*U9])P QW$SR3,@-K?3WXA(%UDD80"Z@#++% MH G3(JGZH9U?Q#Q4Z_??5*P]9 M)_K"BP=73I(E E==U8%1V2R+THMB!HK[K,UI@_K#F 5<9\FI+ M=^99WOS($ZL4PQ^^@-V&J%(_P]
D@E6G1EAU3"C4RSV2"Z62OE\+D?< MPE^Q*?)!R/M*1V_7,ZBQ\6"_;;W95:SO\YM(?W&APQ(X7U\A1YI>YS;"%'U-3@>,Y &X),IEQ?LMYS6!_CIWAB%YI_=-]_//AC0_]^2(7)2ZQ&C!(I).S)MQ.4M BRKL'Q+[:O M/(87.O-
```

```
=4ZG8@X7OMPU_+OK61-_)="":T?YGJ3BKNF.30>/JLKXW:[.6!I2 M.3A!1U#LZ4)576BASM,L:&!)-Z-HDBYA,( P\SB$_*>+P-?$8K[SWE1'=[IZ M'1GZ,L XE?EH]N\H"P13\ I&90GP(V!8Q1S(<-L#LV[5T):_(8+|: MEX6-N^G?
/P.=8?;P-9?^_-_JGG7TY!7ZQWD$]FY3@E< ZMY+T1='I+W3\;]@8U 5Z> M-7M-.%56[;F_^S7O$$0U&D=H =&#:)& 3CWF.+BQK"_%>$5I$)>X3:S1Z9:" M)L#] TL)L6\JO
8FS%6O#^VSKWC)OI:64G3[[HEC3\^T7Y0<(#CK,#UD[C M=>SRD1'HFQ&K!;CO%JK_WR@/UF-ZKN+:/;YCI]*X>=-$4(]M1%6UD]BR0.E? M^)Y%N!L-#.FJY)QN"'ZEJU7M M92-:>(A2180^IYL;6!"WY4QF=G?
>M9"OMTF"QA2ZTI[(Q2^9#ZFKFKVZH32 M3)'=VG0;FEF8/JFL%R:$F'0L?;$L.MT) MJHQN-:,*[U6X,TY; %*J*N7E9Z M=ENQO3T5%B\%B]]ED1,SERGM:&^#H0O^RT^$Q3%S2E@AO=%L"_66G)BZ>K\$O/L.A2Z.M
MIY)G*59JZ+]()Y:_G( LY_@OH[[^H8X W"0D2B^G#YP*:<[_TX>11+",=>D] M44:EM]X5?@5()[8A>0?+?X+Y@Q82?N?+724OI?O!_-V*%#:SW16FAHTFSZ!^ M@ZE.@"(K96Q1R,;+ G/?
*;>11SLEPRR)DT"IDT30'.5(F+MYT^0LHQ&0SU:Y M]?34DKO]HY.90UU_0AL27N>G%MZ&:=NS20AW"B6#HU"%( U;ER'3,_KEYYPN(GYRN"7\C;U6:R'Y\_)]64#@[%M:#C9F&3?0TANAH @ M/N#YI,$<@@#B&-
W>YMAZ@=%$$&T[T/0C>0='1(L!^G<+\&-.Y)V&DL7/.2IK M\M@UCP&9,]YO8AFO<,MHA#PCM5%MWHF8TTW_J_6%$(XBC]^C13"(BX"P+3DV M77MN^S1%FA12$E]] 15HOTH"-
U87B&3^1^$K"J^8_WG@_'1AQ$NA\0:MT LY M >,#XGJ9VE/5=!LB1/"GK-*XML1$=1..UT\OH+EH2)*3.>\?[F;8GS_>,[V>(4]*!P1J/%@K--"OK71ZAECP3I]T._EKTB[UG*;5=R#N88 MX/SE4K-3R9R7)W8F/-$RO_\0I&*#(V'I-
M$L#&KS-6J*&L@H1P8@\;[\|:&= M%V +MP8.0?QT/YV86BT5ES/\()TH WF#LZTN^=^%1XSJ6Z,R(U47OS^VD.:\ M?4UF'L%(;J32CQ'T6C*HGM.N(7\J4S- MZN<6)S."_0DJ*\K?
9CZ6WN^7URB.^N_2["">V$:WPDX&GAD!OTZZNO9L9O=U8 M_+=$I$CMA*7H@9YJ_A MN=S\UV@U-SLV#O7%V)40=3YNWNBAR\N"_SD05-+:7/)#U9QK3]RG_'DKV&2C M.NVE;0C.V)P[H$=7TN%)?
V4+T])3S029V,86/9$JZ MANP^5:^&A'KY\V@U\^\-),]WU^9@FW&94V3"#A^FV>S;4K;6R VYQ5,< M%Q.8)5;ID]>+&OX^>^?Z>JBH$B\LQ_O\=#_G1[&F$H/K,WXX;'N:([U-& M9E^4+#MVT<6=7?]*_MOJA]^?>[^S\ A**Y?
[4^_8H"\NY:O%?!H\8R0]*032 MRA%U\?;DG]K?$\%M"QW51YO:8M6BKGV_KZX[M#FTG/P;A)YZ<^>S)4D5;-,> M9SD=;*@X=;<-VXJKFU2:KCDSO;-]7N1-5943MZ=32\W6!(^SU4G823E%^__N MVD-,.K]>U^X%9O3-
C<4JO\Y>GPU\4NX M1_S]F%<9;>Y1UZ?0T[@&SS4/0'*G<8.],"[O?T01W88'$ M[E\995E>$H]BE"0,_5Y-T0.)5O;]L]?((6](:#Y?Q'ER1T%6),F&9QV/18=C MPI V;P -( <27O/[F>(1T/L] 3NACWZ4C'W(_X>W@]P_>)CU*
$_QJU:PG@))"BIN'R/T>=#_&;XVO0RZZ"OVI/=QSY?UVII; MPWG&/#%I,27@X/Y>D[R(@)P?S6X88HME2%[]S*-G7] BZD[=G(W*G-5BXU?] M1!Y*D+")VJE+9P?8YD]ZWPG\Q,[UKN]O;(?>7(H+_2EPM108AL;F(,6,I!?H
M9M@FG0;@B(WD3YZ5H*9[O(37G1(9!X;03Y8*&1L6I]]OOY#R7)!=E2'$P:'$ M,8F?6(0".2Y>RT8D#&;WHFPJ>)??-\1Q%E6NN")X"9^:K]W_ME_AKH5!!=2] M2B[F5!1S&AWA@Q_N,R-"(9\WRBMGMY7Y5^LU7*I>@?
O8SDMW+A__+AOW8?VN M]]EK["<$COT^)?A7ZAAG)1]2[1T V$]2R+?U?]_@1)RMCRP]OLS754:\I.72!)(NI=FYR M60^NH7G;@C06M72&_&=K;07\]<_*6E(Q^6XFJ0]'0C;@^OF%\< 422P7Z1X<
M\958C\_>NAV[<)UTK5.=^*D7.\E=*KRZ$'!1$%>LOD MX_ZCV+^L>@7(G[V]\E0-QV2GCVC9FG)R_O\1)>OAA0+O_%V M'M,.MXS+V^W#X<'4OD-0E \KUM2TH/$L2-S+'XUK:D[5KG%?<6U9WK;>M*2
MX^FZQ*L]HT2;QOE6YYKL]WX^\A%W7C[5[O[U\-@;OP/LHY74=G[K8KXF ,8* M^V26P/OPVXR/IP!VRB[U-H JILLS&B /^259'!5&=N_/.S_.(KS.RVT8<0[
M)Z4PVM19Z)9RIC4]>]%J=/*;:,QK(VWAK/\NMMH&=ZS2G"*V/4IVN%[ #0Y! MT:&'("_^>25]*:, YP/Y&KBBU >=]T"<=%DRIB"[(.0T E!T#5@CAKV[WMHX M7;/_9O]2O?%PU][2"]?YFMR'+^YM(ZYYYXB'
MU/6':Q^"TOY8A<.T!-;IDHQ$W'(S#@O==J,9T!U8,M^&T8AS6S2R"M5Y6HUN M5@978>3# [W*7>D!%)=IC05G2U($FG?)DA,3M[M=M%=2/[V:0JQW6':ZI=HU M*$Q$?U5B\ABSD/XA](E1C?1 ?M7L)31 !U#SMZCE0
F%B^3UG*E OT7!T$\7 M:#)>PQ#G^ZE@J06=F *B)Z4_9[ZDN77*WU_H!ZEEPA:>)NO M/U$B2=P.JK30*OG2B6_"?_^!P 16NLCL;F!_,\P/03X00"UGD.%%#6+MPH$Y MCJR#]."."^G8J,;"=VD##LE=JIP#\AN:"90G=F/P;[QI3#2
6G&(W9O&S!"L* M[X+%A28Y X%Y@S#YH2?R1EGD-B8/+^T^8H2U$?[M7)H&LMO6 $Q^NGD3X*:= M\B5@0U\86-(,L54RJ67$%!FY$,_D]]PST*QI;R]WK&W4HO;G>U#ME_N>ZZ8P_#QK>9IT&4
:$M.IY(@8@#:)QR.,F-.NNC-P*Q^BZ'03 M2A+JDX=)@IL1(\5OYP; LDFK*N6JOT>$%>8M_8P5[R2AWB/]6-'S9Q"-;V,> MQ]%,X.X4U=0$-YHDFLKZX0#.Z_YDOT'P5B*X >JBVH,'DPE '8?!$53='9 M(M T@"2].J,D.&MVWX8-
@/5G>A,DC$[ ^>:.+_V$"M!-:S9"L0>N#>'\<<0\ MLL\E09?%11>.)K\@O]<-?WXQ6K/F&+;\5[^+^8[-=,$&ZC(CM5.> M;@/<(8M3V5F*#D+,LPA.(*7W'I!/GJ)F,TH#?L<;G:&KD'&)^\@F*URG=
M;DOB%W"VMG5VY=6+O"#6M*J5\C;RV^V2X<:YK-"_NQ@"X3O7'+I1ARZ*I]Y2 M_FQOTTXS/[,PHPV& PZFP%AQ_FCL:YL)H[!=N@K^L'GZD31Q(RQV:?,.5"8L M@X3?4,F_/M5S\/!);^@[G^Q %]];SL<>')?
+,Z$O,&H.0@K56CS'K+;$.EMJ,_DN4H[RYQ_9O:<"?X);K#O MAGY%WP6$2Y>#]LS'I&=;^8S/@[ MLWH(>IGZ17+T3TS,@HGJ=^:<.1I>N_%"Q#!H^,G-G#8^+S/)RW]OER676?*+ M>V&,1*GTC2X-
O>W,H(47O\;J$146@186: M\!QD^=V_R7EJ7_VH&O^FV,*5R$TY6XL4G17Q[FR1?S&>B$]MHZN M13X-W(2;5HT@7AA8E:P_*]9#)>[?DPV#U8IY<]A^WA'>VL6/4-^SY!"97UPE MR0.H*E\TV08:%\+D!G1)_/%
((9SW6**LMAXDQN@\_$ICQVRP1*H<@NO (Z?R2%%!7!IB1EJ*K'2$]:CR 2]\L+QF36/TP<8^D"G6:\S?0I7:8 M79]<!\/PD(&,^>8MMTBEN%/C^[M"< .RR=2Q_;2%D22?X->E4_X7R@HB;X25 M^85V4\V$0Z!MKS\@+9_P_S-
R@.7&@,$?]@VUI;BRT9EO$;]]#N$ M7<0ZMFNQ6P@_5CY%+K\#-_VAB^@SCU71))C3!=.,XZ+H4=FKAA)$X8MQ( MS'+;\2A%K8_%U8_.]*5AXL-OAR UR1C;DXWOEET_1(C'3(7&/'TD MWU62"*XUST73+L+JQM
[C6\F;43V3;67.+(U9"%I!?)/^?]N

3WQ Q/;@8 M@C1KT3G80U"]3G^->!=2N!$C,?0.;MR:N&LV';3-AU^Z5;[TD_+50(?B&X][ MD&;%6V?D:RUL\3'2;0%X?"]^@-KXZFS/S;:.MV^_S\Q20^;KU\M',G/;6KHM M

"(J$T.4?@?>EFV_+4H]UDCDV-]8;BG(L.IBIF[ -M;R;@K*K& M"6=TX+RA"[^ZD?7-=.&B'C0;W(;\B_JXI*9S&9[2%U[T6"C&J!(H(L+=Q'JP8F0Y52F M1!S5>QKI#A490U!C$XQS@:[L('VK?0YJ'3KN MOZ]6][HPI2S7"__
DX:A6O_O3M9#1C9DN<:5!R 24\2OOZ%>!5QH1P YJAL9 ME;C3;E4T1-HV[B^0;6R.OJE3(.(4.U-3LV_9=A?G=PA2KAD@H,ORX8 MG>QEY:(4*FD7F-DQ^<=KAX#-?M;DDU*B.'GCY9I(7K/!D\O/-&QE0*W$A5S:54]&!>>I?
Y8LLHKS4X9E=*H &9O4"A:.3$8(TL7G M.)IQ)Y#+!>#ZM7@C?9]6COKMJ0"F#K!Q=MM @V2Y8'),T1]L&;;0E.KY6<=\ MTF38W/<@@LG-0SO.G$#6[0ZH_>RE#M\%;7U5(XD[VLWA-'+E;B^VV+ M,.
[=*4*]>C8TVTN4/?/J3G6+QUEM;;^F8F?9$@M3LUS]\E;KHE:?6UFA-_RU MFBVS:O9#&QS57OP;ILSY[\K>./P>(_W?B>@%.6)9+W3^(O]+:)U;_R$HW@A,
M^5)!,IF]U8<6I,LM8P2OY,7&$4=E>=8]IO8CI:\5+%EH1WPL;)Z1_W@(,DNH M=1%Z&++?H9;>Q9)]D5$*6T=!&FQY]2Q0?@.DCD*T\&+6--OSM]_;>J['Z*R*R?V77$7% M #7!9:P*8--'0.DLR9!#J9ST]1:WF:T
K0[;XCJUM3ZPQ]/X/L-F<>9(Q-D)?T5F+STR\"+)SL\3\JE^.VB\&I$_&6[!6ITZ*[K@AR#W#E]]2Z@(\S.4T\")TDQJ_^"R M,%:V_@O@[T%(D^>^!HVD]"PX9*S8UP6IWG>Q.VI1%&+V^$V@Z=['FL@L16K M7HFD0U-I2E/1Y,)/-
U,UG[,V;^9-W3T4FU=+[#+>>WFV/"RY@*BIZN]70FZZ MLC>VGU\H-C.\/M48<[9XS\V?QQR=7:]3.QWT[!+&R8#D<]]-T[C.F;K%AK^@./-4<_OZ% MKCI#SS^J\O/_IM;_K^=85].IX%,OOBP[&3PE9/3N9' W MAA1!M-
DJ6D8"%W+HH]'.X_KEB 57!4I.DA$;L]](>QQQ BX-L!>&E=E.M.OP M#E3X($77$G:+ICQ>-GU"FV>LZN?0FC4K/P_+*2"Q7/(J@M/*U,T*V2W#FZ9%=WU7MN+E&8JA>4BUSN(;5)'M\TUI-4<^:HH'>>6%7%TK?A/:#H
M5L&4.19Y;H!37&/H1]O)YIX_4/+=7>"\63?__"&(:$,7H5%?,0J,0)@M3HIF MGY%D&X6KF\#AZ@LA=[+ FPIEM>9H[O+N26YW3I]J;"R(OJH1TI#K% MVVU,XG4+%W_CME@\DB.84=NI#F>ADZCGKJSXMF(:++
2ZDD6!F7RL1"NI1U9 MZ7E3Q*(3,:=K027"XXVQE&BE,^^%W5N33=[;(L[K5[='.PIOR&>'*B!NSD*6 MWR+)3@2\--4&<&$)SV845N,\,=R(3V!^&%V4B 0SOQH)4[X?K/6A$W%'C4[Z
M8EMC8XA5_+%V;;YZ2O%>'^KJ/D0Z,B7,WOCFV%5J:KQ?J.V?JO?1=]A9VC3# MU- +:)I?#:ZR@L.0M>!*Q#B$?'-L09^JQ8B!GZ9I^C+Y 4/R9A=4',Y)T2&U MS%3'IA APH"[Q7Z^TC5MT=/./YD.MEHQCO>38HCV]-/ M"M+,Z-
<943@/?[,N" =3=@/YCZ6@]#F4W:T$(HK;]Z!D*9\<=YT">Z[MHZ]- M2GC6].V-%ZI7^:'JU_4S#DI1!])M,#TGE8=M.;MJ7]\PN>=HUQ!?T.3;&."L MS;9,)>#4TZJS1:2\64;UJ,5 &K9G\TGYLH<@A]8&P(](XQ62-H3U4JOS4A/?
MS7=,.2\.2GW^)= B]Y1I3U=A[5:,22@XSLA$B .9IA!>N +-%S$$)=^$)>*: M7P[->OF$+)PM[Y>4JBP-_?N$NS2[8=/S\O +S<52EU0%@>S*>H=V.Q2Y*S>T+]^"PF&"Y*MI MET1J^GZ .KB^UJ)U>)HV)AA4"+JG-5[%:1V"/*#
9?>5Q<%!Z+PZL1'NPQ5J($8(Y+L0X&Q.-V;!;'F-+H(T813@O/BC<2>9@B/+ MT&@D%U/(;P)N0>%Z81#).8AWHRS5K"0IRV,[IG9WW&)WG-A# HJROOY5C\W0 MV/NSQ?Z_H1MM" 'Z58"+W+P21QETOEL==1^6X?
SPIG%X@O!D^C?B9#Z0($:BP@B@'X MB;L].+P.:; 7)P!8$K/K(JH3WC-*3G>8IM"?XB.G+3'TRU-*L=<;&N^EX56[ MA;E7GZGGTFQ\<1W*:083(;8R317 9EDE,:NT;JSM2?(YR<5+'X.C/E:36
M$]3K+%5(H_O(0C3<):Q3;C5AYZSG-.[=TDE M:2;?I7PA_;^_X+&?M#?\%+OC]^PA\/(_V4M#\,_L]>(?A-J_QM^*>N:%KP5_M#%[#X>N/&/A[P7IB70OK^_\ %CW>IH)HU_/.!=)CMC)=,KLD,GF__42_P""
MMG_!5[]A;7OBE^T!XZ\*_L/_[_&>_AE\6M!\*>$_V9-;^)EKXJ_;6^,?@ M.YUN+2M1\1[VW&K6]L]C TDSVY>U"2?>7_!./]B#]L3X M4?\ !0S_(*+_M<_M(>"O OP\T/]KG0_AC>^$QX*\/[OXR?&/5OC)IW[:OC7XBB_P#CG\5/#\?
B6T\3:+\']*BUBZN;SX?0_;K2 M 7.I:PEEI:V2WFEI*+>Y$KX4).3PKJ;U<)S5H+:-5U,2DE=NWNQH.TI-MREK M9QY::5E'[//6?-Y4U'EL]FF[W5KO3EZGOGB?QA_P4$^)'_!Q[\&O$/@?QS\( MK/PGKO[+FC?
%#X>>"/%;^(;S1]%_9E\5:)#]^MZ%K6B1WL9NOBU?0O>6=UJ\ M*1)+)':3K";D-72_L:?\%9[G]E'_@DYK'Q?^&/[/PRL_C5\\;?^"@'Q<_9U M_9W^"'PXM]4\_^#/&'Q&U;Q8<:YXFDN[F\;3[BS6X^UZS,7M7U%8H3&BRR-&
MGV!XZ_8%_P""B/P^_P""CG[%O[;?P\ A)\*OB%X>T3]C'P-^R]\>_"C3XG MZ1H&L_#_;3/#EMH?B35O#FKQW*Q5=;%FGL[G1UG6=X41GC67>OS7\+O^"#? M[8-[_P $O[?X%%>(=<\&_"/\:]^!7]=?Q!_;$9OUB+Q)8^+_!EY?!
WNM"]T. MP\2ZCI4DCI%K]BBQ3_;BEUIS&/[2 0X%N<8TW&/*I*G6]-/^;Z_*A*.^J=)* MI;?F]Y>[9!&4)3BY27)*KA8/E:O&C++%7K/5.U18NU.-TTJ;49)R?,?7/@W_M (*-_P#!2GJD/J]+]G_]G+_@J?\ #GX"W7A[]L#2]>TOX*?
%S]GQ]1DT?P1\ M9M%TZZU6S^'OCG2[ZZ>74+2.&&WC.KZ.#:R/<&X5GC ,GYW^!?\ @M)_P6B^ M(O[$_P_>?VZ?"_PL_937X-_LA?%SQQX0^*O]JRZFGC#XI>&/"/B/C.UC>7PH
M@O1'HMQX>TV_M+!KF[4'6#$UY9QS2FX@@^\M!_8@_P""I?[??5O[-'Q^_X* M5> ?@1^S[\/V/)?7O$OPS^$_P'O'UO\1)OC+\9]6]/SZ7%XXUS5+61[;PS MH,EUY#C1+AHIXH0\;<9+^=? '_@D[^VI\]
_@AQ^WM^PSXJ\%>";3]HWX^? M$;XZ>(OAUHMGX\|.7'AS6M+\;:[INI^']]\26UY)I.C"ZL[255M-0GAFL=D M45W&F 3-W["I.R]K&-;V<=>5RABL/2H]6I49UI2M*[EBE*,I7+[7#P;? MLYU*;:LM&XPGA\14J.+V4E6A0BN9-
)3E%IMQE'^BG]G_/:-T7XX_LH?"[]J MB/2SI>D?$3X,:+\7I]*>5W&FPS>&#KUWIZ2LJ@?9)%>#S' #@[U+J&(_C]_9 M[_;2^-/[.'_!+?\ X*7_/!:3P5;^'M?_:_;_:*_;GN[*PO?&5A+J>DQ_"'P# MXHT[P7X*\,1V]M+
8+"'3K[5(X5MGB5;NY$\R#&ZOZ]_V,_V??"7PI_X)Z? MC]F7XEV=AI'COPK^S=I_PG\96.G.C::MI]GX@C\)_P!AWT=I]5DSV5];07%Q M<8NX'$51]YRO=625-J4:#F^7VLI1GT2Y5/.^ MVL4G=OKZK]!_O\
P52_X*??"GJK'_@G/I7[(:WPF_9ZT;]FS_@HXA\ ^"=#^ M$M]J.J_$/X5>(]4\Z=K&B7B7B;4YIY[SH[R[U#1KN:WMD6&*SFO\7$=[IQM M9/Y]?^"8^8^Q^R=_P6:U#I[]5]+?$ *G2A*XO)KEW1!+!-T>RNGE;9]E0^7.\410ZI_VU_\
@GG^U#\9_B^M_$ M,$3_&?P_P"#^@[5=/\ V'_B#_B8=W0^ A(4'WZZTW4I(+334DEG1H7C8@[!^57Q_X(++_#E +QT@#X@Q$R?!$X@\^'>H^W+F%IMZ\P[9NYKF3_D\%!=HHJ):M7#(Q3ZW8Z6N\"<I
VMGX1UO5?#FHW:&'4KB M&YMY08BZML9EB%><7#19^9W[*-SXA^,__<8?LO?MH>)>+T2>'_VL?VB/VHQX/TJ7_2K:3P!\ M,M,\2?#72HU6X9K:XT/5H[2>YM"D1292S ;C&3_2/_P0A\67WP6^O/G_!4;_@_MG ]S<77@C]E7]J?
Q+XN^"UOA?#?XKSR^(T\(T\/VOVB6:>.PLM:N9WMH9 M) MLLI"*J=/#?A=_P1R_:G\%"[3/_.\!"KQMH_A;P6_P_?V$@O@??XJ\+?M,.;[:.M>+O#]OJ5AX[\0+J-->IFF-.+WQ>EY>:H\8);AWS(BOZ_P#\$4?_#_MC_$__@H!_P_%%J_VO;&O&?
[6+_9\&K,RQ75UI?P[MQ::M>W-F6:XLPUP MD8M$N$C>36BJ":J>SC-PA*]L+BZ[NTWST*N'A36EO=E&K-M;MI.+233YD MY*BINS;G1BDNBJ5L5"3DKW5HT(2= M[;?(UZ+S_P DQ:***L HHHH ****/_94$L#!!0 (
/"!;EG^CF\$(C8 M &,[ 0 9F]R;3$P+7%?,# U+FIP9\V[=51=R[8FO@@D2'!W@@2"NP9/ M\,#&-3C!-X3@@NI'@%B"XNT-P#Q#W]=]?[_N/WKM,0>, ML6K7]J^]YIS?-VOMQ^G'90!=6EQ*'("!@0'TGC[ XQSP#D!X\0+^Q7,$>'AX
M1$0$)&1L%.27+Y$),+'0L$D(R4A)"(F)7U$QT;RB8* D)G[#3D^ (?Q').<5>0%EH(^/(4--IM71#H"I6A9*X[BR#$5N\$7;T0D7#Q\ M L+7U#1O:.DX.+FX>7CYWKT7$Y>0E))64E9155/7T#0T^F1L8FIE;FMG[^#H
MY.SB\]77SS\@,"@RZGMT3&Q?D%Y1655=4UM7?VOMO:.SJ[N MGM[1L?&)R:GIF=F5U;7UC_H?T#V;\'S/O_%[*_@/TGKED &1;F:?%@,0 AX.KV388GTO^1 MY73/41IW?F8/ NRQ/3=$+K K 04Q[/]S^^
X4Q.RX9D[#".&+?]O6$AOD$8 MT@LI&@ )T*3_5CMY5.5'(_=]9]?+MQ8)N2)<&=Y75U2$HI0N?4S?0%/CZ)/M MQ.+IQ]0>SWM?.PDT6OHF5*3:6^4ENO'#O!**-T=%DN"W"LFLCP"#U<V^.8VT_/RD'UTRF+*N6 Q;54+^
MGX$HVSX">5$/8XI__B-,($@[^?KXZBLGHPY"I(;E08**! ^R\+:-CGDJW@4" MV-)JX=QBJ))?>O(;PXED0_?0$,7^FL"@P-X$)YAZ3GOXT*YPX!$PK@_HH.YL M PM\MDB(78F)MLZ MC(,W7]+T["X+/&B.!1-
7>PY>CUN5CFLFCXC!W1DNI#;JP6$=FL(L(IR0+ 6Y M\7,2]:&5LT;/($4]?H)_]GX>9M;52%F3+/#0?@EG+T9>!--,4R;8)#EPB>&Z M#V.:+FAVU*XL:Y;(QM79X:75DB-S7-LT,2I]DD_+P(OLU?>R(F-24Z!$#H5/ MU$&*+!O$-
GXD3@. 'N37-.0@O-H]80R*H0!Y2+U<>GLU5Q:;;7U_MM )(9P? MYW>T-3E!ZFO#,%5CE["!E;V,_K2.NLO>&[8.57&%XBQ];2YK+G\$?C#PA]/T
M+*TS)X88OCU)7CA+VHPD@]GYK+L]M6.;YUXJY;]_+#T%5]&5M.\AJ#^W(XP. M^=4U N^[/H7_$8:D:WIVR.2HH]-F PR]@N1RS'B0:S'5N6?,;24Z'UQ;=)/G@$! M*#'G4.A%DP?8^'2!$RX0@^&3]?:S/*7:4R*>\U5/,IL3S-$5-
W:;;#Z!ZE+W M2PFLSM;A,*1E]TGXR:+F=EF!DI+1+IF)"R(+VH&F@8GDTKC 5[O X&:G5YVZD@8&;R13EX#=IN M 2/X"*0>I/<>=($;MWA*)%IU&$[0 BH[)R]@,N?,Y'O8Y+#ZS[#%)1D0UXA- M=K0?
#$UU\,;XA3)DLC2IPDWHNP^CN![F!M7=>=-0766NRU86U!0]]H(/6+/W M4U2*#O$L0Z?1\8;!.+[-TO3(D,$1\'?_@0EH-&9(]>D\:PYT M,3XG5KCG!-T76XLY_BM=_BNC%R0L7;;,H1>M=:94<1'8=8/;0RJ\ M5P?"F)K7NP,7%@+
<\F/V G2KUQ&FUOI(%1B#PR(\UH8^&B[6[8DB*W?%(&6B MH-WP7*TV,RR\^-85T93BJ=DJ2W[X[%GSF/K0CLGL_(^S:.>&>=J5O[#&OH3% M=]E&R3\"OVJ.'X%+JEL%F2CDFF*/RMZQ%_.M-GR>'A):4>Y.]69CCB
M]U^!!4JRN .KQ?1L.A$5:X_4U9JQ+ZB.&UW.<:M99W4L=/4J(\$;;N%QSD5X M4;WGL-EV/<=S4H2^'?82D&VB\*C4XP'A2&/TQ M"?PG\YH%4CY-[-Y=S8J@8L#6 ^_:-V\OA<9')NPMBN+$Q$#'8E(4Q2PZ#Z:S
MI_NA#SR_DMTC$#0'YFPH5A)ONN.*SY,"O^Y(TEJ3'/X0?4ORC+"*Q^BU&I=$U,7[^?F MO1V2/@LJ= !,I6L6)&^T?E35I?"N8!5E&MGX"@@ZZK$?3/[@) MR> 0,CS?3
M,V=E',T*=*NR\C>BV*)W<436MY9PJIR/[R0:QAF9VVN^:6MI%F=($:=M_>9I&@O$A#1+[VU;],7/\Q>]$M32(H'K:[.CC/ M85/^L(SXJHSDEX]"3]M)'>Y5]R,@;H:]'++EL'3IV6'Z\;KW M#-1\7*@]V_J07)+QWDC44>1S-
X%$NM+89+SM<85(;55CN4RRZA*HP98JAD6' M3:0V*1*OAG\MMTISW(UP-JQPI65*NE[<3U6]^#**JKS@0'0@20_5Q2@!V*79 M(;M;S<[+^<>?M&=!;_[W]H-?FYSOO8/>MYHI1*MUR.>-.^Z; CAHK&R8G^K M,G*D*%
J>$(34OF@KR5UO(Y'N)F+W?.*B[[^C8:PT(G0 MBP>2SGOGPB=WA*]F5!V4D#*?YFH0Z*XJH?>20XZ&3,":A/9G3ZF#O(\;@*G>_M4H9)W'6=RC5QS7%K9E.PL5#4]%6?LZC7'OT\0%L-N8P83_) QH;:<__(,8L@
M4=+US;PIMMMDIO+)_*"<)^RZC E*IX@V_DXRP!(154RJ5)811-\GF/0F(PCX MR_;>"%A(;W!='%W8^K*RKD7-0LT!AM52!5&GHXN[>WZ";PA?=-3L1ZO3I/RW MZLW'OCO-%G>@1-OF?K30-
7R4!FNY^*.I:AMA0LW=MZ:QH<1C[T_: M!TM?'N@)4]DJ5Q[0'!!^RAHUUXQP)I_UK MCD6#)& [EV1/5_(1^,;H_^#:]0BD!0$^=RA"VY3YD&4EA0>_U'.,\>9CVD+% M(* /V@:Z1=C5O<8>A^CG/L#9,]\CF8]G>+(]<88Q]#=?
+/0Y)\TE!6180O$1 M.;DIUO0^"-+\T/+MO:7(_1M"-8YS/#TK+/L1\))5X2=R M9TI?"9;:BLZ*12[J_R(%-_GPIJ$P5C$QEQN^WN&?^R>;-GL$1$AD'H%G"55O MFWB"8_S4I_T 7=GDTO@,&_RL7CCOMPKOM
MP1!:M%0%!?"S&JY*KLC,E!]J2]%?:N7Z\U[,BEL0>.!<"_'6CL[NKQ$TU$7] M/B"& G;<+M!0@\22"PM\O$D97]U-"VKK@)\HGIB+U&-$).\=D;9./R:XY[8= M(6B@@^^Y,R'@5'+%Z.\07LE.(ZE.CN6NG3=@E/*HW9K?]7G6X!-
A5OS(6 MZ.&/$B8NN$8]^_@IL3.AOSYN$%)Q4/$\XPX'WO9!?HT?+PTM5C27<8Y3O0SE M$IF)IU+T2"-64Y/2%"]:RS 1^,!)%W8JP8KG9UTBQ\DHIDIZ/$,>_OGJBXR' M>DG0Y.1+>M.#XG3)]!!]A1< #B<.6U)V
U/R&R55[Q\*8CC4Z?]">;X !695 MAK?%=AZW4[+4DEJQ-IAUZ5R8_W3_=O9@R%H2V52NBQ\JU0,SDJ#\..)?X\% M#?]VJ6*/52-;+_BM^933/,\"I4:\2>B\]1&(IBG[K):@8W'&N^0WE(I49'1& M7)S:E;JG'6HCA
J5>3OM"B]^/PSQ=9A()O,B<0YZ!,Q3\Y[&G/\+6T$,^)M- MVG^PTF/[S.:2H#1:]PA@]:UWY39GSZJ,^?-__\"*TQ3*+;BT&6*<2"IDY.3Z M",S0'5QFOK[R86(RH]\K;W[3-0D<5]08?2:*)#K*F[ M@>Z&&GUK9&7\E7+R3L<-
<_=3P(X2S@AZ SP9+/(CT'W9?(DL=,NANJ&?>D,Z M!6WU?TJX0?/_^]17^PC@7$>>ZTJLA*,<1.G4RPZ1$\C@@S1TE^X*YR?"\9PR MM,GV;U6C@,:3YU#5T3G^-T<,*0%-3P*T; 7TLF.E@>!#%.=BK@/4_F'OX68=
M&L0',RW_/!S%Z(6]HJ/E1&;-[ M:+I<$R@C117]J[ K^\F,E'F85D5O)SUG+8;Q5%5R[X-F"%1+R8)X:=E"E MU8R\)8SJZF3'MBX]_;K,7M8KZ^ZWMT#O?>U?\)+%%VBM*X,_D^BQ5P_P@P"&ZNFY M+*^E?G L
M*0@"MMQDW0O>&;JC_R9XNJ<.>.I>]^IO+7!?Z)9+W'O92FTMRCT *DJ.8S+C5;F^]2)G5&C]I?XCH'/R%+XI/)E&_BAQ/(6GI;[CQ0QH MS-%]H689O^:<&V/>7;O$EA*S;\*P6B'.9C,[7HN/T:VW"P((RJM=;)."3&2O
MK>".2_;PHH$O2.@9GRW:5:!;\ZNG%*[T]6\9_,G0*&J;"70V-V?;F9!^)'IX M-*J9NJC!K XEMIL+,)[=[S7 X-#-GG\X8>^-],,XO3"#Z-I(VSOGCC,Y))<2 MIW);(10C%!GRZ<%]Z::Z%QW=*4.T4Q_]$$$7.7W%Z;JG[L LW""QH?-
U$XHS M=B[H$0HW51FK)K9/N(=XKF^@6,_MK*/G5&)(4,A$ R3^W%E,2BYX<_L1>,\7]*:$??K/]6<9N@^W> 3TVAZ!3#$K M58)'(.( LH\/.37=?K8OB5^3HHUMO=2/=">T4)N M=(.HN+H?MM%$CU/17
NB=AQ3ABI_OXJDT\NVL8>8\>&'L% <+FF7Z)6"304 M^)JW,]I< "V>]QXJ/?DM@@AC'#9$+676 DH?1(*KM6=Z*6M&)!1=&VOLY,6& MDDK>QMIR=9Z&&BM^7*1IW)!G43'?-)CK$1!9)Y]7T(0#KW]]IOW\B]1JJ*@N
MBEE"7)4W+TVM^N&[K_;#C]^D[QO"7P&279R:@J5O*7\UVI@/2B+U$&66 R]R3N<@M9GT=#SO#"9I&,T UD7H7"[(;2%:YHI^64"KS:3]V_2,V6VV[_HP_P^&JU].Z\*" M!J+=+:3)IK#CVW_,??\)>M*URR.P?T3(_>V&C5P_-%<
8?/O&S_]!!G$[7\T M01.)^B^$_G$?^^>R?,6"KT?S)&1R/*CTLZ=-+K#N[ MH+23ND>R^(] EZ\8R#<97\7E^$),"#&T_C"O^7P0ZY9PGS[LN*XKX.+UA3?E M_5Y9?O9QXB99ET?PZ5-_53S_)=@-
.0E2"N/0)5]J.R,2@+YAJ@$_B[]CZ>L M.[8B84_3;X/?9> Z19:EU6B@Y2U.\]:_5$G'#^5+ONQ]>.I [A"/@@[X81;/ MN!3>/L"0HNC]C>J#+(Y7-WO']YKB!F0SK]1P44 MQ@^R[JI]X+L@9#^RX^_.<1_9E)Y'2D.+J4^:_Q(H]
$#AJ8.-3G8I!\S9WN M',>;I:^AXEN0M"+:BR;QK0!OC5PKN$C(">7.T&1%LF2; W5_.)*;_(])3+M) MS3F9VI -N$A];==35Y\46@Y(@)KF(Q V)SD&UHN5UNZW"CO84/ZR&,?8O&%$
M+*C+G$_$!>B89D>;M5U40GMD9$1!:_Z=X[.A:[H>(KM/O-A7G\08^G$D%.6 M$]^P(OW4:UE4%Q1^\"/0["T6FU!:AW5R67R"I&!FDR1E$TH/@TEZ/=N*N1* M-K&QQ^F?".$_<>_ZM.ZB4O#/+F09%B$^*MFJ &-L\!D@D05L!
5/^J$$,4-R M8XRKJ8H-3TGU)XV10EB1\/K9L!IOMIO6.,.228!=.@,-5,?N/K+YB'SKE+/+ MG##M!"_@@L01&7,5Q#3/.C@=Y74^B'AO%KTSUB;2:FL%)C0K!MD>7P6?"V&+ M=\G\E#(2B?7RZ\':S4WMRK92"W#C"%T?
O_>X3=*/7)+OBEA7:(_DZ>R_;MEL M^EEK(2+]EA_/::+W%.K)GV,_L66U\*=-AKVT2TI&2O1=@O!C71,;NL&TLF'_M!^^UTF>I*Q#D/3[]G#$Y?FZB\?ZK=B_+4H,Y_';^NF2XE_MSE.2\Y0H^4%I<[KJ MNCI2-
FZ1C!4K^@V1'"N@8Y^@R5'>D3_RI(HU9G'%M<.U-AO+$O>[ M=&[(NT\TK_'=>.;*6$W'%>S=I<4MIT-5F^EZ;LC! U75-X_W:K9*,BN<784J MI)ZGB=-_^AL5E9*1I0&BA.,'G=I<9V8[4)&+>>CJNH3-DY-D49(4:MOHEL-=
MI$H-QJM*!5\Y4+T57^E^&R#46Z16+,LS)N^1VSOQW7SUM880<^U3%$QCK_)U MJ%# O[F?>'E?Z/@K7I9]+BH*N2C^WCQ"WN8;*JH8:&4N(+.VL;%>'MJM8-WT"[WB.
;'@8WE6ZI]Y2D$F4X1RE)DI7$STIEW0]#5<8@,K%ZCO]F,-CES:]2-6]\TH Q%;3/2OQ,4LIG!6DU\JCG/> MT%27U=?Z:5%YZ1!M>&$*MV^J\)[A?;/Q6:RE-)-9I%I(;;_FNBTP*Y_;?69& MQ9[5:F1-VTT41I:#[=9! %KD% /*2TPSS#-
J: H(WKJK M'3@>$#TD="773#N9:4-6;."58-S5W3N;K#BRL(IDU-GFDU#DMY#"#Y M6OY$3VY$]52JA+,+7F44R&X*_#F!'&.N(Y8P,^6R9;6^?/3Q)$+U?,_;7D#P MY9S[HG(W\0O%+",38J^QT_B8KXA>0B..6'V1.:
<",A>):0ZQ%A[()17=N<<[O28J.NRX;C6"42@5^/_'W2!]#<%\9 MCVG)8MY)UOKBKM[U1QA6J;9U$R# SSB">RYS3'M602A.$DJI&M_';_!ISR7 M8.KGVC+C(>DRW["SQ^NU[PO^VMC<2)1B,P)_?R9R_\JNPSJXHTB R:'*E30,
M-ZIH='K'+ISD0\)7%T@@HT%YC&T 4[K!,"]TA^:P9JK8X6+3D>N'CI9 4[\_M Q-+=YN/W(B;%/-7:77ST3Z;3-:.IK5G V!H>TKA]D*]&A,\FTI3;X+,&1\K MO@1H,2SOO("VK#NRLUR\=[N-KO<+P@7V[B4]^I_>7?KVNJ94(,4?
U\=T67LW MJ[.="_ES^,^E<%#[5'K%<\5^8< H:O:G\Y2]_0ES7V%A$'R@\UY[U! A\SKN&'Y+:3+7 MAT/H6JK1#/D+]8&03$="%P\*S7V%[E#]KR;I*/G@*#ZJ&X7=1,CCK7M*4IRJ MBF^0"*F[O>K#T1K&&
[M[^NR,H!,B\$+2DY)5_?G2CCIN)MS^K([N="KHRVZ MBLN58X??"N[%#HMOH4Q8Y4=#]#]SN*SP\681?B$-8 :^CJKXICK:+X6#AW4 MVT)\OMH (MNY5$O!_%E;:\&35>6;0I28=U5$]=4,Z3W@6[J]]P$S6,FQN
MX6SY0_H=9Z+PUBL]PQZ%B&XA+C0X).#R/\Z?2W2L"1"]\CF.]A/G*3,0DY'@ MYVU.UVU]!MG'J#TY[J4O3ZX='DJ4L4^)D=,]')(^PQ02_J=44=4-M#$SI:5N]%SH>>^72-5G&$WSR;ADPU0FX1TEY6_J& =]"*(;-8'N8MTJ7W0[
M^;0;\Y94EJ$Q\#?=;$5H*633550J=(5V*+6-?DFL.M?)T?5?LT$>[49@F/YX M:P^MJO@0ZB >^##Q+%6G:&. >B@A'30SIO#4<=HT7=2OF-NJXNMN""']&>-G: M[<1L?CZQ!CO$/KJ9@K9DH7_WM975;'(Q=O>@ NA'+M))>
(G<[NJ32D/^36W; MA$X%2A]\T*"A.'7]?PO(_T&_?WF\-H.2C'&^E!A^+7DTTR>+4YD8#3)>OB\" M$=N7W)) W^L8^+H'UPEWHKZ0V%)>6JD.3M?ZN!M@7%/( MWC-@2IK36#]B$[T8RTL[]OT3K0#S"*
(ZWV)AD=E4==FLV:4CNK93/2P\J7Q( MB;O-H/D!J/;\=7B[)G_9O&1"R'/&*;?B2.#CVN.X#5K&]4S,W9"'M 2030;<2Z)NUNJB.W&Y MRL3;0Y"SS-@_E5BB8D1?@3]1AC;%HX=I)CNTO83=H&*4VHA M>A5H"_/,5U1DW1?
A**%\@_()87E+)L$D*D*AS3!=:SJR<+1@N,_B+!%Y\O2@#K[1Z\3.V)H3 MDDF"=_L.N5/P6_H7_!XXHDUN H*2SA49298E8O9\L[-];^U"I6Y3?C4EK@SY MA?O=TR/-TSW\/"[(V?%7'!CV@'W66-
K&1WLB%%)TOBD_Z>#4T#@D#MSG7Z>. M_O3JY$/:[!B?$,%05'/ ?1+X6*_^U*SQUU])?I+MF?OZ$*D"!3%"W]:A.&WW M;SW?K5H8W[D7U=58BL>]]2\(U7%W"\65''5.V8JM[ 6K"U6NQNQRB37'||.^W M<#/?9I3
HU_+=5ISE14I\0GYJ?,+#I@#Y3_B ME[%3D$1PV]0!,1HK"P]=2)I7Y5G/L_\J43&2G'[+V#VL)QF+609+).<".R"; M^42\,/\%,17J*$ZVE@")T'MX-R"M\7]P=$H$Z1[.-7@8(?66_G+4P]DKE;C!
MSGCK)I%9\|!EO9*$GDEQA4^9Q"XG;? M8*MNQ?UGV5%*&&. 7_Z-F9&RXN>7Q+8ZSA#X.3>-+\K>#>4(1R%]];TCK); MB?5BS?R O>$)>J+WE=7*\K;C45/431\I+C]?!NX>AL<.&)_@Q)"4.G Y/KS4 M?A+LY?
\0P06[[QR2>6"%F#[339 3P+F$R-=02Y^8;A<9RP2_,0[9T(8ABU;' MZ;I6/=Q>XBP:_,#:^=YL6K\L8?^Y<[7.'6]MJHA7.X,8#D?CSQ73C*#V@W^K M;!-F&N-$%=BI,IY_2[B:H4&.!N:^W7,X35TB05MEL:@K$G#\$*G(?
(#EMMU@ M%& ?+= \2]*,\?%BYZQ+MGVBW_R)1T2)DW+UIEKJW6),WRD5#K#_E3P2Y3P7 M+=#%84X/"@%W\H.4("'^U%^%D0<4[Y"<:S AA2&.5X*>CISC.YI?=JI3-,!G MO$L,<7<'4-BT2YPQ_YP-)I,R*;R\C*!S&;36$V9?
RWN)9^P56DLMB-4-P?X! MCX#"+HJU@E361!P-.)S6[W)U3@%,H_95RUQ2KA]26*M[U G)5=#$F;&H?^X? M4"38 \$@UW+[0CY[PFVL-#V5*DN:OM(P?7X ;O_1TU&2\0)7:8;LKO26\*;( MO7W%Y;O#P?3%\?1/ZR^NP9Q-
$]&/P&5G2 ]N5F'5R"78"J1^;6KXLN2HS8/< MO]W%XB,5".Z$-V@54?!<$35SJ53S# W+*4: %+ZFYN8HWJF+'M<%]^H<9^J> M=^)>B,;_@X,;"DEO*MO9@1Q<*/GN^A7I5W?Z!KI+Z-!5*AIHKVPH]-(->O@@
MMYF9PBRX*%G#=J38\/V4C37B(S3W:;\C[;R..?I8B8EV8T)T$WK#9!'=?+V0 MUE9G=T=TM[D_!R<)P=TZ+]7H89SI0\*A.>Y(8JI; >NV?"L?VX,RF=ALI";/ M11P5R4V^)?1A4GJ/SU7T-
/@[T0MIUC9W5D6GH<[;\)"2Y8@#RHH:+\DP,G9G MN NJ95N=OF5U.Q3(+T*==-Q ,R+Q%!VJ0.V(X0,A5@+^D,T&6L/2S/"%;,)Q M@Z1)'P^\:^=SW9>,"T]1/]<#61/HQD_H!0*E@L?M$P>
M^AG24;%OO9V+P910X6JRBR,RJ/>;9P>_Q9_-;&Q[*)G,>.E^=DV#R0^]BO(X M3WA3*U@>P]9]^K(2@ZL6%]F+@X?^R"6:N6G.<9MY]$BW=&>26OQ53S+(&K[E M\\SJB (9G)50\'H8SR/@-
,B&3<]C>7O2B?)%LRO8SC45>^&M-I70S'&/-=V' M5O7Z:KF1%-O9AI&5!P%.%,$+ OQJ5%@1RX8>R7%/Q-8CSQ8IR8.B#L:*M.'+4NS;QV,Q0M7+=YEFUWI&C>J,RTBDL=' MB&]$H:,-)-TN$ZME[0G2C+GQ5:,4R*Y+.--
\+T^"$T6O5H]J:1$*=1XL70GE M,!7'P:,@A'SGDT$*Q[]%;O27CF/E1ZRMUXXA-W[WM M1%-,1]I05O(V-89)!Y*NP&^14QW]D_,^4AW5P*27,/T\%;)D]]YNWG;NE:2O"'^K*?8R5,XDZ8!]B(W@\'145ME*\BDE8S!%^.('-S/0(F$>"<
MB$^X>_0(R]_LG#R%&JRO;)1VH/AE9>-X\LY61\P82&("ZYNJ@2#YNF639ELM M4OVJ/PL)LL;/DE6L-W OE?KEN,1!.[+T#5B\7SKZRKQ*=,5L&(,[YS) ; 82 MNM_5Z'.OKZ3&/Y5+IM?K5O-(2IU.1]I\4NF#Z5+D.5+C:'>L=34+-
)($;=!0 M*8'Y23)G'D+$:^1B/I N\EJ]9#"RXSD*M]5)RN]-3L?:?#/EZV%>H=D\HJ]A MIH#3M#Y90VBPCR138$W]3"PH1/5X*V(?+-6A"- MZC<"OD^VG>Q#V=K0CK)'(##%\,ML7,
<8']]^C14,%!U>F#;R&B*3,#@Y_8XY>\WWO]5:%_%XM:S-9W9HB&W]UAG53)6E\]KB;0(YY?6CRPSK3%6[J:F^W,JDCT/*Y!1T!ODG(X]?#$G>$ MYE*' W?$]$/"R[J<)@U-'AS_G20F$L.!CZLBBFVM*38T09.\].]KO'W5HXH
MA%^=R["5*ST"$L)FEX(D8QP'.D?*U;Z3AWN"^F8OW_3TS.;Z]]RO%6M6C!5; M4C6XVGVRJ!MHGS'XL@Y(GA.COI%V%ZEW[^1"H^(RVEFHRD5GF M X%+T)M2_JM?3PD7^>]GV-'_7-
W]2P*Q<9(@O/G]LNS1(.^7#2&ZXF$\DE=*Y4 MQV=ZL?VLU>,+JZ5,6/Y.2:#Y"'CUT!V"%)>ZS\>QMM@2+<,E&_2?S,D)#2F#1DPC)MA38Q\PN^ M[]*:'K'6N?3.(BEJCX &>U+%(^!Y2:PR^Z8DJZ@HZ
ELW#^]7"KC=GNRFITR M]'MV*;,*_J%=+XH5A/$G4W"']^UN]L'G#3;6/.UY?0W]3T$L1=:MP=DT/T]' M@J(\;BM2B-GFEV<[^&J;?J_@)K/KDFSFI] D^N*9$
M54B#]J!T%CV6=J%JREV7'E'N=F@G$K#@^R&Z(24[Q;O^Q"44;,U=>! MC,%^!B*#:V'PN6O:V,K?2PU[^\V5HO&("E-RQ;#5S,Z\_INWKE^8!*1IW MX M%)VFH;\UYD4BQ;XB:2KXIR1-5Q/HFW^\|0C,P>GH1EZ?V83.R?%=%?
+]%N]/ MVTCPOYPC^M72YV!=YRK'.ZO,X+JWK'M4+;+K86W3#W+DL&G)L*X/V%!N36UR M^IJ4"WRHYQO496Z&XB 2:GI$-J]&)UD=3OCJV MU?1 :Z0'"T;3D[$-_/QP%?"PU)>[HB0[JYFX9C@DNO?$B#WMGP4)FP[AC#IY
MCT@EL N_%*,V*Z4H](L!DI9)SQ$;4*G47J^2>- V/M A)&<98S2L,< V*35/ MTOP,VAR7E)?A2S0A<8#UN0V!;SV@R)(@(G5T-BV;/.4=KR4%,2L,;7IZ'X??K_X,[63 Q? @UD" M;DE,;*YT[3<*B0@"H8ZHE@=SZ:X)RVB3>W.%
```

```
M[^9CVQ?GNR[H&7$AA)SZW:\(/W.ND>DD3W1DA)W';WK%^?]/%=CSOU5@_S1E MZ$ 9=/@.,O/JSIAU:Y_H),1^;S39.7=FEQ6A%*Q?&T+2^DFXA4S'? "[R->( M$\-0[+U\02: ZJF4EQ'WZW\ZBH<0WG-5GGAD6GLP9Y?7A?
+G$W(@4WU8-R)= M2[&HS8B2*F1;453>&, S=A[P;PU'GM-;%#@X0[LYX)H0\EZM;WK[BY1D5!B7 MC_$[E9T^ N--4L)<1F20%D6N9A:4ENL5_FL$%V(]W_W(D#Y!5CZ\-?J"&/E M#5.DR>Q^_TO[/$N2-"OZDT;JG4'*?
FHI:5U$=.APWQ5!4YXK\.@\EH:1=;H M_;LLB2P-REWT0@8,;\1MAZ!MVI^:$'L('=!GC64:D)VJ7*U"(B,(W,N2GXC[ M(<*K5,&A(S /I_CLFKL;RHY5,3)9R$I36?!RW03)S:]X$8=_IF>"H.\|.]3B MK*'>&SP-
VW[!WT&'G72Q$0M_(T^Q?2+^51)6I8HJ,LV:.&+[GBQ7T*S,4:US!-S\35,OR<< M,2LOS5[/IB=/,_IU'ZBA/+(/5*^[F*]A8ID78-,%:G1%:@.A[U2W@F=-P9>> MF-P1RFLG'2Z!59Z'_;S)Z[B]:'%A7Z$]X7G7[&VSC5<5YH0?\3 7?
_WH/V23 M+G%8N\LRR6LMT!ER)+IOFS7 5M875)GL@VBE.%OGS1'@ORN8(T 8;(\3! VK M!+L[R HI@T5Y#_HL3S7P(]%>>4INNPM6C>VXD/F<-[D,R8Z=5WI?R:FJ&R%\ M88M_5:-ZH_O394H=#)YF87G_CL7X!I[*$.
[N6(A<&ZNDP,U& H>881N"E*FC ME>NQDQ3L]JY,47E.:A-X26OC=71^U2%(%N BTXLI%D,>^J1(8*=@:YKLKN*R[WURETP92(R6FCC7O:U7,6LPPU$*PYE MK1D5IN%.BM6S?=\*OE0NY;QMK0EN'ENFF8V%-
QHCWG:G94\;;8:QF[([^+EH MQ \[$OC1NA-(VK76@:J"")6PG,EW.MSG&_/[+:E7ZN.YI'FC"GF7T3_%M8?" MP0F'M(QQP:8]9SCC?E'\R#;7D\;YJ\;CI1BSRYI.;UHH7WM;U3WU/AACCTC5 M<.>FP*"C=\>K D1W>8!
<1D['R.QMSDL"#"A1E'$&D6;<]NCE"BL<+=X[[[M4 M>Z-4%._+;N1+3K^@)*WKVE.%#ZCT>0283\)C'1!>1>RS#CA*(=MD9(@'%;#@ M* /PV>1^7/:VA+@?#UZ+B[NL1G5('2KVF4E8)+VOOXQ"MJ"*/:$K@W$Y!8F,
M9L2VU_.3<^OD,W$_5S&PV0M1JFF.M+4N+M'X17BAV\E\2KI M(OLBWH'P=[]KX0'GGC:7$X*[(1);02;W5+,2/'6&/F'DD./B[D:IW(.@-E#@ MSY%^]*QNE7>TGY! -%"-&L'%B_Q,B*E@]$OSXU82J%:_NK-NH\,:%#9(L(*I
M]2%5IH&7I[>DZ_(TG';^:A2-[F5+?ET<[UE-61ZCFHB(!:VWIX(*%SO:J,EKVJ0G0JZ. MR&SK]XE7-M/K#IS-EZ;&@\LWTX+'^/![1^JQC!E.KDJ1ZW/XA\RO^O#' MZ!0Q6KI$KG;-54(N-
BHXVE;,%LE'O38C/X2)>7AX+]99[N$_3@Y%X!YO+NE*VYT*PC7J0OQHW!VN#:D0FID=G!&*)')'\1$P M.C M^1UEHZ[G4'@YA#!_!6S8":+Y&J7 %]I?8M69%BFL/]U;]]XVA#C%/ZP29F]< M+7Y7LRN7$)P
M@EMP]X'@SB#!'0($=PCNGB#!@P9W"(-KT.#SR/^?<^Y9]]W[UKVO9NVUIJIK M=G][[^KN[ZL>^!Q\#<"1DY*5 D @$&#T^ '@BX $@(J" D9!1@6#P6AHJ.@8 M^)@83YY@$.,]Q<8G)Z&D("#\7S=X)X"+"L0BB"&"J $7!
B+@C> M U " @9]%<#_M% "(A(R"A@5#3T)X\3&G !! B(@(2(C(R$M+C4=_'XP 2 M+C+>"PYQE*$1"8D?DY)3/J6FY>47%!85?RXIK:VK;VAL:FYI_=;=T]O7/S#X?6)R:GIF M=FY^X>BX>("X@"O\]Z38K#RU=[V7+"-L^2 MA5?
<1-T,@4]=#[]422F2:KT<]4RND%6HVO2E' X_?+UU;&%>>1?7-"ST!88L M8E@(N"4]6=;MNS7+HC6>XO*W:GP:YNCTH[Z%GZ-$H\]C+7&18-.0L)S;VU=> M\6ORRN)A$Q.-*O;2-,D@2___;P-D>V>]F"36D)L%90IG>
'0XQ0H9RWIJVEN;FYB#E M3-2DE$$W.B'L8NI?W)Y%<^L/@@/2=QS##Y_+P0; ?3R6HA<;\T3Q*$$FQ$T55C7K$'F*<3 2YH+ M M$[&A'*4QV)4L52=O;1M<0$/G E>L:-T3A82=)L.*X]V?[0OMC%#)NTO"<0 M6T*S-X( /-
H,!SKZ_%E^:(AT9I\MP![@_^ED=+UH2,<@*;]C\9)*B]S#'MQ MLF"FU!P4UGL<8B0N&DK5]'>7?UR/2,\]??#6@ZYNY3SYKX9A8H0[I=G_@9I:*K>3XQ2,T'\_^M_]ZK_WMFA(]V-#]@@1X2=@*X0)?10S9
MT[UG*+1UBN5GB'7<@C3]4=J(98PLL=2$N#!8*$:\2J6*\:K."%W)TO'I7)?0 MY\W?8K%"FVYK""K-0)8WF3+8VL'ALZB_42#IL[F4:-T4VK2$R*^@.&R?65Q7 M^FC<<_<&B)QNU4&/5I,K$V5Z0Y/,<08AV.&[[8\O0C049)-
O"A4"9X1I5#< MHF !=V5R_D*KW6E;;876OS(5Y&F>Z7QP^P6UEE'="$$G"H@1@\Q=5LE4FO:9 MWWTE>YGB<)G9?AB/0NGC"[NC7FGU ACR(OX'%G>>@YQ76P$'&J&-]LB==0\C M"^VR;UV;E9H_?$PY(3]MOH?
QE8P1$D@VK)9 MD9). BQP((R-MBWFA$X9DAIN"V4;3'<$X< !HCXLSYLS[?V,%I9K97#.#P-/AW*/F:U=6,+4 MXG&21HV=MEAAYP -L,]JI*:S0I*NFZC?]C!CFYEM^83(RDVJU\R561"%J1ZV MXB^PP)#GS[6>":EP*'XO)TD3,
[?OS_7N\H&U!A+IC3_#QFQ-(\]X=$;0"EG, MR.(G+UV0MSI96=13\)>E+GMI1X8;D0_)V]$\E:#6^W+:72]UIM1<^ODYP^5U M-/#,?84R]I[6(7E!2IP^'1+7*S-@ CR/PBK0.$]7">3QD8:"@-#8C42*YAVH MW/;1'4NA$(5^\N?
+T<%-[I"WPU1=I,_&C6:5D*>3ON!^:^)(BGX=5;V#PH#( M85?/\MI5*ZJP,[7XM) YA@Q&#ZY:)N8,9NPF%>@U X.9+W"_I%N>V^R'F2\EX:DO\% MEW4.%L48*\9X>O_CO-+O6#_TP$G"+4LABK>,VC.^9NQWJ%
(/^IS\_NO\9^PW MOB=BA+:I,T73:GH!$,S1D1I/>9*M5X)CJ5]@4:P;>N57=WO7# -T)DU1H.B+++#@543?V8-?N@&$_C>";KU$@XL$$+/ M+K#O+QG+5A9XB]%T/X7A-M/PP>+%2'S+7NEG5M3;IFH=FB=)(:<=?3S[(2UT
M>UD&A33\#:Q&>A$"W5YGN]U1!E,;.Z]+E%B54"G1!E@+77ML,_: EQ"-/8C[ MASU+BMI/6!JF)[IQTOCM,U^=)Q Q%WQ-9M'V$A@M=?1W;N ' MQGII,?\_EH"FSBQ$=V3DY1J6Y:MWZYL"!E$_0XQH9UR<@_?/JS?
Y%PKI0LL2XK6ABB_91) M\G/=?"@]3CWHA^.H7U)2D=(Z[Z_+2O.$S2]$%TT649MZL9\ ,7IP)=]VD'[* M(DO'7]&I7 X9PP$VW,?
TO?;GJ"_[ZN2K<7AL&LV2JSFHJ;2\HRDC7HIC"4WEMF#K.6%K/K@X;QTA2LIQ,X=I@B8!^2W2BT>5= MU1'W"6]>:6);([4Z4XT[#FAP8\U2Y,+VL#'_P>"OL](O5HC^O;:0(SY#-U@[ M+CKAP,[KS/M<"]'-/ZE6Q]63$*GZ9"[+
1J=&14Q%B/!5Y$$"+:@^.B5=;DI M7^0U<,?";;*LM$392-=) RZ%2,Z_G\5&2$FER(?0);N;?XQDZ.FLZ>QIB[%\2Y1"*2R0A]O)Z>#WK/C]PBJC:B5TK"^#V-/";.X2]2>Q4)IUX M]$>"^(YOZ3W@U,[;QZUP[?
DPU=2WVTC9+L!V6?%+RS:I,V%4>>FW: M(^7Y>*'5GBZ#&^@7;6Z%*A)FLFF8I38Q_^&;RS MQ3OK%H"L%,W:NCM#O,PX4YHRF,QRU/JPB1 2$$;KJB0+%LJ'D%(\4U\X@L!#
MS&)#&;]0;!HSUUVFA"3="^ZS!V\%!6Q7M\45Z.L+5VI?? M]TZYS5#B/P8^P9W:4#/Y89<[W9=CF29;^Z#@--)"Q?+[$FL>#O 5H7S%[TOF M<95RQ5AUE246E2/47H[(+V/?0T20!$2B'NOSIT9]M9)T&TE(UX=3OHRSR=E+
MAM_+M.' T-B]N\.NY@XHF!J15HM2SD36@6XY^JD]:8HUF'K*6ZU(@@;O^7-" MU9QL1SV>CD!7%]%%EL(#BQE2!^9%>S/:R#*!4+(/D)9+D2G0\K7U?>_=Y]/) MV\AK#6&JF:TQN::FMNS13!#&-7U+Y^-;,S*[Z#7(0?=*8YAD?
9_C=W!.\"U8 MF1, [^IO%<*!YT.QOS$][X?L7DL7 GQ+I3]E1KW6V-.3K1S E(GC\ZM%F(AT]O)L%F"FF*;7S9,2=^JR;G$GFT@-A.\G71'PI@Z MK;'HXT?)ISDDSGDR$_D0202X[&O&';[GO6L>Y"&OIC2+)#-3B\3M0L0'49<.
M#CRG]+(V9XH*^5T.4=.-57PABW$_.U%K=.(#87]'3>I\1U\(N-*X]J&>ETYB M'\&HPNQ-TG"9%5"-LQI(\72I<^^M$+C%+*.K17Y5X+38P1!*BE]Q1+D:.\T9 MQ_?BF&%GQ8[0?@[*?)GXCYKCJ[EY;LO%,: *"YV*F#S?
X6KXBWJ,@^4V M7CW'KA!;.R3NGZEA%I)V\/-I09GH;UEOV"!L H*R/H*0(L2%,!N^KO4^@;H& MP 'F_K-RW*R05FPPM/]B]MZ9T-[IM8]JJM,9_N%!1VZW/?FJ.;)+Q5"4","ZAFT%[?L+L9L@'/" MY@0H2F0F9G ;SZ>$J3%BIR!
[*2U^>HJ+[=.KXC[<)>M $'<3GO6)#$MTTY @ MT=+ @6.7YI-^;D[? MP($RZ2>HOW'$3<_\U(^OE'A:Z.9.]1B$!M68^^/R-T7#*Q,()R^(M [=C&0W M^T9#P_&S CZZE(7G[K(NP@*0ND6F:-
_;&IQ\&MAW(9N7IX@6ZJL.QCTQC/VAND$VV#Z]OF!L9 M6;IUYZI*K6X?RS\^SEW!]*D#E,]L)G3JLZUJ,"_?)(K:BGJTHZUY:09Z1&K8 M;D9U/V5;6.&(//G^8:"?HKWA\PSOBOA9_3?HCX^4S&!*[T+&W1N.-OXHJ:W=
MV!$*$4BVG'"]]PMO42[4JU@=WCY3)!'+N9XLE?;[K<.K,053 JM]DF[]X%LD MD-]\M6?*=M)\UL]%+_=;YGE/JYF##G/T9R;Q36Y>OC9KXRS(?3\Q2TR=V^@ MS_F9[_;].";"?/C&_[).-U&(V:C^S.A*U1< OL=N=UH_%
[NL&PB=E2&B2Y7CSF MQZ^?*NAY40$>AT3'QQXD8W58,-5W-44OU-+9!*KLM MT:-+(>N>L?/7UBVIUS@T.6)TA7ZQ1>9AW9;A*=E+& M[DL+"?J]^'Z;3D$RQ7S!0C]6BT%U5F"8QAGZ(M94E]R6]?O'M8Y!-W-"/".H M2PS1:
<|%0:D' >OL>&&-(I-N04>R^U?+X"ED_QP0ZI[X_LC[WP:DT[0GA;U[ M[VJB+X@LW\GU5_=0H\_[')_*+/;-D9J-&6K)/Y8VO>0MR%FK3:$G^?U/@P+#C-+Q5O[4;,SEQ$&RK.5D!R;]'JTEY: M,.]L26IW,O/QT6Q'#'RYBH'01,-?
Q76N"6&X3V5@0<<*1F+D5\0]$JN M1UM G&^%C1M=9-;'XV/.K&>?YB MP@8H%%[B?7[A3D8 !_S7-?$L MFT0 ZX630@9-'J$JI@@AN'A[BIRK4.K$P.;S7MU)ETP;3/L9[Z&2(Y9U+;WZ MSM.!U(',@152BM3*T@B@[#,
<&."%W7<;>/I^3XS)9!IO$+U&T8,#LUP&4(%D M P:$#U#G&$SSE8+CYQQ9XAN6%58=1^'DXL5!I$9KE@2D"\(7[NVM/.RM10>F%AQO)QFN\J'_&I MXR0!3Q\U"7Q5FNIG<><\#3_-/N]';-MCVK_]64:?Z(B5W5=XST^1PSM?
\0&$= M!0Q05O!.UUGY4TP5.(Z)3O@+P8&>7;;%S!C'C!FANH(^VA!LEH"-V4(#Z_&5 M(C]%K!Y7@G3L4&98BK=YV*R6KKJ 01]X@,M,D1J!S2KV'WJ"*_SG>BT&[R2 MA&M"]@Z &U[R;?
-84$F)M41.NAI^1!D0YGH7!O7+/M:,].FN %2G7O%DY'(T ME^P;6 MZOIK/H]9R0JU2=04_!SWP)'KG+NKC'13]MO3KI$JG:D]D+/._K S% M--+1EW!A:A1>8BOTPC#_4K^ 1H,1KU%>;ZO+T[2S)R<5'7_W1%V\XW'"5[
M6Q8C70Q=KC:S:M3;48Q\.[0Q&\NZC;5]*ML\]JF_]"?>V/0LSJ\5C+EY-"<[ MFFC.".("BWTTX0!Z=+T9P =HW ";=Y8=%K'U\DVWBJMN_>@=/KYKGM2[^I). M?]].X<"Z=,?!;4?
#\_FMEVR9L"/<\7MOK7=BR#P_S%3+06I=X*\"$<#VA3 - MFL[6@F1=4I3MM@2%7FFC6\8O27&*?-JO"]V?^U@*DZU]BH(CJ0&N9&'0)<\D MKCHK<\B,AJ25-D<\*;,N-4K1TK,.0]E?
BW%25/OJHF7+,@Z43E=IJ"LOWGST8Y5;%2K M#IT5Z]DT.3E&;@@JDO>,CU:"-$FJ]*=VG19S2@[ZAON+MXZV)>MBA MPXG5NU73&9VWQ-P

4Z&M6&8G'IU]LZ2K3Q=SE$]FVLRC4W/3U]T5MM'DK"YK@ZG$+4V]^\]SO(?64W+5FGT MNC%"#XY_&U+V'JOY5IHW0RY5X4"5>-)S.(!I(_)A&T[GN)?^PL]392!5!*^
M7LSW&:!LWN&0&VO6&WF8^*#KL\_IMRYQ)@7]JGK?.GTD=J8EXB*!9)K9($C[ MK:LAQS1LR:> 0G8]#0YPY[MP&@V$?AHS'B$)"=Y_CMP.(&[;!]WG:S)FI9+V M6A!L# Z!_.=VXX"M!H8B9+[S
M,H;D9=/&:,FV^K@UWSZ[C5CGQ.MI:Y]7^2/O$]NSG\C$F&'&E"NN*U4)G:TT M6.6@3\[I+,LEC"'(4E%3U6&]KN[&[B? \&+-)/B^1)O!Q,D@^?Y+\)-Z[*&( M#DG I.I#/4T2;:QBS"LQA(\6>]#Q]]Z:TX_:53PO AAI#"W3B0?
C/:YO'9# M5+O/VG^ *MW?XO]#O]DTB1&(C+G" ='BA_N(__C6=\+ZU3E_>:' 0#EXO#[Z M^>Y9WL5A-TE-Z3YG4:HW:W(9376GN6R!%'LUN9CQU*TR2NS\4Q,/#*-*FABV7O =ZDL"YC;*2Y6I3CH'
MU:A.0M5<>N$APOG)=_M-TQT;!(\@]$8<6>?T B;\J6SE3;#NLOO*[M.F=;>6 MA+&L/.?#R=;]?XK15P H"ZNT3JN9PD:-1,3V'@1H$#C 'H@D M5]X.=]#N1AFI38)"MKC>MDDH+99/V)KDIUH%(%/S!I;937$>@C^F=CUC=[-9
MT0:AL10NE8=(D:8LD[4O6B$L=F:(\R+%)6.0,GDW*L[+\K[3\B;?0,^(UIUX8*3[_:(66!,TQT"(3,W_)., MUR/R-!D;RB@N.FHT)QQ3#]2V@1+XW=Z4*85V^&/$?)^?;L6+-)B=K/B35;\P MV#XI*N?
@(C#]%NX]X$+MDR4]7QQQ6Y@]9F>9\.@5Y-O>#/]+^[RXG\;CLL*.%'?.+A $_-VM!3Z\_Z-:U9 MD),JO/C3MUV@8#9)Q3 %B#)IHL&L#[%$KL1A/7LPY6+9$^39#-*P6-] !FJ9/.1=D
MH#3@?!6;V%"L)MG:WBQ!6_.UO>,61M3:&JA_HH7RF4>_UKB/8O+,MQ5=<8=F MW;S0+%D9$Q&]P*>;Q,])#KC1\!RPK2?Z9*4;HU.TT4W?B1=KI7\_*!7I;[RLGV*MET*2Z$62OY7'['0W*]%*B
M\@(9SGG4&Q5LJNTT!17=HPX0_T:9O[>(I)ZE+9,\M;XA>E);GWO%-%Z55KJ M\3!3E)G#WHVN<=43]!NL!MM.F"1*O,U/)'SE1AA0W_(AGN6+3')=TT#'*WIW MO>F/TY"5>^.V&'G9Z,E^HH^FPR^\2LAP+RI:#B94AXM-
JX'J[8!% DU;-XM% M1[Q!4D'"Y^]!1-NB$TEM)"_IFR7=N:W0>LHV0T<]^?GV)RJE78GXGH<]9,'ZW'YWM MV=$F=]^SEM4O+VFBO8?&DZ=DZ9*"ZRG8N9QQ%K5=8<6R%T*EP2 ! 7^F)RY5
M"$EC^:$0HYZ$2!VBMD3BR_&'."*_V)67!,1M8LD$S="QUOW4LHIYA/_KUX3( M\I37GH\KY/">5G]'T1R=:)B'-& ;P-)@ F!70)C@EFEP$]']C3H2JSSKN1< M&?&-2CA& #X_$4N,XVZ:ZZ,/8=T'<2W#B^%9-
!$WUWZ"91LX<(K6^NC5HID_M?($=- *H&*"*?+5A:B&A8GG;$YNY)6";7^0B MW\Z=T,C;\=T/.E+'?:W#3^;]#2KQW)E,7"INNI8ONPARAI7('#4LH\V(C.,\ MAN.,.4]-1[-*W2].+_K;H9#WVBQ?N=*FICH&C5%56M]PNT41
MA[$LDI?Q/!O>F/]2*CFIK%*G[YWV@V,.Q-^YK_ITY5,$F.]NQP)&7B:!<%_= MVYJMEU4O]QZM:#'[W(P_][0[C@'QXPG9:26!(D[,]-";=C-LKJ7@))$]BHM5 M&\(G+E%8(/+]+!$2M\3G;#KAO0WY-14O^S!;I&!?
A(6&NSR5!1'3#G!_@^+? M";A]2K;>\UYO2'K-RC@?K.$C5 [A&5?IHGB6"\)HESG^LSYX<]0U9^F[U" M4">B+?LR7DDA;\=!XS;B?.E'&L=G"6 E3<_K,.-^ $[>],D-ER:H)EIKMV-) M"]LZ?-
M^U41Y,0P5^$9O2=#T4R)]/_8/$>3B*LN+8 ])?INZ K+?./+'[JY M&6]E+G_'UK@W?QM 53MCXZ.XF)W]Y*,?0O?0GV4;;OHF/@67DR,BSW38(RQU?_+M%HW5(29EF44&/\MUQ]R3NEDX$T
MSQGZUKPH;3K$R#]BA]Z]^-08U$H6C]"(S$7Y;ONOI)LK\UJ42"%]HPHZ]_I5W@#\H_VD%O2SX(*3&^+>90R'4R"F!4))*2%'T;Q0\UM,- M"FQ](HH&OPBPXQ7RLL]]G6- MY@O?
VP00!+*=]8F5NY$0A#&U;!G>!2$O=!Y])W/>5_NNDSZ?,3]-U]B(9[@[ MB\.Y^,S:Z'Z]9-4?1+;]]X+4UX+8TBJG/?!U;;DYV<^/2:,B#9[E6-]]1KLW MYL\P3C+N;2I&DQ.':Y4L(1Q/T<0[D
MH;Y>UCW%9T5%,LWXG7>@5^/-53QJ;1NG6Z'YY+UDQ9?RY_%C\Y6-"5W-1 [V M%U:V6O$CFU^C=RCL5 )Q]PP*I&&BYS>C26]'WU*Y6-\"W0X>N[^V$5GJ./NV_7#7H/EUU][^]L]N$N.;=<=T^ZJ$?V$3RO_
M%KJVOT2\KCG59LS,K59DQT*MD .^3[,1G+ MDWO_)4VR+'A^(].*$DKV(%4$_91EH\MSO7&##DB0??C54?$R1*S%'+:OZ5A_ M7LC)8&"%D#*O'=0@?F?=+E_UZZ'!ZBV)[^1,ON62$R8@UADS+;>^F>>4MZ(%
M$TPANG&R.8O7,%.5!/0GYS=KHX<5TD.7[.HP?%K [3;#M;FW.QXH_L]/YSWZ\?OYR*8VZU;*OCM/ M!"11?7%O#4V[#5 M/>/K'#$X>QU1.=E#R=^5(^ELL^<9A>&R%1TE]!$D,!A%8OH*'Z2XKH9N)DF3 M<.Y@>
<%3M]86DJ[8OP7;WD6<<=1 M82-0MJIK0Y@\LP.*WFQ+HY.(HE!?PRYT;]CVHQN_J,+UB($I$)Y)%LA$4K^E M:W;L,W -3?Z1,UYC:DR0#T*QPM7 MC$)+-')[YKR-G\U((WE6LVG%[G#!:D.MIE/S@9"TVK?7;63]7I@^!J5QZD,M
M@LK;]!8C@[]:5%93R?KK[AM;07EW3TM'B6U\IZY)$88L#.Z9%E%IN6) MR%TM21->*R7V#MHJ\|@F&:\ZE#PW B -U,Q&S\1-6=4I4F%SDVI].G;QLE3B MGVNEWND'1S6K?I56G!XWLA3>Z3S/P?+\8EE$6ZM7+Q
6?'GH;,]*=0 Y7*7* M>F";A*4Q&"RJO],=B'Z$9(>1X;BKNRC%$1 KQXZ&%",M!W11L$TN_*SH;2RP MT, :O"1V NUX>9/(W)D6R]76O[=AKN&01:U)V.3^+*3Y@.(]+XL?'U1=X4 M5,1C^A@YA(<0T6-ZGR#W@
_R\.A0>H6R>K"0DO'44ZEZ*+.ES\OKQ[,H[NOA M/"9?V>&W-9V/".V;_XD0P HBSL%R?W@*83HPA)PV8-=!EK?N0_2;[TI./;H5 M@_/>L5S0R3\*]?I(:)V-@>/; M6Y%N5K=MXMW]-WZLDUL)ZC&+]I;ACM#4-L74KH]^L10UYZ(-
(ZU1>#]QB(4PL%[C UGW ME9>=/O_*.R.:?;"L8CK L!XD*?V[4^:9YC2P]P5N] ]M'LL0C<.5]#YOL&TI8 M03AV,D$]YPFL1:+/"O'MG4HA\<*X#?M1)X$@9;G.2]^HBWW57MS YQ$>Y&->4@]F 5$:5.15.7.#BV/\
M9;RFV/1%R&+/C"X)A--])K"-Q<(+!;TT17)]-]C :3,IN2/.-PUUWPL^#QZ+ M$9=5U,E'->7PK>03K^=A*:UKOJHB M4;&=;]LQ=&[-LXNS4>50D7DOO#>,Z4UY#9:,GX,# N8];?A9GX]U&P]Y<001 M[_9(>U@_8,L!VPZN_ H?
7O3#E'5MG$)(TRNTVIOBS419_1K(<(:8NS?0A<$V M0VD^EXVA)L%LIB,CQVX" Y.K1'9I1&0;ZI].G*]!^VI-4+MYK[^Z6B1)?8B<#3(PR"XU!5.:ON]GLUG[$KB:;L\;1;)7/467QY^ M2R7+=W#H6AUAJYR7F/?U&Q;95%$'6ZS-
OJ99\7>RC9THW^!D4T9VK7FA3EST MX3>66,4]*ASHO__K;6/U:LQ%RT_$]+]W#CG(?1_%R1^&@/!H2.::?9M@L%"$ MSM_]OZSFB_2ZO .&]I/](=W!BK-0;ZNF:Q__)\Y]L@B-MFP])-Q^+WZPNK04
M>N1GV^MSQ(=@KNZ*X1N?6$2LF*64<^^:F&OJWM?PT;J;5N66V:[K@U@^#)5I MHPJM,O!ENAWOQWRU?:IZY6E.'[P.3NSS!8OJC'R]DB[2 MKVUNSWH%4ON@6OCF-2?O35S.]HR_0(5S+XF]?\1L]
(MEC,1UVJ4W5IS#OBV4 MF?P^&CGIJ,Q@?T\0*O4M>754B+H+7A"]CZOW/:% M.F/N)RC:XP5]@6>1A56WR\+B"YHSEB!I/:B4G:CKM^Z^5!!XZ'";::_CC^7A$$&GY[ :,>^/7_C[^>G!1W% U6=]YY;8Q[4/ZM"-OQ&!R
IM]9(4P3:/U;]V$L\O;L MD<9MP0$2H$%2X]_[HG7K#W=PX/=U1Y\_:2D<&&#"M*-&MZ(,0M"_- MA9S[HNEQM<9>C8-QHP)4:GWF[3'=H7,"#G>WV+<[<"#ZQ3AW]\P<=%7ZS@HQ MR$^)&-8@,OQS8RRG\MO9-
Q+R.RJF=)8=(G8$+0/I\4EF(>*GOJ%O?/=YR5>" +^5)#K8(7=F [#,!+KC; M2W;?2O2X\3&TL=9?ST*.[86NS]B'?NLA!R*]Z]? M'.*23BIS"*EPDR#Z5O6I'W%/T09Z("SZX L'3F"/"#KE;1)<5:[5K2W"_#2] MQ
6PTKP6X0"L_[$MOQE?1Y-QQ@[7ZX$84I0#&M60MU MQG&DL$=786*C*!CWC5BK?!6[*#\S9H*;'N=A+.A)")$X,\Z.G?] #+D2%'5H';L[HQQM MJ/)YD;N'$U9IUY1CU(FF[WF'*9OO82@S3I>FSSOU[0RH?
W/>M?/_[Y3Q;\._]+OV_=$.PZ9]8UL_NW=,9^L#ZB M)3ZSWF.*.9*_V#]C%Q/M; ;XF)N7;'ERL420T>@ZGIP/*UNB)\<_BP&9+/8$3B:0G8FF'SX?A/SWV.R+L MF/GT]=U*O'F^)[_,,7WK72/Z)#ZA?
_[T>CH^_>W5?]]B_'FQ_G1Y,K4_HU\V M=U_NWK[\B":7'][\1-Z+^]NK0.6YL!=XB2P @X]+GO(O=._IY(#Q^>#X\/!H M\,O=AXE/UPL(SYY=0C\7D1^=GIX._-Z(-$?Y/.5N)/IDH+]G2.!8,O22"GI" MA4343M$[,F9($K\:!)TI4E)
(^CH@)1&I@S-T ML'<[8>0 ?0'[^,"#W1GR.T MBHEG2$Q]H6%'BEAPF2>$QBQ17VY66!22!ETI!D?R#$-]U*![H+H5SW'_\*1_ MJ&7IXB6F\H;QY36>(<\%+[YXR"4S M@IV>)1&?8ZEF]%@A&]
<+C&8ZHI3!@H!5&;:HMM6*P(R/&Z!)S9 SSES\ %Y8 MZ@.LR%(MJG]PQ6!CZ5G$N>@%'Q/R(HD.GA%*?.WA(CRR^FK)>@.%3U4QHB# MVPLL"7A1 %&Z7PNODS9X62]2FO[1X5>*7SRV8C0;K518 ^K#Y572IX7;2SW<
MMBHL-K.V2JP7CQ1Y#@&:#KVFZ!4L0QU"+5Q?[0_7;I6VPGDBF?UYP5P',HQW M7SPB-WF("VBTT'W=!MVDLK];@;IN_3;&]0J)Q8W+G@HVWVV7%HIOVJ"H=%B^ MD@X[+>Q&?(XH^] +%^ WG*)^
9V3#*GD&#:B,JA;3./2AC),:P5F^!H M1>K1:D%YFH4R%.[OIUOQUE:^%2GHT"Q%\P81[I>K1K,;0B$A(,B]I4)R/\<. M8:PCTL'OZ#"+GY(:E,H4A+%@*R&Y ZX4N'":0T"Z05,7PRYYCUUU2$&$&$,4W M-31:L!UE88N$6]%4?Q<-
Y5]^X ZU4M0^('EDE%_Z,+)+ M&]T2%99]$BVL7F:Q"F0&D$6K2/C[6BBW@ZP2,B+]TQIP@#A:15Z8;F/ *@(M MN%X5P15*]$%*R>R@]HCA%]Z@H>NP+]H,+H1C"'"%H@YTH@34 .%'40MTZ@D]CJD6]!
MFBN&:"33'9][9M5),+4H=; \SA5&ZC/L#LKFJ782O)(^+;AR!9%"[',$(+&OD-<3PW9!-L>!U-PA%X8UNI2:T&<*^!$XE7L MDU)@;37$^':H[I]P%*_HEKQ:B.=]0$V2F&Y=MUK7[X0D2Q5S5NN\(;?6
M+,@7G1+K/E:HD0MU>T&CF1!#^&^".>+V8A,/ZE (+,OV>FT^+?3SU:H$^@G, M8V4)Z -U'>S-#O9TBEMVH!=3:4&:KTTE#_)L&MRAMP-Z#RQ9G]##LIA'"]G\ MVSI5R$]6K6]T4#>_^AISLO8CFZ@&
7$/;'G>,DAD2]#69=,!_"17Q4H"OM5D M)519"5T=XCLBOGG@B ID-P.\D$L+[UP9K ;OC954U<'=HH)9G';54FG!6?\R M49='[?B"44G67$^G!6"#%Y Z)%ONNN&:&,(>MB:E050)E1:*E96M:$E&DKM- MM
UZ8N1)]05U=8W!D#KOGC&WB:A(<+3YM!#.5[+R" LKHT=:@W0CU\ MEE.S9DNHM!"MK$I%CY*Z-;L+>NFE%S;6K]R&W%IH5U:A(K2SRS=]]Y;Q'I\2 M%\=3S5BT(,]5]32>''<1UG[>(2X'69=!"^),.WIW>.RY[?%A#I0/D
MRWP9*OM>\O\]>.H_=9_3/9Y9_CU09^KRH8N>(.HFKE[8MN!X=M$#/%?]Z%]@ M7\'M@^>E&Y$H#17W0/G89T8H$U]S&7FU"Z?XM6D\!_0,DW329"DB7Z MHQT:VPL'[8"(Z ,0U!V$;=6VF 5YY:53(+RFT
_WU,V&OXYF,V*KPC?LS6R# ML8KFKPG'MF1E9P+,17,YXY;(D(O95X]2C!>P@<80?V%/5[SKS512\01X"DRJG'R0/' M",)/V-/3/A3VF&#RU4:RM=K +PESV9S8XI;::=NK24QPXI$2_[):N1G-[@BE M6,!!F
&@DL0$)QZ>V,.">0)RSH;QZ ]"B M-=&ML0N!B"(9SN&_T.1]]ZI93'0RK$@O$/>#EMVA;2K*A$$90\+M40<[A2"7 M]]H@>G*4-4YC/6(C'6NX'#5X3' 3)M=-@9%$4[F-M M5UAC828,3&[N-1V,7028,
IT\!VC>G>C,4$)R\9XLYH%E,_(,_X54-CK!L:7ACE1/%^8>0F,%I2,O54/0F: MR5]%%#13_*NB,,&%>T3G>$1QVNQ(UID;&I=A/,S=7R8+N:V$1MLS-B MWV.!U5=I2VIH;9F-=-S?3R8K==T_'.A-/=?E-LQU6#T28SI&$]NO$-GJ-P_J
M7=;C,LU5M?:4V0 5\^:+'(3E[FIS&N9RE FRNLEKV+F?,S!_3E63&.E$P:%0 M0V.8&\/$-M]PQVC :H+3V>]47GE<_>Q2)HLJZ*XU/GA32D9=T^!'V"YZ-IP: M1$8N!9U+1K%$?+./E%;EI[=">-BY]KBZCL>WR;\P0S4K(T:SQ+OS
%B4*]XP MKG[I)DY]]R*J VGBX.GO]-L$;N.CKX4D^=(X4R'Z1U^%PK:LT__1.NMIE;L][/M M[#2".X@U8]I=(H$=]R5&+V8/3V6TK9<'(($CFRXW!3 MAQ*%GR)W?G?W!57][< M15*;VA!8LS//ORFT?
H+FR0SQ)S'^]UB]WXS]SY,56%WB6S,60_PLO:>NZ/+] MG,NMN8WS?GLA2?%])'7^-^8W9 3N\0IMPM_W32*6F,SQTQ8M4F.S@7?/ZLOF M'A$+U1XC%GE7WFVL1WZ4G8L[A\KNN4]ZN=F2C
/LAD\0@7Z$Z#1WC<:XRAC&7-B;Y/J;ZE1O^Z772! %&1C1HSQ>S6/(-_[-N.KIVV'W<>L MP86\8X9!=_">XKOG%0GL%M]HN-OJ_VX B!S[5O-;5]_W,L#!]8*)GYQ*!!7[
M&]8:+4VWXGW7I_8V;907WW:B:FC\7@ZZW"3Z]M'%#B9\MRC\#E._O0D&HQ!^ M&\*3"\;);AYI ZH5&E/X+9Z@58T&-)6\LPXUL:-JQAE,@:7* M_[??H2@G,/5Y_CW,(%=N;C->PYA#%TS/./!PDR]1B/:AI3'T),$-A:ZE1IK[$9.Q
+X9L=^9!J,1H&5=.D'DX-_K;- M5-.OO.72O]]JC?.#7]9I]C/A+@19IGK-2SUV&]'L%I7K_.,XX[_;YK\->N/? M8%CF5X[NC^/B<";A%";/YM ME+WWV,9DG4RMZ\E,#6=NJ:TN1L*W]!ZKAY@V!-W!ED'V19MG.Q$W?'\275C#?
VV/&V M;QF(A"PT%*$%2-G:7U^ (B5")$& $@GLM'F(+1GGX'SG \J!C<2G7UYG 5@@ MRC )SWO#@\,>0*%'?!P^G_>>'OL7CY>C40^P"(8^#$B(SGLAZ?WRC[_^!?!_MG_[6[X,;C +_#%P1KS\*)^0C^ IGZ Q\02&B,"+T(_@-
!K'XAMS@ %%P26;S M $6(_V%5\1EX>W!T,@;]OH;>WU#H$_KT,%KKG4;1G)T-!B\O+PMA^F\E_BG X8\S\=\8,@2XOT)V]LKP>4_4FU;[/WA3-8!^'PF\>ZF520DN9W/#T]'20_#4K6BCY.]9!5L?Q M(#-
GK9G_%2O*YRQA^(PEYMT2#T8)[;75@,H2XE,_*]877_6'1_WCX<$K\WN9 M\Q,/4A*@!S0!XB=G;UWK>\;3(LFE8/#)I7_1D&PE./4X0B5F=">%V3+F"%(71 M%$78@X&17:62>S-2=!\TXQ6PN\G=7'1YWJ9]':>6:MDX(U<:J&C%
[,>(>#^F M)/!YK+S^/<;1TL3B:NE6C+V$;'H3D!S/MCC[#$/^14'81^E\(3VN7 MA'<,RC_"8,EPK:$&*O;GT7@V@W3)VC+^!F":I]&YR@T,>A3 ,1CS]T#BAN\YJ3?&]F9MZA'?H)1P'B%/\@ +> M-
GW>P^N[FI[TWHS]%Z24LWB+X1@'&I&@JOP>^[YY<&H](/'QY8R$246I Q@G MYFZNE9BTA/=J*HZ2ELUKX7%%=$T^ -?HWAJB>PQ(8X9^CWE=UPN=3EQ5ON,( MN=]
(V5K$U*O^FP@P>X(BZ^H]].LA,%+241K0L]Q$1VLI0<]4M50WD5C/4@,5 M70X;KU $<<"^"I,BO$![&$96]=Q?G.'3?C\.>,>ZX-&@[^,@%O4\(B^F..)A M(;6@-L88ZNDX4)I2LYO6%MBY9A&>B;BA#H7&;#73VP+ =?
W_Q'P'^3;WIKN9@9CVZT;*NE@K:@+$4%5K:TGFPW4]>97!'@R\.$@F8[?\LR2!7B,4 M^LC/] BC#38K(QR)\ND6\A#TQ7YS,J[FOZ8EVS2F?$=2,N][6[+>?TFLXE6$ M#/GB-\;G.[X8N(%4$TA5I39G5@?$DRP-
Q&XRV=JSS7;FDSWC"63C9.,X9OUG M".<#0>L !1'+ODF(3DA.O_B^&KQ?QE3LMF6Z SA&05+C]]3<5K&!%5O%-I;H M3?R'2/H+&"3]*[KD+7/)^UBZH!PCE@X[SWC"KA\^%I#93 MW,%/2PR8F
8+-7W,6T8F/Z%DIG)UZE;2!$]>$FY%#[P@_#R-$NOM4/B ^"08 M>[SU"]MKFUU%<3V*CJQ2I$3]$B6/4T*C;XC.1N&"VRQM A89*2^M1\BQ54)4 M.%WBXYZB.<1\,#T7*4,,?Z(IHIQ6DM8CZT3JVP9>,$E\E8&UN515Y),A>^=
M]W)Z2BA\OD60H0=AS=WDB3<387BU\VO$W,@]%9QH07:)H]RB7FW4*BMKJ?_* MBZSUX^**\K;[=[7WM_NZ$K!+#8I;2F/DF[0KA8CMSFY"D![V2QS)46]]HEQ+ M5)V<[?&E-EMZ#M@C9<7EFR_?/M]_WU[3KV9
%*\L;7ND6.]WI?GN=9#JPWDE M4ZV2LM.F)!/$?>HG)M4LLY06MIT/%8AI.W4I\U% M%4B7B+CP?2P@P^">3U='X260 MACPI,SZ8BF=Q8P*Q[B*$*YJ?!-LI;_KFKW<#R9]:DK<'C)EN#X(VD^>=V-SAK
MGAR4X)SHP=FH!&0"-DK!FZ<0QCR=(/]G._N?ZPG;*.0.0+>$*59O2PM;VTA# MXA@F[U17:($",A?N39?+E1M]*C';05'!1G%[K1Y_2:SHVYOZH8"K>UX]M1]P MNR_\&0XQBU:G*FJITY6W'?'U.33SB%-D?B4AD7'6\J<0L8-A%$:
((A:MC$GV MUZJM+RUL.US4LK#5X!2(71KV9F:F8/(HZPD]%;(=$YH2I?" 4^%@_73$A?^? M>'6V8'-(MIJS&C';*P*FK&EYP2G>OO!),1,9"K&\]/I5 (TQFZXLOT)CQ?* MAJCMU0%3_K2]X5*P_!72'R@2>Y>;Q^.>0HI@@/]
OH"D'M/KRNN1^=89,LW\ MXA*C7U&D,QG;*F9]+%)F==7N8$E))U=O=$#5-TRW5FQ,7C>5_AW/"/H)5'=(Z3V=8BZ\]DB"^;P)1Z 2)4OMK5[QW"G/N M*5E@[]3/RR=N_"A<1YGTV.;<&S5*HZBVCO^G
Z/(:D"5*]F0^$TA]/K['%'E@]M3V1;8-C$E2Z-KFTN5;0XU=TUW#9= MN_B?7KIH<;:[*Y^[K&786X]2GO*_F!$:I6\X]MUM,->D1_D[=REOZCR7>K5H MFHE]0A^[R[!NLYQ]DOS03P5[?$*K7Z.0OG1-M6.3IVD'],?W&54USF. M,
[IZ-K'PB> F<\N="C-I#E0K-I8[#/Q7] M:G^Y1'8%^M53YKNMPI7]L/0("%PF:Z WA'(K/81\=L/;@=8[ W1D'5VO4["X M_>"(MH.<2F85N-.7.^[4>DMUV'] *<<(8[$X6WM"V'RTLZ:H^0ZLHZV7@6+ MA<>>=!WD4NA-WJPBOP-
'?NU*\H;H_!>YDO>(8N(74X\7Q.(E:M>OWA2&S^@! M1NAZ,D&>8D&E:SML-S<[?B]ND)B..IS<8W?9F:KTMX,SVUOI=]F9JFCLUA$) MDRMYI"WU#^)M?)AY 6$Q1?Q#7A. H0\272!5!C;:6CT38'9/CX3H=!M1JBPY
M[K!1!S;ZP$9AFZ!TK_')HQD>;J,16E;W\@E :T5 TM0F#,W[?204PVT4F1*0 M:DE:6]H'I(K.!%%Y"Y!D]M&VV:D8*)G+MW,T1NOHS_"XT.3SQWI^^G T?)^= MZVG[M9\Z-P5)MI]LV[[2L8*0.9PE[6.MIVT(=7<(20#>E@%
(-21F;^EH-VY6 M7#(D6?RN&"$S,9#)V8_NRB@_?-\|RH,WV6]MGVQKCB3A+ P0,G4B2$@*P4;C&J03 M(5Z/T,) PB38V^.TX15*$O3BB"3"\;H"C031&>_-KUF2@!>',3G@.;AKY3G4 M*_7=(ZZYE4G"5QS
Y#OO=FJT#45]0Y,$K+C*H (6D>V4WS52T[N;\F"/"X.: M/-B-9I!3#7*Z74"KO-=) EL8^]2 78*\ZJZP:E\!)6&K7]"PD$GT;X:2L!@L M>MA,CS5W1TF0E$.=C*I,4_>]RO@.*0E<<7A3!,= 3G[U5'M5)<="RO1^ZM-TG #UKP( %0
&=T8G M,C R-# Y,S!?9&5F+GAM;.U=67/C.))^ MWXC]#UI/Q$3/@]MEU^GJZ9V0KQK'5ED.6]6]^Z2@1,C6_/H%0$HB M128."B1 M>:AIVP#R"L;8]8+G M7X^^/Q[W'R]O;X]Z4>P$KN/C /UZ%."C?_SW?_Y'C_SO[_]U?-
R[\9#O?NY= MX?'Q;3#!O_3NG!GZW/N" A0Z,0Y_Z?WF^ G]#;[Q?!3V+O%L[J,8D3^D'_[< M>__SV;NGWO&Q!-W?4.#B\/O#[9KN-([GT>>3DY>7EY\#O'!>WV3_2[O_W?>"/S[3_SPY$>H1?071Y]?(^_6(?C?[[,O;GW'X
M?'+VYLWIR?]^^_HXGJ*9<^P%5&]C=+3]1:E4]3LJ/S\_87]=-2VU?T*_=4W MWIZLV%E3)G]UXW6'?./W)^D?\TTJ#ND M-3NFOSH^/3M^>_KS:^0>K7!BR@ZQCQ[0I$?_GP"]_NIS_.3A^=0)9PZ%]X3^
M_>02D^%+F&4]IR&:_'I$VLW)!\[>O3E_^X:2_TNA4;R704'O5.ZG_Z MPO&HAZG",61B(7*QLVP\Q&1BA.1'QU]&GI!1!1+Z-)K,9DZX).AY MSX$W(4,LB/OC,4Z"F'S]'OO>V$-B%2M1T<;\C>.%;-<=3&Z\@*Q"GN/?DNTG
M3!C<(]XENVMC-],(F=!+Y\E'!.('Y).QZ9(9+IY]\^3Y M$BL!U%[CW%=?G!I?D(@I.L,!^U"F@(@ ,YA+;4Q2G;6RZL5L9).OD'6%3DUB MJTM,;XFN&A>DIPC]2,BWKAE;&S%E/O\D"XPFD0ITFIKZ9>3 M0(E(2]N
'.@V(.#Z^__TR'DZ'$^7:S;Z481B]8&H2K&).55<_=7G$K=_M\PP/<7ZWVI5]+K4&A+E"H;=@$W.UIY$Y2Z!/9NE.H2R/(L%61%H.R?X7.6-= M$O'H-6:@]"[/LOT;/-,J[RC2%!H8-IF^^@35A5=C(O/[-\=P-$AB%I$BFRZQ MD*Y?
43CVHEI+]2K%!H3*#-3:*/#[-\=P4679+W?!HA[==DX@JO.Z%K$V?$5U M!%$DU9@O2=UJQKG&0 BGZL + UYOF=\30F)<)P\(7(@(I]E M(?"C7O:AO%+65+P@/B%-3[(V)Y4$FN=[_;%C%\|<3Y'I X[X]:ZL^K8Y)-'$2/ZX]*%?
=BSR37WN!1Y?M MK^3' M_H-4:!B]P5YY2@0JY"[,6T?99LC\5*/]ME9RR MDLC'XX(8/LV.P6%Y $>KD3=QHBF; M#2\^)D/OUZ,X3"I$;AF@2]^)5ED?_5=/9G25NVB%K=*]$<%4U#X $21K!5]F M<,FS>)791Q
@56VU(E$VU40P@!K&0LXA*,[>=!.+T6D%X[K@6!DINZYNM?%B MTD&0O34&V2,*R8GT\IY00V&(7,;QM\QV!QBR:,P]"A^)L<3ZC]Z; 4[.;E 0 \+0V"PK\LX8 MC?I)/,6A]^^-&2^";KM?QR"K9-\Z>Z**Y]LH2E1A2OMT$](W
M&D:YCIT$:IM_T+PP9A!NO/G]^Y9$9^M1DY4!0NZ=!<3EU"2FFC>F\- M0])="NC0/60D]]G4/']EMZ6/.Y7VR)1;YZ!_-N<,%5^,*KO!W MGO0V1'L_?0^";'P/@=K([["B AKT7G=H!;D1M:T,U,=$!&\U)8V1L]: (NFP,(FB&U M-
IK@$W+/:0D3OQ^X?7=&M!_%:=[8]>N<&A:1.+Z@0&9DQCR6FW';L0=%N=I9 M9:,PSH%+?MH 2WX8#:FU.)C<$H-^X;D)8;QZQR-M@::6[G,PP^VX/57U_KL7 M3]F5#VIV3[WY$%\',"\808<+"2TT?CNYZ%,%]Y$S8'=3.[
M83DO^LOPXGXTF$R\,;UU,IO[>(D03>^^\D(T)@3@G8UVE>C9]F:VP[3"RH)9 M%TS]^XPN IB2$36#;KR.(5/"AZO M#W4\7GGB?W7F./JEEWZCX.$[.+P.#]]]<7BMV4['.5T3<, N-,FEO59WL_0P
M(,>|=6ZO+39%_A.@N>$D6*ZNL8P ]CFX= !CI1FO&SQ+75EJ&;&5Z:1FS#[^ M#.$E%;7M=ZH75A=!46K:P"S2#D0UTR ,QG#HNRY3FN/?.YY[&UPZV ^1>.V'@!<]"KWMU^U'5$FP9.AS.P8W%&"SP M(;7*E-YN._I@N3,!8-
FZ'44A.ZNU!Y,N % M80WN_YQ3"'*)!9K))+("9,E8/R34I;'/:\Y=,W='%]#356AYXH#8&O-A\<;G M'7IA?ZDY6=?=NXIDA10@@,9]%'!'87T$M_IW%<(],4 ,VW%SP5XYLEID]:[)
M[VEL.Z&YA"OWC2[G)O\K]@+=E+#@<*CK"]/E]=0Y'.I^I9/#82=AP>%@S*\F M%_.^/=?*_*(]I:20>5AW$+ GZB M1;&]B"81)R$B/^0I]9S [3%:O8Q8;T.MR0(5:H_E%@0ZWQ8H(\82\S?D>AMZ MO0W!!F62?
```

```
4HW+\SIFVUA*)4>(T/E61/]%2@U*(7D$[L%(4ZWA5@1Z654V##+ MZ/0R0@W* +[#6^#Z;)OKK%LOUZ_1&BU2%U1.WY:&>_[RR5\^G9U^7-T^;.CN MOLQ+O076WVVSGM)()5BI.V*#8TVG80E$3_@6^'|?Q7|&@7&]1;/!1-
XXK? M\(?RTKC[UEOU,[Z]3ZM_-5Q=]"|3&>E75]\P,4CDN!AX8(0I5VZM-]M>#:4AHG#>(C" MV15ZDK]^"+0WY#MU44;[6,@_"),=@-PY,R2Z1P?W,'/'D--F'AYE46VZVZ@/%IMO..X,7;ME
M288O>#C%242,DN$+86,Y),W1ZKS%K4LBT]74)3KAM, UY-">(2"+23TXMB0P M=%UN)R0]1 "7-6.[S?H E+YG3\X*N7?)OR&'FM#N('A XR0,TU=V[W 0KGZ\ M<"(OHOV9EW6(QM/ (\?P]. T)"O/6'[#WB-
.;7SHW>&XA$]QF1[FH &H;D< M,,Y,\D3X?KS6C>RP]DNQ$R-E)^$DS-V68UAY[*G/]%_8P^?%?D2N %X/6QQ@<@!U/UXW<<;5CO":@4@>\0X'0QYA>0 M0$(".DN= Y6\2CX[6=W)C(M K',)C.QU%NB&R6:7@48H6W4>2)U+
[7 (R(Q^ MS&5:^^E?9QBAE"!PA^.U"R.3-E*R^A5]FKW4LO2V$U*W8<_*&]US>2:G615 MEX-8]UD^)3N>B(YT+&>S)KEN +NSA-:9*?G8C.CF6G],#K"KD*[:+*]}NQNC M0]^XH(UD[1#9>1#P>T#XS0E[[SM!=+%<96;?
A]X8/3C!LY8AM/.W)VN(Z5$' M:-@9^GC'YO_8&&4[K64/>#V".G M:3^A'WVD;F3F%X(D<3G@H$>QN*:QD-->=TH?V4YKU-'?D)4=T-F M$!WK2ST8];D"NE=03A]E1GW1&GFEF9O"!Q3S,^V3;PDQDQ>N>!-8>[
MS4Y>^\:&I27T5\|!Y8Y'HAK48!=#Q?2E9R66%\.ZY3L[(8NP*30SE856$Y R M[^[J:MDN*KVN]&?T=DICUEQ*?O31)MBUG2KTZ48BIM#VO7BIFVMROIW2Y4B5 M.VP5[AU#+[M@2M"- M(*A-6@Y:VB4E^XFK66-@&-
ZK1R@9=7 M>9M+MT#KWYQ7;Y,;>'HO-&G]:75@L&(.>Y!FWYM+G'>B*5W?%H[/MOKXDIS( ME^2P+G@BFS$M(ZY]%J[%YW=>C#%RQ9T'MXR]1_=,VZ'3;J;MUK-ZL><4=#3UX4LD]FQ,0U@ZZ<Y6;H0@-
/]N-MKFXO;P-61T$4-ZQLWCV40"D@?'+ERMN.V*V]$M=1[,UH?4%^;49NHG*Y/F@N-M47G] 8F*C::3EW,ZF%PX/]U-_SA%*'[PHC^BC82WP003=698B-)Z.Q$U'>GC M,B\=[9.A8DW$3\,@-$.!\N]T/AQ8L4CP
X%@!PM\LP]X8#FAK-L-#LEY*YH0 M(YWL:>F#5\3@-^KP$C:BZC^)PE-ZOV(FW"C"0%#Z-&RN=Y<;'E]7A MTRK?FRB."OTTEHN$7U&A*"UTL< MQ:R6'B>15)'2Z-S,&-!O-M:2W+IXPA;76S((;>G0GP1UO:5H[$_Z"O*W+$5
MX$N(H^A[$&9B?"4_U5T"*DCMSRBH)[IU$13^8-Y(0(5BFKQFG)4?U/(QXXMODA6P6-)LAA]!M=0%^ T'/G-*M"?]-4T2N$+W7W5[0ZX_A>F$):6P:L7\_C@,V>:PWP_1"#!?4R]^F_;*8$H M$%SO-&>)KMG@:9^V+#
<J*RCG\0WK^9'!>?,$+% 94P$L? MO=ZK,F&4B8W.WG0%UUV%A"T2\VY2S+GHRO:(%(03Z$9/^]/2VH*=_B;^:: MVTP)+!A7%D$4\U8D8R@90@TD &$51=ET[#''!M,V'D?9&@Z5GE36[M\$\B2,F M\EH:^=T,O7&1;V9">)B
6>8\QOV3F.S^J@=V:V1%E3Z.7% A=C]![6P>] MMV:K+S2%7EXL<.4TC]X=BIE!N;[)D%>]<_HS'1EE$Q':Z^HO!H[@0+RCYC>#MJP7@*T*F]^]KOI M^QYE-G/)"O(7/]3(6!,E58*6\SRLM.]LCW ^()]>V;IWPGC)DEN=,?/37"SS
M?^'[-U1H6' %1-4^7%M0ZWS]>19%O]BJMF:\$C54#F-FK_MA-W!L=B0T &^K MSUE>+F.\H$E]%Q[V\;,WCFZ#,3>*)@QJ05Q=A$\ICW61[0'-GR;(!A-YW'B]NHB;4!Z)\]R.
M30GB(U=M%=B<)'IV"A@5F4"3P0)GRQ4*O05[]R^7D]./HF3&WD?EUA-X^X;G M;JE0[N5(]W*T33M<=.0ET?]L/L80C:>![R-!;=47X'^YNR4'*N1]H0H!_%5K MG$AM#=
<&:A6(.+7>795+.V79H^(B!G"/3E].$B*));5@G:59Q:K()<+K8\9O M)52X&!]]O55Z(+9>Z4-1DOO!&TSS-YHN^],?RZ&R#]=D]#KBZ)B<2'K$H. MZ]=(6IGM)D3HEHSN$$7Q SD#]0((TS"5<[0SE@*1P(75&ES9./P-
DR,MNT*A M"FEE=U,U+'9&$Y8& K)V&0OM0%Z_SM$X1BZM@]R*8KGOZ$-'(01$@?#8!U^_M5]I"1$[C#%\+&%EO\GOH]#; 3$%4R@*?NMJ]O8&-!
M!0*HP^C4D"FGIGT^^Z#BS_5N\X+G[ME3\H")MGH_D]DE15%EHAEMX00.%-6 M#!L]+ERI+US-6DL&E$9U6FD6R:N\37>X0.O?B,IF">R5(6T*35IWO@"#%7/8 M QT]K2X/WYQ7H6;S35I/!)KML0>I-
F/QMZ%7^W@9&]Y\)ZG:&N&VB4&#N/\T2@SMAZ-X/V/ R&*GU8%S'<:,O]5Y+6/QY, M5K+(I'15=/NS02^A# G/@44IHH4+.=P,TU/%#--E+T\ZEV"Z48-^43,HUCQD M'[VCQZ;
<58MVMBU:1B8GRXK[WI]4H4S9Q]B)V5Y3&]H5=W0KVAJZ=+SB1'2K M>*N=-1F?L-]W[PA72FI]5N6:]>L?BD:RPA@7ZA+!S!6>G-T@V=!L"N]$;1#R*N*@*'%W'^" M"*>>D"2Z%SY#P4A#M>EW!*5""!
/]8#H"X(9RC!44#Z7=4CEFM,)NQ_^XAM: M<@&K]D.*AX#5(6#5Z8"5:EC%[]X#^_DV.]OTE]X316O?WB!DGMZ]A/([F&Q> M>;MT?!^Y%^L])&O(.3+O2-A4XK>T T2'?-8%3]B5H LG0BZU+E"/HO3NCF_=2KR_:KE.G-10::
,UQLC3_<>M'55LZL,[IPPLV MU0O968^UD'GK-@M68.26###D7B4TOG2/0@^[;$1&=^B%_8GK117[;SUP"F* M=I2Y*!EE?HI]PD:4'B/E@D=O2W&Q"&__N73V>G'7WH107NB2/WQ.)DEK$Y. M6C::+*HAFE)C>H%N
Z(4]!5',O53U"D9*Q4GPZ<@/J5&Q9KH55VXRZ7FE'5H M?>2+WG@;3"6!#.B30WYH"IA0F6$S_G.(&#_^,T[MT&?RGXPQ)5PX%#]5-"(C M"X12[2P2I6F3NEW]Z^PB?;-*B?+H?<=0K2LCA/9[S6C?
DS\FU+I"331=V6I7U$2^6VXG,ZYUL"=.#Y\X0QHVLE="!8' M]-H:1>5W+YZREPUIHL'4FP_Q=1!']G*>B]P04$6G_NAL? PY6R MX9V$!/=#AH\!C$5)Z]_0UG#:$ZCA
M2H.^0DH+CV0UL:!R*].&EZ4I3H\HI/=S:0@6A2%RI9*=.)U&IX9>$^?,$*S& M/+@U?=3L\4TY^9\B)WQS@M?%V%L$8M7+L0X]7G=DN9(5=;VO.^$@
M9/NGRZ[FWZ.0"2&%)-1YCQ@EBPBNB.:0+2XD\M.3WZ_K>,I(!RZT=D"I/D_E M^N\7M/5FJ[%8YGV(QPBYT0U1#BW(X 1C-)C+[$$0=:?K^N0RHCG7V^K&T[+RVOHF#SIAVZ M#AY7+ BU#U8E(MA0/*[KHT"'^-
!H^6C5:+E^1>'8BQ![\G[SQLA*E%/%,2(B MMY)RP(O"7N M+[D#%]RGZY"*) /Q,^C;*G,L52]7T'$?D2R)!)IS(_54EG=CH.K(B6(L3$' M5W%H?N)@@<+8>_+19KWAEV25)-!UE)7$!&'.><2,/4*ZNL WCKW%ILKRFNE"
M<>5WO$='5Z]TKBBU],9H29+\4MH/W,SK0-'@RO9>0K:HEZ/=(__7RU'/R6N/ MWZHTCB4=5%1-%XBNY$10#IK7QYKBSW(PR?C3NE78>4^NVDH@L?/%6KNN0Q\N MUE:C9#R+^W"Q5@W*5]\F2=VGM>+94L5+M,T_4-
K0\U#;.5_?B9T9,O-]P-XA MNO>=(+I8%]}4#YPG'_A$=T?Z[VU]"N+4K$VT"*LHRBE;]1CQFZ1=7@Z- V M#D4(V;3U=WT@VFQJ='JPMFKPGA(#%^P M&(EU(U-US]N$HB@LB$4C8-
!J=1)P;)]9*K3=*B!;XD*0O&L"$EHG6HS(I6Q MEQU;!&1+6@B/#XW@X2TD9LBFE:GZV*WB4906PN-3$W@\>]]B.-:-C)5A;A.. M+6EA'WLC>*%"B00V30S5I"Y54RVY051]:VQVW4^^XI?4)C^RYMYG)M"37[5
M=+T(M4!9\Y] !IUE+@&\M]CO<)"*GY;\O0VB.$S8LWJY*=ZG4-UZ.G]^CX, MP28TTA"NX3H98EI;LYPZF0:R6O@=T110&Y @4+G&3T@BB2]-AC$H3..$\O-Z2N; 9 4:@08XZ,FBMT!+HE+5KE:YI M(WV?SPW8]%M?
["T6N>P3_/F+=$U[K306Q:L14CHOI7)&YH[T\STEO2I43B2,M1TES9]U49 M@$U(,0OPW=$_Q-YBX\8M!!0_;0<44YH]1G139RD?1ER%@GMKTE8%$27 KQTP M5*-M9W P)T,$";%C'%#A$Y:'_,H,)L7PGC(>UD?
R4I;)!_@QN*UFUD;/U '" M/#GM/#K4DGHC6>#2#?S.F=4,+>SZ-3-!KFID%2V4';1K?WR]2Z(Y@B5]9'6 M:G!L N\IR2Z#<&;&;6)64E:X_G2X0P-8[G#XT33;L3DX!YC[R8C?U"[#>+0 M(J-
]S*KGMW+.+G[2LAO7.FS49E6U=U[[+^Q4?!NDM<2;&X+%[QS&G8Q^[+2O M2]8LI!/@)!P*C_D>>4\?V: F3T=MB:4:)TS??-F533$?==E@#K^O>.YM\&E M,_=BQP<Y,4H>P$GG%6%2?A.N^R M ?
EQ%$3OF3X8_LW'AM3$IAP9)<]4#-EMM*]J.SA2[*AD$[7.WI:#:]36C8 M&WO*R)*D!/LS5 Z3H4G%0O/"V&OH6O,E5]]]EY>,EBY[P SLZ;AN2W'0N/UH M-/O$2T\0_<"ELXU.,A2,/229>W)>E7N24609)P6:]N2=T ?
I"JR5!DIYDO'Z MF%EW2AP)DCZ@]M9D<(AAV9]_? V82;.(PC@"OEI QSY(9?*Q(U^(AA3?*UXTP6@Z0' ;)22=1GY83)G0! M@4%;"E#HG7HK,Q2:!O>5M,2+I;=^@E9]I M6@(^IR,ZRJ#X@I(^SOA/%R2,SZB)SZ].5\L>-NES]H\Q
M$8X.P[_T(U2/W'V)VZD;&Y&$W!;%A@%N1>N3R;]$5]B)-UYO M$\\A8MQRCWVU:!D+X>>=F%B+P' \4'-LA*/K'C:XYP(AD/D[HBP%+'1[:&: M=$U K" QB+'NNG0Y A^]UQBAX)X8@]04],;4GE/&5H+(Z-10*1B]F$I+"F+Y
M]3DL^[EE93=92F-WAHZP^A%54U<<*LUY]5C]6)7A'.):A>;9MTXU%3*9E%. M\9H_D;NGU-!@P8B2/@&=V^MS]ZMVFP\)-: Q9?RSAY?I5DCL&YP\3TMVC[3M M($$H='IN:*=DT_J^
M\1;\]MR<'J.S]FEL]<:WV095_K9IE>=>AI?5>?XQ^3-31] :2B_Q#6K]G5XW MO"#@\('S!A+Y>^J/EENB168A[>]]O2.C6W!XKQ@VY/:NU!>N9]TERU*C.]VT M(.55WF:T5:#U;]ZK-TMF/+T7FHS.VBZI!8Q6S.,/'-
&GK:Z^WXA21,K--QF=_MM>VA$RNWS!^HW$_&(LS5N>:#EP"%T=2;WY/-B/SL/'/N-4F3&+TU]**P\L4F M19$@7(WY%^Y#/$;(C6Z()@K)@.B)\Z(YKU=WL!-+ 1Y=S27KS--;L]%@(@\7 MKU=WX!)+ :Z:IN#*58U/[RK?
1E&".%7L@ [= 8DK &B.&?.NCL] MH8#]Z>7G[(@5Q/T9W=V!. #8O@..E^ ?TOJY.=:L_BK\1+<0HH%?G>#9_H6$' MX. Q#AZ9=3^/C9>.'R]Q$.)ZGMCCN!5-Z!E/NN@GLWY]E)>Q5MVH5T'@.#P
M#:*@.>Y+T)_@<$:GV3>;[#@QIBE\]3<$6N\Y73]@=#D10/W7=2E 3UP]Y/.R MFJ]NW!&=\Y@'M5W71P!HFY449HP &MXTZ(A6MQD&-5GW+,X;MP\T<:+R^98U MX%F3CFBSS#*HS[KG6:CH0S*;)3ZKB"@1/D&7K;=_A\Y
M'@\"@857;-L157-X!U6M^2A99H$E7[4SIM<35&AUHO=.@M E1@@%G4/F-J8 M"]8K0CX2ZHFG"OURQZ7=OMHM- M;\CT4CKV%)C>DK"$8D4\$>QA*$Q:Y$?TGGAE:VL*2XO@V-Z"\P0[&\LJY^N=#M;3WD>XRI\
(WDN$N%FX_BK0MO,;>&Y$ZX;$ROUTOA)96 M'=OB5U0BI])YVP6>I6<+%Y]VBSL+\N>'U'0;3&X#UUMX;N+X\$TFH*G5NP_ M-KBR&=7^]UX\9E0D8
MK=R[FH/:HOM<@\F$G.=#WI6C0A,##Q'4G4<8E]"=]5+%A.CFR_*&"@NHG]SU M"PT-(',V]$C&2$E(WDNA.XPN?4SLR]#3K!'I'!!V/.(I&+/F&>S2>+9$6_NS MB;/__(:B>'WU1?
3BMJ:O=&G4Z109M+WM6B;+$CX!VP25D=V-84+>.%[(+D\I M/]R^^O>[-*2:$A\;TN]V_&P<[-L]_0_]-/D- ;/4$L#!!0 (/":;EE2*8OA M.U0 *$'!0 5 9W1B<"TR,#(T,#DS,%]L86(N>&UL[7W]<^0VDDN;O%W"_M
\Z[L6%'2':W>AYKS\Q>E%Y>Q:A5M2B]UY^8<&PZ*1[EQNQGNZ3/!+X.0 I*)/_OUW6"7G!>Q%GZEZ_>?_ON*X33,(OB M].DO7WU:GLZ6%?S/W_^-LU>@L]9 FOQ M,9BMS0I__D#_\Q@4&)'Z2HL?7HOX+U_1]]:? M_?
SAVRQ_^N[LW;OWW_V?C[?+!FO@[,XI?46X].+5]*2-_]]]]__QW[M!?E M)%\]Z3YQH?O&CAMR>376"'?05+$/Q0,WFT6!B5K=NUGD%2"_NVT$3NE_W3Z
M_NSTP_MO7XOH]Z;R60WF68+O\0HQ,W\HWS:$2D5,F?!5_6_/.5Z)P21Y_AW5 M_R[%3T&)(_[AJ^F'WO^!?NB?ZG^^#1YQ\A6BDH0?4KN^[Y55*WWG&N"YW$6 M7:7C4_^U/<$G?2L#)1X+N:SF'2X7$UOM-S7]-DG,?
C:KJC M>1#8)0_9NGK%]9K0?[PE?^I!Q*\EFE9V&OW(2. MYEG.VTYG1E;F*B@>6<';XO0I"#;D V>_^PXG9=*\RRG]%U8)]3_\0N=&O,9I M>9$$13%?+;8V@Y'7668@_$ORV)9?53*!(#&D)Y;C(MOF(;9]XZXUIK5:(UPG
M1(,Z;#@[,3\ZM^8&,I6B FBGZGH?_]YNUW1?KA$1GQ<7"Q:3C/<<3 ?<3K M1YS+]%91..63'G]/47Q),S28ARRJM) M%ZC5:?A5]P6EV U9N:QQVUL:!U"L&IP4N- .<51ENA[P1YO4'08L"P)!V#&I^H&1EG-1; M(
D*T@CURT%-00<>/(N\['"9_&W'8_*77O[B,L'SU4T:Q2]QM"4&\T.E0LX% M'[4P*>>D0MYYI4,VY Z39819$5,![Z)QKNG\K$:Q-Y[_^$=(\"#^>+7^:K M51R2=8563AE;Q@7A/^7<8Y#4H!X[#)7"6SOS7_VVC2OA)NX#!
(E?S0Z+KEC!+_+(Z4"&$Z9H!SR:Z># MJ-IG*):#0!.[G$9Q"F.KH(),:M.]0:#3-@EOJ2 N\022X)AE!+>D$J-,&JD M-_;[T[PDV+%G@==WYSM:+GX#2K^8'ZTN0B/:L(R+,@'/)$1!4VK[8O#^ZR M:AKZ8_:K[=KX:@@^
U5@PMA-8W>^Q%$PXL0#1N_EH$S,\S2,H[B9$LW&\K9F!:X'SY'.3X_$U<&&()*M O.O6' M#EJU0_]<]_SWGW9==0PN]2VRI M,!A:ZA!R4SPEX^FY4!?:A&\L>F]EN?4,;!_/D%$&?!F@;\%%%VII-9 QB6= MA/"Z%.H)@*&-
"-60*K4,"'IB!?449]\8)N [1D0/MQ64,L-210AM29B>(]"24 M0>ACEN*WCT'^*RZOMVFD'H!DPBX9HP;<98U8$@QSE/"X71$]C"IIQ,3A##;7 M09RS6U[G;^T?_SW&..G7Y]=;_()%'4^VRDZ]2N#>LZ3D288"EK!Y5PKHE"=
M[D.M#@N$N9O]!&5T:ZVZ23?,LF FO5<.<4H-+R240]'1SQ#L+U+CDC3]EFT\PG/R8O> \97=LLWR3 MY>Q4DH;:SYYP&A*PQN/,B)+<#D"C3>V/3-;%>*?]_M@%=-X5A;IE57>^ZM(.
M,8L#P<05Z^/>1!6@0A0W[^UOU%L2%B4X#;>$-;P_HQB*;:8/AL#9F/M561BU9Y(EN;U7ZG;=/$3DHGYX]W,7NB]WO,X2[*G."QNTE^ORO%G4W5!]#; M.5LAZYU!A@"Y/Q& [4]]+KVP7VX-&:9RL]W^>ICG*:D$LI XY-:
IFKPB"7-5XAU^HK0GXI-Y9LP&VBF>J47&IL>L31M=/61*4<1*?;U;,E>CZ)*W2'!5?A8!@ MJ:I":%2:DC=Z<.E)TV#&59IWL4I"VP4?1);HB*E;P66$I*H1KPL=%%!Z2
MUSPH"^-4G1ZC_[NS]!@B6&UZC.Z/W@DB0\3QH)*!/_9],AVXQ132'#NZ2)^O.ID"%)LL$EF7G%3"[=)/* B&:2IT M?'+"A&AG=8+OCDX5"];Y^[Q\QCD]GX,4]94.NA^\(!?S'!1X]D36+Q2'?!J8 M*NIL_U<#MMWEO,B48 M++)
*C@S^)W[B(@^W$42A-7O^43^H\L8Z_NC6(&1DF9IM"%23@]8"O6C46 M!UTV!/0S]+&]9AKA>V89UFLYR%Q5"5H1DRK,F>[PAJO&V>^A 1&/89AF M5-_2AP:U(ZY,TIVOIX2Z<_6$8C
HI<0F2G;/A'T,B98AL4:*7H8UFT!8 RU@ M$2+FB&%&$P0[P[N'TZ??]T6VLVZ=3AC&(C4 L)-^A';_]'_6HGE&M<NF2*4OFK;]"G+$>;Y\+99C]^[4[MBNI2*NG2E M5&"[OI1(SCLW#,
)O"ETW7.G#N];V\UN,"8SF[D+_%1E/S,!V(WH>'+"Q>84 MKKEMP;Y=]W$5H7/MJ4]%0>DI35&M"?K[$LZ7"MS@OD\GV*,P?U/R:+*/+@D& MP?>%;S+Q^V)U#S8!8>DA6*F]RW)@;]0NZX&Y+@QVV@.6/$[8.!;L#6<_3L=Y
M%N31?-6^]M].O@B2XMM4]K'5P^>:#IB=@@[-S*E5B;_^VG\95D%M$;PSWIG ;FFF$H:!*@.$W*L"3 7]%0U> MZO7#&$O"P.*+#5W LV4460-[%?V"P=LI0:/+0_37C9QP>:>29Y_)>*>YA3R0 M[VW KH!W]A0<>_049DI;Q-
+NOE\G<:/6Y]EC/C4\0L]IA*_I*>5 M<@=1H]?9#;H4 NZIT,9OB&M*@54*M!ET6 'LRKGIND#_S1!REQ6K_,GO6^V[9\ MSO+X'SCZE$8%]SX[SP:2&THSM^N7G$>QD5U ?I>\LCR0;_D[CVM@U55_R&NR3_C
MO>\MW[;MSX#:=HA]W+9$RDW;TNUW7>MV91RW+P]O MT,[[ 4AMS*&2M#*5<]+..*19T\Q>$;>MS(/K.._N+=T!MS(S2-S$5<]["Q,?6 MM7!'Q'$+'<&+=S^#]F%AZ D+=9&EW21^:R#3/PE>Z.]+.Q&&FZ??&V)3^@S-:-
>^DM,?*/S%3 M:;*PF(XN]I6=Y^F!W@9QG1#>A6'K5WZU!@C"_*7.-G&4'DZ99-2O--T;^B" MN-GW:*>,6A8[3-$A>K)@N/3CIH:Q<%!QOQ/@%WM:92S'S8GQ0R=9($<-,
MRP!'/$O@POVN>GD&>%&VW#X6^+_DNPG'5VN0/NX8F?_GE(GO! M^>RO*/,@+ (V[!L91(5)-?,E+L((9I>F5';TQ)PWN@ DU_8=&5@4X(?F="1 M]32PW^.GF$XM]9=29:V]!%5PYA$WO70KX0]G N$PB!(8X)0.EMTE5"KY8E'
MLS3=!LD]WF2YBCY],=>L$8$M1"_G11Z:CQE4:^23_&M=5R$05)AN2;-CR,U\BZ)H@4[I DG" HHLC02"?-W'.1F>.E( M^B$+!U5,E58,(%%&&V'0TH?)>J?'"QS?.>:OF,(Q=U=BBK=N>STKD0!!% XX[ MM:W$>T3Q--=I65,XW
3?+<5A&6(15QQ0P:NX<3P=Q!6;4X*TI'D-I.8,Q=PR0 RRSX*<#" F"(%)V+"396DFO##B@HQ>>9#$&W MU) ![7-C*6('!)%GH$G;4TFAY<^%S)GD(7F\B7*5Z8(?.&H0[(9Y=V210.[SQF) M,"#JJ!%*$&244%_+)Y%NTC#++
UDGW.$BVY(!.TBB^O>BD;++.F.3.A32ZD" MB& F."4TZZF>5#$I]!GBN@!$2_#"N%D4D8H]Z0^YC5/\7FJ_4-8MNQ1P^YP2 M"]BDAR=A#^UY$GS!T1U;/9N(*0YLS#US#]ISDQ)?Z0?18%9TLEO5@ARHDS%X,'ETX M;#]R4
7]SU-5GS1ACM4\7^392YR&F'5PJ:9^46&1%&23_-]XH%^>B82_T M%-(6DJ0G"8\][G@ZPE0ZBE"CY6%C7='4'&L*K9([/?W5T!%#:70'N-_$)2C.0XD(T+_9V>-+ #5MG'G-QA-S-/B6ICU:R+CHR/?9C1&
MZCE+Y0$"O(BKEI-!:UI[^#N(%I> &K8Z$T-,SM-N-_&N)TT(!)?'=^_R[DD5]8<>T6&9?,9EG#Y](O// Y$5HF$7!%"#K!A R\]@@I26%R2 MIE80-9.2;#(,24A)@W!+@%B^G[N?+42SO8]85>DT-NR"&?!$$2+;PA68C"
M:=C10)4*9CI$:7-3%%N<6Y%'H.%)0!E+P$B)Q)A0!) .I56EZ>;2QQNR?SX M]O\L]2$N$]'BDA=Q-D=B>)P+4STN!W$-R0@!IR@?V&LA5Z?.:UXS>HT7+<_'?9 M0QY$9]N9 @%G,I](M #H?_K@P( M"BB
<8N26A0ULCXN).RFK">]$_#DS0EXTC@!3Q"=@"=3)^@)FQ/0?+9*$4+& MI?EC$C(%DN2$2FG7I%(.'O)#(_]**G)TC&C54$[<9+5F*LYMTE>5K]OUK M\@>!E1(Y9SDM53#;]\8B(1
<42'CTEI62>=TB8,B2W%4[:6(3HK4[FXC9C2P^T$S$F$0=#)!* F=HJ[GOU(MU*C5.V%> MF/13EFS3,LC97?)<-#))Y-PR1P*SSYB!$"""FB)%)&-(*HTK:SP7M*GM$ZV31 M 4^8 D8M[OBZMA+TX-:V4!809Y0
97>XZYP?.]^XTO)TQ;+$]+V(^5?!F50 M8]/*Q-W?:E2!7IXFU(D"XA"2H#2^Y.M#DT5$S2<\I8R)K)@KM93IH@2'TBY M3QS#0>1SQ]0B?:@AP]7(().C1M8+%X;K($G.MT6W'/MD*/6,!P(%CW)$ P1$I+)E;W'TKP$_N
MO.UC$H?721;(=UEZ,HX5YO'P!LGR=@*&,"CD]7(8X*(27H__@_37?LKP M,9%G(<8TR]HH1RO=_INAMEO.6)G49Y.1*B"B>V>"5,!7!.J4<=*9L7QNYM@@ M<9K-+0M_73X'I+GV]*C=R,R@!)M\%5RHY/EXP,&!PR*#0 $0] YBR
P>FC?]'M".#457.]T_]LV&4!Q-'YVSU>X9S>.WC K^4Y^="OBA6&@:]KU9NQ.@7]%@H >:8Q8703ZF1:"6"G3OE^^"HI'9N>5.V-'T*@DW%3)R41?.O M.XK6_!+&STR7[4A)8NLVMB0O&AOI^]"H&.,H?RTT?
-SQ%@N8#%1I6&NNXB MB!IM]'.CIY^7LZ+ 9/%X%@%;5!?&!!VYZ^J4^!#*V%(W( MP,FZYX0$+D^-@2 PAHC1R9YV"9B-=)DYX3 MTT,DBE&\YZ&1=0.%) MC-7HN.2,$?PNAY0*8$8C$Y1SDYSE+
(IP?=!E9OFEVC,S5 M79+%U]@NG4QUP8Q EH"YG+$WL_;VYN'FZLEFMU=HN7# .*O_SZ_O;RZ7 [+ M/_WKV?L__@E=_<>GFX>_0^*IV?ZF2L$3'PUV-N72#EGM\>9[!2]TZD.)2T6 MP5OPCF"-
MRT1=CH'*@'WYD2A)!CZ*.%QYRBU,-I4TA!XDV]QO/$S@L#(E#2H0"&E'Y=O'OG4;]E4-CQYN:2SHE?RLZF0!R)=U0 PRUC&#* M9KALL+AK9KR]?RL>*1>^^__ :>G'A_/%+W\+ O(4[;>%R$6"W M]#^"Q;[U\KZKT"
[GF:)W5BUR&L^9XVK/0A56(11T?*PF@SHX1AN*@6&.'!Q_M.ECZ@O,R)FLMU&JAH@H*WP0Y>]"Z)_??]ON_0EZ__N3=^_>T?]'114P'FS+ MYRR/_T&4EC@GXQ>Z0*?H^S^4H*(G*IL3TZAWZ\.X$ M4=(PI4L=H=!2%?*U(/?
OY,3EOQ,6/J[DPJG_\J8]_[DP[^-_G#AP\ZWA8T'/A(M]3N+(A:[' "2+[(YNTHM@$Y?GGC$] H<\(-BW"&:,5!%D=TN-U>+'N@AUS2WM<7\G(SL=0 >028"9]H2PY/?Z M?F9B_] 0M8ANR5Q-4])
(X]@%@EZ(P0$5DJ.5@D>0(30%2:@H2Q14^&=*?VMG M$>3SG"&-V#IY@7-VD]]H7TBN]&^[36>0? =.I@F&>59P!>'LDKTY8(RL$DG_MVFT6H\K@EP?Q4&: G'E##;",D\#4,HW,. /)./80@PW;&@7?3.L#U[&LD@;
ML!Y$4W95>ZT@F27/=R2A:!UAB]@V:;/=R2A:=R27@*5=[GBA9NG1&F[I_MG6R<.0,U,#PTQVIX8 6)?X8.G%+#$]I,7#>%.$1^&3IM?5!'!]\@XBY3NFE3: M^ZE"Z:D$M_#,+1)1F*EX9I7'+0*>@M !I1#!(WAC-
1;C&[0:@ M)OY1*NV26QK(75I)1,$P2HUO2*9*&G5V:^$DY6OO%M3Y*W3Y^13R7NYZR& + MKWD,A<'P28=0?F_4?C!.Y/N<8%)]=&L7Y?X!2?9AG*]OB>_%#].Z5I8<
MR)DE5P##+!.4@AQ:3(=%"T8[+>]46^(DH2]#X930/R$FS:]UG,:T]#81377 M3)63e'E5:&=0[OC32!$-#*[C<,6>E?(*>*G7&RZ!7 /HZ3L-DRX)?__D=$_CG_MW__NCRRJEE9YYU X0F6&LM4]#G%>G* HSG%(F$O^2 O!
MZTV2O>$Z-],RU&)[QC2D)NC(BW6#X7]^I(2A)XR\?.5A_YY[.S M,X:4_>7[R1__4 .OOY#2LJUQ'_C&>Y]MIZK*"[K-N.<5E9)>G H>]M"=V(E"M'E&2^22;9"]OY1ZV2[_]M==UF:]2UHDGT=:WC?YAB#Q/CHJR ,9#2M9]
TNTZ6@]UOX;FO,"01XZ-7SM7DBAF MHF!X4A.WVPLTM@HU?/!&-5W$'X&X&QY]7_$HQ4_TZ$HUX>FA2FE5I] PSJOK M,[9Z=P(+L?]JME8AVO[KOZLL<)HV.2VX9P>^R2ZD C5\F8+D=Y&?R-TPO1*V(
M=GWI+UNAS^#R+_P8Q&E!/4%"MH"O?-3NLRO718!67Q: M+3IA;6OH8(IQ_"77FH#HD N8X]!NQAD689+THTRKTM%9HOBB7QTPF_:$'0,:BY39%T&"JJ"Z.DL"XKCHN$(G1]C(H2 MD%TH2@M*P(Z*36X-
Z+UA&047]6L'}K*TFOQ=%%)Y9!O28U M57::,JQ:."Y!=S@/RU]#_]9'IC.9%SC*:E?S..Z8<,9QD M:H(T5P<1!4_+K1RW05(97"+$>5I7)1/LY$@RV;/QH+]&=+G-25LO&$?802#] M9]K \U7GLLIV_5#LR;KEAG&?
(GK(0VF_X$97IGZL2&9908X,XMU^KZ9W'H^!RP3Z4]DE2 MW2L8,K,T5UF:$/*R="%]1P^3RM'=VQ=-=]@F-HWR8]]E>KQ<+6'=U^R3C6X MCG"SZYF#??XA6^*R3/!(.(VRO'Z[S]8K,RC0MV=A9[B14ZTMS3NS]S/!Q(^H M-
GH)Q0M6#'IAY4SUGN,(9[]8DN?&)?HFN]7I1MZSOCC05+>S07^N<_&=X'5 MQ&+)$Q3B#716D_-N[IVCW_;QD5]$"V?8#A^"4]_DD0XN8"6"?C M!RHG]WXXDI2<,@:I62@PR'DF/AI=BN-;$|+CI*#$;(!U^(!U2O.P[@@_T]S=FJ]
M1AJ)3>W#?.+WQLV^E3,^Q$$!=O<>>G<4"CC,]^[<.!Z^+HCYNFD/;4%$]TP&0] M:?PG?)>D?2MG:Q$>D/8T:W)> E%3(AB'WF0(@[+=@:MS&H^HAQH6YI',VTW M)WN%0,M&,M8 /@<.T0P2E.]V&'G-]T4 C'4_(.'.*K5-F*I0C
LWAQ6W[ MB.[75;D4Y!Z1VVZ?W20S75 !7R?99UV.;K6*EZ"%CW(*Y+W]!)8@Y0]U MD&B@&%S*B&FI2D1_!TN%:!%GKW$Q,W M&&GHX.;$92E@^#!L;.A=(-EO^,I[^G?]MB;TOQ- !?"%U!WNXN?L1S2X>;GYB
MSUQ[YW7/6Z*]6D8)[AWP>0AFX;YA_F4-P=[XL]2^N 3?0=; S[@<<<,>V/D4 MC?'!FX^AM+X:1?^5_ID&R.MO49*DVVUKT<$[8?V?C]"M2O$A3UT(YSDYZ9C M^G"[HV-K6'^_QE3;.[-'0^;]+(]Q4MUG[N7B_Y=_^M>$]\--
F!OQ4;YW7V M_ZLFV?\LC#4@<\1C'2WK8MWB\FH M<4\ST!;14_YN4M(..R-^L5W-)6U,CNC35Z4 ;9@WQ*M(ULU7E MUS1I\S=PLS:3E79..\LEKOZWL[;N#\CT#Z8:%^#X#55+PP:/JAJ@QE.K2&+
M!]\DD. !ADWFCS<.WA1[( ?@[2+'FR".U.Z 1TA7QU\S&D]G9UX$VCAKB'9*Q M:=LW%0*30HWD(.FS9T^"\-L2Y90]=U#^G9C&.9;4C^[GF/>>H]^8_V8_CPWU M@?
@38K,,W8F^.F12*Q$/*=@GQ!G!E!N=))_,CWKW/B*$>WN]W:_N60L[W%),MB2SLY%-I+A[0'ZG"Y6U-RF]TSQ!"(JR( L-C#4@,V*4L",PZ.AZT)0;NY^ MNEI""T%95)F:Z?DHL3C$."JN"1]J:]DODFHR473)6W-
#NCS5:T%;W1DCY@X$ M_^*_?KT@D)Z9DY"MR#&#;*GDGHGFWV[O?0AU0]QM(C\(MD..6N@5-$>CQ#7U=M^PC?H+:@(W 2KN,T2,;]G 1E00 X;6"H_:<5I4!W$O30=4["]1R2)0#]899&_7 H2%;7C?
D]PS#9TBMD5Z\A.UN\)\N)]]4*2ST-UR!<]B__M%=SMA6X1P.K)7FP7C0:2LQTV2-#YC/VA\VWVCSMD[/?C'BP.T4)'U2[4[YD0 M7W^.PB ^&[M%%T%!B<BQ4Y$2U=Y=93@H&W%-&,LC#" +QV/HU!>U.&H#0CBYL_M[=O-
)F&WH8.DN4!]DZZR?,WB8G67VTVUG=YSMS.I=^7=3!7,ZM<.+[=!_FFO MN+WQ>'7W,+M%ES?+B]OY\M/]U1+-KU&]38-N[]G]Q]G#S?SNT/=2V0+H""N M$PO]'0?Y]4ZS-
EDEZ.S^EA)H>S5+*.6=,UIHPI&-1<5%3!]5SQB]$16:C E" M>&=)2=V4U!QIA$E?Q&TH#P^N'ZVS^JT[,Q2@^+^Q2@1 Z]/KVP_!*RXH7+L MD4<9<8*.@[HD0 ?10:%R,T0*R00!.$%!)!5%))]_RX(RU#Q]_=\5L?M7MB-R5>
M:P^DS/6=[I'.FM7;(C55!L[_24>3Z^_\T*6[2YCG4UXWEE1,-B^T,&D2X8]H*:Y* M#PSHYM-U.\AX##M!N$9H$C5!<#"8XVW?LBN1@9^TX#S@%2NR@4ZAS>?9F5
MVI1KNFEWHK*7K"1CIZMZGG*A,#YG2FF7ZI9@M@CJELUVX,#GM,$1(*5?*]H\,7 MOPZ&LGKH.CEF.GKV(?TMA1G=#0,/4*!M'C)^HT[Z@V[=1UL,1J'K.7T2TK=-8Z+B-U$!,$;#0@T9 X(UN, $H01A7R9V(61<9.! M:=A;ZVI<.[T*?
30'>&;L/A%WZS*]JWK=4CH'$I <32.[==ZF M,2'@^ST.^U*.'Y&FPS'4DI)^]R^UC@W[8$W=6+0=2G7-SMO5$UZ/Y%4;$L M&))J/+Q (TX]N0A#85#6[1K;+F\3SZIU] R8;'TH>8#"CEG4?G01$?U4W-MOG#?$-
G]BG3)QBF,[Q\VG,+ <'H"(X:T9T6R!_=H/,]"CTFL_,&GAK3A^>]_M4:_>N\G@N;+"]X'932Q"K)9+6UK#LGZI0HPT15 M#5&A]WP()]C]((L=5UG5#(V9Y@(1ZL(AF)V:(49'X8!,);/65Z^>N!C6X-I<6V\DE
M]!'6@U75F1;IG\MVQNLI;E8><.9;&3'L$-"2XK7AD9U[,9VP1B6[#76]!"V: MF",7E4I0CMMM 'M(;;5,(A&/?^;]7@+[%'.]B;R4!AE@=57[%7GK.D>$U,* MS/Z\W)!O&E#(2MW'&:&I4:*#0IVN]OEU)@#ED>'7U_@@W
(]1Y0L]"ZR_I$5 M^HWWZ94]H$G+*#8F#B73%2]LW4<E$*LS^EY0-]. MZ9,DG93%]6D1]DKZ39)MZ'13'VK]%@B,-%V2T<+4+A$>%-"O!!RK8#W'M--FBNZ.+K]
\NWJ+BP)C]C:GX9"HU"':E4H/O9>=2BX.AFEZC$.&5;+>;705 MY#1C-DUYOWP.G;@-BL*FM8:.3WO-&-) M/-(RK_R!N/CU(L=17-(_21T(A89;ITT+O>^H2<7!T$]/D5\]=#2\LVF)G^AD M?
(\W6=X>!VHV0RQUG<8FV)C3BU,P403#.ANTW(*@TO4_7]]ASYUCZ#Q+R1]# MW-DS-&.A?3%N'_]:9V3_"3"[,L#0="1P?@5!!\Q>$I=>6=Z9O R?<;2E3_/-M"+XH3K9E_(*7.-SF]$KRU2MJ[@A']#$_N@;?-DG ADZ)=L0]P(>
<#!L\]ZC> M6#]Y5\#T]Y(.9QLT2]8?HL0S]U&GS+;3[F/=^=XD?RQV_W7&'LI MH' 6]2B[(ESVE3'&=7N!C$KKH8H\ K6)N$W04(?G)!UUHWHLZ+<(^D]7B M(PYH^'PT3^T]>15TOB[++\0(/2,!\^|]\!^!ODO(-
_T]RI.CI\BY>KUI$+9ZU[Y]S1WQXZ?]!AH%8?K!U<7J&(+O<]]+H>^D4^_I99<1 8=SW M+W9ZX_&*=;PF^=CEA!\X).Q.I0:X9H^ZV7Y]Z@_A(TOD):S .Z<7ZW-K]7@!!Z[#,R(D/!VN@8?*HVGHN$J!(0_U[+=T.Q>$?#&R-#%F/UQ.
08N9L537[AS2Z_]*ZXE"Y]L XY!H30<&_<9YN$P_@FS=&8Z.C6\)U2Y_^9@5 M6+E9K\8IN>P!LC7V&8O=MLI&YW$6+K/=UIEQBN5G%]FT$+?G"|02H/9A V #FDU4WZDL4A+DY0 MBOV'.MQC,Q"P1P7G*T*]57'^8+($]*
<2D]OL')R@HT=W@D#ZB MF<0KC+XFR]TW'.3%-YY6EKLD);]Q;5)2+6'+']^>; 4*CE>7!F<39G#I=?T M(O$+>ZXB=B.Q^[XO0;=+!DN#>G@WOXGC&J6?,?;WT'J_SB''F"BR'DPR>?V[^MT4Q98"]9]W(0-
X,R#0.QHX?Z&G%//\(@EBZ:K-L@R7 ML^XH\]%;Q*04!8.;C.;ZG:Z;JZC:ZH;[X!](..?3@9;Q5?XN[_;U+ARX.R2C+5 M=DI8.Y-Z5#53A4-2*$'S<'?%G^H<?!(/!*8CI"2LZZK5Y]B?1L7SSV7230A2M#<]MG6EIP+:3K$3..SL,P/"+B*
[T,7HV@ ZBC' "/X$2OLIXMUT_XIS,B.UUU(L@ M2>A##L,G["3CU=ZE>5Q]T]X*M$]RFA?]629U@]I_EF9H0V!^TQF-.!=0?Q>MT(PB?6([?.=O.Y'ZV"]&G+VHN]O>/#'>]-,\E-&?$^BPZ2F?<;T!%G;>#2&S:$@ !$_^
MN[EJ*GV%CW66GI4NJJTP]LK<'?],M?AZ"&::<9<1^[6[920D:)+=),E6O; Y[V#+ RWZRV+ *PNB)#1-]+[UBP\Y+/ FRI-B9 L56[%S#[P[WT2]&R1;2@EM&BWOM+S+TC@M,;FSDBZ(TX*F M1<;4Q:4Y#B4UHE-R24,S
WIO#"LUP-#.*;X]G96"R) <*?IZ"]HSC%=+I6HA MD]FFNJ*@IR8A4"Y/2)SCI&R;Q%=+P-OMA]>R$QG$30'U9K]I=)R_$["K5YR' M<8!W$:GN*&%]VT]3E^6]],N4W.UK-<5!&9.V0>]:#L2U^K4N0%PM-L=E)E%
MP\61Z$O!+_.]]$@%FSOS$0F#(9H.(>]F$OEZ8H(**@5Q8]OZ]TXYG/4&-U<"MO#EP)'|E&CRN=K]7&6G<6O&D.F9?]G$2K:.L$\SBPLXFE;6P+=OY"_ZD,IM M2%9)GW^5D]>FC"(T;49F30,99?!?
2E3,/=DNC7+.=P@EZG/I:F^0BQOZ& M=PW]&Z8;(#B:D1$O>,*]?1+M.)?.CRZ\ZNB[BOTG:=/=I2)W8C^E5NNI=**>"G$"O<R%8Y+ M^K;/+(VN?C=QS@]5Q=VZA7#DDZRV<@\|[4]_]W3>S3:9&I>567@Z+N0>LXT
MG@3N-"TUV,/$/1++,4WE>U?WE)/I*"#>>SX$ZZT=@_.,!Q"=@::N'#ZG.Y\ M\LF>]]P#3^[M]]QW:8=&FDS>3><%/&6W9GF8H@V_?4Q3LE5U3CD%@&WW8>__T M8:WU%@O4:X]K1H!S!.HC]Z;FF12G=IL=@F+C'%B Q\
(C,L#@9?IMI,CY/F M9SN89R-SX 21.]]Q![Z]T>_$1<5@53=%_15P 14CP6 M6+E9K$8IN>P!LC7V&8O=MLI&YW$6+K/=UIEQBN5G%]FT$+?G^]Q'4A*"EYK9P);F]%-H3?YDN?D8K>:@IEN<8:\VS0R9^0)+#7XE6#X]>
?^$4!H%JEA=JH@"[.N+/2#H&&@O?H&[N$Z+/IEE!@?>^#5?6L56,7K1G/[(^NU2Z/BO.4F?*Y_UO$=6O&E;PXN#?'8\_?]PW? MD!BX8"$*V(;J-ZGNBW3T5-75D.&L.X]0!.3;[N3K?!G&P+FDJC!?>[-4KQ.D;^I1]=J*5!&+;(P
M4T=a
```

[illegible]

[illegible]
22&9;E=6@>+M@#E#+XQ5Z.\]_CTHZ++"4+@= M,%*HQ+ *=)8.,/NR!-QR 72'9#- Z[+9'*UWPGF@,4O[CMQ=$2B0#IR%ZYVW M"N59NERF099D2#LT)66AX#IP.E5(,<3NK5A&_\6/QI-0LWVKEH6B[, !42'%
MP"AG'D>9]^)E*3F7%O!J-?10@J[8-^. :7\!4SB>)X3=TV

?L*Z ZW76FK MRNX@884=HHA=X,

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end XML 66 form10-q_htm.xml IDEA: XBRL DOCUMENT 0000109657 2024-01-012024-09-30 0000109657 2024-11-10 0000109657 2024-09-30 0000109657 2023-12-31 0000109657 us-gaap:SeriesCPreferredStockMember 2024-09-30 0000109657 us-gaap:SeriesCPreferredStockMember 2023-12-31 0000109657 2024-07-012024-09-30 0000109657 2023-07-012023-09-30 0000109657 2023-01-012023-09-30 0000109657 GTBP:OfficersEmployeesAndDirectorsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-012024-09-30 0000109657 GTBP:OfficersEmployeesAndDirectorsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012023-09-30 0000109657 GTBP:OfficersEmployeesAndDirectorsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-012024-09-30 0000109657 GTBP:OfficersEmployeesAndDirectorsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-012023-09-30 0000109657 us-gaap:PreferredStockMember 2024-06-30 0000109657 us-gaap:CommonStockMember 2024-06-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000109657 us-gaap:RetainedEarningsMember 2024-06-30 0000109657 2024-06-30 0000109657 us-gaap:PreferredStockMember 2023-12-31 0000109657 us-gaap:CommonStockMember 2023-12-31 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000109657 us-gaap:RetainedEarningsMember 2023-12-31 0000109657 us-gaap:PreferredStockMember 2023-06-30 0000109657 us-gaap:CommonStockMember 2023-06-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000109657 us-gaap:RetainedEarningsMember 2023-06-30 0000109657 2023-06-30 0000109657 us-gaap:PreferredStockMember 2022-12-31 0000109657 us-gaap:CommonStockMember 2022-12-31 0000109657 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000109657 us-gaap:RetainedEarningsMember 2022-12-31 0000109657 2022-12-31 0000109657 us-gaap:PreferredStockMember 2024-07-012024-09-30 0000109657 us-gaap:CommonStockMember 2024-07-012024-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000109657 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000109657 us-gaap:PreferredStockMember 2024-01-012024-09-30 0000109657 us-gaap:CommonStockMember 2024-01-012024-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000109657 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0000109657 us-gaap:PreferredStockMember 2023-07-012023-09-30 0000109657 us-gaap:CommonStockMember 2023-07-012023-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000109657 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000109657 us-gaap:PreferredStockMember 2023-01-012023-09-

```
30 0000109657 us-gaap:CommonStockMember 2023-01-012023-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0000109657 us-gaap:RetainedEarningsMember 2023-01-012023-
09-30 0000109657 us-gaap:PreferredStockMember 2024-09-30 0000109657 us-gaap:CommonStockMember 2024-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000109657 us-
gaap:RetainedEarningsMember 2024-09-30 0000109657 us-gaap:PreferredStockMember 2023-09-30 0000109657 us-gaap:CommonStockMember 2023-09-30 0000109657 us-gaap:AdditionalPaidInCapitalMember
2023-09-30 0000109657 us-gaap:RetainedEarningsMember 2023-09-30 0000109657 2023-09-30 0000109657 us-gaap:CommonStockMember 2024-02-02 0000109657 us-gaap:CommonStockMember 2024-02-05
0000109657 srt:MaximumMember 2024-09-30 0000109657 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000109657 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0000109657 us-
gaap:WarrantMember 2024-01-012024-09-30 0000109657 us-gaap:WarrantMember 2023-01-012023-09-30 0000109657 us-gaap:ShortTermInvestmentsMember 2024-09-30 0000109657 us-
gaap:ShortTermInvestmentsMember 2024-01-012024-09-30 0000109657 us-gaap:ShortTermInvestmentsMember 2023-12-31 0000109657 us-gaap:ShortTermInvestmentsMember 2023-01-012023-12-31 0000109657
2023-01-012023-12-31 0000109657 us-gaap:MoneyMarketFundsMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember 2024-09-30 0000109657 us-
gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember 2024-09-30 0000109657 us-
gaap:USTreasurySecuritiesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel2Memberus-
gaap:USTreasurySecuritiesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember 2024-09-30 0000109657 GTBP:USTreasuriesMember 2024-09-30
0000109657 us-gaap:FairValueInputsLevel1MemberGTBP:USTreasuriesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel2MemberGTBP:USTreasuriesMember 2024-09-30 0000109657 us-
gaap:FairValueInputsLevel3MemberGTBP:USTreasuriesMember 2024-09-30 0000109657 us-gaap:FairValueInputsLevel1Member 2024-09-30 0000109657 us-gaap:FairValueInputsLevel2Member 2024-09-30
0000109657 us-gaap:FairValueInputsLevel3Member 2024-09-30 0000109657 us-gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel1Memberus-
gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel3Memberus-
gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel1Memberus-
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31
0000109657 us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000109657 us-
gaap:FairValueInputsLevel2Member 2023-12-31 0000109657 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000109657 GTBP:CytovanceBiologicsIncMember 2024-09-30 0000109657
GTBP:CytovanceBiologicsIncMember 2023-12-31 0000109657 GTBP:UniversityOfMinnesotaMember 2024-09-30 0000109657 GTBP:UniversityOfMinnesotaMember 2023-12-31 0000109657
GTBP:CytovanceBiologicsIncMember 2022-12-31 0000109657 GTBP:CytovanceBiologicsIncMember 2024-01-012024-09-30 0000109657 GTBP:CytovanceBiologicsIncMember 2023-01-012023-09-30 0000109657
GTBP:CytovanceBiologicsIncMember 2023-09-30 0000109657 srt:MaximumMemberGTBP:TwoThousandTwentyThreeCommonWarrantsMember 2023-01-04 0000109657
srt:MaximumMemberGTBP:TwoThousandTwentyThreeWarrantsMember 2023-01-04 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMember 2024-01-012024-09-30 0000109657
GTBP:TwoThousandTwentyThreeWarrantsMember 2024-09-30 0000109657 GTBP:TwentyTwentyWarrantsMember 2020-01-012020-12-31 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMember 2024-01-
012024-09-30 0000109657 GTBP:TwoThousandTwentyWarrantsMember 2024-01-012024-09-30 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMemberus-gaap:MeasurementInputSharePriceMember 2024-
09-30 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMemberus-gaap:MeasurementInputSharePriceMember 2023-12-31 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMemberus-
gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000109657
GTBP:TwoThousandTwentyThreeWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMemberus-
gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000109657 srt:MinimumMemberGTBP:TwoThousandTwentyThreeWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30
0000109657 srt:MaximumMemberGTBP:TwoThousandTwentyThreeWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMemberus-
gaap:MeasurementInputExpectedTermMember 2023-12-31 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0000109657
GTBP:TwoThousandTwentyThreeWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMember 2023-01-012023-12-31
0000109657 GTBP:TwoThousandTwentyWarrantsMemberus-gaap:MeasurementInputSharePriceMember 2024-09-30 0000109657 GTBP:TwoThousandTwentyWarrantsMemberus-
gaap:MeasurementInputSharePriceMember 2023-12-31 0000109657 GTBP:TwoThousandTwentyWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0000109657
GTBP:TwoThousandTwentyWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000109657 GTBP:TwoThousandTwentyWarrantsMemberus-
gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0000109657 GTBP:TwoThousandTwentyWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000109657
GTBP:TwentyTwentyWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0000109657 GTBP:TwoThousandTwentyWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2023-
12-31 0000109657 GTBP:TwoThousandTwentyWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0000109657 GTBP:TwoThousandTwentyWarrantsMemberus-
gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0000109657 GTBP:TwoThousandTwentyWarrantsMember 2023-01-012023-12-31 0000109657 GTBP:PurchaseAgreementMember 2024-05-232024-
05-23 0000109657 us-gaap:CommonStockMemberGTBP:PurchaseAgreementMember 2024-05-23 0000109657 GTBP:TwentyTwentyFourCommonWarrantsMemberGTBP:PurchaseAgreementMember 2024-05-23
0000109657 GTBP:TwentyTwentyFourPlacementAgentWarrantMemberGTBP:PurchaseAgreementMember 2024-05-23 0000109657
GTBP:TwentyTwentyFourCommonSharesAndTwentyTwentyFourCommonWarrantsMemberGTBP:PurchaseAgreementMember 2024-05-23 0000109657 GTBP:PurchaseAgreementMember 2023-01-042023-01-04
0000109657 us-gaap:CommonStockMemberGTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:PrefundedWarrantMemberGTBP:PurchaseAgreementMember 2023-01-04 0000109657
GTBP:TwentyTwentyThreeCommonWarrantsMemberGTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:TwentyTwentyThreePlacementAgentWarrantMemberGTBP:PurchaseAgreementMember 2023-
01-04 0000109657 GTBP:PreFundedWarrantsMemberGTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:PlacementAgentWarrantMemberGTBP:PurchaseAgreementMember 2023-01-04 0000109657
GTBP:TwentyTwentyThreeCommonSharesAndTwentyTwentyThreeCommonWarrantsMemberGTBP:PurchaseAgreementMember 2023-01-04 0000109657
GTBP:PreFundedWarrantsAndTwentyTwentyThreeCommonWarrantsMemberGTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:CommonWarrantAndPlacementAgentWarrantMember 2023-01-042023-
01-04 0000109657 GTBP:BoardOfDirectorsEmployeesAndConsultantsMember 2024-01-012024-09-30 0000109657 GTBP:SeriesKPreferredStocksMember 2021-02-162021-02-16 0000109657
GTBP:SeriesKPreferredStocksMember 2021-02-16 0000109657 GTBP:SeriesKPreferredStockMember 2024-09-30 0000109657 GTBP:SeriesKPreferredStockMember 2023-12-31 0000109657 GTBP:WarrantsMember
2024-01-012024-09-30 0000109657 GTBP:OmnibusIncentivePlanMember 2022-04-012022-04-30 0000109657 GTBP:OmnibusIncentivePlanMember 2024-01-012024-09-30 0000109657 2023-05-152023-05-15
0000109657 2023-05-15 0000109657 2023-01-272023-01-27 0000109657 2023-01-27 0000109657 GTBP:WarrantsMemberGTBP:RangeOneMember 2024-01-012024-09-30 0000109657
GTBP:WarrantsMemberGTBP:RangeOneMember 2024-09-30 0000109657 GTBP:WarrantsMemberGTBP:RangeTwoMember 2024-01-012024-09-30 0000109657 GTBP:WarrantsMemberGTBP:RangeTwoMember 2024-
09-30 0000109657 GTBP:WarrantsMemberGTBP:RangeThreeMember 2024-01-012024-09-30 0000109657 GTBP:WarrantsMemberGTBP:RangeThreeMember 2024-09-30 0000109657
GTBP:WarrantsMemberGTBP:RangeFourMember 2024-01-012024-09-30 0000109657 GTBP:WarrantsMemberGTBP:RangeFourMember 2024-09-30 0000109657 GTBP:WarrantsMemberGTBP:RangeFiveMember
2024-01-012024-09-30 0000109657 GTBP:WarrantsMemberGTBP:RangeFiveMember 2024-09-30 0000109657 GTBP:WarrantsMemberGTBP:RangeSixMember 2024-01-012024-09-30 0000109657
GTBP:WarrantsMemberGTBP:RangeSixMember 2024-09-30 0000109657 GTBP:WarrantsMemberGTBP:RangeSevenMember 2024-01-012024-09-30 0000109657 GTBP:WarrantsMemberGTBP:RangeSevenMember
2024-09-30 0000109657 GTBP:WarrantsMember 2024-09-30 0000109657 GTBP:RangeOneMember 2024-01-012024-09-30 0000109657 GTBP:RangeOneMember 2024-09-30 0000109657 GTBP:RangeTwoMember
2024-01-012024-09-30 0000109657 GTBP:RangeTwoMember 2024-09-30 0000109657 GTBP:RangeThreeMember 2024-01-012024-09-30 0000109657 GTBP:RangeThreeMember 2024-09-30 0000109657
GTBP:CytovanceBiologicsIncMember 2022-08-24 0000109657 GTBP:CytovanceBiologicsIncMember 2024-04-25 0000109657 us-gaap:ResearchAndDevelopmentExpenseMemberGTBP:CytovanceBiologicsIncMember
2024-01-012024-09-30 0000109657 us-gaap:ResearchAndDevelopmentExpenseMemberGTBP:CytovanceBiologicsIncMember 2023-01-012023-09-30 0000109657 GTBP:CytovanceBiologicsIncMember 2024-06-30
0000109657 GTBP:TwoThousandTwentyOneScientificResearchAgreementMember 2021-06-162021-06-16 0000109657 GTBP:TwoThousandTwentyOneScientificResearchAgreementMember 2024-01-012024-09-30
0000109657 GTBP:TwoThousandTwentyOneScientificResearchAgreementMember 2023-01-012023-09-30 0000109657 GTBP:TwoThousandTwentyOneScientificResearchAgreementMember 2024-09-30 0000109657
GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember 2024-05-202024-05-20 0000109657 GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember 2024-01-012024-09-30
0000109657 GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember 2023-01-012023-09-30 0000109657 GTBP:TwoThousandTwentyThreeSponsoredResearchAgreementMember 2024-09-30
0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2016-07-18 0000109657
GTBP:TwoThousandSeventeenThroughTwoThousandTwentyMemberGTBP:TwoThousandSixteenPatentLicenseAgreementMember 2016-07-182016-07-18 0000109657
GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2016-07-182016-07-18 0000109657 srt:MaximumMemberGTBP:TwoThousandSixteenPatentLicenseAgreementMember 2016-07-182016-07-18
0000109657 GTBP:TwoThousandTwentyTwoMemberGTBP:TwoThousandSixteenPatentLicenseAgreementMember 2016-07-182016-07-18 0000109657
GTBP:TwoThousandTwentyFiveMemberGTBP:TwoThousandSixteenPatentLicenseAgreementMember 2016-07-182016-07-18 0000109657
GTBP:TwoThousandTwentySevenMemberGTBP:TwoThousandSixteenPatentLicenseAgreementMember 2016-07-182016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2024-05-13
0000109657 GTBP:TwoThousandTwentyFiveMemberGTBP:TwoThousandSixteenPatentLicenseAgreementMember 2024-05-132024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember
2024-05-132024-05-13 0000109657 srt:MinimumMemberGTBP:TwoThousandSixteenPatentLicenseAgreementMember 2024-05-132024-05-13 0000109657
srt:MaximumMemberGTBP:TwoThousandSixteenPatentLicenseAgreementMember 2024-05-132024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2024-01-012024-09-30
0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2023-01-012023-09-30 0000109657 GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-262021-03-26 0000109657
GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-26 0000109657 srt:MinimumMemberGTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-262021-03-26
0000109657 srt:MaximumMemberGTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-262021-03-26 0000109657 srt:OfficerMemberus-gaap:SubsequentEventMember 2024-10-172024-10-
17 iso4217:USD shares iso4217:USD shares pure utr:sqftfalse--12-31Q30000109657 10-Qtrue2024-09-302024false001-40023GT BIOPHARMA, INC.DE94-1620407415919-4040Common Stock, $0.001 par value per
shareGTBPNASDAQYesYesNon-accelerated Filertruefalsefalse2234328315 Montgomery Street10th FloorSan
FranciscoCA941046418000107900093000128930002480008400067590001405600053000675900014109000261200043280001868000119500058000182000105200046620006633000 0.010.0115000000150000009623
691452000-682065000209700074760006759000141090001307000136400038680005109000054700022200017670002297000175800067330005299000-3604000-3122000-10601000-
1040800096000216000343000600000213000-95000-485000-870000-47960005470002000500010004300019300070600012140005773000-3411000-2416000-9387000-4635000-1.53-1.53-1.77-1.77-5.28-5.28-3.47-
3.472234328223432813672061367206177731317773131336532133653296230100022343282000693546000-6880410005508000-3411000-341100096230100022343282000693546000-
691452000209700096230100013806331000689539000-6820650007476000740000100029750002976000-13902127597810000810000222000222000-9387000-938700096230100022343282000693546000-
691452000209700096230100013546561000688448000-6766870001176300013333100011400011500012644110000110000433000433000-2416000-241600096230100013806332000689105000-
6791030001000500096230100010907481000686200000-6744670001173400096230100010907481000686200000-
674467000117340001200006268000626800096666583100058310001578210004290004300005743770100070100013380001338000-4635000-463500096230100013806332000689105000-
6791030001000500096230100013806332000689105000-679103000100050000-9387000-46350004300002220001337000-870000-47960005470005300078000-100043000164000-16000-2330001437000-58000-82000-
10436000-6805000-12892000248700012892000-24870002976000626800029760006268000543200 0-302400010790005672000651100026480005831000810000700000<p id="xdx_808_eus-gaap--
OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zzGJpInDgCRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-
align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 - <span><span id="xdx_824_zE0ENzpcr7Wg">Organization and Going Concern Analysis</span></span></b>
</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The corporate predecessor of GT
Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data, Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI
Pharmaceuticals, Inc. on March 11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. On July
17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt">Throughout this Quarterly Report on Form 10-Q, the terms “GTBP,” “we,” “us,” “our,” “the Company” and “our Company” refer to GT Biopharma, Inc.</span></p> <p style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The GT Biopharma logo, TriKE®, and other trademarks or service marks of GT Biopharma, Inc.
appearing in this quarterly report are the property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies. All other trademarks,
registered marks and trade names appearing herein are the property of their respective holders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt">The Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our
proprietary Tri-specific Killer Engager (TriKE®), and Tetra-specific Killer Engager (Dual Targeting TriKE®) platforms. The Company’s TriKE® and Dual Targeting TriKE® platforms generate proprietary
therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer cells (NK cells).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern Analysis</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying
unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company does not have any product candidates approved for sale and
has not generated any revenue from its product sales. The Company has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company has
financed its operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and strategic collaborations. For the nine months ended
September 30, 2024, the Company recorded a net loss of approximately $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20240930_z9TWqD2z08Nk" title="Net loss">9.4</span> million and
used cash in operations of approximately $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20240930_zfDTHMJXilPi" title="Net cash used in operating
activities">10.4</span> million. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.</span></p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements do not include
any adjustments that might be necessary if the Company is unable to continue as a going concern. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that
assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated the significance of the uncertainty regarding
the Company’s financial condition in relation to its ability to meet its obligations, which has raised substantial doubt about the Company’s ability to continue as a going concern. While it is very difficult to estimate
the Company’s future liquidity requirements, the Company believes if it is unable to obtain additional financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations
through one year from the date the accompanying unaudited condensed consolidated financial statements are issued. There can be no assurances that the Company will be able to secure additional financing on
acceptable terms. In the event the Company does not secure additional financing, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the
Company’s business prospects, ability to meet long-term liquidity needs and the ability to continue operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -9400000-10400000<p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_zof5sKWMTkQ6"
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - <span
id="xdx_82A_zr0mwVCDLEAd">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zRUxQtKqLvuc" style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zO2Z9C097l31">Basis of Presentation and
Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The condensed
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and
```

~~balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the "2023 Annual Report"). The consolidated balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company's financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--UseOfEstimates_zFoiINRiXKmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Accounting Estimates</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include management's estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPd7krwqtv68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Cash Equivalents and Short-Term Investments</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying unaudited condensed consolidated financial statements. At September 30, 2024 total cash equivalents which consist of money market funds and US treasuries, amounted to approximately $6.2 million. At December 31, 2023 total cash equivalents which consist of money market funds, amounted to approximately $443,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Management generally determines the appropriate classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying unaudited condensed consolidated statements of operations. At September 30, 2024 and December 31, 2023, total short-term investments which consist of US treasuries and US government agencies, amounted to approximately $0 and $12.9 million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zXcDGJY4iRBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Restricted Cash </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of September 30, 2024, the Company has classified certain cash balances as restricted cash in its unaudited condensed consolidated balance sheets. The Company's restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with the same financial institution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z75wsl1zrsya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Fair Value of Financial Instruments</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The three levels of the fair value hierarchy are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The carrying amounts of the Company's other financial assets and liabilities, such as cash and cash equivalents, short term investments, prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The carrying amount of the Company's warrant liability of $182,000 and $1.1 million at September 30, 2024 and December 31, 2023, respectively, was based on Level 3 measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_849_ecustom--WarrantLiabilityPolicyTextBlock_z2oVZknbbqH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Warrant Liability</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, "<i>Derivatives and Hedging</i>" ("ASC 815"). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company's use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_843_ecustom--CommonStockReverseStockSplitPolicyTextBlock_z9wPWICfWb1i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Common Stock (February 2024 Reverse Stock Split)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On February 2, 2024, the Company effectuated a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30. The Company's common stock began trading on a reverse stock-split-adjusted basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol "GTBP."</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission and other expenses). The reverse stock split reduced the number of shares of common stock outstanding on the effective date of the reverse stock-split from 41,419,000 shares to 1,380,633 shares, subject to minor adjustments due to the treatment of fractional shares. The number of authorized shares of common stock remains unchanged at 250,000,000 shares. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Proportionate adjustments have been made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise of outstanding stock options and warrants for the Company's common stock, and to the number of shares of common stock reserved for future issuance pursuant to the Company's 2022 Omnibus Incentive Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">All share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest period presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zNRQrsH2fwD" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Stock-Based Compensation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Stock-based payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, <i>Compensation-Stock Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPhNvXLBMjLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Research and Development Expenses</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Company's products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zgBsQ92AdS2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Leases</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company accounts for its lease in accordance with the guidance of ASC 842, <i>Leases</i>. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company's right to use an underlying asset during the lease term, and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In June 2024, the Company's lease expired and was not renewed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zVaAQnUmDDtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Net Loss Per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon~~

~~exercise of stock options and warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z0yKwZHX2Fj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Schedule of Anti-dilutive Securities</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20240930_zkubFB6enWn8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">September 30, 2024</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">(Unaudited) </p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230101__20230930_z5P3x8vLAX27" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">September 30, 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">(Unaudited) </p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zBgvfZlj8Nug" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Options to purchase common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 22%; text-align: right">101,264</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 22%; text-align: right">124,599</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zrSw1dlI2RQf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,133,762</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">304,962</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zvuAFvmtCK29" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,026</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">429,561</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zpdLC5pJ1Ju4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zAhoBQcFi8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Concentration</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $250,000. Management believes that the financial institutions that hold the Company’s cash are financially sound and, accordingly, minimal credit risk exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company has a significant concentration of expenses incurred from and accounts payable and accrued expenses to Cytovance, a related party, and the University of Minnesota, see Note 4 - Accounts Payable and Related Party.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zycngeLuCydf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Segments</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company determined its reporting units in accordance with “<i>Segment Reporting</i>” (“ASC 280”). Management evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Management has determined that the Company has one consolidated operating segment. The Company’s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company’s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments. As a result no further segment information is presented in these consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zKaKgRrkaBG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Recent Accounting Pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In November 2023, the FASB issued ASU No. 2023-07, “<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>” (“ASU 2023-07”), which introduces new reportable segment disclosure requirements related to significant segment expenses and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable segment’s profits and losses. This standard became effective for the Company on January 1, 2024. The adoption of this standard did not have a material impact on the Company’s results of operations, financial position or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company’s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company’s financial position and results of operations.</p> <p id="xdx_85C_zjtTzZubpYkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zRUxQtKqLvuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Basis of Presentation and Principles of Consolidation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the “2023 Annual Report”). The consolidated balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--UseOfEstimates_zFoiINRiXKmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Accounting Estimates</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include management’s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPd7krwqtv68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Cash Equivalents and Short-Term Investments</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying unaudited condensed consolidated financial statements. At September 30, 2024 total cash equivalents which consist of money market funds and US treasuries, amounted to approximately $6.2 million. At December 31, 2023 total cash equivalents which consist of money market funds, amounted to approximately $443,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Management generally determines the appropriate classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying unaudited condensed consolidated statements of operations. At September 30, 2024 and December 31, 2023, total short-term investments which consist of US treasuries and US government agencies, amounted to approximately $0 and $12.9 million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> 620000044300012900000<p id="xdx_84A_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zXcDGJY4iRBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Restricted Cash </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of September 30, 2024, the Company has classified certain cash balances as restricted cash in its unaudited condensed consolidated balance sheets. The Company’s restricted cash is deposited in a financial institution and held as a collateral for a credit card agreement with the same financial institution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z75wsl1zrsya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Fair Value of Financial Instruments</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The three levels of the fair value hierarchy are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The carrying amounts of the Company’s other financial assets and liabilities, such as cash and cash equivalents, short term investments, prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The carrying amount of the Company’s warrant liability of $182,000 and $1.1 million at September 30, 2024 and December 31, 2023, respectively, was based on Level 3 measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> 1820001100000<p id="xdx_849_ecustom--WarrantLiabilityPolicyTextBlock_z2oVZknbbqH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-~~

```
align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zywLn6WxKqCc">Warrant Liability</span></b></span></p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates its financial instruments to determine if such instruments are derivatives or
contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “<i>Derivatives and Hedging</i>” (“ASC 815”). For derivative financial instruments that are accounted for as liabilities, the
derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.</span></p> <p style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s use of derivative financial instruments is generally limited to warrants issued by
the Company that do not meet the criteria for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.</span></p> <p style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--
CommonStockReverseStockSplitPolicyTextBlock_z9wPWICfWb1i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"><b><span id="xdx_865_zDTSDmQn01Ai">Common Stock (February 2024 Reverse Stock Split)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt
0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20240101__20240930_zjdWEQoIRVV5" title="Revers stock split
ratio">On February 2, 2024, the Company effectuated a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30. The Company’s common stock began trading on a reverse stock-split-
adjusted basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol “GTBP.”</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-
align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined into one
issued and outstanding share of common stock, without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split. Stockholders who otherwise would be
entitled to receive fractional shares of common stock will be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares
resulting from the reverse stock-split (reduced by any customary brokerage fees, commission and other expenses). The reverse stock split reduced the number of shares of common stock outstanding on the effective
date of the reverse stock-split from <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240202__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT7et8vCAdOa"
title="Common stock, shares outstanding">41,419,000</span> shares to <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240205__us-gaap--StatementEquityComponentsAxis__us-gaap--
CommonStockMember_zIpbiDqA4EHf" title="Common stock, shares outstanding">1,380,633</span> shares, subject to minor adjustments due to the treatment of fractional shares. The number of authorized shares
of common stock remains unchanged at <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zaz1VdyD0Y41" title="Common stock, shares authorized">250,000,000</span> shares.
</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font:
10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proportionate adjustments have been made to the per
share exercise price and the number of shares of common stock that may be purchased upon exercise of outstanding stock options and warrants for the Company’s common stock, and to the number of shares of
common stock reserved for future issuance pursuant to the Company’s 2022 Omnibus Incentive Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt">All share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest period presented.</span>
</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> On February 2, 2024,
the Company effectuated a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30. The Company’s common stock began trading on a reverse stock-split-adjusted basis on The
Nasdaq Capital Market on February 5, 2024 under the existing trading symbol “GTBP.”414190001380633250000000<p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zNRQrsH2fwD" style="font:
10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zktkej3aAFVf">Stock-Based
Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company
periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock-based payments to officers, directors,
employees, and consultants in exchange for goods and services, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with
ASC 718, <i>Compensation-Stock Compensation</i>. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and
depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-
employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain
assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense
recorded in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></p> <p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zPhNvXLBMjLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zGyu5hp7UJT8">Research and Development Expenses</span></b></span></p> <p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt
0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs
of personnel conducting research and development of the Company’s products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed.
</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font:
10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--
LesseeLeasesPolicyTextBlock_zgBsQ92AdS2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b><span id="xdx_864_z6soUga6KeN1">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt; background-color: white">The Company accounts for its lease in accordance with the guidance of ASC 842, <i>Leases</i>. The Company determines whether a contract is, or contains, a lease at inception.
Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-
use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based
on the information available at lease commencement in determining the present value of unpaid lease payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In June 2024, the Company’s lease expired and was not renewed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zVaAQnUmDDtg"
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zCbNiPnR4WLa">Net
Loss Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings (loss)
per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and
the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and warrants have been excluded
from the diluted loss per share calculation because their effect is anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z0yKwZHX2Fj4" style="font:
10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following common stock equivalents were excluded in
the computation of the net loss per share because their effect is anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"><span id="xdx_8B1_zQa2lhVhy68a" style="display: none">Schedule of Anti-dilutive Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;
margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"
id="xdx_491_20240101__20240930_zkubFB6enWn8" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited) </b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"
id="xdx_49B_20230101__20230930_z5P3x8vLAX27" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited) </b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_eus-gaap--
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--
EmployeeStockOptionMember_zBgvfZlj8Nug" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Options to purchase common stock</td><td style="width:
2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 22%; text-align: right">101,264</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-
align: left"> </td><td style="width: 22%; text-align: right">124,599</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--
WarrantMember_zrSw1dlI2RQf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom:
1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,133,762</td><td style="padding-bottom: 1pt; text-align: left"> </td><td
style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">304,962</td><td style="padding-bottom: 1pt;
text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zvuAFvmtCK29" style="vertical-align: bottom; background-color:
rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align:
left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,026</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-
bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">429,561</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p
id="xdx_8A0_zpdLC5pJ1Ju4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p
id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z0yKwZHX2Fj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-
dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zQa2lhVhy68a" style="display:
none">Schedule of Anti-dilutive Securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%;
margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20240930_zkubFB6enWn8"
style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><b>September 30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><b>(Unaudited) </b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230101__20230930_z5P3x8vLAX27"
style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><b>September 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><b>(Unaudited) </b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_eus-gaap--
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--
EmployeeStockOptionMember_zBgvfZlj8Nug" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Options to purchase common stock</td><td style="width:
2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 22%; text-align: right">101,264</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-
align: left"> </td><td style="width: 22%; text-align: right">124,599</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--
WarrantMember_zrSw1dlI2RQf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom:
1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,133,762</td><td style="padding-bottom: 1pt; text-align: left"> </td><td
style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">304,962</td><td style="padding-bottom: 1pt;
text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zvuAFvmtCK29" style="vertical-align: bottom; background-color:
rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align:
left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,026</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-
bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">429,561</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
10126412459911337623049621235026429561<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zAhoBQcFi8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zhU6lCTIV6Bc">Concentration</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-
align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of
Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--RangeAxis__srt--MaximumMember_zNb91wNR2Tsb"
title="Cash, FDIC insured amount">250,000</span>. <span style="background-color: white">Management believes that the financial institutions that hold the Company’s cash are financially sound and,
accordingly, minimal credit risk exists.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a significant concentration of expenses incurred from and accounts payable and accrued expenses to Cytovance, a related party, and the University of Minnesota, see Note 4 - Accounts Payable and
Related Party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
250000<p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zycngeLuCydf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zWnjEr2twgY3">Segments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined its reporting units in accordance with “<i>Segment Reporting</i>” (“ASC 280”). Management evaluates a reporting unit by first
identifying its operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within
an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it
```

is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Management has determined that the Company has one consolidated operating segment. The Company's reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company's reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments. As a result no further segment information is presented in these consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zKaKgRrkaBG2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Recent Accounting Pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In November 2023, the FASB issued ASU No. 2023-07, "<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>" ("ASU 2023-07"), which introduces new reportable segment disclosure requirements related to significant segment expenses and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable segment's profits and losses. This standard became effective for the Company on January 1, 2024. The adoption of this standard did not have a material impact on the Company's results of operations, financial position or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company's management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company's financial position and results of operations.</p> <p id="xdx_80B_eus-gaap--FairValueDisclosuresTextBlock_zc7O3g7Xvro5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 3 – Fair Value of Financial Instruments</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Financial Assets</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zsHFZ0EUYDj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table represents the estimated fair values of the Company's financial instruments:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Schedule of Estimated Fair Value of Financial Instrument</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> September 30, 2024 (Unaudited)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> Unrealized</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Unrealized</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Fair</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Cost</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Gains</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> Value</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; padding-bottom: 1.5pt">Short-term investments</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20240930__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zGdhIGdPyJO4" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Cost">—</td> <td style="width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_980_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_c20240101__20240930__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zBkFyk3Igzz7" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Unrealized gains"> — </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_di_c20240101__20240930__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zQRNRMH3JfB2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Unrealized losses">—</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_985_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_c20240101__20240930__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zgSZ7uUinmF9" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Fair value">— </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20240930_zqcrAyGA6V5j" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost">—</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_988_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_c20240101__20240930_zijwsNwONKVb" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized gains"> —</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_di_c20240101__20240930_zXpH30sYocv8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized losses">—</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_c20240101__20240930_zUlMeKnJafU1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value">— </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Short-term investments</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zgkOYwcsl478" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cost">12,845,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zEDNwR1Co2Ih" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Unrealized gains">48,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zioW7WQ9h9R9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Unrealized losses">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zCTjos9ePdM6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Fair value">12,893,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20231231_zFs1km60hrKg" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">12,845,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_c20230101__20231231_zZecBtXOF1gh" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains">48,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_di_c20230101__20231231_zKKNoZqp3loj" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_c20230101__20231231_zGUg8AL89fNb" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">12,893,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zFgOSPOB7e7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zxKcVT8FMNO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table represents the Company's fair value hierarchy for its financial assets (cash equivalents and investments):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Schedule of Fair Value Hierarchy Financial Assets</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240930_zx4n2QuIGQ9b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHzcuQdq72l3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zr2ig2ruU7R7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfMxWpZvLKBl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align:

center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024 (Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash equivalents:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zBQygzgE0eE3" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-left: 10pt">Money market funds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,220,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,220,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--InvestmentTypeAxis__us-gaap--USTreasurySecuritiesMember_zJ99anYgVCr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">US treasuries</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,987,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,987,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short-term investments:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--InvestmentTypeAxis__custom--USTreasuriesMember_zbGyMAhmGMu" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">US treasuries</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetAssetLiability_iI_zhP7k4nBe8N5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,207,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,220,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,987,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_494_20231231_zAb0IHQt3Gk4" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbBPpteJeCL1" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkmDYg05af9b" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn6mtzaWdAqe" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Cash equivalents:</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_z1umKmfCM85l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Money market funds</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">443,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">443,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #C1E4F5"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Short-term investments:</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--InvestmentTypeAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zB2zSSQX9M69" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt">US treasuries and US gov't. agencies</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,893,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,893,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_zFH5OjW0NgSh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total financial assets</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">13,336,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-

family: Times New Roman, Times, Serif; font-size: 10pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$ </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">443,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12,893,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> </tr> </table> <p id="xdx_8AE_z979V7qINak7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Warrant Liability</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">For the details of warrant liability transactions see Note 5 - Warrant Liability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89E_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zsHFZ0EUYDj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> The following table represents the estimated fair values of the Company's financial instruments:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Schedule of Estimated Fair Value of Financial Instrument</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> September 30, 2024 (Unaudited)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Unrealized</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Unrealized</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Fair</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Cost</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Gains </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Losses</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Value</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; padding-bottom: 1.5pt">Short-term investments</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20240930__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zGdhIGdPyJO4" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Cost">—</td> <td style="width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_980_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_c20240101__20240930__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zBkFyk3Igzz7" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Unrealized gains"> —</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_di_c20240101__20240930__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zQRNRMH3JfB2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Unrealized losses">—</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_985_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_c20240101__20240930__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zgSZ7uUinmF9" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Fair value">—</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20240930_zqcrAyGA6V5j" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost">—</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_988_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_c20240101__20240930_zijwsNwONKVb" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized gains"> —</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_984_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_di_c20240101__20240930_zXpH30sYocv8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unrealized losses">—</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_c20240101__20240930_zUlMeKnJafU1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value"> —</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unrealized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Short-term investments</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zgkOYwcsl478" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cost">12,845,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zEDNwR1Co2Ih" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Unrealized gains">48,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zioW7WQ9h9R9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Unrealized losses">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--ShortTermInvestmentsMember_zCTjos9ePdM6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Fair value">12,893,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_c20231231_zFs1km60hrKg" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">12,845,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGain_c20230101__20231231_zZecBtXOF1gh" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized gains">48,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_iN_di_c20230101__20231231_zKKNoZqp3loj" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized losses">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtSecuritiesAvailableForSaleUnrealizedGainLoss_c20230101__20231231_zGUg8AL89fNb" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value">12,893,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 128450004800012893000128450004800012893000<p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zxKcVT8FMNO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table represents the Company's fair value hierarchy for its financial assets (cash equivalents and investments):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Schedule of Fair Value Hierarchy Financial Assets</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240930_zx4n2QuIGQ9b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHzcuQdq72l3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zr2ig2ruU7R7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfMxWpZvLKBl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024 (Unaudited)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight:

bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash equivalents:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_zBQygzgE0eE3" style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-left: 10pt">Money market funds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,220,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,220,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--InvestmentTypeAxis__us-gaap--USTreasurySecuritiesMember_zJ99anYgVCr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">US treasuries</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,987,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,987,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short-term investments:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--InvestmentTypeAxis__custom--USTreasuriesMember_zbGyMAhmGMu" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">US treasuries</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetAssetLiability_iI_zhP7k4nBe8N5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total financial assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,207,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,220,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,987,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_494_20231231_zAb0IHQt3Gk4" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbBPpteJeCL1" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkmDYg05af9b" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zn6mtzaWdAqe" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Cash equivalents:</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--InvestmentTypeAxis__us-gaap--MoneyMarketFundsMember_z1umKmfCM85l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Money market funds</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">443,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">443,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #C1E4F5"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Short-term investments:</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--FairValueNetAssetLiability_iI_hus-gaap--InvestmentTypeAxis__us-gaap--USGovernmentCorporationsAndAgenciesSecuritiesMember_zB2zSSQX9M69" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt">US treasuries and US gov't. agencies</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,893,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,893,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--FairValueNetAssetLiability_iI_zFH5OjW0NgSh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total financial assets</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">13,336,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">443,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-

```
family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt">12,893,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black
2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0691">—</span>
</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table>
1220000122000049870004987000620700012200004987000443000443000128930001289300013336000443000128930000<p id="xdx_80F_eus-gaap--
AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zSUCKSO1dHn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_825_zIR4dBTagn9g">Accounts Payable and Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--
ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zVjlCLiZ8a3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt">Accounts payable consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B0_zqBfKYdQLu86"
style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Accounts Payable</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times,
Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times,
Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20240930_zcJpCQnj04Z3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20231231_zZnZM8CkqDMi" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"><b>September 30, 2024</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
(Unaudited)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td
style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times
New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align:
center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--
RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zyDQiL4gJH4c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 48%">Accounts payable to Cytovance, a related party <sup id="xdx_F45_zTVMlzGqMtma">1</sup></td> <td style="font: 10pt Times
New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt">638,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width:
1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt">3,515,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zRA5GUIXLQB1"
style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Accounts payable to University of
Minnesota</td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times,
Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt">697,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt">130,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr
id="xdx_403_eus-gaap--AccountsPayableOtherCurrent_iI_zt1bExPX8Ri2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times
New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt">Other accounts payable</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> 1,277,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font:
10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times,
Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 683,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_zbxBfu2DqdCh" style="font: 10pt Times New Roman, Times, Serif;
vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
accounts payable</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black
2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,612,000</span></td> <td style="font: 10pt Times New
Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom:
2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt">4,328,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b id="xdx_F0A_zSmycbq6Bpr1"><sup>1</sup></b></span></td><td style="text-align:
justify"><span id="xdx_F13_zQQ9pL7DgH76" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns
greater than 5% of the Company’s issued and outstanding common stock</span></td> </tr></table> <p id="xdx_8A2_zdiGa0bXpdEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-
align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt">See Note 8 – Commitments and Contingencies, Significant Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zUzysbychry9" style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The details of the Company’s accounts payable to Cytovance Biologics, Inc.,
were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zevyOoJaG8m8"
style="display: none">Schedule of Accounts Payable to Related Party</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-
collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2"
id="xdx_498_20240101__20240930_zckKvL7nr8Kd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td>
<td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230101__20230930_zxKMvOki3Nki" style="border-bottom: Black 1pt solid; font-weight: bold; text-align:
center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-
bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ending</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr
style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align:
center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-
weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-
weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight:
bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--
CytovanceBiologicsIncMember_z0cMtD47g6Ij" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Beginning balance</td><td style="width: 2%"> </td> <td
style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">3,515,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align:
left">$</td><td style="width: 22%; text-align: right">2,283,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--
RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_ztgceY5fp0yf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left:
10pt">Invoices, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,365,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-
align: right">3,691,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--
CytovanceBiologicsIncMember_zdpGWeMlDRH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Payments in cash</td><td> </td> <td
style="text-align: left"> </td><td style="text-align: right">(3,432,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,710,000</td><td
style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--RepaymentsOfRelatedPartyCommonStock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--
CytovanceBiologicsIncMember_zC1UkDG7Cx0f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Payments in common stock, at fair
value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(810,000</td><td style="padding-
bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">
(1,120,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--
CytovanceBiologicsIncMember_zlPLFmUjVsO2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom:
2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">638,000</td><td style="padding-bottom: 2.5pt; text-align:
left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,144,000</td><td
style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zknokqxLRmij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"><b>University of Minnesota</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt">See Note 8 – Commitments and Contingencies, Significant Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"></span></p> <p id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zVjlCLiZ8a3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt
0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-
align: justify"><span id="xdx_8B0_zqBfKYdQLu86" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Accounts Payable</span></p> <table cellpadding="0"
cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align:
bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif;
padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20240930_zcJpCQnj04Z3" style="font: 10pt Times
New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-
bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align:
center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20231231_zZnZM8CkqDMi" style="font: 10pt Times New Roman, Times, Serif; text-
align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align:
center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times
New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align:
center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-
align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2024</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt;
text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align:
center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-
align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt;
text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td
style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align:
```

```
center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b>
</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td
style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_40F_eus-gaap--
AccountsPayableTradeCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_zyDQiL4gJH4c" style="font: 10pt Times New Roman, Times, Serif; vertical-align:
bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 48%">Accounts payable to Cytovance, a related party <sup
id="xdx_F45_zTVMlzGqMtma">1</sup></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width:
22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">638,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New
Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,515,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width:
1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccountsPayableTradeCurrent_iI_hus-gaap--
RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfMinnesotaMember_zRA5GUIXLQB1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td
style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Accounts payable to University of Minnesota</td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">697,000</span></td> <td style="font: 10pt Times New Roman, Times,
Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New
Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--AccountsPayableOtherCurrent_iI_zt1bExPX8Ri2" style="font: 10pt Times New Roman, Times, Serif; vertical-
align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt">Other accounts payable</td> <td style="font: 10pt Times New
Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman,
Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 1,277,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 683,000</span></td> <td style="font:
10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--
AccountsPayableCurrent_iI_zbxBfu2DqdCh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-
bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accounts payable</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt">2,612,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-
bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double;
font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,328,000</span></td> <td style="font: 10pt Times New Roman, Times,
Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0;
margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b
id="xdx_F0A_zSmycbq6Bpr1"><sup>1</sup></b></span></td><td style="text-align: justify"><span id="xdx_F13_zQQ9pL7DgH76" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock</span></td> </tr></table>
638000351500069700013000012770006830002612000432800<p id="xdx_897_ecustom--ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock_zUzysbychry9" style="font: 10pt Times New Roman, Times,
Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The details of the Company’s accounts payable to Cytovance Biologics, Inc., were as
follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zevyOoJaG8m8"
style="display: none">Schedule of Accounts Payable to Related Party</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-
collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2"
id="xdx_498_20240101__20240930_zckKvL7nr8Kd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td>
<td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20230101__20230930_zxKMvOki3Nki" style="border-bottom: Black 1pt solid; font-weight: bold; text-align:
center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-
bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ending</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr
style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align:
center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-
weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-
weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight:
bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iS_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--
CytovanceBiologicsIncMember_z0cMtD47g6Ij" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Beginning balance</td><td style="width: 2%"> </td> <td
style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">3,515,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align:
left">$</td><td style="width: 22%; text-align: right">2,283,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_hus-gaap--
RelatedPartyTransactionsByRelatedPartyAxis__custom--CytovanceBiologicsIncMember_ztgceY5fp0yf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left:
10pt">Invoices, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,365,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-
align: right">3,691,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_iN_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--
CytovanceBiologicsIncMember_zdpGWeMlDRH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Payments in cash</td><td> </td> <td
style="text-align: left"> </td><td style="text-align: right">(3,432,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,710,000</td><td
style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--RepaymentsOfRelatedPartyCommonStock_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--
CytovanceBiologicsIncMember_zC1UkDG7Cx0f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Payments in common stock, at fair
value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(810,000</td><td style="padding-
bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">
(1,120,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--AccountsPayableTradeCurrent_iE_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--
CytovanceBiologicsIncMember_zlPLFmUjVsO2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom:
2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">638,000</td><td style="padding-bottom: 2.5pt; text-align:
left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,144,000</td><td
style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 351500022830001365000369100034320001710000-810000-11200006380003144000<p id="xdx_802_ecustom--
WarrantLiabilityTextBlock_zcaah99fs8E7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>Note 5 - <span><span id="xdx_825_zcfngfJTaoaa">Warrant Liability</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"><b>2023 Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt">On January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate of <span id="xdx_901_eus-gaap--
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeCommonWarrantsMember__srt--RangeAxis__srt-
-MaximumMember_ztPj41b4Z2o5" title="Warrants to purchase">216,667</span> shares of the Company’s common stock (the “2023 Common Warrants”), and placement agent warrants to purchase up to <span
id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--
RangeAxis__srt--MaximumMember_z08PISOQk5Jb" title="Warrants to purchase">13,000</span> shares of the Company’s common stock (the “2023 Placement Agents Warrants”).</span></p> <p style="font: 10pt
Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times,
Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the
“2023 Warrants”), provide for a value calculation for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides for a floor on the volatility
amount utilized in the value calculation at <span id="xdx_906_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--
TwoThousandTwentyThreeWarrantsMember_zJg8Q8TyNN3d" title="Volatility amount utilized in the value calculation percentage">100</span>% or greater. The Company has determined this provision introduces
leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Company’s own equity shares. Therefore, pursuant to ASC 815, the Company has
classified the 2023 Warrants as a liability in its consolidated balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is evaluated at the end of each
reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span>
</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2023 Warrants were initially
recorded at a fair value at $<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20240930__us-gaap--StatementEquityComponentsAxis__custom--
TwoThousandTwentyThreeWarrantsMember_z2bI5KvwE42d" title="Warrant fair value">5.8</span> million at the grant date, and upon the closing of placement, was recorded as a cost of capital. The fair value of
the 2023 Warrants classified as a liability in the Company’s unaudited condensed consolidated balance sheets and will be re-measured at the end of every reporting period with the change in value reported in the
unaudited condensed consolidated statements of operations until they are either exercised or expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--
FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zuEjHeHWsnEi"
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2023 Warrant liability is valued using a
Binomial pricing model with the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B4_zvrztLxkVGM6" style="display: none; font-family:
Times New Roman, Times, Serif; font-size: 10pt">Schedule of Derivative Liabilities Assumptions</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left:
auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6"
style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023 Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-
align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td
style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align:
center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td
colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">
(Unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Stock price</td><td style="width: 2%"> </td> <td
style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zH44PsMaItwj" style="width: 22%; text-align: right" title="Warrants measurement
input">2.31</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyThreeWarrantsMember_zLf8WuXDPfXe" style="width: 22%; text-align: right" title="Warrants measurement input">7.20</td><td style="width: 1%; text-align: left"> </td></tr> <tr
style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate <b><sup>1</sup></b>
</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ____zYF19TuemMwj" style="text-align: right" title="Warrants
measurement input">3.58</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--
DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ____zFmpX96WaNJi" style="text-align: right" title="Warrants measurement input">4.6</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup>2</sup>
</b></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-
gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg____zdWxbBo3wOb2" style="text-align: right" title="Warrants measurement
input">114</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--
MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg____zCeZTe8izyqe" style="text-align: right"
title="Warrants measurement input">119.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup>3</sup></b></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw____z7mePQAV6Ib2" title="Expected life
(in years)">3.25</span> - <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap-
-DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw____zzmOgCY4kwNb" title="Expected life (in years)">3.75</span></span></td><td
```

style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--
MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMw____zDPFlT123DOk" title="Expected life
(in years)">4.5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt">Expected dividend yield ⁴</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--
DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA____zuSIWjs9ryth" style="text-align: right" title="Warrants measurement input">—
</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--
MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA____zvhLXzBjfFUh" style="text-
align: right" title="Warrants measurement input">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White">
<td>Fair value of warrants</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyThreeWarrantsMember_zY12Ytly4e76" style="text-align: right" title="Fair value of warrants">182,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td
id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zUKA8oNkni56" style="text-align: right"
title="Fair value of warrants">1,051,000</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-
bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F02_z5LkQTBW1Wqb" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt">¹</td><td style="text-align: justify">Based on rates established
by the Federal Reserve Bank</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr
style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">²
</td><td style="text-align: justify">Historical volatility of the Company's common stock is used
to estimate the future volatility of its common stock</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width:
100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F05_z28KFdDGUyRc" style="width: 15pt; text-align: right">
³</td><td style="text-align: justify">Determined by the remaining contractual life
of the derivative instrument</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr
style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">⁴
</td><td style="text-align: justify">Based on no dividends paid or expected to be paid
</td> </tr></table> <p id="xdx_8AF_zakWZMiFLHWe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">2020 Warrants</p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify">The Company issued warrants underlying <span id="xdx_903_eus-gaap--
StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyWarrantsMember_zarRzRA7cLq8" title="Issued warrants of common
stock">58,824 shares of common stock during the year ended December 31, 2020 (the "2020 Warrants"), that contained a fundamental transaction provision that could give rise to an obligation to pay cash
to the warrant holder upon occurrence of certain change in control type events. In accordance with ASC 480, the fair value of the 2020 Warrants is classified as a liability in the Company's unaudited condensed
consolidated balance sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed consolidated statements of operations until they are either
exercised or expire.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">
</p> <p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyWarrantsMember_z0UvqRHoSSz" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt">The 2020 Warrant liability is valued using a Binomial pricing model with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt">Schedule of Derivative Liabilities Assumptions</p> <table cellpadding="0" cellspacing="0"
style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td
style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020 Warrants</td><td style="padding-bottom: 1pt; font-weight:
bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-
weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-
bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align:
center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td
colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Stock
price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240930__us-gaap--
MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_zOsjaYOPoT66" style="width: 22%; text-align: right"
title="Warrants measurement input">2.31</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyWarrantsMember_zf3AYFLHfeIb" style="width: 22%; text-align: right" title="Warrants measurement input">7.20</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-
align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate ¹</td>
<td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fMQ____zbbSpCYCFscc" style="text-align: right" title="Warrants measurement
input">3.98</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--
MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fMQ____zNM2UZh8IRIg" style="text-align:
right" title="Warrants measurement input">5.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility ²</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyWarrantsMember_fMg____zmWSNOh9ecf7" style="text-align: right" title="Warrants measurement input">114</td><td style="text-align: left">%</td><td> </td> <td style="text-align:
left"> </td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-
gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fMg____zhzpR1lWEcmc" style="text-align: right" title="Warrants measurement input">89.0</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (in years) ³
</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_fMw____zQGFtE4CEoU6" style="text-align: right" title="Expected life (in years)">0.8</td><td
style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fMw____zCiuxZTyzHL3" style="text-align: right" title="Expected life (in years)">1.8</td>
<td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt">Expected dividend yield ⁴</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--
DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fNA____zLlLwhfugtU9" style="text-align: right" title="Warrants measurement input">—
</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--
MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fNA____zIVC0St1CEU6" style="text-align:
right" title="Warrants measurement input">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White">
<td>Fair value of warrants</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyWarrantsMember_z0zTDfNAgV91" style="text-align: right" title="Fair value of warrants">—</td><td style="text-align: left"> </td>
<td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyWarrantsMember_z159HNWQNufc" style="text-align: right" title="Fair value of warrants">2,000</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"> <tr
style="display: none; vertical-align: top; text-align: justify"> <td id="xdx_F00_zwKcrolsbQI" style="text-align: right; width: 15pt">
¹</td><td style="text-align: justify">Based on rates established by the Federal
Reserve Bank</td> </tr> <tr style="display: none; vertical-align: top; text-align: justify"> <td style="text-align: right"><span id="xdx_F06_zSWD1OwI0y1" style="font-family: Times New Roman, Times,
Serif; font-size: 10pt">²</td><td style="text-align: justify">Historical
volatility of the Company's common stock is used to estimate the future volatility of its common stock</td> </tr> <tr style="display: none; vertical-align: top; text-align: justify"> <td
id="xdx_F03_zmzoWPg0pqCe" style="text-align: right">³</td><td style="text-align: justify">Determined by the remaining contractual life of the derivative instrument</td> </tr> <tr style="display:
none; vertical-align: top; text-align: justify"> <td style="text-align: right">⁴
</td><td style="text-align: justify">Based on no dividends paid or expected to be paid</td> </tr>
</table> <p id="xdx_8A7_zxOGxyIlrdx6" style="display: none; margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Warrant Liability</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_ziA1jhbbyjH4" style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The details of warrant liability transactions were as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Schedule of Derivative Liability Transactions</p> <table cellpadding="0"
cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-
align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20240930_zyO1Vkwj5Aag" style="border-bottom: Black 1pt solid; font-weight: bold; text-
align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2"
id="xdx_49F_20230101__20230930_zd8O9N4j8Ilh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td>
</tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold;
text-align: center">Nine Months Ending</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold;
padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td
style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-
weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)
</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td></tr> <tr
id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zunsEkXptKu" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Beginning balance</td><td
style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">1,052,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td
style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">18,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--
IssuanceOfStockAndWarrantsForServicesOrClaims_zF1DZnHlFGOc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Issuance of warrants at fair value</td>
<td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align:
left"> </td><td style="text-align: right">5,831,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zIeQJHqg9boi" style="vertical-align: bottom;
background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(870,000</td><td
style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,796,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--
ExtinguishmentOfWarrant_zN7wjtB1P3b5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Extinguishment</td><td style="padding-bottom:
1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td
style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align:
right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zOU4ibZKfrC4"
style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt
double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">182,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td
style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,053,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table> <p id="xdx_8AB_zShyiZ0eVmN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </p> 2166671300015800000<p id="xdx_89E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--
DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zuEjHeHWsnEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt">The 2023 Warrant liability is valued using a Binomial pricing model with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times,
Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify">Schedule of Derivative Liabilities Assumptions</p> <table
cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-
align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023 Warrants</td><td style="padding-
bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-
bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td
colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom">
<td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight:
bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td

```
style="width: 48%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyThreeWarrantsMember_zH44PsMaItwj" style="width: 22%; text-align: right" title="Warrants measurement input">2.31</td><td style="width: 1%; text-align: left"> </td><td style="width:
2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-
gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zLf8WuXDPfXe" style="width: 22%; text-align: right" title="Warrants measurement
input">7.20</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt">Risk-free interest rate <b><sup>1</sup></b></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--
DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ____zYF19TuemMwj" style="text-align: right" title="Warrants measurement input">3.58</td><td style="text-align: left">%</td>
<td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMQ____zFmpX96WaNJi" style="text-align: right" title="Warrants
measurement input">4.6</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup>2</sup></b></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyThreeWarrantsMember_fMg____zdWxbBo3wOb2" style="text-align: right" title="Warrants measurement input">114</td><td style="text-align: left">%</td><td> </td> <td style="text-align:
left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-
gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMg____zCeZTe8izyqe" style="text-align: right" title="Warrants measurement input">119.7</td><td style="text-align: left">%</td>
</tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup>3</sup>
</b></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--
WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MinimumMember_fMw____z7mePQAV6Ib2" title="Expected life (in years)">3.25</span> - <span id="xdx_90F_eus-gaap--
WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyThreeWarrantsMember__srt--RangeAxis__srt--MaximumMember_fMw____zzmOgCY4kwNb" title="Expected life (in years)">3.75</span></span></td><td style="text-align: left"> </td>
<td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fMw____zDPFlT123DOk" title="Expected life (in years)">4.5</span></td><td
style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt">Expected dividend yield <b><sup>4</sup></b></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--
DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA____zuSIWjs9ryth" style="text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0757">—
</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--
MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_fNA____zvhLXzBjfFUh" style="text-
align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0759">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White">
<td>Fair value of warrants</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyThreeWarrantsMember_zY12Ytly4e76" style="text-align: right" title="Fair value of warrants">182,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td
id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeWarrantsMember_zUKA8oNkni56" style="text-align: right"
title="Fair value of warrants">1,051,000</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup> </sup></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-
bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F02_z5LkQTBW1Wqb" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt"><b><sup>1</sup></b></span></td><td style="text-align: justify"><span id="xdx_F1C_zMUpQEuVVt9g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on rates established
by the Federal Reserve Bank</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr
style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F0F_zacdmNJZYRV3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>2</sup>
</b></span></td><td style="text-align: justify"><span id="xdx_F1C_zMDQuPlQjkde" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical volatility of the Company’s common stock is used
to estimate the future volatility of its common stock</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width:
100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F05_z28KFdDGUyRc" style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
<sup>3</sup></b></span></td><td style="text-align: justify"><span id="xdx_F1B_zjXKD8qcy5Ug" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determined by the remaining contractual life
of the derivative instrument</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr
style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F06_zFBhLv7zOgQj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>4</sup>
</b></span></td><td style="text-align: justify"><span id="xdx_F12_zSW6jplhjrB6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on no dividends paid or expected to be paid</span>
</td> </tr></table> 2.317.203.584.6114119.7P3Y3MP3Y9MP4Y6M182000105100058824<p id="xdx_89E_eus-gaap--
FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_z0UvqRHoSSz"
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2020 Warrant liability is valued using a
Binomial pricing model with the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span
id="xdx_8B0_zCxip1xM96il" style="display: none">Schedule of Derivative Liabilities Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif;
margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td
colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020 Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td
style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td>
<td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align:
center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td
colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align:
center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Stock price</td><td style="width: 2%"> </td> <td
style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_zOsjaYOPoT66" style="width: 22%; text-align: right" title="Warrants measurement
input">2.31</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyWarrantsMember_zf3AYFLHfeIb" style="width: 22%; text-align: right" title="Warrants measurement input">7.20</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-
align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate <b><sup>1</sup></b></span></td>
<td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fMQ____zbbSpCYCFscc" style="text-align: right" title="Warrants measurement
input">3.98</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--
MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fMQ____zNM2UZh8IRlg" style="text-align:
right" title="Warrants measurement input">5.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility <b><sup>2</sup></b></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyWarrantsMember_fMg____zmWSNOh9ecf7" style="text-align: right" title="Warrants measurement input">114</td><td style="text-align: left">%</td><td> </td> <td style="text-align:
left"> </td><td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-
gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fMg____zhzpR1lWEcmc" style="text-align: right" title="Warrants measurement input">89.0</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (in years) <b><sup>3</sup></b>
</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyWarrantsMember_fMw____zQGFtE4CEoU6" style="text-align: right" title="Expected life (in years)">0.8</td><td
style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--
MeasurementInputExpectedTermMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fMw____zCiuxZTyzHL3" style="text-align: right" title="Expected life (in years)">1.8</td>
<td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt">Expected dividend yield <b><sup>4</sup></b></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--
WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--
DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fNA____zLlLwhfugtU9" style="text-align: right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0789">—</span>
</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--
MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyWarrantsMember_fNA____zIVC0St1CEU6" style="text-align:
right" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0791">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White">
<td>Fair value of warrants</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyWarrantsMember_z0zTDfNAgV91" style="text-align: right" title="Fair value of warrants"><span style="-sec-ix-hidden: xdx2ixbrl0793">—</span></td><td style="text-align: left"> </td>
<td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--
TwoThousandTwentyWarrantsMember_z159HNWQNufc" style="text-align: right" title="Fair value of warrants">2,000</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"> <tr
style="display: none; vertical-align: top; text-align: justify"> <td id="xdx_F00_zwKcrolsbQI" style="text-align: right; width: 15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
<sup>1</sup></b></span></td><td style="text-align: justify"><span id="xdx_F14_z1JCNatGglp5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on rates established by the Federal
Reserve Bank</span></td> </tr> <tr style="display: none; vertical-align: top; text-align: justify"> <td style="text-align: right"><span id="xdx_F06_zSWD1OwI0y1" style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"><b><sup>2</sup></b></span></td><td style="text-align: justify"><span id="xdx_F1E_zdO7JO6EedX5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
volatility of the Company’s common stock is used to estimate the future volatility of its common stock</span></td> </tr> <tr style="display: none; vertical-align: top; text-align: justify"> <td
id="xdx_F03_zmzoWPg0pqCe" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>3</sup></b></span></td><td style="text-align: justify"><span
id="xdx_F18_zDkuUkgkzgXb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determined by the remaining contractual life of the derivative instrument</span></td> </tr> <tr style="display:
none; vertical-align: top; text-align: justify"> <td style="text-align: right"><span id="xdx_F06_zjTiicQn5Pf7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>4</sup></b></span>
</td><td style="text-align: justify"><span id="xdx_F1C_zwZQJBabzoSd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on no dividends paid or expected to be paid</span></td> </tr>
</table> 2.317.203.985.011489.0P0Y9M18DP1Y9M18D2000<p id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_ziA1jhbbyjH4" style="font: 10pt Times New Roman, Times, Serif;
margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The details of warrant liability transactions were as follows:</span></p> <p style="font: 10pt
Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times,
Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B8_zZZ0OEQT5B6g" style="display: none">Schedule of Derivative Liability Transactions</span></p> <table cellpadding="0" cellspacing="0"
style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"><tr style="display: none; vertical-align: bottom"> <td style="text-align:
center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20240930_zyO1Vkwj5Aag" style="border-bottom: Black 1pt solid; font-weight: bold; text-align:
center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2"
id="xdx_49F_20230101__20230930_zd8O9N4j8Ilh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td>
</tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold;
text-align: center">Nine Months Ending</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold;
padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td
style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-
weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)
</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td></tr> <tr
id="xdx_407_ecustom--WarrantLiabilityCurrent_iS_zunsEkXptKu" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Beginning balance</td><td
style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">1,052,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td
style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">18,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--
IssuanceOfStockAndWarrantsForServicesOrClaims_zF1DZnHIFGOc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Issuance of warrants at fair value</td>
<td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0806">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align:
left"> </td><td style="text-align: right">5,831,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_zIeQJHqg9boi" style="vertical-align: bottom;
background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(870,000</td><td
style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,796,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--
ExtinguishmentOfWarrant_zN7wjtB1P3b5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Extinguishment</td><td style="padding-bottom:
1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0812">—</span></td><td
style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align:
right"><span style="-sec-ix-hidden: xdx2ixbrl0813">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WarrantLiabilityCurrent_iE_zOU4ibZKfrC4"
style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt
double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">182,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td
style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,053,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table> 1052000180005831000-870000-47960001820001053000<p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zDYsomrpxeff" style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 - <span id="xdx_82A_zrzj98ESTU9g">Stockholders’ Equity</span></b></span></p> <p
```

```
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company's authorized capital as of September 30, 2024 was <span
id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zmnvi8RY4US" title="Common stock, shares authorized">250,000,000</span> shares of common stock, par value $<span id="xdx_900_eus-
gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240930_zyCwq00QfcNg" title="Common stock, par value">0.001</span> per share, and <span id="xdx_90B_eus-gaap--
PreferredStockSharesAuthorized_iI_pid_c20240930_zPEpQdy5LJ5i" title="Preferred stock, shares authorized">15,000,000</span> shares of preferred stock, par value $<span id="xdx_90A_eus-gaap--
PreferredStockParOrStatedValuePerShare_iI_pid_c20240930_zhLQBwbKvqX7" title="Preferred stock, par value">0.01</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent:
0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024 Common Stock Offering</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 23, 2024, the Company received gross proceeds of approximately $<span id="xdx_90E_eus-gaap--
ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20240523__20240523__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zYIfq4wHc8c4" title="Proceeds from private
placement">3.2</span> million, before deducting placement agent fees and other offering expenses of $<span id="xdx_901_eus-gaap--NoninterestExpenseOfferingCost_c20240523__20240523__us-gaap--
TypeOfArrangementAxis__custom--PurchaseAgreementMember_zMJHoBm0YOyl" title="Other offering expenses">243,000</span> in relation to a purchase agreement <span style="background-color: white">(the
"Purchase Agreement") </span>signed on May 21, 2024, between the Company and institutional investors (the "Purchasers") for the issuance and sale, in a registered direct offering, of <span id="xdx_90B_eus-gaap-
-CommonStockSharesIssued_iI_pid_c20240523__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zG4i7ubsZ2Sj"
title="Direct offering">740,000</span> shares of the Company's common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20240523__us-gaap--
StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zhI73PBLfboj" title="Common stock par value">0.001</span> per share
(the "2024 Shares"). In a concurrent private placement, the Company issued and sold to the Purchasers warrants to purchase <span id="xdx_905_eus-gaap--
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240523__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyFourCommonWarrantsMember__us-gaap--
TypeOfArrangementAxis__custom--PurchaseAgreementMember_zDJchazf8Zfh" title="Purchase of warrants">740,000</span> shares of the Company's common stock (the "2024 Common Warrants"). In addition, the
Company issued warrants to the placement agent to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240523__us-gaap--
StatementEquityComponentsAxis__custom--TwentyTwentyFourPlacementAgentWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zWyl5aAec9Bi" title="Placement
agents">88,800</span> shares of common stock (the "2024 Placement Agents Warrants"). The 2024 Common Warrants have an exercise price equal to $<span id="xdx_90F_eus-gaap--
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20240523__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyFourCommonWarrantsMember__us-gaap--
TypeOfArrangementAxis__custom--PurchaseAgreementMember_zsLYfD3ndL9j" title="Warrant exercise price">4.35</span> per share, and the 2024 Placement Agents Warrants have an exercise price equal to
$<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240523__us-gaap--StatementEquityComponentsAxis__custom--
TwentyTwentyFourPlacementAgentWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zQT6uJyOKhmc" title="Warrant exercise price">5.4375</span> per share, both are
exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial exercise date. The 2024 Shares and 2024 Common Warrants were sold at an offering price
of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20240523__us-gaap--StatementEquityComponentsAxis__custom--
TwentyTwentyFourCommonSharesAndTwentyTwentyFourCommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zFKghunBrQr1" title="Price per share">4.35</span>
per share and accompanying 2024 Common Warrant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt">Pursuant to the Purchase Agreement, the Company agreed, with certain exceptions, for a period of 60 days following the closing of the offering not to issue, enter into an agreement to issue or
announce the issuance or proposed issuance of the 2024 Shares or any other securities convertible into, or exercisable or exchangeable for, shares of the Company's common stock. The Company has also agreed for
a period of one year following the closing date of the offering not to (i) issue or agree to issue equity or debt securities convertible into, or exercisable or exchangeable for, shares at a conversion price, exercise price
or exchange price which floats with the trading price of the 2024 Shares or which may be adjusted after issuance upon the occurrence of certain events or (ii) enter into any agreement, including an equity line of
credit, whereby the Company may issue securities at a future-determined price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company
determined that under ASC 815-40, the 2024 Common Warrants and the 2024 Placement Agent Warrants do not contain a clause that adjusts the exercise price based on circumstances not considered to be within
the Company's control and are considered indexed to the Company's own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2024 Common Warrants and the 2024
Placement Agent Warrants are classified as equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><b>2023 Private Placement of Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt">On January 4, 2023, the Company received gross proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20230104__20230104__us-gaap--
TypeOfArrangementAxis__custom--PurchaseAgreementMember_z2sUFpXi3B3k" title="Proceeds from private placement">6.5</span> million, before deducting placement agent fees and other offering expenses of
$<span id="xdx_90A_eus-gaap--NoninterestExpenseOfferingCost_c20230104__20230104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ztSX42VzANY3" title="Other offering
expenses">232,000</span> in relation to a purchase agreement signed on December 30, 2022, between the Company and an institutional investor for the issuance and sale, in a registered direct offering, of <span
id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--
PurchaseAgreementMember_z45qS4s7JzN5" title="Direct offering">120,000</span> shares of the Company's common stock, par value $<span id="xdx_90E_eus-gaap--
CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--
PurchaseAgreementMember_zudAmcXze792" title="Common stock par value">0.001</span> per share (the "2023 Shares"), pre-funded warrants to purchase up to <span id="xdx_90E_eus-gaap--
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember__us-gaap--
TypeOfArrangementAxis__custom--PurchaseAgreementMember_zqTwJRC7jNh" title="Purchase of warrants">96,667</span> shares of the Company's common stock (the "Pre-Funded Warrants"), warrants to
purchase up to an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--
TwentyTwentyThreeCommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zDaPPIGkMAW5" title="Purchase of warrants">216,667</span> shares of the Company's
common stock (the "2023 Common Warrants") and placement agent warrants to purchase up to <span id="xdx_907_eus-gaap--
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyThreePlacementAgentWarrantMember__us-gaap--
TypeOfArrangementAxis__custom--PurchaseAgreementMember_z1Kg3v491Irf" title="Purchase of warrants">13,000</span> of the Company's common stock (the "2023 Placement Agents Warrants"). The 2023
Common Warrants have an exercise price equal to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20230104__us-gaap--
StatementEquityComponentsAxis__custom--TwentyTwentyThreeCommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zXCMycczXSW1" title="Warrant exercise
price">30.00</span> per share, are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial issuance date. The Pre-Funded Warrants had an
exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230104__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--
ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zqDvVZED8e93" title="Exercise price of warrant">0.003</span> per share, are immediately exercisable and could be exercised at any time after
their original issuance until such Pre-Funded Warrants were exercised in full. The 2023 Placement Agents Warrants have an exercise price equal to $<span id="xdx_904_eus-gaap--
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230104__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantMember__us-gaap--TypeOfArrangementAxis__custom--
PurchaseAgreementMember_z8MleHohD0zf" title="Warrant exercise price">37.50</span> per share, are exercisable commencing six months following issuance, and have a term of exercise equal to five years
following the initial issuance date. The 2023 Shares and 2023 Common Warrants were sold at an offering price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230104__us-
gaap--StatementEquityComponentsAxis__custom--TwentyTwentyThreeCommonSharesAndTwentyTwentyThreeCommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--
PurchaseAgreementMember_zXwBP7wSxcD9" title="Price per share">30.00</span> per share and accompanying 2023 Common Warrant and the Pre-Funded Warrants and 2023 Common Warrants were sold at an
offering price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230104__us-gaap--StatementEquityComponentsAxis__custom--
PreFundedWarrantsAndTwentyTwentyThreeCommonWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zoY8OTsRLlbj" title="Price per share">29.997</span> per Pre-
Funded Warrant and accompanying 2023 Common Warrant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt">The 2023 Common Warrants and the 2023 Placement Agents Warrants contained a clause not considered to be within the Company's control. The Company determined that the provision represented a
variable that is not an input to the fair value of a "fixed-for-fixed" option as defined under ASC 815-40, and thus the 2023 Common Warrants and the 2023 Placement Agent Warrants are not considered indexed to
the Company's own stock and not eligible for an exception from derivative accounting. Accordingly, the 2023 Common Warrants and the 2023 Placement Agent Warrants were classified as a warrant liability, and
$<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20230104__20230104__us-gaap--StatementEquityComponentsAxis__custom--
CommonWarrantAndPlacementAgentWarrantMember_z9Y6XLxXqA46" title="Change in fair value of warrant liability">5.8</span> million of the initial common stock offering was classified as a warrant liability (see
Note 5 – Warrant Liability).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>Common Stock Issued for Services</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the
nine months ended September 30, 2023, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20240930__srt--TitleOfIndividualAxis__custom--
BoardOfDirectorsEmployeesAndConsultantsMember_zxhgdO8IqYx2" title="Common stock issued for services, shares">15,782</span> shares of common stock with a fair value of $<span id="xdx_90B_eus-gaap--
StockIssuedDuringPeriodValueIssuedForServices_c20240101__20240930__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsEmployeesAndConsultantsMember_zQlAar4GNQ1e" title="Common stock issued for
services, value">430,000</span> to members of the Company's Board of Directors (the "Board"), employees, and consultants. The shares were valued at the respective date of the agreements.</span></p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series C Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt
0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024 and December 31, 2023, there were <span id="xdx_901_eus-gaap--
PreferredStockSharesIssued_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zCuGmT5svDOh" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--
PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zuXseVt6GT8a" title="Preferred stock, shares outstanding">96,230</span>
</span> shares of series C preferred stock, par value $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--
SeriesCPreferredStockMember_zmCEJn9Rrwid" title="Preferred stock, par value"><span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-
gaap--SeriesCPreferredStockMember_zOAslMjhI7Ch" title="Preferred stock, par value">0.01</span></span> per share (the "Series C Preferred Stock") issued and outstanding.</span></p> <p style="font: 10pt
Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times,
Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of reverse stock splits in previous years and the agreement terms for adjusting
the rights of the related shares, the <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zxzwMQPMpMWb"
title="Preferred stock, shares issued">96,230</span> shares of Series C Preferred Stock are not currently convertible, have no voting rights, and in the event of liquidation, the holders of the Series C Preferred
Stock would not participate in any distribution of the assets or surplus funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by the
Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through September 30, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series K Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 16, 2021, the Board designated <span id="xdx_906_eus-gaap--
StockIssuedDuringPeriodSharesNewIssues_pid_c20210216__20210216__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zIav73bCD2w1" title="Preferred stock shares
designated">115,000</span> shares of Series K preferred stock, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210216__us-gaap--
StatementClassOfStockAxis__custom--SeriesKPreferredStocksMember_zzMuW7qRic56" title="Preferred stock, par value">.01</span> (the "Series K Preferred Stock").</span></p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of the Series K Preferred Stock are convertible at any time, at the option of the holders, into
shares of the Company's common stock at an effective conversion rate of <span id="xdx_901_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_pid_c20210216__us-gaap--StatementClassOfStockAxis__custom--
SeriesKPreferredStocksMember_z0WTaazWMuR8" title="Convertible shares issuable">100</span> shares of common stock for each share of Series K Preferred. Shares of the Series K Preferred Stock have the same
voting rights as the shares of the Company's common stock, with the holders of the Series K Preferred Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation,
together with the holders of the Company's common stock on all matters presented to the Company's stockholders. The Series K Preferred Stock are not entitled to any dividends (unless specifically declared by the
Board) but will participate on an as-converted-to-common-stock basis in any dividends to the holders of the Company's common stock. In the event of the Company's dissolution, liquidation or winding up, the
holders of the Series K Preferred Stock will be on parity with the holders of the Company's common stock and will participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the
Company's common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30,
2024 and December 31, 2023, there were <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_do_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zDpuiPYDdJZ4"
title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240930__us-gaap--StatementClassOfStockAxis__custom--
SeriesKPreferredStockMember_zpQ0lXk1G2Mc" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231__us-gaap--
StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_zVKsjmox7Bgd" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231__us-
gaap--StatementClassOfStockAxis__custom--SeriesKPreferredStockMember_z2auCCGjTxtk" title="Preferred stock, shares outstanding">no</span></span></span></span> shares of Series K Preferred stock issued
and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span>
</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt
Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p>
2500000000.001150000000.01320000024300074000000.001740000888004.355.43754.35650000023200012000000.0019666721666713000030.000.00337.5030.0029.99758000001578243000096230962300.010.0196230
```

id="xdx_80B_ecustom--CommonStockWarrantsAndOptionsTextBlock_zRXseoIMjsk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 7 - Common Stock Warrants and Options</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Common Stock Warrants</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ziq101Df6a86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Stock warrant transactions for the six months ended September 30, 2024 were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Schedule of Warrant Activity</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Warrants outstanding at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20240930_z9qHZSalTQ8j" style="width: 22%; text-align: right" title="Warrants outstanding, beginning balance">304,962</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930_z88MEv6Fw79h" style="width: 22%; text-align: right" title="Weighted average exercise price, beginning balance">63.30</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20240930_z7whNKvwJlba" style="text-align: right" title="Number of warrants, granted">828,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20240101__20240930_zh7X2HjutzMj" style="text-align: right" title="Weighted average exercise price, granted">4.47</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited/cancelled</td> <td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20240930_zwLBli6CHX4h" style="text-align: right" title="Number of warrants, forfeited/cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20240101__20240930_zzAjMmVFvCmd" style="text-align: right" title="Weighted average exercise price, forfeited/cancelled">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20240930_zqZNrW9beqKe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, exercised">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20240101__20240930_zZx1PmNHSQ13" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20240930_zwGPh902zpIf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">1,133,762</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_z786wxoTQNw7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">20.57</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20240930_zl38VzIts4d5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance">1,133,762</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240930_zPGRu5Yulnie" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance">20.57</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zlk9I5e3ip98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of September 30, 2024, all outstanding warrants are fully vested and had an exercise price greater than the market price of the Company's common stock, which resulted in no intrinsic value. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zMiKXotYehf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">Warrants outstanding as of September 30, 2024 are exercisable as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Schedule of Warrants Outstanding and Exercisable</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding and Exercisable as of September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Range of</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Exercise</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Price</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Number</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Outstanding</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Weighted Average</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Remaining Contractual Life (Years)</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Weighted Average</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Exercise Price</p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right">4.35</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z03D29Tl9fi9" style="width: 21%; text-align: right" title="Number of outstanding">740,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 22%; text-align: right">4.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">4.35</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">5.4375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zBtPqUyeJ4g5" style="text-align: right" title="Number of warrants outstanding">88,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 5.4375</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">30.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zUVCSJtLyVN2" style="text-align: right" title="Number of warrants outstanding">216,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 30.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">37.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBTYADJNAuF3" style="text-align: right" title="Number of warrants outstanding">13,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 37.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">102.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zyecOQIHrVej" style="text-align: right" title="Number of warrants outstanding">1,867</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_ziLsD0Heilha"

title="Warrants outstanding, weighted average remaining contractual life (years)">0.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">
<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zfqTxyEqvZ78"
title="Warrants exercisable, weighted average exercise price">102.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align:
left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240930__us-gaap-
-ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z5hCUR6AppFf"
title="Range of exercise price">165.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zERTTtqWQOyh" style="text-align: right" title="Number of warrants
outstanding">65,649</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF5tJp6kxNP4"
title="Warrants outstanding, weighted average remaining contractual life (years)">1.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">
<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_ztLx378h9P6i"
title="Warrants exercisable, weighted average exercise price">165.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td
style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_903_eus-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z3fANG7wEXVd" title="Range of exercise price">206.25</td><td
style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zzoN0gfaQ6O7" style="border-bottom: Black 1pt solid; text-align: right" title="Number
of warrants outstanding">7,780</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-
bottom: 1pt; text-align: right"><span id="xdx_90F_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zcpM9XcEeTFb"
title="Warrants outstanding, weighted average remaining contractual life (years)">1.4</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td
style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90D_ecustom--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--
WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zeZdagbUH36d" title="Warrants exercisable, weighted
average exercise price">206.25</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align:
left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt
double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoP2T38xkKpg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding">1,133,762</td><td style="padding-
bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-
gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember_zzbs4jgacfs1" title="Warrants outstanding, weighted average remaining contractual life (years)">4.2</td><td style="padding-bottom: 2.5pt; text-
align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_907_ecustom--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--
WarrantsMember_zNQNYezPiKmj" title="Warrants exercisable, weighted average exercise price">20.57</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p
id="xdx_8A7_z073e1vEDhH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Common Stock Options
</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt
Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In April 2022 the Company established the 2022 Omnibus
Incentive Plan (the “Plan”). The Plan was approved by our Board and stockholders. The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees,
directors, and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards granted under the Plan is <span id="xdx_909_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220401__20220430__us-gaap--AwardTypeAxis__custom--OmnibusIncentivePlanMember_zEqCkPs4Z0Nl" title="Common
stock awards granted">166,667. The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant under the Plan. As of September 30,
2024, there were <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240101__20240930__us-gaap--AwardTypeAxis__custom--
OmnibusIncentivePlanMember_zuNyRYWNKqh8" title="Awards granted plan">39,467 shares available for grant under the Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_891_eus-gaap--
ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3A8s9B5Tlv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock option transactions for the nine months ended September 30, 2024:</p> <p style="font: 10pt Times New Roman, Times,
Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt
0">Schedule of Options Activity</p> <table cellpadding="0"
cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align:
center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2024</td>
<td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight:
bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td
style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom:
Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2"
style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color:
rgb(204,238,255)"> <td style="width: 48%">Options outstanding at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930_z4SivVNRcQD4" style="width: 22%; text-align: right" title="Number of options
outstanding, beginning">126,265</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930_zPYgElPstuu5" style="width: 22%; text-align: right"
title="Weighted-Average Exercise Price, beginning">40.15</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left:
10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930_zl2X1hXVHAef" style="text-align: right" title="Number of options, granted"><span style="-sec-
ix-hidden: xdx2ixbrl1004">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zCKyUMxhVApj" style="text-align: right" title="Weighted-
Average Exercise Price, granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td
style="padding-left: 10pt">Forfeited/cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20240930_z4yK13ZnAph5" style="text-align: right" title="Number of options,
forfeited/cancelled">(25,001</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zKg8Re888H8a" style="text-align: right"
title="Weighted-Average Exercise Price, forfeited/cancelled">14.80</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-
bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--
StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240101__20240930_zADXhHUhkCVc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="-sec-
ix-hidden: xdx2ixbrl1012">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td
id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zA0apZT9mrOd" style="border-
bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised">—</td><td style="padding-bottom: 1pt; text-align: left"> </td>
</tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td
style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930_z4hvAgrfsLT8" style="border-bottom: Black 2.5pt double; text-align: right"
title="Number of options outstanding, ending">101,264</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-
align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zczUL6L5TmTb"
style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending">39.74</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align:
bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-
align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20240930_zLX9aUFfcyQ6" style="border-bottom: Black 2.5pt
double; text-align: right" title="Number of options outstanding exercisable">101,264</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-
bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240930_zvLCuyQ1SY0c" style="border-bottom: Black 2.5pt double; text-align: right"
title="Weighted-Average Exercise Price,exercisable, ending">39.74</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zOqb1vRwX02l" style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of September 30, 2024 was <span
id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zJM5o5DtPJ2e" title="Share-
based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term">8.2 years. Furthermore, all options outstanding and all options vested
and exercisable as of September 30, 2024 had an exercise price greater than the market price of the Company’s common stock, which resulted in no intrinsic value.</p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify">The total fair value of options that vested during the nine months ended September 30, 2024 and 2023,
was $<span id="xdx_90A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20240101__20240930_zxh02bGiZT54" title="Fair value of
vested stock options">222,000 and $<span id="xdx_901_eus-gaap--
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c20230101__20230930_z3TqUuwcKyX3" title="Fair value of vested stock
options">1,338,000, respectively, and is included in selling, general and administrative expense in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2024,
all outstanding stock options were fully vested and exercisable and there was no unvested compensation expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On May 15, 2023, the Company granted stock options to a member of the Board to purchase <span id="xdx_90E_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230515__20230515_zMfiuDf2gE5k" title="Purchase an aggregate">16,666 shares of common stock.
The stock options are exercisable at $<span id="xdx_907_eus-gaap--
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20230515_zNt7dSkSJCnb" title="Price per
share">10.50 per share, expire in <span id="xdx_905_eus-gaap--
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230515__20230515_zocEje1sSMvf" title="Expiry
period">10 years, vest over twelve months and have a fair value of $<span id="xdx_90C_eus-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230515_zWQ3fnMsgyv4" title="Share vested value">150,000 on at the date of
grant which will be amortized over the vesting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin:
0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify">On January 27, 2023, the Company granted stock options to employees and members of the Board to purchase an aggregate of
66,667
shares of common stock. The stock options are exercisable at $<span id="xdx_90B_eus-gaap--
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_uUSDPShares_c20230127_z9IQLmare7N5" title="Exercise
price">25.50 per share, expire in <span id="xdx_90E_eus-gaap--
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230127__20230127_zMkaev43ay77" title="Stock
options expire">10 years, vest over twelve months and have a fair value of $<span id="xdx_902_eus-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pn5n6_c20230127_zOMVzUdSldxb" title="Fair value">1.4 million at the date of grant
which will be amortized over the vesting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"> </p> <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zgPEfFNR61Fc" style="font: 10pt
Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Options outstanding as of September 30, 2024 are exercisable
as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_zi9pRueAmMl2"
style="display: none">Schedule of Options Outstanding and Options Exercisable</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto;
border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-

```
align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="10" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Options Outstanding and Exercisable as of September 30, 2024</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom:
1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td
colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt
0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-
align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-
align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Contractual Life (Years)</b>
</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span>
</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td
colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif;
width: 21%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zajHXfedpI57" title="Range of excercise price">10.50</span></span></td> <td
style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width:
2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z6TNhX7EXmMg" style="font: 10pt Times New Roman, Times, Serif; width: 21%; text-align:
right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,666</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times
New Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zSfzFoMSZyfa" title="Options outstanding, weighted average remaining contractual life
(years)">8.6</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt
Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z86iZgthgyz2" title="Options outstanding, weighted average exercise price">10.50</span>
</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New
Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span>
</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZjIRjRIvR3k" title="Range of excercise price">25.50</span></span></td> <td
style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zgBDLfmfomia" style="font: 10pt Times New Roman, Times, Serif; text-align: right"
title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align:
right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zMysC3u2UOg9" title="Options outstanding, weighted average remaining contractual life
(years)">8.3</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New
Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span
id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z76jUjnJsdG4" title="Options outstanding, weighted average exercise price">25.50</span>
</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times,
Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span
id="xdx_901_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zhUH61feEvda" title="Range of excercise price">74.40</span></span></td> <td
style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times,
Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zFvicppdC5ol" style="border-bottom: black 1pt solid; font: 10pt Times New Roman,
Times, Serif; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,598</span></td> <td style="font: 10pt Times New Roman, Times, Serif;
padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span
id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap-
-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIifIpPYYtif" title="Options outstanding, weighted average remaining contractual life
(years)">7.8</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times,
Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align:
right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z2hKQxHr6MDa" title="Options outstanding, weighted average exercise
price">74.40</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr
style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double;
font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_989_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240930_zDl8xbuLTI87" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times,
Serif; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,264</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-
bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family:
Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times,
Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></td></tr> </table> <p id="xdx_8AC_zLWoyDpVrTHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_ziq101Df6a86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt
0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock warrant transactions for the six months ended September 30, 2024 were as follows:</span></p> <p
style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BB_zvYrk2H7gz39" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of Warrant
Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align:
bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months
Ended September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td
colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align:
center">Weighted Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td
colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom:
1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-
align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Warrants outstanding at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td
id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20240930_z9qHZSalTQ8j" style="width: 22%; text-
align: right" title="Warrants outstanding, beginning balance">304,962</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td
id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930_z88MEv6Fw79h" style="width: 22%;
text-align: right" title="Weighted average exercise price, beginning balance">63.30</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td
style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20240930_z7whNKvwJlba" style="text-align: right" title="Number of warrants,
granted">828,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_pid_c20240101__20240930_zh7X2HjutzMj" style="text-align: right" title="Weighted average
exercise price, granted">4.47</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited/cancelled</td>
<td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20240101__20240930_zwLBli6CHX4h" style="text-align: right" title="Number of
warrants, forfeited/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0912">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsWeightedAverageExercisePrice_pid_c20240101__20240930_zzAjMmVFvCmd" style="text-align: right"
title="Weighted average exercise price, forfeited/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0914">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color:
White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20240930_zqZNrW9beqKe" style="border-bottom: Black 1pt solid; text-align: right"
title="Number of warrants, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0916">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td
style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice_pid_c20240101__20240930_zZx1PmNHSQ13" style="border-bottom: Black 1pt solid; text-
align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0918">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align:
bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Warrants outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black
2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--
```

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20240930_zwGPh902zpIf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">1,133,762</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_z786wxoTQNw7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, ending balance">20.57</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_iI_pid_c20240930_zl38VzIts4d5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable, ending balance">1,133,762</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240930_zPGRu5Yulnie" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance">20.57</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
30496263.308288004.47113376220.57113376220.570<p id="xdx_893_ecustom--ScheduleOfWarrantsOustandingAndExercisableTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zMiKXotYehf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">Warrants outstanding as of September 30, 2024 are exercisable as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Schedule of Warrants Outstanding and Exercisable</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding and Exercisable as of September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Range of</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Exercise</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Price</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Number</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Outstanding</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Weighted Average</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Remaining Contractual Life (Years)</p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Weighted Average</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">Exercise Price</p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right"><span id="xdx_908_eus-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zGk78j1vlmHb" title="Range of exercise price">4.35</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z03D29Tl9fi9" style="width: 21%; text-align: right" title="Number of outstanding">740,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 22%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zJHitoKRXQ4d"
title="Warrants outstanding, weighted average remaining contractual life (years)">4.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><span id="xdx_900_ecustom--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--
WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zPQAuC3l3ml4" title="Warrants outstanding, weighted average exercise price">4.35</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z8VgwkRkfrk5"
title="Range of exercise price">5.4375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zBtPqUyeJ4g5" style="text-align: right" title="Number of warrants outstanding">88,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zbLb1qVRkiIj"
title="Warrants outstanding, weighted average remaining contractual life (years)">4.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">
<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zVudRsexSoT8"
title="Warrants exercisable, weighted average exercise price">5.4375</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zNxD4vWUfvr4" title="Range of exercise price">30.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zUVCSJtLyVN2" style="text-align: right" title="Number of warrants outstanding">216,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zPO62iDxOSB9"
title="Warrants outstanding, weighted average remaining contractual life (years)">3.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">
<span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zvZzivpCF5z8"
title="Warrants exercisable, weighted average exercise price">30.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zZnO95Jnhi87"
title="Range of exercise price">37.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBTYADJNAuF3" style="text-align: right" title="Number of warrants outstanding">13,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zRjnLo59IyH"
title="Warrants outstanding, weighted average remaining contractual life (years)">3.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">
<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zmta5Rko4Yk2"
title="Warrants exercisable, weighted average exercise price">37.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zGN8cJveclwk" title="Range of exercise price">102.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zyecOQIHrVej" style="text-align: right" title="Number of warrants outstanding">1,867</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_ziLsD0Heilha"
title="Warrants outstanding, weighted average remaining contractual life (years)">0.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">
<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zfqTxyEqvZ78"
title="Warrants exercisable, weighted average exercise price">102.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z5hCUR6AppFf"
title="Range of exercise price">165.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zERTTtqWQOyh" style="text-align: right" title="Number of warrants outstanding">65,649</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zF5tJp6kxNP4"
title="Warrants outstanding, weighted average remaining contractual life (years)">1.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">
<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_ztLx378h9P6i"
title="Warrants exercisable, weighted average exercise price">165.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_903_eus-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z3fANG7wEXVd" title="Range of exercise price">206.25</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zzoN0gfaQ6O7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants outstanding">7,780</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90F_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zcpM9XcEeTFb"
title="Warrants outstanding, weighted average remaining contractual life (years)">1.4</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_90D_ecustom--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--
WarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zeZdagbUH36d" title="Warrants exercisable, weighted average exercise price">206.25</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember_zoP2T38xkKpg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants outstanding">1,133,762</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240930__us-gaap--
ClassOfWarrantOrRightAxis__custom--WarrantsMember_zzbs4jgacfs1" title="Warrants outstanding, weighted average remaining contractual life (years)">4.2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_907_ecustom--
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--
WarrantsMember_zNQNYezPiKmj" title="Warrants exercisable, weighted average exercise price">20.57</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
4.35740000P4Y8M12D4.355.437588800P4Y7M6D5.437530.00216666P3Y9M18D30.0037.5013000P3Y3M18D37.50102.001867P0Y9M18D102.00165.0065649P1Y4M24D165.00206.257780P1Y4M24D206.251133762P4Y
id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z3A8s9B5Tlv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes stock option transactions for the nine months ended September 30, 2024:</p> <p style="font: 10pt

```
Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times,
Serif; margin: 0pt 0pt 0pt 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_ztYCjuabugbh">Schedule of Options Activity</span></span></p> <table
cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-
align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,
2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-
weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average</td><td
style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom:
Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2"
style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color:
rgb(204,238,255)"> <td style="width: 48%">Options outstanding at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930_z4SivVNRcQD4" style="width: 22%; text-align: right" title="Number of options
outstanding, beginning">126,265</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930_zPYgElPstuu5" style="width: 22%; text-align: right"
title="Weighted-Average Exercise Price, beginning">40.15</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left:
10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930_zl2X1hXVHAef" style="text-align: right" title="Number of options, granted"><span style="-sec-
ix-hidden: xdx2ixbrl1004">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zCKyUMxhVApj" style="text-align: right" title="Weighted-
Average Exercise Price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1006">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td
style="padding-left: 10pt">Forfeited/cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20240930_z4yK13ZnAph5" style="text-align: right" title="Number of options,
forfeited/cancelled">(25,001</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zKg8Re888H8a" style="text-align: right"
title="Weighted-Average Exercise Price, forfeited/cancelled">14.80</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-
bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--
StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240101__20240930_zADXhHUhkCVc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, exercised"><span style="-sec-
ix-hidden: xdx2ixbrl1012">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td
id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zA0apZT9mrOd" style="border-
bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1014">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td>
</tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td
style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930_z4hvAgrfsLT8" style="border-bottom: Black 2.5pt double; text-align: right"
title="Number of options outstanding, ending">101,264</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-
align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zczUL6L5TmTb"
style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, ending">39.74</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align:
bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-
align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20240930_zLX9aUFfcyQ6" style="border-bottom: Black 2.5pt
double; text-align: right" title="Number of options outstanding exercisable">101,264</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-
bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20240930_zvLCuyQ1SY0c" style="border-bottom: Black 2.5pt double; text-align: right"
title="Weighted-Average Exercise Price,exercisable, ending">39.74</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
12626540.152500114.8010126439.7410126439.74P8Y2M12D22200013380001666610.50P10Y1500006666725.50P10Y1400000<p id="xdx_896_eus-gaap--
ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zgPEfFNR61Fc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options outstanding as of September 30, 2024 are exercisable as follows:</span></p> <p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt
0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zi9pRueAmMl2" style="display: none">Schedule of Options Outstanding and Options
Exercisable</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr
style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span>
</td> <td colspan="10" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Options Outstanding and Exercisable as of September 30, 2024</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; font:
10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>Range of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>Price</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b>
</span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New
Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Contractual Life (Years)</b></span></p></td> <td
style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt
Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" style="border-
bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New
Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times
New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 21%; text-align: right">
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zajHXfedpI57" title="Range of excercise price">10.50</span></span></td> <td
style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width:
2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z6TNhX7EXmMg" style="font: 10pt Times New Roman, Times, Serif; width: 21%; text-align:
right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,666</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times
New Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zSfzFoMSZyfa" title="Options outstanding, weighted average remaining contractual life
(years)">8.6</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt
Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: right"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z86iZgthgyz2" title="Options outstanding, weighted average exercise price">10.50</span>
</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New
Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span>
</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZjIRjRIvR3k" title="Range of excercise price">25.50</span></span></td> <td
style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zgBDLfmfomia" style="font: 10pt Times New Roman, Times, Serif; text-align: right"
title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align:
right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zMysC3u2UOg9" title="Options outstanding, weighted average remaining contractual life
(years)">8.3</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New
Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span
id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z76jUjnJsdG4" title="Options outstanding, weighted average exercise price">25.50</span>
</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times,
Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-
size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span
id="xdx_901_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_pid_c20240101__20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zhUH61feEvda" title="Range of excercise price">74.40</span></span></td> <td
style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times,
Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_98D_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zFvicppdC5ol" style="border-bottom: black 1pt solid; font: 10pt Times New Roman,
Times, Serif; text-align: right" title="Options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,598</span></td> <td style="font: 10pt Times New Roman, Times, Serif;
padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-
family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span
id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap-
-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zIifIpPYYtif" title="Options outstanding, weighted average remaining contractual life
(years)">7.8</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td
style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times,
Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align:
right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20240930__us-gaap--
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z2hKQxHr6MDa" title="Options outstanding, weighted average exercise
price">74.40</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr
style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times
```

New Roman, Times, Serif; font-size: 10pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20240930_zDl8xbuLTI87" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options outstanding">101,264</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td></tr> </table> 10.5016666P8Y7M6D10.5025.5050000P8Y3M18D25.5074.4034598P7Y9M18D74.40101264<p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkQa00dWt0q8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 8 - Commitments and Contingencies</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.05pt">Litigation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under, and are being handled in, the normal course of business:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Ohri Matter</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the Demand, the Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing that the Company may characterize Mr. Ohri’s termination as “for cause” under his Employment Agreement, and that the Company may revoke the Separation Agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri’s breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri’s violations, and attorneys’ fees and any forum and arbitration fees. On September 3, 2024, Mr. Ohri filed both a general denial of the Company’s claims against him and counterclaims for breach of his Employment Agreement and Separation Agreement. At this early stage in the proceedings the Company is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Berk Matter</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On November 14, 2023, former interim Chief Executive Officer, Dr. Gregory Berk filed a lawsuit in the US District Court for the District of Massachusetts alleging that the Company discriminated and retaliated against Dr. Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act (“SOX”). The Company vigorously defended this matter and believes it to be without merit; however, the parties have agreed to resolve the matter and the Company expects the lawsuit to be dismissed shortly. The Company believes it has recorded appropriate accruals for the matter.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">TWF Global Matter</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 24, 2023, TWF Global, LLC (“TWF”) filed a Complaint in the California Superior Court for the County of Los Angeles naming the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (“Notes”) and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its Complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint for Interpleader against TWF and Z-One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine if the Company’s shares of common stock are properly registered to TWF or Z-One LLC, as both of these entities have made conflicting demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice and will reconsider the motion without further briefing upon the filing of a supplemental party affidavit. On May 9, 2024, Z-One filed a motion for summary judgement seeking dismissal of the action, representing that Z-One and TWF have settled their dispute over the entitlement to the Company’s shares of common stock and there is no remaining dispute before the Court. On May 21, 2024, the Company filed a supplemental affidavit in support of its motion for entry of default. The Court has set a hearing on Z-One’s motion for November 14, 2024. The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these claims.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Significant Agreements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Cytovance Biologics, Inc., a Related Party</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In October 2020, the Company entered into a Master Services Agreement with Cytovance Biologics, Inc. (“Cytovance”), to perform biologic development and manufacturing services, and to produce and test compounds used in the Company’s potential product candidates. The Company subsequently executed numerous Statements of Work (“SOWs”) for the research and development of products for use in clinical trials.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and allowed for future invoices to be settled in in a combination of cash and issuance of the Company’s common stock. The Agreement also set Cytovance’s beneficial ownership limitation at 4.9% of the issued and outstanding shares of the Company’s common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> On April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance’s beneficial ownership limitation to 9.9% of the issued and outstanding shares of the Company’s common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">During the nine months ended September 30, 2024 and 2023, the Company recognized research and development expenses of $1,365,000 and $3,691,000, respectively and made cash payments amounting to $3,432,000 and $1,710,000, respectively to Cytovance. In addition, the Company issued 127,597 and 57,437 shares of common stock to Cytovance to settle accounts payable valued at approximately $810,000 and $1,120,000, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded 5% of the issued and outstanding shares of the Company’s common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of September 30, 2024 the Company’s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from Cytovance for services that have not yet been rendered as of September 30, 2024, amounted to approximately $1.3 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">University of Minnesota</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">2021 Scientific Research Agreement</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Effective June 16, 2021, the Company entered into a scientific research agreement with the Regents of the University of Minnesota, expiring on June 30, 2023. Payments totaling approximately $2.1 million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work with the Company with three major goals in mind: (1) support the Company’s TriKE®product development and GMP manufacturing efforts; (2) TriKE® pharmacokinetics optimization in humans; and (3) investigation of the patient’s native NK cell population based on insights obtained from the analysis of the human data generated during our GTB-3550 clinical trial. The major deliverables proposed are: (1) creation of IND enabling data for TriKE®constructs in support of our product development and GMP manufacturing efforts; (2) TriKE® platform drug delivery changes to allow transition to alternative drug delivery means and extended PK in humans; and (3) gain an increased understanding of changes in the patient’s native NK cell population as a result of TriKE®therapy. Most studies will use TriKE®DNA/amino acid sequences created by the Company under existing licensing terms.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company recorded an expense classified as research and development of approximately $0 and $192,000, pursuant to the 2021 Scientific Research Agreement, for the nine months ended September 30, 2024 and 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of September 30, 2024 the Company’s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant to the 2021 Scientific Research Agreement for services that have not yet been rendered as of September 30, 2024, amounted to $0.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">2023 Sponsored Research Agreement </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the “2016 Exclusive Patent License Agreement”), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $1.7 million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work with the Company with three major goals in mind: (1) support the Company’s TriKE® product development and commercial GMP manufacturing efforts; (2) TriKE® pharmacokinetics optimization in humans and investigation of effects of altering the route of administration; and (3) research and development of TriKE® platform. The major deliverables proposed are: (1) creation of IND enabling data for TriKE® constructs in support of the Company’s product development and commercial GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE® platform drug delivery changes to allow transition from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ]) and extended PK in humans and gain an increased understanding of changes in the patient’s native NK cell population as a result of alteration of TriKE® administration; and (3) research and development of TriKE® platform combination with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE® platform through formation of immune complexes. Most studies will use TriKE® DNA/amino acid sequences created by the Company under existing licensing terms.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times

```
New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded an expense classified as research and
development of approximately $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandTwentyThreeSponsoredResearchAgreementMember_zhSwE5dxpr2j" title="Research and development expense">863,000</span> and $<span id="xdx_906_eus-gaap--
ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zVkp1Hemlwok" title="Research and
development expense">0</span>, pursuant to the 2023 Sponsored Research Agreement, for the nine months ended September 30, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt
0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024 the Company's commitments in relation to unbilled and unaccrued amounts from the
University of Minnesota pursuant to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of September 30, 2024, amounted to approximately $<span id="xdx_900_eus-gaap--
UnbilledReceivablesCurrent_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeSponsoredResearchAgreementMember_zIySFRbQoY97" title="Unbilled and unaccrued
amounts">862,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt"><b>2016 Exclusive Patent License Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt">Effective July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (as amended, the "2016 Exclusive Patent License
Agreement"), to further develop and commercialize cancer therapies using TriKE<sup>®</sup> technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of
the agreement, the Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE<sup>®</sup> technology worldwide for the treatment of any disease, state, or condition
in humans. The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that is
responsible for the regulation of products such as the TriKE<sup>®</sup> technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European
Union. The agreement requires an upfront payment of $<span id="xdx_906_ecustom--ProceedsFromUpfrontAmount_iI_c20160718__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandSixteenPatentLicenseAgreementMember_zoZ5K0eG2T8k" title="Proceeds from upfront amount">200,000</span>, and license maintenance fees of $<span id="xdx_90E_eus-gaap--
CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--
TwoThousandSeventeenThroughTwoThousandTwentyMember_zus5KlH7pSU3" title="Maintenance fee">200,000</span> for years 2017 through 2020, and $<span id="xdx_907_eus-gaap--
CostMaintenance_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zKyEjlVLY36e" title="Maintenance fee">100,000</span> per year
beginning in year 2021 and each year thereafter. The agreement also includes <span id="xdx_904_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandSixteenPatentLicenseAgreementMember_zcOskR9zc26d" title="Royalty fee percentage">4</span>% royalty fees on the net sales of licensed products, not to exceed <span id="xdx_902_ecustom--
RoyaltyFeePercentage_pid_dp_uPure_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--
MaximumMember_zYMIfrCqI9O6" title="Royalty fee percentage">6</span>% under subsequent license agreements or amendments to this agreement, and minimum royalty payments due upon the commencement
of commercial sales of licensed product is $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoMember_zh4mjbteQUh9" title="Annual royalty payments">250,000</span> beginning in 2022,
$<span id="xdx_903_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--
TwoThousandTwentyFiveMember_zFypmMj8lUH9" title="Annual royalty payments">2</span> million beginning in 2025, and $<span id="xdx_905_eus-gaap--RoyaltyExpense_pn6n6_c20160718__20160718__us-gaap--
TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenMember_zxYYiKNo9GDc" title="Annual royalty
payments">5</span> million beginning in 2027 throughout the remainder of the term. The agreement also includes numerous performance milestone payments including clinical development milestone payments
totaling $<span id="xdx_906_ecustom--PerformanceMilestonePayments_pn5n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandSixteenPatentLicenseAgreementMember_zroDuJLbWAOh" title="Milestone payments">3.1</span> million, and one-time sales milestone payments of $<span id="xdx_908_ecustom--
SalesMilestonePayments_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z6XRQl5Mj1Id" title="Sales milestone
payments">1</span> million upon reaching $<span id="xdx_906_ecustom--GrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandSixteenPatentLicenseAgreementMember_ztJrlvAsN2Gi" title="Sales">250</span> million in cumulative gross sales, and $<span id="xdx_901_ecustom--SalesRevenue_pn6n6_c20160718__20160718__us-
gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_ziD4S8BXTJt5" title="Sales revenue">5</span> million upon reaching $<span id="xdx_90A_ecustom--
CummulativeGrossSales_pn6n6_c20160718__20160718__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z7FOIrVmv9kl" title="Cumulative gross sales">500</span>
million in cumulative gross sales of licensed products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman,
Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size:
10pt">Effective May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University of Minnesota. The amendment requires an upfront payment
of $<span id="xdx_90C_ecustom--ProceedsFromUpfrontAmount_iI_c20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zZwpldWWKbqa" title="Proceeds
from upfront amount">145,000</span> and amends the license maintenance fees to $<span id="xdx_901_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandSixteenPatentLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveMember_zYmqxJYYhGh" title="Maintenance fees">50,000</span> in 2025, and $<span
id="xdx_902_eus-gaap--CostMaintenance_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z5vz0EGq8Ere" title="Maintenance
fees">100,000</span> per year beginning in year 2026 and each year thereafter. The amendment also includes <span id="xdx_908_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--
TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zhDL9anbaK82" title="Royalty fee percentage">1</span>% to <span
id="xdx_90C_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember__srt--RangeAxis__srt--
MaximumMember_zmskScCcVDyl" title="Royalty fee percentage">5</span>% royalty fees on the net sales of licensed products, not to exceed 6% under subsequent license agreements or amendments, and minimum
royalty payments due upon the commencement of commercial sales of licensed product is $<span id="xdx_906_ecustom--RoyaltyExpenseYearOne_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandSixteenPatentLicenseAgreementMember_zr9zsOsDLXk5" title="Royalty expense">250,000</span> in year one, $<span id="xdx_903_ecustom--
RoyaltyExpenseYearTwoThroughFive_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zBNoYTXW9zY4" title="Royalty
expense">2</span> million in years two through five, and $<span id="xdx_900_ecustom--RoyaltyExpenseYearAfterSix_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandSixteenPatentLicenseAgreementMember_zcvrpAQuNHs6" title="Royalty expense">5</span> million in year six throughout the remainder of the term. The amendment also includes numerous
performance milestone payments including clinical development milestone payments totaling $<span id="xdx_90B_ecustom--PerformanceMilestonePayments_pn5n6_c20240513__20240513__us-gaap--
TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z29lqpekENp6" title="Milestone payments">3.1</span> million, and one-time sales milestone, and one-time sales milestone
payments of $<span id="xdx_90B_ecustom--SalesMilestonePayments_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandSixteenPatentLicenseAgreementMember_zN0M0a8aHIQf" title="Milestone payments">1</span> million upon reaching $<span id="xdx_902_ecustom--GrossSales_pn6n6_c20240513__20240513__us-
gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zCDDIWZGdXfj" title="Gross sales">250</span> million in cumulative gross sales, and $<span id="xdx_904_ecustom--
SalesRevenue_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_z00PUAgGoTke" title="Sales revenue">5</span> million upon
reaching $<span id="xdx_902_ecustom--CummulativeGrossSales_pn6n6_c20240513__20240513__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zFuSsBoiqXTk"
title="Cumulative gross sales">500</span> million in cumulative gross sales of licensed products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt">The Company recorded an expense classified as research and development of $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-
gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zeNaFbyQGMq1" title="Research and development expense">145,000</span> and $<span id="xdx_908_eus-gaap--
ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--TwoThousandSixteenPatentLicenseAgreementMember_zuY1jPkc6cN5" title="Research and development
expense">0</span>, pursuant to the 2016 Exclusive Patent License Agreement, for the nine months ended September 30, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times,
Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0;
text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-
indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021 Exclusive License Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt
0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of
Minnesota (the "2021 Exclusive Patent License Agreement"), specific to the B7H3 targeted TriKE<sup>®</sup>. The agreement requires an upfront payment of $<span id="xdx_90A_ecustom--
UpfrontLicenseFee_pp0p0_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zB9Zpdw5sZec" title="Upfront license
fee">20,000</span>, and license maintenance fees of $<span id="xdx_90D_ecustom--LicenseMaintenanceFeeReceivable_iI_c20210326__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandAndTwentyOnePatentLicenseAgreementMember_zFy1VpqTgNKb" title="License maintenance fee, receivable">5,000</span> per year beginning in year 2022 and each year thereafter. The agreement
also includes <span id="xdx_90D_ecustom--RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandAndTwentyOnePatentLicenseAgreementMember_zY0Mj37W04Yl" title="Royalty fee percentage">2.5</span>% to <span id="xdx_904_ecustom--
RoyaltyFeePercentage_pid_dp_uPure_c20210326__20210326__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandAndTwentyOnePatentLicenseAgreementMember_zBWJ9QJ8Hlg6" title="Royalty fee percentage">5</span>% royalty fees on the net sales of licensed products, and minimum royalty payments due upon
the commencement of commercial sales of licensed product is $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandAndTwentyOnePatentLicenseAgreementMember_zh8LQCWyswmd" title="Annual royalty payments">250,000</span> in year one though four, and $<span id="xdx_907_eus-gaap--
CostMaintenance_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zV9LVeyWXX0b" title="Maintenance fee">2</span>
million beginning in year five and throughout the remainder of the term. The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $<span
id="xdx_907_ecustom--PerformanceMilestonePayments_pn5n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z471szuk4UK2"
title="Performance milestone payments">3.1</span> million, and one-time sales milestone payments of $<span id="xdx_90E_ecustom--SalesMilestonePayments_pn6n6_c20210326__20210326__us-gaap--
TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zOs6IrrV4jHi" title="Sales milestone payments">1</span> million upon reaching $<span id="xdx_905_ecustom--
GrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_zsQw4jR5D1ug" title="Gross sales">250</span> million in
cumulative gross sales, and $<span id="xdx_906_ecustom--SalesRevenue_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--
TwoThousandAndTwentyOnePatentLicenseAgreementMember_zt4ExfMFqdN7" title="Sales revenue">5</span> million upon reaching $<span id="xdx_90D_ecustom--
CummulativeGrossSales_pn6n6_c20210326__20210326__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyOnePatentLicenseAgreementMember_z5AC5MG3NAui" title="Cumulative gross
sales">500</span> million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has been paid under the 2016 restated exclusive patent license
agreement no further payment is due for the corresponding milestone.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times
New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif;
font-size: 10pt">The Company did not incur any expenses pursuant to the 2021 Exclusive License Agreement, for the nine months ended September 30, 2024 and 2023, respectively.</span></p> <p style="font: 10pt
Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
0.0490.0991365000369100034320001710000127597574378100001120000 0.05130000021000000192000017000008630000862000200000200000100000 0.040.0625000020000005000000310000010000002500000005
id="xdx_806_eus-gaap--SubsequentEventsTextBlock_z86et5Ng4Wbl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times,
Serif; font-size: 10pt"><b>Note 9 - <span id="xdx_828_zXlBCB6SKWY2">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:
justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 17, 2024, the Company granted stock options to an officer to purchase an aggregate of <span id="xdx_90B_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241017__20241017__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--
TitleOfIndividualAxis__srt--OfficerMember_z3CKW5IJczK1" title="Stock options granted">23,335</span> shares of common stock. The stock options are exercisable at $<span id="xdx_901_eus-gaap--
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20241017__20241017__us-gaap--SubsequentEventTypeAxis__us-gaap--
SubsequentEventMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zSM3BTZfTN88" title="Stock options exercisable price per share">2.11</span> per share, expire in <span id="xdx_908_eus-gaap--
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20241017__20241017__us-gaap--
SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zOZ901m28AaI" title="Stock options expire">10</span> years, vest over <span id="xdx_904_eus-gaap--
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20241017__20241017__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--
TitleOfIndividualAxis__srt--OfficerMember_zjW5D0WnevNg" title="Stock options vest years">three years</span> and have a fair value of approximately $<span id="xdx_90D_eus-gaap--
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20241017__20241017__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--
TitleOfIndividualAxis__srt--OfficerMember_zk9bUvHBB3Qg" title="Stock option vested value">45,000</span> at the date of grant which will be amortized over the vesting period.</span></p>
233352.11P10YP3Y45000 Accounts Payable to Cytovance Biologics, Inc. ("Cytovance"), a Related Party, since Cytovance owns greater than 5% of the Company's issued and outstanding common stock Based on rates
established by the Federal Reserve Bank Historical volatility of the Company's common stock is used to estimate the future volatility of its common stock Determined by the remaining contractual life of the
derivative instrument Based on no dividends paid or expected to be paid Based on rates established by the Federal Reserve Bank Historical volatility of the Company's common stock is used to estimate the future
volatility of its common stock Determined by the remaining contractual life of the derivative instrument Based on no dividends paid or expected to be paid
```

```
+-0EOD0LJ,Q\MF]-N3_ "JW9>(9M;^'-[J>?)NT MM)UI-9DE[ M=CXK168NIOLILMQ@\P[,\|[>F:5@N1_;KO\ X6S]B^U3_9?LF[R/,.S.WKMZ M9KMJ\_EE2#XP/+*P2-+$LS'H
%R34EM<:GXWUE;FUN;O3] M6*AXI&C>Z;OT MPX?GR8AD$CU/!_+U.1EZIH&O: M!ITVK6?B:^NY;8>:|-RQ:-U'+<9./\*5AW.^HKC?$.MRWGPRDU>SEDMII8XF M#1.59&,BA@".?456TS1M?
|0:#8WEQXBO+%F@0Q1P>@7 =VR"Q;[QR>]%@N=W M17FF@W_B?Q"9] EOC:FP=H[R^3F1N<*JD8P>ZWHFN>'-(FU>T\3ZA.=MR,N1G"DD#U^ MG%=IHU^=4T6RORFQKB%9&4= 2.0/;-
)KJ%R]1112&%%%% !7F[>-M33QF6+; MM ^V?8N$7&_ &X-C)Y^;KT_"NO\ %>]?V-X8OKQ6VRB,I$AUYOXJ\7ZQHGC/R8)MVG0K%)- M#Y:GY20&^;&1U'?K77>$]7.N>&K.]<_OBI27_>4X/Y]?
QKE=0TZ'5OB=?V$_ M^KGTW:3Z'C!_ X-$='J#VT/08I4GA26)@\;J&5AT(/(-9GB76%T+0+J_)&]% MVQ ]W/"C\ZQ_A_J$\ND3:3>Y%[I4IMY ><+SMY[]"/H!5;7PWB/QOI^A#)L[ M#%W=\9!;'RJ?
PX^C&E;4=]"3X>ZWJNM6FH'5;@S2P3!!F-5V\DG]:ETC_DK>O_| M7K'_ .@QTVM6);([>BBBH*"BBB@ HHHH **** "BBB@ KA?AK]S7/^OYJ[JN M%^&OW-
<_Z_FJELQ/1YQ&1*"1@JQ[$<\"N)_P"%F:U_ MSZV'_?M__BZZ/XF?\BW;_P#7VO\ Z ]>4UZ>%HTYT[R5SPL=B*M.MRPE961V M?_"S-:_Y];#_+]O_P#%T?\ "S-:_P"?6P_[]O|_%UQE%=/U>E_*
<7URO\ MSL[/_A9FM?\ /K8?]^W_ /BZ/^%F:U_SZV'_ '[?_P"+KC**]/J]++^^4/KE?\ MG9V?_"S-:_Y];#_OV_ \ \71_PLS6O^?6P_[]O_\ %UQE%U>E_*'URO_ #L[ M/_A9FM?\^MA_W[?_
.+H_P"%F:U_SZV'_?M__BZXRBZO2_E#ZY7_G9V?_"S M-:_Y];#_ +]O_P#%T?\ "S-:_P"?6P_[]O|_%UQE%U>E_*'URO_.SL_P#A M9FM?\^MA_P!^W_\ BZ/^%F:U_P ^MA_W[?|
^+KC**]/J]+^^4/KE?^=G9_P#" MS-:_Y];#_OV__P"+H_P"%F:U_P"?6P_[]O_ /%UQE%U>E_*'URO_.SL_ | A9FM M?\^MA_W[?_XNC_A9FM?\^MA_W[?_ .+KC**]/J]+^^4/KE?^=G9_| "S-:_P"? M6P_[]O|
_%T?\+,UK_GUL/\ OV__ ,77&&44?5Z7\H?7*_\ P#.SL_^%F:U_ P ^ MMA_W[?\ ^+H_X69K_GUL/\ ?M__ (NN,HH^KTOY0_N5_P"=G|+,UK_ GUL M/^_;_P#Q='_"S-:_Y];#_OV_P 77&&44?5Z7\H?7*_ |
.SL_^%F:U_SZV'_?M MM_| XNC_ (69K7_/K8?]^W_\ %UQE%U>E_*'URO_ #L[ M/_A9FM?\ /K8?]^W_ /BZ/^%F:U_P"?6P_[]O_ '[? M_P"+H_P"%F:U_SZV'_?M__BZX MM_] \ #ZV'_?M__BZ?
M_P#XNN,HH^KTOY0^N5_5_P"=G_/;__ \ )V/;;!ZK[:!E_OV_P"+H_\!MV_P"/_1\_O V^X /_O9FM?\^MA_W[?_P# MZ;H_X69K_GUL/ ^_;_P#XNN,HH^KTOY0^N5_5_U_VV_O
)];#_OV_P 7F/\_/_S!MYN^_ZV'_?M__P!$YO1F]:_SZV'_?M__BZX M%T?\+,UK_GUL/^_;_\ ^+KC**]/J]+^^4/KE?^=G9_| "S-:_Y];#_OV_\ \71_PLS6O^?6P_[]O_\
)];#_OV__P"+H_P"%F:U_SZV'_?M__BZXRBZO2_E#ZY7_G9V?_"S M-:_Y];#_ +]O_P#%T?\ "S-:_P"?6P_[]O|_%UQE%U>E_*'URO_.SL_P#A M9FM?\^MA_P!^W_\ BZ/^%F:U_P ^MA_W[?|
```

```
/BZ/^%F M:U_SZV'_'[?_P"+KC**/J]+^4/KE?\ G9V?_"S-:_Y];#_OV_| \71_PLS6 MO^?6P_[]O_| %UQE%'U>E_*'URO_ #L[/_A9FM?\^MA_W[?_ .+H_P"%F:U_ MSZV'_?
M__BZXRBCZO2_E#ZY7_G9V?_"S-:_Y];#_ +]O_P#%T?\ "S-:_P"? M6P_[]O\ _%UQE%'U>E_*'URO_.SL_P#A9FM?\^MA_P!^W_\ BZ/^%F:U_P ^ MMA_W[?\ ^+KC**/J]+^4/KE?^=G9_P#"S-
:_Y];#_OV_P 71_PLS6O^?6P_M[]O\_/%UQE%'U>E_*'URO_.SL_\ A9FM?\^MA_W[?_XNC_A9FM?\^MA_W[?_ M .+KC**/J]+^4/KE?^=G9_\ "S-:_P"?6P_[]O\ _%T?\+,UK_GUL/\ OV__ M ,77&44?
5Z7\H?7*_P#.SL_^%F:U_P ^MA_W[?\ ^+H_X69K7_/K8?\ ?M__ M (NN,HH^KTOY0_N5_P"=G9_\+,UK_GUL/^_ UK_GUL/^_;#_OV__P 7 M7&44?5Z7\H?7* .SL_^%F:U_SZV'_?M__ ^+K_ ?M_\ XNC_
(69K7_/K8?]^W_^+KC* M*/J]+^4/KE?^=G9_\+,UK_GUL/\ OV__ ,71_P +,UK_ )];#_OV_P#\|77&44 M4?5Z7\H?7*_\[.S_ .%F:U_SZV'_'[?_P"+H_X69K7_ #ZV'_?M_P#XNN,H MH^KTOY0^N5_YV=G_
,+,UK_GUL/^_ ;__ !='_"S-:_Y];#_OV_| \77&44?5 MZ7\H?7*_\[.S_P"%F:U_SZV'_?M__BZ/^%F:U_SZV'_?M_\ XNN,HH^KTOY0 M^N5_YV=G_P +,UK_ )];#_OV_P#\|71_PLS6O^?6P_P"_;_| Q=
<911]7I?RA M]&'. MUI$8LE_*'URO_ #L[/_A9FM?\^MA_W[?_ .+H_P"%F:U_SZV'_ ?M_ M__BZXRBCZO2_E#ZY7_G9V?_"S-:_Y];#_ +]O_P#%T?\ "S-:_P"?6P_[ M]O\
_%UQE%'U>E_*'URO_.SL_P#A9FM?\^MA_P!^W_\ BZ/^%F:U_P ^MA_W M[?\ ^+KC**/J]+^4/KE?^=G9_P#"S-:_Y];#_OV_P 71_PLS6O^?6P_[]O_ M /%UQE%'U>E_*'URO_.SL_\ A9FM?
\^MA_W[?_XNC_A9FM?\^MA_W[?_ .+K MC**/J]+^4/KE?^=G9_\ "S-:_P"?6P_[]O\ _%T?\+,UK_GUL/\ OV__ ,77&44?5Z7\H?7*_P#.SL_^%F:U_P ^MA_W[?\ ^+H_X69K7_/K8?\ ?M__ (NN
M,HH^KTOY0^N5_P"=G9_\+,UK_GUL/^_;_P#\ 77&44?5Z7\H?7* M5Z7\H?7*_P"%F:U_SZV'_?M_\ XNC_ (69K7_/K8?]^W_^+KC**/J]+^4/KE?^=G9_\+,UK_GUL/\ OV__ ,71_P
+,UK_ )];#_OV_P#\|77&44?5Z7\H?7* M7\H?7*_\[.S_ .%F:U_SZV'_'[?_P"+H_X69K7_ #ZV'_?M_P#XNN,HH^KT MOY0^N5_YV=G_ +,UK_GUL/^_;__ !='_"S-:_Y];#_OV_| \77&44?5Z7\H M?7*_\
[.S_P"%F:U_SZV'_?M__BZ/^%F:U_SZV'_?M_\ XNN,HH^KTOY0^N5_ MYV=G_P +,UK_ )];#_OV_P#\|71_PLS6O^?6P_P"_;_| Q=<911]7I?RA]BBBI&%%% M% !1110 4C=*6D;I0!R7B/
Y".B_P#82A_G7>UP7B/_ )".B_ 82A_G7>U0 MBOCE\OR/0K?K1_[?_| 2D%%%%%:""%5=1OH]-TZXO9>4A0L1Z^@ .K58GC"& M2?PQ[*1J6;R]V!Z @G] :F;:BVC?
#0C4K0A+9M)_>CS[3K'4_'^L3W%U=>5; MQ8+$#('.%5<^QY_$^^_=?"^S,)^R:A.DNWCS0&4G\ ,#_/-0_"^\@$-]9%E M6:?V';?)K M_8N^;[-]H\K=D;\?7&,_A7JOA7_D5=,_Z]UKSW_FJO\
V^UI7C%\LK;M"E. M(KPE7HN;:A&5O)IO4["T\(Z?X>M=0N+2:Y=Y+5T(E92,8SV4>E<+X)T&RU^] MNH;WS-L<093&V"#G%>LZG_R"KS_K@_| Z":\>|*^'$|275Q ]RT'E('#!-V>
M<>HHK02G%17R#+,34JX7$5:M1^[[V7W%O1K^+(-19-(TRTN M+3:,22L 2>_\8 E3H24(NZZ[&.<49XFK2E&2LXZ2;2O;O=;^1O7EN+NRGMBV MT31M'NQG&1C-
>?:]X%TC2/#\]V+NX%Q@ORM(Z[7;TQCO]:[70YM6GL"^LVL5 MM=;R D1R-N!@_>/OWKB]:^';)'>:C#]0:0;YS')%@'N1G/U[5I67-&ZC?2]#D
MRNI]7KNE*MR*ZVU4O*_;S+_PSGNI=%N8YB[012@0ELX&1R![=/SKG-1MK'5O MB+?0ZG=_9K;<0TA=4^ZH &3QVKI/AYKTVI6D]A/'&OV4*8VC0("ISP0.,Y_G M5V^\ Z1]%[/=S2W?FS.78K(,
GT^6L^1SI1Y=;'<\3#"9A7=:')67+K:]M> MGKZAX>|):+IUXNI:;?37) * ^:CIR/\ 9']:YSX@+9<^*+M+M)Y?*A:-)(2 M#5I""A+VE-QBK:A.I]2QT:V(J.2E!V=M=59:>6YDZ3X+\.?;H+NPU
M2:YDMY%E 2XC<9!R,X7ID55^)FKRPQ6NEPNZ"4&2;&Y>@'TSGCV%#^S+J1F"B5<_>?7)(VG'7('ZU?^);C7;20_ZMK8*&,)Q67XKC?$7@N+1/#=O?QRRF[1D%P&8;02/X<>AP.M M=QX-U.;5?
#5M/<-OF0F-W/5L'@GWQBJGCRZC_P"$+G*D,MPT80^OS!OY"H_A MS$T"A168$"2=V7W' _F#6T(J%;ECM8[W$UIXG*_:U]9*=D_S7]=CK:***ZSY
MDX+PY_R$=:_["4W\ZZU>EY/0M22)D7=41>X, < M5GCQ"HA?8-8T\M_=^U)G^=>/6]>N_$ 777#SA8U^=MQ(B@7M@=SZ=SW/>NH/P MA@\L :S)OQR?LXP3]-
W]:KE2W8KM['H5SJE9VZ7%U>6\]$#D!9)9556)&1@D MX/ JI_PDN@_]O3?_I/\:P?^$%^U>"['0+R\VM:S+YL*Y#9+X'L_Z5Y]X MV\(P>%%?L/DW4D_VGS,[U V[=OI_O4**>EP;:/7_^$ET'_H-
Z;_X%)_C4]SJ^ MF67E_:M1M(/,7HR>17FN@_#2TU?0[34'U&>-ITW%%0$#FJ_Q3A%M M>:1 #N$=KL!/?1]RJ]@N[7/3!XDT(D :UIQ@R 72?XUHQR]+&'C=71NC*<@ MUY1+\.]@R/6(;V>.X-
DMRPE93'D]&(X ([@7AU&]LM[&Q$/FE3 MR%DW #'ID9^N/:AQ5KH+N^IZO1114%%%ZU3+@*YQW>HVENXZK+.J'\B_EWPR
MUO8_,M;F&=+/[T3AA^8KA[GX86^HZC>WU[J,PDN+B255B4852Q(&3U.,>E<;X M;-QH'Q%33[:X9T%V;:3;P)%R1R/;K[$5?*GL3=GM=S=VUE 9[JXB@B! ,DKA M5'XFJ/\ PDN@P#0;TW_ ,"D_P
:Y[XI/M\'XQG=>)YTW%0$#DC^E"2M=@V[V1ZE:WMK?P^=9W,-Q%G&;OAD#KGTR*@N=;T MJRG,%UJ=E!,N,QRW"JPS[$U4\|->'X_#6EM8Q3O.IE,FYEP>0!C]*\RUS35\0 M_%>XT]F:-9G"EEP2
L0YY_W:22;!NQZHGB+1)%CCUC3V B,JK=(22>PYK2K MSZU^%%5G:7D%NRISLT4BR &,8)!S5GXF:_I6C06=I,8KB[UW517-9:P^=3QP0X=(*X51DX&2>.IJ
M6N7^(G_(B:E_VR_]I26K&SH[>Y@O(%GM9XYX6SMDB<,IP<'!'45+7GGPZN M9-,N[GP_<,O4=-X;WKT)F5$9W8#JC)8G H:LQ)W*\|^HV M-MV\5Q+CRXI)55GR<# )R>>*LUXQ<7,NL>-]-UQR!!
<:K'!:KG_EG& MR]]L4)-B;L=[J.HVFDV$E[>R^5;Q8WOM+8R0!0 3U(J6VN8KRUA MNH'WPS(LD;8(RI&0<'GH:Y'QCJEGJEGK'PWU"]L)O.MV,8#[2N2)5!X(!JQI_BG M1=1:$|-Z/#]'#!*^Q$[ &
K.P!0=0H)%.V7U.KHJKI^I6>\N/+FO'\|N!=<>V0,9 P.6'7'6G9A5+FTB\Z=65@ M$3 .2Q&/XAW[TK#-.BL"U\:^'+V+\6U@U2(S,VU0RL@)]2 #"=7]2UO3M'DM
MDO[@PFY?9%^[9@S<<9 ('4=:=F*YH4450LM:L-1O;NTM)S+-:-LG C8!&SC& MXC!/!Z&D,OT444 %%%% !7"_#7_5:W_U_-7=5POPU_U6M_| 7\U4MF)[G=44 M45(PHHHH **** "BBB@ HHHH
***Y;QMXAN-(M+:QT[G4]0D\]#C.WD GZY( M_| K4TK@S?N]2L=/"FJO;:V#=/.E5,_F:+34["_)%G?6UP0,D0RJ^!^KF= M*^'NEP1>=JX;4M0D"::::1B-W< 9Y'NN=AI;6M*O)/+M=3L MYY/[L4ZL?
R:KBHM*L=7*^7^FNPWJK">!BGI:'W MI%_Z"'"I>O/C,K, ,)NZW]\*KT+W<'M7 ,-L KL 9AO-LKM/V<-Y9X)<" ::E:=V:^^Y M1-8VJ#M&R!OYL>=L;0E_*H@!
"#.-!,MAB 8_ M=(N^#*B@OB(3PBI^%ZY8^.IV]+:UB)%TB:>8%G^A^5<-2*&E&@I8V/-S K8%)2_ZR[SD@MWY @^1K2P9%I@ ^F_J/!KH]]ED3P#XRY3$P MQA? +^ZE2\$*?0)W (.U;^-O4-U8E
1MSG+/%N?$_(U&X*P(^)<G2:W_HMKC^X M@=T9D]6)(Z'H4)JZV;%ACDN'J.5QOB?\9!VYZ1C1J^]"<5S>>[2)$AD[Y2+R[&2K#&Y:)+?,D]B6+>*?;]/.RT M+1W/AXW\&JW36 $:T0>//ZS)^UC_IH]YL>
'AX-FM@ZP42.HZ=(SNJ)]P-1.PO1U\=]OH2$K^)[$IGOM:8B89 M(8YZNK,5;KQ5& !'Z$5I&*5G"*=X??3)@DZI;KG?JYRCC$<
*<<8)"JA%DLP);DF)@ *E@O^1MYAQ2O MEA4H$1H]N3KX>:?Z3RNAZ0-T"L!G3^*+X1+$@K^!P]N3%LFC?,20 +]H5!#0]6
W!A8\NHX_X8W$A[X\O'[2G$(>H^N4>@Q^>QB% 4N<I]]3\
7LXQ_-#U)>\A0[:V2QF^0N_;,V9GA@XI,VN!\-1$+&7L&5'6U&^$E#Z]Z+
=(Z"[$-JUV+A,.9I9VL/R!E7>Q@D1:QU&[,7Q ,@ F@>%4M:'H]+-LZN[\'
```

!%_P#^ S_X5[Q11]?E_*']E0_F?X'@ M_P#PC^M?] B__P# 9_| "C_A']:_Z!%__P" S_X5[Q11]?E_*']E0_F?X'@_M_"/ZU_T"+_| \!G_ ,/^$?UK_H$7_| X#/_ (5[Q11]?E_*']E0_F?X'@__M C^M?\ 0(O_
/P&? "C_A']:_Z!%_| ^ S_ .%>\44?7Y?RA_94/YG^!X/_M ,(_K7_0(O| _P !G_PH_P"$?UK_ *!%_P#^ S_X5[Q11]?E_*']E0_F?X'@ M_P#PC^M?] B__P# 9_| "C_A']:_Z!%__P" S_X5[Q11]?E_*']E0_F?X'@L
MNB:M!$\LNEWL<:*6=WMW 4#J2<<"F6^D:G=P+/;:==S0O]V2.%F4]N"!7M/B M;_D5=7_Z\IO_ $ UF_#[_D1M-^DG_HQ]?UZ5KV%_9<+-_!/\#RW_ (1_6O\ MH$7_/X#/_A1_P (_K7_
$"+_P#\!G_PKWBBE]?E_*/^RH?S/\#P?_A']:_Z M!%^_ . S_ .%'_"/ZU_T"+_ ,!G_P *]XHH^OR_E#^RH?S/\#P?_A']:_Z! M!%^_ . S_P"%'_"/ZU_T"+_ _,!G_P *]XHH^OR_E#^RH?S/\#P?_ (1_6O\ MH$7_
/X#/_A1_P (_K7_ $"+_P#\!G_PKWBBCZ_+^4/[*A_ _P #P?\ X1_6 MO^@1?_| @_^%'_"/ZU_T"+_ /\ 9_|*]XHH^OR_E#^RH?S/\#P?_A']:_Z M!%_ . S_P"%'_"/ZU_T"+_ ,!G_P *]XHH^OR_E#^RH?
S/\#P?_A']:_Z! M%_| ^ S_ .%'_"/ZU_T"+_| \!G_ ,*]XHH^OR_E#^RH?S/\#P?_ (1_6O\ MH$7_/X#/_A1_P (_K7_ $"+_P#\!G_PKWBBCZ_+^4/[*A_ _P #P?\ X1_6 MO^@1?_| @_^%'_"/ZU_T"+_ /\
9_|*]XHH^OR_E#^RH?S/\#P?_A']:_Z M!%^_ . S_P"%'_"/ZU_T"+_ ,!G_P *]XHH^OR_E#^RH?S/\#P?_A']:_Z! M%_| ^ S_ .%'_"/ZU_T"+_| \!G_ ,*]XHH^OR_E#^RH?S/\#P?_ (1_6O\ MH$7_
/X#/_A1_P (_K7_ $"+_P#\!G_PKWBBCZ_+^4/[*A_ _P #P?\ X1_6 MO^@1?_| @_^%'_"/ZU_T"+_ /\ 9_|*]XHH^OR_E#^RH?S/\#P?_A']:_Z M!%_ . S_P"%'_"/ZU_T"+_ ,!G_P *]XHH^OR_E#^RH?
S/\#P?_A']:_Z! M%_| ^ S_ .%'_"/ZU_T"+_| \!G_ ,*]XHH^OR_E#^RH?S/\#P?_ (1_6O\ MH$7_/X#/_A1_P (_K7_ $"+_P#\!G_PKWBBCZ_+^4/[*A_ _P #P?\ X1_6 MO^@1?_| @_^%'_"/ZU_T"+_ /\
9_|*]XHH^OR_E#^RH?S/\#P?_A']:_Z M!%^_ . S_P"%'_"/ZU_T"+_ ,!G_P *]XHH^OR_E#^RH?S/\#P?_A']:_Z! M%_| ^ S_ .%'_"/ZU_T"+_| \!G_ ,*]XHH^OR_E#^RH?S/\#P?_ (1_6O\ MH$7_
/X#/_A77>"?!\S79U\$K5K1HXXO\ 50S(06;^\0>P]^OX5Z5143QDY1Y4 MK&E+*+:<)J3=[!1117$>F(,.E244 9 M-U8A@>*YK4=%W3+<0L\%S&$O ,(_P#O>A_3Z5VJL'4,I!4C((/!%<1J&E)+&R/&&4]0
M1678:AJGA9JL :\TW/S6[GYHQZH?Z?\ ZZR]Z&^J_'_@G=RT<5\-H3[?9?I_ M*)Z=FCTRBL_2=:L=;M?M%C,' X9#PR'T([5H5HFFKHX9PE3DX35F@HHHID! M17)?
$;_D5&_Z[I_6F^!KRULO!MO)=7,,'">8_S2N%'WO4UE[3]YR>1Z*P+>#6 M)3NW+EM;^OR.OJ"ZL[6]B$5W;0W$8X+*@< ^N#WY-(+^S:T-VMW ;8O? MK_F5;73-/L9#]:6-
M;NPP6BB5"1Z<"K55KK4+*QQ]KN[>WW=/-D"9_,T^VO+ M\0O:W$,ZCJT3A@/RH5EHBI*I]<\KOS=_P W_F3454N=5TZRD\NZO[6!\9VR MS*I_(FK,1U1!U9C@"N5\8ZC97W@S41:7EO<;?
+W>5*KX_>+UP:FVU_P"NYUE%O.C>_*[7"BBBK.8X M+PY_R$=:_P"PE-_.NM7I7)>'/^0CK7_82F_G76KT]*/P+^NK.W,?]ZG\O_28 MBT445]< 4444 %%%% '&?%#_)$YO^N\]?:]2T[_
)!EI_UQ3_T$5Y;\4/| MD3F_Z[Q_UKU+3O\ D&6G_%/_013>R!;EFBBBH*"N3^O>).M8_ZYI_Z,6NL MKD_B;_R3K6/^N:?C%%IQW0GL9GA;_D4](_Z]O\ T$5KUD>%O^13TC_KTB_]
M!%:]4]R4%%%(84444 %%%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !7"_%+_D":=_U_)
MZ"U=U7"_%+_D":=_U_) Z"U5'<3V.ZHHHJ1A1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"_# M7_5:W_U_-7=5POPU_P!5K?\
U_-5+9B>YW5%%%2,**** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M*X7Q+_R4KPU_NM_6NZKA?$O_
"4KPU_NM_6JCN)G=4445(PHHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "N%^&OW-
<_Z_FKNJX7X:_7_D*["Z_X])O^N;?RKC_A;_R*'_;R_P#(M52V%U.UHHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444
%%%% !1110 4444 9 M?B;_)%75_KRF_J-9OP^_Y$;3?I)_Z_:M+Q-_R*NK_P#7E- Z :S?A]_R M(VF_23_T8U5]D74Z:BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110!S?C[_D2-3_W$_| 0UJ[X6_Y%/2/^O2+_P!!%4O'W (D:G_N)_Z& MM7?"W (IZ1_UZ1?^@BJ^R+J:]%%%2,**** "@C-%%
$,D(<=*RKNP!!(%;=1 MR("M ' S6[:9XATRZMF:&66\CBD*' =6/((U!Z7G_B! NI:,1_T$8?YUZ!6 M,5:1Z6)DY8:C*3N_>7R4E;[@HHHK0\|Y+XC?\BHW_ %W3^M<]X5\&6FNZ
M$MY>W5SN+,D2(P"H ?<'ODUT_CVUN+SPTT5S[KS;RSR>PKE-'N_%^@ M;(+?22))89&9DWP,7C<'Y1@^XR/ZUPU4O:WDKJQ>)$5?[-Y*%%11GS]6EI\
MR/P(\D.OWNB3_O+:>.2.6,GY6%%U)NI(8Y64I'&_WN>K'T]JYW4/4_R/B9/WR;9@+*Q:RU2U+X]9+*" MC>S+T/Y'X%H90]2J\#JG7HXG&U<)%IJI%*ZVDYM_Z[$?E3XA^(-UJCC M,4+-*O/_ %!^7/Z???*?#
[3OL7AE)V&)+MS*?]WHOZ#/XUU==5"-H7>[U/MGLXK*IBG'"PP2BOE_P_ $\|7O6CB\8W1\2QW$\L?F.&\(O()'.TKG'R],>U=E8W. MC:/X4U74?#T[R?
"4D.3$YX&O1GOWR#BJ.HZKXQ@G2:PU#PM]NP62.8P,0 > M<@$9Z#[Y=$U6'4!]G^W1B-(VY((R0Q'U/3KUZ5S034FHJ^_35'T&X MJ4YQ+_J\N6W*N523C))KHM5H*O"'G6::,]U#(^\;$:09Z9!
M7U&.OI76:0^K:_I^I1:W9_9(9E\|J)-N" 00QYY[C^E32@[KH_3]37_,3#DGS M2IOE^VGU6T;774XGPKX='BVZO+[4[J8A6&XH1O=C[D<"NBU>S'@CPM>C3)Y MLW4RJCN1NCR.><<\
X],UB:?:^*O!EY<);:;N*;)2-I%;&<<$;>0>O7_"N@ M:RUKQ9X8O8]4MEM+@R*]K&5V@8'?.3SDCFJII'O'1 M-;>F^CW\ON,;POX&L\N[9T)=0O;B;S)RWEB,@;0"5R>:UO!?A:_M-
M2EUG5QMN'#;$8Y;+YZ4OCK'D5FMRL76BZ59\OO)M^)&A*N"M!/B\.A\$#Y JLI?B&!=[JIV\M(&95\76:P$:\^F?HKl_CJ6QX-
TO4+7QE<3W%C=0PE9<220LJG)&.2*/&6EZA=>,K>>WL;J:$+%F2 M.%F48)SR!6?)^[YK:W.MXR^.=%S7Z>UU:]OS^8WXCWT]SK%II,;E8@JN03@ M,[$@$@$_0?S-
+XD|$6FB>&Y;VUNKAIH]@FWL L@+ = /7!QGMWJ_X]\-W]J>V^ MJZ=$TSQH$D1 -PP20P]>N/P'X9>JW'B[Q!H3PW&E21PP[2^(&629L@#"GD]2 M>!CBM*B]Z?,KOH]_|GT.A^&O_ "*[_P#7R_|
M):["N5^I]I_ M+_TF(M%%%%:G %%%%% !1110!QGQ0_%%%%%%%%%% _Y$Y9O^N\]\?]]?]2T[_D&6G_%Q3_T$5Y:UKQ0_ %%%%% !1110 4444 %%%%% !1110 4444 %%%% M1110 4444 %%%% ! M11110 4444 %%%% !1110
6_^A)U?_OA__B*^$WUO_H2=7_[X?\ ^(KUZBCF78_?Y^*8]? ^MOKZ!_8@^Z!^?*B6-N^!7PAAZ0Q_8/JO&& ZUYL3G0Q_Q?_)Y_>Y+X8ON_|
$).MK_|?#__ _$5Z]11S+!S^?K+ZX\\S3\%%%%% _Y$Y_ O^N]M]^*M=JBZ9B!'$(__ *%UUI'G_ "_UJRB3^% 1_[F}@N5_|K_
$). MK_|?#__ _$5Z]11S+!S^?K+ZX\\S3\%%%%% _Y$Y_ O^N]M]^*M=JBZ9B!'$(__ *%UUI'G_ "_UJRB3^% 1_[F}@N5_|K_
!%(G%]J^PFM-S*_X3?6_^A)U?_OA__B*^$WUO_H2=7_[X?\ ^(KUZBCF78.5]SR'_A-Z3?6_^A)U?_OA__B*^$WUO_H2=7_[X?\ ^(KUZBCF78_?Y^*8]? ^MOKZ!_8@^Z!^?*B6-N^!7PAAZ0Q_8/JO&& ZUYL3G0Q_Q?_)Y_>Y+X8ON_|

```
(_X'72> O#W_C7A&SLY$*7 M,@\^X!QD2,!D<>@ 'X4-Z7!;V.7^$'_,R?\ 7_\ XU8T/_DN7B?_*\HO_0( MJK_"#_F9/^O_/QK-N/%&F^%?C-XANM3,HBEMHHU,:;CN\N(_P!#3>K8NB/7 MZ*XK3?
BIX9U74K:PMI+KS[B01Q[H2!N/ R"5(()!'(([5[S\._ M&0\1:;]CO95_M.V&&SP94[/[GU_^O7E8S#V_>1^9[N78NZ]C/Y?Y&[XO_P"1 M*UW_ +!\_P#Z+:LKX7?\DWTC=E_]&O6KXO_
.1*UW_L'S_^BVK*^%W_ "3? M2/\ =E_]&O7G_9/8ZG7T445)04444 %%%% !16=K&NZ=H-HMUJ5QY,3.(U.Q MFRQ!.,'L#6'_P ++!\*_]!?%O_>3_P"]'4C%V;.JE@\15CS4X-KNDV=;17(
M_P#"R"W_01;_P !Y/\ XFC_(67X6_Z"+?^ \G_,32]K3_)D:?W=C/^?4^?4MON9UU%3_P"\)H_X67X6_Z"+?^ \G_P 31[6G_,@_L[&? M\^?3_P"\)H]K3_F0? MV=C/^?4ON9UU%3_XFCV_A9?A;_H(M_X#R?\G_Q-'M:?^SL9_SZE]S.NHKD?^%O^%E^%O\@BW_@/) \ $T?\|++|+ M?]!?%O_>3_XFCVM/^9!_9V_Y]2^YG745R/_LOPM_T$6_\ !Y/_(FC_A9 MA;_H(M_X#R?\ Q-'M:?|R^SL9_SZE]S.NHKD?\
A9?A;_H(M_X#R?\ Q-'_M LOPM_T$6_\!Y/_(FCVM/^9!_9V_Y]2^YG745R/\ PLOPM_T$6_\ >3_M_.)H_P"%E^%O^@BW_@/)_P#$T>UI_P R#^SL9_SZE]S.NHKD?^%E^%O^@BW_M (#R?_$T?
|++|+?]!?%O_'D_P#B/:?!/(FCVM/^9!_9V_Y]2^YG745R/_PLOPM_T$6_\ !>3_XFCA9A?A;_H(M_X#R?\ Q-'M:?\R#^SL9_P ^?3 XFCVM/^9!_9V_Y]2^YG745R/_ "R_W_$$6_P# "R"\G_Q-'M:?\R#^SL9_P ^?I3_XFCVM/^9!_9V_< MC_PLOPM_T$6_\!Y/_B:/^Q%O\
H(M_X#R?_$T>UI_S(/[,G_J7W,ZZBN M1_X67X6_Z"+?^ \G_P 31_PLOPM_T$6_\!Y/_B:/_YD'G8S_GU+Y+$+1+\$ (D:'P!>J_Z *XWQQXWT'6O:FHZ?8WIEN9D4(A
MA='=.|+Z5975\R7%O:QQR+Y+G#!0",@8-5[6GR_$A?V= MC+_PI?>;J>85,3K\N0,\@>HK=IJ2DKHYJM*I2ER MU(M/L] HHHIF84444 %-?[M.IK_=H X'QQ_Q]:'_-A2'^M=/7,?.\ CZT/
M_L*0_P!:Z>LX_'+Y?D=]I_=J_ ;W_I2"BBBBM#@"BN1^(EY=67A^"6TN9K0 W M2J6B+=0\\J]2:H|=M!&[8]YEED5226+=3T(P3V^)UN6 M3C:Y&&RIUJ$:[J**;Y=;[_\$]2HKB_
.MWVKZ7>VS],TL]MM\N5^3A@<9/? M!4\GUK(O[37(87N+_P 8PP7BJ6^S+?3 (&?PH]M[JDD"RJ2KSH5*B3C;H MW>_9)/3UV/2Z*Y#P#X@N:L;F&];S)K4KB4X!96S@'W&T\]\UR'AB_\ $VJW
MT]G9ZG,7>$EI+B5G$8R.1G/)Z<#/-)UU:+2OO45 MY9I6KZ[HGC2/2]1OI;D/,D,J-(9%._&TKGIJX'M6QXV\3WUOJ$6B:2Q6XD"[ MW3[^6Z(/3L<^XH6(CRN36PY9-
65>%&$DU):J[MH;@Y[$$5R&IV?B_PW:IJ,E:SL;X?*^2M2J]4:E-R2=N_9IG2>@M1N]5\ M.17=[+YL[.X+;0O /' %;]>5>'M.\3ZIX>5=.OTL[.-
F"!7*/(VSWT^E:G.TI5&=))22P*]5)],9//I13K:1C);]0QV5>]6JT91?*]8K M=+\OD>A45Y<=\9\0>,MZD\@@YX[X^E/ZPM[:=S/^PZOP<\?:6ORZW_RN>HUSOC3 M4[S2?#YNK&;RIO-5=VT-
P<]B"*PO&WB:_BU.#1](F(*R2*I=HOOLS'Y5![=CQ MZUB^(M,\2:5H6-3U 7EI-(NX-(TC1O@DR^;.SN"VT+P#QP !6_7FEE##=M\+QF.?PK6\*>)6?P;=W-
Y,TT]AOW,Y+,XQE5CM:*X/X=2ZEJ!OK^]OKF>,$1(LDK,N[JQP M3@?P_G7>5M3GSQYCS,9A7A:SHN5VNP44459R',P#CZUS_ +"DW]*[Y/NU MP/@?_CZUS_L*3?TKOD^[6=+X%_75G?
F/^\R^7_I,1U%%%:' %%%% !1110!Y M_P#&3_D07_Z^8_ZUV^G^@RT_P"N*^?! H(KB/C)_R(+_/7S'_6NWT[_ !E MI_UQ3_T$53^%$]2S1114E!7)_$W_ ))UK'_7/T8M=97)_$W_DG6L7_DUYM\
M9_\ D7=*_P"PDG_H#U4/B/EL>DUQOQ5)YKJW_' P!')795QOQ5_P"2:ZM_ MVQ_')1'=#>QROA1O^$2\;=;L<:?XBT^&1.P2<(,_4DY_[^*#T-?:G:QJD&BZ M/=ZE<$>5;1&0C.Q-'O'0?
B<#\:XCQ1HO>(3X]M?#/AZR?RSJH6YOJ]G(1$SN7KV9&/\ P%:IJ[^I-[,'16$\]>#M M9OD(OMP8])Q(]B*]\]2>(D'KOHTFI7[-Y:D(B+]Z1ST4>_!/ MT!KB/B-'!^'#XO^\42*D?7^U448"@208
'85+|4I(UU7P@+E@+/\ M(-/N^[@ M,G7\"WZT/WK M+DL&N_$C48!>VGAW2[:VDPT<%U*WFE3R.=PQ^'TK:\'>,H M_%$=U;3VCV.J61"W-KU!Z9?'?&01[?B*ZFO.--;?\=M6:UYC73U6Z*CC=A,
M^_3IZ'WI:,>PT_$/5SXQU?0+;2X+R>%S'91Q[D+'NTC$D!0/I3I_&_B?PWJM MDGBS2Z^ME"'3;N01BZM')\HGKNRQSC@G@< XS4/@P#_ (6YXO.!D<9_X$*G^-0!
M\#Q$@$B]C(JOE>GI>UA:VN=KKFMV7A@2])3U"X7EG/95'&'UY X_6/XQOC1-(64XM6U)/.R/E(VM MU_#-
>CJRNH92"I&00>"*G97'NSD_"'C3_A(;F[TO4+)]/UFSYGMF.05SC>WUUXV/Q3TR2:PTH:V+$B&)6;R3%^|R6^;.?O=_2NIN"'^/5K]D! M)CTP_;-HZ?>QG\X_S%+JG_)>=$_[!;?
SFJEH_D)ZAXWEUB7X0ZFVNP6T-_NC MWI;$E,>>F,9)[>]5]"U_Q9?>%=,7POH]I):VMG#";B^!W,:YI7]T=M3,\$^,9/$OV MZRU"S%EJVGOLN(0V5/)&5[\$$'KVYY]#7/&.H-
KK:!X5L(M0U^%>S),V(8! MZ$Y$6Z<9_Y,QE^&P%^+WBX ?(AX_P" USWA6R\K)5:CKWBA]%UV#3Y%U%_M*3 M6ZNS'(-(URQT(Q?I=K;17[>7;W5FQ*!\@!6R3Z] M?
<>]6_'/C.Y)ZIH$2);&TOIV6Z>522B*T>2I# X9NN>@K$U;P)XUUU+>/5 M?$]G*]5UL'4M 2QT6XA:2VD)S*8W_ #<9!/I7S7N-:^(%Y=S#=2_#NGVMK_[ M*KW(K[Q9I0.A
!4C..X[CGK7:7=S%96<]W.VV&&'-I';T51DG\A7 :7KOC?QC:C M4M&BTO2],=V6)KK=)*X!P6P!C'CJ,=NWJV>;/&@16.(\ =, #_ "I=*6*$_M ZX9-N\6 M*F+)YW;(>GOC=^M.RNQ7=BSJ'BSBQ'Q=3=^T
(M&2VNM,F=/M'F(Q<1MC!7#@@YY(J#6]XJDCB\( M:T\N-L9L@Y] D/%@1 M2I/"DL;!HW4,LK,9.A^:KF(N&N#R7^?"2^?$^H^*Y-5O)(K>/2X,EH+,HA$D#@'.6)8CH5Z#@J M?:N4L_R72'^ZN/\(??IE?
PKOO".A)X<\|+6&F*N)(XPT MQX),CN*],KR_P"(3_V+)XV(%BK>1*^"?+Y.2PB,JNI5@"I&"" "*\[T/_)+EXG_Z&\HO_ $"*O1:J M1,3ROPU;_P#"+?&'4]#M2$T^_@\^.(# 4XW
#Z?._'Z>D7^KZ9I7E_VCJ-I-9^9G9]HG6/=C&<;B,XR/SKSK077Q-|9M3UBU;?8:!]G64M=IJ_AW2->\G^U;"*Z\G=Y?F9^7.,X_(?3EQ]"VT.&OY[;QO\0]"ET53/ M:Z.[2W=\JXC.=I5
W\1RO3:/O7I,TT5O!)--(D44:EW=V"JJ@9))0 5Y;X MOTR/X?WVD:UX;+VJS72V)Q8B5C'.3R[/X8 MHG>?TRHWEGSA=+X>2W;S#Y'G3)B?'TH!7(I[/*^\H%DS:33-/ENQ-26-1Z
W\1RO3 :/O7I,TT5O!)--(D44:EW=V"JJ@9))0 5Y;X MOTR/X?WVD:UX;+VJS72V)Q8B5C'.?0CCH2"!FO4+FWAO+6:VN(Q(),C M1R(>C*1@C\]) = 1Q?C'Q=H5SX$=-TVYQY\ 7[P
YPQ)8C/L3BLG5/AMXHHN 4444 %%%% !1110 4444 %>;?"/[GB/_L)-7I->;?" M/[GB/_L)-5+9DO=$_P 8_P#D4/3_*_T_P#1(5[?|8_\ D4;3_K_3_P!% MR5XA7LX+^%\V?-YE_O@V[]%%%%%=AYP4444
%%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %?*-U2[T74X-0LI-D\+97/0CN#Z@CBJ=%5)I-68TVG='T#=^(+3Q+|,M8O[ M5ADZ=.LL?>-_+.5-
+|+O^2;Z1_NR_P#HUZY'PQXWUKKOA=_P DWTC_ '9?_1KUX%:,8MJ.USZW#SG.$935G8Z^ MBBBL#I"BL;Q+KLGA_26OTL9+Q4<"14;:L7G+'@\#C\ZPK?XEZ<\"376G:E;1 ML,B5H-
T9'LP//Y5FZD8NS9V4L#B*M/VE.-UMTW]+W.VI&X%<]:>.O#5YCR]7 MMU)[2DQ_^A 5LQ7EM=1[[>XBF7UC<,/TJE*+V9C4H5:7\2+7JFOT.A 'DFY MM"3_*BL/]:WMB?W5_*N:\|<'-SH?
_84A_K73U$?CE\OR.FO_+M1_P"WO_2D_M-V)_=7\J-B?W5_*G45J<-V-V)_=7\J-B?W5_*G44!=C=B?W5_*C8GJU?RK#\ M3>++'PS;H9P9KF3_#ZUQ2?$/Q3=QF+RT.]|[<<%UMY9 #_O
M@5SU,13@^5[^6IZ^$R;&8]G[6"2CWDU%/TN>H[$_NK^5&@J_E7'Z3XMU/5 M_"I7T6G)]OM&V)"JLX=N/X>O<\|9KF[OXA>+=/56O=&M[96.%UK*@)]LM4R MQ5.5*=[R-
:.18RK.5./+S1=FG))[7T[Z=CU38G]U?RHV)_=7\J/\SM/"C*[ M$4D6@))!(1B2.SF*D9Z@D[L5=\6>.=6T3Q$=-LK:TD38A7S48L2W;AA1]:I\O M-K;T'_8..]LJ*<7)IO22>UKW[;]3OJB?W5_*C8GJU?
RKS.X^(/B;2)T_MC0X M8XGZ (\>[Z,2P_2O0M*M^J5!]+M[^ ,(YTW -U'J#^-73K0]-I-G;G)C,LQ,9A&A MI4LXO9IIK\|"UL3^ZOY4;$_NK^5.KB_$&6]/N@^*(@U((E56]KL)Q G^A:&.DGF0D(Z=^:H+*\VLF]CBP+%S1#94_
MC'Y[]NI4AC!79SX3"5<5/DIM7M5I+[V=EL3^ZOY4;$_NK^5<+X:^(%QJ.L+I M.KV*VUTY**R!E B M-L1EV*H5XX>EM;6]^S1H[$_NK^5&Q[J_E7FT7CSQ5J -SIGAT/:=CY4D MF?7^H@ '\|JZ[4-
I]85X23:Z>1K7RG%4 M)0A.UY.UE)-I^=MC;V)_=7\J/-B?W5_*O+K;Q[XQO831:-Z%%x&\/$3@/%:3,I_$- M7>Z'J-W=>3'8;_ 5X!9W&UVFC+@*O^*QYPW(X -%.O"H[1O]J8P8S"Q M<C3,W9
M23=:1:F1L7^ZOY4;$_NK^5>;3_$;5]0NIAH@E"*"":$99I(VD;!)"D8^G/2Z/*'^C\|&V>AA*7$Z/R^<S7(#"CKUT:RK4F^W'QN@+7`"K*_.$]99%C1
L^ZOY4;$_NK^5.KS75'VNVOB:ZTFPLK.8I*8XE;EV_ADU=6K& MDDY=3GP. KXZ4HT;:*N[:'I&Q/[\LW=4[E1L3^ZOY5YDGQ*UG3KT0ZYHR1]ZX41 MXG ]1N)S^E:7C_Q/J&E6^D3Z->B.*
[61RPC5@ZX0]?F!_O\|ZR^M4^5R73[S MN_L+&*O"C*RY[V=[QT5]U<[O8G]U?RHV)_=7\JK:7-)P?<%9T^OJSNQO\ RZ_P1_|;B6BBBM#@"BB MB@ IK_=IU-?2[M ' ^./^/K0_^PI#_6NGKF/"_'UH'?\
V%(?ZUT]P7 ^.7R_?4^\$7 M[ M(_[4^7/'\*_[?HK?^.TO&^/_3'CJU/FW3.ZS%*Z%.N0=FRP-^*/Z+P)(!QF>F ^P" M!'.\#H$!=!/HD_P%%'P$?0!,S@*=E
V%(?ZUT]P7 ^.7R_?4^\$7 M[ TI!1116AP'[1*!)I&1U@AP#H1N:V?.+B-ZI7(T+K-C(_&) ^ HO3^|<|9PR(T2Z] ML8S;4@TA4TS*WT!TZ`O"](P*3R6X#EI]H(U+*?,XB /
MNZLH>HL=%82&'K(A!1L8$5!HRK8AH3+5S5*&DHD2(0H'4Q0D'F\^7MUI@HDD&+JN B)DIKV&4IMLF9@1NHCKUOO6NB#Q0L]U#AT^ FIOCTR*0CQ*Y2W6%\
M=#*TL5A:I(X*LZPJ"P/4$XZ5BL.TEKL>K+/*4I5&X-G_JHT"EUV.?$9O"K[>T'^\44MM+=SS;7_ /DJ MEK_U\VW_ ++3 '%O<:5XOMM:$1DAW1R \XW(1\I/;H/SKT:33-/ENQ-26-1Z
MR"")FB4N".ASC/%6)(TE0I(BNAZJPR#0Z%?*<=W(9RH2I-0NHP<&K[W(=CS3 MQ1XYL]9T]M/LK>;S)ROF&0 ;0"&P,'DY I-0TJ?2?A@D5RI2:6Y$K1L.4SP! M^O!_&O0K;2=.LY?-M=/M8)[T4*J?S
J:YM;>\B\JZMXIX\YV2H&&?H:'1E* M[D];6%'--)0IT*4;(RYG=W;?Y'FWA7QK9X'H0L[RVN"ZLS1F, AP3[D8YS3_M4 .FW.I:=ZK,I6 HZEP,!G?J]2 2?RKT5M'TQH$H@ ;3K0PH25C,"[5SUP,8'
M2K<<4<,:QQ(J(HPJJ, ?041H2NN9Z(=;-J/+5]A3<95-VW?3R1Y'X>U$^"_$ M-U!J=O+M*F-BHY&#D, >H/\ 6EUV_;QQXCMH-,MY0BIL!<#.Y9CS ?7^>* M]6NK*TO5"W=K#
<*O02QAP/SI;:SM;*/R[6VA@3^J$@4?D*7U>5N2_NFO]M4O M:?9??O;6O?W=K7L7^X,9M4&\86FRGC+ACC'C(S ..I?%6OC"VU_14 MM;*WG7#B29I %% X
&.O)_2O39&>YB,5Q@#+^J2&*&: U7&D+B7VPTZTT M!.XQ>2NTGUQC&:47HR*6&+T4I5;B:E=E;T[F[#X%X (S'0HZAE9Y M1D@9-Q! ,GG%Y&Q-BkJvRiqqnUdo56ubWK)MbrOsbXB6+N+?!'b-
[N%Z(#W.>O].*RJQTC37Q([\MKOGKX MRHK4I7>K7Q)W27F=]X;TL:1H%I:;=L@0-+_OGD_X?A6K117,/_H K=K"\%_\B1H?_7C#_P"@"KVMZO:;#HMWJEV2(:;N0.K'H%'N20!
M]:'N'V+DLL<$;22R+'&O)9S@#!:RQX]\.M)Y8U_2R_3:+R/Y9KP>UB\2?%? MQ(KW(F\G?<2(=,\| +W/4#N>YZFNQ/P]MO*4#7Y1)CEC:C!/TW?U]^5+=D M\S>R\/4[O5-/L+6.ZO+*UM[>@@)+-
J/Q(R "3@Y )JC_ ,)=X:_Z&'2?2_V/ M_P"*KFO^%S:;Q/JIOAB_OJC6=PTYF@T(;+2$#!JI/TKRWXA:V@SI ;E MN?M?F[O,0+MV;F/J][\*Q(Q3TN#;/I{JJO?7Z:XE\9G-]_<-QA6'I*^
M_E?;=5L;S5WQ*@'(F)49/(JZ\B|-P"&QUWPY8ZI)MQ$JS'O*+&I"\F|JOQHMHQ:AH=L&+*&R\L,>^#BCE3:GG:YZ^/%OAMF 'B#2B3P +V/G]:U8I8YX MUDBD62-N0R'(/XUXG/\ "K2V\ 1:]J-
S%=$3TNW6=E,18H&(& "!U Y/44[ MX'7]^=6U#3]|MIPM *GD)+N4#'ID;OKM'I0XJUT"D[V9[;111699GWFNZ/I MTIBOM5L;608RD]PB$9Z<$U8L[^SU"+S;*[@N8_[\,@DHJUV-O6R/;;2]M-
0@$]E=0W,).!)#('7/U%5+OQ#HFGW+6]K&GV MTZX+137*(PSR,@G-9?@SP=%X-L[NU@O'N8IYO-4N@K\H&"0>>G7BO)?3$>D+ MXI^-MUI;N\*SR*A9,$]@!SS_NT**;!MI'M,?BKP[
(L<>OZ6\CD^]K>1DL3 MT &:UZ\NLO@K865_;W::QYIN*M"4M=3URBBBLRPHHHH **** "BBB@ HHHH **** "BBB@ MHHHH *\V^__ "+NE?\ 823_- >O2:\V^_(NZ5_V$D_\ 0'JH?"$3+8])K M
|:Z'<^)/"-]I-F\*79QY<UIB0HVR*QR0">BGM6_14IV**66X36> B65C/L=H M;9(7QRI(4 ]>W%%$]?U?4/1X(@E+14EF.(MN*MD=U=Q13NQ M6.0\7>%%;[7_$/AG4+66W2+[ZKSIQ*S!F7F7?
&WRX!R<(>N.U:_B?PW9*M%DTV MJW*I8/'(GWHW'1A^9'T)K8HHNPL>>0Z#\2+\|%+&T\1Z9-QC8EQC1'S@O0'&
MT@D#U)^M;_A'PC#X#8MIY)+A[W4[MM]W>2=9#SP/0&TTZPEMXYA<++NG8A< M,,P//-=712N[W'VEC,\0:%9)^%N-+O0?*F PR_>1@QB&V*2[B/FHO8?=.<#ID^W2O1**$[TDNK^\O'U
M#6+TYN;MQCCCKM4=_Q.G %3Q=U23M4M$.X,JH'-I(H[ZFN/K#IE%HRU%L)/RQ9SF@A|2(3P2|C^6$@IZAO9FB,3C;&MTM6XF[3V|BbO04*!J-T2ZO-K12MgRD]JdnLA=6CT2l0Q3cj+x2dOB4dNkDTXnnrt3mF54Jpdd/MtFRa6E1n9f2u1Rr5OT7ZxD8WBXcKPv4lFrHDE1drE3Ni4ErQHxDy6UzWvfo1e0//
Y.$/7':NOHIVD6H6%Q93@F&XB:) MP.NU@0T'->>Z1X0\<^'8#I6E>(-._LH%C$\T):6+)R2JX(Z]B<_X5[%7(:?X5OK3XG:MXFDEMS97EJL,:*S M>8& B'(QC'[L]_2J4MVQ-&3=>$/&7B15L?
$NO62Z5Y@:2*PC(:8 YP25&.@] M1GG!P*[^UM8+&TBM;6)8H(4"1QJ.% Z"IJP_$MOXCN((!X0?YTKW':QYX-#BO_C5=6$$AETV.1=3O(.-@F"\|<="=SC/?D^F:]?KF
MO!WA0^&K6[ENKLWFJ7^OG7ESC 9N<*!Z EN>^3TX Z6B3N"5@HHHJ1A11I10 M5YM\|O\ 4^(O^PDU^DUYM(O]3XB_PPDU4MF2?)T445 04444 %%%% !1 M110 4444 %9^MZ?8>
(=*ET[481)!)^#(W9E/8C_/%:%% 'FUGX1\>>'H_L6A M^);*?3T/[J_^C.4&.GW6P!QP#PCV%;6@Z-XOCUE+[7_$$#! J./L=M%M3$O%T/CO4_$.@7VEPI>1I'MN2Y; "H@.0$(ZIZT2^%?'N
MMQFTUOQ1:V]DY/F)\9#,N.F=JG';&<8ZYKT6BCF8N4S-!T#3O#>EII^F0^5 M"#N8DY9W68 ]R<#^F!7/:GH_CJ'4[F;1/?$%D]I.Y;>^B/G/96 8D?D/N:MTHI7'8X6Q\%M:J6M6VK>,,-4BOWL|-
;6ELNV&-_[QX&>+0#T(<\#%%;OB73:>30M8&G74#$X>/>DH/&&';ZX/X5NT4786//)#@OQ|UFW>QU7Q]IMO92X68V M,;&1D[KDJ,9&4K]_O2Z5V5VFBZ 9!9I,&FV$99WA&@9'J23W)/-7Z*#
[@D%%%% !1110 4444 %%%% !M4;?4>+ 1110 4444 %>:>+O\ DKGA#A#+ =?^M>DUYMN_Y*YX0_W7_K51W) MEL>DUYO\7+S5+=:#TT6'ZYM9(FZ8,FC@)FCW$@+5 D$<9->D5YQ\|5?*.N7
Q%X%NM;F=F:[AS;W)8E@E#JJFG:]'J]H@4$!4E@UTM8HP3DA0F*T/B#$_,CSX$,ZZ_Z_9/_ $**J^T3T'2_#7OVDVO:>M/M961<>3NTBG|-^^ZTQ;T?Q'X4\|7&.6XF -G?Q@ 2YS@G-TZXP#@'(YS MG->BUY?
|842*3PW?(N;J*]PF!R1P$)O$MO M:7>G77V75)/^IW>BV]|:/:V^I7*W5Y&FV6Z)_ ,BC:?\ 7^G_*+DKQ"O_C' ,BC:?\ 7^G_*+DKQ"O M9P7' +YL^;S+_ 'A^B'BBBNPXBBBVBBX#**** "BBB@ HHHH *** "BBB@
"BBB@ HHHH *** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N MY^'/@S_A(=1-]?1$Z9;GD'T*_&%^G.3^7>N>|->';OQ+K$5C;*PCR#-*!D1) MGDG^@[FOH[3--M='TV#3[*/R[>%=J+G/?))]R23^-
<.+Q'(N6.[/3P&$]K+G M€> |*#$H>+@%\$Z+5 [?NVK*^%W_ "3?2/\ =E_]&O6KXO_^1*UW_L' MS_\ HMJROA=_R3?2/V7_P'%O7C5@^S%UQPC\HTWWWWWW<}9/Q5\5^% $>&RLH92_\$$9!%%'&NEGJWD'Y^LQ=QL#>.
M:_@O4RR!!GT*X*YX^IM7^W7ZKLUT?Z-C9=,,TK4HEEEKKXZX5VC5L5@P:RYO V@2/OCM' MMY/[\|$K*1*^N*Q-V-IU"U'MS | HMJROA=_R3?2/VI7/J@$+#]BYEX7W?'V\S\%9<;[&&$
MHS^):G34GB,*TZ51\CV:'U^7\5&N3N^I"\WI^B044451SA1110!XS!1?1V]ZM?&RP3QE$_AX[JM/UKOM/EC?0>B'C=?!"TH9'D-ZJGMS',. '3-2-5-UV4(NH@!8A*Xd\H';
TJS;@,^7(.2& ["ZD5HR_%.QN=)FAET^X2YDB*85E*9(P+<@_I7 MDQG[-SC]LKWOY'Z#6P[QL<5-I4 :TE'E<4[6EI=O7H;WA#Q@OB>XO$73A:& M(*[,)=^\GCGY1V K&^+7_(-
TW_KLW]JI?"1'^7ZG)L;9L1=V.,Y/&:N_%K_D M&Z;_-=F_E6CG^>$+I/%)@+2>U73K>-][,[-(<],\*,,=L5Z MCHTFE:1X8L.F+U"'["D8"7,CA%3P2<=NE5LXCBG5F/X UB^+ M/%
[^&);=%TYKL3*S%A+LV8Q_LFKFF^$-"TB]2\L;'RKA 0K^<[8R,'@L165> M?$;3--U6[L+RVN5>WN>*G^*]TS:S8699Q&D M'FD \99B,X]?EK.B=0%GQ@BO-)LWAB\.5S@ J]D;G;' /X]?>M_XI:/<.]I
MK,,?F11)Y4PVYVC.5)]B21^7K7GZ@ZSMKKOW/L&X4\VPJ].UX-+*+M[CMHK^> MN^I7D\|=:[IK9:NGA^.UTG^'IYL'.I!^?:!X'YNC+:~P,D#/3WGB[_,RA~X2X&FZ1M1J<||5Hk@
],$5RGBWQS9@&| Bl+2UN%N))%9PX&%([#'WN?I_2NDTF=^MQ@2TFU"W=F:7=+&G#)O)QP>X&..*VA.[E#FO&V_8\$X94Z=^$*@H5^?2-W M[R6MW=OKUZ_Y?3_ !1XD\
(Z3;65SHJI9QE@K31.K'+%B-V<=SVKJM;\10ZQ M\-;[4K0O'O01.G=&+*K+GN,'\C6#XM\?Z?K6A3:986]P7G*@O*@ # |&+I_AK>:?/'LN+TM.D:]\%3A=@/IDH#^*-ETE,=*E7_=S~
MDJ53VBNK_$KW;;;YeqMS]_-uYLzJ5XT8G8N5jYXNi+F6sNdNWbYMe3xRL6EysS0YG7lr3Tgk8sDnExoXpSY&@jNM&EnsEpLdJ8IK+4+a
S^)'O40DIJE&.ZW.C%4JF'ECZ];2$TE'S;M:QZC M7BUY>0:?\5);NZD\N"*\W.V"<#'H.:]IKQ>ZM8+[XJRVMS&)(9;S:Z'N,5T8 MV]H6[GC<,\O-B.?;D=[;VZDOOQ \0Z=XCNK&'2P\
[0[AYH0C>6QA0",GIZ5+X M^LI=.\/^%[.? EA@D5P.S8CR/SKTK3O#>C:3+YMCIT$4O:3&6T)R1UKAOB[ M_P P;_MO_P"TZRKT91ISJ3>KMMZGHY9F-&MB\-A,-%J$.9^\[MMQ?8S]2A\8
M6_ABUUIJ4-O:1PQ!;.>"5HRB<*I('!SD$Y;.>?:CK?#&LZIK_@ <>&:9:<&4WPI M*5 !< %2_PJ$.V8IG[YJ] MLX'XTKNE4!:?:\7E6[&^&]EWZW;SH==>^8@$EN\S+:VVQ'^"R_EH
K'='D^Q7 [**Z#3/&-]03R@G"'"1DR?[I]!QQD8XY["O3?"^L G70+X.^?7 M|:UL;[X?G3HHFO-)N1+& /57D.Y@.<'?CD_2O2O"|-A%X?X^?7 MZU-K;3KYRQ*RA&[W]KKHPM^?
25U;:[?YGD9\H?5TI4G&2EI)QC%%6UT]UZKL[& MQ1117HGQARK_)3T_[!?_M2N^@^X*X%%_P#DIZ]@J@@O\ IJ5WT'W!6!=/KZL[! M; RZ_P_$?_;BBBBM#@"BBB@ IK_ ':=37^^J]O[^P[CCZT/
+"D/J:Z>N)@MP'N3@?Ic7E'|JQ^/=1F(G,?G;GO;GOM|]>H=U;>Ajr*`G$T'79/MWWVG$K1<>5 MLQA6_P!H^M3"M*6O+D_OR^VM:.OIMu0jfVbkVUv4uG3Xv'sAaNlGsV%n*qRkCo
[5FM/6YZM114-Y%)-93Q0R>7*\;*CY(VL1P7ZOX!ETW2)M2?5C)<0)YA!C(!/H&SFM_X=ZM=ZCI-Q#=R-+]G<*DC MG)VD=">^,?K6$:K<^22L>O7RVG'8#O$4*O.D[/1K\]SL:*\SU;5M3\5CHVE
MW+06B$]S*Q 8#[S'H2/02MG0_ C:'K%M%[1ZD95CW"2,Q;=P*D>I[D4*]Y/W M5==PJ9=3H4E^O549M74,^EWTN=G17E_C.U.L>/;33Q(()T4<6 ;G;DLUIPE4]*+G?E5F[V]CURBLW0-2;5
M]"M+YU"O*GS 'C<"0?U%:5:"::NCQ:E.5.;A+=. WW!11113(.8\# _/'UKG8_84F_I7?)]VN!\ 'UKG_84F_I7?)]VN!\ )-F6K>@_G\.P5PC6U_^'^M'O_CJ@9$BL^[TFV/U^/G_1ke_DRX*0VPX.N
6NWTJ[D&6G_7%\] T$5Q'D_Y$%\:^OF_M ^M=OIW_N*^P@BJ/PHZ'KK!W^OH4??3DH*BK!q~&GS1*&~WNeNk;zW$HaeY
```

```
[91];H]P_L_$?R_BCR:BO6?^ M%*?]3!_Y)?| VRC_ (4I_P!3!_Y)?_;*/K='N']GXC^7|4>345ZS_P *4_ZF M#_R2_P#ME'_"E/\ J8/_ "2_^V4?6Z/L_P#"E/\ J8/_ "2_^V4? M\*4_ZF#_
,DO_ME'UNCW#^S\1_+^*/)J*]9_X4I_U,'_ ))?_;*/^%*?]3!_ MY)?_ &RCZW1[A_9^(_E_%'DU%>L_\*4_ZF#_ ,DO_ME'_"E/^I@_\DO_ +91 M];H]P_L_$?R_BCR:BO6?^%*?]3!_Y)?_ &RC_A2G_4P?^27
-LH^MT>X?V? MB/Y?Q1Y-17K/_"E/^I@_\DO_ +91_P *4_ZF#_R2_P#ME'UNCW#^S\1_+^*/ M)J*]9_X4I_U,'_DE_P#;*/\ A2G_ %,'_DE_]LH^MT>X?V?B/Y?Q1Y-4UK:S
MWMU';6T32SRL%1$&2QKU/_A2G_4P?^27_P!LKH_"'PYL_"]^]_)=F]NL%8G, M6P1@|' R>3TSZ9J9XRDHMQ=V73RZNY)25E\C1|%^%8/"VBK$%S>SJKW3YSEL M?
='L,D"NDHHKQI2B@#DM9TB*Z@DBEC#QN,,#7.:%]LWAV]31=3D+63G%GQJHRYD9XBA*C*S=T]4^C M7?| K9Z,****HYPHHHH 0@,I5@"",$'O6>WA_1GD\QM(L"Y.=QMDSGZXK1HI M.*>Z-
(59P^"37HVOR:&1Q1PQB.*-8T'15& /PJ&[T^RU!56]M+>Y53E1-&' M/MD59HHLFK$JS&:[TVSG ME(P7E@5FQ]2*NT4.*:LT5&I.,N:,FGWN[_F4(-#TBVF66WTNQBD4Y5X[=%(^ MA
J_110DEL*=2;;]6W^;853NM)TV^:?:W#CHTT*N1^8J1;^S>\:S2[ M@:Z49,(D!<#UVYS4WRUM^!-;6MO9Q"*U@B@C!SLB0*/R%2LJNC(ZAE88((R"*6]]Q?V=I)'' MD<"JWY@5>I&941G=@JJ,DDX
%0VMY:WT/FVES#<19V[X7#C/ID4E9:(< MG4J+GDV[=7=_CK^9'M/1:@G4J6@KOLM7]RU_!%BJ?]D:;]L^V?V?: M?:MV[SO)7?GUW8SFKE%#2>XHSE&_*VK]F%5;S3;'4-
GVVRMKG9G9YT2OMSUQ MD<=!^56]*&D]&*,I0?-%V?EH02V=K/:?9);:&2VP%\ET!3 Z#;TXP/RIMOI] ME9V[V]M:6\$+DEHXHPJL2,'( P>*5;^S>\:S2[@:Z49,(D!<#UVYS5BE:+U+
M'[DM&V=N)0C@?W6S@'_ .MT%31K&21F9VMXRS,()XSJI0",X5I)$PH/7 3Z M"O2[&W-II]M;,P8PQ+&2.^ !2H)J3=G;S-,XJTY4*4>:+FF[\J5O+9'F&B?\ ME8E_Z_+K^4E>C>(/^1;U3_KSE_|
0#7'Z7X:U>V^(4FJ2VFVR-S.XD\Q#\K! M]IQG/<=J[36();K1+^WA7=++;2(BY RQ4@#FG1BU"2:ZLC,ZU.>*H2C)-*,+ MZ[6:N>2^%-&U;5UO5TS439A @E E=-
^=V/N]>AZ^M:'ARZD\*^+CIE_;6[RR M2+"]P"2R[L$$'T.1G@4_1M%\:Z")Q86*)Y^W>6DB;IG'5OW"'^=:6AZE2X*,X>(;E^HY_K72>$/"W_".6LQFE M66[G(\PI]U0,X R,]^?_ *U*:76Y[^-
K0^HNE6G&4KKEY/UM9??]J> M=>%M)O-XM4O&M08RUQ(OWF7<,KQZG'MQ5R$7/@OQI%9Q73S0,Z"0*N/,1 ML9^7/4=OI6[JGA76M+U^35?#3#]]DM'E5VY.2,-P5SR/3\!1H_A'5[[7UUCQ
M$Z[D8.(MP8L1T'R\ #@XK)4I*T4G>^_2QZ-3,*-12]SJ1]E*%N7[7-;TOZ,T M=>\"IKNK27[ZBT6]54((@< #'7-"?%D5DEX9H"Z;T4D+(C'NO9NOTK MK-;B\9Q:UF*TG"\O#[,N>&:0]/0;S_\
7_.NEJO8V<.GV4-I;J5BA4*H M)R<58KKA'EBD?,8]JJU>=5;-M_B%%%%6?\ MQD_Y$%%_^OF/^M=OIW_(,M/\ KBG_ *"*XCXR?\B"_P#U\Q_UKM]_P"09:?]] M<4_]!%A1/4LT445)05R?Q-
_P"2=:Q_US3_-&+765R?Q-_Y)UK'_7-/_1_1B MTX[H3V+_(+_ .1(T/\ Z\8?6%X+_Y$C0_^O&'_ - %;M#W!/;!1112& M%%%% !1163H7B;2/$L,TND7?VE(6"R'RW3!//\0% &M1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !7FWQG_P"1=TK_+"2?^@/7I->;?&?_D7=* ["2?\ H#U4/B)EL>DT445) M04444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 5YM\(O]3XB_["35Z37FWPB_U/B+_L)-5+9DO='I M-%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
%%%% ! M1110 4444 %%%% !1110 4444 %>;>+O^2N>$/\ =?\ K7I->;>+O^2N>$/] MU_ZU4=R9;'I-%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444
%%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 5YM\(_N>(_\ L)-7I->;?"/[GB/_+"352V9+W1Z31114E!1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!1110 M4444 %%%% !1110 4444 %%%% !1110 4444 07O_'CJ^ MR3U.OHHHJ2@HHHH ",U4N;<.AXJW37'RT >:^+;<0W^B-CG^TX1^IKLZY?QN M,76A_P#84A_K745G'XY?
+\COK_[M1_[>_P#2D%%%%:' %%%% 'B'BF]\4WMI M'_4UZCX+_Y$[2_^N/]37,_%K_D&Z;_-=F_E73 M>"_^1.TO_KC_%->=0CRXB2;OH?8YG75?)Z-2,%!.;T6VB?]7-N61(8GED.$
M12S''0#K7D^J>.YYO&4#6NJ.-$CGA)V(5RGRE\C&X\[N/RKUF2-98VC==R." MK ]P:\6UC2[*W^)T>FQ6Z)9FZMD,(Z;6"9'XY/YU>,E-*/*^O]?(PX;I8:I4 MJ^VC=J+?2UK:
[]>S/4&\7:&FDI]C7V+)Y?)67RGY?!.,;<]CVI/^$PT#_1/^ M)BF;O'D]$?+9.T9&,CD=\5S'Q'TZTTOP=:VUE L$/VY6V+TR4>CP3X.TN[T* MSU6]1Y[IV\R,F1@(PK' !YZ=_6G[6M[3V:2V1"P&7K!?
7)RFDY226E_+_@_M@=1J'B[0-+G,%W]<2R@X9$#2%3Z':#@_6KNF:QI^L0&;3[N.X1<;MIY7/3(/ M(_&O.I=6\/7FL7ATKPM/K-Q([222,3@\|D#!POX#K5'P')+;?$"6W\E[02>: MK6P)PF,D*<]
<8ZU*Q4N=+1INVE_SV-IY%3^]SJ+FC.$>;WN77O[]?,O)LW+# M2] 7XD23PZW*U^9Y7^QB!UQ)ABP+]",;N._K6-XS_P"2FVO^_;_S%.TC_DLL MG_7U\>WAX2ACH*4G+]Q?6VFFVB7^9Z
M]7GGC[3M!NM:M)=4UE["80A2BV[2;T#'H1T.2?7Z5Z'7D?Q8_P"0_9?]]>O\ M[,U=N,;5)M]^Q\QPY3E4Q\8QDZU5K[>::_])U/6M-\/6T!U&Z:)&^1&96 ML>%>+N5KU?[/EA):>+YMH]
<#G(].M<_X)&A:%HNI7=M MK+WD",K3RF!XU0 <84@G//)&>WI7/>%)I&^'/B2$L3&@+*/0E>?Y"M'X7VL% M[H>]VUS&)(9)5#HW0C%1&K[2I"5E=IG55P*PF$$Q-)SDX1G%%-*VJT?;>S[V,Z
MS\=SOXX\Z\U1QH]32A J$+Y>&V94#)ZKU&?RK7|;)X> 0<^OY5S&CZ797'Q.DTV6W1[,75R@A/3:H?_#_*M+XHVL%D^D6 MUM&(X8XI B+T R*YU.?
L9N>JOY]_R/6GA\LRP\,/>$G"]URURVMROR^)]3T?[ M=INC:/:M/>I':K$B123OAG 48Z\DXYJG9>-?#M_<+;V^J1F1CA1(C1Y/IE@! MFL/Q/J]>@V>AZ/%K%K+=N(TEB@C. <+C+'(XY_P C-(L0
MLAR/,XZ8P/K755Q,J?PVTMIK_P ,CQ,!DM+%]]7F3DY6E>*6C>R;YI>=D>D^ M-O$R:%I,L5O="4Y%5K<>66R-P#'D%>F>M8_@'Q?#<6ILM5U*274IKDB%9%9 MB5VK@9
P.0W>F^)+>WU'X8V^K7$7FWT=I %G[AO&$HZD7S*=FU:_,KVL_Y M>ZWW'6&EZ OQ(DGAUN5K\SRO]C$#KB3#%@7Z$8W<=_6NWU/6-/T>%9=0NX[= M&.%W'EOH!R:\QTC_
)++)_U]7'_H#U'>Q'Q1\4VL+Z1_LZS-$%4GA(U)P/3. MWGZFIA6Y(OE6KE8VQ66K$UX>WJ/DA24F]+V[+1?C<]$T_P 8>']4N5M[34HV MF8@*CJR%%B>3J\_PW 9-
6]6UW3="BCDU*Y\A)250[&;)'^Z#7GGQ#\|+:9HNFVM_IL M'V=C,(F57)!R"0"><|_+57Q;>S:AX"\|.W5PY>9RX9BSG)Q:=N9-)O=:=#T"X\|9^'K2**2;4XP)5#H C,V",@E M0,C\16O9WMKJ-JEU9SI-
XRKH5X2.$J5\/*3=. M7*[VUUZ6/0:***[3YD**** .5?\ Y*>G_8+_/:E=]!!]P5P+_P#)3T_[!?\ M[4KOH/N/"LZ?7U9WXW_EU_@C_.W$M%%%:' %%%% !37^[3]:_P!V@#@?'' MUH?_&%(?
ZUT]9)K%33\O_$F(ZBBBM3@"BBB@ HHHH \_^,G_"(+_P#7S'_6NWT[ M_D&6G_7%/_017%$?&3_D07_ZUV^G?\@RT_P"N*?\ H(JG\*)ZEFBBBI*"MN3^)O_).M8_ZYI_Z,6NLKD_B;_R3K6/^^N:?
^C%IQW0GL7_!?_D:')/_UXP_UXP_\ MH JKMY-I_A[4[VV_/UA%Y*[(%U!*[Z[M"_S);_&LVYP>E=[XQ\|=:9X1M&$$KK/J#KF*T1OF/H6_NK[]^V:
M\T^$_AV_U?Q2WBF\0K;1-(ZN5P)I6R#@>@W$Y]0!ZXUO>+;1&ST.LU3Q]KUK M\0KWPWIVDP7XCC7R$7*N6,:MEG+;0H)/;T'O5GP/X\U'7=9U'1M=L(.;^LXS M(QQRJ@*P5@02>FX(M9U&[N-
\.QW M>C6;?O69B)63U!R "<9P V*9\"_^0/J_7PG_H)K,\(IXT\&2WVA6WAJ2Y-Q M+NBNVBL2'[NXM@J1@ XR#_*MIX,Z7J&EZ5JB:A875H5HSH56XA:L-O49 S1* MR3L)7NCTVO+??B'B4)4M"OGT?
1%C:[0#$[AP&$9Z[0.A/KGI_+U*OFKP!#'KWQ M,LI+YBYDGDN6W')=P&<9SUY&34P2W8Y/HC=@T?XJZY +_P"W:A LN756O/LY M/_1M]L@5VGPZ@\9V.IWMGXG:[>W6$&%YG$H+9[,]NQ-
6?'/Q(_P"$,U2W MLO[]^V>=#YN_[1Y>/F(QC:?2J7A'XK_\|3XB@TG^Q?LOE]][>;]WXVJ3TV#T M]:IW:V$K)[GI%%%5@L"&Q)%#S(>2^
@@,(]GK1/,9!A(@S(!)D4A^S*Y*MUH(AVQP8$:HGHVWQ@I-4&((JU)):AA)A+[%T?0(B62HAG^9MZ%&4#/ZMV]PQ>/L(HLJ[)RU0S!&Q)QQ2^Q)*AQG_&C(2-(*AEBB
^[*5(/T=]>V_]+1JV9QU@4W42E/CRN,RH#Q?WS=4I)*=D(ZV!=?7U:[R=X!B,F:DI)WRK^.&+'-2+<CS@:LXDF=!H7&(_8N(*@ZI/;<4^WA8\<IXN(G@[\5+(=GOZ
%UM?,SX=;:5=RD\|)>#_!#XP\)F*'54L]+AE810MNQ- M)U)8#MR!GGZ>J4-+MAS:V1] T5X#\|-9U#3O&J:')(YMKE9(WA9LJCH&;(]# M\I''7-
6OB#XMU#7O%S>&K6_33M/AF\B2227RU=OXFD;^Z#G ]L]>CY'>PH>&?%UM?,SX=;:5=RD1LR*%?$_C+0!;6,D,6F6;N5\Z1D6 M20X)X .3C'. !ZUZ7XS\ZKJ&GZ/:-KL6C:7!;!+R62?
8C/\N!C(W=">3CBD MXI.UQJ5^AZ-574KS^S]+N[W9YGV>%Y=F<;MJDXSVZ5\Y>(--L?"=S;WGA[Q: MM_=%R'-O\K)CG.X$@@D=/IUKT;6];.E^(GPRT[6][U;>:U@EN) L6X2,H((^\ M-
N2I]>O2GR6L+F-#P-\1;GQEXAO+3[!%:VD-OYJ#>7WXU2^*?A M'Q'XDOM.ETA?/MXD*M#YP38^<[_F('3 XYXKR[P-X._X3/5+BR^W_8_)A\W? MY/F9^8#&-P]:Z3XQ6?\ 9]QX?LM_F?9[
1;\8W;3C..W2JLE+0F]XZGM>@VM MW8^']/M+Z7S;N&W1)7SG+!0#SW^O>M"O-M:\5S>%/A+H4UF0+ZYLK>&!B =G M[H$M@C!P!^9%<+X?^'VN^/-.?7+YUR[9ENA/[LN[>+YBR=?
@>.F8Y>K+ MYNB/H.BO"/"7B6_!?CD>&=5NGN+1IUMF25V*QEC\KIG[H.X'T(/XU%%|;_| MD=+/_L')_L'A@)L#Y*K87S%SJ/N/PX$<$N%K1{)&^JUTc+>
MV0#T^O)/7L/@MKU[J>CZC87DSS"RD1HGD.6"ON^7/H"I/XTG'2]QJ6MCT^BB MBH*"BBB@ HHHH *\V^_(NZ5_V$D_\ 0'KTFO_C8F_PUI@#$9U!1Q[H_-5 M#XD3+8],HKR#_A ;[_H;=6_[^-
_\51_P@-] T-NK?] &_P#BJ?*NX7?8]?HK MR#_A ;[_*&W5O\ OXW_,51_P (#??]#;JW_?QO_BJ.5=PN^QZ_17D' " W MW_0VZM_W\; XJC A ;[_*&W5O\ OXW_,51RKN%WV/7Z*\@_P"$!OO^AMU;
M_OXW_P 51_P@-] T-NK?] &_^*HY5W"[['K]%>0?\(#??;JW_?QO\ XJC_M (0&^_Z&W5O^_C_!5'*NX7?8]?HKR#_A ;[_H;=6_[^-_T-NK M?] &_P#BJ?*NX7?8]?HKR#_A ;[_H;=6_[^-_\51_P@-_ ?
QO_(JC_A ;[_H;=6_[^-_| M51RKN%WV/7Z*\@_X0&^_Z&W5O\ OXW_,%4?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D' \ BJ.5=PN^ MQZ_17D'_ @-] T-NK?] &_P#BJ/\ A ;[_H;=6_[^-_\%40?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_$!OO^AMU;
H;=6_P" C?| Q5'*NX7?8]?HKR#_A ;[_H;=6_[^-_\51_P@-]|%40?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_ @-] T-NK?] &_P#BJ/\ A ;[_H;=6_[^-_\%40?\(#??
BJ/^$!OO^AMU;_OXW_5'*NX M7?8]?HKR#_A ;[_H;=6_[^-_\51_P@-] P!#;JW_ '\|; P"*HY5W"[['K]%>0?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_$!OO^AMU;_OXW_ 51_P@-]|%40?\(#??
@-] T-NK?] &_^*HY5W M"[['K]%>0?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_@-] T-NK?] &_P#BJ/\ A ;[_H;=6_[^-_\%40?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_$!OO^AMU;_OXW_51_P@-]
MX0&^_Z&W5O\ OXW_,%4?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_@-] T-NK?] &_P#BJ/\ A ;[_H;=6_[^-_\%40?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_$!OO^AMU;_OXW_51_P@-]
MJ[A=]CU^BO(/(/^$!OO^AMU;_OXW_5'*NX7?8]?HKR#_A ;[_H;=6_[^-_\51_P@-] T-NK?] &_P#BJ?*NX7?8]?HKR#_A ;[_H;=6_[^-_\51_P@-]|%40?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_$!OO^AMU;_OXW_51_P@-]
QO_BJ.5=PN^QZ_17D'_@-] T-NK?] &_P#BJ/\ A ;[_H;=6_[^-_\%40?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_$!OO^AMU;_OXW_ 51_P@-] T-NK?] &_^*HY5W"[['K]%>0?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_@-] T-NK?] &_P#BJ/\ A ;[_H;=6_[^-_\%40?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_$!OO^AMU;_OXW_51_P@-]
_P#%4?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_@-] T-NK?] &_P#BJ/\ A ;[_H;=6_[^-_\%40?\(#??]#;JW_?QO_BJ.5=PN^QZ_17D'_$!OO^AMU;_OXW_51_P@-]
```

```
(D+@?61#67HG@^ M/Q!X>T^ZURYN),V\:P01OL2*-1A>.Y(P2?>KWC#_))=+_UPM_| T-*M^#]? MTZZ\+V"&ZABEMX$ADCD<*054#/..",'\:6J6@^IE:+]K\+>-4\.-=27.FWD+ M36HD;+1$9)'_
(ZWMR#US27/_)9K/_KS/_H+TEO.OB/XHPWU@WFV.EVYC>=< M%'=@X^4]_O?^.GZTMS_R6:S_.O,_P#H+T_\A%3Q5%>7'Q3TB&PF$%Q)9;!* M1G8I\T,P]PN2/?
%2>)/!%II6CW&KZ=>7R:A:J)/.>?3?RFKHO%_| R*&K?]>S_P_J+[#MN.T>[GUWPG;7$DAAGNK;#21]58C& MX>G/-<[<^__#T"F34=5N3>,,_:KBZ"MN_O#/O]:KRZC=Z9\'[6XLBZ3>4B>:
MAP8P7P3_$_&EL=&\$6WA^#4[V2"Y=H0\DTMP69VQDC;GKSC&,^O-+8";P3) M)XC\)7VEZK.UQ'%,8/-5\EDP"/F[\YY],5@Z%X,TC4/%>N:?.LWV>S91$%DP M><]3WK<^%I#:=JI$9B!O"0A&-O
XQ[4>'KB&S^(GB:*YE2%WVNHD.,KUS^1! MIWLW8787XE6Z6G@>VMH\^7#/%&N3S@*P%7_%6MW>E:%IUKII O[]D@A8_P . M0,D>_('XU4^*+*_@^)T8,K7,9#
Y!&UJB\=17$&FZ#K,47FQZ;/'+(@]/E(/ MTRN/Q%"Z#?4L0_#32Y(@^HW=[=WK?-)<--@[N^/;//.31X2N]0TWQ#?^%]1N MC="WC66UF?J4XX_4?3!ZBNBM?
$.CW=DEW%J5L(67=EY54K]03QCWKE_#;_V_MX\U/7X WV"*(6T$FT@2'C)Y^A/XBEJT[AIT,BQTZYU7XA^(+2*[>VMF;-R\3 M8D9>RJ>V2>?85)XFT*/P-]CUW1)KA-
MPJ3PO+E9!@GGZX(/UXQ6CX6_Y*1XF M_#^8J;XJ?\BBG_7TG\FIWU2%;0[>BBBLRPHHHH **** "N%^&O\ JM;_.OY MJ[JN%^&O^JUO_K^:J6S$]SNJ***D84444 %%%% !1110 4444 %%%%
!1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5POB7_DI7AK M_=;^M=U7"^)?^2E>&O\ =;^M5'<3.ZHHJ"XO;2S,8N;J& RMMC$L@7>?09ZF MI&3T444 %%%% !1110
450_MK3_[9_LC[1_I^SS/*V-]W&Y5#AC#*K@'WP:YW5%<9\3/^1;M_^OM?_0'KRFNNCA?:PYKV M/.Q./]A4Y.6_S/HFBOG:BMOJ']{\#F_M7^Y^/_/HFBOG:BCZA_>_/[5_N? MC_P#Z)HKYVHH^H?
WOP#^U?[GX_| /HFBOG:BCZA_>_/[5_N?C_ , ^B:*^ M=J*/J']{\_M7^Y^/_/HFBOG:BCZA_>_/[5_N?C_P#Z)HKYVHH^H?WOP#^ MU?[GX_| /HFBOG:BCZA_>_/[5_N?C_ , ^B:*^=J*/J']{\
_M7^Y^/_ / MHFBOG:BCZA_>_/[5_N?C_P#Z)HKYVHH^H?WOP#^U?[GX_| /HFBOG:BCZA M_>_/[5_N?C_ , ^B:*^=J*/J']{\_M7^Y^/_ /HFBOG:BCZA_>_/[5_N? MC_P#Z)HKYVHH^H?
WOP#^U?[GX_| /HFBOG:BCZA_>_/[5_N?C_ , ^B:*^ M=J*/J']{\_M7^Y^/_ /HFBOG:BCZA_>_/[5_N?C_P#Z)HKYVHH^H?WOP#^ MU?[GX_| /HFBOG:BCZA_>_/[5_N?C_ , ^A+K_(])O^N;?
RKC_A;_ ,BA M_P!O+_R%>5T4?4=+_ /[5_N?C_P#Z)HKYVHH^H?WOP#^U?[GX_| /HFBOG:BCZA_>_M/[5_N?C_ , ^B:*^=J*/J']{\_M7^Y^/_ /HFBOG:BCZA_>_/[5_N?C_P# MZ)HKYVHH^H?
WOP#^U?[GX_| /HFBO,O /BG[-(NCWTN(7/^CNW\+$_=^A[> M_P!:]-KAJTG2ERL]3#UXUH,^JL ?\ /K7=U#=VD%]:R6MU M$LL$J[71AP12JP]I!Q[BR_%+"8]G7:NHN_|
7WGE.@Z&^K>'XL>-9+:)D,8."/;G-=7X4T[3O#.@7]S_:\5]8LY9I0FU!M&"!R0V>GO4G3Z%%HR3W<%E&YS5:7)*2;7)%66^ZU;Z+\6>,7-O)=K?:E:6C0Z>MP!
MM!R(]VXJ/PQC/N/6O7XM1L]3^&EW-8QK%$NGRQF%?^6;",Y7W^O?K5^V\)Z7 M:^')M#1)#:S!O,9B"Y8_Q9QC(P,<=A66WA:T\,^%M>6RNKN2.:RE+1S.I4$(
MW(PHP:FGAYTKOHT[^NIMC$=)\.L\EG&[SN,&:9MS8]!@ M ?05G1IU*E."TY4[^9UYCC<)@L;B*B-_M,[.(X?,7S&R3P!^\)KM MM=\):1XA827L#"=5VB:)MK@?
R/X@UG:7\.]$TJ_AO(WNY986WIYL@P".GW0* MT^JR4FFDTWW:_Y?[>HRHPE&;A.,;64(N[2_F>]3Z_D<3KSKIWQ5^TZB ;?[ M1%(689&S /X?TKU--R\*Z79Z"VC&)KBS8EF$S9))[Y&,'Z5'U'>?
OQZ2U.M9QA5]5KZ M\]))EE@8@,S9)(V]\Y]\YKFOA/_R'[W_K MU_\ 9EKK+3X:^'[6^6YQ\/>#-.\-7DMS9S74CR1^6 M1,RD8R#V4>E5&E6V_KJSHJ\5O[*#4OBE M-9W*EH9KS:X!P2/K7M5"E5E-
M.46E;OT]#,U3X>^'K;2+V>*WE62*!W0^JLQ B0DGMR:].NK=+NSGMI"P2:-HV*]0",'%86B>"]-T%+Q+6>Z<7YOEEG?>P1T"@^V5-;XF-2 M4.6F>/DU?!T,1[7%[)::7U[M>7YE/PKIOA;PX@G?6M-
N-0*X:8W*83(Y"C/Z M]?Y5A_%FS==5L+[!\N2 PY[ JQ/_ +-^E;O_ JG0O\ G[U'_OXG_P 177:G MI=GK%B]G?0B6%N<'@@]B#V-8^PG.DZ;278]19IA\/CX8R%252]U*Z2LGVU_# M3;S.*\
<^)M.O_!*K:7<4DEXT?[I7!90"&.1U&" *@TC4W\(?#**[9,75W(S0 M(P[MT)'IM7/XCUK7M/AIX?MKL3LMS< '(BFD!0?D 2/[J:U_$'A>Q\26UO!=R M3Q)
Q9/(*KVQW!H]E6;=1VYK60OKV6PIT\)#F=+GYI-K7R5D]>EV><^'M/T_M7[IM:\4ZY:EF;Y;>6Y1&?&?O#(VKZ 8_+KW'B/S]8\*2V_AB:&H_]_$_^(KI/#_A^T]-V$EG9R3/&\IE)F8$Y( [ M A>'KZU73
M8(K)XI&N7WQ,Q7:=QSNSP,]*G^&#ZN+]EMHU.EES]J0&!!Q[\UF>'?#-EX9@GBLI;B19F#,9F!((&., 4+"N M-2+BW9#GGT*^#K0JPBJDVMD[/S;ONNAM4445WGR1Q.K?
\E%C_P"P/^M>I:=_R#+3 M_KBG_H(KRWXH?\B/^M>I:=_R#+3_KBG_H(IO9 MRS1114%!7)_$W_DG M6L?]:AJT336EJ558RQ DD.3S MCD@#!QWR.O(KVB3PEX0X0D A@2>
<8QZX/M7MLLL<$;22R+'&O)9S@#\:J;=Q02L<[XKU]/ M!7AJ*>UL#<[7CM8+=7QU! YP3P!^->?W?Q.\2/GEMIEX/3Y MBV.?7%=#\2O'9\.6=A'IT5O<75T//AG&3G9(HSM)&,C&#QV-><:-
\:-6N)YX[W2[:=S"?LT-G$X>27(P"2S?+C<3QV MJ?X2,3X(\3)GY0&('N8S_@*Q/@G$DGC:X9E!,=A(R'T.]!G\B?SI\J5PNW8U M+'XUZI#K(AUG2K:*U\S;(L2NLL0]3N)R1Z8&?:I-8^,NLQ3"?
3=$CCTUG(BF MO(W)E'J"" #P>.:P/C+&B>/695 +VL;,?4\C^0%>D?$.WAC^$$\:1($AAMA& M,?*_#?]JF,6S1.T=PK-\J,H!)!/;!!]L^U M<1J7Q:U.^UJ33_"&CK?A,XDDC=S(!U8*I!
SW)_+-8'@8RCX6>,O)!+^7SC^ M[L.[],UD?#J'Q5//J">%K^TM9MJ&99@A9UR<%=RMP#UQZC/:CE6H^9Z'I'@__MXH2:MK9T+7[%+#42Q1&7*J7'5"K..3GIUQGSWXP_\E G_.O>+^5= GPZ
M\;7GBZTU[4[FPEN8[F&6257"DA"N.%4#HH_*N?\ C#_R4"?_*]XOY4XIVIZ7\5?$%/$D<_P[MM?U".VLXD MBE>1+9"L:*CLH"KD]E'':_&G_D6]+_.PB MG_H#UZ57FOQI_P"1;TO_+"*?
^@/50^)$RV.BHHHH Q]3\*Z'J\IEOM.BDE/ M5URC'ZE2":BL?!OA[3IXY[;2XEEC8,C.66-KJ-LUO> M6\<\+=4D4$?
7Z^]8UOX%\-6MP)XM)B+@Y&]WM5=+TFRT:S%II\'DP!BVS>SB@"I;Z996VF+IT=NALU38(7^==OH=V<_C69:>"O#EE=BZ@TJ( M2AMP+LS@'U
8D#\JWJ*=V%BCIFCV&CK,MA!Y(GD,DGSLVYCWY)JKJGA;1-:N M4N=0L$FF48#AF4D>^TC/XUL44786,Z_T+3=3TV+3KRV$EI%MV1AV7&T8'((/ M2KWE1^3Y.P&/;MVGD$=,4^BD!SLO@/PQ-
<>>VDQ!\YPCNJ_]\@@?ABMVVMH+ M.V2WMH4AAC&%1%P!^%2T4[L+%"UT73[+4KG4+>WV75U_KI-['=^!.!^%+JNC MV&MV@M=1@\Z .'"[V7D9YRI![FKU%*X!1110 4444 %%%%
!7"_#7_5:W_U_ M-7=5POPU_P!5K?\ U_-5+9B>YW5%%%2,**** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7Q+_R4 MKPU_NM_6NZKA?
$O__"4KPU_NM_6JCN)G=5PWQ$_X^?#O_7^O\Q7^&&G\D:M'OSC)C<+_ -]8Q^M;MQ=0VMG+ M=S2!8(HS*[@9PH&2>.O'I7GUSXE\,7.FR6/_C&HI$Z;!ML4!7T((;J.M3> M'9KF3X3ZG%=+
(K06]S$HD!!V["1U^N/PJG$5SN+"_MM3L8KVSE\VWE!*/M*Y MYQT.#VJ(ZQ8#6%TDS_Z'^-*VK'PSWK>\):')=R+XGUB5;K4;I=\(!!2!#T"^^/R M^N3Y0![YK&M?''AN]NEMH-4C,K':H9'0$Y
MQ@$@"N7\;ZI;MXQT^PU""ZN=-MXABR( K%MK#*D@#*Y'/.*YG5KBXN?@SYEUO\[RHD;? M]X[9E7G?BMSPIH.FQ^%-\,LX)WN+9))7EC#%MR@X)/8 X'L*5DEJ%S3E\ M1:/#I2ZF^H0"S8960-
G/L .2?;&:9I7B;1M;D:/3K^.:11DH05;'J P!/^?6 MN'\#:%9R^)M;AF5IK?2[EH[6&4[E3;1DL%?7#; M_94<.%GY!8=/E_BZ].:5M$,I6_CKPU=7 @BU:(.3@;T=!_WTP_6NAKR_P 4
M^(/#.J^';JTT^PE=UPT4T-IM5"".IX MH:LK@F;%%4=7U-=(L#=O:W5RH8*4MH]]\]9'%<__P + M?^@%KW @(/_BJ2 M387.NHKE[3QQ;W=Y!;+HNM1F:18P\E]ЕЈ JY.,D[N!744-6'<9--';P232L%CC
M4N['L ,DUX[*;L,/'RM(,ZF0$_Z8?=ZGJ.-G^>.U^)&L#3/'TENK$3WI\E<' M&%ZN?ICC_@59.OB'PB?'!)T :HN1:^6#]GE(\P#.[E?[W-7'17)9Z)'(DL:2( MVY' 92.X->1^
K:XF\=7<]H6%Q9VD=TFTZG+::&EA:D&D]U*06L29Y(/#$?F!_P(50\%L=#UW5?"\S$) M&YN+/<02T9Z\^N-I_.ET_P#XJ3XAW6H'+66CCR(=P^5I3D,1]#GU_A/I1:S" M^A7^%T
MH=9MPVX1700,.^,C-6=(_P"2MZ___->L?_H,=0_#/_F._P#7Y_C4 MVD?\E;U__KUC_P#08Z;W8+9';T445F4%%%% !1110 4444 %%%% !7"_#7[F MN?\ 7\U=U7"_#7[FN?\ 7\U4MF)
[D_Q,_P"1;M_^OM?_$!Z\IKU;XF?\BW; M_P#7VO\ Z ]>4UZ^#_A?>?.9E_'?H@HHHKL/."BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M %!(((.".A%>N^"O$XUJQ^R70U9L+^YTR]BO+239-&< M@^QJ#[5A7HJK&W4ZL+B'0G?
IU/H"BLW0M:M]=TR.\@.#]V1#U1NXK2KPFG%V M9]3&2DE*.S"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110!E^)O^15U?_KRF_P#0#6;\/O\ D1M-^DG_
*,:M+Q-_P B MKJ__%Y3?^@&LWX??\B-IOTD_P#1C57V1=3IJ***D84444 %(W2EI#TH Y/Q M/#VNDF,>X+D+D]33SXZU13SX=_\FQ_\36Y_77HT4_^$\U/_H7O_)L?_$T?\)YJ?_0O?^38_P#B M:M?
V6/2C^RQZ4O9R_F?X?Y%?6Z7_#YC]\O_)(J_P#">:_G_"38_| MB:/^$\U/_H7O_)L?_$U:_LL>E']ECTI^S?\,_P_R#ZW2V7?2_Y]Q^^7_D5?\M^A/-3_P"A>_\
!-0W7C:]NK6:VN/#FZ&9&CD7[7C*D8(R!GI6A_98]*: M=)!(4O9O^9_A_D-8RFG=48W]9?\ R1AZ/XA70UE73/"OD"4@N/MQ;..GW@?4 MUJ?\)YJ?_0O?^38_^)J<:0!VI_| 98]*2I_|FQ_|35K^RQZ4?
V6/2]]G+^9_A_D M1];I?I;?\ 8_?+_ .2*O_">:_G_"38_| H7O_";' P 35K^R MQZ4?V6/2CV;_ )G^'^0?0?6Z7_#YC]\O_)(J_P#">:_G_"38_| B:/^ M$\U/_H7O_)L?
_$U:_LL>E']ECTH]F_YG^'^0?\ 'FQ_| 2*O_ GFI_\"38_^)J<:0!VI_ | M0O?^38_^)J<:0!VI_| 98]*2I_|FQ_|35K^RQZ4?V6/2CV;_ F?X?Y!]?RQZ4?V6/2CV;_ )G^'^0?\
V6/2CV:G_T+W_DV/_B:/^$\U/_H7O_)L?_$U;_LL>E']ECTH]F_YG^'^0?_F_YG^'^0?_F_YG^'^0?_F_YG^'^0?V6/2CV;_)P#/1.O%BD M3YGM?PB7@_%B/@9)Q)/X0X6DBSH1YB_2+I0:0WV4+=&!^T$JD$23Z
^38_| H7O_)L?_$U:_LL>E' M]ECTI^S?\,_P_R#ZW2V7?2_Y]Q^^7_D5?\ )\U/_H7O_)L?_$U:_LL>E']E MCTH]F_YG^'^0?6Z7_#YC]\O_)(J_P#">:_G_"38_| H7O_ "; F?P_R#ZW2
_$U:_LL>E']ECTH]F_YG^'^0?6Z7_#YC]\O_)(J_P#">:_G_"38_| B:/^$\U/_H7O_)L?
_$U:_LL>E']ECTH]F_YG^'^0?\ &FQ_| 2*O_ G_P#Z ]>4UZ^#_A?>?.9E_'?H@HHHKL/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
```

<5[')#I'O'!9<%L'U^[_M^I]7XH?|B_8?]A"/_P! >FK73$]C;T'Q1;>()9HX+.^MS$H8_:8@F[/I@FN* M\ >(;'0O"DHNC+)--?2>5! F^1\1IG KU&O//A+96ZZ+>WPC'VE[@PESUV!5 M(
],6/UX]*%:S#]=%H?C/2M>NWM(//@NE&?(N4",1WQ@G/TK7U'4K32;&2]O M9EBAC'+'N?0#N?:N-\31K#\2/#5Q'\DLFY'9>"0/_K,15?QUFW/3ID=Z+)L+FG'\2=&:1?,MM1@@8@"XE@
CP>AR"3C\ M*Z34=5MM-TB74Y-TMO''YF8<,67L1S@]?6N/U+7M>U/3+FQF\$W!CGC9"3< MXR.#]S[#S^%11;WMI\(+JUU"%X9X8G78XP=N_(_0T607-2X^(VAVZ61;[2SW
M2AQ&B*6C!.!OYP/H"3^8K1UWQ7IGA^6-"Z,\ES(NY([(BS..1GL.WK5'P'IM MK#X.M,*.]TF^9G&2_) !SV P *LZOXHTS2M3%]MK<7N]%,>3:0[Y.QT/[/IW MI65[(.@S2O&^E:I?
I8E+]SNI.8X[N+87^F"15W7/$5IX?^R?:XYW^U2^4GE* M#@^^2...X+Q1]MYJFK:!/<:'>VA#!C'7YB1G'J*V(=?L;O0I M-7LF>[MXT9RL(^?Y>2,$CGVJ];VEO:VB6L$*1VZ+L6-1P!Z5Q/A!$L?'/B33
M[7Y;0%9!&#D*WMZ?>/Z>E+1CU.LT76+77M+BU"SWB*0D;7P&4@X((!.*@OO$ M5K8Z[9:.T4|MW>#<@B"D(O.6;)&!P3QGH:Y_P6K:-K^M^'!]$<-M9U]CF"W8V5O^&,G^O_J+
(5SMZ***DH*X7X:_P"JUO|_MZ_FKNJX7X:_ZK6_^OYJJ:,3W.ZHHHJ1A1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"^)?^2E
M>&O]UOZUW5<+XE_Y*5X:_P!UOZU4=O,[JJ.HZ/8:LULU[!YIMI/,B^=EVMZ\ M$9_&KU%2,1E5T9'4,K#!4C([MIVFVFDV26=C"(;="2] D\DY/]YZFK5% %#
M^Q=/_MG^U_L_^G[/+\W>WW<8QC./T]+6/#NE;_Y/]IVOG^3N\O\ >,NW.,_= M(]!6I13N!S47@#PO$^Y=*0G_&I9&'Y%JZ*&&*WB6*&-(XU^ZB* !] *?11= ML+%#4]%TW6(U34+.*X"_=+#D?
0CFLVU\"^&K.82Q:3$6!R/,=Y!'^3$BNAHHN MQ6$ "]%4 # [4M%%(84444 %%%% !1110 4444 %%%% M% !1110 4444 %%%% !1110 4444 %%%% !1110
5POPU^YKG_7\U=U7"_#7 M[FN?]?S52V8GN=I=6=K>QB.[MH9XP=P65 X!]<'OR;J?\(_HO_0(L/\ P&3_M K1HH4FMF)PB]6C_X1_1?^@18?^ R?X4?\(_HO_0(L/_9/*T:*.>7<7L MX=E]R_R,
[_A'|% Z!%A_X#) A1_PC^B_] BP_P# 9/\ "M&BCGEW#V<.R^Y? MY&= PC^B_P#0(L/_ &3_"C (1_1?| H$6'_@,G^%:-%/|+N'LX=E]R_R_P C M_X1_1?^@18?^ R?X4?\(_HO_0(L/_
9/*T:*.>7SAV7W+_(SO^$7T_H$6' (#) A1_PC^B M_P#_(_HO_$^"+# PC&3_M"C A']%_Z! M%A_X#) A6C11SR[A[/.9SMAV MW+_A'|%Z!/%A_X#) A6C11SR[A[.'9SMAV MW+_
9/*T:*.>7SAV7W+_(SO^$7T_H$6' (#@ A1_PC^B M_P#X!]&%P[?%Y[&= P(_HO$_$^"+# P P &_"C A']%_Z!M%A_X#) A6C11SR[A[.'9SMAV MW+_A'|%Z! P"@18?^ R?
X4?\ "/Z+_P! BP_\!D_PK1HHYY=Y!]GLON7^M1G?7/ !\D^*KKPI(\ M1G?7/{E^/_J:_(?;7}*@!Y#E}!*T [0(L&EH!4E*W@!!1!{FJ [F*IM4 M1G?7/{E*(/I)/!_P!1G?7 @6]^]P^ BH!
MBP_!D_PH_X1_1?^@18?^ R?X5HT4<\NX>SAV7W+_(SO^$7T_H$6' @,G^%:-%/|+N'LX=E]R_R_P C ,!D_P K1HHY)#^*T:*>_{/_0+L_]_-_9#^%#_"4 (S!P A/@ A1_Z_ ^O_0(8@]
BP_!D_PK1HHYY=Y!]GLON7^1DW.@Z,MK*1I-@#"$)!%LGI*Y/X;<:9I]]X6 M\Z|L;:XE^T.-[T*NV/#C)%'I-_US:?5>77SAV7W+_(CA@AMH5A@B2*9)NI&H51] *DHHJ2] M@HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH R_$W_(JZO_->4W_H!K-^'W_(C:;]]/_1C5I>)O^15U?\ Z\IO M_0#6;\/O^1&TWZ2?^C&]OLBZG34445(PHHHH ****
"BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** .;|??\B1]?^XG_*&M7?"W_(IZ1_UZ1?\ H(]EX^_Y M$C4_]Q/_$-
:N^%O^13TC_KTB_\015?9%U->BBBI&%%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%%
!!1110!QGQ0_Y$YO\ KO'_%KU+3O^09:?]<4_M]!%>6_%#_D3F_P"N\?\ 6O4M._Y!EI_UQ3_T$4WL@6Y9HHHH]"@KD_B;_DZ_MUC_KFG_HQ:ZRN3^)O_).).M8_ZYI_Z,6G'=">Q?]%_\B1H?_7C@#_Z
*W:PO!?_M_")&A_\ 7C@#_.@"MVA]@M@HHH]#"BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M\U^-/_(MZ7_V$4_]
>O2]U^-/_R+>E_P#813_T/Z]Q'O(F6OT54=8T]WUO2 MI]/NL^7*N-PZ]>H(]P:O44 >>Z=>>>*"$0TVYT>35K&(X@GMA !_(XQ MZD8K4MO%&NZA?6T,'A:ZMX7E43371*[(\_,<$#G&>_X'-
==157]A6.+U*QNY M/BQH]XEK.UK'9LKSB,E%.)>"W0'D?F*W?%,_MQX6U.&"-Y97MV"HBEF8XZ # MK6O12N%CF-&T8WWP]M]O8W@:6V,_+(A?1MDX.#CD'!Q6-I>L>(O#%%&:3?
MZ#>:BEM]D-S:@L&3L.!TQ_A7H%%X.X6,30M3U;4Y9Y+[2#]L /)$CY=CWR.W MY5C>"[&[M?$GBN6XM9X8Y[S=$D942#?]RJ/4:."\W2O'&6$8WQ\L1T"!Z"AKH_$$4DWAO5(HD:21[.541DL2AP
.Y MK1HHN%CE?"&E-)/K73-1MY8O,CFCEBD4HP#,8\[X.16/I-SBX\V5:7OO]*=PL<(MG]_C'7;&\U'3GT]2K!#2F29 -2&F29 M_E%X<^TZW"QCJX_(('KPV<>U=311?
4+&)H&N M7>L!'Q:>449:X0]&&;N%!&<<5C?2#+&QN[#PW<17EK/;2&\]9@DT9OD;$YP>W! M"NTHI7"QOOB6RNY_&ANXAM9I(87;S)$C)5.1U(X'XU-XPT2_N+FQUS1B/[
M1TJG]WWE0]5'Z\=PQ]]ZRBG<+'%IXRUN2,1IX/U'[5C^+*QY_P!XKTK1\0QW M]]XOEM3]NDM_F@A&_YLC@8SFNCHI7?"QB>$)(K;PEIL-Q$$4]189]%*LIR>
MH/2N9N8]7|^_:5UTFYU.ROU"A[<:Y$P!O@9,!C'IC'\[HHN%CS/O$RF]ECTT_ *+&<KR#BFCR6*CQQN4=KHA6'8D*FOO M:XGXA6-W>_V-
]DM9Y_+N]S^5&6VCCDXZ"]3UOFM![>*O$%H@M;CPM>3WRC:9 M8,F%%STW!L<]<5<\'Z!=#:MY[6]E6U74'WS!<$1CLH(^ISCCIZ9KIZAOGMK
M*>>>.%IY(XV=8DZN0,A1[GI2N.QP_Q">XT2]T_P 26>WS422T<,<9W*Q4^O!W M'!?72^%e="&A^&[.R.?:Y<_WVY/Y=/PKFO/]GC37;&>>TN?3M)L6\SR[G(: M:3MQP?Z?7%=
[0]K"6]PHHHJ2@KA?AK_*K6_P#HK:NZKA?AK_JM:_F_JEL MQ/<[JBBBI&%%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %
<+XE_Y*5X:_W6_K7=5POB7_DI7AK_ K51W$SNJ***D84444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%% !7"_#7[FN?]?S5W5<+\-?N:Y_U_-5+9+9B>YW5%%%%2,**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH ****
"BBB@"*Z_X]O\ KFW]X_X6_](H?]O+_R M%=A=?!>DW_7-OY5Q_P +?^10_P"WE_Y"]6PNIVM%%%%2,**** "BBB@ HHHH M**** "BBB@ HHHH ****
"BBB@ H MHHH **** "BBB@ HHHH **** "BBB@#+\3?\BK]_7E-_P"@&LWX?*(C:; M]]/_$8U:7B;_D5=7_Z\IO\ T UF_#[_)$;3?I)_P"C&OLBZG34445(PHH MHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** .;|??\B1]?^ N)_Z M&M7?"W_(IZ1_UZ1?^@BJ7C[_)$C4_\ <3_T-:N^%O\ D4](P"O2+_T$57V
M1=37HHHJ]A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <9|4 M/^1.;_KO'_6O4M._Y!EI_P!<4_|
017EOQ0^N\?]:]2T[_D&6G_%O3 M_P!!%-[(%N6:***@H*Y'XGDK\.=7(?&DC&/^VBUUU._$=EXI?]]O_M /&]/^%B*^?^B=ZE_P!]O_]_J)HHNNP6?<\V_X6+X+P"B=ZE_WV M&_/
M_P"%B^*^?^B=ZE_WV_P#\|:KTFBBZ[!9SS;_A0BG_HG>I?_ ?;__JJ|JC_A0 MBG_HG>I?_]]JO_/&]J)HHNNP6?<\V_X6+X+P"B=ZE_WV_P#\|:H_X6+X+P"B=ZE_WV M_P!!K]
;KTFBBZ[!9SS;_A0BG_HG>I?_/&J]JHHNNP6?<\V_X6+X+P"B=ZE_WV_P#\|:H_X6+X+P"B=ZE_WV M_P!!K]&J]JHHHNNP6?<\V_X6+X+P"B=ZE_WV_P#\|:
!JC_A0OBG_HG>I?_/&J]JHHNNP6?<\V_X6+X+P"B=ZE_WV_P#|:H_X6+X+P"B=ZE_WV_P#\|:KTFBBZ[!9_M M6+X+P"B=ZE_WV__:H_X6+X+P"B=ZE_WV_P#\|:KTFBBZ[!9SS;_A0BG_HG>I?
M6+X+P"B=ZE_WV__:H_X6+X+P"B=ZE_WV_P#\|:KTFBBZ[!9SS;_A0BG_HG>I?_/&J]JHHNNP6?<\V_X6+X+P"B=ZE_WV_P#\|:H_X6+X+P"B=ZE_WV_P#\|:KTFBBZ[!9_A0
MBG_HG>I?_/&J]JHHNNP6?<\V_X6+X+P"B M=ZE_WV__:KTFBBZ[!9SS;_A0BG_HG>I?_/&J]JHHNNP6?<\V_X6+X+P"B=ZE_P! &J]JHHNNP6?
<|V_X6+X+P"B=ZE_WV__:KD/DX7XKUK7-(LH-0*7FE M1QW:R)+,S$.VUAM&4'/]X5[Q7FWQG_Y%W2O^PDG_H#U46K]"DG;FI"Q(\WFHB6Z+&+=^Z/^Z<#>:^@Z[V^$7^I[\ 82:FI*ST
M$UJ9G "6^*/^A"U/_P ?_P#C=' '^Q__P"-UZYT12YEV'R^9Y'_PEOBC_H0M3 |? |XW1 PEOBC_H0M3 |? | C=>N441_|);XH_Z$+4__!_ _-T M?1;XH_Z$+4__!_'_ '
(W7KE%',NP1_P#"6^*/^A"U/_Q_P"-T?|_"6^*/^A"U/\ |?|_C=>N44N441_|_"6^*/\ |?|_C=' "6^*/^A"U/ |?|_H0M3_P#'_P#XW7KE%'N MP1_\);XH_P"A"U/_Q_P"-T?|_/C='"6^*/^A"U/_P_?
_P#C=>N44N446]U"#*Y-H^[?/UZ?*#^AKZ#KS;QO=_R5SPA M_NO_%[QDK]":S_(2WQ1_T(6I_P#C_P#_P :KUR MBES+L/E\SR/_(2WQ1_T(6I_^A/|_P_
H_X2WQ1_T(6I_P#C_P#KURBCF7FM7.7S/(_A$M\ M+?%'^0A:G_X_P".^J#F_^D M]"U/_ /&Z/^&$\M\4^D]"U/_ 0A:G_^/_\:KUR3RMWW[IO[IPYI:*O7_:_ QS%/_;_P#_ Cr+:
%'_0A:G_X_P"-T?|_"6^*/^A"U/\ |?|_C=>N441O?_P!_ Q/_/^G]_:0D_:_ SUSTYR9X(%R92U'_Z&Z2 H/2+5@O_P#C/T:N+A8%C9R/{_ C/_0:2P]_&_{:#PGFUFEN(__!_ _
%'_0A:G_X_P"-T?|_"6^*/^A"U/\ |?|_C=>N441_);XH_Z$+4__!_'_ '_(W7KE%'N MP1_P#"6^*/^A"U/\ |?|_C=' "6^*/^A"U/_Q_P"-T?|_C=>N441_|);XH_Z$+4__!_'_ '
|);XH_Z$+4__!_'_ '_(W7KE%',NP1_P#"6^*/^A"U/_ Q_P"- MT?|_"6^*/^A"U/|_|?|_C=>N44H0S^"M0MX9+:1'F?B-2I! M8_(_.:I^$_$6OV/AFSMK/PC?7UN@?9::"U[IL'F]/FW;O2:\V|^_(NZ
M5_V$D_0'H]$3+8]HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;X1ZZGO%_V$FK MTFO-OA%_V$FK:X_MTFO-OA%_V$FK
$7_82;J6S)>Z/2:***DH*** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *|V|7?|E<| M(?[K_P!:]KS;Q=_R5SPA_NO_6]CN3+8])HHHJ2@HHHH
**** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "O-OA'|SQ'_P!A]J]KS;X1_<|1_|82:J M6S)>Z/2:***DH**** "BBB@
HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@" M"] X|;C_*Y-_*N$^#/_"(A_P"ON3^2UW=[_P >-Q_UR;^5<\|&?
^1$/_7W M)_):I?"R>IZ%1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 8OB__D2M=_[!|_|
Z+:LKX7?\DWTC_=E_P#1KU]^+_|_D2M=_P"P?7\ M^BVK*^%W_)-[(_W9?_1KU7V2>IU]%%%%24%%%%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1 M110 4444 %%%% !1110!R70- P"2=:Q_N] Z,6M'P9_R)&A_]>:/_H K.^)O M_).M8_W$_P#1BUH^#/_D2-# M_P"O&"_T 57V2>IN4445)04444 %%%% !111 M0 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% 'G_QD_Y$%_KYC_*UV_G^?|@RT_MZXI_Z"*XCXR?|B"_7S'_6NWT[D&6G
%Q3_P!!%4_A1/4LT445)05R?Q-_MY)UK'_7-/_1BUUEDUYM\9_P#D7=*_[_"2?^@/50^?F6QZ35/5=5LM$_MTV;4=1F\FTAQODVLV,D*.%!/4BKE<;\5?2^2;ZM_VQ_1R4DKL;V.DTC6-/U
M[3DO],N5N+9R0''E>0<$$$ C\15ZO)_AI_ASQ#+X;N&*V^HVL6HV6[^(L@+ M?D1S_SS/X^]7$\5K;2W$SA(HD+N%'DG\]OZ;XCT]NF7*S1=&'1D;&<&,.I--#NF:=%.Y%%^%.>
%;P2332)%%&I=W=@]JH&223T%<-)\6M!,T]\6/]I(RBLGP_P"=*\3V)NM+N1*]G:Z$8=#_M#@6O* MK[XA6_Q+TS5A8ZPMG!:-&;1H@&
<^9\RINP>&'.>Q]*:BV#:1ZQX@URV-Z M'<:M>),]O;[=RP@%CN8*_D#]P[U:TZ^BU/2\]!&|,D]+&:<9YP M:X/QQK<'B#X0X0ZG]%O;W-C-OEW*%4%*!"5$Z@D FET[X@Z/H7AC1[-
H;Z]N(--M MC.EE#YGD@Q@+C<20!^?>CET%%$HK\|>]|+|4V#7>F3EPC.PS(9@S7(=W&UXSVR/?L M>E5_$GC/Z/G$(["0Q7KRRW4W,YZ|>_ D([?Q7"(BV|$<!IV+3)K!G045R
M>U)=._6.\LKQP6CAO8A&9!_LX]|]>Q]_KWBRP]ZCI-E>5*]Q+J-5*H%)%GL%%%M'WO4M[)#4K%%@W^8MO=V^R,GURI']1WYQS6WMXC\6V'AB.QFOH;[:[:[E9X54I&3R-Q=%
(R>,*:5A=&|116'H?B]R|0ZAM]5K8PW!6PE,D[A?+=LD?*0QJZ *0 MG%Q$N6MEXV:I.ZTB]2\OJ-7I^AX;94V7F8RMR1N[5]@=]W].Z0/;/K#4L7KBAG5+*MDTM,0,@R-5@]E1O_Y[7Q.Y7Y-OR+^G
(*V-A]@AP3_IJ1%'Q/%3=K]/VV:JUH@] GL@U:8[U_Z[=H^[!YOH%D]@YF,@DJ#@^([(R=[$;J,$*Q]8$WSF)HRC5@[[)]MUR$G)T#@U:Y/=I]K*ZBMD9Y%^A+T@^E7S%=3&WX:D-Q
VFD[V9QUN>L00/O'B=M]MT

```
M^%-2|%Z==S6KVUS/8132W2W#\,8P2V&)7&3GIBN)^#^L7MGXSBTJ*5GLKQ9/M,C!^4,]%@_3@_+CMUIZ6=A=5<^@Z*|Z\8?\ "R?^$@?_(1G_D&^6NW_(]_MO8^:
[_S5K>]/^$Q\F^_X2_[^Y/L_^IZ<[O\ 5_AUK/ETN:7UL>2_V[INC?%S M5]2U6WFN;6.ZN(S&B*Y)R5'#$#'X^E>H^&?&/@SQ%>1P6 M#:WV'_B8UIH#M MLM[](PJK[BCG:2F>^&\'KV/ ::2(UB>I?
&N7R_|*Y/[R^C7C_=<\_E7->$? MB!X/TS0 /TS4=,F:XB0K+AZ Z:EUH[6[6:EJ<4 MT]I!.1)&BJS B+.!AC@C._2NO\ @9+<-HN]Q.6-NEPACST#%?FQ^2UV\WA' MPQ]TAM M+MV
BCNK5$+G_9(R,^V<^EX?W(^5?YM^=<3X_TNP\.^ M.)+;0V*+;&D5$?<<89.NT'KZ'\:ZKXWV\_P]T.[E51YD#QL!_"X*D_\ H7/ M8U2233);=FCK='\*:8_PBCMFLHBJUI_VEG"Y;S63<&SUR./RO7&-
V]E3Q!J M=@&/E2VHF*X_B1P ?R=_VTD M?Q+]5X!^ZBL_*8X[NZD?^@&ET=Q]4>ZT445D:!1110 4444 %%%% !1110 4 M4444 %%%% !1110 5YM\9_P#D7=*_["2?^@/7I->?&?_)%W2O\ L))_Z
]5 M#XB9;'I %%%24%%%% !1110 4444 %%%% !1110 4444 %%%59M2L,:[AM][ MVVBN9_| 50R2]KR?[JDY/X4 6]*** "BH8+RUNGF2WN89FA6]WBV9N81=,GF+
M7&\KG&X+UO[T(9OW@,0M2&IZGXIUZ#R.2U(A8H*V3?\O\PO1]SA>,9&T=R17;T M44 W$E8****0PHHHB *\V^$7^I\1?2]A)]]\KS;X1?ZGQ9_V$FJELR7NCTFBB MBI*"BBB@ HHHH **** "BBB@
KSGXS$+X5TTL0-4B))[?))?HU>< &8!O"N MFA@"#]D0(/?Y*]/O(F6QN;[XW\ VVC73)]UG>2/&8X]>UF65Y&88"A5)Z E M5;X7Z#>^'_!R0:A&8KB>9K@O$\H" #Z"YO[^N:GN?
AGX0NH#&VC11YZ/$[ M(P..N0?Y\]5D?"^^O!<^(M N;J6ZBTB\|]"64Y8[6<8/_'QGKWIZ6T#K]=_< M3Q6MM+<3.$BB0N['LH&2?RK@/A]!]X@UC5/&MY$0;]0V]BK ?+"O!(X]L9]F
]M]S\5M6FLO"R;;;/B[U686]ZAIH ?;Z=2A^J^Z>KK &T]#1 &M;MA^ZMHP@/]XI$ M^]R?QL(V<)]2X;7QEX'GN)4BACNY@/!SA^+<20@J T622>@KL/^$N\ ?\ 0PZ3 M_P"!L?\ \57'?$NU@O?
%W@FUN8EE@FNI4D1NC*3$"*Z3 A7GA'_H!6OY'_&F M[65PUN['ZYJFGZI@"DFGWUK=HB.&:WF60*<-P<$XKTVXN8+.W>XN9HX((
MQEY)7"JH]23P*LU70M+T+XL^%8M+LH[6.179UCSR<,.UZC>V5MJ G+9WD*S M6\HVO&W1A1*V@+]<+X[\3:/]WARXT+2[B+5=1OPL<,%FPEP=P.YB. !CU]/K M77>'=-?2/#>FZ=
(:'MH"WU.FHH MHH]"BBB@ HHHH *M\V?2_K<(?]K_:1)KS;Q=_R5SPA_NO_M %]H[DRV/2:\T^*=K6=6VH^.!$+1[ROTR)K83;7>I*P7+PD[9(_|->7K[9Z>A=EQ/%:V
MTMQ/(L<,2%Y'8X"]!DD A7->+?AU8"WN-7!WTG5+=&F5K9BB/@$D8'W2?4? MB#52[\17GB/X'7VI3@K=F(Q2LBX#XD + >Z]?? 59/85^Y9M_&?BSQ-))/X4 MT.U&F(Q5;K47(\TC^ZH8$?KTY(Z^
[H?C?4!XC3PYXHTV.PU*4;H)86)AF&,X M&?70]SR,=:V? Y@;P-H9MBI3[%&#M_O[1N-|>S7+_$QMWB+P;;TFVBMGM]2E MV3-(K%E&X#Y2"_O<&L+QG_R5KPA^/ Z$;/'W_)2O!7_7?
G6G;]G[G5>-M,?%UOX3TZ*5H7N;VY?R[6U3]TC?SP,CIG]6L,;\0.*$7^>H>'=/DLE*>6"U MD/VA\[IX+$+$@.P]#4'B'B0]-WH\I<$>0+>1DW-WXDQ^.0OZ5Z-2T2'N>.?!N M9+G3+Q3@2
MP^N03RTT0'UW9_I3LN9!?1EQQ=XKOM\#V^MVL5L]SY65E5BGSC)X!_6LY MO%/C;4] CU/0O#]D]D4W!KB0[YP!RR(&!$YP]D_G5/XE?\ ));/_MV_]!KO M]%-70=._%M&!V^44:)7#=G"Z?
|2M1\36<%OX;T99=6*%KD7#'R+8 X&6X MW;NPX_2KNA^_83Q9'X:\4Z=;6M]/(YMO+:N3&XP3C!) NMSG],8K_^$ &?$ MIP,F_P 9_P"^J7QD2OQ;\[$$C],/JXT[*]A7=KG5^+?%MIX3U(I987N;NX?
R M[6UC/S2M_0)Y(Q M9O"BW3 6X@80X'X[MGZ5Z12T2'N8/A+Q59^+=+],1O#)&YCF@<_&W M]1Z'_UQ.G?$C!O'JWVZPTW1[U9+ED@?2*1QO+Q_K@#EWM5?
X/QH)/$T@4;VO@I/J!NQ__G3LE<5V[& MQ/'C74=%< .3+]D:]>U&7R$L4;8OF;L=23Q]WUZCGO4FGWWQ/_M*W74M(TC M[$\@$K6\I[QH3R>6P<=>*O>,O"2^*,*V\]>SO[*7SK6X3/R
Z'VR%.>HQ^? M.P^,?$?A;5[/3/&I!_:7+^5%J5]/O'U91]1P O'8TEJM![;GH]%%%04%%%%% M !1110 4444 %%%% !1110 4444 %%%% !7FWPC^YXC_.PDU>DUYM)( N>(
M_P#L)-5+9DO=$_QC_P"11M/^O]/_$?7)7B%>W_&/ D4;3/K_$_]%R5XA7LX M+^%\V? YE_O#]$%%%%%=AYP4444 %%%%% !1110 4444 %%%% !1110 4444 % M%%%% !1110 4444 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 5T/@?^TO\A+]/_LK_%_F?
G_MW9_%NQVQ_2N?!&D=412S,*6U@,[Z%.L5[&P?#(&\Q1G*C/ /3\O>N2T M7Q1XNO[/SX$TN]"::)$VZ*: AV8=!??72D]<5Y_K=E=:7]9US25_T@?\? O__M W"? %?
Y^OS52+OS)L_0,%6IN#H3C&F\/;77LW=-)]'T?D]_=?&FKVW&H>%+ MY<=6M7$W\O\ &I4^(^@,=ES)KDD:2H4D174]0ORT]*5KQE?Y&5K>TFOP:9OGBC6=.U6YT[#>
MP3D;G"2J."0,GDCK7:UFGP]HYN8[@:9:K &P=72(*01T(%:5.$9)MRZF6)K4 MIPA3DVC?>W5WZ!1116AO!1110 4R66."%YI7"1QJ6=CT ')-/K*\2]I[^&-3 M6/
[I_3TQS^E*3LFS2C!3]1@^K2^]H\GU36_'&LM:V#O;V]_,$W%511_$Q M'4\ YZUV&!AJD^%LD(EU*(X\|JC#CJHSG]2/S MJEXDL?$^A0F^GUR8P2S[$6*[ER,Y(X.!C KSDDX>TFF[_@?
<2J5(8MX+#2C3 M4q635^:Z.KUSPC XAT-2X[B_$U$S0B$OD?9O8A=G'2QTD?:KS- /+\IJ/YVM6ZI['6FOQN=T=]D,*4LN(@EK#,&W(G=D*6+M[/1'X*(]L?FUPI+NTF?MJ'C=E
JS+3NCBO'?BR^T]6ST+04677=0.(@<'RESC?@\=CC/'!) MZ5GQ?">UOX5F\2ZQJ.IW[ [G\I"(3V0$$\=/3CH.E5H=LW[0-QYV&,_B/)W?
MPG8O3\&,:\S?IU4W;85KIG+^%_!%KX2O;B2PU"]EMIHPIM[APP5@>^_=N,GX MUT-W>VFGP&>]NH::$"!DFD"+GZFIZ\]\-Z1^\1M;U37]>+W-E;736UE9ER]( M!@Y[!ZX*Y[$DY]
M]6&VB/2;'6=+U1F73]2L[ME&6%O.LA ]$U+>7]GIUO] MHOKN"UA! K>0(N3T&3Q7G/COP51^BZ(_B'PZG]EZAIY$H-N<+(NX9!'MU_0 MCGA/B/J0UCX1V\>HX"FY O*5 X!
(R1^!S3Y4[6"YZ#=:WI5EY7VQ4[*W\T!H__M-N%3>#T(R>:GN;ZTL[7[5=74$%OP? ED"ISTY/%<?I/PZ\WOAVW?4[3[?2? M,"O-=L[!RS*/N\ *!P !Q@=*Y+X;^(O$(N[?6YY+ZPT>5H+6TT-'3[-
:ZC"8Y[=,[3U&>3Z[3]5SWI/B3;W W\1_"]M:7#VTTHV"9 M/Q1@O@L/<#.*:6HFI#TB37]&BO/L)<2W,X;Z5;&9N8E4*8%L)@P?=P2W7GWXK8BUG2Y MX9YHM2LY[<[9G2=2L9]&.>#]:X#X4?]A?Q?
_P!?_P#[.)6'*O#XAO]M=]XFT;2=;TH0:VP6QBE69B9?+7(R "W8<^DP/I.GMO$$&BWMS] MFM=8T^>?_GE%NT2RM?$_PUL;S6;=+NX33_5 MY,Y#^7]]ZG&&:?*MQ7&^ O&D&M:!:.JVKV\
:LTK]]#*B.?FPH"9ST_M&;1 M/#K^/[?5WO$&NI 52V^T*"R[2_^S]?E^]'[9YKE?A3X9T6Z$]*6.K3Z?3^$^D[ MLLYSN!5^_;%/Q/^3@+#_KP/_H#TVM785]<]+=TCC:21E5%+,P_]W-W9T'
MB/0{]Y%M;ZSITT['BCND9P73 .:X?Q^'+XR^L^(7A26XDBTFRMA=7<49P9CD M8!/B/R3G\ G4/AAX7N]>UMM/2RF"8BN822\9'0Y)^WSU1>39=1W?0\U'1 MV@8 -I)&544$LS' '!]0N]4^!I
MV]_*9;O3Q/:N]'/8!,@D]"N/PK^%GA#3]:\ K?ZPGVV ]G2WML,^7%CEC@? M>)]][A3Y;7N%^QZO9:A9:E#YUC>6]U%TWP2]X_&K>66FEP^$?C/86.D#R+
M#5;1VFM\D]"]N>.GU0$>F2.E>IU+5AIW"O OA%_]?$7_&$FKTFO OA%_]?$ M7_82;FMF)[H]]HHHH]2@HHHH **** "BBB@ HHHH *Y+XA^&+_P 5Z#;66FS6 M\4\ VMQNN&(7
5QV!YRP[5UM%..SN)JYYW/I'Q1NXS#)K^CV\;@JSVZ O-/I MF/@_0BNC\(>$;/PAL6MO(T\K;[BX<8,K?3)P\V'ZZ&BFY,+'<>( "VH:Y MXST#4O ;C3M,8RM&Y/F%\@Y&!@_=3]>U=?
112N%CE/%/AFUOO)X:U&VEMTA MTNX:699&(9@2A^7 .3\]ZX[5U=%%%QV.2UOPO>ZEX[T+7(9;=;6P5A*CLP)].07S6EQX?UE+^>WW[XIH]T<^[;@-UQC:>=<$_,>E=#11<5C MSNX\+>.=?
@^P:]X@L8=/D.)UL(SO=?3)4<'_#GI7(]/M[*1=DWV..EY%/!!R]]L]# MCFNPTKPYI^D^&TT*/S+,1 %('ZRAL[BV/7]K7HH,;!(\YMO!?BWPQYEMX5U MZU;3GI M[#N^2'M6M];9+?
39=\RR,P9AN!^4$'$'IW(KL**7,PL /"5UX1LM1MKF2W99[HRPB%V:F #N YX]ZZ^BBAN^H)6*^H6 M[W4FW5O&5+RPNBEN@))!" 8?@?P_=&^/"L&EWLD,D\NQ:%B5P6)+*J7244
M7TL,QP_BCP3]%[XDM_$GAW48K'5(U"2+,I*2@#'}>W&,?D161K/'\5^*= M+;V=8LI+V=-!!L;%J11S1]Y ^ -"''UTVUMY"I>*%$8KT) XJO12OT'8X_P)X4O MO"_]K_;9::3]9<+^'Y+,<#GKD#GFCQ?X4OM6|
<:%K<$MLMMI_P#K5D9@|6S^0;748RT3<9XR,C@=OT'-8 M!T3XERPFS?Q'I:0,NPW*I'SL>H&T#/OGWSFO0[]*;DPL8OA?PS9>%=6PM"SL M3OFG?]TKGJO]/8=OUK)\">%+[PO
&O]MEMI/MESYT?DLQP.>N0.>:["BE=A M8YSQ1!?B&]DL;KP]\=E/;>?8'AG4F*<_C&[&>FWC@_>/3OA+X_1Z]J5A<>+ MM5LY,6QE\V.UL4(61AC!9B!Z>A/XQFO0**%)H+!!1112&%%%%% !1110
4444 M%%%% !1110 4444 %%%% !7FWPC^YXC_.PDU>DUYM)(_P#5^C(_^PDU4MF2] MT3_&/_D4;3_K_3_T7)7B%>W_.!C_11M/\_K_3_$_%%R5XA7LX+^%\V?_YE_MO#]$%%%%%=AYP4444
%%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!1110 4444 %%%% M% !1110 4444 %%%% !1178*#[PBWB;5_/GP-/LW5I@P_P:8(]<@BTC8=.\B*%51@ M*!@ >E+7@5;KJ2YF?64*$:.%"(OT#"LB_L@ZD@5M4R1
PK(W/++N"[\.F^K M:=&7MW_X_+4=''|Y?GZA;:I8O7EI()9!D'N/8^A];4+ .'0*X23[ M1X/U [^U1GTR9O\ 2K=?X/\ ;4?Y_P_7^[=UL>G!K&15.7\1;/^;^Z/^5_
M)]#OZ*BM;]&]M8[FVD62&1=R.O0BI:V/ ::=GN%%%%% @HHHH *0@,I5@" ,$ M'O2T4 >>H![K]3[8B*CS1C*2V;6OWF;H&FR:1H=K82NKO M"I#,O0Y)/"YUR&J>&M7N?
B%'|D5INLA]A7K%%%%X2D MIM O8>#S">%C.$8]2E:Z>NWS1Y!#X\[&&OZPEWXB<1QC_;YU+%1_"H7@?\ MZSS7O]0 8_':EHITZ:A>W4C&8ZKBN5322CLDK)!7G9M_B)#$;59![F
MOFAXB_N1E?^97V['>#O!\FA227U]*CWDB;0J M'(0'D\]SQ_\ KS5?5(?'$&\IW?]ENLMI)(6BRT9@]OGY'TZ5V]%3[&*BHIV
MO[3]RK2K58QFW[9]ZTVMV."\_^#=1&MKK.N2]TRMY@C#;F+XX+$<<>W]6GXD MA\5#4[C09 8)"!$63]VYN< QT(Y'I7544*C%1Y4$\SJU*ZK5(Q=E9)KW4Q
M0\VB\Y'Z_X@U+O?'.L<:8!/:8K_^Z_J2:+6H^[#>>>_N]>5>&U\0Z6D3K%%<0'="Q M^(TP_OX_(5OT4%X>X58_X>9W9MC&HURR818 M9Y$@(H.G(RO [#V^E=_HND0:)I<5C 2RIRSG]S'1:T**
<*48.XL7F57$P5 I1 MC> ]DK7?=E+6()K1+^AWA7=++;2(BY RQ4@#FN8 :#]6B?VC_-MY/G>7L^= M6SC=G[I/]*[2BFZ: YZGNI]C_/%;U%)4H]+CW :F95IU MH5]%*"25O+^M3@_?AW5=%U"
[EU"U\E)(@]GS%;)S[$UD7/AKO3;>*+O5 M M-K&YE>&3S(\K%N<,?0]Q7]=%1?7CR]_]C]6=5U7G6<8MS2333M9?J\QG\_^ M,?$,T:ZO.L<2(,C[@<[)J65/#M!W,S=78]2?
\]JT*N%N%*!_7C\B\RK8F'^F#-I[%M#2%G\X&FT(-5M@+!#B4H)_^/\_<2! \O^D3A6CV_\-2*N+*Q@&E&*ED5$3Y%%-M%K3\^ IM'3K)0)WR%& MR4^/ P7_U*Z#/@[@K.GU6=^_Y=?X(_P#MQ+
)&A_\ D^Z@_+^6C MX_X$Q3%EF'J&MKQ4%?%!Y&\Y@D &+#K,I_S#7[>-L@V&LLH&%H^VKAPT&Y@/J/6 ]C1*=(1%6?FG_/Z,X&!N$^<@AHXYDH7JHN[]OP_&+CYML[B\UQ&!DH^>0!ZP9=P_Q%T6%
!1110 M4444 %%%% !1110!Y | &3 D07 Z^8_ZUV^G?\@RT ZXI Z"*XCXR?\(@Q_M_?.?09:7]<4 ]!%4 A1/4LT445)05R?Q_Y)UK'_%S3 P!&+765 MR?Q"2=:Q US3
+&3CNA/8O^'' | D2 #_P"O&'_T 5NUA>^_1(T/ KQ MA_| 0!6[0]P6P4444AA1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
%>;?&?_)%W M2O\ L)) Z J>DUYM\9_^1=TK_L))_P"@/50^(F6QZ73%;1[W6/!C+8O/+= M;7"W!C09++ M/;?"P/'?[V<=>U=O123L[C:N<7I7O1\+WVEQ7 SJ4=I.5_>P2JVY&[ M@<
ICX O3=>%%=+N)180R"XU$#RQ*G0H,_>XS@9R0Q&*!=N?#^B MWMSIINM'T'>>?_GK+;(S?F1FKT%0#:PK#;Q1PO)PJ1]%4?0"J4DM4)O1G(>$ M?
&OABT]3M,L91:7&T0I8.AWHP'IC!Z$[N_L>*[J2:I<6H'4(] LT06)) MN5@42$G@_C 7:EVZ#1UX_T&\UWN9Y*)]WW_=ESU H^;2/GG&<>&8#]0_ M'MQI:;|4Q"=_:)+)0]M2;M#<<P9#Z P?P
=G69<^'_#O)FFNM&TZ>5B27 MM48DG]|GEE5OG'&<<^$_E7#>5 BY RQ4@#FN8)[M6B^VEQ^M^U-N:X)-|6KX*+ *L L1+C"< M6SCR=G/[J/%U%)4H]+CW :F95IU MH5]%*"25O+^M3@_?AW5=%U"
C7AB7^T1=1U$A#Y*G;& M@.223P.GX#)..%K73D;9H(MV>1 P3^ ->@V.DZ;I88:?]]II:]O MO?9X5CSI<5>6%G]QI6G]OGOK2*"ZA)|!N>..N1T.#3Y6YDK6^"Q%HW_(#T_ *]H M_P#T$5Y_|
(/^9D_P_ !KTM$&* JC 'B57,T(/F,)$WL,JLX&*4(O/&F/+/ZJ-? M[D$MVJ+ %@V4#[#*#Y.G&U(&/'7\+WJ?+@S8IQ(Z5@+Y_,L)6SIXYGVCF$S[[Q^]$:N=>[B+CF]HR[*1 )@Q=UAT(!IZ:Y2&J@FQ[NYRUB7.T(QN-G-
R@4ZJ4G*K$DKJ-$ZP|-7U&A|R@Q&I[T_EB_UUPVKH*)I?V(_+R&:W<_.M ?C*3@U&FM&;JK !D&@3$_((@DB<9|_W8>JNQ]\4QN5#J@_RHE$IN9Q?#/OQHA#=IK-@YYXDDTI=QW:>?]XNR4S
 M-?4J5#@[1&X0*_L$4R@$2Y(&[0S%:)J%SH_M6$&@VDXMB/&M^4:[EP95=W&I8XC$_R(6:_=AL;$7;K2[X2R(X-_A-S4HXVM@[]UQ:5(LY&$0N[=1&3H>6B/S6%%5-V=B[#WZ0P>PDFHPGO)$Z
Y&. M?O8S7]%SI]EE>RP2W5G;SR6]|[X7EB#&-N5)'X'(*DN+ ;M+&>\FB]J(KSQ]MMWVHC!_?2F;&V!!D%69S!++(FE)(JXJRZ:1_E)S=ND@YQL.J9FT!=Q(NY6F,H"9\FPVB59*97?%/'D
```

```
M>_X' 1 'XL'(S_I;?^@FIOB@!_:UB<<^0?| T(UV"^#]/3Q#_;8FNOM/F&3; MN79DC'3;G]:=KWA.P\17$4UW-<@T.C/DE'NPAFN'6+HU6WR MQARO3K8QO'H |$V@ P!+%@?|!-<[BZOH-KK6EQZ?
>^W&.?2JG2E*3;[6,<'F M5"E0IPFW=5.9Z=-3'T>VT^]^&=G::C.MO#,SJLIP K^:Q!R>G3^G>N;O8=8| M$F*2QUF*:VD<[4C?(/'5D.1R.XS__"KT+_A%=/;PY'H;F9[6,EE8N-X.XMG(
M&.Y[5EV_PWT*"4.[7_AL]3:T23RWQAE)/OG (;U]^M9FB:WK6C^*(-% MO+Y;R%I%B;Y_, ST*L>>_3]*[#6O!VEZY+#+/YT+11B)/(8* @S@8(([T:/X M,T?1;D7,$=]_D9PS'"K#.E.\E9VBXKW6[VM+
MLM#C_*_Y*W)_U\S_/H#U%K+II_Q/%S?'$(GCEWD$@+M&#^&/TKN;?PCI]MX MB.MI PERM=_M;W-/[6PZKQEJXNFH/35>AS/Q#U?3KC08[6&[AGG>9658G#8 !R3CIUQ6%J<.
ML/PLTL2\;KS>HST4B0C_!_&NLL_AWH5K,)'%QQM4445TG@A1110 4444 %%%% '*O_P E/3-L%_| M2N^@^X*X%_^2GI__MV"___&I7?0?<%9T^OJSOQO\ RZ_P1_|_;B6BBBM#@"BBB@ HHHH
****.2^ M)O| R3K6/]Q/_1BUH^#/^1(T/_KQA_| 0!6=|3?^2=:Q_N)_Z,6M'P9_R)&A M_P#7C#_Z *K[)/4W****DH**** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@#S_XR?| (@O__?,?]:[?3O^09:?]<4_]!%<1\9/^1!?_KYC K7; MZ=_R#+3_*XI_P"@BJ?PHGJ6:***DH*Y/XF_\DZUC_KFG_HQ:ZRN1^)Z[OAS
MJXR1\D9X]I%IQW0GL:/@O_D2-#_Z\8?_$-5NUXAHG@);[0K"[_MS4HO.@23 MRTDPJY .![5?_P"%<+-T,&J_]_*IQ5]R4WV/8**\?_X5PO\ T,&J_P#?RC_A M7"_]#!]O_?RCE7<=WV/8**\?_P"%
<+-T,&J_]_*/^%<+-P!#!JO__'\HY5W" M[['L%%>/_P#"N%_Z?^_E'_"N%_P"A@U7_+^4 MP45X_P#\*X7__*?| OY1_PKA?^A@U7_OY1RKN%WV/8**\?_X5PO\ T,&J M_P#?RC_A7"_]#!JO_?
RCE7<+OL>P45X__P *X7_H8-5_[^4?|\*X7_H8-5_[^ M4P45X_| |*X7_H8-5_[^4?| "N%_Z?^_E'*NX M7?8]@HKQ_P#X5PO_$,&J_| ?RC_(5PO_0P:K_W\HY5W"[['L%%>/\_"N% M_P"A@U7_+^4?
|*X7_H8-5_[^4/_| "N%_Z?^_E'_"N%_Z?^_E'*NX7?8]@H MKQ__(5PO_0P:K_W\H_X5PO_$,&J_| ?RCE7<+OL>P5YM\9_P#D7=*_["2? M^@/61_PKA?| H8-5_P"_E;P45X_P#\*X7__*?| OY1_PKA?
^A@U7_OY1RKN%WV/ M8**\?_X5PO\ T,&J_P#?RC_A7"_]#!JO_?RCE7<+OL>P45X__P *X7_H8-5__M[^4?|\*X7_H8-5_[^4P45X_| |*X7_H8-5_[^4?| M"N%_Z?^_E'*NX7?8]@HKQ_P#X5PO_$,&J_| ?
RC_(5PO_0P:K_W\HY5 MW"[['L%%>/\_"N%_P"A@U7_+^4?|*X7_H8-5_[^4/_| "N%_Z?^_E'_"N%_Z& M#5?^_E'*NX7?8]@HKQ__(5PO_0P:K_W\H_X5PO_$,&J_| ?RCE7<+OL>P4 M5X__
,*X7_H8-5_[^4?|*X7_*?| OY1RKN%WV/8*\V^$7^I\1?| 82:L MC_A7"_| 0P:K_P!_*YGP?X2&LQZB3JM[;>1/_P#"N%_Z?^_E'_"N%_P"A@U7_+^4P45X_P#\*X7__*?| OY1_PKA?
^A@U7_OY1RKN%WV/ M8**\?_X5PO\ T,&J_P#?RC_A7"_]#!JO_?RCE7<+OL>P45X__P *X7_H8-5__M[^4?|\*X7_H8-5_[^4P5YMXN_Y*YX0_W7_K61_P * MX7_H8-5_[^5S.L>$A9^_
'TW^U;V070|\YW^>/&?NFG%%^XFV?0U%>/_/"N M%_Z?^_E'_KA?^A@U7_OY2Y5W'-=]CV"BO'_^%<+-_#!JO_W\H-X5PO M_0P:K_W\HY5W"[['L%%>/_/"N%_Z?^_E'*NX7?8]@H
MKQ__(5PO_0P:K_W\H_X5PO_$,&J_| ?RCE7<+OL>P45X_ ,*X7_H8-5_[ M^4?|*X7_*?| OY1RKN%WV/8**\?_.%<+-_#!JO__ MW\HY5W"[['L%%>/_/"N%_Z?^_E'_KA?
^A@U7_OY1RKN%WV/8**\?| M^%<+- P!#!JO__'\H_P"%<+-T,&J_]_*/^%<+-T,&J_]_*.5=PN^Q[!17 KA?^A@U7_OY1_PKA?^A@U7_OY1RKN%WV/8**\?_X5PO\ T,&J_P#?RC_A7"_]#!JO_?RCE7<+OL>P45X__P *X7_H8-5_[^4?|*X7_H8-
M7_OY1RKN%WV/8**\?_X5PO\ T,&J_P#?RC_A7"_]#!JO_?RCE7<+OL>P45X__P *X7_H8-5_[^4?|*X7_H8-5_[^4VWV>Y, M?[E\-_<*\)6>HFW<^AJ*\?_ .%<+-T,&J_]_*/^%<+-_#!JO|\ W\I/
M_P#"N%_Z?^_E'_"N%_P"A@U7_+^4^P45X_P#| M*X7_*?| OY1_PKA?^A@U7_OY1RKN%WV/8**\?_X5PO\ T,&J_P#?RC_A M7"_]#!JO_?RCE7<+OL>P45X__P *X7_H8-
5_[^4P45X_| |*X7_H8-5_[^4?| "N%_Z?^_E'*NX7?8]@HKQ_P#X5PO_$,&J_| ?RC_(5PO_0P:K_W\HY5W"[['L%%>/\_"N%_P"A@U7_+^4?|*X7_H8-5_[^4/_| "N%_Z?^_E'_"N%_Z?^_E'*NX7?
8]@HKQ__(5P MO_0P:K_W\H_X5PO_$,&J_| ?RCE7<+OL>LWO_'C,<_K3 MLK;BN[GT%17C_P#PKA?^A@U7_OY1_P *X7_H8-5_[^4N5=QW?8]@HKQ__A7"_M_P#0P:K___*/^%
<+-T,&J_]_*.5=PN^Q[!17C__KA?^A@U7_OY1_PKA?^ MA@U7_OY1RKN%WV/8**\?_ P"%<+-T,&J_]_*/^%<+-P!#!JO__'\HY5W"[['L M%%>/_P#"N%_Z&'5?^_E'_"N%_P"AAU7_+^4P45X
M_P#\*X7_*&'5?| OY1_PKA?^AAU7_OY1RKN%WV/8**\?| X5PO\ T,_J_P#?RC_A M7"_]#!JO_?RCE7<+OL>P45X__P *X7_H8=5_[^4?|*X7_H8=5_[^4?| "N%_Z&'5?
^_E'*NX7?8]@HKQ__ M@HKQ_P#X5PO_$,_J_| ?RC_(5PO_0PZK_W\HY5W"[['L%%>/\_"N%_P"A MAU7_+^4?|*X7_H8=5_[^40_P"N%_Z&'5?^_E'*NX7?8]@HKQ_P#X5PO_$,&J_^ M:
('S9S]>*]A M6_W6C_V___P"E(****T,$**** "BBB@ HHHH **** "BBB@ HKD-3\9S6GBZ' M0X;_"#/%&\KN3D/M/'3 :NO]{S4FTNATU\+5H1A*HK36I]%UYRQHI0>6]X))] *)5$I M*/<*6#]5SV-WM;P+]
MU]K.B3?^^/W_:/^/JTW+(&V*N%"I<<+>]]56C*(C:KE>(18;ZS424=/778Z>BBN_MU_4_$\FM2:=H5%LOEQJ1:?8."1G&6^?1*N#_P#6(X=3XN\3'PY81:%$LMS.Q:OG:
M.I_O4<>]0]T6F]K'75RK$0]PI*TN?9IZ/Y^1T5%>73>)/&6EVMMJ=[Y;6;7:_;[S:EOD9'EQ,$STSCD?_7KLO#WB M!_;T+^T*Y;QY65%Y 8#)Q[8(/XTX5E)\MK/S(Q.65:%55*,HWM>+O9]C:H
MKRK2]:\%O\ A(?L]Q_PD'^LW#RO]7TQS]S^ MM*%%93>B9>+RN>%BW.I%M=$]?NL;]%%%;GDG'O_R4]\ L%_^U*]Z#[@KR/QC MI UKQO#:FZGML6*OOA.&X=AC[;:'\.5*C_BH 4'
&T]*23OZL[<< X7^"/_M +<>OT5X P#|*X7_*&'5?| OY1_PKA?^AAU7_OY6W"KN%WV/8**\?| X5PO\ T,&J_P#?RC_A MQ_PJ[Z:T=IV(IK6DL\!D42%Y&'H:RA,D)(5*)U)E;+.!<%%
OY1RKN%WV/8**\?_.%<+-_#!JO|\ W\HY5W" M['9_$W_DG6L?]?B2^C%K1\&?B1H?_7C# P"@"O)/%'@A=*\-WEZ-9U"?RE4^ M5*^5;+ <_G5C1/ 2WVAV%W_;FI1>= DGEI)A5R
<#VIV5MQ7=SV^BO'_/A7 M" \ 0PZK_P!_*|A A7" ]##JO_?RERKN.[['L%%>/\ "N%_Z&'5?^_E'_"N M%_Z&'5?^_E'*NX7?8]@HKQ__(5PO_0PZK_W\H_X5PO_$,_J_| ?RCE7<+O ML>P45X__
,*X7_H8=5_[^4?|*X7_*&'5?| OY1RKN%WV/8**\?_.%<+-_T, M,J_]_*/^%<+-P!#!JO__'\HY5W"[['L%%>/_/"N%_Z&'5?^_E'_KA?^A MU7_OY1RKN%WV/8**\?_X5PO\ T,&J_P#?
<+-_T,_J_| _*.5=PN^Q[!17 M17C__KA?^A@U7_OY1_PKA?^AAU7_OY1 MRKN%WV/8**\?_P"%<+-_T,_J_| */^%<+-P!#!JO__'\HY5W"[['L%%>/_P#" MN%_Z&'5?^_E'_"N%_P"AAU7_+
^4P45X_P#\*X7_*&'5?| OY1_PKA?^AAU7_OY1RKN%WV/8**\?| X5PO\ T,_J_P#?RC_A7"_]
M##JO_?RCE7<+OL>P45X__P *X7_H8=5_[^4?|*X7_H8=5_[^4V'O]U]%\_? +@KD_B;_ZKIZ\_DZUC_KFG_H
MQ:ZRN3^)O_).M8_ZYI_6O_YW5%%%%2.**** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M*
"BBB@ HHHH *X7Q+_R4KPU_NM_6NZKA?$O_)2O#7^ZW]:J.XF=U1114C"B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH *X7X:_(_P#D(Z+__A*'==;[6*^.7R_(!"M_NM'_M_M___*05SGC77)M#T/S+)MMQ_MW/5V=_/<K$RE".&7LH.5+DULX)XY5|O;G&>J=!U6&UATQHHL,992Y<+@<=-,<^M;
6^WS^=CS@0Z5-I3WT^O2_VRV7\LMQNEM=_P"KGUV/E7:480? S+DE>/X6UY;?AN<=9>);O1O#^I;( MZ,LS.40G@Q9R)!^GYDFNA@\.?V)/M2N+A,7US'"'X(YC7(PO]3[_$KGH?#=
MYJ/AB^U^5Y&F$F]0WJD09WMS]W\2/M+=_=_"_];F3X2\/7GB#3[][;D]I9)(R(N?_M8COR.@QU]:L>%KF|\^,SHLDS20/(874=" MYR_%^A6+]HOK/UBWLK:?%^=_4J:]K8UWO )97^HO9Z3#(R?
*C'.WOM'4D]S MT_G#IF]0^_$_]NNDZG)=Z;(RK(K*RC!."''IQR.H(_P :GU;3[_#7BR:_N M]TYY&OOFFD MW/5V=_/<K$RE".&7LH.5+DULX)XY5|O;G&>J=!U6&UATQHHL,992Y<+@<=-,<^M;
M0Y7-^TWOH<>)>(CA(/!6]ER^]MOUO?6_8X&-T&.S\8IHBSLT;311>:5Y^<+S MCVW5V&N/)X\*Q:=87#M-D[#M1OM-37(]4>&]<&2$ ;B<=-MS$]\?E^5-^&^ ([#';]YXI
MOPP_Y#EY_P!>W_LRTX3?\U5_[?:WQ,JCZGB\/R495FU=*#T[D]YXT M\33V Q# I,21/&RNWV:0:5(P3DMZ5\+??^/W4?\ KFG\S??ZS_R]0_Z]|/_M $$UP'PM_P"/W4?^N;?S:?S 0XN-:_W%Z^!MY_O^=?
DCM*IZG]MGH]FUS>SK'&.@/5CZ =S M5RO?&/VIM>^+94N%9(-:U<IK&K:K<:&S.%C!=D ME=]_]-:[]/ |'BA;D6YAL8@$9R.%C!)P3W8Y/]?:I/BQ1#P9F_ P"'
!++248>;]7[1.;]+9(Y/J4XX2&! MJ*;P$DD8W;B"" F.O(Z^U=+%H.@3Z-X0G MLB ]W,DCL@%]EP%ST[_9Z5P/AOQ79;X:?!QV &TX'X| P O M0-
)\3RZSX;O]4ALO+EM_,"0[S]O94##H!U)QBBE..Y,4GK:[A9CAZ^&HQH48 M6I]2U;5Y2OHWKHCB[32O&?ABSGEM(Q'#]^4)Y/^M>I:=_R#+3_*XI_P"@BF]D"W+-M%%%04%D?]>D7_H(K7\+?
]BGI'_7I%_P"@BM>]>Y"BBBBD**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ KA?RE R!._Z_D_]!:[CN)['
M=445C*?M6GT/PU=ZE:I&\T:S.LH)4Y=5.<$'H?6I&;-% [;1+**VDMS/%!/*X+$.S M#(!! &>^>0:[JAJPKA1112&%%%% !1110 445FS:Y9P:Z,OD-Y7&95-7Y
M0HW7L?.&QF10"".A.7]#N9;S0_ MNIWWS36L4DC8 RQ4$G XZFG;2X%^BBBD 4444 %%%% !1110 4444 %%%% ! M1110 4444 %<+|_?]3K?2_7Q^U=U7"_#7_%%M_P#7\U4MF)
[G=4445(PHHHH M**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA?$O_)2O#7^ZW]:J.XF=U1114 MC"BBB@ HHHH **** "BBB@ HHHH
"BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7X:_O*;[*&%52'V;>7BL=*C4Y&X[Q;PD_BB_M]!>P_P# E/A &C_A(
%_Z"]A_P"!*?XUX/16_P!0C_P"5?B>B>_]S?"<^O_*?| W"_GT5_ "B_QW/A/SYT_TF_|&^0M]G=G^AY:!)>DlL[V!^_RJB3#?%VXMD+<+K/^|"7&RU7D..
```

```
I^G>'+.S@LKJ6|M[:.+YPJQEE4#.02<9'I^59'PR MT>ZNO$D>J^6RVML'S(5PK,RE=H[9^;/M7]8\ Z$""" %TX$="+5/\*TE54141 M0JJ,!0, "GS*V@K/J8FI^$ "UF] Y?V/G3E0I?SG7@=. P%6
*\.:5HL,\6G MVODI/CS!YC NQD=R<=3TK4HJ,L=CQ&QFN?ASXRE^U6SRPE&CX/\ K(B00RGI MG('Y$4S7]4NO' B.VBTZR=0J" .3R0">68CH.?PKVJZLK2^B\N[M8;B/^[ &
M"Y&DM+"SL$*6=!!;*W588P@/Y"KY^O4GEZ'.>(?$!\$Z;I4?V?[5#@0 \VO ML*HY'7)OUKC?%/Q&BUS19=,L;&6/SRH=Y2"< YP .Y(%>LS00W,9CGBCEC/5 M9%##\C52#0](M9!);Z790R*:=
(3;7$D2R0N#N"L0"0>G ]37H 4KK2 ,O9 M#)=Z=:7#GJTL"N?S(HNF[L=M #QFY:]^(?BV;6ICC.U"1R(HQ_$Q]>O\JJ/ MXF^'YK[2;2]LH=YL0PD51EO+(^/J0,?]37)?L<.\1 MGW)
('Y5JZ+KNGZ_9FYT^;S$5MK]1AE/N*XKPKK6G>#[/4 ;UEFMKV&=I-S(3 M]H4XP5(]\=/_*^ ;P3871O]8UR>V>TAU*4/# _#;1D[F';.[^?]";:1*9V- M%<_X=URZU;4];MKB.%4L;HPQ-
$#\RY;KDGG@9Q705+5BADTT5O"T\B11(,L M[L%51ZDGI7)W/Q(T**9H[9+V^VYW/;0Y5?\ OHC\ZS_%32^)/&-EX661TLD7 MS[LH<$]\?EC'NWM7,V5C:Z=:).V<"00(.*B#_ | KGWIV2W%N9/A P
6Z;XD MDFBLO.DL(#.DR;3@_0D5O4SRH .\[RU\W;MWXYQUQGTKG 9\90Z2]\ 9=A8 MW&IZB!EH(.B# .;!QU';COBE:^P.;G345QT?CI[2\B@U_1KC25F.V.9W\Q"> M.IP,=>O-;'BC7_\ A&]&.H?
9OM&)%3R_V=>^<&BS"YLT5QT_CBZ-L+K3O#M M[>6JKEYPVU,/O;>#N-Z9XZ&G#X@6=W9VYTFRN+^^G5F^O[@ &!U+GD->GK3Y M6%T=?
6![OB7^S/$FF:1]D\S[=_RU\S&SG'3'/YB]^B^,1]&KG2-1TV?3-0*[ MTBD;<'&,\' YQD].QK#\9W4%EX^\/7 S(L<,2EW=N@ )H2ULP;T/0Z*XR?QQ MJ,*&Z'A6_.G#YO/9\ L_Q;.?
UKIM*U6TUG3HKZRDWPR#OP5/<$=B*3307*'A M P 1 P!NW.I0_89K,[% Y69/X^OMP>.1SC(YYK)?]N=3A^R>1\AF\ MK/F;M_+#/08^[UD6GO"6\ S##I$\M('*8XK:"3>7
ZL3@;1^=.S"YVU%G%*S"YI45O4OCJ_L$SJOA>\M+(L%,PD#E<],K@8_/VK3\2:Q(_+\7PZ! M]AF/FPF7[3_", GICIQC.>IQBN0^'VM:G!I-E81:%_9M,5:]$N%4%N3MV]O MK762^)?
+\9P^'OLF?,A\WS_,Z<$XVX]O6G;S"YOT5C>(/$MEX=@C P));B8[ M8+>(9>0^WMR/_KUAR>. 3LXA=:CX4O+:QX+S>;N* G&2NT8^A ))L+H[6BJ, M.K6UWHO]J6;": Q *A'&< Y'L:?
IVH1+O\B4YW#V.!['IT/%=+0U885POPU_MU.M_]?S5W5<+\-?]3K?_%_36S$]SN]***D84444 %%%%<M1\4/^1?L/^PA'_Z ]=O4%U96M]&L=W:0W"*P=5EC#@
Z@'OR::=G<3U)ZX;X MB?\ 'SX=_P"O]?YBNY]"XLK2\,9N;6&_X ZU8\>ZT(QINE1WZVMOJ#$W%PO)6'CH?0Y/Y5V-S:6U[ 8+JWBGB)!,JVWVBQN$GAW%=Z=,CM57 A&M! Z FF_^]?X5=M,*UL
M(?)L[:&WBSNV0QA%SZX%)V!7)Z***0PHHHH **** "BBB@ HHHH *X7Q+ R4 MKPU_NM_6NZKA?$O_"4KPU_NM_6JCN)G=5@:WXML/#VH6]OJ"2I%.FY9T7'KVX^%KZ5+NCN9XW>_'_
(IW["MW.%\+>.].M &ATS69?L%]8](^CF0KD+P#T],5!> MWGZ@RM>V-K&?Q F_/&7_"/?A7_K MM_[,M=K+8VD]S%,%D^A/(HFL;2YGBGGM8)9H3F*1XPS(?]DG MD?
A1S!8X[QGYNC^)=%\3")YK:WW07 49**0?F_)F]L@>M:DOCO0>LP>TN MD MAVPVT*YDC=A@CCZFND95=&1U#*PP5(R"*]6VDZ;93&:TT^T@E/5XH55C^( M%%UU"QQ PN,C:?
]IF4+*;TEU'0' S7>5!;65I9!Q:VL, D;*"($D1Q(%4?@*+Z6#]<%>:A'X8^*%Q>Z@ICL]2MU19NH4@ M*,GVRN#]0:@^('B>QU30'L=+ 3ZD]O8UZ]0F&ZMXI MXB<]4##\C4 T?
3!:&T&G6@MF.3#Y"["'>OW<8]KK<5CC_'?_"3>U_[8?RKL MM+ Y!.E_UP3 _!%/GL;2ZMA;7%K! .8BDC#*=.#QMMMZ6'8X/X9 \ = Z /\ &CO3_P
E(\,C_,UVMM8VEEYGV2U@@\QMS^5&%W' MU..IHEL;2>YBN9K6"2>+-5RO&"R?0GD4^;6X6T..:QW6E:_I/BB"%YX+,&* MX11DJASS^3,,]CCUK4?Q P"&DLS<#4E;"[A&J
O/MC'6NEJ@NAZ0D_GKI5B) M@<^8+= V?KC %UU"QSG@6QNG?4]?O86AEU.7?%&W!$?)'X]_0'OS4^&? ,= M_P"OS &N]]O;6 I9>9]DM8(/;< E1A=Q]3CJ:.;<+%#6Q$.EZ+-:VVIN8TO M
X5V7*?+C(;Z[O2N"U<;/)XGTB;PA(/[1DG_'HM =FSC)(Z#C.1TQG->G7_ML;7D)ANK>*>(G.R5 P_(U':.;8Z>&%E96UL&Z^3$]9 (4)V!JY;HHHJ1A111 M0 4444 %%%% !1110 4444 %%%% !1110
5POPU^YKG_%_7=5POPU^YKG_M %_5+9B>Y\3/\ D6[?_K[7_P! >O*.]6^)G_(MV_\ U]K_.@/7E->O@_X M7WGSF9?QWZ(****[#S@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJ?!? MAEM;U 7 PF."W;]YG_EHV,A1^F?,ZUC:+H]SKFI)9VH&XC<[\'HB]R?SKV 3M
M.MM*L8K.TCV11C'N3W)]2:X\57Y%RQW9Z6!POM9<\OA7XDEPJI92JH"JR M. #%1T/HNIVM% M%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+\3?\BKJ_M_7E_P"@&LWX?\ (C:;]/_$8U:7B; D5=7_Z\IO\ T UF_#[_)$;3?I) M_P"C&JOLBZG34445(PHHHH **** "BBB@ HHHH **** "BBB@
HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** .;\??\B1]?\ N) Z&M7?"W_(IZ1_UZ1?^@BJ7C[_)$C4_\ <3_T :N^ M%O\ D4]
(_P"O2+_T$57V1=37HHHJ1A1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444
<9\4/^1.;_KO'_6O4M,_Y!EI_P!<4_\ 017EOQ0_Y$YO M^N\?].2T[_D&6G_^%O3_P!!%[(%N6:***@H*Y/XF \DZUC_KFG_HQ;ZRN3 M^)O__"3K6/\ KFG_*,6G'=">QF>%O\ D4]
(_P"O2+_T$5KUD>%O^13TC_KT MB_\ 016O5/&WGM2%N9I%B@B<_P$ M@DG\@:Z6LCQ+H,7B/19;"20Q@2'C<#.UAT_"DM]0>QFV?@'1(.':"]MOM=S* M 9KB5RSE\QE<@NK 9\LG\A^1QUJY;
M3^/=.MH[(Z797_E+M6Z%Z(Z#(]/XRA*(]DZ /ZOXG62X\27PB>(PMK2V/R0L M>A)[_P |=ZOU8O0U_!&ESZ=H/GWH_P! OI6NIR>N6Z GZ<-4FNEKDM\6] MW!!?IVEK-
:1D]] YH+-&'4(Q[CUKOZP/%%'YVNS&%Y\0+*\6\NE6 M6H[,KYZS*A?T]RP_D*>XMCMZX7X:*D][[]^^UKN: <2-W(P"/U9]V]!;Q^+= MSRZY'9P0;
(H;]8TWA[7/#VMW>J>&Q;W%M>-NFL96V8;DY4\#[3 MW&,XP:%V#S-/Q]#!-X*U$$A?D570MV;<,8I^WXX[USGBF62?X2Z=) G>R6^2 M1UXZ_C5VZTOQ1XM:&TU]W@TO3$
(=$L8XU"HMN@"@<#Y17%_#&\"UQTC M56%UL! Z*X'TKN;")X=.MHI!ATB16<_M#U"WMJ]K;_ZZ3>HV\"A.3^2%&]A$]:\+ 9R/RK>\Z#%X%X;T:QCI_0#\*G9#W9S/PZ_Y":"?B;
*_/ZO3/AG%'YVNS;%'1W[5LWXYQDG%:7@O1= M0TF^UR2^W_ *2ZN?.A.]6W+EN>"<=1UH\#:+J&C_VM]OM_J)^Y\R/YU;C\ M?IR/RK/P[O/$\Y:#,U^<
Q5'Q7H]ff J6L>'9[2#S(K-\L[L[;U&Q=R^/)YZ'47B_0-2OK_3M97M\]F4X$@R"WKW4"[4M++AW;GQ3>^*KSPY?2K>:)96ED4R^^<2.""";3C_M0.U;^B3\DYMO^P>?>?2?0#6-6-K
GXQ\2:/<6US96UC$$S]GCF#23L.@W9VA<\]>V M*Z0M.E@\*6>G7L921;812H6>+Q\4'2FCO]M/IZSY^V"9#*$\X*]-HJY/HNH/A $RVU M=;? @EL8VEWKPVUAC&
<]QVHZL.A3B5+OXPW N-K?9; & 'L?EZ?]M7<211+ M&T>&P.AV@$D'V/UHW#8I^!'/ "'ZY"AW6\4TRO UXV# MOW?OJ[\+HHT\)>8J*'DG?>P'+8P!FMRPT"+1O"SZ59EI&\EQN; +NP//MS5
M/P)I-[HWAI;34(/)G$KMLWJW!Z<@D4 W3!(S 515^+VA.% 9K63'05U-)]!H*X7X; ZG6_\ K^:N MZKA?AK_J=; Z_FH6S!|G=4445(PHHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@
HHHH **** "BBB@ KA?$O\ )2O#7^Z_MW1:[JN%\ ]2O#7^ZW]-]&_UC4[]U=U1114C"BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ H MHHH **** "BBB@ HHHH *X7X;_7_ ]"NPNO^/2;_*YM_*N/^%O_"*'_;R \A5+874[6BBB MI&%%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444
%%%% !1110 4444 %%%% !1110!E^)O^15U?\ MZ\IO_0#6;\/O^1&TWZ2?^C&K2\3?]BKJ_P#UY3?^@&LWX?P\B IOTD_]& 5? M9%U.FHHHJ]A1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 /\ K7]6G?\ (,M/^N*?^@BO+?BA_P BA\ MK7J6G?\ (,M/^N*?^@BFJD^W+
%%%04%;Z+\]1]+T_0[&SDL=1=X( M$C9DC4J2 !Q\W2KW "T]( Z!VI ]^D_^*]W%W(31W5%<+_PM/2/^@=J? ?I/ M/BJ/^%IZ1_T#M3_[]) \51RL=T=U17" |+3TC_H':G_WZ3_XJC A:>D?] [4
M_P#OTG_Q5'*PNCNJ*X7_(6GI'.0.U/_ +]) P#%4?\ "T]( P"@=J?_'Z3_M_P"*HY6%T=U17" |+3TC_H':G_WZ3_XJC A:>D?] [4_^ 2?_%4D?] [4_^_2?_M %4?\+3TC_H':G_WZ3_XJCE871W5%<+_
,+3TC_H':G_^D_P#B]\A ;>D M?] [4_\ OTG_,51RL+H[JBN%_X6GI'_$#M3_[]) \ %4?\+3TC_H':G_WZ 3_XJCE871W5%<+_PM/2/^@=J? ?I/ BJ/^%IZ1_T#M3_ . 2?_%4D?] [4_\ OTG_,51_P
+3TC_*!VI \ ?I/_(JCE871W5%<+_PM M/2/^@=J? ?I/ BJ/^%IZ1_T#M3_[]) \51RL+H[JBN%_X6GI'_0.U/\ []) M\51_PM/2/^@=J?\ WZ3_.*HY6%T=U17" |+ "T]( P"@=J?_'Z3_P"*H_X6 MGI'
$#M3_[]) \ %4D?] 0.U/_OTG_P 51_PM/2/^@=J? ?I/ BJ.5A='=45PO_"T M[( Z!VI ]^D_^*H_X6GI' 0.U/\ []) \51RL+H[JBN%^*7 ($T[_*_D_P#0 M6H_X6GI' 0.U/_OTG_Q5D?\ 0.U/_OTG_P
51_PM/2/^@=J? ?I/ BJ.5A='=45PO "T]( Z M!VI ]^D_^*H_X6GI' 0.U/\ []) \51RL+H[JBN% P"%IZ1_T#M3_P" 2? MQ5'_ M/2/^@=J? ?I/ BJ.5A='=45PO "T]( Z!VI ]^D_^*H_X6GI'
M_0.U/_OTG_Q5'*PNCNJ*X7 A:>D?] [4_P#OTG_Q5' "T]( Z!VI P#?\ MXJCE871W5%<+_P +3TC_*!VI \ ?I/_(JC A:>D?] 0.U/_OTG_P 51RL+ MH[JBN%_X6GI'_0.U/_OTG_Q5'_"T]
( Z!VI ]^D_^*HY6%T=U17" P#"T]( M[MZ]Z!VI P#?\ XJC_ (6GI'_0.U/_ +]) P#%4?\ "T]( P"@=J?_'Z3_M_P"*HY6%T=U17" |+3TC_H':G_WZ3_XJC A:>D?] [4_P#OTG_Q5'*PNCNJ*X7 A:>D?] [4_P#OTG_Q5' "T]( Z!VI ]^D_
'Z3_P"*HY6%T=U17" |+3TC_H':G_WZ3_XJC A:>D?] [4_^ 2? %4D?] [4_M_^ 2? %4?\+3TC_H':G_WZ3_XJCE871W5%<+J?3K? 7\U" Z!VI P#?\ MI\ XJN:\(>_;#0DU%BTO)?M%R95\E%.
>QR1S3479BNKGKJ%<+_P +3TC_M *!VI \ ?I/_(JC A:>D?] 0.U/_OTG_P 52Y6.Z.ZHKA?%IZ1_P! [4_^ M_2? ]5' "T]( Z!VI ]^D_^*HY6%T=U17" |+3TC_H':G_WZ3_XJC A:>D? M]
[4_P#OTG_Q5'*PNCNJ*X7 (GI'.0.U/_ +]) P#%4?\ "T]( P"@=J?_M 'Z3_P"*HY6%T=U17" |+3TC_H':G_WZ3_XJC A:>D?] [4_^ 2? %4D?] [4_M^ 2? %4?\+3TC_H':G_WZ3_XJCE871W5%<+_
,+3TC_H':G_^D_P#B]\A ;MA:>D?] [4_\ OTG_,51RL+H[JBN%_X6GI'_$#M3_[]) \ %4?\+3TC_H': MG_WZ3_XJCE871W5%<+_PM/2/^@=J? ?I/ BJ/^%IZ1_T#M3_ . 2?_%4D?] [4_\ OTG_,51_P
+3TC_*!VI \ ?I/_(JCE871W5%<+ M+_PM/2/^@=J? ?I/ BJ/^%IZ1_T#M3_[]) \51RL+H[JBN%_X6GI'_0.U/\ []) \51_PM/2/^@=J?\ WZ3_.*HY6%T=U17" |+ "T]( P"@=J?_'Z3_P"*H_X6 MH_X6GI'
$#M3_[]) \ %4D?] 0.U/_OTG_P 5 M1_PM/2/^@=J? ?I/ BJ.5A='=45PO_"T [( Z!VI ]^D_^*H_X6GI' 0.U/\ []) \51RL+H[JBN% P"%IZ1_T#M3_P" 2? MQ5'_ M/2/^@=J? ?I/ BJ.5A='=45PO "T]
( Z!VI ]^D_^*H_X6GI' 0.U/_OTG_Q5'*PNCNJ*X7 A:>D?] [4_P#OTG_Q5' "T]( Z!VI ]^D_^*H_X6GI' 0.U/\ []) \51RL+H[JBN%
MG_Q5'*PNCNJ*X7_(6GI'.0.U/_ +]) P#%4?\ "T]( P"@=J?_'Z3_M_P"*HY6%T=U17" |+3TC_H':G_WZ3_XJC A:>D?] [4_P#OTG_Q5'*PNCNJ*X7 A:>D?] [4_P#OTG_Q5' "T]
( Z!VI ]^D_^*H_X6GI' 0.U/\ []) \51RL+H[JBN%_X6GI'_0.U/\ []) \ MZ 3_XJCE871W5%<+_PM/2/^@=J? ?I/ BJ/^%IZ1_T#M3_ . 2?_%4D?] [4_\
MHY6%T=U17" |+3TC_H':G_WZ3_XJC A:>D?] [4_^ 2? %4D?] [4_ %4?% M\+3TC_H':G_WZ3_XJCE871W5%<+_ ,+3TC_H':G_^D_P#B]\A ;>D?] [4_\ OTG_,51RL+H[JBN%_X6GI' ]
$#M3_[]) \ %4?\+3TC_H':G_WZ 3_XJCE871VMU_P>DW_7 OY5Q_PM_P"10 ]>7 D*KS?%#29()$&GZF"RD#,2>G^] M6#X+\<6'A_0?L5S:7LLGG,^Z%%*X,/5AZ4^5V%=7/6Z*X7 A:>D?]
[4_P#OTG_Q5' "T]( Z!VI P#?\ XJERL=T=U17" P#"T]( Z!VI P#?\ M_(6GI'.0.U/_ +]) P#%4?\ "T]( P"@=J?
'Z3_P"*HY6%T=U1 M7" |+3TC_H':G_WZ3_XJC A:>D?] [4_^ 2? %4D?] [4_^_2?_%4?\+3TC_H' M:G_WZ3_XJCE871W5%<+_ ,+3TC_H':G_^D_P#B]\A ;>D?] [4 \ OTG_ M
,51RL+H[JBN% X6GI'_$#M3_[]) \ %4?\+3TC_H':G_WZ3_XJCE871W5% M<+_PM/2/^@=J? ?I/ BJ/^%IZ1_T#M3_ . 2?_%4D?] [ M4_\ OTG_,51_P +3TC_*!VI \ ?I/_(JCE871W5%
<+_PM/2/^@=J? ?I/ M BJ/^%IZ1_T#M3_[]) \51RL+H[JBN% X6GI'_0.U/\ []) \51_PM/2/^@=J? M\ WZ3_.*HY6%T=U17" |+ "T]( P"@=J?_'Z3_P"*H_X6GI'
$#M3_[]) \ %4D?] 0.U/_OTG_P 51_PM/2/^@= M]? ?I/ BJ/^%IZ1_T#M3_[]) \51RL+H[JBN%_X6GI'_0.U/\ []) \51_P MM/2/^@=J? ?I/ BJ.5A='=45PO "T]( Z!VI ]^D_^*H_X6GI' 0.U/_OTG_Q5D?\ 0.U/
MN>UCXDZ7?Z]?V<=C]*Q/R1*SQ]%92 3\W3F]GA:Q_INB^&[/3Y[* DEA#; MFBC4D?] [4_^ 2? %4?\+3TC_H':G_WZ 3_X MJERL=T=U17" |+3TC_H':G_WZ3_XJC A:>D?]
[4_P#OTG_Q5'*PNCNJ*X7_M (6GI'.0.U/_ +]) P#%4?\ "T]( P"@=J?_'Z3_P"*HY6%T=U17" |+3TC_M H':G_WZ3_XJC A:>D?] [4_^ 2? %4D?] [4_^ 2? %4?\+3TC_H':G_WZ3_XJCE871W5%<+_
,+3TC_H':G_^D_P#B]\A ;>D?] [4 \ OTG_ ,51RL+H M[JBN%_X6GI'_$#M3_[]) \ %4?\+3TC_H':G_WZ3_XJCE871W5%<+_PM/2/ M^@=J? ?I/ BJ/^%IZ1_T#M3_ . 2?_%4D?] [4 \ OTG_ M ,51_P
+3TC_*!VI \ ?I/_(JCE871W5%<+_PM/2/^@=J? ?I/ BJ/^%IZ M1_T#M3_[]) \51RL+H[JBN% X6GI'_0.U/\ []) \51_PM/2/^@=J?\ WZ3_ M .*HY6%T=U17" |+ "T]( P"@=J?_'Z3_P"*H_X6GI'
$#M3_[]) \ %4D?] 0.U/ M_ OTG_P 51_PM/2/^@=J? ?I/ BJ/^%IZ1_T#M3_[]) \51RL+H[JBN%_X6GI'_0.U/\ []) \51_PM/2/^@=J? ?I/ BJ.5A='=45PO "T]
( Z!VI ]^D_^*H_X6GI' 0.U/_OTG_Q5'_PM/2 0.U/\ []) \ XJCE871K)<^O@<M_<3 ___#6KOA,_D4[_C]O T$5PWB?X@Z;K'AR\T^ROXY)E4*TL:A1A@><
M,?2K&B_$?2]/T.QLY+'47>"!(V9(U*D@ D45PO\ PM/2/^@=J? M]?\ WZ3_.*H_P"%IZ1_T#M3_P" 2? Q5+E8[H[JBN%_X6GI'_0.U/_ +]) P#%4?\ PM/2/^@=J? ?I/ BJ.5A='=45PO "T]
( Z!VI ]^D_^*H_X M6GI' 0.U/_OTG_Q5'*PNCNJ*X7 A:>D?] [4_P#OTG_Q5' "T]( Z!VI P#?\ MXJCE871W5%<+_P +3TC_*!VI \ ?I/_(JCE871W5%<+_PM/2/^@=J? ?I/ BJ/^%IZ1_T#M3_ . 2?_%4D?] [4_P#OTG_Q5'*PNCNJ*X7
M1RL+H[JBN%_X6GI'_0.U/_OTG_Q5'_"T]( Z!VI P#?\ MT( Z!VI ]^D_^*HY6%T=U17" P#"T]( P"@=J?_'Z3_P"*H_X6GI'_0.U/\ []) \51RL+H[JBN%_X6GI'_0.U/\ []) \ 'Z3_P"*HY6%T=U17"
'Z3_P"*HY6%T=U17" |+3TC_H':G_WZ3_XJC A:>D?] [4 ^ 2? %4< MK"Z.ZHKA?%IZ1_T#M3_ . 2?_%4D?] [4_^ 2? %4D?\+3TC_H':G_^D_P#B/M\ 0.U/\ []) \
!5*PNCNJ*X7 A:>D?] [4_P#OTG_Q5'*PNCNJ*X7 ,+3TC_H':G_WZ3_XJCE871W5%<+_ ,+3TC_H':G_^D_P#B]\A ;>D?] [4_\ OTG_,51RL+H[JBN%_X6GI'_0.U/\ []) \51RL+H[JBN%_X6GI'_0.U/_OTG_Q5'*PNCNJ*X7
M H':G_WZ3_XJCE871W5%<+_PM/2/^@=J? ?I/ BJ/^%IZ1_T#M3_ . 2?_%4D?] [4_\ OTG_,51_P +3TC_*!VI \ ?I/_(JCE871 MW5%<+_PM/2/^@=J? ?
I/ BJ/^%IZ1_T#M3_[]) \51RL+H[JBN%_X6GI'_0.U/\ []) \51_PM/2/^@=J?\ WZ3_.*HY6%T=U17" |+ "T]( P"@=J?_'Z3_P"*H_X6GI'_0.U/\ []) \ %4D?] 0.U/_OTG_P 51_PM/2/^@=J? ?I/ BJ/^%IZ1_T#M3_[]) \51RL+H[JBN%_X6GI'_0.U/\ []) \ %4Z/2 M:***DH**** "BBB@ HHHH ****
"BBB@ HHHH **** " MBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""] X\;C M_KDW\JX3X, \B(?^ON3^2UW=[_QXW'_7OY5PGP9_P"1$\ U)R?R6J7PLG]
M>A4445)04444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% &+XO\ M^1*UW_L'S \ HM]ROA=_R3?
2/!V7_P!&O6KXO_Y$K7?^P?]/_.BVK*^%W_)_M](_W9?\ T;]5]DGJ=?1114E!1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
%%%% M !1110 4444 IN4445)04444 %%%% M !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% 'G_9/^1!?
_KYC_K7;Z= R#+3_*XI P@BN(^M,G_(@O\ ]?.?]:[?3O\ D&6G_7%/_015/X43U+ %%%%24%^ ^ M1(T/_KOA P#0!6[0]P6P4444AA1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>;? M&?\ Y%%W2O^PDG_H#UZ37FWQG P"1=TK_+"2?"^@/50^(F6QZ3114 W>6UA;/ M]ZK9;)ILVHZC Y-I#C?)M9L9(4<*"'>I%36=W!?
V4%Y;/OM[ MB 98GP1N5AD'!Y'[T 34444 %%%% !1110 4444 %%%% M% !7FWBP_P!]3KB J"35Z37FWPB_U/B+ +"352V9+W1Z31E!1110 4444 M %%%% !1110 4444 %%%%
%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !7FWB[_DKGA#_=?2^M^DUYMXN_Y*YX0_P!U_P_M5';?2^_5^[ P#L) 5+9DO=!'I %<]XQ]4?\!4[EI$5 \
8_M7F3B'9YOE MXRK'.<'^[^M<1 PNO MO_]7_P#R=!_M=:!PPP]2:YHK0PJXNC2ERS=F>L45Y/ PN MO_J7_P#R= M=V[4K=C+^T,]_ ^#/6*X77_&NC A=?
4O /D[_P#:Z/E;JE/L'1]H8?= M#?* 4.!?P^:P#R@0M_ !1 /R L_JE] J8 ^3O M_KH_P' ?C#X'R0B%M+'/C %@X=>L'Y
M^UT?2?'& [71]K4=@ M_##_ W/?#[_ )/ ,(F?M M_R I0O M_KH_P'W ?F!C#X '/ -@ M NC A=?
M .UT?2?+K P"I' '\ JW [71]K4=@ M_## ,WX{;8HKR? A=?_ 4O P#D[ [ _:Z/ '_ ^3O M _KH_P'W ? A=?"$
@SUBBO) P#A=?_J3 U+ ) _:Z/ ']2 .3O P:KH_P'W ?F4O P#D[ _ :Z/ '_ ^3O M _KH_P ' Z ^J] (W ^]2_^?%3?
KH^J5NP4OEZ71 YOP9Z=4ASK. P#W[ [71]K4=@ M_# /\ JW M_.U?2?+K P _ :Z/ "_P ? U_' [D[ JNP4 W ?F4_ _!P_ QF(N:\~ EH-1M
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M*** .2^)O_ ).M8 W$ P#1UH^*4 D2 #_P"O& ' T 5G?$W DG6L?[B?^C%K1 M&?\B1H?
7C# P"@"]^R3U-RBBBI*"BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH \ ( C) R(+ ]?,?1:[?3O^09:?\
7%/_$$5Q'QD P"1 M?!:Z^8_ZUV^G?:X'?+ MN^*P?@B]PHGJ6:***DH*Y/X/E_\).M8_MM_P"N^?! MHQ:ZRN3^?\ R3K6&?^N:??^C%K?I^X"CH\M?/WC@7V_ J|I\XP\^ MI\ UXP^M'MVL+P7_R) M&A_J>/
*W:"N"V"BBBD.**** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;XS M_P#(NZ5_V$D_ ]->O2:\V^ *+NE?!823
>JA\1,MCTFN_**O\ R375 MO^V/_ HY*[*N_^*O_ "375O\ MC_Z.2B.Z&\CG?A3=RZ/27GA_*>]*+4+O0Q MN5T4L!Z!]T[IAO>O4G=(XVDD95102S,< =S7E/B>VETC1"/C.S1FFTV"WBN M,8YA9
/YL5Z_QUO_!$U_'A"'TUTIVFNM<*06ABS\R @EA[%2!_P(4VKNY*=D M>:75Y/KWO$TCQ'(0+:ZU].VLUS_RSB=!G'ON!^1?0+,]*68@^!DDG@"O)?%ZMND0:#]_PVTNWP8;9L=B22?
OK:^*=Q<36^B:!#,T*:O?+!,ZG& M4RC!KZC98"#,UL"TN:L.Q\6UR8'UN(N@F..1U_[Z52/UKI+& M-2M([NRN M([B"0962L@_Y]H6/A?0].L$LK?2K00* "&A5B &,L2.3[FN*%)VT?A_Z!]ZSUO
MQX=LBXTVYMENHH2V1& R^OU8?0:"[[_"UTG^UR*^T[K_UR'U:\]"N<X1&W^$@~ZNS19?LN:M(AW"S'S7K%JQ* F]7PW*NL%HU(*^F*4:3N?@$T-5@K!+!\S^N]jMFQ9G
```

```
[YP"PZ'&3CWJ[\7M+M-/T.PUJP@BM=0M;R,1S0QA6Q@D#(_M]"H(].?6]Y5>PKNUSU&N5N_B3X0L;AH)M;B+]<'RHWD&?]JD5F_%C4;FU\,6 M]A:2M$^I72VKN/\ GF0=P_'@?3-=%I7A/0]&T^.SM
-MMBJ%9Y(E9Y/=F(Y/ M^14V5KLJ[O9%_3M3LM7LUN]/NHKFW8D"2-LC(ZCV->8WOQ-TQ_B)ITT&MRCP M_':MYX6*0*9OG'*[=QZIVQ5O2+*+PE\87TC3\QZ?]MD;C[.#\L;@MR!V^XV/ M9J
3TZQ'QQT:W%G;B$Z8S&,1+M)_?&=*MO!NG226D-S/>6L4L\L\8=GW*"%)/\ M*C"@= !2TY1ZW.CTO5K#6[%;S3;J.YMV)7>AZ$=01U!]C4.M>(=)\.VR3ZM> MQVL;DA-P)+$=<* 2?RKA/
5LFD_$CQ;I=H!'9*4D6(#A3G(QZ8W$5S]MXHTJ M3QUK>JZ[I6HZI+#,UM9I%;K+'!&K$="0 W?\3ZTCWMA9W]UY-QJ$GE6R>6S>8V5&,@$#EE MZXZUY!XF\1:;J.I:/J6@:!J]=AJ-ER^(?A/
M4+Y,*VUJ$SLVQ0Z.@8^@9@-?;GGCUK3U?Q%I6@R6D>I71@:[?RX3Y3L&;C@E M00.HZX_0UC>-/"NCZCX3U$-8P120P/-%+%&JLCJI(Y-Z<8([BN9DM;GQC\"; M>2;=-
>P1&6,XW,QA=E^I)0$>N3WHLF%V>IUF:=X@TS5=0O;&QN&FN+%S'< 1 M.!&P)&-Q&"<@]#VK$TWQ=&_PR3Q)*ZM)%9DR YPTR_+CUYZ/2:***DH**** "BBB@ HHHH **** "BBB@ MHHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\V\7?\ ME<\(?[K_ _:])KS;Q=_R5SPA_NO_ %JH[DRV/2:***DH**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ KS;X1_P"K\1_]A)]])KS;X1_ZOQ'_M_A)]I;,E[HG^,?_"*_I_U_I_Z+DKQ"O;_C'_R*_I_U_I_Z+DKQ"O9P7\+Y ML^;S+_>'Z(****
[#S@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH ]0^%OC+[_,OA[4)?W,K?Z&['[K'^#Z$]/?COQ[#7R>"5(()!'
M(([5[S\_&0\1:;]CO95_M.V&&SP94[/[GU_^O7E8S#V_>1^9[V78NZ]C/Y? MY';T445YI[(4444 %%%% !1110 4444 %%%% !1110 4444 07O_!XW'_7) MOY5PGP9_Y$0_]?M7Q?\ \B5KO_8/G_|
1;5E?"[_))OI'^[ M+_Z->J^R3U.OHHHJ2@HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M***
.2^)O_).M8_W$_\ 1BUH^#/^1(T/_KQA_P#0!6=\3?\ DG6L?[B?^C%K M1\&?\B1H?_7C#_Z *K[)/4W****DH**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ MHHHH **** "BBB@#S_XR?\B"_P#U\Q_UKM]._P"09:?]<4_]!%<1\9/^1!?_ M *^8_P"M=OIW_(,M/^N*?^@BJ?PHGJ6:***DH*Y/XF_\DZUC_KFG_HQ:ZRN3 M^)O_
"3K6/\ KFG_*,6G'=">Q?\%_\ (D:'_P!>,/\ Z *W:PO!?_(D:'_U MXP_^@"D\9:^?#/A6^U1%#S1]%A4CC>QVJ3[_G)^E#U8=!NO^_O#_(:?RM2O MU2XP"((U+O@].!T_'%>_#[P>?'6M7E[JUQ M.UM
P>=L_//(Q)QN/T))Z].FJ':C\0=%T[PM9^(L75Q87#_#B\.VVA2VGVFPMI&DB2=MQ#$L(_MOB/H_AG[#]MMKZ3[9_)X_)1#A3V.6'/YUD^"?!/AK4?!FE7EYH]O-<2P[GD8
M'+')]ZY#XW1)!J^CQ1J%C2T*JH[_@"FE%RL%VE"*R+/_M_P#A=_AK_GQU;_OU'_\ '*/^%W^&O^?'5O\ OU'_/'*Z_A_P"#XXVDDT2S M5%!+,V0 !W/->,Z?H]AXU^)1LM,M$MM'1RQ6(%?
W*=6SSRQ]?[P%:I19FW)' MN&K^+=/T7PQ#K]S%)K+Q9I3:C817$<(E,6V=0&R #V)XYK"\0_%/0_#> MMSZ3>6VH27$&W>T,:%?F4,,$N#T([5TVB:;I6F:<(]&BACLY&,@\EMRL2 ,@ MY/H*\
UVYTE_C5=S:\Z?V8LVV0?8UYMI?P\T2;X5B:6T4ZA<61NQ=,?G5RFY<$?P]./KWK(^!FI2 MK]NIZ43F*2 7(!SPRL%./KN&?H*;BK-KH";OJ>VT445F6%%%% !1110 4444 M %%%% !1110 4444
%%%% !7FWQG_P"1=TK_+"2?^@/7I->;?&?_D7=*_[" M22?\ H#U4/B)EL>DUQOQ5_P"2:ZM_VQ_]')7944D[.XWJ8.GZ?!JO@.ST^Y4_M#<:;'&V1G ,8&?].M><_#O0]2N_&!765+1^&HVM(,C
+EFP>>HVDD'V3\?9* M*:E:X6/-/B5_R.G@+_L(G_T9#6M\2/#NH:SI=E?Z1DZGI^0I M'T([UVM%'L%CSR'XNZ/%"D6I6&I6NI ;9+3[/EM_HN2.IX&<5)X(TO4M1\1
M:EXRUBU:UDO4$5I;29WQ1#')';.T>YY/?GOZ*+KH%NYYEX,_Y*UXO_#__"% M6/C3_P_B_'_U^Q_^@O7HM%'K<5M+'(?$?PW=>(_#0&GD_VA9RKA?]@ZW_|
1:ULT4KZ6';6YYQX4_Y*_P"+O^N+M5>]LIY] U64W"3P+O,+9Y!ZE@:ZGE7@>YOKSXM>(+G4;7[+::+__M_,E^\1_]@Y/_$&WJD[W]):L1Z[\08O%&DW.A>%[']N[^]4V[EX=J0HW#%CGC MC(]!U/3!
[CPOHB^'/#5CI(<2&W0AG&<,Q)9B,]LDUKUA^)?%>G>%8()M16X* M3L43R8]V6 SCKW_I4WOHBMM6>53Z?>IKEW\.(TDCL[S4Q>1R_*MMM+E<>VU M?Q4\9KV]$2. 8XU544 *JC
'85P'@:PN]9\1ZGXTU.UDMS= 0Z?#*N&6'CY MB,=P%P<_WNQ%>@TY/H**"BBBH*"BBB@ KS;X1?ZGQ%_V$FKTFO-OA%_J?$7_M &$FJELR7NCTFBBBI*"BBB@ HHHH **** "BBB@ I&944LQ
4#))/ %+7G/Q M-U"\O;W1_"%A(8WU63_2'4X*Q9Q^7WB?]WWII78F[&AJ/Q4\-65T;6V>ZU.8 M'#+81>8![Y) (]P35CPY\1M%\3;G_9UK'>P76PN([F(+D#KT)[' M=-CL=-MUBB4?,V/FD/\
>8]S_GI5]H8GECE>)&DCSLV:>@:G'ZS\ M2M+T77;K2)=.U6YN;::9#;0*Z_,H8?Q_]".U4HOC#X;_SY%W!]=B>/FN;88' MX*Q/Z5%H?_)CE4,#^!INR$KL6TO M+:_M([JSGCGMY!E)(V(V#*P]B*E
%;PO_/*D42#+.[!54>I)KR_P6LWA3XE:K MX31V;39D-S;(SD[_1C\"0?7:#74>)/ UOXIUF"YU'4+LV$403[!&Y5&<%CO M)SUY X&?EZTFDF%]"_H'BS3/$UQJ$6F_)(EE(J/*5 20G/*'.2.#S@5]7U];
MZ;8S7M[.D%M"NZ21SP!_GMWKS?X10QV^H>*X(5"11WJHBCL 9 !5CXJE;B[\ M+Z9-_NOT.[] M.U=Q;7,%Y;17-M*DL$JATD0Y#_]P:9-86EQI[V$MO&UH\?E&'-A=F,8QV&*X
M+X/W3_V#].ELS.NGWKI&Q/\ >;>+O\ DKGA#_=???^M5'6'6T6S;2I+!*H=)$.0P/<&L+QS>:=-M>#=4&I21".6VD1$DY+N1\H4-SG'TZ\8SV\X6%]IIW@.PAOUDCE)=UCDZHA8E
M1CMQSCWH:5KB5[V.NHHKF?_(@D\>$+N^@@Q]I;$,!/9FXS^R?PI)?7T*>@ MGB#Q_P'"O#DQMKN\MX/^7;7S),^A[_^Q(ZUD6_QPYYJ3^&.OFABN M(FBFB26-
NJ.H8'\#3]U$ZCZ*R/$7B.P\,:6U]?N<$[8HD&7E?LJCUKE)?B/J MUC']KU/P5]-IIH(WW!ERR*3@$H5&.O3/M246QMI'4^*]>_X1CPU=ZQ]F^T_9 M]G[KS-F[ST[5!=^)OLO@5?$OV/=FSCNOL_F8^|
=N[';/7%8WQ(O M;;4?A1J%Y:3+-;S) \#_ - 2]2T0FSK/#NK_ -O> M'[+5?(\C[3'O\K?NV\XQG S^5:=Z5%"2-&2&"D,3V)Y X!K]J^?+FTN;?6?$_B:Q&;K1M=, MC '!,32.&'YA?P)KWK3[Z#4]MK^V8M!
<1++&3UP1D9]Z]2ML*+N4_$7B&Q\ M.:/)J>H&0PHP4)& 7=B> 2!ZGKT!IWA_7+;,Q)H=OJUFDR6]QNVK, &&UBIR M 2.]GO7G/Q"N#XE\13:1&SFPT.QFO[S;]UI F4!YP2.!Z_U=/\ "K_DFND_
M]MO_$<]#C-POK8[*BN%N/'VJS7#=2OH879&FD<0]O']WA@PX/?T]: MUO"GC*U\4&[M_LL]EJ]%FVVXM) O+R1D>HXP>!@_AF>5CNA++Q;]J\?ZCX6^P
M[/L5N) M/FYWY$9QMQQ K.N3T]Z=-XK\KQW;^&/[-N#YUN9OM?\_GICIQ MC.>I Q7+Z+-R7[Q'P_P!@Y\ T&WKI9O%WE?$"W\+?8<^=;F;Y$O@@@@^T)+
<7=RVVWM81EY#D#\.H-I6(?B)?Z?&9M?\ M"=]IEL5.R?S/.0/_AR%%&T$\9Y[<>DJ+8[H[VBN[\.^*_[?(-K-P!B\C:L_MK>1YN[[F?XL#KCTKG],_^*,FLZ:CZ:X=N;S468[K2"8L2YP&>3:N3T&*?P
MNCT2BN0\>.TUW5KC1[_$N?2=5A3>:>=LJ[FSV.!G@@].0P76YO45Y^/B5=-=OKC/%=!XR\3?\(EH#(:I]C^UXE6/R_\OKWS@_RHY6%T=!M17!R$_$.%KWS@_RHY6%T=!M17!R$_$.%K3/2K+4U5TE
```

```
!1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110!R7Q_P"2=:Q_N)_Z,6M'P9_R)&A_]>,/_H
K.^)O_).M8_W$_P#1BUH^ M#/\ D2-#_P"O&'_T-57V2>IN4445)04444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110
4444 %%%% 'G_QD_Y$%_| KYC_*UV^G?|@RT_ZXI_Z"*XCXR?|B"_M_7S'_6NWT[_D&6G_%Q3_P!!%4_A1/4LT445)05R/Q/!/PYU< X.R,_^1%KK MJY/XF_|_).M8_P"N:?| HQ:<=T)['
Z'HOBZ;0;"6T\6RV]N]NC1PA3A%P,+ MU[5?_L#QM_T.LW_?!_QK<|+?|BGI'_7I%_Z"*UZMRU(2.,_L#QM_T.LW_?!_MQH_L#QM_T.LW_?!_QKLZ*.8=CC/[_|;?]#K_P!|'_&C^P/&W_0ZS?|_?!_Q
MKLZ*.8+'&?V!XV_Z'6;__+X/^_']@>-O^AUF_P"^#_C79T4-O|_H=9O^^#__(UV=%';%CC/[_|;?]#K_WP?|:/_M[_|;?]#K_WP?|:[.BCF"QQG]@>-O^AUF_[X/^_']@>-O^AUF_[X/^_=G11S
M!8XS^P/&W_0ZS?|_?!_QH_L#QM_T.LW__'P?|:[.BCF"QQG]@>-O^AUF_P"^_M#_C1_8'C;_H=9O|_O@_XUV=%';%CC/[_|;?]#K_WP?|:/[_|;?]#K_WP?|_M:[.BCF"QQG]@>-O^AUF_[X/^_']@>-
O^AUF_[X/^_=G11S!8XS^P/&W__$.L_MW_?!_P_:/[_|;?|_0ZS?]|'_!KLZ*.8+'&?V!XV_P"AUF_[X/|_C1_8'C;__M_*'6;_O@_P"_=G11S!8XS^P/&W_0ZS?]|'_&C^P/&W_0ZS?]|'_&NSHHY@L<
M9_8'C;_H=9O^^#_C1_8'C;_H=9O^^#_C79T4MUPOQ2_P"0)IW_%_)_P"@M3B]1-:$_P#8'C;__*'6_M;_O@_P"_']@>-O|_H=9O^^#__(UV=%+F'8XS^P/&W_0ZS?|_?!_QH_L#QM_T_M.LW__'P?|:
[.BCF"QQG]@>-O^AUF_P"^#_C1_8'C;_H=9O|_O@_XUV=%';%C_MC/[_|;?]#K_WP?|:/[_|;?]#K_WP?|:[.BCF"QQG]@>-O^AUF_[X/^_']@_M>-O^AUF_[X/^_=G11S!8XS^P/&W__$.LW_?!_P_:/[_|;?|
0ZS?]|'_!KL_MZ*.8+'&?V!XV_P"AUF_[X/|_C1_8'C;_*'6;_O@_P"_=G11S!8XS^P/&W_0_MZS?]|'_&C^P/&W_0ZS?]|'_&NSHHY@L<9_8'C;_H=9O^^#_C1_8'C;_H=9O^_M^#_C79T4-O|_H=9O^^#_
M_(T?V!XV_P"AUF_[X/|_C79T4-O|_H=9O_M^^#__(UV=%';%CC/[_|;?]#K_WP?|:/[_|;?]#K_WP?|:[.BCF"QQG]@>-_MO^AUF_[X/^_']@>-O^AUF_[X/^_=G11S!8XS^P/&W_0ZS?|_?!_QH_L#QM_T
M.LW__'P?|:[.BCF"QQG]@>-O^AUF_P"^#_C1_8'C;_H=9O|_O@_XUV=%';%C_MC/[_|;?]#K_WP?|:/[_|;?]#K_WP?|:[.BCF"QQG]@>-O^AUF_[X/^_']@_M>-O^AUF_[X/^_=G11S!8XS^P/&W_
$.LW_?!_P_:/[_|;?|_0ZS?]|'_!KL_MZ*.8+'&?V!XV_P"AUF_[X/|_C1_8'C;__*'6;_O@_P"_=G11S!8XS^P/&W_0_MZS?]|'_&C^P/&W_0ZS?]|'_&NSHHY@L<9_8'C;_H=9O^^#_C1_8'C;_H=9O^
M^#_C79T4Y|0R3WT@/D714YAZUZU7"^)?^2E>&O|_=;^M.+$T3_V!XV_Z'6;__M_+X/^_']@>-O^AUF_P"^#_C79T4N8=CC/[_|;?|_0ZS?]|'__!H_L#QM_P!#_MK_WP?|_&NSHHY@L<9_8'C;_
*'6;_O@_P"_']@>-O|_H=9O^^#__(UV=%',_M%CC/[_|;?]#K_WP?|:/[_|;?]#K_WP?|:[.BCF"QQG]@>-O^AUF_[X/^_'_M]@>-O^AUF_[X/^_=G11S!8XS^P/&W_0ZS?|_?!_QH_L#QM_T.LW__'P?|:[.
MBCF"QQG]@>-O^AUF_P"^#_C1_8'C;_H=9O|_O@_XUV=%';%CC/[_|;?]#K__MWP?|:/[_|;?]#K_WP?|:[.BCF"QQG]@>-O^AUF_[X/^_']@>-O^AUF_[X/^_M_=G11S!8XS^P/&W__$.LW_?!_P_:/[_|;?|
0ZS?]|'_!KLZ*.8+'&?V!XV_M_P"AUF_[X/|_C1_8'C;__*'6;_O@_P"_=G11S!8XS^P/&W_0ZS?]|'_&C^P/_M&W_0ZS?]|'_&NSHHY@L<9_8'C;_H=9O^^#_C1_8'C;_H=9O^^#_C79T4-O|_H=9O^^#__(T?
V!XV_P"A_MUF_[X/|_C79T4-O^AUF_P"^_M#_C79T4-O|_H=9O^^#__(UV=%',_M%CC/[_|;?]#K_WP?|:/[_|;?]#K_WP?|:[.BCF"QQG]@>-O^AUF_[X/^_'_M]@>-O^AUF_[X/^_=G11S!8XS^P/&W_0ZS?|
?!_QH_L#QM_T.LW__'P?|:[._MBCF"QQG]@>-O^AUF_P"^#_C1_8'C;_H=9O|_O@_XUV=%';%CC/[_|;?]#K__MWP?|:/[_|;?]#K_WP?|:[.BCF"QQG]@>-O^AUF_[X/^_']@>-O^AUF_[X/^_M_
=G11S!8XS^P/&W__$.LW_?!_P_:/[_|;?|_0ZS?]|'_!KLZ*.8+'&?V!XV_M_P"AUF_[X/|_C1_8'C;__*'6;_O@_P"_=G11S!8XS^P/&W_0ZS?]|'_&C^P/
M&W_0ZS?]|'_&NSHHY@L<9_8'C;_H=9O^^#_C1_8'C;_H=9O^^#_C79T4DW_7-OY5Q_PM_P"10_[>7_D*_M=]!6U'?V!XV_Z'6;_O@_XT?V!XV_Z'6;_O@_XUV=%+F'8XS^P/&W_0ZS?]|'
M_&C^P/&W_0ZS?]|'_&NSHHY@L<9_8'C;_H=9O^^#_C1_8'C;_H=9O^^#_C79_MT4-O|_MH=9O^^#__(T?V!XV_P"AUF_[X/|_C79T4-O^AUF_P"^#_C79T4-O|_H=9O_M^^#__(UV=%',%CC/[
|;?]#K_WP?|:/[_|;?]#K_WP?|:[.BCF"QQG]@>-_MO^AUF_[X/^_']@>-O^AUF_[X/^_=G11S!8XS^P/&W_0ZS?|_?!_QH_L#QM_T_M.LW__'P?|:[.BCF"QQG]@>-O^AUF_P"^#_C1_8'C;_H=9O|
O@_XUV=%';%C_MC/[_|;?]#K_WP?|:/[_|;?]#K_WP?|:[.BCF"QQG]@>-O^AUF_[X/^_']@_M>-O^AUF_[X/^_=G11S!8XS^P/&W__$.LW_?!_P_:/[_|;?|_0ZS?]|'_!KL_MZ*.8+'&?V!XV_P"AUF_[X/|_C1_8'C;_
*'6;_O@_P"_=G11S!8|^UK1/%|6_MA:A)=>+II[=+:1I82I_>*%.5Z]QQ5/PGI'BFY|,64VG>*);*T8/Y=NJDA/G;_M/?UR?QKN?$W__"*NK_|_7E_Z_:S?A]_R(VF_23__&-3OH*VI2_L#QM_P!#_MK_WP?|
&C^P/&W__$.LW_?!_P_:[.BES#L<9_8'C;_H=9O^^#_C1_8'C;_H_M=9O^^#_C79T4-O|_H=9O_M^^#__(T?V!XV_P"AUF_[X/|_C79T4-O_M^AUF_P"^#_C79T4-O|_H=9O^^#__M_(UV=%';%CC/[
|;?]#K_WP?|:/[_|;?]#K_WP?|:[.BCF"QQG]@>-O^AU_MF_[X/^_']@>-O^AUF_[X/^_=G11S!8XS^P/&W_0ZS?|_?!_QH_L#QM_T.LW__M_'P?|:[.BCF"QQG]@>-O^AUF_P"^#_C1_8'C;_H=9O|
O@_XUV=%';%CC/[_M|;?]#K_WP?|:/[_|;?]#K_WP?|:[.BCF"QYIX]T?Q5;>&;V;4/%,MY;JJ^_M9_RD!_F&._K@_A5G0]%|7S:#82VOBV6WMWMT:*$*<(N!A>O:M[Q]_P_B1J?^_MXG_H:U=|+?|
(IZ1_P!>D7_H(IWT%;4P_P"P/&W__$.LW_?!_P_:/[_|;?|_M0ZS?]|'__!KLZ*7,.QQG]@>-O^AUF_[X/^_']@>-O^AUF_[X/^_=G11S!8XS_M^P/&W_0ZS?|_?!_QH_L#QM_T.LW__'P?|:[.BCF"QQG]@>-
O^AUF_P"^#_C1_M_8'C;_H=9O|_O@_XUV=%';%CC/[_|;?]#K_WP?|:/[_|;?]#K_WP?|:[.B_MCF"QQG]@>-O^AUF_[X/^_']@>-O^AUF_[X/^_=G11S!8XS^P/&W__$.LW_?!_M_P_:/[_|;?|_0ZS?]|'_
!KLZ*.8+'&?V!XV_P"AUF_[X/|_C1_8'C;__*'6_M;_O@_P"_=G11S!8XS^P/&W_0ZS?]|'_&C^P/&W_0ZS?]|'_&NSHHY@L<9_8'_MC;_H=9O^^#_C1_8'C;_H=9O^^#_C79T4-O|_H=9O^^#__(T?
V!XV_P"AUF_[X/|_C79T4-O^AUF_P"^#_C79T4:75/$DE_;>:H,+*0,|X->Y:6&&DV09_MMS"!,G&,G:*|O^*'_(G_P!=X_ZUZEIW_(,M/^N*?^@BE)W2".Y9HHHJ"PKD_M_B;_
,DZUC_KFG_HQ:ZRN3^)O_).M8_ZYI_Z,6G'=">QF>%O^13TC_KTB_|_M016O61X6_P"13TC_*](O_016O5/YW5%%%2,**** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH *** M* "BBB@
HHHH **** "BBB@_HHHH *X7Q+_R4KPU_NM_6NZKA?$O_)2O#7^Z_MW]:J.XF=U1114C"BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH *** M* "BBB@_HHHH **** "BBB@_HHHH ****
"BBB@_HHHH **** "BBB@_HHHH M *X7X:_4W_H!K_^'W_(C:;])/|_T8U5]D74Z:BBBI&%%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444
%%%% !1110 4444 %%%% !1110!S?C[_D2-3__-Q/_0UJ M[X6_Y%/2/^O2+_T$52|??|B1J?|_N)_Z&M7?"W_(IZ1_UZ1?^@BJ^R+J:]%% M%2,**** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@
HHHH **** "BBB M@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@#C/BA_R)S?] M=X_ZUZEIW_(,M/|_KBG_*"*|M^*'_(G_UWC_K7J6G?|@RT_P"N*?|_H(IO M9
MRS1114%!7)_$W_DG6L?|_7-/_$8M=97)_$W__))UK'_7-/|_T8M..Z$] MC,|+?|BGI'_7I%_Z"*UZR/"W_(IZ1_UZ1?|_H(K7JGN2@HHHI#"BBB@_HHHH M **** "BBB@_HHHH **** "BBB@_HHHH ****
"BBB@_HHHH **** "BBB@_MHHHH **** "BBB@_HHHH *X7XI?|@33O^OY/_06KNJX7XI?|@33O^OY/_06] MH[B>QW59?B+6/[_T*YU/R/AG;^[W[=V6"]<'U]*U*Y?XB?|B)]7_;+__&I
M26X/8N^%O$;>'6_X1OQ990DX MLM;LHG7L%F"C||G/_?8KOM3U"+2M+N;^<_NX(RY&<9]!^)P/QIM:Z GH<]JO MCB+3O%MKH$=F9WEDBCDE|W;Y9R>8FWC_@1/T(KU37=;M/#^EO?
WA.Q2%5%^|['HH_7|C3DMK"3 *BN*AU? MQU?1"[MM$T^"!_F2*XD/F%>O]X8_$#Z5]^&/%">($N()K=[34+4A9[=^Q]1[ M9!^E39CN=!17"GQMJ9|3ZEHT&GQ74T3;+5$RI)
[L[$XP/PI9O%GB#0M1M5|1 MZ=9Q6-RX07%LQ_=GWR3TX[#C.,T^5A='*S|0 MK"26STX:L+0B*.2?*,?S|GYLY^]W]*:B#9W__(JU:?0_#5WJ5JD;S0[_JR@E
M3EU4YP0>A]:NZ1=R7^BV%Y*%$EQ;QRN$&_"R@G'MS7*>+) 3D^&FH J|,$5Y MNCW+_24QYJ8QDGM4.D:SXCN_#M@OA_3+9[>WMHHC/=N1YKJH#!%!' (QD|<& MBV@KZG>T5S?
A3Q/)KOVNTO;46NHV;[9H@>#R1D=^HP?PYYJ+5_$]Z=7;1O#U MG'>W|:[YWE;$4(]"".|;9#<6 MI)0/D *V2?S]_K5CQ=XIG|.:AHT:) ;:[E9;AY 250%,E<$ '#'KFCE87.JH MKE]#UGQ%J.K WVC+::5-
$7@BP7.NHKFO#'BB;6+N]TW4+1;74K(XD1&W*PSC(],<>O4 M?AFWOC6^L_&.H:(EBESY<2_9(XE/F22E4;#'. H!8DXZ"CE871V]%>)/% MNB)]NU;1[)].5P)#:R$NBG@'DGV[?
EFKOB3Q1EK;W%A*Z^=O4EMC M="N",'J#GN1Z&GRL+G5T4V.1)8TD1MR. RD=P:YWPIK][XB?4+IXX$T^*:?|)!K7_07O|_P "7_QKT7XF?|BW;_| 7VO_* ]>4UZ MV#BG2U7<^>S&?[2?
=_>_|S1_X2#6O^@O?_P#@2_| C1_PD&M?]!>__P# E_| M&LZBCDCV#VD^[^]_YFC_,)!K7_07O|_P "7_QH_P"$@UK_*"]_P#^!+_X MUG44P>TGW?WO_#_'_A(:_Z"]_|_^!+_:'_"0:U_T%[_|_|"7
,:S MJ*.2/8/:3[O[W_F:/_"0:U_T%[__,"7_P_:/^$@UK_H+W__($O_C6=11R1 M[!]2?=_>_P#,T?|_A(:_P"@O?_P#@2_^_'__D&M?|_07O_/P)?_&LZBCD MCV#VD^[^]_YFC_PD&M?]!>__/_E_P#&C_A(
:_Z"]__!+_P"_P"9U%')'|'L'_MM)]W][_S_'_A(:_Z"]__P"_"!+_XT?)!K7_07O|_P "7_QK.HHY(]@]I M[_S_'_A(:_Z"]__!+_P"_P"_"0:U_T%[
,"7_P_:SJ*.2/8/:3[O[W_F:/_"0:U_T%[__M:/|_PD&M?]!>__/P)?_&LZBC MF/_X5'_E P#&C_A(:_Z"]_|_^!(?M/?ZC_A(:_Z"]__/P)?_&LZ|@)|2ZW!/*$ZW!/'*4O'*&VR3LRGV()Y%95%+DCV'[6?|S^]_YGNV@Z MU!KNEQWD/#'Y98||H_U:=>
(^%_$$OA_5! RUK+A9XQW7U'N.WXCO7M4$ M|5S!'/"X>*10R,O0@UXV(H^REILSZ3!XE5X:[K?_#)****YCM"BBB@"*Z_X M])O^N;?RKC_A;_R*'_;R_P#(5V%U_P >DW_7
OY5Q_PM_P"10_[>7_D*I;"Z MG:T445(PHHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH M **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** ,OQ_R M*NK_/7E-
_Z :S?A]_R(VF_23_T8U:7B;_D5=7_Z|IO_$ UF_#[_D1M_^DG M_HQJK[(NITU%%%2,**** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_H MHHH **** "BBB@_HHHH **** "BBB@_HHHH ****
"BBB@_HHHH **** "BB MB@#F_'W__")&I_[B?^AK5WPM_P BGI'_%Z1?^@BJ7C[_D2-3_W$_P#0UJ[X M6_Y%/2/^O2+_-!%5]D74UZ***D84444 %%%% !1110 4444 %%%% !1110 M4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% '&?%#__)$YO^N|?]:]2T[__)!EI_UQ3_T$5Y;|4/| D3F__MZ[Q_UKU+3O|
D&6G_7%/_013>R!;EFBBBH*"N3^)O_).M8_ZYI_Z,6NLKD_B M;_R3K6/^N:?^C%IQW0GL9GA;_D4](_Z]O|_T$5KUD>%O^13TC_KTB_]!%:D
MTT=O!)/,ZI%&I=W8X"@#))]GN2A]%>0ZGX_U[7M3^P^'HY(8W;;&L:!I7'J3 M_#Z|=/6E_P"$>^(R@2B]O"QR2G]H=/;&[%5R=Q MX@UA9R9V,ODN4!< $C&>-GUZUPVO+XP|.?
9_[0UB^7S]VS9?.WW<9[_[0H4; M]0-Z?HOCO5-/AO;;5KLPS+N0M?N#CZ9J_|1=2U72Y])A@U"[MW^R_MO?*G9=S X).#R?>CEUM<.8]5HKQV31_&|6A1ZRFMW,T#0+<;$O92X0@-R#QP
M#ZGH:W_AQXNOJ8N+C3 1: M>*_B)]%GJ%WI6EVBQRP,5>X;YS@=PN,#ZG 'PNU74-2O=2%]?7 R%1"HFE9P MI)/0$|57*[7)YM;'I=%HR,5P++XYAT M1?$3:C>"V #A3.<[2)[_7+
[XA7.E:5JEW%N9$BC2X:_1&">A]OT5 MY99>&O'L5_;23ZE?9D!?'GE25'5@G3'7|J[CX?^*[CQ%8 MW$-^R->6Q&74!?,4]#@=|@YQQTH<;"4CLJ***DH**** "BBB@_HHHH **** M"BBB@_HHHH
**** "N%^*7_($T[_*_D_P#06KNJX7XI?|@33O| K^3__!: MJCN)['=5R_Q$_P"1$U+__+9?^C4KJ*QO%6DSZYX:N] M7C2:;9M:4D*,.K'. M 3T'I26X/8P?$&DR:C\/M/N+7<+RPMX;F$KU^5!D?
ES]0*S]8UK__(3&WT'1 M;5]AU$">|V=$5<[EZ_WE8_| 17>Z?:M;Z3:VDVUFB@2)|<@D* >O:N<|+>" MU|.:S]5[YB,DQ*6RKG*1DYP>.O_'7M5)H5C.|<1I%XF|&1QHJ(MYM55&_'B_MP
*D^(3HNH^&1.<6OV|&7/W< KU__FM7Q+X>N]9UK0;RWD@6/3[CS91(Q!8;_MD/RX!Y^4]<=JTM?T*U|1:4]A=[@I(='7JC#H1^9'T)HOL%MS3KAK$[_B]J1M M^4%DJW!'3=A,9]^G^&_#<
M6@03.|[75__MJ.M:1;:[I4VGW8/ER#AEZJ1R"/>N8@T/QKID*65AK=C:1C:&]S&?,5>P^Z< MX]S^E+=#ZC9L|8;?[_D[-/VG:.GWL9__/TI=0_Y+!I7_8/;_VK6OX;|,#1
M'N+RZNFO=3NCF>Y88_X"!V'^>.E5O$OAO4+__%>QUG1KN&WU"V4QD3@['0Y[_M@'U/&.<]LN5B_#JV.F>@/:MK2+22PT6PLY2IDM[>.)RAR"54 X]N* M72P^IR7AP_?
$OQ+@8^1/Z5B>';7Q#?:QX@;2M7ALG%ZWGI)"KLQW-@|@X[UV_M&E>'[NQ|7ZOJ]LD)M[Q5$:JQW#&.HQCMZU4U;PG?IKK:WX=OTL[R5<3I,"T<_MO3V..G/'TQ570K&?
J/A#Q5K"0QZCK]K/'#*)4'V<(0P]U4'O2^/XTE|2^$8W_M7X+Q5J6.E^*+I;ZWEU76[5+>)P[0VD7^MP>A) ('^<5+XE|/7>LZUH_M_Y;R0+'I]QYLHD8@L-R'Y<
|_*>N.U*^H6T.@N;B.UM9;B9ML42%W/H_,FN-_MT_5_%GB>W%]I<>GZ?8,Y6-KC<|C@'&>..V.W>NQN[:.|LY[68$Q31M&X'H1@_M_P_ZXO3?#/BW1(3IVG:U9?V>"?
+>6(F2///"XQU]3CDTE8;*WA2.|B^).M1Z_MA=I=70M4|R9$"@GY._!Z#__"I_.$1^,^KF3;N%HICR?XMD73|,UH^'/"_UH7_MB>^U!
[I;B">!4#NQ,K/I9F!&!E@QZGJ*Y^;39]2^+&L"TO'M+N"V2:"5>0&_M"Q###NI!(([ZK=LD[SQ$Z1^&M4:3&P6DN0>_R'BN<|,Z7_;'PK@TZ;*F>*4*_MSC.T^8Q4X]
<&FW'AKQ1KH%IKNL6]Z=O#21V:$_* (GMOA7<)(<7UMNT[9U(;[H_)3_P"_A79>&M(_M70_#]G8!<.B9E/'+GEN1[G_]@*X@:1'>?%6XLXI#)8(XO[F'C8)0O''?EA^9_MKTRG(2"BBBH*"BBB@_KA?
AK_*G6_P#K^:NZKA?AK_J=;_Z_FJELQ/<[JBBB_MI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110_M_4444 %%%% !1110 4444 %
<+XE_Y*5X:_W6_K7=5POB7_DI7AK__'6_K51W_M$SNJ**XWQW>W=G<:"+:ZF@$MZJR"*0KO&1P<=122N#.RHHKC_%U[=6WBCPM# M!><'G/?U_(+G9T53T]_35-)M
M+Z/A9XE?'H2.1^!XKG?'VHWD%C8:9IT|L-]]_RL:/&VTA01GDO*:]?!_P_+[SYS,OX[]$%%%%=AYP4444 %%%% !1110_44_M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!111_M0 4444 %=SX!|3?8KA=(NV_MYF_95]?J._YUU]>#4@X2<6?5TJL:L%.(4445!J_M177__!Z3?]4W_H!K_^_M'W_(C:;])/|_T8U5]D74Z:BBBI&%%%% !1110 4444 %%%% !1110 4444 % M%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110!S?C[_D2-3__-Q/_0UJ[X6_Y%/2/^O2+_T$52|??|B1J?| MN)_Z&M7?"W_(IZ1_UZ1?^@BJ^R+J:]%%%2,****
"BBB@_HHHH **** "BBB M@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** M"BBB@_HHHH **** "BBB@#C/BA_R)S?]=X_ZUZEIW_(,M/| KBG_*"*|M^* M'_(G-
_UWC_K7J6G?|@RT_P"N*?|_H(IO9_MRS1114%!7)_$W_DG6L?|_7-/_M_$8M=97)_$W__))UK'_7-/|_T8M..Z$]C,|+?|BGI'_7I%_Z"*R/B3.|'@NY_M5&(|V1$8@]LY_I6OX6_Y%/2/^O2+_P!!%+XETC^W?
#UYIX(5Y%!C)'1@01^H_MQ^_7]HGH<5|(|.$6NHWO6"=9N;>^M9#$Y"7$/_=2#PPSUX)XS@YZ]*U/&/B_0_;T9[;3[_M.5+IY0YE:%5Z=]J1?0[[PCXH_P"$IL9[G['JE|J7R]OF]|| YS@>
MMWT|6Z1"Y2UD!:,+C[Q]'([BNA^%G]BI M'<"":0Z]Z#S5E_7Y?]C!.1TSWX'_JW8?$#P]IWA6Q@:=Y[F&TCC>W6)N6" $ M9(QC/O| G7(?#.TN+CQA%OW6LZ593&&[U M.SMY0,E)9U1L?0FI:/4;'4
YLKVWN0F_QAE5]N>F<'BN?UWP%I7B#4VQ[NXO M$E90I$3]%P/]I]X<|*V/AB.X2REN)!.5+>I'XJM+:'PM MK4T5O%'+);/O=4_9N.Y[UQ/PA_X_=4_ZYQ_S=YXQ_Y%#5O^O9_Y5P?PA_X_
M=4_ZYQ_S-6OA9+^)%3XM2,?$MI'_K9JP^I=_| 5Z'>0]_@&:'_"_V85&1 MG'[KBN+^+.E3_-9:M'&6B6/R)6&?EY)7/H.33;GX@V4W@@Z>/_.I/:_9G&S"_M] I:/3D9/U]*=KI6#9LB^$;$:IJ2YX,*D_|_?
7_UZCUG1?%47C6]UK2K*;<) M6,,P5#QMV]&Z|9[5L_"C29+?3KO4YD*_:6$<6>I5-G2U!AE8B:%T9U>DPHW@&SB_M_5]_7.>>L?/Z||^$S$>)[M<|&S8G_OM/|:O67Q"L;?P(/D|UM2CMC;HNSY
M>A53GT"XS4WPETF1!>ZO(FU'_@B)'WN'+";RI]5AWC@B_M(_)CZE0<46N!OT5F:3XATG7-XTV]2>2_VMS;B)$#'>"!&.1C&_M/D/?TKI:*=P"LG78-2>;Q/_P_);XC__M_.A*NO|
P)_^PK!U;5]2U3Q=X8_M#19=,|NZ.SS)=_F9*9[#&,#|Z]0KB/&G_M_(W>$/| KZ?^<=--7V$T2_$__D3G_P"N|?| 6ND>SCU#0C9S#,<]OY;?0KBN_M;^)__(G/_P!=X_ZUUEG_
,>5O_US7^5+HA]3C/AG>2)IE]HMP0+C3KAEV^BD_MG_V8-^=,M'_X2+XHSS[/]%T:(Q+D9!DR1SZ');'^X*J^(;O_(0_QT=61_+?_M4+.0,O8RJ../K?$S_D6[?|Z^U_]>O*:]?!_POO/G,
MR_COT04445V'G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 445);V|MU<)!!&TDLAVJB MC))H!*YL>$K"]O?
$5J;)FC:)P[R@9"+WS]>F.^:]MK&|->'X?#VF"!3OGDPT_MTG]YO0>P[5LUX>)K*I/39'U&"P[HT[2W84445S':177__!Z3?]4W_H!K_^'W_(C:;])/| T8U5]D74_MZ:BBBI&%%%% !1110 4444 %%%%
!1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S?C[_D_M2-3__-Q/_0UJ[X6_Y%/2/^O2+_T$52|??|B1J?| N)_Z&M7?"W_(IZ1_UZ1?
M^@BJ^R+J:]%%%2,**** "BBB@_HHHH **** "BBB@_HH_MHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB_M@#C/BA_R)S?]=X_ZUZEIW_(,M/|
KBG_*"*|M^*'_(G_UWC_K7J6G?|@RT_M_P"N*?|_H(IO9_MRS1114%!7)_$W_DG6L?|_7-/_$8M=97)_$W__))UK'_7_M_/|_T8M..Z$]C,|+?|BGI'_7I%_Z"*UZR/"W_(IZ1_UZ1?|_H(K7JGN2C.U/
M0=*UG;_:%C#.R|*[##_>FXRMUM[6".&%>B1]%_JCK'AW2M?|G^T[7S_"=WE_O&7;G&?ND>@K4HI7&5_M[*RM].LHK.TC|N")=J)N)P/J>:H:OX8T?7IHY=2L_/>-=J'S77_X"16O11<
M#F!|//"H((TH<>L|O_Q5;]E86FG6PM[*VBMX1SLC4*,^I]3QUJQ13NV*P444_M4AD%Y:07]G++:7*>7:9!I1UR1D'W'_4=(|:1H+ROIEIY#2@!SYCMD#I]XGUK5
MHHN!'/!%=6|D$\:R12*5=&&0P/8U@Q^!/#,5R)UTF(N#G#,S+_WR3C]*Z*BG_M=A8;'&D4:QQHJ(H"JJC_'0_5AWW@OP[J5S)<76F1M_(VYV1V3<>Y.TCFMZB
MBX&;I6@:5H@8:=91P%AAF&2Q'N3DUH21I+&T4:JC[GIGL/?C)R*T>M[$;;G1:)K_/;&H:M: M&U,#:?<>3N|S=Y@R<'H,=.G/6MJN5|!64|6BSZC>(5NM3N'NG!XP&/"YG|:
MZJH>Y2.%|8WEWK&O6?A*QF:%;A?,NY5YPG)V_D,^^0*Z+3O"VB:7:+;P:=;L_M_,|L8=W^I(Y_E7,H?L_QGD|T%?M%G^ZR/O84=/^^6_*N^IO302*5KH^FV-T_M]S9V,%O*Z[&,*!-
PSGD#@_6L_7/%VDZ!*D%U*|MT_P!VW@7>_MQT'XGFMVN$_M^'<$=^^KZ[<*'O9KQXM[:1?7RV_$+1K,|1W_MEP%QYC00Y6(]PQ)_R.^,U9N?&VB6^FVUZDTER+G/DPP)ND;'7Y3C&,=ZT-$L
MX+?P[8VL<:^2+=04(R#D!^GY46_M0:G3Z'XPTO7KI[2#S[>[0;C!)&@*[#'CY<>F*XOX:MY=OK-E&Q-O;WS"($YP#QU_5.C6@^IN_M^']9TS5;G4TT^T:"2"?;
<,T:KYC|C=P3G[O4U13X@:*UO<2LMTC0S&$1&,%Y_M6'7:_3G|<5F?#K_D)^)O^OS^KU7^&EE;M?ZW>M&#<+<&-7/55))('UX_*G9:_MBNSHM&|:Z7K6HG3XTNK6|_)$-U&$9L#)Q@GMSCV
:FKZS8Z%8F|OY3'#NV@A_M"Q+8)_X^EXKE_%?B&|U;PW?6Y|,:A%;E0WGW0|O9@@AL?ATS__M_#KHM%);X=6Q))/IG8Y_W*=EN*YS7@'Q9!!IEGI4UK?RW$LY7SQ&&CRS<98G_M/?TKK9=9TQ?
&$.E_:,=2:_LEQY:X"C^)&CLT9_MFM_2MX'(Q<2VX$>#T.02_M);6ZB66"5=KHPX(I:+<>K&_;8&T|WT;B6W|LRAHSG&GNTC_N)IF5W[D+T'TZ_G3LE<5S=T#Q;IGB*66&T,T5Q$,O!.FUP,XS
MP2.N/S%;M<+J420_I()JT]J_F8_BPLF,_D/R%=U4M#05POPU_U.M_]?S5_MW5<+|_?]3K?_%_36S![G=4445(PHHHH **** "BBB@_HHHH **** "BBB@_M HHHH **** "BBB@_HHHH **** "BBB@
HHHH **** "BBB@_KA?$O|_R4KP_MU_NM_6NZKA?$O_)2O#7^ZW]:J.XF=U5'4='L-6:V:]@|TVTGF1?.R[6]>",_MC5ZBI&%4;W1[#4;NSNKJ#S)[-R|#;V&PG'.<'H.M7J*_*6]:39:S9FTU"#S
MH"P;9O9>1TY!!JVB+&BHHPJ@_#VIU%_&=J^A:;KL,<6I6WGI&VY!O9<'IU4B_MKT,,=O!'#$H6-0B*.P_P!3Z* "BBB@_HHHH **** "B_MBB@_HHHH **** "BBB@_HHHH ****
"BBB@_HHHH **** "BBB@_HHHH *X7_MX:_O*:]?!_P_+[SYS,OX[]$%%%%=AYP4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44
%>I>_O#'V"V&K7:$74RD1HP_U:'O]3_(^YKGO_GAG^U+S^T;I6%K;."@(_MXE<DW_7-_MOY5Q_P_+?^10_P"WE_Y"NPNO^/2;_KFW|JX_X6_|BA_V|O|_R%4MA=3M:*** MD84444 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7XF_P"15U?_M *|IO_0#6;|/O^1&TWZ2?^C&K2|3?|BKJ_| UY3?^@&LWX??
|B-IOTD_]&-5 M?9%U.FHHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 D?
M]>D7_H(JOLBZFO1114C"BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHH MH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_M HHHH XSXH?|BD?|
7I%_Z"*UZI[DH*** M*0PHHHH **** "BBB@_HHHH **** "BBB@_HHHH **** M "BBB@_HHHH **** "BBB@_HHHH **** "N%^*7__"!._Z_D_| 06KNJX7X MI?|
($T[_K^3_P!!:JCN)['=5@^,_?Q'H$EE$ZI.KB6(L._P!X]L@D9K>HJ M4[#.'MO%?B&QMH[74?"NH3WB+M:6W&Y']R0" ?7D^M4M3T'Q!XXC,^H1QZ9;_M0HYM;8C=
(S]MQ[9X_(<5Z+15E==1128SE_%_A>76EM[_3YO(U6S.Z!ST;G.#^/3|?6]$'C#Q#:QB' M4O"5])<)D-):J61B.XP"/U-=O13OW%8P_!U?6=4NYS?Z*VG6JH/+,CY=F_3M M[5S|=CK/@G6;V;3].?
4M'NW|SRH3^|A;V'4^G?(_Y!KOZ*+A8|_U*;7?&T4> ME1Z/<:58.X:YN+L$,0#D!5.,|X_'TP:O^/=,E?P4EAIUK+_Y3Q*D4,98A5XZ M 5V_%',%BMIRLFEVB.I5EA0%2,$'.*Y+X>V-W9?
VS]KM9X/,N]R>;&5W#GD9 MZBNVHI7"QQ/B2'ABV_'ZYAM9Y((O]9*D9*IR>I'_JKXVT[5KOQ=HL^EV|C/ M"N1-Y;&_MZBE<++'$^ K&[L]0|0M=6L|"R MW>Z,RQE0XR_(SU'(H^'MC=V7]L_:
[6>#S+OHKM]*;D%CC_&5E M=76N>&)+>VFF2&^#RM'&6$:[DY8CH.#U]*C|;:=JAU72 ;T^U:^73W+26P/. M,@Y4>IQC@$|#@UVE%%PL>>^(-3|0>(]!NK:TT"|LK?9F9IU/F/CHB)U.3W]*
MZ;P_9R'P9965PCPR&T$;JZX9"1CD'O6Y12;Z!8|_|'7>KZ##'X?O-!O"4N"/ MM2*?*"L<[MW0XSVJU<6-VWQ9M+T6LYM5M"IG$9V_[6XW=,|UVU%/F"QQGB31 M-4M?
$5OXFT*)9[A$|NYMBV/-7U'X*_$_;O::=X6O[>[D&T37 * MI'V)R0-<=N??VKMZ*+A8YS1_#W_"/^#IM.1O.G:*1Y&1?ONR]AU/8#Z56^'5 MG98R44E M9."W0=1^==A110V_5POPU_U.M_|
7|U=U7"_#7_4ZW_U_36S![G=4445(PH MHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BB MB@_HHHH **** "BBB@_KA?$O_)2O#7^ZW]:[JN%^*7_($T[_*_D_P#06KNJX7XI?|@33O| K^3__!:
```

```
M1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7X: (J4X\L3EK8.E5ESSW]3RG_A6>M?\ /U8?
M]_'_/B*/^%9ZU_S]6'_'\?_P"(KU:BM/KE7^D8_P!FT.S^\|I_X5GK7_/U M8?\ ?Q__(BC_A6>M?\ /U8?]_'_/B*]6HH^N5?Z0?V;0[/[SRG_A6>M?\ M/U8?]_'_/B*/^%9ZU_S]6'_'\?_P"
(KU:BCZY5_I!_9M#L_O/*?^%9ZU_S M]6'_'\?_P"(H_X5GK7_#]6'_?Q_P#XBO5]*/KE7^D'|FT.S^\|I_X5GK7_M #]6'_?Q_P#XBC_A6>M?\_5A_P!_'_|_B*]6HH^N5?Z0?V;0[/[SRG_A6>M?
M\_5A_P!_'_|_B*/^%9ZU_P_5A_W\?\ ^(KU:BCZY5_I!_9M#L_O/*?^%9ZU M_P_5A_W\?\ ^(H_X5GK7_/U8?]_?Q__(BO5]*/KE7^D'|FT.S^\|I_X5GK M7 /U8?]_?Q__(BC_A6>M?\ /U8?]_'_
/B*]6HH^N5?Z0?V;0[/[SRG_A6> MM?\ /U8?]_'_/B*/^%9ZU_S]6'_'\?_P"(KU:BCZY5_I!_9M#L_O/*?^%9 MZU_S]6'_'\?_P"(H_X5GK7_#]6'_?Q_P#XBO5]*/KE7^D'|FT.S^\|I_X5 MGK7_#]6'_?
Q_P#XBC_A6>M?\_5A_P!_'_|_B*]6HH^N5?Z0?V;0[/[SRG_A M6>M?\_5A_P!_'_|_B*/^%9ZU_P_5A_W\?\ ^(KU:BCZY5_I!_9M#L_O/*?^ M%9ZU_P_5A_W\?\ ^(H_X5GK7_/U8?\ ?Q__
(BO5]*/KE7^D'|FT.S^\|I_MX5GK7_/U8?\ ?Q__(BC_A6>M?\ /U8?]_'_/B*]6HH^N5?Z0?V;0[/[SRG M_A6>M?\ /U8?]_'_/B*/^%9ZU_S]6'_'\?_P"(KU:BCZY5_I!_9M#L_O/*?^%9 MZU_S]6'_'\?_P"
(H_X5GK7_#]6'_?Q_P#XBO5]*/KE7^D'|FT.S^\| MI_X5GK7_#]6'_?Q_P#XBI;?X9:F;A!4W_H!K-^'W_(C:;]|/_1C5I>)O^15U?_KRF_\ 0#6;\/O^1&TWZ2?^C&JO MLBZG34455(PHHHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ;\ M??\ (D:G_N) Z&M7?"W_"*>D?\ 7I% Z"*I>/O^1(U/_<3_#6KOA; D4]
M(_Z](O\ T$57V1=37HHHJ1A1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 <9|4/\ D3F Z[O_UKU+3O\
D&6G_7%/_017EOQ0_P"1.;_KO'_6 MO4M._P"09:?]<4_]!%-[(%N6:***@H*Y/XF \DZUC_KFG_HQ:ZRN3^)O_):M M8 ZYI Z,6G'=">QF>%O^13TC KTB P#016O61X6_Y%/2/^O2+_T$5KU3W)04
M444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %<+\4O^0)IW_7\G_H+5W5<+\4
MO^0)IW_7\G_H+54=Q/8[JBBBI&%%%% !1110 4444 %%%% !1110 4444 % M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<+\ ?]3K2_7\U M=U7"_#7_%.M_P#7\U4MF]
[G=4445(PHHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ KA?$O_)2O M#7^ZW]:[JN%\2_\)2O#7^ZW]:J.XF=U1114C"BBB@ HHHH ****
"BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH *X7X: 4W_H!K-^'W_(C:;]|/_1C M57V1=3I]***D84444 %%%% !1110 4444
%%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ' M ^/O^1(U/_<3_P!#6KOA; D4](_Z](O_$$52?\]B1]?"XG_H:U=|+?\BGI
M4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M_7I%_Z"*K[(NIKT445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH ****.,^*'_(G
_P!=X_ZUZEIW_(,M/^N*?^@BO+?BA R)S?\ 7>/^M>I: M=_R#+3_KBG_H(IO9 MRS1114%!7)?$Y@OPYU@DX&R,?G(M=;7)?$T_#K6,C M/R) Z,6G'=">QQ6@>//#ECX>TZUN+\I
#;HCKY$APP4 C(6M'_A$N*?^@BO+?BA R)S?\ 7>/^M>I: M=_R#+3_KBG_H(IO9 MRS1114%!7)?$Y@OPYU@DX&R,?G(M=;7)?$T_#K6,C M/R) Z,6G'=">QQ6@>//#ECX>TZUN+\I
^ D?^%'_",>'_| H!:9_P" D?\ A2O$=F<'_P +&\|+?]!(_M^? \G_P 31_PL;PM_T$C_ \G_Q_=Y_PC'A_ H!:9_X"1'X_X4?^ D?^%'_",>'_ H!:9 X"1_X4?^ P"@%IG_M (CY_P"%%XA9G! |+&\|+?]!
=Y_PC'A_ * 6F?\ @)'_ (4?(QX?_Z 6F?^ D?^%%XA9G! |+&\|+?]! 02/_(#R M?_$T?!+&\|+?]!(_^ \G_,37>?( ",>' P#H!:9 X"1_X4?(QX?_P"@%IG_M ("1_P"%%XA9G! |+&\|+?]!
(_P#@/) \31_PL;PM_P!!( | @/) |37>?(Q MX?\ ^@%IG_@)'_A1_P (QX?_.@%IG_@)' A1>(69P?_ L;PM_T$C X#R?_ M ! ' ^@%IG_@)'_A1_PC'A P#Z 6F?^ D?
M^%%XA9G! P#"QO"W_02/_@/) P#$T?\ "QO"W_02/_@/) | $UWG_",>' | MH!:9_P" D?\ A1_PC'A_ H!:9 X"1_X47B%F<' PL;PM P!!( | @/) \31_MPL;PM_T$C X#R?\ Q =Y_PC (QX?_
.@%IG_@)'_A1_PC'A_ * 6F?\ @)'_M (47B%F<' PL;PM_T$C _ \G_Q ' "QO"W_$$C_P" \G_Q =Y_PC'A P#Z_M 6F?^ D?^%' C'A | Z 6F?^ D?^%%XA9G! | "QO"W_02/_@/) | $T?\ M+&\|+?]!
(_P#@/) \37>?(QX?_Z 6F?^ D?^%' ",>' /H!:9 X"1_X47B%F MF<' ,+&\|+?]!(_^ \G_,31_P +&\|+?]!(_^ \G_P 37>?(QX? P"@%IG_M ("1_P"%%XA9G! |+&\|+?]!(_P#@/) \37>?(QX?\ ^@%IG_@)' A1>(69P? "QO"W_$$C_P" \G_Q
_' "QO"W M_02/_@/) P#$UWG_C'A | Z 6F?^ D?^%' ",>' | H!:9_P" D?\ A1>( M69P? "QO"W_02/\ X#R?_$T?!+&\|+?]! 02/_(#R?_$UWG_",>' /H!:9_X M"1_X4?\ ",>' P#H!:9_X"1_X47B%F<' P
+&\|+?]!(_^ \G_P 31_PL;PM_ MT$C _ \G_Q =Y_PC'A H!:9 X"1_X4?(QX?\ ^@%IG_@)' A1>(69P? MPL;PM_T$C X#R?\ Q ' L;PM_T$C X#R?_ ! =Y_PC'A * 6F?\ @)' M (47B%F<' PL;PM
^%%XA9G! |+&\|+?]! 02/_(#R?_$T?!+&\|+?]!(_^ M \G_,37>?( ",>' P#H!:9 X"1_X4?(QX? P"@%IG_(_"1_P"%%XA9G! | M+&\|+?]!(_P#@/) \31_PL;PM P!!(_| @/) |37>?(QX?\ ^@%IG_@)' A1 M P
(QX? .@%IG_@)' A1>(69P? L;PM_T$C X#R?_ ! ' "QO"W_02/ MX#R?_$UWG_",>' ^@%IG_@)' A1_PC'A_P#Z 6F?^ D?^%%XA9G! P#"QO"W_M 02/_@/) P#$URGCWQ9HHNMZ79PZ?
=F62.Z61QY3KA0K#/(']*]G_.$8\|\ M_0"TS_P$C_PKS[XN: I=AH.F26>FV=L[Z@BLT,"H2 K<$@=*]+5R6G8E P"% MC>%O^@D? ->3_P")H X6 X6 Z"1 \|Y/ B:[S_A&/#__$ M,_| 2/_H
MX1CP M_P#] +3/_2/ "IO$]S.# X6 X6 Z"1_\|Y/ B:/^%C>%O\ H)'_.|Y M/ B:[S A&/#_/T M,_\|(_|*/\ A&/#_P#T M,_\|(_|*+O"S.#_P"%C>%O M@D? ->3 P")H X6 X6 Z"1 \|Y/ B:[S_A&/#__$ M,_|
2/_H_X1CP M_P#] +3/_2/ "B\0LS@_P#A8WA; H)' P !Y/\ XFC_(6 X6 Z"1_\|Y/_ M (FN\ X1CP___+3/\ P$C_,*/^$8\/ | 0"TS_P !(_| "B\0LS@_^%C> M%O\ H)'_.|Y/ B:/^%C>%O^@D? 'D_P#B:
[S_(1CP_| | +3/_2/_"C M_A&/#_| T M,_P# 2/\ PHO$+,X/_A8WA; H)' P'D_^)H X6 X6 P"@D?| MP'D_^)KO/^$8\/\_0"TS_P$C_PH_P"$8\/_/0"TS_P$C_PHO$+,X/_(6 MX6 Z"1_\|Y/
(FC_A8WA; H)' P'D_^)KO/^$8\/ | 0"TS_P !(_| "C_A M&/#_/T M,_\|(_|*+O"S.#_.%C>%O^@D?_'D_P#B:/\ A8WA; H)' P'MD | B:[S_A&/#_| T M,_P# 2/\ PH_X1CP_P! +3/ $C_P *+O"S.# X M6 X6
P"@D?| P'D_^)H_X6 X6 Z"1_| >3_.)KO/\ A&/#_P#T M,_\|(_ M\ |*/^$8\/ P#0"TS_!( P#"B\0LS@_^%C>%O^@D?_->3_XFC_A8WA;_*"1 M_P# >3 XFN\ X1CP P! +3/_2/_"C_(1CP_| | +3/
2/_"B\0LS@_| MA8WA; H)' P'D_| B:/^%C>%O^@D?_->3 XFN\ X1CP_P! +3/_$C_P *_M/^$8\/\_0"TS_P$C_PHO$+,X/\ X6 X6 Z"1_| >3_.)H_P"%C>%O^@D? M_->3 P")KO/^$8\/ P#0"TS_.!(
P#"C_A&/#__$ M,_| 2/_HO$+,X M/_A8WA; *"1_P# >3_XFC_A8WA; H)' P !Y/\ XFN\ P"$8\/ /0"TS P M$C_PH_X1CP__+3/\ P$C_,*+O"S.#_X6 X6 Z"1_\|Y/ B:/^%C>%O\ MH)'_.|Y/ B:[S_A&/#_/T M,_\|(_|*/\
A&/#_P#T M,_\|(_|*+O"S.# M P"%C>%O^@D? ->3 P")H X6 X6 Z"1_\|Y/ B:[S_A&/#__$ M,_| 2/_M H X1CP P#] +3/_2/ "B\0LS@_P#A8WA; H)' P !Y/\ XFC_(6 X6 Z
M"1_\|Y/_ (FN\ X1CP___+3/\ P$C_,*/^$8\/ | 0"TS P !(_| "B\0 MLS@_^%C>%O\ H)'_.|Y/ B:Y3P1XLT71X]4%]=F(SW9DC =.V5]> :]G X1 MCP___+3/\ P$C_,*\^^%FC:7?1:\;O3;.X.>H,J>; K[1Z#
(X%4FK,EIW M)?\ A8WA; H)' P'D | B:/^%C>%O^@D? ->3 XFN\ X1CP_P! +3/_$C_M P_*/^$8\/\_0"TS_P$C_PJ;Q*LS@_^%C>%O^@D? ->3 XFC_A8WA; *"1 M P# >3 XFN\ X1CP P#] +3/
2/_"C (1CP_| | +3/ 2/_"B\0LS@_| MA8WA; H)' P'D | B:/^%C>%O^@D? ->3 XFN\ X1CP P! +3/_$C_P *_M/^$8\/\_0"TS_P$C_PHO$+,X/\ X6 X6 Z"1_| >3 ,)H_P"%C>%O^@D? M
->3_P")KO/^$8\/ P#0"TS_.!(_P#"C A&/#__$ M,_| 2/_HO$+,X M/ A8WA; *"1 P# >3 XFC_A8WA; H)' P !Y/\ XFN\ P"$8\/ /0"TS P M$C_PH_X1CP__+3/\ P$C_,*+O"S.# X6
X6 Z"1_\|Y/ B:/^%C>%O\ MH)'_.|Y/ B:[S A&/#_/T M,_\|(_|*/\ A&/#_P#T M,_\|(_|*+O"S.# M P"%C>%O^@D? ->3 P")H X6 X6 Z"1_\|Y/ B:[S_A&/#__$ M,_| 2/_M H X1CP_P#] +3/
2/_"B\0LS@_P#A8WA; H)' P !Y/\ XFC (6 X6 Z M"1_\|Y/_(FN\ X1CP___+3/\ P$C_,*/^$8\/ | 0"TS_P !(_| "B\0 MLS@_^%C>%O\ H)'_.|Y/ B:/^%C>%O^@D? 'D_P#B:[S (1CP_| | +3 M/
2/_"C A&/#_| T M,_P# 2/\ PHO$+,X/ A8WA; H)' P'D ^)H X6 X6 M_P"@D?| P'D_^)KO/^$8\/ | 0"TS_P$C_PH_P"$8\/_/0"TS_P$C_PHO$+ M,X/_(6 X6 Z"1_\|Y/ (FC A8WA; H)' P'D ^)KO/^$8\/
0"TS P !(_M( | "C A&/#_/T M,_\|(_|*+O"S.# .%C>%O^@D? 'D P#B:/\ A8WA M; H)' P'D | B:[S_A&/#_| T M,_P# 2/\ PH_X1CP P! +3/ $C_P *+O"S.# X6 X6 P"@D?| P'D_^)H X6 X6 Z"1 |
>3_.)KO/\ A&/#_P#T M,_\|(_|*/^$8\/ P#0"TS ,!( P#"B\0LS@_^%C>%O^@D? >3_XFC_A8WA M8 *"1_P# >3 XFN\ X1CP P! +3/ $C_P *+O"S.# X6 X6 Z"1 | >3_ M ->3 .)H P"%C>%O^@D? ->3 P")KO/^$8\/
P#0"TS_.!( P#"C A&/#_ M HO$+,X/ A8WA; *"1 P# >3_XFN4ZHO4HMYXWT348+LM:VH83/Y3C;G/8 MC) "O9_9&S*WF1) H1^O M4 8 5%]Y+3)?^%C>%O\ H)'_
.|Y/ B:/^%C>%O^@D?_'D_P#B:[S_(1C MP | | +3/_2/_"C_A&/#_| T M,_P# 2/\ PJ;O*LS@_P#A8WA; H)' P ! MY/\ XFC (6 X6 Z"1 |Y/ (FN\ X1CP___+3/\ P$C_,*/^$8\/ | M0"TS P !(_|
"B\0LS@_^%C>%O\ H)'_.|Y/ B:/^%C>%O^@D?_'D P#B M:[S (1CP_| | +3/_2/_"C A&/#_| T M,_P# 2/\ PHO$+,X/ A8WA; H M)' P'D ^)H X6 X6 P"@D?| P'D_^)KO/^$8\/
0"TS_P$C_PH_M /0"TS_P$C_PHO$+,X/ (6 X6 Z"1_\|Y/ (FC A8WA; H)' P'D ^)KO/ M^$8\/ | 0"TS_P !(_| "C A&/#_/T M,_\|(*+O"S.# .%C>%O^@D? M 'D P#B:/\ A8WA; H)' P'D |
B:[S_A&/#_| T M,_P# 2/\ PH_X1CP_P! +3/ $C_P *+O"S.# X6 X6 P"@D?| P'D_^)H X6 X6 Z"1_| >3_M .)KO/\ A&/#_P#T M,_\|(_|*/^$8\/ P#0"TS_.!( P#"B\0LS@_^%C>%O^@D? ->3 XFC A8WA; H)' P'D |
B:/^%C>%O^@D? 'D P#B:[S_A8WA; H)' P'D |
```

```
6MZSNH[ZQM[N'=Y4\:RIN&#AAD9_.E8]Y-1112 **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\V^$?^ MK\1_]A)]])KS;X1_ZOQ'_P!A)JI;,E[H])HHHJ2@HHHH
**** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** (+W_CQN/\ KDW\JX3X,_\ (B'_*^Y/Y+7 M=WO_
!XW'_7)OY5PGP9_Y$0_]? M?_&3_D07_P"OF/\ K7;Z=_R#+3_KBG_H(KB/C)_R(+_]?,?]:[?3O^09:?\ M7%/_$$53^%$]2S1114E!7)_$W_DG6L?]"_\ D2-#_P"O&'_T 5HZO?\ ]E:+?ZCY M7F_9+>2?
R]VW=M4MC/.,XZT/<%L7**X?P+\1/^$TOKNV_LK[']GB$F[[1YF[ M)QC&T8K;\7^(_P#A%?#TVK?9/M7ENB^5YFS.XXZX/\J+.]@NK7 VBN6\#>,O
M^$TTVYN_L'V/R)O*V>=YF[@'.=H]:ZFAJV@T[A1112 ***\GT7XG:UJ/Q 30 M9K73UM6NI(2Z1N'VKNQR7QG@=J:38F['K%%>6^./BCJ/A?Q5_9=II]M+!$B- M(TV[<^X9^4@@#TZ&O4(W\R-
7VLNX [6&"/8T_:@G<=1112&%%%<1\2?&.H> M#K"QGT^&UE:XE9&%PK, ,\884TKNPF[';T5@>"M4^,OB;K7AWQE+H]I:V#V MZ>7AI8W+_,H)Y#@=_2FDWL)NQZM1112&%%%% !1110
4444 %%%% !1110 5 MYM\9_P#D7=*_["2?^@/7I->;?&?_)%W2O\ L))_Z ]5#XB9;'I-%%8WBO7O M^$8\-7>L?9OM/V?9^Z\S9NW.J]<'"WL].U24;-%<[X,\60>,=#.H10&WD25H MI8"^_81R.<#
(((/3U':NBIM6 **X?6OB-!I7CBS\,Q:>;B2:6&*6;SMGE-(1 MCY=IS@$'J.M=Q0TT*X4444AA1110 4444 %%%49=8T^#5X *DND%_.A>.#DL MRC//L/E/)]*
+U%8'C77+GPWX1OM6LTA>XM_+VK,"5.Z15.0"#T8]ZOZ%?2Z MGX>TW4)E19;JUBF<("%#,@8XSGC)IVTN*_0T****0PHHHH **** "BBB@ HH MHH **** "BBB@ HHHH *\V^$7^I\1?\
82:O2:\V^$7^I\1?]A)JI;,E[H]) MHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ KS;Q=_R5SPA_NO_6O2:\V\7?\ )7/"'^Z_
M]:J.Y,MCTFL;Q-X8T[Q7I9L=0C/!W12H:;*G[R>W&6B?)X]#QSCCIUI*]]!OS.5=O&GPVB,CR_V_X?B&,,2)8%]>Y M 'NH]JZK6_%<4GPWO/$6D2 M>V)@,_,OXK*>W\.Z2_G+)N*
;W8:6LAWC/_DK7A#\?_0C1X^_Y*5X*_P"N_P#[.M'C/_DK7A#\?_0C M1X^_Y*5X*_Z[_P#LZTUT!]23Q[$?$'CGPWX4G=UL)M]U.JG'F;0Q S]$8?\ M OR[&[\*Z%>:6=.ETJU^S%-@58@I7C&5(Y!X'
A<$]L@XX-20_%&QU9/LV@Z;J%YJDGRI;/#M$9]9&SA5'EWIPH&:]+KS/X-+*NEZVL[!IA]#"1AT+; M1D_G7IE*?Q!'8X+Q=JU]K6O#P3HP@66:_RWUS/%YB11^FTC!)RO)]1^&#<_# M:^\(26VN:#
<)]DE@F]2^0'..6:/'0YR0.H]2>M[Q!'JGA'XC/XK@TZ>^TN^ M@6"[6V!9X\!1G';[BD=NHR,UZU(JP9\GT!V\GJ&S]/3;2VCL[." MUBSY<,:QKGK@#_E7C%KI^M^"O$">
M6T6)X+LRFZMK0$M9AB/FZX!_'')'' M;U/PWXGL/%5G+=ZDUYM\( \ 5^(_^PDU4MF2]T=QK.N:;X?LTN]4N?(@>01JVQFR MQ!.,*">@ 8G_LSPA_T%_\ R6E_^(K)^?_"*I_U_I_Z+DKQ"N_#X6%2'
M,V>3B\=4HU>2*5M#Z%_X69X0_P"@O_Y+2_\ Q%'_LSPA_T%_\ R6E_^(KY MZHK?ZC3[LY?[4K=E_7S/H7_A9GA#_H+_/DM+_\ $4?\+,\(?]!?2_P EI?\
MXBOGJBCZC3[L/[4K=E_7S/H7_A9GA#_H+_\ DM+_/$4?\+,\(?]!?\ \EI? M_B*^>]*/J /NP_M2MV7]?,^A?2^%F>$/^@O\ ^2TO_P 11_PLSPA_T%__"6E M_P#B*^>]*/J /NP_M2MV7]?,^A?
^%F>$/^@O_P"2TO\ \11_PLSPA_T%_P#R M6E_^(KYZHH^HT^[#^U*W9?U\SZ%_X69X0_Z"_P#Y+2__ !%'_"S/"'_07_\ M):7_.(KYZHH^HT^[#^U*W9?U\SZ%'Q+\
(L0!JXYXYMY1_[+75HZR(KHP96&-M0P.01ZU\GUZW\+/&6]4\.ZA+\R@_8Y&/4?\ /,G]1^7H*PKX-0CS0.K"YBZD M^2I97V/5]***\X]@**** "BBB@ HHHH **** "BBB@ H MHHH
**** "BBB@ HHHH @O?^/&X_ZY_*N$^#/\ R(A_Z^Y/Y+7=WO\ QXW' M_7)OY5PGP9_Y$0_]?IU]%%24%%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
%%%% M !1110 4444 %%%% !1110 4444 %%%% !1110!R7Q-_Y)UK'^XG_HQ:T?!G M_(D:'_UXP_\ H K.^)O_"3K6/\ <3_T8M:/@S_D2-#_.O&'_T 57V2>IN4 M445)04444 %%%% !1110 4444
%%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_QD_P"1 M!?\ Z^8_ZUV^G?\ (,M/^N*?^@BN(^,G_(@O_P!?,?\
6NWT[_D&6G_7%/\ MT$53^%$]2S1114E!7)_$W_DG6L?]9!7'GYB%.2<>G^_7+XR%\)D?!VX>U\%:Y<1A2\4S.H;H2(P>:S] M'^_6]S3SI?Z9;3,83]FAM(W#23;E
!)9N,;CTSP*TOA7:20_#36KAP0L[S%/ M<+&!G\|C\*YCX)PQR^_YW= S16,CH3_"=Z+D?@Q'XTVEJV+71&M9?&G58-96 M#6])MX;7?MD6-'66)3W^8G)'!Q@9KU#Q
XFLO"^@R:K=$R)PL,:'F5R,A0?P M)SZ UXW\;41?&MJ5507L$+$#J=\@R?P 'X5H_%YI!X:\)J ?*,+%CC@'9'C^ M9HY4[#NU<+7XR>);JX:>'P_;SV,1S*L22%E7G]X) X[E>U\ED
/4!@Q_K7LGPS:T7X=Z8]OY:KL8RD#'SACN)]^/BO'?!I@;XN6AMM MGV*:\M3)(A/)P MVX8_"NT\=^.;?P78PGR/M [<[A##NV@ 8RS'T&1QW_,CR+XP_P#)0)_^O>+^ M5>H?
$CP)+XPM+::RG6.^M_^Q)/NRJ<<9['(X/N<^TV6EQW>MCE8OB9X[DMCJ M \*H^GD%UD2UFQLZYW9QC'?&*]#\7^+['P?I:W=VK2RR M@@0X,A[\]@.YKQ MVV\5>
/AQU092VGVLI3I\D@R<>V>/2G?%^^.IZKHE]&C+;7.EQSQ M;O\ :9B1^16GRIM!S61J)\7?%U\YET_P];R6X/\ #!+*?*^^@P'Z5)\5M1EU; MP3X:OYH?
(EN&+O%S\C%1D<^]>H>$Q9#PCI(T\QFU%K'L*="<#8H(([?[5?SC>0>?,Y(_P#'2E>@?$/X?WOBVWLK^TF1=2MX
M1&\4APL@Z\$=""3['VHM&Z87>],>S^(WCIY+>XNO"Z#3YB#YRVDRA4)'S%BQ M&,'.<#=/5Y%^T7LW^HM@V-WJS'LH_7\|>46/C?QCX!OX_*UN)Y M;>)5_P!&N,%O+Y
V2#/'&!R1Q5;XOW#W7C*&?#"&2QA>$MW0[C_FGRW8#T 1&Z/+(5R!D[2 /R.,]ZX;Q_KQ]2^_[3>U:UD?9C&5$D0?R\8W[5W9QWS MU]ZJ N:R1+O:Y](4445@;!1110 4444 %%%% !1110 4444
%>;?&?\ Y%W2 MO^PDG_H#UZ37FWQG_P"1=TK_+"2?^@/50^(F6QZ37&_%7_DFNK?]L?2_$O9D8_P#_5]FK MZDWLL"TN2P:[\2-1@%[:>'=+MK:3#1P74K>:5/( MYW#'X@?
2MKP=XRC\41W5M/:/8ZI9$+EHQ[#3\0]7/C'5] MM+@O)X7,=E"N0L>[2,20 M%_^E.G\;^)_#>]V2>+_*L(=-NY!&+]TN[+'..">!P#C-0^#_/\ A;GB M\X&1QG_@0]?XU 'P/$2
2+V,CV^5Z>E[6%K:YVNN:W9>'M(GU/4)"D$(SA>6 M<]E4=R?\X%<9:^(OB'K N+[3/#^F6ME* \(O9&,CJ>AX8?7D#C]8_C&^_$TA M93BU;4D\[(^4C:W7\,UZ.K*ZAE(*D9!!X(J=E<>[.3\(>
/^$AN;O2]0LGT_M6;/F>V8Y!7._RGTY'YC&76 M)?A#J;:;[!;0W^Z/>EL24QYZ8QDGM[U7T+7_%E]X5TQ?"^CVDEK:V<,)N+YRO MG.J]7"*". PQDG!P:V_BK_R375O^V\V\$Z.2MCP>]KX*T(*
!_9\!X'^RXA#94\D97OP00>O;GFH-<\8Z@VNMH'A6P MBU#4H5WW,DS8A@'H3D9;IQG\SG&7X3 7XO>+@ !\B'C_(#7/>%;+Q5J.O>* M'T778-/D747^TI-J[,=S8/*G
X(Q3LKBNSJK7QEX@TC7+'3O%^EVMM%?MY= MO=6;$H'R %;)/KU]Q[U;\<^,[GPGJF@1(EL;2^G9;IY5)*(K1Y*D,#AFZYZ M"L35O GC774MX]5\3V=S%!.)D46JH0P]U4'N:=\3XDG\7>!8I%#1O?
E64]P9 M(01197"[L;?ASQ!XKU76P=2T!+'1,B%I+:0G,H(QC?\ -QD$\%1^G->XUKX@ M7EW,-+\.Z?:VL;LJO?S%FE Z$ %2,X[CN.>M=I=W,5E9SW<[;88(VD=O15&2 M?R%N^_&J-
2T:+2]+TQW98FNMTDK@'!; &.HQVYS26NMALUO!WC*?7K M[4-(U2Q6RU;3SB6-'W(XS@E?3!QW4/'IDZC\0M1L/'VI^'H].2\$4"_8HH4 M;S99BB AFS@* 7).!POYT!,5-!\6_$,>]7L=
[>K9IYL\.!%8XCP !TP,#\* METI83^T#KADV[Q8J8LGG=LAZ>^-WZT[*[%=V+.H>+/"AU/[1US0-/DT17 E M-G(3)&IX!R6(/MCZ9R-'Q;XRN]])\.:9XBT9+:ZTR9T^T>8C%Q&V.%<,,']" M#GDCT-
;WBJ2.+PAK3RXV"QFR#W^0\5R?@_1O[>^"UMI5P2AN8)E5G7.T^:Y1 ML>@(4TE;<>NQZ!%*D\*2QL&C=0RL.X/(_P%)]R"]S;HHHJ2@HHHH *\V^$7^I\1?] MA)]])KS;X1?2
ZGQ%_V$FJELR7NCTFBBBI*"BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-O%W_M "5SPA_NO_6O2:\V\7?\E<\(?[K_
:J.Y,MCTFBBBI*"BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH *\V^$?^K\1_\ 82:O2:\V^$?^K\1_
M]A)JI;,E[HG^,?\ R*_I_P!?Z?\ HN2O$*]O^,?_"*_I_U_I_Z+DKQ"O9P7 M\+YL^;S+_>'Z(****[#S@HHHH **** "BBB@ HHHH **** "G1R/%(LD;LDB M$,K*<%2.A!IM% 'T+X#\7IXITG;.0NHVP"SKP
_HX'H>_H?PKK*^7]"UJZT# M5X 1M&(>,_,F2!(O=3[&OI#1 8M=>TF#4;-B8I1]TXRA[J?<5XF*H>SES+9G MTV!Q7MH\LOB7XFA1117&>B%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!!>_\>-Q_P!,\ Z *K M()/4W****DH**** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@#S_M .,G_(@O_P!?,?\ 6NWT[_D&6G_7%/\ T$5Q'QD_Y$%_^OF/^M=OIW_(,M/^ MN*?^@BJ?PHGJ6:***DH*Y/XF_P#).M8_ZYI_Z,6NLKD_B;_R3K6/^N:?^C%I MQW0GL7_!?
_(D:'_UXP_^@"MVL+P7_P B1H?_ %XP_P#H K=H>X+8\C\4?!C[ M=J,EYH-W#;K*Q9[>XW;4/^R0"<9SQCBLVP^"&JS7(;,5M7M4CR-QMJTC,/3+!
M<'\Z]NHHJ%T*:N
M<'|Z]NHHJ%T*:N
```

~~GPIL]5L'N/$5_>WFLW"*7N3)CR3C[JCD$ GOGIQBH=.\5WG@:^GT#Q9 M.9[:* RV%^D>WSD49V$=-V.!SUXR<@U+9^-O%.FV<5EJW@O4[B_C4*TUJ-\< MG8$L 0">_)]>^*SM7\,^*?B-&;G58HM'M+='-E:,NZ5G/3>>H! /T'%:?XM MB?0Z+X9Z=~~